TAB-4334 147157625 Small Molecule Anti-cancer Agents that Stabilize the MYC-G-Quadruplex NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics David Calabrese, Kenneth Felsenstein, Peter Gareiss, Elena Leon, Beverly Mock, Lindsey Saunders, John (Jay) Schneekloth, John Simmons <p>The proto-oncogene c-Myc is deregulated and overexpressed in ~70% of all cancers. Thus, c-Myc is an attractive therapeutic target since disrupting c-Myc activity could be used as pan-chemotherapy. Beyond cancer, Myc is also a positive effector of tissue inflammation, and its function has been implicated in the pathophysiology of heart failure. Because c-Myc is a transcription factor, a rationally designed small molecule targeting c-Myc would be required to exhibit significant specificity. Unfortunately, several physical characteristics of Myc make it a very difficult protein to target and, to date, there are no approved drugs targeting c-Myc.</p> <p>The invention is directed to small molecules that stabilize the transcription repressing quadruplex in the c-Myc gene promoter region. Invention compounds target c-Myc at the transcriptional level are shown to inhibit c-Myc expression. Invention compounds are effective in selective killing in a variety of c-Myc driven cancer cell lines, including leukemia, non-small-cell lung cancer, colon, central nervous system, melanoma, ovarian, renal prostate and breast. Minimal unwanted activity is observed in peripheral blood mononucleocytes or cancer cell lines that resist inhibition of c-Myc protein expression.</p> <p>Current efforts are focused on developing more potent molecules with improved ability to decrease c-Myc expression and superior bioavailability.&nbsp; Through synthesis of a focused library of analogs, we have identified inhibitors with improved Kd values for the quadruplex, improved toxicity towards c-Myc-driven cancer cells, and improved efficacy for decreasing c-Myc expression.&nbsp; By solving an NMR structure of the quadruplex in complex with the small molecule, we have begun to establish a molecular basis for selectivity observed in cell-based and biophysical assays and are working to use this information to design improved inhibitors.&nbsp; Additionally, we&nbsp; show that one compound of interest is orally bioavailable, albeit with a Cmax in oral dosing slightly below the concentration required for oral efficacy.</p> <p>This technology is available for licensing and co-development to qualified entities.</p> <h2>Competitive Advantages:</h2> <ul> <li>First in class drug since no c-Myc drugs have been approved for any cancer indication</li> <li>Drug-like in nature, satisfying all of Lipinski&rsquo;s rule of five parameters&nbsp;</li> <li>Orally bioavailable&nbsp;</li> <li>Decreasing c-Myc expression without affecting expression from other quadruplex-driven genes</li> <li>Compound has significant potential for improvement with very minor structural alternations</li> <li>The methodologies used by the lab have explored the biological potential of c-Myc G-quadruplex-stabilizing agents to a degree of complexity greater than what has ever been done before.</li> </ul> <h2>Commercial Applications:</h2> <ul> <li>Therapeutic for multiple myeloma, carcinoma of the cervix, colon, breast, lung and stomach&nbsp;</li> <li>Tissue Inflammation</li> </ul> 2017-10-27 2025-04-22 2018-04-03 2026-09-11 2017-10-27 C-MYC, G-Quadruplex (G4), MULTIPLE MYELOMA, Schneekloth False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-04-03 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162260 Kenneth M. Felsenstein et al. https://www.ncbi.nlm.nih.gov/pubmed/26462961 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26462961">Kenneth M. Felsenstein et al.</a> 147164345 Mock, Beverly NIH - NCI NCI Mock, Beverly (NCI) 1 147164347 Felsenstein, Kenneth NIH - NCI Felsenstein, Kenneth 2 147164344 Simmons, John NIH - NCI Simmons, John 3 147164348 Saunders, Lindsey NIH - NCI Saunders, Lindsey 4 168911931 Schneekloth, John (Jay) University of Michigan NCI Schneekloth, John (Jay) (NCI) 5 147164349 Gareiss, Peter Yale University Gareiss, Peter 6 147164350 Calabrese, David NIH - NCI Leidos Calabrese, David (Leidos) 7 147164351 Leon, Elena NIH - NLM Leon, Elena 8 147164345 Mock, Beverly NIH - NCI NCI Mock, Beverly (NCI) 1 147164347 Felsenstein, Kenneth NIH - NCI Felsenstein, Kenneth 2 147164344 Simmons, John NIH - NCI Simmons, John 3 147164348 Saunders, Lindsey NIH - NCI Saunders, Lindsey 4 168911931 Schneekloth, John (Jay) University of Michigan NCI Schneekloth, John (Jay) (NCI) 5 147164349 Gareiss, Peter Yale University Gareiss, Peter 6 147164350 Calabrese, David NIH - NCI Leidos Calabrese, David (Leidos) 7 147164351 Leon, Elena NIH - NLM Leon, Elena 8 147157876 A New Class Of C-Myc G-quadruplex Stabilizing Small Molecules With Anticancer Activity E-053-2015-0 Filing authorized NCI, Yale University 147162503 A New Class Of C-Myc G-quadruplex Stabilizing Small Molecules With Anticancer Activity E-053-2015-1 Filing authorized NCI, NLM, Yale University 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4334] Small Molecule Anti-cancer Agents that Stabilize the MYC-G-Quadruplex&body=Please send me information about technology [TAB-4334] Small Molecule Anti-cancer Agents that Stabilize the MYC-G-Quadruplex.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4334] Small Molecule Anti-cancer Agents that Stabilize the MYC-G-Quadruplex&body=Please send me information about technology [TAB-4334] Small Molecule Anti-cancer Agents that Stabilize the MYC-G-Quadruplex.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147160970 E-053-2015-1 E-053-2015-1-PCT-01 MYC G-Quadruplex Stabilizing Small Molecules and Their Use PCT COMB Patent Cooperation Treaty PCT/US2016/012222 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2016/012222<br />Filed on 2016-01-05<br />Status: Expired 147168251 E-053-2015-0 E-053-2015-0-US-01 Myc G-quadruplex Stabilizing Small Molecules And Their Use PRV US 62/099,938 Abandoned US <br />Provisional (PRV) 62/099,938<br />Filed on 2015-01-05<br />Status: Abandoned 147168252 E-053-2015-1 E-053-2015-1-US-02 MYC G-QUADRUPLEX STABILIZING SMALL MOLECULES AND THEIR USE National Stage US 10,196,372 15/541,676 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10196372 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10196372">10,196,372</a><br />Filed on 2017-07-05<br />Status: Issued 147168253 E-053-2015-1 E-053-2015-1-EP-03 MYC G-Quadruplex Stabilizing Small Molecules and Their Use EP European Patent 3242661 16709158.6 Issued European Patent <br />European patent (EP) 16709158.6<br />Filed on 2016-01-05<br />Status: Issued 147168254 E-053-2015-1 E-053-2015-1-US-04 MYC G-QUADRUPLEX STABILIZING SMALL MOLECULES AND THEIR USE DIV US 10,604,499 16/218,341 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10604499 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10604499">10,604,499</a><br />Filed on 2018-12-12<br />Status: Issued 147168256 E-053-2015-1 E-053-2015-1-EP-05 MYC G-Quadruplex Stabilizing Small Molecules and Their Use DIV European Patent 3597186 19185807.5 Issued European Patent <br />Divisional (DIV) 19185807.5<br />Filed on 2019-07-11<br />Status: Issued 147168257 E-053-2015-1 E-053-2015-1-CH-06 MYC G-Quadruplex Stabilizing Small Molecules and Their Use EP Switzerland 3242661 16709158.6 Issued Switzerland <br />European patent (EP) 16709158.6<br />Filed on 2016-01-05<br />Status: Issued 147168258 E-053-2015-1 E-053-2015-1-DE-07 MYC G-Quadruplex Stabilizing Small Molecules and Their Use EP Germany 3242661 16709158.6 Issued Germany <br />European patent (EP) 16709158.6<br />Filed on 2016-01-05<br />Status: Issued 147168259 E-053-2015-1 E-053-2015-1-FR-08 MYC G-Quadruplex Stabilizing Small Molecules and Their Use EP France 3242661 16709158.6 Issued France <br />European patent (EP) 16709158.6<br />Filed on 2016-01-05<br />Status: Issued 147168260 E-053-2015-1 E-053-2015-1-GB-09 MYC G-Quadruplex Stabilizing Small Molecules and Their Use EP United Kingdom 3242661 16709158.6 Issued United Kingdom <br />European patent (EP) 16709158.6<br />Filed on 2016-01-05<br />Status: Issued 147168261 E-053-2015-1 E-053-2015-1-US-10 MYC G-QUADRUPLEX STABILIZING SMALL MOLECULES AND THEIR USE DIV US 11,014,902 16/835,102 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11014902 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11014902">11,014,902</a><br />Filed on 2020-03-30<br />Status: Issued 147168262 E-053-2015-1 E-053-2015-1-US-11 MYC G-QUADRUPLEX STABILIZING SMALL MOLECULES AND THEIR USE CON US 17/306,756 Abandoned US <br />Continuation (CON) 17/306,756<br />Filed on 2021-05-03<br />Status: Abandoned 147168263 E-053-2015-1 E-053-2015-1-DE-13 MYC G-Quadruplex Stabilizing Small Molecules and Their Use EP Germany 3597186 19185807.5 Issued Germany <br />European patent (EP) 19185807.5<br />Filed on 2019-07-11<br />Status: Issued 147168264 E-053-2015-1 E-053-2015-1-CH-12 MYC G-Quadruplex Stabilizing Small Molecules and Their Use EP Switzerland 3597186 19185807.5 Issued Switzerland <br />European patent (EP) 19185807.5<br />Filed on 2019-07-11<br />Status: Issued 147168265 E-053-2015-1 E-053-2015-1-FR-14 MYC G-Quadruplex Stabilizing Small Molecules and Their Use EP France 3597186 19185807.5 Issued France <br />European patent (EP) 19185807.5<br />Filed on 2019-07-11<br />Status: Issued 147168266 E-053-2015-1 E-053-2015-1-GB-15 MYC G-Quadruplex Stabilizing Small Molecules and Their Use EP United Kingdom 3597186 19185807.5 Issued United Kingdom <br />European patent (EP) 19185807.5<br />Filed on 2019-07-11<br />Status: Issued 147170361 C-MYC 147170363 G-Quadruplex (G4) 147170364 MULTIPLE MYELOMA 147170366 Schneekloth TAB-4118 147157400 Methods of making and using dopamine receptor selective antagonists/partial agonists NIDA Collaboration, Licensing, Neurology, Therapeutics Collaboration Licensing Neurology Therapeutics Vivek Kumar, Amy Newman, Anverbasha Shaik <p>Dopamine is a major neurotransmitter in the central nervous system and among other functions is directly related to the rewarding effects of drugs of abuse.  Dopamine signaling is mediated by D1, D2, D3, D4 and D5 receptors.  The dopamine D3 receptor is a known target to treat a variety of neuropsychiatric disorders, including substance use disorders (e.g. cocaine and opioid), schizophrenia and depression.  Despite extensive efforts, it has proven difficult to identify a lead molecule that selectively binds to D3 receptors (versus D2 receptors, for example), with the desired pharmacological and pharmacokinetic profile.  For example, metabolic instability or predicted toxicity has precluded successful translation of previously reported D3R-selective antagonists to clinical use for cocaine abuse.</p> <p>The library of compounds of this technology is designed to have high affinity and specificity for the dopamine D3 receptor.  Preliminary studies at NIDA indicate that selected lead compounds have promising in vivo activity in rodents, including reduced acquisition to self-administration of oxycodone, inhibition of reinstatement to oxycodone seeking, and ameliorating naloxone-precipitated withdrawal from oxycodone dependence, and that these lead compounds are metabolically stable.</p> <h2>Competitive Advantages:</h2> <ul><li>Despite extensive efforts to develop  D<sub>3</sub> receptor-selective compounds, it has proven difficult to identify a ligand with the desired pharmacological and pharmacokinetic profile for translation to the clinic.   The D<sub>3</sub> receptor ligands described herein may be useful to treat a variety of diseases, including opioid use disorders and schizophrenia.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treatment of Opioid Use Disorders, Schizophrenia, Bipolar Disorder, and of cannabis (Tetrahydrocannabinol, THC) dependence</li> </ul> 2016-11-10 2025-04-22 2018-11-13 2026-09-11 2016-11-10 Bipolar Disorder, Cannabis, DEPENDENCE, dopamine D3 receptor, drug addiction, oxycodone, SCHIZOPHRENIA False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-11-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162413 A. Newman et al. https://www.ncbi.nlm.nih.gov/pubmed/27508895 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27508895">A. Newman et al.</a> 168905664 C.-K. Wu, Y.-C. Lin, J. Huang, et al., “ Developing the Dopamine D3 Receptor (D3R) Antagonist, (R)-VK4-116, as a Non-Opioid Medication for the Treatment of Opioid Use Disorder,” Medicinal Research Reviews 0 (2026): 1-15. https://doi.org/10.1002/med.70101. C.-K. Wu, Y.-C. Lin, J. Huang, et al., “ Developing the Dopamine D3 Receptor (D3R) Antagonist, (R)-VK4-116, as a Non-Opioid Medication for the Treatment of Opioid Use Disorder,” Medicinal Research Reviews 0 (2026): 1-15. https://doi.org/10.1002/med.70101. 147163570 Newman, Amy NIH - NIDA NIDA Newman, Amy (NIDA) 1 147163571 Kumar, Vivek NIH - NIDA NIDA Kumar, Vivek (NIDA) 2 147163572 Shaik, Anverbasha NIH - NIDA NIDA Shaik, Anverbasha (NIDA) 3 147163570 Newman, Amy NIH - NIDA NIDA Newman, Amy (NIDA) 1 147163571 Kumar, Vivek NIH - NIDA NIDA Kumar, Vivek (NIDA) 2 147163572 Shaik, Anverbasha NIH - NIDA NIDA Shaik, Anverbasha (NIDA) 3 147157877 Novel Dopamine D3 Receptor Selective Antagonists/partial Agonists With High Affinity And Metabolic Stability For Treatment Of Neuropsychiatric Disorders E-053-2016-0 Filing authorized National Institute on Drug Abuse (NIDA) 147162504 Novel Dopamine D3 Receptor Selective Antagonists/partial Agonists With High Affinity And Metabolic Stability For Treatment Of Neuropsychiatric Disorders E-053-2016-1 Filing authorized National Institute on Drug Abuse (NIDA) 147162505 Use Of Dopamine D3R Antagonist To Mitigate Development Of Opioid Addiction E-053-2016-2 Filing authorized National Institute on Drug Abuse (NIDA) 83737255 Baxter, Merissa merissa.baxter@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4118] Methods of making and using dopamine receptor selective antagonists/partial agonists&body=Please send me information about technology [TAB-4118] Methods of making and using dopamine receptor selective antagonists/partial agonists.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Baxter, Merissa<br><a href="mailto:merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4118] Methods of making and using dopamine receptor selective antagonists/partial agonists&body=Please send me information about technology [TAB-4118] Methods of making and using dopamine receptor selective antagonists/partial agonists.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">merissa.baxter@nih.gov</a><br> 147166649 E-053-2016-0 E-053-2016-0-US-01 Dopamine D3 Receptor Selective Antagonists/Partial Agonists; Method of Making; and Use Thereof PRV US 62/307,600 Abandoned US <br />Provisional (PRV) 62/307,600<br />Filed on 2016-03-14<br />Status: Abandoned 147166650 E-053-2016-1 E-053-2016-1-PCT-01 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders PCT COMB Patent Cooperation Treaty PCT/US2017/021328 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2017/021328<br />Filed on 2017-03-08<br />Status: Expired 147166652 E-053-2016-1 E-053-2016-1-CA-02 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF National Stage Canada 3017342 Pending Canada <br />National Stage 3017342<br />Filed on 2017-03-08<br />Status: Pending 147166653 E-053-2016-1 E-053-2016-1-EP-03 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders National Stage European Patent 3429993 17711971.6 Issued European Patent <br />National Stage 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166654 E-053-2016-1 E-053-2016-1-US-04 Novel Dopamine D3 Receptor Selective Antagonists/partial Agonists With High Affinity And Metabolic Stability For Treatment Of Neuropsychiatric Disorders National Stage US 11,299,476 16/084,093 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11299476 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11299476">11,299,476</a><br />Filed on 2018-09-11<br />Status: Issued 147166655 E-053-2016-1 E-053-2016-1-AU-05 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders National Stage Australia 2017233716 2017233716 Issued Australia <br />National Stage 2017233716<br />Filed on 2017-03-08<br />Status: Issued 147166656 E-053-2016-1 E-053-2016-1-EP-06 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF DIV European Patent 3848351 21158632.6 Issued European Patent <br />Divisional (DIV) 21158632.6<br />Filed on 2021-02-23<br />Status: Issued 147166657 E-053-2016-1 E-053-2016-1-AT-07 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Austria 3429993 17711971.6 Issued Austria <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166658 E-053-2016-1 E-053-2016-1-BE-08 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Belgium 3429993 17711971.6 Issued Belgium <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166659 E-053-2016-1 E-053-2016-1-CH-09 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Switzerland 3429993 17711971.6 Issued Switzerland <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166660 E-053-2016-1 E-053-2016-1-CZ-10 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Czech Republic 3429993 17711971.6 Issued Czech Republic <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166661 E-053-2016-1 E-053-2016-1-DE-11 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Germany 3429993 17711971.6 Issued Germany <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166662 E-053-2016-1 E-053-2016-1-DK-12 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Denmark 3429993 17711971.6 Issued Denmark <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166663 E-053-2016-1 E-053-2016-1-ES-13 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Spain 3429993 17711971.6 Issued Spain <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166664 E-053-2016-1 E-053-2016-1-FI-14 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Finland 3429993 17711971.6 Issued Finland <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166665 E-053-2016-1 E-053-2016-1-FR-15 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP France 3429993 17711971.6 Issued France <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166666 E-053-2016-1 E-053-2016-1-GB-16 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP United Kingdom 3429993 17711971.6 Issued United Kingdom <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166667 E-053-2016-1 E-053-2016-1-GR-17 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Greece 3429993 17711971.6 Issued Greece <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166668 E-053-2016-1 E-053-2016-1-HR-18 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Croatia 3429993 17711971.6 Issued Croatia <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166669 E-053-2016-1 E-053-2016-1-HU-19 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Hungary 3429993 17711971.6 Issued Hungary <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166670 E-053-2016-1 E-053-2016-1-IE-20 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Ireland 3429993 17711971.6 Issued Ireland <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166671 E-053-2016-1 E-053-2016-1-IT-21 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Italy 3429993 17711971.6 Issued Italy <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166672 E-053-2016-1 E-053-2016-1-NL-22 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP The Netherlands 3429993 17711971.6 Issued The Netherlands <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166673 E-053-2016-1 E-053-2016-1-NO-23 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Norway 3429993 17711971.6 Issued Norway <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166674 E-053-2016-1 E-053-2016-1-PL-24 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Poland 3429993 17711971.6 Issued Poland <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166675 E-053-2016-1 E-053-2016-1-PT-25 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Portugal 3429993 17711971.6 Issued Portugal <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166676 E-053-2016-1 E-053-2016-1-RO-26 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Romania 3429993 17711971.6 Issued Romania <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166677 E-053-2016-1 E-053-2016-1-RS-27 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Serbia 3429993 17711971.6 Issued Serbia <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166678 E-053-2016-1 E-053-2016-1-SE-28 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Sweden 3429993 17711971.6 Issued Sweden <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166679 E-053-2016-1 E-053-2016-1-SI-29 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Slovenia 3429993 17711971.6 Issued Slovenia <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166680 E-053-2016-1 E-053-2016-1-SK-30 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Slovakia 3429993 17711971.6 Issued Slovakia <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166681 E-053-2016-1 E-053-2016-1-TR-31 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Turkey 3429993 17711971.6 Issued Turkey <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166682 E-053-2016-1 E-053-2016-1-US-32 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF DIV US 12,162,861 17/685,709 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12162861 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12162861">12,162,861</a><br />Filed on 2022-03-03<br />Status: Issued 147166684 E-053-2016-2 E-053-2016-2-US-01 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF PRV US 62/729,709 Abandoned US <br />Provisional (PRV) 62/729,709<br />Filed on 2018-09-11<br />Status: Abandoned 147166685 E-053-2016-2 E-053-2016-2-PCT-02 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2019/050165 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/050165<br />Filed on 2019-09-09<br />Status: Expired 147166686 E-053-2016-2 E-053-2016-2-AU-03 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF National Stage Australia 2019340675 2019340675 Issued Australia <br />National Stage 2019340675<br />Filed on 2021-02-12<br />Status: Issued 147166687 E-053-2016-2 E-053-2016-2-CA-04 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF National Stage Canada 3111785 Pending Canada <br />National Stage 3111785<br />Filed on 2019-09-09<br />Status: Pending 147166688 E-053-2016-2 E-053-2016-2-EP-05 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF National Stage European Patent 19773300.9 Pending European Patent <br />National Stage 19773300.9<br />Filed on 2019-09-09<br />Status: Pending 147166689 E-053-2016-2 E-053-2016-2-US-06 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF National Stage US 11,337,971 17/265,150 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11337971 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11337971">11,337,971</a><br />Filed on 2021-02-01<br />Status: Issued 147166690 E-053-2016-2 E-053-2016-2-US-07 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF CON US 12,097,196 17/738,301 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12097196 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12097196">12,097,196</a><br />Filed on 2022-05-06<br />Status: Issued 147170368 Bipolar Disorder 147170369 Cannabis 147170370 DEPENDENCE 147170372 dopamine D3 receptor 147170374 drug addiction 147170376 oxycodone 147170377 SCHIZOPHRENIA TAB-5029 159051371 NeoExpansion – A Method to Identify and Selectively Expand Neoantigen-specific T Cells, Including T Cell Receptor-engineered T Cells and Tumor Infiltrating Lymphocytes NCI Collaboration, Immunology, Licensing, Oncology, ResearchProducts Collaboration Immunology Licensing Oncology ResearchProducts Sanghyun (Peter) Kim, Noam Levin, Lior Levy, Steven Rosenberg <h2>Summary:</h2> <p>&nbsp;The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a method of identifying and selectively expanding neoantigen-specific T cells.</p> <h2>Description of Technology:&nbsp;</h2> <p>Somatic mutations are spontaneous changes in the DNA sequence of somatic cells which drive the development of most cancers. These somatic mutations may also create neoantigens, newly formed antigens that can be recognized by T cells. Adoptive cell transfer (ACT) and T cell receptor- (TCR-) engineered T cell therapies (TCR-T) can be used to target cells expressing these neoantigens and treat cancer patients. Traditionally, TCR-T or tumor infiltrating lymphocyte (TIL) cell therapy products utilize an in vitro expansion step in their manufacture called a rapid expansion protocol (REP). However, recent evidence suggests that conventional REPs reduce the frequency of neoantigen-reactive T cells in the final product, which may diminish treatment efficacy.</p> <p>Researchers at the National Cancer Institute (NCI) have developed a method to identify and selectively expand neoantigen-specific T cells, including TCR-T and TIL-based products. This method, termed &ldquo;NeoExpand,&rdquo; promotes the selective growth of neoantigen-reactive T cells and, additionally, enables the sensitive identification of novel neoantigen-reactive TCRs.</p> <p>The NCI seeks co-development partners and/or licensees. As &ldquo;NeoExpand&rdquo; provides a novel method of identify and selectively expanding neoantigen-specific T cells, this technology may be particularly appealing to companies developing cell therapies.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Manufacturing method for ACT products</li> <li>Manufacturing method for TCR-T products</li> <li>Discovery engine for the isolation of neoantigen-specific TCRs</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Increase the efficacy of immunotherapies treating cancer</li> <li>Identify neoantigen-specific T cells</li> <li>Selectively expand neoantigen-specific T cells</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a method to identify and selectively expand neoantigen-specific T cells. 2024-11-12 2026-04-16 2026-09-08 2024-11-12 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 159081648 Wölfl M, et al. Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells. (PMID 24675735) https://pubmed.ncbi.nlm.nih.gov/24675735/ <a href="https://pubmed.ncbi.nlm.nih.gov/24675735/">Wölfl M, et al. Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells. (PMID 24675735)</a> 159081651 Cafri G, et al. Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. (PMID 30683863) https://pubmed.ncbi.nlm.nih.gov/30683863/ <a href="https://pubmed.ncbi.nlm.nih.gov/30683863/">Cafri G, et al. Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. (PMID 30683863)</a> 159081940 Levin N, et al. Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy. (PMID 34168045) https://pubmed.ncbi.nlm.nih.gov/34168045/ <a href="https://pubmed.ncbi.nlm.nih.gov/34168045/">Levin N, et al. Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy. (PMID 34168045)</a> 159051713 Levin, Noam National Cancer Institute (NCI) NCI Levin, Noam (NCI) 1 159051753 Kim, Sanghyun (Peter) Surgery Branch NCI Kim, Sanghyun (Peter) (NCI) 2 159051764 Levy, Lior NCI Levy, Lior (NCI) 3 159051780 Rosenberg, Steven NCI Rosenberg, Steven (NCI) 4 159051713 Levin, Noam National Cancer Institute (NCI) NCI Levin, Noam (NCI) 1 159051753 Kim, Sanghyun (Peter) Surgery Branch NCI Kim, Sanghyun (Peter) (NCI) 2 159051764 Levy, Lior NCI Levy, Lior (NCI) 3 159051780 Rosenberg, Steven NCI Rosenberg, Steven (NCI) 4 159051374 NeoExpansion - Method to identify and selectively expand neoantigen-specific T cells, including T cell receptor-engineered T cells and tumor infiltrating lymphocytes. E-101-2024-0 Filing authorized NCI - CCR, NIH - NCI, Surgery Branch 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-5029] NeoExpansion – A Method to Identify and Selectively Expand Neoantigen-specific T Cells, Including T Cell Receptor-engineered T Cells and Tumor Infiltrating Lymphocytes&body=Please send me information about technology [TAB-5029] NeoExpansion – A Method to Identify and Selectively Expand Neoantigen-specific T Cells, Including T Cell Receptor-engineered T Cells and Tumor Infiltrating Lymphocytes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-5029] NeoExpansion – A Method to Identify and Selectively Expand Neoantigen-specific T Cells, Including T Cell Receptor-engineered T Cells and Tumor Infiltrating Lymphocytes&body=Please send me information about technology [TAB-5029] NeoExpansion – A Method to Identify and Selectively Expand Neoantigen-specific T Cells, Including T Cell Receptor-engineered T Cells and Tumor Infiltrating Lymphocytes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 159502980 E-101-2024-0 E-101-2024-0-US-01 METHODS TO IDENTIFY AND SELECTIVELY EXPAND TUMOR ANTIGEN-SPECIFIC T CELLS . PRV US 63/572,693 Expired US <br />Provisional (PRV) 63/572,693<br />Filed on 2024-04-01<br />Status: Expired 162827652 E-101-2024-0 E-101-2024-0-PC-01 METHODS TO IDENTIFY AND SELECTIVELY EXPAND TUMOR ANTIGEN-SPECIFIC T CELLS PCT Patent Cooperation Treaty PCT/US2025/022247 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/022247<br />Filed on 2025-03-31<br />Status: Pending 168850193 E-101-2024-0 E-101-2024-0-US-02 METHODS TO IDENTIFY AND SELECTIVELY EXPAND TUMOR ANTIGEN-SPECIFIC T CELLS National Stage US In Preparation US <br />National Stage None<br />Filed on None<br />Status: In Preparation 168850240 E-101-2024-0 E-101-2024-0-EP-01 METHODS TO IDENTIFY AND SELECTIVELY EXPAND TUMOR ANTIGEN-SPECIFIC T CELLS National Stage European Patent In Preparation European Patent <br />National Stage None<br />Filed on None<br />Status: In Preparation TAB-4959 153984999 Development of LEAPS Technology in Enhancing Immune Response Against Influenza Virus Infection NIAID Animal Models, Antibodies, Collaboration, Computational models/software, Diagnostics, Human Cell Lines, Immunology, Infectious Disease, Licensing, Materials Available, Rare/Neglected Diseases, Research Materials, Respiratory, Therapeutics, Vaccines Animal Models Antibodies Collaboration Computational models/software Diagnostics Human Cell Lines Immunology Infectious Disease Licensing Materials Available Rare/Neglected Diseases Research Materials Respiratory Therapeutics Vaccines Kobporn Boonnak, Kanta Subbarao, Eyal Talor <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">The Ligand Epitope Antigen Presentation System (LEAPS) represents a breakthrough in immunotherapeutic technology developed by CEL-SCI Corporation. This technology employs a novel approach to boost the immune system&#39;s response to influenza, aiming to treat, manage, or even prevent the illness. By combining LEAPS with a specific peptide from the influenza virus, and administering it intravenously in mice, there&#39;s a marked improvement in the immune system&#39;s ability to fight off the virus. The method has shown promising results, with a significant reduction in viral replication within the lungs, leading to a decrease in disease severity. This innovative treatment has potential not only as a standalone therapy but also as a complementary treatment alongside existing antiviral medications, offering new hope in the fight against influenza.</span></span></span></p> The LEAPS technology platform offers a competitive edge in the realm of immunotherapies for influenza by leveraging a distinctive dual-action mechanism. First, it directly stimulates a targeted immune response against specific viral epitopes, enhancing the body's natural ability to combat the influenza virus. Second, LEAPS has demonstrated a potential to reduce viral replication in the lungs, thereby decreasing the severity of the infection and possibly curtailing transmission. Unlike conventional vaccines, which may need annual reformulation, LEAPS's epitope-specific approach could offer broader and more durable protection. Furthermore, its synergistic application with existing antiviral drugs suggests an adjunctive benefit, potentially reducing drug resistance and improving patient outcomes. These unique advantages position LEAPS as a pioneering treatment in infectious disease management and a strong contender in the global market for influenza therapeutics. The LEAPS technology is poised to revolutionize the field of immunotherapy with its versatile applications. Primarily targeting influenza, this platform has the potential to extend beyond a single disease, offering a scaffold for developing treatments for a range of viral infections. Its mechanism of stimulating the immune system at a cellular level opens doors to customized therapies for individual strains of viruses, potentially including emerging pathogens and those resistant to current medications. In the sphere of public health, LEAPS could be instrumental in the swift creation of prophylactics during outbreaks, enhancing pandemic preparedness. Additionally, its ability to reduce viral load suggests applications in chronic viral infections where sustained viral replication is a challenge. The technology also presents an adjunctive role in enhancing the efficacy of existing antiviral drugs, thus broadening its scope to a supportive treatment strategy in infectious disease management. 2024-03-25 2026-08-26 2026-09-03 2026-08-26 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 153985012 Subbarao, Kanta NIAID - DIR NIAID Subbarao, Kanta (NIAID) 1 153985028 Boonnak, Kobporn National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Boonnak, Kobporn (NIAID) 2 153985036 Talor, Eyal Cel-Sci Corporation Talor, Eyal 3 153985012 Subbarao, Kanta NIAID - DIR NIAID Subbarao, Kanta (NIAID) 1 153985028 Boonnak, Kobporn National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Boonnak, Kobporn (NIAID) 2 153985036 Talor, Eyal Cel-Sci Corporation Talor, Eyal 3 153985004 Immune Based Treatment For Influenza E-154-2011-0 Filing authorized Cel-Sci Corporation, NIAID 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-4959] Development of LEAPS Technology in Enhancing Immune Response Against Influenza Virus Infection&body=Please send me information about technology [TAB-4959] Development of LEAPS Technology in Enhancing Immune Response Against Influenza Virus Infection. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-4959] Development of LEAPS Technology in Enhancing Immune Response Against Influenza Virus Infection&body=Please send me information about technology [TAB-4959] Development of LEAPS Technology in Enhancing Immune Response Against Influenza Virus Infection.">maryann.puglielli@nih.gov</a><br> TAB-5089 165621401 Real-time AI System for Echocardiography Analysis and Quantification NLM Cardiology, Collaboration, Diagnostics, Software / Apps Cardiology Collaboration Diagnostics Software / Apps Ghada Alzamzmi, Sameer Antani, Li-Yueh Hsu, Sivarama Krishnan Rajaraman, Vandana Sachdev <h2>Summary:</h2> <p>We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology.</p> <h2>Description of Technology:</h2> <p>Scientists have developed an artificial intelligence (AI) system to automatically extract predictive biomarkers from echocardiography. This AI system takes an echocardiography study as input and produces predictive biomarkers as output in real-time. It performs several automated image analysis tasks including echocardiography quality (quality for the acquired echo clips) assessment, echocardiography view retrieval (e.g., 2D four chamber or parasternal long axis view, Doppler), echocardiography cardiac region segmentation (e.g. inferior vena cava) and cardiac biomarker quantification (e.g. right atrial pressure). This system is:</p> <ol> <li>efficient (in terms of time and space)</li> <li>robust (can handle missing data)</li> <li>interpretable (can provide human-understandable insights)</li> </ol> <p>Such features allow its use in embedded devices for real-world clinical practice and point of care testing. This technology can be used to assist the diagnosis of a wide range of common cardiac diseases as well as to evaluate cardiac function in minority populations such as sickle cell disease patients.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Cardiologists in clinical practice, to: <ul> <li>streamline cross-functional workflows</li> <li>obtain temporal biomarkers of a full study in a single run</li> </ul> </li> <li>Cardiology researchers, to: <ul> <li>Enable systematic comparison across millions of echocardiograms</li> <li>rapidly analyze cardiac data across hospitals and research centers</li> <li>perform analysis and quantification for pattern detection, verification, and informed hypothesis testing</li> </ul> </li> <li>Perform diagnosis and assessment of wide range of cardiac diseases including coronary artery disease, heart failure, and cardiopulmonary complications in sickle cell disease patients</li> <li>Once converted into a software application, can be installed in bedside and handheld ultrasound devices to extract imaging biomarkers</li> <li>Can combine the extracted imaging biomarkers with non-imaging biomarkers (e.g., lab tests, age)</li> <li>Applicable to other clinical fields; e.g., endocrinology</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Real-time medical imaging <ul> <li>No comparable system in the market that performs a series of medical image tasks in real-time to extract predictive imaging biomarkers from different echo types and views including Doppler, M-model, and B-mode (A2C, A4C, PLAX, IVC, etc.)</li> </ul> </li> <li>Enhance efficiency and save time &ndash; hours to minutes or seconds</li> <li>Enable deeper analysis of a patient&rsquo;s condition</li> <li>Enables the streamlining of tedious clinical tasks (e.g., image analysis tasks and visual biomarkers observation), potentially saving hours of physicians&rsquo; time</li> <li>Reduced costs to payers and patients resulting from decreased physician time</li> <li>Reproducible and precise image analysis anywhere</li> <li>Enables unprecedented portability and standardized access to care &mdash; including visual analytics, predictive biomarker calculation, diagnosis, assessment, and prognosis</li> </ul> Researchers at the NLM are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. 2026-01-14 2026-02-18 2026-08-31 2026-02-18 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52406769 Prototype 52406769 NCI 37470483 Website Abstract 165622365 Zamzmia G, et al. Evaluation of An Artificial Intelligence-Based System for Echocardiographic Estimation of Right Atrial Pressure, International Journal of Cardiovascular Imaging, DOI: 10.1007/s10554-023-02941-8, September 2023. Zamzmia G, et al. Evaluation of An Artificial Intelligence-Based System for Echocardiographic Estimation of Right Atrial Pressure, International Journal of Cardiovascular Imaging, DOI: 10.1007/s10554-023-02941-8, September 2023. 165622368 Zamzmi G, et al. Real-time echocardiography image analysis and quantification of cardiac indices. Medical image analysis, 80, 102438. (2022). https://doi.org/10.1016/j.media.2022.102438 Zamzmi G, et al. Real-time echocardiography image analysis and quantification of cardiac indices. Medical image analysis, 80, 102438. (2022). https://doi.org/10.1016/j.media.2022.102438 165622371 Zamzmi G, et al. Open-world active learning for echocardiography view classification. Medical Imaging 2022: Computer-Aided Diagnosis. Vol. 12033. SPIE, 2022. DOI: https://doi.org/10.1117/12.2612578 Zamzmi G, et al. Open-world active learning for echocardiography view classification. Medical Imaging 2022: Computer-Aided Diagnosis. Vol. 12033. SPIE, 2022. DOI: https://doi.org/10.1117/12.2612578 165622504 Zamzmi G, et al. Fully automated spectral envelope and peak velocity detection from Doppler echocardiography images. Medical Imaging 2020: Computer-Aided Diagnosis. Vol. 11314G. SPIE, 2020. DOI: https://doi.org/10.1117/12.2551183 Zamzmi G, et al. Fully automated spectral envelope and peak velocity detection from Doppler echocardiography images. Medical Imaging 2020: Computer-Aided Diagnosis. Vol. 11314G. SPIE, 2020. DOI: https://doi.org/10.1117/12.2551183 166059633 Zamzmi G, Hsu LY, Li W, Sachdev V, Antani S. Echo doppler flow classification and goodness assessment with convolutional neural networks. 2019 18th IEEE International Conference On Machine Learning And Applications (ICMLA), 2019. DOI: https://doi.org/10.1109/ICMLA.2019.00283 Zamzmi G, Hsu LY, Li W, Sachdev V, Antani S. Echo doppler flow classification and goodness assessment with convolutional neural networks. 2019 18th IEEE International Conference On Machine Learning And Applications (ICMLA), 2019. DOI: https://doi.org/10.1109/ICMLA.2019.00283 165621507 Alzamzmi, Ghada NIH - NLM Alzamzmi, Ghada 1 165621532 Antani, Sameer NIH - NLM NLM Antani, Sameer (NLM) 2 165621551 Hsu, Li-Yueh NIH - CC NHLBI Hsu, Li-Yueh (NHLBI) 3 165622134 Sachdev, Vandana NIH - NHLBI NHLBI Sachdev, Vandana (NHLBI) 4 165622149 Rajaraman, Sivarama Krishnan NIH - NLM NLM Rajaraman, Sivarama Krishnan (NLM) 5 165621507 Alzamzmi, Ghada NIH - NLM Alzamzmi, Ghada 1 165621532 Antani, Sameer NIH - NLM NLM Antani, Sameer (NLM) 2 165621551 Hsu, Li-Yueh NIH - CC NHLBI Hsu, Li-Yueh (NHLBI) 3 165622134 Sachdev, Vandana NIH - NHLBI NHLBI Sachdev, Vandana (NHLBI) 4 165622149 Rajaraman, Sivarama Krishnan NIH - NLM NLM Rajaraman, Sivarama Krishnan (NLM) 5 165621416 Real-time AI System For Echocardiography Analysis And Quantification E-111-2022-0 Filing authorized Clinical Center (CC), National Heart, Lung, and Blood Institute (NHLBI), NLM 166060406 Real-time AI System For Echocardiography Analysis And Quantification E-111-2022-1 Filing authorized Clinical Center (CC), National Heart, Lung, and Blood Institute (NHLBI), NIH - NLM, NLM 166060441 Real-time AI System For Echocardiography Analysis And Quantification E-111-2022-2 Filing authorized NIH - CC, NIH - NHLBI, NIH - NLM, NLM 91828331 Beka, Lidia lidia.beka@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America lidia.beka@nih.gov?subject=Web Inquiry on [TAB-5089] Real-time AI System for Echocardiography Analysis and Quantification&body=Please send me information about technology [TAB-5089] Real-time AI System for Echocardiography Analysis and Quantification.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Beka, Lidia<br><a href="mailto:lidia.beka@nih.gov?subject=Web Inquiry on [TAB-5089] Real-time AI System for Echocardiography Analysis and Quantification&body=Please send me information about technology [TAB-5089] Real-time AI System for Echocardiography Analysis and Quantification.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">lidia.beka@nih.gov</a><br> 166060412 E-111-2022-1 E-111-2022-1-US-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM PRV US 63/458,054 Expired US <br />Provisional (PRV) 63/458,054<br />Filed on 2023-04-07<br />Status: Expired 166060445 E-111-2022-2 E-111-2022-2-PC-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM PCT COMB Patent Cooperation Treaty PCT/US2023/024902 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2023/024902<br />Filed on 2023-06-09<br />Status: Expired 166060446 E-111-2022-2 E-111-2022-2-JP-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM National Stage Japan 2024-572228 Abandoned Japan <br />National Stage 2024-572228<br />Filed on 2024-12-06<br />Status: Abandoned 166060447 E-111-2022-2 E-111-2022-2-CA-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM National Stage Canada 3258628 Abandoned Canada <br />National Stage 3258628<br />Filed on 2024-12-06<br />Status: Abandoned 166060448 E-111-2022-2 E-111-2022-2-IL-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM National Stage Israel 317482 Abandoned Israel <br />National Stage 317482<br />Filed on 2024-12-05<br />Status: Abandoned 166060450 E-111-2022-2 E-111-2022-2-CN-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM National Stage China 202380055216.5 Abandoned China <br />National Stage 202380055216.5<br />Filed on 2025-01-21<br />Status: Abandoned 166060455 E-111-2022-2 E-111-2022-2-KR-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM National Stage South Korea 10-2025-7000599 Abandoned South Korea <br />National Stage 10-2025-7000599<br />Filed on 2025-01-08<br />Status: Abandoned 166060458 E-111-2022-2 E-111-2022-2-US-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM National Stage US 18/872,402 Pending US <br />National Stage 18/872,402<br />Filed on 2024-12-06<br />Status: Pending 166060459 E-111-2022-2 E-111-2022-2-EP-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM National Stage European Patent 23738969.7 Pending European Patent <br />National Stage 23738969.7<br />Filed on 2024-12-18<br />Status: Pending TAB-4661 151854315 Novel Reassortant Mammalian Orthoreovirus Isolate for the Development of Vaccines and Diagnostic Tools CDC Diagnostics, Research Materials, Therapeutics, Vaccines Diagnostics Research Materials Therapeutics Vaccines Wenjun Ma, Suxiang (Sue) Tong, Liping Wang <p>This technology includes a novel, isolated reassortant mammalian Orthoreovirus (MRV) isolated from pigs with neurological symptoms, for use in the development of vaccines and diagnostic tests. This isolate has S1 gene from MRV1 closed to bovine isolated, M2 gene from MRV2 and other 8 genes from MRV3 based on full-genome sequence analysis. MRV3 has been reported and isolated from the US pigs with diarrhea symptom. Compared to the reported swine MRV3 isolates that cause diarrhea in pigs, the novel reassortant MRV causes neurological disease in pigs.</p> This is the first time to report that the novel reassortant MRV causes neurological disease in pigs. Development of vaccines and diagnostic tools. 2023-12-18 2026-08-26 2026-08-26 2026-08-26 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151854322 Wang, Liping Kansas State University Wang, Liping 1 151854330 Ma, Wenjun Kansas State University Ma, Wenjun 2 151854338 Tong, Suxiang (Sue) CDC - DIR CDC Tong, Suxiang (Sue) (CDC) 3 151854322 Wang, Liping Kansas State University Wang, Liping 1 151854330 Ma, Wenjun Kansas State University Ma, Wenjun 2 151854338 Tong, Suxiang (Sue) CDC - DIR CDC Tong, Suxiang (Sue) (CDC) 3 151854318 Novel Reassortant Mammalian Orthoreovirus Isolated From Pigs With Neurological Symptoms E-130-2019-0 Filing authorized Centers for Disease Control and Prevention (CDC), Kansas State University 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4661] Novel Reassortant Mammalian Orthoreovirus Isolate for the Development of Vaccines and Diagnostic Tools&body=Please send me information about technology [TAB-4661] Novel Reassortant Mammalian Orthoreovirus Isolate for the Development of Vaccines and Diagnostic Tools. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4661] Novel Reassortant Mammalian Orthoreovirus Isolate for the Development of Vaccines and Diagnostic Tools&body=Please send me information about technology [TAB-4661] Novel Reassortant Mammalian Orthoreovirus Isolate for the Development of Vaccines and Diagnostic Tools.">jonathan.motley@nih.gov</a><br> TAB-4659 151854125 Escherichia coli Isolate with MCR-1 Gene for Diagnostic Test Development CDC Diagnostics, Infectious Disease, Plasmids/Vectors, Research Materials Diagnostics Infectious Disease Plasmids/Vectors Research Materials Jean Patel <p>This technology includes Escherichia coli isolate with MCR-1 gene which can be used in the development of diagnostic tests. The MCR-1 gene makes bacteria resistant to the antibiotic colistin, which is used as a last-resort drug to treat patients with multi-drug-resistant infections, including carbapenem-resistant Enterobacteriaceae (CRE). This gene exists on a plasmid, a small piece of DNA that is capable of moving from one bacterium to another, spreading antibiotic resistance among bacterial species.</p> Novel E. coli isolate. Utilized as a control organism in a new diagnostic test. 2023-12-18 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151854132 Patel, Jean CDC - DIR CDC Patel, Jean (CDC) 1 151854132 Patel, Jean CDC - DIR CDC Patel, Jean (CDC) 1 151854128 Escherichia Coli Isolate With MCR-1 Gene E-121-2017-0 Research Material Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4659] Escherichia coli Isolate with MCR-1 Gene for Diagnostic Test Development&body=Please send me information about technology [TAB-4659] Escherichia coli Isolate with MCR-1 Gene for Diagnostic Test Development. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4659] Escherichia coli Isolate with MCR-1 Gene for Diagnostic Test Development&body=Please send me information about technology [TAB-4659] Escherichia coli Isolate with MCR-1 Gene for Diagnostic Test Development.">benjamin.hurley@nih.gov</a><br> TAB-4658 151853833 Cell Line for Adult T-cell Leukemia with Stable Co-expression of CD4 and CD8 for the Development of Therapeutics CDC Human Cell Lines, Oncology, Research Materials, Therapeutics Human Cell Lines Oncology Research Materials Therapeutics Thomas Folks, Patricia Guenthner, Thomas Hodge, Michael Lairmore, Altaf Lal, Lee Lam, Thomas Rowe <p>This technology includes a cell line of Adult T-cell Leukemia (ATL) which contains a full-length copy of the HTLV-I genome and dually expressed CD4 and CD8, which can be used for developing therapeutics against HIV and other diseases which may involve interaction with dual-positive T-cells. This cell line can also be used to study the regulation of various cellular genes by HTLV-I since it contains a single integrated copy of the virus expressing all of the viral gene products. This cell line can be used to determine the efficacy of various pharmaceutical agents and has wide potential for application.</p> Stable co-expression of CD4 and CD8 is a valuable tool for studying the function of the dual CD4/CD8 population that exists in the peripheral blood. This cellular model could prove invaluable in determining the efficacy of pharmaceutical agents against HIV and other diseases which might involve interaction with dual-positive T-cells. 2023-12-18 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151853955 Rowe T, et al. https://pubmed.ncbi.nlm.nih.gov/7564472/ <a href="https://pubmed.ncbi.nlm.nih.gov/7564472/">Rowe T, et al.</a> 151853840 Guenthner, Patricia CDC - DIR CDC Guenthner, Patricia (CDC) 1 151853848 Lal, Altaf CDC - DIR CDC Lal, Altaf (CDC) 2 151853895 Lam, Lee CDC - DIR CDC Lam, Lee (CDC) 3 151853910 Folks, Thomas Folks, Thomas 4 151853921 Lairmore, Michael University of California, Davis (UCD) Lairmore, Michael 5 151853936 Hodge, Thomas Zirus, Inc. Hodge, Thomas 6 151853947 Rowe, Thomas CDC - DIR CDC Rowe, Thomas (CDC) 7 151853840 Guenthner, Patricia CDC - DIR CDC Guenthner, Patricia (CDC) 1 151853848 Lal, Altaf CDC - DIR CDC Lal, Altaf (CDC) 2 151853895 Lam, Lee CDC - DIR CDC Lam, Lee (CDC) 3 151853910 Folks, Thomas Folks, Thomas 4 151853921 Lairmore, Michael University of California, Davis (UCD) Lairmore, Michael 5 151853936 Hodge, Thomas Zirus, Inc. Hodge, Thomas 6 151853947 Rowe, Thomas CDC - DIR CDC Rowe, Thomas (CDC) 7 151853836 DERIVED FROM A PATIENT WITH ADULT T-CELL LEUKEMIA WITH STABLE CO-EXPRESSION OF CD4 AND CD8 E-117-2020-0 Research Material Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4658] Cell Line for Adult T-cell Leukemia with Stable Co-expression of CD4 and CD8 for the Development of Therapeutics&body=Please send me information about technology [TAB-4658] Cell Line for Adult T-cell Leukemia with Stable Co-expression of CD4 and CD8 for the Development of Therapeutics. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4658] Cell Line for Adult T-cell Leukemia with Stable Co-expression of CD4 and CD8 for the Development of Therapeutics&body=Please send me information about technology [TAB-4658] Cell Line for Adult T-cell Leukemia with Stable Co-expression of CD4 and CD8 for the Development of Therapeutics.">jonathan.motley@nih.gov</a><br> TAB-4656 151853307 Application Chimeric Antibodies as Training and Quality Management Tools for Serology-based Tests CDC Antibodies, Diagnostics, Research Materials Antibodies Diagnostics Research Materials Luciana Kohatsu, Bharat Parekh <p>This technology includes a novel application of chimeric monoclonal antibodies (i.e.animal-human) as substitutes for patient /organism specimens to create standardized training (TP), proficiency testing (PT), quality control (QC), lot-to-lot validation, and new serologic test evaluation and validation panels to support the implementation of quality management systems (QMS) of serology-based tests. Although humanized and chimeric antibodies are being used for therapeutic applications, or as controls in the development of therapeutics, their application for serological laboratory or waived test&#39;s QMS has not been previously described. This is a novel approach in response to experienced difficulty on finding quality materials for production of TP, PT, and QC for HIV testing, high cost of obtaining commercially available specimens, and increased challenges finding specimens from recently infected HIV patients, as the epidemic gets under control. This new application is equally needed to assure quality of several tests, especially rapid or Point of Care (PoC) tests, while lowering the cost.</p> Allows for the bypass the challenging collection/purchase of hard-to-find and costly patient specimens while assuring continuous availability of standardized materials for TP, PT, QC, and test kit evaluation/validation, decrease transportation cost given stability/ease of room temperature transportation of lyophilized/dried purified monoclonals vs need for cold transport of human specimens. This will facilitate implementation of QMS in thousands of sites conducting tests, including Point-of-Care (PoC) and rapid test testing implementation. Panels can be developed in less than a year for hundreds of different tests. The technology can revolutionize implementation of PoC and rapid tests, with great impact on improving the quality of test results. Access to well characterized monoclonal antibodies will also allow to have a standardized panel to compare similar test kits for testing consistency and limit of detection, which was impossible to do when using human specimens. 2023-12-18 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151853350 Kohatsu, Luciana CDC - DIR CDC Kohatsu, Luciana (CDC) 1 151853358 Parekh, Bharat CDC - DIR CDC Parekh, Bharat (CDC) 2 151853350 Kohatsu, Luciana CDC - DIR CDC Kohatsu, Luciana (CDC) 1 151853358 Parekh, Bharat CDC - DIR CDC Parekh, Bharat (CDC) 2 151853310 Application Chimeric Antibodies As Training And Quality Management Tools For Serology-based Tests E-113-2020-0 Research Material Centers for Disease Control and Prevention (CDC) 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-4656] Application Chimeric Antibodies as Training and Quality Management Tools for Serology-based Tests&body=Please send me information about technology [TAB-4656] Application Chimeric Antibodies as Training and Quality Management Tools for Serology-based Tests. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-4656] Application Chimeric Antibodies as Training and Quality Management Tools for Serology-based Tests&body=Please send me information about technology [TAB-4656] Application Chimeric Antibodies as Training and Quality Management Tools for Serology-based Tests.">peter.tung@nih.gov</a><br> TAB-4655 151853146 A Dissolving Microneedle Patch for the Co-administration of Inactivated Rotavirus Vaccine (IRV) and Inactivated Polio Vaccine (IPV) CDC Infectious Disease, Research Equipment, Research Materials, Vaccines Infectious Disease Research Equipment Research Materials Vaccines Baoming Jiang, Devin McAllister, Matt Mistilis, Sung-SIl Moon <p>This technology includes a new concept to develop a bivalent IRV-IPV combination vaccine against rotavirus and polio using a dissolving microneedle patch. Specifically, we describe the formulation for IRV, the fabrication of a microneedle patch for combined IRV-IPV, and the proof of concept for assessing potential interference of immunogenicity and dose sparing in animal studies. Licensed oral rotavirus vaccines, while effective in developed and middle-income countries, are significantly less effective in reducing cases of severe diarrhea among children in developing countries. Currently, an inactivated rotavirus vaccine for intramuscular administration has been tested effective against rotavirus infection and disease in animals; studies are in progress for clinical trials in humans.</p> A microneedle patch delivery has several advantages over the current technology: simple to administer and require minimally-trained personnel; no applicator and sharps-free waste, painless administration, and thermal stability and thus potentially reducing or eliminating cold chain. A combined IRV-IPV dosage form would help improve the performance of orally administered rotavirus vaccines and sustain polio eradication efforts. Bivalent patch vaccine against polio and rotavirus. 2023-12-18 2026-08-26 2026-08-26 2026-08-26 False True True 72159138 Clinical Phase I 72159138 37470483 Website Abstract 151853163 Jiang, Baoming CDC - DIR CDC Jiang, Baoming (CDC) 1 151853167 McAllister, Devin Micron Biomedical, Inc. McAllister, Devin 2 151853180 Mistilis, Matt Janssen Research & Development, LLC Mistilis, Matt 3 151853188 Moon, Sung-SIl CDC - DIR CDC Moon, Sung-SIl (CDC) 4 151853163 Jiang, Baoming CDC - DIR CDC Jiang, Baoming (CDC) 1 151853167 McAllister, Devin Micron Biomedical, Inc. McAllister, Devin 2 151853180 Mistilis, Matt Janssen Research & Development, LLC Mistilis, Matt 3 151853188 Moon, Sung-SIl CDC - DIR CDC Moon, Sung-SIl (CDC) 4 151853149 A Dissolving Microneedle Patch To Co-administer Inactivated Rotavirus Vaccine (IRV) And Inactivated Polio Vaccine (IPV) E-108-2018-0 Closed Centers for Disease Control and Prevention (CDC), Janssen Research & Development, LLC, Micron Biomedical, Inc. 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4655] A Dissolving Microneedle Patch for the Co-administration of Inactivated Rotavirus Vaccine (IRV) and Inactivated Polio Vaccine (IPV)&body=Please send me information about technology [TAB-4655] A Dissolving Microneedle Patch for the Co-administration of Inactivated Rotavirus Vaccine (IRV) and Inactivated Polio Vaccine (IPV). Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4655] A Dissolving Microneedle Patch for the Co-administration of Inactivated Rotavirus Vaccine (IRV) and Inactivated Polio Vaccine (IPV)&body=Please send me information about technology [TAB-4655] A Dissolving Microneedle Patch for the Co-administration of Inactivated Rotavirus Vaccine (IRV) and Inactivated Polio Vaccine (IPV).">jonathan.motley@nih.gov</a><br> TAB-4651 151851742 Mycoplasma-free Pitman-Moore (PM) Strain Rabies Virus Stocks for Vaccine Manufacturing CDC Infectious Disease, Research Materials, Vaccines Infectious Disease Research Materials Vaccines Victoria Olson, Xianfu Wu, Yong Yang <p>This technology includes clean, mycoplasma-free, rabies virus stocks for use in vaccine manufacturing. Rabies virus causes a nearly uniformly fatal disease, but can be prevented by timely vaccination. An inactivated rabies vaccine for human use was first prepared in cell culture in 1964, using the Pitman-Moore (PM) strain of fixed rabies virus. Typical rabies vaccine virus stocks stored at the Centers for Disease Control are heavily contaminated by mycoplasma, there this stock provides an alternative supply which is free of mycoplasma. </p> Mycoplasma contamination is a challenge for the vaccine industry. Utilized for vaccine manufacturing. 2023-12-18 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151852029 Yang, Yong CDC - DIR CDC Yang, Yong (CDC) 2 151852066 Olson, Victoria CDC - DIR CDC Olson, Victoria (CDC) 3 151852073 Wu, Xianfu CDC - DIR CDC Wu, Xianfu (CDC) 4 151852029 Yang, Yong CDC - DIR CDC Yang, Yong (CDC) 2 151852066 Olson, Victoria CDC - DIR CDC Olson, Victoria (CDC) 3 151852073 Wu, Xianfu CDC - DIR CDC Wu, Xianfu (CDC) 4 151851745 Mycoplasma Free PM Virus Stocks E-099-2018-0 Research Material Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4651] Mycoplasma-free Pitman-Moore (PM) Strain Rabies Virus Stocks for Vaccine Manufacturing&body=Please send me information about technology [TAB-4651] Mycoplasma-free Pitman-Moore (PM) Strain Rabies Virus Stocks for Vaccine Manufacturing. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4651] Mycoplasma-free Pitman-Moore (PM) Strain Rabies Virus Stocks for Vaccine Manufacturing&body=Please send me information about technology [TAB-4651] Mycoplasma-free Pitman-Moore (PM) Strain Rabies Virus Stocks for Vaccine Manufacturing.">benjamin.hurley@nih.gov</a><br> TAB-4650 151851193 Hearing Protection Attenuation and Fit Using a Neural Network CDC Computational models/software, Consumer Products, Occupational Safety and Health, Research Equipment, Software / Apps Computational models/software Consumer Products Occupational Safety and Health Research Equipment Software / Apps Gregory Ciccarelli, William Murphy, Christopher Smalt <p>This technology includes systems and methods which allow for a determination of the attenuation and fit of a hearing protection device based on images of a user&rsquo;s ear. This technology can be used in a wide range of industrial and military settings including but not limited to factories, construction sites, mines, mills, airports, railroads, and military combat training environments. A photograph of a person&rsquo;s ears wearing hearing protection devices can be used to estimate whether or not that person is achieving sufficient or adequate attenuation to protect their ears against harmful noise exposure. Earplug manufacturers could provide the test attenuation data from their laboratory tests along with paired photographs of the subjects and the fitting estimation algorithm can be trained for new products.</p> The methods provide immediate feedback about the users’ ear protection, would not require any specialized acoustic testing space or equipment beyond a camera and the software to perform the analysis, and could be developed to extend across all earplug designs. The product could be as simple as a software application for a mobile device where the user photographs their earplugs in each ear and the software estimates the attenuation that the user has achieved. A second more commercialized product would be a dedicated system or technology that can monitor workers’ hearing protector use from a series of video images. 2023-12-18 2026-08-26 2026-08-26 2026-08-26 False True True 52406769 Prototype 52406769 37470483 Website Abstract 151851292 Smalt, Christopher Lincoln Laboratory, Massachusetts Institute of Technology Smalt, Christopher 1 151851300 Ciccarelli, Gregory Ciccarelli, Gregory 2 151851308 Murphy, William CDC - NIOSH CDC Murphy, William (CDC) 3 151851292 Smalt, Christopher Lincoln Laboratory, Massachusetts Institute of Technology Smalt, Christopher 1 151851300 Ciccarelli, Gregory Ciccarelli, Gregory 2 151851308 Murphy, William CDC - NIOSH CDC Murphy, William (CDC) 3 151851196 Hearing Protection Attenuation And Fit Using A Neural Network E-098-2020-0 Closed Centers for Disease Control and Prevention (CDC), Lincoln Laboratory, Massachusetts Institute of Technology 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4650] Hearing Protection Attenuation and Fit Using a Neural Network&body=Please send me information about technology [TAB-4650] Hearing Protection Attenuation and Fit Using a Neural Network. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4650] Hearing Protection Attenuation and Fit Using a Neural Network&body=Please send me information about technology [TAB-4650] Hearing Protection Attenuation and Fit Using a Neural Network.">yogikala.prabhu@nih.gov</a><br> TAB-4649 151850981 Engineering Noise Controls for a Longwall Cutting Drum Used in Underground Coal Mining CDC Consumer Products, Occupational Safety and Health, Research Equipment Consumer Products Occupational Safety and Health Research Equipment Hugo Camargo, Joseph Defibaugh, Junyi Yang <p>This technology includes a set of noise controls in the form of structural modifications to the cutting drums used in underground coal mining. Longwall shearer operators are exposed to high levels of noise, i.e., above 98 dB(A), which are clearly well above the permissible exposure level of 90 dB(A). In an effort to reduce this noise exposure, research was conducted that identified the longwall cutting drums as the most significant sound radiating components. The developed noise controls will reduce the sound radiated by the longwall cutting drums, and thus will reduce the noise exposure of the longwall operators.</p> The developed noise controls consist of structural modifications of the cutting drum that do not compromise any of the drum’s three critical features which are: 1) its structural integrity, 2) its loading ability and 3) its cutting performance. Utilized for the reduction of noise in underground coal mining. 2023-12-18 2026-08-26 2026-08-26 2026-08-26 False True True 52406769 Prototype 52406769 37470483 Website Abstract 151851117 Pettitt M, et al. https://ntrl.ntis.gov/NTRL/dashboard/searchResults/titleDetail/PB87102257.xhtml <a href="https://ntrl.ntis.gov/NTRL/dashboard/searchResults/titleDetail/PB87102257.xhtml">Pettitt M, et al.</a> 151850988 Defibaugh, Joseph JOY GLOBAL Defibaugh, Joseph 1 151850996 Yang, Junyi CDC - NIOSH CDC Yang, Junyi (CDC) 2 151851003 Camargo, Hugo CDC - NIOSH CDC Camargo, Hugo (CDC) 3 151850988 Defibaugh, Joseph JOY GLOBAL Defibaugh, Joseph 1 151850996 Yang, Junyi CDC - NIOSH CDC Yang, Junyi (CDC) 2 151851003 Camargo, Hugo CDC - NIOSH CDC Camargo, Hugo (CDC) 3 151850984 Engineering Noise Controls For A Longwall Cutting Drum Used In Underground Coal Mining. E-094-2015-0 Filing authorized Centers for Disease Control and Prevention (CDC), JOY GLOBAL 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4649] Engineering Noise Controls for a Longwall Cutting Drum Used in Underground Coal Mining&body=Please send me information about technology [TAB-4649] Engineering Noise Controls for a Longwall Cutting Drum Used in Underground Coal Mining. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4649] Engineering Noise Controls for a Longwall Cutting Drum Used in Underground Coal Mining&body=Please send me information about technology [TAB-4649] Engineering Noise Controls for a Longwall Cutting Drum Used in Underground Coal Mining.">yogikala.prabhu@nih.gov</a><br> TAB-4648 151850663 A Murine IgG1 Monoclonal Antibody with Specificity for Chaetomium globosum Enolase for the Development of Immunoassay Platforms CDC Antibodies, Diagnostics, Research Materials Antibodies Diagnostics Research Materials Donald Beezhold, Brett Green, Angela Lemons, Ajay Nayak <p>This technology includes a murine IgG1 monoclonal antibody (mAb), 1C7, for the detection of Chaetomium globosum. The development of mAb-based detection methods may provide a standardized approach to quantify the target organism(s) using rapid immunoassay platforms. To date, mAbs are not available for Chaetomium species. C. globosum enolase was selected as a candidate biomarker for the detection of this species due to its presence within the cytosol and cell wall. C. globosum enolase was cloned and a recombinant expressed in Escherichia coli for the production of mAbs. The production of enolase mAb 1C7 may have unique application for the detection of this cellulolytic fungal species as well as other closely related Chaetomium species in the built environment.</p> This mAb, 1C7, is specific for a highly conserved enolase epitope that is restricted within the fungal class Sordariomycetes. In addition to reacting with C. globosum and C. atrobrunneum, mAb 1C7 may additionally react with other closely related species within the fungal orders, Sordariales and Hypocreales. Currently, there are no mAbs that have been developed for this fungal species. Products that could be developed include commercial sandwich ELISAs or lateral flow assays; however, preliminary characterization studies demonstrated best application with western blotting methodologies. This mAb may also have research applications for the detection of enolase derived from fungi placed in the class, Sordariomycetes. 2023-12-18 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151850706 Provost N, et al. https://pubmed.ncbi.nlm.nih.gov/22985087/ <a href="https://pubmed.ncbi.nlm.nih.gov/22985087/">Provost N, et al.</a> 151850670 Green, Brett CDC - NIOSH CDC Green, Brett (CDC) 1 151850682 Nayak, Ajay CDC - NIOSH CDC Nayak, Ajay (CDC) 2 151850690 Beezhold, Donald CDC - NIOSH CDC Beezhold, Donald (CDC) 3 151850698 Lemons, Angela CDC - NIOSH CDC Lemons, Angela (CDC) 4 151850670 Green, Brett CDC - NIOSH CDC Green, Brett (CDC) 1 151850682 Nayak, Ajay CDC - NIOSH CDC Nayak, Ajay (CDC) 2 151850690 Beezhold, Donald CDC - NIOSH CDC Beezhold, Donald (CDC) 3 151850698 Lemons, Angela CDC - NIOSH CDC Lemons, Angela (CDC) 4 151850666 A Murine IgG1 Monoclonal Antibody With Specificity For Chaetomium Globosum Enolase E-093-2015-0 Research Material Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4648] A Murine IgG1 Monoclonal Antibody with Specificity for Chaetomium globosum Enolase for the Development of Immunoassay Platforms&body=Please send me information about technology [TAB-4648] A Murine IgG1 Monoclonal Antibody with Specificity for Chaetomium globosum Enolase for the Development of Immunoassay Platforms. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4648] A Murine IgG1 Monoclonal Antibody with Specificity for Chaetomium globosum Enolase for the Development of Immunoassay Platforms&body=Please send me information about technology [TAB-4648] A Murine IgG1 Monoclonal Antibody with Specificity for Chaetomium globosum Enolase for the Development of Immunoassay Platforms.">yogikala.prabhu@nih.gov</a><br> TAB-4647 151850452 Dengue Virus Type 2 Isolates for Development of Diagnostics, Antivirals, and Vaccinations CDC Infectious Disease, Research Materials, Vaccines Infectious Disease Research Materials Vaccines Jorge Munoz-Jordan, Martin Schriefer <p>This technology includes isolates of the Dengue Virus (type 2) which can be used to develop diagnostic tests, antivirals and vaccinations. These isolates are from Puerto Rico DENV-2 and have complete whole genome sequencing completed. Additionally, these isolates represent current stains of Dengue Virus which are circulating in the Caribbean.</p> Representative of current strains circulating among the population. Isolates can be used to development diagnostic tests, vaccinations, and antiviral therapies for Dengue Virus. 2023-12-18 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151850496 McElroy K, et al. https://pubmed.ncbi.nlm.nih.gov/21192856/ <a href="https://pubmed.ncbi.nlm.nih.gov/21192856/">McElroy K, et al.</a> 151850462 Munoz-Jordan, Jorge CDC - DIR CDC Munoz-Jordan, Jorge (CDC) 1 151850477 Schriefer, Martin CDC - DIR CDC Schriefer, Martin (CDC) 2 151850462 Munoz-Jordan, Jorge CDC - DIR CDC Munoz-Jordan, Jorge (CDC) 1 151850477 Schriefer, Martin CDC - DIR CDC Schriefer, Martin (CDC) 2 151850455 Dengue Virus Type 2 and 3 Isolates E-092-2017-0 Research Material Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4647] Dengue Virus Type 2 Isolates for Development of Diagnostics, Antivirals, and Vaccinations&body=Please send me information about technology [TAB-4647] Dengue Virus Type 2 Isolates for Development of Diagnostics, Antivirals, and Vaccinations. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4647] Dengue Virus Type 2 Isolates for Development of Diagnostics, Antivirals, and Vaccinations&body=Please send me information about technology [TAB-4647] Dengue Virus Type 2 Isolates for Development of Diagnostics, Antivirals, and Vaccinations.">benjamin.hurley@nih.gov</a><br> TAB-4646 151850131 Yellow Fever Virus, Zika Virus, and Powassan Virus Isolates for Research, Diagnostic and Vaccine Development CDC Collaboration, Diagnostics, Human Cell Lines, Immunology, Infectious Disease, Licensing, Plasmids/Vectors, Research Materials, Vaccines Collaboration Diagnostics Human Cell Lines Immunology Infectious Disease Licensing Plasmids/Vectors Research Materials Vaccines Barbara Johnson, Brandy Russell <p>This technology includes natural Yellow Fever Virus, Zika Virus, and Powassan Virus isolates for various uses in research and development of diagnostics and immunizations.</p> These are natural isolates with potential for wide application. Research, diagnostic, and vaccine development against these viruses. 2023-12-18 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151850150 Johnson, Barbara CDC - DIR CDC Johnson, Barbara (CDC) 1 151850172 Russell, Brandy Centers for Disease Control and Prevention (CDC) Russell, Brandy 2 151850150 Johnson, Barbara CDC - DIR CDC Johnson, Barbara (CDC) 1 151850172 Russell, Brandy Centers for Disease Control and Prevention (CDC) Russell, Brandy 2 151850142 Yellow Fever Virus, Zika Virus, And Powassan Virus Isolates E-092-2016-0 Research Material Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4646] Yellow Fever Virus, Zika Virus, and Powassan Virus Isolates for Research, Diagnostic and Vaccine Development&body=Please send me information about technology [TAB-4646] Yellow Fever Virus, Zika Virus, and Powassan Virus Isolates for Research, Diagnostic and Vaccine Development. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4646] Yellow Fever Virus, Zika Virus, and Powassan Virus Isolates for Research, Diagnostic and Vaccine Development&body=Please send me information about technology [TAB-4646] Yellow Fever Virus, Zika Virus, and Powassan Virus Isolates for Research, Diagnostic and Vaccine Development.">benjamin.hurley@nih.gov</a><br> TAB-4645 151850060 Borrelia hermsii Isolate for Diagnostic Development CDC Diagnostics, Infectious Disease, Research Materials Diagnostics Infectious Disease Research Materials Martin Schriefer <p>This technology includes Borrelia hermsii isolate for diagnostic development of serologic tests. Borrelia hermsii is the major identified cause of Tick-Borne Relapsing Fever (TBRF) in humans in the western United States. Initial signs and symptoms of infection include fever, nausea, headache and malaise. Most cases are diagnosed on clinical suspicion and epidemiologic risk. Common source, case clusters notable. Microscopy and serologic detection of antibody responses to infection may aid in the laboratory confirmation or infection. Culture recovery of the infectious agent is not often attempted.</p> Develop serologic tests for detection of antibody responses to infection. Development of assays to aid in laboratory support of TBRF clinical diagnosis. 2023-12-18 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151850067 Schriefer, Martin CDC - DIR CDC Schriefer, Martin (CDC) 1 151850067 Schriefer, Martin CDC - DIR CDC Schriefer, Martin (CDC) 1 151850063 Borrelia Hermsii Isolate For Diagnostic Development E-087-2017-0 Research Material Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4645] Borrelia hermsii Isolate for Diagnostic Development&body=Please send me information about technology [TAB-4645] Borrelia hermsii Isolate for Diagnostic Development. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4645] Borrelia hermsii Isolate for Diagnostic Development&body=Please send me information about technology [TAB-4645] Borrelia hermsii Isolate for Diagnostic Development.">benjamin.hurley@nih.gov</a><br> TAB-4644 151849670 A Combined IRV and IPV for the Prevention of Diarrhea and Poliomyelitis in Children CDC Infectious Disease, Research Equipment, Vaccines Infectious Disease Research Equipment Vaccines Roger Glass, Baoming Jiang, Ravindra Kadam, Abhijeet Kamble, Sambhaji Pisal, Rajendra Sabale, Jagdish Zade <p>This technology includes a combined IPV and IRV for co-administration and global immunization against polio and rotavirus among children. Currently IPV and IRV are administered by parenteral administration in two separate injections, which complicates routine immunization schedules and is costly.</p> This discovery describes the co-administration of a combined IPV and IRV in a single shot, thus simplifies immunization schedules and saves administration cost. Vaccine for the immunization against polio and rotavirus in children. 2023-12-18 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151849909 Pisal, Sambhaji Serum Institute of India PVT. LTD. Pisal, Sambhaji 1 151849923 Zade, Jagdish Zade, Jagdish 2 151849927 Sabale, Rajendra Sabale, Rajendra 3 151849937 Kadam, Ravindra Serum Institute of India PVT. LTD. Kadam, Ravindra 4 151849943 Kamble, Abhijeet Serum Institute of India PVT. LTD. Kamble, Abhijeet 5 151849954 Jiang, Baoming CDC Jiang, Baoming (CDC) 6 151849962 Glass, Roger CDC - DIR CDC Glass, Roger (CDC) 7 151849909 Pisal, Sambhaji Serum Institute of India PVT. LTD. Pisal, Sambhaji 1 151849923 Zade, Jagdish Zade, Jagdish 2 151849927 Sabale, Rajendra Sabale, Rajendra 3 151849937 Kadam, Ravindra Serum Institute of India PVT. LTD. Kadam, Ravindra 4 151849943 Kamble, Abhijeet Serum Institute of India PVT. LTD. Kamble, Abhijeet 5 151849954 Jiang, Baoming CDC Jiang, Baoming (CDC) 6 151849962 Glass, Roger CDC - DIR CDC Glass, Roger (CDC) 7 151849673 A Combined IRV And IPV For The Co-administration To Prevent Diarrhea And Poliomyelitis In Children E-079-2017-0 Filing authorized Centers for Disease Control and Prevention (CDC), Serum Institute of India PVT. LTD. 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4644] A Combined IRV and IPV for the Prevention of Diarrhea and Poliomyelitis in Children&body=Please send me information about technology [TAB-4644] A Combined IRV and IPV for the Prevention of Diarrhea and Poliomyelitis in Children. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4644] A Combined IRV and IPV for the Prevention of Diarrhea and Poliomyelitis in Children&body=Please send me information about technology [TAB-4644] A Combined IRV and IPV for the Prevention of Diarrhea and Poliomyelitis in Children.">jonathan.motley@nih.gov</a><br> TAB-4643 151849384 Novel Human Rotavirus Vaccine Strains and Diagnostics CDC Infectious Disease, Research Materials, Vaccines Infectious Disease Research Materials Vaccines Baoming Jiang <p>This technology includes a vaccine for immunizing against different strains of rotavirus. Rotavirus is a highly contagious virus causing severe diarrhea in children and can be fatal. Due to various circumstances, the number of available, efficacious vaccines for rotavirus is declining at a time when infections remain a serious worldwide problem. This technology meets the need for vaccines against human rotavirus A strains of both common and less common types.</p> Provides immunity against several strains of the virus. Vaccine against rotavirus. 2023-12-18 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151849534 Jiang, Baoming CDC - DIR CDC Jiang, Baoming (CDC) 1 151849534 Jiang, Baoming CDC - DIR CDC Jiang, Baoming (CDC) 1 151849387 Development And Application Of A New EIA For The Detection Of Group A Rotavirus And Comparison With Two Commercial EIA Kits E-079-2014-0 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4643] Novel Human Rotavirus Vaccine Strains and Diagnostics&body=Please send me information about technology [TAB-4643] Novel Human Rotavirus Vaccine Strains and Diagnostics. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4643] Novel Human Rotavirus Vaccine Strains and Diagnostics&body=Please send me information about technology [TAB-4643] Novel Human Rotavirus Vaccine Strains and Diagnostics.">jonathan.motley@nih.gov</a><br> TAB-4642 151836095 Candida auris Isolate (B11903) for Diagnostic and Therapeutic Development CDC Collaboration, Computational models/software, Diagnostics, Human Cell Lines, Immunology, Infectious Disease, Licensing, Materials Available, Plasmids/Vectors, Research Materials, Therapeutics Collaboration Computational models/software Diagnostics Human Cell Lines Immunology Infectious Disease Licensing Materials Available Plasmids/Vectors Research Materials Therapeutics Shawn Lockhart <p>This technology includes an isolate of the yeast species Candida auris to be used in the development of diagnostic tools or anti-fungal for therapeutic use.</p> Candida auris is an emerging fungus that presents a serious global health threat. Antimicrobial susceptibility testing and microbial identification. 2023-12-15 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151836219 Lockhart, Shawn CDC - DIR CDC Lockhart, Shawn (CDC) 1 151836219 Lockhart, Shawn CDC - DIR CDC Lockhart, Shawn (CDC) 1 151836098 Candida Auris Isolate B11903 E-078-2017-0 Research Material Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4642] Candida auris Isolate (B11903) for Diagnostic and Therapeutic Development&body=Please send me information about technology [TAB-4642] Candida auris Isolate (B11903) for Diagnostic and Therapeutic Development. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4642] Candida auris Isolate (B11903) for Diagnostic and Therapeutic Development&body=Please send me information about technology [TAB-4642] Candida auris Isolate (B11903) for Diagnostic and Therapeutic Development.">benjamin.hurley@nih.gov</a><br> TAB-4640 151836012 Escherichia coli Isolate for Research and Diagnostic Development CDC Collaboration, Diagnostics, Human Cell Lines, Immunology, Infectious Disease, Licensing, Materials Available, Plasmids/Vectors, Research Materials Collaboration Diagnostics Human Cell Lines Immunology Infectious Disease Licensing Materials Available Plasmids/Vectors Research Materials <p>This technology includes an Escherichia coli isolate to be used in for research purposes and the development of diagnostics. The isolate is unique because it has the mcr-1 gene.</p> Escherichia coli with mcr-1 gene. The isolate can be used for research and development of new diagnostic tools. 2023-12-15 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151836015 Escherichia Coli E-071-2019-0 Research Material Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4640] Escherichia coli Isolate for Research and Diagnostic Development&body=Please send me information about technology [TAB-4640] Escherichia coli Isolate for Research and Diagnostic Development. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4640] Escherichia coli Isolate for Research and Diagnostic Development&body=Please send me information about technology [TAB-4640] Escherichia coli Isolate for Research and Diagnostic Development.">benjamin.hurley@nih.gov</a><br> TAB-4639 151835872 Klebsiella pneumoniae Isolate for Research and Diagnostic Development CDC Collaboration, Computational models/software, Diagnostics, Human Cell Lines, Immunology, Infectious Disease, Licensing, Materials Available, Non-Medical Devices, Oncology, Research Materials Collaboration Computational models/software Diagnostics Human Cell Lines Immunology Infectious Disease Licensing Materials Available Non-Medical Devices Oncology Research Materials James Rasheed <p>This technology includes Klebsiella pneumoniae isolate to be used for research studies and diagnostic tests to detect antimicrobial resistance.</p> This isolate has a characterized antimicrobial susceptibility profile and determined whole genome sequence. The isolate can be used for research and development of new diagnostic tests to detect antimicrobial resistance. 2023-12-15 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 151835879 Rasheed, James CDC - DIR CDC Rasheed, James (CDC) 1 151835879 Rasheed, James CDC - DIR CDC Rasheed, James (CDC) 1 151835875 CDC Antibiotic Resistant (AR) Bank Isolates (see Available Materials For List Of Isolates) E-069-2021-0 Research Material Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4639] Klebsiella pneumoniae Isolate for Research and Diagnostic Development&body=Please send me information about technology [TAB-4639] Klebsiella pneumoniae Isolate for Research and Diagnostic Development. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4639] Klebsiella pneumoniae Isolate for Research and Diagnostic Development&body=Please send me information about technology [TAB-4639] Klebsiella pneumoniae Isolate for Research and Diagnostic Development.">benjamin.hurley@nih.gov</a><br> TAB-4637 151835494 Unique HIV Clone Types and Subtypes CDC Diagnostics, Infectious Disease, Research Equipment, Research Materials Diagnostics Infectious Disease Research Equipment Research Materials Dennis Ellenberger <p>This technology includes HIV clones to develop proteomic microarrays for HIV research. The microarray chip can be used to monitor the antibody response to all proteins and many epitopes of HIV-1.</p> Unique HIV type and subtype. Development of a protein microarray. 2023-12-15 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151835501 Ellenberger, Dennis CDC - DIR CDC Ellenberger, Dennis (CDC) 1 151835501 Ellenberger, Dennis CDC - DIR CDC Ellenberger, Dennis (CDC) 1 151835497 HIV Clones From The NIH AIDS Reagent Repository E-067-2015-0 Research Material Centers for Disease Control and Prevention (CDC) 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-4637] Unique HIV Clone Types and Subtypes&body=Please send me information about technology [TAB-4637] Unique HIV Clone Types and Subtypes. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-4637] Unique HIV Clone Types and Subtypes&body=Please send me information about technology [TAB-4637] Unique HIV Clone Types and Subtypes.">peter.tung@nih.gov</a><br> TAB-4636 151835302 Combination Dosing Regimens for the Prevention of HIV CDC Infectious Disease, Research Materials, Therapeutics Infectious Disease Research Materials Therapeutics Jose Garcia Lerma, Richard Haaland, Walid Heneine, Ivana Massud <p>This technology includes combinations of currently approved antiretrovirals (ARVs) which could allow for simpler dosing regimens that improve adherence to HIV prevention strategies. Event-Driven PrEP (ED-PrEP) with 2 oral doses of tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) taken 2-24 hours before sex, a 3rd dose 24 hours after sex, and a 4th dose 48 hours after sex (2+1+1) is considered as a PrEP option by the World Health Organization for men who have sex with men (MSM). Recommended post-exposure prophylaxis (PEP) regimens require 28 days of daily oral dosing. Simpler ED-PrEP and PEP dosing strategies with ARV combinations allowing for one or two doses that effectively reduce risk of infection could provide alternatives conducive to improved adherence. Rapid penetration of elvitegravir and darunavir in rectal tissues could prevent initial rounds of virus replication in mucosal tissues exposed to HIV and persistence of tenofovir diphosphate and emtricitabine triphosphate in rectal tissues may prevent dissemination of virus from sites of virus exposure.</p> Combinations of currently approved ARVs could allow for simpler ED-PrEP or PEP dosing regimens that improve adherence to HIV prevention strategies. ARV regimens for the prevention of HIV. 2023-12-15 2026-08-26 2026-08-26 2026-08-26 False True True 72159140 Clinical Phase II 72159140 37470483 Website Abstract 151835422 Haaland R, et al. https://pubmed.ncbi.nlm.nih.gov/36512383/ <a href="https://pubmed.ncbi.nlm.nih.gov/36512383/">Haaland R, et al.</a> 151835318 Haaland, Richard CDC - DIR CDC Haaland, Richard (CDC) 1 151835323 Massud, Ivana CDC - DIR CDC Massud, Ivana (CDC) 2 151835327 Heneine, Walid CDC - DIR CDC Heneine, Walid (CDC) 3 151835418 Garcia Lerma, Jose CDC - DIR CDC Garcia Lerma, Jose (CDC) 4 151835318 Haaland, Richard CDC - DIR CDC Haaland, Richard (CDC) 1 151835323 Massud, Ivana CDC - DIR CDC Massud, Ivana (CDC) 2 151835327 Heneine, Walid CDC - DIR CDC Heneine, Walid (CDC) 3 151835418 Garcia Lerma, Jose CDC - DIR CDC Garcia Lerma, Jose (CDC) 4 151835305 Pharmacology Of Potential Event-driven Dosing Regimens For HIV Prevention Among Men Who Have Sex With Men E-060-2020-0 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4636] Combination Dosing Regimens for the Prevention of HIV&body=Please send me information about technology [TAB-4636] Combination Dosing Regimens for the Prevention of HIV. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4636] Combination Dosing Regimens for the Prevention of HIV&body=Please send me information about technology [TAB-4636] Combination Dosing Regimens for the Prevention of HIV.">jonathan.motley@nih.gov</a><br> TAB-4635 151835170 Virus isolation of the Florida strain of MERS-CoV for Anti-viral Research, Diagnostic and Vaccine Development CDC Infectious Disease, Research Materials Infectious Disease Research Materials Dean Erdman, Azaibi Tamin, Suxiang (Sue) Tong <p>This technology includes isolate of Middle East respiratory syndrome coronavirus (MERS-CoV) for antiviral and diagnostic development. The isolate was confirmed by full genome sequencing and further characterized by serologic and molecular testing and electron-microscopical studies. This is the first MERS-CoV strain isolated from a US imported case of MERS. The isolation of this virus underscores the importance of combing classic techniques such as virus isolation and electron microscopy and molecular techniques, such as real-time PCR and full genome sequencing, in identifying etiologic pathogens.</p> Multiple potential options for utilization, and is the first MERS-CoV strain isolated from a US imported case of MERS. Valuable reagent for vaccine, diagnostic and anti-viral research and development. 2023-12-15 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151835226 Tamin, Azaibi CDC - DIR CDC Tamin, Azaibi (CDC) 1 151835234 Erdman, Dean CDC - DIR CDC Erdman, Dean (CDC) 2 151835238 Tong, Suxiang (Sue) CDC - DIR CDC Tong, Suxiang (Sue) (CDC) 3 151835226 Tamin, Azaibi CDC - DIR CDC Tamin, Azaibi (CDC) 1 151835234 Erdman, Dean CDC - DIR CDC Erdman, Dean (CDC) 2 151835238 Tong, Suxiang (Sue) CDC - DIR CDC Tong, Suxiang (Sue) (CDC) 3 151835222 Virus Isolation Of The Florida Strain Of MERS-CoV ( Middle East Respiratory Syndrome Coronavirus Isolate Florida/USA-2_Saudi Arabia_2014) E-058-2016-0 Research Material Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4635] Virus isolation of the Florida strain of MERS-CoV for Anti-viral Research, Diagnostic and Vaccine Development&body=Please send me information about technology [TAB-4635] Virus isolation of the Florida strain of MERS-CoV for Anti-viral Research, Diagnostic and Vaccine Development. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4635] Virus isolation of the Florida strain of MERS-CoV for Anti-viral Research, Diagnostic and Vaccine Development&body=Please send me information about technology [TAB-4635] Virus isolation of the Florida strain of MERS-CoV for Anti-viral Research, Diagnostic and Vaccine Development.">jonathan.motley@nih.gov</a><br> TAB-4633 151834687 Real-Time RT-PCR Diagnostic Panel Assay for Universal Detection and Characterization of Asian Lineage Highly-Pathogenic Influenza Viruses A/H5 Subtype CDC Diagnostics, Infectious Disease, Research Equipment, Research Materials Diagnostics Infectious Disease Research Equipment Research Materials LaShondra Berman, Stephen Lindstrom, Ji Liu, Bo Shu, Christine Warnes, Kai-Hui Wu <p>This technology includes an optimized influenza A/H5 subtyping real-time RT-PCR assay for detection and characterization of Asian lineage A/H5N1 viruses. The highly pathogenic avian influenza (HPAI) A/H5N1 viruses, first isolated in human in 1997, have spread among birds over seventy countries on three continents. In 2014 a novel reassortant HPAI A/H5N8 virus has been detected in poultry in Asia, Europe, As well as Canada and USA. In addition, genetic reassortment of this virus with circulating avian influenza viruses has resulted in the novel viral combinations. Due to the newly emerging novel reasserted A/H5Nx viruses detected in the USA, the assay, has been further updated and optimized by including extra primers and probe into the assay.</p> Assay allows for universal detection and characterization of Asian lineage highly pathogenic influenza viruses A/H5 subtype with high sensitivity and specificity. May be licensed to commercial entities to manufacture and sell commercial reagents to research and clinical laboratories. 2023-12-15 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151834728 Shu, Bo CDC - DIR CDC Shu, Bo (CDC) 2 151834737 Lindstrom, Stephen CDC - DIR CDC Lindstrom, Stephen (CDC) 3 151834741 Wu, Kai-Hui CDC - DIR CDC Wu, Kai-Hui (CDC) 4 151834750 Warnes, Christine CDC Warnes, Christine (CDC) 5 151834890 Berman, LaShondra CDC - DIR CDC Berman, LaShondra (CDC) 6 151834914 Liu, Ji CDC - DIR CDC Liu, Ji (CDC) 7 151834728 Shu, Bo CDC - DIR CDC Shu, Bo (CDC) 2 151834737 Lindstrom, Stephen CDC - DIR CDC Lindstrom, Stephen (CDC) 3 151834741 Wu, Kai-Hui CDC - DIR CDC Wu, Kai-Hui (CDC) 4 151834750 Warnes, Christine CDC Warnes, Christine (CDC) 5 151834890 Berman, LaShondra CDC - DIR CDC Berman, LaShondra (CDC) 6 151834914 Liu, Ji CDC - DIR CDC Liu, Ji (CDC) 7 151834696 The CDC Human Influenza Real-Time RT-PCR Diagnostic Panel Influenza A/H5 Subtyping Assay For Universal Detection And Characterization Of Asian Lineage Highly Pathogenic Influenza Viruses A/H5 Subtype E-049-2017-0 Research Material Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4633] Real-Time RT-PCR Diagnostic Panel Assay for Universal Detection and Characterization of Asian Lineage Highly-Pathogenic Influenza Viruses A/H5 Subtype&body=Please send me information about technology [TAB-4633] Real-Time RT-PCR Diagnostic Panel Assay for Universal Detection and Characterization of Asian Lineage Highly-Pathogenic Influenza Viruses A/H5 Subtype. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4633] Real-Time RT-PCR Diagnostic Panel Assay for Universal Detection and Characterization of Asian Lineage Highly-Pathogenic Influenza Viruses A/H5 Subtype&body=Please send me information about technology [TAB-4633] Real-Time RT-PCR Diagnostic Panel Assay for Universal Detection and Characterization of Asian Lineage Highly-Pathogenic Influenza Viruses A/H5 Subtype.">jonathan.motley@nih.gov</a><br> TAB-4632 151834447 Real-time RT-PCR Assay for Detection and Characterization of North American Lineage of A/H7 Influenza Viruses CDC Infectious Disease, Research Materials, Therapeutics Infectious Disease Research Materials Therapeutics LaShondra Berman, Stephen Lindstrom, Ji Liu, Bo Shu, Christine Warnes, Kai-Hui Wu <p>This technology includes an updated North American Lineage H7 (N.A H7) real-time RT-PCR assay is designed for specific detection and characterization of North American lineage of A/H7 influenza viruses. Since 1995, poultry infection with N.A lineage influenza A/H7 viruses has been greatly increasing. The outbreaks of N.A A/H7 viruses in poultry as well as wild birds occurred many times in Canada, Mexico and USA; meanwhile a number of human infection caused by N.A A/H7 viruses have been confirmed following exposure to infected poultry. This assay was optimized in order to facilitate surveillance of this virus with pandemic potential and improve the control and treatment of infected patients.</p> This assay allows for specific detection and characterization of North American lineage influenza A/H7 viruses with high sensitivity and specificity and will complement with CDC human Influenza Viruses Real-Time RT-PCR Detection and Characterization Panel to detect these viruses. May be licensed to commercial entities to manufacture and sell commercial reagents to research and clinical laboratories. 2023-12-15 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151834516 Liu, Ji CDC - DIR CDC Liu, Ji (CDC) 1 151834548 Shu, Bo CDC - DIR CDC Shu, Bo (CDC) 2 151834561 Lindstrom, Stephen CDC - DIR CDC Lindstrom, Stephen (CDC) 3 151834570 Wu, Kai-Hui CDC - DIR CDC Wu, Kai-Hui (CDC) 4 151834574 Warnes, Christine CDC - DIR CDC Warnes, Christine (CDC) 5 151834582 Berman, LaShondra CDC - DIR CDC Berman, LaShondra (CDC) 6 151834516 Liu, Ji CDC - DIR CDC Liu, Ji (CDC) 1 151834548 Shu, Bo CDC - DIR CDC Shu, Bo (CDC) 2 151834561 Lindstrom, Stephen CDC - DIR CDC Lindstrom, Stephen (CDC) 3 151834570 Wu, Kai-Hui CDC - DIR CDC Wu, Kai-Hui (CDC) 4 151834574 Warnes, Christine CDC - DIR CDC Warnes, Christine (CDC) 5 151834582 Berman, LaShondra CDC - DIR CDC Berman, LaShondra (CDC) 6 151834450 The North American Lineage H7 (N.A H7) Real-time RT-PCR Assay Is Designed For Specific Detection And Characterization Of North American Lineage Of A/H7 Influenza Viruses E-048-2017-0 Research Material Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4632] Real-time RT-PCR Assay for Detection and Characterization of North American Lineage of A/H7 Influenza Viruses&body=Please send me information about technology [TAB-4632] Real-time RT-PCR Assay for Detection and Characterization of North American Lineage of A/H7 Influenza Viruses. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4632] Real-time RT-PCR Assay for Detection and Characterization of North American Lineage of A/H7 Influenza Viruses&body=Please send me information about technology [TAB-4632] Real-time RT-PCR Assay for Detection and Characterization of North American Lineage of A/H7 Influenza Viruses.">jonathan.motley@nih.gov</a><br> TAB-4631 151834310 Identifying Inhibitors of Highly-pathogenic Arenaviruses Through Minigenome and Recombinant Virus Reporter Systems CDC Infectious Disease, Research Materials, Therapeutics Infectious Disease Research Materials Therapeutics Cesar Albarino, Christina Spiropoulou, Stephen Welch <p>This technology includes a novel minigenome assay for arenaviruses that allows for high-throughput screening (HTS) of potential antiviral compounds. To complement to minigenome assay, we have also developed a technique to generate recombinant arenaviruses expressing a reporter protein to allow to HTS of antiviral compounds at BSL-4. This allows for confirmation of potential hits identified by the initial minigenome screen. Human infections with some Arenaviruses such as Lassa (LASV) and Junin (JUNV) virus can result in viral hemorrhagic fever (VHF) disease. LASV in particular is an important global health issues resulting in significant morbidity and mortality, but treatment options remain limited. A major factor impeding the development of antiviral compounds to treat these infections is the need to manipulate the virus under BSL-4 containment, limiting research to a few institutes worldwide.</p> There are currently no available systems to assess inhibitors of replication and transcription processes of the pathogenic arenaviruses such as LASV and JUNV at BSL-2. Utilized in the development of antivirals. 2023-12-15 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151834317 Welch, Stephen CDC - DIR CDC Welch, Stephen (CDC) 1 151834321 Albarino, Cesar Centers for Disease Control and Prevention (CDC) CDC Albarino, Cesar (CDC) 2 151834330 Spiropoulou, Christina CDC - DIR CDC Spiropoulou, Christina (CDC) 3 151834317 Welch, Stephen CDC - DIR CDC Welch, Stephen (CDC) 1 151834321 Albarino, Cesar Centers for Disease Control and Prevention (CDC) CDC Albarino, Cesar (CDC) 2 151834330 Spiropoulou, Christina CDC - DIR CDC Spiropoulou, Christina (CDC) 3 151834313 Identifying Inhibitors Of Highly-pathogenic Arenaviruses Using Minigenome And Recombinant Virus Reporter Systems E-045-2017-0 Research Material Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4631] Identifying Inhibitors of Highly-pathogenic Arenaviruses Through Minigenome and Recombinant Virus Reporter Systems&body=Please send me information about technology [TAB-4631] Identifying Inhibitors of Highly-pathogenic Arenaviruses Through Minigenome and Recombinant Virus Reporter Systems. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4631] Identifying Inhibitors of Highly-pathogenic Arenaviruses Through Minigenome and Recombinant Virus Reporter Systems&body=Please send me information about technology [TAB-4631] Identifying Inhibitors of Highly-pathogenic Arenaviruses Through Minigenome and Recombinant Virus Reporter Systems.">benjamin.hurley@nih.gov</a><br> TAB-4072 147157354 Synergistic Use of Exo VII Inhibitors And Quinolone Antibiotics For Treating Bacterial Infection NCI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Shar-yin Huang, Yves Pommier <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks licensees to further develop novel exonuclease VII (ExoVII) inhibitors as antibiotic adjuvants for enhancing the efficacy of quinolone antibiotics, particularly in quinolone-resistant bacterial infection. &nbsp;&nbsp;</p> <h2>Description of Technology:</h2> <p>Quinolone antibiotics are a class of broad-spectrum antibiotics that act by trapping prokaryotic type IIA topoisomerases (DNA gyrase and TOPO IV), resulting in DNA damage, inhibition of DNA synthesis, and downstream bacterial death. However, current U.S. Food and Drug Administration (FDA) guidance reserves the use of quinolones for the most serious bacterial infections due to their associated side effects and to limit the occurrence of drug-resistant bacterial strains. Bacterial resistance, including to quinolone antibiotics, is a global challenge and has been dramatically increasing in incidence over the last 30 years. One mechanism of resistance to quinolone antibiotics is exonuclease VII (ExoVII). ExoVII is a well-conserved enzyme that repairs quinolone-induced DNA damage by excising the tyrosyl-DNA linkage between DNA and trapped DNA gyrase. Combination of antibiotics with antibiotic adjuvants offers a productive strategy to address the widespread emergence of antibiotic-resistant strains. However, there are currently no approved quinolone antibiotic adjuvants or drugs targeting ExoVII-mediated bacterial resistance.</p> <p>Investigators in NCI&rsquo;s Developmental Therapeutics Branch have discovered a family of isoquinolinedione derivatives that function as exonuclease VII (ExoVII) inhibitors that synergize with the antibacterial activity of quinolone antibiotics. In vitro, the inhibitors improved the efficacy of quinolone antibiotics and increased sensitivity to treatment of multiple bacteria strains. In quinolone-resistant bacterial strains, the co-treatment with ExoVII inhibitors reversed resistance and restored sensitivity to treatment with quinolone antibiotics. The inhibitors also exhibited no activity against the analogous repair enzyme in eukaryotes (tyrosyl DNA-phosphodiesterase 2; TDP2) and were not harmful to human cells in vitro. Overall, these inhibitors present strong potential as antibiotic adjuvants increasing the potency of quinolones, even in resistant bacterial strains.</p> <p>The NCI seeks licensees to further develop these novel ExoVII inhibitors as antibiotic adjuvants for the synergistic use with quinolone antibiotics for the treatment in bacterial infections, even quinolone-resistant bacterial infections.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Antibiotic adjuvant used in combination with ciprofloxacin and other quinolone antibiotics&nbsp;</li> <li>Antibiotic adjuvant used in combination with other topoisomerase poisons</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Increase efficacy of quinolone antibiotics, allowing for potential antibiotic dose reduction and decreased side-effects</li> <li>Overcome ExoVII-mediated bacterial resistance to quinolone antibiotics</li> <li>Highly specific</li> <li>Potential to be first-in-class drug &nbsp;</li> </ul> Researchers at the NCI seek licensing for further development novel exonuclease VII (ExoVII) inhibitors as antibiotic adjuvants for enhancing the efficacy of quinolone antibiotics, particularly in quinolone-resistant bacterial infection. 2021-05-07 2026-08-26 2026-08-26 2026-08-26 2021-05-12 Antibacterial, Antibiotic Adjuvants, Antibiotic Resistance, DNA gyrase, Exonuclease VII, ExoVII, Infection, Pommier, Quinolone, TOPO IV, Topoisomerase Poisons False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2026-08-26 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162122 Huang SN, et al. Exonuclease VII repairs quinolone-induced damage by resolving DNA gyrase cleavage complexes. (PMID: 33658195) https://pubmed.ncbi.nlm.nih.gov/33658195/ <a href="https://pubmed.ncbi.nlm.nih.gov/33658195/">Huang SN, et al. Exonuclease VII repairs quinolone-induced damage by resolving DNA gyrase cleavage complexes. (PMID: 33658195)</a> 147163421 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 1 147163422 Huang, Shar-yin NIH - NCI NCI Huang, Shar-yin (NCI) 2 147163421 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 1 147163422 Huang, Shar-yin NIH - NCI NCI Huang, Shar-yin (NCI) 2 147158139 Isoquinolinedione Derivatives Specifically Inhibit Exonuclease VII And Synergizes With Quinolones As Antimicrobials E-171-2020-0 Filing authorized NCI 91826910 McCrary, Michaela michaela.mccrary@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4072] Synergistic Use of Exo VII Inhibitors And Quinolone Antibiotics For Treating Bacterial Infection&body=Please send me information about technology [TAB-4072] Synergistic Use of Exo VII Inhibitors And Quinolone Antibiotics For Treating Bacterial Infection.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov McCrary, Michaela<br><a href="mailto:michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4072] Synergistic Use of Exo VII Inhibitors And Quinolone Antibiotics For Treating Bacterial Infection&body=Please send me information about technology [TAB-4072] Synergistic Use of Exo VII Inhibitors And Quinolone Antibiotics For Treating Bacterial Infection.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michaela.mccrary@nih.gov</a><br> 147166338 E-171-2020-0 E-171-2020-0-US-01 EXO VII INHIBITOR AND QUINOLONE ANTIBIOTIC COMBINATION USEFUL FOR TREATING BACTERIAL INFECTION PRV US 63/129,271 Abandoned US <br />Provisional (PRV) 63/129,271<br />Filed on 2020-12-22<br />Status: Abandoned 147166339 E-171-2020-0 E-171-2020-0-PCT-02 EXO VII Inhibitor and Quinolone Antibiotic Combination Useful for Treating Bacterial Infection PCT Patent Cooperation Treaty PCT/US2021/064996 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/064996<br />Filed on 2021-12-22<br />Status: Expired 147166340 E-171-2020-0 E-171-2020-0-CA-01 EXO VII Inhibitor and Quinolone Antibiotic Combination Useful for Treating Bacterial Infection National Stage Canada 3205044 Pending Canada <br />National Stage 3205044<br />Filed on 2023-06-12<br />Status: Pending 147166341 E-171-2020-0 E-171-2020-0-AU-01 EXO VII Inhibitor and Quinolone Antibiotic Combination Useful for Treating Bacterial Infection National Stage Australia 2021409956 Pending Australia <br />National Stage 2021409956<br />Filed on 2023-06-25<br />Status: Pending 147166342 E-171-2020-0 E-171-2020-0-CN-01 EXO VII Inhibitor and Quinolone Antibiotic Combination Useful for Treating Bacterial Infection National Stage China 202180086835.1 Pending China <br />National Stage 202180086835.1<br />Filed on 2023-06-21<br />Status: Pending 147166343 E-171-2020-0 E-171-2020-0-US-02 EXO VII Inhibitor and Quinolone Antibiotic Combination Useful for Treating Bacterial Infection National Stage US 12,702,665 18/268,603 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12702665 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12702665">12,702,665</a><br />Filed on 2023-06-20<br />Status: Issued 147166344 E-171-2020-0 E-171-2020-0-EP-01 EXO VII Inhibitor and Quinolone Antibiotic Combination Useful for Treating Bacterial Infection National Stage European Patent 21851911.4 Pending European Patent <br />National Stage 21851911.4<br />Filed on 2023-05-16<br />Status: Pending 147172955 Antibacterial 147172957 Antibiotic Adjuvants 147172959 Antibiotic Resistance 147172961 DNA gyrase 147172963 Exonuclease VII 147172965 ExoVII 147172966 Infection 147172967 Pommier 147172969 Quinolone 147172971 TOPO IV 147172973 Topoisomerase Poisons TAB-4630 151834042 Crimean-Congo Hemorrhagic Fever Virus (Nairovirus) Replicon Particles System-based Vaccine Candidate CDC Infectious Disease, Plasmids/Vectors, Therapeutics, Vaccines Infectious Disease Plasmids/Vectors Therapeutics Vaccines Eric Bergeron, Stuart Nichol, Scott Pegan, Florine Scholte, Jessica Spengler, Christina Spiropoulou, Stephen Welch <p>This technology includes a new reverse genetics-based approach that generates Crimean-Congo hemorrhagic fever virus (CCHF) viral replicon particles (CCHF VRPs) to be developed into a vaccine for CCHFV. With mortality rates as high as 80% and with no FDA-approved vaccines or therapeutics, CCHFV is considered a dangerous emerging human pathogen. Unlike transcriptionally competent virus like particles (tc-VLPs), that only include CCHFV virus proteins and minigenome RNA, VRPs undergo one full round of replication closely mimicking authentic viral replication. Unlike most vaccine approaches tested, VRPs do not solely rely on the expression of hypervariable GPC gene, which is unlikely on its own, to confer adequate protection against divergent strains of CCHFV. In contrast, VRPs abundantly produce the most conserved viral proteins and consequently are expected to build protective immunity against genetically divergent strains of CCHFV. We recently demonstrated that CCHF VRPs can be produced; these undergo only one round of replication, but can be amplified by expressing GPC in trans and that this approach can infer in a single dose complete protection in a CCHFV mouse model.</p> There is currently no safe and efficacious vaccine for CCHFV and other experimental vaccines require multiple doses and limited to the expression of the hypervariable glycoprotein precursor gene. Vaccine for CCHFV. 2023-12-15 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151834156 Nichol, Stuart CDC - DIR CDC Nichol, Stuart (CDC) 1 151834168 Bergeron, Eric CDC - DIR CDC Bergeron, Eric (CDC) 2 151834195 Scholte, Florine CDC - DIR CDC Scholte, Florine (CDC) 3 151834221 Welch, Stephen CDC - DIR CDC Welch, Stephen (CDC) 4 151834241 Spengler, Jessica CDC - DIR CDC Spengler, Jessica (CDC) 5 151834245 Spiropoulou, Christina CDC - DIR CDC Spiropoulou, Christina (CDC) 6 151834249 Pegan, Scott University of Georgia Pegan, Scott 7 151834156 Nichol, Stuart CDC - DIR CDC Nichol, Stuart (CDC) 1 151834168 Bergeron, Eric CDC - DIR CDC Bergeron, Eric (CDC) 2 151834195 Scholte, Florine CDC - DIR CDC Scholte, Florine (CDC) 3 151834221 Welch, Stephen CDC - DIR CDC Welch, Stephen (CDC) 4 151834241 Spengler, Jessica CDC - DIR CDC Spengler, Jessica (CDC) 5 151834245 Spiropoulou, Christina CDC - DIR CDC Spiropoulou, Christina (CDC) 6 151834249 Pegan, Scott University of Georgia Pegan, Scott 7 151834059 Crimean-Congo Hemorrhagic Fever Virus (Nairovirus) Replicon Particles System Based Vaccine Candidate E-042-2019-0 Filing authorized Centers for Disease Control and Prevention (CDC), University of Georgia 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4630] Crimean-Congo Hemorrhagic Fever Virus (Nairovirus) Replicon Particles System-based Vaccine Candidate&body=Please send me information about technology [TAB-4630] Crimean-Congo Hemorrhagic Fever Virus (Nairovirus) Replicon Particles System-based Vaccine Candidate. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4630] Crimean-Congo Hemorrhagic Fever Virus (Nairovirus) Replicon Particles System-based Vaccine Candidate&body=Please send me information about technology [TAB-4630] Crimean-Congo Hemorrhagic Fever Virus (Nairovirus) Replicon Particles System-based Vaccine Candidate.">benjamin.hurley@nih.gov</a><br> TAB-4629 151833772 Hybridomas and Mouse Monoclonal Antibodies for Marburg and Lassa Virus Identification CDC Antibodies, Diagnostics Antibodies Diagnostics Stuart Nichol, Pierre Rollin <p>This technology includes eight mouse monoclonal antibodies (mAb) and their corresponding hybridomas used for the Enzyme Linked Immunosorbent Assay (ELISA) detection and identification of Marburg (3) and Lassa (5) virus antigens. Lateral flow assays for hemorrhagic fevers are being developed in response to the Ebola outbreak. Our cocktail can identify different proteins for each virus; Marburg viral proteins 35 and 40 (VP35, VP40) and Lassa nucleoprotein (NP) and glycoprotein (G2). All known Marburg and Lassa viruses can be captured in the ELISA assay. These assays are used for detection of virus and antigens in experimental and clinical specimens. These antibodies have potential for use in a lateral flow rapid tests for an easier, low resource identification of infection with Marburg or Lassa viruses.</p> There are currently very few monoclonal antibodies targeting Marburg and Lassa viruses commercially available. These antibodies have the potential to be used in such products which would be able to detect whether a patient is infected or has been infected with Marburg or Lassa viruses. 2023-12-15 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151833819 Rollin, Pierre CDC Rollin, Pierre (CDC) 1 151833947 Nichol, Stuart CDC - NIOSH CDC Nichol, Stuart (CDC) 2 151833819 Rollin, Pierre CDC Rollin, Pierre (CDC) 1 151833947 Nichol, Stuart CDC - NIOSH CDC Nichol, Stuart (CDC) 2 151833779 Hybridomas And Mouse Monoclonal Antibodies (MAb)for Marburg And Lassa Viruses E-042-2017-0 Closed Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4629] Hybridomas and Mouse Monoclonal Antibodies for Marburg and Lassa Virus Identification&body=Please send me information about technology [TAB-4629] Hybridomas and Mouse Monoclonal Antibodies for Marburg and Lassa Virus Identification. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4629] Hybridomas and Mouse Monoclonal Antibodies for Marburg and Lassa Virus Identification&body=Please send me information about technology [TAB-4629] Hybridomas and Mouse Monoclonal Antibodies for Marburg and Lassa Virus Identification.">benjamin.hurley@nih.gov</a><br> TAB-4628 151833305 Mycoplasma-free PV and SAD/ERA Virus Stocks for Rabies Vaccine Manufacturing CDC Infectious Disease, Plasmids/Vectors, Research Equipment, Research Materials, Vaccines Infectious Disease Plasmids/Vectors Research Equipment Research Materials Vaccines Victoria Olson, Xianfu Wu, Yong Yang <p>This technology includes mycoplasma-free PV (isolated in 1882) and SAD/ERA (isolated in 1935) virus stock for rabies vaccine development. Rabies virus causes a nearly uniformly fatal disease, but can be prevented by timely vaccination. Two of the most common rabies virus vaccine strains are PV and SAD/ERA, both of which have had extensive passaging in both animals and subsequently cultivation in cells. The rabies vaccine virus stocks stored at CDC are heavily contaminated by mycoplasma.</p> Mycoplasma contamination is a challenge for the vaccine industry. The clean virus seed can be used for rabies vaccine manufacturing. 2023-12-15 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151833379 Wu, Xianfu CDC - DIR CDC Wu, Xianfu (CDC) 1 151833388 Yang, Yong CDC - DIR CDC Yang, Yong (CDC) 2 151833588 Olson, Victoria CDC - DIR CDC Olson, Victoria (CDC) 3 151833379 Wu, Xianfu CDC - DIR CDC Wu, Xianfu (CDC) 1 151833388 Yang, Yong CDC - DIR CDC Yang, Yong (CDC) 2 151833588 Olson, Victoria CDC - DIR CDC Olson, Victoria (CDC) 3 151833308 Mycoplasma Free PV Virus Stocks E-040-2018-0 Research Material Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4628] Mycoplasma-free PV and SAD/ERA Virus Stocks for Rabies Vaccine Manufacturing&body=Please send me information about technology [TAB-4628] Mycoplasma-free PV and SAD/ERA Virus Stocks for Rabies Vaccine Manufacturing. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4628] Mycoplasma-free PV and SAD/ERA Virus Stocks for Rabies Vaccine Manufacturing&body=Please send me information about technology [TAB-4628] Mycoplasma-free PV and SAD/ERA Virus Stocks for Rabies Vaccine Manufacturing.">benjamin.hurley@nih.gov</a><br> TAB-4627 151833003 Streptococcus pneumoniae Invasive and Non-invasive Clinical Isolates for Various Diagnostic and Therapeutic Uses CDC Collaboration, Diagnostics, Human Cell Lines, Immunology, Infectious Disease, Licensing, Materials Available, Pulmonology, Research Equipment, Research Materials, Respiratory, Therapeutics, Vaccines Collaboration Diagnostics Human Cell Lines Immunology Infectious Disease Licensing Materials Available Pulmonology Research Equipment Research Materials Respiratory Therapeutics Vaccines Bernard Beall, Lesley McGee <p>This technology includes Streptococcus pneumoniae isolates collected through CDC&rsquo;s Global Strain Bank project with particular serotypes. They were collected as part of routine clinical and surveillance activities and have a wide variety of uses including research, diagnostic, and the development of therapeutics.</p> Repository of S. pneumoniae isolates from invasive and non-invasive disease with confirmed serotypes. The isolates can be used for therapeutics, diagnostics, and commercial research use. 2023-12-15 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151833010 Beall, Bernard CDC - DIR CDC Beall, Bernard (CDC) 1 151833020 McGee, Lesley CDC - DIR CDC McGee, Lesley (CDC) 2 151833010 Beall, Bernard CDC - DIR CDC Beall, Bernard (CDC) 1 151833020 McGee, Lesley CDC - DIR CDC McGee, Lesley (CDC) 2 151833006 Streptococcus Pneumoniae Invasive And Non-invasive Clinical Isolates With Various Capsular Serotypes E-040-2016-0 Research Material Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4627] Streptococcus pneumoniae Invasive and Non-invasive Clinical Isolates for Various Diagnostic and Therapeutic Uses&body=Please send me information about technology [TAB-4627] Streptococcus pneumoniae Invasive and Non-invasive Clinical Isolates for Various Diagnostic and Therapeutic Uses. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4627] Streptococcus pneumoniae Invasive and Non-invasive Clinical Isolates for Various Diagnostic and Therapeutic Uses&body=Please send me information about technology [TAB-4627] Streptococcus pneumoniae Invasive and Non-invasive Clinical Isolates for Various Diagnostic and Therapeutic Uses.">jonathan.motley@nih.gov</a><br> TAB-4625 151832567 Tumor Necrosis Factor (TNF) and Glucocorticoid Antagonist for Gulf War Illness-Associated Homeostatic Reset CDC Research Materials, Therapeutics Research Materials Therapeutics Gordon Broderick, Travis Craddock, Maryann Fletcher, Nancy Klimas, Mariana Morris, James O'Callaghan <p>This technology includes therapeutics for Gulf War Illness (GWI). (GWI) patient symptoms, clinical laboratory tests and computational analyses of results from genomic, immunological, autonomic and endocrine changes in animal models therapeutic target were narrowed down to tumor necrosis factor (TNF) and Glucocorticoid receptor for a carefully timed &ldquo;two hit&rdquo; treatment model, manipulating cytokine mediated inflammation and the HPA axis.</p> Genomic, immunological, autonomic and endocrine changes observed in GW veterans were assessed and used to discover the pathological pathways and key mediators underlying GWI, then identified therapeutic targets that manipulate those pathways. Drugs targeting the TNF and Glucocorticoid receptors could be repurposed to use in treatment of multi symptom illnesses such as GWI and ME/CFS associated homeostatic reset. 2023-12-15 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151832575 Klimas, Nancy Nova Southeastern University Klimas, Nancy 1 151832580 O'Callaghan, James CDC - NIOSH CDC O'Callaghan, James (CDC) 2 151832588 Craddock, Travis Nova Southeastern University Craddock, Travis 3 151832650 Morris, Mariana Nova Southeastern University Morris, Mariana 4 151832656 Broderick, Gordon Rochester Regional Health Broderick, Gordon 5 151832666 Fletcher, Maryann East Carolina University Fletcher, Maryann 6 151832575 Klimas, Nancy Nova Southeastern University Klimas, Nancy 1 151832580 O'Callaghan, James CDC - NIOSH CDC O'Callaghan, James (CDC) 2 151832588 Craddock, Travis Nova Southeastern University Craddock, Travis 3 151832650 Morris, Mariana Nova Southeastern University Morris, Mariana 4 151832656 Broderick, Gordon Rochester Regional Health Broderick, Gordon 5 151832666 Fletcher, Maryann East Carolina University Fletcher, Maryann 6 151832570 Tumor Necrosis Factor (TNF) And Glucocorticoid Antagonist For Gulf War Illness Associated Homeostatic Reset E-033-2019-0 Filing authorized Centers for Disease Control and Prevention (CDC), East Carolina University, Nova Southeastern University, Rochester Regional Health 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4625] Tumor Necrosis Factor (TNF) and Glucocorticoid Antagonist for Gulf War Illness-Associated Homeostatic Reset&body=Please send me information about technology [TAB-4625] Tumor Necrosis Factor (TNF) and Glucocorticoid Antagonist for Gulf War Illness-Associated Homeostatic Reset. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4625] Tumor Necrosis Factor (TNF) and Glucocorticoid Antagonist for Gulf War Illness-Associated Homeostatic Reset&body=Please send me information about technology [TAB-4625] Tumor Necrosis Factor (TNF) and Glucocorticoid Antagonist for Gulf War Illness-Associated Homeostatic Reset.">yogikala.prabhu@nih.gov</a><br> TAB-4624 151832381 Diagnostic Real-time TaqMan® PCR for Human Adenovirus Type 4 CDC Diagnostics, Infectious Disease, Plasmids/Vectors, Research Materials Diagnostics Infectious Disease Plasmids/Vectors Research Materials Dean Erdman, Xiaoyan Lu <p>This technology includes a real-time polymerase chain reaction (PCR) assay using hydrolysis probe (TaqMan&reg;) chemistry which was developed for detection and type-specific identification of human adenovirus type 4 (HAd4) genomic DNA in clinical specimens. The assay uses unique oligonucleotide primer and probes designed to conserved regions of the HAd4 hexon protein gene. Assay reagents and amplification conditions were optimized and sensitivity and specificity characteristics determined with DNA extracts from multiple HAd4 laboratory strains and other respiratory viral pathogens.</p> Utilizes unique oligonucleotide primer and probes designed to conserved regions of the HAd4 hexon protein gene. Diagnostic test for Had4. 2023-12-15 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151832388 Erdman, Dean CDC - DIR CDC Erdman, Dean (CDC) 1 151832396 Lu, Xiaoyan CDC - DIR CDC Lu, Xiaoyan (CDC) 2 151832388 Erdman, Dean CDC - DIR CDC Erdman, Dean (CDC) 1 151832396 Lu, Xiaoyan CDC - DIR CDC Lu, Xiaoyan (CDC) 2 151832384 Real-time TaqMan PCR For Human Adenovirus Type 4 E-032-2015-0 Research Material Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4624] Diagnostic Real-time TaqMan® PCR for Human Adenovirus Type 4&body=Please send me information about technology [TAB-4624] Diagnostic Real-time TaqMan® PCR for Human Adenovirus Type 4. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4624] Diagnostic Real-time TaqMan® PCR for Human Adenovirus Type 4&body=Please send me information about technology [TAB-4624] Diagnostic Real-time TaqMan® PCR for Human Adenovirus Type 4.">jonathan.motley@nih.gov</a><br> TAB-4623 151831797 Enterobacteriaceae Strains for Accelerate Diagnostics Licensing CDC Diagnostics, Human Cell Lines, Infectious Disease, Licensing, Materials Available, Plasmids/Vectors, Research Materials, Therapeutics Diagnostics Human Cell Lines Infectious Disease Licensing Materials Available Plasmids/Vectors Research Materials Therapeutics James Rasheed <p>This technology includes a repository of unique Enterobacteriaceae isolates for various therapeutic and diagnostic uses:</p> <p>Enterobacter cloacae (Known Acquired Resistance: NDM-1) &ndash; Strain 0038</p> <p>Klebsiella pneumoniae (Known Acquired Resistance: CTX-M-14) &ndash; Strain 0079</p> <p>Citrobacter freundii (Known Acquired Resistance: KPC-2) &ndash; Strain 0116</p> <p>Escherichia coli (Known Acquired Resistance: NDM-1) &ndash; Strain 0118</p> <p>Klebsiella pneumoniae (Known Acquired Resistance: NDM-1) &ndash; Strain 0148</p> <p>Escherichia coli (Known Acquired Resistance: NDM-5) &ndash; Strain 0150</p> <p>Escherichia coli (Known Acquired Resistance: NDM-7) &ndash; Strain 0162</p> Repository of unique isolates not currently available in the market. The isolates can be used for therapeutics, diagnostics, and commercial research tool use. 2023-12-15 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151831861 Rasheed, James CDC - DIR CDC Rasheed, James (CDC) 1 151831861 Rasheed, James CDC - DIR CDC Rasheed, James (CDC) 1 151831800 Enterobacteriaceae Strains For Accelerate Diagnostics Licensing E-031-2017-0 Research Material Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4623] Enterobacteriaceae Strains for Accelerate Diagnostics Licensing&body=Please send me information about technology [TAB-4623] Enterobacteriaceae Strains for Accelerate Diagnostics Licensing. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4623] Enterobacteriaceae Strains for Accelerate Diagnostics Licensing&body=Please send me information about technology [TAB-4623] Enterobacteriaceae Strains for Accelerate Diagnostics Licensing.">benjamin.hurley@nih.gov</a><br> TAB-4622 151831614 DENV-2, 1710 as a Cancer Therapeutic CDC Collaboration, Licensing, Oncology, Therapeutics, Vaccines Collaboration Licensing Oncology Therapeutics Vaccines Duane Gubler <p>This technology includes a Dengue-2 isolated virus for use as a cancer vaccine therapeutic.</p> Unmodified strain of the virus is being utilized. Therapeutic cancer vaccine. 2023-12-15 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151831634 Gubler, Duane Duke-NUS Medical School Gubler, Duane 1 151831634 Gubler, Duane Duke-NUS Medical School Gubler, Duane 1 151831619 DENV-2, 1710 As A Cancer Therapeutic E-030-2016-0 Research Material Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4622] DENV-2, 1710 as a Cancer Therapeutic&body=Please send me information about technology [TAB-4622] DENV-2, 1710 as a Cancer Therapeutic. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4622] DENV-2, 1710 as a Cancer Therapeutic&body=Please send me information about technology [TAB-4622] DENV-2, 1710 as a Cancer Therapeutic.">benjamin.hurley@nih.gov</a><br> TAB-4621 151831195 HIV-2 Plasmid DNA Library for Diagnostic Assay Development CDC Diagnostics, Infectious Disease, Plasmids/Vectors Diagnostics Infectious Disease Plasmids/Vectors Kelly Curtis, Timothy Granade, Sherry Owen, Chou-Pong Pau, Ae Saekhou Youngpairoj <p>This technology includes a HIV-2 plasmid library for use in diagnostic assay development. In December of 2012, the Centers for Disease Control and Prevention (CDC) and the Association of Public Health Laboratories (APHL) proposed a new US laboratory testing algorithm for the diagnosis of HIV infections. This new algorithm recommends additional testing for confirmation of HIV infection using a nucleic acid amplification test (NAAT) in the event of discordant serological test results. This invention is significant because there are few HIV-2 specimens available for use in assay development and optimization. Additionally, there is limited availability of material for use as assay controls and for the monitoring of laboratory quality and operator proficiency.</p> At present, there is no FDA-approved NAAT for the diagnosis of HIV-2 infections, and, due to the low prevalence of HIV-2 in the US, HIV-2 specimens are not readily available for optimization and validation of new procedures or technologies. The plasmid library described here would be useful for HIV-2 diagnostic assay development and for quality control or proficiency testing reagents in existing or new diagnostic assays. 2023-12-15 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151831472 Branson B, et al. https://pubmed.ncbi.nlm.nih.gov/22207652/ <a href="https://pubmed.ncbi.nlm.nih.gov/22207652/">Branson B, et al.</a> 151831246 Youngpairoj, Ae Saekhou CDC - DIR CDC Youngpairoj, Ae Saekhou (CDC) 1 151831411 Curtis, Kelly CDC - DIR CDC Curtis, Kelly (CDC) 2 151831429 Pau, Chou-Pong CDC - DIR CDC Pau, Chou-Pong (CDC) 3 151831447 Owen, Sherry CDC - DIR CDC Owen, Sherry (CDC) 4 151831458 Granade, Timothy CDC - DIR CDC Granade, Timothy (CDC) 5 151831246 Youngpairoj, Ae Saekhou CDC - DIR CDC Youngpairoj, Ae Saekhou (CDC) 1 151831411 Curtis, Kelly CDC - DIR CDC Curtis, Kelly (CDC) 2 151831429 Pau, Chou-Pong CDC - DIR CDC Pau, Chou-Pong (CDC) 3 151831447 Owen, Sherry CDC - DIR CDC Owen, Sherry (CDC) 4 151831458 Granade, Timothy CDC - DIR CDC Granade, Timothy (CDC) 5 151831198 HIV-2 Plasmid DNA Library E-025-2014-0 Research Material Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4621] HIV-2 Plasmid DNA Library for Diagnostic Assay Development&body=Please send me information about technology [TAB-4621] HIV-2 Plasmid DNA Library for Diagnostic Assay Development. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4621] HIV-2 Plasmid DNA Library for Diagnostic Assay Development&body=Please send me information about technology [TAB-4621] HIV-2 Plasmid DNA Library for Diagnostic Assay Development.">jonathan.motley@nih.gov</a><br> TAB-4620 151830966 Methods for Delivery of Bacteriophage to Lung for Reducing Bacterial Colonization CDC Infectious Disease, Research Materials, Respiratory, Therapeutics Infectious Disease Research Materials Respiratory Therapeutics Rodney Donlan <p>This technology includes methods for the delivery of active bacteriophages or other agents to the lung, with the goal of reducing bacterial colonization and improving clinical outcomes. This is accomplished by encapsulating, immobilizing, or otherwise incorporating bacteriophages to polymer particles in the micro- to nano-scale size range in order to target their delivery to specific lung regions. The current example of this involves poly(lactic-co-glycolic) acid (PLGA) particles conjugated to phages that kill Pseudomonas aeruginosa in the lungs of cystic fibrosis patients. Bacteriophages are viruses that infect and kill specific strains of bacteria, are self-replicating and self-limiting, are able to kill multi-drug-resistant bacteria, and are able to penetrate infected tissues. Evidence exists that they can be safely administered therapeutically to humans. We have a collection of more than 30 phages infecting Pseudomonas aeruginosa, and have determined that at least some of them can kill P. aeruginosa isolated from the lungs of cystic fibrosis patients. PLGA is an FDA-approved biodegradable synthetic polymer that is well-suited for pulmonary delivery.</p> <ul> <li>This invention addresses technological and therapeutic gaps, specifically the shortage of antibacterial agents available to combat chronic lung infections that are refractory to current drug treatments, and the current difficulties in targeting therapeutic agents to specific areas of the lung, wholly or partly independent of the size of the therapeutic agent itself.</li> <li>This technology should be extendable to antibacterial agents other than bacteriophages.</li> <li>A major strength of using these particles as delivery vehicles is the ability to incorporate or co-deliver other molecules that may enhance the efficacy of bacteriophages or act independently.</li> <li>The current example of the invention uses particles that follow a two-phase decay process, which potentially allows for delayed release of small molecules as the particle decays.</li> </ul> <ul> <li>Improved delivery of novel therapeutics to the small airways of the lung by controlling particle properties</li> <li>Use of therapeutic agents that are able to kill multi-drug resistant pathogenic bacteria that are directly responsible for patient morbidity and mortality</li> </ul> 2023-12-15 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151830987 Donlan, Rodney CDC - DIR CDC Donlan, Rodney (CDC) 1 151830987 Donlan, Rodney CDC - DIR CDC Donlan, Rodney (CDC) 1 151830969 Methods For Delivery Of Bacteriophage To Lung For Reducing Bacterial Colonization E-024-2014-0 Closed Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4620] Methods for Delivery of Bacteriophage to Lung for Reducing Bacterial Colonization&body=Please send me information about technology [TAB-4620] Methods for Delivery of Bacteriophage to Lung for Reducing Bacterial Colonization. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4620] Methods for Delivery of Bacteriophage to Lung for Reducing Bacterial Colonization&body=Please send me information about technology [TAB-4620] Methods for Delivery of Bacteriophage to Lung for Reducing Bacterial Colonization.">benjamin.hurley@nih.gov</a><br> TAB-4619 151800672 Small molecule Inhibitors of Mycobacterium Tuberculosis Eis as Aminoglycoside Adjuvants for Tuberculosis Therapy CDC Infectious Disease, Research Materials, Respiratory, Therapeutics Infectious Disease Research Materials Respiratory Therapeutics Sylvie Garneau-Tsodikova, James Posey, Oleg Tsodikov <p>This technology includes compositions useful as inhibitors of acetyltransferase Eis, whose upregulation causes kanamycin (KAN) resistance of tuberculosis (TB) infections, and therefore can be developed and utilized as a treatment for TB. In particular, the compositions are sulfonamide-based and sulfonyl isothiazole-based small molecules. Drug adjuvants in TB represent a conceptually novel approach to combatting a serious global epidemic of drug-resistant TB. This approach is an alternative to developing a new antibiotic, because the adjuvant is targeting a non-essential enzyme and is meant to function only in combination with an already established anti-TB therapeutic, KAN. A KAN adjuvant is especially important, because KAN is used as a drug of last resort in treating drug-resistant TB.</p> This is the first example of an adjuvant of a clinically used anti-TB drug. Development a treatment for tuberculosis. 2023-12-14 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151800679 Posey, James CDC - DIR CDC Posey, James (CDC) 1 151800683 Garneau-Tsodikova, Sylvie University of Kentucky Garneau-Tsodikova, Sylvie 2 151800687 Tsodikov, Oleg University of Kentucky Tsodikov, Oleg 3 151800679 Posey, James CDC - DIR CDC Posey, James (CDC) 1 151800683 Garneau-Tsodikova, Sylvie University of Kentucky Garneau-Tsodikova, Sylvie 2 151800687 Tsodikov, Oleg University of Kentucky Tsodikov, Oleg 3 151800675 Small Molecule Inhibitors Of Mycobacterium Tuberculosis Eis As Aminoglycoside Adjuvants For Tuberculosis Therapy E-023-2017-0 Filing authorized Centers for Disease Control and Prevention (CDC), University of Kentucky 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4619] Small molecule Inhibitors of Mycobacterium Tuberculosis Eis as Aminoglycoside Adjuvants for Tuberculosis Therapy&body=Please send me information about technology [TAB-4619] Small molecule Inhibitors of Mycobacterium Tuberculosis Eis as Aminoglycoside Adjuvants for Tuberculosis Therapy. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4619] Small molecule Inhibitors of Mycobacterium Tuberculosis Eis as Aminoglycoside Adjuvants for Tuberculosis Therapy&body=Please send me information about technology [TAB-4619] Small molecule Inhibitors of Mycobacterium Tuberculosis Eis as Aminoglycoside Adjuvants for Tuberculosis Therapy.">jonathan.motley@nih.gov</a><br> TAB-4618 151800433 The North American Lineage H7 (N.A H7) real-time (RT)-PCR Assay for Detection and Characterization of North American Lineage of A/H7 Avian Influenza Viruses CDC Diagnostics, Infectious Disease, Research Equipment, Research Materials Diagnostics Infectious Disease Research Equipment Research Materials LaShondra Berman, Stephen Lindstrom, Bo Shu, Christine Warnes, Kai-Hui Wu <p>This technology includes an optimized N.A H7 influenza A virus subtyping real-time (RT)-PCR assay for detection and characterization of N.A A/H7 influenza viruses. Since 1995, infection of poultry with N.A A/H7 influenza viruses has greatly increased, the outbreaks of N.A A/H7 influenza viruses in poultry as well as wild birds occurred many times in Canada, Mexico and USA; meanwhile a number of human infection caused by N.A A/H7 influenza viruses have been confirmed following exposure to infected poultry. The assay may be licensed to commercial entities to manufacture and sell commercial reagents to research and clinical laboratories, and the assay will be in process to obtain clearance under FDA emergency use authorization for domestic human diagnostic testing procedures in the United States if necessary.</p> The assay allows for the qualitative detection of N.A A/H7 influenza viruses in the shortest time with the highest sensitivity and specificity. The assay may be licensed to commercial entities to manufacture and sell commercial reagents to research and clinical laboratories. 2023-12-14 2026-08-26 2026-08-26 2026-08-26 False True True 72159134 Analytical Assay Performance Stage 72159134 37470483 Website Abstract 151800440 Lindstrom, Stephen CDC - DIR CDC Lindstrom, Stephen (CDC) 1 151800459 Wu, Kai-Hui CDC - DIR CDC Wu, Kai-Hui (CDC) 2 151800463 Berman, LaShondra CDC - DIR CDC Berman, LaShondra (CDC) 3 151800467 Warnes, Christine CDC - DIR CDC Warnes, Christine (CDC) 4 151854121 Shu, Bo CDC - DIR CDC Shu, Bo (CDC) 5 151800440 Lindstrom, Stephen CDC - DIR CDC Lindstrom, Stephen (CDC) 1 151800459 Wu, Kai-Hui CDC - DIR CDC Wu, Kai-Hui (CDC) 2 151800463 Berman, LaShondra CDC - DIR CDC Berman, LaShondra (CDC) 3 151800467 Warnes, Christine CDC - DIR CDC Warnes, Christine (CDC) 4 151854121 Shu, Bo CDC - DIR CDC Shu, Bo (CDC) 5 151800436 The North American Lineage H7 (N.A H7) Real-time RT-PCR Assay Is Designed For Detection And Characterization Of North American Lineage Of A/H7 Avian Influenza Viruses E-022-2014-0 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4618] The North American Lineage H7 (N.A H7) real-time (RT)-PCR Assay for Detection and Characterization of North American Lineage of A/H7 Avian Influenza Viruses&body=Please send me information about technology [TAB-4618] The North American Lineage H7 (N.A H7) real-time (RT)-PCR Assay for Detection and Characterization of North American Lineage of A/H7 Avian Influenza Viruses. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4618] The North American Lineage H7 (N.A H7) real-time (RT)-PCR Assay for Detection and Characterization of North American Lineage of A/H7 Avian Influenza Viruses&body=Please send me information about technology [TAB-4618] The North American Lineage H7 (N.A H7) real-time (RT)-PCR Assay for Detection and Characterization of North American Lineage of A/H7 Avian Influenza Viruses.">jonathan.motley@nih.gov</a><br> TAB-4617 151799969 Influenza A/H9 viruses Real-time (RT)-PCR Assay for Detection and Characterization of Influenza A/H9 Viruses CDC Diagnostics, Infectious Disease, Research Equipment, Research Materials Diagnostics Infectious Disease Research Equipment Research Materials LaShondra Berman, Stephen Lindstrom, Bo Shu, Christine Warnes, Kai-Hui Wu <p>This technology includes an optimized influenza A/H9 virus real-time (RT)-PCR assay for detection and characterization influenza A/H9 viruses, which are considered to be one of the most likely candidates to cause an influenza pandemic in humans. The H9 real-time RT-PCR assay will be in compliment with CDC human Influenza Viruses RT-PCR Detection and Characterization Panel to detect of A/H9 influenza viruses.</p> The H9 real-time RT-PCR assay allows to qualitative detection of A/H9 influenza viruses in the shortest time with the highest sensitivity and specificity. The assay may be licensed to commercial entities to manufacture and sell commercial reagents to research and clinical laboratories. 2023-12-14 2026-08-26 2026-08-26 2026-08-26 False True True 72159134 Analytical Assay Performance Stage 72159134 37470483 Website Abstract 151799987 Lindstrom, Stephen CDC - DIR CDC Lindstrom, Stephen (CDC) 1 151800299 Wu, Kai-Hui CDC - DIR CDC Wu, Kai-Hui (CDC) 2 151800307 Berman, LaShondra CDC - DIR CDC Berman, LaShondra (CDC) 3 151800315 Warnes, Christine CDC - DIR CDC Warnes, Christine (CDC) 4 151854117 Shu, Bo CDC - DIR CDC Shu, Bo (CDC) 5 151799987 Lindstrom, Stephen CDC - DIR CDC Lindstrom, Stephen (CDC) 1 151800299 Wu, Kai-Hui CDC - DIR CDC Wu, Kai-Hui (CDC) 2 151800307 Berman, LaShondra CDC - DIR CDC Berman, LaShondra (CDC) 3 151800315 Warnes, Christine CDC - DIR CDC Warnes, Christine (CDC) 4 151854117 Shu, Bo CDC - DIR CDC Shu, Bo (CDC) 5 151799972 The Influenza A/H9 Viruses Real-Time RT-PCR Assay Is Designed For Detection And Characterization Of Influenza A/H9 Viruses E-021-2014-0 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4617] Influenza A/H9 viruses Real-time (RT)-PCR Assay for Detection and Characterization of Influenza A/H9 Viruses&body=Please send me information about technology [TAB-4617] Influenza A/H9 viruses Real-time (RT)-PCR Assay for Detection and Characterization of Influenza A/H9 Viruses. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4617] Influenza A/H9 viruses Real-time (RT)-PCR Assay for Detection and Characterization of Influenza A/H9 Viruses&body=Please send me information about technology [TAB-4617] Influenza A/H9 viruses Real-time (RT)-PCR Assay for Detection and Characterization of Influenza A/H9 Viruses.">jonathan.motley@nih.gov</a><br> TAB-4616 151799817 Plasmodium falciparum Strains for Therapeutic, Diagnostic, and Commercial Research Use CDC Diagnostics, Infectious Disease, Research Materials, Therapeutics Diagnostics Infectious Disease Research Materials Therapeutics Michael Aidoo <p>This technology includes plasmodium falciparum parasites (PH1, Benin, FCQ79, Santa Lucia and Borneo) which have all been isolated from infected persons from various geographic locations and have been modified/adapted for growth in the laboratory for multiple uses. Plasmodium falciparum strain W2 is a parasite clone from a parasite isolate called Indochina III/CDC which in turn originated from a patient in Laos infected with chloroquine-resistant parasites. Gametocytes from W2 can be grown experimentally and used in experimental infection of chimpanzees and aotus monkeys.</p> Multiple uses and opportunities for further development. Isolates can be used for therapeutics, diagnostics and as commercial research tools. 2023-12-14 2026-08-26 2026-08-26 2026-08-26 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151799831 Aidoo, Michael CDC - DIR CDC Aidoo, Michael (CDC) 1 151799831 Aidoo, Michael CDC - DIR CDC Aidoo, Michael (CDC) 1 151799820 Plasmodium Falciparum Strains PH1 , Benin, FCQ79, Santa Lucia, Borneo And W2 E-020-2017-0 Research Material Centers for Disease Control and Prevention (CDC) 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-4616] Plasmodium falciparum Strains for Therapeutic, Diagnostic, and Commercial Research Use&body=Please send me information about technology [TAB-4616] Plasmodium falciparum Strains for Therapeutic, Diagnostic, and Commercial Research Use. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-4616] Plasmodium falciparum Strains for Therapeutic, Diagnostic, and Commercial Research Use&body=Please send me information about technology [TAB-4616] Plasmodium falciparum Strains for Therapeutic, Diagnostic, and Commercial Research Use.">peter.tung@nih.gov</a><br> TAB-4615 151799562 Therapeutic Use of Artificially Generated Mononegavirales Defective Interfering Particles (DIP) CDC Infectious Disease, Research Materials, Therapeutics Infectious Disease Research Materials Therapeutics Markus Kainulainen, Michael Lo, Stuart Nichol, Jessica Spengler, Christina Spiropoulou, Stephen Welch <p>This technology includes using defective interfering (DI) genomes as a therapeutic against various mononegavirales. DI genomes are defective versions of the wildtype viral genome, incapable of replicating by itself but able to interfere with replication of the wildtype virus. We developed both a system to identify and characterize multiple naturally occurring henipaviruses Nipah (NiV) DI genomes species, and a methodology to artificially produce high titer stocks of virions containing these DI genomes, termed DI particles (DIPs). In vitro data showed that several of these DIPs were capable of reducing wildtype NiV titers by over 3-logs. Preliminary in vivo data using a small animal (hamster) disease model indicates efficacy of DIP treatment, with significantly improved survival rates in treated versus untreated animals, with a clear reduction or absence of clinical signs in the former group.</p> DIP therapy offers several advantages over current treatment options, both those in use today and any future experimental/theoretical options: <ul> <li>DIPs are transmissible (in the presence of wildtype standard virus) and therefore able to disseminate, and target the same infected cells and tissues as the virus. The inherent targeting of DIPs to the analogous cells/tissues in a patient as the wildtype standard virus ensures that: a) the DIP will always likely be present in any virally-infected cell; and b) there will be no physiological compartment in the patient where virus could potential “hide” from the DIPs.</li> <li>Our data indicates that DIPs are able to activate the innate immune system, especially upregulation of interferon and RIG-I-like pathways. Therefore, as well as directly interfering with viral replication they are also able to interfere indirectly by priming an antiviral state.</li> <li>Our data indicates that both copyback- and deletion-type DI genome species are able to inhibit replication of wildtype standard virus. Deletion DI genomes are unique in that some retain the ability to express a protein. Therefore, any inherent inhibitory effects could be enhanced by encoding an immunogenic protein payload on the deletion DI genome, increasing its therapeutic potential.</li> <li>DIPs are unable to replicate unless in the presence of wildtype standard virus, and therefore likely to have minimal (if any) potential side effects.</li> <li>Unlike antivirals, DIPs will be much more resistant to escape mutants as any deleterious mutations potentially affecting the ability of the virus to replicate the DI genome will have analogous deleterious effects on wildtype standard virus replication. Secondly, the DIP treatment would be able to co-evolve alongside the wildtype standard virus, remaining effective throughout any future epidemics of disease for example.</li> <li>Unlike vaccine-mediated immunity via priming of the adaptive and innate immune pathways, DIP-mediated protection is effective straightaway. This would allow effective treatment of both the patient and any potential susceptible contacts to begin immediately after a diagnosis is either suspected or confirmed.</li> </ul> Therapeutics against many viral members within the order mononegavirales which are capable of causing severe human disease with high case fatality rates, including the filoviruses Ebola (EBOV) and Marburg (MARV), and the henipaviruses Nipah (NiV) and Hendra (HeV). 2023-12-14 2026-08-26 2026-08-26 2026-08-26 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151799569 Kainulainen, Markus CDC - DIR CDC Kainulainen, Markus (CDC) 1 151799583 Welch, Stephen CDC - DIR CDC Welch, Stephen (CDC) 2 151799599 Spiropoulou, Christina CDC - DIR CDC Spiropoulou, Christina (CDC) 3 151799603 Spengler, Jessica CDC - DIR CDC Spengler, Jessica (CDC) 4 151799777 Lo, Michael CDC - DIR CDC Lo, Michael (CDC) 5 151799790 Nichol, Stuart CDC - DIR CDC Nichol, Stuart (CDC) 6 151799569 Kainulainen, Markus CDC - DIR CDC Kainulainen, Markus (CDC) 1 151799583 Welch, Stephen CDC - DIR CDC Welch, Stephen (CDC) 2 151799599 Spiropoulou, Christina CDC - DIR CDC Spiropoulou, Christina (CDC) 3 151799603 Spengler, Jessica CDC - DIR CDC Spengler, Jessica (CDC) 4 151799777 Lo, Michael CDC - DIR CDC Lo, Michael (CDC) 5 151799790 Nichol, Stuart CDC - DIR CDC Nichol, Stuart (CDC) 6 151799565 Therapeutic Use Of Artificially Generated Mononegavirales Defective Interfering Particles E-019-2020-0 Closed Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4615] Therapeutic Use of Artificially Generated Mononegavirales Defective Interfering Particles (DIP)&body=Please send me information about technology [TAB-4615] Therapeutic Use of Artificially Generated Mononegavirales Defective Interfering Particles (DIP). Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4615] Therapeutic Use of Artificially Generated Mononegavirales Defective Interfering Particles (DIP)&body=Please send me information about technology [TAB-4615] Therapeutic Use of Artificially Generated Mononegavirales Defective Interfering Particles (DIP).">benjamin.hurley@nih.gov</a><br> TAB-4614 151799077 Novel Small Molecule Inhibitors of Ebola Virus CDC Infectious Disease, Research Materials, Therapeutics, Vaccines Infectious Disease Research Materials Therapeutics Vaccines Frank Amblard, Michael Flint, Michael Lo, Raymond Schinazi, Christina Spiropoulou <p>This technology includes a compound, CDEU050, which has shown to have anti-Ebola virus activity in cell culture. CDEU050 is a novel small molecule, unrelated to any previously described inhibitor that blocks Ebola virus infection in cell culture.</p> There are no therapeutics or vaccines approved to protect from infection with Ebola virus. Development of a clinical candidate for Ebola virus. 2023-12-14 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151799105 Flint, Michael CDC - DIR CDC Flint, Michael (CDC) 1 151799285 Spiropoulou, Christina CDC - DIR CDC Spiropoulou, Christina (CDC) 2 151799289 Amblard, Frank Emory University Amblard, Frank 3 151799331 Schinazi, Raymond Emory University Schinazi, Raymond 4 151799340 Lo, Michael CDC - DIR CDC Lo, Michael (CDC) 5 151799105 Flint, Michael CDC - DIR CDC Flint, Michael (CDC) 1 151799285 Spiropoulou, Christina CDC - DIR CDC Spiropoulou, Christina (CDC) 2 151799289 Amblard, Frank Emory University Amblard, Frank 3 151799331 Schinazi, Raymond Emory University Schinazi, Raymond 4 151799340 Lo, Michael CDC - DIR CDC Lo, Michael (CDC) 5 151799080 Novel Small-molecule Inhibitors Of Ebola Virus E-018-2019-0 Filing authorized Centers for Disease Control and Prevention (CDC), Emory University 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4614] Novel Small Molecule Inhibitors of Ebola Virus&body=Please send me information about technology [TAB-4614] Novel Small Molecule Inhibitors of Ebola Virus. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4614] Novel Small Molecule Inhibitors of Ebola Virus&body=Please send me information about technology [TAB-4614] Novel Small Molecule Inhibitors of Ebola Virus.">benjamin.hurley@nih.gov</a><br> TAB-4613 151798966 Real-time RT-PCR Assay for Rapid, Highly Sensitive and Specific Detection of Human Enterovirus D68 (EV-D68 CDC Diagnostics, Infectious Disease, Medical Devices, Plasmids/Vectors, Pulmonology Diagnostics Infectious Disease Medical Devices Plasmids/Vectors Pulmonology William Nix <p>This technology includes a real-time RT-PCR (reverse transcriptase &ndash; polymerase chain reaction) Taqman assay using primers and probes specific for EV-D68 viral protein 1 nucleic acid. This assay provides a more specific identification of EV-D68 strains allowing better diagnosis. Human Enterovirus D68 (EV-D68) is a non-polio enterovirus that can cause mild to severe respiratory illness, especially in infants and children with asthma. The assay is simple, validated, and allows rapid testing and detection of EV-D68 in respiratory samples. This assay can be used in a kit or an array format for high-throughput (large scale) screening of samples, which is useful for public health facilities and surveillance programs.</p> <ul> <li>Detection of currently circulating, newly evolved human EV- D68 strains</li> <li>Simple and rapid as compared to previous methods, making the diagnosis easier</li> <li>High sensitivity and specificity</li> <li>Validated and easily implementable as a kit or array for high-throughput sample screening</li> <li>Faster screening than culturing and serological identification methods</li> <li>This assay was approved under an Emergency Use Authorization (EUA) by the FDA in May, 2015</li> </ul> Rapid, simple and specific detection of new human EV-D68 strains for research or clinical settings to diagnose respiratory infections directly attributable to EV-D68 versus other causative agents. 2023-12-14 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151799012 Nix, William CDC - DIR CDC Nix, William (CDC) 1 151799012 Nix, William CDC - DIR CDC Nix, William (CDC) 1 151798969 Enterovirus D68 Virus Isolates, Genomic Sequences, And A Real-time RT-PCR (Taqman) Assay For Specific Detection E-011-2015-1 Research Material Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4613] Real-time RT-PCR Assay for Rapid, Highly Sensitive and Specific Detection of Human Enterovirus D68 (EV-D68&body=Please send me information about technology [TAB-4613] Real-time RT-PCR Assay for Rapid, Highly Sensitive and Specific Detection of Human Enterovirus D68 (EV-D68. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4613] Real-time RT-PCR Assay for Rapid, Highly Sensitive and Specific Detection of Human Enterovirus D68 (EV-D68&body=Please send me information about technology [TAB-4613] Real-time RT-PCR Assay for Rapid, Highly Sensitive and Specific Detection of Human Enterovirus D68 (EV-D68.">jonathan.motley@nih.gov</a><br> TAB-4612 151798799 Development of Pneumococcal Vaccines CDC Infectious Disease, Research Materials, Therapeutics, Vaccines Infectious Disease Research Materials Therapeutics Vaccines Bernard Beall, Maria Da Gloria Carvalho, Monica Farley, Fernanda Lessa, Jennifer Milucky, Fabiana Pimenta, Cynthia Whitney <p>This technology includes 8 novel strains of the species Streptococcus mitis, Streptococcus oralis, and Streptococcus infantis for vaccine or probiotic development. The capsular biosynthetic genes from each of these strains are highly related to pneumococcal counterparts encoding 5 capsular serotypes. All 8 of these non-pneumococcal strains were recovered from nasopharyngeal (NP) or oropharyngeal (OP) specimens. To achieve their isolation, OP and NP specimens were screened while employing serotype-specific PCR assays and subsequently isolated the positive strains from these specimens through culturing on blood agar plates.</p> These 5 serotypes are common causes of pneumococcal infections and it is possible that these commensal pathogens (S. mitis and S. oralis) expressing surface polysaccharides that cross-react with pneumococci could lead to cross-protection against pneumococcal disease. To be used for the development as a vaccine against pneumococcal disease or a probiotic that would enable the microbiome to be more protective against disease. 2023-12-14 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151798919 Sørensen U, et al. https://pubmed.ncbi.nlm.nih.gov/27935839/ <a href="https://pubmed.ncbi.nlm.nih.gov/27935839/">Sørensen U, et al.</a> 151798812 Farley, Monica Emory University Farley, Monica 1 151798817 Beall, Bernard CDC - DIR CDC Beall, Bernard (CDC) 2 151798864 Carvalho, Maria Da Gloria CDC - DIR CDC Carvalho, Maria Da Gloria (CDC) 3 151798873 Pimenta, Fabiana CDC - DIR CDC Pimenta, Fabiana (CDC) 4 151798881 Whitney, Cynthia CDC - DIR CDC Whitney, Cynthia (CDC) 5 151798891 Lessa, Fernanda CDC - DIR CDC Lessa, Fernanda (CDC) 6 151798908 Milucky, Jennifer CDC - DIR CDC Milucky, Jennifer (CDC) 7 151798812 Farley, Monica Emory University Farley, Monica 1 151798817 Beall, Bernard CDC - DIR CDC Beall, Bernard (CDC) 2 151798864 Carvalho, Maria Da Gloria CDC - DIR CDC Carvalho, Maria Da Gloria (CDC) 3 151798873 Pimenta, Fabiana CDC - DIR CDC Pimenta, Fabiana (CDC) 4 151798881 Whitney, Cynthia CDC - DIR CDC Whitney, Cynthia (CDC) 5 151798891 Lessa, Fernanda CDC - DIR CDC Lessa, Fernanda (CDC) 6 151798908 Milucky, Jennifer CDC - DIR CDC Milucky, Jennifer (CDC) 7 151798802 Streptococcus Mitis And Oralis Expressing Pneumococcal Capsular Polysaccharide E-009-2018-1 Closed Centers for Disease Control and Prevention (CDC), Emory University 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4612] Development of Pneumococcal Vaccines&body=Please send me information about technology [TAB-4612] Development of Pneumococcal Vaccines. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4612] Development of Pneumococcal Vaccines&body=Please send me information about technology [TAB-4612] Development of Pneumococcal Vaccines.">jonathan.motley@nih.gov</a><br> TAB-4611 151798620 Novel F(ab’)2 Antibodies for the Detection of Bacillus Anthracis Lethal Factor CDC Antibodies, Diagnostics, Infectious Disease, Research Materials Antibodies Diagnostics Infectious Disease Research Materials Monica Epperson, Nazia Kamal, Panagiotis Maniatis, Jarad Schiffer <p>This technology includes human F(ab&rsquo;)2 fragments specific for anthrax lethal factor for the development of a lateral flow immunoassay for Bacillus anthracis Lethal Factor. The F(ab&rsquo;)2 fragments are generated from a Human Combinatorial Antibody Library (HuCAL) and are highly specific with high affinity. A multi-step process was utilized beginning by screening a phage display library with over 45 billion functional human antibody specificities. The primary screen against Bacillus anthracis Lethal Factor (LF) generated 360 positive clones. This was followed up by a step to reduce non-specific interactions to normal human serum resulting in more specific F(ab&rsquo;)2. -Bio- Layer Interferometry identified 95 high affinity clones. Sequencing of the 20 highest affinity clones revealed 12 unique F(ab&rsquo;)2 antibodies. These 12 antibodies were evaluated for LF detection using sandwich ELISAs. The F(ab&rsquo;)2 were screened as both capture and detection antibodies to identify possible LF detection pairs.</p> The human F(ab’)2 fragments provide a unique and distinct advantage to mouse monoclonal antibodies: <ul> <li>The F(ab’)2antibodies lack the Fc region and their use, either in Fab-Fab or Fab-mAb pairs eliminates interference by HAMA or heterophilic antibodies.</li> <li>The F(ab’)2 fragments are highly reproducible in a time efficient manner from E.coli stocks from the phage display thus not requiring animal immunizations.</li> </ul> The F(ab’)2 fragments have been used in conjunction with mouse mAbs to develop a lateral flow immunoassay for Bacillus anthracis Lethal Factor. The research has established optimized device conditions and is being currently being evaluated for sensitivity and specificity; at that point, the device will be ready to be transferred to a 3rd party manufacturer to seek 510k approval. In addition to use in a lateral flow immunoassay the F(ab’)2 can be used in multiple platforms for anthrax diagnostics. 2023-12-14 2026-08-26 2026-08-26 2026-08-26 False True True 72159134 Analytical Assay Performance Stage 72159134 37470483 Website Abstract 151798636 Epperson, Monica CDC - DIR CDC Epperson, Monica (CDC) 1 151798644 Kamal, Nazia CDC - DIR CDC Kamal, Nazia (CDC) 2 151798658 Schiffer, Jarad CDC - DIR CDC Schiffer, Jarad (CDC) 3 151798715 Maniatis, Panagiotis CDC - DIR CDC Maniatis, Panagiotis (CDC) 4 151798636 Epperson, Monica CDC - DIR CDC Epperson, Monica (CDC) 1 151798644 Kamal, Nazia CDC - DIR CDC Kamal, Nazia (CDC) 2 151798658 Schiffer, Jarad CDC - DIR CDC Schiffer, Jarad (CDC) 3 151798715 Maniatis, Panagiotis CDC - DIR CDC Maniatis, Panagiotis (CDC) 4 151798623 Novel F(ab’)2 Antibodies For The Detection Of Bacillus Anthracis Lethal Factor E-006-2018-0 Research Material Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4611] Novel F(ab’)2 Antibodies for the Detection of Bacillus Anthracis Lethal Factor&body=Please send me information about technology [TAB-4611] Novel F(ab’)2 Antibodies for the Detection of Bacillus Anthracis Lethal Factor. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4611] Novel F(ab’)2 Antibodies for the Detection of Bacillus Anthracis Lethal Factor&body=Please send me information about technology [TAB-4611] Novel F(ab’)2 Antibodies for the Detection of Bacillus Anthracis Lethal Factor.">jonathan.motley@nih.gov</a><br> TAB-3842 145339564 Development of SARS-CoV-2 Monoclonal Antibodies for Research, Novel Diagnostics, and Thera peutics CDC Antibodies, Collaboration, Infectious Disease, Licensing, Materials Available, Vaccines Antibodies Collaboration Infectious Disease Licensing Materials Available Vaccines Dennis Bagarozzi, Asheley Chapman, Asiya Chida, M.G. Finn, Jason Goldstein, Liangjun Zhao <p>This technology includes a large panel of monoclonal antibodies (mAbs) against the spike glycoprotein, capable of recognizing intact SARS-CoV-2 virions with high affinity. Data to support SARS-CoV-2-specific binding include ELISA and label-free (biolayer interferometry) binding measurements using recombinant proteins, immunofluorescence in culture, immunofluorescence staining of tissue from infected patients, and virus neutralization assays. This invention comprises a potentially large panel of mAbs, some of which will be selective for SARS-CoV-2, and others of which will bind multiple members of the coronavirus family. Additional specifications to the invention could include identification of the precise binding site of each antibody.</p> <ol> <li>Diagnostics: These mAbs have the properties of specific detection of SARS-CoV-2 and limited or non-cross-reactivity with related coronavirus members (SARS-1, MERS). These mAbs are high affinity and will provide higher sensitivity than many commercially available and academic mAbs currently available, will allow for maximizing testing method efficiencies, and will have antibodies that recognize all of the recent human coronaviruses for the development of a pan-coronavirus assay.</li> <li>Therapeutics: Strongly neutralizing antibodies can be developed as therapeutic agents, delivered either directly or via mRNA for in situ expression.</li> <li>Vaccines: The large panel of antibodies that we have will allow us to identify those that neutralize the virus and avoid antibody-dependent enhancement of infectivity. Identifying the epitopes bound by these antibodies will guide the development of targeted immunogens as vaccines.</li> <ol> A rapid, sensitive, and specific point-of-care or point-of-entry diagnostic assay for SARS-CoV-2 active infection, as well as useful for the development of antibody-based therapy and of vaccines. 2023-05-16 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract E-002-2021-0 145339580 Finn, M.G. The Scripps Research Institute Finn, M.G. 1 145339584 Chapman, Asheley Georgia Institute of Technology Chapman, Asheley 2 145339588 Goldstein, Jason CDC - DIR CDC Goldstein, Jason (CDC) 3 145339592 Zhao, Liangjun Georgia Institute of Technology Zhao, Liangjun 4 145339596 Bagarozzi, Dennis CDC - DIR CDC Bagarozzi, Dennis (CDC) 5 145339662 Chida, Asiya CDC - DIR CDC Chida, Asiya (CDC) 6 145339580 Finn, M.G. The Scripps Research Institute Finn, M.G. 1 145339584 Chapman, Asheley Georgia Institute of Technology Chapman, Asheley 2 145339588 Goldstein, Jason CDC - DIR CDC Goldstein, Jason (CDC) 3 145339592 Zhao, Liangjun Georgia Institute of Technology Zhao, Liangjun 4 145339596 Bagarozzi, Dennis CDC - DIR CDC Bagarozzi, Dennis (CDC) 5 145339662 Chida, Asiya CDC - DIR CDC Chida, Asiya (CDC) 6 145339567 Development Of SARS-CoV-2 Monoclonal Antibodies For Research, Novel Diagnostics, And Therapeutics E-002-2021-0 Filing authorized Centers for Disease Control and Prevention (CDC), Georgia Institute of Technology, Georgia Institute of Technology 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3842] Development of SARS-CoV-2 Monoclonal Antibodies for Research, Novel Diagnostics, and Thera peutics&body=Please send me information about technology [TAB-3842] Development of SARS-CoV-2 Monoclonal Antibodies for Research, Novel Diagnostics, and Thera peutics. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3842] Development of SARS-CoV-2 Monoclonal Antibodies for Research, Novel Diagnostics, and Thera peutics&body=Please send me information about technology [TAB-3842] Development of SARS-CoV-2 Monoclonal Antibodies for Research, Novel Diagnostics, and Thera peutics.">benjamin.hurley@nih.gov</a><br> TAB-4868 152586851 Monoclonal Antibodies Targeting Bacillus anthracis Lethal Factor: Potential Tools for Anthrax Detection and Intervention NIAID Antibodies, Collaboration, Diagnostics, Infectious Disease, Licensing, Therapeutics Antibodies Collaboration Diagnostics Infectious Disease Licensing Therapeutics Stephen Leppla <p>The technology involves the development of monoclonal antibodies produced by hybridomas, including cell lines such as 10G3, 3E6, 10D4, 10G4, 1D8, 13D10, 9E5, and 9F10, which specifically react with Bacillus anthracis Lethal Factor (LF). These monoclonal antibodies offer valuable applications in anthrax detection, therapeutic intervention, and research into the biology of Bacillus anthracis and its lethal toxin. This advancement provides promising tools for mitigating the impact of anthrax infections and advancing our understanding of this deadly pathogen.</p> Monoclonal antibodies targeting Bacillus anthracis Lethal Factor (LF) offer a precise and versatile solution for anthrax detection, intervention, and research. Their specificity and established reliability make them a competitive asset in various applications, from diagnostics to therapeutics. These monoclonal antibodies have diverse applications. They can be used in accurate anthrax detection, rapid response to outbreaks, and therapeutic development. In research, they deepen our understanding of Bacillus anthracis. Their versatility makes them valuable in biodefense, public health, and scientific exploration. 2024-02-05 2026-08-26 2026-08-26 2026-08-26 False True True 72159134 Analytical Assay Performance Stage 72159134 37470483 Website Abstract 152586862 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 1 152586862 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 1 152586858 Monoclonal Antibodies That React With Anthrax Lethal Factor (LF) E-047-2018-0 Research Material NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4868] Monoclonal Antibodies Targeting Bacillus anthracis Lethal Factor: Potential Tools for Anthrax Detection and Intervention&body=Please send me information about technology [TAB-4868] Monoclonal Antibodies Targeting Bacillus anthracis Lethal Factor: Potential Tools for Anthrax Detection and Intervention. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4868] Monoclonal Antibodies Targeting Bacillus anthracis Lethal Factor: Potential Tools for Anthrax Detection and Intervention&body=Please send me information about technology [TAB-4868] Monoclonal Antibodies Targeting Bacillus anthracis Lethal Factor: Potential Tools for Anthrax Detection and Intervention.">wade.green@nih.gov</a><br> TAB-4864 152464344 Novel Broadly-Neutralizing Anti-HIV Antibody: A Potential Game-Changer in HIV Prevention and Treatment NIAID Antibodies, Collaboration, Infectious Disease, Licensing, Research Equipment, Therapeutics Antibodies Collaboration Infectious Disease Licensing Research Equipment Therapeutics Mark Connors, Jinghe Huang, Byong Kang, John Mascola, Andrew Ward <p>This groundbreaking technology introduces a highly potent, human anti-HIV antibody that targets a novel epitope, surpassing the efficacy of existing anti-HIV antibodies. With a prolonged half-life, it offers versatile applications, including early-stage HIV treatment, newborn prophylaxis, and vaccine development validation. Collaborative efforts aim to harness its potential for antibody-dependent cell-mediated cytotoxicity (ADCC) against HIV-infected cells. In addressing a pressing global health concern, this innovation signifies a promising stride forward in HIV prevention and treatment.</p> This groundbreaking technology offers distinct competitive advantages. It targets a novel HIV epitope, expanding protection beyond existing antibodies. Its remarkable potency, neutralizing over 80% of HIV strains, surpasses current options. With a prolonged half-life, it reduces the need for frequent administration. Versatile applications include early-stage HIV treatment, newborn prophylaxis, and vaccine validation. Collaborative efforts enhance its potential for cell-mediated cytotoxicity against HIV-infected cells. Overall, it presents a potent, unique, and adaptable solution in HIV management. This innovative technology offers versatile applications in HIV management. It has potential as a potent early-stage HIV treatment, a safeguard for newborns against transmission, and a tool for validating HIV vaccine candidates. Collaborative research may also enhance its therapeutic capabilities. In summary, it presents a multifaceted solution for addressing various aspects of the HIV challenge. 2024-01-29 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 152464357 Ward, Andrew The Scripps Research Institute Ward, Andrew 1 152464361 Connors, Mark NIAID - DIR NIAID Connors, Mark (NIAID) 2 152464365 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 3 152464369 Huang, Jinghe National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Huang, Jinghe (NIAID) 4 152464373 Kang, Byong NIAID Kang, Byong (NIAID) 5 152464357 Ward, Andrew The Scripps Research Institute Ward, Andrew 1 152464361 Connors, Mark NIAID - DIR NIAID Connors, Mark (NIAID) 2 152464365 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 3 152464369 Huang, Jinghe National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Huang, Jinghe (NIAID) 4 152464373 Kang, Byong NIAID Kang, Byong (NIAID) 5 152464347 A Potent, Broadly-neutralizing, Anti-HIV Antibody (35022) That Binds A Novel Epitope E-043-2014-0 Filing authorized NIAID, Scripps Research Institute Immunology Lab 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4864] Novel Broadly-Neutralizing Anti-HIV Antibody: A Potential Game-Changer in HIV Prevention and Treatment&body=Please send me information about technology [TAB-4864] Novel Broadly-Neutralizing Anti-HIV Antibody: A Potential Game-Changer in HIV Prevention and Treatment. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4864] Novel Broadly-Neutralizing Anti-HIV Antibody: A Potential Game-Changer in HIV Prevention and Treatment&body=Please send me information about technology [TAB-4864] Novel Broadly-Neutralizing Anti-HIV Antibody: A Potential Game-Changer in HIV Prevention and Treatment.">benjamin.hurley@nih.gov</a><br> TAB-4863 152464111 Development of a Prime-Boost Vaccine Strategy for Comprehensive Protection Against Filovirus Infections NIAID Animal Models, Collaboration, Infectious Disease, Plasmids/Vectors, Research Equipment, Vaccines Animal Models Collaboration Infectious Disease Plasmids/Vectors Research Equipment Vaccines Clement Asiedu, Cheng Cheng, Jaap Goudsmit, Gary Nabel, Maria Pau, Nancy Sullivan <p>This technology presents a sophisticated two-step vaccination approach designed to provide comprehensive protection against filovirus infections, including Ebola and Marburg viruses. It involves administering a prime-boost vaccine sequence, employing replication-defective adenoviral serotype 26 (Ad26) as the priming agent and replication-defective adenoviral serotype 35 (Ad35) as the boosting agent. Both vectors are engineered to express the crucial filovirus envelope glycoprotein (GP), encompassing various strains of Ebolavirus (EBOV) and Marburg (MAR). The primary application of this technology is for preventative vaccination, offering significant potential in the fight against filovirus outbreaks and their devastating consequences.</p> This innovative technology offers a two-step prime-boost vaccination strategy using Ad26 and Ad35 vectors expressing various filovirus GP strains. This approach provides comprehensive immunity against different filovirus strains and adaptability to emerging variants. It has potential applications in both prevention and treatment, promising significant advancements in the fight against filovirus infections. This technology offers versatile applications. It can serve as a potent preventive vaccine against Ebola and Marburg viruses, safeguarding at-risk populations and healthcare workers during outbreaks. Its adaptability to diverse filovirus strains enhances its effectiveness in countering evolving viral threats. Furthermore, it holds potential for therapeutic use in treating individuals already infected with filoviruses, contributing significantly to public health efforts worldwide. 2024-01-29 2026-08-26 2026-08-26 2026-08-26 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 152464118 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 1 152464122 Nabel, Gary ModeX Therapeutics, Inc. NIAID Nabel, Gary (NIAID) 2 152464193 Asiedu, Clement Asiedu, Clement 3 152464198 Cheng, Cheng NIAID - VRC NIAID Cheng, Cheng (NIAID) 4 152464247 Pau, Maria Crucell Holland BV Pau, Maria 5 152464257 Goudsmit, Jaap Crucell Holland BV Goudsmit, Jaap 6 152464118 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 1 152464122 Nabel, Gary ModeX Therapeutics, Inc. NIAID Nabel, Gary (NIAID) 2 152464193 Asiedu, Clement Asiedu, Clement 3 152464198 Cheng, Cheng NIAID - VRC NIAID Cheng, Cheng (NIAID) 4 152464247 Pau, Maria Crucell Holland BV Pau, Maria 5 152464257 Goudsmit, Jaap Crucell Holland BV Goudsmit, Jaap 6 152464114 Adenovirus Serotype 26/ Adenovirus Serotype 35 Prime Boost Filovirus Vaccine E-043-2011-0 Filing authorized Crucell Holland BV, NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4863] Development of a Prime-Boost Vaccine Strategy for Comprehensive Protection Against Filovirus Infections&body=Please send me information about technology [TAB-4863] Development of a Prime-Boost Vaccine Strategy for Comprehensive Protection Against Filovirus Infections. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4863] Development of a Prime-Boost Vaccine Strategy for Comprehensive Protection Against Filovirus Infections&body=Please send me information about technology [TAB-4863] Development of a Prime-Boost Vaccine Strategy for Comprehensive Protection Against Filovirus Infections.">wade.green@nih.gov</a><br> TAB-4862 152463916 Discovery and Application of Anti-Idiotypic Antibodies for Enhanced Therapeutic Control NIAID Antibodies, Collaboration, Diagnostics, Infectious Disease, Therapeutics Antibodies Collaboration Diagnostics Infectious Disease Therapeutics John Mascola, Gary Nabel, Lan Wu, Zhi-yong Yang <p>This technology introduces a groundbreaking method for discovering and isolating anti-idiotypic antibodies, with a primary focus on inhibiting or extinguishing the activity of VRCOl, a broadly neutralizing anti-HIV-1 antibody. These anti-idiotypic antibodies provide a vital mechanism for controlling adverse events that may result from therapeutic antibody administration. The innovative method involves immunizing animals with specific antibody fragments, followed by systematic selection and isolation of somatically mutated B cells. This versatile approach can be applied to generate tailored anti-idiotypic antibodies against various therapeutic antibodies, opening doors to safer and more effective immunotherapies in diverse fields.</p> This technology offers a competitive advantage by enhancing the safety and efficacy of therapeutic antibodies, controlling their activity to prevent adverse events. Its versatility applies to various therapeutic areas, including HIV-1 and cancer immunotherapy. Customization ensures precise targeting, while an innovative discovery method streamlines development, reducing costs and time. These uniquely matched antibodies have broad implications, revolutionizing immunotherapy. This technology has broad applications in healthcare and biotechnology. It can improve treatments for infectious diseases like HIV-1, enhance cancer immunotherapy, develop precise therapies for autoimmune diseases, and aid in vaccine design, offering versatile solutions across various fields. 2024-01-29 2026-08-26 2026-08-26 2026-08-26 False True True 52406769 Prototype 52406769 37470483 Website Abstract 152463923 Nabel, Gary ModeX Therapeutics, Inc. NIAID Nabel, Gary (NIAID) 1 152463927 Wu, Lan Sanofi U.S. Services Inc. Wu, Lan 2 152463931 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 3 152463935 Yang, Zhi-yong Sanofi-Aventis NIAID Yang, Zhi-yong (NIAID) 4 152463923 Nabel, Gary ModeX Therapeutics, Inc. NIAID Nabel, Gary (NIAID) 1 152463927 Wu, Lan Sanofi U.S. Services Inc. Wu, Lan 2 152463931 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 3 152463935 Yang, Zhi-yong Sanofi-Aventis NIAID Yang, Zhi-yong (NIAID) 4 152463919 Development Of Anti-Idiotypic Antibodies Against HIV Neutralizing Monoclonal Antibodies E-041-2012-0 Filing authorized NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4862] Discovery and Application of Anti-Idiotypic Antibodies for Enhanced Therapeutic Control&body=Please send me information about technology [TAB-4862] Discovery and Application of Anti-Idiotypic Antibodies for Enhanced Therapeutic Control. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4862] Discovery and Application of Anti-Idiotypic Antibodies for Enhanced Therapeutic Control&body=Please send me information about technology [TAB-4862] Discovery and Application of Anti-Idiotypic Antibodies for Enhanced Therapeutic Control.">sabrina.hafiz@nih.gov</a><br> TAB-4860 152463459 Advancements in Cytokine Gene Research: Non-Destructive Detection and Isolation through Genetically Modified Mice NIAID Animal Models, Collaboration, Diagnostics, Immunology, Licensing, Plasmids/Vectors, Research Equipment, Research Materials, Therapeutics Animal Models Collaboration Diagnostics Immunology Licensing Plasmids/Vectors Research Equipment Research Materials Therapeutics Xin Chen, William Paul (Estate Of) <p>This groundbreaking technology entails the utilization of genetically modified mice, specifically engineered to enable the non-destructive detection and isolation of cells actively transcribing the IL-4 and IL-13 genes. By expressing Amcyan and DsRed-DR fluorescent proteins under the control of these gene loci, researchers gain a powerful tool for studying cytokine gene expression without the need for cell death, offering significant advantages over traditional intracellular staining methods. This innovative approach simplifies experiments, facilitates microscopic observations, and opens new avenues for immunology and cell biology research.</p> The utilization of genetically modified mice for non-destructive detection and isolation of cells transcribing IL-4 and IL-13 genes offers several competitive advantages. These mice simplify experimental setups by providing a dual-reporter system, reducing the need for multiple animal models. Moreover, their non-destructive nature preserves cell viability, enabling dynamic, long-term studies, and expanding possibilities for novel experimental manipulations. This technology enhances our understanding of cytokine gene expression in immunology and cell biology research. This technology has broad applications in immunology and cell biology. It enables real-time studies of immune responses, identification of disease-related cell populations, and investigation of IL-4 and IL-13 roles in various conditions. It also supports drug development by isolating and analyzing cells involved in cytokine signaling pathways. Longitudinal studies are feasible, offering insights into gene expression changes over time. Ultimately, this technology enhances our understanding of cytokine gene regulation and its implications for health and disease. 2024-01-29 2026-08-26 2026-08-26 2026-08-26 False True True 52406769 Prototype 52406769 37470483 Website Abstract 152463595 Paul (Estate Of), William National Institute of Allergy and Infectious Diseases (NIAID/NIH) Paul (Estate Of), William 1 152463599 Chen, Xin University of California, San Francisco (UCSF) Chen, Xin 2 152463595 Paul (Estate Of), William National Institute of Allergy and Infectious Diseases (NIAID/NIH) Paul (Estate Of), William 1 152463599 Chen, Xin University of California, San Francisco (UCSF) Chen, Xin 2 152463462 Generation Of 4C13R Mice (IL-4-Amcyan/IL-13-DsREd Reporter Mice E-039-2020-0 Research Material NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4860] Advancements in Cytokine Gene Research: Non-Destructive Detection and Isolation through Genetically Modified Mice&body=Please send me information about technology [TAB-4860] Advancements in Cytokine Gene Research: Non-Destructive Detection and Isolation through Genetically Modified Mice. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4860] Advancements in Cytokine Gene Research: Non-Destructive Detection and Isolation through Genetically Modified Mice&body=Please send me information about technology [TAB-4860] Advancements in Cytokine Gene Research: Non-Destructive Detection and Isolation through Genetically Modified Mice.">yogikala.prabhu@nih.gov</a><br> TAB-4859 152463161 Development and Application of a High-Affinity Polyclonal Antibody to BST-2: A Versatile Tool for Investigating Viral Host Restriction NIAID Antibodies, Collaboration, Diagnostics, Immunology, Infectious Disease, Licensing, Materials Available, Rare/Neglected Diseases, Research Materials Antibodies Collaboration Diagnostics Immunology Infectious Disease Licensing Materials Available Rare/Neglected Diseases Research Materials Amy Andrew, Klaus Strebel <p>The developed technology is a high-affinity polyclonal antibody targeting BST-2, a crucial surface antigen involved in restricting the replication of HIV-1 and other enveloped viruses. This antibody, generated from recombinant BST-2 ectodomain protein, offers versatility in various research techniques, such as FACS, immunoblotting, immunofluorescence, and immunoprecipitation. Additionally, it exhibits bioactivity, effectively inhibiting BST-2 function in virus-producing cells. With the added benefit of cross-reactivity with rhesus macaque BST-2, this antibody serves as a valuable diagnostic tool for identifying BST-2 expression in tissues of human and rhesus macaque origin, providing insights into host-virus interactions and potential therapeutic applications. Further comparative studies with commercial monoclonal antibodies could illuminate its suitability for specific research needs.</p> <p>&nbsp;</p> The high-affinity polyclonal BST-2 antibody offers competitive advantages in viral research and diagnostics. Its versatility across various techniques, bioactivity inhibiting BST-2 function, and cross-reactivity with rhesus macaque BST-2 make it a valuable tool for diverse applications. Researchers benefit from its unique combination of functionality and compatibility with different species, while comparative studies with commercial antibodies can highlight its specific advantages for tailored research needs. The high-affinity polyclonal BST-2 antibody has diverse potential applications. It can be used to uncover the mechanisms of viral host restriction, explore therapeutic strategies against viral infections by inhibiting BST-2 function, and facilitate research in animal models due to its cross-reactivity with rhesus macaque BST-2. Additionally, it serves as a valuable diagnostic tool for identifying BST-2 expression in human and rhesus macaque tissues, aiding in viral infection diagnosis and monitoring. 2024-01-29 2026-08-26 2026-08-26 2026-08-26 False True True 52406769 Prototype 52406769 37470483 Website Abstract 152463172 Strebel, Klaus NIAID - DIR NIAID Strebel, Klaus (NIAID) 1 152463319 Andrew, Amy Andrew, Amy 2 152463172 Strebel, Klaus NIAID - DIR NIAID Strebel, Klaus (NIAID) 1 152463319 Andrew, Amy Andrew, Amy 2 152463164 Production Of A High-affinity Polyclonal Antibody To Human BST-2 E-039-2013-0 Research Material NIAID 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-4859] Development and Application of a High-Affinity Polyclonal Antibody to BST-2: A Versatile Tool for Investigating Viral Host Restriction&body=Please send me information about technology [TAB-4859] Development and Application of a High-Affinity Polyclonal Antibody to BST-2: A Versatile Tool for Investigating Viral Host Restriction. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-4859] Development and Application of a High-Affinity Polyclonal Antibody to BST-2: A Versatile Tool for Investigating Viral Host Restriction&body=Please send me information about technology [TAB-4859] Development and Application of a High-Affinity Polyclonal Antibody to BST-2: A Versatile Tool for Investigating Viral Host Restriction.">peter.tung@nih.gov</a><br> TAB-4858 152462771 Highly Potent Monoclonal Antibodies Targeting CSP NIAID Antibodies, Collaboration, Infectious Disease, Research Equipment, Therapeutics Antibodies Collaboration Infectious Disease Research Equipment Therapeutics Barbara Flynn, Stephen Hoffman, Azza Idris, Neville Kisalu, Robert Seder <p>Cutting-edge research has led to the development of highly potent monoclonal antibodies (mAbs) targeting the circumsporozoite protein (CSP) in the fight against malaria. These fully human recombinant mAbs, isolated from immunized volunteers, exhibit exceptional blocking capacity, with a potency 100 times greater than existing mouse monoclonal CSP antibodies. This breakthrough paves the way for a novel strategy in malaria prevention, offering hope to millions of individuals worldwide, including travelers, military personnel, diplomats, and those residing in malaria-endemic regions. Clinical trials are on the horizon to assess their efficacy and safety in humans, marking a critical step towards eradicating this deadly disease.</p> <p>&nbsp;</p> Monoclonal antibodies (mAbs) targeting CSP for malaria prevention possess a significant competitive edge due to their exceptional 100-fold potency increase compared to existing mouse monoclonal CSP antibodies. These fully human recombinant mAbs are poised for clinical trials, offering a potent and advanced solution with the potential to reshape malaria prevention strategies. Their capacity to target additional parasite surface immunogens further enhances their versatility, establishing them as leaders in the fight against malaria. These CSP-targeting monoclonal antibodies have wide-ranging potential applications. They can be instrumental in preventing malaria for travelers, military personnel, and diplomats in endemic regions. Additionally, their efficacy makes them a valuable tool for malaria eradication efforts among residents and healthcare workers in these regions. Moreover, their versatility extends to potentially targeting other parasite surface immunogens, offering a broader scope for malaria prevention strategies. In summary, these antibodies have the potential to revolutionize malaria control efforts and bring us closer to a malaria-free world. 2024-01-29 2026-08-26 2026-08-26 2026-08-26 False False True 72159140 Clinical Phase II 72159140 37470483 Website Abstract 152462778 Flynn, Barbara NIAID - VRC NIAID Flynn, Barbara (NIAID) 1 152462782 Seder, Robert NIAID - VRC NIAID Seder, Robert (NIAID) 2 152462797 Kisalu, Neville NIAID - VRC NIAID Kisalu, Neville (NIAID) 3 152462840 Idris, Azza NIAID - VRC NIAID Idris, Azza (NIAID) 4 152462844 Hoffman, Stephen Sanaria, Inc. Hoffman, Stephen 5 152462778 Flynn, Barbara NIAID - VRC NIAID Flynn, Barbara (NIAID) 1 152462782 Seder, Robert NIAID - VRC NIAID Seder, Robert (NIAID) 2 152462797 Kisalu, Neville NIAID - VRC NIAID Kisalu, Neville (NIAID) 3 152462840 Idris, Azza NIAID - VRC NIAID Idris, Azza (NIAID) 4 152462844 Hoffman, Stephen Sanaria, Inc. Hoffman, Stephen 5 152462774 Identification Of Potent Fully Human Malaria Neutralizing Antibodies From A Volunteer Immunized With Plasmodium Falciparum Sporozoites (PfSPZ) E-038-2017-0 Filing authorized NIAID, Sanaria, Inc. 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-4858] Highly Potent Monoclonal Antibodies Targeting CSP&body=Please send me information about technology [TAB-4858] Highly Potent Monoclonal Antibodies Targeting CSP. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-4858] Highly Potent Monoclonal Antibodies Targeting CSP&body=Please send me information about technology [TAB-4858] Highly Potent Monoclonal Antibodies Targeting CSP.">polung.yang@nih.gov</a><br> TAB-4856 152462176 Advancing Infectious Disease Prevention and Diagnostics: An Innovative Approach to Attenuated RSV Vaccines NIAID Collaboration, Diagnostics, Infectious Disease, Licensing, Research Equipment, Respiratory, Therapeutics, Vaccines Collaboration Diagnostics Infectious Disease Licensing Research Equipment Respiratory Therapeutics Vaccines Peter Collins, Thomas McCarty <p>This technology involves the development of live attenuated vaccine candidates for respiratory syncytial virus (RSV), a significant cause of severe respiratory tract diseases, particularly in infants and young children. The approach focuses on relocating the NS1 and NS2 genes within the RSV genome to downstream positions, resulting in reduced transcription and expression. This gene-shifting strategy allows for controlled attenuation of the virus, avoiding over-attenuation seen with gene deletion. Combining gene shifts with other mutations fine-tunes the level of attenuation. Reduced NS1 and NS2 expression may enhance immunogenicity by promoting increased interferon production. The technology offers a flexible and promising solution for creating RSV vaccines to address a critical healthcare need.</p> <p>&nbsp;</p> This technology holds a competitive edge by addressing the urgent need for an RSV vaccine. Its gene-shifting method offers precise control of viral attenuation, avoiding over-attenuation seen with gene deletion. The potential to enhance immunogenicity through reduced NS1 and NS2 expression further distinguishes it, making it a promising and adaptable solution for RSV vaccine development. This technology has immediate applications in developing vaccines against respiratory syncytial virus (RSV), addressing a critical healthcare need. Beyond RSV, its adaptable gene-shifting approach could revolutionize vaccine development for various infectious diseases, offering a versatile platform for creating effective vaccines. Additionally, its potential to enhance immunogenicity holds promise for improving vaccine efficacy across different viral pathogens, making it a valuable tool in the fight against infectious diseases. 2024-01-29 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 152462192 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 152462209 McCarty, Thomas NIAID - DIR NIAID McCarty, Thomas (NIAID) 2 152462192 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 152462209 McCarty, Thomas NIAID - DIR NIAID McCarty, Thomas (NIAID) 2 152462179 Attenuated RSV Vaccine Strains In Which The NS1 And/or NS2 Genes Have Been Shifted To Promoter-distal Positions E-037-2016-0 Filing authorized NIAID 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-4856] Advancing Infectious Disease Prevention and Diagnostics: An Innovative Approach to Attenuated RSV Vaccines&body=Please send me information about technology [TAB-4856] Advancing Infectious Disease Prevention and Diagnostics: An Innovative Approach to Attenuated RSV Vaccines. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-4856] Advancing Infectious Disease Prevention and Diagnostics: An Innovative Approach to Attenuated RSV Vaccines&body=Please send me information about technology [TAB-4856] Advancing Infectious Disease Prevention and Diagnostics: An Innovative Approach to Attenuated RSV Vaccines.">maryann.puglielli@nih.gov</a><br> TAB-4854 152461770 Autologous Granulocyte Therapy as a Game-Changer NIAID Collaboration, Human Cell Lines, Immunology, Infectious Disease, Licensing, Plasmids/Vectors, Research Equipment, Therapeutics Collaboration Human Cell Lines Immunology Infectious Disease Licensing Plasmids/Vectors Research Equipment Therapeutics Suk See De Ravin, Harry Malech <p>Autologous Granulocyte Therapy, a cutting-edge advancement in the treatment of Chronic Granulomatous Disease (CGD), offers a groundbreaking solution to the challenges faced by CGD patients. This innovative technology involves correcting the genetic defects in the patient&#39;s own phagocytes by providing the missing messenger RNA (mRNA) required for protein production. These functionally corrected autologous granulocytes can then be reintroduced into the patient&#39;s system to combat severe infections. By eliminating the need for donor granulocytes and mitigating the risks associated with allo-immunization, infections, and incompatibility, this approach represents a promising and patient-centric alternative for treating CGD, potentially providing a more cost-effective and safer therapeutic option.</p> Autologous Granulocyte Therapy for Chronic Granulomatous Disease (CGD) offers notable competitive advantages. By utilizing the patient's own cells, it simplifies treatment logistics by eliminating the need for donor compatibility considerations and significantly reduces the risk of immune reactions. Moreover, this approach holds the potential for cost savings, as it bypasses the expenses associated with donor procurement and compatibility testing. In essence, Autologous Granulocyte Therapy represents a patient-centered paradigm shift in CGD treatment, ensuring greater safety, availability, and cost-efficiency. Autologous Granulocyte Therapy, initially developed for treating Chronic Granulomatous Disease (CGD), has the potential for broader applications. By addressing genetic defects in a patient's own cells, it offers personalized treatments for various genetic disorders where cell dysfunction is a critical factor. Additionally, this innovative approach can improve immune-based therapies for severe infections in individuals with compromised immune systems, providing a safer alternative to traditional donor cell transfusions. 2024-01-29 2026-08-26 2026-08-26 2026-08-26 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 152461788 De Ravin, Suk See NIAID - DIR NIAID De Ravin, Suk See (NIAID) 1 152461799 Malech, Harry NIAID - DIR NIAID Malech, Harry (NIAID) 2 152461788 De Ravin, Suk See NIAID - DIR NIAID De Ravin, Suk See (NIAID) 1 152461799 Malech, Harry NIAID - DIR NIAID Malech, Harry (NIAID) 2 152461773 Treatment Of Infections In Patients With Primary Immune Deficiencies Using MRNA-Corrected Autologous Granulocytes E-035-2018-0 Filing authorized CellScript, LLC, NIAID 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-4854] Autologous Granulocyte Therapy as a Game-Changer&body=Please send me information about technology [TAB-4854] Autologous Granulocyte Therapy as a Game-Changer. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-4854] Autologous Granulocyte Therapy as a Game-Changer&body=Please send me information about technology [TAB-4854] Autologous Granulocyte Therapy as a Game-Changer.">polung.yang@nih.gov</a><br> TAB-4853 152461286 Advancing HIV-1 gp120 Stabilization for Enhanced Vaccine Design and Therapeutic Development NIAID Collaboration, Infectious Disease, Therapeutics Collaboration Infectious Disease Therapeutics Edward Berger, Barna Dey, Paolo Lusso <p>This technology focuses on a groundbreaking approach to enhance the development of HIV/AIDS prevention and treatment strategies. By identifying a previously unrecognized constraint that stabilizes the closed conformation of the crucial HIV-1 envelope glycoprotein gp120, researchers have devised a novel means of blocking HIV-1 entry and fusion using a V1V2 stem mimetic peptide. Furthermore, engineered mutants of gp120, named L1 mutants, exhibit increased stability and a trimer-like configuration, making them promising candidates for immunogens capable of eliciting broadly neutralizing antibodies, essential for a protective vaccine. This innovative approach presents new avenues for advancing HIV prevention, treatment, and vaccine design.</p> <p>&nbsp;</p> This technology introduces a novel approach to stabilize gp120 and inhibit HIV-1 entry effectively. Additionally, the engineered L1 mutants provide a unique platform for generating broadly neutralizing antibodies, offering promising prospects for HIV vaccine development. These innovations provide a significant edge in addressing the HIV/AIDS challenge. The new HIV/AIDS technology, focusing on stabilizing the HIV-1 envelope glycoprotein gp120, offers a novel approach to prevent HIV entry and fusion. The development of V1V2 stem mimetic peptide and engineered L1 mutants shows promise for creating effective HIV vaccines. These advancements represent a significant step forward in HIV treatment and prevention strategies. This technology is crucial for advancing global HIV eradication efforts. 2024-01-29 2026-08-26 2026-08-26 2026-08-26 False True True 72159138 Clinical Phase I 72159138 37470483 Website Abstract 152461326 Lusso, Paolo NIAID - DIR NIAID Lusso, Paolo (NIAID) 1 152461330 Berger, Edward NIAID - DIR NIAID Berger, Edward (NIAID) 2 152461445 Dey, Barna NIAID - DIR NIAID Dey, Barna (NIAID) 3 152461326 Lusso, Paolo NIAID - DIR NIAID Lusso, Paolo (NIAID) 1 152461330 Berger, Edward NIAID - DIR NIAID Berger, Edward (NIAID) 2 152461445 Dey, Barna NIAID - DIR NIAID Dey, Barna (NIAID) 3 152461289 Gp120-derived Peptides, Mimetics And Mutants Reproducing A Key Structural Constraint That Stabilizes The Native HIV-1 Envelope For Use As Inhibitors Or Vaccine Immungens E-035-2014-0 Filing authorized NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4853] Advancing HIV-1 gp120 Stabilization for Enhanced Vaccine Design and Therapeutic Development&body=Please send me information about technology [TAB-4853] Advancing HIV-1 gp120 Stabilization for Enhanced Vaccine Design and Therapeutic Development. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4853] Advancing HIV-1 gp120 Stabilization for Enhanced Vaccine Design and Therapeutic Development&body=Please send me information about technology [TAB-4853] Advancing HIV-1 gp120 Stabilization for Enhanced Vaccine Design and Therapeutic Development.">benjamin.hurley@nih.gov</a><br> TAB-4850 152460462 Advancements in Modular Nanoparticle-Based Influenza Vaccines for Enhanced Immunogenicity and Broad-Spectrum Protection NIAID Animal Models, Antibodies, Collaboration, Diagnostics, Immunology, Infectious Disease, Licensing, Research Materials, Respiratory, Therapeutics, Vaccines Animal Models Antibodies Collaboration Diagnostics Immunology Infectious Disease Licensing Research Materials Respiratory Therapeutics Vaccines Seyhan Boyoglu-Barnum, Daniel Ellis, Rebecca Gillespie, Barney Graham, Masaru Kanekiyo, Neil King, Jing Wang <p>Researchers have developed a groundbreaking influenza vaccine using a modular nanoparticle platform that displays hemagglutinin (HA) from various influenza strains on either separate or combined particles. Unlike traditional vaccines with limited efficacy due to antigenic mismatch, these novel nanoparticles can be customized to target seasonal strains, offering stronger immune responses and broader protection against multiple subtypes, including those not included in the annual vaccine formulation. This innovation has the potential to greatly improve pandemic preparedness by enabling rapid response to emerging influenza strains through swift reconfiguration of vaccine components.</p> The new modular nanoparticle-based flu vaccine outperforms traditional vaccines with its broad-spectrum efficacy and adaptability to multiple virus subtypes, ensuring rapid response to mutating strains and offering a versatile solution to annual flu outbreaks. The innovative nanoparticle-based influenza vaccine technology has vast potential applications, extending beyond seasonal flu prevention. It could revolutionize pandemic response by enabling quick customization to combat emergent virus strains. Additionally, the technology's modular nature holds promise for creating more effective combination vaccines against multiple pathogens and may pave the way for next-generation immunotherapies targeting a range of infectious diseases. 2024-01-29 2026-08-26 2026-08-26 2026-08-26 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 152460475 Ellis, Daniel University of Washington Ellis, Daniel 1 152460490 Wang, Jing University of Washington Wang, Jing 2 152460495 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 3 152460499 Graham, Barney Morehouse School of Medicine NIAID Graham, Barney (NIAID) 4 152460509 Boyoglu-Barnum, Seyhan NIAID - VRC NIAID Boyoglu-Barnum, Seyhan (NIAID) 5 152460726 King, Neil University of Washington King, Neil 6 152460730 Gillespie, Rebecca NIAID - VRC NIAID Gillespie, Rebecca (NIAID) 7 152460475 Ellis, Daniel University of Washington Ellis, Daniel 1 152460490 Wang, Jing University of Washington Wang, Jing 2 152460495 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 3 152460499 Graham, Barney Morehouse School of Medicine NIAID Graham, Barney (NIAID) 4 152460509 Boyoglu-Barnum, Seyhan NIAID - VRC NIAID Boyoglu-Barnum, Seyhan (NIAID) 5 152460726 King, Neil University of Washington King, Neil 6 152460730 Gillespie, Rebecca NIAID - VRC NIAID Gillespie, Rebecca (NIAID) 7 152460466 Adaptive Modular Nanoparticle-Based Universal Influenza Vaccine Platform E-032-2019-0 Filing authorized NIAID, University of Washington 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4850] Advancements in Modular Nanoparticle-Based Influenza Vaccines for Enhanced Immunogenicity and Broad-Spectrum Protection&body=Please send me information about technology [TAB-4850] Advancements in Modular Nanoparticle-Based Influenza Vaccines for Enhanced Immunogenicity and Broad-Spectrum Protection. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4850] Advancements in Modular Nanoparticle-Based Influenza Vaccines for Enhanced Immunogenicity and Broad-Spectrum Protection&body=Please send me information about technology [TAB-4850] Advancements in Modular Nanoparticle-Based Influenza Vaccines for Enhanced Immunogenicity and Broad-Spectrum Protection.">wade.green@nih.gov</a><br> TAB-4846 152410948 Advancements in Live Attenuated Vaccines: A Novel Approach for Japanese Encephalitis and Beyond NIAID Animal Models, Antibodies, Collaboration, Diagnostics, Infectious Disease, Licensing, Plasmids/Vectors, Therapeutics Animal Models Antibodies Collaboration Diagnostics Infectious Disease Licensing Plasmids/Vectors Therapeutics Gregory Gromowski, Stephen Whitehead <p>The development of live attenuated vaccines for Japanese encephalitis (JE) represents a groundbreaking technology with the potential to transform vaccination approaches. These vaccines offer the advantage of single-dose administration, simplifying vaccination schedules and reducing logistical challenges. In addition to their potential cost-effectiveness and accessibility, combining live attenuated JEV vaccines with existing dengue vaccines could provide a comprehensive solution for regions facing the dual threat of JE and dengue viruses, marking a significant advancement in public health strategies.</p> <p>&nbsp;</p> The competitive advantages of live attenuated Japanese encephalitis (JE) vaccines include single-dose administration, cost-effectiveness, improved accessibility, and the potential for combined protection against other vector-borne diseases, enhancing overall public health strategies. The potential applications of live attenuated vaccines for Japanese encephalitis (JE) extend beyond just this disease. These innovative vaccines, with their single-dose convenience and cost-effectiveness, could serve as a model for combating other viral infections. Furthermore, their adaptability for combining with existing vaccines opens up possibilities for creating multifaceted immunization solutions against various vector-borne diseases, addressing critical public health challenges in diverse regions. 2024-01-25 2026-08-26 2026-08-26 2026-08-26 False True True 72159138 Clinical Phase I 72159138 37470483 Website Abstract 152410958 Whitehead, Stephen NIAID - DIR NIAID Whitehead, Stephen (NIAID) 1 152410965 Gromowski, Gregory NIAID - DIR NIAID Gromowski, Gregory (NIAID) 2 152410958 Whitehead, Stephen NIAID - DIR NIAID Whitehead, Stephen (NIAID) 1 152410965 Gromowski, Gregory NIAID - DIR NIAID Gromowski, Gregory (NIAID) 2 152410951 Generation Of Chimeric JEV/DEN4 Vaccine Candidates For Control Of Japanese Encephalitis E-031-2012-0 Filing authorized NIAID 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-4846] Advancements in Live Attenuated Vaccines: A Novel Approach for Japanese Encephalitis and Beyond&body=Please send me information about technology [TAB-4846] Advancements in Live Attenuated Vaccines: A Novel Approach for Japanese Encephalitis and Beyond. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-4846] Advancements in Live Attenuated Vaccines: A Novel Approach for Japanese Encephalitis and Beyond&body=Please send me information about technology [TAB-4846] Advancements in Live Attenuated Vaccines: A Novel Approach for Japanese Encephalitis and Beyond.">maryann.puglielli@nih.gov</a><br> TAB-4842 152409779 Enhancing Flavivirus Research: Utilizing Replicons, Cell Lines, and Reporter Virus Particles (RVPs) NIAID Collaboration, Diagnostics, Infectious Disease, Licensing, Research Equipment, Research Materials Collaboration Diagnostics Infectious Disease Licensing Research Equipment Research Materials Theodore Pierson <p>This technology summary highlights the pivotal role of replicons, cell lines, and reporter virus particles (RVPs) in advancing Flavivirus research. Replicons, engineered from the viral genome, allow for controlled replication in host cells, while cell lines stably harboring these replicons provide valuable tools for drug discovery and the production of pseudo-infectious virus particles. These RVPs, composed of flavivirus structural proteins, underpin a high-throughput quantitative method for studying antibody-mediated neutralization of infection. This comprehensive approach not only aids in drug development but also facilitates a deeper understanding of Flavivirus-host interactions, paving the way for improved antiviral strategies and vaccine development.</p> The competitive advantages of our technology stem from its reliability, safety, and efficiency. By utilizing replicons and stable cell lines, we provide a controlled and secure environment for Flavivirus research. The creation of reporter virus particles (RVPs) enhances the speed and accuracy of antibody-mediated neutralization studies, offering a valuable tool for vaccine development and drug screening. Our laboratory's extensive experience and track record in using these techniques ensure their effectiveness and trustworthiness, enabling researchers to make rapid and informed progress in Flavivirus-related research and therapeutic development. The potential applications of this technology span across drug discovery, vaccine development, and fundamental research. By leveraging replicons, cell lines, and reporter virus particles (RVPs), researchers can rapidly screen antiviral compounds, accelerate vaccine assessment, and gain insights into virus-host interactions. This versatile tool offers a broad range of practical applications, with the potential to drive advancements in Flavivirus research and the development of therapeutic solutions. 2024-01-25 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 152409786 Pierson, Theodore National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Pierson, Theodore (NIAID) 1 152409786 Pierson, Theodore National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Pierson, Theodore (NIAID) 1 152409782 BHK-21 Cell Line That Stably Propagates A WNV Replicon E-022-2012-0 Research Material NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4842] Enhancing Flavivirus Research: Utilizing Replicons, Cell Lines, and Reporter Virus Particles (RVPs)&body=Please send me information about technology [TAB-4842] Enhancing Flavivirus Research: Utilizing Replicons, Cell Lines, and Reporter Virus Particles (RVPs). Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4842] Enhancing Flavivirus Research: Utilizing Replicons, Cell Lines, and Reporter Virus Particles (RVPs)&body=Please send me information about technology [TAB-4842] Enhancing Flavivirus Research: Utilizing Replicons, Cell Lines, and Reporter Virus Particles (RVPs).">jonathan.motley@nih.gov</a><br> TAB-4840 152409159 Development and Testing of a Novel CMV-Based Vaccine Prototype NIAID Animal Models, Collaboration, Infectious Disease, Licensing, Plasmids/Vectors, Vaccines Animal Models Collaboration Infectious Disease Licensing Plasmids/Vectors Vaccines Heinrich (Heinz) Feldmann, Michael Jarvis, Andrea Marzi, Aisling Murphy, Ilhem Powers <p>The collaborative effort between the Jarvis Laboratory at the University of Plymouth and Feldmann&#39;s laboratory led to the development and testing of a groundbreaking Cytomegalovirus (CMV)-based vaccine designed to express the Ebola virus glycoprotein. This innovative approach aimed to enhance Ebola virus-specific immunogenicity and efficacy. The Jarvis Laboratory was responsible for the initial design and construction of the vaccine prototype, while Feldmann&#39;s team conducted extensive testing for immunogenicity and efficacy using a nonhuman primate model. The successful outcomes of these studies, documented in the 2016 publication by Marzi et al., represent a significant advancement in Ebola virus vaccine research, demonstrating the potential of CMV-based vaccines in combating infectious diseases.</p> The CMV-based Ebola vaccine, collaboratively developed by the Jarvis and Feldmann laboratories, stands out for its use of the CMV vector, known for inducing strong, lasting immune responses. This innovative approach potentially offers greater efficacy and durability than traditional vaccines. Successfully tested in a nonhuman primate model, it demonstrates significant promise for human efficacy, particularly with its targeted response against the Ebola glycoprotein. The combined expertise of both labs in design and testing further enhances its competitive edge in the vaccine research field. The CMV-based Ebola vaccine has significant potential for controlling and preventing Ebola outbreaks due to its enhanced immunity. Its successful testing in nonhuman primate models indicates strong prospects for human application, especially in Ebola-prone areas. Furthermore, the innovative use of the CMV vector could revolutionize vaccine development for other challenging infectious diseases, contributing substantially to global pandemic preparedness and health security. 2024-01-25 2026-08-26 2026-08-26 2026-08-26 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 152409169 Jarvis, Michael University of Plymouth Jarvis, Michael 1 152409173 Murphy, Aisling University of Plymouth Murphy, Aisling 2 152409185 Powers, Ilhem The Regents of the University of California Powers, Ilhem 3 152409200 Feldmann, Heinrich (Heinz) NIAID - DIR NIAID Feldmann, Heinrich (Heinz) (NIAID) 4 152409206 Marzi, Andrea NIAID - DIR NIAID Marzi, Andrea (NIAID) 5 152409169 Jarvis, Michael University of Plymouth Jarvis, Michael 1 152409173 Murphy, Aisling University of Plymouth Murphy, Aisling 2 152409185 Powers, Ilhem The Regents of the University of California Powers, Ilhem 3 152409200 Feldmann, Heinrich (Heinz) NIAID - DIR NIAID Feldmann, Heinrich (Heinz) (NIAID) 4 152409206 Marzi, Andrea NIAID - DIR NIAID Marzi, Andrea (NIAID) 5 152409162 CYTOMEGALOVIRUS-BASED VACCINE EXPRESSING EBOLA VIRUS GLYCOPROTEIN E-020-2018-0 Closed NIAID, The Regents of the University of California, University of Plymouth 146046171 Joyce, Terrence terrence.joyce@nih.gov
United States of America terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-4840] Development and Testing of a Novel CMV-Based Vaccine Prototype&body=Please send me information about technology [TAB-4840] Development and Testing of a Novel CMV-Based Vaccine Prototype. Joyce, Terrence<br><a href="mailto:terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-4840] Development and Testing of a Novel CMV-Based Vaccine Prototype&body=Please send me information about technology [TAB-4840] Development and Testing of a Novel CMV-Based Vaccine Prototype.">terrence.joyce@nih.gov</a><br> TAB-4839 152408793 Development and Characterization of Anti-Idiotypic Monoclonal Antibodies for PGT121 Anti-HIV Therapy Monitoring NIAID Animal Models, Antibodies, Collaboration, Diagnostics, Immunology, Infectious Disease, Licensing, Plasmids/Vectors, Research Materials, Therapeutics, Vaccines Animal Models Antibodies Collaboration Diagnostics Immunology Infectious Disease Licensing Plasmids/Vectors Research Materials Therapeutics Vaccines John Mascola, Amarendra ("Amar") Pegu, Wei Shi <p>The document details the creation of an anti-idiotypic monoclonal antibody specifically targeting the PGT121 monoclonal antibody (mAb) used in HIV treatment, highlighting its potential in both therapeutic and preventative applications. To ensure the consistent quality and effectiveness of the PGT121 mAb, these anti-idiotypic antibodies are developed for monitoring purposes during clinical applications. The research involved immunizing female BALB/cJ mice with a fragment of the PGT121 antibody, followed by cell fusion, screening for antibody production, and subsequent cloning to establish stable hybridomas. These procedures culminated in the isolation of monoclonal antibodies with desired specificities. The antibodies were then subjected to isotyping, reverse transcription, PCR amplification, and expression in Expi-293 cells, ensuring a consistent supply of high-fidelity reagents for the assessment of PGT121 mAb in various settings.</p> <p>&nbsp;</p> The anti-idiotypic monoclonal antibodies targeting PGT121 offer distinct competitive advantages in HIV therapy: enhanced assay specificity for accurate mAb monitoring, consistent production for reliable supply, and optimized dosing for improved patient outcomes. These attributes strengthen their position in therapeutic protocols, ensuring superior efficacy and safety in clinical use. The anti-idiotypic monoclonal antibodies against PGT121 mAb are promising for fine-tuning HIV treatment dosages, conducting detailed pharmacological research, improving diagnostic tests, and potentially aiding in the development of novel HIV therapies and vaccines. 2024-01-25 2026-08-26 2026-08-26 2026-08-26 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 152408806 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 1 152408813 Pegu, Amarendra ("Amar") NIAID - VRC NIAID Pegu, Amarendra ("Amar") (NIAID) 2 152408823 Shi, Wei NIAID - VRC NIAID Shi, Wei (NIAID) 3 152408806 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 1 152408813 Pegu, Amarendra ("Amar") NIAID - VRC NIAID Pegu, Amarendra ("Amar") (NIAID) 2 152408823 Shi, Wei NIAID - VRC NIAID Shi, Wei (NIAID) 3 152408796 PGT121 Anti-idiotype HIV Antibody E-019-2021-0 Research Material NIAID 91025211 Rainwater, Charles crainwater@mail.nih.gov
United States of America crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-4839] Development and Characterization of Anti-Idiotypic Monoclonal Antibodies for PGT121 Anti-HIV Therapy Monitoring&body=Please send me information about technology [TAB-4839] Development and Characterization of Anti-Idiotypic Monoclonal Antibodies for PGT121 Anti-HIV Therapy Monitoring. Rainwater, Charles<br><a href="mailto:crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-4839] Development and Characterization of Anti-Idiotypic Monoclonal Antibodies for PGT121 Anti-HIV Therapy Monitoring&body=Please send me information about technology [TAB-4839] Development and Characterization of Anti-Idiotypic Monoclonal Antibodies for PGT121 Anti-HIV Therapy Monitoring.">crainwater@mail.nih.gov</a><br> TAB-4836 152366901 Candidacy of PfCg4 as a Transmission-Blocking Malaria Vaccine: A Comprehensive Assessment of its Prospective Role NIAID Antibodies, Collaboration, Infectious Disease, Licensing, Rare/Neglected Diseases, Research Equipment, Therapeutics, Vaccines Antibodies Collaboration Infectious Disease Licensing Rare/Neglected Diseases Research Equipment Therapeutics Vaccines Joan Aebig, Nicholas Macdonald, David Narum <p>In this study, the research explores the potential of PfCg4, a novel heat shock protein, as a candidate for a transmission-blocking malaria vaccine. By producing recombinant PfCg4 and conducting experiments demonstrating its susceptibility to antibody blockade in the mosquito midgut, the study presents evidence for its vaccine candidacy. This discovery holds promise for enhancing current efforts to combat malaria transmission and potentially offers cross-species transmission-blocking activity, given its similarity to the P. vivax Cg4 protein. This research marks a significant step towards the development of an effective tool in the fight against malaria.</p> <p>&nbsp;</p> PfCg4's competitive advantages stem from its unique properties as a transmission-blocking malaria vaccine candidate. It is the first heat shock protein shown to be susceptible to antibody blockade in the mosquito midgut, with scalable production capabilities for human clinical trials. Its conservation with P. vivax Cg4 also hints at cross-species transmission-blocking potential, making PfCg4 a promising tool for malaria control. The potential applications of PfCg4 in the field of malaria control are significant. If successfully developed into a vaccine, PfCg4 could play a pivotal role in blocking the transmission of the malaria parasite from mosquitoes to humans. This could aid in reducing the spread of malaria in endemic regions and contribute to the global efforts for malaria elimination and eradication. Furthermore, its cross-species transmission-blocking potential may extend its applicability to other malaria-causing species, enhancing its impact on a broader scale. PfCg4 holds promise as a vital tool in the fight against this deadly disease. 2024-01-24 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 152367023 Narum, David NIAID - DIR NIAID Narum, David (NIAID) 1 152367027 Aebig, Joan NIAID - DIR NIAID Aebig, Joan (NIAID) 2 152367065 Macdonald, Nicholas NIAID Macdonald, Nicholas (NIAID) 3 152367023 Narum, David NIAID - DIR NIAID Narum, David (NIAID) 1 152367027 Aebig, Joan NIAID - DIR NIAID Aebig, Joan (NIAID) 2 152367065 Macdonald, Nicholas NIAID Macdonald, Nicholas (NIAID) 3 152366904 Identification Of HSP7 0f A Novel Malaria Transmission Blocking Vaccine Candidate E-010-2014-0 Filing authorized NIAID 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-4836] Candidacy of PfCg4 as a Transmission-Blocking Malaria Vaccine: A Comprehensive Assessment of its Prospective Role&body=Please send me information about technology [TAB-4836] Candidacy of PfCg4 as a Transmission-Blocking Malaria Vaccine: A Comprehensive Assessment of its Prospective Role. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-4836] Candidacy of PfCg4 as a Transmission-Blocking Malaria Vaccine: A Comprehensive Assessment of its Prospective Role&body=Please send me information about technology [TAB-4836] Candidacy of PfCg4 as a Transmission-Blocking Malaria Vaccine: A Comprehensive Assessment of its Prospective Role.">polung.yang@nih.gov</a><br> TAB-4835 152366812 Tailored HIV Vaccines: Regional Strategies for Clade-Specific Protection and Treatment NIAID Animal Models, Antibodies, Collaboration, Diagnostics, Immunology, Infectious Disease, Licensing, Plasmids/Vectors, Research Equipment, Therapeutics, Vaccines Animal Models Antibodies Collaboration Diagnostics Immunology Infectious Disease Licensing Plasmids/Vectors Research Equipment Therapeutics Vaccines Rama Amara, Bernard Moss, Harriet Robinson, Linda Wyatt <p>In this groundbreaking approach, a versatile AIDS vaccine technology is tailored to target distinct HIV clades prevalent in different regions, including Clade B for the United States, Clade AG for West Africa, and Clade C for South Africa and India. The vaccine serves a dual purpose, functioning both as a prophylactic and therapeutic solution against HIV/AIDS. Furthermore, it can be employed in synergy with DNA vaccines and the immune-boosting properties of GM-CSF to enhance the immune response. This innovative strategy offers hope for more effective and region-specific HIV prevention and treatment options, potentially revolutionizing the global fight against the virus.</p> This AIDS vaccine technology offers competitive advantages through its tailored approach targeting region-specific HIV clades (e.g., Clade B, Clade AG, Clade C). Its dual prophylactic and therapeutic capabilities provide a comprehensive solution. The potential for synergy with DNA vaccines enhances efficacy, and the use of GM-CSF as an adjuvant strengthens its competitive edge, positioning it as a leading candidate in HIV vaccine research. This AIDS vaccine technology holds diverse applications, offering region-specific protection and treatment against HIV/AIDS by targeting different clades. Its dual-purpose design accommodates both prevention and therapy, adaptable to varying disease stages. Combined with DNA vaccines, it introduces innovative strategies for enhanced efficacy. The inclusion of GM-CSF as an adjuvant further broadens its applications, making it a versatile asset in the quest for comprehensive HIV/AIDS solutions. 2024-01-24 2026-08-26 2026-08-26 2026-08-26 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 152366819 Amara, Rama Emory University Amara, Rama 1 152366824 Moss, Bernard National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Moss, Bernard (NIAID) 2 152366828 Wyatt, Linda NIAID - DIR NIAID Wyatt, Linda (NIAID) 3 152366832 Robinson, Harriet Robinson, Harriet 4 152366819 Amara, Rama Emory University Amara, Rama 1 152366824 Moss, Bernard National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Moss, Bernard (NIAID) 2 152366828 Wyatt, Linda NIAID - DIR NIAID Wyatt, Linda (NIAID) 3 152366832 Robinson, Harriet Robinson, Harriet 4 152366815 Recombinant MVA Viruses Expressing Clades A/G, B, And C Modified HIV Env, Gag And Pol Genes; Recombinant MVA Expressing GM-CSF E-010-2011-0 Filing authorized Emory University, NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4835] Tailored HIV Vaccines: Regional Strategies for Clade-Specific Protection and Treatment&body=Please send me information about technology [TAB-4835] Tailored HIV Vaccines: Regional Strategies for Clade-Specific Protection and Treatment. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4835] Tailored HIV Vaccines: Regional Strategies for Clade-Specific Protection and Treatment&body=Please send me information about technology [TAB-4835] Tailored HIV Vaccines: Regional Strategies for Clade-Specific Protection and Treatment.">jonathan.motley@nih.gov</a><br> TAB-5001 157765068 Genetically Modified Bdellovibrio and E. coli Strains for Advancing Antibiotic Resistance Research and Drug Development NIAID Infectious Disease, Plasmids/Vectors, Research Materials, Therapeutics Infectious Disease Plasmids/Vectors Research Materials Therapeutics Kwanyee Leung, Gary Nabel, Udy Olshevsky <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">This technology includes genetically modified strains of <em>Bdellovibrio</em> and <em>E. coli</em> bacteria, along with associated plasmids, that have been engineered for antibiotic resistance. These modified bacterial strains and plasmids have been developed to replace specific genes with antibiotic resistance markers, allowing for more precise studies in genetic research, as well as the development and testing of new antibiotics. The potential use of this technology lies in enhancing research on antibiotic resistance mechanisms and facilitating the creation of novel therapeutic approaches to combat resistant bacterial infections.</span></span></span></p> This technology offers a competitive advantage by providing precisely engineered bacterial strains with antibiotic resistance, enabling more accurate and controlled studies of resistance mechanisms. Additionally, it facilitates the development and testing of new antibiotics, potentially accelerating the discovery of effective treatments for resistant bacterial infections. This technology can be applied in research laboratories for studying the genetic mechanisms of antibiotic resistance, helping scientists understand how resistance develops and spreads. It also has potential applications in the pharmaceutical industry for screening and developing new antibiotics that can overcome resistance in pathogenic bacteria. 2024-08-13 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 157765449 Nabel, Gary ModeX Therapeutics, Inc. NIAID Nabel, Gary (NIAID) 1 157765453 Olshevsky, Udy NIAID - VRC NIAID Olshevsky, Udy (NIAID) 2 157765457 Leung, Kwanyee National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Leung, Kwanyee (NIAID) 3 157765449 Nabel, Gary ModeX Therapeutics, Inc. NIAID Nabel, Gary (NIAID) 1 157765453 Olshevsky, Udy NIAID - VRC NIAID Olshevsky, Udy (NIAID) 2 157765457 Leung, Kwanyee National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Leung, Kwanyee (NIAID) 3 157765440 Bdellovibrio Bacterial Strains And E. Coli Strains Genetically Modified For Antibiotic Resistance And Related Plasmids E-197-2014-0 Research Material NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-5001] Genetically Modified Bdellovibrio and E. coli Strains for Advancing Antibiotic Resistance Research and Drug Development&body=Please send me information about technology [TAB-5001] Genetically Modified Bdellovibrio and E. coli Strains for Advancing Antibiotic Resistance Research and Drug Development. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-5001] Genetically Modified Bdellovibrio and E. coli Strains for Advancing Antibiotic Resistance Research and Drug Development&body=Please send me information about technology [TAB-5001] Genetically Modified Bdellovibrio and E. coli Strains for Advancing Antibiotic Resistance Research and Drug Development.">sabrina.hafiz@nih.gov</a><br> TAB-5000 157764987 Implications for HIV/AIDS Research and Therapy Development NIAID Collaboration, Immunology, Infectious Disease, Licensing, Plasmids/Vectors, Rare/Neglected Diseases, Research Equipment, Research Materials Collaboration Immunology Infectious Disease Licensing Plasmids/Vectors Rare/Neglected Diseases Research Equipment Research Materials Rajeev Gautam, Malcolm Martin, Yoshiaki Nishimura, Reza Sadjadpour, Masashi Shingai <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">The discovery involves the development and characterization of a novel SHIVAD8EO virus, which has significant implications for HIV/AIDS research and therapy development. This virus, when propagated in DH101 cells and used to infect rhesus PBMC, exhibits efficient replicative properties and utilizes CCR5 to enter monkey cells. Importantly, the virus displays a tier 2 neutralization phenotype similar to circulating HIV-1 strains. In vivo studies have shown that SHIVAD8EO can generate sustained levels of plasma viremia, cause irreversible depletions of CD4+ T cells, induce fatal immunodeficiency, and resist certain treatments. These properties make SHIVAD8EO a valuable tool for studying HIV/AIDS pathogenesis and for evaluating new therapeutic approaches. This discovery is documented in lab records and has been described in a publication in the Proceedings of the National Academy of Sciences.</span></span></span></p> The novel SHIVAD8EO virus offers several key competitive advantages over existing models and technologies in HIV/AIDS research. Its efficient replicative properties, utilization of CCR5 for cell entry, and tier 2 neutralization phenotype closely mimic those of circulating HIV-1 strains, providing a more accurate model for studying HIV/AIDS pathogenesis and evaluating potential therapies. Importantly, SHIVAD8EO's ability to generate sustained levels of plasma viremia, induce fatal immunodeficiency, and resist certain treatments in vivo make it a valuable tool for preclinical studies. These unique characteristics set SHIVAD8EO apart from other models and technologies, offering researchers a more reliable and relevant platform for advancing our understanding of HIV/AIDS and developing novel treatment strategies. The novel SHIVAD8EO virus has a wide range of potential applications in HIV/AIDS research and therapy development. As a robust model that closely mimics the properties of circulating HIV-1 strains, SHIVAD8EO can be used to study various aspects of HIV/AIDS pathogenesis, including viral replication, immune response, and disease progression. Additionally, its ability to generate sustained levels of plasma viremia and induce fatal immunodeficiency in vivo makes it a valuable tool for evaluating the efficacy of new antiretroviral drugs and immunotherapies. SHIVAD8EO can also be utilized to investigate viral reservoirs and the mechanisms of viral persistence, which are critical areas of research for developing strategies to achieve HIV cure or long-term remission. Furthermore, SHIVAD8EO may be instrumental in the development and testing of novel HIV vaccines, providing a realistic model for evaluating vaccine candidates. Overall, the versatility and relevance of SHIVAD8EO make it a valuable resource for advancing HIV/AIDS research and therapeutic interventions. 2024-08-13 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 157764999 Martin, Malcolm NIAID - DIR NIAID Martin, Malcolm (NIAID) 1 157765003 Nishimura, Yoshiaki National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Nishimura, Yoshiaki (NIAID) 2 157765007 Shingai, Masashi Hokkaido University Shingai, Masashi 3 157765011 Gautam, Rajeev National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Gautam, Rajeev (NIAID) 4 157765015 Sadjadpour, Reza NIAID - DIR NIAID Sadjadpour, Reza (NIAID) 5 157764999 Martin, Malcolm NIAID - DIR NIAID Martin, Malcolm (NIAID) 1 157765003 Nishimura, Yoshiaki National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Nishimura, Yoshiaki (NIAID) 2 157765007 Shingai, Masashi Hokkaido University Shingai, Masashi 3 157765011 Gautam, Rajeev National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Gautam, Rajeev (NIAID) 4 157765015 Sadjadpour, Reza NIAID - DIR NIAID Sadjadpour, Reza (NIAID) 5 157764990 Pathogenic SHIVAD8EO Molecular Clone E-195-2017-0 Research Material NIAID 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-5000] Implications for HIV/AIDS Research and Therapy Development&body=Please send me information about technology [TAB-5000] Implications for HIV/AIDS Research and Therapy Development. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-5000] Implications for HIV/AIDS Research and Therapy Development&body=Please send me information about technology [TAB-5000] Implications for HIV/AIDS Research and Therapy Development.">peter.tung@nih.gov</a><br> TAB-4977 154765401 Implications for Mammalian Gene Regulation and Disease Pathogenesis NIAID Antibodies, Collaboration, Diagnostics, Immunology, Infectious Disease, Licensing, Oncology, Rare/Neglected Diseases, Research Materials, Therapeutics Antibodies Collaboration Diagnostics Immunology Infectious Disease Licensing Oncology Rare/Neglected Diseases Research Materials Therapeutics Michael Lenardo, Feng-Yi Wan <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">The discovery of RPS3 and phospho-RPS3 antibodies represents a significant advancement in understanding mammalian gene regulation and its implications for disease. These antibodies serve as critical tools for detecting and studying the NF-kB transcription factor, particularly its specifier subunit RPS3 and its phosphorylated form. By enabling the precise identification and localization of these regulatory proteins, this technology opens avenues for investigating their roles in various diseases, including cancer and immune disorders. This discovery provides a foundation for further research and potential therapeutic applications targeting these pathways.</span></span></span></p> <p>&nbsp;</p> The RPS3 and phospho-RPS3 antibodies offer several competitive advantages over existing technologies. Firstly, they provide a high level of specificity and sensitivity in detecting these key regulatory proteins, allowing for precise and reliable measurements in various biological samples. Additionally, these antibodies offer versatility, as they can be used in a wide range of applications, including Western blotting, immunofluorescence, and immunoprecipitation assays. Furthermore, their ability to detect both the regulator and its phosphorylated form provides a comprehensive understanding of the protein's function and localization within cells. This comprehensive approach sets these antibodies apart from other tools currently available in the field, making them invaluable for researchers studying gene regulation and its role in disease. The RPS3 and phospho-RPS3 antibodies hold immense potential for various applications in both research and clinical settings. In research, these antibodies can be used to elucidate the role of the NF-kB transcription factor in different disease processes, such as cancer and immune disorders. They can also aid in understanding the mechanisms underlying gene regulation and cell signaling pathways. Furthermore, these antibodies may have diagnostic utility, potentially serving as biomarkers for diseases associated with dysregulated NF-kB signaling. Additionally, the antibodies could be utilized in drug discovery efforts, facilitating the development of novel therapeutics targeting NF-kB-related pathways. Overall, the applications of these antibodies are diverse and far-reaching, making them valuable tools in advancing our understanding and treatment of various diseases. 2024-04-01 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 154766722 Lenardo, Michael NIAID Lenardo, Michael (NIAID) 1 154770511 Wan, Feng-Yi NIAID Wan, Feng-Yi (NIAID) 2 154766722 Lenardo, Michael NIAID Lenardo, Michael (NIAID) 1 154770511 Wan, Feng-Yi NIAID Wan, Feng-Yi (NIAID) 2 154765471 Identification Of RPS3 And Phosphor RPS3 Antibodies E-195-2011-0 Research Material NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4977] Implications for Mammalian Gene Regulation and Disease Pathogenesis&body=Please send me information about technology [TAB-4977] Implications for Mammalian Gene Regulation and Disease Pathogenesis. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4977] Implications for Mammalian Gene Regulation and Disease Pathogenesis&body=Please send me information about technology [TAB-4977] Implications for Mammalian Gene Regulation and Disease Pathogenesis.">yogikala.prabhu@nih.gov</a><br> TAB-4976 154742108 Advancements in Vaccine Manufacturing: Novel Methods for Efficient Production of Peptide-Based Vaccines NIAID Animal Models, Collaboration, Immunology, Infectious Disease, Licensing, Oncology, Research Equipment, Therapeutics, Vaccines Animal Models Collaboration Immunology Infectious Disease Licensing Oncology Research Equipment Therapeutics Vaccines Vincent Coble, Andrew Ishizuka, Geoffrey Lynn, Yaling Zhu <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">This technology presents innovative methods for manufacturing peptide-based vaccines that effectively induce T cell responses. By linking peptide antigens to adjuvants with hydrophobic blocks, a conjugate vaccine is created that self-assembles into nanoparticles, also known as immunotherapeutic nanoscaffolds (IMNs). These methods, which improve the efficiency and reduce the costs of peptide vaccine production, include constructing the conjugate entirely on resin to reduce reaction steps, producing a product solution with an excess of unreacted hydrophobic block to minimize purification steps, enhancing formulation stability by mixing several conjugates, and providing a simple sterilization process through sterile filtering and reconstitution in aqueous solution.</span></span></span></p> This novel technology offers several competitive advantages over existing methods for manufacturing peptide-based vaccines. By streamlining the process to construct the conjugate entirely on resin, it reduces reaction steps and minimizes the complexity of purification processes, leading to cost savings and increased efficiency. The ability to produce a product solution with an excess of unreacted hydrophobic block further simplifies purification, enhancing scalability and reducing manufacturing time. Additionally, the improved formulation stability achieved by mixing several conjugates provides a more robust vaccine product. Lastly, the facile sterilization process, involving sterile filtering and reconstitution in aqueous solution, adds to the technology's appeal by simplifying the final manufacturing steps. These advantages position the technology as a promising solution for the efficient and cost-effective production of peptide-based vaccines with enhanced stability and scalability. The potential applications of this technology are broad, spanning various fields including personalized medicine, infectious disease prevention, and cancer immunotherapy. The ability to efficiently manufacture peptide-based vaccines that induce T cell responses opens doors for personalized therapies tailored to individual patients. In infectious disease prevention, these vaccines could be used to target specific pathogens, offering a more precise and effective approach compared to traditional vaccines. Additionally, in cancer immunotherapy, peptide-based vaccines have shown promise in stimulating immune responses against tumor cells. The technology's scalability and efficiency also make it suitable for large-scale vaccine production, addressing global health challenges such as pandemics. Overall, the technology has the potential to revolutionize vaccine development and personalized medicine, impacting healthcare on a global scale. 2024-04-01 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 154747961 Lynn, Geoffrey Vaccitech North America NIAID Lynn, Geoffrey (NIAID) 1 154750490 Coble, Vincent Avidea Technologies Coble, Vincent 2 154753080 Ishizuka, Andrew NIAID - VRC NIAID Ishizuka, Andrew (NIAID) 3 154754621 Zhu, Yaling Avidea Technologies Zhu, Yaling 4 154747961 Lynn, Geoffrey Vaccitech North America NIAID Lynn, Geoffrey (NIAID) 1 154750490 Coble, Vincent Avidea Technologies Coble, Vincent 2 154753080 Ishizuka, Andrew NIAID - VRC NIAID Ishizuka, Andrew (NIAID) 3 154754621 Zhu, Yaling Avidea Technologies Zhu, Yaling 4 154742174 Improved Methods Of Manufacturing Peptide-Based Vaccines E-191-2018-0 Filing authorized Avidea Technologies, NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4976] Advancements in Vaccine Manufacturing: Novel Methods for Efficient Production of Peptide-Based Vaccines&body=Please send me information about technology [TAB-4976] Advancements in Vaccine Manufacturing: Novel Methods for Efficient Production of Peptide-Based Vaccines. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4976] Advancements in Vaccine Manufacturing: Novel Methods for Efficient Production of Peptide-Based Vaccines&body=Please send me information about technology [TAB-4976] Advancements in Vaccine Manufacturing: Novel Methods for Efficient Production of Peptide-Based Vaccines.">wade.green@nih.gov</a><br> TAB-4975 154735752 Antimicrobial Resistant Staphylococcus Aureus Strains NR-46192 and NR-46201 NIAID Antibodies, Collaboration, Diagnostics, Human Cell Lines, Infectious Disease, Licensing, Plasmids/Vectors, Research Materials, Therapeutics Antibodies Collaboration Diagnostics Human Cell Lines Infectious Disease Licensing Plasmids/Vectors Research Materials Therapeutics <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">The discovery of antimicrobial-resistant Staphylococcus aureus strains NR-46192 and NR-46201 represents a significant advancement in the study and treatment of antibiotic resistance. Isolated from patient samples and resistant to multiple antibiotics, these strains offer valuable insights into the mechanisms of resistance and provide a critical resource for antimicrobial research and testing. Their unique resistance profiles make them particularly useful for quality control in assay manufacture, aiding in the development of new antimicrobial agents and susceptibility testing methods. This discovery, made under the DMID Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA) program, underscores the importance of collaborative efforts in combating antibiotic resistance and highlights the potential for these strains to drive future innovations in antimicrobial therapy.</span></span></span></p> The competitive advantages of antimicrobial-resistant Staphylococcus aureus strains NR-46192 and NR-46201 lie in their unique resistance profiles and their potential applications in antimicrobial research and testing. These strains offer a distinct advantage over standard laboratory strains, as they more closely resemble clinical isolates and provide a more accurate representation of real-world antimicrobial resistance scenarios. Their resistance to multiple antibiotics makes them particularly valuable for evaluating the efficacy of new antimicrobial agents and for developing more targeted treatment strategies. Additionally, their use in quality control during assay manufacture ensures the reliability and accuracy of antimicrobial susceptibility testing methods, further enhancing their value in the field. Overall, the availability of these strains provides researchers and clinicians with a competitive edge in the fight against antibiotic resistance, offering new avenues for understanding, monitoring, and addressing this global health challenge. The antimicrobial-resistant Staphylococcus aureus strains NR-46192 and NR-46201 have a wide range of potential applications in antimicrobial research, clinical diagnostics, and drug development. These strains can be used to study the mechanisms of antibiotic resistance, helping researchers identify new targets for drug development and strategies to overcome resistance. In clinical diagnostics, these strains can serve as valuable tools for evaluating the effectiveness of antimicrobial treatments and for monitoring the spread of resistant strains in healthcare settings. Furthermore, these strains can be used in the development and validation of new antimicrobial susceptibility testing methods, improving the accuracy and reliability of these tests. Overall, the availability of these strains opens up new possibilities for advancing our understanding of antibiotic resistance and developing more effective strategies to combat it. 2024-04-01 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 154735823 Antimicrobial Resistant Staphylococcus Aureus Strains E-188-2019-0 Research Material NIAID 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-4975] Antimicrobial Resistant Staphylococcus Aureus Strains NR-46192 and NR-46201&body=Please send me information about technology [TAB-4975] Antimicrobial Resistant Staphylococcus Aureus Strains NR-46192 and NR-46201. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-4975] Antimicrobial Resistant Staphylococcus Aureus Strains NR-46192 and NR-46201&body=Please send me information about technology [TAB-4975] Antimicrobial Resistant Staphylococcus Aureus Strains NR-46192 and NR-46201.">peter.tung@nih.gov</a><br> TAB-4974 154722160 Innovative Thermo-Responsive Adjuvant Scaffolds for Enhanced Vaccine Delivery and Immunotherapy NIAID Collaboration, Infectious Disease, Licensing, Oncology, Research Equipment, Therapeutics, Vaccines Collaboration Infectious Disease Licensing Oncology Research Equipment Therapeutics Vaccines Richard Laga, Geoffrey Lynn, Robert Seder, Leonard Seymour <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">The Thermo-responsive adjuvant scaffolds (TRAS) technology offers a groundbreaking approach to vaccine delivery and immunotherapy. TRAS utilizes carriers consisting of Toll-like receptor agonists (TLRa) attached to linear polymer carriers. These carriers are designed to assemble into particles in vivo, addressing the limitations of current particle-based delivery platforms. TRAS enhances immune responses by providing the benefits of particulate delivery while avoiding issues such as scalability, heterogeneity, and stability. This technology has the potential to revolutionize vaccine development and immunotherapy for cancer treatment.</span></span></span></p> The Thermo-responsive adjuvant scaffolds (TRAS) technology offers several competitive advantages over existing vaccine delivery platforms. Unlike traditional particle-based platforms, TRAS is designed to exist as single molecules in solution during storage, minimizing issues related to scalability, heterogeneity, and stability. TRAS carriers assemble into particles in vivo, enhancing immune responses without the need for complex formulation processes. This innovative approach provides the benefits of particulate delivery while avoiding drawbacks associated with current technologies. Additionally, TRAS has demonstrated efficacy in murine vaccine studies, indicating its potential as a versatile platform for vaccine development and immunotherapy. The Thermo-responsive adjuvant scaffolds (TRAS) technology has vast potential applications in vaccine development and immunotherapy. TRAS could be utilized to enhance the efficacy of a wide range of vaccines by improving the delivery of Toll-like receptor agonists (TLRa), which are potent immunostimulants. This technology could be particularly beneficial for developing vaccines against infectious diseases and cancer. Additionally, TRAS could be explored for its potential in direct immunotherapy for the treatment of cancer, leveraging its ability to enhance immune responses. The versatility and efficacy of TRAS make it a promising platform for advancing vaccine development and immunotherapy strategies. 2024-04-01 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 154724756 Laga, Richard Institute Of Macromolecular Chemistry AS CR Laga, Richard 1 154726066 Lynn, Geoffrey NIAID Lynn, Geoffrey (NIAID) 2 154727472 Seymour, Leonard Seymour, Leonard 3 154728488 Seder, Robert NIAID - VRC NIAID Seder, Robert (NIAID) 4 154724756 Laga, Richard Institute Of Macromolecular Chemistry AS CR Laga, Richard 1 154726066 Lynn, Geoffrey NIAID Lynn, Geoffrey (NIAID) 2 154727472 Seymour, Leonard Seymour, Leonard 3 154728488 Seder, Robert NIAID - VRC NIAID Seder, Robert (NIAID) 4 154722233 Thermo-responsive Adjuvant Scaffolds (TRAS) E-188-2015-0 Filing authorized Institute Of Macromolecular Chemistry AS CR, NIAID, University of Oxford 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4974] Innovative Thermo-Responsive Adjuvant Scaffolds for Enhanced Vaccine Delivery and Immunotherapy&body=Please send me information about technology [TAB-4974] Innovative Thermo-Responsive Adjuvant Scaffolds for Enhanced Vaccine Delivery and Immunotherapy. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4974] Innovative Thermo-Responsive Adjuvant Scaffolds for Enhanced Vaccine Delivery and Immunotherapy&body=Please send me information about technology [TAB-4974] Innovative Thermo-Responsive Adjuvant Scaffolds for Enhanced Vaccine Delivery and Immunotherapy.">wade.green@nih.gov</a><br> TAB-4972 154689436 Advanced Prime-Boost Vaccine Strategy Using LCMV Vectors for Lentiviral Infection Prevention NIAID Collaboration, Infectious Disease, Licensing, Plasmids/Vectors, Therapeutics Collaboration Infectious Disease Licensing Plasmids/Vectors Therapeutics Cheng Cheng, Lukas Flatz, Sung-Youl Ko, Wing-pui Kong, Gary Nabel <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">This technology presents a novel prime-boost vaccine strategy using recombinant Lymphocytic Choriomeningitis Virus (LCMV) vectors to protect against lentiviral infections, particularly HIV. The approach involves different prime-boost combinations with LCMV vectors expressing HIV proteins, demonstrating efficacy in eliciting immune responses. The strategy, developed by a team including Gary Nahel, Sung-Youl Ko, Cheng Cheng, Wing-pui Kong, and Lukas Platz, has been shown to effectively stimulate T cell and antibody responses, providing protection against viral challenges. This innovative approach holds promise for improving vaccination strategies against lentiviral infections.</span></span></span></p> <p>&nbsp;</p> The prime-boost vaccine strategy utilizing recombinant Lymphocytic Choriomeningitis Virus (LCMV) vectors offers several competitive advantages over traditional vaccine approaches. This innovative strategy has demonstrated superior efficacy in eliciting immune responses, including robust T cell and antibody responses, which are crucial for protecting against viral infections like HIV. Additionally, the flexibility of the prime-boost combinations allows for tailored immunization regimens to optimize immune responses. The technology's ability to stimulate both cellular and humoral immunity makes it a promising candidate for combating lentiviral infections. Furthermore, the expertise and collaboration of the inventors, including Gary Nahel, Sung-Youl Ko, Cheng Cheng, Wing-pui Kong, and Lukas Platz, ensure the continued advancement and potential commercialization of this groundbreaking vaccine strategy. The prime-boost vaccine strategy utilizing recombinant Lymphocytic Choriomeningitis Virus (LCMV) vectors has broad potential applications beyond HIV prevention. This innovative approach could be adapted to target other lentiviral infections, such as simian immunodeficiency virus (SIV) in non-human primates, as well as lentiviruses affecting other animal species. Furthermore, the flexibility of the prime-boost combinations could allow for the development of vaccines against other viral diseases, leveraging the strong immune responses elicited by this strategy. Additionally, this technology may have implications for improving vaccine efficacy against other challenging pathogens, opening up new avenues for vaccine development and infectious disease control. 2024-04-01 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 154693523 Flatz, Lukas Centre Hospitalier Universitaire Vaudois (CHUV) Flatz, Lukas 1 154694757 Nabel, Gary ModeX Therapeutics, Inc. NIAID Nabel, Gary (NIAID) 2 154697004 Cheng, Cheng National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Cheng, Cheng (NIAID) 3 154698422 Ko, Sung-Youl NIAID Ko, Sung-Youl (NIAID) 4 154699994 Kong, Wing-pui NIAID Kong, Wing-pui (NIAID) 5 154693523 Flatz, Lukas Centre Hospitalier Universitaire Vaudois (CHUV) Flatz, Lukas 1 154694757 Nabel, Gary ModeX Therapeutics, Inc. NIAID Nabel, Gary (NIAID) 2 154697004 Cheng, Cheng National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Cheng, Cheng (NIAID) 3 154698422 Ko, Sung-Youl NIAID Ko, Sung-Youl (NIAID) 4 154699994 Kong, Wing-pui NIAID Kong, Wing-pui (NIAID) 5 154689506 Prime-boost Vaccine Strategies Incorporating Recombinant Lymphocytic Choriomeningitis Virus (LCMV) Vaccines To Protect Against Lentiviral Infection E-186-2011-0 Filing authorized Centre Hospitalier Universitaire Vaudois (CHUV), NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4972] Advanced Prime-Boost Vaccine Strategy Using LCMV Vectors for Lentiviral Infection Prevention&body=Please send me information about technology [TAB-4972] Advanced Prime-Boost Vaccine Strategy Using LCMV Vectors for Lentiviral Infection Prevention. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4972] Advanced Prime-Boost Vaccine Strategy Using LCMV Vectors for Lentiviral Infection Prevention&body=Please send me information about technology [TAB-4972] Advanced Prime-Boost Vaccine Strategy Using LCMV Vectors for Lentiviral Infection Prevention.">sabrina.hafiz@nih.gov</a><br> TAB-4971 154672727 Enhancing Gene Delivery for Precision Immunotherapy NIAID Collaboration, Immunology, Infectious Disease, Licensing, Plasmids/Vectors, Rare/Neglected Diseases, Therapeutics, Vaccines Collaboration Immunology Infectious Disease Licensing Plasmids/Vectors Rare/Neglected Diseases Therapeutics Vaccines Geoffrey Lynn, Robert Seder, Leonard Seymour <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">The &quot;Adjuvant pro-drug platform for gene delivery and spatiotemporal control over immune activation&quot; is a groundbreaking technology that addresses the limitations of DNA and RNA-based vaccines by providing spatiotemporal control over immune activation. This platform utilizes a cationic polymer with pro-drug Toll-like receptor-7/8 agonists attached, allowing for the complexation of RNA and DNA to form nanoparticles for in vivo administration. The pro-drug TLR-7/8 agonists have enzyme-degradable bonds with slow release rates, enabling the delay of immune activation for up to 8 days. This precise control ensures optimal innate immune stimulation without compromising transgene expression, making it a promising approach for enhancing the efficacy of DNA and RNA-based vaccines for infectious diseases and cancer immunotherapy.</span></span></span></p> The adjuvant pro-drug platform offers several competitive advantages over existing technologies. Its ability to provide spatiotemporal control over immune activation sets it apart from traditional adjuvants, which often activate immune responses indiscriminately and can lead to reduced transgene expression. By delaying immune activation until after adequate gene expression has occurred, this platform maximizes the effectiveness of DNA and RNA-based vaccines. Additionally, the platform's versatility allows for the delivery of a wide range of antigens, making it applicable to various infectious diseases and cancer types. Its potential to significantly enhance the immunogenicity of vaccines while maintaining high levels of transgene expression positions it as a leading candidate for improving vaccine efficacy and personalized medicine approaches. The adjuvant pro-drug platform has diverse potential applications in the fields of infectious diseases and cancer immunotherapy. For infectious diseases, this technology could enable the rapid development and deployment of highly immunogenic DNA-based vaccines against emerging pathogens. Its ability to enhance immune responses without compromising transgene expression is particularly valuable in the context of rapidly evolving pathogens where quick and effective vaccination is critical. In cancer immunotherapy, the platform could be used to deliver personalized neoantigens, offering a tailored approach to treatment that targets specific cancer mutations. This technology has the potential to revolutionize vaccine development and immunotherapy by providing a versatile platform for enhancing immune responses against a variety of diseases. 2024-04-01 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 154674977 Lynn, Geoffrey Vaccitech North America NIAID Lynn, Geoffrey (NIAID) 1 154679262 Seder, Robert NIAID - VRC NIAID Seder, Robert (NIAID) 2 154681700 Seymour, Leonard Seymour, Leonard 3 154674977 Lynn, Geoffrey Vaccitech North America NIAID Lynn, Geoffrey (NIAID) 1 154679262 Seder, Robert NIAID - VRC NIAID Seder, Robert (NIAID) 2 154681700 Seymour, Leonard Seymour, Leonard 3 154672809 Adjuvant Pro-drug Platform For Gene Delivery And Spatiotemporal Control Over Immune Activation E-185-2015-0 Filing authorized NIAID, University of Oxford 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4971] Enhancing Gene Delivery for Precision Immunotherapy&body=Please send me information about technology [TAB-4971] Enhancing Gene Delivery for Precision Immunotherapy. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4971] Enhancing Gene Delivery for Precision Immunotherapy&body=Please send me information about technology [TAB-4971] Enhancing Gene Delivery for Precision Immunotherapy.">wade.green@nih.gov</a><br> TAB-4970 154651859 Development of Messenger RNA (mRNA) Vaccines Targeting SARS-CoV-2 Antigens NIAID Animal Models, Antibodies, Collaboration, Human Cell Lines, Infectious Disease, Licensing, Plasmids/Vectors, Rare/Neglected Diseases, Research Equipment, Vaccines Animal Models Antibodies Collaboration Human Cell Lines Infectious Disease Licensing Plasmids/Vectors Rare/Neglected Diseases Research Equipment Vaccines Olubukola Abiona, Kizzmekia Corbett, Barney Graham, Geoffrey Hutchinson, John Mascola, Kaitlyn Morabito, Cynthia Zamanda <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">The development of mRNA vaccines targeting SARS-CoV-2 antigens represents a groundbreaking advancement in vaccine technology. These vaccines, currently in Clinical Phase I, utilize messenger RNA to encode coronavirus antigens, triggering a potent immune response that includes the production of neutralizing antibodies. Unlike traditional vaccines, mRNA vaccines do not use live or inactivated viruses, which enhances safety and allows for rapid development. The use of a stabilized prefusion spike protein as a key antigen further enhances the vaccine&#39;s efficacy. This innovative approach not only holds promise for combatting COVID-19 but also paves the way for more efficient vaccine development against future infectious diseases.</span></span></span></p> This mRNA vaccine technology for SARS-CoV-2 offers several competitive advantages over traditional vaccine approaches. Firstly, its use of mRNA allows for a faster development timeline, critical in responding to rapidly evolving infectious diseases. Secondly, the vaccines do not contain any live virus, reducing the risk of adverse reactions and allowing for safer administration. Additionally, the ability to encode various coronavirus antigens, including the stabilized prefusion spike protein, enables a targeted and robust immune response. This targeted approach may result in higher efficacy rates compared to conventional vaccines. Furthermore, the mRNA platform is highly versatile, potentially allowing for the rapid adaptation of the vaccine to address new variants of the virus. These advantages position mRNA vaccines as a promising solution not only for the current COVID-19 pandemic but also for future infectious disease outbreaks. The potential applications of mRNA vaccines targeting SARS-CoV-2 extend beyond the current COVID-19 pandemic. These vaccines represent a versatile platform that can be rapidly adapted to address emerging variants of the virus. Furthermore, the mRNA technology can be applied to develop vaccines against other infectious diseases, offering a more efficient and scalable approach compared to traditional methods. Additionally, mRNA vaccines have the potential to be used in cancer immunotherapy, where they can be tailored to target specific tumor antigens, offering a personalized treatment option. Moreover, the mRNA platform can be utilized for the development of prophylactic vaccines against a wide range of pathogens, providing a valuable tool in global health security efforts. 2024-04-01 2026-08-26 2026-08-26 2026-08-26 False True True 72159138 Clinical Phase I 72159138 37470483 Website Abstract 154654521 Morabito, Kaitlyn NIAID Morabito, Kaitlyn (NIAID) 1 154656401 Mascola, John NIAID Mascola, John (NIAID) 2 154658970 Graham, Barney Morehouse School of Medicine NIAID Graham, Barney (NIAID) 3 154662061 Hutchinson, Geoffrey NIAID Hutchinson, Geoffrey (NIAID) 4 154663461 Corbett, Kizzmekia NIAID Corbett, Kizzmekia (NIAID) 5 154664806 Zamanda, Cynthia NIAID Zamanda, Cynthia (NIAID) 6 154666416 Abiona, Olubukola NIAID Abiona, Olubukola (NIAID) 7 154654521 Morabito, Kaitlyn NIAID Morabito, Kaitlyn (NIAID) 1 154656401 Mascola, John NIAID Mascola, John (NIAID) 2 154658970 Graham, Barney Morehouse School of Medicine NIAID Graham, Barney (NIAID) 3 154662061 Hutchinson, Geoffrey NIAID Hutchinson, Geoffrey (NIAID) 4 154663461 Corbett, Kizzmekia NIAID Corbett, Kizzmekia (NIAID) 5 154664806 Zamanda, Cynthia NIAID Zamanda, Cynthia (NIAID) 6 154666416 Abiona, Olubukola NIAID Abiona, Olubukola (NIAID) 7 154651961 CORONAVIRUS MRNA VACCINES E-182-2020-0 Filing authorized NIAID 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-4970] Development of Messenger RNA (mRNA) Vaccines Targeting SARS-CoV-2 Antigens&body=Please send me information about technology [TAB-4970] Development of Messenger RNA (mRNA) Vaccines Targeting SARS-CoV-2 Antigens. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-4970] Development of Messenger RNA (mRNA) Vaccines Targeting SARS-CoV-2 Antigens&body=Please send me information about technology [TAB-4970] Development of Messenger RNA (mRNA) Vaccines Targeting SARS-CoV-2 Antigens.">bbailey@mail.nih.gov</a><br> TAB-4969 154635206 The PSY2 Shuttle Vector System NIAID Collaboration, Immunology, Infectious Disease, Licensing, Materials Available, Plasmids/Vectors, Research Materials, Vaccines Collaboration Immunology Infectious Disease Licensing Materials Available Plasmids/Vectors Research Materials Vaccines Patricia Rosa, Philip Stewart <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">The PSY2 Bovidae aurbeta/gamma shuttle vector represents a pioneering technology in the field of genetic engineering. This innovative vector system has been designed for use in Bovidae species, potentially offering a novel approach to gene delivery and manipulation. It leverages a dual-functionality mechanism that could enable both autonomous replication and the precise insertion of genetic material. Although in its conceptual phase, the technology promises to overcome existing challenges associated with current gene delivery methods, such as limited host range and low efficiency, by utilizing a unique combination of aurbeta/gamma sequences. This breakthrough has the potential to accelerate research in bovine genetics and enhance applications in agriculture and medicine, paving the way for the development of new treatments and improved livestock breeds through advanced biotechnological interventions.</span></span></span></p> <p>&nbsp;</p> The PSY2 Bovidae aurbeta/gamma shuttle vector is a groundbreaking tool in genetic engineering, tailored for Bovidae species. Its competitive edge lies in its exceptional host range adaptability and heightened gene transfer efficiency. This vector circumvents common barriers faced by existing vectors, such as species-specific limitations and low transformation rates. By enabling more precise and efficient genetic manipulation, it sets the stage for significant advancements in agricultural biotechnology and therapeutic development, offering an unparalleled resource for researchers aiming to drive innovation in genetic studies within bovine and related species. The PSY2 Bovidae aurbeta/gamma shuttle vector has far-reaching potential applications that extend across various domains. In agriculture, it could revolutionize livestock breeding by introducing desirable traits such as disease resistance or improved productivity, thereby enhancing food security and supply sustainability. In the pharmaceutical sector, the technology offers a platform for the development of novel bovine models for human diseases, which could lead to breakthroughs in understanding and treating complex conditions. Additionally, its application in bioremediation could aid in environmental management by engineering bovine species capable of breaking down agricultural waste products. This vector system, by enabling precise genetic modifications, could also facilitate the production of specialized bioproducts, including pharmaceutical proteins and enzymes, within the Bovidae system, thereby contributing to a bio-based economy and advancing the field of synthetic biology. 2024-04-01 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 154639160 Stewart, Philip National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Stewart, Philip (NIAID) 1 154641714 Rosa, Patricia National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Rosa, Patricia (NIAID) 2 154639160 Stewart, Philip National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Stewart, Philip (NIAID) 1 154641714 Rosa, Patricia National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Rosa, Patricia (NIAID) 2 154635314 PBSV2 Borrelia Burgdorferi Shuttle Vector E-180-2012-0 Research Material NIAID 146046171 Joyce, Terrence terrence.joyce@nih.gov
United States of America terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-4969] The PSY2 Shuttle Vector System&body=Please send me information about technology [TAB-4969] The PSY2 Shuttle Vector System. Joyce, Terrence<br><a href="mailto:terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-4969] The PSY2 Shuttle Vector System&body=Please send me information about technology [TAB-4969] The PSY2 Shuttle Vector System.">terrence.joyce@nih.gov</a><br> TAB-4967 153987274 A Novel, GMP-Compliant Method for Pathogenesis and Vaccine Development Studies NIAID Animal Models, Antibodies, Collaboration, Immunology, Infectious Disease, Licensing, Research Equipment, Vaccines Animal Models Antibodies Collaboration Immunology Infectious Disease Licensing Research Equipment Vaccines Mathew Memoli, Jeffery Taubenberger <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">The technology involves a laboratory-derived version of the 2009 pandemic H1N1 virus, produced under Good Manufacturing Practices (GMP) to ensure safety and reproducibility for human studies. It&#39;s designed for use in controlled research settings to advance our understanding of influenza pathogenesis and to assess the efficacy of vaccines and drugs. The method enables continuous updating of the virus strain to keep pace with the natural evolution of the influenza virus, ensuring relevance in research and potential clinical applications. This novel approach aims to overcome the unpredictability and inefficiency of current methods that rely on naturally acquired infections for study, offering a more controlled and reliable way to conduct influenza research and to expediently test new treatments and vaccines.</span></span></span></p> The laboratory-derived H1N1 virus offers several competitive advantages over existing influenza research models. Its creation under GMP conditions ensures a high standard of quality and safety, pivotal for research and potential therapeutic use. The ability to modify the virus in accordance with the natural evolution of influenza allows for up-to-date studies, which is critical given the rapid mutation rates of the virus. This ensures that vaccines and drugs developed using this system are likely to be more effective against current strains. Additionally, the use of this virus in controlled research settings circumvents the unpredictability of natural infection, leading to more reliable and efficient studies. This controlled environment is particularly advantageous for assessing pathogenesis and testing new treatments, which could significantly accelerate the development of effective influenza interventions. This GMP-compliant H1N1 virus serves as a versatile tool with potential applications across a spectrum of influenza-related research and development fields. It is particularly valuable for creating more accurate models of disease pathogenesis, which is crucial for understanding the mechanics of viral infection and progression. The virus can be instrumental in vaccine development, providing a stable platform for testing the efficacy of new vaccines against evolving influenza strains. Additionally, it holds promise in drug discovery and testing, as it allows for the assessment of antiviral drugs in a controlled environment, closely mimicking human influenza infections. Beyond research, this technology could be applied in clinical settings for the development of personalized medicine approaches and in public health for more rapid response to influenza outbreaks by informing vaccine strain selection and antiviral stockpiling strategies. 2024-03-25 2026-08-26 2026-08-26 2026-08-26 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 153987330 Memoli, Mathew NIAID - DIR NIAID Memoli, Mathew (NIAID) 1 153987339 Taubenberger, Jeffery NIAID - DIR NIAID Taubenberger, Jeffery (NIAID) 2 153987330 Memoli, Mathew NIAID - DIR NIAID Memoli, Mathew (NIAID) 1 153987339 Taubenberger, Jeffery NIAID - DIR NIAID Taubenberger, Jeffery (NIAID) 2 153987277 Influenza A 2009 H1N1 Challenge Virus E-178-2012-0 Research Material NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4967] A Novel, GMP-Compliant Method for Pathogenesis and Vaccine Development Studies&body=Please send me information about technology [TAB-4967] A Novel, GMP-Compliant Method for Pathogenesis and Vaccine Development Studies. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4967] A Novel, GMP-Compliant Method for Pathogenesis and Vaccine Development Studies&body=Please send me information about technology [TAB-4967] A Novel, GMP-Compliant Method for Pathogenesis and Vaccine Development Studies.">ganelinaa@niaid.nih.gov</a><br> TAB-4966 153987033 Licensing Recommendation for CHO-DG44 Cell Adaptation for RSV F Protein Expression NIAID Collaboration, Human Cell Lines, Infectious Disease, Licensing, Oncology, Vaccines Collaboration Human Cell Lines Infectious Disease Licensing Oncology Vaccines Elizabeth Carey, Mingzong Chen, Peifeng Chen, Mridul Ghosh, Joseph Horwitz, Attila Nagy <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">The technology involves the adaptation of CHO-DG44 cells to ActiCHO P medium, improving their doubling time and suitability for generating stable cell lines for GMP purposes. These stable cell lines are designed for expressing the RSV F protein stabilized in the prefusion conformation, including the DS-Cav1 mutation, developed by the Vaccine Research Center. This adaptation process aims to create an optimal host line for manufacturing stabilized RSV F, ensuring stable expression and high protein yields without compromising function or stability. The technology is fully developed and serves as a valuable research tool for various commercial entities developing RSV prefusion F vaccines, such as GSK and China National Biotech Group.</span></span></span></p> The technology's competitive advantages lie in its ability to significantly enhance the production efficiency and stability of the RSV F protein, a crucial component in RSV vaccine development. By adapting CHO-DG44 cells to ActiCHO P medium, the technology offers improved doubling times, which can lead to faster and more cost-effective production processes. Additionally, the stable cell lines developed using this technology exhibit high expression levels of the RSV F protein in its prefusion conformation, a critical requirement for vaccine efficacy. This innovation not only streamlines the manufacturing process but also ensures that the produced vaccine maintains its functional integrity and stability, providing a competitive edge in the development of RSV vaccines. The technology's potential applications extend beyond RSV vaccine development, encompassing a wide range of biopharmaceutical and research endeavors. The adapted CHO-DG44 cells can serve as a versatile platform for the production of various biologics beyond the RSV F protein, including other viral antigens, therapeutic proteins, and monoclonal antibodies. This flexibility makes the technology valuable for addressing diverse medical needs, from infectious diseases to oncology and beyond. Furthermore, the stable expression and high protein yields achievable with this technology make it an attractive option for biopharmaceutical companies seeking efficient and reliable cell lines for the development and production of novel biologics. 2024-03-25 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153987049 Chen, Peifeng National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Chen, Peifeng (NIAID) 1 153987057 Ghosh, Mridul NIAID - VRC NIAID Ghosh, Mridul (NIAID) 2 153987113 Nagy, Attila National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Nagy, Attila (NIAID) 3 153987143 Horwitz, Joseph Horwitz, Joseph 4 153987161 Chen, Mingzong National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Chen, Mingzong (NIAID) 5 153987180 Carey, Elizabeth Carey, Elizabeth 6 153987049 Chen, Peifeng National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Chen, Peifeng (NIAID) 1 153987057 Ghosh, Mridul NIAID - VRC NIAID Ghosh, Mridul (NIAID) 2 153987113 Nagy, Attila National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Nagy, Attila (NIAID) 3 153987143 Horwitz, Joseph Horwitz, Joseph 4 153987161 Chen, Mingzong National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Chen, Mingzong (NIAID) 5 153987180 Carey, Elizabeth Carey, Elizabeth 6 153987036 Modified CHO Cell Line To Manufacture The RSV Vaccine Candidate 0SCAV1 E-177-2018-0 Research Material NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4966] Licensing Recommendation for CHO-DG44 Cell Adaptation for RSV F Protein Expression&body=Please send me information about technology [TAB-4966] Licensing Recommendation for CHO-DG44 Cell Adaptation for RSV F Protein Expression. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4966] Licensing Recommendation for CHO-DG44 Cell Adaptation for RSV F Protein Expression&body=Please send me information about technology [TAB-4966] Licensing Recommendation for CHO-DG44 Cell Adaptation for RSV F Protein Expression.">sabrina.hafiz@nih.gov</a><br> TAB-4965 153986511 Enhancing Immunogenicity and Protection in Calves NIAID Animal Models, Antibodies, Collaboration, Diagnostics, Immunology, Infectious Disease, Licensing, Plasmids/Vectors, Pulmonology, Research Materials, Respiratory, Therapeutics, Vaccines Animal Models Antibodies Collaboration Diagnostics Immunology Infectious Disease Licensing Plasmids/Vectors Pulmonology Research Materials Respiratory Therapeutics Vaccines Lei Chen, Davide Corti, Peter Kwong, Antonio Lanzavecchia, Geraldine Taylor, Baoshan Zhang <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">The discovery outlined in the Employee Discovery and Invention Report represents a significant advancement in veterinary vaccine technology, specifically targeting the bovine respiratory syncytial virus (bRSV). This innovation involves a &quot;DS2&quot; version of the bRSV F vaccine, which has been engineered to enhance immunogenicity through a prefusion-stabilized form of the F protein, absent of the fusion peptide and reinforced by cavity-filling mutations and inter-protomer disulfides. The altered vaccine has shown a marked increase in neutralizing titers in calves, demonstrating an immune response over 100 times greater than those elicited by post-fusion F protein-targeted vaccines. Recognized by prefusion-specific antibodies, such as AM14, D25, and MPE8, this refined vaccine formulation holds the potential to mitigate risks associated with live and attenuated vaccines, which can enhance disease if administered amid an active RSV infection. The technology is poised to not only elevate the standard of bRSV prevention in bovine populations but also has implications for human RSV vaccine development, showcasing a promising avenue for cross-species vaccine research and development.</span></span></span></p> The novel DS2-stabilized bovine RSV F vaccine offers a suite of competitive advantages over existing RSV vaccines. Firstly, the prefusion stabilization of the F protein significantly increases the vaccine’s immunogenicity, eliciting a neutralizing response far superior to traditional post-fusion protein vaccines. Secondly, it addresses the challenge of maternal antibody interference, which can neutralize live vaccines, thereby providing effective immunity even in the presence of maternal antibodies. Thirdly, the DS2 vaccine minimizes the risk of vaccine-enhanced disease, a critical safety concern with live vaccines. Lastly, its innovative design may offer broader protection by effectively targeting the conserved prefusion conformation of the F protein, potentially offering cross-protection against diverse RSV strains. This pioneering approach is set to not only transform bRSV prevention strategies in calves but also has potential applications in developing more efficacious human RSV vaccines, placing it at the forefront of vaccine research. The DS2-stabilized bovine RSV F vaccine has a range of promising potential applications. Primarily, it is positioned to significantly improve the prophylactic measures against bRSV in cattle, an area of substantial economic importance to the livestock industry due to the high morbidity associated with the virus. Beyond veterinary applications, the technology has implications for human RSV vaccine development, as the prefusion-stabilized F protein can potentially elicit stronger immune responses in humans. This innovation could lead to the development of more effective RSV vaccines for high-risk populations, such as infants and the elderly. Furthermore, the platform technology underlying this vaccine could be adapted to target other respiratory viruses in both animals and humans, indicating its versatile application in the broader field of vaccine research. Additionally, the method of stabilization may inform vaccine design principles that can be applied to emerging infectious diseases, thus enhancing global health security. 2024-03-25 2026-08-26 2026-08-26 2026-08-26 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 153986528 Chen, Lei National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Chen, Lei (NIAID) 1 153986533 Taylor, Geraldine The Pirbright Institute Taylor, Geraldine 2 153986542 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 3 153986567 Zhang, Baoshan NIAID Zhang, Baoshan (NIAID) 4 153986618 Corti, Davide HUMABS BioMed SA (subsidiary of Vir Biotechnology) [CH] Corti, Davide 5 153986622 Lanzavecchia, Antonio Institute for Research in Biomedicine (IRB) [CH] Lanzavecchia, Antonio 6 153986528 Chen, Lei National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Chen, Lei (NIAID) 1 153986533 Taylor, Geraldine The Pirbright Institute Taylor, Geraldine 2 153986542 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 3 153986567 Zhang, Baoshan NIAID Zhang, Baoshan (NIAID) 4 153986618 Corti, Davide HUMABS BioMed SA (subsidiary of Vir Biotechnology) [CH] Corti, Davide 5 153986622 Lanzavecchia, Antonio Institute for Research in Biomedicine (IRB) [CH] Lanzavecchia, Antonio 6 153986514 NOVEL RECOMBINANT PREFUSION RSV F PROTEINS AND USES THEREOF E-174-2017-0 Filing authorized INSTITUTE FOR RESEARCH IN BIOMEDICINE, NIAID, The Pirbright Institute 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4965] Enhancing Immunogenicity and Protection in Calves&body=Please send me information about technology [TAB-4965] Enhancing Immunogenicity and Protection in Calves. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4965] Enhancing Immunogenicity and Protection in Calves&body=Please send me information about technology [TAB-4965] Enhancing Immunogenicity and Protection in Calves.">sabrina.hafiz@nih.gov</a><br> TAB-4964 153986295 Development of Multivalent Peptide Tolerogen for Therapeutic Treatment of Multiple Sclerosis NIAID Antibodies, Collaboration, Diagnostics, Human Cell Lines, Immunology, Licensing, Neurology, Plasmids/Vectors, Rare/Neglected Diseases, Research Materials, Therapeutics Antibodies Collaboration Diagnostics Human Cell Lines Immunology Licensing Neurology Plasmids/Vectors Rare/Neglected Diseases Research Materials Therapeutics Michael Lenardo, Lixin Zheng <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">The technology pertains to a novel multivalent peptide tolerogen designed for the therapeutic treatment of Multiple Sclerosis (MS), a condition where the immune system erroneously attacks the central nervous system. This advanced therapeutic strategy involves a fusion-peptide composed of myelin oligodendrocyte glycoprotein (MOG), myelin-basic protein (MBP), and myelin proteolipid protein (PLP), along with myelin-associated glycoprotein (MAG). This composition is tailored to specifically target and mitigate the activity of autoimmune T cells responsible for the pathological process in MS, without affecting other immune system functions. The inclusion of MAG is particularly significant as it broadens the scope of major antigenic epitopes covered, potentially enhancing the efficacy of MS tolerance induction. This discovery is at the initial &#39;Discovery&#39; stage, indicating that it is in the early phases of identifying and understanding the mechanisms and benefits of the proposed treatment.</span></span></span></p> <p>&nbsp;</p> The competitive advantage of this cutting-edge multivalent peptide tolerogen lies in its strategic design, which combines multiple myelin-derived peptides to create a more comprehensive approach to inducing tolerance in Multiple Sclerosis (MS). By targeting a broader range of antigenic epitopes—thanks to the inclusion of MAG (myelin-associated glycoprotein)—it promises enhanced efficacy over existing therapies that may only focus on singular antigens. This multifaceted tolerogen approach could lead to a more robust and durable immune tolerance, potentially reducing the frequency and severity of MS relapses. Moreover, this peptide tolerogen is crafted to target only the pathological autoimmune T cells, which may reduce the overall immune suppression risk, leading to a better safety profile. The technology is at the forefront of therapeutic innovation, potentially setting a new standard for MS treatment modalities and positioning it as a strong candidate for future clinical development and market leadership. The potential applications of the multivalent peptide tolerogen are vast and transformative within the realm of autoimmune disease management, particularly for Multiple Sclerosis (MS). Beyond MS, this technology has the potential to be adapted to address a spectrum of autoimmune disorders where pathogenic T cells play a pivotal role, such as rheumatoid arthritis, systemic lupus erythematosus, and type 1 diabetes. Its specificity in targeting autoimmune T cells offers a promising avenue for developing personalized medicine strategies, minimizing off-target effects and maximizing therapeutic efficacy. Additionally, the underlying principles of this tolerogen could inspire novel prophylactic treatments that may prevent the onset of autoimmune diseases in high-risk individuals. The research could also catalyze advancements in immunological research by providing a platform for studying the mechanisms of immune tolerance and the pathophysiology of autoimmune diseases, thereby broadening its utility to both therapeutic and research-based applications. 2024-03-25 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153986313 Lenardo, Michael NIAID - DIR NIAID Lenardo, Michael (NIAID) 1 153986325 Zheng, Lixin NIAID - DIR NIAID Zheng, Lixin (NIAID) 2 153986313 Lenardo, Michael NIAID - DIR NIAID Lenardo, Michael (NIAID) 1 153986325 Zheng, Lixin NIAID - DIR NIAID Zheng, Lixin (NIAID) 2 153986298 Development Of Multivalent Peptide Tolerogen For Therapeutic Treatment Of Multiple Sclerosis E-173-2017-0 Closed NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4964] Development of Multivalent Peptide Tolerogen for Therapeutic Treatment of Multiple Sclerosis&body=Please send me information about technology [TAB-4964] Development of Multivalent Peptide Tolerogen for Therapeutic Treatment of Multiple Sclerosis. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4964] Development of Multivalent Peptide Tolerogen for Therapeutic Treatment of Multiple Sclerosis&body=Please send me information about technology [TAB-4964] Development of Multivalent Peptide Tolerogen for Therapeutic Treatment of Multiple Sclerosis.">yogikala.prabhu@nih.gov</a><br> TAB-4962 153985662 A Novel Approach to Enhancing Viral Envelope Protein Maturation Inhibition NIAID Antibodies, Collaboration, Diagnostics, Human Cell Lines, Immunology, Infectious Disease, Licensing, Materials Available, Oncology, Research Materials, Therapeutics, Vaccines Antibodies Collaboration Diagnostics Human Cell Lines Immunology Infectious Disease Licensing Materials Available Oncology Research Materials Therapeutics Vaccines Stephen Leppla <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">The technology pertains to the development of furin-deficient Chinese Hamster Ovary (CHO) cells, specifically the CHO FD11 cell line, which plays a pivotal role in proteolytic maturation of various proteins critical for physiological processes and pathogen virulence. By inhibiting furin, a protease involved in the activation of many important proteins and pathogens, these modified cells provide a unique platform for research into viral infections and potential therapeutic interventions. The absence of furin in these cells prevents the cleavage and subsequent activation of pathogenic proteins, offering a more specific and robust method for studying furin-dependent processes. This technology holds significant promise for improving the efficacy of treatments against furin-dependent infections and advancing the understanding of proteolytic maturation in disease progression.</span></span></span></p> The furin-deficient CHO FD11 cell line represents a significant advancement over current methods, offering several competitive advantages in the field of therapeutic research and biotechnological applications. Unlike small molecule inhibitors of furin or RNA interference techniques which may partially reduce furin activity, the genetic deletion in these cells completely abolishes the enzyme's function, ensuring higher specificity and eliminating off-target effects. This allows for precise studies of protein activation and virus infectivity, directly attributable to furin activity. Additionally, the stable genetic modification circumvents the variability and reversibility associated with pharmacological inhibitors, thus providing a consistent and reliable research tool. The CHO FD11 cells open avenues for the development of novel therapeutic strategies, particularly for diseases where furin-like proteases are key to pathogenicity, enabling the discovery of new drugs with potentially fewer side effects due to their target-specific action. The discovery of furin-deficient CHO FD11 cells unlocks a spectrum of potential applications, particularly in the biomedical and pharmaceutical industries. As a robust model, these cells could be instrumental in screening for antiviral compounds that target proteolytic processing, providing a clear path to identifying new drug candidates for diseases where furin is implicated, such as certain bacterial infections and cancers. They can also be used in the development of safer and more effective vaccines by facilitating the study of viral protein maturation in the absence of furin, which may lead to novel vaccine strategies that present viral antigens in their non-fusogenic form. Additionally, the CHO FD11 cell line could revolutionize gene therapy approaches, as they offer a platform for the production of recombinant proteins with a reduced risk of unwanted proteolytic processing, enhancing both the yield and purity of therapeutic proteins. These cells could also have significant implications in research on cellular biology and protein engineering, providing insights into the role of proteases in cellular processes and the development of protein-based therapeutics with enhanced stability and function. 2024-03-25 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153985676 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 1 153985676 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 1 153985669 Furin-deficient Chinese Hamster Ova Cells, CHO FD11 E-166-2019-0 Research Material NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4962] A Novel Approach to Enhancing Viral Envelope Protein Maturation Inhibition&body=Please send me information about technology [TAB-4962] A Novel Approach to Enhancing Viral Envelope Protein Maturation Inhibition. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4962] A Novel Approach to Enhancing Viral Envelope Protein Maturation Inhibition&body=Please send me information about technology [TAB-4962] A Novel Approach to Enhancing Viral Envelope Protein Maturation Inhibition.">wade.green@nih.gov</a><br> TAB-4961 153985355 A Novel Approach for Targeted Genetic Manipulation NIAID Antibodies, Collaboration, Immunology, Infectious Disease, Licensing, Plasmids/Vectors, Rare/Neglected Diseases, Research Equipment, Therapeutics, Vaccines Antibodies Collaboration Immunology Infectious Disease Licensing Plasmids/Vectors Rare/Neglected Diseases Research Equipment Therapeutics Vaccines Thomas Bugge, Rolf Heumann, Stephen Leppla, Carly Merritt, Sebastian Neumann, Dennis Palaga <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">The technology offers a novel and efficient method for inducing targeted DNA recombination using a tripartite fusion protein, LFn-NLS-Cre, in combination with anthrax toxin protective antigen (PA). This system enables precise genetic manipulation in cells carrying a gene flanked by loxP sites, allowing for specific recombination events. Unlike other inducible systems that require multiple injections, our technology requires only a single administration, reducing experimental complexity and stress on animals. Recombination can occur rapidly, with effects seen in as little as 10 hours post-injection. The simplicity, efficiency, and specificity of our method make it a valuable tool for researchers in a wide range of genetic and molecular biology studies.</span></span></span></p> This technology offers several key competitive advantages over existing methods for inducing DNA recombination. First, unlike traditional methods that require multiple injections or complex breeding schemes, our system requires only a single administration, saving time and resources. Second, our method allows for rapid recombination, with effects observed in as little as 10 hours, compared to other systems that may take days to achieve similar results. Third, our technology is highly specific, targeting only cells carrying loxP sites, thereby minimizing off-target effects and improving the accuracy of genetic manipulation. Additionally, our system is cost-effective and does not require the use of viral vectors or complex cell culture techniques, making it accessible to a wide range of researchers. Overall, these advantages position our technology as a powerful and efficient tool for targeted genetic manipulation. The technology has broad potential applications across various fields, including basic research, biotechnology, and gene therapy. In basic research, it can be used to study gene function and regulation by allowing researchers to control the expression of specific genes in a targeted manner. In biotechnology, the method could facilitate the development of genetically modified organisms (GMOs) and the production of recombinant proteins. Moreover, the technology holds promise for gene therapy applications, where precise genetic manipulation is crucial. By enabling targeted DNA recombination, this method could potentially be used to correct genetic mutations or introduce therapeutic genes into specific cell types. Its versatility and precision make it applicable to a wide range of research and therapeutic areas. 2024-03-25 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153985366 Bugge, Thomas NIDCR NIDCR Bugge, Thomas (NIDCR) 1 153985370 Leppla, Stephen NIAID Leppla, Stephen (NIAID) 2 153985402 Neumann, Sebastian Ruhr University Bochum [DE] Neumann, Sebastian 3 153985426 Heumann, Rolf Ruhr University Bochum [DE] Heumann, Rolf 4 153985449 Palaga, Dennis Ruhr-Universitat Bochurn Palaga, Dennis 5 153985498 Merritt, Carly NIDCR NIDCR Merritt, Carly (NIDCR) 6 153985366 Bugge, Thomas NIDCR NIDCR Bugge, Thomas (NIDCR) 1 153985370 Leppla, Stephen NIAID Leppla, Stephen (NIAID) 2 153985402 Neumann, Sebastian Ruhr University Bochum [DE] Neumann, Sebastian 3 153985426 Heumann, Rolf Ruhr University Bochum [DE] Heumann, Rolf 4 153985449 Palaga, Dennis Ruhr-Universitat Bochurn Palaga, Dennis 5 153985498 Merritt, Carly NIDCR NIDCR Merritt, Carly (NIDCR) 6 153985358 Induction Of LoxP-dependent DNA Recombination Via Cre-conjugated Anthrax Toxin E-165-2019-0 Research Material NIAID, NIDCR, Ruhr-Universitat Bochurn 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4961] A Novel Approach for Targeted Genetic Manipulation&body=Please send me information about technology [TAB-4961] A Novel Approach for Targeted Genetic Manipulation. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4961] A Novel Approach for Targeted Genetic Manipulation&body=Please send me information about technology [TAB-4961] A Novel Approach for Targeted Genetic Manipulation.">wade.green@nih.gov</a><br> TAB-4831 152365936 Anti-Puromycin Antibodies Illuminate the World of Cellular Protein Translation NIAID Collaboration, Computational models/software, Diagnostics, Research Equipment Collaboration Computational models/software Diagnostics Research Equipment Alexandre David, Jonathan (Jon) Yewdell <p>The Ribopuromycylation (RPM) technology, developed by Dr. Jon Yewdell and Dr. Alexandre David, offers a powerful and universal method for visualizing and studying protein translation within cells. RPM involves the use of puromycin, a molecule that mimics a tyrosyl-tRNA and terminates translation by becoming covalently incorporated into the nascent protein chain&#39;s C-terminus within the ribosome&#39;s A site. This technique enables the immobilization of puromycylated nascent protein chains on ribosomes when chain elongation inhibitors like cycloheximide or emetine are utilized. Anti-puromycin monoclonal antibodies (mAbs) are then employed to localize actively translating ribosomes through immunofluorescence analysis of fixed and permeabilized cells or tissues. RPM has revolutionized the study of protein translation, providing researchers with a straightforward and versatile tool to investigate this fundamental cellular process in various biological contexts.</p> <p>&nbsp;</p> Ribopuromycylation (RPM) offers a competitive edge in cellular biology due to its universality, specificity, and compatibility with fluorescence detection. This versatile method simplifies the study of protein translation, making it accessible to a broader range of researchers, and provides accurate insights into active translation processes within cells. With various pathological conditions and advancing our understanding of cellular processes. Ribopuromycylation (RPM) finds diverse applications in cellular and molecular biology. It enables the exploration of dynamic protein translation regulation in response to environmental stressors, infections, and differentiation states, offering valuable insights into cellular adaptations. RPM also facilitates the specific investigation of individual gene expression patterns, aiding in the comprehension of gene-specific translation dynamics. Its versatility extends to drug discovery and disease research, making it a valuable tool for uncovering translation abnormalities associated 2024-01-24 2026-08-26 2026-08-26 2024-12-10 False True True 52406769 Prototype 52406769 37470483 Website Abstract 152365968 David, Alexandre INSERM David, Alexandre 2 152366109 Yewdell, Jonathan (Jon) NIAID - DIR NIAID Yewdell, Jonathan (Jon) (NIAID) 3 152365968 David, Alexandre INSERM David, Alexandre 2 152366109 Yewdell, Jonathan (Jon) NIAID - DIR NIAID Yewdell, Jonathan (Jon) (NIAID) 3 152365939 Hybridoma Cell Lines 2A4 And 5B12 Against Puromycin E-003-2021-0 Research Material NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4831] Anti-Puromycin Antibodies Illuminate the World of Cellular Protein Translation&body=Please send me information about technology [TAB-4831] Anti-Puromycin Antibodies Illuminate the World of Cellular Protein Translation. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4831] Anti-Puromycin Antibodies Illuminate the World of Cellular Protein Translation&body=Please send me information about technology [TAB-4831] Anti-Puromycin Antibodies Illuminate the World of Cellular Protein Translation.">jonathan.motley@nih.gov</a><br> TAB-4960 153985177 Enhanced Stability and Manufacturing of Ebola Virus Antibodies: Discovery of S1-4-A09 and its A80P Derivative from Survivor B-cells NIAID Antibodies, Collaboration, Infectious Disease, Licensing, Therapeutics, Vaccines Antibodies Collaboration Infectious Disease Licensing Therapeutics Vaccines Nancy Sullivan <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">The discovery of the S1-4-A09 antibody and its A80P derivative from a survivor of Ebola virus disease represents a significant advancement in the development of therapeutics against Ebola virus. These antibodies, isolated using innovative techniques, demonstrate potent antiviral activities in vitro and have shown improved stability and manufacturing feasibility compared to existing antibodies. When used in combination therapy with mAb114, they provide consistent protection against lethal Ebola virus infection. This discovery opens new possibilities for the development of more effective and practical treatments for Ebola virus disease.</span></span></span></p> <p>&nbsp;</p> The S1-4-A09 antibody and its A80P derivative offer several competitive advantages over existing Ebola virus antibodies. Unlike some current antibodies, such as mAb100, which suffer from aggregation issues and manufacturing risks, S1-4-A09 and its derivative have been engineered for enhanced stability and manufacturing feasibility. Their unique binding characteristics and synergistic effects with mAb114 make them promising candidates for combination therapy, providing consistent protection against Ebola virus infection. Additionally, the antibodies were isolated from a survivor of Ebola virus disease, indicating their potential relevance to human immune responses and improving their likelihood of clinical success. These advantages position S1-4-A09 and its derivative as promising candidates for further development as therapeutics against Ebola virus. The discovery of the S1-4-A09 antibody and its A80P derivative opens up a range of potential applications in the field of Ebola virus therapeutics. These antibodies could be further developed as components of novel combination therapies for the treatment of Ebola virus disease, potentially increasing treatment efficacy and patient outcomes. Additionally, their enhanced stability and manufacturing feasibility make them attractive candidates for large-scale production and distribution, particularly in resource-limited settings where outbreaks often occur. Furthermore, the antibodies' unique binding characteristics and synergistic effects with other antibodies suggest they may also have utility in prophylactic applications, such as post-exposure prophylaxis for individuals at high risk of Ebola virus exposure. Overall, the discovery of S1-4-A09 and its derivative has the potential to significantly impact the field of Ebola virus therapeutics and improve the global response to Ebola virus outbreaks 2024-03-25 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153985192 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 1 153985192 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 1 153985180 Unique Ebola Survivor MAb And Derivative ( S 1-4-A09 And S L-4-A09 A80P) Modified For Enhanced Stability And Manufacturing E-154-2017-0 Filing authorized National Institute of Biomedical Research (INRB, Institut National de la Recherche Bio) [CD], NIAID, NIH - NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4960] Enhanced Stability and Manufacturing of Ebola Virus Antibodies: Discovery of S1-4-A09 and its A80P Derivative from Survivor B-cells&body=Please send me information about technology [TAB-4960] Enhanced Stability and Manufacturing of Ebola Virus Antibodies: Discovery of S1-4-A09 and its A80P Derivative from Survivor B-cells. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4960] Enhanced Stability and Manufacturing of Ebola Virus Antibodies: Discovery of S1-4-A09 and its A80P Derivative from Survivor B-cells&body=Please send me information about technology [TAB-4960] Enhanced Stability and Manufacturing of Ebola Virus Antibodies: Discovery of S1-4-A09 and its A80P Derivative from Survivor B-cells.">wade.green@nih.gov</a><br> TAB-4958 153984883 FDA-Approved Drugs Show Antiviral Activity Against MERS-CoV NIAID Application, Collaboration, Computational models/software, Infectious Disease, Licensing, Respiratory, Therapeutics, Vaccines Application Collaboration Computational models/software Infectious Disease Licensing Respiratory Therapeutics Vaccines Matthew Frieman, Lisa Hensley, Peter Jahrling <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">This technology involves the screening of a library of 290 FDA-approved or clinically advanced compounds for their antiviral activity against Middle Eastern respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV). The screening identified 27 compounds with dual antiviral activity against both viruses, belonging to thirteen different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptors used as antipsychotics. This discovery holds promise for repurposing existing FDA-approved drugs for the treatment of MERS-CoV, potentially providing a faster and more cost-effective solution compared to developing new drugs.</span></span></span></p> <p>&nbsp;</p> This discovery offers several competitive advantages over existing approaches to treating Middle Eastern respiratory syndrome coronavirus (MERS-CoV). Firstly, repurposing FDA-approved drugs reduces the time and cost associated with traditional drug development processes, enabling a quicker response to emerging viral threats. Secondly, the identification of compounds with dual antiviral activity against both MERS-CoV and SARS-CoV underscores the potential broad-spectrum effectiveness of these drugs, which could be crucial in managing future coronavirus outbreaks. Additionally, the use of existing drugs with established safety profiles may expedite regulatory approval and facilitate rapid deployment in clinical settings. The discovery of 27 FDA-approved compounds with antiviral activity against MERS-CoV and SARS-CoV has wide-ranging potential applications in the field of infectious disease management. These compounds could be further evaluated for their efficacy in treating MERS-CoV infections, offering a much-needed therapeutic option for a disease with currently no approved treatments. Additionally, the broad-spectrum antiviral activity of these compounds suggests potential utility in combating other coronaviruses, including those that may emerge in the future. The repurposing of existing drugs also opens up possibilities for rapid deployment in outbreak situations, helping to mitigate the impact of novel viral threats on public health. 2024-03-25 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153984890 Frieman, Matthew University of Maryland, School of Medicine Frieman, Matthew 1 153984894 Jahrling, Peter NIAID - DIR NIAID Jahrling, Peter (NIAID) 2 153984902 Hensley, Lisa NIAID - DIR NIAID Hensley, Lisa (NIAID) 3 153984890 Frieman, Matthew University of Maryland, School of Medicine Frieman, Matthew 1 153984894 Jahrling, Peter NIAID - DIR NIAID Jahrling, Peter (NIAID) 2 153984902 Hensley, Lisa NIAID - DIR NIAID Hensley, Lisa (NIAID) 3 153984886 Identification Of FDA Approved Molecules For The Treatment Of Middle East Respiratory Syndrome (MERs) Cornonavirus (CoV) E-153-2015-0 Filing authorized NIAID, University of Maryland 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4958] FDA-Approved Drugs Show Antiviral Activity Against MERS-CoV&body=Please send me information about technology [TAB-4958] FDA-Approved Drugs Show Antiviral Activity Against MERS-CoV. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4958] FDA-Approved Drugs Show Antiviral Activity Against MERS-CoV&body=Please send me information about technology [TAB-4958] FDA-Approved Drugs Show Antiviral Activity Against MERS-CoV.">wade.green@nih.gov</a><br> TAB-4957 153932519 Development of a Probiotic-Based Inhalational Therapeutic for Protection Against Acute Respiratory Virus Infections NIAID Collaboration, Licensing, Respiratory, Therapeutics Collaboration Licensing Respiratory Therapeutics Jesse Keicher, Helene Rosenberg, David Wilfret <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">The technology involves the development of a probiotic-based inhalational therapeutic for the prevention and treatment of acute respiratory virus infections. This innovative approach utilizes live or heat-inactivated cells of Lactobacillus plantarum, administered directly to the respiratory mucosa. This method has shown significant protection against lethal outcomes of respiratory virus infections by suppressing virus-induced proinflammatory cytokines. The technology is currently in the prototype stage, with further development aimed at creating an effective and safe therapeutic for human use.</span></span></span></p> The probiotic-based inhalational therapeutic offers several competitive advantages over existing treatments for acute respiratory virus infections. Unlike traditional antiviral medications, which often target specific viruses and may be associated with viral resistance, our approach focuses on enhancing the body's natural defense mechanisms. By priming the respiratory mucosa with Lactobacillus plantarum, we induce a robust and sustained protective response that is not virus-specific, potentially offering broad-spectrum protection. Additionally, our therapy targets the inflammatory response, which is a major contributor to the severity of respiratory virus infections, thereby addressing a key aspect of the disease pathogenesis. Furthermore, the use of a probiotic-based approach may offer a favorable safety profile compared to traditional antiviral medications, making it a promising alternative for the prevention and treatment of acute respiratory virus infections. The potential applications of our probiotic-based inhalational therapeutic extend beyond acute respiratory virus infections. The ability of Lactobacillus plantarum to modulate the immune response suggests broader implications for respiratory health. This technology could be explored for its potential in preventing and treating other respiratory conditions characterized by excessive inflammation, such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. Additionally, the concept of mucosal priming with probiotics could be applied to other mucosal surfaces in the body, opening up possibilities for novel treatments in areas such as gastrointestinal health and urogenital infections. Overall, our technology has the potential to revolutionize the field of mucosal immunology and lead to the development of innovative therapies for a range of respiratory and mucosal diseases. 2024-03-19 2026-08-26 2026-08-26 2026-08-26 False True True 52406769 Prototype 52406769 37470483 Website Abstract 153932526 Wilfret, David GlaxoSmithKline (GSK) Wilfret, David 1 153932531 Rosenberg, Helene NIAID Rosenberg, Helene (NIAID) 2 153932540 Keicher, Jesse Symmune Therapeutics LLC Keicher, Jesse 3 153932526 Wilfret, David GlaxoSmithKline (GSK) Wilfret, David 1 153932531 Rosenberg, Helene NIAID Rosenberg, Helene (NIAID) 2 153932540 Keicher, Jesse Symmune Therapeutics LLC Keicher, Jesse 3 153932522 Probiotic Therapeutic Applications E-152-2015-0 Filing authorized GlaxoSmithKline LLC, NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4957] Development of a Probiotic-Based Inhalational Therapeutic for Protection Against Acute Respiratory Virus Infections&body=Please send me information about technology [TAB-4957] Development of a Probiotic-Based Inhalational Therapeutic for Protection Against Acute Respiratory Virus Infections. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4957] Development of a Probiotic-Based Inhalational Therapeutic for Protection Against Acute Respiratory Virus Infections&body=Please send me information about technology [TAB-4957] Development of a Probiotic-Based Inhalational Therapeutic for Protection Against Acute Respiratory Virus Infections.">sabrina.hafiz@nih.gov</a><br> TAB-4956 153932340 Immunogenicity and Efficacy Studies in Animal Models NIAID Animal Models, Antibodies, Collaboration, Infectious Disease, Licensing, Rare/Neglected Diseases, Research Equipment, Respiratory, Vaccines Animal Models Antibodies Collaboration Infectious Disease Licensing Rare/Neglected Diseases Research Equipment Respiratory Vaccines Tiago Abreu Mota, Reed Johnson, Matthias Schnell <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">The bivalent rabies and Lassa virus vaccine represents a significant advancement in vaccine development, offering dual protection against two deadly viral diseases. By combining antigens from both viruses, this vaccine has shown promising immunogenicity in mice and efficacy in reducing viral yield in a relevant animal model. Developed through collaboration with experts from Thomas Jefferson University, including Matthias Schnell and Tiago Abreu Mota, this vaccine has the potential to address major global health challenges posed by Lassa fever and rabies, particularly in endemic regions. As the technology is in the Discovery stage, further research is underway to evaluate its safety and efficacy, with plans for future publication and potential advancement to clinical trials.</span></span></span></p> <p>&nbsp;</p> The bivalent rabies and Lassa virus vaccine holds several key competitive advantages over existing vaccines. Firstly, its dual-action design offers simultaneous protection against two severe viral diseases, providing a comprehensive solution in regions where both diseases are prevalent. Secondly, the vaccine's demonstrated immunogenicity in mice and efficacy in animal models suggest a strong potential for effectiveness in humans. Thirdly, the collaboration with experts from Thomas Jefferson University ensures that the vaccine benefits from cutting-edge research and expertise in virology and vaccine development. Additionally, the vaccine's development at the Discovery stage indicates the potential for further optimization and enhancement, positioning it as a frontrunner in the quest for a safe and effective bivalent vaccine against rabies and Lassa virus. The bivalent rabies and Lassa virus vaccine has the potential for diverse applications in public health. Primarily, it could be used in regions where both Lassa fever and rabies are endemic, offering a comprehensive approach to disease prevention. Additionally, the vaccine may find utility in travel medicine, providing travelers to endemic areas with protection against these diseases. Furthermore, the vaccine's bivalent nature opens up possibilities for inclusion in routine immunization schedules, particularly in areas where these diseases pose a significant health burden. Lastly, the technology behind this vaccine could serve as a platform for the development of other bivalent or multivalent vaccines, leveraging the success and knowledge gained from this innovative approach. 2024-03-19 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153932354 Johnson, Reed NIAID - DIR NIAID Johnson, Reed (NIAID) 1 153932364 Schnell, Matthias Thomas Jefferson University Schnell, Matthias 2 153932380 Abreu Mota, Tiago Thomas Jefferson University Abreu Mota, Tiago 3 153932354 Johnson, Reed NIAID - DIR NIAID Johnson, Reed (NIAID) 1 153932364 Schnell, Matthias Thomas Jefferson University Schnell, Matthias 2 153932380 Abreu Mota, Tiago Thomas Jefferson University Abreu Mota, Tiago 3 153932343 NON-NEUTRALIZING ANTIBODIES ELICITED BY RECOMBINANT LASSA-RABIES VACCINE ARE CRITICAL FOR PROTECTION AGAINST LASSA FEVER E-148-2019-0 Filing authorized NIAID, Thomas Jefferson University 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4956] Immunogenicity and Efficacy Studies in Animal Models&body=Please send me information about technology [TAB-4956] Immunogenicity and Efficacy Studies in Animal Models. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4956] Immunogenicity and Efficacy Studies in Animal Models&body=Please send me information about technology [TAB-4956] Immunogenicity and Efficacy Studies in Animal Models.">wade.green@nih.gov</a><br> TAB-4954 153932003 Broadly Neutralizing Antibodies Targeting the V1V2 Epitope of HIV-1 Env from CAPRISA Donor CAP 256: Therapeutic Potential and Preferential Clade A and Clade C Neutralization NIAID Antibodies, Collaboration, Infectious Disease, Licensing, Research Equipment, Therapeutics Antibodies Collaboration Infectious Disease Licensing Research Equipment Therapeutics Salim Abdool Karim, Nicole Doria-Rose, Jason Gorman, Peter Kwong, John Mascola, Lynn Morris, Lawrence Shapiro, Carolyn Williamson <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">This technology encompasses the discovery of broadly neutralizing antibodies against HIV-1, derived from the CAPRISA Donor CAP 256. These antibodies target the V1V2 epitope of the virus envelope and exhibit a high level of neutralization, particularly against Clade A and Clade C subtypes. With potential applications in therapeutic or prophylactic interventions against HIV-1, this discovery represents a significant advancement in the field, offering a novel approach to combating the virus.</span></span></span></p> <p>&nbsp;</p> The broadly neutralizing antibodies discovered from CAPRISA Donor CAP 256 offer several competitive advantages over existing approaches. These antibodies demonstrate a remarkable ability to neutralize a broad range of HIV-1 variants, including challenging Clade A and Clade C subtypes, which are prevalent in many regions heavily affected by HIV. This specificity and potency make them promising candidates for therapeutic or prophylactic interventions against HIV-1. Additionally, the discovery of these antibodies represents a unique approach that could potentially overcome the limitations of current treatments, providing a new avenue for combating the virus. The discovery of broadly neutralizing antibodies targeting the V1V2 epitope of HIV-1 from CAPRISA Donor CAP 256 has significant potential applications in the field of HIV treatment and prevention. These antibodies could be developed into novel therapeutic agents for HIV-infected individuals, offering a more targeted and potentially more effective treatment option. Additionally, they could be used in prophylactic interventions, such as pre-exposure prophylaxis (PrEP), to prevent HIV infection in high-risk populations. Furthermore, these antibodies could be valuable tools for HIV vaccine development, serving as templates for designing vaccine candidates that elicit similar broadly neutralizing antibodies in individuals. Overall, this discovery opens up new possibilities for combating HIV and improving the lives of those affected by the virus. 2024-03-19 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153932010 Abdool Karim, Salim Centre for the AIDS Programme of Research in South Africa Abdool Karim, Salim 1 153932026 Morris, Lynn National Institute for Communicable Diseases Morris, Lynn 2 153932043 Williamson, Carolyn University of Cape Town (UCT) [ZA] Williamson, Carolyn 3 153932047 Shapiro, Lawrence Columbia University Irving Medical Center (CUIMC) (formerly Columbia University NIAID Shapiro, Lawrence (NIAID) 4 153932051 Gorman, Jason FDA NIAID Gorman, Jason (NIAID) 5 153932055 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 6 153932059 Doria-Rose, Nicole NIAID - VRC NIAID Doria-Rose, Nicole (NIAID) 7 153932070 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 8 153932010 Abdool Karim, Salim Centre for the AIDS Programme of Research in South Africa Abdool Karim, Salim 1 153932026 Morris, Lynn National Institute for Communicable Diseases Morris, Lynn 2 153932043 Williamson, Carolyn University of Cape Town (UCT) [ZA] Williamson, Carolyn 3 153932047 Shapiro, Lawrence Columbia University Irving Medical Center (CUIMC) (formerly Columbia University NIAID Shapiro, Lawrence (NIAID) 4 153932051 Gorman, Jason FDA NIAID Gorman, Jason (NIAID) 5 153932055 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 6 153932059 Doria-Rose, Nicole NIAID - VRC NIAID Doria-Rose, Nicole (NIAID) 7 153932070 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 8 153932006 BROADLY NEUTRALIZING, CROSS REACTIVE ANTIBODIES TO HIV-1 E-147-2015-0 Filing authorized Columbia University, National Institute for Communicable Diseases, NIAID, South African Medical Research Council (SAMRC), University of Cape Town 91025211 Rainwater, Charles crainwater@mail.nih.gov
United States of America crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-4954] Broadly Neutralizing Antibodies Targeting the V1V2 Epitope of HIV-1 Env from CAPRISA Donor CAP 256: Therapeutic Potential and Preferential Clade A and Clade C Neutralization&body=Please send me information about technology [TAB-4954] Broadly Neutralizing Antibodies Targeting the V1V2 Epitope of HIV-1 Env from CAPRISA Donor CAP 256: Therapeutic Potential and Preferential Clade A and Clade C Neutralization. Rainwater, Charles<br><a href="mailto:crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-4954] Broadly Neutralizing Antibodies Targeting the V1V2 Epitope of HIV-1 Env from CAPRISA Donor CAP 256: Therapeutic Potential and Preferential Clade A and Clade C Neutralization&body=Please send me information about technology [TAB-4954] Broadly Neutralizing Antibodies Targeting the V1V2 Epitope of HIV-1 Env from CAPRISA Donor CAP 256: Therapeutic Potential and Preferential Clade A and Clade C Neutralization.">crainwater@mail.nih.gov</a><br> TAB-4953 153931788 Discovery and Development of Novel Plasmodial Surface Anion Channel (PSAC) Inhibitors as Potent Antimalarial Drug Leads NIAID Antibodies, Collaboration, Infectious Disease, Licensing, Research Equipment, Therapeutics Antibodies Collaboration Infectious Disease Licensing Research Equipment Therapeutics Sanjay Desai <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">The technology involves the discovery and development of novel compounds that inhibit the plasmodial surface anion channel (PSAC), a promising drug target for malaria treatment. These compounds have been identified through high-throughput screening as specific and potent inhibitors of PSAC, effectively killing malaria parasite cultures by blocking nutrient acquisition from human plasma. Importantly, the compounds exhibit drug-like properties and show no cytotoxicity to other cells. The discovery has attracted interest from pharmaceutical partners, such as Microbiotix, Inc., for further evaluation of their antimalarial therapeutic potential. Protection of these compounds through patenting is crucial for advancing drug development efforts against malaria.</span></span></span></p> <p>&nbsp;</p> The novel PSAC inhibitors offer several competitive advantages in the field of antimalarial drug development. Their specificity and potency in targeting the malaria parasite set them apart from existing treatments, potentially offering a more effective therapeutic approach. Additionally, their drug-like properties and lack of cytotoxicity to other cells enhance their safety profile, which is crucial for developing a viable and safe antimalarial drug. Furthermore, the compounds' novelty and distinctiveness from known inhibitors of PSAC or other targets suggest a unique mechanism of action, which could lead to the development of a new class of antimalarial drugs with reduced risk of resistance development. These advantages position the compounds as promising candidates for further preclinical and clinical development. The PSAC inhibitors have significant potential applications in the field of malaria treatment and control. They could serve as the foundation for the development of new, more effective antimalarial drugs that could help combat drug-resistant strains of the malaria parasite. Additionally, these compounds could be used in combination therapies to enhance treatment outcomes and reduce the risk of resistance development. Beyond direct treatment, the inhibitors could also be valuable tools for research, enabling a deeper understanding of the biology of the malaria parasite and the mechanisms of antimalarial drug action. Overall, these compounds have the potential to make a significant impact on the global fight against malaria. 2024-03-19 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153931797 Desai, Sanjay NIAID - DIR NIAID Desai, Sanjay (NIAID) 1 153931797 Desai, Sanjay NIAID - DIR NIAID Desai, Sanjay (NIAID) 1 153931791 Plasmodial Surface Anion Channel Inhibitors As Antimalarial Drug Leads E-146-2011-0 Filing authorized NIAID 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-4953] Discovery and Development of Novel Plasmodial Surface Anion Channel (PSAC) Inhibitors as Potent Antimalarial Drug Leads&body=Please send me information about technology [TAB-4953] Discovery and Development of Novel Plasmodial Surface Anion Channel (PSAC) Inhibitors as Potent Antimalarial Drug Leads. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-4953] Discovery and Development of Novel Plasmodial Surface Anion Channel (PSAC) Inhibitors as Potent Antimalarial Drug Leads&body=Please send me information about technology [TAB-4953] Discovery and Development of Novel Plasmodial Surface Anion Channel (PSAC) Inhibitors as Potent Antimalarial Drug Leads.">peter.tung@nih.gov</a><br> TAB-4952 153931591 Discovery Submission Form: Attenuated RSV Vaccine with Enhanced Genetic Modifications NIAID Antibodies, Collaboration, Human Cell Lines, Immunology, Infectious Disease, Licensing, Plasmids/Vectors, Pulmonology, Respiratory, Therapeutics, Vaccines Antibodies Collaboration Human Cell Lines Immunology Infectious Disease Licensing Plasmids/Vectors Pulmonology Respiratory Therapeutics Vaccines Ursula Buchholz, Peter Collins <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">The technology under discussion represents a significant advancement in the field of virology and immunization. It involves a novel live-attenuated respiratory syncytial virus (RSV) vaccine that is genetically modified by deleting the NS2 gene, which is known to elicit cellular responses to viral infection, and by incorporating a stabilized I030s mutation in the L protein to improve its safety and efficacy. This pioneering approach is designed to generate a more robust immune response, particularly in infants and young children who are most at risk from severe RSV infections. The vaccine&#39;s level of attenuation can be finely adjusted, which may offer a unique advantage in providing tailored immunogenicity and potentially filling the gap where no licensed vaccines currently exist. This discovery is poised for clinical evaluation and represents a promising stride towards preventing a common and serious respiratory illness.</span></span></span></p> The live-attenuated RSV vaccine with NS2 gene deletion and stabilized I030s mutation stands out in the competitive landscape for its innovative approach to immunization. The deletion of the NS2 gene disrupts viral mechanisms that typically undermine the host's immune response, offering a stronger defense against infection. The I030s mutation further enhances this effect by stabilizing the vaccine, allowing for a safer administration to vulnerable populations like infants and young children. Moreover, the tunable attenuation provides the flexibility to adapt the vaccine's strength, potentially improving efficacy across varied demographic groups. This vaccine not only promises heightened effectiveness but also sets a new standard in the safety profile of live vaccines, positioning it as a front-runner in the market for RSV prevention. The improved RSV vaccine's potential applications extend beyond the primary aim of preventing respiratory infections in young children. Its tunable attenuation makes it a versatile platform for elderly populations and individuals with compromised immune systems, who are also at high risk for severe RSV complications. Moreover, the vaccine's technology could pave the way for the development of similar vaccines against other respiratory pathogens, utilizing the same genetic modifications for enhanced immunogenic responses. The ability to fine-tune immune activation also opens up possibilities for use in therapeutic settings, potentially aiding in the treatment of established infections by modulating the immune system's response. Additionally, the underlying genetic technology can be applied to veterinary medicine, protecting livestock from viral diseases and mitigating economic losses in the agricultural sector. This multi-faceted application potential makes the vaccine a valuable candidate for wide-ranging impacts in public health and beyond. 2024-03-19 2026-08-26 2026-08-26 2026-08-26 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 153931610 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 153931616 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 2 153931610 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 153931616 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 2 153931594 Improved Live-attenuated Respiratory Syncytial Virus (RSV) Vaccines Bearing An NS2 Gene Deletion And Stabilized 1030s Mutation In L Protein E-145-2018-0 Research Material NIAID 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-4952] Discovery Submission Form: Attenuated RSV Vaccine with Enhanced Genetic Modifications&body=Please send me information about technology [TAB-4952] Discovery Submission Form: Attenuated RSV Vaccine with Enhanced Genetic Modifications. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-4952] Discovery Submission Form: Attenuated RSV Vaccine with Enhanced Genetic Modifications&body=Please send me information about technology [TAB-4952] Discovery Submission Form: Attenuated RSV Vaccine with Enhanced Genetic Modifications.">maryann.puglielli@nih.gov</a><br> TAB-4951 153931367 Inhibitors of HIV-1 Entry: Targeting the Phe43 Cavity of gp120 NIAID Collaboration, Computational models/software, Infectious Disease, Licensing, Therapeutics, Vaccines Collaboration Computational models/software Infectious Disease Licensing Therapeutics Vaccines Francesca Curreli, Asim Debnath, Young Do Kwon, Peter Kwong <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">The discovery involves the development of substituted phenylpyrrolecarboxamides as therapeutic agents for HIV-1 infection. These compounds target the Phe43 cavity of the HIV-1 gp120 protein, disrupting the interaction between gp120 and host cell receptors CD4 and CCR5/CXCR4, thereby inhibiting viral entry into host cells. This targeted approach presents a novel strategy for HIV therapy and prophylaxis, distinct from current treatments that target other stages of the viral life cycle. The discovery holds promise for the development of new drugs to combat HIV/AIDS, addressing a critical need for more effective and targeted antiviral therapies.</span></span></span></p> The substituted phenylpyrrolecarboxamides offer several competitive advantages over existing HIV therapies. Firstly, they target a specific site on the HIV-1 gp120 protein, the Phe43 cavity, which is crucial for viral entry into host cells. This targeted mechanism of action is distinct from current drugs, which target different stages of the viral life cycle. Additionally, the compounds have shown therapeutic activity in HIV-1, suggesting their potential efficacy in treating HIV/AIDS. Furthermore, by inhibiting viral entry, these compounds may also reduce the risk of viral resistance, a common challenge with current HIV therapies. Overall, the substituted phenylpyrrolecarboxamides represent a promising new approach to HIV therapy with the potential for improved efficacy and reduced risk of resistance compared to existing treatments. The discovery of substituted phenylpyrrolecarboxamides with therapeutic activity in HIV has broad potential applications in the field of antiviral therapy. These compounds could be developed into novel drugs for the treatment of HIV/AIDS, offering a targeted approach to inhibit viral entry into host cells. Additionally, these compounds may have applications in HIV prophylaxis, providing a new tool for preventing HIV infection in high-risk populations. Furthermore, the discovery of these compounds opens up possibilities for further research into the development of new classes of antiviral agents targeting other viral pathogens. Overall, the potential applications of these compounds extend beyond HIV therapy, paving the way for new approaches to combating viral infections. 2024-03-19 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153931379 Debnath, Asim New York Blood Center NIAID Debnath, Asim (NIAID) 1 153931384 Curreli, Francesca New York Blood Center Curreli, Francesca 2 153931397 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 3 153931401 Kwon, Young Do NIAID - VRC NIAID Kwon, Young Do (NIAID) 4 153931379 Debnath, Asim New York Blood Center NIAID Debnath, Asim (NIAID) 1 153931384 Curreli, Francesca New York Blood Center Curreli, Francesca 2 153931397 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 3 153931401 Kwon, Young Do NIAID - VRC NIAID Kwon, Young Do (NIAID) 4 153931370 Substituted Phenylpyrrolecarboxamides With Therapeutic Activity In HIV E-145-2015-0 Filing authorized New York Blood Center, NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4951] Inhibitors of HIV-1 Entry: Targeting the Phe43 Cavity of gp120&body=Please send me information about technology [TAB-4951] Inhibitors of HIV-1 Entry: Targeting the Phe43 Cavity of gp120. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4951] Inhibitors of HIV-1 Entry: Targeting the Phe43 Cavity of gp120&body=Please send me information about technology [TAB-4951] Inhibitors of HIV-1 Entry: Targeting the Phe43 Cavity of gp120.">wade.green@nih.gov</a><br> TAB-4949 153931005 Enhanced Live-Attenuated Respiratory Syncytial Virus Vaccine with Deletion and Point Mutations in the L Protein NIAID Antibodies, Collaboration, Human Cell Lines, Immunology, Infectious Disease, Licensing, Plasmids/Vectors, Respiratory, Therapeutics, Vaccines Antibodies Collaboration Human Cell Lines Immunology Infectious Disease Licensing Plasmids/Vectors Respiratory Therapeutics Vaccines Ursula Buchholz, Peter Collins <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">The reported technology encompasses an advanced formulation of a live-attenuated respiratory syncytial virus (RSV) vaccine, distinct due to strategic genetic modifications. This vaccine candidate incorporates a deletion of the ORF encoding the RSV M2-2 protein, alongside A1313 and I1314L point mutations in the L protein. These alterations not only confer attenuation but also enhance the temperature sensitivity of the vaccine, optimizing it for intranasal administration in pediatric populations. This tailored approach aims to bolster the vaccine&#39;s safety profile and efficacy, leveraging insights from extensive pre-clinical evaluations. The LID/&Delta;M2-2/A1313/I1314L vaccine variant represents a promising leap forward in prophylactic interventions against RSV, a major causative agent of respiratory illness, particularly in infants and young children, for which limited therapeutic options currently exist. The technology signifies a pivotal step towards fulfilling an unmet medical need by offering a potentially more robust and safer RSV vaccine solution.</span></span></span></p> <p>&nbsp;</p> The novel RSV vaccine technology stands out for its unique competitive advantages. Firstly, the deletion of the ORF encoding the RSV M2-2 protein, combined with precise point mutations in the L protein, ensures a heightened attenuation level, potentially leading to a safer profile for use in vulnerable pediatric populations. Secondly, the enhanced temperature sensitivity due to these genetic modifications may allow for more stable and consistent vaccine performance, particularly during storage and transportation, which is critical for global immunization programs. Additionally, the intranasal administration route capitalizes on mucosal immunity, potentially offering more effective localized protection where RSV infections initiate. These innovations represent a considerable improvement over existing RSV vaccines, which may lack these sophisticated levels of attenuation and delivery systems. Furthermore, the meticulous design of this vaccine reflects an extensive analysis of pre-clinical data, ensuring that it is not only scientifically advanced but also tuned to meet the practical needs of real-world vaccine distribution and administration. This technology positions the vaccine as a front-runner in the quest to mitigate the substantial global health burden posed by RSV. The innovative RSV vaccine presents significant potential across various applications and collaborations. As a therapeutic agent, it is poised to make substantial contributions to pediatric healthcare by preventing severe respiratory infections in infants and children, thereby addressing a critical therapeutic area in respiratory and infectious diseases. The vaccine's cutting-edge design also opens avenues for consumer products, such as vaccine kits tailored for ease of use in both clinical and possibly home settings. In the sphere of research, the underpinning technologies, including the specific antibodies and human cell lines used in development, are valuable as research materials. These components can be shared or licensed, fostering further advancements in the field through collaboration with academic and industry partners. Moreover, the plasmids and vectors that are integral to the vaccine's genetic engineering hold the potential to be adapted for other medical applications, underscoring the vaccine's utility beyond its primary purpose. These aspects collectively highlight the far-reaching implications of the vaccine, offering a multi-faceted opportunity for entities looking to invest in the future of immunological and infectious disease therapeutics. 2024-03-19 2026-08-26 2026-08-26 2026-08-26 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 153931012 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 153931016 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 2 153931012 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 153931016 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 2 153931008 Improved Live-attenuated Respiratory Syncytial Virus (RSV) Vaccines Bearing An Delta M2-2 Deletion And Stabilized Delta1313/1314L Mutations In L Protein E-144-2018-0 Research Material NIAID 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-4949] Enhanced Live-Attenuated Respiratory Syncytial Virus Vaccine with Deletion and Point Mutations in the L Protein&body=Please send me information about technology [TAB-4949] Enhanced Live-Attenuated Respiratory Syncytial Virus Vaccine with Deletion and Point Mutations in the L Protein. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-4949] Enhanced Live-Attenuated Respiratory Syncytial Virus Vaccine with Deletion and Point Mutations in the L Protein&body=Please send me information about technology [TAB-4949] Enhanced Live-Attenuated Respiratory Syncytial Virus Vaccine with Deletion and Point Mutations in the L Protein.">maryann.puglielli@nih.gov</a><br> TAB-4948 153930936 Development of Live-Attenuated Respiratory Syncytial Virus Vaccines with Enhanced Immunogenicity by Deletion of the NS1 Gene NIAID Antibodies, Collaboration, Human Cell Lines, Immunology, Infectious Disease, Licensing, Pulmonology, Respiratory, Therapeutics, Vaccines Antibodies Collaboration Human Cell Lines Immunology Infectious Disease Licensing Pulmonology Respiratory Therapeutics Vaccines Ursula Buchholz, Peter Collins <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">The document outlines a significant advancement in the field of vaccinology with the development of a new live-attenuated respiratory syncytial virus (RSV) vaccine. This vaccine is distinguished by the deletion of the NS1 gene, which is hypothesized to enhance the immunogenic response by not antagonizing the body&rsquo;s cellular mechanisms. Further refinements include combining the &Delta;NS1 mutation with a set of additional mutations designed to stabilize the temperature-sensitivity of the virus and to maximize the expression of RSV neutralization antigens. These modifications are aimed at increasing the vaccine&#39;s safety profile and its efficacy in inducing a robust immune response. Clinical trial preparations for two lead vaccine candidates incorporating these innovations have been underway, positioning the technology at the forefront of preventative strategies against RSV, a major cause of respiratory illness in infants and young children.</span></span></span></p> <p>&nbsp;</p> The novel live-attenuated RSV vaccine presents a series of competitive advantages over existing solutions, primarily through the innovative deletion of the NS1 gene, which plays a crucial role in boosting the host immune response. By mitigating the virus's ability to dampen the body's interferon induction, the vaccine promises a stronger, more durable immunogenicity, potentially reducing the severity and incidence of RSV in vaccinated individuals. Furthermore, the additional mutations engineered into the vaccine strain, including those that stabilize the virus at physiological temperatures and enhance antigen expression, aim to deliver a higher efficacy and safety profile than current vaccines. These enhancements could lead to improved outcomes in pediatric respiratory health, a notable concern given RSV's status as a leading cause of respiratory infections in young children. Anticipating the move into phase I clinical trials, this vaccine stands out for its targeted approach to immunity, which could translate into a substantial reduction in RSV's global health burden, positioning it favorably in the market. The live-attenuated RSV vaccine, with its deletion of the NS1 gene, has wide-reaching potential applications. It is poised to set a new standard in pediatric vaccine regimens, offering a more robust defense against one of the leading causes of infant hospitalization due to respiratory infections. The vaccine’s heightened immunogenic response could also be particularly beneficial in vulnerable populations such as the elderly or immunocompromised, who are at increased risk of severe RSV infections. Moreover, the technology underpinning this vaccine could be adapted to combat other respiratory viruses by applying similar genetic attenuation strategies. Beyond direct clinical use, this vaccine could be instrumental in reducing healthcare costs associated with RSV, contribute to fewer disease outbreaks in community settings like daycares and nursing homes, and potentially be integrated into pandemic preparedness programs, due to its broad applicability and enhanced safety profile. 2024-03-19 2026-08-26 2026-08-26 2026-08-26 False True True 72159138 Clinical Phase I 72159138 37470483 Website Abstract 153930943 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 153930947 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 2 153930943 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 153930947 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 2 153930939 New Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines Bearing Deletion Of The NS1 Gene E-143-2018-0 Filing authorized NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4948] Development of Live-Attenuated Respiratory Syncytial Virus Vaccines with Enhanced Immunogenicity by Deletion of the NS1 Gene&body=Please send me information about technology [TAB-4948] Development of Live-Attenuated Respiratory Syncytial Virus Vaccines with Enhanced Immunogenicity by Deletion of the NS1 Gene. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4948] Development of Live-Attenuated Respiratory Syncytial Virus Vaccines with Enhanced Immunogenicity by Deletion of the NS1 Gene&body=Please send me information about technology [TAB-4948] Development of Live-Attenuated Respiratory Syncytial Virus Vaccines with Enhanced Immunogenicity by Deletion of the NS1 Gene.">ganelinaa@niaid.nih.gov</a><br> TAB-4946 153930458 A Novel Target for HIV Inhibition and Vaccine Enhancement NIAID Antibodies, Collaboration, Immunology, Infectious Disease, Licensing, Rare/Neglected Diseases, Research Equipment, Respiratory, Therapeutics, Vaccines Antibodies Collaboration Immunology Infectious Disease Licensing Rare/Neglected Diseases Research Equipment Respiratory Therapeutics Vaccines David Auerbach, Paolo Lusso <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">Platelet Factor 4 (CXCL4) has emerged as a promising natural inhibitor of HIV-1, offering new avenues for combating the AIDS virus. This discovery showcases CXCL4&#39;s ability to inhibit HIV-1 through a unique mechanism, primarily produced by activated platelets, which release it in high concentrations during blood clotting or inflammatory conditions. CXCL4&#39;s potential applications are diverse, ranging from therapeutic interventions to preventive measures. Derivatives or strategies to induce CXCL4 production/release could serve as inhibitors for treating or preventing HIV-1 infection. Additionally, CXCL4 or its derivatives could act as vaccine adjuvants, enhancing vaccine efficacy and providing protection against HIV, particularly in therapeutic vaccination scenarios. This novel discovery&#39;s impact extends to gene therapy strategies, where CXCL4 could be leveraged to express protective alleles directly in patient cells. Overall, CXCL4&#39;s unique inhibitory mechanism and versatile applications position it as a valuable asset in the fight against HIV/AIDS.</span></span></span></p> The use of Platelet Factor 4 (CXCL4) as an inhibitor for HIV-1 and a vaccine adjuvant presents several competitive advantages over existing treatments and adjuvants. Firstly, CXCL4's unique inhibitory mechanism distinguishes it from current HIV therapies, potentially offering a novel approach to combating the virus. This uniqueness extends to its role as a vaccine adjuvant, where its antiviral properties could significantly enhance vaccine efficacy, particularly in individuals already infected with HIV. Furthermore, CXCL4 derivatives or mimicking compounds could be developed to target specific aspects of HIV infection, potentially minimizing side effects associated with current treatments. Additionally, the identification of CXCL4 genetic polymorphisms could enable personalized treatment strategies, enhancing treatment outcomes. Overall, CXCL4's multifaceted utility and unique mode of action position it as a highly competitive candidate for advancing HIV/AIDS therapeutics and vaccine development. Platelet Factor 4 (CXCL4) offers a wide range of potential applications in the field of HIV/AIDS therapeutics and vaccine development. As a potent inhibitor of HIV-1, CXCL4 could be utilized as a novel therapeutic agent for treating HIV-infected individuals. Its ability to inhibit HIV-1 through a unique mechanism makes it a promising candidate for developing next-generation HIV treatments with potentially reduced side effects. Furthermore, CXCL4's role as a vaccine adjuvant could significantly enhance the efficacy of HIV vaccines, particularly in individuals already infected with HIV. Additionally, the identification of CXCL4 genetic polymorphisms could lead to the development of personalized treatment strategies, improving patient outcomes. Overall, CXCL4's diverse applications make it a valuable asset in the ongoing efforts to combat the HIV/AIDS epidemic. 2024-03-19 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153930465 Lusso, Paolo NIAID - DIR NIAID Lusso, Paolo (NIAID) 1 153930469 Auerbach, David Teva Biopharmaceuticals Auerbach, David 2 153930465 Lusso, Paolo NIAID - DIR NIAID Lusso, Paolo (NIAID) 1 153930469 Auerbach, David Teva Biopharmaceuticals Auerbach, David 2 153930461 Identification Of A Novel HIV-supressive Chemokine E-140-2012-0 Filing authorized NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4946] A Novel Target for HIV Inhibition and Vaccine Enhancement&body=Please send me information about technology [TAB-4946] A Novel Target for HIV Inhibition and Vaccine Enhancement. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4946] A Novel Target for HIV Inhibition and Vaccine Enhancement&body=Please send me information about technology [TAB-4946] A Novel Target for HIV Inhibition and Vaccine Enhancement.">sabrina.hafiz@nih.gov</a><br> TAB-4945 153755094 Innovations in Peptide Delivery and Immune Activation NIAID Antibodies, Collaboration, Diagnostics, Human Cell Lines, Infectious Disease, Licensing, Oncology, Rare/Neglected Diseases, Respiratory, Therapeutics, Vaccines Antibodies Collaboration Diagnostics Human Cell Lines Infectious Disease Licensing Oncology Rare/Neglected Diseases Respiratory Therapeutics Vaccines Andrew Ishizuka, Geoffrey Lynn <p>This innovative technology centers on advanced peptide-based vaccine formulations that aim to significantly boost T cell-mediated immune responses. The core of this invention is the strategic conjugation of modified peptides with polymers attached to immunostimulants, a design poised to enhance the efficacy of vaccines. This approach not only promises to refine the manufacturing process, making it more efficient but also aims to augment the generation of immune responses, potentially leading to superior vaccine performance against various pathogens.</p> The cutting-edge peptide-based vaccine technology stands out in the competitive landscape for its ability to induce potent T cell responses irrespective of the antigen's peptide sequence. This platform’s versatility is underpinned by its novel polymeric conjugate system that ensures consistent and enhanced immunogenicity. The conjugation technique employed not only simplifies the manufacturing process, enabling scalability, but also stabilizes the vaccine, leading to a potentially broader application against a wide array of pathogens. Additionally, the modification of peptides linked to polymers and immunostimulants is an innovative step that could result in stronger and more durable immune responses, offering a significant edge over existing vaccine technologies. The versatile nature of this peptide-based vaccine platform has vast potential applications, ranging from infectious diseases to personalized medicine. It can be tailored to combat emerging pathogens by quickly adapting the peptide sequences without altering the manufacturing process. This makes it invaluable for rapid response to epidemic threats. Moreover, its ability to generate robust T cell responses positions it as a promising candidate for cancer vaccines, where cellular immunity is crucial. The technology could also be extended to allergy treatments, auto-immune conditions, and as a tool in therapeutic vaccines, potentially revolutionizing the approach to immunotherapy and vaccine development across various health conditions. 2024-03-11 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153755101 Lynn, Geoffrey Vaccitech North America NIAID Lynn, Geoffrey (NIAID) 1 153755105 Ishizuka, Andrew NIAID - VRC NIAID Ishizuka, Andrew (NIAID) 2 153755101 Lynn, Geoffrey Vaccitech North America NIAID Lynn, Geoffrey (NIAID) 1 153755105 Ishizuka, Andrew NIAID - VRC NIAID Ishizuka, Andrew (NIAID) 2 153755097 Peptide-based Vaccines, Methods Of Manufacturing, And Uses Thereof For Inducing An Immune Response E-137-2018-0 Filing authorized Avidea Technologies, NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4945] Innovations in Peptide Delivery and Immune Activation&body=Please send me information about technology [TAB-4945] Innovations in Peptide Delivery and Immune Activation. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4945] Innovations in Peptide Delivery and Immune Activation&body=Please send me information about technology [TAB-4945] Innovations in Peptide Delivery and Immune Activation.">sabrina.hafiz@nih.gov</a><br> TAB-4944 153754971 Generation and Application of c-Cbl floxed Transgenic Mice for Conditional Gene Deletion Studies NIAID Animal Models, Collaboration, Diagnostics, Immunology, Licensing, Materials Available, Oncology, Rare/Neglected Diseases, Research Materials, Therapeutics Animal Models Collaboration Diagnostics Immunology Licensing Materials Available Oncology Rare/Neglected Diseases Research Materials Therapeutics Hua Gu <p>This technology presents a novel strain of transgenic mice where the proto-oncogene c-Cbl (Casitas B-lineage lymphoma) has been engineered with loxP (locus of X-over P1) sites, commonly referred to as &quot;floxed.&quot; This design enables the conditional knockout of the c-Cbl gene when the mice are crossed with strains that express the Cre recombinase enzyme. Cre recombinase is an enzyme that can specifically target loxP sites, excising the floxed gene only in the presence of Cre, thus allowing tissue-specific or temporal deletion of the target gene.</p> The c-Cbl fl/fl transgenic mice represent a unique resource that allows for conditional gene manipulation with high specificity. Their ability to enable targeted gene deletion in a tissue-specific manner offers a significant advantage over traditional knockout models, which can lead to embryonic lethality or compensatory mechanisms that obscure the gene's function. These mice provide a refined model to study the intricate roles of genes in various biological processes and diseases, particularly cancer and immune function. Moreover, the precision of this genetic approach facilitates the dissection of complex pathways, potentially accelerating the discovery of novel drug targets and enhancing the understanding of gene function in vivo. This specificity and versatility position the c-Cbl fl/fl mice as an essential tool in advanced genetic research and therapeutic development. The c-Cbl fl/fl transgenic mice hold vast potential across multiple applications in biomedical research. They are particularly valuable for uncovering the functions of c-Cbl in disease models, such as in oncogenesis, where c-Cbl’s role in cell signaling and tumor suppression can be elucidated. In immunology, these mice can be used to study c-Cbl's impact on immune cell development and autoimmune diseases. Their use can extend to pharmacology for testing the efficacy and toxicity of new drugs targeting the c-Cbl pathway. Furthermore, they could be instrumental in gene therapy research by offering insights into the safe and effective delivery of gene-editing tools to specific tissues. This conditional deletion model could also serve as a template for developing other genetically modified organisms to study different genes with similar precision, broadening the scope of genetic research and its translational applications to therapeutic interventions. 2024-03-11 2026-08-26 2026-08-26 2026-08-26 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 153754978 Gu, Hua Montreal Clinical Research Institute (IRCM) NIAID Gu, Hua (NIAID) 1 153754978 Gu, Hua Montreal Clinical Research Institute (IRCM) NIAID Gu, Hua (NIAID) 1 153754974 C-Cbl Fl/fl Transgenic Mice E-136-2017-0 Research Material NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4944] Generation and Application of c-Cbl floxed Transgenic Mice for Conditional Gene Deletion Studies&body=Please send me information about technology [TAB-4944] Generation and Application of c-Cbl floxed Transgenic Mice for Conditional Gene Deletion Studies. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4944] Generation and Application of c-Cbl floxed Transgenic Mice for Conditional Gene Deletion Studies&body=Please send me information about technology [TAB-4944] Generation and Application of c-Cbl floxed Transgenic Mice for Conditional Gene Deletion Studies.">yogikala.prabhu@nih.gov</a><br> TAB-4943 153754867 Tick Salivary Antigen-Based Vaccine: A Novel Approach for Enhanced Tick Control and Disease Prevention NIAID Antibodies, Collaboration, Immunology, Infectious Disease, Licensing, Rare/Neglected Diseases, Research Equipment, Respiratory, Therapeutics Antibodies Collaboration Immunology Infectious Disease Licensing Rare/Neglected Diseases Research Equipment Respiratory Therapeutics Jose Ribeiro, Jesus Valenzuela <p>The technology is a groundbreaking vaccine formulation developed through a meticulous analysis of tick salivary antigens crucial for parasitism. By examining gene expression in tick salivary glands across various life stages and comparing them with ticks feeding on naturally resistant hosts, key antigens were pinpointed. These antigens target molecules that inhibit host homeostatic responses and are predicted to be secreted toxins, making them ideal candidates for inducing immunity against tick parasitism. The vaccine aims to stimulate immunity in animals, leading to tick rejection and prevention of pathogen transmission. Compared to traditional methods, this approach offers a more sustainable, environmentally friendly solution, targeting crucial tick molecules and utilizing multiple antigens to induce varied immunity levels. This technology represents a significant advancement in tick control and disease prevention, promising a more effective, targeted approach to combating tick-borne diseases in animals.</p> This innovative vaccine formulation offers several competitive advantages over existing tick control methods. Unlike traditional approaches reliant on acaricides, which are becoming less effective due to increasing resistance and environmental concerns, this vaccine provides a sustainable, non-toxic solution. By targeting crucial tick molecules related to parasitism and employing multiple antigens to induce varied immunity levels, it offers a more comprehensive defense mechanism against tick infestations. Additionally, the vaccine's ability to stimulate immunological memory upon re-exposure to tick saliva enhances its long-term effectiveness. This technology represents a significant advancement in tick control, providing a safer, more effective, and environmentally friendly solution for protecting animals against tick-borne diseases. The potential applications of this technology extend beyond animal health, with implications for human health and environmental conservation. In the agricultural sector, the vaccine could significantly improve livestock production by reducing losses caused by tick infestations. This would not only benefit farmers economically but also contribute to food security and safety by minimizing the need for acaricides. In the companion animal sector, the vaccine could enhance the health and well-being of pets by protecting them from tick-borne diseases. Moreover, the technology's environmentally friendly nature makes it suitable for use in conservation efforts to protect wildlife from tick-borne pathogens. In human health, the vaccine could potentially be adapted for use in humans to prevent diseases transmitted by ticks, such as Lyme disease and tick-borne encephalitis. Overall, this technology has broad-ranging applications with significant potential to improve health outcomes and environmental sustainability. 2024-03-11 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153754877 Valenzuela, Jesus NIAID - DIR NIAID Valenzuela, Jesus (NIAID) 1 153754881 Ribeiro, Jose NIAID - DIR NIAID Ribeiro, Jose (NIAID) 2 153754877 Valenzuela, Jesus NIAID - DIR NIAID Valenzuela, Jesus (NIAID) 1 153754881 Ribeiro, Jose NIAID - DIR NIAID Ribeiro, Jose (NIAID) 2 153754873 Anti-tick Vaccine: Immunity Induced With Antigens Discovered By Mining A Salivary Gland Transcriptome Of The Ecto-parasite Affected By Immunity Of Hosts Naturally Resistant To Infestations E-135-2013-0 Filing authorized NIAID 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-4943] Tick Salivary Antigen-Based Vaccine: A Novel Approach for Enhanced Tick Control and Disease Prevention&body=Please send me information about technology [TAB-4943] Tick Salivary Antigen-Based Vaccine: A Novel Approach for Enhanced Tick Control and Disease Prevention. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-4943] Tick Salivary Antigen-Based Vaccine: A Novel Approach for Enhanced Tick Control and Disease Prevention&body=Please send me information about technology [TAB-4943] Tick Salivary Antigen-Based Vaccine: A Novel Approach for Enhanced Tick Control and Disease Prevention.">peter.tung@nih.gov</a><br> TAB-4942 153754671 Design and Efficacy of Non-Human Protein-Derived PCSK9 Immunogens for Cholesterol Management NIAID Antibodies, Cardiology, Collaboration, Endocrinology, Geriatrics, Human Cell Lines, Licensing, Metabolic Disease, Plasmids/Vectors, Therapeutics, Vaccines Antibodies Cardiology Collaboration Endocrinology Geriatrics Human Cell Lines Licensing Metabolic Disease Plasmids/Vectors Therapeutics Vaccines Cara Chao, Gwo-yu Chauang, Wing-pui Kong, Peter Kwong, Ou Li, John Mascola, Yiran Wang, Yongping Yang, Baoshan Zhang, Tongqing Zhou <p>The technology involves the development of novel PCSK9 immunogens that are specifically designed to eliminate sequence overlap with human proteins, thereby reducing potential self-reactivity and immunogenicity issues. By selectively grafting epitope residues from non-human PCSK9 or structurally similar sequences onto the epitope-scaffold, these immunogens can induce an immune response against the PCSK9 enzyme without triggering a significant reaction against the body&rsquo;s own proteins. This innovative approach has led to the creation of a new PCSK9 immunogen named HIT01, which has demonstrated a significant reduction in low-density lipoprotein (LDL) and overall cholesterol levels in immunized mice. The PCSK9 immunogens offer a promising new avenue for creating vaccines or treatments to manage hyperlipidemia and prevent heart disease.</p> The developed PCSK9 immunogens exhibit competitive advantages over existing therapies for hyperlipidemia by minimizing immune system reactions against self-proteins, a common drawback of current treatments. This is achieved through the innovative design of epitopes that eliminate sequence homology with human proteins, which in turn reduces potential adverse immunogenicity. When compared to existing monoclonal antibody therapies that target PCSK9, this approach offers a potentially safer and more sustainable long-term treatment option by harnessing the body’s own immune system rather than relying on regular external administration of therapeutic antibodies. Additionally, the technology's adaptability to various delivery systems, such as nanoparticles or carrier constructs, not only enhances the immunogen's efficacy but also provides flexibility in formulation and administration methods, positioning it as a versatile and less invasive alternative in the hyperlipidemia therapeutic landscape. The novel PCSK9 immunogens represent a transformative approach with broad applications across various fields of medicine. Primarily, they can be utilized to develop vaccines for the prevention and long-term management of hyperlipidemia and associated cardiovascular diseases, reducing the dependency on daily medications and improving patient compliance. Beyond cardiovascular health, these immunogens could be adapted for therapeutic interventions in metabolic disorders where cholesterol regulation is disrupted. The technology could also be employed in the design of precision medicine strategies, where individual patient’s immunogenic profiles are considered to optimize therapeutic efficacy. Furthermore, the foundational methodology of minimizing human protein sequence overlap in immunogens could be extended to other therapeutic targets, revolutionizing the way we design and implement immunotherapies for a range of autoimmune and inflammatory diseases. 2024-03-11 2026-08-26 2026-08-26 2026-08-26 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 153754678 Wang, Yiran NIAID - VRC NIAID Wang, Yiran (NIAID) 1 153754682 Chao, Cara National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Chao, Cara (NIAID) 2 153754686 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 3 153754690 Chauang, Gwo-yu Chauang, Gwo-yu 4 153754694 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 5 153754698 Kong, Wing-pui NIAID - VRC NIAID Kong, Wing-pui (NIAID) 6 153754708 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 7 153754712 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 8 153754794 Li, Ou Hengenix Biotech, Inc. Li, Ou 9 153754802 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 10 153754678 Wang, Yiran NIAID - VRC NIAID Wang, Yiran (NIAID) 1 153754682 Chao, Cara National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Chao, Cara (NIAID) 2 153754686 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 3 153754690 Chauang, Gwo-yu Chauang, Gwo-yu 4 153754694 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 5 153754698 Kong, Wing-pui NIAID - VRC NIAID Kong, Wing-pui (NIAID) 6 153754708 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 7 153754712 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 8 153754794 Li, Ou Hengenix Biotech, Inc. Li, Ou 9 153754802 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 10 153754674 Antibody-guided PCSK9 Immunogens Lacking 9-residue Sequence Overlap With Human Proteins E-134-2020-0 Filing authorized NIAID 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-4942] Design and Efficacy of Non-Human Protein-Derived PCSK9 Immunogens for Cholesterol Management&body=Please send me information about technology [TAB-4942] Design and Efficacy of Non-Human Protein-Derived PCSK9 Immunogens for Cholesterol Management. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-4942] Design and Efficacy of Non-Human Protein-Derived PCSK9 Immunogens for Cholesterol Management&body=Please send me information about technology [TAB-4942] Design and Efficacy of Non-Human Protein-Derived PCSK9 Immunogens for Cholesterol Management.">bbailey@mail.nih.gov</a><br> TAB-4941 153754542 Live-Attenuated Protection Utilizing Recombinant Vesicular Stomatitis Virus (VSV) NIAID Antibodies, Collaboration, Infectious Disease, Licensing, Plasmids/Vectors, Vaccines Antibodies Collaboration Infectious Disease Licensing Plasmids/Vectors Vaccines Emmie De Wit, Blair Debuysscher, Heinrich (Heinz) Feldmann, Andrea Marzi, Joseph Prescott <p>The live-attenuated Nipah virus vaccines, based on recombinant Vesicular Stomatitis Virus (VSV) vectors, represent a groundbreaking approach to combating Nipah virus infections. These vaccines, expressing Nipah virus glycoprotein (G) or fusion protein (F), have demonstrated exceptional protective efficacy in animal models. Key advantages include their ability to replicate within the vaccinated individual, eliciting a robust immune response superior to non-replicating vaccine platforms. Furthermore, the expression of the Ebola virus glycoprotein (EBOV-GP) in the vectors enhances immune cell targeting, potentially resulting in a more potent and targeted immune response. This innovative technology has the potential to significantly advance Nipah virus vaccine development, offering a promising solution to combat this deadly pathogen.</p> The live-attenuated Nipah virus vaccines based on VSV vectors offer several key advantages over existing experimental vaccine approaches. Firstly, their ability to replicate within the vaccinated individual leads to a stronger innate and adaptive immune response, providing potentially longer-lasting immunity. Secondly, the expression of EBOV-GP in the vectors enhances targeting to crucial immune cells, resulting in a more effective immune response. This unique combination of features distinguishes these vaccines from non-replicating vaccine platforms, potentially offering superior protection against Nipah virus infection. Additionally, the ease of production and the demonstrated efficacy in animal models further enhance the competitive advantages of this technology. The live-attenuated Nipah virus vaccines based on VSV vectors have broad potential applications in both human and animal health. In the realm of human health, these vaccines could be crucial in preventing Nipah virus outbreaks, especially in regions where the virus is endemic. The ability of these vaccines to induce a robust immune response makes them promising candidates for use in both pre-exposure and post-exposure prophylaxis. Furthermore, the technology's adaptability could allow for the development of multivalent vaccines targeting other emerging pathogens, enhancing preparedness against future outbreaks. In veterinary medicine, these vaccines could be invaluable for protecting livestock, particularly in regions where Nipah virus poses a threat to both animal and human populations. Overall, the potential applications of these vaccines extend beyond Nipah virus to address a range of infectious disease challenges. 2024-03-11 2026-08-26 2026-08-26 2026-08-26 False True True 52406769 Prototype 52406769 37470483 Website Abstract 153754561 Feldmann, Heinrich (Heinz) National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Feldmann, Heinrich (Heinz) (NIAID) 1 153754565 De Wit, Emmie NIAID - DIR NIAID De Wit, Emmie (NIAID) 2 153754569 Marzi, Andrea NIAID - DIR NIAID Marzi, Andrea (NIAID) 3 153754573 Prescott, Joseph National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Prescott, Joseph (NIAID) 4 153754577 Debuysscher, Blair National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Debuysscher, Blair (NIAID) 5 153754561 Feldmann, Heinrich (Heinz) National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Feldmann, Heinrich (Heinz) (NIAID) 1 153754565 De Wit, Emmie NIAID - DIR NIAID De Wit, Emmie (NIAID) 2 153754569 Marzi, Andrea NIAID - DIR NIAID Marzi, Andrea (NIAID) 3 153754573 Prescott, Joseph National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Prescott, Joseph (NIAID) 4 153754577 Debuysscher, Blair National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Debuysscher, Blair (NIAID) 5 153754545 VSV-Nipah Vaccine E-134-2019-0 Research Material NIAID 146046171 Joyce, Terrence terrence.joyce@nih.gov
United States of America terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-4941] Live-Attenuated Protection Utilizing Recombinant Vesicular Stomatitis Virus (VSV)&body=Please send me information about technology [TAB-4941] Live-Attenuated Protection Utilizing Recombinant Vesicular Stomatitis Virus (VSV). Joyce, Terrence<br><a href="mailto:terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-4941] Live-Attenuated Protection Utilizing Recombinant Vesicular Stomatitis Virus (VSV)&body=Please send me information about technology [TAB-4941] Live-Attenuated Protection Utilizing Recombinant Vesicular Stomatitis Virus (VSV).">terrence.joyce@nih.gov</a><br> TAB-4940 153754367 Targeted Modifications in Mosaic Envelopes Elicit Potent Neutralizing Antibodies NIAID Antibodies, Collaboration, Immunology, Infectious Disease, Licensing, Plasmids/Vectors, Rare/Neglected Diseases, Research Equipment, Respiratory, Therapeutics, Vaccines Antibodies Collaboration Immunology Infectious Disease Licensing Plasmids/Vectors Rare/Neglected Diseases Research Equipment Respiratory Therapeutics Vaccines Gary Nabel, Lan Wu, Zhi-yong Yang <p>The technology involves modifying HIV-1 envelope mosaic constructs to enhance the efficacy of HIV vaccines. These modifications target specific regions of the envelope protein, aiming to elicit antibodies similar to potent anti-HIV neutralizing antibodies naturally produced during infection. By replacing highly variable patches in the V1, V2, and V3 loops with defined sequences and eliminating immune-dominant epitopes, the modified constructs induce the production of quaternary antibodies. These antibodies target the V1, V2 loops and exhibit neutralization potential akin to naturally occurring potent antibodies like PG9/PG16. The technology has been demonstrated in animal studies to successfully elicit these potent antibodies, marking a significant advancement in HIV vaccine development.</p> The modified HIV envelope mosaic constructs offer several competitive advantages in the field of HIV vaccine development. By specifically targeting the V1, V2, and V3 loops of the envelope protein, these constructs can elicit quaternary antibodies that closely resemble naturally occurring potent anti-HIV neutralizing antibodies, such as PG9/PG16. This targeted approach enhances the likelihood of inducing a broad and potent immune response against diverse HIV strains. Additionally, the modifications eliminate immune-dominant epitopes, potentially reducing the likelihood of immune evasion by the virus. The ability to induce PG-like neutralizing antibodies through vaccination represents a significant advancement in HIV vaccine development, offering a promising avenue for achieving effective protection against HIV infection. The technology of modifying HIV envelope mosaic constructs has several potential applications beyond HIV vaccine development. These modified constructs could be utilized in research settings to better understand the immune response to HIV infection and aid in the development of novel therapeutics. Furthermore, the approach of targeting specific regions of viral proteins to induce potent neutralizing antibodies could be applied to other infectious diseases, potentially leading to the development of vaccines against other pathogens. Additionally, the technology's ability to elicit quaternary antibodies could have implications for the design of vaccines against other viruses that require a similar antibody response for neutralization. Overall, this technology has the potential to significantly impact the fields of vaccinology and infectious disease research. 2024-03-11 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153754374 Nabel, Gary ModeX Therapeutics, Inc. NIAID Nabel, Gary (NIAID) 1 153754378 Wu, Lan Sanofi U.S. Services Inc. Wu, Lan 2 153754472 Yang, Zhi-yong Sanofi-Aventis NIAID Yang, Zhi-yong (NIAID) 3 153754374 Nabel, Gary ModeX Therapeutics, Inc. NIAID Nabel, Gary (NIAID) 1 153754378 Wu, Lan Sanofi U.S. Services Inc. Wu, Lan 2 153754472 Yang, Zhi-yong Sanofi-Aventis NIAID Yang, Zhi-yong (NIAID) 3 153754370 Modified HIV Mosaic Envelopes Targeted To Elicit B Cell Responses E-134-2011-0 Filing authorized NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4940] Targeted Modifications in Mosaic Envelopes Elicit Potent Neutralizing Antibodies&body=Please send me information about technology [TAB-4940] Targeted Modifications in Mosaic Envelopes Elicit Potent Neutralizing Antibodies. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4940] Targeted Modifications in Mosaic Envelopes Elicit Potent Neutralizing Antibodies&body=Please send me information about technology [TAB-4940] Targeted Modifications in Mosaic Envelopes Elicit Potent Neutralizing Antibodies.">sabrina.hafiz@nih.gov</a><br> TAB-4939 153754280 Revolutionizing Lassa Fever Vaccination: A Live-Attenuated VSV-Lassa Virus Vaccine NIAID Animal Models, Antibodies, Collaboration, Infectious Disease, Licensing, Plasmids/Vectors, Therapeutics, Vaccines Animal Models Antibodies Collaboration Infectious Disease Licensing Plasmids/Vectors Therapeutics Vaccines Heinrich (Heinz) Feldmann, Andrea Marzi, Kyle Rosenke, David Safronetz <p>The live-attenuated Lassa virus vaccine, based on a recombinant Vesicular Stomatitis Virus (VSV) vector expressing the Lassa virus glycoprotein (GPC), represents a significant advancement in Lassa fever vaccination. This vaccine has demonstrated protective efficacy in animal models, showing promise for further development. Key advantages of this vaccine platform include its ability to replicate in the vaccinated individual, leading to a stronger immune response compared to non-replicating platforms. Additionally, the vaccine&#39;s favorable targeting of immune cells enhances its immunogenicity. The scalability of production further enhances its potential as a viable vaccine candidate. Overall, this technology has the potential to revolutionize Lassa fever vaccination by providing a more effective and scalable solution.</p> The live-attenuated Lassa virus vaccine based on recombinant Vesicular Stomatitis Virus (VSV) offers several competitive advantages over existing vaccine approaches. Its ability to replicate in the vaccinated individual triggers a robust and long-lasting immune response, potentially leading to improved efficacy. The vaccine's targeting of key immune cells, such as monocytes, macrophages, and dendritic cells, enhances its immunogenicity compared to non-replicating vaccine platforms. Furthermore, the scalability of VSV-based vaccine production allows for cost-effective and large-scale manufacturing, making it a practical solution for widespread vaccination campaigns. These advantages position the VSV-based Lassa virus vaccine as a promising candidate for addressing the challenges of Lassa fever prevention and control. The live-attenuated Lassa virus vaccine based on recombinant Vesicular Stomatitis Virus (VSV) has broad potential applications in the field of infectious disease prevention. Beyond its specific use as a vaccine against Lassa fever, this technology could be adapted for other viral diseases. The platform's ability to generate a robust immune response and its scalability for large-scale production make it an attractive candidate for addressing other emerging and re-emerging infectious diseases. Additionally, the favorable immune cell targeting of the VSV-based vaccine could be leveraged for the development of novel vaccines against other pathogens. Overall, this technology has the potential to significantly impact the field of vaccinology and infectious disease control. 2024-03-11 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153754287 Feldmann, Heinrich (Heinz) NIAID - DIR NIAID Feldmann, Heinrich (Heinz) (NIAID) 1 153754291 Marzi, Andrea NIAID - DIR NIAID Marzi, Andrea (NIAID) 2 153754295 Safronetz, David Public Health Agency of Canada Safronetz, David 3 153754311 Rosenke, Kyle NIAID - DIR NIAID Rosenke, Kyle (NIAID) 4 153754287 Feldmann, Heinrich (Heinz) NIAID - DIR NIAID Feldmann, Heinrich (Heinz) (NIAID) 1 153754291 Marzi, Andrea NIAID - DIR NIAID Marzi, Andrea (NIAID) 2 153754295 Safronetz, David Public Health Agency of Canada Safronetz, David 3 153754311 Rosenke, Kyle NIAID - DIR NIAID Rosenke, Kyle (NIAID) 4 153754283 VSV-Lassa Vaccine E-133-2019-0 Research Material NIAID 146046171 Joyce, Terrence terrence.joyce@nih.gov
United States of America terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-4939] Revolutionizing Lassa Fever Vaccination: A Live-Attenuated VSV-Lassa Virus Vaccine&body=Please send me information about technology [TAB-4939] Revolutionizing Lassa Fever Vaccination: A Live-Attenuated VSV-Lassa Virus Vaccine. Joyce, Terrence<br><a href="mailto:terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-4939] Revolutionizing Lassa Fever Vaccination: A Live-Attenuated VSV-Lassa Virus Vaccine&body=Please send me information about technology [TAB-4939] Revolutionizing Lassa Fever Vaccination: A Live-Attenuated VSV-Lassa Virus Vaccine.">terrence.joyce@nih.gov</a><br> TAB-4938 153754162 Advancing Adenovirus Serotype 14 Vaccine Development: A Novel Approach NIAID Animal Models, Antibodies, Computational models/software, Human Cell Lines, Infectious Disease, Plasmids/Vectors, Research Equipment, Respiratory, TherapeuticArea, Vaccines Animal Models Antibodies Computational models/software Human Cell Lines Infectious Disease Plasmids/Vectors Research Equipment Respiratory TherapeuticArea Vaccines Jason Gall, Christoph Kahl, Gary Nabel <p>The technology represents a groundbreaking approach to combatting adenovirus serotype 14 (Ad14) infections by employing a live attenuated Ad14 virus to induce a robust immune response in mammals. This method is designed to provide protection against severe infections and fatalities resulting from the emergence of Ad14 variants. Currently advancing through the Clinical Phase I stage of development, this innovative strategy holds significant promise in addressing a critical public health need for effective Ad14 vaccines.</p> This technology offers several key competitive advantages in the field of adenovirus serotype 14 (Ad14) vaccine development. Firstly, its focus on utilizing a live attenuated Ad14 virus sets it apart from traditional vaccine approaches, potentially leading to a more potent and durable immune response. Additionally, by targeting specific emerging variants of the Ad14 virus, this method addresses a critical public health need, providing a unique solution to combat these evolving threats. Furthermore, its advancement to the Clinical Phase I stage indicates promising progress towards clinical efficacy, positioning it as a frontrunner in the race to develop effective Ad14 vaccines. The potential applications of this technology extend beyond Ad14 vaccine development. The use of live attenuated viruses to induce immune responses could also be applied to other adenovirus serotypes or even to other viral infections. Furthermore, the strategy of targeting specific emerging variants of a virus could be adapted for use in developing vaccines against other rapidly evolving viruses, addressing a broader range of infectious disease threats. Additionally, the success of this approach in inducing robust immune responses could have implications for the development of vaccines against other pathogens, potentially revolutionizing vaccine design and efficacy. 2024-03-11 2026-08-26 2026-08-26 2026-08-26 False True True 72159138 Clinical Phase I 72159138 37470483 Website Abstract 153754169 Gall, Jason GenVec, Inc. NIAID Gall, Jason (NIAID) 1 153754180 Nabel, Gary ModeX Therapeutics, Inc. NIAID Nabel, Gary (NIAID) 2 153754184 Kahl, Christoph GenVec, Inc. Kahl, Christoph 3 153754169 Gall, Jason GenVec, Inc. NIAID Gall, Jason (NIAID) 1 153754180 Nabel, Gary ModeX Therapeutics, Inc. NIAID Nabel, Gary (NIAID) 2 153754184 Kahl, Christoph GenVec, Inc. Kahl, Christoph 3 153754165 Vaccines Directed Against Adenovirus Serotype 14 E-133-2011-0 Filing authorized GenVec, Inc., NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4938] Advancing Adenovirus Serotype 14 Vaccine Development: A Novel Approach&body=Please send me information about technology [TAB-4938] Advancing Adenovirus Serotype 14 Vaccine Development: A Novel Approach. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4938] Advancing Adenovirus Serotype 14 Vaccine Development: A Novel Approach&body=Please send me information about technology [TAB-4938] Advancing Adenovirus Serotype 14 Vaccine Development: A Novel Approach.">wade.green@nih.gov</a><br> TAB-4937 153753941 nnovative Monoclonal Antibodies for Enhanced Coronavirus Detection and Therapy NIAID Antibodies, Collaboration, Diagnostics, Infectious Disease, Licensing, Research Materials, TherapeuticArea, Therapeutics, Vaccines Antibodies Collaboration Diagnostics Infectious Disease Licensing Research Materials TherapeuticArea Therapeutics Vaccines Olubukola Abiona, Kizzmekia Corbett, Ester Falconer, Barney Graham, Kevin Jepson, Wing-pui Kong, Julie Ledgerwood, Kwanyee Leung, John Mascola, Krithika Muthuraman, Wei Shi, Lingshu Wang, Kathryn Westendorf, Eun Yang, Stefanie Zentelis, Yi Zhang <p>The technology encompasses a novel set of fully human monoclonal antibodies targeting the spike (S) protein of coronaviruses, notably the SARS-CoV-2 virus responsible for COVID-19. These antibodies, derived from convalescent patients, offer potential for use in the diagnosis, monitoring, and treatment of coronavirus infections. This discovery includes a comprehensive library of antibody or antibody fragment candidates with high specificity for the coronavirus spike protein. With the ability to bind to various coronavirus strains, these antibodies represent a significant advancement in both therapeutic and diagnostic applications, providing a versatile platform for addressing current and future coronavirus-related health challenges. The discovery is meticulously documented, adhering to stringent lab record-keeping practices, ensuring the integrity and reproducibility of the research.</p> The discovery of these anti-coronavirus monoclonal antibodies holds a competitive edge due to their unique origin from convalescent patient sera, conferring them with a high degree of specificity and affinity for the coronavirus spike protein. This specificity not only enhances the precision of diagnostic tests but also increases the effectiveness of therapeutic interventions by targeting the virus directly. Additionally, the broad reactivity across different coronavirus strains suggests potential for these antibodies to remain efficacious against emerging variants. The human origin of the antibodies minimizes the risk of immunogenicity, a common concern with therapeutic antibodies, thereby increasing their safety profile for patients. Furthermore, the extensive documentation and adherence to regulatory lab record-keeping provide a solid foundation for expedited approval processes, paving the way for rapid clinical development and deployment. These factors collectively position this technology as a front-runner in the race for solutions to manage and curb the spread of coronavirus diseases. This suite of human monoclonal antibodies is poised to revolutionize multiple facets of public health concerning coronavirus management. For diagnostics, they can be integrated into assays that provide rapid and accurate detection of infection, crucial for outbreak containment and patient care. In therapeutic applications, they have the potential to be developed into treatments that can neutralize the virus, lessen disease severity, and reduce transmission. Their use as prophylactics could also offer temporary immunity for high-risk populations such as healthcare workers and immunocompromised individuals. Furthermore, the antibodies' compatibility with various coronavirus strains opens the door for their incorporation into broad-spectrum antiviral drugs, as well as future vaccine enhancement strategies. In the research sector, these antibodies could be pivotal tools in the study of coronavirus pathogenesis and immune response, thereby expanding our understanding and capability to combat not just current, but also future coronavirus threats. 2024-03-11 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 153753948 Westendorf, Kathryn AbCellera Biologics Inc. Westendorf, Kathryn 1 153753954 Zentelis, Stefanie AbCellera Biologics Inc. Zentelis, Stefanie 2 153753965 Muthuraman, Krithika AbCellera Biologics Inc. Muthuraman, Krithika 3 153753969 Jepson, Kevin AbCellera Biologics Inc. Jepson, Kevin 4 153753973 Falconer, Ester AbCellera Biologics Inc. Falconer, Ester 5 153753977 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 6 153754040 Zhang, Yi National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Zhang, Yi (NIAID) 7 153754055 Wang, Lingshu NIAID - VRC NIAID Wang, Lingshu (NIAID) 8 153754066 Kong, Wing-pui NIAID - VRC NIAID Kong, Wing-pui (NIAID) 9 153754070 Ledgerwood, Julie NIAID - VRC NIAID Ledgerwood, Julie (NIAID) 10 153754074 Graham, Barney Morehouse School of Medicine NIAID Graham, Barney (NIAID) 11 153754087 Shi, Wei NIAID - VRC NIAID Shi, Wei (NIAID) 12 153754091 Leung, Kwanyee NIAID - VRC NIAID Leung, Kwanyee (NIAID) 13 153754103 Yang, Eun NIAID - VRC NIAID Yang, Eun (NIAID) 14 153754107 Corbett, Kizzmekia NIAID - DIR NIAID Corbett, Kizzmekia (NIAID) 15 153754111 Abiona, Olubukola NIAID - VRC NIAID Abiona, Olubukola (NIAID) 16 153753948 Westendorf, Kathryn AbCellera Biologics Inc. Westendorf, Kathryn 1 153753954 Zentelis, Stefanie AbCellera Biologics Inc. Zentelis, Stefanie 2 153753965 Muthuraman, Krithika AbCellera Biologics Inc. Muthuraman, Krithika 3 153753969 Jepson, Kevin AbCellera Biologics Inc. Jepson, Kevin 4 153753973 Falconer, Ester AbCellera Biologics Inc. Falconer, Ester 5 153753977 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 6 153754040 Zhang, Yi National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Zhang, Yi (NIAID) 7 153754055 Wang, Lingshu NIAID - VRC NIAID Wang, Lingshu (NIAID) 8 153754066 Kong, Wing-pui NIAID - VRC NIAID Kong, Wing-pui (NIAID) 9 153754070 Ledgerwood, Julie NIAID - VRC NIAID Ledgerwood, Julie (NIAID) 10 153754074 Graham, Barney Morehouse School of Medicine NIAID Graham, Barney (NIAID) 11 153754087 Shi, Wei NIAID - VRC NIAID Shi, Wei (NIAID) 12 153754091 Leung, Kwanyee NIAID - VRC NIAID Leung, Kwanyee (NIAID) 13 153754103 Yang, Eun NIAID - VRC NIAID Yang, Eun (NIAID) 14 153754107 Corbett, Kizzmekia NIAID - DIR NIAID Corbett, Kizzmekia (NIAID) 15 153754111 Abiona, Olubukola NIAID - VRC NIAID Abiona, Olubukola (NIAID) 16 153753944 Anti-Coronavirus Antibodies And Methods Of Use E-131-2020-0 Filing authorized AbCellera Biologics Inc., NIAID, NIAID - VRC 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-4937] nnovative Monoclonal Antibodies for Enhanced Coronavirus Detection and Therapy&body=Please send me information about technology [TAB-4937] nnovative Monoclonal Antibodies for Enhanced Coronavirus Detection and Therapy. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-4937] nnovative Monoclonal Antibodies for Enhanced Coronavirus Detection and Therapy&body=Please send me information about technology [TAB-4937] nnovative Monoclonal Antibodies for Enhanced Coronavirus Detection and Therapy.">bbailey@mail.nih.gov</a><br> TAB-4936 153753538 Modification and Optimization of HIV Neutralizing Antibodies for Improved Therapeutic and Vaccinogenic Efficacy NIAID Antibodies, Application, Collaboration, Human Cell Lines, Immunology, Infectious Disease, Licensing, Materials Available, Plasmids/Vectors, Therapeutics Antibodies Application Collaboration Human Cell Lines Immunology Infectious Disease Licensing Materials Available Plasmids/Vectors Therapeutics John Mascola, Gary Nabel, Tongqing Zhou <p>The technology pertains to the enhancement of HIV neutralizing antibodies, specifically VRC01, VRC07, and 10E8, which have been isolated and characterized for their potent antiviral activity. These antibodies have undergone specific mutations to improve their breadth and potency against a range of HIV strains. The aim is to extend their half-life, augment their in vivo effectiveness, and reduce immunogenicity. These modifications could lead to more effective therapeutic applications and inform the design of HIV vaccines, with potential incorporation into various vectors like AAV or adenovirus, and DNA expression vectors. This discovery stage technology holds promise for advancing HIV treatment and prevention methodologies.</p> This novel modification of HIV neutralizing antibodies offers competitive advantages by enhancing their breadth and potency against a diverse array of HIV strains, exceeding the capabilities of current antiviral agents. The mutations enhance antibody stability and half-life, reducing the frequency of administration and improving patient compliance. Additionally, these antibodies are designed to be less immunogenic, which minimizes adverse reactions and makes them suitable for a broader patient population. The adaptability of these antibodies for integration into different delivery vectors also positions this technology at the forefront of therapeutic innovation, potentially streamlining the path toward both prophylactic and therapeutic vaccine development. The enhanced HIV neutralizing antibodies could revolutionize therapeutic strategies for HIV, offering new avenues for treatment with increased efficacy and reduced side effects. They hold promise for long-acting HIV prevention methods, potentially simplifying pre-exposure prophylaxis regimens. In vaccine development, these antibodies can serve as templates to design vaccines that elicit robust and broad immune responses. Furthermore, the technology could be adapted for diagnostic purposes, aiding in the precise detection of diverse HIV strains. These applications underline the technology's versatility, with the potential to make significant impacts across various healthcare settings and patient populations. 2024-03-11 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153753548 Nabel, Gary ModeX Therapeutics, Inc. NIAID Nabel, Gary (NIAID) 1 153753555 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 2 153753559 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 3 153753548 Nabel, Gary ModeX Therapeutics, Inc. NIAID Nabel, Gary (NIAID) 1 153753555 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 2 153753559 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 3 153753541 Modifications To HIV Neutralizing Antibodies To Improve Function E-131-2012-0 Filing authorized NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4936] Modification and Optimization of HIV Neutralizing Antibodies for Improved Therapeutic and Vaccinogenic Efficacy&body=Please send me information about technology [TAB-4936] Modification and Optimization of HIV Neutralizing Antibodies for Improved Therapeutic and Vaccinogenic Efficacy. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4936] Modification and Optimization of HIV Neutralizing Antibodies for Improved Therapeutic and Vaccinogenic Efficacy&body=Please send me information about technology [TAB-4936] Modification and Optimization of HIV Neutralizing Antibodies for Improved Therapeutic and Vaccinogenic Efficacy.">sabrina.hafiz@nih.gov</a><br> TAB-4933 153553422 A Potent and Broadly Neutralizing Antibody Targeting the CD4 Binding Site on HIV-1 Envelope Glycoprotein NIAID Antibodies, Collaboration, Infectious Disease, Licensing, Therapeutics, Vaccines Antibodies Collaboration Infectious Disease Licensing Therapeutics Vaccines Barton Haynes, Rui Kong, Peter Kwong, John Mascola, Tongqing Zhou <p>The N6 antibody represents a significant advancement in the quest for an effective HIV-1 vaccine. This novel antibody, isolated from B-cells of an HIV-1 infected individual, demonstrates potent and broad neutralizing activity against a wide range of HIV-1 isolates, including those resistant to other potent antibodies. N6 targets the CD4 binding site on the HIV envelope glycoprotein, particularly in the D-loop region, and exhibits higher potency than previously discovered antibodies like VRC01. In testing against pseudoviruses, N6 showed the ability to neutralize 80% of isolates resistant to VRC01, with a median IC50 of 0.1 &micro;g per ml against highly resistant viruses. This discovery sheds light on potential targets for vaccine-induced antibodies and could pave the way for the development of more effective HIV-1 vaccines.</p> N6's unique characteristics give it several competitive advantages in the field of HIV-1 vaccine development. Its exceptional potency and broad neutralizing activity against diverse HIV-1 isolates, including those resistant to other potent antibodies, set it apart as a promising candidate for vaccine design. Compared to existing antibodies like VRC01, N6 demonstrates superior efficacy, making it a valuable asset in combating HIV-1. Additionally, its ability to target the CD4 binding site on the HIV envelope glycoprotein in the D-loop region provides a novel approach that could lead to the development of more effective vaccines. These competitive advantages position N6 as a frontrunner in the search for an effective HIV-1 vaccine. The discovery of the N6 antibody opens up a range of potential applications in the field of HIV-1 prevention and treatment. One key application is its use as a template for the design of novel HIV-1 vaccines. N6's potent and broad neutralizing activity makes it an ideal candidate for inclusion in vaccine formulations aimed at inducing similar antibody responses in individuals. Additionally, N6 could be utilized in passive immunization strategies, where the antibody is administered directly to individuals at high risk of HIV-1 infection to provide immediate protection. Furthermore, N6's ability to target the CD4 binding site on the HIV envelope glycoprotein could inform the development of new therapeutic approaches for HIV-1-infected individuals. Overall, the discovery of N6 has the potential to significantly impact the field of HIV-1 research and lead to the development of new and more effective strategies for combating the virus. 2024-03-04 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153553429 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 1 153553433 Kong, Rui NIAID - DIR NIAID Kong, Rui (NIAID) 2 153553437 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 3 153553441 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 4 153553445 Haynes, Barton Haynes, Barton 5 153553429 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 1 153553433 Kong, Rui NIAID - DIR NIAID Kong, Rui (NIAID) 2 153553437 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 3 153553441 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 4 153553445 Haynes, Barton Haynes, Barton 5 153553425 HIV Neutralizing Antibodies CH540-VRC40.01 And Its Clonal Members E-130-2015-0 Filing authorized Duke University School of Medicine, NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4933] A Potent and Broadly Neutralizing Antibody Targeting the CD4 Binding Site on HIV-1 Envelope Glycoprotein&body=Please send me information about technology [TAB-4933] A Potent and Broadly Neutralizing Antibody Targeting the CD4 Binding Site on HIV-1 Envelope Glycoprotein. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4933] A Potent and Broadly Neutralizing Antibody Targeting the CD4 Binding Site on HIV-1 Envelope Glycoprotein&body=Please send me information about technology [TAB-4933] A Potent and Broadly Neutralizing Antibody Targeting the CD4 Binding Site on HIV-1 Envelope Glycoprotein.">sabrina.hafiz@nih.gov</a><br> TAB-4932 153553233 Modulation of Host Cell Signaling Pathways as a Promising Therapeutic Strategy for Ebola Virus Disease NIAID Antibodies, Collaboration, Infectious Disease, Licensing, Therapeutics Antibodies Collaboration Infectious Disease Licensing Therapeutics Joseph Blaney, Peter Jahrling, Victoria Jenson, Kenneth Kindrachuk, Scott Napper <p>This technology represents a groundbreaking approach to combating Ebola virus disease (EVD) by targeting key host cell signaling pathways implicated in the pathogenesis of the disease. Through innovative investigational strategies, the technology has identified specific kinase inhibitors that effectively reduce EVD progression in both cell culture and animal models. By focusing on pathways related to cell growth, survival, proliferation, and anti-apoptotic responses, this approach offers a novel therapeutic avenue for EVD treatment. The technology&#39;s potential lies not only in its ability to combat EVD but also in its broader implications for understanding and treating other viral hemorrhagic fevers.</p> This technology holds several competitive advantages in the field of Ebola virus disease (EVD) treatment. Firstly, it addresses a critical gap in the current EVD therapeutic landscape by targeting host cell signaling pathways, offering a novel approach distinct from conventional antiviral strategies. Secondly, the technology has demonstrated efficacy in reducing EVD progression in both cell culture and animal models, providing strong preclinical evidence of its potential effectiveness. Additionally, the identification of specific kinase inhibitors as therapeutic candidates highlights the precision and specificity of this approach, minimizing off-target effects and enhancing safety profiles. Lastly, by elucidating the role of key signaling pathways in EVD pathogenesis, this technology not only offers therapeutic potential but also provides valuable insights into the molecular mechanisms underlying viral hemorrhagic fevers, paving the way for future advancements in the field. The technology's potential applications extend beyond Ebola virus disease (EVD) treatment, encompassing a broader impact on infectious disease therapeutics and host-directed therapies. By targeting host cell signaling pathways, this approach may be applicable to other viral hemorrhagic fevers and infectious diseases where similar pathways are implicated in disease progression. Additionally, the technology's precision in identifying specific kinase inhibitors opens avenues for personalized medicine approaches, tailoring treatments to individual patients based on their signaling pathway profiles. Furthermore, the insights gained from studying these pathways could lead to the development of novel therapeutics for a range of diseases beyond infectious diseases, including cancer and inflammatory disorders, where dysregulated signaling pathways play a pivotal role. 2024-03-04 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153553240 Kindrachuk, Kenneth Kindrachuk, Kenneth 1 153553245 Blaney, Joseph NIAID - DIR NIAID Blaney, Joseph (NIAID) 2 153553249 Napper, Scott University of Saskatchewan Napper, Scott 3 153553258 Jenson, Victoria NIAID - DCR NIAID Jenson, Victoria (NIAID) 4 153553269 Jahrling, Peter NIAID - DIR NIAID Jahrling, Peter (NIAID) 5 153553240 Kindrachuk, Kenneth Kindrachuk, Kenneth 1 153553245 Blaney, Joseph NIAID - DIR NIAID Blaney, Joseph (NIAID) 2 153553249 Napper, Scott University of Saskatchewan Napper, Scott 3 153553258 Jenson, Victoria NIAID - DCR NIAID Jenson, Victoria (NIAID) 4 153553269 Jahrling, Peter NIAID - DIR NIAID Jahrling, Peter (NIAID) 5 153553236 Targeting Host Cell Signaling Pathways With Kinase Inhibitors For The Treatment Of Ebola Virus Disease E-130-2012-0 Filing authorized NIAID, University of Saskatchewan 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4932] Modulation of Host Cell Signaling Pathways as a Promising Therapeutic Strategy for Ebola Virus Disease&body=Please send me information about technology [TAB-4932] Modulation of Host Cell Signaling Pathways as a Promising Therapeutic Strategy for Ebola Virus Disease. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4932] Modulation of Host Cell Signaling Pathways as a Promising Therapeutic Strategy for Ebola Virus Disease&body=Please send me information about technology [TAB-4932] Modulation of Host Cell Signaling Pathways as a Promising Therapeutic Strategy for Ebola Virus Disease.">wade.green@nih.gov</a><br> TAB-4931 153552966 Development of a Novel Bivalent Vaccine Offering Concurrent Protection Against MERS-CoV and Rabies Virus NIAID Animal Models, Antibodies, Collaboration, Immunology, Infectious Disease, Licensing, Pulmonology, Rare/Neglected Diseases, Respiratory, Vaccines Animal Models Antibodies Collaboration Immunology Infectious Disease Licensing Pulmonology Rare/Neglected Diseases Respiratory Vaccines Joseph Blaney, Christopher Coleman, Matthew Frieman, Lisa Hensley, Reed Johnson, Matthias Schnell, Christoph Wirblich <p>The technology in focus is a cutting-edge bivalent vaccine that simultaneously offers protection against the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and the rabies virus. In pre-clinical trials utilizing mouse models, the vaccine has demonstrated significant immunogenicity, prompting a strong immune response, and has effectively reduced the viral yield of MERS-CoV. Its dual-protective nature sets a new precedent for vaccine development, particularly in the context of zoonotic diseases where the potential for interspecies transmission poses a global health risk. Designed for use in both humans and animals, this vaccine candidate is poised to be a vital tool in areas with high exposure risk to these viruses, offering a strategic defense for communities and service personnel in affected regions and enhancing overall epidemic preparedness.</p> The bivalent vaccine's primary competitive advantage lies in its dual-action formula, capable of inducing immunity against both MERS-CoV and rabies with a single inoculation. This not only streamlines vaccination protocols but also reduces healthcare costs and logistical complexity. Additionally, it addresses a critical need for vaccines that can protect against multiple pathogens, particularly in regions where both viruses are a concern. The vaccine’s efficacy in animal models suggests a high potential for success in human applications, promising to fill a gap in current vaccine offerings and providing a unique solution in the fight against these infectious diseases. This innovative bivalent vaccine has the potential to transform public health strategies through its application in several key areas. It can be utilized in general healthcare settings for routine immunization programs, significantly impacting global health by reducing the incidence of both MERS-CoV and rabies. In the veterinary sector, it can protect wildlife and domestic animals, thereby curbing the zoonotic transmission of these viruses to humans. The vaccine is particularly beneficial for high-risk groups such as laboratory personnel, veterinarians, animal handlers, travelers to endemic areas, and military or diplomatic staff stationed overseas. Moreover, its deployment in epidemic response initiatives can enhance emergency preparedness against potential MERS-CoV outbreaks, providing a robust tool for international health organizations and governments in managing public health crises. 2024-03-04 2026-08-26 2026-08-26 2026-08-26 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 153552973 Johnson, Reed NIAID - DIR NIAID Johnson, Reed (NIAID) 1 153552977 Schnell, Matthias Thomas Jefferson University Schnell, Matthias 2 153552985 Frieman, Matthew University of Maryland, School of Medicine Frieman, Matthew 3 153552989 Hensley, Lisa NIAID - DIR NIAID Hensley, Lisa (NIAID) 4 153553003 Wirblich, Christoph Thomas Jefferson University Wirblich, Christoph 5 153553027 Blaney, Joseph NIAID - DIR NIAID Blaney, Joseph (NIAID) 6 153553031 Coleman, Christopher University of Maryland, School of Medicine Coleman, Christopher 7 153552973 Johnson, Reed NIAID - DIR NIAID Johnson, Reed (NIAID) 1 153552977 Schnell, Matthias Thomas Jefferson University Schnell, Matthias 2 153552985 Frieman, Matthew University of Maryland, School of Medicine Frieman, Matthew 3 153552989 Hensley, Lisa NIAID - DIR NIAID Hensley, Lisa (NIAID) 4 153553003 Wirblich, Christoph Thomas Jefferson University Wirblich, Christoph 5 153553027 Blaney, Joseph NIAID - DIR NIAID Blaney, Joseph (NIAID) 6 153553031 Coleman, Christopher University of Maryland, School of Medicine Coleman, Christopher 7 153552969 Live-Attenuated Or Inactive Bivalent Vaccines That Confer Dual Protection Against Rabies And Middles East Respiratory Syndrome Coronavirus (MERs CoV) For Use In Animal And Humans. E-128-2016-0 Filing authorized NIAID, Thomas Jefferson University, University of Maryland 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4931] Development of a Novel Bivalent Vaccine Offering Concurrent Protection Against MERS-CoV and Rabies Virus&body=Please send me information about technology [TAB-4931] Development of a Novel Bivalent Vaccine Offering Concurrent Protection Against MERS-CoV and Rabies Virus. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4931] Development of a Novel Bivalent Vaccine Offering Concurrent Protection Against MERS-CoV and Rabies Virus&body=Please send me information about technology [TAB-4931] Development of a Novel Bivalent Vaccine Offering Concurrent Protection Against MERS-CoV and Rabies Virus.">wade.green@nih.gov</a><br> TAB-4930 153552831 Advancements in Prion Disease Detection: Exploring Broadly Reactive Substrates and Strain Discrimination NIAID Collaboration, Diagnostics, Infectious Disease, Licensing, Neurology, Rare/Neglected Diseases Collaboration Diagnostics Infectious Disease Licensing Neurology Rare/Neglected Diseases Byron Caughey, Bradley Groveman, Christina Groveman, Romolo Nonno, Lynne Raymond <p>The technology is centered around the Real Time Quaking Induced Conversion (RT-QuIC) assay, which aims to enhance the detection and discrimination of prion diseases in humans and animals. This assay utilizes recombinant prion protein (rPrPSen) to detect prion-seeded fibrillization, offering a highly specific and ultra-sensitive method for detecting multiple prion diseases across various species. A key innovation of the technology is the use of recombinant bank vole prion protein as a broadly reactive substrate. This substrate, when expressed in E. coli and purified, has demonstrated effectiveness in detecting prions from multiple species, including those for which no effective substrate was previously available. Additionally, the technology explores the analysis of the products of bank vole-based RT-QuIC reactions to improve the discrimination between different prion strains within a given host species. This approach has the potential to revolutionize prion disease detection and management, offering a practical and sensitive assay for routine use in clinical medicine, agriculture, and wildlife management, ultimately improving outcomes for affected individuals and populations.</p> The technology offers competitive advantages in prion disease detection. The Real Time Quaking Induced Conversion (RT-QuIC) assay provides highly specific and ultra-sensitive detection of a wide range of prion diseases in humans and animals. The use of recombinant bank vole prion protein as a broadly reactive substrate enables detection of prions from multiple species and strains previously challenging to detect. Its practicality and ease of use make it a more feasible option for routine diagnostic use compared to other assays, which are often more complex and time-consuming. These advantages position the technology as a leading solution for improving the detection and discrimination of prion diseases, offering significant benefits to clinical, agricultural, and wildlife management settings. The technology has a wide range of potential applications in clinical medicine, agriculture, and wildlife management. In clinical settings, it can be used for early and accurate detection of prion diseases in humans, enabling timely intervention and management. In agriculture, the technology can improve surveillance and control measures for prion diseases in livestock, such as scrapie in sheep and chronic wasting disease (CWD) in deer and elk. Additionally, in wildlife management, it can aid in the monitoring and conservation efforts of affected animal populations. Overall, the technology's versatility and sensitivity make it a valuable tool for addressing the challenges posed by prion diseases across different sectors. 2024-03-04 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153552838 Caughey, Byron NIAID - DIR NIAID Caughey, Byron (NIAID) 1 153552842 Groveman, Christina NIAID - DIR NIAID Groveman, Christina (NIAID) 2 153552846 Groveman, Bradley NIAID - DIR NIAID Groveman, Bradley (NIAID) 3 153552854 Nonno, Romolo Istituto Superiore di Sanita Nonno, Romolo 4 153552863 Raymond, Lynne NIAID Raymond, Lynne (NIAID) 5 153552838 Caughey, Byron NIAID - DIR NIAID Caughey, Byron (NIAID) 1 153552842 Groveman, Christina NIAID - DIR NIAID Groveman, Christina (NIAID) 2 153552846 Groveman, Bradley NIAID - DIR NIAID Groveman, Bradley (NIAID) 3 153552854 Nonno, Romolo Istituto Superiore di Sanita Nonno, Romolo 4 153552863 Raymond, Lynne NIAID Raymond, Lynne (NIAID) 5 153552834 Bank Vole Prion Protein As A Broad-spectrum Substrate For RT-QuIC-based Detection And Discrimination Of Prion Strains E-128-2015-0 Filing authorized Istituto Superiore di Sanita, NIAID 146046171 Joyce, Terrence terrence.joyce@nih.gov
United States of America terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-4930] Advancements in Prion Disease Detection: Exploring Broadly Reactive Substrates and Strain Discrimination&body=Please send me information about technology [TAB-4930] Advancements in Prion Disease Detection: Exploring Broadly Reactive Substrates and Strain Discrimination. Joyce, Terrence<br><a href="mailto:terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-4930] Advancements in Prion Disease Detection: Exploring Broadly Reactive Substrates and Strain Discrimination&body=Please send me information about technology [TAB-4930] Advancements in Prion Disease Detection: Exploring Broadly Reactive Substrates and Strain Discrimination.">terrence.joyce@nih.gov</a><br> TAB-4929 153552668 Identification of Biomarkers for Onchocerciasis Control and Elimination NIAID Antibodies, Application, Collaboration, Dermatology, Diagnostics, Infectious Disease, Licensing, Ophthalmology, Plasmids/Vectors, Rare/Neglected Diseases, Therapeutics, Vaccines Antibodies Application Collaboration Dermatology Diagnostics Infectious Disease Licensing Ophthalmology Plasmids/Vectors Rare/Neglected Diseases Therapeutics Vaccines David Abraham, Sasi Bennuru, Sara Lustigman, Thomas Nutman <p>The technology outlined in the document is focused on the discovery of novel biomarkers for Onchocerciasis, a parasitic disease also known as river blindness, which is transmitted by blackfly vectors. The document describes the identification of the first Onchocerca volvulus-encoded molecules that are adult-specific and can be used as markers for macrofilaricidal activity, which is the ability to kill adult worms. Using advanced methods such as proteomics, comparative transcriptomics, and genomics, the researchers have identified 14 biomarkers that are indicative of viable adult worms and can be used in assays to detect active infections. These antigens are highly specific to Onchocerca volvulus and do not have homology to other filariae or to humans or mice, which could potentially lead to more targeted and effective treatments for onchocerciasis.</p> The technology presents a significant advance in the fight against Onchocerciasis by offering highly specific biomarkers for detecting active infections, which are crucial for accurate diagnosis and monitoring of the disease. This specificity confers a considerable advantage over existing diagnostic methods, potentially reducing false positives and enhancing the effectiveness of eradication programs. With its innovative approach to identifying adult worms of Onchocerca volvulus, this technology promises to be a valuable tool in the global effort to eliminate a disease that affects millions in resource-limited communities. The discovery of specific biomarkers for Onchocerciasis has wide-reaching potential applications, including the development of precise diagnostic assays that could revolutionize the monitoring and treatment of the disease. These biomarkers enable the creation of tests to measure the efficacy of drug treatments by detecting the presence of adult Onchocerca volvulus worms, thereby informing elimination strategies. Moreover, they may aid in vaccine research by identifying immune responses that correlate with protection, and in public health, where they could be used to map disease prevalence and intensity, optimizing resource allocation for intervention programs. 2024-03-04 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153552562 Nutman, Thomas National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Nutman, Thomas (NIAID) 1 153552566 Bennuru, Sasi NIAID - DIR NIAID Bennuru, Sasi (NIAID) 2 153552570 Lustigman, Sara New York Blood Center Lustigman, Sara 3 153552883 Abraham, David Thomas Jefferson University Abraham, David 4 153552562 Nutman, Thomas National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Nutman, Thomas (NIAID) 1 153552566 Bennuru, Sasi NIAID - DIR NIAID Bennuru, Sasi (NIAID) 2 153552570 Lustigman, Sara New York Blood Center Lustigman, Sara 3 153552883 Abraham, David Thomas Jefferson University Abraham, David 4 153552553 Onchocerca Volvulus Specific Biomarkers For Detection Of Active Infection And Macrofilaricidal Activity E-124-2018-0 Filing authorized New York Blood Center, NIAID, Thomas Jefferson University 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4929] Identification of Biomarkers for Onchocerciasis Control and Elimination&body=Please send me information about technology [TAB-4929] Identification of Biomarkers for Onchocerciasis Control and Elimination. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4929] Identification of Biomarkers for Onchocerciasis Control and Elimination&body=Please send me information about technology [TAB-4929] Identification of Biomarkers for Onchocerciasis Control and Elimination.">jonathan.motley@nih.gov</a><br> TAB-4926 153550527 A Highly Potent Neutralizing Antibody Specific to the Prefusion Conformation of the Respiratory Syncytial Virus Fusion Glycoprotein NIAID Antibodies, Collaboration, Infectious Disease, Licensing, Respiratory, Therapeutics Antibodies Collaboration Infectious Disease Licensing Respiratory Therapeutics Man Chen, Barney Graham, Liang-Min Huang, Peter Kwong, Jason McLellan, Ning-Shao Xia, Min Zhao, Zi-Zheng Zheng <p>The development of 5C4, a monoclonal antibody targeting the prefusion conformation of the Respiratory Syncytial Virus (RSV) Fusion (F) glycoprotein, represents a significant advancement in RSV vaccine research. Unlike the postfusion state, the prefusion conformation of the F glycoprotein contains unique epitopes targeted by neutralizing antibodies. 5C4 was discovered through screening hybridomas for antibodies that neutralized the virus but did not bind to a stabilized form of postfusion F, with 5C4 exhibiting approximately 50-fold higher neutralizing activity than the licensed monoclonal antibody palivizumab (Synagis). Further characterization revealed 5C4&#39;s specificity for the prefusion conformation of the F glycoprotein, with binding sites identified at residues 60-75 and 200-212. The atomic-level crystal structure of the RSV F glycoprotein in the prefusion conformation in complex with 5C4 elucidated the unique antigenic site targeted by potent neutralizing antibodies like 5C4.</p> <p>&nbsp;</p> 5C4 stands out in RSV vaccine development due to its exceptional potency, surpassing palivizumab by approximately 50-fold. Its specificity for the prefusion conformation of the RSV F glycoprotein, targeting unique epitopes at residues 60-75 and 200-212, enhances its efficacy and safety profile. 5C4's competitive advantage is further demonstrated by its ability to compete with antibodies targeting the apex of the prefusion F trimer, showcasing its versatility in immune response studies. These attributes position 5C4 as a promising candidate for advancing RSV immunotherapy and vaccine strategies. The potential applications of 5C4 extend beyond RSV vaccine development, with implications for both preventive and therapeutic interventions. As a highly potent neutralizing antibody, 5C4 could be incorporated into novel RSV vaccine formulations aimed at enhancing immune responses, especially in high-risk populations such as infants and the elderly. Additionally, 5C4's specificity for the prefusion conformation of the RSV F glycoprotein makes it a promising candidate for passive immunotherapy, offering immediate protection against RSV infection in vulnerable individuals. Furthermore, 5C4's ability to compete with other antibodies targeting the prefusion F trimer suggests its utility as a research tool for studying RSV pathogenesis and immune responses, potentially leading to new insights and therapeutic strategies for combating RSV- 2024-03-04 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153550587 Zheng, Zi-Zheng Zheng, Zi-Zheng 1 153550618 Zhao, Min Zhao, Min 2 153550623 Huang, Liang-Min Xiamen Innovax Biotech Co., Ltd. [CN] NIAID Huang, Liang-Min (NIAID) 3 153550627 Xia, Ning-Shao Xia, Ning-Shao 4 153550631 Graham, Barney NIAID Graham, Barney (NIAID) 5 153550636 McLellan, Jason University of Texas at Austin NIAID McLellan, Jason (NIAID) 6 153550647 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 7 153550726 Chen, Man NIAID - VRC NIAID Chen, Man (NIAID) 8 153550587 Zheng, Zi-Zheng Zheng, Zi-Zheng 1 153550618 Zhao, Min Zhao, Min 2 153550623 Huang, Liang-Min Xiamen Innovax Biotech Co., Ltd. [CN] NIAID Huang, Liang-Min (NIAID) 3 153550627 Xia, Ning-Shao Xia, Ning-Shao 4 153550631 Graham, Barney NIAID Graham, Barney (NIAID) 5 153550636 McLellan, Jason University of Texas at Austin NIAID McLellan, Jason (NIAID) 6 153550647 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 7 153550726 Chen, Man NIAID - VRC NIAID Chen, Man (NIAID) 8 153550530 A Monoclonal Antibody (5C4) With Potent Neutralizing Activity Against RSV Is Specific For A Structurally-defined Antigenic Site Uniquely Present On The RSV Prefusion F Protein E-117-2013-0 Filing authorized NIAID, Xiamen University 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4926] A Highly Potent Neutralizing Antibody Specific to the Prefusion Conformation of the Respiratory Syncytial Virus Fusion Glycoprotein&body=Please send me information about technology [TAB-4926] A Highly Potent Neutralizing Antibody Specific to the Prefusion Conformation of the Respiratory Syncytial Virus Fusion Glycoprotein. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4926] A Highly Potent Neutralizing Antibody Specific to the Prefusion Conformation of the Respiratory Syncytial Virus Fusion Glycoprotein&body=Please send me information about technology [TAB-4926] A Highly Potent Neutralizing Antibody Specific to the Prefusion Conformation of the Respiratory Syncytial Virus Fusion Glycoprotein.">sabrina.hafiz@nih.gov</a><br> TAB-4925 153549037 Stabilizing the Prefusion Conformation of the RSV F Glycoprotein without Foldon Domain Dependency NIAID Antibodies, Collaboration, Infectious Disease, Licensing, Research Equipment, Respiratory, Vaccines Antibodies Collaboration Infectious Disease Licensing Research Equipment Respiratory Vaccines Man Chen, Aliaksandr Druz, Barney Graham, Michael Joyce, Peter Kwong, Thomas Paul, Mallika Sastry, Guillaume Stewart-Jones, Yongping Yang <p>The technology focuses on stabilizing the respiratory syncytial virus (RSV) fusion (F) glycoprotein in its prefusion conformation, crucial for developing effective RSV vaccines. By introducing specific mutations (S155C-S290C, S190F, V207L) and creating interprotomer disulfides, trimer stabilization is achieved without relying on a foldon domain. This innovative approach enhances the immunogenicity of the RSV F protein, potentially leading to more potent and focused immune responses against RSV. The technology&#39;s impact extends to reducing the risk of unwanted immune responses and improving the overall efficacy and safety of RSV vaccines.</p> The technology presents competitive advantages in RSV vaccine development by stabilizing the F glycoprotein in its prefusion conformation without requiring a foldon domain. This streamlined approach simplifies vaccine design and production, potentially reducing costs and increasing efficiency. By enhancing the immunogenicity of the RSV F protein, the vaccine may elicit a more potent immune response compared to existing candidates. Moreover, the removal of non-RSV F sequences reduces the risk of unwanted immune responses, enhancing the vaccine's safety and specificity. Overall, these advantages position the technology as a promising and competitive option in the RSV vaccine market. The technology's potential applications extend beyond RSV vaccine development. It could be utilized in other viral vaccines where stabilizing glycoproteins in prefusion conformation is beneficial for eliciting potent immune responses. Additionally, the approach of stabilizing proteins without the need for foldon domains could have implications in protein engineering and biotechnology, enabling the design of more stable and functional proteins for various applications. The removal of non-essential sequences to focus the immune response could also be relevant in designing vaccines for other pathogens or in immunotherapy approaches. Overall, the technology's broad applicability highlights its potential impact across multiple fields beyond RSV vaccine development. 2024-03-04 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153549182 Chen, Man National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Chen, Man (NIAID) 1 153549265 Graham, Barney Morehouse School of Medicine NIAID Graham, Barney (NIAID) 2 153549609 Joyce, Michael The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. NIAID Joyce, Michael (NIAID) 3 153549647 Sastry, Mallika NIAID - VRC NIAID Sastry, Mallika (NIAID) 4 153549675 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 5 153549713 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 6 153549741 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 7 153549855 Paul, Thomas 3rd Party Law Firm Paul, Thomas 8 153549984 Druz, Aliaksandr NIAID - DIR NIAID Druz, Aliaksandr (NIAID) 9 153549182 Chen, Man National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Chen, Man (NIAID) 1 153549265 Graham, Barney Morehouse School of Medicine NIAID Graham, Barney (NIAID) 2 153549609 Joyce, Michael The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. NIAID Joyce, Michael (NIAID) 3 153549647 Sastry, Mallika NIAID - VRC NIAID Sastry, Mallika (NIAID) 4 153549675 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 5 153549713 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 6 153549741 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 7 153549855 Paul, Thomas 3rd Party Law Firm Paul, Thomas 8 153549984 Druz, Aliaksandr NIAID - DIR NIAID Druz, Aliaksandr (NIAID) 9 153549044 Cysteine Zipper-stabilized Pre-fusion RSV F Glycoprotein Immunogens And Their Use E-112-2015-0 Filing authorized NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4925] Stabilizing the Prefusion Conformation of the RSV F Glycoprotein without Foldon Domain Dependency&body=Please send me information about technology [TAB-4925] Stabilizing the Prefusion Conformation of the RSV F Glycoprotein without Foldon Domain Dependency. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4925] Stabilizing the Prefusion Conformation of the RSV F Glycoprotein without Foldon Domain Dependency&body=Please send me information about technology [TAB-4925] Stabilizing the Prefusion Conformation of the RSV F Glycoprotein without Foldon Domain Dependency.">sabrina.hafiz@nih.gov</a><br> TAB-4922 153311458 Self-Assembling Nanoparticle System for Scalable and Potent Individualized Cancer Vaccines NIAID Antibodies, Collaboration, Computational models/software, Diagnostics, Human Cell Lines, Immunology, Licensing, Medical Devices, Oncology, Rare/Neglected Diseases, Research Materials, Therapeutics, Vaccines Antibodies Collaboration Computational models/software Diagnostics Human Cell Lines Immunology Licensing Medical Devices Oncology Rare/Neglected Diseases Research Materials Therapeutics Vaccines Geoffrey Lynn, Robert Seder <p>The technology pertains to a novel polymer nanoparticle platform designed for the creation of individualized cancer vaccines. It utilizes a two-component system that combines patient-specific peptide neoantigens with immunostimulants within self-assembling nanoparticles. This approach ensures the targeted delivery of neoantigens to the immune system, enhancing the immune response against cancer cells while avoiding the systemic activation often seen with conventional adjuvants. The innovation lies in its ability to consistently produce scalable and potent vaccines tailored to individual patients, potentially transforming the landscape of cancer immunotherapy.</p> <p>&nbsp;</p> This polymer nanoparticle technology for individualized cancer vaccines distinguishes itself with several competitive advantages. Its precision delivery system leverages self-assembling nanoparticles, ensuring consistent and potent immune response activation directly targeting cancer cells. Unlike conventional methods that often produce variable immune responses, this approach offers scalability and potency, with the potential to reduce systemic immune activation and associated side effects. This platform represents a significant leap forward, potentially setting a new standard in the personalized immunotherapy landscape. The polymer nanoparticle technology for individualized cancer vaccines has broad potential applications across the field of oncology. By enabling the creation of personalized vaccines, it opens up possibilities for targeted treatment of a wide array of cancers, each characterized by unique genetic mutations. It can be used not only as a therapeutic intervention for existing cancers but also holds potential for prophylactic use in high-risk patient populations. Additionally, its scalability and adaptability could allow for rapid response to tumor evolution and resistance mechanisms, offering a dynamic approach to long-term cancer management and treatment personalization. This technology could also be leveraged in the development of precision medicine strategies and in clinical research, where individualized responses to therapy are critical. 2024-02-26 2026-08-26 2026-08-26 2026-08-26 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 153311465 Lynn, Geoffrey Vaccitech North America NIAID Lynn, Geoffrey (NIAID) 1 153311628 Seder, Robert NIAID - VRC NIAID Seder, Robert (NIAID) 2 153311465 Lynn, Geoffrey Vaccitech North America NIAID Lynn, Geoffrey (NIAID) 1 153311628 Seder, Robert NIAID - VRC NIAID Seder, Robert (NIAID) 2 153311461 Polymer Nanoparticle Technology For Individualized Cancer Vaccines E-106-2016-0 Filing authorized NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4922] Self-Assembling Nanoparticle System for Scalable and Potent Individualized Cancer Vaccines&body=Please send me information about technology [TAB-4922] Self-Assembling Nanoparticle System for Scalable and Potent Individualized Cancer Vaccines. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4922] Self-Assembling Nanoparticle System for Scalable and Potent Individualized Cancer Vaccines&body=Please send me information about technology [TAB-4922] Self-Assembling Nanoparticle System for Scalable and Potent Individualized Cancer Vaccines.">wade.green@nih.gov</a><br> TAB-4920 153311205 Targeting a Second CD4-Binding Site with Innovative Engraftment Techniques NIAID Antibodies, Collaboration, Infectious Disease, Licensing, Therapeutics Antibodies Collaboration Infectious Disease Licensing Therapeutics Qingbo Liu, Paolo Lusso, Mohammad Sajadi <p>This innovative technology represents a significant advancement in the field of HIV-1 therapy and prevention. By targeting a second, quaternary CD4-binding site with the engraftment of the VRC03 FR3 loop, it enhances the potency of broadly neutralizing antibodies against HIV-1. Importantly, this approach also addresses issues of autoreactivity and extends the antibody&#39;s half-life in vivo. Unlike previous methods that relied on random mutagenesis or the structural modification of classic interactive sites, this technology offers a novel and more effective strategy for improving the efficacy of anti-HIV antibodies.</p> This technology offers several competitive advantages over existing approaches in the field of HIV-1 therapy and prevention. By specifically targeting a second, quaternary CD4-binding site with the engraftment of the VRC03 FR3 loop, it enhances the potency of broadly neutralizing antibodies against HIV-1. This targeted approach not only increases the effectiveness of the antibodies but also reduces the risk of autoreactivity, a common concern with previous methods. Additionally, the technology's ability to prolong the antibody's half-life in vivo provides a more sustained and durable immune response against HIV-1. Overall, these advantages position this technology as a promising and innovative strategy for advancing HIV-1 therapy and prevention efforts. This technology has the potential for a wide range of applications in the field of HIV-1 therapy and prevention. It could lead to the development of more effective treatments for HIV-1 infection, particularly in cases where current therapies have proven less successful. Additionally, this technology could be used to enhance the efficacy of vaccines aimed at preventing HIV-1 infection. By improving the potency of broadly neutralizing antibodies, this approach could help to bolster the immune response against HIV-1 and provide longer-lasting protection. Furthermore, the ability to reduce autoreactivity and prolong the antibody's half-life in vivo could make this technology suitable for use in a variety of therapeutic and prophylactic settings. Overall, the potential applications of this technology are vast and could have a significant impact on the field of HIV-1 research and treatment. 2024-02-26 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153311258 Sajadi, Mohammad University of Maryland, School of Medicine Sajadi, Mohammad 1 153311266 Lusso, Paolo NIAID - DIR NIAID Lusso, Paolo (NIAID) 2 153311274 Liu, Qingbo National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Liu, Qingbo (NIAID) 3 153311258 Sajadi, Mohammad University of Maryland, School of Medicine Sajadi, Mohammad 1 153311266 Lusso, Paolo NIAID - DIR NIAID Lusso, Paolo (NIAID) 2 153311274 Liu, Qingbo National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Liu, Qingbo (NIAID) 3 153311254 Improvement Of HIV-neutralizing Antibodies By Modification Of The Heavy Chain FR3 Loop And Other Regions E-103-2020-0 Filing authorized NIAID, University of Maryland 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4920] Targeting a Second CD4-Binding Site with Innovative Engraftment Techniques&body=Please send me information about technology [TAB-4920] Targeting a Second CD4-Binding Site with Innovative Engraftment Techniques. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4920] Targeting a Second CD4-Binding Site with Innovative Engraftment Techniques&body=Please send me information about technology [TAB-4920] Targeting a Second CD4-Binding Site with Innovative Engraftment Techniques.">benjamin.hurley@nih.gov</a><br> TAB-4919 153311014 Synthetic Peptide Immunogens for Broadly Neutralizing Antibody Induction Against HIV-1 NIAID Antibodies, Collaboration, Computational models/software, Diagnostics, Human Cell Lines, Immunology, Infectious Disease, Licensing, Rare/Neglected Diseases, Therapeutics, Vaccines Antibodies Collaboration Computational models/software Diagnostics Human Cell Lines Immunology Infectious Disease Licensing Rare/Neglected Diseases Therapeutics Vaccines Peter Kwong, Rebecca Lynch, John Mascola, Tongqing Zhou <p>The technology in focus encompasses a novel suite of synthetic peptide immunogens, collaboratively developed by leading institutions, aimed at evoking a robust immune response against HIV-1. This breakthrough harnesses the latest advancements in immunology to craft immunogens that elicit broadly neutralizing antibodies in humans, a significant stride in HIV-1 therapeutic and preventive strategies. The strategic formulation and delivery of these immunogens represent a cutting-edge approach to potentially overcome the limitations of existing interventions by inducing an enhanced, targeted immune defense. This innovation stands at the forefront of HIV-1 research, embodying a potential paradigm shift in the management and prevention of this global health challenge.</p> The collaborative immunogen technology for HIV-1 stands out by inducing broadly neutralizing antibodies, directly targeting the virus's evasion mechanisms. Its precision in stimulating the immune system may lead to more effective vaccines and therapies compared to current options. The use of synthetic peptides ensures adaptability to viral mutations, offering a significant edge in vaccine design. This approach represents a significant leap forward in the field of HIV-1 prophylactic and therapeutic strategies. The innovative immunogen technology for HIV-1 has the potential for broad application across various domains of healthcare. In therapeutics, it could lead to the development of more effective treatment regimens that provide long-lasting viral suppression. As a prophylactic, it opens avenues for vaccines that could prevent infection, thereby curtailing the spread of HIV-1 globally. Additionally, this technology has implications for personalized medicine, as it could be tailored to individual immunological profiles, enhancing the precision of immune responses. Furthermore, its adaptability to viral evolution makes it a valuable tool for ongoing research and response to emerging HIV-1 strains. 2024-02-26 2026-08-26 2026-08-26 2026-08-26 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 153311031 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 1 153311035 Lynch, Rebecca George Washington University NIAID Lynch, Rebecca (NIAID) 2 153311044 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 3 153311048 Zhou, Tongqing NIAID Zhou, Tongqing (NIAID) 4 153311031 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 1 153311035 Lynch, Rebecca George Washington University NIAID Lynch, Rebecca (NIAID) 2 153311044 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 3 153311048 Zhou, Tongqing NIAID Zhou, Tongqing (NIAID) 4 153311017 Antibody Evolution Immunogens E-103-2014-0 Filing authorized NIAID 91025211 Rainwater, Charles crainwater@mail.nih.gov
United States of America crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-4919] Synthetic Peptide Immunogens for Broadly Neutralizing Antibody Induction Against HIV-1&body=Please send me information about technology [TAB-4919] Synthetic Peptide Immunogens for Broadly Neutralizing Antibody Induction Against HIV-1. Rainwater, Charles<br><a href="mailto:crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-4919] Synthetic Peptide Immunogens for Broadly Neutralizing Antibody Induction Against HIV-1&body=Please send me information about technology [TAB-4919] Synthetic Peptide Immunogens for Broadly Neutralizing Antibody Induction Against HIV-1.">crainwater@mail.nih.gov</a><br> TAB-4918 153310634 Infectious Molecular Clone of SIVsmE543-3: A Tool for Studying SIV-Induced Encephalitis and Neutralization Resistance NIAID Collaboration, Immunology, Infectious Disease, Licensing, Therapeutics, Vaccines Collaboration Immunology Infectious Disease Licensing Therapeutics Vaccines Diane Adger-Johnson, Vanessa Hirsch <p>The development of an infectious molecular clone of simian immunodeficiency virus SIVsm, known as SIVsmE543-3, marks a significant breakthrough in SIV research. This clone, derived from a late-stage biological isolate from an immunodeficient rhesus macaque with SIV-induced encephalitis, has shown robust replication in macaque immune cells and macrophages. Notably, SIVsmE543-3 exhibits resistance to neutralization by heterologous sera, which can typically neutralize genetically diverse SIV variants in vitro. This resistance suggests unique characteristics of SIVsmE543-3 that enable it to evade the immune system&#39;s neutralizing antibodies. Furthermore, the ability of SIVsmE543-3 to induce AIDS in pig-tailed macaques when intravenously inoculated underscores its pathogenicity and potential as a model for studying SIV-induced disease. Overall, SIVsmE543-3 represents a valuable tool for researchers studying SIV-induced encephalitis, offering insights into neutralization resistance and its in vivo implications.</p> <p>&nbsp;</p> One key competitive advantage of SIVsmE543-3 is its ability to replicate well in macaque immune cells and macrophages, making it a robust tool for studying SIV-induced encephalitis and other aspects of SIV pathogenesis. Additionally, its resistance to neutralization by heterologous sera distinguishes it from other SIV variants and offers a unique model for investigating the mechanisms of immune evasion. Furthermore, the ability of SIVsmE543-3 to induce AIDS in pig-tailed macaques highlights its pathogenic potential and relevance for studying AIDS progression. Overall, SIVsmE543-3's combination of robust replication, neutralization resistance, and pathogenicity positions it as a valuable and distinctive resource for researchers in the field of SIV and AIDS research. The unique properties of SIVsmE543-3 make it a promising candidate for several potential applications in the field of virology and immunology. Firstly, its robust replication in macaque immune cells and resistance to neutralization suggest that SIVsmE543-3 could serve as a valuable tool for studying viral pathogenesis and the development of immune responses. Researchers could use this model to investigate the mechanisms underlying viral evasion of host immunity, potentially leading to the development of novel antiviral strategies. Additionally, the ability of SIVsmE543-3 to induce AIDS in pig-tailed macaques could make it a valuable model for preclinical testing of antiretroviral drugs and vaccines. Overall, SIVsmE543-3's unique characteristics position it as a versatile tool with applications in basic research, drug development, and vaccine design in the field of viral infections and immunology. 2024-02-26 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153310943 Adger-Johnson, Diane NIAID - DIR Adger-Johnson, Diane 1 153310951 Hirsch, Vanessa NIAID Hirsch, Vanessa (NIAID) 2 153310943 Adger-Johnson, Diane NIAID - DIR Adger-Johnson, Diane 1 153310951 Hirsch, Vanessa NIAID Hirsch, Vanessa (NIAID) 2 153310681 A Molecularly Cloned, Pathogenic, Neutralization-Resistant Simian Immunodeficiency Virus SIVsmE543-3 And Cell Line E-102-2021-0 Research Material NIAID 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-4918] Infectious Molecular Clone of SIVsmE543-3: A Tool for Studying SIV-Induced Encephalitis and Neutralization Resistance&body=Please send me information about technology [TAB-4918] Infectious Molecular Clone of SIVsmE543-3: A Tool for Studying SIV-Induced Encephalitis and Neutralization Resistance. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-4918] Infectious Molecular Clone of SIVsmE543-3: A Tool for Studying SIV-Induced Encephalitis and Neutralization Resistance&body=Please send me information about technology [TAB-4918] Infectious Molecular Clone of SIVsmE543-3: A Tool for Studying SIV-Induced Encephalitis and Neutralization Resistance.">peter.tung@nih.gov</a><br> TAB-4917 153310552 Advancements in Hematopoietic Stem Cell Transplantation: Non-Toxic Conditioning with CD117-Targeted Monoclonal Antibodies NIAID Antibodies, Collaboration, Diagnostics, Human Cell Lines, Immunology, Licensing, Oncology, Rare/Neglected Diseases, Research Materials, TherapeuticArea, Therapeutics Antibodies Collaboration Diagnostics Human Cell Lines Immunology Licensing Oncology Rare/Neglected Diseases Research Materials TherapeuticArea Therapeutics Agnieszka Czechowicz, Zhanzhuo Li, Philip Murphy, Derrick Rossi <p>The technology revolves around an innovative monoclonal antibody-based conditioning regimen for enhancing the engraftment of hematopoietic stem cells during bone marrow transplants. It features a novel antibody-drug conjugate that targets CD117, a marker on stem cells, to enable effective transplantation without the harmful side effects of traditional conditioning methods. This approach has shown remarkable success in pre-clinical in vivo studies, offering a significant leap forward in transplant medicine with its potential to facilitate safe, non-toxic, and universally applicable bone marrow transplants.</p> The CD117 antibody-drug conjugate technology offers a non-toxic, highly effective alternative for bone marrow transplant conditioning. It achieves robust, long-term engraftment, reducing the need for chronic immunosuppression. Its effectiveness in both syngeneic and allogeneic settings enhances its versatility. This positions it as a leading candidate for transforming current transplant protocols and improving patient care. The CD117 antibody-drug conjugate technology holds promise for a wide array of applications including safer bone marrow transplants across mismatched donors, gene therapies requiring hematopoietic stem cell vectors, and potentially, treatments for a range of hematologic conditions. Its ability to facilitate engraftment without traditional conditioning could revolutionize the therapeutic landscape for patients requiring stem cell transplantation. 2024-02-26 2026-08-26 2026-08-26 2026-08-26 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 153310560 Rossi, Derrick Childrens Medical Center Corporation, Children's Hospital Rossi, Derrick 1 153310565 Czechowicz, Agnieszka Boston Children’s Hospital Czechowicz, Agnieszka 2 153310578 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 3 153310582 Li, Zhanzhuo NIAID - DIR NIAID Li, Zhanzhuo (NIAID) 4 153310560 Rossi, Derrick Childrens Medical Center Corporation, Children's Hospital Rossi, Derrick 1 153310565 Czechowicz, Agnieszka Boston Children’s Hospital Czechowicz, Agnieszka 2 153310578 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 3 153310582 Li, Zhanzhuo NIAID - DIR NIAID Li, Zhanzhuo (NIAID) 4 153310555 Antibody-mediated Conditioning With Immunosuppression To Enable Allogeneic Transplantation E-102-2018-0 Filing authorized Childrens Medical Center Corporation, Children's Hospital, NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-4917] Advancements in Hematopoietic Stem Cell Transplantation: Non-Toxic Conditioning with CD117-Targeted Monoclonal Antibodies&body=Please send me information about technology [TAB-4917] Advancements in Hematopoietic Stem Cell Transplantation: Non-Toxic Conditioning with CD117-Targeted Monoclonal Antibodies. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-4917] Advancements in Hematopoietic Stem Cell Transplantation: Non-Toxic Conditioning with CD117-Targeted Monoclonal Antibodies&body=Please send me information about technology [TAB-4917] Advancements in Hematopoietic Stem Cell Transplantation: Non-Toxic Conditioning with CD117-Targeted Monoclonal Antibodies.">dawn.taylor-mulneix@nih.gov</a><br> 163477210 E-102-2018-0 E-102-2018-0-US-02 ANTIBODY-MEDIATED CONDITIONING WITH IMMUNOSUPPRESSION TO ENABLE ALLOGENEICTRANSPLANTATION CON US 19/273,430 Pending US <br />Continuation (CON) 19/273,430<br />Filed on 2025-07-18<br />Status: Pending TAB-4916 153310356 Clonal Lineage Antibodies: Pioneering HIV-1 Vaccine Design NIAID Antibodies, Collaboration, Infectious Disease, Licensing, Therapeutics Antibodies Collaboration Infectious Disease Licensing Therapeutics Scott Boyd, Andrew Fire, Barton Haynes, Thomas Kepler, John Mascola <p>The technology focuses on developing clonal lineage antibodies targeting the CD4 binding site of HIV-1, serving as templates for an effective HIV-1 vaccine. Developed through collaboration with Duke, Boston, and Stanford Universities, the patent filed by Duke University in 2012. These antibodies exhibit neutralizing activity against HIV-1, designed for therapeutic and prophylactic benefits, targeting a critical site of vulnerability on the virus to stimulate the immune system. Currently in the discovery stage, ongoing research focuses on characterizing antibodies and optimizing their efficacy as vaccine candidates, potentially revolutionizing HIV-1 vaccine development with a novel and targeted approach.</p> <p>&nbsp;</p> The technology offers several competitive advantages in the field of HIV-1 vaccine design. Firstly, the approach targets the CD4 binding site, a critical and conserved region of the virus, which allows for the development of broadly neutralizing antibodies effective against a wide range of HIV-1 strains. This specificity enhances the potential efficacy of the vaccine compared to traditional approaches. Additionally, the collaboration with leading universities has enabled access to cutting-edge research and expertise, ensuring that the technology remains at the forefront of innovation in the field. Furthermore, the patent protection provides a strong foundation for commercialization, offering a unique and valuable asset in the competitive landscape of HIV-1 vaccine development. The technology holds promise for diverse applications, particularly in vaccine development and therapeutic antibody production. By targeting the CD4 binding site of HIV-1, these clonal lineage antibodies could serve as potent templates for an effective HIV-1 vaccine, addressing a critical need in global health. Additionally, the antibodies may be utilized as therapeutic agents for treating HIV-1 infection, offering a novel approach to managing the disease. Beyond HIV-1, the technology's innovative targeting strategy could be adapted for other infectious diseases or cancer, where similar molecular targets are present, potentially revolutionizing treatment approaches in these areas as well. 2024-02-26 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153310425 Kepler, Thomas Duke University Kepler, Thomas 1 153310448 Mascola, John NIAID Mascola, John (NIAID) 2 153310453 Haynes, Barton Duke University Haynes, Barton 3 153310457 Boyd, Scott Stanford University (aka Leland Stanford Junior University) Boyd, Scott 4 153310462 Fire, Andrew Stanford University (aka Leland Stanford Junior University) Fire, Andrew 5 153310425 Kepler, Thomas Duke University Kepler, Thomas 1 153310448 Mascola, John NIAID Mascola, John (NIAID) 2 153310453 Haynes, Barton Duke University Haynes, Barton 3 153310457 Boyd, Scott Stanford University (aka Leland Stanford Junior University) Boyd, Scott 4 153310462 Fire, Andrew Stanford University (aka Leland Stanford Junior University) Fire, Andrew 5 153310359 Clonal Lineage Antibodies E-102-2014-0 Filing authorized Duke University, Duke University School of Medicine, NIAID, Stanford University 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4916] Clonal Lineage Antibodies: Pioneering HIV-1 Vaccine Design&body=Please send me information about technology [TAB-4916] Clonal Lineage Antibodies: Pioneering HIV-1 Vaccine Design. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4916] Clonal Lineage Antibodies: Pioneering HIV-1 Vaccine Design&body=Please send me information about technology [TAB-4916] Clonal Lineage Antibodies: Pioneering HIV-1 Vaccine Design.">wade.green@nih.gov</a><br> TAB-4915 153308455 Enhanced Neutralization Breadth of Bispecific Antibodies Against HIV-1 Env NIAID Antibodies, Collaboration, Diagnostics, Human Cell Lines, Immunology, Infectious Disease, Licensing, Therapeutics, Vaccines Antibodies Collaboration Diagnostics Human Cell Lines Immunology Infectious Disease Licensing Therapeutics Vaccines Javier Guenaga, Yuxing Li, John Mascola, James Steinhardt <p>The technology described pertains to the development of bispecific antibodies with enhanced ability to neutralize HIV-1. By structurally designing single chain fragment variable antibodies that join variable regions of multiple broadly neutralizing antibodies (bNAbs) with flexible linkers, the research has yielded a bispecific antibody that targets different epitopes on the HIV-1 envelope. The combination of VRC01&mdash;targeting the CD4 binding site&mdash;and PGT121&mdash;targeting the V3 glycan&mdash;has shown promising results. In tests against a stringent virus panel, the optimized VRC01-PGT121 bispecific antibody demonstrated 100% coverage and potent neutralization of HIV-1, suggesting a significant advancement in HIV-1 therapeutic strategies.</p> <p>&nbsp;</p> The bispecific antibody design offers a competitive edge by combining the neutralization capabilities of two potent bNAbs, VRC01 and PGT121, against HIV-1, thereby enhancing both potency and breadth of viral coverage. This dual-targeting approach has demonstrated complete neutralization of a panel of highly resistant HIV-1 strains, indicating superior efficacy compared to traditional monoclonal antibodies. This bispecific antibody technology has the potential to revolutionize HIV-1 therapeutic and prophylactic strategies. Its enhanced neutralization breadth and potency could lead to more effective treatments for individuals with HIV, potentially reducing the viral load more efficiently than current monoclonal antibody therapies. Additionally, its ability to neutralize resistant HIV-1 strains may offer a new line of defense in preventing the spread of the virus, particularly in vaccine development where broad coverage is crucial. This could also pave the way for new diagnostics to monitor HIV-1 response to treatment, as well as inform the design of future vaccines and therapeutic agents. 2024-02-26 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153308512 Steinhardt, James University of Maryland, School of Medicine Steinhardt, James 1 153308518 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 2 153308524 Li, Yuxing University of Maryland, School of Medicine Li, Yuxing 3 153308554 Guenaga, Javier International AIDS Vaccine Initiative, Inc. NIAID Guenaga, Javier (NIAID) 4 153308512 Steinhardt, James University of Maryland, School of Medicine Steinhardt, James 1 153308518 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 2 153308524 Li, Yuxing University of Maryland, School of Medicine Li, Yuxing 3 153308554 Guenaga, Javier International AIDS Vaccine Initiative, Inc. NIAID Guenaga, Javier (NIAID) 4 153308458 Multi-Specific Antibodies Targeting Human Immunodeficiency Virus And Methods Of Using The Same E-101-2018-0 Filing authorized International AIDS Vaccine Initiative, Inc., NIAID, University of Maryland 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4915] Enhanced Neutralization Breadth of Bispecific Antibodies Against HIV-1 Env&body=Please send me information about technology [TAB-4915] Enhanced Neutralization Breadth of Bispecific Antibodies Against HIV-1 Env. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4915] Enhanced Neutralization Breadth of Bispecific Antibodies Against HIV-1 Env&body=Please send me information about technology [TAB-4915] Enhanced Neutralization Breadth of Bispecific Antibodies Against HIV-1 Env.">wade.green@nih.gov</a><br> TAB-4911 153012351 Isolating Potent CD8+ T Cell Receptors from HIV Controllers for Advanced Therapies NIAID Collaboration, Diagnostics, Human Cell Lines, Immunology, Infectious Disease, Licensing, Plasmids/Vectors, Rare/Neglected Diseases, Research Materials, Therapeutics Collaboration Diagnostics Human Cell Lines Immunology Infectious Disease Licensing Plasmids/Vectors Rare/Neglected Diseases Research Materials Therapeutics Mark Connors, Stephen Migueles, Peter Rhode, Hing Wong <p>Novel CD8+ T cell receptors (TCRs) isolated from elite HIV controllers show unprecedented affinity for conserved HIV epitopes, offering new avenues for direct immunotherapies and T cell engineering. These TCRs exhibit potential for cytotoxicity mediation against HIV-infected cells, with prospects for use in toxin-coupled treatments or as part of engineered T cell therapies. Collaborations, such as with Altor Biosciences, are enhancing these TCRs with proprietary molecules like IL-15, to bolster therapeutic efficacy.</p> The isolated TCRs from HIV elite controllers represent a significant leap forward, possessing an unrivaled specificity for conserved HIV sequences. Their high affinity and cytotoxic potential position them at the forefront of immunotherapy, outpacing previous technologies that lacked such precision. The capability to engineer these TCRs into T cells or pair them with cytotoxic agents opens up powerful treatment modalities. These high-affinity TCRs have the potential to revolutionize HIV treatment, with applications ranging from adoptive cell therapies, where T cells are engineered to express these receptors and target the virus more effectively, to the creation of TCR-based biologics. They could also pave the way for the development of new vaccine strategies or serve as research tools to further understand the mechanisms of HIV control. Additionally, the adaptability of these TCRs may allow for their use in other viral infections where antigen conservation is key, showcasing their versatility and broad therapeutic implications. 2024-02-20 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153012358 Connors, Mark NIAID - DIR NIAID Connors, Mark (NIAID) 1 153012362 Migueles, Stephen NIAID Migueles, Stephen (NIAID) 2 153012382 Wong, Hing Altor BioScience Corp. (acq by NantWorks 6/27/17; merged Immunity Bio 6/3/19) [U Wong, Hing 3 153012386 Rhode, Peter Rhode, Peter 4 153012358 Connors, Mark NIAID - DIR NIAID Connors, Mark (NIAID) 1 153012362 Migueles, Stephen NIAID Migueles, Stephen (NIAID) 2 153012382 Wong, Hing Altor BioScience Corp. (acq by NantWorks 6/27/17; merged Immunity Bio 6/3/19) [U Wong, Hing 3 153012386 Rhode, Peter Rhode, Peter 4 153012354 HIV-Specific CD8+ T Cell Receptors From Long-Term Nonprogressors/Elite Controllers E-096-2019-0 Filing authorized Altor BioScience Corporation, NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4911] Isolating Potent CD8+ T Cell Receptors from HIV Controllers for Advanced Therapies&body=Please send me information about technology [TAB-4911] Isolating Potent CD8+ T Cell Receptors from HIV Controllers for Advanced Therapies. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4911] Isolating Potent CD8+ T Cell Receptors from HIV Controllers for Advanced Therapies&body=Please send me information about technology [TAB-4911] Isolating Potent CD8+ T Cell Receptors from HIV Controllers for Advanced Therapies.">benjamin.hurley@nih.gov</a><br> TAB-4910 153011058 Enhancing Malaria Resistance: CIS43 Monoclonal Antibody Variants with Increased Protective Efficacy NIAID Antibodies, Collaboration, Infectious Disease, Licensing, Research Materials, Therapeutics, Vaccines Antibodies Collaboration Infectious Disease Licensing Research Materials Therapeutics Vaccines Gwo-yu Chauang, Joseph Francica, Sven Kratochvil, Peter Kwong, Reda Rawi, Mateo Reveiz, Robert Seder, Chen-Hsiang Shen, Prabhanshu Tripathi, Kai Xu <p>The CIS43 antibody represents a cutting-edge advancement in the fight against malaria, a disease caused by Plasmodium parasites and transmitted by mosquitoes. CIS43 targets the junctional epitope of the Plasmodium falciparum circumsporozoite protein, showing promising efficacy in preventing malaria infection in controlled human infection-based studies. The latest developments have focused on generating improved variants of CIS43 with enhanced protective capabilities. Through an innovative mouse model using B cells with the inferred germline version of CIS43, researchers have successfully identified and isolated potent CIS43 variants. These variants, produced via somatic hypermutation and epitope-contact residue optimization, offer a 3-5 fold increase in protection over the original CIS43. This progress marks a significant stride towards a more effective prophylactic strategy against malaria, with potential implications for vaccine development and antibody-based interventions.</p> <p>&nbsp;</p> The CIS43 antibody variants stand out in the competitive landscape of malaria prophylactics with their heightened efficacy—a 3-5 fold increase in malaria protection compared to the original antibody. This superior performance is rooted in the targeted somatic hypermutation and fine-tuning of epitope-contact residues, ensuring a robust immune response. The use of a novel mouse model that mimics the human immune response to the Plasmodium falciparum circumsporozoite protein further underscores the potential for these variants to transition smoothly from pre-clinical studies to human trials. The CIS43 antibody variants stand at the forefront of malaria intervention, offering a substantial competitive advantage with their markedly improved protective efficacy against the Plasmodium falciparum circumsporozoite protein. The leap in efficacy is achieved through informed enhancements in the antibodies' binding affinity, a result of targeted somatic hypermutations—a feature that sets these variants apart from other prophylactic options. The refined specificity and enhanced potency could translate to longer-lasting immunity, lower dosages, and greater cost-effectiveness, all of which are critical factors in the global battle against malaria, particularly in regions where the disease burden is highest. 2024-02-20 2026-08-26 2026-08-26 2026-08-26 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 153011072 Kratochvil, Sven Massachusetts General Hospital Kratochvil, Sven 1 153011076 Shen, Chen-Hsiang NIAID - VRC NIAID Shen, Chen-Hsiang (NIAID) 2 153011080 Reveiz, Mateo NIAID - VRC NIAID Reveiz, Mateo (NIAID) 3 153011197 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 4 153011201 Chauang, Gwo-yu Chauang, Gwo-yu 5 153011208 Seder, Robert NIAID - VRC NIAID Seder, Robert (NIAID) 6 153011222 Francica, Joseph NIAID - VRC NIAID Francica, Joseph (NIAID) 7 153011226 Xu, Kai NIAID - DIR NIAID Xu, Kai (NIAID) 8 153011230 Tripathi, Prabhanshu NIAID - VRC NIAID Tripathi, Prabhanshu (NIAID) 9 153011238 Rawi, Reda NIAID - VRC NIAID Rawi, Reda (NIAID) 10 153011072 Kratochvil, Sven Massachusetts General Hospital Kratochvil, Sven 1 153011076 Shen, Chen-Hsiang NIAID - VRC NIAID Shen, Chen-Hsiang (NIAID) 2 153011080 Reveiz, Mateo NIAID - VRC NIAID Reveiz, Mateo (NIAID) 3 153011197 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 4 153011201 Chauang, Gwo-yu Chauang, Gwo-yu 5 153011208 Seder, Robert NIAID - VRC NIAID Seder, Robert (NIAID) 6 153011222 Francica, Joseph NIAID - VRC NIAID Francica, Joseph (NIAID) 7 153011226 Xu, Kai NIAID - DIR NIAID Xu, Kai (NIAID) 8 153011230 Tripathi, Prabhanshu NIAID - VRC NIAID Tripathi, Prabhanshu (NIAID) 9 153011238 Rawi, Reda NIAID - VRC NIAID Rawi, Reda (NIAID) 10 153011061 CIS43 Antibody Variants With Improved Malaria Protective Efficacy E-095-2021-0 Filing authorized Massachusetts General Hospital, NIAID 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-4910] Enhancing Malaria Resistance: CIS43 Monoclonal Antibody Variants with Increased Protective Efficacy&body=Please send me information about technology [TAB-4910] Enhancing Malaria Resistance: CIS43 Monoclonal Antibody Variants with Increased Protective Efficacy. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-4910] Enhancing Malaria Resistance: CIS43 Monoclonal Antibody Variants with Increased Protective Efficacy&body=Please send me information about technology [TAB-4910] Enhancing Malaria Resistance: CIS43 Monoclonal Antibody Variants with Increased Protective Efficacy.">polung.yang@nih.gov</a><br> TAB-4908 153009973 Development of a Novel mRNA-Based Immunization Strategy for Inducing Protective Immunity to HIV NIAID Collaboration, Infectious Disease, Licensing, Rare/Neglected Diseases, TherapeuticArea, Vaccines Collaboration Infectious Disease Licensing Rare/Neglected Diseases TherapeuticArea Vaccines Giuseppe Ciaramella, Paolo Lusso, Elisabeth Narayanan, Peng Zhang <p>This innovative HIV immunization strategy relies on mRNA technology to prime and boost immune responses, using full-length or minimally truncated Env proteins to maintain native conformation for effective membrane expression. Co-formulating Env and Gag proteins promotes virus-like particle (VLP) production in vivo, mimicking HIV&#39;s structure for better immune recognition. The regimen involves an intensive schedule of 8+ sequential immunizations and includes boosting with diverse Envs from different HIV-1 clades to broaden the immune response. By using only glycan-repaired, tier-2 Env immunogens, the strategy avoids vaccine-irrelevant epitopes and glycan holes that could elicit non-neutralizing antibodies, focusing the immune response on generating broadly neutralizing antibodies.</p> <p>&nbsp;</p> This mRNA-based HIV immunization strategy offers unique advantages. Its adaptability to new viral strains is unmatched, crucial for combating HIV's genetic diversity. By maintaining native protein conformation, it enhances immune recognition, and co-formulating Env and Gag promotes potent immune responses. The intensive schedule and diverse boosting aim to elicit broadly neutralizing antibodies, a key challenge in HIV vaccine development. Additionally, its focus on glycan-repaired Env minimizes the risk of non-neutralizing antibody responses, potentially enhancing vaccine efficacy. This mRNA-based immunization strategy has broad potential applications. Its adaptability allows for rapid development of vaccines against new pathogens, vital for pandemic response. The strategy's ability to induce potent immune responses and generate broadly neutralizing antibodies makes it promising for vaccines against challenging viruses like influenza. Additionally, its flexibility enables personalized cancer vaccines, harnessing the immune system against specific tumor antigens. This approach could revolutionize vaccine development and enhance our ability to prevent and treat various diseases. 2024-02-20 2026-08-26 2026-08-26 2026-08-26 False True True 72159138 Clinical Phase I 72159138 37470483 Website Abstract 153009997 Narayanan, Elisabeth Moderna Therapeutics, Inc. Narayanan, Elisabeth 1 153010019 Lusso, Paolo NIAID - DIR NIAID Lusso, Paolo (NIAID) 2 153010036 Zhang, Peng NIAID - DIR NIAID Zhang, Peng (NIAID) 3 153010053 Ciaramella, Giuseppe Beam Therapeutics, Inc. (BTI) Ciaramella, Giuseppe 4 153009997 Narayanan, Elisabeth Moderna Therapeutics, Inc. Narayanan, Elisabeth 1 153010019 Lusso, Paolo NIAID - DIR NIAID Lusso, Paolo (NIAID) 2 153010036 Zhang, Peng NIAID - DIR NIAID Zhang, Peng (NIAID) 3 153010053 Ciaramella, Giuseppe Beam Therapeutics, Inc. (BTI) Ciaramella, Giuseppe 4 153009976 Induction Of Protective Immunity To HIV By An MRNA-based Vaccine E-095-2019-0 Filing authorized Moderna Therapeutics, Inc., ModernaTX, Inc., NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4908] Development of a Novel mRNA-Based Immunization Strategy for Inducing Protective Immunity to HIV&body=Please send me information about technology [TAB-4908] Development of a Novel mRNA-Based Immunization Strategy for Inducing Protective Immunity to HIV. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4908] Development of a Novel mRNA-Based Immunization Strategy for Inducing Protective Immunity to HIV&body=Please send me information about technology [TAB-4908] Development of a Novel mRNA-Based Immunization Strategy for Inducing Protective Immunity to HIV.">benjamin.hurley@nih.gov</a><br> TAB-4909 153010385 Enhanced Immunogenicity via Alphavirus VLPs: A Novel Malaria Vaccine Strategy Targeting PfCSP Junctional Epitopes NIAID Animal Models, Collaboration, Infectious Disease, Licensing, Vaccines Animal Models Collaboration Infectious Disease Licensing Vaccines Gwo-yu Chauang, S. Farney, Joseph Francica, Peter Kwong, John Mascola, Li Ou, Robert Seder, Wei Shi <p>This technology entails a novel vaccine design against malaria, employing an alphavirus Virus-Like Particle (VLP) system to present a critical epitope from the Plasmodium falciparum circumsporozoite protein (PfCSP). The vaccine targets the junctional region between the N-terminus and the central repeat domain of PfCSP, a segment previously identified as vital for generating protective immunity. The VLPs are engineered by fusing the PfCSP junctional region to components of the Chikungunya virus (CHIKV), maintaining structural integrity critical for immunogenicity, as confirmed by negative-stain electron microscopy.</p> The competitive edge of this vaccine technology lies in its targeted approach to eliciting a robust immune response. By focusing on the junctional epitope of the Plasmodium falciparum circumsporozoite protein (PfCSP), the vaccine offers a highly specific attack on a crucial stage of the malaria parasite's life cycle. The use of alphavirus Virus-Like Particles (VLPs) enables a structural mimicry that is superior to traditional vaccine carriers, enhancing the immune system's ability to recognize and remember the pathogen. This vaccine technology has the potential to revolutionize malaria prevention. Its application could be far-reaching, from being incorporated into global vaccination programs in malaria-endemic regions to serving as a travel vaccine for tourists and military personnel. Moreover, the underlying technology of using virus-like particles to present specific epitopes could be adapted to create vaccines for other parasitic diseases, thereby broadening its impact on global health. With its demonstrated pre-clinical success, this vaccine could be a critical tool in the worldwide effort to eradicate malaria. 2024-02-20 2026-08-26 2026-08-26 2026-08-26 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 153010397 Farney, S. NIAID - VRC NIAID Farney, S. (NIAID) 1 153010524 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 2 153010590 Francica, Joseph NIAID Francica, Joseph (NIAID) 3 153010614 Chauang, Gwo-yu Chauang, Gwo-yu 4 153010788 Ou, Li NIAID - VRC NIAID Ou, Li (NIAID) 5 153010870 Shi, Wei NIAID - VRC NIAID Shi, Wei (NIAID) 6 153010874 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 7 153010878 Seder, Robert NIAID - VRC NIAID Seder, Robert (NIAID) 8 153010397 Farney, S. NIAID - VRC NIAID Farney, S. (NIAID) 1 153010524 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 2 153010590 Francica, Joseph NIAID Francica, Joseph (NIAID) 3 153010614 Chauang, Gwo-yu Chauang, Gwo-yu 4 153010788 Ou, Li NIAID - VRC NIAID Ou, Li (NIAID) 5 153010870 Shi, Wei NIAID - VRC NIAID Shi, Wei (NIAID) 6 153010874 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 7 153010878 Seder, Robert NIAID - VRC NIAID Seder, Robert (NIAID) 8 153010388 Structure-based Vaccine Design Of An Alphavirus-VLP Presenting A Junctional CSP Epitope Elicits Protection Against Malaria E-094-2021-0 Filing authorized NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4909] Enhanced Immunogenicity via Alphavirus VLPs: A Novel Malaria Vaccine Strategy Targeting PfCSP Junctional Epitopes&body=Please send me information about technology [TAB-4909] Enhanced Immunogenicity via Alphavirus VLPs: A Novel Malaria Vaccine Strategy Targeting PfCSP Junctional Epitopes. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4909] Enhanced Immunogenicity via Alphavirus VLPs: A Novel Malaria Vaccine Strategy Targeting PfCSP Junctional Epitopes&body=Please send me information about technology [TAB-4909] Enhanced Immunogenicity via Alphavirus VLPs: A Novel Malaria Vaccine Strategy Targeting PfCSP Junctional Epitopes.">sabrina.hafiz@nih.gov</a><br> TAB-4907 153008935 Enhancing Vaccine Efficacy: The Role of HA-Ferritin Nanoparticle Mutation in Protein Production NIAID Collaboration, Infectious Disease, Licensing, Research Equipment, Vaccines Collaboration Infectious Disease Licensing Research Equipment Vaccines Barney Graham, Masaru Kanekiyo, Gary Nabel, James Whittle <p>The technology involves the development of viral hemagglutinin (HA) mutants that enhance the binding affinity to sialic acid (SA) receptors on host cell surfaces. This enhanced interaction is achieved by introducing specific mutations into the HA protein, leading to increased immunogenicity and vaccine efficacy. The mutated HA proteins are then incorporated into ferritin nanoparticles, which serve as a delivery platform to enhance protein production and stability. This technology shows promise in improving vaccine design and efficacy against viral infections.</p> <p>&nbsp;</p> This technology offers competitive advantages by enhancing vaccine immunogenicity through improved HA-SA binding affinity and increased protein stability using ferritin nanoparticles. These advantages could lead to more effective vaccines, targeted against specific viral strains, and potentially reduce the risk of viral escape mutants. This technology has the potential to revolutionize vaccine development for a range of viral infections. By enhancing the immunogenicity of vaccines through improved HA-SA binding, it could lead to more effective vaccines against influenza, Zika virus, and other diseases. The use of ferritin nanoparticles also opens up possibilities for developing vaccines against other pathogens, including bacteria and parasites. Additionally, this technology could be applied to enhance existing vaccines, improving their efficacy and potentially reducing the need for frequent updates. 2024-02-20 2026-08-26 2026-08-26 2026-08-26 False True True 72159134 Analytical Assay Performance Stage 72159134 37470483 Website Abstract 153008969 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 1 153009080 Graham, Barney Morehouse School of Medicine NIAID Graham, Barney (NIAID) 2 153009108 Nabel, Gary National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Nabel, Gary (NIAID) 3 153009155 Whittle, James George Washington University Whittle, James 4 153008969 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 1 153009080 Graham, Barney Morehouse School of Medicine NIAID Graham, Barney (NIAID) 2 153009108 Nabel, Gary National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Nabel, Gary (NIAID) 3 153009155 Whittle, James George Washington University Whittle, James 4 153008938 Influenza Hemaglutinin (HA) Engineered To Knock Out Sialic Acid (SA)binding Capability To Improve Immunogenicity And Prevent Selfaggregation Of HA-based Immunogens E-094-2014-0 Research Material NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4907] Enhancing Vaccine Efficacy: The Role of HA-Ferritin Nanoparticle Mutation in Protein Production&body=Please send me information about technology [TAB-4907] Enhancing Vaccine Efficacy: The Role of HA-Ferritin Nanoparticle Mutation in Protein Production. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4907] Enhancing Vaccine Efficacy: The Role of HA-Ferritin Nanoparticle Mutation in Protein Production&body=Please send me information about technology [TAB-4907] Enhancing Vaccine Efficacy: The Role of HA-Ferritin Nanoparticle Mutation in Protein Production.">wade.green@nih.gov</a><br> TAB-4906 153008285 Bispecific Antibodies: A Novel Approach to Treating Ebola Virus Infections NIAID Antibodies, Collaboration, Diagnostics, Human Cell Lines, Infectious Disease, Licensing, Rare/Neglected Diseases, Therapeutics Antibodies Collaboration Diagnostics Human Cell Lines Infectious Disease Licensing Rare/Neglected Diseases Therapeutics Mangaiarkarasi Asokan, Ke Bai, Megan DeMouth, Kendra Leigh, John Mascola, John Misasi, Olamide Oloniniyi, Amarendra ("Amar") Pegu, Aurelie Ploquin, Christopher Stringham, Nancy Sullivan <p>The described technology pertains to the development of bispecific antibodies targeting the Ebola virus glycoprotein. These antibodies, mAb114 and either S1-4-A09 or its engineered variant S1-4-A09 A80P, demonstrate specificity towards the Ebola virus (EBOV) glycoproteins from different strains, including Kikwit and Bundibugyo. The variant S1-4-A09 A80P retains binding specificity and activity but lacks a glycosylation motif, enhancing manufacturability without compromising function.</p> The bispecific antibodies technology offers several competitive advantages over existing treatments for Ebola virus infection. The BiSp107 combines the antigen-binding regions of two monoclonal antibodies, which may result in higher potency and efficacy due to synergistic effects on virus neutralization. This bispecific approach could potentially lead to lower required dosages, enhancing patient compliance and reducing treatment costs. The BiSp107 antibody technology is poised for application in a range of scenarios that extend beyond the immediate treatment of Ebola virus infection. Its design for use as both a prophylactic and a therapeutic agent broadens its utility significantly. Healthcare workers, military personnel, and individuals in Ebola-endemic regions could benefit from pre-exposure prophylaxis, offering a safeguard against potential outbreaks. 2024-02-20 2026-08-26 2026-08-26 2026-08-26 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 153008292 Pegu, Amarendra ("Amar") NIAID - VRC NIAID Pegu, Amarendra ("Amar") (NIAID) 1 153008296 Ploquin, Aurelie Ploquin, Aurelie 2 153008354 Stringham, Christopher NIAID - VRC NIAID Stringham, Christopher (NIAID) 3 153008358 Bai, Ke National Institute on Deafness and Other Communication Disorders (NIDCD) NCI Bai, Ke (NCI) 4 153008362 DeMouth, Megan Albert Einstein College of Medicine DeMouth, Megan 5 153008420 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 6 153008462 Misasi, John NIAID - VRC NIAID Misasi, John (NIAID) 7 153008466 Asokan, Mangaiarkarasi Asokan, Mangaiarkarasi 8 153008485 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 9 153008515 Leigh, Kendra NIAID Leigh, Kendra (NIAID) 10 153008576 Oloniniyi, Olamide Oloniniyi, Olamide 11 153008292 Pegu, Amarendra ("Amar") NIAID - VRC NIAID Pegu, Amarendra ("Amar") (NIAID) 1 153008296 Ploquin, Aurelie Ploquin, Aurelie 2 153008354 Stringham, Christopher NIAID - VRC NIAID Stringham, Christopher (NIAID) 3 153008358 Bai, Ke National Institute on Deafness and Other Communication Disorders (NIDCD) NCI Bai, Ke (NCI) 4 153008362 DeMouth, Megan Albert Einstein College of Medicine DeMouth, Megan 5 153008420 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 6 153008462 Misasi, John NIAID - VRC NIAID Misasi, John (NIAID) 7 153008466 Asokan, Mangaiarkarasi Asokan, Mangaiarkarasi 8 153008485 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 9 153008515 Leigh, Kendra NIAID Leigh, Kendra (NIAID) 10 153008576 Oloniniyi, Olamide Oloniniyi, Olamide 11 153008288 Bispecific Antibodies To Ebola Virus Glycoprotein And Their Use E-090-2021-0 Filing authorized NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4906] Bispecific Antibodies: A Novel Approach to Treating Ebola Virus Infections&body=Please send me information about technology [TAB-4906] Bispecific Antibodies: A Novel Approach to Treating Ebola Virus Infections. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4906] Bispecific Antibodies: A Novel Approach to Treating Ebola Virus Infections&body=Please send me information about technology [TAB-4906] Bispecific Antibodies: A Novel Approach to Treating Ebola Virus Infections.">wade.green@nih.gov</a><br> TAB-4905 153007854 Bolstering HIV Vaccine Development: MVA Vector Expressing Functional B13R Gene NIAID Collaboration, Infectious Disease, Licensing, Plasmids/Vectors, Vaccines Collaboration Infectious Disease Licensing Plasmids/Vectors Vaccines Bernard Moss, Linda Wyatt <p>The technology involves the use of Modified Vaccinia Ankara (MVA) as a vaccine vector for HIV. MVA is a safe and immunogenic poxvirus vector that can accommodate large gene insertions. In this case, researchers have modified MVA to express a functional B13R gene, which helps delay apoptosis (cell death) of infected cells. This modification aims to enhance the immune response against HIV. The technology has shown promise in pre-clinical studies, demonstrating its potential as a candidate for an HIV vaccine.</p> <p>&nbsp;</p> The use of Modified Vaccinia Ankara (MVA) as a vaccine vector for HIV offers a compelling advantage due to its safety, immunogenicity, and capacity for large gene insertions. By expressing a functional B13R gene, MVA enhances the immune response against HIV by delaying cell death, potentially leading to a more effective vaccine. These characteristics position MVA as a strong candidate for developing a preventative HIV vaccine, addressing a critical need in combating the spread of the virus. The application of Modified Vaccinia Ankara (MVA) as a vaccine vector for HIV has broad implications beyond HIV prevention. MVA's safety profile, immunogenicity, and ability to accommodate large gene insertions make it a versatile platform for developing vaccines against various infectious diseases and cancers. Its potential applications include the development of vaccines for other viral infections, such as influenza, Ebola, and Zika virus, as well as for certain types of cancer. Additionally, MVA-based vaccines could be used in combination with existing therapies to enhance their efficacy or as part of a preventive strategy in outbreak situations. 2024-02-20 2026-08-26 2026-08-26 2026-08-26 False True True 72159138 Clinical Phase I 72159138 37470483 Website Abstract 153007861 Wyatt, Linda National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Wyatt, Linda (NIAID) 1 153007869 Moss, Bernard NIAID - DIR NIAID Moss, Bernard (NIAID) 2 153007861 Wyatt, Linda National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Wyatt, Linda (NIAID) 1 153007869 Moss, Bernard NIAID - DIR NIAID Moss, Bernard (NIAID) 2 153007857 Delaying MVA Induced Apoptosis For Enhancing Immunogenicity (B13R) E-090-2017-0 Filing authorized NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4905] Bolstering HIV Vaccine Development: MVA Vector Expressing Functional B13R Gene&body=Please send me information about technology [TAB-4905] Bolstering HIV Vaccine Development: MVA Vector Expressing Functional B13R Gene. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4905] Bolstering HIV Vaccine Development: MVA Vector Expressing Functional B13R Gene&body=Please send me information about technology [TAB-4905] Bolstering HIV Vaccine Development: MVA Vector Expressing Functional B13R Gene.">jonathan.motley@nih.gov</a><br> TAB-4685 151875084 NeurEx®: A Mobile App for Streamlined Neurological Examination Documentation and Precise Disability Scale Computation NIAID Application, Collaboration, Computational models/software, Diagnostics, Licensing, Medical Devices, Neurology, Research Materials, Software / Apps Application Collaboration Computational models/software Diagnostics Licensing Medical Devices Neurology Research Materials Software / Apps Bibiana ('Bibi') Bielekova, Peter Kosa <p>This technology includes the NeurEx&reg; mobile application, a groundbreaking tool designed for neurologists to conduct and document neurological examinations efficiently. Deployed on iPads, it integrates with a secure, cloud-based database, automating the computation of four key disability scales used in neuroimmunology. The app&#39;s robust design enables precise mapping of neurological deficits, blending spatial distribution with quantitative assessments. Its effectiveness is underscored by a study involving 865 neurological exams, where the app&#39;s computed scales matched the accuracy of multiple sclerosis-trained clinicians. Crucially, NeurEx&reg; enhances the sensitivity and specificity in tracking disability progression, outperforming traditional scales like the EDSS. This makes it an invaluable asset not only in clinical settings but also in research and multicentric trials, offering a more economical and precise alternative to conventional documentation of neurological examinations.</p> Revolutionizes neurological assessment with its unparalleled precision in disability measurement, cost-effectiveness over traditional imaging, and seamless integration of comprehensive data analysis, setting a new standard in neurology practice and research. Offers transformative potential in neurology, streamlining patient assessments in clinical practice, enhancing the precision of research in neuroimmunology, and revolutionizing data gathering in multicentric trials and studies. 2023-12-20 2026-08-26 2026-08-26 2026-08-26 False True True 52406769 Prototype 52406769 37470483 Website Abstract 151875107 Kosa, P., et al. https://pubmed.ncbi.nlm.nih.gov/30349859/ <a href="https://pubmed.ncbi.nlm.nih.gov/30349859/">Kosa, P., et al.</a> 151875091 Kosa, Peter NIAID - DIR NIAID Kosa, Peter (NIAID) 1 151875099 Bielekova, Bibiana ('Bibi') NIAID - DIR NIAID Bielekova, Bibiana ('Bibi') (NIAID) 2 151875091 Kosa, Peter NIAID - DIR NIAID Kosa, Peter (NIAID) 1 151875099 Bielekova, Bibiana ('Bibi') NIAID - DIR NIAID Bielekova, Bibiana ('Bibi') (NIAID) 2 151875087 Development Of A Mobile Application, Called NeurEx, For Convenient Documentation Of A Neurological Examination, That Also Represents Highly Sensitive Neurological Disability Scale And Automatically Computes 4 Disability Scales Used In Neuroimmunology E-089-2021-0 Filing authorized NIAID 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-4685] NeurEx®: A Mobile App for Streamlined Neurological Examination Documentation and Precise Disability Scale Computation&body=Please send me information about technology [TAB-4685] NeurEx®: A Mobile App for Streamlined Neurological Examination Documentation and Precise Disability Scale Computation. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-4685] NeurEx®: A Mobile App for Streamlined Neurological Examination Documentation and Precise Disability Scale Computation&body=Please send me information about technology [TAB-4685] NeurEx®: A Mobile App for Streamlined Neurological Examination Documentation and Precise Disability Scale Computation.">polung.yang@nih.gov</a><br> TAB-4904 153007229 Characterization of Signal Regulatory Protein Alpha (SIRPα) Expression as a Biomarker of Functional CD8+ T Cell Activity During Immunological Exhaustion NIAID Antibodies, Collaboration, Diagnostics, Human Cell Lines, Immunology, Infectious Disease, Licensing, Oncology, Therapeutics Antibodies Collaboration Diagnostics Human Cell Lines Immunology Infectious Disease Licensing Oncology Therapeutics Kim Hasenkrug, Lara Myers, Michal Tal, Irving Weissman, Ying Yiu <p>The technology revolves around the discovery of SIRP&alpha; (Signal Regulatory Protein alpha) expression on CD8+ T cells as a novel biomarker for assessing T cell functionality during immune exhaustion, a state commonly induced by chronic infections and cancer. The unique expression profile of SIRP&alpha; on a subset of functional CD8+ T cells that retain cytotoxic capabilities despite an exhausted phenotype opens new avenues for therapeutic interventions. By counterbalancing inhibitory signals with costimulatory receptors, these SIRP&alpha;+ CD8+ T cells maintain their proliferative and IFN-gamma secreting abilities, offering a potential target for therapies aimed at reinvigorating T cell responses. Evaluating patients for SIRP&alpha; expression could enable the identification of individuals likely to benefit from checkpoint inhibitor treatments and aid in monitoring the efficacy of such therapies, significantly impacting the management of chronic infections and cancer immunotherapy.</p> The identification of SIRPα as a biomarker for functionally resilient CD8+ T cells during immunological exhaustion offers a competitive advantage in the field of precision immunotherapy. This discovery enables the stratification of patients who are most likely to respond to checkpoint inhibitors, thus optimizing treatment efficacy and potentially reducing the costs associated with less targeted therapies. Moreover, the ability to monitor SIRPα expression provides a real-time assessment of treatment efficacy, allowing for timely adjustments to therapeutic strategies. This biomarker also opens the possibility for the development of novel therapeutic agents that can specifically enhance the function of SIRPα+ CD8+ T cells, leading to improved outcomes for patients with chronic infections or cancer. Furthermore, as a prognostic tool, SIRPα expression can guide clinical decision-making, moving towards more personalized and effective care, and setting this technology apart in a rapidly evolving oncology landscape. The potential applications of SIRPα expression profiling are vast and transformative, particularly within personalized medicine. In oncology, assessing SIRPα levels could refine patient selection for immunotherapies, leading to improved response rates and personalized treatment plans. For chronic infectious diseases, this biomarker could predict the durability of the immune response, guiding vaccine development and therapeutic interventions. 2024-02-20 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153007241 Tal, Michal Stanford University (aka Leland Stanford Junior University) Tal, Michal 1 153007533 Yiu, Ying Stanford University (aka Leland Stanford Junior University) Yiu, Ying 2 153007579 Myers, Lara NIAID - DIR NIAID Myers, Lara (NIAID) 3 153007583 Weissman, Irving Stanford University Weissman, Irving 4 153007587 Hasenkrug, Kim NIAID - DIR NIAID Hasenkrug, Kim (NIAID) 5 153007241 Tal, Michal Stanford University (aka Leland Stanford Junior University) Tal, Michal 1 153007533 Yiu, Ying Stanford University (aka Leland Stanford Junior University) Yiu, Ying 2 153007579 Myers, Lara NIAID - DIR NIAID Myers, Lara (NIAID) 3 153007583 Weissman, Irving Stanford University Weissman, Irving 4 153007587 Hasenkrug, Kim NIAID - DIR NIAID Hasenkrug, Kim (NIAID) 5 153007232 SIRPalpha Expression On T Cells Is A Biomarker For Functional T Cells During Exhaustion E-089-2019-0 Filing authorized NIAID, Stanford University, Stanford University (aka Leland Stanford Junior University) 146046171 Joyce, Terrence terrence.joyce@nih.gov
United States of America terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-4904] Characterization of Signal Regulatory Protein Alpha (SIRPα) Expression as a Biomarker of Functional CD8+ T Cell Activity During Immunological Exhaustion&body=Please send me information about technology [TAB-4904] Characterization of Signal Regulatory Protein Alpha (SIRPα) Expression as a Biomarker of Functional CD8+ T Cell Activity During Immunological Exhaustion. Joyce, Terrence<br><a href="mailto:terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-4904] Characterization of Signal Regulatory Protein Alpha (SIRPα) Expression as a Biomarker of Functional CD8+ T Cell Activity During Immunological Exhaustion&body=Please send me information about technology [TAB-4904] Characterization of Signal Regulatory Protein Alpha (SIRPα) Expression as a Biomarker of Functional CD8+ T Cell Activity During Immunological Exhaustion.">terrence.joyce@nih.gov</a><br> TAB-4903 153006593 Novel Anti-Idiotype Monoclonal Antibodies for Monitoring Broadly Neutralizing HIV Antibody N6 NIAID Antibodies, Collaboration, Diagnostics, Infectious Disease Antibodies Collaboration Diagnostics Infectious Disease Wing-pui Kong, John Mascola, Wei Shi <p>The technology involves the development of two specific anti-idiotype monoclonal antibodies, N6-I and N6-2, which target a broadly neutralizing monoclonal antibody (mAb), N6, known for its effectiveness against HIV. These anti-idiotype antibodies are crucial for detecting and monitoring the N6 mAb&#39;s quality and quantity in various settings, including in vivo, in vitro, and in clinical trials.</p> <p>These antibodies are essential tools for researchers and clinicians working on HIV prevention and treatment strategies. They enable the accurate measurement and tracking of the N6 mAb, which is vital for assessing its efficacy and optimizing its use in therapeutic and preventive interventions. The development of these anti-idiotype antibodies represents a significant advancement in HIV research and could lead to improved strategies for combating the virus.</p> The competitive advantages of the developed anti-idiotype monoclonal antibodies, N6-I and N6-2, lie in their specificity and utility for monitoring the broadly neutralizing HIV antibody N6. These antibodies offer a precise and reliable method for detecting and quantifying N6 mAb in various biological samples, providing researchers and clinicians with a valuable tool for assessing the efficacy of HIV therapies and vaccines. The anti-idiotype monoclonal antibodies, N6-I and N6-2, have diverse applications in HIV research and clinical care. They enable precise monitoring of the broadly neutralizing HIV antibody N6, offering insights into HIV pathogenesis and immune responses. These antibodies are valuable for evaluating new HIV therapies and vaccines, optimizing treatment strategies, and improving patient outcomes. They also have potential applications in the development of novel HIV interventions by assessing immune responses to these treatments. 2024-02-20 2026-08-26 2026-08-26 2026-08-26 False True True 72159144 Investigational Device Exemption - Feasibility Study 72159144 37470483 Website Abstract 153006600 Mascola, John NIAID Mascola, John (NIAID) 1 153006604 Shi, Wei Nanjing Normal University Shi, Wei 2 153006608 Kong, Wing-pui NIAID - VRC NIAID Kong, Wing-pui (NIAID) 3 153006600 Mascola, John NIAID Mascola, John (NIAID) 1 153006604 Shi, Wei Nanjing Normal University Shi, Wei 2 153006608 Kong, Wing-pui NIAID - VRC NIAID Kong, Wing-pui (NIAID) 3 153006596 Development Of Anti-idiotype Monoclonal Antibodies Against Anti-HIV Antibody N6 E-088-2019-0 Research Material NIAID 91025211 Rainwater, Charles crainwater@mail.nih.gov
United States of America crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-4903] Novel Anti-Idiotype Monoclonal Antibodies for Monitoring Broadly Neutralizing HIV Antibody N6&body=Please send me information about technology [TAB-4903] Novel Anti-Idiotype Monoclonal Antibodies for Monitoring Broadly Neutralizing HIV Antibody N6. Rainwater, Charles<br><a href="mailto:crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-4903] Novel Anti-Idiotype Monoclonal Antibodies for Monitoring Broadly Neutralizing HIV Antibody N6&body=Please send me information about technology [TAB-4903] Novel Anti-Idiotype Monoclonal Antibodies for Monitoring Broadly Neutralizing HIV Antibody N6.">crainwater@mail.nih.gov</a><br> TAB-4902 153002946 Enhanced Half-Life and ADCC Activity: Amino Acid Substitution in HIV Neutralizing Antibodies NIAID Antibodies, Collaboration, Human Cell Lines, Immunology, Infectious Disease, Licensing, Therapeutics Antibodies Collaboration Human Cell Lines Immunology Infectious Disease Licensing Therapeutics Sung-Youl Ko, Gary Nabel <p>This technology pertains to the strategic enhancement of HIV neutralizing antibodies through the insertion of specific amino acid substitutions. The substitutions, as described and potentially contributed by biotechnology companies such as Xencor, Genentech, and MedImmune, aim to extend the antibodies&#39; half-life within serum and improve their Antibody-Dependent Cellular Cytotoxicity (ADCC) capabilities. This innovation has the potential to significantly improve the therapeutic and preventative efficacy of these antibodies against HIV.</p> <p>The Vaccine Research Center (VRC) has conducted thorough in vitro studies to test the effects of both single and combined mutations on the VRC01 class of HIV neutralizing antibodies. The mutations tested include QL, LS, and YTE variants. Early results from these studies suggest that these engineered antibodies could be promising candidates for future treatments, offering enhanced half-life and ADCC activities. The technology is currently in the pre-clinical (in vitro) stage, indicating that while it has not yet been tested in living organisms, its initial lab results are promising for future development stages.</p> The competitive advantage of this technology lies in its innovative approach to extending the half-life and enhancing the ADCC of HIV neutralizing antibodies. By incorporating specific amino acid substitutions that have been developed and refined by leaders in the biotechnology industry, this method could significantly reduce the frequency of antibody administration, offering improved patient compliance and quality of life. Additionally, the heightened ADCC activity promises a more robust immune response, potentially leading to better clinical outcomes in both therapeutic and preventative applications against HIV. The technology's adaptability, evidenced by the testing of both single and combination mutations, further underscores its potential to be tailored to various strains of HIV, positioning it at the forefront of adaptive and long-lasting HIV treatment and prevention strategies. The technology's tailored amino acid substitutions in HIV neutralizing antibodies present potential applications across a spectrum of HIV management strategies. In therapeutic contexts, the prolonged half-life could revolutionize treatment regimens, significantly reducing dosing frequency and enhancing patient adherence. For preventive measures, these antibodies could offer a sustained protective effect, particularly vital for high-risk populations and as a part of pre-exposure prophylaxis protocols. Furthermore, the technology may hold special promise for pediatric HIV management, where treatment adherence can be challenging, and for integration into combination therapies, potentially working synergistically with other antiretroviral medications to improve outcomes and hinder viral resistance. 2024-02-20 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 153003737 Nabel, Gary ModeX Therapeutics, Inc. NIAID Nabel, Gary (NIAID) 1 153004156 Ko, Sung-Youl NIAID - VRC NIAID Ko, Sung-Youl (NIAID) 2 153003737 Nabel, Gary ModeX Therapeutics, Inc. NIAID Nabel, Gary (NIAID) 1 153004156 Ko, Sung-Youl NIAID - VRC NIAID Ko, Sung-Youl (NIAID) 2 153002949 Modifications Of Broadly Neutralizing Anti-HIV-1 Monoclonal Antibodies For Improved Efficacy And Half-life E-088-2011-0 Filing authorized NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4902] Enhanced Half-Life and ADCC Activity: Amino Acid Substitution in HIV Neutralizing Antibodies&body=Please send me information about technology [TAB-4902] Enhanced Half-Life and ADCC Activity: Amino Acid Substitution in HIV Neutralizing Antibodies. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-4902] Enhanced Half-Life and ADCC Activity: Amino Acid Substitution in HIV Neutralizing Antibodies&body=Please send me information about technology [TAB-4902] Enhanced Half-Life and ADCC Activity: Amino Acid Substitution in HIV Neutralizing Antibodies.">sabrina.hafiz@nih.gov</a><br> TAB-4900 153002022 Development of a Self-Amplifying mRNA Zika Vaccine: Merging GSK's mRNA Delivery Vector System with VRC's Zika Proteins NIAID Collaboration, Infectious Disease, Licensing, Vaccines Collaboration Infectious Disease Licensing Vaccines Kimberly Dowd, Barney Graham, Sung-Youl Ko, Wing-pui Kong, John Mascola, Theodore Pierson, Mayuri Sharma, Dong Yu <p>The inventors have developed an RNA Zika vaccine construct using the self-amplifying mRNA (SAM&reg;) vaccine platform. This technology combines the GSK SAM mRNA delivery vector system with the VRC&rsquo;s Zika proteins to optimize immune responses against Zika virus, with the ultimate goal of preventing infection. The vaccine is designed to elicit strong and durable immune responses, potentially offering a promising approach to combat Zika virus disease. The current development stage of this technology is likely in the pre-clinical or early clinical stages of testing.</p> <p>&nbsp;</p> The RNA Zika vaccine construct based on the self-amplifying mRNA (SAM®) vaccine platform offers a potent and targeted approach to combating Zika virus. By combining the GSK SAM mRNA delivery vector system with the VRC’s Zika proteins, the vaccine aims to elicit strong and long-lasting immune responses. This technology not only has the potential to prevent Zika virus infection but also demonstrates versatility for addressing other infectious diseases. Its scalability, safety profile, and potential for enhanced immune responses position it as a promising candidate in the field of vaccine development. The RNA Zika vaccine construct based on the SAM® vaccine platform has the potential for widespread application in both endemic regions and areas at risk of Zika virus outbreaks. If successful, this vaccine could significantly reduce the burden of Zika virus disease, particularly in pregnant women and their offspring who are most at risk of complications. Furthermore, the adaptability of the SAM® platform could enable rapid development and deployment of vaccines against other emerging infectious diseases, providing a valuable tool for global health security. 2024-02-20 2026-08-26 2026-08-26 2026-08-26 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 153002040 Sharma, Mayuri GlaxoSmithKline Biologics SA Sharma, Mayuri 1 153002058 Graham, Barney Morehouse School of Medicine NIAID Graham, Barney (NIAID) 2 153002074 Dowd, Kimberly National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Dowd, Kimberly (NIAID) 3 153002141 Ko, Sung-Youl NIAID - VRC NIAID Ko, Sung-Youl (NIAID) 4 153002150 Pierson, Theodore National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Pierson, Theodore (NIAID) 5 153002154 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 6 153002167 Kong, Wing-pui NIAID Kong, Wing-pui (NIAID) 7 153002201 Yu, Dong GlaxoSmithKline Biologicals, S.A. Yu, Dong 8 153002040 Sharma, Mayuri GlaxoSmithKline Biologics SA Sharma, Mayuri 1 153002058 Graham, Barney Morehouse School of Medicine NIAID Graham, Barney (NIAID) 2 153002074 Dowd, Kimberly National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Dowd, Kimberly (NIAID) 3 153002141 Ko, Sung-Youl NIAID - VRC NIAID Ko, Sung-Youl (NIAID) 4 153002150 Pierson, Theodore National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Pierson, Theodore (NIAID) 5 153002154 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 6 153002167 Kong, Wing-pui NIAID Kong, Wing-pui (NIAID) 7 153002201 Yu, Dong GlaxoSmithKline Biologicals, S.A. Yu, Dong 8 153002025 Zika Viral Antigen Constructs E-086-2018-0 Filing authorized GlaxoSmithKline Biologics SA, NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4900] Development of a Self-Amplifying mRNA Zika Vaccine: Merging GSK's mRNA Delivery Vector System with VRC's Zika Proteins&body=Please send me information about technology [TAB-4900] Development of a Self-Amplifying mRNA Zika Vaccine: Merging GSK's mRNA Delivery Vector System with VRC's Zika Proteins. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4900] Development of a Self-Amplifying mRNA Zika Vaccine: Merging GSK's mRNA Delivery Vector System with VRC's Zika Proteins&body=Please send me information about technology [TAB-4900] Development of a Self-Amplifying mRNA Zika Vaccine: Merging GSK's mRNA Delivery Vector System with VRC's Zika Proteins.">wade.green@nih.gov</a><br> TAB-4899 153001516 Therapeutic Filovirus Counteraction: A Novel MVA Vector-Based Vaccine Development NIAID Collaboration, Infectious Disease, Licensing, Plasmids/Vectors, Vaccines Collaboration Infectious Disease Licensing Plasmids/Vectors Vaccines Arban Domi, Michael Hellerstein, Bernard Moss, Harriet Robinson <p>This innovative technology revolves around a novel vaccine development strategy for combating filoviruses, notorious for causing severe hemorrhagic fevers in humans and non-human primates. At the heart of this advancement is a modified vaccinia Ankara (MVA) vector, ingeniously engineered to encode specific viral antigens that trigger a protective immune response against various filoviruses, including the Sudan ebolavirus (SEBOV), Zaire ebolavirus (ZEBOV), and the Marburg virus. The proposed solution stands out by potentially offering a broad-spectrum prophylactic application, addressing a significant unmet medical need given the lack of approved vaccines or treatments for filovirus infections to date. This pre-clinical (in vitro) stage research promises to pave the way for future clinical applications, aiming to significantly enhance global health security against these deadly pathogens.</p> The proposed MVA vector-based vaccine platform offers a suite of competitive advantages over existing approaches in the fight against filoviruses. Firstly, the versatility of the MVA vector allows for the encoding of multiple filovirus antigens, which could potentially yield a broad-spectrum vaccine capable of targeting several strains of Ebola and Marburg viruses simultaneously. This multivalent approach is particularly advantageous given the genetic variability of filoviruses and the emergence of new strains. Secondly, the use of a non-replicating vector ensures a safety profile that is superior to live attenuated vaccines, making it suitable for a wider demographic, including immunocompromised individuals. Additionally, the technology's scalability and stability at varying temperatures may offer logistical benefits, facilitating easier distribution and storage, particularly in resource-limited settings where filoviruses often emerge. Lastly, the platform's adaptability positions it well for rapid response to new filovirus threats, offering a nimble solution in the face of potential outbreaks. The MVA vector-based vaccine technology has the potential for wide-ranging applications in infectious disease prophylaxis. Foremost, it could be employed in the preemptive vaccination of populations at high risk of filovirus outbreaks, such as those in endemic regions. Healthcare workers and military personnel deployed to outbreak zones could also benefit significantly from this protective measure. Moreover, the vaccine could be integrated into emergency response protocols, offering a rapid deployment tool to contain and control epidemic situations. On a broader scale, the technology could serve as a template for developing vaccines against other hemorrhagic fevers or similarly structured viruses, underlining its versatile utility in pandemic preparedness and global health security initiatives. 2024-02-20 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 153001551 Robinson, Harriet Emory University Robinson, Harriet 1 153001556 Domi, Arban GeoVax, Inc. Domi, Arban 2 153001647 Hellerstein, Michael Hellerstein, Michael 3 153001701 Moss, Bernard NIAID - DIR NIAID Moss, Bernard (NIAID) 4 153001551 Robinson, Harriet Emory University Robinson, Harriet 1 153001556 Domi, Arban GeoVax, Inc. Domi, Arban 2 153001647 Hellerstein, Michael Hellerstein, Michael 3 153001701 Moss, Bernard NIAID - DIR NIAID Moss, Bernard (NIAID) 4 153001519 Composition And Methods For Generating And Immune Response To Filovirus E-085-2016-0 Filing authorized GeoVax, Inc., NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4899] Therapeutic Filovirus Counteraction: A Novel MVA Vector-Based Vaccine Development&body=Please send me information about technology [TAB-4899] Therapeutic Filovirus Counteraction: A Novel MVA Vector-Based Vaccine Development. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4899] Therapeutic Filovirus Counteraction: A Novel MVA Vector-Based Vaccine Development&body=Please send me information about technology [TAB-4899] Therapeutic Filovirus Counteraction: A Novel MVA Vector-Based Vaccine Development.">jonathan.motley@nih.gov</a><br> TAB-4893 152850030 Multiplexed Nanoparticle Platform for Broad-Spectrum Coronavirus Vaccination NIAID Collaboration, Immunology, Infectious Disease, Licensing, Materials Available, Vaccines Collaboration Immunology Infectious Disease Licensing Materials Available Vaccines Kizzmekia Corbett, Barney Graham, Geoffrey Hutchinson, Masaru Kanekiyo <p>The &quot;Multiplexed Nanoparticle Platform for Broad-Spectrum Coronavirus Vaccination&quot; represents a cutting-edge approach in the realm of immunization technology. This innovative platform utilizes meticulously engineered nanoparticles, comprised of self-assembling proteins, to present the coronavirus&#39;s distinctive spike proteins to the immune system. These nanoparticles are uniquely designed to attach to an immunogenic segment of the virus, ensuring that this critical component is effectively exhibited on the nanoparticle surface. The design facilitates the induction of an immune response against a diverse array of coronavirus strains, potentially offering broad-spectrum protection. Currently, this vaccine technology is in the pre-clinical in vivo stage, where it undergoes rigorous testing in live models to assess its safety and efficacy profiles before it can advance to human clinical trials. The successful development of this technology could herald a new era in the prophylactic arsenal against coronaviruses, with implications for both current and future pandemic preparedness.</p> <p>&nbsp;</p> The "Multiplexed Nanoparticle Platform for Broad-Spectrum Coronavirus Vaccination" offers a distinctive competitive edge with its ability to target multiple coronavirus strains, ensuring effectiveness against viral mutations. The vaccine's nanoparticle-based design ensures stability and ease of mass production, key factors for rapid deployment during outbreaks. Its modular nature allows swift adaptation to new pathogens, potentially providing a rapid response to emergent viral threats and establishing this platform as a pivotal innovation in vaccine technology. The potential applications of the "Multiplexed Nanoparticle Platform for Broad-Spectrum Coronavirus Vaccination" are extensive and impactful. This platform can be pivotal for global health, not only by providing a robust defense against current and emerging strains of coronaviruses but also by serving as a template for rapid vaccine development against a variety of viral pathogens. Its adaptability could significantly shorten vaccine development timelines in response to pandemics. Moreover, the technology could be instrumental in routine vaccinations in areas prone to coronavirus outbreaks, potentially transforming the landscape of infectious disease prevention and enhancing pandemic preparedness on a global scale. 2024-02-12 2026-08-26 2026-08-26 2026-08-26 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 152850041 Graham, Barney Morehouse School of Medicine NIAID Graham, Barney (NIAID) 1 152850045 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 2 152850049 Hutchinson, Geoffrey NIAID Hutchinson, Geoffrey (NIAID) 3 152850053 Corbett, Kizzmekia NIAID Corbett, Kizzmekia (NIAID) 4 152850041 Graham, Barney Morehouse School of Medicine NIAID Graham, Barney (NIAID) 1 152850045 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 2 152850049 Hutchinson, Geoffrey NIAID Hutchinson, Geoffrey (NIAID) 3 152850053 Corbett, Kizzmekia NIAID Corbett, Kizzmekia (NIAID) 4 152850033 Nanoparticle Vaccines For Coronaviruses E-078-2021-0 Filing authorized NIAID 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-4893] Multiplexed Nanoparticle Platform for Broad-Spectrum Coronavirus Vaccination&body=Please send me information about technology [TAB-4893] Multiplexed Nanoparticle Platform for Broad-Spectrum Coronavirus Vaccination. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-4893] Multiplexed Nanoparticle Platform for Broad-Spectrum Coronavirus Vaccination&body=Please send me information about technology [TAB-4893] Multiplexed Nanoparticle Platform for Broad-Spectrum Coronavirus Vaccination.">bbailey@mail.nih.gov</a><br> TAB-4892 152849879 Development and Licensing Strategies for Monoclonal Antibody CI.11B11.B4.C4 Targeting APOBEC3 in Retroviral Defense NIAID Antibodies, Diagnostics, Immunology, Infectious Disease, Licensing, Research Materials, Therapeutics, Vaccines Antibodies Diagnostics Immunology Infectious Disease Licensing Research Materials Therapeutics Vaccines Stefano Boi, Leonard Evans <p>The technology in focus involves monoclonal antibody CI.11B11.B4.C4, a pioneering biological tool designed to target and bind with high specificity to both isoforms of mouse APOBEC3, mA3 and mA3d5. APOBEC3 proteins play a crucial role in innate immune defense against retroviruses by inducing hypermutation in the viral genome, thereby hindering viral replication and infection. Developed by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, this antibody serves as a vital research tool in the study of viral-host interactions, offering potential breakthroughs in the understanding and suppression of retroviral diseases. Recognized for its utility in various assays, including Western blot and ELISA, the technology stands out as a prototype, ready for licensing as a biological material without the need for additional development or capital investment. This approach aligns with NIH&#39;s policy favoring the use of research tools that facilitate broad scientific advancement over pursuing patent protection.</p> <p>&nbsp;</p> The monoclonal antibody CI.11B11.B4.C4 offers a unique competitive advantage by precisely targeting mouse APOBEC3 proteins, crucial for studying retroviral defense mechanisms. Its specificity minimizes cross-reactivity, enhancing research accuracy. Developed by the NIH and NIAID, it boasts credibility, making it highly attractive to researchers and pharmaceutical companies focused on retroviral therapy advancements. CI.11B11.B4.C4 stands out as a pivotal research tool, facilitating groundbreaking discoveries in virology and immunology. Monoclonal antibody CI.11B11.B4.C4 presents significant potential in advancing retroviral research and therapy development. It enables precise studies of the APOBEC3 protein's role in inhibiting viral replication, facilitating the discovery of novel antiviral strategies and diagnostics. This antibody is instrumental in developing targeted treatments and vaccines, particularly against retroviruses like HIV. Its specificity also makes it a valuable tool in pharmaceutical research, accelerating drug discovery and efficacy testing. CI.11B11.B4.C4's applications extend across academic and pharmaceutical fields, underscoring its importance in the fight against viral diseases. 2024-02-12 2026-08-26 2026-08-26 2026-08-26 False True True 52406769 Prototype 52406769 37470483 Website Abstract 152849889 Evans, Leonard NIAID - DIR NIAID Evans, Leonard (NIAID) 1 152849897 Boi, Stefano National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Boi, Stefano (NIAID) 2 152849889 Evans, Leonard NIAID - DIR NIAID Evans, Leonard (NIAID) 1 152849897 Boi, Stefano National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Boi, Stefano (NIAID) 2 152849882 Anti-Mouse APOBEC3 (mA3) Antibody Cl.11B11.B4.C4 E-078-2018-0 Research Material NIAID 146046171 Joyce, Terrence terrence.joyce@nih.gov
United States of America terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-4892] Development and Licensing Strategies for Monoclonal Antibody CI.11B11.B4.C4 Targeting APOBEC3 in Retroviral Defense&body=Please send me information about technology [TAB-4892] Development and Licensing Strategies for Monoclonal Antibody CI.11B11.B4.C4 Targeting APOBEC3 in Retroviral Defense. Joyce, Terrence<br><a href="mailto:terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-4892] Development and Licensing Strategies for Monoclonal Antibody CI.11B11.B4.C4 Targeting APOBEC3 in Retroviral Defense&body=Please send me information about technology [TAB-4892] Development and Licensing Strategies for Monoclonal Antibody CI.11B11.B4.C4 Targeting APOBEC3 in Retroviral Defense.">terrence.joyce@nih.gov</a><br> TAB-4891 152849802 Characterization and Application of a Novel Monoclonal Antibody Targeting GARP: A Cell Surface Antigen and Receptor for Latent TGF-β1 on Activated Human T Regulatory Cells NIAID Antibodies, Collaboration, Human Cell Lines, Immunology, Licensing, Materials Available, Oncology, Research Materials, Therapeutics Antibodies Collaboration Human Cell Lines Immunology Licensing Materials Available Oncology Research Materials Therapeutics Patricia Korty, David Margulies, Kannan Natarajan, Ethan Shevach <p>This technology involves the discovery and characterization of a novel cell surface antigen uniquely expressed on activated T regulatory (Treg) cells, serving as a receptor for latent transforming growth factor beta-1 (TGF-&beta;1). To explore its role in immune regulation, a specific monoclonal antibody was developed through immunization of hamsters, capable of recognizing this antigen with high specificity. This antibody facilitates the identification and isolation of activated human FOXP3+ Treg cells from mixed populations, offering a valuable tool for studying Treg cell functions and potentially for therapeutic applications. Biochemical assays confirm the antibody&#39;s specificity, able to bind both GARP-bound and unoccupied TGF-&beta;1, showcasing its potential in immunoprecipitation and Biacore studies. This advancement represents a significant step in immunology, providing insights into Treg cell-mediated immune regulation and opening avenues for targeted therapies in autoimmune diseases and cancer.</p> This monoclonal antibody technology stands out for its unparalleled specificity to an antigen on activated T regulatory cells, enabling precise cell identification and isolation. It uniquely targets both GARP-bound and unoccupied molecules, broadening its application in immunological research and therapy development. This specificity, combined with its potential in diverse biochemical assays, positions it as a superior tool for advancing studies in immune regulation and offering novel therapeutic avenues. The monoclonal antibody targeting the novel antigen on activated T regulatory cells holds promising potential for multiple applications. In research, it enables detailed studies on the role and mechanisms of Treg cells in immune regulation, contributing to a deeper understanding of immune tolerance and the pathogenesis of autoimmune diseases and cancer. Clinically, it offers a pathway to develop targeted therapies aimed at modulating Treg cell activity, providing new strategies for treating autoimmune disorders, enhancing cancer immunotherapy, and improving transplant outcomes. Additionally, its use in isolating specific Treg cell populations could facilitate the development of personalized medicine approaches, tailoring treatments to individual immune profiles. 2024-02-12 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 152849815 Korty, Patricia NIAID - DIR NIAID Korty, Patricia (NIAID) 1 152849819 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 2 152849823 Natarajan, Kannan NIAID Natarajan, Kannan (NIAID) 3 152849827 Margulies, David NIAID Margulies, David (NIAID) 4 152849815 Korty, Patricia NIAID - DIR NIAID Korty, Patricia (NIAID) 1 152849819 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 2 152849823 Natarajan, Kannan NIAID Natarajan, Kannan (NIAID) 3 152849827 Margulies, David NIAID Margulies, David (NIAID) 4 152849807 Monoclonal Antibody Against Human GARP E-077-2013-0 Research Material NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4891] Characterization and Application of a Novel Monoclonal Antibody Targeting GARP: A Cell Surface Antigen and Receptor for Latent TGF-β1 on Activated Human T Regulatory Cells&body=Please send me information about technology [TAB-4891] Characterization and Application of a Novel Monoclonal Antibody Targeting GARP: A Cell Surface Antigen and Receptor for Latent TGF-β1 on Activated Human T Regulatory Cells. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4891] Characterization and Application of a Novel Monoclonal Antibody Targeting GARP: A Cell Surface Antigen and Receptor for Latent TGF-β1 on Activated Human T Regulatory Cells&body=Please send me information about technology [TAB-4891] Characterization and Application of a Novel Monoclonal Antibody Targeting GARP: A Cell Surface Antigen and Receptor for Latent TGF-β1 on Activated Human T Regulatory Cells.">yogikala.prabhu@nih.gov</a><br> TAB-4889 152848182 Innovative Vaccine Technology Advancing Comprehensive Immunity Against Filoviruses NIAID Collaboration, Infectious Disease, Licensing, Vaccines Collaboration Infectious Disease Licensing Vaccines Benoit Christophe St Callendret, Ulrike Dirmeier, Maria Pau, Robin Steigerwald, Ariane Volkmann, Lucy Ward <p>This cutting-edge vaccine technology revolutionizes the field of filovirus immunization by combining adenovirus and vaccinia virus vectors in a prime-boost approach. Its primary objective is to confer comprehensive immunity against various ebolaviruses and marburgviruses, including the most lethal strains. By doing so, it addresses the limitations often associated with single-vector vaccines, providing a more robust and enduring immune response. Moreover, this approach offers flexibility in vaccination scheduling and ensures heightened safety and efficacy. Ultimately, the goal is to create a single-vial pan-filovirus vaccine, simplifying the immunization process and offering swift, long-lasting protection against these formidable pathogens.</p> The competitive advantages of this vaccine technology stem from its comprehensive protection against various ebolaviruses and marburgviruses. Its dual-vector approach overcomes limitations of single-vector vaccines, ensuring robust and long-lasting immunity. Flexibility in vaccination scheduling, enhanced safety, and efficacy further bolster its appeal. The goal of creating a single-vial pan-filovirus vaccine simplifies administration, making it accessible and efficient. These advantages position it as a strong contender in filovirus immunization. This vaccine technology has diverse potential applications. Primarily, it can combat filovirus infections, offering broad protection against various strains. It may also be adapted for other viral diseases with high variability and lethality. Its flexibility and safety make it suitable for outbreak control and at-risk populations. The single-vial pan-filovirus vaccine simplifies distribution, making it suitable for global vaccination campaigns and potentially revolutionizing immunization strategies for challenging infectious diseases. 2024-02-12 2026-08-26 2026-08-26 2026-08-26 False True True 72159140 Clinical Phase II 72159140 37470483 Website Abstract 152848189 Volkmann, Ariane Bavarian Nordic A/S (BAVA) Volkmann, Ariane 1 152848193 Steigerwald, Robin Bavarian Nordic GmbH Steigerwald, Robin 2 152848199 Callendret, Benoit Christophe St Callendret, Benoit Christophe St 3 152848226 Dirmeier, Ulrike Dirmeier, Ulrike 4 152848243 Ward, Lucy Joint Vaccine Acquisition Program (JVAP) (DoD) [US] NIAID Ward, Lucy (NIAID) 5 152848271 Pau, Maria Crucell Holland BV Pau, Maria 6 152848189 Volkmann, Ariane Bavarian Nordic A/S (BAVA) Volkmann, Ariane 1 152848193 Steigerwald, Robin Bavarian Nordic GmbH Steigerwald, Robin 2 152848199 Callendret, Benoit Christophe St Callendret, Benoit Christophe St 3 152848226 Dirmeier, Ulrike Dirmeier, Ulrike 4 152848243 Ward, Lucy Joint Vaccine Acquisition Program (JVAP) (DoD) [US] NIAID Ward, Lucy (NIAID) 5 152848271 Pau, Maria Crucell Holland BV Pau, Maria 6 152848185 Methods For Inducing Protective Immunity Against Filovirus Infection E-076-2015-0 Filing authorized Bavarian Nordic GmbH, Crucell Holland BV, NIAID 83657420 Hsu, Su Cheng (Dana) dh164a@nih.gov
United States of America OTD dh164a@nih.gov?subject=Web Inquiry on [TAB-4889] Innovative Vaccine Technology Advancing Comprehensive Immunity Against Filoviruses&body=Please send me information about technology [TAB-4889] Innovative Vaccine Technology Advancing Comprehensive Immunity Against Filoviruses. Hsu, Su Cheng (Dana)<br><a href="mailto:dh164a@nih.gov?subject=Web Inquiry on [TAB-4889] Innovative Vaccine Technology Advancing Comprehensive Immunity Against Filoviruses&body=Please send me information about technology [TAB-4889] Innovative Vaccine Technology Advancing Comprehensive Immunity Against Filoviruses.">dh164a@nih.gov</a><br> TAB-4888 152848023 Comprehensive Examination of Nuclear Envelope Defects Through a Rabbit Polyclonal Antibody Targeting Human Sun1 Inner Nuclear Membrane Protein NIAID Antibodies, Cardiology, Collaboration, Dermatology, Diagnostics, Immunology, Infectious Disease, Licensing, Metabolic Disease, Oncology, Rare/Neglected Diseases, Research Equipment, Research Materials, Therapeutics Antibodies Cardiology Collaboration Dermatology Diagnostics Immunology Infectious Disease Licensing Metabolic Disease Oncology Rare/Neglected Diseases Research Equipment Research Materials Therapeutics Kuan-teh Jeang (Estate) <p>The technology at hand involves a rabbit polyclonal antibody specifically designed for the human Sun1 inner nuclear envelope protein, even though it is directed against the mouse Sun1 inner nuclear membrane protein. Sun1 is known to be an inner nuclear envelope protein, and defects in such proteins can lead to debilitating conditions like Emery-Dreifuss muscular dystrophy and Hutchinson Gilford Progeria Syndrome. Importantly, the antibody serves as a valuable tool for diagnostic and analytical studies concerning cells afflicted with nuclear envelope defects. Given the high conservation between mouse and human Sun1 proteins, this antibody offers promising applications in unraveling the mysteries of nuclear envelope-related disorders.</p> <p>&nbsp;</p> This antibody's unique specificity for human Sun1, despite targeting mouse Sun1, offers precision in human cell research. Its cross-species compatibility facilitates versatile experiments. Its adaptability for diagnostics and analytical studies makes it a valuable tool across various research and medical applications, positioning it as a key asset for advancing nuclear envelope defect research and related disorders. This antibody holds promise for various applications. It can aid in researching and diagnosing nuclear envelope defects in human cells, shedding light on related diseases. Its cross-species compatibility enables comparative studies, while its diagnostic potential offers clinical utility. In summary, this antibody has versatile applications in research and diagnostics, advancing our understanding and management of nuclear envelope-related disorders. 2024-02-12 2026-08-26 2026-08-26 2026-08-26 False True True 52406769 Prototype 52406769 37470483 Website Abstract 152848039 Jeang (Estate), Kuan-teh NIAID Jeang (Estate), Kuan-teh (NIAID) 1 152848039 Jeang (Estate), Kuan-teh NIAID Jeang (Estate), Kuan-teh (NIAID) 1 152848029 Rabbit Polyclonal Antibody Directed To Mouse Sunl Inner Nuclear Membrane Protein E-074-2013-0 Research Material NIAID 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-4888] Comprehensive Examination of Nuclear Envelope Defects Through a Rabbit Polyclonal Antibody Targeting Human Sun1 Inner Nuclear Membrane Protein&body=Please send me information about technology [TAB-4888] Comprehensive Examination of Nuclear Envelope Defects Through a Rabbit Polyclonal Antibody Targeting Human Sun1 Inner Nuclear Membrane Protein. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-4888] Comprehensive Examination of Nuclear Envelope Defects Through a Rabbit Polyclonal Antibody Targeting Human Sun1 Inner Nuclear Membrane Protein&body=Please send me information about technology [TAB-4888] Comprehensive Examination of Nuclear Envelope Defects Through a Rabbit Polyclonal Antibody Targeting Human Sun1 Inner Nuclear Membrane Protein.">peter.tung@nih.gov</a><br> TAB-4887 152847560 Cell Lines and Plasmids Expressing Chemokine Receptors in the Development of Therapeutics for Inflammatory Diseases NIAID Collaboration, Human Cell Lines, Immunology, Licensing, Plasmids/Vectors, Therapeutics Collaboration Human Cell Lines Immunology Licensing Plasmids/Vectors Therapeutics Ji-Liang Gao, Philip Murphy, Jesus Pontejo <p>The technology involves the use of specialized cell lines, including HEK 293 cells expressing human CCR1 and CCR2, along with plasmids encoding mouse CCR1 (Ccr1) and CCR2B (Ccr2), as well as their corresponding human receptor sequences. These tools serve as crucial components in the study of chemokine receptors&#39; functions, particularly in the context of inflammatory diseases. By manipulating and analyzing these receptors, researchers can gain insights into their roles in cellular responses related to inflammation. Furthermore, this technology provides a foundation for drug development efforts aimed at modulating these receptors to develop innovative therapeutics for various inflammatory conditions.</p> This technology provides a competitive edge in inflammatory disease drug development. The specialized cell lines offer reliable models for studying receptor functions, while versatile plasmids enable tailored experiments. This flexibility accelerates research and facilitates the development of targeted therapies for inflammatory conditions, making it a valuable asset in advancing healthcare solutions. This technology finds applications in studying and potentially treating a variety of inflammatory diseases, including arthritis, asthma, and autoimmune disorders. It also has the potential to advance vaccine development, immunotherapy research, and drug screening for inflammatory conditions, making it a versatile tool with broad biomedical applications. 2024-02-12 2026-08-26 2026-08-26 2026-08-26 False True True 52406769 Prototype 52406769 37470483 Website Abstract 152847574 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 152847578 Gao, Ji-Liang NIAID - DIR NIAID Gao, Ji-Liang (NIAID) 2 152847586 Pontejo, Jesus NIAID Pontejo, Jesus (NIAID) 3 152847574 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 152847578 Gao, Ji-Liang NIAID - DIR NIAID Gao, Ji-Liang (NIAID) 2 152847586 Pontejo, Jesus NIAID Pontejo, Jesus (NIAID) 3 152847563 L1.2 Cell Lines And Plasmids Expressing Mouse CC CKR1 (Ccr1) And CC (Ccr2) And Plasmids For Their Human Receptors E-073-2019-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-4887] Cell Lines and Plasmids Expressing Chemokine Receptors in the Development of Therapeutics for Inflammatory Diseases&body=Please send me information about technology [TAB-4887] Cell Lines and Plasmids Expressing Chemokine Receptors in the Development of Therapeutics for Inflammatory Diseases. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-4887] Cell Lines and Plasmids Expressing Chemokine Receptors in the Development of Therapeutics for Inflammatory Diseases&body=Please send me information about technology [TAB-4887] Cell Lines and Plasmids Expressing Chemokine Receptors in the Development of Therapeutics for Inflammatory Diseases.">dawn.taylor-mulneix@nih.gov</a><br> TAB-4886 152847213 Elucidation of CD300 Family Proteins' Roles in Immune Response: A Study Utilizing Transduced L929 Cells and Genetically Modified Murine Models NIAID Animal Models, Antibodies, Collaboration, Diagnostics, Immunology, Research Equipment Animal Models Antibodies Collaboration Diagnostics Immunology Research Equipment John Coligan, Konrad Krzewski, Ha Na Lee, Linjie Tian, Oliver Voss <p>In this research endeavor, a multifaceted approach has been employed to investigate the intricate roles of CD300 family proteins in immunological processes. Lentiviral transduction of the L929 cell line with mouse and human CD300f genes, followed by puromycin selection, has established cellular models to examine the functions of these receptors. Concurrently, engineered constructs encoding extracellular domains of mouse CD300lb and CD300ld, fused with human IgG1, have been developed for the production of receptor extracellular domain proteins, facilitating studies on protein interactions. Additionally, genetically modified murine models, including CD300f-deficient mice created on a C57BL/6 background and CD300a-deficient mice obtained as embryos and cross-bred, enable the exploration of the biological functions of these genes in vivo. This comprehensive approach allows for a thorough investigation into the immunological significance of CD300 family proteins across various experimental contexts.</p> <p>&nbsp;</p> This research's competitive edge lies in its holistic approach to studying CD300 family proteins in immunological processes. By transducing both mouse and human CD300f genes into L929 cells and employing rigorous selection, we enable comparative analysis for species-specific insights. Engineered protein constructs facilitate in vitro investigations into protein interactions. The inclusion of genetically engineered murine models offers valuable in vivo context for studying CD300 gene functions. This comprehensive strategy positions our research at the forefront of understanding CD300 family proteins in immunology. The results of this research offer potential applications in immunotherapy development, diagnostics, and a deeper understanding of immune system regulation. The engineered protein constructs can be used in antibody-based assays for detecting protein interactions. Additionally, insights from the genetically engineered murine models may have broader implications for immune-related diseases and basic immunological research. This research has the potential to advance both fundamental immunology and practical applications in medicine and diagnostics. 2024-02-12 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 152847235 Coligan, John NIAID Coligan, John (NIAID) 1 152847241 Krzewski, Konrad NIAID - DIR NIAID Krzewski, Konrad (NIAID) 2 152847353 Voss, Oliver University of Maryland, School of Medicine Voss, Oliver 3 152847357 Lee, Ha Na NIAID Lee, Ha Na (NIAID) 4 152847369 Tian, Linjie Tian, Linjie 5 152847235 Coligan, John NIAID Coligan, John (NIAID) 1 152847241 Krzewski, Konrad NIAID - DIR NIAID Krzewski, Konrad (NIAID) 2 152847353 Voss, Oliver University of Maryland, School of Medicine Voss, Oliver 3 152847357 Lee, Ha Na NIAID Lee, Ha Na (NIAID) 4 152847369 Tian, Linjie Tian, Linjie 5 152847216 Mouse/Human CD300f Expressing L929 Cells, Mouse CD300lb And CD300ld Constructs And Mice Deficient In CD300a, CD300f And Both CD300a And CD300f E-072-2018-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-4886] Elucidation of CD300 Family Proteins' Roles in Immune Response: A Study Utilizing Transduced L929 Cells and Genetically Modified Murine Models&body=Please send me information about technology [TAB-4886] Elucidation of CD300 Family Proteins' Roles in Immune Response: A Study Utilizing Transduced L929 Cells and Genetically Modified Murine Models. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-4886] Elucidation of CD300 Family Proteins' Roles in Immune Response: A Study Utilizing Transduced L929 Cells and Genetically Modified Murine Models&body=Please send me information about technology [TAB-4886] Elucidation of CD300 Family Proteins' Roles in Immune Response: A Study Utilizing Transduced L929 Cells and Genetically Modified Murine Models.">dawn.taylor-mulneix@nih.gov</a><br> TAB-4884 152846326 Advancements in RSV Vaccine Development for Enhanced Immune Response NIAID Antibodies, Collaboration, Infectious Disease, Licensing, Research Equipment, Respiratory, Therapeutics, Vaccines Antibodies Collaboration Infectious Disease Licensing Research Equipment Respiratory Therapeutics Vaccines Ursula Buchholz, Peter Collins <p>This technology presents a groundbreaking approach to developing a vaccine for Respiratory Syncytial Virus (RSV), a major cause of severe pediatric respiratory illness. The method involves the creation of a live attenuated RSV vaccine candidate by removing the M2-2 protein, resulting in decreased viral replication. Surprisingly, this modification induces a stronger immune response. The vaccine, derived from LID M2-2 with minor mutations, effectively separates viral replication from immunogenicity. Initial results suggest that children who received this vaccine produced anti-RSV antibodies without experiencing severe illness during subsequent RSV seasons, highlighting its potential to provide protection against RSV infection.</p> <p>&nbsp;</p> The competitive advantage of this RSV vaccine technology lies in its ability to induce a stronger immune response while limiting viral replication. By removing the M2-2 protein, it enhances safety and effectiveness, reducing the risk of vaccine-induced illness. This unique approach sets it apart from previous candidates, making it a promising solution for combating RSV in young children. The potential applications of this RSV vaccine technology extend beyond addressing severe respiratory illness in young children. Its unique approach, which separates viral replication from immunogenicity, may have broader implications, potentially revolutionizing vaccine development strategies for other infectious diseases. Furthermore, it could contribute to advancements in immunology and innovative vaccine design, ultimately benefiting public health. 2024-02-12 2026-08-26 2026-08-26 2026-08-26 False True True 72159138 Clinical Phase I 72159138 37470483 Website Abstract 152846347 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 152846362 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 2 152846347 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 152846362 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 2 152846335 A Novel Method Of Vaccination With An Attenuated RSV Vaccine Formulation E-067-2016-0 Filing authorized NIAID 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-4884] Advancements in RSV Vaccine Development for Enhanced Immune Response&body=Please send me information about technology [TAB-4884] Advancements in RSV Vaccine Development for Enhanced Immune Response. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-4884] Advancements in RSV Vaccine Development for Enhanced Immune Response&body=Please send me information about technology [TAB-4884] Advancements in RSV Vaccine Development for Enhanced Immune Response.">maryann.puglielli@nih.gov</a><br> TAB-4882 152843024 Advancements in HIV-1 Therapeutics: Development of Trispecific Antibodies via Second-Generation CD4-Binding Site Integration NIAID Antibodies, Collaboration, Diagnostics, Human Cell Lines, Immunology, Infectious Disease, Licensing, Plasmids/Vectors, Research Materials Antibodies Collaboration Diagnostics Human Cell Lines Immunology Infectious Disease Licensing Plasmids/Vectors Research Materials Mangaiarkarasi Asokan, Richard Koup, Young Do Kwon, Peter Kwong, Qingbo Liu, Paolo Lusso, John Mascola, Amarendra ("Amar") Pegu, Zhi-yong Yang <p>The discovery of a secondary CD4-binding site has led to a breakthrough in the efficacy of HIV-1 neutralizing antibodies. Sanofi&#39;s development of trispecific antibodies incorporating this site promises enhanced neutralization and T-cell stimulation. This advancement diverges from prior methods by engrafting the FR3 loop of another antibody, granting new functional properties. The potential extension of this technique to bi- or tri-specific antibodies could transform HIV-1 therapeutic strategies. Documentation and exploration of this innovation are crucial for advancing treatment modalities and improving patient outcomes.</p> The discovery of a second CD4-binding site has led to antibodies with heightened neutralization capabilities and prolonged activity in HIV-1 treatment. Sanofi's trispecific antibodies, leveraging this advancement, offer improved patient outcomes through enhanced potency and T-cell response. This innovation sets a new standard for antibody therapeutics, potentially reducing viral resistance. The ability to document and refine this technology underpins its competitive advantage in the fast-evolving pharmaceutical landscape. The discovery of a second CD4-binding site on HIV-1 antibodies enables more effective virus neutralization and immune response. This innovation paves the way for personalized, potent antibody treatments, potentially overcoming viral resistance. Its application could extend to other viral infections, marking a significant advancement in immunotherapy. This breakthrough has the potential to transform global health strategies. 2024-02-12 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 152843040 Lusso, Paolo NIAID - DIR NIAID Lusso, Paolo (NIAID) 1 152843044 Liu, Qingbo NIAID - DIR NIAID Liu, Qingbo (NIAID) 2 152843056 Mascola, John NIAID Mascola, John (NIAID) 3 152843060 Pegu, Amarendra ("Amar") NIAID - VRC NIAID Pegu, Amarendra ("Amar") (NIAID) 4 152843064 Asokan, Mangaiarkarasi National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Asokan, Mangaiarkarasi (NIAID) 5 152843074 Kwon, Young Do NIAID - VRC NIAID Kwon, Young Do (NIAID) 6 152843079 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 7 152843083 Koup, Richard NIAID - VRC NIAID Koup, Richard (NIAID) 8 152843090 Yang, Zhi-yong NIAID Yang, Zhi-yong (NIAID) 9 152843040 Lusso, Paolo NIAID - DIR NIAID Lusso, Paolo (NIAID) 1 152843044 Liu, Qingbo NIAID - DIR NIAID Liu, Qingbo (NIAID) 2 152843056 Mascola, John NIAID Mascola, John (NIAID) 3 152843060 Pegu, Amarendra ("Amar") NIAID - VRC NIAID Pegu, Amarendra ("Amar") (NIAID) 4 152843064 Asokan, Mangaiarkarasi National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Asokan, Mangaiarkarasi (NIAID) 5 152843074 Kwon, Young Do NIAID - VRC NIAID Kwon, Young Do (NIAID) 6 152843079 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 7 152843083 Koup, Richard NIAID - VRC NIAID Koup, Richard (NIAID) 8 152843090 Yang, Zhi-yong NIAID Yang, Zhi-yong (NIAID) 9 152843036 Improvement Of Trispecific Antibodies To HIV-1 By Engraftment Of The FR3 Loop Of VRC03 (FR3-03) E-066-2020-0 Filing authorized NIAID, Sanofi Aventis 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4882] Advancements in HIV-1 Therapeutics: Development of Trispecific Antibodies via Second-Generation CD4-Binding Site Integration&body=Please send me information about technology [TAB-4882] Advancements in HIV-1 Therapeutics: Development of Trispecific Antibodies via Second-Generation CD4-Binding Site Integration. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4882] Advancements in HIV-1 Therapeutics: Development of Trispecific Antibodies via Second-Generation CD4-Binding Site Integration&body=Please send me information about technology [TAB-4882] Advancements in HIV-1 Therapeutics: Development of Trispecific Antibodies via Second-Generation CD4-Binding Site Integration.">benjamin.hurley@nih.gov</a><br> TAB-4881 152596302 Innovative Treatment for Graft Versus Host Disease Using Pregnancy Specific Glycoproteins NIAID Collaboration, Immunology, Licensing, Reproductive Health, Therapeutics Collaboration Immunology Licensing Reproductive Health Therapeutics Gabriela Dveksler, Harry Malech <p>This technology presents an innovative approach to the treatment of Graft Versus Host Disease (GvHD) by harnessing the therapeutic potential of Pregnancy Specific Glycoproteins (PSG1 and PSG9). The method involves a novel administration technique for these glycoproteins, which had not been previously disclosed prior to the patent application. The technology holds promise in addressing the challenges associated with GvHD treatment, potentially offering new avenues for improving patient outcomes in this complex medical condition. To obtain detailed information about the methodology and the patent application, one should contact the Henry M. Jackson Foundation Inventor or their authorized representatives.</p> <p>&nbsp;</p> This innovative technology gains a competitive edge in Graft Versus Host Disease (GvHD) treatment through its unique use of Pregnancy Specific Glycoproteins (PSG1 and PSG9) and an undisclosed administration method. This proprietary approach, protected by a patent application, distinguishes it from conventional treatments and holds promise for enhanced patient outcomes, making it a leading contender in GvHD management. This innovative technology, based on Pregnancy Specific Glycoproteins (PSG1 and PSG9) and a proprietary administration method, holds promise not only in Graft Versus Host Disease (GvHD) treatment but also in immunology, autoimmune disease management, tissue transplantation, women's health, reproductive medicine, and potential applications in cancer immunotherapy and other immunological disorders. Its versatility and novel approach make it a valuable asset in various medical fields. 2024-02-05 2026-08-26 2026-08-26 2026-08-26 False True True 72159146 Investigational Device Exemption - Pivotal Study 72159146 37470483 Website Abstract 152596309 Dveksler, Gabriela Henry M. Jackson Foundation (HJF) Dveksler, Gabriela 1 152596314 Malech, Harry NIAID - DIR NIAID Malech, Harry (NIAID) 2 152596309 Dveksler, Gabriela Henry M. Jackson Foundation (HJF) Dveksler, Gabriela 1 152596314 Malech, Harry NIAID - DIR NIAID Malech, Harry (NIAID) 2 152596305 COMPOSITIONS COMPRISING PREGNANCY SPECIFIC GLYCOPROTEINS AND METHODS OF USE THEREOF E-065-2018-0 Filing authorized Henry M. Jackson Foundation (HJF), NIAID 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-4881] Innovative Treatment for Graft Versus Host Disease Using Pregnancy Specific Glycoproteins&body=Please send me information about technology [TAB-4881] Innovative Treatment for Graft Versus Host Disease Using Pregnancy Specific Glycoproteins. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-4881] Innovative Treatment for Graft Versus Host Disease Using Pregnancy Specific Glycoproteins&body=Please send me information about technology [TAB-4881] Innovative Treatment for Graft Versus Host Disease Using Pregnancy Specific Glycoproteins.">polung.yang@nih.gov</a><br> TAB-4880 152595870 Electrochemiluminescence-Based Assays for Type 1 Diabetes Autoantibodies NIAID Antibodies, Collaboration, Diagnostics, Endocrinology, Licensing, Materials Available, Research Equipment Antibodies Collaboration Diagnostics Endocrinology Licensing Materials Available Research Equipment Amy Connolly, Lawrence Jerome, Michael Lenardo, Bernice Lo, Kimberly Shafer-Weaver, Austin Swafford <p>The technology at hand represents a pivotal advancement in the early detection of Type 1 Diabetes (T1D) and the associated autoimmune processes. By utilizing electrochemiluminescence (ECL)-based assays, it enables the precise measurement of diabetes-associated antibodies, particularly Insulin Autoantibodies (IAA) in non-obese diabetic (NOD) mice and anti-insulin antibodies (IA) in individuals with Type 1 diabetes. Notably, these assays are non-radioactive, ensuring safety and compliance, while also offering exceptional reproducibility and efficiency. The primary application lies in the early identification of autoimmune insulitis, a crucial precursor to clinical T1D. This technology&#39;s potential to contribute to a panel of diagnostic markers holds promise for enhancing predictive diagnoses and supporting future therapeutic trials, ultimately advancing our ability to manage and understand Type 1 Diabetes more effectively.</p> This technology's competitive edge lies in its non-radioactive electrochemiluminescence (ECL)-based assays, ensuring safety and regulatory compliance. Its exceptional reproducibility and efficiency make it a reliable choice for diabetes-associated antibody detection. Most significantly, it excels in early identification of autoimmune insulitis, enabling timely intervention, and its potential for a diagnostic marker panel enhances predictive diagnoses and supports therapeutic trials, making it pivotal in advancing Type 1 Diabetes research and care. This technology has diverse potential applications. In research, it can identify high-risk NOD mice for preclinical studies. In clinical practice, it enables early diagnosis of T1D by detecting Insulin Autoantibodies (IAA) in at-risk individuals. Furthermore, its adaptability for other diabetic autoantibodies enhances predictive diagnosis, offering valuable insights for research and therapeutic trials in the prevention and management of T1D. 2024-02-05 2026-08-26 2026-08-26 2026-08-26 False True True 52406769 Prototype 52406769 37470483 Website Abstract 152595885 Jerome, Lawrence Wellstat Diagnostics, LLC Jerome, Lawrence 1 152595890 Lenardo, Michael NIAID Lenardo, Michael (NIAID) 2 152595988 Swafford, Austin NIAID - DIR NIAID Swafford, Austin (NIAID) 3 152596086 Shafer-Weaver, Kimberly NIAID Shafer-Weaver, Kimberly (NIAID) 4 152596090 Lo, Bernice NIAID Lo, Bernice (NIAID) 5 152596099 Connolly, Amy Connolly, Amy 6 152595885 Jerome, Lawrence Wellstat Diagnostics, LLC Jerome, Lawrence 1 152595890 Lenardo, Michael NIAID Lenardo, Michael (NIAID) 2 152595988 Swafford, Austin NIAID - DIR NIAID Swafford, Austin (NIAID) 3 152596086 Shafer-Weaver, Kimberly NIAID Shafer-Weaver, Kimberly (NIAID) 4 152596090 Lo, Bernice NIAID Lo, Bernice (NIAID) 5 152596099 Connolly, Amy Connolly, Amy 6 152595881 Assay For Diabetes-Associated Autoantibodies E-061-2012-0 Filing authorized NIAID, Wellstat Diagnostics, LLC 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4880] Electrochemiluminescence-Based Assays for Type 1 Diabetes Autoantibodies&body=Please send me information about technology [TAB-4880] Electrochemiluminescence-Based Assays for Type 1 Diabetes Autoantibodies. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4880] Electrochemiluminescence-Based Assays for Type 1 Diabetes Autoantibodies&body=Please send me information about technology [TAB-4880] Electrochemiluminescence-Based Assays for Type 1 Diabetes Autoantibodies.">yogikala.prabhu@nih.gov</a><br> TAB-4879 152595671 Discovery of p40-CD5L Cytokine: Implications for Allergy, Asthma, and Tumor Immunology NIAID Antibodies, Collaboration, Immunology, Research Equipment, Therapeutics Antibodies Collaboration Immunology Research Equipment Therapeutics Kaveh Abdi, Allison Gerber, Nevil Singh <p>Researchers from the National Institute of Allergy and Infectious Diseases (NIAID) and the University of Maryland have unveiled a groundbreaking discovery, revealing the formation of a recombinant heterodimer known as p40-CD5L by combining two known proteins, p40 and CD5L. This heterodimer&#39;s significance lies in its ability to stimulate the production of interleukin-4 (IL-4) and interleukin-10 (IL-10) by T cells, which holds great promise for addressing conditions such as allergies, asthma, and tumor immunology. Furthermore, the researchers have identified antibodies that serve dual roles in assays for detecting and quantifying p40-CD5L and as reagents for blocking its activity, opening up new avenues for research and potential therapeutic applications in the fields of immunology and healthcare.</p> The discovery of p40-CD5L cytokine technology presents several competitive advantages. It introduces a unique mechanism for influencing immune responses by promoting IL-4 and IL-10 production in T cells. The specific antibodies developed for detecting and blocking p40-CD5L offer precision in research and potential therapeutic applications. This comprehensive technology, encompassing protein sequences, nucleic acid embodiments, and assays, provides a versatile toolkit for advancing immunology research and healthcare solutions, making it highly competitive in the field. The p40-CD5L cytokine discovery has versatile applications. It can be a therapeutic target for allergies, asthma, and tumors due to its impact on IL-4 and IL-10 production. The antibodies enable precise diagnostics, aiding in disease detection and monitoring. This technology's flexibility, including protein sequences, nucleic acids, and assays, benefits both research and clinical applications, offering opportunities for targeted therapies and improved diagnostics. 2024-02-05 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 152595809 Gerber, Allison University of Maryland, Baltimore Gerber, Allison 1 152595814 Abdi, Kaveh NIAID - DIR NIAID Abdi, Kaveh (NIAID) 2 152595822 Singh, Nevil NIAID - DIR NIAID Singh, Nevil (NIAID) 3 152595809 Gerber, Allison University of Maryland, Baltimore Gerber, Allison 1 152595814 Abdi, Kaveh NIAID - DIR NIAID Abdi, Kaveh (NIAID) 2 152595822 Singh, Nevil NIAID - DIR NIAID Singh, Nevil (NIAID) 3 152595674 A Recombinant Heterodimeric Cytokine Based On P40-CD5L E-059-2021-0 Filing authorized NIAID, University of Maryland, Baltimore 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-4879] Discovery of p40-CD5L Cytokine: Implications for Allergy, Asthma, and Tumor Immunology&body=Please send me information about technology [TAB-4879] Discovery of p40-CD5L Cytokine: Implications for Allergy, Asthma, and Tumor Immunology. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-4879] Discovery of p40-CD5L Cytokine: Implications for Allergy, Asthma, and Tumor Immunology&body=Please send me information about technology [TAB-4879] Discovery of p40-CD5L Cytokine: Implications for Allergy, Asthma, and Tumor Immunology.">dawn.taylor-mulneix@nih.gov</a><br> TAB-4877 152594355 High-Frequency Cell Mechanics for Health and Viability Assessment NIAID Cardiology, Collaboration, Computational models/software, Diagnostics, Immunology, Licensing, Medical Devices, Oncology, Research Equipment, Research Materials Cardiology Collaboration Computational models/software Diagnostics Immunology Licensing Medical Devices Oncology Research Equipment Research Materials Sanjay Desai, Charles Eggleton, David Marr, Tobias Sawetzki <p>The groundbreaking technology of high-frequency cell mechanics assessment represents a paradigm shift in the field of cell analysis. This innovation enables rapid and non-invasive evaluation of cell health and viability, eliminating the need for cell labeling or modification. By measuring cell viscoelastic properties at high frequencies, it offers real-time insights into the mechanical characteristics of individual cells and entire populations. With versatile applications across biomedical research, drug discovery, disease diagnosis, and bioprocessing quality control, this technology has the potential to revolutionize cell analysis, accelerate drug development, improve disease diagnosis, and deepen our understanding of cellular biomechanics, all while offering a non-destructive and high-throughput approach to assessing cell populations.</p> <p>&nbsp;</p> This high-frequency cell mechanics assessment technology excels with its non-invasive approach, eliminating cell labeling, preserving natural states, and enabling high-throughput, real-time analysis. Its versatility spans biomedicine, pharmaceuticals, diagnostics, and biotechnology, making it a disruptive force in cell analysis, accelerating research, drug development, and disease diagnosis while maintaining cell integrity and efficiency. This technology finds applications in various domains. It enhances biomedical research by studying cell behavior and biomechanics. In drug discovery, it streamlines candidate screening. Disease diagnosis benefits from its ability to detect abnormalities early. It ensures quality in bioprocessing and offers versatile tools for research, pharmaceuticals, diagnostics, and biotechnology. 2024-02-05 2026-08-26 2026-08-26 2026-08-26 False True True 52406769 Prototype 52406769 37470483 Website Abstract 152594362 Desai, Sanjay NIAID - DIR NIAID Desai, Sanjay (NIAID) 1 152594366 Sawetzki, Tobias Colorado School of Mines Sawetzki, Tobias 2 152594390 Marr, David Colorado School of Mines Marr, David 3 152594400 Eggleton, Charles Eggleton, Charles 4 152594362 Desai, Sanjay NIAID - DIR NIAID Desai, Sanjay (NIAID) 1 152594366 Sawetzki, Tobias Colorado School of Mines Sawetzki, Tobias 2 152594390 Marr, David Colorado School of Mines Marr, David 3 152594400 Eggleton, Charles Eggleton, Charles 4 152594358 Dynamic Viscoelasticity As A Rapid Single-Cell Biomarker E-056-2014-0 Filing authorized Colorado School of Mines, NIAID, University of Maryland 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-4877] High-Frequency Cell Mechanics for Health and Viability Assessment&body=Please send me information about technology [TAB-4877] High-Frequency Cell Mechanics for Health and Viability Assessment. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-4877] High-Frequency Cell Mechanics for Health and Viability Assessment&body=Please send me information about technology [TAB-4877] High-Frequency Cell Mechanics for Health and Viability Assessment.">peter.tung@nih.gov</a><br> TAB-4876 152593586 Ebola Virus Treatment with Sangivanycin and Analogs NIAID Collaboration, Infectious Disease, Research Equipment, Therapeutics Collaboration Infectious Disease Research Equipment Therapeutics Ryan Bennett, Peter Jahrling, Harold Smith <p>Innovating the landscape of Ebola virus treatment, this technology harnesses the potential of small molecules, particularly Sangivanycin and its analogs, as promising therapeutic agents. Addressing the current gap in Ebola treatment options, which primarily rely on antibodies, vaccines, or RNAi, this breakthrough offers the prospect of drug-like small molecule oral or injectable treatments. With the swift progression of Ebola, where acquired immunity through vaccination proves time-consuming, this innovation carries immense significance. It not only presents the possibility of fast-acting treatments with therapeutic or curative potential but also plays a pivotal role in delaying the disease&#39;s progression, allowing sufficient time for natural or vaccine-based acquired immunity to develop. Presented at the III International Conference on Clinical Sciences and Drug Discovery (CSDD-2017), this technology marks a noteworthy stride in the quest to combat Ebola effectively.</p> <p>&nbsp;</p> The competitive advantages of this technology stem from its unique approach to Ebola treatment. Unlike conventional methods like antibodies or vaccines, it leverages small molecules, particularly Sangivanycin and its analogs, offering the potential for oral or injectable treatments. This innovation's rapid action capability is especially advantageous in dealing with the virus's fast progression, providing a more timely therapeutic response. By slowing down the disease's advance, it complements natural and vaccine-based immunity strategies, making it a valuable addition to the Ebola treatment arsenal. The competitive potential of this technology extends beyond Ebola treatment. Its utilization of small molecules like Sangivanycin and analogs opens the door to broader applications in antiviral therapy. These compounds could be explored as treatments for various RNA viruses, potentially offering new solutions for viral infections beyond Ebola. Additionally, the rapid action and oral/injectable delivery capabilities make this technology adaptable for addressing other fast-progressing diseases, enhancing its competitive edge in the field of antiviral therapeutics. 2024-02-05 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 152593594 Smith, Harold OyaGen, Inc. Smith, Harold 1 152593598 Jahrling, Peter NIAID Jahrling, Peter (NIAID) 2 152593602 Bennett, Ryan OyaGen, Inc. Bennett, Ryan 3 152593594 Smith, Harold OyaGen, Inc. Smith, Harold 1 152593598 Jahrling, Peter NIAID Jahrling, Peter (NIAID) 2 152593602 Bennett, Ryan OyaGen, Inc. Bennett, Ryan 3 152593589 Methods Of Treating And Inhibiting Ebola Virus Infection E-053-2018-0 Filing authorized NIAID, OyaGen, Inc., University of Rochester Medical Center 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4876] Ebola Virus Treatment with Sangivanycin and Analogs&body=Please send me information about technology [TAB-4876] Ebola Virus Treatment with Sangivanycin and Analogs. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4876] Ebola Virus Treatment with Sangivanycin and Analogs&body=Please send me information about technology [TAB-4876] Ebola Virus Treatment with Sangivanycin and Analogs.">wade.green@nih.gov</a><br> TAB-4875 152590619 Enhanced Influenza Vaccination with Engineered Neuraminidase Antigens for Stabilization and Design NIAID Antibodies, Collaboration, Diagnostics, Infectious Disease, Licensing, Research Equipment, Vaccines Antibodies Collaboration Diagnostics Infectious Disease Licensing Research Equipment Vaccines David Baker, David Ellis, Barney Graham, Masaru Kanekiyo, Neil King, Julia Lederhofer, Una Nattermann <p>Engineered Influenza Neuraminidase Antigens represent a cutting-edge approach to revolutionize Influenza vaccine development. This technology harnesses the sequences of neuraminidase (NA) proteins, pivotal components of the Influenza virus, to create stabilized tetramers for multiple NA subtypes. By identifying specific mutations, the technology enables the control of NA protein conformations, particularly closed states, which significantly enhances their stability. These stabilized NA structures have immense potential as vaccine antigens, available either in soluble forms or presented on scaffolds, providing versatility in Influenza vaccine design. Overall, this breakthrough technology promises to elevate the efficacy and design of Influenza vaccines, ultimately contributing to better public health outcomes.</p> <p>&nbsp;</p> Engineered Influenza Neuraminidase Antigens offer a competitive edge through their capacity to stabilize and control neuraminidase (NA) proteins, a crucial component in Influenza vaccines. This technology ensures consistent NA protein stability, crucial for vaccine production. Its unique ability to manipulate NA protein conformations, favoring closed states, provides a novel approach to stabilization. Moreover, the versatility of these stabilized NA structures, available in soluble or scaffold-presented forms, offers flexibility in vaccine design, catering to various Influenza strains and subtypes. Engineered Influenza Neuraminidase Antigens offer versatile potential applications. They are poised to play a pivotal role in the development of more effective Influenza vaccines, ensuring robust protection against a range of Influenza strains, including those prone to rapid mutation. Additionally, these stabilized NA antigens can find utility in research and diagnostics, serving as valuable tools for studying Influenza virus biology and enhancing the accuracy of diagnostic assays. Moreover, their adaptability in soluble or scaffold-presented forms opens avenues for innovative drug delivery systems and targeted therapeutic applications. 2024-02-05 2026-08-26 2026-08-26 2026-08-26 False True True 52406769 Prototype 52406769 37470483 Website Abstract 152591591 Ellis, David SmartGene, Inc. Ellis, David 1 152591602 Nattermann, Una Nattermann, Una 2 152591630 King, Neil University of Washington King, Neil 3 152591757 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 4 152591772 Lederhofer, Julia NIAID - VRC NIAID Lederhofer, Julia (NIAID) 5 152591776 Graham, Barney Morehouse School of Medicine NIAID Graham, Barney (NIAID) 6 152591780 Baker, David University of Washington Baker, David 7 152591591 Ellis, David SmartGene, Inc. Ellis, David 1 152591602 Nattermann, Una Nattermann, Una 2 152591630 King, Neil University of Washington King, Neil 3 152591757 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 4 152591772 Lederhofer, Julia NIAID - VRC NIAID Lederhofer, Julia (NIAID) 5 152591776 Graham, Barney Morehouse School of Medicine NIAID Graham, Barney (NIAID) 6 152591780 Baker, David University of Washington Baker, David 7 152590622 Engineered Influenza Neuraminidase Antigens E-052-2021-0 Filing authorized NIAID, University of Washington 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4875] Enhanced Influenza Vaccination with Engineered Neuraminidase Antigens for Stabilization and Design&body=Please send me information about technology [TAB-4875] Enhanced Influenza Vaccination with Engineered Neuraminidase Antigens for Stabilization and Design. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4875] Enhanced Influenza Vaccination with Engineered Neuraminidase Antigens for Stabilization and Design&body=Please send me information about technology [TAB-4875] Enhanced Influenza Vaccination with Engineered Neuraminidase Antigens for Stabilization and Design.">wade.green@nih.gov</a><br> TAB-4874 152590442 Trispecific and Trivalent Binding Proteins for Enhanced Prevention and Cure of HIV Infection NIAID Antibodies, Collaboration, Computational models/software, Diagnostics, Human Cell Lines, Immunology, Infectious Disease, Licensing, Plasmids/Vectors, Research Equipment, Therapeutics Antibodies Collaboration Computational models/software Diagnostics Human Cell Lines Immunology Infectious Disease Licensing Plasmids/Vectors Research Equipment Therapeutics Gary Nabel, Zhi-yong Yang <p>Trispecific and trivalent binding proteins represent a breakthrough in the battle against HIV infection. These specialized proteins are engineered with four polypeptide chains forming three antigen binding sites, enabling precise targeting of HIV target proteins. Addressing the formidable challenges of HIV treatment, including the virus&#39;s high mutation rate and the persistence of viral reservoirs, these binding proteins offer a potential solution to breakthrough infections. Their unique structure incorporates dual variable domains in one pair of polypeptides and a single variable domain in the other, enhancing their ability to recognize and neutralize HIV. By engaging HIV-1 envelope proteins and human T cell antigens, these proteins activate viral reservoirs and host T cells, effectively redirecting T cells to combat HIV-1 latency. This technology holds the promise of broadening the scope of neutralizing antibodies, potentially revolutionizing treatment options for HIV/AIDS.</p> <p>&nbsp;</p> The trispecific and trivalent binding proteins offer a distinct competitive edge in HIV treatment. Their precise targeting through four-polypeptide chains with three antigen binding sites is unparalleled. The incorporation of dual and single variable domains makes them adaptable to combat HIV's mutation rate. They excel in addressing viral reservoirs by activating latent HIV-1 viral reservoirs and redirecting T cells, providing multi-layered protection against HIV-1. This versatility positions them as a promising advancement in HIV/AIDS treatment. Trispecific and trivalent binding proteins are poised to transform the landscape of HIV/AIDS management with their precision targeting. They offer the potential to enhance HIV treatment, reduce viral reservoirs, and improve prevention strategies, representing a versatile and groundbreaking advancement in the ongoing fight against HIV/AIDS. 2024-02-05 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 152590457 Nabel, Gary ModeX Therapeutics, Inc. NIAID Nabel, Gary (NIAID) 1 152590473 Yang, Zhi-yong ModeX Therapeutics, Inc. Yang, Zhi-yong 2 152590457 Nabel, Gary ModeX Therapeutics, Inc. NIAID Nabel, Gary (NIAID) 1 152590473 Yang, Zhi-yong ModeX Therapeutics, Inc. Yang, Zhi-yong 2 152590445 Trispecific And/or Trivalent Binding Proteins For Prevention Or Treatment Of HIV Infection E-052-2017-0 Filing authorized Sanofi Pasteur Biologics Co, Sanofi R&D 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4874] Trispecific and Trivalent Binding Proteins for Enhanced Prevention and Cure of HIV Infection&body=Please send me information about technology [TAB-4874] Trispecific and Trivalent Binding Proteins for Enhanced Prevention and Cure of HIV Infection. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4874] Trispecific and Trivalent Binding Proteins for Enhanced Prevention and Cure of HIV Infection&body=Please send me information about technology [TAB-4874] Trispecific and Trivalent Binding Proteins for Enhanced Prevention and Cure of HIV Infection.">wade.green@nih.gov</a><br> TAB-4873 152589508 Genetically Modified Traf3ip2-/- Mice as a Valuable Resource for Exploring IL-17 Signaling in Autoimmune, Inflammatory Diseases, and Beyond NIAID Animal Models, Collaboration, Immunology, Licensing, Oncology, Rare/Neglected Diseases, Research Materials, Therapeutics Animal Models Collaboration Immunology Licensing Oncology Rare/Neglected Diseases Research Materials Therapeutics Ulrich Siebenlist (Estate) <p>Traf3ip2-/- C57/BL6 mice are a genetically modified mouse model in which the Traf3ip2 gene, responsible for encoding the CIKS adaptor protein essential for IL-17 cytokine signaling, has been disrupted. These mice offer a robust platform for research in autoimmune and inflammatory diseases, as well as potential applications in cancer studies. By eliminating IL-17 signaling and cross-interactions with other pathways, they provide a unique opportunity for drug discovery and proof-of-principle studies, shedding light on disease mechanisms and therapeutic development.</p> <p>&nbsp;</p> Traf3ip2-/- C57/BL6 mice provide researchers with a focused and efficient tool for investigating IL-17 signaling pathways and related diseases. By eliminating CIKS adaptor protein expression, these mice streamline research efforts, enabling targeted drug discovery, proof-of-principle studies, and a deeper understanding of autoimmune, inflammatory, and potentially cancer-related conditions. Traf3ip2-/- C57/BL6 mice find utility in research on autoimmune and inflammatory diseases, cancer studies, and drug development targeting IL-17 signaling pathways. These genetically engineered mice offer a valuable platform for gaining insights into disease mechanisms and testing novel therapeutic interventions. Their versatility makes them an essential resource for diverse biomedical research endeavors. 2024-02-05 2026-08-26 2026-08-26 2026-08-26 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 152589524 Siebenlist (Estate), Ulrich National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Siebenlist (Estate), Ulrich (NIAID) 1 152589524 Siebenlist (Estate), Ulrich National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Siebenlist (Estate), Ulrich (NIAID) 1 152589514 Traf3ip2-/-C57/BL6 Mice E-051-2014-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-4873] Genetically Modified Traf3ip2-/- Mice as a Valuable Resource for Exploring IL-17 Signaling in Autoimmune, Inflammatory Diseases, and Beyond&body=Please send me information about technology [TAB-4873] Genetically Modified Traf3ip2-/- Mice as a Valuable Resource for Exploring IL-17 Signaling in Autoimmune, Inflammatory Diseases, and Beyond. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-4873] Genetically Modified Traf3ip2-/- Mice as a Valuable Resource for Exploring IL-17 Signaling in Autoimmune, Inflammatory Diseases, and Beyond&body=Please send me information about technology [TAB-4873] Genetically Modified Traf3ip2-/- Mice as a Valuable Resource for Exploring IL-17 Signaling in Autoimmune, Inflammatory Diseases, and Beyond.">dawn.taylor-mulneix@nih.gov</a><br> TAB-4872 152589015 Advancements in HIV-1 Treatment with Broadly Neutralizing Monoclonal Antibodies N6 and VRC07-523LS NIAID Antibodies, Immunology, Infectious Disease, Licensing, Therapeutics, Vaccines Antibodies Immunology Infectious Disease Licensing Therapeutics Vaccines Mangaiarkarasi Asokan, Gwo-Yu Chuang, Nicole Doria-Rose, Peter Kwong, John Mascola, Krisha McKee, Amarendra ("Amar") Pegu, Baoshan Zhang <p>The Vaccine Research Center has engineered two monoclonal antibodies, N6 and VRC07-523LS, as new contenders in the fight against HIV-1. These antibodies are designed to target the virus more effectively by removing certain glycans and modifying amino acids to enhance their neutralizing capability and reduce the risk of autoimmunity. The technology holds promise for improved HIV-1 treatments and may offer broader protection due to its potential coverage of various viral variants. This advancement signifies a strategic move towards more effective clinical solutions for HIV-1 prevention and treatment, with a focus on antibody-based therapies.</p> <p>&nbsp;</p> N6 and VRC07-523LS monoclonal antibodies offer a competitive advantage in the HIV-1 treatment landscape due to their enhanced neutralizing efficacy and reduced autoreactivity. Their tailored design increases product uniformity and anticipates broad effectiveness across HIV-1 variants, positioning them as promising candidates for future therapeutic developments. The N6 and VRC07-523LS antibodies are promising tools for HIV-1 prophylaxis and active treatment. Their broad neutralization profiles suggest potential for inclusion in vaccine formulations. These antibodies could adapt to combat diverse HIV-1 strains, enhancing treatment efficacy. Their development represents a significant step forward in the personalized approach to HIV-1 management. 2024-02-05 2026-08-26 2026-08-26 2026-08-26 False True True 72159138 Clinical Phase I 72159138 37470483 Website Abstract 152589041 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 152589051 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 2 152589077 Chuang, Gwo-Yu NIAID - DIR NIAID Chuang, Gwo-Yu (NIAID) 3 152589088 Zhang, Baoshan NIAID Zhang, Baoshan (NIAID) 4 152589109 Asokan, Mangaiarkarasi Asokan, Mangaiarkarasi 5 152589116 Doria-Rose, Nicole NIAID - VRC NIAID Doria-Rose, Nicole (NIAID) 6 152589138 McKee, Krisha NIAID - VRC NIAID McKee, Krisha (NIAID) 7 152589200 Pegu, Amarendra ("Amar") NIAID - VRC NIAID Pegu, Amarendra ("Amar") (NIAID) 8 152589041 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 152589051 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 2 152589077 Chuang, Gwo-Yu NIAID - DIR NIAID Chuang, Gwo-Yu (NIAID) 3 152589088 Zhang, Baoshan NIAID Zhang, Baoshan (NIAID) 4 152589109 Asokan, Mangaiarkarasi Asokan, Mangaiarkarasi 5 152589116 Doria-Rose, Nicole NIAID - VRC NIAID Doria-Rose, Nicole (NIAID) 6 152589138 McKee, Krisha NIAID - VRC NIAID McKee, Krisha (NIAID) 7 152589200 Pegu, Amarendra ("Amar") NIAID - VRC NIAID Pegu, Amarendra ("Amar") (NIAID) 8 152589032 Removal Of Light Chain Glycan From HIV-1 Neutralizing Antibody N6 And VRC07-523LS For Improved Product Homogeneity E-049-2019-0 Research Material NIAID 91025211 Rainwater, Charles crainwater@mail.nih.gov
United States of America crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-4872] Advancements in HIV-1 Treatment with Broadly Neutralizing Monoclonal Antibodies N6 and VRC07-523LS&body=Please send me information about technology [TAB-4872] Advancements in HIV-1 Treatment with Broadly Neutralizing Monoclonal Antibodies N6 and VRC07-523LS. Rainwater, Charles<br><a href="mailto:crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-4872] Advancements in HIV-1 Treatment with Broadly Neutralizing Monoclonal Antibodies N6 and VRC07-523LS&body=Please send me information about technology [TAB-4872] Advancements in HIV-1 Treatment with Broadly Neutralizing Monoclonal Antibodies N6 and VRC07-523LS.">crainwater@mail.nih.gov</a><br> TAB-4871 152588726 Monoclonal Antibodies in the Advancement of Bacillus anthracis Diagnosis and Surveillance NIAID Antibodies, Collaboration, Diagnostics, Infectious Disease Antibodies Collaboration Diagnostics Infectious Disease Stephen Leppla <p>Monoclonal antibodies produced by hybridomas IE5, IE9, and 13B3 are specific for the Bacillus anthracis PA20 fragment. These antibodies hold significant potential for rapid and precise Bacillus anthracis diagnosis in clinical and environmental samples. They can be employed in various diagnostic assays, offering a valuable tool for public health and biosecurity applications. Rigorous testing and validation are essential before their integration into diagnostic devices.</p> <p>&nbsp;</p> These monoclonal antibodies, developed by hybridomas IE5, IE9, and 13B3, hold a unique competitive advantage due to their exceptional specificity for Bacillus anthracis. Their integration into diagnostic assays enables rapid and precise detection, providing a valuable tool for emergency responses. With a well-documented history of reliability dating back to 1988, these antibodies offer a proven and trusted solution for Bacillus anthracis diagnosis and surveillance. These monoclonal antibodies offer quick and precise Bacillus anthracis detection, aiding in emergencies and biosecurity. They also assist in vaccine development, validate diagnostic results, and contribute to research, including environmental monitoring. In short, their specificity and versatility are valuable assets in anthrax-related applications. 2024-02-05 2026-08-26 2026-08-26 2026-08-26 False True True 52406769 Prototype 52406769 37470483 Website Abstract 152588750 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 1 152588750 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 1 152588729 Monoclonal Antibodies That May React With Anthrax Protective Antigen 20 (PA20) E-049-2018-0 Research Material NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4871] Monoclonal Antibodies in the Advancement of Bacillus anthracis Diagnosis and Surveillance&body=Please send me information about technology [TAB-4871] Monoclonal Antibodies in the Advancement of Bacillus anthracis Diagnosis and Surveillance. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4871] Monoclonal Antibodies in the Advancement of Bacillus anthracis Diagnosis and Surveillance&body=Please send me information about technology [TAB-4871] Monoclonal Antibodies in the Advancement of Bacillus anthracis Diagnosis and Surveillance.">wade.green@nih.gov</a><br> TAB-4870 152588131 Extended Serum Half-Life in Therapeutic Antibodies: Advancements with Enhanced lgG1 Fe Variants NIAID Antibodies, Collaboration, Computational models/software, Licensing, Plasmids/Vectors, Research Equipment, Therapeutics Antibodies Collaboration Computational models/software Licensing Plasmids/Vectors Research Equipment Therapeutics Brandon Dekosky, Wei Jin, Young Do Kwon, Peter Kwong, Baoshan Zhang <p>This technology involves the development of lgG1 Fe variants designed to interact more effectively with the neonatal Fc receptor (FcRn) in a pH-dependent manner. By enhancing this interaction, these variants extend the serum half-life of therapeutic antibodies, reducing the need for frequent administration. This breakthrough holds the potential to make therapeutic antibody treatments more convenient, cost-effective, and accessible for a wide range of diseases.</p> These lgG1 Fe variants possess a unique competitive edge in the therapeutic antibody arena. Their pH-dependent interaction with FcRn extends serum half-life, reducing the need for frequent dosing. This enhanced convenience not only benefits patients but also lowers treatment costs, making these variants an attractive choice for healthcare providers. By addressing the challenges of short serum half-life and high production costs, this technology offers a compelling solution, enhancing the feasibility and affordability of antibody-based therapies for various diseases. The extended serum half-life of these lgG1 Fe variants holds promise across a wide range of therapeutic antibody treatments, including oncology, autoimmune disorders, and infectious diseases. This innovation may enhance treatment effectiveness and convenience in various medical fields. 2024-02-05 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 152588138 Dekosky, Brandon University of Kansas Dekosky, Brandon 1 152588380 Jin, Wei University of Kansas Jin, Wei 2 152588407 Kwong, Peter NIAID Kwong, Peter (NIAID) 3 152588431 Kwon, Young Do NIAID - VRC NIAID Kwon, Young Do (NIAID) 4 152588435 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 5 152588138 Dekosky, Brandon University of Kansas Dekosky, Brandon 1 152588380 Jin, Wei University of Kansas Jin, Wei 2 152588407 Kwong, Peter NIAID Kwong, Peter (NIAID) 3 152588431 Kwon, Young Do NIAID - VRC NIAID Kwon, Young Do (NIAID) 4 152588435 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 5 152588134 COMPOSITIONS INCLUDING IGG Fe MUTATIONS AND USES THEREOF E-048-2020-0 Filing authorized NIAID, University of Kansas 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4870] Extended Serum Half-Life in Therapeutic Antibodies: Advancements with Enhanced lgG1 Fe Variants&body=Please send me information about technology [TAB-4870] Extended Serum Half-Life in Therapeutic Antibodies: Advancements with Enhanced lgG1 Fe Variants. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4870] Extended Serum Half-Life in Therapeutic Antibodies: Advancements with Enhanced lgG1 Fe Variants&body=Please send me information about technology [TAB-4870] Extended Serum Half-Life in Therapeutic Antibodies: Advancements with Enhanced lgG1 Fe Variants.">wade.green@nih.gov</a><br> TAB-4869 152587412 Advancing Anthrax Detection with Monoclonal Antibodies Against Bacillus anthracis Protective Antigen NIAID Antibodies, Collaboration, Diagnostics, Infectious Disease, Licensing, Medical Devices Antibodies Collaboration Diagnostics Infectious Disease Licensing Medical Devices Stephen Leppla <p>This technology involves the creation of monoclonal antibodies through hybridoma technology, specifically, hybridomas 3B6, 14B7, 2D3, 2G4, 1G3, 6H3, 6C5, and 3D12, which exhibit a high degree of reactivity with Bacillus anthracis protective antigen (PA). These monoclonal antibodies have shown great promise in the field of anthrax detection and diagnosis. Their exceptional specificity for Bacillus anthracis PA suggests their potential application in diagnostic devices. The utilization of these antibodies by organizations like InBios has the potential to significantly enhance the accuracy and speed of anthrax detection, a critical advancement in the realms of public health and biodefense. Further research and development efforts may unlock the full potential of these antibodies for practical diagnostic solutions.</p> <p>&nbsp;</p> The monoclonal antibodies produced by hybridomas 3B6, 14B7, 2D3, 2G4, 1G3, 6H3, 6C5, and 3D12 offer a significant competitive advantage in anthrax detection. Their exceptional specificity for Bacillus anthracis protective antigen (PA) ensures highly accurate and reliable diagnosis, reducing the likelihood of false results. This precision and reliability make them a valuable asset for organizations in the field of public health and biodefense seeking to develop advanced anthrax detection methods. The monoclonal antibodies produced by hybridomas 3B6, 14B7, 2D3, 2G4, 1G3, 6H3, 6C5, and 3D12 offer promising applications in the field of anthrax detection, enabling the development of rapid and highly accurate diagnostic tests for Bacillus anthracis infections. These antibodies have the potential to enhance public health efforts by facilitating swift and precise identification of anthrax cases, thus improving patient outcomes. Additionally, they can play a crucial role in biodefense and biosafety measures, aiding in the detection of Bacillus anthracis in various settings and contributing to the safeguarding of public health and national security. 2024-02-05 2026-08-26 2026-08-26 2026-08-26 False True True 52406768 Discovery 52406768 37470483 Website Abstract 152587437 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 1 152587437 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 1 152587415 Monoclonal Antibodies That React With Anthrax Protective Antigen (PA) E-048-2018-0 Research Material NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-4869] Advancing Anthrax Detection with Monoclonal Antibodies Against Bacillus anthracis Protective Antigen&body=Please send me information about technology [TAB-4869] Advancing Anthrax Detection with Monoclonal Antibodies Against Bacillus anthracis Protective Antigen. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-4869] Advancing Anthrax Detection with Monoclonal Antibodies Against Bacillus anthracis Protective Antigen&body=Please send me information about technology [TAB-4869] Advancing Anthrax Detection with Monoclonal Antibodies Against Bacillus anthracis Protective Antigen.">wade.green@nih.gov</a><br> TAB-4867 152586532 Advancements in Coronavirus Vaccine Development: Innovative Engineered RBD Antigens Redefining the Landscape NIAID Antibodies, Collaboration, Computational models/software, Infectious Disease, Licensing, Vaccines Antibodies Collaboration Computational models/software Infectious Disease Licensing Vaccines Thayne Dickey, Niraj Tolia <p>Novel Engineered RBD Antigens: Elevating Coronavirus Vaccine Efficiency and Efficacy. These groundbreaking antigens, derived from the spike protein&#39;s receptor-binding domain, are meticulously designed through a computational pipeline, resulting in superior attributes. They increase protein yield sevenfold, ensuring efficient large-scale manufacturing. With elevated thermal stability and a tenfold boost in antibody production, these antigens present a significant stride towards potent and globally accessible coronavirus vaccines.</p> <p>&nbsp;</p> This technology provides a competitive edge in coronavirus vaccine development. Engineered RBD antigens, designed computationally, offer sevenfold production efficiency, superior thermal stability, and tenfold increased antibody production, potentially leading to more potent vaccines and cost-effective large-scale manufacturing. This technology has diverse potential applications. Beyond coronavirus vaccines, its engineered RBD antigens can serve as a platform for vaccines against other viruses and be valuable for long-term storage in resource-limited areas. They may also enhance diagnostic assays. Furthermore, the computational protein design pipeline could have applications in various biotechnological and pharmaceutical fields. 2024-02-05 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 152586548 Tolia, Niraj Tolia, Niraj 1 152586559 Dickey, Thayne NIAID - DIR NIAID Dickey, Thayne (NIAID) 2 152586548 Tolia, Niraj Tolia, Niraj 1 152586559 Dickey, Thayne NIAID - DIR NIAID Dickey, Thayne (NIAID) 2 152586544 Novel Compositions Of Matter Comprising Stabilized Coronavirus Antigens And Their Use E-045-2021-0 Filing authorized NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4867] Advancements in Coronavirus Vaccine Development: Innovative Engineered RBD Antigens Redefining the Landscape&body=Please send me information about technology [TAB-4867] Advancements in Coronavirus Vaccine Development: Innovative Engineered RBD Antigens Redefining the Landscape. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4867] Advancements in Coronavirus Vaccine Development: Innovative Engineered RBD Antigens Redefining the Landscape&body=Please send me information about technology [TAB-4867] Advancements in Coronavirus Vaccine Development: Innovative Engineered RBD Antigens Redefining the Landscape.">benjamin.hurley@nih.gov</a><br> TAB-4833 152366476 Clinical Advancements in Intracellular Pathogen Infection Treatment through CD47 Blockade for Augmented Phagocytic Clearance NIAID Antibodies, Collaboration, Diagnostics, Immunology, Infectious Disease, Licensing, Research Equipment, Therapeutics Antibodies Collaboration Diagnostics Immunology Infectious Disease Licensing Research Equipment Therapeutics Kim Hasenkrug, Cheryl Stoddart, Kipp Weiskopf, Irving Weissman <p>The technology described involves a groundbreaking method for treating intracellular pathogen infections by targeting CD47, a widely expressed transmembrane glycoprotein that acts as a ligand for phagocytic receptors. By administering agents that inhibit CD47 binding to these receptors, the approach enhances the phagocytic removal of infected cells, leading to increased clearance of intracellular pathogens. The inventors demonstrated the effectiveness of this approach in reducing viral infections caused by various intracellular pathogens, including HIV-1 and Chlamydia trachomatis serovar A. Notably, a prior art search suggests that this innovative method is novel, as there is no identified patent or non-patent literature related to the use of CD47 blockade against intracellular pathogens.</p> <p>&nbsp;</p> The technology's competitive advantages lie in its novel approach to intracellular pathogen infection treatment. By specifically targeting CD47, a broadly expressed molecule, it offers versatility and efficacy across a spectrum of intracellular pathogens. The method's potential to enhance phagocytic clearance represents a targeted and efficient treatment strategy. Furthermore, the absence of existing patents or literature on this precise approach underscores its unique and innovative nature, positioning it favorably in the field of infectious disease treatment. This technology has diverse potential applications, primarily in treating intracellular pathogen infections like HIV-1 and Chlamydia trachomatis serovar A. Additionally, it may have broader implications in regulating immune responses, potentially offering therapeutic solutions for autoimmune disorders and cancer. Its adaptability across various disease contexts makes it a promising avenue for advancing disease management and immunotherapy. 2024-01-24 2026-08-26 2026-08-26 2026-08-26 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 152366483 Hasenkrug, Kim National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Hasenkrug, Kim (NIAID) 1 152366580 Weiskopf, Kipp Stanford University (aka Leland Stanford Junior University) Weiskopf, Kipp 2 152366584 Weissman, Irving Stanford University Weissman, Irving 3 152366588 Stoddart, Cheryl University of California, San Francisco (UCSF) Stoddart, Cheryl 4 152366483 Hasenkrug, Kim National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Hasenkrug, Kim (NIAID) 1 152366580 Weiskopf, Kipp Stanford University (aka Leland Stanford Junior University) Weiskopf, Kipp 2 152366584 Weissman, Irving Stanford University Weissman, Irving 3 152366588 Stoddart, Cheryl University of California, San Francisco (UCSF) Stoddart, Cheryl 4 152366479 CD47-targeted Therapies For The Treatment Of Infectious Disease E-007-2015-0 Filing authorized NIAID, Stanford University, University of California, San Francisco (UCSF) 146046171 Joyce, Terrence terrence.joyce@nih.gov
United States of America terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-4833] Clinical Advancements in Intracellular Pathogen Infection Treatment through CD47 Blockade for Augmented Phagocytic Clearance&body=Please send me information about technology [TAB-4833] Clinical Advancements in Intracellular Pathogen Infection Treatment through CD47 Blockade for Augmented Phagocytic Clearance. Joyce, Terrence<br><a href="mailto:terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-4833] Clinical Advancements in Intracellular Pathogen Infection Treatment through CD47 Blockade for Augmented Phagocytic Clearance&body=Please send me information about technology [TAB-4833] Clinical Advancements in Intracellular Pathogen Infection Treatment through CD47 Blockade for Augmented Phagocytic Clearance.">terrence.joyce@nih.gov</a><br> TAB-5146 168629270 Bifunctional Antibody Fusion Molecules for Use in Cancer Immunotherapy NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics James Gulley, Scott Norberg, Ling Zhang <h2>Summary:</h2> <p>The National Cancer Institute is seeking research co-development partners and licensing collaborators to accelerate the development and commercialization of innovative bifunctional antibody fusion molecules designed to activate and expand engineered TCR-expressing cells, advancing next-generation cancer immunotherapies.</p> <h2>Description of Technology:</h2> <p>T cell receptor (TCR)-T cell technologies equip a patient&rsquo;s immune system with engineered receptors designed to recognize specific disease targets. They harness the power of adoptive cell therapy (ACT). The engineered receptors often comprise mouse constant regions to improve the expression, stability, and safety of the receptor when expressed in human T cells. While clinically effective against several human malignancies, the future of ACT lies in maximizing efficacy while minimizing patient burden. Current protocols often rely on high-dose cytokine regimens, such as aldesleukin (IL-2). These expand T cells non-specifically and are associated with substantial toxicities &ndash; including capillary leak syndrome, high fevers, and hypotension. There is a critical need for technologies that increase the purity and potency of T cell products and enable the selective expansion of engineered TCR-T cells without significant systemic side effects.</p> <p>To address this need, inventors at the National Cancer Institute (NCI) have designed novel bifunctional antibody fusion molecules. These molecules comprise a single-chain variable fragment (scFv) or a fragment antigen-binding (Fab) region derived from the H57-597 antibody fused to a native IL-2 molecule and a fragment crystallizable (Fc) domain. The resulting molecules, named H57scFv_IL2 and H57Fab_IL2, recognize an epitope in the constant region of the mouse TCR&beta; chain and deliver IL-2 specifically to engineered TCR-T cells. This potentially improves T cell product manufacturing, patient safety, and therapeutic efficacy. The inventors have assessed the function of H57scFv_IL2 and H57Fab_IL2 in engineered T cells expressing HPV16 E7-targeting TCRs or NY-ESO-1-targeting TCRs. These in vitro studies demonstrate enhanced cytotoxic activity compared to untreated TCR-T cells and the H57-597 antibody alone.</p> <p>The NCI is seeking research co-development partners and/or licensees to advance the bifunctional antibody fusion molecules for use in adoptive cell therapy. These molecules have the potential to be used during cell manufacturing and/or as adjuvant immunotherapy following administration of the TCR-T cell product. The benefits include selective activation and expansion of engineered TCR-T cells ex vivo or in patients.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Metastatic, relapsed or refractory cancers.</li> <li>Autoimmune diseases.</li> <li>Certain rare diseases.</li> <li>Bifunctional molecules may be applicable to the treatment of a variety of diseases that is addressed by ACT.</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Bifunctional molecules support and enhance adoptive cell therapy (ACT), in particular, engineered TCR-based therapies.</li> <li>Bifunctional antibody-fusion molecules specifically expand T cells engineered to express TCRs &ndash; compared to non-specific CD3/CD28 agonizing antibodies and IL-2.</li> <li>Expected to be safer and more effective than high-dose IL-2.</li> <li>Single step approach for targeted delivery of cytokines into engineered TCR-T cells</li> </ul> <p><img alt="" src="https://nih.technologypublisher.com/files/sites/picture216.jpg" style="height:537px; width:955px" /></p> Researchers at the NCI seek licensing and/or co-development research collaborations for bifunctional antibody fusion molecules to use in adoptive cell therapy. 2026-08-18 2026-08-25 2026-08-25 2026-08-18 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 168629319 Norberg, Scott NIH - NCI NCI Norberg, Scott (NCI) 1 168629323 Gulley, James NIH - NCI NCI Gulley, James (NCI) 2 168629429 Zhang, Ling NIH - NCI NCI Zhang, Ling (NCI) 3 168629319 Norberg, Scott NIH - NCI NCI Norberg, Scott (NCI) 1 168629323 Gulley, James NIH - NCI NCI Gulley, James (NCI) 2 168629429 Zhang, Ling NIH - NCI NCI Zhang, Ling (NCI) 3 168629273 Bifunctional antibodies that target mouse TCR beta constant region and selectively deliver cytokines to cells expressing engineered TCRs and the use of such antibodies in adoptive cell therapy E-211-2025-0 Filing authorized NIH - NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-5146] Bifunctional Antibody Fusion Molecules for Use in Cancer Immunotherapy&body=Please send me information about technology [TAB-5146] Bifunctional Antibody Fusion Molecules for Use in Cancer Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-5146] Bifunctional Antibody Fusion Molecules for Use in Cancer Immunotherapy&body=Please send me information about technology [TAB-5146] Bifunctional Antibody Fusion Molecules for Use in Cancer Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">suna.gulay@nih.gov</a><br> 168629278 E-211-2025-0 E-211-2025-0-US-01 BIFUNCTIONAL PROTEINS TARGETING MURINE TCR CONSTANT REGION AND METHODS OF ACTIVATING AND EXPANDING THE NUMBER OF HUMAN T CELLS EXPRESSING THE MURINE TCR CONSTANT REGION USING SAME PRV US 63/976,687 Pending US <br />Provisional (PRV) 63/976,687<br />Filed on 2026-02-05<br />Status: Pending TAB-4466 149818526 Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging NEI Collaboration, Ear, Nose, & Throat, Licensing, Software / Apps, TherapeuticArea Collaboration Ear Nose & Throat Licensing Software / Apps TherapeuticArea Catherine Cukras, Wathudurage De Silva <h2>Summary:</h2> <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for an automatic deep learning-based algorithm to detect and quantitate ellipsoid zone (EZ) loss in Spectral Domain Optical Coherence Tomography (SD-OCT) images.</p> <h2>Description of Technology:</h2> <p>The present disclosure generally relates a method of automatically detecting ellipsoid zone (EZ) loss in spectral domain optical coherence tomography (SD-OCT) imaging. EZ band represents outer segments of photoreceptors in the retina, and its loss reflects a deterioration of the photoreceptors. EZ loss has been proposed to be evidence of progression of several retinal degenerative diseases including, but not limited to, retinitis pigmentosa and hydroxychloroquine (HCQ)-induced retinal toxicity. HCQ is a first-line drug used to treat autoimmune diseases such as systemic lupus erythematosus, Sj&ouml;gren&rsquo;s syndrome, and rheumatoid arthritis. One of the major side-effects that can occur in long-term users of HCQ, is EZ loss that can result in retinal toxicity and permanent damage to photoreceptors and retinal pigment epithelium (RPE), eventually leading to irreversible loss of central vision. The American Academy of Ophthalmology (AAO) recommends two main screening modalities including SD-OCT imaging and functional tests such as visual fields with the goal of recognizing early definitive signs of HCQ-induced retinal toxicity to prevent vision loss. Although this side-effect is estimated to occur in 7.5% of patients taking the drug for more than 10 years, we currently have no treatment for this serious side effect that tends to continue even after the cessation of the drug.</p> <p>Researchers at the NEI have developed a method that can automatically detect and quantitate EZ loss in SD-OCT images immediately after image acquisition. The method includes a deep learning framework with a two-step approach. In the first stage, the method detects and annotates EZ loss regions in individual OCT B-scans. A 2D map is constructed twice in a dual architecture to enhance robustness, where horizontal and vertical slices extracted from the 3D image are trained separately. The second stage of the model operates on these two 2D maps and estimates the final EZ loss map representing the 3D OCT volume. Compared to other screening methods, the algorithm demonstrated excellent performance in diagnosing toxicity even as a stand-alone test, with an F1 score, a measure of test accuracy, of 0.91. This indicates the utility of the tool in assisting with screening for toxicity in an automatic, accurate, time-effective, cost-effective, and objective manner. Addition of this methodology onto current SD-OCT screening could assist the clinician in making diagnostic and treatment decisions immediately after SD-OCT acquisitions.</p> <p>Protected claims for this invention include the method of detecting and outlining the region of EZ loss directly from acquired OCT images, associated algorithms, and the device containing these algorithms and capabilities. This technology is available for licensing.</p> <h2>Potential Commercial Applications:</h2> <ul> <li style="margin-left:8px">Methodology to integrate with SD-OCT imaging for screening applications for different retinal degeneration diseases</li> <li style="margin-left:8px">Implementation of this automatic algorithm also in screening outside of ophthalmology offices (OCTs become more ubiquitous in internal medicine settings)</li> <li style="margin-left:8px">Quantitative data produced from the algorithms could provide surrogate end points for use in clinical trials and interventional studies aimed at halting progression of degenerative changes</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li style="margin-left:8px">Accurate and robust method: Provides excellent performance in diagnosing toxicity as a stand-alone test and compared to qualitative inspection of SD-OCT images</li> <li style="margin-left:8px">Time-efficient (can evaluate SD-OCT volumes): Fully automatic and available within seconds after SD-OCT acquisition</li> <li style="margin-left:8px">Objective: Performs as well as human grading in eyes that demonstrate even small amounts of EZ loss</li> <li style="margin-left:8px">Does not require segmentation of intact layers, avoiding failures in cases of layer deterioration</li> <li style="margin-left:8px">Does not require a large number of training examples, useful for rare diseases</li> </ul> <p><img alt="" src="https://nih.technologypublisher.com/files/sites/image435.png" style="height:391px; width:1042px" /></p> <p><br /> &emsp;</p> 2023-09-20 2026-04-30 2026-08-24 2023-10-05 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 150109557 De Silva T, et al. Deep Learning-Based Automatic Detection of Ellipsoid Zone Loss in Spectral-Domain OCT for Hydroxychloroquine Retinal Toxicity Screening (PMID 36246938) https://pubmed.ncbi.nlm.nih.gov/36246938/ <a href="https://pubmed.ncbi.nlm.nih.gov/36246938/">De Silva T, et al. Deep Learning-Based Automatic Detection of Ellipsoid Zone Loss in Spectral-Domain OCT for Hydroxychloroquine Retinal Toxicity Screening (PMID 36246938)</a> 150044076 De Silva, Wathudurage National Eye Institute (NEI) De Silva, Wathudurage 3 150044080 Cukras, Catherine Division of Epidemiology and Clinical Application NEI Cukras, Catherine (NEI) 4 150044076 De Silva, Wathudurage National Eye Institute (NEI) De Silva, Wathudurage 3 150044080 Cukras, Catherine Division of Epidemiology and Clinical Application NEI Cukras, Catherine (NEI) 4 149818530 Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging E-194-2021 Filing authorized National Eye Institute (NEI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4466] Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging&body=Please send me information about technology [TAB-4466] Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4466] Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging&body=Please send me information about technology [TAB-4466] Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 150655563 E-194-2021 E-194-2021-0-US-01 SYSTEMS AND METHODS TO AUTOMATICALLY DETECT HYDROXYCHLOROQUINE-INDUCED RETINAL TOXICITY IN SD-OCT IMAGING PRV US 63/241,823 Abandoned US <br />Provisional (PRV) 63/241,823<br />Filed on 2021-09-08<br />Status: Abandoned 150655571 E-194-2021 E-194-2021-0-PCT-02 Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging PCT Patent Cooperation Treaty PCT/US2022/076135 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/076135<br />Filed on 2022-09-08<br />Status: Expired 164119729 E-194-2021 E-194-2021-0-CA-03 Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging National Stage Canada 3230840 Pending Canada <br />National Stage 3230840<br />Filed on 2024-03-01<br />Status: Pending 164119730 E-194-2021 E-194-2021-0-AU-04 Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging National Stage Australia 2022344259 Pending Australia <br />National Stage 2022344259<br />Filed on 2024-02-22<br />Status: Pending 164119731 E-194-2021 E-194-2021-0-US-05 Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging National Stage US 12,718,368 18/690,130 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12718368 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12718368">12,718,368</a><br />Filed on 2024-03-07<br />Status: Issued 164119732 E-194-2021 E-194-2021-0-EP-06 Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging National Stage European Patent 22789416.9 Pending European Patent <br />National Stage 22789416.9<br />Filed on 2024-03-08<br />Status: Pending 168674640 E-194-2021 E-194-2021-1-US-05 SYSTEMS AND METHODS TO AUTOMATICALLY DETECT ELLIPSOID ZONE LOSS IN SD-OCT IMAGING DIV US 19/784,715 Pending US <br />Divisional (DIV) 19/784,715<br />Filed on 2026-08-24<br />Status: Pending TAB-5044 160834770 Precision, Optimally Targeted, ElectroConvulsive Therapy (PROTECT) NIMH Zhi-De Deng, George Dold, Junghee Kim, Sarah Lisanby, Bruce Pritchard, Robert Schor <p style="font-family:Arial Narrow; font-size:16px"><span style="font-size:12pt"><span style="tab-stops:28.0pt 56.0pt 84.0pt 112.0pt 140.0pt 168.0pt 196.0pt 224.0pt 3.5in 280.0pt 308.0pt 336.0pt"><span style="text-autospace:none"><span style="font-family:&quot;Times New Roman&quot;,serif">The PRecision, Optimally Targeted Electroconvulsive Therapy (PROTECT) is a novel stimulator device, which aims to improve the treatment of treatment-resistant depression (TRD). Millions of individuals suffer from TRD for which electroconvulsive therapy (ECT) is often the most efficacious treatment option; yet present devices lack precision in electric field delivery, leading to variable outcomes and cognitive side effects. PROTECT is a next-generation stimulator designed to revolutionize ECT through its novel waveforms and pulse patterns, which optimize brain stimulation with unparalleled precision. By integrating cutting-edge computational modeling and advanced hardware, PROTECT enables customized stimulation paradigms, enhancing efficacy while reducing unwanted side effects. This technology sets a new standard for ECT, offering clinicians and patients a more targeted, effective, and personalized approach to treatment.</span></span></span></span></p> First ECT device of its kind to: <ul> <li>offer both conventional AND complex stimulation patterns along with advanced computational modeling</li> <li>be complemented with state-of-the-art computational E-field modeling and optimization algorithms that can used to achieve optimized dosimetry for seizure therapy</li> <li>allow individualized dosing to maximize therapeutic effect, while reducing side effects of convention ECT</li> </ul> Treatment of a broad range of clinical disorders for which ECT has shown efficacy, including: <ul> <li>Treatment Resistant Depression (TRD) </li> <li>Major Depressive Episode associated with major depressive disorder (MDD) or bipolar disorder (BP) </li> <li>Catatonia</li> <li>Schizophrenia</li> <li>Schizoaffective disorder</li> <li>Schizophreniform disorder</li> <li>Status epilepticus</li> </ul> The National Institute of Mental Health is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology: electroconvulsive therapy devices. For collaboration opportunities, please contact: Jennifer Wong, MS at wongje@mail.nih.gov 2025-02-27 2025-04-08 2026-08-17 2025-03-03 False False In vivo data available (animal) True 52406769 Prototype 52406769 37470483 Website Abstract 160835133 Deng, Zhi-De National Institute of Mental Health (NIMH) NIMH Deng, Zhi-De (NIMH) 1 160835140 Pritchard, Bruce National Institute of Mental Health (NIMH) NIMH Pritchard, Bruce (NIMH) 2 160835155 Dold, George National Institute of Mental Health (NIMH) NIMH Dold, George (NIMH) 3 160835353 Kim, Junghee National Institute of Mental Health (NIMH) NIMH Kim, Junghee (NIMH) 4 160835375 Schor, Robert National Institute of Mental Health (NIMH) NIMH Schor, Robert (NIMH) 5 160835471 Lisanby, Sarah National Institute of Mental Health (NIMH) NIMH Lisanby, Sarah (NIMH) 6 160835133 Deng, Zhi-De National Institute of Mental Health (NIMH) NIMH Deng, Zhi-De (NIMH) 1 160835140 Pritchard, Bruce National Institute of Mental Health (NIMH) NIMH Pritchard, Bruce (NIMH) 2 160835155 Dold, George National Institute of Mental Health (NIMH) NIMH Dold, George (NIMH) 3 160835353 Kim, Junghee National Institute of Mental Health (NIMH) NIMH Kim, Junghee (NIMH) 4 160835375 Schor, Robert National Institute of Mental Health (NIMH) NIMH Schor, Robert (NIMH) 5 160835471 Lisanby, Sarah National Institute of Mental Health (NIMH) NIMH Lisanby, Sarah (NIMH) 6 160834773 Precision, Optimally Targeted, ElectroConvulsive Therapy (PROTECT) E-214-2023-0 Filing authorized National Institute of Mental Health (NIMH), National Institute of Mental Health (NIMH), National Institute of Mental Health (NIMH) 83739514 Dawson, Anton anton.dawson@nih.gov
United States of America anton.dawson@nih.gov?subject=Web Inquiry on [TAB-5044] Precision, Optimally Targeted, ElectroConvulsive Therapy (PROTECT)&body=Please send me information about technology [TAB-5044] Precision, Optimally Targeted, ElectroConvulsive Therapy (PROTECT). Dawson, Anton<br><a href="mailto:anton.dawson@nih.gov?subject=Web Inquiry on [TAB-5044] Precision, Optimally Targeted, ElectroConvulsive Therapy (PROTECT)&body=Please send me information about technology [TAB-5044] Precision, Optimally Targeted, ElectroConvulsive Therapy (PROTECT).">anton.dawson@nih.gov</a><br> 160834778 E-214-2023-0 E-214-2023-0-US-01 SYSTEMS AND METHODS FOR ADJUSTABLE CURRENT INDIVIDUALIZED STIMULATION THERAPY PRV US 63/656,515 Expired US <br />Provisional (PRV) 63/656,515<br />Filed on 2024-06-05<br />Status: Expired 161154641 E-214-2023-0 E-214-2023-0-PC-01 SYSTEMS AND METHODS FOR ADJUSTABLE CURRENT INDIVIDUALIZED STIMULATION THERAPY PCT Patent Cooperation Treaty PCT/US2025/027755 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/027755<br />Filed on 2025-05-05<br />Status: Pending 168611274 E-214-2023-0 E-214-2023-0-US-02 Precision, Optimally Targeted, ElectroConvulsive Therapy (PROTECT) National Stage US In Preparation US <br />National Stage None<br />Filed on None<br />Status: In Preparation 168611402 E-214-2023-0 E-214-2023-0-EP-01 Precision, Optimally Targeted, ElectroConvulsive Therapy (PROTECT) National Stage European Patent In Preparation European Patent <br />National Stage None<br />Filed on None<br />Status: In Preparation TAB-5070 163753648 C8166-45 and C8166 Cells NCI Infectious Disease, Licensing, Oncology, Research Materials Infectious Disease Licensing Oncology Research Materials Genoveffa Franchini, Robert Gallo, V Kalyanaraman, Phillip Markham, Syed Salahuddin, Flossie Wong-Staal <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks licensees for human T-cell lines, C8166 and C8166-45, transformed by HTLV-1. C8166-45, a subclone of C8166, contains three transcriptionally active proviruses useful for testing biological activities involved in T-cell immortalization and growth.</p> <h2>Description of Technology: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h2> <p>Human T-cell leukemia virus type 1 (HTLV-1) was the first human retrovirus reported and is recognized as an etiological agent of adult T-cell leukemia (ATL). However, only a small percentage of individuals develop symptomatic ATL which carries a poor prognosis. The latency period can last for decades and universal screening for HTLV-1 infection has ceased. Thus, the C8166-45 and C8166 cell lines are &nbsp;necessary components for understanding the mechanisms of HTLV-1 infection and improving clinical outcomes.</p> <p>NCI researchers derived C8166-45 by cocultivation or fusion of umbilical cord blood lymphocyte with T-cells cultures from leukemia-lymphoma patients. It is highly permissive to HIV-1 infection and characterized for its suitability in replication-competent lentiviral (RCL) assays to assess its safety for gene therapy products, such as lentiviral vectors. Both cell lines are highly useful in studying viral protein interactions, immortalization of human T-cells, and HIV replication.</p> <p>NCI is seeking parties to non-exclusively license the C8166-45 and C8166 cell lines.</p> <h2>Potential Commercial Applications: &nbsp;</h2> <ul> <li>Investigation of HTLV pathogenesis and replication</li> <li>Studies of virus-induced T-cell transformation</li> <li>Studies of HTLV expression regulation by human T-cells</li> <li>Studies of HIV replication</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Contains a low amount of viral proteins</li> <li>Does not release detectable virus particles</li> <li>Suitable for testing RCL assay sensitivity</li> </ul> The NCI seeks licensing for the C8166-45 and C8166 cell lines. 2025-08-19 2026-08-14 2026-08-05 2026-08-14 2025-08-19 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2026-08-05 72159134 Analytical Assay Performance Stage 72159134 NCI 37470483 Website Abstract 163753705 DeBoer J, et al. Alterations in the nuclear proteome of HIV-1 infected T-cells. (PMID 25240327) https://pubmed.ncbi.nlm.nih.gov/25240327/ <a href="https://pubmed.ncbi.nlm.nih.gov/25240327/">DeBoer J, et al. Alterations in the nuclear proteome of HIV-1 infected T-cells. (PMID 25240327)</a> 163753890 Salahuddin SZ, et al. Restricted expression of human T-cell leukemia-lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes. (PMID 6412453) https://pubmed.ncbi.nlm.nih.gov/6412453/ <a href="https://pubmed.ncbi.nlm.nih.gov/6412453/">Salahuddin SZ, et al. Restricted expression of human T-cell leukemia-lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes. (PMID 6412453)</a> 163753898 Cornetta K, et al. Absence of replication-competent lentivirus in the clinic: analysis of infused T cell products. (PMID 28970045) https://pubmed.ncbi.nlm.nih.gov/28970045/ <a href="https://pubmed.ncbi.nlm.nih.gov/28970045/">Cornetta K, et al. Absence of replication-competent lentivirus in the clinic: analysis of infused T cell products. (PMID 28970045)</a> 163753789 Franchini, Genoveffa NCI - CCR NCI Franchini, Genoveffa (NCI) 1 163753806 Salahuddin, Syed NIH - NCI Salahuddin, Syed 2 163753818 Wong-Staal, Flossie NIH - NCI Wong-Staal, Flossie 3 163753838 Gallo, Robert NIH - NCI NCI Gallo, Robert (NCI) 4 163753857 Markham, Phillip NIH - NCI Markham, Phillip 5 163753861 Kalyanaraman, V NIH - NCI Kalyanaraman, V 6 163753789 Franchini, Genoveffa NCI - CCR NCI Franchini, Genoveffa (NCI) 1 163753806 Salahuddin, Syed NIH - NCI Salahuddin, Syed 2 163753818 Wong-Staal, Flossie NIH - NCI Wong-Staal, Flossie 3 163753838 Gallo, Robert NIH - NCI NCI Gallo, Robert (NCI) 4 163753857 Markham, Phillip NIH - NCI Markham, Phillip 5 163753861 Kalyanaraman, V NIH - NCI Kalyanaraman, V 6 163753654 C8166-45 Cell Line (NIH AIDS Reagent Repository Catalog No. 404) and C8166 cell line E-272-2007-0 Research Material NCI 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-5070] C8166-45 and C8166 Cells&body=Please send me information about technology [TAB-5070] C8166-45 and C8166 Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-5070] C8166-45 and C8166 Cells&body=Please send me information about technology [TAB-5070] C8166-45 and C8166 Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">diptadip.dattaroy@nih.gov</a><br> TAB-2808 114096988 Use of Antihistamine Compounds for the Treatment of Hepatitis C Virus NIDDK Infectious Disease, Licensing, Therapeutics Infectious Disease Licensing Therapeutics Shanshan (Melissa) He, Zongyi Hu, Tsanyang (Jake) Liang, Wei Zheng The vast majority of people infected with Hepatitis C Virus (HCV) will have chronic infection. Over decades, this can lead to liver disease and liver cancer. In fact, HCV infection is the leading cause of liver transplants in the U.S. Several new drugs have recently come into the market that will likely change the HCV treatment paradigm. However, the effectiveness of these new drugs can vary depending on the HCV genotype. Thus, there is still the need for additional new therapeutics against HCV.<br /><br /> The subject technology are small molecule compounds identified using a novel cell-based high throughput assay of HCV infection. The compounds are antihistamines that show potent antiviral properties against HCV. One advantage of these compounds is that they are already on the market for the treatment of allergic reactions and, thus, have been used extensively in humans and have excellent safety profiles with known pharmaceutical properties. The subject technology can also potentially be used in combination with other HCV therapeutics. <ul> <li>These compounds are already on the market and, thus, have known safety profiles and pharmaceutical properties.</li> </ul> <ul> <li>Prevention or treatment of HCV infection.</li> <ul> 2022-03-08 2026-08-14 2026-08-14 2017-04-18 Analogs, C, Chlorcyclizine, DB4BXX, Hepatitis, RELATED, treatment, VLXXXX, WKXXXX, YAXXXX, YBXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114108684 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114108685 He, Shanshan (Melissa) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) He, Shanshan (Melissa) 0 114108686 Hu, Zongyi National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Hu, Zongyi (NIDDK) 0 114107484 Liang, Tsanyang (Jake) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Liang, Tsanyang (Jake) (NIDDK) 1 114107484 Liang, Tsanyang (Jake) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Liang, Tsanyang (Jake) (NIDDK) 1 114108684 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114108685 He, Shanshan (Melissa) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) He, Shanshan (Melissa) 0 114108686 Hu, Zongyi National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Hu, Zongyi (NIDDK) 0 114101692 Use Of Chlorcyclizine And Its Related Analogs In Treatment Of Hepatitis C E-011-2014-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NCATS - NCGC 83728636 Buller, Carolyn carolyn.buller@nih.gov
United States of America Technology Advancement Office carolyn.buller@nih.gov?subject=Web Inquiry on [TAB-2808] Use of Antihistamine Compounds for the Treatment of Hepatitis C Virus&body=Please send me information about technology [TAB-2808] Use of Antihistamine Compounds for the Treatment of Hepatitis C Virus. Buller, Carolyn<br><a href="mailto:carolyn.buller@nih.gov?subject=Web Inquiry on [TAB-2808] Use of Antihistamine Compounds for the Treatment of Hepatitis C Virus&body=Please send me information about technology [TAB-2808] Use of Antihistamine Compounds for the Treatment of Hepatitis C Virus.">carolyn.buller@nih.gov</a><br> 114161387 E-011-2014-0 E-011-2014-0-PCT-02 Heterocyclic Compounds and Methods of Use Thereof PCT Patent Cooperation Treaty PCT/US2014/066680 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/066680<br />Filed on 2014-11-20<br />Status: Expired 114166359 E-011-2014-0 E-011-2014-0-US-08 Piperidine and Piperazine Derivatives and Their Use in Treating Viral Infections and Cancer National Stage US 15/039,781 Abandoned US <br />National Stage 15/039,781<br />Filed on 2016-05-26<br />Status: Abandoned 114167748 E-011-2014-0 E-011-2014-0-US-01 Heterocyclic Compounds and Methods of Use Thereof PRV US 61/909,414 Abandoned US <br />Provisional (PRV) 61/909,414<br />Filed on 2013-11-27<br />Status: Abandoned 114125940 DB4BXX 114125941 VLXXXX 114125942 WKXXXX 114125943 YAXXXX 114125944 YBXXXX 114147147 Chlorcyclizine 114147148 RELATED 114147149 Analogs 114147150 treatment 114147151 Hepatitis 114147152 C TAB-2420 114096622 Alb-tTA (Tg(Alb1-tTA)3123Lng) Mouse Model for Liver Function Studies NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Tsanyang (Jake) Liang Tetracycline-responsive transcriptional activator driven by the liver-specific mouse albumin promoter (Alb-tTA). <br /><br /> The E. Coli tetracycline operon regulatory system was used to generate a liver-specific transcription activation system that was inhibited by tetracycline. The transcription activator was a fused protein consisting of a tetracycline repressor gene (tetR) that was only active in the presence of tetracycline and a herpes simplex virus protein (VP-16) transcription activating domain. Transcription was induced only in the absence of tetracycline (Tet-Off). A liver-specific promoter such as mouse albumin determined that the tetracycline-regulated transcriptional activator (tTA) would be expressed specifically in liver. To study the effect of the transcription activator on a target gene (for example, Simian Virus 40 (SV4) large tumor (T) antigen (TAg)) specifically in liver, Alb-tTA mice were mated with transgenic mice in which the Target gene (TAg) was controlled by the E.Coli Tetracycline Operator (Tet-O). In this example, TAg was expressed in hepatocytes in the absence of Tetracycline, leading to hepatoma formation. When the mice were treated with tetracycline, TAg was not expressed and hepatomas did not form. Mouse model to liver function. Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2026-08-14 2026-08-14 2017-04-18 Alb-tTA, IDXXXX, IXXXXX, Mouse, TgAlb1-tTa3123Lng False True Pre-clinical True NIHTT 37470483 Website Abstract 114171565 Manickan E, et al. http://www.ncbi.nlm.nih.gov/pubmed/11278564 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11278564">Manickan E, et al.</a> 114107523 Liang, Tsanyang (Jake) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Liang, Tsanyang (Jake) (NIDDK) 1 114107523 Liang, Tsanyang (Jake) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Liang, Tsanyang (Jake) (NIDDK) 1 114101722 Alb-tTA (Tg(Alb1-tTa)3123Lng) Mouse E-125-2012-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83728636 Buller, Carolyn carolyn.buller@nih.gov
United States of America Technology Advancement Office carolyn.buller@nih.gov?subject=Web Inquiry on [TAB-2420] Alb-tTA (Tg(Alb1-tTA)3123Lng) Mouse Model for Liver Function Studies&body=Please send me information about technology [TAB-2420] Alb-tTA (Tg(Alb1-tTA)3123Lng) Mouse Model for Liver Function Studies. Buller, Carolyn<br><a href="mailto:carolyn.buller@nih.gov?subject=Web Inquiry on [TAB-2420] Alb-tTA (Tg(Alb1-tTA)3123Lng) Mouse Model for Liver Function Studies&body=Please send me information about technology [TAB-2420] Alb-tTA (Tg(Alb1-tTA)3123Lng) Mouse Model for Liver Function Studies.">carolyn.buller@nih.gov</a><br> 114122721 IXXXXX 114122722 IDXXXX 114142903 Alb-tTA 114142904 TgAlb1-tTa3123Lng 114142905 Mouse TAB-2421 114096623 MUP-tTA Mouse Model for Liver Function Studies NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Tsanyang (Jake) Liang Tetracycline-responsive transcriptional activator driven by the liver-specific mouse major urinary protein promoter (MUP-tTA). <br /><br /> The E. Coli tetracycline operon regulatory system was used to generate a liver-specific transcription activation system that was inhibited by tetracycline. The transcription activator was a fused protein consisting of a tetracycline repressor gene (tetR) that was only active in the presence of tetracycline and a herpes simplex virus protein (VP-16) transcription activating domain (Tet-Off). Transcription was induced only in the absence of tetracycline (Tet-Off). A liver-specific promoter such as the mouse major urinary protein (MUP) promoter determined that the tetracycline-regulated transcriptional activator (tTA) would be expressed specifically in liver. To study the effect of the transcription activator on a target gene (for example, beta-galactosidase, LacZ) specifically in liver, MUP-tTA mice would be mated with transgenic mice in which the TAg Target gene was controlled by the E.Coli Tetracycline Operator (Tet-O). The Tet technology may require a separate license. Mouse model to study liver function. Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2026-08-14 2026-08-14 2017-04-17 IDXXXX, IXXXXX, Mouse, MUP-tTA False True Pre-clinical True NIHTT 37470483 Website Abstract 114171566 Manickan E, et al. http://www.ncbi.nlm.nih.gov/pubmed/11278564 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11278564">Manickan E, et al.</a> 114107524 Liang, Tsanyang (Jake) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Liang, Tsanyang (Jake) (NIDDK) 1 114107524 Liang, Tsanyang (Jake) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Liang, Tsanyang (Jake) (NIDDK) 1 114101723 MUP-tTA Mouse E-126-2012-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83728636 Buller, Carolyn carolyn.buller@nih.gov
United States of America Technology Advancement Office carolyn.buller@nih.gov?subject=Web Inquiry on [TAB-2421] MUP-tTA Mouse Model for Liver Function Studies&body=Please send me information about technology [TAB-2421] MUP-tTA Mouse Model for Liver Function Studies. Buller, Carolyn<br><a href="mailto:carolyn.buller@nih.gov?subject=Web Inquiry on [TAB-2421] MUP-tTA Mouse Model for Liver Function Studies&body=Please send me information about technology [TAB-2421] MUP-tTA Mouse Model for Liver Function Studies.">carolyn.buller@nih.gov</a><br> 114122723 IXXXXX 114122724 IDXXXX 114142906 MUP-tTA 114142907 Mouse TAB-1930 114096151 Small Molecule Activators of Human Pyruvate Kinase for Treatment of Cancer and Enzyme-Deficient Hemolytic Anemia NCATS Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Craig Thomas NIH investigators have discovered a series of small compounds with the potential to treat a variety of cancers as well as hemolytic anemia. Contrary to most cancer medications, these molecules can be non-toxic to normal cells because they target a protein specific to the metabolic pathways in tumors, thus representing a significant clinical advantage over less-specific chemotherapeutics. <br><br> The invention described here is a series of small molecules that activate pyruvate kinase (PK) isoform M2. PK-M2 is a critical metabolic enzyme that is affected in all forms of cancer. Inactivation of PK-M2 leads to a buildup of metabolic intermediates inside the cell. Tumor cells require a buildup of metabolic intermediates in order to undergo rapid cell growth and proliferation. Hence, activation of PK-M2 in tumor cells may prevent the buildup of metabolic intermediates and thereby stall tumor cell proliferation or destroy the tumor cells. Further, while in normal adult cells only PK isoforms R, L, or M1 are active, in all tumors only PK-M2 is active. Therefore, PK-M2 activation would affect only tumor cells, and small-molecule PK-M2 activators are not expected to be toxic to healthy cells. <br><br> In addition, in patients with PK-R deficiency the buildup of metabolic intermediates in red blood cells ultimately leads to the loss of water from the cells and cell death. Small-molecule induced activation of PK-R in PK-deficient red blood cells may enhance vitality of these cells and decrease or eliminate enzyme-deficient hemolytic anemia in a patient. <ul> <li>Therapeutic for cancer</li> <li>Therapeutic for enzyme-deficient hemolytic anemia</li> </ul> The NIH Chemical Genomics Center is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize appropriate lead compounds described in U.S. Provisional Application No. 61/199,763. Please contact Dr. Craig J. Thomas via e-mail (<a href="mailto:craigt@nhgri.nih.gov">craigt@nhgri.nih.gov</a>) for more information. Available for licensing. 2022-03-08 2026-08-14 2026-08-14 2009-05-05 3-@hydroxyacyl-coa dehydrogenase deficiency, ACTIVATORS, CB3CXX, CB3XXX, CBXXXX, CXXXXX, HAD deficiency, HIS deficiency, Histidinemia, Human, Kinase, MOLECULE, Patent Category - Chemistry, PYRUVATE, Small False True Early stage True NIHTT 37470483 Website Abstract 114170807 In preparation In preparation 114106578 Thomas, Craig National Human Genome Research Institute (NHGRI) NCATS Thomas, Craig (NCATS) 1 114106578 Thomas, Craig National Human Genome Research Institute (NHGRI) NCATS Thomas, Craig (NCATS) 1 114101203 Small Molecule Activators Of Human Pyruvate Kinase E-326-2008-0 Filing authorized NCATS - NCGC 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-1930] Small Molecule Activators of Human Pyruvate Kinase for Treatment of Cancer and Enzyme-Deficient Hemolytic Anemia&body=Please send me information about technology [TAB-1930] Small Molecule Activators of Human Pyruvate Kinase for Treatment of Cancer and Enzyme-Deficient Hemolytic Anemia. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-1930] Small Molecule Activators of Human Pyruvate Kinase for Treatment of Cancer and Enzyme-Deficient Hemolytic Anemia&body=Please send me information about technology [TAB-1930] Small Molecule Activators of Human Pyruvate Kinase for Treatment of Cancer and Enzyme-Deficient Hemolytic Anemia.">rebecca.erwin-cohen@nih.gov</a><br> 114165153 E-326-2008-0 E-326-2008-0-US-01 Activators of Human Pyruvate Kinase PRV US 61/104,091 Abandoned US <br />Provisional (PRV) 61/104,091<br />Filed on 2008-10-09<br />Status: Abandoned 114165624 E-326-2008-0 E-326-2008-0-PCT-02 Activators Of Human Pyruvate Kinase PCT Patent Cooperation Treaty PCT/US2009/060237 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2009/060237<br />Filed on 2009-10-09<br />Status: Expired 114166388 E-326-2008-0 E-326-2008-0-US-07 Activators Of Human Pyruvate Kinase M2 Receptor CON US 8,841,305 13/123,297 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8841305 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8841305">8,841,305</a><br />Filed on 2011-04-25<br />Status: Issued 114166695 E-326-2008-0 E-326-2008-0-US-08 Activators Of Human Pyruvate Kinase CON US 8,937,067 13/433,656 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8937067 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8937067">8,937,067</a><br />Filed on 2012-03-29<br />Status: Issued 114167103 E-326-2008-0 E-326-2008-0-US-11 Activators Of Human Pyruvate Kinase CON US 9,707,230 15/076,258 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9707230 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9707230">9,707,230</a><br />Filed on 2016-03-21<br />Status: Issued 114168036 E-326-2008-0 E-326-2008-0-US-10 Activators Of Human Pyruvate Kinase DIV US 9,290,512 14/576,333 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9290512 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9290512">9,290,512</a><br />Filed on 2014-12-19<br />Status: Issued 114120140 CB3CXX 114120141 CXXXXX 114120142 CBXXXX 114120143 CB3XXX 114137595 Small 114137596 MOLECULE 114137597 ACTIVATORS 114137598 Human 114137599 PYRUVATE 114137600 Kinase 114137601 Patent Category - Chemistry 114156780 3-@hydroxyacyl-coa dehydrogenase deficiency 114156781 Histidinemia 114158487 HAD deficiency 114158488 HIS deficiency TAB-2202 114096417 Pyruvate Kinase M2 Activators for the Treatment of Cancer NCATS Collaboration, Oncology, Therapeutics Collaboration Oncology Therapeutics Douglas Auld, Matthew Boxer, Min Shen, Craig Thomas NIH investigators have discovered a series of small compounds with the potential to treat a variety of cancers as well as hemolytic anemia. Contrary to most cancer medications, these molecules can be non-toxic to normal cells because they target a protein specific to the metabolic pathways in tumors, thus representing a significant clinical advantage over less-specific chemotherapeutics.<br /><br /> The invention described here is a series of small molecules that activate pyruvate kinase (PK) isoform M2. PK-M2 is a critical metabolic enzyme that is affected in all forms of cancer. Inactivation of PK-M2 leads to a buildup of metabolic intermediates inside the cell. Tumor cells require a buildup of metabolic intermediates in order to undergo rapid cell growth and proliferation. Hence, activation of PK-M2 in tumor cells may prevent the buildup of metabolic intermediates and thereby stall tumor cell proliferation or destroy the tumor cells. Further, while in normal post-embryonic cells only PK isoforms R, L, or M1 are active, in all tumors only PK-M2 is active. So, PK-M2 activation would affect only tumor cells, and small-molecule PK-M2 activators may not be toxic to healthy cells.<br /><br /> This invention discloses the use of two new small molecule pharmacophores that can activate PKM2 through the allosteric site: 3-oxo-3,4-dihydro-2H-benzo [b] [1,4] oxazine-7-sulfonamides, and 2-oxo-1,2,3,4-tetrahydroquinoline-6-sulfonamides. <ul> <li>Small molecule (series of analogs can be derived in search of improved performance)</li> <li>Target a select group of cells (Cancerous cells)</li> </ul> <ul> <li>Therapeutic developments for various cancers</li> <li>Diagnostic assays for various cancers</li> <li>Regulation of embryonic stem cell proliferation</li> </ul> The National Center for Advancing Translational Sciences is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize these pyruvate kinase M2 activators. Please contact Dr. Matthew Boxer at <a href="mailto:boxerm@mail.nih.gov">boxerm@mail.nih.gov</a> for more information. 2022-03-08 2026-08-14 2026-08-14 2010-12-08 [1, [b], 2, 2-oxo-1, 3, 3-oxo-3, 4], 4-dihydroquinoline-2H-benzo, 4-tetrahydroquinoline-6-sulfonamides, ACTIVATORS, CB3CXX, CB3XXX, CBXXXX, CXXXXX, Human, Kinase, MOLECULE, Oxazine-7-sulfonamides, Patent Category - Chemistry, PYRUVATE, Small, Substituted False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114171229 Jiang JK, et al. http://www.ncbi.nlm.nih.gov/pubmed/20451379 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20451379">Jiang JK, et al.</a> 114171230 Boxer MB, et al. http://www.ncbi.nlm.nih.gov/pubmed/20017496 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20017496">Boxer MB, et al.</a> 114107073 Shen, Min National Human Genome Research Institute (NHGRI) NCATS Shen, Min (NCATS) 0 114107074 Thomas, Craig National Human Genome Research Institute (NHGRI) NCATS Thomas, Craig (NCATS) 0 114107075 Auld, Douglas National Human Genome Research Institute (NHGRI) Auld, Douglas 0 114107076 Boxer, Matthew National Human Genome Research Institute (NHGRI) Boxer, Matthew 1 114107076 Boxer, Matthew National Human Genome Research Institute (NHGRI) Boxer, Matthew 1 114107073 Shen, Min National Human Genome Research Institute (NHGRI) NCATS Shen, Min (NCATS) 0 114107074 Thomas, Craig National Human Genome Research Institute (NHGRI) NCATS Thomas, Craig (NCATS) 0 114107075 Auld, Douglas National Human Genome Research Institute (NHGRI) Auld, Douglas 0 114101514 Substituted 3-oxo-3,4-dihydroquinoline-2H-benzo [b] [1,4] Oxazine-7-sulfonamides And 2-oxo-1,2,3,4-tetrahydroquinoline-6-sulfonamides Small Molecule Activators Of Human Pyruvate Kinase E-120-2010-0 Filing authorized NCATS - NCGC 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-2202] Pyruvate Kinase M2 Activators for the Treatment of Cancer&body=Please send me information about technology [TAB-2202] Pyruvate Kinase M2 Activators for the Treatment of Cancer. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-2202] Pyruvate Kinase M2 Activators for the Treatment of Cancer&body=Please send me information about technology [TAB-2202] Pyruvate Kinase M2 Activators for the Treatment of Cancer.">rebecca.erwin-cohen@nih.gov</a><br> 114162345 E-120-2010-0 E-120-2010-0-PCT-02 Activators Of Human Pyruvate Kinase PCT Patent Cooperation Treaty PCT/US2011/033852 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/033852<br />Filed on 2011-04-26<br />Status: Expired 114164120 E-120-2010-0 E-120-2010-0-US-07 Activators Of Human Pyruvate Kinase National Stage US 13/643,594 Abandoned US <br />National Stage 13/643,594<br />Filed on 2012-10-26<br />Status: Abandoned 114166265 E-120-2010-0 E-120-2010-0-US-01 Activators Of Human Pyruvate Kinase PRV US 61/329,158 Abandoned US <br />Provisional (PRV) 61/329,158<br />Filed on 2010-04-29<br />Status: Abandoned 114168095 E-120-2010-0 E-120-2010-0-US-09 Activators Of Human Pyruvate Kinase CON US 9,708,267 14/643,107 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9708267 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9708267">9,708,267</a><br />Filed on 2015-03-10<br />Status: Issued 114121772 CB3CXX 114121773 CXXXXX 114121774 CBXXXX 114121775 CB3XXX 114140938 4-dihydroquinoline-2H-benzo 114140939 3-oxo-3 114140940 Substituted 114140941 [b] 114140942 [1 114140943 4] 114140944 Oxazine-7-sulfonamides 114140945 2-oxo-1 114140946 2 114140947 3 114140948 4-tetrahydroquinoline-6-sulfonamides 114140949 Small 114140950 MOLECULE 114140951 ACTIVATORS 114140952 Human 114140953 PYRUVATE 114140954 Kinase 114140955 Patent Category - Chemistry TAB-4020 147157301 Use of Acetalax for Treatment of Triple Negative Breast Cancer NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Matthew Garnett, Augustin Luna, Yves Pommier, Vinodh Rajapakse, William Reinhold <h2>Summary:</h2> <p>NCI seeks research co-development and/or potential licensees for a potential novel treatment for triple-negative breast cancer (TNBC) with acetalax (oxyphenisatin acetate).</p> <h2>Description of Technology:</h2> <p>Triple negative (progesterone receptor (PR)-, estrogen receptor (ER)-, human epidermal growth receptor 2 (HER2)-) breast cancer (TNBC) is an aggressive subtype that affects 15-20% of the 1.7 million cases of breast cancer occurring annually.&nbsp; Currently, standard treatments of TNBC include cytotoxic chemotherapies, surgery, and radiation. However, TNBC readily becomes resistant to chemotherapy, and those with TNBC are more likely to have a recurrence or die within five years compared to those with other breast cancer types. Therefore, there is a need for safer and more effective TNBC treatments to improve patient outcomes.</p> <p>Investigators from the National Cancer Institute (NCI) and collaborating institutions have identified the compound acetalax (oxyphenisatin acetate) as a promising potential therapy for TNBC. Strikingly, acetalax&rsquo;s cytotoxic effect checked first against ~178 FDA-approved or clinical trial oncology drugs on the three TNBC against the NCI-60 panel of cancer cell lines &ndash; subsequently followed up using the 22 different TNBC cell lines checked against 15 oncology drugs &ndash; were significantly most cytotoxic.<br /> Acetalax&rsquo;s efficacy in vivo has been investigated using a TNBC patient-derived xenograft (PDX) mouse model. Untreated PDX mice exhibited a tumor volume doubling rate of approximately 7-8 days whereas acetalax-treated mice tumor volumes decreased to undetectable levels in approximately 13 days.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>A therapeutic for Triple Negative Breast Cancer</li> <li>Potential therapeutic for recalcitrant or estrogen-dependent cancers</li> <li>Potential applicability to breast (non-Triple Negative), ovarian, pancreatic, sarcoma, and uterine cancers</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Repurposed, previously approved FDA drug for a novel use as a therapeutic for TNBC and other cancers</li> <li>Repurposed, previously approved drugs can have an expedited approval process due in part to pre-existing safety data</li> </ul> 2020-09-25 2026-04-24 2020-09-25 2026-08-13 2020-09-25 Acetalax, Oxyphenisatin Acetate, Pommier, TNBC, Triple Negative Breast Cancer, Uterine Cancer False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-09-25 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162411 Rajapakse VN, et al. CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines. https://pubmed.ncbi.nlm.nih.gov/30553813/ <a href="https://pubmed.ncbi.nlm.nih.gov/30553813/">Rajapakse VN, et al. CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines.</a> 147163245 Reinhold, William NIH - NCI NCI Reinhold, William (NCI) 1 147163248 Garnett, Matthew The Wellcome Trust Sanger Institute Garnett, Matthew 2 147163246 Rajapakse, Vinodh NIH - NCI NCI Rajapakse, Vinodh (NCI) 3 147163244 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 4 147163247 Luna, Augustin Harvard Medical School Luna, Augustin 5 147163245 Reinhold, William NIH - NCI NCI Reinhold, William (NCI) 1 147163248 Garnett, Matthew The Wellcome Trust Sanger Institute Garnett, Matthew 2 147163246 Rajapakse, Vinodh NIH - NCI NCI Rajapakse, Vinodh (NCI) 3 147163244 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 4 147163247 Luna, Augustin Harvard Medical School Luna, Augustin 5 147157846 Use Of Acetalax For Treatment Of Triple Negative Breast Cancer. E-041-2018-0 Filing authorized Harvard Medical School, NCI, The Wellcome Trust Sanger Institute 91826910 McCrary, Michaela michaela.mccrary@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4020] Use of Acetalax for Treatment of Triple Negative Breast Cancer&body=Please send me information about technology [TAB-4020] Use of Acetalax for Treatment of Triple Negative Breast Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov McCrary, Michaela<br><a href="mailto:michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4020] Use of Acetalax for Treatment of Triple Negative Breast Cancer&body=Please send me information about technology [TAB-4020] Use of Acetalax for Treatment of Triple Negative Breast Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michaela.mccrary@nih.gov</a><br> 147160946 E-041-2018-0 E-041-2018-0-US-01 A METHOD OF TREATING TRIPLE-NEGATIVE BREAST CANCER PRV US 62/627,926 Abandoned US <br />Provisional (PRV) 62/627,926<br />Filed on 2018-02-08<br />Status: Abandoned 147166039 E-041-2018-0 E-041-2018-0-PCT-02 A METHOD OF TREATING TRIPLE-NEGATIVE BREAST CANCER PCT Patent Cooperation Treaty PCT/US2019/017239 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/017239<br />Filed on 2019-02-08<br />Status: Expired 147166040 E-041-2018-0 E-041-2018-0-EP-03 A METHOD OF TREATING TRIPLE-NEGATIVE BREAST CANCER National Stage European Patent 3749302 19707221.8 Issued European Patent <br />National Stage 19707221.8<br />Filed on 2019-02-08<br />Status: Issued 147166041 E-041-2018-0 E-041-2018-0-US-04 A METHOD OF TREATING TRIPLE-NEGATIVE BREAST CANCER National Stage US 16/967,472 Pending US <br />National Stage 16/967,472<br />Filed on 2020-08-05<br />Status: Pending 168571302 E-041-2018-0 E-041-2018-0-US-02 A METHOD OF TREATING TRIPLE-NEGATIVE BREAST CANCER CON US 19/785,381 Pending US <br />Continuation (CON) 19/785,381<br />Filed on 2026-08-25<br />Status: Pending 147170058 Acetalax 147170060 Oxyphenisatin Acetate 147170061 Pommier 147170063 TNBC 147170065 Triple Negative Breast Cancer 147170067 Uterine Cancer TAB-5142 168516626 Electrochemical Impedance Spectroscopy (EIS) Device to Resolve Individual Membrane Electrical Properties of Epithelial and Endothelial Tissues NEI Ear, Nose, & Throat, Medical Devices, Non-Medical Devices Ear Nose & Throat Medical Devices Non-Medical Devices Kapil Bharti, Colby Lewallen, Arvydas Maminishkis, Ruchi Sharma <p>Understanding the electrical properties of barrier tissues is crucial for deciphering their physiological functions and pathological conditions. These tissues, such as epithelial and endothelial layers, play critical roles in regulating the transport of ions, nutrients, and signaling molecules. By quantifying membrane-specific resistances, capacitances, and potentials, researchers gain valuable insights into epithelial development, barrier integrity, and disease progression.&nbsp;</p> <p>However, current commercial setups fall short in providing comprehensive data, often oversimplifying complex electrical properties into a few parameters like trans-epithelial resistance (TER) and trans-epithelial potential (TEP). While some academic techniques exist for evaluating membrane-specific properties, they tend to be invasive or depend on chemical compound intervention. Additionally, these methods are often low-throughput and demand highly trained operators. These limitations hamper researchers&#39; capability to obtain high-quality data for assessing epithelial cell health, maturation, and drug response.&nbsp;</p> <p>Scientists at the NEI have developed a novel device to overcome these challenges by offering membrane-specific measurements in a non-invasive, high-throughput manner, rendering it a superior choice for researchers and clinicians. Utilizing Electrochemical Impedance Spectroscopy (EIS) measurements, they introduced a new technique to assess apical and basolateral electrical responses to stimuli, providing great insights into cell quality and function compared to existing commercial and academic approaches.<br /> &nbsp;</p> <h2>Advantages of Invention</h2> <ul> <li>Enables a non-invasive measurement into the electrical properties of barrier tissue membranes without using additional chemical perturbations.</li> <li>Can be performed using low-cost hardware and software.</li> <li>Does not require extensive training.</li> </ul> <p>&nbsp;</p> <h2>Potential Application</h2> <ul> <li>Assessment of electrical properties of epithelial tissue</li> <li>Assessment of electrical properties of endothelial tissue</li> <li>High-throughput drug screening assays</li> <li>Long-term evaluation of epithelial or endothelial barrier development</li> </ul> 2026-08-07 2026-08-12 2026-08-12 2026-08-07 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52406769 Prototype 52406769 NCI 37470483 Website Abstract 168516851 Lewallen CF, et al. A biologically validated mathematical model for decoding epithelial apical, basolateral, and paracellular electrical properties. (PMID: 37899750) https://pubmed.ncbi.nlm.nih.gov/37899750/ <a href="https://pubmed.ncbi.nlm.nih.gov/37899750/">Lewallen CF, et al. A biologically validated mathematical model for decoding epithelial apical, basolateral, and paracellular electrical properties. (PMID: 37899750)</a> 168516651 Bharti, Kapil National Eye Institute (NEI) NEI Bharti, Kapil (NEI) 1 168516655 Maminishkis, Arvydas National Eye Institute (NEI) NEI Maminishkis, Arvydas (NEI) 2 168516659 Sharma, Ruchi National Eye Institute (NEI) NEI Sharma, Ruchi (NEI) 3 168516663 Lewallen, Colby National Eye Institute (NEI) NEI Lewallen, Colby (NEI) 4 168516651 Bharti, Kapil National Eye Institute (NEI) NEI Bharti, Kapil (NEI) 1 168516655 Maminishkis, Arvydas National Eye Institute (NEI) NEI Maminishkis, Arvydas (NEI) 2 168516659 Sharma, Ruchi National Eye Institute (NEI) NEI Sharma, Ruchi (NEI) 3 168516663 Lewallen, Colby National Eye Institute (NEI) NEI Lewallen, Colby (NEI) 4 168516632 Electrochemical impedance spectroscopy (EIS) device to resolve individual membrane electrical properties of epithelial/endothelial tissues E-249-2023-0 Filing authorized National Eye Institute (NEI), NIH - NEI 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5142] Electrochemical Impedance Spectroscopy (EIS) Device to Resolve Individual Membrane Electrical Properties of Epithelial and Endothelial Tissues&body=Please send me information about technology [TAB-5142] Electrochemical Impedance Spectroscopy (EIS) Device to Resolve Individual Membrane Electrical Properties of Epithelial and Endothelial Tissues.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5142] Electrochemical Impedance Spectroscopy (EIS) Device to Resolve Individual Membrane Electrical Properties of Epithelial and Endothelial Tissues&body=Please send me information about technology [TAB-5142] Electrochemical Impedance Spectroscopy (EIS) Device to Resolve Individual Membrane Electrical Properties of Epithelial and Endothelial Tissues.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">tedd.fenn@nih.gov</a><br> 168516637 E-249-2023-0 E-249-2023-0-US-01 ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY (EIS) DEVICE TO RESOLVE INDIVIDUAL MEMBRANE ELECTRICAL PROPERTIES OF EPITHELIAL AND ENDOTHELIAL TISSUES PRV US 63/708,904 Expired US <br />Provisional (PRV) 63/708,904<br />Filed on 2024-10-18<br />Status: Expired 168516638 E-249-2023-0 E-249-2023-0-PC-01 ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY (EIS) DEVICE TO RESOLVE INDIVIDUAL MEMBRANE ELECTRICAL PROPERTIES OF EPITHELIAL AND ENDOTHELIAL TISSUES PCT Patent Cooperation Treaty PCT/US2025/050192 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/050192<br />Filed on 2025-10-09<br />Status: Pending TAB-5141 168516221 Electrochemical Impedance Spectroscopy (EIS) for Non-Destructive Assessment of Epithelial Integrity NEI Diagnostics, Infectious Disease, Medical Devices, Oncology, Research Materials Diagnostics Infectious Disease Medical Devices Oncology Research Materials Kapil Bharti, Craig Forest, Colby Lewallen, Arvydas Maminishkis <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">This technology includes a novel apparatus and method that utilizes Electrochemical Impedance Spectroscopy (EIS) to assess the integrity of epithelial cell membranes non-destructively. By applying frequency-modulated voltage signals and facilitating fluid exchange on both sides of the epithelial tissue, this technology allows researchers to characterize membrane-specific responses with unprecedented accuracy. This advancement opens new avenues for drug discovery and evaluation of stem cell therapies, making it a vital tool for both academic and commercial research.</span></span></span></p> <p>&nbsp;</p> <h2><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">Potential Commercial Applications</span></span></span></h2> <ul> <li>Assessment of drug effects on epithelial cells in pharmaceutical research.</li> <li><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">Standardized evaluation of stem cell therapies targeting epithelial tissues.</span></span></span></li> <li><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">Research into epithelial physiology and pathology in various medical fields.</span></span></span></li> </ul> <h2>&nbsp;</h2> <h2><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">Competitive Advantages</span></span></span></h2> <ul> <li><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">Non-invasive technique that preserves tissue integrity, allowing for repeated measurements.</span></span></span></li> <li><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">High-throughput capability enables faster drug discovery and evaluation processes.</span></span></span></li> <li><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">Reduces reliance on traditional invasive methods, making it accessible to a broader range of researchers.</span></span></span></li> </ul> 2026-08-07 2026-08-12 2026-08-12 2026-08-07 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52406769 Prototype 52406769 NCI 37470483 Website Abstract 168516274 Maminishkis, Arvydas National Eye Institute (NEI) NEI Maminishkis, Arvydas (NEI) 1 168516278 Bharti, Kapil National Eye Institute (NEI) NEI Bharti, Kapil (NEI) 2 168516282 Forest, Craig Georgia Institute of Technology Forest, Craig 3 168516299 Lewallen, Colby National Eye Institute (NEI) NEI Lewallen, Colby (NEI) 4 168516274 Maminishkis, Arvydas National Eye Institute (NEI) NEI Maminishkis, Arvydas (NEI) 1 168516278 Bharti, Kapil National Eye Institute (NEI) NEI Bharti, Kapil (NEI) 2 168516282 Forest, Craig Georgia Institute of Technology Forest, Craig 3 168516299 Lewallen, Colby National Eye Institute (NEI) NEI Lewallen, Colby (NEI) 4 168516224 Using Electrochemical Impedance Spectroscopy (EIS) to determine epithelial integrity and cell membranes functional state E-203-2023-0 Filing authorized Georgia Institute of Technology, National Eye Institute (NEI), NIH - NEI 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5141] Electrochemical Impedance Spectroscopy (EIS) for Non-Destructive Assessment of Epithelial Integrity&body=Please send me information about technology [TAB-5141] Electrochemical Impedance Spectroscopy (EIS) for Non-Destructive Assessment of Epithelial Integrity.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5141] Electrochemical Impedance Spectroscopy (EIS) for Non-Destructive Assessment of Epithelial Integrity&body=Please send me information about technology [TAB-5141] Electrochemical Impedance Spectroscopy (EIS) for Non-Destructive Assessment of Epithelial Integrity.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">tedd.fenn@nih.gov</a><br> 168516228 E-203-2023-0 E-203-2023-0-US-01 APPARATUS AND METHOD FOR EXTRACELLULAR IMPEDANCE SPECTROSCOPY OF EPITHELIA PRV US 63/479,798 Expired US <br />Provisional (PRV) 63/479,798<br />Filed on 2023-01-13<br />Status: Expired 168516230 E-203-2023-0 E-203-2023-0-PC-01 APPARATUS AND METHOD FOR EXTRACELLULAR IMPEDANCE SPECTROSCOPY OF EPITHELIA PCT Patent Cooperation Treaty PCT/US2024/011553 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/011553<br />Filed on 2024-01-15<br />Status: Expired 168516231 E-203-2023-0 E-203-2023-0-CA-01 APPARATUS AND METHOD FOR EXTRACELLULAR IMPEDANCE SPECTROSCOPY OF EPITHELIA National Stage Canada 3279965 Pending Canada <br />National Stage 3279965<br />Filed on 2025-07-14<br />Status: Pending 168516232 E-203-2023-0 E-203-2023-0-GB-01 APPARATUS AND METHOD FOR EXTRACELLULAR IMPEDANCE SPECTROSCOPY OF EPITHELIA National Stage United Kingdom 2513195.4 Pending United Kingdom <br />National Stage 2513195.4<br />Filed on 2025-08-13<br />Status: Pending 168516233 E-203-2023-0 E-203-2023-0-EP-01 APPARATUS AND METHOD FOR EXTRACELLULAR IMPEDANCE SPECTROSCOPY OF EPITHELIA National Stage European Patent 24705896.9 Pending European Patent <br />National Stage 24705896.9<br />Filed on 2025-08-13<br />Status: Pending 168516234 E-203-2023-0 E-203-2023-0-US-02 APPARATUS AND METHOD FOR EXTRACELLULAR IMPEDANCE SPECTROSCOPY OF EPITHELIA ORD US 18/412,842 Pending US <br />Ordinary Patent (ORD) 18/412,842<br />Filed on 2024-01-15<br />Status: Pending TAB-5143 168525851 T Cell Receptors Targeting HPV 6 or HPV 11 NCI Collaboration, Immunology, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Immunology Infectious Disease Licensing Oncology Therapeutics Clint Allen, Ke Bai, Scott Norberg, Cem Sievers <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a collection of T cell receptors (TCRs) that specifically target HPV 6 or HPV 11 antigens.</p> <h2>Description of Technology:</h2> <p>Recurrent Respiratory Papillomatosis (RRP) and anogenital condyloma arise from chronic infection with human papillomavirus (HPV) 6 or 11. They can cause significant morbidity due to persistent papillomatous growths in the upper aerodigestive or anogenital tract. In RRP, lesions may obstruct the airway; leading to dysphonia, dyspnea, recurrent pneumonia, or pulmonary failure. In rare cases, it may progress to malignancy. Current treatment options for RRP include zopapogene imadenovec (Papzimeos), systemic bevacizumab, and repeated surgical debulking. Papzimeos can lead to durable responses in some patients but remains ineffective against pulmonary disease. Systemic bevacizumab can control disease, but prolonged use can lead to intolerable toxicities. Repeat surgical debulking causes cumulative surgical and anesthetic risks. Therefore, there remains a critical unmet need for safe and effective therapies for patients with aggressive or pulmonary RRP refractive to standard‑of‑care treatments.</p> <p>Researchers at the National Cancer Institute (NCI) identified several T cell receptors (TCRs) with potential utility in adoptive cell therapy and other TCR-based approaches to treat HPV 6- or HPV 11-associated diseases, including RRP. These TCRs used engineered T cells derived from peripheral blood mononuclear cells (PBMCs), an easily accessible source of human immune cells. The engineered T cells demonstrated reproducible, antigen-specific recognition of multiple HPV 6 and HPV 11 proteins presented by diverse HLA class I subtypes. The inventors further showed that these TCR-engineered T cells effectively eliminated HPV 6/11-infected target cells. The results support the therapeutic potential of these TCRs for HPV-associated disease.</p> <p>The NCI seeks research co-development partners and/or licensees to advance TCRs that specifically target HPV 6 or HPV 11 antigens. These TCRs have potential applications in the development of experimental cell-based immunotherapies and other TCR-based therapeutic platforms. Additional markets include diagnostics and research settings.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment and diagnosis of recurrent respiratory papillomatosis (RRP) and other premalignant and nonmalignant conditions <ul> <li>Adoptive cell therapy</li> <li>TCR-based therapy</li> <li>Combination therapy</li> </ul> </li> <li>Treatment and diagnosis of additional HPV 6- or HPV 11-associated diseases and chronic infections <ul> <li>Adoptive cell therapy</li> <li>TCR-based therapy</li> <li>Combination therapy</li> </ul> </li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Novel adoptive cell therapies, either as monotherapies or in combination with other therapeutic modalities</li> <li>Promising freedom to practice as part of a comprehensive intellectual property portfolio for RRP therapeutics and diagnostics</li> <li>Established FDA regulatory precedent for TCR-based therapeutics</li> <li>Opportunity to qualify for regulatory incentives for rare diseases, including: orphan drug designation, priority review, and breakthrough therapy designation</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a collection of T-cell receptors (TCRs) that specifically target HPV 6 or HPV 11 antigens. 2026-08-10 2026-08-12 2026-08-12 2026-08-10 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-143-2024-0 E-019-2025-0 168525915 Allen, Clint NIH - NCI NCI Allen, Clint (NCI) 1 168526169 Norberg, Scott NIH - NCI NCI Norberg, Scott (NCI) 2 168526173 Bai, Ke NIH - NCI NCI Bai, Ke (NCI) 3 168526177 Sievers, Cem NIH - NCI NCI Sievers, Cem (NCI) 4 168525915 Allen, Clint NIH - NCI NCI Allen, Clint (NCI) 1 168526169 Norberg, Scott NIH - NCI NCI Norberg, Scott (NCI) 2 168526173 Bai, Ke NIH - NCI NCI Bai, Ke (NCI) 3 168526177 Sievers, Cem NIH - NCI NCI Sievers, Cem (NCI) 4 168525854 Discovery of a library of TCRs specific for T cell antigens from HPV 6 or 11 E-002-2026-0 Filing authorized Center for Immuno-Oncology, National Institute on Deafness and Other Communication Disorders (NIDCD), NIH - NCI, Surgical Oncology Program 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-5143] T Cell Receptors Targeting HPV 6 or HPV 11&body=Please send me information about technology [TAB-5143] T Cell Receptors Targeting HPV 6 or HPV 11.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-5143] T Cell Receptors Targeting HPV 6 or HPV 11&body=Please send me information about technology [TAB-5143] T Cell Receptors Targeting HPV 6 or HPV 11.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">suna.gulay@nih.gov</a><br> 168525859 E-002-2026-0 E-002-2026-0-US-01 T CELL RECEPTORS TARGETING HPV 6 OR HPV 11 PRV US 64/026,093 Pending US <br />Provisional (PRV) 64/026,093<br />Filed on 2026-04-02<br />Status: Pending TAB-5144 168526678 Matched Patient-Derived 3D Isocitrate Dehydrogenase (IDH)-Mutant Glioma Cell Lines for Modeling Malignant Transformation NCI Licensing, Neurology, Oncology, Research Materials Licensing Neurology Oncology Research Materials Jing Wu <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks licensees for matched patient-derived 3D Isocitrate Dehydrogenase (IDH)-mutant glioma cell lines, 403L and 403H, generated from the same patient before and after malignant transformation from WHO grade 2 to WHO grade 4 disease. This research material provides an opportunity to study IDH-mutant glioma progression, temozolomide-associated hypermutation, invasion, metabolism, and treatment resistance.</p> <h2>Description of Technology:</h2> <p>IDH-mutant gliomas often begin as lower-grade tumors but remain incurable and frequently progress to higher-grade disease through malignant transformation. This is clinically important but difficult to study because matched low-grade and high-grade tumor materials from the same patient are rare. Further, fixed tumor specimens are limited for repeated mechanistic or drug-response experiments.</p> <p>Researchers at the National Cancer Institute (NCI) developed a matched pair of patient-derived cell models, 403L and 403H, from the same patient before and after malignant transformation. 403L was established from a WHO grade 2 IDH-mutant astrocytoma. 403H was derived from the recurrent WHO grade 4 tumor following radiation and temozolomide treatment. Both cell lines: (1) grow as 3D spheroids, (2) retain endogenous IDH1 R132H expression, and (3) were authenticated to the patient&#39;s germline by short tandem repeat (STR) profiling (100% match for 403L; 93.33% match for 403H).</p> <p>The high-grade 403H line shows increased invasive behavior, temozolomide-associated hypermutation (tumor mutational burden of 70.07/Mb vs. 3.96/Mb in 403L), upregulated epithelial-mesenchymal transition (EMT) signaling (whereas Notch signaling is enriched in 403L), and changes in glioma-associated metabolism, including 2-hydroxyglutarate (2-HG), glutamine, fatty acid metabolism, and lactate/pyruvate flux. Furthermore, 403H showed significantly greater 3D invasion than 403L (p&lt;0.0001). 403H formed infiltrative high-grade glioma in 4 of 5 orthotopically xenografted NSG mice. In contrast, 403L did not form tumors within 18 months.</p> <p>Researchers at NCI seek licensees interested in using these cell lines as research tools for neuro-oncology studies. The models may be useful for studying IDH-mutant glioma progression, malignant transformation, tumor recurrence, treatment resistance, and preclinical response to IDH-targeted, DNA damage response, metabolic, or combination therapies.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Development of cancer therapeutics targeting IDH-mutant gliomas, including: <ul> <li>IDH inhibitors</li> <li>DNA damage response agents</li> <li>Metabolic drugs</li> </ul> </li> <li>Modeling of tumor evolution, recurrence, and temozolomide-associated hypermutation</li> <li>Development of novel assays for glioma invasion, metabolism, and drug screening</li> <li>Preclinical screening tool for IDH-targeted, DNA damage response, metabolic, or combination therapies</li> <li>Comparative profiling of molecular, epigenetic, and metabolomic differences between low-grade and transformed gliomas</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Minimized genetic background variability</li> <li>Unique clinical model of the temozolomide-associated hypermutator phenotype and acquired treatment resistance</li> <li>Stable 3D tumor spheroids provide a unique model retaining endogenous IDH1 R132H expression and grade-specific stem and lineage markers (SOX2, NESTIN, GFAP, OLIG2, beta 3-Tubulin)</li> <li>Distinct functional models permitting the comparative interrogation of in vitro invasion and in vivo tumorigenicity</li> </ul> Researchers at NCI seek licensees interested in using these cell lines as research tools for neuro-oncology studies. 2026-08-10 2026-08-10 2026-08-10 2026-08-10 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52406768 Discovery 52406768 NCI 37470483 Website Abstract 168526896 Kim O, et al. A patient-derived cell model for malignant transformation in IDH-mutant glioma. (PMID: 39256867). https://pubmed.ncbi.nlm.nih.gov/39256867/ <a href="https://pubmed.ncbi.nlm.nih.gov/39256867/">Kim O, et al. A patient-derived cell model for malignant transformation in IDH-mutant glioma. (PMID: 39256867).</a> 168526696 Wu, Jing NIH - NCI NCI Wu, Jing (NCI) 1 168526696 Wu, Jing NIH - NCI NCI Wu, Jing (NCI) 1 168526681 403L and 403H, Patient-Derived 3D IDH-Mutant Glioma Cell Lines for Studying Malignant Transformation E-145-2026-0 Research Material NIH - NCI 83687903 Pollack, Michael michael.pollack@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michael.pollack@nih.gov?subject=Web Inquiry on [TAB-5144] Matched Patient-Derived 3D Isocitrate Dehydrogenase (IDH)-Mutant Glioma Cell Lines for Modeling Malignant Transformation&body=Please send me information about technology [TAB-5144] Matched Patient-Derived 3D Isocitrate Dehydrogenase (IDH)-Mutant Glioma Cell Lines for Modeling Malignant Transformation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollack, Michael<br><a href="mailto:michael.pollack@nih.gov?subject=Web Inquiry on [TAB-5144] Matched Patient-Derived 3D Isocitrate Dehydrogenase (IDH)-Mutant Glioma Cell Lines for Modeling Malignant Transformation&body=Please send me information about technology [TAB-5144] Matched Patient-Derived 3D Isocitrate Dehydrogenase (IDH)-Mutant Glioma Cell Lines for Modeling Malignant Transformation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">michael.pollack@nih.gov</a><br> TAB-5074 163873661 Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy NCI Immunology, Licensing, Oncology, Therapeutics Immunology Licensing Oncology Therapeutics Drew Deniger, Steven Feldman, Steven Rosenberg <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks capable licensees interested in commercializing T cell receptor (TCR)-engineered T cells expressing murine/human hybrid receptors.</p> <h2>Description of Technology:</h2> <p>TCR-T therapies, particularly those targeting patient-specific neoantigens, remain a promising approach to the treatment metastatic cancers. Contemporary gene engineering techniques permit both the targeted integration of the exogenous receptor(s) and further genetic manipulation of the host cells to enhance persistence and performance following adoptive transfer (e.g., through disruption of immune checkpoints such as CISH or PD1). However, these techniques often suffer from low transduction efficiencies and may result in the generation of infusion products with sub-optimal percentages of targeted cells.</p> <p>NCI scientists designed a new method that enables the selective expansion of T lymphocytes, under GMP conditions, that have been engineered to stably express a murine-human hybrid TCR. These hybrid TCRs consist of human variable regions and murine constant regions. The inventive approach uses irradiated feeder cells and an anti-mouse TCR beta constant region antibody (e.g., H57) to provide stimulation, enabling the specific activation and expansion of T cells transduced with the hybrid TCRs. Critically, replacement of the OKT3 activating antibody from the standard rapid expansion protocol with one specific for the TCR murine constant region prevents the outgrowth of non-transduced cells. Consequently, the new method produces a cell population highly enriched for the desired engineered cells.</p> <p>NCI seeks to market this method, which is analogous to an antigen-specific stimulation of the T cell, to companies interested in developing personalized ACT.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Enables the GMP production of personalized T cell therapy products targeting tumor specific mutations with a high percentage of engineered cells</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Increased therapeutic benefit due to enhanced persistence and performance following adoptive T cell transfer</li> <li>Increased therapeutic benefit due to improved surface expression of the therapeutic TCR &alpha;&beta; <ul> <li>TCR alpha/beta chains substantially eliminate the risk of mis-pairing with the endogenous alpha/beta chain sequences expressed by the host cell</li> </ul> </li> <li>Improved manufacturing since the population is highly enriched for the desired engineered cells <ul> <li>Greatly increases the frequency of tumor-specific T cells following expansion, exceeding what is achieved using alternative methods to generate mutation- or tumor-specific T cells</li> </ul> </li> </ul> <p>&nbsp;</p> Researchers at the NCI seek licensing for TCR-engineered T cells that will facilitate the ACT process. 2025-08-25 2025-08-25 2026-08-05 2025-08-25 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 72159140 Clinical Phase II 72159140 NCI 37470483 Website Abstract 163873915 Parkhurst M, et al. Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results. (PMID 38992) https://pubmed.ncbi.nlm.nih.gov/38992/ <a href="https://pubmed.ncbi.nlm.nih.gov/38992/">Parkhurst M, et al. Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results. (PMID 38992)</a> 163873942 Kim SP, et al. Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells targeting common p53 neoantigens in human solid tumors. (PMID 35749374) https://pubmed.ncbi.nlm.nih.gov/35749374/ <a href="https://pubmed.ncbi.nlm.nih.gov/35749374/">Kim SP, et al. Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells targeting common p53 neoantigens in human solid tumors. (PMID 35749374)</a> 163873951 Lowery FL, et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. (PMID 35113651) https://pubmed.ncbi.nlm.nih.gov/35113651/ <a href="https://pubmed.ncbi.nlm.nih.gov/35113651/">Lowery FL, et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. (PMID 35113651)</a> 163873866 Feldman, Steven NIH - NCI NCI Feldman, Steven (NCI) 1 163873878 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 163873886 Deniger, Drew NIH - NCI Deniger, Drew 3 163873866 Feldman, Steven NIH - NCI NCI Feldman, Steven (NCI) 1 163873878 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 163873886 Deniger, Drew NIH - NCI Deniger, Drew 3 163873664 Sorting And/or Selective Expansion Of T Lymphocytes For Use In Adoptive Cell Immunotherapy. E-182-2017-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-5074] Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy&body=Please send me information about technology [TAB-5074] Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-5074] Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy&body=Please send me information about technology [TAB-5074] Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">burkear@nih.gov</a><br> 163873669 E-182-2017-0 E-182-2017-0-US-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION PRV US 62/568,339 Abandoned US <br />Provisional (PRV) 62/568,339<br />Filed on 2017-10-05<br />Status: Abandoned 163873670 E-182-2017-0 E-182-2017-0-PCT-02 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION PCT Patent Cooperation Treaty PCT/US2018/052432 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/052432<br />Filed on 2018-09-24<br />Status: Expired 163873710 E-182-2017-0 E-182-2017-0-AU-03 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage Australia 2018345400 2018345400 Issued Australia <br />National Stage 2018345400<br />Filed on 2018-09-24<br />Status: Issued 163873711 E-182-2017-0 E-182-2017-0-CA-04 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage Canada 3077595 Pending Canada <br />National Stage 3077595<br />Filed on 2018-09-24<br />Status: Pending 163873712 E-182-2017-0 E-182-2017-0-CN-05 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage China ZL201880076862.9 201880076862.9 Issued China <br />National Stage 201880076862.9<br />Filed on 2018-09-24<br />Status: Issued 163873713 E-182-2017-0 E-182-2017-0-EP-06 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage European Patent 3692140 18786145.5 Issued European Patent <br />National Stage 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873714 E-182-2017-0 E-182-2017-0-IL-07 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage Israel 273698 273698 Issued Israel <br />National Stage 273698<br />Filed on 2020-03-30<br />Status: Issued 163873715 E-182-2017-0 E-182-2017-0-JP-08 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage Japan 7867764 2020-519092 Issued Japan <br />National Stage 2020-519092<br />Filed on 2020-04-02<br />Status: Issued 163873716 E-182-2017-0 E-182-2017-0-KR-09 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage South Korea 10-2757789 10-2020-7012314 Issued South Korea <br />National Stage 10-2020-7012314<br />Filed on 2020-04-28<br />Status: Issued 163873717 E-182-2017-0 E-182-2017-0-SG-10 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage Singapore 11202003112Q Abandoned Singapore <br />National Stage 11202003112Q<br />Filed on 2018-09-24<br />Status: Abandoned 163873718 E-182-2017-0 E-182-2017-0-US-11 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage US 12,227,554 16/652,948 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12227554 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12227554">12,227,554</a><br />Filed on 2020-04-01<br />Status: Issued 163873719 E-182-2017-0 E-182-2017-0-HK-12 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP Hong Kong HK40031098B 62020020943.0 Issued Hong Kong <br />European patent (EP) 62020020943.0<br />Filed on 2020-11-26<br />Status: Issued 163873720 E-182-2017-0 E-182-2017-0-EP-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION DIV European Patent 23185846.5 Pending European Patent <br />Divisional (DIV) 23185846.5<br />Filed on 2023-07-17<br />Status: Pending 163873721 E-182-2017-0 E-182-2017-0-ES-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP Spain 3692140 18786145.5 Issued Spain <br />European patent (EP) 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873722 E-182-2017-0 E-182-2017-0-FI-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP Finland 3692140 18786145.5 Issued Finland <br />European patent (EP) 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873723 E-182-2017-0 E-182-2017-0-FR-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP France 3692140 18786145.5 Issued France <br />European patent (EP) 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873724 E-182-2017-0 E-182-2017-0-IT-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP Italy 3692140 18786145.5 Issued Italy <br />European patent (EP) 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873725 E-182-2017-0 E-182-2017-0-DE-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP Germany 3692140 18786145.5 Issued Germany <br />European patent (EP) 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873726 E-182-2017-0 E-182-2017-0-GB-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP United Kingdom 3692140 18786145.5 Issued United Kingdom <br />European patent (EP) 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873727 E-182-2017-0 E-182-2017-0-CH-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP Switzerland 3692140 18786145.5 Issued Switzerland <br />European patent (EP) 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873728 E-182-2017-0 E-182-2017-0-NO-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP Norway 3692140 18786145.5 Issued Norway <br />European patent (EP) 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873729 E-182-2017-0 E-182-2017-0-SG-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION DIV Singapore 10202302822Q Pending Singapore <br />Divisional (DIV) 10202302822Q<br />Filed on 2023-10-03<br />Status: Pending 163873730 E-182-2017-0 E-182-2017-0-JP-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION DIV Japan 7747724 2023-220106 Issued Japan <br />Divisional (DIV) 2023-220106<br />Filed on 2023-12-26<br />Status: Issued TAB-5069 163660392 Chimeric VLP vaccines to Prevent HTLV-1 Infection NCI Collaboration, Immunology, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Immunology Infectious Disease Licensing Oncology Therapeutics Massimiliano Bissa, Genoveffa Franchini, Cynthia Masison, Ramona Moles, Sarkis Sarkis <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for Chimeric VLP Vaccines to Prevent HTLV-1 Infection.</p> <h2>Description of Technology:</h2> <p>There is currently no approved vaccine to prevent human T-cell leukemia virus type I (HTLV-1) infection, a highly oncogenic virus linked to serious diseases like adult T-cell leukemia/lymphoma (ATLL) and Tropical Spastic paraparesis /HTLV-1-Associated Myelopathy (HAM/TSP). Existing interventions are limited to behavioral prevention, leaving millions at risk, especially in underserved global regions. A safe and effective vaccine is urgently needed to fill this critical public health gap.</p> <p>This invention is a nucleic acid-based vaccine that generates virus-like particles (VLPs) in the body using HTLV-1 Env and gag proteins to trigger a protective immune response against HTLV-1 infection. With no approved vaccines available and millions at risk&mdash;particularly in underserved regions&mdash;this first-of-its-kind solution addresses a critical public health need. It offers broad protection across HTLV-1 subtypes and is currently being tested in non-human primates, with strong potential for future clinical development and commercial interest.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>HTLV-1 Infection</li> <li>Adult T-cell leukemia/lymphoma (ATLL)</li> <li>Tropical Spastic paraparesis /HTLV-1-Associated Myelopathy (HAM/TSP)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>No approved HTLV-1 vaccines</li> <li>Preventative vaccine to reduce healthcare costs and economic burden of treating people developing related diseases</li> </ul> The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for development of a nucleic acid-based vaccine for use as a preventative to human T-lymphotrophic virus-1 (HTLV-1) infection. 2025-08-12 2025-08-12 2026-08-05 2025-08-12 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 163660868 Franchini G, et al. HTLV-1 and HTLV-2: Pathogenesis and role of viral proteins. Viruses. 2022;14(10):2084. https://doi.org/10.3390/v14102084 <a href="https://doi.org/10.3390/v14102084">Franchini G, et al. HTLV-1 and HTLV-2: Pathogenesis and role of viral proteins. Viruses. 2022;14(10):2084.</a> 163660611 Franchini, Genoveffa NIH - NCI NCI Franchini, Genoveffa (NCI) 1 163660616 Sarkis, Sarkis NIH - NCI Sarkis, Sarkis 2 163660620 Moles, Ramona NIH - NCI NCI Moles, Ramona (NCI) 3 163660649 Masison, Cynthia NIH - NCI NCI Masison, Cynthia (NCI) 4 163660654 Bissa, Massimiliano NIH - NCI NCI Bissa, Massimiliano (NCI) 5 163660611 Franchini, Genoveffa NIH - NCI NCI Franchini, Genoveffa (NCI) 1 163660616 Sarkis, Sarkis NIH - NCI Sarkis, Sarkis 2 163660620 Moles, Ramona NIH - NCI NCI Moles, Ramona (NCI) 3 163660649 Masison, Cynthia NIH - NCI NCI Masison, Cynthia (NCI) 4 163660654 Bissa, Massimiliano NIH - NCI NCI Bissa, Massimiliano (NCI) 5 163660395 Chimeric VLP Vaccines To Prevent HTLV-1 Infection E-126-2022-0 Filing authorized NCI 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-5069] Chimeric VLP vaccines to Prevent HTLV-1 Infection&body=Please send me information about technology [TAB-5069] Chimeric VLP vaccines to Prevent HTLV-1 Infection.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-5069] Chimeric VLP vaccines to Prevent HTLV-1 Infection&body=Please send me information about technology [TAB-5069] Chimeric VLP vaccines to Prevent HTLV-1 Infection.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">diptadip.dattaroy@nih.gov</a><br> 163660555 E-126-2022-0 E-126-2022-0-US-01 VACCINE FOR HUMAN T-LYMPHOTROPIC VIRUS-1 PRV US 63/340,400 Expired US <br />Provisional (PRV) 63/340,400<br />Filed on 2022-05-10<br />Status: Expired 163660556 E-126-2022-0 E-126-2022-0-PC-01 VACCINE FOR HUMAN T-LYMPHOTROPIC VIRUS-1 PCT Patent Cooperation Treaty PCT/US2023/066839 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/066839<br />Filed on 2023-05-10<br />Status: Expired 163660557 E-126-2022-0 E-126-2022-0-AU-01 VACCINE FOR HUMAN T-LYMPHOTROPIC VIRUS-1 National Stage Australia 2023268543 Pending Australia <br />National Stage 2023268543<br />Filed on 2024-11-14<br />Status: Pending 163660558 E-126-2022-0 E-126-2022-0-IN-01 VACCINE FOR HUMAN T-LYMPHOTROPIC VIRUS-1 National Stage India 202417088469 Pending India <br />National Stage 202417088469<br />Filed on 2024-11-15<br />Status: Pending 163660559 E-126-2022-0 E-126-2022-0-US-02 VACCINE FOR HUMAN T-LYMPHOTROPIC VIRUS-1 National Stage US 18/864,213 Pending US <br />National Stage 18/864,213<br />Filed on 2024-11-08<br />Status: Pending TAB-5071 163810508 Method of Detecting Circulating Cell-Free HPV 6 and 11 DNA in Patients Afflicted With Diseases Caused by Chronic HPV 6 or 11 Infection and Use Thereof NCI Collaboration, Diagnostics, Infectious Disease, Licensing, Oncology, Pulmonology Collaboration Diagnostics Infectious Disease Licensing Oncology Pulmonology Clint Allen, Scott Norberg, Xiaolin Wu <h2>Summary:</h2> <p>The National Cancer Institute (NCI) and Frederick National Laboratory for Cancer Research (FNLCR) seek research co-development partners and/or licensees for commercial development of a novel liquid biopsy diagnostic for non-invasive detection of cell-free HPV 6 and 11 DNA for recurrent respiratory papillomatosis (RRP).</p> <h2>Description of Technology:</h2> <p>Recurrent respiratory papillomatosis (RRP), caused by chronic infection with human papillomavirus (HPV) types 6 and 11, is a rare but potentially fatal disease characterized by the growth of papillomas throughout the respiratory tract. While HPV 6/11 infections are common, affecting approximately 40% of U.S. adults, a subset of patients can develop a range of conditions from benign papillomas to dysplasia and invasive cancers. Current treatment for RRP typically involves repetitive surgical intervention or laser ablation to alleviate symptoms, which carries significant procedural risks. A recent breakthrough with a therapeutic HPV vaccine demonstrated that 51% of patients avoided surgery for at least a year, with some experiencing durable remission. However, there remains no reliable diagnostic tool to confirm viral clearance or guide systemic therapy decisions.</p> <p>Researchers at the NCI and FNLCR have developed a novel hybridization-based next-generation sequencing (NGS) liquid biopsy method to detect circulating cell-free HPV 6 and 11 DNA in the plasma of patients with RRP. This innovative approach uses the established relevance of circulating viral DNA as a valuable biomarker for disease monitoring and therapeutic decision-making in other virally-associated conditions. The method is designed to target multiple regions across the entire HPV 6 and 11 genomes. It employs a pull-down DNA technology to enhance coverage &ndash; overcoming limitations of fixed-primer PCR for small cell-free DNA fragments. While low-risk HPV-associated diseases like RRP exhibit less tumor cell turnover compared to advanced cancers, the inherent high vascularity of papillomas may facilitate the release of viral DNA into peripheral blood. This method offers a non-invasive, sensitive and potentially prognostic tool to aid in (1) diagnosis, (2) monitoring progression and (3) guiding systemic therapies such as HPV vaccination or predicting severity &ndash; including pulmonary risk.</p> <p>Investigators at the NCI and FNLCR continue to evaluate circulating HPV 6 and 11 DNA in patients previously treated in clinical trials to further assess its prognostic and predictive capabilities. This technology presents a compelling opportunity for commercial development and seamless integration into existing diagnostic platforms. NCI and FNLCR offer licensing and collaborative development opportunities to advance this critical diagnostic and prognostic tool for RRP.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Liquid biopsy diagnostic for RRP confirmation</li> <li>Monitoring RRP disease progression</li> <li>Prognostic test for RRP severity, especially pulmonary disease</li> <li>Companion diagnostic to guide systemic RRP therapies</li> <li>HPV 6/11 detection assay for anogenital condyloma</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Non-invasive, sensitive and potentially prognostic and diagnostic tool</li> <li>Reduces the need for, and risk from, repeat surgical procedures</li> <li>Detects disease even with a Derkay score of 0 (minimal laryngeal involvement)</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for commercial development of a novel liquid biopsy diagnostic for non-invasive detection of cell-free HPV 6 and 11 DNA for Recurrent Respiratory Papillomatosis (RRP). 2025-08-21 2025-08-21 2026-08-05 2025-08-21 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 163810747 Norberg SM, et al. PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trial. (PMID 39855244) https://pubmed.ncbi.nlm.nih.gov/39855244/ <a href="https://pubmed.ncbi.nlm.nih.gov/39855244/">Norberg SM, et al. PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trial. (PMID 39855244)</a> 163810649 Norberg, Scott NIH - NCI NCI Norberg, Scott (NCI) 1 163810679 Allen, Clint NIH - NCI NCI Allen, Clint (NCI) 2 163810697 Wu, Xiaolin NIH - NCI Leidos Wu, Xiaolin (Leidos) 3 163810649 Norberg, Scott NIH - NCI NCI Norberg, Scott (NCI) 1 163810679 Allen, Clint NIH - NCI NCI Allen, Clint (NCI) 2 163810697 Wu, Xiaolin NIH - NCI Leidos Wu, Xiaolin (Leidos) 3 163922749 Method of detecting circulating cell-free HPV 6 and 11 DNA in patients afflicted with disease caused by chronic HPV 6 or 11 infection and use thereof (LBR# 25-004) (LBR Greater Rights Requested) E-019-2025-0 Filing authorized NIH - NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-5071] Method of Detecting Circulating Cell-Free HPV 6 and 11 DNA in Patients Afflicted With Diseases Caused by Chronic HPV 6 or 11 Infection and Use Thereof&body=Please send me information about technology [TAB-5071] Method of Detecting Circulating Cell-Free HPV 6 and 11 DNA in Patients Afflicted With Diseases Caused by Chronic HPV 6 or 11 Infection and Use Thereof.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-5071] Method of Detecting Circulating Cell-Free HPV 6 and 11 DNA in Patients Afflicted With Diseases Caused by Chronic HPV 6 or 11 Infection and Use Thereof&body=Please send me information about technology [TAB-5071] Method of Detecting Circulating Cell-Free HPV 6 and 11 DNA in Patients Afflicted With Diseases Caused by Chronic HPV 6 or 11 Infection and Use Thereof.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">suna.gulay@nih.gov</a><br> 163922754 E-019-2025-0 E-019-2025-0-US-01 METHODS OF DETECTING CIRCULATING CELL-FREE HPV 6 AND HPV 11 DNA IN LIQUID BIOPSIES PRV US 63/803,323 Expired US <br />Provisional (PRV) 63/803,323<br />Filed on 2025-05-09<br />Status: Expired 166910976 E-019-2025-0 E-019-2025-0-PC-01 METHODS OF DETECTING CIRCULATING CELL-FREE HPV 6 AND HPV 11 DNA IN LIQUID BIOPSIES PCT Patent Cooperation Treaty PCT/US2026/027273 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2026/027273<br />Filed on 2026-05-08<br />Status: Pending TAB-5060 162906659 Establishment and characterization of the A 1847 human ovarian carcinoma line NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Stuart Aaronson, Nelson Ellmore (Estate) <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks licensees for a tumorigenic cell line, A1847, from a patient with metastatic ovarian cancer. As a BRCA1 deficient cell line, it serves as a model to researchers studying cell cycle regulation, tumor suppression and effective drugs aiding in repair of DNA damage.</p> <h2>Description of Technology:</h2> <p>Mutations, such as loss of function, in the BRCA1 gene increase the risk of developing ovarian cancer. In its early stages, ovarian cancer may not cause any definitive symptoms but can rapidly progress within a year to advanced stage. This metastatic growth can occur by shedding cancerous cells into peritoneal fluid, often associated with epithelial ovarian cancer, its most common type. While treatments exist, it is limited by the development of drug resistance that is not succumbed to damage in cell death.</p> <p>The National Cancer Institute (NCI) researchers derived a metastatic ovarian carcinoma cell line, A1847, from a 50-year-old female. It was established as a continuous tumorigenic cell line and characterized by isozyme phenotype, short tandem repeat (STR) analysis and karyotypically with modal number 68 and 3 marker chromosomes. This cell line may be used to identify therapeutic targets and to screen drug candidates against ovarian cancer.</p> <p>NCI is seeking parties to nonexclusively license the A1847 human ovarian carcinoma cell line.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Tool to conduct preclinical proof-of-concept studies required for commercial development of anti-cancer agents and targeted therapies in ovarian cancer</li> <li>Research model to investigate epithelial ovarian cancer</li> <li>Research model for mechanistic studies of ovarian cancer and BRCA1-deficient tumors</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Well-characterized metastatic ovarian cancer cell line</li> <li>Tumorigenic cell line to generate animal models of metastatic ovarian cancer for commercial and research development</li> </ul> Researchers at the NCI seek licensing for the A1847 ovarian cancer cell line. 2025-06-12 2025-06-27 2026-08-05 2025-06-27 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-018-2020-0 163125989 Standing, D., et al. Selective targeting of IRAK1 attenuates low molecular weight hyaluronic acid-induced stemness and non-canonical STAT3 activation in epithelial ovarian cancer. (PMID 38796478) https://pubmed.ncbi.nlm.nih.gov/38796478/ <a href="https://pubmed.ncbi.nlm.nih.gov/38796478/">Standing, D., et al. Selective targeting of IRAK1 attenuates low molecular weight hyaluronic acid-induced stemness and non-canonical STAT3 activation in epithelial ovarian cancer. (PMID 38796478)</a> 163126001 Sethi, G., et al. An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer. (PMID 23056589) https://pubmed.ncbi.nlm.nih.gov/23056589/ <a href="https://pubmed.ncbi.nlm.nih.gov/23056589/">Sethi, G., et al. An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer. (PMID 23056589)</a> 163126008 Godwin, A.K., et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. (PMID 1348364) https://pubmed.ncbi.nlm.nih.gov/1348364/ <a href="https://pubmed.ncbi.nlm.nih.gov/1348364/">Godwin, A.K., et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. (PMID 1348364)</a> 162906829 Aaronson, Stuart NIH - NCI Aaronson, Stuart 1 162906896 Ellmore (Estate), Nelson NIH - NCI NCI Ellmore (Estate), Nelson (NCI) 2 162906829 Aaronson, Stuart NIH - NCI Aaronson, Stuart 1 162906896 Ellmore (Estate), Nelson NIH - NCI NCI Ellmore (Estate), Nelson (NCI) 2 162906662 Establishment and characterization of the A 1847 human ovarian carcinoma line E-137-2023-0 Research Material 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-5060] Establishment and characterization of the A 1847 human ovarian carcinoma line&body=Please send me information about technology [TAB-5060] Establishment and characterization of the A 1847 human ovarian carcinoma line.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-5060] Establishment and characterization of the A 1847 human ovarian carcinoma line&body=Please send me information about technology [TAB-5060] Establishment and characterization of the A 1847 human ovarian carcinoma line.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">suna.gulay@nih.gov</a><br> TAB-5066 163312519 Compositions and Methods for Producing Dendritic Cell-based Vaccines with Enhanced Efficacy NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Jay Berzofsky, Shweta Tiwary <h2>Summary:</h2> <p>The National Cancer Institute (NCI) is seeking research co-development partners and/or licensees for NCI&rsquo;s compositions and methods to enhance the efficacy of dendritic cell (DC)-based cancer vaccines.&nbsp;&nbsp;</p> <h2>Description of Technology:</h2> <p>Current dendritic cell (DC)-based cancer vaccines are limited by impaired DC function due to cancer-driven lipid imbalances and other immunosuppressive factors reducing vaccine effectiveness. To address this issue, NCI has generated dendritic cells in the presence of omega-3 fatty acids (docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA]) and their derivatives, or specialized pro-resolving lipid mediators, to restore and enhance the dendritic cells&rsquo; antigen-presenting function and anti-tumor efficacy. This approach could significantly improve the potency of DC-based cancer vaccines, offering a promising strategy to overcome a major limitation in current cancer immunotherapies. NCI is actively continuing development of this technology and seeks licensing and/or collaboration partners to support further preclinical validation and potential clinical translation.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Cancer immunotherapy</li> <li>Development of human DC vaccines</li> <li>Formulations involving omega-3 fatty acids or pro-resolving lipids</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Production of DCs with enhanced antigen-presenting function, anti-tumor efficacy and potency</li> <li>Significant tumor reduction and improved survival compared in animals compared with wild-type DCs</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for the development of NCI’s compositions and methods to enhance the efficacy of dendritic cell (DC)-based cancer vaccines by using omega-3 fatty acids or pro-resolving lipid mediators. 2025-07-15 2025-08-21 2026-08-05 2025-07-15 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 163312808 Tiwary, S., "Endogenously high Omega-3 levels lead to a less suppressive tumor microenvironment." https://doi.org/10.4049/jimmunol.210.Supp.172.18 <a href="https://doi.org/10.4049/jimmunol.210.Supp.172.18">Tiwary, S., "Endogenously high Omega-3 levels lead to a less suppressive tumor microenvironment."</a> 163312813 Tiwary, S., K. Hsu, K. C. Goldfarbmuren, Z. Xia, and J. A. Berzofsky. High levels of endogenous omega-3 fatty acids prolong the lifespan, promote antigen presentation, and improve DC-based cancer vaccine efficacy in mice. 2025. Cancer Immunology Research, in press. Tiwary, S., K. Hsu, K. C. Goldfarbmuren, Z. Xia, and J. A. Berzofsky. High levels of endogenous omega-3 fatty acids prolong the lifespan, promote antigen presentation, and improve DC-based cancer vaccine efficacy in mice. 2025. Cancer Immunology Research, in press. 163312555 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 1 163312567 Tiwary, Shweta NIH - NCI Tiwary, Shweta 2 163312555 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 1 163312567 Tiwary, Shweta NIH - NCI Tiwary, Shweta 2 163312522 Improving the efficacy of dendric cell-based cancer vaccines by DHA treatment E-231-2023-0 Filing authorized NIH - NCI 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-5066] Compositions and Methods for Producing Dendritic Cell-based Vaccines with Enhanced Efficacy&body=Please send me information about technology [TAB-5066] Compositions and Methods for Producing Dendritic Cell-based Vaccines with Enhanced Efficacy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-5066] Compositions and Methods for Producing Dendritic Cell-based Vaccines with Enhanced Efficacy&body=Please send me information about technology [TAB-5066] Compositions and Methods for Producing Dendritic Cell-based Vaccines with Enhanced Efficacy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">diptadip.dattaroy@nih.gov</a><br> 163312527 E-231-2023-0 E-231-2023-0-US-01 COMPOSITIONS AND METHODS FOR PRODUCING DENDRITIC CELL-BASED VACCINES WITH ENHANCED EFFICACY PRV US 63/586,629 Expired US <br />Provisional (PRV) 63/586,629<br />Filed on 2023-09-29<br />Status: Expired 163312528 E-231-2023-0 E-231-2023-0-PC-01 COMPOSITIONS AND METHODS FOR PRODUCING DENDRITIC CELL-BASED VACCINES WITH ENHANCED EFFICACY PCT Patent Cooperation Treaty PCT/US2024/049057 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/049057<br />Filed on 2024-09-27<br />Status: Expired TAB-5067 163489281 A conserved viral peptide for use in cancer immunotherapy NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Man Hsin Hung, Lichun Ma, Xin Wei Wang <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for viral peptide (CE1)-based therapeutics for HCC prevention and treatment.</p> <h2>Description of Technology:</h2> <p>Hepatocellular carcinoma (HCC) is a common and aggressive primary liver cancer. It develops mainly from at-risk individuals with underlying chronic liver diseases, such as hepatitis and cirrhosis. HCC is a leading cause of cancer-related death worldwide and its global incidence and mortality rate continues to rise. The current methods for early detection, surveillance and treatment are suboptimal due to complex etiologies and intricate tumor biology.</p> <p>Through serological profiling across three independent cohorts, researchers at the National Cancer Institute (NCI) have identified a common epitope (CE1) shared among protective viral antigens enriched in healthy individuals compared to HCC patients. A synthetic CE1 peptide was demonstrated to have utility in eliciting a T cell response to HCC cells and can be developed as an immunotherapy for HCC, such as a CE1-based HCC vaccine. Currently, as there are limited therapeutic options for HCC patients, novel treatments would offer tremendous commercial and public health benefits.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>HCC prevention and treatment</li> <li>Predictive biomarker for HCC risk <ul> <li>Serological response test</li> <li>Patient stratification for CE1-based therapy</li> <li>Monitoring the efficacy of the CE1-based vaccine</li> </ul> </li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>VirScan data support that this peptide correlates with better outcomes in HCC and breast cancer</li> <li>CE1 peptide shows an immunomodulatory effect; immunomodulators are a promising approach to cancer treatment</li> <li>CE1 peptide is biologically active in inducing T cell cytolytic activity</li> <li>HCC cell killing in an HLA-specific manner &nbsp;</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for viral peptide (CE1)-based therapeutics for HCC prevention and treatment 2025-07-28 2025-08-21 2026-08-05 2025-07-28 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-171-2022 E-174-2019 163489749 Ma L, et al. Beneficial infections of the enterovirus genus in patients with liver cancer. (PMID: 40345802) https://pubmed.ncbi.nlm.nih.gov/40345802/ <a href="https://pubmed.ncbi.nlm.nih.gov/40345802/">Ma L, et al. Beneficial infections of the enterovirus genus in patients with liver cancer. (PMID: 40345802)</a> 163489378 Wang, Xin Wei NIH - NCI NCI Wang, Xin Wei (NCI) 1 163489408 Ma, Lichun NIH - NCI Ma, Lichun 2 163489418 Hung, Man Hsin NIH - NCI NCI Hung, Man Hsin (NCI) 3 163489378 Wang, Xin Wei NIH - NCI NCI Wang, Xin Wei (NCI) 1 163489408 Ma, Lichun NIH - NCI Ma, Lichun 2 163489418 Hung, Man Hsin NIH - NCI NCI Hung, Man Hsin (NCI) 3 163489284 A conserved viral peptide for use in cancer immunotherapy E-023-2024-0 Filing authorized NIH - NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-5067] A conserved viral peptide for use in cancer immunotherapy&body=Please send me information about technology [TAB-5067] A conserved viral peptide for use in cancer immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-5067] A conserved viral peptide for use in cancer immunotherapy&body=Please send me information about technology [TAB-5067] A conserved viral peptide for use in cancer immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">changke@mail.nih.gov</a><br> 163489289 E-023-2024-0 E-023-2024-0-US-01 VIRUS ANTIGEN-DERIVED IMMUNOGENIC PEPTIDES AND THEIR USE FOR THE PREVENTION AND TREATMENT OF HEPATOCELLULAR CARCINOMA PRV US 63/735,040 Expired US <br />Provisional (PRV) 63/735,040<br />Filed on 2024-12-17<br />Status: Expired 164898215 E-023-2024-0 E-023-2024-0-PC-01 VIRUS ANTIGEN-DERIVED IMMUNOGENIC PEPTIDES AND THEIR USE FOR THE EARLY INTERVENTION AND TREATMENT OF LIVER CANCER PCT Patent Cooperation Treaty PCT/US2025/059785 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/059785<br />Filed on 2025-12-16<br />Status: Pending TAB-5068 163496618 T Cell Receptor Targeting HPV6 E2 and a Panel of Cos7 Cells Expressing Different HLA Class I Proteins for Use in Validation and Potency Studies NCI Immunology, Infectious Disease, Licensing, Oncology, Research Materials Immunology Infectious Disease Licensing Oncology Research Materials Clint Allen, Scott Norberg <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks licensees for this invention comprising (1) a novel T cell receptor (TCR) specific to the E2 protein of Human papillomavirus (HPV) type 6 &nbsp;in the context of the human leukocyte antigen, HLA-B55, and (2) a panel of Cos7 cells expressing different HLA proteins for validation of T cell responses in immunotherapies for low-risk HPV-related diseases such as recurrent respiratory papillomatosis and anogenital condyloma.</p> <h2>Description of Technology:</h2> <p>Chronic infections with low-risk HPV types 6 and 11 can lead to such diseases as recurrent respiratory papillomatosis and anogenital condyloma. Such diseases can lower quality of life considerably, expose patients to repeated invasive procedures (such as surgery) and are often recurrent and unresponsive to standard treatments. There are few targeted treatments in development against these diseases. Therefore, there may be a need for reliable research tools to test the potency of targeted treatments, particularly immunotherapies, prior to the product&rsquo;s release for patient use.</p> <p><br /> The researchers at the National Cancer Institute (NCI) identified a novel T cell receptor (TCR) specific for an antigen derived from HPV6 E2, restricted to HLA-B55. This TCR was reconstructed with a mouse constant region for tracking in donor T cells and may be used in potency testing and release assays of vaccines and other immunotherapies that target HPV6.</p> <p>The NCI seeks licensees for the research-use TCR and the panel of Cos7 cells. This invention offers a unique opportunity for developing new TCR-based therapies and validation tools for HPV-related diseases.</p> <h2>Potential Commercial Applications: &nbsp;</h2> <ul> <li>Research materials to support therapeutic or diagnostic development against HPV-related diseases</li> <li>Potency testing and other release assays of HPV 6-containing immunotherapy products</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Unique TCR and cell line panel to validate T cell responses in immunotherapies for low-risk HPV-related diseases such as recurrent respiratory papillomatosis and anogenital condyloma</li> <li>Superior tools &ndash; together or separately &ndash; in release assays for HPV 6-targeting immunotherapy products</li> <li>Unique tools for lot release assays for low- or high-risk HPV-targeting immunotherapy products</li> <li>Unique tools for lot release, stability and comparability studies</li> </ul> Researchers at the NCI seek licensing for this invention that comprises a novel T cell receptor (TCR) targeting HPV6 E2 in the context of HLA-B55 and a panel of Cos7 cells expressing different Class I human leukocyte antigen (HLA) proteins, that may be used in development of validation and potency assays for vaccines and other therapies designed to induce HPV6-specific T cell responses. 2025-07-28 2025-08-21 2026-08-05 2025-07-28 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 163496887 Bai K, Norberg SM, Sievers C, Meyer T, et al. Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockade. Case Reports Head Neck. 2022 Oct;44(10):E31-E37. doi: 10.1002/hed.27144. Bai K, Norberg SM, Sievers C, Meyer T, et al. Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockade. Case Reports Head Neck. 2022 Oct;44(10):E31-E37. doi: 10.1002/hed.27144. 163496740 Allen, Clint NIH - NCI NCI Allen, Clint (NCI) 1 163496774 Norberg, Scott NIH - NCI NCI Norberg, Scott (NCI) 2 163496740 Allen, Clint NIH - NCI NCI Allen, Clint (NCI) 1 163496774 Norberg, Scott NIH - NCI NCI Norberg, Scott (NCI) 2 163496621 Discovery of a T cell receptor targeting an antigen derived from HPV6 E2 and a panel of Cos7 cells expressing different HLA class I proteins E-010-2024-0 Research Material NIH - NCI 142435134 Sherwani, Zehra zehra.sherwani@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America zehra.sherwani@nih.gov?subject=Web Inquiry on [TAB-5068] T Cell Receptor Targeting HPV6 E2 and a Panel of Cos7 Cells Expressing Different HLA Class I Proteins for Use in Validation and Potency Studies&body=Please send me information about technology [TAB-5068] T Cell Receptor Targeting HPV6 E2 and a Panel of Cos7 Cells Expressing Different HLA Class I Proteins for Use in Validation and Potency Studies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Sherwani, Zehra<br><a href="mailto:zehra.sherwani@nih.gov?subject=Web Inquiry on [TAB-5068] T Cell Receptor Targeting HPV6 E2 and a Panel of Cos7 Cells Expressing Different HLA Class I Proteins for Use in Validation and Potency Studies&body=Please send me information about technology [TAB-5068] T Cell Receptor Targeting HPV6 E2 and a Panel of Cos7 Cells Expressing Different HLA Class I Proteins for Use in Validation and Potency Studies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">zehra.sherwani@nih.gov</a><br> TAB-5072 163822312 Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients with Chronic Viral Infection(s) NCI Collaboration, Immunology, Infectious Disease, Licensing, Therapeutics Collaboration Immunology Infectious Disease Licensing Therapeutics Clint Allen, Ke Bai, Zulmarie Franco, Scott Norberg <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for development of papilloma-infiltrating lymphocytes (PIL) as treatment for patients with chronic human papillomavirus (HPV) 6 or 11 infections.</p> <h2>Description of Technology:</h2> <p>Recurrent Respiratory Papillomatosis (RRP) and anogenital condyloma are caused by chronic infection with human papillomavirus (HPV) types 6 or 11. These conditions lead to the development of papillomatous growths in different regions of the body &ndash; RRP affects the upper aerodigestive tract, while condylomas involve the anogenital area. In RRP, growths in the aerodigestive tract can cause dysphonia, dyspnea, and, in severe cases, airway obstruction, which may lead to recurrent pneumonia or respiratory failure.</p> <p>Current treatment for RRP primarily involves repeated surgical debulking or laser ablation to manage symptoms. However, the virus often persists in a latent state, resulting in continual papilloma regrowth. The need for frequent procedures exposes patients to cumulative anesthetic and surgical risks, emotional distress, and significantly diminished quality of life. Despite progress in localized treatments such as surgery and laser ablation, there are no approved systemic therapies for chronic HPV 6 or 11-related conditions. This highlights a clear unmet need for effective, curative therapy options.</p> <p>Researchers at the National Cancer Institute (NCI) have developed a novel adoptive cell therapy approach to target conditions driven by HPV types 6 or 11. They have successfully identified and preferentially expanded HPV 6 and/or 11-specific T cells from papilloma tissue obtained from patients with RRP. These papilloma-infiltrating lymphocytes (PILs) have demonstrated the ability to eliminate papillomatous tissue. This T cell manufacturing method holds promise for developing cell-based therapies for chronic HPV 6/11-related conditions, including RRP and potentially anogenital condyloma. Notably, the ability to isolate and expand antigen-specific lymphocytes from non-cancerous growths represents an exciting advancement in the field of adoptive cell therapy &ndash; potentially paving the way for treating a broader range of non-malignant diseases.</p> <p>This technology is available for licensing and offers a compelling opportunity for companies developing next-generation immunotherapies. The Center for Immuno-Oncology and the Surgical Oncology Program of the NCI, Center for Cancer Research are actively seeking industry partners to support the clinical development and commercialization of this approach. It is particularly well-suited for biotech firms focused on T cell therapies or addressing HPV-related diseases. Strategic collaboration could accelerate market entry and unlock significant value in an area with high unmet medical need.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Immunotherapy for chronic HPV-related conditions such as recurrent respiratory papillomatosis (RRP) and anogenital condyloma.</li> <li>Development of personalized T cell therapies targeting HPV 6 or HPV 11 infections.</li> <li>Generation of T cell receptor (TCR) libraries for research and therapeutic purposes.</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Selective expansion of T cells with high specificity for HPV 6 or HPV 11 antigens.</li> <li>Potential to treat both non-cancerous and cancerous HPV-related conditions.</li> <li>Ability to produce oligoclonal T cell populations, increasing the efficacy of the therapy.</li> <li>Methodology applicable to both therapeutic and preventative treatments for chronic HPV infections.</li> <li>Drug development for RRP may qualify for regulatory incentives due to the rarity of the disease.</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for papilloma-infiltrating lymphocytes (PIL) in treatment for chronic HPV6/11-associated diseases 2025-08-21 2025-08-21 2026-08-05 2025-08-21 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 163822392 Bai K, Norberg SM, Sievers C, Meyer T, et al. Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockade. Case Reports Head Neck. 2022 Oct;44(10):E31-E37. doi: 10.1002/hed.27144. Bai K, Norberg SM, Sievers C, Meyer T, et al. Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockade. Case Reports Head Neck. 2022 Oct;44(10):E31-E37. doi: 10.1002/hed.27144. 163822341 Norberg, Scott NIH - NCI NCI Norberg, Scott (NCI) 1 163822345 Allen, Clint NIH - NCI NCI Allen, Clint (NCI) 2 163822349 Franco, Zulmarie NIH - NCI NCI Franco, Zulmarie (NCI) 3 163822353 Bai, Ke NIH - NCI NCI Bai, Ke (NCI) 4 163822341 Norberg, Scott NIH - NCI NCI Norberg, Scott (NCI) 1 163822345 Allen, Clint NIH - NCI NCI Allen, Clint (NCI) 2 163822349 Franco, Zulmarie NIH - NCI NCI Franco, Zulmarie (NCI) 3 163822353 Bai, Ke NIH - NCI NCI Bai, Ke (NCI) 4 163822315 Method of Manufacturing Papilloma Infiltrating Lymphocyte Cell Therapy Products as a Treatment for Patients with Chronic Viral Infection(s) E-143-2024-0 Filing authorized NIH - NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-5072] Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients with Chronic Viral Infection(s)&body=Please send me information about technology [TAB-5072] Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients with Chronic Viral Infection(s).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-5072] Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients with Chronic Viral Infection(s)&body=Please send me information about technology [TAB-5072] Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients with Chronic Viral Infection(s).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">suna.gulay@nih.gov</a><br> 163822320 E-143-2024-0 E-143-2024-0-US-01 METHODS OF PREPARING CELL THERAPY PRODUCTS FOR THE TREATMENT OF CONDITIONS CAUSED BY HUMAN PAPILLOMAVIRUS 6 OR 11 INFECTION PRV US 63/709,683 Expired US <br />Provisional (PRV) 63/709,683<br />Filed on 2024-10-21<br />Status: Expired 164010270 E-143-2024-0 E-143-2024-0-PC-01 METHODS OF PREPARING CELL THERAPY PRODUCTS FOR THE TREATMENT OF CONDITIONS CAUSED BY HUMAN PAPILLOMAVIRUS 6 OR 11 INFECTION PCT Patent Cooperation Treaty PCT/US2025/051640 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/051640<br />Filed on 2025-10-20<br />Status: Pending TAB-5065 163297774 Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1 NICHD Immunology, Oncology, Therapeutics Immunology Oncology Therapeutics Avik Dutta, Paul Love <h2>Summary:</h2> <p>The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is actively seeking potential licensees interested in further developing these inhibitory transmembrane adapter proteins as targets for T-cell immunotherapy for the treatment of cancer, infectious diseases, and autoimmune diseases.</p> <h2>Description of Technology:</h2> <p>Cellular immunotherapy holds much promise for the treatment of cancer. However, certain cellular therapies have limited success because of immunosuppression in the tumor microenvironment. Thus, there is an unmet need for improved methods of cellular immunotherapy.</p> <p>T cells constitutively express inhibitory molecules that limit the activation response to antigens by the T cell antigen receptor (TCR). Among these are the transmembrane adapter proteins SIT1, LAX 1 and TRA T1. These appear to tonically associate with the TCR and inhibit signal transduction. Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) have identified SIT1, LAX 1 and TRA T1 as potential targets for T-cell immunotherapy. Mouse models have demonstrated that deletion of SIT1, LAX1 and TRA T1 &ndash; or expression of nonfunctional mutant versions of these proteins in mouse T cells &ndash; enhances TCR signaling and significantly increases T cell cytotoxicity against tumor cells. Experiments confirming these results in human T cells are currently underway. This discovery provides a new therapeutic approach to greatly improve clinical outcomes of T-cell immunotherapy in treating cancers. It also holds potential to treat infectious diseases or autoimmune diseases</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment for cancer</li> <li>Treatment for infectious diseases</li> <li>Treatment for autoimmune diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Potentially superior therapeutic benefit in cancer by: <ul> <li>Enhancing tumoricidal activity of T-cell immunotherapy</li> <li>Overcoming immunosuppression in the tumor microenvironment</li> </ul> </li> <li>Potentially superior therapeutic benefit in infectious diseases by enhancing immune responses to pathogens</li> <li>Potentially superior therapeutic benefit in autoimmune disease by enhancing the generation or function of antigen-specific regulator T cells (Tregs)</li> </ul> Researchers at the NICHD seek licensing for further developing these inhibitory transmembrane adapter proteins as targets for T-cell immunotherapy for the treatment of cancer, infectious diseases, and autoimmune diseases. 2025-07-14 2025-08-21 2026-08-05 2025-07-14 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 163298026 Love, Paul NICHD NICHD Love, Paul (NICHD) 1 163298037 Dutta, Avik NICHD NICHD Dutta, Avik (NICHD) 2 163298026 Love, Paul NICHD NICHD Love, Paul (NICHD) 1 163298037 Dutta, Avik NICHD NICHD Dutta, Avik (NICHD) 2 163297777 Enhanced tumor of T cells lacking SIT1, LAX1 or TRAT1 E-004-2024-0 Filing authorized NIH - NICHD 91789173 Guyton, Nicole darackn@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America darackn@mail.nih.gov?subject=Web Inquiry on [TAB-5065] Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1&body=Please send me information about technology [TAB-5065] Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Guyton, Nicole<br><a href="mailto:darackn@mail.nih.gov?subject=Web Inquiry on [TAB-5065] Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1&body=Please send me information about technology [TAB-5065] Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">darackn@mail.nih.gov</a><br> 163363211 E-004-2024-0 E-004-2024-0-US-01 Enhanced Tumor Reactivity of T cells lacking SIT1, LAX1 or TRAT1 PRV US 63/625,354 Expired US <br />Provisional (PRV) 63/625,354<br />Filed on 2024-01-26<br />Status: Expired 163363216 E-004-2024-0 E-004-2024-0-PC-01 Enhanced Tumor Reactivity of T cells lacking SIT1, LAX1 or TRAT1 PCT Patent Cooperation Treaty PCT/US2025/013054 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2025/013054<br />Filed on 2025-01-24<br />Status: Expired TAB-5073 163873358 Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptor NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Lauren Cutmore, James Kochenderfer <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a set of Chimeric Antigen Receptors (CARs) that target the &gamma;&delta; T-Cell Receptor.</p> <h2>Description of Technology:</h2> <p>T cells express two main types of receptors based on the proteins that make up the T-cell receptor (TCR) heterodimers: ab (alpha beta) and gd (gamma delta). T cells expressing the gd TCR are detected at lower frequencies compared with T cells expressing the ab TCR. gd T cells make up 0.3-10% of peripheral blood T cells. The gd TCR is expressed on the cell surface of several aggressive cancers, including &ndash; but not limited to &ndash; hepatosplenic T-cell lymphoma, primary cutaneous gd T-cell lymphoma and T-cell acute lymphoblastic leukemia (T-ALL). These cancers carry poor prognosis as they are often resistant to chemotherapy. In addition, to their roles in cancer development, gd T cells may also play role in autoimmune diseases, including psoriasis, rheumatoid arthritis, multiple sclerosis and myositis. There is evidence that gd T cells are involved in initiation or persistence of these autoimmune diseases. To this end, new treatment options are needed for gd T-cell malignancies and autoimmune diseases.</p> <p>Researchers at the National Cancer Institute (NCI) have developed several CARs targeting the gd TCR. These CARs can specifically bind to and immunologically recognize human gd TCR. Binding of the CAR to the gd TCR elicits an immune response that allows for killing of cells expressing this TCR.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of &gamma;&delta; T cell cancers <ul> <li>hepatosplenic T-cell lymphoma</li> <li>primary cutaneous gd T-cell lymphoma</li> <li>T-ALL</li> </ul> </li> <li>Treatment of &gamma;&delta; T cell autoimmune diseases <ul> <li>psoriasis</li> <li>rheumatoid arthritis</li> <li>multiple sclerosis</li> <li>myositis</li> </ul> </li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Promising new treatment option for several major market opportunities, including gd T cell malignancies and autoimmune diseases</li> <li>Promising new treatment option for patients resistant to chemotherapy</li> <li>In vivo proof-of-concept studies completed</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a set of Chimeric Antigen Receptors (CARs) that target the γδ T-Cell Receptor, and if applicable, CARs that target the αβ T-Cell Receptor, too. 2025-08-25 2025-08-25 2026-08-05 2025-08-25 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 163873535 Kochenderfer JN, et al. Development of Novel Chimeric Antigen Receptors Targeting the Gamma-Delta (γδ) T-Cell Receptor. https://doi.org/10.1182/blood-2024-204126 <a href="https://doi.org/10.1182/blood-2024-204126">Kochenderfer JN, et al. Development of Novel Chimeric Antigen Receptors Targeting the Gamma-Delta (γδ) T-Cell Receptor.</a> 163873409 Kochenderfer, James NIH - NCI NCI Kochenderfer, James (NCI) 1 163873416 Cutmore, Lauren NIH - NCI NCI Cutmore, Lauren (NCI) 2 163873409 Kochenderfer, James NIH - NCI NCI Kochenderfer, James (NCI) 1 163873416 Cutmore, Lauren NIH - NCI NCI Cutmore, Lauren (NCI) 2 163873361 Development of chimeric antigen receptors targeting the gamma-delta T-cell receptor E-214-2024-0 Filing authorized NIH - NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-5073] Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptor&body=Please send me information about technology [TAB-5073] Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptor.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-5073] Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptor&body=Please send me information about technology [TAB-5073] Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptor.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">burkear@nih.gov</a><br> 163873366 E-214-2024-0 E-214-2024-0-US-01 CHIMERIC ANTIGEN RECEPTORS TARGETING THE GAMMA DELTA T CELL RECEPTOR PRV US 63/678,625 Expired US <br />Provisional (PRV) 63/678,625<br />Filed on 2024-08-02<br />Status: Expired 163873367 E-214-2024-0 E-214-2024-0-PC-01 CHIMERIC ANTIGEN RECEPTORS TARGETING THE GAMMA DELTA T CELL RECEPTOR PCT Patent Cooperation Treaty PCT/US2025/040252 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/040252<br />Filed on 2025-08-01<br />Status: Pending TAB-5081 164388769 Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2 NICHD Licensing, Rare/Neglected Diseases, Research Materials Licensing Rare/Neglected Diseases Research Materials Bjorn Knollmann, Karl Pfeifer <h2>Summary:</h2> <p>&nbsp;The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is seeking potential licensees interested in further developing or utilizing these Casq2 mouse strains. As a research tool, patent protection is not being pursued for this technology. More information to access these strains can be found here: https://www.jax.org/strain/036291 and https://www.jax.org/strain/036290.</p> <h2>Description of Technology:</h2> <p>Cardiac calsequestrin (Casq2) plays an essential role in maintaining cardiac Ca2+ homeostasis. Human CASQ2 mutations are associated with catecholaminergic polymorphic ventricular tachycardia (CPVT), a rare familial arrhythmogenic disorder within a group of diseases characterized as Sudden Arrhythmic Death.</p> <p>The inventors have generated Casq2Flox and Casq2RevFlox mouse strains that model CPVT. The two novel strains successfully phenocopy aspects of CPVT, including stress-induced arrhythmias and reduced basal heart rates. The strains allow investigators to determine the importance of Casq2 gene function in specific tissues and at specific developmental time points. They also allow investigators to determine the efficacy of gene therapy and to address key mechanism questions. The materials are validated and fully functional.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Study of Casq2 function</li> <li>Study of calcium storage in cardiac muscle and CPVT</li> <li>Determining the efficacy of gene therapy for CPVT</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Only available conditional and reverse conditional loss-of-function alleles in mouse Casq2</li> <li>Allows the study of Casq2 gene function in specific tissues and at specific developmental points</li> </ul> NICHD seeks licensing for further developing or utilizing these Casq2 mouse strains. 2025-09-29 2025-09-29 2026-08-05 2025-09-29 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52406768 Discovery 52406768 NCI 37470483 Website Abstract 164390469 Knollmann BC, et al. Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. (PMID 16932808) https://pubmed.ncbi.nlm.nih.gov/16932808/ <a href="https://pubmed.ncbi.nlm.nih.gov/16932808/">Knollmann BC, et al. Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. (PMID 16932808)</a> 164390478 Flores DJ, et al. Conditional ablation and conditional rescue models for Casq2 elucidate the role of development and of cell-type specific expression of Casq2 in the CPVT2 phenotype. (PMID 29452352) https://pubmed.ncbi.nlm.nih.gov/29452352/ <a href="https://pubmed.ncbi.nlm.nih.gov/29452352/">Flores DJ, et al. Conditional ablation and conditional rescue models for Casq2 elucidate the role of development and of cell-type specific expression of Casq2 in the CPVT2 phenotype. (PMID 29452352)</a> 164390525 Blackwell DJ, et al. The Purkinje–myocardial junction is the anatomic origin of ventricular arrhythmia in CPVT. (PMID 34990403) https://pubmed.ncbi.nlm.nih.gov/34990403/ <a href="https://pubmed.ncbi.nlm.nih.gov/34990403/">Blackwell DJ, et al. The Purkinje–myocardial junction is the anatomic origin of ventricular arrhythmia in CPVT. (PMID 34990403)</a> 164388829 Pfeifer, Karl NICHD NICHD Pfeifer, Karl (NICHD) 1 164388840 Knollmann, Bjorn Vanderbilt University Knollmann, Bjorn 2 164388829 Pfeifer, Karl NICHD NICHD Pfeifer, Karl (NICHD) 1 164388840 Knollmann, Bjorn Vanderbilt University Knollmann, Bjorn 2 164388772 Generating conditional and reverse conditional loss-of-function alleles in mouse Casq2 E-128-2024-0 Research Material NIH - NICHD, Vanderbilt University 83746064 Whitman, Nathan nathan.whitman@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC nathan.whitman@nih.gov?subject=Web Inquiry on [TAB-5081] Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2&body=Please send me information about technology [TAB-5081] Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Whitman, Nathan<br><a href="mailto:nathan.whitman@nih.gov?subject=Web Inquiry on [TAB-5081] Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2&body=Please send me information about technology [TAB-5081] Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">nathan.whitman@nih.gov</a><br> TAB-5083 164393859 Identification and Characterization of HLA-A24 Agonist Epitopes of MUC1 Oncoprotein NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Jeffrey Schlom, Kwong-Yok Tsang <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks co-development partners and licensees for a human cytotoxic T lymphocyte agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), in a cancer vaccine or T-cell targeted therapy to target many tumor types.</p> <h2>Description of Technology:</h2> <p>Many human carcinomas and hematologic malignancies overexpress mucin 1 (MUC1), a transmembrane glycoprotein composed of heterodimers formed by a large, N-terminal subunit (MUC1-N) and a smaller, C-terminal subunit (MUC1-C). In tumors, the MUC-1 heterodimer becomes abnormally hypoglycosylated &ndash; leading to the exposure of antigenic epitopes to the immune system. Aberrant MUC1 expression, and in particular its MUC1-C subunit, has been associated with poor prognosis and correlates with cancer metastasis &ndash; further establishing MUC1 as a target for cancer therapy.</p> <p>Inventors at the National Cancer Institute have identified epitopes of MUC1-C and enhancer agonist peptides that can activate cytotoxic T lymphocytes. These epitopes and enhancers may be suitable to develop into immunotherapies, such as cancer vaccines against various malignancies. In particular, the agonist peptides are expected to further enhance responses in patients when used in vaccines or T-cell therapy. The epitopes span the human leukocyte antigen HLA-A24 allele and facilitate recognition of MUC1-C in the context of HLA-A24.</p> <p>This technology is available for collaboration and licensing opportunities.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of MUC1-expressing cancers</li> <li>Cancer vaccine compositions</li> <li>MUC1-targeting epitopes and agonists</li> <li>Activation of cytotoxic T cell response as an enhanced cancer treatment</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Agonist epitopes can be incorporated into various vaccine platforms</li> <li>Agonist epitopes can be used for the ex vivo generation of human T cells</li> <li>Epitopes span the HLA-A24 allele and facilitate recognition and killing of human tumor cells in an MHC-restricted manner</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for agonist epitopes of the MUC1-C oncoprotein. 2025-09-29 2025-09-29 2026-08-05 2025-09-29 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 164394007 Jochems C, et al. Identification and characterization of agonist epitopes of the MUC1-C oncoprotein. (PMID 24233342) https://pubmed.ncbi.nlm.nih.gov/24233342/ <a href="https://pubmed.ncbi.nlm.nih.gov/24233342/">Jochems C, et al. Identification and characterization of agonist epitopes of the MUC1-C oncoprotein. (PMID 24233342)</a> 164393890 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 164393911 Tsang, Kwong-Yok NIH - NCI NCI Tsang, Kwong-Yok (NCI) 2 164393890 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 164393911 Tsang, Kwong-Yok NIH - NCI NCI Tsang, Kwong-Yok (NCI) 2 164393862 Identification And Characterization Of HLA-A24 Agonist Epitopes Of MUC1-Oncoprotein E-520-2013-0 Filing authorized NCI 83687903 Pollack, Michael michael.pollack@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michael.pollack@nih.gov?subject=Web Inquiry on [TAB-5083] Identification and Characterization of HLA-A24 Agonist Epitopes of MUC1 Oncoprotein&body=Please send me information about technology [TAB-5083] Identification and Characterization of HLA-A24 Agonist Epitopes of MUC1 Oncoprotein.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollack, Michael<br><a href="mailto:michael.pollack@nih.gov?subject=Web Inquiry on [TAB-5083] Identification and Characterization of HLA-A24 Agonist Epitopes of MUC1 Oncoprotein&body=Please send me information about technology [TAB-5083] Identification and Characterization of HLA-A24 Agonist Epitopes of MUC1 Oncoprotein.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">michael.pollack@nih.gov</a><br> 164411756 E-520-2013-0 E-520-2013-0-US-01 Identification And Characterization Of HLA-A24 Agonist Epitopes Of MUC1-Oncoprotein PRV US 61/894,482 Abandoned US <br />Provisional (PRV) 61/894,482<br />Filed on 2013-10-23<br />Status: Abandoned 164411761 E-520-2013-0 E-520-2013-0-PCT-02 HLA-A24 Agonist Epitopes Of MUC1-C Oncoprotein and Compositions and Methods of Use PCT Patent Cooperation Treaty PCT/US2014/061723 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/061723<br />Filed on 2014-10-22<br />Status: Expired 164412485 E-520-2013-0 E-520-2013-0-US-02 Identification And Characterization Of HLA-A24 Agonist Epitopes Of MUC1-Oncoprotein DIV US 11,732,017 17/240,260 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11732017 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11732017">11,732,017</a><br />Filed on 2021-04-26<br />Status: Issued 164412490 E-520-2013-0 E-520-2013-0-US-03 HLA-A24 AGONIST EPITOPES OF MUC1-C ONCOPROTEIN AND COMPOSITIONS AND METHODS OF USE CON US 12,325,731 18/344,242 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12325731 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12325731">12,325,731</a><br />Filed on 2023-06-29<br />Status: Issued 164412495 E-520-2013-0 E-520-2013-0-US-07 HLA-A24 Agonist Epitopes Of MUC1-Oncoprotein and Compositions and Methods of Use National Stage US 10,035,832 15/031,435 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10035832 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10035832">10,035,832</a><br />Filed on 2016-04-22<br />Status: Issued 164412622 E-520-2013-0 E-520-2013-0-US-18 Identification And Characterization Of HLA-A24 Agonist Epitopes Of MUC1-Oncoprotein DIV US 10,508,141 16/034,654 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10508141 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10508141">10,508,141</a><br />Filed on 2018-07-13<br />Status: Issued 164412777 E-520-2013-0 E-520-2013-0-US-19 Identification And Characterization Of HLA-A24 Agonist Epitopes Of MUC1-Oncoprotein DIV US 11,155,588 16/715,038 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11155588 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11155588">11,155,588</a><br />Filed on 2019-12-16<br />Status: Issued 166454591 E-520-2013-0 E-520-2013-0-CA-01 HLA-A24 Agonist Epitopes Of MUC1-C Oncoprotein and Compositions and Methods of Use DIV Canada 3205348 Pending Canada <br />Divisional (DIV) 3205348<br />Filed on 2023-06-30<br />Status: Pending TAB-5086 164407714 Photoactivatable Dye Compounds For Conjugate Formation And Methods of Making And Using the Same NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Peter Choyke, Daiki Hara, Hisataka Kobayashi, Hideo Takakura <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a new series of photo-absorbing silicon-phthalocyanine derivatives (IR702HKT) for use in near-infrared photoimmunotherapy (NIR-PIT) in the treatment of cancer.</p> <h2>Description of Technology:</h2> <p>Near-infrared photoimmunotherapy (NIR-PIT) is a method of treating cancers that utilizes an antibody-photoabsorber conjugate (APC), which is activated by near-infrared light to kill cells. The antibody binds to the appropriate cell surface antigen and a photo-activatable compound induces lethal damage to the cell membrane after NIR-light exposure. NIR-light exposure induces highly selective, necrotic cancer cell death within minutes without damage to adjoining cells.</p> <p>Researchers at the National Cancer Institute (NCI) and Kansai Medical University (KMU) have developed the current invention which is a new series of photo-absorbing silicon-phthalocyanine derivatives (IR702HKT) as alternatives to the current IRDye700DX. This series of IR702HKTs have modified linkers that improve the efficacy of cellular cytotoxicity of IR702HKT bound to target cancer cells. Additionally, appropriate modifications improved in vivo stability of these new APCs and required less energetic therapeutic light exposure, which should improve clinical therapeutic efficacy and safety of NIR-PIT.</p> <p>The inventors are open to co-development partners and/or licensing opportunities.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Cancer treatment</li> <li>Cancer diagnosis</li> <li>Cancer imaging</li> <li>Treatment against viral, fungus, parasite, or bacterial infection</li> <li>Age-related macular degeneration and lymphangioma, via depletion of abnormal vessels</li> <li>Improved metabolic and physical function, via targeting of senile senescent cells</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Improved in vivo stability</li> <li>Improved cytotoxicity against APC-bound target cells by the same light exposure</li> <li>Reduced therapeutic light exposure clinical therapeutic efficacy and safety, compared to current photo-absorbing silicon-phthalocyanine derivatives</li> <li>Improved synthesis yields</li> </ul> Researchers at the NCI seek licensing for a new series of photo-absorbing silicon-phthalocyanine derivatives (IR702HKT) as alternatives to the current IRDye700DX. 2025-09-30 2025-09-30 2026-08-05 2025-09-30 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-137-2024-1 164407776 Choyke, Peter NIH - NCI NCI Choyke, Peter (NCI) 1 164407780 Kobayashi, Hisataka NIH - NCI NCI Kobayashi, Hisataka (NCI) 2 164407791 Takakura, Hideo Kansai Medical University Takakura, Hideo 3 164407795 Hara, Daiki Kansai Medical University Hara, Daiki 4 164407776 Choyke, Peter NIH - NCI NCI Choyke, Peter (NCI) 1 164407780 Kobayashi, Hisataka NIH - NCI NCI Kobayashi, Hisataka (NCI) 2 164407791 Takakura, Hideo Kansai Medical University Takakura, Hideo 3 164407795 Hara, Daiki Kansai Medical University Hara, Daiki 4 164407717 Photoabsorbing Dyes (IR702HKTs) for Near Infrared PhotoImmuno Therapy (NIR-PIT) E-137-2024-0 Filing authorized Kansai Medical University, Molecular Imaging Branch 83736770 Cheng, Eric eric.cheng2@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-5086] Photoactivatable Dye Compounds For Conjugate Formation And Methods of Making And Using the Same&body=Please send me information about technology [TAB-5086] Photoactivatable Dye Compounds For Conjugate Formation And Methods of Making And Using the Same.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Cheng, Eric<br><a href="mailto:eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-5086] Photoactivatable Dye Compounds For Conjugate Formation And Methods of Making And Using the Same&body=Please send me information about technology [TAB-5086] Photoactivatable Dye Compounds For Conjugate Formation And Methods of Making And Using the Same.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">eric.cheng2@nih.gov</a><br> 164407722 E-137-2024-0 E-137-2024-0-US-01 PHOTOACTIVATABLE DYE COMPOUNDS FOR CONJUGATE FORMATION AND METHODS OF MAKING AND USING THE SAME PRV US 63/690,585 Expired US <br />Provisional (PRV) 63/690,585<br />Filed on 2024-09-04<br />Status: Expired 164407723 E-137-2024-0 E-137-2024-0-PC-01 PHOTOACTIVATABLE DYE COMPOUNDS FOR CONJUGATE FORMATION AND METHODS OF MAKING AND USING THE SAME PCT Patent Cooperation Treaty PCT/US2025/044361 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/044361<br />Filed on 2025-09-03<br />Status: Pending TAB-5087 164409186 Acyloxyacyl Hydrolase (AOAH) and Methods of Use NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Lanqi Gong, Peng Jiang <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the development of AOAH as a cancer immunotherapy.</p> <h2>Description of Technology:</h2> <p>Immune CheckPoint Inhibitors (ICIs) and T-cell based therapies are part of the emerging immunology-based therapies being used to treat cancers.&nbsp; However, the efficacy of ICI therapies can be limited and a substantial portion of patients develop resistance or tolerance to treatment.&nbsp; T-cell based cancer immunotherapies have only been approved for hematological cancers. They are suboptimal in solid tumor cancers due to physical barriers and the immuno-suppressive tumor microenvironment.&nbsp; Thus, additional therapies and strategies are needed to improve efficacy and expand the types of cancer amendable to treatment.</p> <p>Scientists at the National Cancer Institute have identified a secreted lipase, Acyloxyacyl Hydrolase (AOAH), produced by cells such as macrophages and dendritic cells that can potentiate immunotherapies in murine tumor models.&nbsp; The protein sensitizes T cell receptors to weak antigens and protects dendritic cells through depleting immunosuppressive arachidonyl phoshatidylcholines and oxidized derivatives.&nbsp; Thus, the protein can potentially enhance the efficacy and types of cancers treated by ICI based and T-cell based immunotherapies.</p> <p>The National Cancer Institute is seeking collaborators and/or licensees to develop this technology as a cancer immunotherapy.</p> <h2>Potential Commercial Applications:&nbsp; &nbsp;</h2> <ul> <li>Cancer immunotherapy</li> <li>Combination therapy with ICIs or T-cell based therapies</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Novel therapeutic entity</li> <li>Potentially improved efficacy</li> <li>Increased types of addressable cancers</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for the development of AOAH as an immunotherapy for cancer treatment. 2025-09-30 2025-09-30 2026-08-05 2025-09-30 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 164409372 Gong L et al. Cancer Immunology Data Engine Reveals Secreted AOAH as a Potential Immunotherapy. (PMID 40730154) https://pubmed.ncbi.nlm.nih.gov/40730154/ <a href="https://pubmed.ncbi.nlm.nih.gov/40730154/">Gong L et al. Cancer Immunology Data Engine Reveals Secreted AOAH as a Potential Immunotherapy. (PMID 40730154)</a> 164409292 Jiang, Peng NIH - NCI NCI Jiang, Peng (NCI) 1 164409296 Gong, Lanqi NIH - NCI NCI Gong, Lanqi (NCI) 2 164409292 Jiang, Peng NIH - NCI NCI Jiang, Peng (NCI) 1 164409296 Gong, Lanqi NIH - NCI NCI Gong, Lanqi (NCI) 2 164409189 Big data-driven discovery and development of AOAH as new immunotherapy E-038-2024-0 Filing authorized NIH - NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-5087] Acyloxyacyl Hydrolase (AOAH) and Methods of Use&body=Please send me information about technology [TAB-5087] Acyloxyacyl Hydrolase (AOAH) and Methods of Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-5087] Acyloxyacyl Hydrolase (AOAH) and Methods of Use&body=Please send me information about technology [TAB-5087] Acyloxyacyl Hydrolase (AOAH) and Methods of Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">changke@mail.nih.gov</a><br> 164409194 E-038-2024-0 E-038-2024-0-US-01 ACYLOXYACYL HYDROLASE AND METHODS OF USE PRV US 63/717,036 Expired US <br />Provisional (PRV) 63/717,036<br />Filed on 2024-11-06<br />Status: Expired 164409195 E-038-2024-0 E-038-2024-0-PC-01 ACYLOXYACYL HYDROLASE AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2025/053940 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/053940<br />Filed on 2025-11-04<br />Status: Pending TAB-5075 163996507 Automated Cell Radiolabeling Device Using Acoustophoresis Micro-Fluidic Technology NCI Collaboration, Licensing, Medical Devices, Oncology, Research Materials Collaboration Licensing Medical Devices Oncology Research Materials Stephen Adler, Peter Choyke, Noriko Sato <h2>Summary:</h2> <p>The National Cancer Institute (NCI) sees research co-development partners and/or licensees for an automated acoustophoresis device to radio-label and isolate cells.</p> <h2>Description of Technology:</h2> <p>This technology includes an automated cell radiolabeling device that utilizes acoustophoresis microfluidic technology. The device streamlines the radiolabeling process by integrating cell washing and concentrating steps, which enhances reproducibility and standardization. This innovation simplifies the GMP (Good Manufacturing Practice) compliance for radiolabeling cells intended for human use. It also addresses the limitations of current manual methods that rely on centrifugation. The result is a benchtop system designed for clinical radio-pharmacies, ensuring efficient and reliable cell preparation for diagnostic and therapeutic applications.</p> <p><a href="https://cbiit.webex.com/recordingservice/sites/cbiit/recording/f287687265fd103cbf9de650e0bf904c/playback" target="_blank">Automated Acoustophoresis Device to Radio-Label &amp; Isolate Cells for Immunotherapy and Isolated Cells for Immunotherapy Treatment</a></p> <h2>Potential Commercial Applications:</h2> <ul> <li>Clinical radio-pharmacies for radiolabeled cell diagnostics</li> <li>Research institutions focused on cellular therapies and diagnostics</li> <li>Pharmaceutical companies developing radiolabeled therapeutics</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Fully automated process reduces manual intervention, increasing efficiency and consistency</li> <li>Micron-scale acoustophoresis technology enhances reproducibility and standardization of cell radiolabeling</li> <li>Streamlined GMP compliance simplifies regulatory processes for clinical applications</li> <li>Benchtop system</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for an automated acoustophoresis device to radio-label and isolate cells. 2025-09-04 2025-12-15 2026-08-05 2025-12-08 False False True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52406769 Prototype 52406769 NCI 37470483 Website Abstract 165083181 Adler, S, et al. Using Acoustophoresis Cell Washing In The Immune Cell Radiolabeling Procedure. https://jnm.snmjournals.org/content/63/supplement_2/2755 <a href="https://jnm.snmjournals.org/content/63/supplement_2/2755">Adler, S, et al. Using Acoustophoresis Cell Washing In The Immune Cell Radiolabeling Procedure.</a> 163996723 Adler, Stephen NCI - FCRDC (Leidos) Leidos Adler, Stephen (Leidos) 1 163996730 Sato, Noriko National Cancer Institute (NCI) NCI Sato, Noriko (NCI) 2 163996736 Choyke, Peter National Cancer Institute (NCI) NCI Choyke, Peter (NCI) 3 163996723 Adler, Stephen NCI - FCRDC (Leidos) Leidos Adler, Stephen (Leidos) 1 163996730 Sato, Noriko National Cancer Institute (NCI) NCI Sato, Noriko (NCI) 2 163996736 Choyke, Peter National Cancer Institute (NCI) NCI Choyke, Peter (NCI) 3 163996510 Novel Device For Cell Radiolabeling Using Acoustophoresis Micro-fluidic Technology E-096-2021-0 Filing authorized NCI 83736770 Cheng, Eric eric.cheng2@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-5075] Automated Cell Radiolabeling Device Using Acoustophoresis Micro-Fluidic Technology&body=Please send me information about technology [TAB-5075] Automated Cell Radiolabeling Device Using Acoustophoresis Micro-Fluidic Technology.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Cheng, Eric<br><a href="mailto:eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-5075] Automated Cell Radiolabeling Device Using Acoustophoresis Micro-Fluidic Technology&body=Please send me information about technology [TAB-5075] Automated Cell Radiolabeling Device Using Acoustophoresis Micro-Fluidic Technology.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">eric.cheng2@nih.gov</a><br> 163996515 E-096-2021-0 E-096-2021-0-US-01 LABELING BIOLOGICAL PARTICLES USING ACOUSTOPHORESIS PRV US 63/191,103 Abandoned US <br />Provisional (PRV) 63/191,103<br />Filed on 2021-05-20<br />Status: Abandoned 163996516 E-096-2021-0 E-096-2021-0-PCT-02 LABELING BIOLOGICAL PARTICLES USING ACOUSTOPHORESIS PCT Patent Cooperation Treaty PCT/US2022/028819 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/028819<br />Filed on 2022-05-11<br />Status: Expired 163996517 E-096-2021-0 E-096-2021-0-US-02 LABELING BIOLOGICAL PARTICLES USING ACOUSTOPHORESIS National Stage US 18/290,442 Pending US <br />National Stage 18/290,442<br />Filed on 2023-11-13<br />Status: Pending TAB-5090 165796379 Humanized 40H3 Antibody NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Antonella Antignani, David Fitzgerald, Robert Sarnovsky <h2>Summary:</h2> <p>The NCI seeks research co-development partners or licensees for monoclonal antibodies that specifically target cancer-expressed EGFR.</p> <h2>Description of Technology:</h2> <p>Epidermal growth factor receptor (EGFR) is a well-known oncogenic driver in lung cancer, head and neck cancer, glioblastoma multiforme (GBM) and other cancers. NCI inventors have previously isolated a mouse monoclonal antibody that binds to the human EGFRvIII &ndash; but not wildtype EGFR known as the 40H3 antibody (NCI Ref: E-103-2019). To improve the 40H3 antibody&rsquo;s suitability for the clinic, the inventors humanized the antibody through the generation of multiple variants with distinct sequences. The inventors produced about 14 humanized candidates of the 40H3 antibody. Significantly, CAR Ts using one of the antibodies (A10) showed potent killing of cancer cells in various pre-clinical models overexpressing EGFR. The pre-clinical results obtained to date suggest that the A10 antibody is a promising candidate for development as various therapeutics for the treatment of EGFRvIII-expressing cancers.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Cancer therapeutic against numerous EGFRvIII-expressing tumor types &ndash; including, but not limited to, lung cancer, head and neck cancer and GBM.</li> <li>Therapeutic applications of the unconjugated antibodies</li> <li>Use of the unconjugated antibodies as a targeting moiety in antibody-drug conjugates (ADCs), radio-immunotherapies (RITs) and chimeric antigen receptors (CARs)</li> <li>Diagnostic agent for detection and monitoring levels of EGFRvIII-expressing cancers</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Less non-specific cell killing using humanized EGFRvIII antibodies with high EGFRvIII binding specificity will result in fewer and lower grade potential side effects</li> <li>Therapeutic development against various common and rare cancers represent many paths to market and out-licensing opportunities</li> <li><span style="font-size:12pt"><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-family:&quot;Times New Roman&quot;,serif">CAR Ts using the A10 antibody are available for immediate testing</span></span></span></span></li> <li><span style="font-size:12pt"><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-family:&quot;Times New Roman&quot;,serif">A10 binding EGFR when over-expressed from amplified EGFR is specific to various cancers&nbsp;&nbsp;</span></span></span></span></li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for monoclonal antibodies that specifically target cancer-expressed EGFR. 2026-01-28 2026-02-05 2026-08-05 2026-02-05 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-103-2019 165796614 Fitzgerald, David NIH - NCI NCI Fitzgerald, David (NCI) 1 165796640 Antignani, Antonella NIH - NCI NCI Antignani, Antonella (NCI) 2 165796655 Sarnovsky, Robert NIH - NCI NCI Sarnovsky, Robert (NCI) 3 165796614 Fitzgerald, David NIH - NCI NCI Fitzgerald, David (NCI) 1 165796640 Antignani, Antonella NIH - NCI NCI Antignani, Antonella (NCI) 2 165796655 Sarnovsky, Robert NIH - NCI NCI Sarnovsky, Robert (NCI) 3 165796382 Humanization of the monoclonal antibody, 40H3: generation of improved variants E-188-2023-0 Filing authorized Laboratory of Molecular Biology, National Cancer Institute (NCI), NIH - NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-5090] Humanized 40H3 Antibody&body=Please send me information about technology [TAB-5090] Humanized 40H3 Antibody.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-5090] Humanized 40H3 Antibody&body=Please send me information about technology [TAB-5090] Humanized 40H3 Antibody.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">abritee.dhal@nih.gov</a><br> 165796387 E-188-2023-0 E-188-2023-0-US-01 HUMANIZED 40H3 ANTIBODY PRV US 63/525,493 Expired US <br />Provisional (PRV) 63/525,493<br />Filed on 2023-07-07<br />Status: Expired 165796388 E-188-2023-0 E-188-2023-0-PC-01 HUMANIZED 40H3 ANTIBODY PCT Patent Cooperation Treaty PCT/US2024/037091 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/037091<br />Filed on 2024-07-08<br />Status: Expired 165796389 E-188-2023-0 E-188-2023-0-JP-01 HUMANIZED 40H3 ANTIBODY National Stage Japan 2026-500043 Pending Japan <br />National Stage 2026-500043<br />Filed on 2026-01-05<br />Status: Pending 165796390 E-188-2023-0 E-188-2023-0-CA-01 HUMANIZED 40H3 ANTIBODY National Stage Canada 3297257 Pending Canada <br />National Stage 3297257<br />Filed on 2025-12-30<br />Status: Pending 165796391 E-188-2023-0 E-188-2023-0-AU-01 HUMANIZED 40H3 ANTIBODY National Stage Australia 2024296940 Pending Australia <br />National Stage 2024296940<br />Filed on 2026-01-13<br />Status: Pending 165796392 E-188-2023-0 E-188-2023-0-CN-01 HUMANIZED 40H3 ANTIBODY National Stage China 202480057586.7 Pending China <br />National Stage 202480057586.7<br />Filed on 2026-04-01<br />Status: Pending 165796393 E-188-2023-0 E-188-2023-0-US-02 HUMANIZED 40H3 ANTIBODY National Stage US 19/497,173 Pending US <br />National Stage 19/497,173<br />Filed on 2025-12-24<br />Status: Pending 165796394 E-188-2023-0 E-188-2023-0-EP-01 HUMANIZED 40H3 ANTIBODY National Stage European Patent 24748511.3 Pending European Patent <br />National Stage 24748511.3<br />Filed on 2026-01-27<br />Status: Pending TAB-5082 164393007 Novel Human Immunogenic Epitopes of the Human Endogenous Retrovirus ERVMER34-1 NCI Collaboration, Immunology, Licensing, Oncology, Vaccines Collaboration Immunology Licensing Oncology Vaccines Renee Donahue, Duane Hamilton, Claudia Palena, Jeffrey Schlom <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the clinical translation of novel peptide-based therapeutic cancer vaccines derived from ERVMER34-1, a human endogenous retrovirus (HERV) antigen, offering a unique opportunity to address a significant unmet need in the treatment of various carcinomas.</p> <h2>Description of Technology:</h2> <p>Human Endogenous Retroviruses (HERVs), remnants of ancient retroviral germline infections that comprise ~8% of the human genome, represent a promising yet underexplored frontier in targeted cancer therapy. Although typically epigenetically silenced in normal adult tissues, select HERV components, including RNAs and envelope proteins, are frequently overexpressed in various carcinomas due to epigenetic dysregulation &ndash; a hallmark of cancer. The challenge lies in identifying specific, highly immunogenic HERV targets that elicit potent anti-tumor immune responses without triggering autoimmunity. Addressing this need is critical to advancing broadly applicable cancer immunotherapies.</p> <p>Inventors at the NCI have developed and characterized a novel cancer immunotherapy platform targeting ERVMER34-1, a specific HERV envelope protein that is highly expressed across multiple human carcinomas while exhibiting minimal expression in normal tissues. Using transcriptomic and proteomic datasets, the team confirmed the tumor-selective expression profile of ERVMER34-1. To improve safety and specificity, they engineered an artificial antigen-presenting cell line to express the full-length ERVMER34-1 protein, HLA-A2 and CD80 to facilitate efficient priming and expansion of ERVMER34-1-reactive CD8+ T cells. To therapeutically target ERVMER34-1, they modified the ERVMER34-1 protein by removing the signal peptide, cleavage site, predicted immunosuppressive domain, transmembrane domain and a 170-amino acid region homologous to human proteins. These modifications prevent surface trafficking, antigen shedding, immune dampening, and off-target reactivity. This modified sequence was incorporated into a recombinant adenoviral vector as a therapeutic cancer vaccine. In preclinical murine models (e.g., MC38 colon cancer, EMT6 breast cancer), vaccination with this construct alone or in combination with immune checkpoint blockade or an IL-15 superagonist elicited robust, multifunctional CD4⁺ and CD8⁺ T cell responses. Those enhanced T cell responses induced tumor clearance, increased intratumoral lymphocyte infiltration, broadened neoantigen spreading and prolonged tumor control. ERVMER34-1-reactive T cells could be expanded from both healthy donor and cancer patient Peripheral Blood Mononuclear Cells (PBMCs) and demonstrated specific cytolytic activity against ERVMER34-1⁺ human carcinoma cell lines in vitro. To support peptide-based approaches, researchers developed an overlapping 15-mer peptide library spanning the modified ERVMER34-1 protein sequence. These peptides elicited strong, polyfunctional T cell responses in vitro &ndash; including both CD4⁺ and HLA-A2-restricted CD8⁺ T cell activation, enabling precise epitope mapping and facilitating future peptide vaccine design and adoptive T cell receptor (TCR)-based therapies.</p> <p>The NCI invites industry partners and translational researchers to collaborate on or license this pioneering HERV ERVMER34-1 protein targeted vaccine technology. With promising preclinical data, this technology addresses a critical gap in the cancer vaccine landscape. It offers a unique opportunity to advance a novel therapeutic targeting widespread carcinomas, opening a substantial market for cancer treatment.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Peptide-based therapeutic cancer vaccines</li> <li>Adenoviral vector-based therapeutic cancer vaccines</li> <li>Liposome- or nanoparticle-formulated therapeutic cancer vaccines</li> <li>Artificial Antigen-Presenting Cell platforms expressing ERVMER34-1 with HLA-A2 and CD80 to expand antigen-specific T cells for adoptive cell therapies</li> <li>Adoptive T cell therapies using ERVMER34-1-specific TCRs isolated from PBMCs or engineered T cells redirected against shared HERV antigens</li> <li>Combination immunotherapies pairing the ERVMER34-1 vaccine with checkpoint inhibitors and/or epigenetic modifiers to boost response breadth and tumor infiltration</li> <li>Cytokine or immuno-cytokine-enhanced combination regimens incorporating immune-oncology agents to amplify tumor-specific T cell activation</li> <li>Companion diagnostic tools to identify ERVMER34-1-expressing tumors for patient selection and treatment stratification</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Broad tumor coverage across ~62% of carcinomas</li> <li>Minimal expression in normal tissues reduces toxicity risk and expands market potential</li> <li>Engineered antigen design in vaccine eliminates immunosuppressive and off-target domains, improving safety and therapeutic precision</li> <li>Elicits potent, multifunctional T cell responses with cytokine production and broad epitope recognition, enhancing anti-tumor efficacy</li> <li>Selectively clears tumor cells based on ERVMER34-1 expression, enabling precise targeting across variable antigen levels</li> <li>Demonstrates remarkable synergistic efficacy with immune checkpoint inhibitors, achieving ~89% tumor clearance in established large tumors in mouse models</li> <li>Exhibits synergistic interaction with cytokine agonists such as N-803 (Anktiva), significantly enhancing neoepitope-reactive T cell responses and improving tumor control in combination therapies</li> <li>Potential for use in combination with epigenetic modulators to enhance expression of targeted antigen in human carcinomas</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for the clinical translation of novel peptide-based therapeutic cancer vaccines derived from ERVMER34-1, a human endogenous retrovirus (HERV) antigen, offering a unique opportunity to address a significant unmet need in the treatment of various carcinomas. 2025-09-29 2025-09-29 2026-08-05 2025-09-29 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-056-2023 164393294 Maldonado MDM, et al. Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control (PMID: 40360436) https://pubmed.ncbi.nlm.nih.gov/40360436/ <a href="https://pubmed.ncbi.nlm.nih.gov/40360436/">Maldonado MDM, et al. Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control (PMID: 40360436)</a> 164393297 Gracia-Hernandez M, et al. Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer (PMID: 40387511) https://pubmed.ncbi.nlm.nih.gov/40387511/ <a href="https://pubmed.ncbi.nlm.nih.gov/40387511/">Gracia-Hernandez M, et al. Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer (PMID: 40387511)</a> 164393132 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 164393153 Hamilton, Duane NIH - NCI NCI Hamilton, Duane (NCI) 2 164393157 Palena, Claudia NIH - NCI NCI Palena, Claudia (NCI) 3 164393178 Donahue, Renee NIH - NCI NCI Donahue, Renee (NCI) 4 164393132 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 164393153 Hamilton, Duane NIH - NCI NCI Hamilton, Duane (NCI) 2 164393157 Palena, Claudia NIH - NCI NCI Palena, Claudia (NCI) 3 164393178 Donahue, Renee NIH - NCI NCI Donahue, Renee (NCI) 4 164393010 Identification Of Novel Human Immunogenic Epitopes Of HEMO And HHLA2 Human Endogenous Retroviruses (HERVs) E-159-2019-0 Filing authorized Chan Soon-Shiong Institute of Molecular Medicine at Windber, MDR Global Systems, LLC, NCI, NIH - NCI, Uniformed Services University of the Health Sciences 83687903 Pollack, Michael michael.pollack@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michael.pollack@nih.gov?subject=Web Inquiry on [TAB-5082] Novel Human Immunogenic Epitopes of the Human Endogenous Retrovirus ERVMER34-1&body=Please send me information about technology [TAB-5082] Novel Human Immunogenic Epitopes of the Human Endogenous Retrovirus ERVMER34-1.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollack, Michael<br><a href="mailto:michael.pollack@nih.gov?subject=Web Inquiry on [TAB-5082] Novel Human Immunogenic Epitopes of the Human Endogenous Retrovirus ERVMER34-1&body=Please send me information about technology [TAB-5082] Novel Human Immunogenic Epitopes of the Human Endogenous Retrovirus ERVMER34-1.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">michael.pollack@nih.gov</a><br> 164393022 E-159-2019-0 E-159-2019-0-US-01 HUMAN IMMUNOGENIC EPITOPES OF HEMO AND HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVs) PRV US 62/963,872 Abandoned US <br />Provisional (PRV) 62/963,872<br />Filed on 2020-01-21<br />Status: Abandoned 164393023 E-159-2019-0 E-159-2019-0-PCT-02 HUMAN IMMUNOGENIC EPITOPES OF HEMO and HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVS) PCT Patent Cooperation Treaty PCT/US2021/014335 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/014335<br />Filed on 2021-01-21<br />Status: Expired 164393024 E-159-2019-0 E-159-2019-0-CA-03 HUMAN IMMUNOGENIC EPITOPES OF HEMO and HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVS) National Stage Canada 3165251 Pending Canada <br />National Stage 3165251<br />Filed on 2022-07-19<br />Status: Pending 164393025 E-159-2019-0 E-159-2019-0-AU-04 HUMAN IMMUNOGENIC EPITOPES OF HEMO and HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVS) National Stage Australia 2021210915 Pending Australia <br />National Stage 2021210915<br />Filed on 2022-08-18<br />Status: Pending 164393026 E-159-2019-0 E-159-2019-0-EP-05 HUMAN IMMUNOGENIC EPITOPES OF HEMO and HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVS) National Stage European Patent 21705769.4 Pending European Patent <br />National Stage 21705769.4<br />Filed on 2022-08-18<br />Status: Pending 164393027 E-159-2019-0 E-159-2019-0-US-06 HUMAN IMMUNOGENIC EPITOPES OF HEMO AND HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVS) National Stage US 17/793,753 Pending US <br />National Stage 17/793,753<br />Filed on 2022-07-19<br />Status: Pending 164393028 E-159-2019-0 E-159-2019-0-HK-07 HUMAN IMMUNOGENIC EPITOPES OF HEMO and HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVS) EP Hong Kong 62023070659.5 Pending Hong Kong <br />European patent (EP) 62023070659.5<br />Filed on 2023-03-27<br />Status: Pending TAB-5092 166395418 MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Therapeutics Collaboration Ear Nose & Throat Licensing Ophthalmology Therapeutics S. Patricia Becerra, Alexandra Bernardo-Colon, Burchelle Blackman, Natarajan Raju, Rolf Swenson, Carolyn Woodroofe <h2>Summary:</h2> <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an eyedrop formulation to deliver a series of peptides as a gene-agnostic approach to treating inherited retinal diseases.</p> <h2>Description of Technology:</h2> <p>Retinitis pigmentosa (RP) is one of the most common inherited retinal diseases (IRDs) that is estimated to affect 1 in 4,000 people in the United States and worldwide. Over 100,000 people in the US, and 1.5 million people worldwide suffer from RP. RP leads to progressive photoreceptor cell degeneration and ultimately vision loss, with more than 90 genes implicated in molecular pathways towards photoreceptor cell death. Due to this high heterogeneity, therapeutic approaches targeting specific genes generally benefit few patients, while for most forms of RP few or no medical options are available.</p> <p>Peptide drug development has made great progress recently thanks to new production, modification, and analytical technologies. Solutions of chemically synthesized bioactive peptides have unique advantages over mixed formulations. They are free of inactive ingredients that cause secondary effects. Structural biology and recombinant biologics aid in peptide design to modify amino acids, enhancing target affinity, specificity, and regulating bioactivity, as well as improving the solubility and stability of peptide drugs. Peptides can diffuse better than biologics (proteins, antibodies) with better penetrability. Compared with biologics, therapeutic peptides have demonstrably less immunogenicity and lower production costs.</p> <p>This technology optimizes synthetic peptides that are soluble, stable, and protect the retina. A series of peptides derived from the neurotrophic region of PEDF 17-mer (human sequence 98-114 amino acids, N- and C-terminus uncapped) is designed and synthesized. They have a series of truncations from the amino and carboxy ends, and internal region, as well as isosteric amino acid replacements, and amino terminal additions such as capping (X) and amidation (Y) to prevent exopeptidases from degrading the peptide. The peptides are optimized to protect photoreceptors and other retinal cells against death and degeneration. They optimized for solubility, stability, efficacy, in protecting the retina at the structural, morphological and functional level. The peptides can be tested in vitro, ex vivo, in cells and in vivo using models of retinal degeneration. The peptides can be used as eyedrops in vivo.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Potential simple and effective treatment for inherited eye diseases contributing to Retinitis Pigmentosa (RP) and macular degenerations, such as AMD and geographic atrophy</li> <li>Prevent disease progression by protecting degenerating photoreceptors</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Chemically synthesized bioactive peptide solutions are free of inactive ingredients that cause secondary effects as compared to mixed formulations</li> <li>Enhanced target affinity, specificity, bioactivity, as well as in improved solubility, and stability</li> <li>Peptides can diffuse better than biologics (proteins, antibodies) with better penetrability</li> <li>Compared to biologics, therapeutic peptides have demonstrably less immunogenicity and lower production costs</li> <li>Eye drop formulation is accessible to more patients and provides an easy administration route</li> <li>PEDF formulation mimics the natural protective process lost in patients with inherited eye diseases, contributing to RP</li> </ul> The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an eyedrop formulation to deliver a series of peptides as a gene-agnostic approach to treating inherited retinal diseases. 2026-03-11 2026-03-11 2026-08-05 2026-03-11 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-028-2023 166395672 Bernardo-Colon A, et al. H105A peptide eye drops promote photoreceptor survival in murine and human models of retinal degeneration. (PMID: 40118996) https://pubmed.ncbi.nlm.nih.gov/40118996/ <a href="https://pubmed.ncbi.nlm.nih.gov/40118996/">Bernardo-Colon A, et al. H105A peptide eye drops promote photoreceptor survival in murine and human models of retinal degeneration. (PMID: 40118996)</a> 166395675 Valiente-Soriano FJ, et al. Pigment Epithelium-Derived Factor (PEDF) Fragments Prevent Mouse Cone Photoreceptor Cell Loss Induced by Focal Phototoxicity In Vivo. (PMID: 33008127) https://pubmed.ncbi.nlm.nih.gov/33008127/ <a href="https://pubmed.ncbi.nlm.nih.gov/33008127/">Valiente-Soriano FJ, et al. Pigment Epithelium-Derived Factor (PEDF) Fragments Prevent Mouse Cone Photoreceptor Cell Loss Induced by Focal Phototoxicity In Vivo. (PMID: 33008127)</a> 166395678 Hernández-Pinto A, et al. PEDF peptides promote photoreceptor survival in rd10 retina models. (PMID: 30980815) https://pubmed.ncbi.nlm.nih.gov/30980815/ <a href="https://pubmed.ncbi.nlm.nih.gov/30980815/">Hernández-Pinto A, et al. PEDF peptides promote photoreceptor survival in rd10 retina models. (PMID: 30980815)</a> 166395684 Kenealey J, et al. Small Retinoprotective Peptides Reveal a Receptor-binding Region on Pigment Epithelium-derived Factor. (PMID: 26304116) https://pubmed.ncbi.nlm.nih.gov/26304116/ <a href="https://pubmed.ncbi.nlm.nih.gov/26304116/">Kenealey J, et al. Small Retinoprotective Peptides Reveal a Receptor-binding Region on Pigment Epithelium-derived Factor. (PMID: 26304116)</a> 166395566 Becerra, S. Patricia National Eye Institute (NEI) NEI Becerra, S. Patricia (NEI) 1 166395574 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 2 166395593 Raju, Natarajan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Raju, Natarajan (NHLBI) 3 166395604 Bernardo-Colon, Alexandra National Eye Institute (NEI) Bernardo-Colon, Alexandra 4 166395611 Woodroofe, Carolyn National Heart, Lung, and Blood Institute (NHLBI) NHLBI Woodroofe, Carolyn (NHLBI) 5 166395635 Blackman, Burchelle National Heart, Lung, and Blood Institute (NHLBI) NHLBI Blackman, Burchelle (NHLBI) 6 166395566 Becerra, S. Patricia National Eye Institute (NEI) NEI Becerra, S. Patricia (NEI) 1 166395574 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 2 166395593 Raju, Natarajan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Raju, Natarajan (NHLBI) 3 166395604 Bernardo-Colon, Alexandra National Eye Institute (NEI) Bernardo-Colon, Alexandra 4 166395611 Woodroofe, Carolyn National Heart, Lung, and Blood Institute (NHLBI) NHLBI Woodroofe, Carolyn (NHLBI) 5 166395635 Blackman, Burchelle National Heart, Lung, and Blood Institute (NHLBI) NHLBI Blackman, Burchelle (NHLBI) 6 166395421 Photoreceptor-protective Peptides based on truncated PEDF E-156-2023-0 Filing authorized National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Heart, Lung, and Blood Institute (NHLBI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5092] MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE&body=Please send me information about technology [TAB-5092] MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5092] MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE&body=Please send me information about technology [TAB-5092] MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">ricquita.pollard@nih.gov</a><br> 166395426 E-156-2023-0 E-156-2023-0-US-01 MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE PRV US 63/604,026 Expired US <br />Provisional (PRV) 63/604,026<br />Filed on 2023-11-29<br />Status: Expired 166395427 E-156-2023-0 E-156-2023-0-PC-01 MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2024/057784 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/057784<br />Filed on 2024-11-27<br />Status: Expired 166895073 E-156-2023-0 E-156-2023-0-JP-01 MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE National Stage Japan 2026-531738 Pending Japan <br />National Stage 2026-531738<br />Filed on 2026-05-27<br />Status: Pending 166895169 E-156-2023-0 E-156-2023-0-CA-01 MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE National Stage Canada 3313052 Pending Canada <br />National Stage 3313052<br />Filed on 2026-05-28<br />Status: Pending 166895224 E-156-2023-0 E-156-2023-0-AU-01 MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE National Stage Australia 2024388722 Pending Australia <br />National Stage 2024388722<br />Filed on 2026-06-03<br />Status: Pending 166895361 E-156-2023-0 E-156-2023-0-US-02 MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE National Stage US 19/590,855 Pending US <br />National Stage 19/590,855<br />Filed on 2026-05-27<br />Status: Pending 166895416 E-156-2023-0 E-156-2023-0-EP-01 MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE National Stage European Patent 24840943.5 Pending European Patent <br />National Stage 24840943.5<br />Filed on 2026-06-26<br />Status: Pending TAB-5091 166130102 Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Therapeutics Collaboration Ear Nose & Throat Licensing Ophthalmology Therapeutics S. Patricia Becerra, Alexandra Bernardo-Colon, Andrea Bighinati, Valeria Marigo <h2>Summary:&nbsp;&nbsp;</h2> <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an AAV2-based delivery system or an eyedrop formulation to deliver a Pigment Epithelium-Derived Factor (PEDF) peptide as a gene-agnostic approach to treating inherited retinal diseases.&nbsp;</p> <h2>Description of Technology:&nbsp;&nbsp;</h2> <p>Retinitis pigmentosa (RP) is one of the most common inherited retinal diseases (IRDs) &ndash; estimated to affect 1 in 4,000 people worldwide. Over 100,000 people in the US and 1.5 million people worldwide suffer from RP. This disease leads to progressive photoreceptor cell degeneration and, ultimately, vision loss. More than 90 genes are implicated in molecular pathways towards photoreceptor cell death. Due to this high heterogeneity, therapeutic approaches targeting specific genes generally benefit few patients. For most forms of RP, few or no medical options are available. Thus, there remains a need to identify new and more effective treatments for RP and other inherited retinal degenerations. Mutation-independent strategies to protect photoreceptors against continued damage and degradation are appealing approaches.&nbsp;&nbsp;</p> <p>To delay photoreceptor degeneration, we propose using neurotrophic molecules as a mutation-independent approach using pigment epithelium-derived factor (PEDF). PEDF is a multifunctional member of the serine proteinase inhibitor (serpin) family with neurotrophic and antiangiogenic properties in the retina. Researchers at the NEI developed a peptide of 17 amino acid residues (17-mer) from the receptor-binding domain of PEDF. It contains amino acid substitution at position 105 from a histidine to an alanine (PEDF 17-mer[H105A]). H105A exhibits a highly potent protective effect on photoreceptors using in vivo mouse models of RP.&nbsp;&nbsp;</p> <p>The technology encompasses two delivery approaches for this proprietary peptide: (1) an eyedrop formulation and/or (2) an Adeno-Associated Vector 2 (AAV2). A sustained delivery system delivers the 17-mer [H105A] to treat or prevent photoreceptor degradation and vision loss in patients with IRDs (e.g., retinitis pigmentosa, Leber congenital amaurosis, cone-rod dystrophy, Stargardt-like macular degeneration or maculopathy) or age-related macular degenerations (AMD). The technology is available for licensing and co-development.&nbsp;</p> <h2>Potential Commercial Applications:&nbsp;&nbsp;</h2> <ul> <li>Minimally invasive therapy to prevent photoreceptor degeneration in retinal disorders (IRDs and AMD)&nbsp;</li> <li>Retinitis Pigmentosa (RP), macular degeneration, and other related diseases&nbsp;</li> <li>AAV2 vectors for delivery of genes to retinal cells both preventative and therapeutic&nbsp;</li> <li>Prevent disease progression to late-stage RP&nbsp;</li> </ul> <h2>Competitive Advantages:&nbsp;</h2> <ul> <li>Favorable safety profile&nbsp;</li> <li>Large addressable market given applications to IRDs and AMD (USD 13.7 billion in 2023 and an estimated compound annual growth rate (CAGR) of 9.6% from 2024 to 2032&nbsp;</li> <li>Partially established regulatory path, as their AAV2 vector is identical to Luxturna, an FDA-approved therapy for retinal dystrophy&nbsp;</li> <li>Superior diffusion and penetrability than biologics&nbsp;</li> <li>Demonstrably less immunogenicity and lower production costs than biologics&nbsp;</li> <li>Eye drop formulation has larger addressable market&nbsp;</li> <li>Eye drop formulation provides easy administration route&nbsp;&nbsp;</li> <li>Broad-spectrum therapeutic approach:&nbsp;&nbsp; <ul> <li>PEDF mimics the natural protective process lost in patients with inherited eye diseases&nbsp;</li> <li>Protective effects on photoreceptors are independent of the gene mutations causing degeneration&nbsp;</li> </ul> </li> <li>Chemically synthesized bioactive peptide solutions are free of inactive ingredients, causing fewer secondary effects than mixed formulations&nbsp;</li> </ul> Researchers at the ​NEI​ seek ​licensing and/or co-development research collaborations ​ for the development of an AVV2-based delivery system or an eyedrop formulation to deliver a PEDF peptide as a gene-agnostic approach to treating inherited retinal diseases. 2026-02-23 2026-03-24 2026-08-05 2026-03-13 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-156-2023 166427821 Bernardo-Colón A, et al. H105A peptide eye drops promote photoreceptor survival in murine and human models of retinal degeneration. (PMID: 40118996) https://pubmed.ncbi.nlm.nih.gov/40118996/ <a href="https://pubmed.ncbi.nlm.nih.gov/40118996/">Bernardo-Colón A, et al. H105A peptide eye drops promote photoreceptor survival in murine and human models of retinal degeneration. (PMID: 40118996)</a> 166427825 Valiente-Soriano FJ, et al. Pigment Epithelium-Derived Factor (PEDF) Fragments Prevent Mouse Cone Photoreceptor Cell Loss Induced by Focal Phototoxicity In Vivo. (PMID: 33008127) https://pubmed.ncbi.nlm.nih.gov/33008127/ <a href="https://pubmed.ncbi.nlm.nih.gov/33008127/">Valiente-Soriano FJ, et al. Pigment Epithelium-Derived Factor (PEDF) Fragments Prevent Mouse Cone Photoreceptor Cell Loss Induced by Focal Phototoxicity In Vivo. (PMID: 33008127)</a> 166427828 Hernández-Pinto A, et al. PEDF peptides promote photoreceptor survival in rd10 retina models. (PMID: 30980815) https://pubmed.ncbi.nlm.nih.gov/30980815/ <a href="https://pubmed.ncbi.nlm.nih.gov/30980815/">Hernández-Pinto A, et al. PEDF peptides promote photoreceptor survival in rd10 retina models. (PMID: 30980815)</a> 166427831 Kenealey J, et al. Small Retinoprotective Peptides Reveal a Receptor-binding Region on Pigment Epithelium-derived Factor. (PMID: 26304116) https://pubmed.ncbi.nlm.nih.gov/26304116/ <a href="https://pubmed.ncbi.nlm.nih.gov/26304116/">Kenealey J, et al. Small Retinoprotective Peptides Reveal a Receptor-binding Region on Pigment Epithelium-derived Factor. (PMID: 26304116)</a> 166427764 Becerra, S. Patricia National Eye Institute (NEI) NEI Becerra, S. Patricia (NEI) 1 166427768 Bernardo-Colon, Alexandra National Eye Institute (NEI) Bernardo-Colon, Alexandra 2 166427772 Marigo, Valeria University of Modena and Reggio Emilia Marigo, Valeria 3 166427779 Bighinati, Andrea University of Modena and Reggio Emilia Bighinati, Andrea 4 166427764 Becerra, S. Patricia National Eye Institute (NEI) NEI Becerra, S. Patricia (NEI) 1 166427768 Bernardo-Colon, Alexandra National Eye Institute (NEI) Bernardo-Colon, Alexandra 2 166427772 Marigo, Valeria University of Modena and Reggio Emilia Marigo, Valeria 3 166427779 Bighinati, Andrea University of Modena and Reggio Emilia Bighinati, Andrea 4 166130105 In Vivo Assay For Drug Discovery And Detection Of Photoreceptor Survival Factors: Discovery Of The PEDF Peptide 17- mer[H105A] E-028-2023-0 Filing authorized National Eye Institute (NEI), University of Modena and Reggio Emilia, University of Modena and Reggio Emilia 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5091] Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration&body=Please send me information about technology [TAB-5091] Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5091] Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration&body=Please send me information about technology [TAB-5091] Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">ricquita.pollard@nih.gov</a><br> 166130110 E-028-2023-0 E-028-2023-0-US-01 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL DEGENERATION PRV US 63/430,251 Expired US <br />Provisional (PRV) 63/430,251<br />Filed on 2022-12-05<br />Status: Expired 166130111 E-028-2023-0 E-028-2023-0-PC-01 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL DEGENERATION PCT Patent Cooperation Treaty PCT/US2023/064947 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/064947<br />Filed on 2023-03-24<br />Status: Expired 166130112 E-028-2023-0 E-028-2023-0-JP-01 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL DEGENERATION National Stage Japan 2025-555099 Pending Japan <br />National Stage 2025-555099<br />Filed on 2025-06-04<br />Status: Pending 166130113 E-028-2023-0 E-028-2023-0-CA-01 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL DEGENERATION National Stage Canada 3275801 Pending Canada <br />National Stage 3275801<br />Filed on 2025-06-03<br />Status: Pending 166130114 E-028-2023-0 E-028-2023-0-AU-01 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL DEGENERATION National Stage Australia 2023390868 Pending Australia <br />National Stage 2023390868<br />Filed on 2025-06-05<br />Status: Pending 166130115 E-028-2023-0 E-028-2023-0-US-02 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL DEGENERATION National Stage US 19/135,668 Pending US <br />National Stage 19/135,668<br />Filed on 2025-06-04<br />Status: Pending 166130116 E-028-2023-0 E-028-2023-0-EP-01 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL DEGENERATION National Stage European Patent 23720018.3 Pending European Patent <br />National Stage 23720018.3<br />Filed on 2025-07-01<br />Status: Pending 166849971 E-028-2023-0 E-028-2023-0-HK-01 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL DEGENERATION EP Hong Kong 62026121881.7 Pending Hong Kong <br />European patent (EP) 62026121881.7<br />Filed on 2026-04-15<br />Status: Pending TAB-5097 166811027 Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Catherine Ade, Kenichi Hanada, Vid Leko, Aidan Pursley, James Yang, Zhiya Yu <h2>Summary:&nbsp;</h2> <p>The NCI seeks research co-development partners or licensees for Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia.</p> <h2>Description of Technology:&nbsp;</h2> <p>Acute myeloid leukemia (AML) is a rare form of blood cancer affecting myeloid stem and progenitor cells, associated with a poor prognosis and a 5-year survival rate of ~33%. Current treatments, including intensive chemotherapy and stem cell transplantation, are not suitable for all patients and can cause significant toxicities, including low blood cell counts, infection and graft-versus-host disease. Therefore, there is a need for safer and more effective treatments.&nbsp;</p> <p>This specific invention concerns the isolation of two highly specific T cell receptors (TCRs), known as TCR6 and TCR7, recognizing a neoepitope, AVEEVSLRK. The neoepitope is derived from mutant Nucleophosmin 1 (NPM1) and presented in the context of HLA-A*11:01. Pre-clinical results for these TCRs revealed robust and specific cytotoxicity against a leukemia cell line and several patient-derived AML samples expressing the NPM1 mutation and HLA-A*11:01. Furthermore, they showed no cross-reactivity to normal peripheral blood mononuclear cells, structurally similar peptides or unrelated HLA alleles. These results suggest these novel TCRs represent a potential adoptive T cell therapy for the treatment of AML.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Acute myeloid leukemia patients expressing HLA-A*11:01.&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Highly specific targeting of mutant NPM1</li> <li>Minimed off-target effects with enhanced safety profile</li> <li>&bull;Significant unmet medical need for AML patients</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for NPM1 Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia. 2026-04-10 2026-04-10 2026-08-05 2026-04-10 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 166811280 https://ashpublications.org/blood/article/146/Supplement%201/4132/555170/T-cell-receptors-targeting-mutant-NPM1-for https://ashpublications.org/blood/article/146/Supplement%201/4132/555170/T-cell-receptors-targeting-mutant-NPM1-for 166811062 Leko, Vid NIH - NCI NCI Leko, Vid (NCI) 1 166811066 Pursley, Aidan NIH - NCI NCI Pursley, Aidan (NCI) 2 166811070 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 3 166811074 Yu, Zhiya NIH - NCI NCI Yu, Zhiya (NCI) 4 166811086 Ade, Catherine NIH - NCI NCI Ade, Catherine (NCI) 5 166811092 Yang, James NIH - NCI NCI Yang, James (NCI) 6 166811062 Leko, Vid NIH - NCI NCI Leko, Vid (NCI) 1 166811066 Pursley, Aidan NIH - NCI NCI Pursley, Aidan (NCI) 2 166811070 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 3 166811074 Yu, Zhiya NIH - NCI NCI Yu, Zhiya (NCI) 4 166811086 Ade, Catherine NIH - NCI NCI Ade, Catherine (NCI) 5 166811092 Yang, James NIH - NCI NCI Yang, James (NCI) 6 166811031 NPM1 mutation-specific T cell receptors for treatment of HLA-A*11:01-positive acute myeloid leukemia E-200-2025-0 Filing authorized NIH - NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-5097] Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia&body=Please send me information about technology [TAB-5097] Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia.&bcc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-5097] Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia&body=Please send me information about technology [TAB-5097] Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia.&bcc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">abritee.dhal@nih.gov</a><br> 166811036 E-200-2025-0 E-200-2025-0-US-01 NUCLEOPHOSMIN 1 MUTATION-SPECIFIC T CELL RECEPTORS PRV US 63/908,266 Pending US <br />Provisional (PRV) 63/908,266<br />Filed on 2025-10-30<br />Status: Pending TAB-5088 165166556 DNA Methylation-Based Cancer Diagnostics for Accurate Tumor Classification NCI Collaboration, Diagnostics, Licensing, Oncology Collaboration Diagnostics Licensing Oncology Ziedulla Abdullaev, Kenneth Aldape, Elaine Jaffe, Antonios Papanicolau-Sengos, Stefania Pittaluga, Mark Raffeld, Omkar Singh, Rustamzhon Turakulov <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a collection of T-cell receptors (TCRs) that specifically target the mutated KRAS antigen.</p> <p>This technology encompasses a DNA methylation&ndash;based diagnostic platform designed to improve the accuracy and consistency of cancer classification, with demonstrated utility for tumors of the central nervous system, kidney, and hematopoietic system. By identifying disease-specific methylation signatures, the approach reduces interobserver variability and enhances diagnostic confidence. The central nervous system (CNS) classifier is built from a curated reference set of 16,567 methylation profiles and organizes tumors into 22 families and 133 clinically relevant diagnostic classes, including 21 newly developed methylation classes not represented in other existing tools. Across multiple independent validation cohorts (n = 5,875), the classifier demonstrated robust performance, and in a clinical-impact analysis of 1,204 NIH validation cases, methylation profiling materially influenced final diagnosis in 74.4% of cases by refining, increasing precision, or reclassifying. The CNS classifier was deployed as a user-facing software tool, MethylScape Analysis, which streamlines methylation-based classification workflows for CNS tumors (https://methylscape.ccr.cancer.gov/). The development of multiple specialized classifiers supports a more granular understanding of tumor biology and&nbsp; informed clinical decision-making.</p> <h2>Description of Technology:</h2> <p>Accurate CNS tumor classification can be challenging when tumors show overlapping histology, limited tissue or atypical features. A meaningful fraction of cases remains unclassified or assigned with limited confidence with current molecular tools. These diagnostic ambiguities directly affect subtype and grade assignment which, in turn, influence treatment planning, prognosis, and clinical trial eligibility. Variability across observers and institutions can lead to additional testing, delays, and inconsistent diagnoses.</p> <p>The NCI/Bethesda classifier addresses this gap using DNA methylation patterns as a robust molecular fingerprint. It applies a stratified machine learning framework to extend diagnostic coverage and improve assignment confidence for CNS tumors. The classifier was developed from a rigorously curated reference set of over 16k methylation profiles, structured into 22 tumor families and 133 clinically relevant diagnostic classes and includes 21 recently developed methylation classes not represented in existing tools. The approach has been validated across multiple independent cohorts (n = 5,875) and supports deployment through MethylScape, a public web-based portal that streamlines classifier execution for broad accessibility. In an NIH validation cohort analysis of 1,204 high-confidence matches with pre-methylation diagnoses available, methylation profiling confirmed the initial diagnosis in 25.6% of cases while driving clinically meaningful diagnostic evolution in the remainder, including refined diagnosis (subtyping) in 14.6%, new diagnosis with increased precision in 54.7%, and substantial diagnostic reclassification in 5.0%&mdash;changes that are expected to affect patient management in the reclassification subset.</p> <p>Renal neoplasms present a parallel diagnostic challenge due to morphologic and molecular heterogeneity, overlapping microscopic features, and interobserver variability. As a result, a subset of cases are unclassifiable even after immunohistochemical, mutation and cytogenetic workups. To address this, the Kidney Classifier component of this platform leverages genome-wide DNA methylation profiling (feasible on formalin-fixed paraffin-embedded tissue using robust array-based methods). It was developed through examination of methylation signatures from over 2,000 renal neoplasms, identifying 23 coherent methylation groups that correlate with known tumor types and reveal clinically relevant novel subtypes. A machine learning classifier trained on 1,284 samples was externally tested on 287 renal neoplasms, demonstrating &gt;90% concordance between expected neoplasm type and high-score methylation-based classification, with discordant cases highlighting opportunities for diagnostic reclassification and improved precision in challenging renal tumor evaluations.</p> <p>Licensing and collaboration opportunities include commercial development of methylation-based diagnostic tests and/or software-enabled classification solutions for clinical laboratories, reference labs, and diagnostic companies. Partners may engage in external validation (retrospective and prospective), assay standardization, integration into pathology workflows and reporting systems, and extension of classifier coverage to additional tumor types and multi-institutional datasets. Consistent with consensus recommendations for complementary classifiers, the inventors are also interested in collaborations that: (1) operationalize multi-classifier strategies (concordant/complementary prediction to increase confidence; (2) leverage discordance to trigger orthogonal follow-up) and (3) accelerate clinical translation through scalable deployment models- including CLIA laboratory workflows and regulated diagnostic pathways.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Molecular classification and diagnosis of CNS and kidney tumors, including difficult-to-classify and low-confidence cases</li> <li>Diagnostic subtyping aligned to WHO-guided entities</li> <li>Reference-lab and hospital-lab deployment</li> <li>Clinical trial stratification and translational research cohort harmonization</li> <li>Multi-classifier diagnostic decision support</li> <li>Cancer treatment development</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Developed from a rigorously curated, large reference set of methylation profiles</li> <li>Clinically relevant CNS diagnostic</li> <li>CNS tumor methylation classes not represented in existing tools, expanding diagnostic coverage</li> <li>Clinical-impact analysis creating superior diagnostic precision</li> <li>Superior classifier for kidney cancer</li> <li>Superior classifiers for multiple solid, difficult-to-diagnose tumors</li> <li>Integrative into clinical workflows, improving diagnostic practices and enhancing patient care</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations to further develop and possibly expand the classification capabilities of the software. 2025-12-12 2026-04-23 2026-08-05 2026-04-10 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52406769 Prototype 52406769 NCI 37470483 Website Abstract 166817637 Singh O., et.al. Robust DNA Methylation-Based Diagnosis and Classification for Central Nervous 1 System Tumors, submitted Singh O., et.al. Robust DNA Methylation-Based Diagnosis and Classification for Central Nervous 1 System Tumors, submitted 166817672 Aldape K., et.al. cIMPACT-NOW update 9: Recommendations on utilization of genome-wide DNA methylation profiling for central nervous system tumor diagnostics. Neurooncol Adv. 2025 Jan 3;7(1):vdae228. PMID: 39902391 https://pubmed.ncbi.nlm.nih.gov/39902391/ <a href="https://pubmed.ncbi.nlm.nih.gov/39902391/">Aldape K., et.al. cIMPACT-NOW update 9: Recommendations on utilization of genome-wide DNA methylation profiling for central nervous system tumor diagnostics. Neurooncol Adv. 2025 Jan 3;7(1):vdae228. PMID: 39902391</a> 166817702 Papanicolau-Sengos A., et.al., Mod Pathol. 2025 Nov;38(11):100884, PMID: 40939817 https://pubmed.ncbi.nlm.nih.gov/40939817/ <a href="https://pubmed.ncbi.nlm.nih.gov/40939817/">Papanicolau-Sengos A., et.al., Mod Pathol. 2025 Nov;38(11):100884, PMID: 40939817</a> 165166621 Aldape, Kenneth Laboratory of Pathology NCI Aldape, Kenneth (NCI) 1 165166625 Abdullaev, Ziedulla National Cancer Institute (NCI) NCI Abdullaev, Ziedulla (NCI) 2 165166629 Turakulov, Rustamzhon Laboratory of Pathology Turakulov, Rustamzhon 3 165166639 Pittaluga, Stefania National Cancer Institute (NCI) NCI Pittaluga, Stefania (NCI) 4 165166643 Raffeld, Mark National Cancer Institute (NCI) NCI Raffeld, Mark (NCI) 5 165166647 Jaffe, Elaine NCI - CCR NCI Jaffe, Elaine (NCI) 6 165166651 Singh, Omkar National Cancer Institute (NCI) NCI Singh, Omkar (NCI) 7 165166699 Papanicolau-Sengos, Antonios Laboratory of Pathology NCI Papanicolau-Sengos, Antonios (NCI) 8 165166621 Aldape, Kenneth Laboratory of Pathology NCI Aldape, Kenneth (NCI) 1 165166625 Abdullaev, Ziedulla National Cancer Institute (NCI) NCI Abdullaev, Ziedulla (NCI) 2 165166629 Turakulov, Rustamzhon Laboratory of Pathology Turakulov, Rustamzhon 3 165166639 Pittaluga, Stefania National Cancer Institute (NCI) NCI Pittaluga, Stefania (NCI) 4 165166643 Raffeld, Mark National Cancer Institute (NCI) NCI Raffeld, Mark (NCI) 5 165166647 Jaffe, Elaine NCI - CCR NCI Jaffe, Elaine (NCI) 6 165166651 Singh, Omkar National Cancer Institute (NCI) NCI Singh, Omkar (NCI) 7 165166699 Papanicolau-Sengos, Antonios Laboratory of Pathology NCI Papanicolau-Sengos, Antonios (NCI) 8 165166559 DNA methylation-based cancer diagnostics for tumors of the central nervous system, kidney and hematopoietic system E-105-2023-0 Filing authorized Laboratory of Pathology, National Cancer Institute (NCI), NCI - CCR 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-5088] DNA Methylation-Based Cancer Diagnostics for Accurate Tumor Classification&body=Please send me information about technology [TAB-5088] DNA Methylation-Based Cancer Diagnostics for Accurate Tumor Classification.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-5088] DNA Methylation-Based Cancer Diagnostics for Accurate Tumor Classification&body=Please send me information about technology [TAB-5088] DNA Methylation-Based Cancer Diagnostics for Accurate Tumor Classification.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">greenejaime@mail.nih.gov</a><br> 165166607 E-105-2023-0 E-105-2023-0-US-01 DNA methylation-based cancer diagnostics ORD US 18/499,833 Pending US <br />Ordinary Patent (ORD) 18/499,833<br />Filed on 2023-11-01<br />Status: Pending TAB-4123 147157405 Combined RNA and DNA Vaccination Strategy for Improving the Vaccine Immune Response NCI Collaboration, Infectious Disease, Licensing, Oncology, Vaccines Collaboration Infectious Disease Licensing Oncology Vaccines Barbara Felber, George Pavlakis <h2>Description of Technology:</h2> <p>The development of an effective HIV vaccine has been ongoing. HIV sequence diversity and immunodominance are major obstacles in the design of an effective vaccine. Researchers at the National Cancer Institute (NCI) developed a novel vaccine strategy combining both DNA and mRNA vaccination to induce an effective immune response. This combination strategy could also be used to develop vaccines against cancer or other infectious diseases (ex. SARS-CoV-2).&nbsp;<br /> Previous studies by NCI determined that regions of the polypeptides Gag and Env are both essential to the core structure and envelope of the HIV-1 virus. Co-administration of DNA expressing Gag and Env elicits a protective immune response and reduces infection burden.&nbsp;&nbsp;This current technology relates to earlier technology from the same inventors describing the identification of the conserved elements (CE) within HIV-1 p24Gag. Specifically, the inventors demonstrated that priming with p24gag CE followed by vaccination with either a full-length p55gag DNA plasmid or p24gag CE DNA together with full-length p55gag DNA increased the CE responses compared to vaccination with p24CE DNA alone.&nbsp;&nbsp;</p> <p>The current invention expands upon the earlier technology, combining DNA and RNA vaccination strategies to induce an effective HIV immune response.&nbsp;&nbsp;The inventors demonstrated that administration of gag mRNA/LNP efficiently boosted both humoral and cellular responses in rhesus macaques previously immunized by a Gag DNA-based vaccine. Furthermore, the mRNA/LNP as booster vaccination induced more potent cytotoxic T cell responses than using mRNA as prime. Overall, this invention describes a heterologous prime/boost regimen including a DNA prime followed by mRNA boost vaccination with the same or similar immunogens &ndash; resulting in optimal levels of humoral and cellular immune response. The use of a mRNA booster to stimulate DNA primed immunity may be broadly applicable as a vaccination strategy for other infectious diseases and cancer.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Prophylactic and therapeutic vaccines for HIV</li> <li>Prophylactic and therapeutic vaccines for&nbsp;infectious diseases</li> <li>Prophylactic and therapeutic vaccines for cancer</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Addresses key hurdle faced by current HIV vaccines: sequence diversity of HIV and immunodominance of specific epitopes</li> <li>Induces optimal cellular and humoral responses</li> <li>Reduces infectious burden</li> <li>Potential vaccine strategy applicable to other non-HIV diseases, such as cancer</li> <li>In vivo validation of vaccine strategy in non-human primates (rhesus macaques)</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for development of a RNA/DNA combination vaccine against infectious diseases (ex: HIV, SARS-CoV-2) or cancer 2023-07-04 2026-04-24 2023-07-05 2026-08-05 2023-07-04 CANCER VACCINE, DNA vaccine, ENV, Felber, GAG, HIV, Infectious Disease, Nci, Pavlakis, RNA Vaccine, SARS-CoV-2, Vaccine False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-07-05 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-087-2015 E-132-2012 147162002 Valentin A, et al. 2022. Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques. (PMID: 35935984) https://pubmed.ncbi.nlm.nih.gov/35935984/ <a href="https://pubmed.ncbi.nlm.nih.gov/35935984/">Valentin A, et al. 2022. Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques. (PMID: 35935984)</a> 147163589 Felber, Barbara NIH - NCI NCI Felber, Barbara (NCI) 1 147163588 Pavlakis, George NIH - NCI NCI Pavlakis, George (NCI) 2 147163589 Felber, Barbara NIH - NCI NCI Felber, Barbara (NCI) 1 147163588 Pavlakis, George NIH - NCI NCI Pavlakis, George (NCI) 2 147158103 Immunogens And Methods To Improve Vaccine Immune Response E-158-2022-0 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4123] Combined RNA and DNA Vaccination Strategy for Improving the Vaccine Immune Response&body=Please send me information about technology [TAB-4123] Combined RNA and DNA Vaccination Strategy for Improving the Vaccine Immune Response.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4123] Combined RNA and DNA Vaccination Strategy for Improving the Vaccine Immune Response&body=Please send me information about technology [TAB-4123] Combined RNA and DNA Vaccination Strategy for Improving the Vaccine Immune Response.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147161119 E-158-2022-0 E-158-2022-0-US-01 IMMUNOGENS AND METHODS FOR INDUCING AN IMMUNE RESPONSE PRV US 63/358,919 Expired US <br />Provisional (PRV) 63/358,919<br />Filed on 2022-07-07<br />Status: Expired 147166705 E-158-2022-0 E-158-2022-0-PC-01 IMMUNOGENS AND METHODS FOR INDUCING AN IMMUNE RESPONSE PCT Patent Cooperation Treaty PCT/US2023/069057 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/069057<br />Filed on 2023-06-26<br />Status: Expired 147172586 CANCER VACCINE 147172587 DNA vaccine 147172588 ENV 147172589 Felber 147172590 GAG 147172591 HIV 147172592 Infectious Disease 147172593 Nci 147172594 Pavlakis 147172596 RNA Vaccine 147172597 SARS-CoV-2 147172598 Vaccine TAB-5099 167270778 Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Sanghyun (Peter) Kim, Steven Rosenberg <div> <div> <div class="msocomtxt" id="_com_2"> <h2>Summary:&nbsp;</h2> <p>Scientists at the National Cancer Institute (NCI) have developed a novel tightly regulated drug-responsive, membrane-bound IL-12 cytokine platform, that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs) while improving safety. The NCI seeks research co-development partners and/or licensees to advance this technology toward clinical translation.&nbsp;</p> <h2>Description of Technology:&nbsp;</h2> <p>ACT offers hope for patients with refractory or metastatic cancers, but effectiveness is frequently undermined by the immunosuppressive tumor microenvironment and T-cell dysfunction. Interleukin-12 (IL-12), a powerful cytokine with strong anti-tumor properties, has long been recognized for its potential to invigorate T-cell responses within tumors. However, systemic administration of IL-12 results in severe toxicity. Further, prior gene therapy strategies failed to provide sufficient control over IL-12 expression. These two factors compromise safety and therapeutic performance.</p> <p>This invention introduces a Nuclear Factor of Activated T cells (NFAT)-inducible, drug-regulatable, membrane-bound IL-12 (DRIM-IL-12) system that delivers spatiotemporally controlled cytokine expression within the engineered T cell therapy product. This platform ensures IL-12 is expressed only upon T-cell activation. Concurrently, the degron (D) sequence confers lenalidomide-dependent proteasome-mediated degradation&ndash;serving as a drug-controlled safety switch to limit systemic toxicity. A transmembrane (TM) domain anchors IL-12 in the plasma membrane, preventing unintended secretion and promoting localized immune modulation. When paired with tumor-specific TCRs or CARs (e.g., anti-mutant p53 or KRAS TCRs, or CD19 CAR), this platform enhances tumor cell killing and long-term survival in preclinical models. In a mouse model, DRIM-IL-12 demonstrated substantially improved safety compared to the previous generation of NFAT-inducible IL-12. The inventors also demonstrate that DRIM-IL-12 expression can be dialed down or fine-tuned to prevent T-cell exhaustion or differentiation, which can occur with uncontrolled IL-12 expression.</p> <p>The NCI invites industry partners and translational researchers to collaborate or license this technology for the next generation of safer, more effective ACT-based immunotherapies.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Solid tumors expressing p53 or KRAS mutations</li> <li>Hematologic malignancies</li> <li>Melanoma</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Versatile platform for inducible cytokine regulation</li> <li>Superior survival in mouse models compared with TCR-only T-cells</li> <li>Enhanced tumor cell killing and long-term survival in murine models</li> <li>Decreased IL-12&ndash;associated toxicity</li> <li>Maintenance of higher IL-12 expression&nbsp;</li> <li>Improved sensitivity to lenalidomide-mediated degradation</li> </ul> </div> </div> </div> Researchers at the NCI seek licensing and/or co-development research collaborations for developing a novel tightly regulated drug-responsive, membrane-bound IL-12 cytokine platform, that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs). 2026-05-14 2026-05-14 2026-08-05 2026-05-14 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 167271215 Kim SP, et al. Drug-regulatable, inducible, and membrane-bound interleukin 12 (IL-12TM-D) for use in adoptive cell therapies against advanced cancers. https://doi.org/10.1136/jitc-2024-SITC2024.0344 Kim SP, et al. Drug-regulatable, inducible, and membrane-bound interleukin 12 (IL-12TM-D) for use in adoptive cell therapies against advanced cancers. https://doi.org/10.1136/jitc-2024-SITC2024.0344 167270829 Rosenberg, Steven National Cancer Institute (NCI) NCI Rosenberg, Steven (NCI) 1 167270833 Kim, Sanghyun (Peter) NCI - CCR NCI Kim, Sanghyun (Peter) (NCI) 2 167270829 Rosenberg, Steven National Cancer Institute (NCI) NCI Rosenberg, Steven (NCI) 1 167270833 Kim, Sanghyun (Peter) NCI - CCR NCI Kim, Sanghyun (Peter) (NCI) 2 167270784 Drug-regulatable, inducible expression of membrane-bound interleukin 12 for use in adoptive cell therapy. E-217-2023-0 Filing authorized National Cancer Institute (NCI), Surgery Branch 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-5099] Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy&body=Please send me information about technology [TAB-5099] Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-5099] Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy&body=Please send me information about technology [TAB-5099] Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">burkear@nih.gov</a><br> 167270791 E-217-2023-0 E-217-2023-0-US-01 DRUG-REGULATABLE, INDUCIBLE CYTOKINE EXPRESSION PRV US 63/652,871 Expired US <br />Provisional (PRV) 63/652,871<br />Filed on 2024-05-29<br />Status: Expired 167270792 E-217-2023-0 E-217-2023-0-PC-01 DRUG-REGULATABLE, INDUCIBLE CYTOKINE EXPRESSION PCT Patent Cooperation Treaty PCT/US2025/031121 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/031121<br />Filed on 2025-05-28<br />Status: Pending TAB-5085 164394726 Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions NCI Collaboration, Diagnostics, Immunology, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Diagnostics Immunology Infectious Disease Licensing Oncology Therapeutics Swati Choksi, Zheng-gang Liu, Yeon-Ji Park, PeiXing Wan <h2>Summary:</h2> <p>Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in-class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions,<span style="font-size:11.0pt"> and others.&nbsp;&nbsp;&nbsp; </span></p> <h2>Description of Technology:</h2> <p><span style="font-size:11.0pt">Investigators at the National Cancer Institute (NCI) have identified and therapeutically validated a distinctive, disease-restricted driver of thrombosis: soluble tissue factor (sTF). sTF is generated through proteolytic cleavage during inflammatory cell death.</span></p> <p><span style="font-size:11.0pt">Mechanistically, the researchers demonstrated that sTF generation is not limited to necroptosis but represents a conserved outcome of multiple inflammatory cell death pathways, including pyroptosis and NETtosis.</span></p> <p><span style="font-size:11.0pt">Pathological thrombosis remains a leading cause of morbidity and mortality in sepsis, cancer, autoimmune diseases, viral infections, and inflammatory disorders. Current anticoagulant and thrombosis treatments options such as Heparins and Warfarin are effective at reducing clot formation, but act indiscriminately on the coagulation cascade, disrupt normal hemostasis, and are associated with significant bleeding risk. Current thrombosis diagnostics, D-dimer, a fibrin degradation byproduct, is a late stage marker that lacks sensitivity. This invention provides an alternative for early detection based on sTF that is more sensitive and specific. </span></p> <p><span style="font-size:11.0pt">To selectively target this mechanism, the team developed novel humanized monoclonal antibodies (e.g., 58B3 and 56E5) that specifically recognize human soluble tissue factor (hsTF), but not full-length membrane-bound tissue factor (flTF). This selectivity preserves physiological hemostasis while inhibiting pathological coagulation.</span></p> <p><span style="font-size:11.0pt">In vivo validation using human samples of various clinical diseases demonstrated that administration of sTF-specific antibodies prevents fibrinogen depletion and reduces thrombin&ndash;antithrombin (TAT) complex elevation, effectively normalizing coagulation parameters. These results establish proof of concept that selective sTF neutralization can block pathological thrombosis without systemic anticoagulation.</span></p> <p><span style="font-size:11.0pt">By establishing sTF as a unifying mechanistic link between inflammatory cell death and thrombosis across sepsis, cancer, infection, autoimmune disease, cardiovascular disorders, and metabolic inflammation, this antibody platform represents a first-in-class strategy to selectively inhibit pathological coagulation while preserving normal hemostasis. The approach offers a safer, more precise therapeutic and diagnostic alternative to conventional anticoagulants.</span></p> <p><span style="font-size:11.0pt">The humanized monoclonal antibodies, as well as methods of using sTF as a target for diagnosis, treatment and prevention of thrombosis and associated diseases are available for licensing or collaborative development to advance clinical translation. Partnership opportunities include preclinical optimization, clinical development, and diagnostic assay co-development.</span></p> <h2>Potential Commercial Applications:</h2> <ul> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Diagnostic tool for early detection and monitoring of sTF in plasma.</span></span></span><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Diagnostic tool for early detection and monitoring of thrombosis, </span>much more sensitive and specific test than the currently used D-dimer test<span style="font-size:11.0pt">.</span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Basis for diagnostic kits such as ELISA and point-of-care assays.</span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Diagnostic tool for early detection of DVT and PE with radiolabeled anti-sTF antibody in combination with ultrasound /CT scan </span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Therapeutic use </span><span style="font-size:11.0pt">for sepsis-associated thrombosis.</span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Therapeutic use for cancer-associated thrombosis.</span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Therapeutic use viral infection&ndash;associated thrombosis. </span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Therapeutic use autoimmune disorders.</span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Therapeutic use cardiovascular inflammatory diseases.</span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Therapeutic use </span><span style="font-size:11.0pt">for acute lung injury including <span style="background-color:white"><span style="color:#0a0a0a">Acute Respiratory Distress Syndrome ARD.</span></span></span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Therapeutic use for metabolic and vascular inflammatory diseases</span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Therapeutic use for high efficient inhibition of thrombosis with anti-sTF-based bispecific antibodies. </span></span></span></li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Selective targeting of pathological soluble tissue factor (sTF).</li> <li>Preservation of normal hemostasis.</li> <li>Potential for long-acting biologic prevention.</li> <li>Specific mechanism-based intervention tied to inflammatory cell death.</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for developing diagnostic, prognostic, preventative and therapeutic development of sTF. NCI is seeking collaborators with Access to clinical samples of thrombosis, and with experience of in vivo detection of thrombosis (e.g. DVT) in patients with current tools. Also seeking collaborators with experience in developing bi-specific antibodies. 2025-09-29 2026-05-12 2026-05-07 2026-08-05 2025-09-29 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2026-05-07 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 164395085 Wan, P., Choksi, S., Park, YJ. et al. Soluble tissue factor generated by necroptosis-triggered shedding is responsible for thrombosis. Cell Res 35, 840–858 (2025). https://doi.org/10.1038/s41422-025-01167-8 Wan, P., Choksi, S., Park, YJ. et al. Soluble tissue factor generated by necroptosis-triggered shedding is responsible for thrombosis. Cell Res 35, 840–858 (2025). https://doi.org/10.1038/s41422-025-01167-8 167182477 Yan J, Wan P, Choksi S, Liu ZG. Necroptosis and tumor progression. Trends Cancer. 2022 Jan;8(1):21-27. doi: 10.1016/j.trecan.2021.09.003. Yan J, Wan P, Choksi S, Liu ZG. Necroptosis and tumor progression. Trends Cancer. 2022 Jan;8(1):21-27. doi: 10.1016/j.trecan.2021.09.003. 164394956 Liu, Zheng-gang NIH - NCI NCI Liu, Zheng-gang (NCI) 1 164394984 Choksi, Swati NIH - NCI NCI Choksi, Swati (NCI) 2 164395025 Wan, PeiXing NIH - NCI NCI Wan, PeiXing (NCI) 3 167182419 Park, Yeon-Ji NIH - NCI NCI Park, Yeon-Ji (NCI) 4 164394956 Liu, Zheng-gang NIH - NCI NCI Liu, Zheng-gang (NCI) 1 164394984 Choksi, Swati NIH - NCI NCI Choksi, Swati (NCI) 2 164395025 Wan, PeiXing NIH - NCI NCI Wan, PeiXing (NCI) 3 167182419 Park, Yeon-Ji NIH - NCI NCI Park, Yeon-Ji (NCI) 4 164394729 The soluble Tissue Factor generated by necroptosis-triggered shedding of the cell surface TF is responsible for septic shock and viral infection-induced thrombosis E-263-2023-0 Filing authorized National Institute on Alcohol Abuse and Alcoholism (NIAAA), NCI - CCR, NIH - NCI 83683663 Cremesti, Aida aida.cremesti@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB aida.cremesti@nih.gov?subject=Web Inquiry on [TAB-5085] Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions&body=Please send me information about technology [TAB-5085] Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Cremesti, Aida<br><a href="mailto:aida.cremesti@nih.gov?subject=Web Inquiry on [TAB-5085] Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions&body=Please send me information about technology [TAB-5085] Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">aida.cremesti@nih.gov</a><br> 164394734 E-263-2023-0 E-263-2023-0-US-01 HUMANIZED ANTIBODIES SPECIFIC AGAINST SOLUBLE TISSUE FACTOR PRV US 63/783,685 Expired US <br />Provisional (PRV) 63/783,685<br />Filed on 2025-04-04<br />Status: Expired 166015111 E-263-2023-0 E-263-2023-0-PC-01 SOLUBLE TISSUE FACTOR, A NOVEL TARGET, AND ANTIBODIES, FOR DIAGNOSIS, PREVENTION AND TREATMENT OF THROMBOSIS AND RELATED CONDTIONS PCT Patent Cooperation Treaty PCT/US2026/022285 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2026/022285<br />Filed on 2026-04-03<br />Status: Pending TAB-5134 168064923 Monoclonal Antibody (RO4) that Reacts with the Juxta-membrane Region of Mesothelin NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Mitchell Ho, Xiu Fen Liu, Masanori Onda, Ira Pastan, Di Xia <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a novel monoclonal antibody (mAb), RO4, that can be used to treat mesothelin (MSLN) expressing cancers.</p> <h2>Description of Technology:</h2> <p>Mesothelin (MSLN) is a surface antigen highly expressed in many solid tumors, such as mesothelioma, ovarian, and pancreatic cancers. MSLN is present at relatively low levels in mesothelial cells of healthy individuals, making it an ideal candidate for targeted therapeutics. However, the efficacy of MSLN-targeted agents is often reduced as a portion of the protein is shed from the cell surface and binds to available anti-MSLN antibodies. This reduces therapeutic engagement at the cell surface as shed MSLN acts as a decoy within tumor microenvironments, limiting antibodies from reaching and destroying tumor cells.</p> <p>Researchers at National Cancer Institute (NCI) developed a novel mAb, RO4, which specifically binds&nbsp;to the juxta-membrane region of MSLN to block shedding. RO4 binds to the same region of MSLN as a previously developed mAb, 15B6 (NCI Ref. #E-106-2017), but in a different conformation. This allows for increased binding affinity and specificity. CAR-T cells made with humanized RO4 demonstrated higher cytotoxicity both in vitro and in vivo compared to h15B6 CAR-Ts. Additionally, hRO4 exhibited broader binding across MSLN-positive cell types compared to h15B6, suggesting wider utility in patient populations.</p> <p>Researchers at the NCI seek licensing and/or co-development research collaborations for further development of RO4 that can be used to treat MSLN-positive cancers.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of various MSLN-positive cancers &ndash; including mesothelioma, ovarian and pancreatic cancer</li> <li>Development of CAR T cells and bispecific antibodies to target MSLN and CD3</li> <li>Development of Antibody-Drug Conjugates (ADCs) and Antibody-nanoparticle conjugates to deliver cytotoxic payloads to MSLN-positive tumors</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Increased therapeutic effectiveness via avoiding shed decoy interference</li> <li>Enhanced binding affinity and selectivity compared to earlier antibodies</li> <li>Improved cytotoxicity across various MSLN-positive tumors</li> <li>Versatility in use of CAR T cells and bispecific antibodies targeting MSLN and CD3</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a novel monoclonal antibody (mAb), RO4, that can be used to treat mesothelin (MSLN) expressing cancers. 2026-07-01 2026-07-01 2026-08-05 2026-07-01 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-106-2017 E-033-2022 168065263 Onda M, et al. RO4, a high-affinity humanized antibody against the juxtamembrane region of mesothelin for targeted cancer therapy. (PMID41550974) https://pubmed.ncbi.nlm.nih.gov/41550974/ <a href="https://pubmed.ncbi.nlm.nih.gov/41550974/">Onda M, et al. RO4, a high-affinity humanized antibody against the juxtamembrane region of mesothelin for targeted cancer therapy. (PMID41550974)</a> 168065266 Liu X, et al. Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin. (PMID35512094) https://pubmed.ncbi.nlm.nih.gov/35512094/ <a href="https://pubmed.ncbi.nlm.nih.gov/35512094/">Liu X, et al. Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin. (PMID35512094)</a> 168065133 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 1 168065140 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 2 168065196 Onda, Masanori NIH - NCI NCI Onda, Masanori (NCI) 3 168065201 Xia, Di NIH - NCI NCI Xia, Di (NCI) 4 168065205 Liu, Xiu Fen NIH - NCI NCI Liu, Xiu Fen (NCI) 5 168065133 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 1 168065140 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 2 168065196 Onda, Masanori NIH - NCI NCI Onda, Masanori (NCI) 3 168065201 Xia, Di NIH - NCI NCI Xia, Di (NCI) 4 168065205 Liu, Xiu Fen NIH - NCI NCI Liu, Xiu Fen (NCI) 5 168064926 Monoclonal Antibody R04 that Reacts with the Juxta-membrane Region of Mesothelin E-051-2024-0 Filing authorized NIH - NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-5134] Monoclonal Antibody (RO4) that Reacts with the Juxta-membrane Region of Mesothelin&body=Please send me information about technology [TAB-5134] Monoclonal Antibody (RO4) that Reacts with the Juxta-membrane Region of Mesothelin.&bcc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-5134] Monoclonal Antibody (RO4) that Reacts with the Juxta-membrane Region of Mesothelin&body=Please send me information about technology [TAB-5134] Monoclonal Antibody (RO4) that Reacts with the Juxta-membrane Region of Mesothelin.&bcc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">greenejaime@mail.nih.gov</a><br> 168064931 E-051-2024-0 E-051-2024-0-US-01 MONOCLONAL ANTIBODIES THAT BIND THE JUXTA-MEMBRANE REGION OF MESOTHELIN AND USES THEREOF (RO4 antibody) PRV US 63/550,703 Expired US <br />Provisional (PRV) 63/550,703<br />Filed on 2024-02-07<br />Status: Expired 168064932 E-051-2024-0 E-051-2024-0-PC-01 MONOCLONAL ANTIBODIES THAT BIND THE JUXTA-MEMBRANE REGION OF MESOTHELIN AND USES THEREOF (R04 antibody) PCT Patent Cooperation Treaty PCT/US2025/014973 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2025/014973<br />Filed on 2025-02-07<br />Status: Expired 168064933 E-051-2024-0 E-051-2024-0-CA-01 MONOCLONAL ANTIBODIES THAT BIND THE JUXTAMEMBRANE REGION OF MESOTHELIN AND USES THEREOF National Stage Canada 3315513 Pending Canada <br />National Stage 3315513<br />Filed on 2026-06-17<br />Status: Pending 168064934 E-051-2024-0 E-051-2024-0-US-02 MONOCLONAL ANTIBODIES THAT BIND THE JUXTA-MEMBRANE REGION OF MESOTHELIN AND USES THEREOF National Stage US 19/613,559 Pending US <br />National Stage 19/613,559<br />Filed on 2026-08-07<br />Status: Pending 168064935 E-051-2024-0 E-051-2024-0-EP-01 MONOCLONAL ANTIBODIES THAT BIND THE JUXTAMEMBRANE REGION OF MESOTHELIN AND USES THEREOF National Stage European Patent 25708322.0 Pending European Patent <br />National Stage 25708322.0<br />Filed on 2026-06-23<br />Status: Pending 168064936 E-051-2024-0 E-051-2024-0-AU-01 MONOCLONAL ANTIBODIES THAT BIND THE JUXTA-MEMBRANE REGION OF MESOTHELIN AND USES THEREOF (R04 antibody) National Stage Australia 2025218272 Pending Australia <br />National Stage 2025218272<br />Filed on 2026-06-05<br />Status: Pending TAB-5135 168117616 Quantitative Particle Identification (QPID) Digital Autoradiography System NCI Collaboration, Licensing, Non-Medical Devices, Oncology, Radiology Collaboration Licensing Non-Medical Devices Oncology Radiology Stephen Adler <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a Quantitative Particle Identification (QPID) digital autoradiography system with particle identification capabilities.</p> <h2>Description of Technology:</h2> <p>Autoradiography is a photographic process that exposes a medium, sensitive to radiation, to a sample emitting radiation. The current state of the art involves exposing a thin slice of tissue to an ionization-sensitive film for several hours or days and then scanning the film into an autoradiography image. This image is created using the sum of the ionizations from all the decays that occurred during the time of exposure on the ionization-sensitive medium. Imaging quality of these samples can be improved by collecting information from each individual decay to enhance the autoradiographic measurement.</p> <p>Researchers at National Cancer Institute (NCI) developed a&nbsp;Quantitative Particle Identification (QPID) digital autoradiography system to measure the energy deposition from charged particles for each individual radioactive decay. The QPID leverages the ionizing radiation detection features of the Timepix3 detector to generate autoradiograph images in units of dose per unit time and area. The high readout speed of the Timepix3 gives the detector the capability to measure separate decay ionizations. It also segregates the image into one generated only by alpha and the other only by beta particles. A gamma detector was interfaced with the Timepix3 &ndash; allowing tagging charged particle ionization events in coincidence with a gamma emission during the isotope decay. This allows for a method to distinguish between alpha and positron emitting radioisotopes when imaged concurrently in the same pathology sample. This is the most unique feature of the QPID which will aid the development of new theranostic treatments in which two similar ligands are used.</p> <p>Researchers at the NCI seek licensing and/or co-development research collaborations to continue developing the QPID system for improved autoradiography imaging.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Improved radiotherapy dosing for cancer treatment</li> <li>Improved radiotherapy guidance for cancer treatment</li> <li>Improve accuracy of biopsy procedures through real-time tracer measurement and detection</li> <li>Measuring dual radioligand pathology samples</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>QPID can measure charge particle activity for individual decays (alpha, beta, and gamma)</li> <li>QPID measures absolute time of decay relative to the start of data acquisition</li> <li>QPID more accurately measures radioactive dose in a tissue sample</li> </ul> <p><img alt="" src="https://nih.technologypublisher.com/files/sites/e-201-2023_abstract_figure_withlabels_mr2.jpg" style="height:720px; width:1280px" /></p> <p>The figure shows the unique ability of the QPID to image two radioisotopes simultaneously. A mouse was injected with a mixture of 223RaCl and Na18F, a theranostic agent pair which treats and images bone metastasis from prostate cancer. An hour after injection, a 50 micron thick spine sample was imaged on the QPID. The 223RaCl and Na18F uptake into the bone was separated into two images, one as the distribution of 223RaCl and the other as the distribution of Na18F. Because the QPID records individual decays of either radioisotope, accurate amounts of the two radioisotopes can be measured and studies of the biodistribution and micro-dosimetry are possible. The top row (panels a, b, and c) are autoradiography images generated by the QPID. The bottom row (panels d, e and f) are co-registered images of photographs of the sample overlayed&nbsp; with the radioisotope distribution.</p> Researchers at the NCI seek licensing and/or co-development research collaborations for developing the QPID system for improved autoradiography imaging. 2026-07-08 2026-07-09 2026-08-05 2026-07-08 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52406769 Prototype 52406769 NCI 37470483 Website Abstract 168117779 Adler SS, et al. A Quantitative Particle Identification (QPID) spectral autoradiography system. (PMID40374923) https://pubmed.ncbi.nlm.nih.gov/40374923/ <a href="https://pubmed.ncbi.nlm.nih.gov/40374923/">Adler SS, et al. A Quantitative Particle Identification (QPID) spectral autoradiography system. (PMID40374923)</a> 168117759 Adler, Stephen NIH - NCI Leidos Adler, Stephen (Leidos) 1 168117759 Adler, Stephen NIH - NCI Leidos Adler, Stephen (Leidos) 1 168117619 Quantitative Particle Identification (QPID) Digital Autoradiography System Leidos EIR # 23-008 E-201-2023-0 Filing authorized NCI - FCRDC (Leidos), NIH - NCI 83736770 Cheng, Eric eric.cheng2@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-5135] Quantitative Particle Identification (QPID) Digital Autoradiography System&body=Please send me information about technology [TAB-5135] Quantitative Particle Identification (QPID) Digital Autoradiography System.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Cheng, Eric<br><a href="mailto:eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-5135] Quantitative Particle Identification (QPID) Digital Autoradiography System&body=Please send me information about technology [TAB-5135] Quantitative Particle Identification (QPID) Digital Autoradiography System.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">eric.cheng2@nih.gov</a><br> 168117624 E-201-2023-0 E-201-2023-0-US-01 QUANTITATIVE PARTICLE IDENTIFICATION DIGITAL AUTORADIOGRAPHY PRV US 63/651,184 Expired US <br />Provisional (PRV) 63/651,184<br />Filed on 2024-05-23<br />Status: Expired 168117625 E-201-2023-0 E-201-2023-0-PC-01 QUANTITATIVE PARTICLE IDENTIFICATION DIGITAL AUTORADIOGRAPHY PCT Patent Cooperation Treaty PCT/US2025/028714 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/028714<br />Filed on 2025-05-09<br />Status: Pending TAB-5137 168206424 MC38 B2m KO Cell Line NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Duane Hamilton, Jeffrey Schlom <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks licensees for a CRISPR/Cas9-engineered MC38 B2m knockout murine colon cancer cell line that models tumor resistance to PD-1/PD-L1 checkpoint blockade caused by loss of MHC-I antigen presentation. This research tool provides an opportunity to study checkpoint-refractory tumors and evaluate alternative or combination immunotherapy strategies for cancers that evade conventional T-cell&ndash;mediated recognition.</p> <h2>Description of Technology:</h2> <p>Immune checkpoint blockade (ICB) is a type of cancer immunotherapy targeting proteins such as programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1), which tumors use to reduce T-cell immune activity. These therapies can be effective in some patients. However, ICB targeting PD-1/PD-L1 fails to provide clinical benefit for most cancer patients due to primary resistance. In such cases, tumors either do not respond from the outset or acquire resistance after initially responding. One important cause of resistance is defective antigen presentation, the process by which tumor cells display internal protein fragments on their surface using major histocompatibility complex class I (MHC-I) molecules for cancer-killing T cell recognition.</p> <p>Researchers at the National Cancer Institute (NCI) have developed and validated an MC38 B2m knockout murine colon cancer cell line designed to reproduce a clinically relevant form of immunotherapy resistance. Using CRISPR/Cas9, NCI researchers eliminated B2m, a gene required for tumor cells to display MHC-I antigen-presenting molecules to cancer-killing T cells. The resulting MC38 B2m KO cell line produces tumors that lack this key immune-recognition signal and are resistant to anti-PD-1 and anti-PD-L1 therapy in syngeneic mouse models. This gives researchers a defined, practical preclinical model to: (1) study tumor immune escape and (2) evaluate new immunotherapy strategies in a checkpoint-resistant setting. This is a superior approach versus models only in tumors that remain responsive to checkpoint blockade. This model uses a clinically relevant checkpoint-resistance mechanism by deleting B2m, which causes loss of MHC-I antigen presentation and prevents conventional CD8+ T-cell recognition. It is based upon the MC38 colon cancer model, which has significant response to PD-1/PD-L1 immune checkpoint blockade before B2m knockout. MC38 B2m KO tumors show abrogated response to anti-PD-1 and anti-PD-L1 treatment in vivo, while wild-type MC38 tumors showed significant tumor growth reduction under the same treatment framework</p> <p>The Center for Immuno-Oncology seeks licensees interested in using this cell line as a research tool for immuno-oncology studies. This model may be useful for evaluating alternative or combination immunotherapy strategies for checkpoint-refractory tumors, including cancers that evade conventional T-cell-mediated recognition due to defective antigen presentation. It facilitates mechanistic studies of tumor immune escape, CD8+ T-cell recognition, and tumor microenvironment remodeling.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Development of cancer therapeutics overcoming of PD-1/PD-L1 checkpoint blockade resistance</li> <li>Development of alternative or combination immunotherapies for checkpoint-refractory tumors</li> <li>Preclinical screening of alternative or combination immunotherapies for checkpoint-refractory tumors</li> <li>Evaluation of cancer therapeutic strategies for cancers with defective antigen processing/presentation or loss of MHC-I expression</li> <li>Companion model for comparing checkpoint-resistant MC38 B2m KO tumors against checkpoint-responsive wild-type MC38 tumors</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Uniquely models a clinically relevant checkpoint-resistance mechanism</li> <li>Uses the MC38 colon cancer model, which is well-established and regulatorily de-risked &nbsp;</li> <li>Unique model permitting the interrogation of abrogated response to anti-PD-1 and anti-PD-L1 treatment</li> </ul> 2026-07-14 2026-07-14 2026-08-05 2026-07-14 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True NCI 37470483 Website Abstract 168206563 Chariou, PL, et al. Generation of murine tumor models refractory to αPD-1/-L1 therapies due to defects in antigen processing/presentation or IFNγ signaling using CRISPR/Cas9 (PMID: 38427670) https://pubmed.ncbi.nlm.nih.gov/38427670/ <a href="https://pubmed.ncbi.nlm.nih.gov/38427670/">Chariou, PL, et al. Generation of murine tumor models refractory to αPD-1/-L1 therapies due to defects in antigen processing/presentation or IFNγ signaling using CRISPR/Cas9 (PMID: 38427670)</a> 168206447 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 168206455 Hamilton, Duane NIH - NCI NCI Hamilton, Duane (NCI) 2 168206447 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 168206455 Hamilton, Duane NIH - NCI NCI Hamilton, Duane (NCI) 2 168206427 MC 38 B2m KO cell line E-123-2026-0 Research Material NIH - NCI 166619691 Jansen, Nathan nathan.jansen@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
nathan.jansen@nih.gov?subject=Web Inquiry on [TAB-5137] MC38 B2m KO Cell Line&body=Please send me information about technology [TAB-5137] MC38 B2m KO Cell Line.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Jansen, Nathan<br><a href="mailto:nathan.jansen@nih.gov?subject=Web Inquiry on [TAB-5137] MC38 B2m KO Cell Line&body=Please send me information about technology [TAB-5137] MC38 B2m KO Cell Line.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">nathan.jansen@nih.gov</a><br> TAB-5139 168445142 Human Antibodies Targeting Beneficial Viral Peptide in Liver Cancer NCI Collaboration, Gastroenterology, Licensing, Oncology, Therapeutics Collaboration Gastroenterology Licensing Oncology Therapeutics Jesse Buffington, Zhijian Duan, Mitchell Ho, Man Hsin Hung, Limin Wang, Xin Wei Wang <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees to develop a collection of anti-CE1 antibodies for liver cancer treatment.</p> <h2>Description of Technology:</h2> <p>Liver cancer is the sixth most common and the third leading cause of cancer death worldwide. The most common liver cancer in adults is hepatocellular carcinoma (HCC), an aggressive malignancy with an increasing global incidence and mortality rate. The current methods for early detection, surveillance, and treatment are suboptimal. This is due to complex etiologies, demonstrating a need for more effective treatments.</p> <p>Previously, NIH investigators identified a novel viral peptide antigen known as CE1. CE1 belongs to the rhinovirus and enterovirus families (NIH Ref: E-023-2024) producing a dominant humoral response associated with reduced incidence and mortality of HCC. Through phage display from a human single-chain fragment variable (scFv) phage library, NCI inventors isolated two human antibodies (B9 and B10) against the viral peptide, CE1. Human anti-CE1 B9 and B10 antibodies were constructed. These antibodies showed specific binding to liver cancer cell lines and clinical tumor tissues. They inhibited HCC tumor growth via inducting NK cell-mediated antibody-dependent cellular cytotoxicity in vitro and in vivo. These anti-CE1 antibodies have the potential as liver cancer therapeutics, either on their own or as the targeting domain of an immunoconjugate.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Liver Cancer treatment <ul> <li>Recombinant immunotoxins (RITs)</li> <li>Antibody drug conjugates (ADCs)</li> <li>Chimeric antigen receptors (CAR)</li> <li>Bispecific monoclonal antibody</li> <li>Radiopharmaceuticals</li> </ul> </li> <li>Liver Cancer diagnosis</li> <li>Therapeutics for tumors expressing a molecule recognized by a CE1-specific antibody, such as: <ul> <li>Prostate cancer</li> <li>Lung cancer</li> </ul> </li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Preferential binding to tumor cells</li> <li>Potentially reduced systemic toxicity</li> <li>Well-established regulatory path</li> <li>Well-established antibody market</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for developing a collection of anti-CE1 antibody-based therapeutics to treat liver cancer. 2026-07-31 2026-08-03 2026-08-05 2026-07-31 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-023-2024 168445197 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 168445208 Duan, Zhijian NIH - NCI NCI Duan, Zhijian (NCI) 2 168445213 Buffington, Jesse NIH - NCI NCI Buffington, Jesse (NCI) 3 168445219 Wang, Xin Wei NIH - NCI NCI Wang, Xin Wei (NCI) 4 168445223 Hung, Man Hsin NIH - NCI NCI Hung, Man Hsin (NCI) 5 168445393 Wang, Limin NIH - NCI NCI Wang, Limin (NCI) 6 168445197 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 168445208 Duan, Zhijian NIH - NCI NCI Duan, Zhijian (NCI) 2 168445213 Buffington, Jesse NIH - NCI NCI Buffington, Jesse (NCI) 3 168445219 Wang, Xin Wei NIH - NCI NCI Wang, Xin Wei (NCI) 4 168445223 Hung, Man Hsin NIH - NCI NCI Hung, Man Hsin (NCI) 5 168445393 Wang, Limin NIH - NCI NCI Wang, Limin (NCI) 6 168445145 Human antibodies targeting oncogenic viral peptide in liver cancer E-021-2025-0 Filing authorized NIH - NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-5139] Human Antibodies Targeting Beneficial Viral Peptide in Liver Cancer&body=Please send me information about technology [TAB-5139] Human Antibodies Targeting Beneficial Viral Peptide in Liver Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-5139] Human Antibodies Targeting Beneficial Viral Peptide in Liver Cancer&body=Please send me information about technology [TAB-5139] Human Antibodies Targeting Beneficial Viral Peptide in Liver Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">abritee.dhal@nih.gov</a><br> 168445150 E-021-2025-0 E-021-2025-0-US-01 HUMAN MONOCLONAL ANTIBODIES TARGETING A VIRAL PEPTIDE AND THEIR USE FOR TREATING CANCER PRV US 63/872,927 Expired US <br />Provisional (PRV) 63/872,927<br />Filed on 2025-08-29<br />Status: Expired 168445151 E-021-2025-0 E-021-2025-0-PC-01 HUMAN MONOCLONAL ANTIBODIES TARGETING A VIRAL PEPTIDE AND THEIR USE FOR TREATING CANCER PCT Patent Cooperation Treaty PCT/US2026/043291 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2026/043291<br />Filed on 2026-08-28<br />Status: Pending TAB-5140 168452674 D3-Selective Dopamine Agonist Platform: Eliminating D2-Mediated Side Effects in Parkinson’s and Movement Disorders NINDS Neurology, Therapeutics Neurology Therapeutics Jeffrey Aube, Marc Ferrer-Alegre, Kevin Frankowski, Benjamin Free, Juan Marugan, Amy Moritz, David Sibley, Noel Southall, Joseph Steiner, Warren Weiner, Xin Xu <p>Every major dopaminergic therapy on the market today shares the same fundamental limitation: it cannot distinguish between two closely related receptor subtypes (D2 and D3). This technology changes that.</p> <p>We have discovered and optimized a novel small molecule, ML417, that selectively activates the D3 dopamine receptor while leaving its close cousin, the D2 receptor, untouched. While primarily positioned for&nbsp;Parkinson&#39;s Disease and Restless Legs Syndrome, the D3-selective profile and strong brain penetrance demonstrated by this scaffold open high-value pipeline expansion opportunities in broader neurological and neuropsychiatric indications, including substance use disorders, schizophrenia, and cognitive decline.</p> <p>&nbsp;</p> <ul>Our lead compound, ML417, represents a meaningful advance in a field where "selective" has historically only meant modest improvement. Superior Selectivity Profile: In head-to-head comparisons, ML417 outperforms the most selective D3 agonists previously reported in scientific literature, leaving the D2 receptor virtually untouched. <li>Demonstrated Neuroprotection: In preclinical models, our compound demonstrated stronger neuroprotective activity than pramipexole, one of the most widely prescribed D3-preferring drugs on the market today. Robust, De-Risked Foundation: The platform emerged from a systematic medicinal chemistry campaign spanning over 100 synthesized analogs. It features confirmed selectivity across multiple orthogonal assays, favorable early pharmacokinetic signals (including excellent brain penetrance), and a clean genetic toxicity profile. Secured Intellectual Property: Issued US and EP patents, offering a clean, proprietary runway for clinical development.</li> </ul> <ul>Current FDA-approved dopamine agonists work by activating both D2 and D3 receptors together, since the two are nearly indistinguishable at the molecular level. This lack of selectivity comes at a massive cost: patients on these medications frequently develop severe impulse control disorders (compulsive gambling, shopping, and hypersexuality)—serious, life-altering side effects tied specifically to D2 activation that limit physician dosing confidence. By contrast, D3-selective activation preserves the desired therapeutic effects (including motor symptom relief and neuroprotection) without triggering the D2-driven side effects that destroy patient quality of life. <li>The Market: Parkinson's Disease alone carries an estimated $14.4 billion annual economic burden in the U.S. The Opportunity: A partner collaborating on this platform has the unique strategic opportunity to replace imprecise, standard-of-care drugs (like pramipexole and ropinirole) with a safer, highly tolerated, next-generation therapeutic class.</li> </ul> 2026-07-31 2026-08-04 2026-08-04 2026-08-04 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract E-146-2016-0 E-146-2016-1 168475952 Moritz et al., "Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist", J. Med. Chem. 2020, 63(10), 5526-5567 https://dx.doi.org/10.1021/acs.jmedchem.0c00424 <a href="https://dx.doi.org/10.1021/acs.jmedchem.0c00424">Moritz et al., "Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist", J. Med. Chem. 2020, 63(10), 5526-5567</a> 168474925 Sibley, David NINDS NINDS Sibley, David (NINDS) 1 168474929 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 2 168474933 Free, Benjamin NINDS Free, Benjamin 3 168474937 Moritz, Amy NINDS NINDS Moritz, Amy (NINDS) 4 168474941 Aube, Jeffrey University of North Carolina, Chapel Hill Aube, Jeffrey 5 168474945 Steiner, Joseph NINDS NINDS Steiner, Joseph (NINDS) 6 168474949 Frankowski, Kevin University of North Carolina, Chapel Hill Frankowski, Kevin 7 168474953 Ferrer-Alegre, Marc NCATS - NCGC Ferrer-Alegre, Marc 8 168474957 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 9 168474961 Xu, Xin NCATS - TRND NCATS Xu, Xin (NCATS) 10 168475207 Weiner, Warren unknown Weiner, Warren 11 168474925 Sibley, David NINDS NINDS Sibley, David (NINDS) 1 168474929 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 2 168474933 Free, Benjamin NINDS Free, Benjamin 3 168474937 Moritz, Amy NINDS NINDS Moritz, Amy (NINDS) 4 168474941 Aube, Jeffrey University of North Carolina, Chapel Hill Aube, Jeffrey 5 168474945 Steiner, Joseph NINDS NINDS Steiner, Joseph (NINDS) 6 168474949 Frankowski, Kevin University of North Carolina, Chapel Hill Frankowski, Kevin 7 168474953 Ferrer-Alegre, Marc NCATS - NCGC Ferrer-Alegre, Marc 8 168474957 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 9 168474961 Xu, Xin NCATS - TRND NCATS Xu, Xin (NCATS) 10 168475207 Weiner, Warren unknown Weiner, Warren 11 168452678 Identification Of A Novel D3 Dopamine Receptor-selective Agonist E-146-2016-0 Filing authorized NCATS - NCGC, NINDS, University of Kansas, University of North Carolina, Chapel Hill 168477411 Identification Of A Novel D3 Dopamine Receptor-selective Agonist E-146-2016-1 Filing authorized NCATS - NCGC, NINDS, Northeastern University, University of North Carolina, Chapel Hill 83667829 Ano, Susan susan.ano@nih.gov
United States of America susan.ano@nih.gov?subject=Web Inquiry on [TAB-5140] D3-Selective Dopamine Agonist Platform: Eliminating D2-Mediated Side Effects in Parkinson’s and Movement Disorders&body=Please send me information about technology [TAB-5140] D3-Selective Dopamine Agonist Platform: Eliminating D2-Mediated Side Effects in Parkinson’s and Movement Disorders. Ano, Susan<br><a href="mailto:susan.ano@nih.gov?subject=Web Inquiry on [TAB-5140] D3-Selective Dopamine Agonist Platform: Eliminating D2-Mediated Side Effects in Parkinson’s and Movement Disorders&body=Please send me information about technology [TAB-5140] D3-Selective Dopamine Agonist Platform: Eliminating D2-Mediated Side Effects in Parkinson’s and Movement Disorders.">susan.ano@nih.gov</a><br> 168477415 E-146-2016-1 E-146-2016-1-PCT-01 Selective D3 Dopamine Receptor Agonists and Methods of Their Use PCT Patent Cooperation Treaty PCT/US2017/027618 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/027618<br />Filed on 2017-04-14<br />Status: Expired 168477417 E-146-2016-1 E-146-2016-1-EP-02 Selective D3 Dopamine Receptor Agonists and Methods of Their Use National Stage European Patent 3442955 17733098.2 Issued European Patent <br />National Stage 17733098.2<br />Filed on 2018-10-23<br />Status: Issued 168477418 E-146-2016-1 E-146-2016-1-US-03 SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE National Stage US 11,634,404 16/093,365 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11634404 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11634404">11,634,404</a><br />Filed on 2018-10-12<br />Status: Issued 168477419 E-146-2016-1 E-146-2016-1-DE-04 Selective D3 Dopamine Receptor Agonists and Methods of Their Use EP Germany 3442955 17733098.2 Issued Germany <br />European patent (EP) 17733098.2<br />Filed on 2018-10-23<br />Status: Issued 168477420 E-146-2016-1 E-146-2016-1-GB-05 ESelective D3 Dopamine Receptor Agonists and Methods of Their Use EP United Kingdom 3442955 17733098.2 Issued United Kingdom <br />European patent (EP) 17733098.2<br />Filed on 2018-10-23<br />Status: Issued 168477421 E-146-2016-1 E-146-2016-1-FR-06 Selective D3 Dopamine Receptor Agonists and Methods of Their Use EP France 3442955 17733098.2 Issued France <br />European patent (EP) 17733098.2<br />Filed on 2018-10-23<br />Status: Issued 168477422 E-146-2016-1 E-146-2016-1-BE-07 Selective D3 Dopamine Receptor Agonists and Methods of Their Use EP Belgium 3442955 17733098.2 Issued Belgium <br />European patent (EP) 17733098.2<br />Filed on 2018-10-23<br />Status: Issued 168477423 E-146-2016-1 E-146-2016-1-IE-08 Selective D3 Dopamine Receptor Agonists and Methods of Their Use EP Ireland 3442955 17733098.2 Issued Ireland <br />European patent (EP) 17733098.2<br />Filed on 2018-10-23<br />Status: Issued 168477424 E-146-2016-1 E-146-2016-1-CH-09 Selective D3 Dopamine Receptor Agonists and Methods of Their Use EP Switzerland 3442955 17733098.2 Issued Switzerland <br />European patent (EP) 17733098.2<br />Filed on 2018-10-23<br />Status: Issued 168477425 E-146-2016-1 E-146-2016-1-US-02 SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE CON US 12,145,922 18/111,241 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12145922 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12145922">12,145,922</a><br />Filed on 2023-02-17<br />Status: Issued TAB-4568 151739556 Astrocyte Differentiation of Neural Stem Cells with StemPro Embryonic Stem Cell Serum Free Medium for Research and Potential Therapeutic Use NIAMS Human Cell Lines, Materials Available, Neurology, Research Materials Human Cell Lines Materials Available Neurology Research Materials Nasir Malik, Mahendra Rao, Xianmin Zeng <p>This technology includes an innovative method for differentiating astrocytes from neural stem cells (NSCs). The process involves using Life Technologies StemPro embryonic stem cell serum-free medium to initially guide NSCs towards a neuronal lineage. Over a period of 28-35 days, as the cells are continually passaged, neurons gradually die off, leading to the proliferation of astrocytes. By the end of this differentiation protocol, approximately 70% of the cells exhibit markers characteristic of mature astrocytes, specifically GFAP. Additionally, this method allows for the astrocytes to be frozen at early stages and later thawed to continue their differentiation into the astrocyte lineage. This technology stands out from previous methods by significantly enhancing the efficiency and speed of astrocyte derivation. The potential applications of this technology are extensive, including facilitating research into astrocyte development mechanisms and providing a scalable way to produce astrocytes for potential clinical applications in cellular replacement therapies for brain and spinal cord injuries.</p> This astrocyte differentiation technology offers a competitive advantage by enabling the efficient and rapid generation of mature astrocytes, surpassing previous methods in both speed and efficacy. The technology holds promise for advancing research in astrocyte development and could be pivotal in cellular replacement therapies for treating brain and spinal cord injuries. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2025-08-13 2026-07-29 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151739563 Malik, Nasir NINDS NINDS Malik, Nasir (NINDS) 1 151739567 Rao, Mahendra New York Stem Cell Foundation Rao, Mahendra 2 151739571 Zeng, Xianmin Buck Institute for Research on Aging Zeng, Xianmin 3 151739563 Malik, Nasir NINDS NINDS Malik, Nasir (NINDS) 1 151739567 Rao, Mahendra New York Stem Cell Foundation Rao, Mahendra 2 151739571 Zeng, Xianmin Buck Institute for Research on Aging Zeng, Xianmin 3 151739559 Astrocyte Differentiation Of Neural Stem Cells With StemPro Embryonic Stem Cell Serum Free Medium E-612-2013-0 Research Material Buck Institute for Research on Aging, NIAMS 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4568] Astrocyte Differentiation of Neural Stem Cells with StemPro Embryonic Stem Cell Serum Free Medium for Research and Potential Therapeutic Use&body=Please send me information about technology [TAB-4568] Astrocyte Differentiation of Neural Stem Cells with StemPro Embryonic Stem Cell Serum Free Medium for Research and Potential Therapeutic Use. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4568] Astrocyte Differentiation of Neural Stem Cells with StemPro Embryonic Stem Cell Serum Free Medium for Research and Potential Therapeutic Use&body=Please send me information about technology [TAB-4568] Astrocyte Differentiation of Neural Stem Cells with StemPro Embryonic Stem Cell Serum Free Medium for Research and Potential Therapeutic Use.">vlado.knezevic@nih.gov</a><br> TAB-4205 147157490 Novel Dopamine Receptor Ligands As Therapeutics For Central Nervous System Disorders NIDA Gastroenterology, Licensing, Research Materials Gastroenterology Licensing Research Materials Jianjing Cao, George Cyriac, Peter Grundt, Robert Luedtke, Amy Newman <h2>Summary:</h2> <p>The National Institute on Drug Abuse&#39;s Medications Discovery Research Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize 4-phenylpiperazine derivatives as dopamine D3 selective ligands.</p> <h2>Description of Technology:</h2> <p>The dopamine D3 receptor subtype is a member of the dopamine D2 subclass of receptors.&nbsp; These receptors have been implicated in a number of CNS disorders, including psychostimulant abuse, psychosis and Parkinson&#39;s disease.&nbsp; Compounds that bind with high affinity and selectivity to D3 receptors can not only provide important tools with which to study the structure and function of this receptor subtype, but may also have therapeutic potential in the treatment of numerous psychiatric and neurologic disorders.&nbsp;</p> <p>The 4-phenylpiperazine derivatives are an important class of dopamine D3 selective ligands.&nbsp; However, due to their highly lipophilic nature, these compounds suffer from solubility problems in aqueous media and reduced bioavailability.&nbsp; To address this problem, a process was designed to introduce functionality into the carbon chain linker of these compounds.&nbsp; Compared to currently available dopamine D3 receptor ligands, the resulting compounds show improved pharmacological properties and D3 selectivities but due to their more hydrophilic nature, these derivatives are predicted to have improved water solubility and bioavailability.</p> <p>R&amp;D Status: Pre-clinical discovery</p> <p>Further R&amp;D Needed:</p> <ul> <li>Evaluate selected compounds in animal models of drug abuse, psychosis, obesity and Parkinson&#39;&#39;s disease</li> <li>Design and synthesize novel, functionalized analogs using both classical and computational drug design to improve D3 receptor affinity and selectivity</li> <li>Evaluate compounds for binding in D3 and D2 receptor expressing cell lines and in in vitro functional assays</li> <li>Correlate in vitro binding affinities with in vivo function in rats and monkeys and evaluate compounds in knockout mice models</li> <li>Pursue PET and SPECT imaging agents by radiolabel of D3 ligands and evaluation in rats and non-human primates.</li> </ul> <p>IP Status:&nbsp; PCT Application PCT/US2007/071412 filed 6/17/2007</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutics for a variety of psychiatric and neurologic disorders</li> <li>Research tools to study D3 receptor structure and function</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Improved pharmacological properties and selectivity over existing dopamine D3 receptor ligands.</li> <li>Hydrophilic nature likely to lead to improved water solubility and bioavailability</li> </ul> 2016-02-16 2026-07-29 2017-11-20 2026-07-29 2023-04-06 False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-11-20 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163907 Newman, Amy NIH - NIDA NIDA Newman, Amy (NIDA) 1 147163909 Grundt, Peter NIH - NIDA NIDA Grundt, Peter (NIDA) 2 147163910 Cao, Jianjing NIH - NIDA NIDA Cao, Jianjing (NIDA) 3 147163908 Luedtke, Robert University of North Texas Health Science Center Luedtke, Robert 4 147163911 Cyriac, George NIH - NIDA Cyriac, George 5 147163907 Newman, Amy NIH - NIDA NIDA Newman, Amy (NIDA) 1 147163909 Grundt, Peter NIH - NIDA NIDA Grundt, Peter (NIDA) 2 147163910 Cao, Jianjing NIH - NIDA NIDA Cao, Jianjing (NIDA) 3 147163908 Luedtke, Robert University of North Texas Health Science Center Luedtke, Robert 4 147163911 Cyriac, George NIH - NIDA Cyriac, George 5 147158037 4-Phenylpiperazine Derivatives With Functionalized Linkers As Dopamine D3 Receptor Selective Ligands With Drug Abuse Therapeutic Potential E-128-2006-0 Filing authorized National Institute on Drug Abuse (NIDA), University of North Texas Health Science Center 83737255 Baxter, Merissa merissa.baxter@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4205] Novel Dopamine Receptor Ligands As Therapeutics For Central Nervous System Disorders&body=Please send me information about technology [TAB-4205] Novel Dopamine Receptor Ligands As Therapeutics For Central Nervous System Disorders.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Baxter, Merissa<br><a href="mailto:merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4205] Novel Dopamine Receptor Ligands As Therapeutics For Central Nervous System Disorders&body=Please send me information about technology [TAB-4205] Novel Dopamine Receptor Ligands As Therapeutics For Central Nervous System Disorders.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">merissa.baxter@nih.gov</a><br> 147167344 E-128-2006-0 E-128-2006-0-PCT-01 4-Phenylpiperazine Derivatives With Functionalized Linkers as Dopamine D3 Receptor Selective Ligands and Methods Of Use PCT Patent Cooperation Treaty PCT/US2007/071412 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2007/071412<br />Filed on 2007-06-15<br />Status: Expired 147167345 E-128-2006-0 E-128-2006-0-US-02 4-Phenylpiperazine Derivatives With Functionalized Linkers As Dopamine D3 Receptor Selective Ligands And Methods of Use National Stage US 8,748,608 12/664,668 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8748608 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8748608">8,748,608</a><br />Filed on 2010-06-25<br />Status: Issued 147167346 E-128-2006-0 E-128-2006-0-AU-03 4-Phenylpiperazine Derivatives With Functionalized Linkers as Dopamine D3 Receptor Selective Ligands and Methods Of Use National Stage Australia 2007354861 2007354861 Issued Australia <br />National Stage 2007354861<br />Filed on 2007-06-15<br />Status: Issued 147167347 E-128-2006-0 E-128-2006-0-CA-04 4-Phenylpiperazine Derivatives With Functionalized Linkers as Dopamine D3 Receptor Selective Ligands and Methods Of Use National Stage Canada 2690789 2690789 Issued Canada <br />National Stage 2690789<br />Filed on 2012-03-20<br />Status: Issued 147167348 E-128-2006-0 E-128-2006-0-US-05 4-Phenylpiperazine Derivatives With Functionalized Linkers As Dopamine D3 Receptor Selective Ligands And Methods of Use DIV US 14/266,076 Abandoned US <br />Divisional (DIV) 14/266,076<br />Filed on 2014-04-30<br />Status: Abandoned TAB-4403 147157698 Novel Chemoattractant-Based Toxins To Improve Vaccine Immune Responses for Cancer and Infectious Diseases NIA Immunology, Licensing, Oncology, Therapeutics Immunology Licensing Oncology Therapeutics Bira Arya, Dolgor Bataar, Kouji Matsushima <h2>Description of Technology:</h2> <p>Cancer is one of the leading causes of death in United States and it is estimated that there will be more than half a million deaths caused by cancer in 2009.&nbsp; A major drawback of the current chemotherapy-based therapeutics is the cytotoxic side-effects associated with them.&nbsp; Thus there is a dire need to develop new therapeutic strategies with fewer side-effects.&nbsp; Immunotherapy has taken a lead among the new therapeutic approaches.&nbsp; Enhancing the innate immune response of an individual has been a key approach for the treatment against different diseases such as cancer and infectious diseases.</p> <p>This technology involves the generation of novel chemoattractant toxins that deplete the T regulatory cells (Treg) or other immunosuppressive or hyperactivated cells locally.&nbsp; Treg controls activation of immune responses by suppressing the induction of adaptive immune responses, particularly T cell responses.&nbsp; Immunosuppressive cells such as tumor infiltrating macrophages, regulatory T cells, regulatory B cells, or NKT and other cells down regulate antitumor immune responses.&nbsp; The chemoattractant toxins consist of a toxin moiety fused with a chemokine receptor ligand, such as chemokines and various chemoattractants, that enables specific targeting and delivery to the regulatory cells. This technology is advantageous over the more harmful antibodies and chemicals that are currently used for the systemic depletion of regulatory cells.&nbsp; The current technology can be used therapeutically in a variety of ways.&nbsp; They can be used together with vaccines to increase efficacy of the vaccine for the treatment of cancer, and can be used to locally deplete Treg, Bregs, or other immuno suppressive cells to induce cytolytic cell responses at the tumor site or to eliminate chronic infectious diseases such as HIV and tuberculosis.</p> <p>Development Status:&nbsp;<br /> The technology is currently in the pre-clinical stage of development.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>New chemoattractant-based toxins targeted towards Treg cells.</li> <li>New chemoattractant-based toxins targeted towards immunosuppressive B cells, NKT and macrophages.</li> <li>New chemoattractant based toxins targeted towards local depletion of hyperactivated CD4 T cells to treat autoimmune diseases.</li> <li>Chemoattractant-based toxins depleting Treg cells or other immunosuppressive cells causing enhanced vaccine immune responses.</li> <li>Novel immunotherapy by increasing vaccine efficacy against cancer and infectious diseases.</li> </ul> 2016-02-16 2026-07-29 2017-11-20 2026-07-29 2023-04-06 AIDS/HIV, Chemoattractant toxins, Immune Diseases, immunosuppressant, T regulatory (Treg) cells, TUBERCULOSIS False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-11-20 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162023 R Schiavo et al. Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses. Blood 2006 Jun 15; 107(12):4597-4605. http://www.ncbi.nlm.nih.gov/pubmed/16514063?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/16514063?dopt">R Schiavo et al. Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses. Blood 2006 Jun 15; 107(12):4597-4605.</a> 147162062 D Baatar, P Olkhanud, D Newton, K Sumitomo, A Biragyn. CCR4-expressing T cell tumors can be specifically controlled via delivery of toxins to chemokine receptors. J Immunol. 2007 Aug 1;179(3):1996-2004. http://www.ncbi.nlm.nih.gov/pubmed/17641067?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/17641067?dopt">D Baatar, P Olkhanud, D Newton, K Sumitomo, A Biragyn. CCR4-expressing T cell tumors can be specifically controlled via delivery of toxins to chemokine receptors. J Immunol. 2007 Aug 1;179(3):1996-2004.</a> 147162140 M Coscia, A Biragyn. Cancer immunotherapy with chemoattractant peptides. Semin Cancer Biol. 2004 Jun; 14(3):209-218. http://www.ncbi.nlm.nih.gov/pubmed/15246057?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/15246057?dopt">M Coscia, A Biragyn. Cancer immunotherapy with chemoattractant peptides. Semin Cancer Biol. 2004 Jun; 14(3):209-218.</a> 147162179 D Baatar, P Olkhanud, K Sumitomo, D Taub, R Gress, A Biragyn. Human peripheral blood T regulatory cells (Tregs), functionally primed CCR4+ Tregs and unprimed CCR4- Tregs, regulate effector T cells using FasL. J Immunol. 2007 Apr 15;178(8):4891-4900. http://www.ncbi.nlm.nih.gov/pubmed/17404270?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/17404270?dopt">D Baatar, P Olkhanud, K Sumitomo, D Taub, R Gress, A Biragyn. Human peripheral blood T regulatory cells (Tregs), functionally primed CCR4+ Tregs and unprimed CCR4- Tregs, regulate effector T cells using FasL. J Immunol. 2007 Apr 15;178(8):4891-4900.</a> 147164607 Arya, Bira NIH - NIA NIA Arya, Bira (NIA) 1 147164606 Matsushima, Kouji University of Tokyo Matsushima, Kouji 2 147164608 Bataar, Dolgor NIH - NIA NIA Bataar, Dolgor (NIA) 3 147164607 Arya, Bira NIH - NIA NIA Arya, Bira (NIA) 1 147164606 Matsushima, Kouji University of Tokyo Matsushima, Kouji 2 147164608 Bataar, Dolgor NIH - NIA NIA Bataar, Dolgor (NIA) 3 147157819 Chemoattractant-based Toxins Which Deplete T Regulatory Cells To Improve Vaccine Immune Responses For Cancer And Other Clinically Relevant Diseases E-027-2005-0 Filing authorized National Institute on Aging (NIH/NIA), University of Tokyo 91789173 Guyton, Nicole darackn@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America darackn@mail.nih.gov?subject=Web Inquiry on [TAB-4403] Novel Chemoattractant-Based Toxins To Improve Vaccine Immune Responses for Cancer and Infectious Diseases&body=Please send me information about technology [TAB-4403] Novel Chemoattractant-Based Toxins To Improve Vaccine Immune Responses for Cancer and Infectious Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Guyton, Nicole<br><a href="mailto:darackn@mail.nih.gov?subject=Web Inquiry on [TAB-4403] Novel Chemoattractant-Based Toxins To Improve Vaccine Immune Responses for Cancer and Infectious Diseases&body=Please send me information about technology [TAB-4403] Novel Chemoattractant-Based Toxins To Improve Vaccine Immune Responses for Cancer and Infectious Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">darackn@mail.nih.gov</a><br> 147168726 E-027-2005-0 E-027-2005-0-US-01 METHODS AND COMPOSITIONS FOR MODULATING IMMUNE TOLERANCE PRV US 60/722,675 Abandoned US <br />Provisional (PRV) 60/722,675<br />Filed on 2005-09-30<br />Status: Abandoned 147168727 E-027-2005-0 E-027-2005-0-PCT-02 Chemoattractant-based Toxins Which Deplete T Regulatory Cells To Improve Vaccine Immune Responses For Cancer And Other Clinically Relevant Diseases PCT Patent Cooperation Treaty PCT/US2006/038195 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/038195<br />Filed on 2006-09-28<br />Status: Expired 147168728 E-027-2005-0 E-027-2005-0-AU-03 Chemoattractant-based Toxins Which Deplete T Regulatory Cells To Improve Vaccine Immune Responses For Cancer And Other Clinically Relevant Diseases National Stage Australia 2006297126 Abandoned Australia <br />National Stage 2006297126<br />Filed on 2006-09-28<br />Status: Abandoned 147168729 E-027-2005-0 E-027-2005-0-CA-04 Chemoattractant-based Toxins Which Deplete T Regulatory Cells To Improve Vaccine Immune Responses For Cancer And Other Clinically Relevant Diseases National Stage Canada 2624662 Abandoned Canada <br />National Stage 2624662<br />Filed on 2006-09-28<br />Status: Abandoned 147168730 E-027-2005-0 E-027-2005-0-EP-05 Chemoattractant-based Toxins Which Deplete T Regulatory Cells To Improve Vaccine Immune Responses For Cancer And Other Clinically Relevant Diseases National Stage European Patent 06825277.4 Abandoned European Patent <br />National Stage 06825277.4<br />Filed on 2006-09-28<br />Status: Abandoned 147168731 E-027-2005-0 E-027-2005-0-US-06 METHODS AND COMPOSITIONS FOR MODULATING IMMUNE TOLERANCE National Stage US 8,795,674 11/992,880 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8795674 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8795674">8,795,674</a><br />Filed on 2008-03-28<br />Status: Issued 147168732 E-027-2005-0 E-027-2005-0-EP-07 Chemoattractant-based Toxins Which Deplete T Regulatory Cells To Improve Vaccine Immune Responses For Cancer And Other Clinically Relevant Diseases DIV European Patent 6825277.4 Administratively Closed European Patent <br />Divisional (DIV) 6825277.4<br />Filed on 2006-09-28<br />Status: Administratively Closed 147168733 E-027-2005-0 E-027-2005-0-US-08 Methods and Compositions for Modulating Immune Tolerance DIV US 9,605,044 14/313,481 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9605044 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9605044">9,605,044</a><br />Filed on 2014-06-24<br />Status: Issued 147168734 E-027-2005-0 E-027-2005-0-US-09 Methods and Compositions for Modulating Immune Tolerance DIV US 10,300,115 15/404,189 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10300115 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10300115">10,300,115</a><br />Filed on 2017-01-11<br />Status: Issued 147169754 AIDS/HIV 147169756 Chemoattractant toxins 147169758 Immune Diseases 147169759 immunosuppressant 147169761 T regulatory (Treg) cells 147169762 TUBERCULOSIS TAB-4110 147157392 RP2 and RPGR Vectors For Treating X-linked Retinitis Pigmentosa NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Therapeutics Collaboration Ear Nose & Throat Licensing Ophthalmology Therapeutics Suja Hiriyanna, Tiansen Li, Suddhasil Mookherjee, Anand Swaroop, Zhijian Wu <p>X-linked forms of retinitis pigmentosa (XLRP) are relatively severe blinding disorders, resulting from progressive photoreceptor dysfunction primarily caused by mutations in RPGR or RP2 gene.</p> <p>This technology is poised to advance RPGR or RP2 gene therapy to clinical stage using AAV8 or AAV9 vector carrying human full-length RPGR or RP2-coding sequence.  The investigators have performed a wide dose range study over 18-months and found it to preserve rod and/or cone function as evidenced by ERG and/or OCT, optomotor tests. Morphologically, the treatment preserved rod and cone viability, and corrected mistrafficking of cone opsin and/or rhodopsin. The therapeutic effect was also achieved in advanced disease stage. The broad treatment window and long-lasting therapeutic effects make the RPGR and RP2 gene therapy attractive for clinical development.</p> <p>This technology is available for licensing, or the NEI research team will entertain potential collaborations that will advance this technology through the remaining preclinical stage toward IND development under a CRADA or a license combined with a CRADA project.</p> <blockquote><p><em>This patented treatment of albinism has not been approved by the U.S. Food and Drug Administration (FDA), and currently there is no active clinical trial to assess this albinism therapy benefit. However, if you are interested in participating in a future or upcoming NIH clinical trial on albinism, please contact NIH clinical coordinator, Ms. Ellaine Galindez-Balut (<a href="mailto:ellaine.galindez-balut@nih.gov">ellaine.galindez-balut@nih.gov</a>), for helpful information. Thank you.</em></p> </blockquote> <h2>Competitive Advantages:</h2> <ul><li>Pre-clinical dose efficacy study done </li> <li>RPGR and RP2 available in both AAV-8 and AAV-9 vectors. </li> <li>Preclinical data to show that treatment at advanced age also shows remarkable preservation of retinal structure and function.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Use in gene therapy to prevent or cure XLRP</li> <li>Preserving cone and/or rod function, restoring ERG and protein in the retina, increasing photoreceptor numbers, decrease in retinal detachments </li> <li>Improving quality of life, visual acuity, ability to drive and independent living</li> </ul> 2018-06-01 2025-05-15 2018-06-01 2026-07-27 2018-06-01 GENE THERAPY, hereditary ocular disease, Pigmentosa, Retina, Wu False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-06-01 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-162-2016 E-164-2014 147162027 Wu Z, et al. A long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration https://www.ncbi.nlm.nih.gov/pubmed/25877300 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25877300">Wu Z, et al. A long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration</a> 147162066 Zhang H, et al. Mistrafficking of prenylated proteins causes retinitis pigmentosa 2. https://www.ncbi.nlm.nih.gov/pubmed/25422369 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25422369">Zhang H, et al. Mistrafficking of prenylated proteins causes retinitis pigmentosa 2.</a> 147162105 Li L, et al. Ablation of the X-linked retinitis pigmentosa 2 (Rp2) gene in mice results in opsin mislocalization and photoreceptor degeneration https://www.ncbi.nlm.nih.gov/pubmed/23745007 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23745007">Li L, et al. Ablation of the X-linked retinitis pigmentosa 2 (Rp2) gene in mice results in opsin mislocalization and photoreceptor degeneration</a> 147162183 Mookherjee S, et al. Long-term rescue of cone photoreceptor degeneration in retinitis pigmentosa 2 (RP2)-knockout mice by gene replacement therapy https://www.ncbi.nlm.nih.gov/pubmed/26358772 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26358772">Mookherjee S, et al. Long-term rescue of cone photoreceptor degeneration in retinitis pigmentosa 2 (RP2)-knockout mice by gene replacement therapy</a> 147163543 Wu, Zhijian NIH - NEI NEI Wu, Zhijian (NEI) 1 147163540 Swaroop, Anand NIH - NEI NEI Swaroop, Anand (NEI) 2 147163544 Mookherjee, Suddhasil National Eye Institute (NEI) NEI Mookherjee, Suddhasil (NEI) 3 147163542 Hiriyanna, Suja NIH - NEI NEI Hiriyanna, Suja (NEI) 4 147163541 Li, Tiansen NIH - NEI NEI Li, Tiansen (NEI) 5 147163543 Wu, Zhijian NIH - NEI NEI Wu, Zhijian (NEI) 1 147163540 Swaroop, Anand NIH - NEI NEI Swaroop, Anand (NEI) 2 147163544 Mookherjee, Suddhasil National Eye Institute (NEI) NEI Mookherjee, Suddhasil (NEI) 3 147163542 Hiriyanna, Suja NIH - NEI NEI Hiriyanna, Suja (NEI) 4 147163541 Li, Tiansen NIH - NEI NEI Li, Tiansen (NEI) 5 147157871 Novel Gene Therapy Vectors For Treating X-linked Retinitis Pigmentosa Caused Bymutations In RPGR And/or RP2 Genes E-050-2015-0 Filing authorized National Eye Institute (NEI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4110] RP2 and RPGR Vectors For Treating X-linked Retinitis Pigmentosa&body=Please send me information about technology [TAB-4110] RP2 and RPGR Vectors For Treating X-linked Retinitis Pigmentosa.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4110] RP2 and RPGR Vectors For Treating X-linked Retinitis Pigmentosa&body=Please send me information about technology [TAB-4110] RP2 and RPGR Vectors For Treating X-linked Retinitis Pigmentosa.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147166581 E-050-2015-0 E-050-2015-0-US-01 RP2 and RPGR Vectors For Treating X-linked Retinitis Pigmentosa PRV US 62/131,661 Abandoned US <br />Provisional (PRV) 62/131,661<br />Filed on 2015-03-11<br />Status: Abandoned 147166583 E-050-2015-0 E-050-2015-0-PCT-03 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa PCT Patent Cooperation Treaty PCT/US2016/022072 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/022072<br />Filed on 2016-03-11<br />Status: Expired 147166584 E-050-2015-0 E-050-2015-0-AU-04 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa National Stage Australia 2016228751 2016228751 Issued Australia <br />National Stage 2016228751<br />Filed on 2016-03-11<br />Status: Issued 147166585 E-050-2015-0 E-050-2015-0-CA-05 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa National Stage Canada 2979229 Pending Canada <br />National Stage 2979229<br />Filed on 2016-03-11<br />Status: Pending 147166586 E-050-2015-0 E-050-2015-0-EP-06 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa National Stage European Patent 3268481 16762623.3 Issued European Patent <br />National Stage 16762623.3<br />Filed on 2017-10-11<br />Status: Issued 147166587 E-050-2015-0 E-050-2015-0-JP-07 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa National Stage Japan 6935049 2017-547425 Issued Japan <br />National Stage 2017-547425<br />Filed on 2017-09-08<br />Status: Issued 147166588 E-050-2015-0 E-050-2015-0-US-08 RP2 AND RPGR VECTORS FOR TREATING X-LINKED RETINITIS PIGMENTOSA National Stage US 10,646,588 15/556,746 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10646588 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10646588">10,646,588</a><br />Filed on 2017-09-08<br />Status: Issued 147166589 E-050-2015-0 E-050-2015-0-US-09 RP2 AND RPGR VECTORS FOR TREATING X-LINKED RETINITIS PIGMENTOSA DIV US 11,617,801 16/854,605 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11617801 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11617801">11,617,801</a><br />Filed on 2020-04-21<br />Status: Issued 147166590 E-050-2015-0 E-050-2015-0-DE-10 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa EP Germany 3268481 16762623.3 Issued Germany <br />European patent (EP) 16762623.3<br />Filed on 2017-10-11<br />Status: Issued 147166591 E-050-2015-0 E-050-2015-0-FR-11 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa EP France 3268481 16762623.3 Issued France <br />European patent (EP) 16762623.3<br />Filed on 2017-10-11<br />Status: Issued 147166592 E-050-2015-0 E-050-2015-0-GB-12 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa EP United Kingdom 3268481 16762623.3 Issued United Kingdom <br />European patent (EP) 16762623.3<br />Filed on 2017-10-11<br />Status: Issued 147166593 E-050-2015-0 E-050-2015-0-EP-13 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa DIV European Patent 3719134 20176667.2 Issued European Patent <br />Divisional (DIV) 20176667.2<br />Filed on 2020-05-26<br />Status: Issued 147166594 E-050-2015-0 E-050-2015-0-JP-14 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa DIV Japan 2020-167984 Abandoned Japan <br />Divisional (DIV) 2020-167984<br />Filed on 2020-10-02<br />Status: Abandoned 164118779 E-050-2015-0 E-050-2015-0-FR-14 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa EP France 3719134 20176667.2 Issued France <br />European patent (EP) 20176667.2<br />Filed on 2020-05-26<br />Status: Issued 164118780 E-050-2015-0 E-050-2015-0-IT-15 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa EP Italy 3719134 20176667.2 Issued Italy <br />European patent (EP) 20176667.2<br />Filed on 2020-05-26<br />Status: Issued 164118781 E-050-2015-0 E-050-2015-0-DE-16 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa EP Germany 3719134 20176667.2 Issued Germany <br />European patent (EP) 20176667.2<br />Filed on 2020-05-26<br />Status: Issued 164118782 E-050-2015-0 E-050-2015-0-GB-17 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa EP United Kingdom 3719134 20176667.2 Issued United Kingdom <br />European patent (EP) 20176667.2<br />Filed on 2020-05-26<br />Status: Issued 168372670 E-050-2015-0 E-050-2015-0-CA-01 RPGR VECTORS FOR TREATING X-LINKED RETINITIS PIGMENTOSA DIV Canada 3321359 Pending Canada <br />Divisional (DIV) 3321359<br />Filed on 2026-08-18<br />Status: Pending 147170314 GENE THERAPY 147170316 hereditary ocular disease 147170317 Pigmentosa 147170318 Retina 147170320 Wu TAB-5138 168368107 Replication-Competent VSV–BDBV Vaccine for Rapid Prevention and Post- Exposure Protection Against Bundibugyo Virus NIAID Antibodies, Collaboration, Infectious Disease, Licensing, Materials Available, Vaccines, Virus/Bacteria Antibodies Collaboration Infectious Disease Licensing Materials Available Vaccines Virus/Bacteria Heinrich (Heinz) Feldmann, Andrea Marzi <p>Bundibugyo virus (BDBV) is one of several ebolaviruses that cause Ebola virus disease (EVD). Sporadic outbreaks continue to occur in Central Africa, highlighting the need for effective vaccines that provide rapid protection.</p> <p>Researchers at NIAID&rsquo;s Laboratory of Virology developed a vaccine against BDBV using vesicular stomatitis virus (VSV) to carry the BDBV surface glycoprotein (GP), a key target of the immune response, to BDBV. The team also created the DNA plasmid pATX&ndash; VSVDG&ndash;BDBV GP, a circular DNA molecule used to produce the vaccine virus in cell culture. Subsequent laboratory studies confirmed that the vaccine could be produced in cells and express the BDBV glycoprotein as intended. This design stimulates both early immune defenses and longer- lasting immune responses against BDBV. The BDBV glycoprotein may also facilitate delivery of the vaccine to antigen-presenting cells, including monocytes, macrophages, and dendritic cells, which play a central role in initiating antiviral immune responses.</p> <p>In nonhuman primate studies, a single intramuscular dose of the vaccine protected animals from disease within 3 days of vaccination, supporting further development of the vaccine for rapid protection and post-exposure use. The licensable materials include both the recombinant rVSV&ndash;BDBV vaccine and the corresponding DNA plasmid to support further development, manufacturing, and outbreak response.</p> <p>This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.&nbsp;</p> <ul> <li>VSV vectors replicate transiently, producing rapid strong innate immune activation and early antibody responses. Recent nonhuman primate studies showed complete protection within 3 days after a single vaccination, which is exceptionally rapid for an Ebola vaccine platform.</li> <li>Proven viral platform built on the same rVSV technology as the licensed Ebola vaccine Ervebo, providing clinical and regulatory familiarity. </li> <li>Designed to provide rapid protection with a single intramuscular dose, simplifying use during outbreak response.</li> <li>May stimulate both early immune defenses and longer-lasting immune responses against BDBV.</li> <li>Ideal for ring vaccinations by supporting rapid immunization of contacts and contacts-of-contacts to help contain outbreaks.</li> <li>Includes the BDBV glycoprotein, which may direct the vaccine to immune cells like monocytes, macrophages, and dendritic cells involved in activating antiviral responses.</li> <li>Available for licensing as both the recombinant rVSV–BDBV vaccine and the DNA plasmid construct used to produce it.</li> </ul> <ul> <li>Leverages existing rVSV platforms, potentially reducing development and scale-up risk in manufacturing. </li> <li> Emergency vaccination programs, including vaccination of close contacts and surrounding communities during BDBV outbreaks.</li> <li>Pre-exposure vaccination for healthcare workers, laboratory personnel, outbreak-response teams, and others at increased risk of BDBV exposure.</li> <li>Post-exposure use and related development programs for BDBV and other filovirus countermeasures. </li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Terrence Joyce at 301–761– 7235, or terrence.joyce@nih.gov. 2026-07-27 2026-07-27 2026-07-27 2026-07-24 False False Preclinical Research True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 168369591 O’Donnell, KL, et al., "A single-dose Bundibugyo virus vaccine protects macaques within 3 days", bioRxiv. Published online June 15, 2026. doi:10.64898/2026.06.14.732188. O’Donnell, KL, et al., "A single-dose Bundibugyo virus vaccine protects macaques within 3 days", bioRxiv. Published online June 15, 2026. doi:10.64898/2026.06.14.732188. 168370976 91 Fed. Reg. 46,793 (July 24, 2026) 91 Fed. Reg. 46,793 (July 24, 2026) 168368321 Marzi, Andrea NIAID - DIR NIAID Marzi, Andrea (NIAID) 1 168368449 Feldmann, Heinrich (Heinz) NIAID - DIR NIAID Feldmann, Heinrich (Heinz) (NIAID) 2 168368321 Marzi, Andrea NIAID - DIR NIAID Marzi, Andrea (NIAID) 1 168368449 Feldmann, Heinrich (Heinz) NIAID - DIR NIAID Feldmann, Heinrich (Heinz) (NIAID) 2 168368110 Vesicular stomatitis virus-based vaccine against Bundibugyo virus (VSV-BDBV) E-122-2026-0 Research Material National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID - DIR, RML 146046171 Joyce, Terrence terrence.joyce@nih.gov
United States of America terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-5138] Replication-Competent VSV–BDBV Vaccine for Rapid Prevention and Post- Exposure Protection Against Bundibugyo Virus&body=Please send me information about technology [TAB-5138] Replication-Competent VSV–BDBV Vaccine for Rapid Prevention and Post- Exposure Protection Against Bundibugyo Virus. Joyce, Terrence<br><a href="mailto:terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-5138] Replication-Competent VSV–BDBV Vaccine for Rapid Prevention and Post- Exposure Protection Against Bundibugyo Virus&body=Please send me information about technology [TAB-5138] Replication-Competent VSV–BDBV Vaccine for Rapid Prevention and Post- Exposure Protection Against Bundibugyo Virus.">terrence.joyce@nih.gov</a><br> TAB-5096 166779508 48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio CDC Collaboration Sought, Diagnostics, Endocrinology, Geriatrics, Hematology, Obstetrics/Neo-Natal, Reproductive Health, Research Materials, TherapeuticArea, Urology Collaboration Sought Diagnostics Endocrinology Geriatrics Hematology Obstetrics/Neo-Natal Reproductive Health Research Materials TherapeuticArea Urology Ashley Ribera, Hubert Vesper, Hui Zhou <p>CDC scientists have developed a new design for a multi-well dialysis microplate for equilibrium dialysis. The unique design accommodates a 1:1 buffer to sample ratio and provides additional room at the base of the well to enable optimal cartridge immersion and analyte diffusion. The microplate is readily adaptable into existing automated analytical systems and meets the criteria of American National Standards Institute (ANSI). The microplate is designed for measuring blood or other biological fluid samples over a wide range of sample volumes and may be used in a high throughput manner. Use of the microplate has been shown to reduce errors, while increasing accuracy, precision, and sensitivity.</p> <p>&nbsp;Thus far, the microplate has been successfully used for free testosterone measurement. The microplate may also be used for measuring other analytes and has the potential to be used in both clinical and research settings.&nbsp;&nbsp;</p> <ul> <li> Diagnostics: Dialysis microplate for measuring free hormone analytes such as free testosterone, free thyroxine (FT4), triiodothyronine, as well as measuring unbound drugs such as dolutegravir in diagnostic or research settings. </li> <li> Public Health: Use of the dialysis microplate to provide dialysis testing services for customers. </li> </ul> <ul> <li> Diagnostics: Meets the criteria of American National Standards Institute (ANSI). </li> <li> Research Materials. </li> </ul> The CDC-NICHD is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the multi-well dialysis microplate. For collaboration opportunities, please contact: Madhavi Sriram nxu2@cdc.gov; TTO@cdc.gov. 2026-04-08 2026-06-17 2026-07-22 2026-04-10 False False Clinical Assay Development Stage True 72159134 Analytical Assay Performance Stage 72159134 37470483 Website Abstract 166779738 Ribera, Ashley Battelle Memorial Institute CDC Ribera, Ashley (CDC) 1 166779783 Zhou, Hui CDC - DIR CDC Zhou, Hui (CDC) 2 166779790 Vesper, Hubert CDC - DIR CDC Vesper, Hubert (CDC) 3 166779738 Ribera, Ashley Battelle Memorial Institute CDC Ribera, Ashley (CDC) 1 166779783 Zhou, Hui CDC - DIR CDC Zhou, Hui (CDC) 2 166779790 Vesper, Hubert CDC - DIR CDC Vesper, Hubert (CDC) 3 166779511 48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio E-101-2023-0 Filing authorized CDC - DIR 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-5096] 48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio&body=Please send me information about technology [TAB-5096] 48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-5096] 48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio&body=Please send me information about technology [TAB-5096] 48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio.">dawn.taylor-mulneix@nih.gov</a><br> 166779516 E-101-2023-0 E-101-2023-0-US-01 MULTI-WELL DIALYSIS MICROPLATE PRV US 63/551,965 Expired US <br />Provisional (PRV) 63/551,965<br />Filed on 2024-02-09<br />Status: Expired 166779517 E-101-2023-0 E-101-2023-0-PC-01 MULTI-WELL DIALYSIS MICROPLATE PCT Patent Cooperation Treaty PCT/US2025/014980 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2025/014980<br />Filed on 2025-02-07<br />Status: Expired 168322715 E-101-2023-0 E-101-2023-0-US-02 MULTI-WELL DIALYSIS MICROPLATE National Stage US 19/613,944 Pending US <br />National Stage 19/613,944<br />Filed on 2026-08-10<br />Status: Pending TAB-5034 159362020 Next generation MRI platform Signal Amplification by Reversible Exchange (SABRE) hyperpolarization NHLBI Murali Cherukuri, Jessica Ettedgui-Benjamini, Rolf Swenson <p>Hyperpolarized magnetic resonance imaging (MRI) is an emerging molecular imaging method for metabolic imaging for detecting cancer, cardiovascular disease, stroke, and traumatic brain injury and monitoring therapy with no Gadolinium or Iron. Available for licensing and commercial development is a patent estate covering a perfluorinated single amplification by reversible exchange (SABRE) catalyst for generating MRI agents that includes a d-block element and a perfluorinated ligand hyperpolarized substrate comprising a 1/2 spin nucleus or nuclei using the perfluorinated SABRE catalysts, and isolating the resulting hyperpolarized substrate for administration. The invention also provides methods for separating a hyperpolarized substrate from the SABRE catalyst and/or hyperpolarized SABRE catalyst complex containing a heavy metal. These changes can be observed in patients in real time with a specialized MRI approach called hyperpolarization. By transiently changing the nuclear spin of naturally occurring intermediates in cellular energy production, the metabolic fate can be observed with greater than 10,000-fold sensitivity. Current methods of hyperpolarization require expensive machines with limited throughput.</p> <ul> <li>High Sensitivity: Over 10,000-fold sensitivity improvement.</li> <li>Cost Efficiency: Avoids expensive hyperpolarization machines.</li> <li>Metal-Free Imaging: No gadolinium or iron required.</li> <li>Real-Time Monitoring: Enables immediate observation of metabolic changes.</li> </ul> <ul> <li>MRI imaging</li> <li>Hyperpolarization</li> <li>Infusion Device for imaging reagents</li> <li>Cancer diagnostics</li> <li>Cardiovascular disease diagnostics</li> </ul> 2024-11-27 2025-08-19 2026-07-17 2024-12-03 False False True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 159422126 Ettedgui J, 2024 https://pubmed.ncbi.nlm.nih.gov/38154120/ <a href="https://pubmed.ncbi.nlm.nih.gov/38154120/">Ettedgui J, 2024</a> 159422129 Hong D, 2023 https://pubmed.ncbi.nlm.nih.gov/38024238/ <a href="https://pubmed.ncbi.nlm.nih.gov/38024238/">Hong D, 2023</a> 159422144 Schmidt AB, 2022 https://pubmed.ncbi.nlm.nih.gov/36379005/ <a href="https://pubmed.ncbi.nlm.nih.gov/36379005/">Schmidt AB, 2022</a> 159422158 Adelabu I, 2022 https://pubmed.ncbi.nlm.nih.gov/36136056/ <a href="https://pubmed.ncbi.nlm.nih.gov/36136056/">Adelabu I, 2022</a> 159422206 Adelabu I, 2022 https://pubmed.ncbi.nlm.nih.gov/34813142/ <a href="https://pubmed.ncbi.nlm.nih.gov/34813142/">Adelabu I, 2022</a> 159422221 AbuSalim JE, 2021 https://pubmed.ncbi.nlm.nih.gov/34554724/ <a href="https://pubmed.ncbi.nlm.nih.gov/34554724/">AbuSalim JE, 2021</a> 159422229 Miura N, 2021 https://pubmed.ncbi.nlm.nih.gov/34263489/ <a href="https://pubmed.ncbi.nlm.nih.gov/34263489/">Miura N, 2021</a> 159422271 Chapman B, 2021 https://pubmed.ncbi.nlm.nih.gov/34102835/ <a href="https://pubmed.ncbi.nlm.nih.gov/34102835/">Chapman B, 2021</a> 159422274 Yamamoto K, 2021 https://pubmed.ncbi.nlm.nih.gov/34108512/ <a href="https://pubmed.ncbi.nlm.nih.gov/34108512/">Yamamoto K, 2021</a> 159422074 Ettedgui-Benjamini, Jessica National Heart, Lung, and Blood Institute (NHLBI) NHLBI Ettedgui-Benjamini, Jessica (NHLBI) 1 159422090 Swenson, Rolf NHLBI Swenson, Rolf (NHLBI) 2 159422096 Cherukuri, Murali NCI Cherukuri, Murali (NCI) 3 159422074 Ettedgui-Benjamini, Jessica National Heart, Lung, and Blood Institute (NHLBI) NHLBI Ettedgui-Benjamini, Jessica (NHLBI) 1 159422090 Swenson, Rolf NHLBI Swenson, Rolf (NHLBI) 2 159422096 Cherukuri, Murali NCI Cherukuri, Murali (NCI) 3 159362025 Synthesis Of Iridium SABRE Catalysts Containing Heavy Perfluorinated Carbon Chains For Its Facile Removal And Delivery Of Metal-free Hyperpolarized Contrast Agents Such As Pyruvate E-036-2022-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NCI 159362038 Preparation Of Deuterated 12C, 13C-ketoglutarate (1-13C-3-D2-4-D-512C Ketoglutarate) And Methods To Hyperpolarization Using SABRE-Signal Amplification By Reversible Exchange E-035-2022-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NCI 159362045 TEMPERATURE CYCLING METHOD FOR HYPERPOLARIZATION OF TARGET MOLECULES AND CONTRAST AGENTS USING PARAHYDROGEN E-039-2022-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 159362213 INFUSION DEVICE FOR THE USE OF HYPERPOLARIZED MRI PROBES PREPARED BY FLUOROUS CATALYZED SABRE E-052-2022-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NCI 159362336 Real-time Monitoring Of In Vivo Free Radical Scavengers Through Hyperpolarized [1-13C] N-acetyl Cysteine E-069-2020-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NCI 159362413 Isotopes Of Alpha Ketoglutarate And Related Compounds For Hyperpolarized MRI Imaging E-070-2020-0 Filing authorized National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Heart, Lung, and Blood Institute (NHLBI), Radiation Biology Branch 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-5034] Next generation MRI platform Signal Amplification by Reversible Exchange (SABRE) hyperpolarization&body=Please send me information about technology [TAB-5034] Next generation MRI platform Signal Amplification by Reversible Exchange (SABRE) hyperpolarization. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-5034] Next generation MRI platform Signal Amplification by Reversible Exchange (SABRE) hyperpolarization&body=Please send me information about technology [TAB-5034] Next generation MRI platform Signal Amplification by Reversible Exchange (SABRE) hyperpolarization.">shmilovm@nih.gov</a><br> 159362050 E-039-2022-0 E-039-2022-0-US-01 TEMPERATURE CYCLING METHOD FOR HYPERPOLARIZATION OF TARGET MOLECULES AND CONTRAST AGENTS USING PARAHYDROGEN PRV US 63/203,591 Abandoned US <br />Provisional (PRV) 63/203,591<br />Filed on 2021-07-27<br />Status: Abandoned 159362051 E-039-2022-0 E-039-2022-0-PCT-02 TEMPERATURE CYCLING METHOD FOR HYPERPOLARIZATION OF TARGET MOLECULES AND CONTRAST AGENTS USING PARAHYDROGEN PCT Patent Cooperation Treaty PCT/US2022/074122 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/074122<br />Filed on 2022-07-26<br />Status: Expired 159362052 E-039-2022-0 E-039-2022-0-US-02 TEMPERATURE CYCLING METHOD FOR HYPERPOLARIZATION OF TARGET MOLECULES AND CONTRAST AGENTS USING PARAHYDROGEN National Stage US 12,566,228 18/291,681 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12566228 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12566228">12,566,228</a><br />Filed on 2024-01-24<br />Status: Issued 159362079 E-035-2022-0 E-035-2022-0-US-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) PRV US 63/303,190 Expired US <br />Provisional (PRV) 63/303,190<br />Filed on 2022-01-26<br />Status: Expired 159362080 E-035-2022-0 E-035-2022-0-PCT-02 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) PCT Patent Cooperation Treaty PCT/US2023/011640 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/011640<br />Filed on 2023-01-26<br />Status: Expired 159362081 E-035-2022-0 E-035-2022-0-JP-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) National Stage Japan 2024-544466 Abandoned Japan <br />National Stage 2024-544466<br />Filed on 2024-07-25<br />Status: Abandoned 159362082 E-035-2022-0 E-035-2022-0-CA-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) National Stage Canada 3243219 Pending Canada <br />National Stage 3243219<br />Filed on 2024-07-23<br />Status: Pending 159362083 E-035-2022-0 E-035-2022-0-IL-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) National Stage Israel 314428 Pending Israel <br />National Stage 314428<br />Filed on 2024-07-22<br />Status: Pending 159362084 E-035-2022-0 E-035-2022-0-CN-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) National Stage China 202380026889.8 Abandoned China <br />National Stage 202380026889.8<br />Filed on 2024-09-11<br />Status: Abandoned 159362085 E-035-2022-0 E-035-2022-0-US-02 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) National Stage US 18/833,627 Pending US <br />National Stage 18/833,627<br />Filed on 2024-07-26<br />Status: Pending 159362086 E-035-2022-0 E-035-2022-0-EP-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) National Stage European Patent 23707534.6 Pending European Patent <br />National Stage 23707534.6<br />Filed on 2024-07-23<br />Status: Pending 159362087 E-035-2022-0 E-035-2022-0-HK-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) EP Hong Kong Administratively Closed Hong Kong <br />European patent (EP) None<br />Filed on None<br />Status: Administratively Closed 159362218 E-052-2022-0 E-052-2022-0-US-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES PRV US 63/328,556 Expired US <br />Provisional (PRV) 63/328,556<br />Filed on 2022-04-07<br />Status: Expired 159362219 E-052-2022-0 E-052-2022-0-PC-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES PCT Patent Cooperation Treaty PCT/US2023/017895 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/017895<br />Filed on 2023-04-07<br />Status: Expired 159362220 E-052-2022-0 E-052-2022-0-JP-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES National Stage Japan 2024-559257 Abandoned Japan <br />National Stage 2024-559257<br />Filed on 2024-10-04<br />Status: Abandoned 159362221 E-052-2022-0 E-052-2022-0-CA-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES National Stage Canada 3246953 Pending Canada <br />National Stage 3246953<br />Filed on 2024-09-26<br />Status: Pending 159362222 E-052-2022-0 E-052-2022-0-IL-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES National Stage Israel 315942 Pending Israel <br />National Stage 315942<br />Filed on 2024-09-26<br />Status: Pending 159362223 E-052-2022-0 E-052-2022-0-CN-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES National Stage China 202380040403.6 Abandoned China <br />National Stage 202380040403.6<br />Filed on 2024-11-14<br />Status: Abandoned 159362224 E-052-2022-0 E-052-2022-0-US-02 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES National Stage US 18/854,462 Pending US <br />National Stage 18/854,462<br />Filed on 2024-10-04<br />Status: Pending 159362225 E-052-2022-0 E-052-2022-0-EP-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES National Stage European Patent 23721501.7 Pending European Patent <br />National Stage 23721501.7<br />Filed on 2024-11-06<br />Status: Pending 159362341 E-069-2020-0 E-069-2020-0-US-01 REAL-TIME MONITORING OF IN VIVO FREE RADICAL SCAVENGERS THROUGH HYPERPOLARIZED N-ACETYL CYSTEINE ISOTOPES PRV US 62/961,855 Abandoned US <br />Provisional (PRV) 62/961,855<br />Filed on 2020-01-16<br />Status: Abandoned 159362342 E-069-2020-0 E-069-2020-0-PCT-02 REAL-TIME MONITORING OF IN VIVO FREE RADICAL SCAVENGERS THROUGH HYPERPOLARIZED N-ACETYL CYSTEINE ISOTOPES PCT Patent Cooperation Treaty PCT/US2021/013634 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/013634<br />Filed on 2021-01-15<br />Status: Expired 159362343 E-069-2020-0 E-069-2020-0-EP-03 REAL-TIME MONITORING OF IN VIVO FREE RADICAL SCAVENGERS THROUGH HYPERPOLARIZED N-ACETYL CYSTEINE ISOTOPES National Stage European Patent 21741034.9 Abandoned European Patent <br />National Stage 21741034.9<br />Filed on 2021-01-15<br />Status: Abandoned 159362344 E-069-2020-0 E-069-2020-0-IL-04 REAL-TIME MONITORING OF IN VIVO FREE RADICAL SCAVENGERS THROUGH HYPERPOLARIZED N-ACETYL CYSTEINE ISOTOPES National Stage Israel 294365 Abandoned Israel <br />National Stage 294365<br />Filed on 2022-06-28<br />Status: Abandoned 159362345 E-069-2020-0 E-069-2020-0-US-05 REAL-TIME MONITORING OF INVIVO FREE RADICAL SCAVENGERS THROUGH HYPERPOLARIZED N-ACETYL CYSTEINE ISOTOPES National Stage US 17/793,083 Abandoned US <br />National Stage 17/793,083<br />Filed on 2022-07-15<br />Status: Abandoned 159362418 E-070-2020-0 E-070-2020-0-US-01 Isotopes Of Alpha Ketoglutarate And Related Compounds For Hyperpolarized MRI Imaging PRV US 62/962,473 Abandoned US <br />Provisional (PRV) 62/962,473<br />Filed on 2020-01-17<br />Status: Abandoned 159362419 E-070-2020-0 E-070-2020-0-PCT-02 ISOTOPES OF ALPHA KETOGLUTARATE AND RELATED COMPOUNDS FOR HYPERPOLARIZED IMAGING PCT Patent Cooperation Treaty PCT/US2021/013658 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/013658<br />Filed on 2021-01-15<br />Status: Expired 159362420 E-070-2020-0 E-070-2020-0-EP-03 ISOTOPES OF ALPHA KETOGLUTARATE AND RELATED COMPOUNDS FOR HYPERPOLARIZED IMAGING National Stage European Patent 21741941.5 Pending European Patent <br />National Stage 21741941.5<br />Filed on 2021-01-15<br />Status: Pending 159362421 E-070-2020-0 E-070-2020-0-IL-04 ISOTOPES OF ALPHA KETOGLUTARATE AND RELATED COMPOUNDS AND THEIR USE IN HYPERPOLARIZED IMAGING National Stage Israel 294464 294464 Issued Israel <br />National Stage 294464<br />Filed on 2022-07-03<br />Status: Issued 159362422 E-070-2020-0 E-070-2020-0-US-05 ISOTOPES OF ALPHA KETOGLUTARATE AND RELATED COMPOUNDS AND THEIR USE IN HYPERPOLARIZED IMAGING National Stage US 17/793,089 Pending US <br />National Stage 17/793,089<br />Filed on 2022-07-15<br />Status: Pending 160031297 E-052-2022-0 E-052-2022-0-HK-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES CN Hong Kong 62025104551.9 Abandoned Hong Kong <br />China Patent (CN) 62025104551.9<br />Filed on 2025-03-11<br />Status: Abandoned 168255888 E-052-2022-0 E-052-2022-0-FR-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES EP France 23721501.7 Pending France <br />European patent (EP) 23721501.7<br />Filed on 2024-11-06<br />Status: Pending 168255928 E-052-2022-0 E-052-2022-0-DE-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES EP Germany 23721501.7 Pending Germany <br />European patent (EP) 23721501.7<br />Filed on 2024-11-06<br />Status: Pending 168256052 E-052-2022-0 E-052-2022-0-GB-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES EP United Kingdom 23721501.7 Pending United Kingdom <br />European patent (EP) 23721501.7<br />Filed on 2024-11-06<br />Status: Pending 168256092 E-052-2022-0 E-052-2022-0-IE-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES EP Ireland 23721501.7 Pending Ireland <br />European patent (EP) 23721501.7<br />Filed on 2024-11-06<br />Status: Pending 168256132 E-052-2022-0 E-052-2022-0-CH-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES EP Switzerland 23721501.7 Pending Switzerland <br />European patent (EP) 23721501.7<br />Filed on 2024-11-06<br />Status: Pending TAB-4449 147157744 Lentiviral Vectors with Dual Fluorescence/Luminescence Reporters NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Chi-Ping Day, Dominic Esposito, Glenn Merlino <p>In research settings, visualization of &nbsp;tumors or tumor cells is often done using either bioluminescence or fluorescence.&nbsp; However, both of these methods have shortcomings: bioluminescence is not sensitive enough to sort individual tumor cells, and fluorescence cannot be used effectively to view internal tumors and is best used with surface tumors.</p> <p>Researchers at NCI developed twelve lentiviral vectors that express both fluorescent and luminescent markers as a single fusion protein under various gene promoters.&nbsp; By combining the two reporters into a single fusion protein, the tumor can be visualized within the animal as well as sorted from non-tumor cells for post-necropsy experiments. &nbsp;The advantage of bioluminescent visualization allows for <em>in vivo</em> experiments that more closely simulate the biological development of tumors in organs, rather than at the skin surface. Additionally, since twelve different vectors with different gene promoters were constructed, they can be tested in individual tumor models to find the best vector for visualizing that particular tumor cell line. The vectors are able to sustain long-term expression of both visualization markers, depending on the cell type and promoter in each vector.</p> <h2>Competitive Advantages:</h2> <ul> <li>The bioluminescent marker allows for effective visualization of deep (non-surface) tumors in mice</li> <li>The fluorescence label permits efficient sorting of tumor cells from normal (non-labeled) cells after tumors are excised from the mice</li> <li>The vectors allow <em>in vivo </em>experiments that more closely simulate the biological development of tumors in organs rather than at surface of skin</li> <li>The vectors sustain long-term expression</li> </ul> <h2>Commercial Applications:</h2> <ul> <li>Useful for experiments in which both <em>in vivo</em> and <em>in vitro </em>analysis is desired</li> <li>For screening cancer cell lines and in tumor models for reporter gene activity</li> <li>Useful in drug development</li> </ul> 2016-02-16 2026-07-17 2020-08-12 2026-07-17 2016-08-11 Bioluminescence, Fluorescence, tumor visualization, vectors False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-12 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147161883 Day CP, et al. Lentivirus-mediated bifunctional cell labeling for in vivo melanoma study. https://www.ncbi.nlm.nih.gov/pubmed/19175523 <a href="https://www.ncbi.nlm.nih.gov/pubmed/19175523">Day CP, et al. Lentivirus-mediated bifunctional cell labeling for in vivo melanoma study.</a> 147164777 Esposito, Dominic NIH - NCI Leidos Esposito, Dominic (Leidos) 1 147164778 Day, Chi-Ping NIH - NCI NCI Day, Chi-Ping (NCI) 2 147164776 Merlino, Glenn NIH - NCI NCI Merlino, Glenn (NCI) 3 147164777 Esposito, Dominic NIH - NCI Leidos Esposito, Dominic (Leidos) 1 147164778 Day, Chi-Ping NIH - NCI NCI Day, Chi-Ping (NCI) 2 147164776 Merlino, Glenn NIH - NCI NCI Merlino, Glenn (NCI) 3 147158047 Lentiviral Vectors For Long-term In Vivo Expression Of Dual Luorescence/luminescence Reporters E-132-2011-0 Research Material NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4449] Lentiviral Vectors with Dual Fluorescence/Luminescence Reporters&body=Please send me information about technology [TAB-4449] Lentiviral Vectors with Dual Fluorescence/Luminescence Reporters.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4449] Lentiviral Vectors with Dual Fluorescence/Luminescence Reporters&body=Please send me information about technology [TAB-4449] Lentiviral Vectors with Dual Fluorescence/Luminescence Reporters.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147172069 Bioluminescence 147172070 Fluorescence 147172072 tumor visualization 147172073 vectors TAB-5136 168201777 Characterization of novel pan anti-HLA antibodies that block LILR inhibitory receptors and activate anti-tumor immunity NIAID Application, Collaboration Sought, Infectious Disease, Oncology, TherapeuticArea, Therapeutics Application Collaboration Sought Infectious Disease Oncology TherapeuticArea Therapeutics Patricia Korty, David Margulies, Kannan Natarajan, Abir Panda, Ethan Shevach <p>&nbsp; &nbsp; &nbsp; &nbsp;Cancer immunotherapy has transformed treatment for some patients, but many tumors still do not respond well to current options, including checkpoint inhibitors. Researchers at NIAID&rsquo;s Laboratory of Immune System Biology (LISB) have developed new antibodies designed to help the immune system fight tumors. These lab-made antibodies, called pan-anti-HLA monoclonal antibodies, block signals that can limit immune cell activity.</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; These signals are part of a pathway that regulates immune responses. In this pathway, inhibitory receptors in the leukocyte immunoglobulin-like receptor (LILR) family, found on many immune cells like natural killer (NK) cells and T cells, act like a brake when they interact with molecules called MHC-I. The antibodies are designed to block this interaction and release that brake. Earlier studies showed that antibodies targeting this interaction could activate both innate immunity, the body&rsquo;s first line of defense, and adaptive immunity, the part of the immune system that builds more targeted responses and immune memory.</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The new pan anti-HLA antibodies 3C10 and 15B1 block LILR interactions by binding to a different site on MHC-I than previously developed antibodies DX17 and W6/32. They also bind more than 50 times better and activate human NK and T cells for tumor control. To support development of next-generation checkpoint therapies, researchers will further evaluate the 3C10 and 15B1 antibodies in animal and tissue-based models.</p> <ul> <li>Target a broad immune “brake” pathway rather than just individual LILR receptors</li> <li>Bind to a different site on MHC-I and does so over 50 times more strongly than earlier antibodies</li> <li>Activates human natural killer (NK) cells and T cells for tumor control</li> <li>Builds on earlier findings showing that blocking this pathway can trigger anti-tumor immune responses</li> </ul> <ul> <li>An antibody-based cancer immunotherapy that helps release immune “brakes” on tumor-fighting cells</li> <li>A next-generation checkpoint therapy that could be used alone or with other immunotherapies, including CAR-T or CAR-NK cells</li> <li>A potential immune-based treatment strategy for chronic infections such as TB, HIV, and hepatitis B or C</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Yogikala Prabhu at 202-365-4785, or yogikala.prabhu@nih.gov 2026-07-14 2026-07-16 2026-07-16 2026-07-16 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 168201924 Margulies, David NIAID - DIR NIAID Margulies, David (NIAID) 1 168201937 Panda, Abir NIAID - DIR NIAID Panda, Abir (NIAID) 2 168201948 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 3 168202080 Natarajan, Kannan NIAID - DIR NIAID Natarajan, Kannan (NIAID) 4 168202084 Korty, Patricia NIAID - DIR NIAID Korty, Patricia (NIAID) 5 168201924 Margulies, David NIAID - DIR NIAID Margulies, David (NIAID) 1 168201937 Panda, Abir NIAID - DIR NIAID Panda, Abir (NIAID) 2 168201948 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 3 168202080 Natarajan, Kannan NIAID - DIR NIAID Natarajan, Kannan (NIAID) 4 168202084 Korty, Patricia NIAID - DIR NIAID Korty, Patricia (NIAID) 5 168201780 Characterization of novel pan anti-HLA antibodies that block LILR inhibitory receptors and activate anti-tumor immunity E-005-2026-0 Filing authorized NIAID - DIR 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-5136] Characterization of novel pan anti-HLA antibodies that block LILR inhibitory receptors and activate anti-tumor immunity&body=Please send me information about technology [TAB-5136] Characterization of novel pan anti-HLA antibodies that block LILR inhibitory receptors and activate anti-tumor immunity. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-5136] Characterization of novel pan anti-HLA antibodies that block LILR inhibitory receptors and activate anti-tumor immunity&body=Please send me information about technology [TAB-5136] Characterization of novel pan anti-HLA antibodies that block LILR inhibitory receptors and activate anti-tumor immunity.">yogikala.prabhu@nih.gov</a><br> 168201785 E-005-2026-0 E-005-2026-0-US-01 ANTI-PAN HLA ANTIBODIES THAT BLOCK LILRB AND ACTIVATE IMMUNE CELLS PRV US 64/053,946 Pending US <br />Provisional (PRV) 64/053,946<br />Filed on 2026-04-30<br />Status: Pending TAB-4551 151737494 Treatment of Periodontal Disease via ENPPI Inhibition NIAMS Collaboration, Collaboration Sought, Dental, Therapeutics Collaboration Collaboration Sought Dental Therapeutics Demetrios Braddock, Emily Chu, Brian Foster, Francisco Nociti, Martha Somerman, Vivek Thumbigere-Math <p>This technology focuses on enhancing cementum production, a key component in treating periodontal regression. The method involves inhibiting ectonucleotide pyrophosphatase phosphodiesterases (ENPP1), enzymes that play a significant role in mineralization processes. Pyrophosphate (PPi) is known to impede the growth of hydroxyapatite crystals, essential for mineralization. ENPP1 catalyzes the hydrolysis of ATP, generating PPi, which then hinders mineralization. Research indicates that the balance between inorganic phosphate (Pi) and PPi (Pi/PPi ratio) significantly influences cementum formation, a crucial tissue for dental health. Notably, cementum production can be considerably enhanced, by over ten times, when PPi levels are reduced. This has been observed in both murine models and humans with impaired ENPP1 function. Since ENPP1 is the primary extracellular source of PPi, its inhibition creates a favorable environment for increased cementum production, offering a promising avenue for treating periodontal diseases.</p> Current therapies for treating periodontal disease, such as dental hygiene, antibiotics, and teeth replacement via surgery, do not have predictable outcomes and do not demonstrate reliable cementum regeneration. Use for periodontal regeneration and beyond for other disorders, conditions, trauma related to mineralized tissues. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. Technology is also available for non-exclusive or exclusive licensing 2023-12-11 2024-12-31 2026-07-16 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151737504 Braddock, Demetrios Yale University Braddock, Demetrios 1 151737508 Somerman, Martha NIDCR NIDCR Somerman, Martha (NIDCR) 2 151737524 Chu, Emily NIAMS Chu, Emily 3 151737536 Thumbigere-Math, Vivek University of Maryland, Baltimore NIAMS Thumbigere-Math, Vivek (NIAMS) 4 151737540 Foster, Brian NIAMS Foster, Brian 5 151737545 Nociti, Francisco State University of Campinas Nociti, Francisco 6 151737504 Braddock, Demetrios Yale University Braddock, Demetrios 1 151737508 Somerman, Martha NIDCR NIDCR Somerman, Martha (NIDCR) 2 151737524 Chu, Emily NIAMS Chu, Emily 3 151737536 Thumbigere-Math, Vivek University of Maryland, Baltimore NIAMS Thumbigere-Math, Vivek (NIAMS) 4 151737540 Foster, Brian NIAMS Foster, Brian 5 151737545 Nociti, Francisco State University of Campinas Nociti, Francisco 6 151737497 Method Of Treating Periodontal Disease Via ENPPl Inhibition E-024-2018-0 Filing authorized NIAMS, Yale University 83739611 Yonter, Ediz ediz.yonter@nih.gov
United States of America Technology Advancement Office ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-4551] Treatment of Periodontal Disease via ENPPI Inhibition&body=Please send me information about technology [TAB-4551] Treatment of Periodontal Disease via ENPPI Inhibition. Yonter, Ediz<br><a href="mailto:ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-4551] Treatment of Periodontal Disease via ENPPI Inhibition&body=Please send me information about technology [TAB-4551] Treatment of Periodontal Disease via ENPPI Inhibition.">ediz.yonter@nih.gov</a><br> 157760390 E-024-2018-0 E-024-2018-0-EP-04 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING AND/OR PREVENTING PERIODONTAL DISEASE National Stage European Patent 18816451.1 Abandoned European Patent <br />National Stage 18816451.1<br />Filed on 2018-11-27<br />Status: Abandoned TAB-846 114095180 Codon-optimization of HIV-1 Viral Infectivity Factor (VIF) Gene NIAID Diagnostics, Infectious Disease, Licensing, Research Materials Diagnostics Infectious Disease Licensing Research Materials Stephan BOUR, Kim-Lien Nguyen, Klaus Strebel Expression of the HIV-1 Vif protein in the absence of other viral factors such a Tat and Rev is extremely inefficient due to the presence of inhibitory sequences on its mRNA. This invention uses codon optimization to remove such inhibitory sequences without altering the amino acid sequence of the protein. The modified vif gene in the resulting pcDNA -hVIF vector is expressed under the control of the CMV promoter. In this, the protein functions as wild type and is more amendable to high-level expression in mammalian cells.<br /><br /> Currently this vector is used in on-going studies of HIV infection and its ability to overcome cellular restriction to replication. As such, the reagent will be valuable to other researchers in discovering mechanisms of replication, next generation therapeutics and potentially prevention of infection as well. <ul> <li>A plasmid pcDNA-hVif capable of expressing VIF independent of other HIV genes through removal of inhibitory sequences on its mRNA.</li> </ul> Research Material - Patent protection is not being pursued for this technology. (IC Reference No. 2004-036) 2022-03-08 2024-10-28 2026-07-15 2004-01-01 AAXXXX, AXXXXX, DA4AXX, DAXXXX, DDXXXX, DXXXXX, PLASMID, RM, VLXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114104604 Strebel, Klaus NIAID Strebel, Klaus (NIAID) 0 114104605 BOUR, Stephan NIAID BOUR, Stephan (NIAID) 0 114104606 Nguyen, Kim-Lien Nguyen, Kim-Lien 0 114104604 Strebel, Klaus NIAID Strebel, Klaus (NIAID) 0 114104605 BOUR, Stephan NIAID BOUR, Stephan (NIAID) 0 114104606 Nguyen, Kim-Lien Nguyen, Kim-Lien 0 114100019 Condon-optimization Of HIV-1 Vf Gene` E-041-2004-0 Research Material NIAID 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-846] Codon-optimization of HIV-1 Viral Infectivity Factor (VIF) Gene&body=Please send me information about technology [TAB-846] Codon-optimization of HIV-1 Viral Infectivity Factor (VIF) Gene. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-846] Codon-optimization of HIV-1 Viral Infectivity Factor (VIF) Gene&body=Please send me information about technology [TAB-846] Codon-optimization of HIV-1 Viral Infectivity Factor (VIF) Gene.">peter.tung@nih.gov</a><br> 114114918 DA4AXX 114114919 AAXXXX 114114920 DDXXXX 114114921 DAXXXX 114114922 AXXXXX 114114923 DXXXXX 114127361 VLXXXX 114127362 WIXXXX 114149408 RM 114149409 PLASMID TAB-3996 147157277 Use of Neurotrophic Factor-alpha1/Carboxypeptidase E (CPE) to Treat Alzheimer Disease NICHD Collaboration, Licensing, Neurology, Therapeutics Collaboration Licensing Neurology Therapeutics Yong Cheng, Yoke Peng Loh <h2>Summary:</h2> <p>The NICHD is seeking licensees&nbsp;for development&nbsp;of Carboxypeptidase E (CPE)&nbsp;as a therapy for MCI or AD.</p> <h2>Description of Technology:</h2> <p>There is no known cure for Alzheimer&rsquo;s disease, a brain disorder that severely affects memory, thinking, learning, and organizing skills. It eventually decreases a person&rsquo;s ability to carry out simple, daily activities. It is predicted that over 14 million Americans will develop Alzheimer&rsquo;s without effective treatment options. Mild cognitive impairment (MCI) is a stage prior to Alzheimer&rsquo;s when memory problems become noticeable. A patient&rsquo;s ability to function and live independently remain intact as the brain compensates for disease-related changes. Disease symptoms worsen over a period that may progress over 10 years. In some people, MCI can hold steady at this stage. However, people with MCI are at high risk for progressing to dementia. Alzheimer&rsquo;s disease is the most common form of dementia.</p> <p>MCI is associated with neurological cell death in the hippocampus. The technology from the <em>Eunice Kennedy Shriver</em> National Institute of Child Health and Human Development (NICHD), describes that direct administration of an adenovirus carrying the Carboxypeptidase E (CPE) gene to the hippocampus results in overexpression of the CPE protein in an experimental mouse model of AD. CPE protein overexpression averts neurological cell death in the hippocampus. Treated mice do not develop memory impairment. This technology was effective in mice with normal expression of brain-derived neurotrophic factor (BNDF). It may be applicable to a wider range of patients, including those with BNDF deficiency and no deficiency of BNDF expression. Further, this technology may provide for a combination therapy with CPE and BNDF to treat AD.</p> <p>This technology protects neurons prior to the appearance of cell damage due to accumulation of intracellular tau-containing neurofibrillary tangles and extracellular &beta;-amyloid (A&beta;) deposits in the brain.</p> <p>The use of CPE as an early intervention in the initial diagnosis of MCI may stabilize the neurological condition of patients and avoid progression of AD in a large population of aging patients.</p> <p>There is also opportunity for preclinical co-development of the technology with the NICHD laboratory of Dr. Peng Loh.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of patients: <ul> <li>Diagnosed with mild cognitive impairment (MCI)</li> <li>Diagnosed with neurologic damage to the hippocampus</li> <li>With early signs of Alzheimer&rsquo;s Disease (AD)</li> </ul> </li> <li>Combination therapy with Brain-Derived Neurotrophic Factor (BDNF)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Halt the progression from MCI to AD</li> <li>Combination therapy with CPE and BNDF</li> <li>Neuroprotective prior to the appearance of cell damage</li> </ul> Researchers at the NICHD seek licensing and/or co-development research collaborations for Carboxypeptidase E (CPE) to Treat Mild Cognitive Impairment and Alzheimer Disease 2021-12-21 2026-04-24 2021-12-21 2026-07-13 2021-12-21 “Cognitive impairment”, Ad, Alzheimer’s Disease, BNDF, brain, Brain-Derived Neurotrophic Factor, Carboxypeptidase E, CPE, Hippocampus, LOH, MCI, MEMORY, Mild Cognitive Impairment, NEURODEGENERATION, NEUROTROPHIC False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-12-21 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161932 Xiao L, et.al. Neurotrophic factor-α1, a novel tropin is critical for the prevention of stress-induced hippocampal CA3 cell death and cognitive dysfunction in mice: comparison to BDNF. https://pubmed.ncbi.nlm.nih.gov/33414376/ <a href="https://pubmed.ncbi.nlm.nih.gov/33414376/">Xiao L, et.al. Neurotrophic factor-α1, a novel tropin is critical for the prevention of stress-induced hippocampal CA3 cell death and cognitive dysfunction in mice: comparison to BDNF.</a> 147163162 Loh, Yoke Peng NIH - NICHD NICHD Loh, Yoke Peng (NICHD) 1 147163163 Cheng, Yong Minzu University of China Cheng, Yong 2 147163162 Loh, Yoke Peng NIH - NICHD NICHD Loh, Yoke Peng (NICHD) 1 147163163 Cheng, Yong Minzu University of China Cheng, Yong 2 147158202 Use Of Neurotrophic Factor-alpha1/Carboxypeptidase E To Treat Alzheimer Disease E-200-2021-0 Filing authorized Minzu University of China, NICHD 91827321 Jinnah, Zarpheen zarpheen.jinnah@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-3996] Use of Neurotrophic Factor-alpha1/Carboxypeptidase E (CPE) to Treat Alzheimer Disease&body=Please send me information about technology [TAB-3996] Use of Neurotrophic Factor-alpha1/Carboxypeptidase E (CPE) to Treat Alzheimer Disease.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Jinnah, Zarpheen<br><a href="mailto:zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-3996] Use of Neurotrophic Factor-alpha1/Carboxypeptidase E (CPE) to Treat Alzheimer Disease&body=Please send me information about technology [TAB-3996] Use of Neurotrophic Factor-alpha1/Carboxypeptidase E (CPE) to Treat Alzheimer Disease.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">zarpheen.jinnah@nih.gov</a><br> 147161187 E-200-2021-0 E-200-2021-0-US-01 Use of Carboxypeptidase E / Neurotrophic Factor-Alpha 1 to Treat Neurodegenerative Disease PRV US 63/273,312 Abandoned US <br />Provisional (PRV) 63/273,312<br />Filed on 2021-10-29<br />Status: Abandoned 147165788 E-200-2021-0 E-200-2021-0-PCT-02 USE OF CARBOXYPEPTIDASE E/NEUROTROPHIC FACTOR-ALPHA1 TO TREAT NEURODEGENERATIVE DISEASE PCT Patent Cooperation Treaty PCT/US2022/078713 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/078713<br />Filed on 2022-10-26<br />Status: Expired 168187737 E-200-2021-0 E-200-2021-0-CA-01 USE OF CARBOXYPEPTIDASE E/NEUROTROPHIC FACTOR-ALPHA1 TO TREAT NEURODEGENERATIVE DISEASE National Stage Canada 3231009 Pending Canada <br />National Stage 3231009<br />Filed on 2024-03-04<br />Status: Pending 168187748 E-200-2021-0 E-200-2021-0-US-02 USE OF CARBOXYPEPTIDASE E/NEUROTROPHIC FACTOR-ALPHA1 TO TREAT NEURODEGENERATIVE DISEASE National Stage US 18/705,869 Pending US <br />National Stage 18/705,869<br />Filed on 2024-04-29<br />Status: Pending 168187758 E-200-2021-0 E-200-2021-0-AU-01 USE OF CARBOXYPEPTIDASE E/NEUROTROPHIC FACTOR-ALPHA1 TO TREAT NEURODEGENERATIVE DISEASE National Stage Australia 2022379620 Pending Australia <br />National Stage 2022379620<br />Filed on 2024-03-05<br />Status: Pending 168187763 E-200-2021-0 E-200-2021-0-EP-01 USE OF CARBOXYPEPTIDASE E/NEUROTROPHIC FACTOR-ALPHA1 TO TREAT NEURODEGENERATIVE DISEASE National Stage European Patent 22802481.6 Pending European Patent <br />National Stage 22802481.6<br />Filed on 2024-05-13<br />Status: Pending 147173562 “Cognitive impairment” 147173563 Ad 147173564 Alzheimer’s Disease 147173566 BNDF 147173567 brain 147173569 Brain-Derived Neurotrophic Factor 147173571 Carboxypeptidase E 147173573 CPE 147173575 Hippocampus 147173576 LOH 147173578 MCI 147173579 MEMORY 147173581 Mild Cognitive Impairment 147173582 NEURODEGENERATION 147173583 NEUROTROPHIC TAB-4168 147157452 Tamperless Tensor Elastography Imaging NICHD Collaboration, Diagnostics, Licensing, Neurology, Oncology Collaboration Diagnostics Licensing Neurology Oncology Peter Basser, Magdoom Mohamed Kulam Najmudeen <h2>Summary:</h2> <p>The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for the development of tamper-less tensor elastography imaging in assessing disease (e.g., cancer), normal and abnormal developmental processes, degeneration and trauma in the brain and other soft tissues, and other applications.</p> <h2>Description of Technology:</h2> <p>Measuring and mapping nervous tissue microstructure noninvasively is a long sought-after goal in neuroscience. Several neuropathologies &ndash; such as cancer and stroke &ndash; are associated with changes in tissue microstructure. Changes in material properties, such as stiffness, represent a sensitive measure of<br /> underlying changes in tissue architecture, organization, and microstructure. Elastography techniques used to map material stiffness typically involves measuring displacement resulting from shear waves of known frequency imposed on the material by an external actuator or tamper. Material stiffness is estimated from measured displacement by inverting a model relating the material&rsquo;s strain to its stress. A minimal description of a constitutive law relating the stress and strain in the anisotropic material requires a rank-4 anisotropic elasticity tensor (E-tensor). The E-tensor has a number of free parameters ranging from 2 to 21 depending on the degree of material symmetry &ndash; instead of the 1-parameter isotropic scalar shear modulus used in conventional methods. Reconstructing the full E-tensor from a single mechanical excitation is an ill-posed inverse problem since the number of unknowns typically exceeds the number of available equations.</p> <p>The disclosure describes elastography methods permitting measurement of small physiological tissue displacements using spin echo MRI, ultrasound, or other techniques. It allows reconstruction of a full rank-4 anisotropic elasticity tensor (E-tensor). It includes strategies that denoise the measured displacement field using physically motivated compatibility conditions. Also, it includes a family of new intrinsic, invariant stains or parameters to characterize different features of the measured E-tensor. The disclosed E-tensor estimation pipelines are evaluated using simulated 3D displacement data in the presence of noise which confirm the applicability of the disclosed approaches. With the selected E-tensor and associated stains, physiological disorders &ndash; such as Alzheimer&rsquo;s disease and traumatic brain injury (TBI) &ndash; is more readily detected versus conventional methods not utilizing the full E-tensor.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Neuro or whole-body MRI suites for disease assessment and diagnosis in neural and other tissues</li> <li>Assessing disease (e.g., cancer), normal and abnormal developmental processes, degeneration and trauma in the brain and other soft tissues, and other applications</li> <li>Brain tissue stiffness atlas to design head gear which minimizes impact</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Superior non-invasive measurement and mapping of nervous tissue microstructure</li> <li>Produces estimates of a full rank-4 elasticity tensors (E-tensors) using suitable constraints</li> <li>Incorporates intrinsic deformation of the tissue caused by physiological motion, such as from cardiac pulsation and/or respiratory motion, rather than reliance on external tampers</li> </ul> 2022-04-01 2026-04-23 2022-04-01 2026-07-13 2022-04-01 Alzheimer’s Disease, Anisotropy, Basse, brain, CANCER, Elasticity Tensor, Elastography, Eunice Kennedy Shriver National Institute of Child Health an, Magnetic Resonance Imaging, MRI, Najmudeen, NICHD, TBI, TRAUMA, Traumatic Brain Injury False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2022-04-01 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-170-2020 147163754 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 1 147163755 Kulam Najmudeen, Magdoom Mohamed NIH - NICHD NICHD Kulam Najmudeen, Magdoom Mohamed (NICHD) 2 147163754 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 1 147163755 Kulam Najmudeen, Magdoom Mohamed NIH - NICHD NICHD Kulam Najmudeen, Magdoom Mohamed (NICHD) 2 147157824 MR Viscoelasticity Tensor MRI Of The Brain And Other Tissue E-028-2020-0 Filing authorized NICHD 119617417 Ravilious, Geoffrey geoffrey.ravilious@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4168] Tamperless Tensor Elastography Imaging&body=Please send me information about technology [TAB-4168] Tamperless Tensor Elastography Imaging.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ravilious, Geoffrey<br><a href="mailto:geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4168] Tamperless Tensor Elastography Imaging&body=Please send me information about technology [TAB-4168] Tamperless Tensor Elastography Imaging.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">geoffrey.ravilious@nih.gov</a><br> 147160929 E-028-2020-0 E-028-2020-0-US-01 TAMPERLESS TENSOR ELASTOGRAPHY IMAGING PRV US 63/192,920 Abandoned US <br />Provisional (PRV) 63/192,920<br />Filed on 2021-05-25<br />Status: Abandoned 147167062 E-028-2020-0 E-028-2020-0-PCT-02 TAMPERLESS TENSOR ELASTOGRAPHY IMAGING PCT Patent Cooperation Treaty PCT/US2022/030846 Administratively Closed Patent Cooperation Treaty <br />(PCT) PCT/US2022/030846<br />Filed on 2022-05-25<br />Status: Administratively Closed 168187724 E-028-2020-0 E-028-2020-0-US-03 TAMPERLESS TENSOR ELASTOGRAPHY IMAGING CON US 19/545,175 Pending US <br />Continuation (CON) 19/545,175<br />Filed on 2026-02-20<br />Status: Pending 168187729 E-028-2020-0 E-028-2020-0-US-02 TAMPERLESS TENSOR ELASTOGRAPHY IMAGING National Stage US 12,566,230 18/563,237 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12566230 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12566230">12,566,230</a><br />Filed on 2023-11-21<br />Status: Issued 147169816 Alzheimer’s Disease 147169817 Anisotropy 147169819 Basse 147169820 brain 147169821 CANCER 147169823 Elasticity Tensor 147169824 Elastography 147169825 Eunice Kennedy Shriver National Institute of Child Health an 147169826 Magnetic Resonance Imaging 147169827 MRI 147169829 Najmudeen 147169830 NICHD 147169831 TBI 147169832 TRAUMA 147169833 Traumatic Brain Injury TAB-4054 147157336 Methods of Determining Homeostatic Perturbations NICHD Collaboration, Diagnostics, Licensing, Neurology, Oncology Collaboration Diagnostics Licensing Neurology Oncology Peter Basser, Teddy Cai, Rea Ravin, Nathan Williamson <h2><strong>Description of Technology:</strong></h2> <p>Biological homeostasis is a state of steady internal, physical, and chemical conditions maintained by a living organism observed at the cellular level.&nbsp; Biological homeostasis can vary in order to alter the cellular physical and chemical conditions. Thus, it acts as a mechanism to define the physiological state of cellular activity; for instance resting states or active states (e.g., intensive physical or mental activity or intensive physical or mental stimulation).&nbsp; Deviations or perturbations from biological homeostasis, even at the cellular level, can be caused by pathological conditions such as diseases within the organism.&nbsp; Such deviations result in physical and chemical conditions that feedback to prolong pathological states as part of an injury or disease.&nbsp; In the extreme case, cell death can be characterized by a complete loss of homeostasis.&nbsp; In these ways, states of biological homeostasis are linked to physiological and pathological activities occurring at various levels of the organism (e.g., organelle, cell, tissue, organ).&nbsp; States of biological homeostasis can be difficult to detect using conventional analytical techniques.</p> <p>The disclosed technology consists of methods to determine a homeostatic steady-state of a biological entity.&nbsp; Also disclosed are methods to use Nuclear Magnetic Resonance (NMR) or Magnetic Resonance Imaging (MRI) to quantify a water exchange rate between at least two compartments in a biological system, to characterize physiological water transport, and methods for non-invasively measuring transmembrane exchange rates of endogenous water in a biological system under steady-state or non-steady-state conditions in near-real time.</p> <p>Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development are highly motivated in seeking licensing and/or collaboration partners further to develop methods and/or assays arising out of these technologies. An ideal partner would enter into both a Cooperative Research and Development Agreement (CRADA) and an exclusive license agreement towards commercialization of this diagnostic in the area of neurology or another suitable field.</p> <h2><strong>Potential Commercial Applications:</strong></h2> <ul> <li><span style="tab-stops:list .5in">Diagnosis of benign tumors capable of immune stimulation (&ldquo;hot&rdquo;)</span></li> <li><span style="tab-stops:list .5in">Diagnosis of abnormal central nervous system (CNS) states (ex: those caused by stroke, brain aneurysm, traumatic brain injury, migraine aura, and seizure)</span></li> <li><span style="tab-stops:list .5in">Determining the physiological or functional activity state of the central nervous system (CNS) (e.g. sleep, wake, intense stimulation)</span></li> <li><span style="tab-stops:list .5in">Evaluating CNS therapeutics and their mechanism of action</span></li> </ul> <h2><strong>Competitive Advantages:</strong></h2> <ul> <li><span style="tab-stops:list .5in">Absolute measurement&mdash;can directly detect the homeostatic state&mdash;does not require a relative reading.&nbsp;</span></li> <li><span style="tab-stops:list .5in">Uses endogenous water&mdash;does not require a tracer or contrast agent</span></li> <li><span style="tab-stops:list .5in">Less invasive than the current state of the art methods to measure spreading depolarization</span></li> </ul> Researchers at the NICHD seek licensing and/or co-development research collaborations for methods to determine homeostatic perturbations. 2023-01-21 2026-04-16 2023-01-22 2026-07-13 2023-01-23 Basser, Biomarkers, Central Nervous System, CNS, functional imaging, HOMEOSTASIS, Magnetic Resonance Imaging, MRI, NICHD, NMR, Nuclear Magnetic Resonance, r, Steady-state, The Eunice Kennedy Shriver National Institute of Child Healt False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2023-01-22 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147161885 Cai TX, et al. Disentangling the effects of restriction and exchange with diffusion exchange spectroscopy https://doi.org/10.3389/fphy.2022.805793 <a href="https://doi.org/10.3389/fphy.2022.805793">Cai TX, et al. Disentangling the effects of restriction and exchange with diffusion exchange spectroscopy</a> 147162001 Cai TX, et al. Rapid detection of the presence of diffusion exchange https://scholar.google.com/citations?view_op=view_citation&hl=en&user=xGKhQ3sAAAAJ&sortby=pubdate&citation_for_view=xGKhQ3sAAAAJ:_FxGoFyzp5QC <a href="https://scholar.google.com/citations?view_op=view_citation&hl=en&user=xGKhQ3sAAAAJ&sortby=pubdate&citation_for_view=xGKhQ3sAAAAJ:_FxGoFyzp5QC">Cai TX, et al. Rapid detection of the presence of diffusion exchange</a> 147162273 Williamson NH, Magnetic resonance measurements of cellular and sub-cellular membrane structures in live and fixed neural tissue https://pubmed.ncbi.nlm.nih.gov/31829935 <a href="https://pubmed.ncbi.nlm.nih.gov/31829935">Williamson NH, Magnetic resonance measurements of cellular and sub-cellular membrane structures in live and fixed neural tissue</a> 147163350 Ravin, Rea NIH - Celoptics, Inc. NIBIB Ravin, Rea (NIBIB) 1 147163351 Williamson, Nathan NIGMS NIGMS Williamson, Nathan (NIGMS) 2 147163352 Cai, Teddy NICHD NICHD Cai, Teddy (NICHD) 3 147163349 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 4 147163350 Ravin, Rea NIH - Celoptics, Inc. NIBIB Ravin, Rea (NIBIB) 1 147163351 Williamson, Nathan NIGMS NIGMS Williamson, Nathan (NIGMS) 2 147163352 Cai, Teddy NICHD NICHD Cai, Teddy (NICHD) 3 147163349 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 4 147158084 Magnetic Resonance Method Of Measuring Water Exchange For Identifying Brain Physiology And Pathology E-151-2021-0 Filing authorized Celoptics, Inc., NICHD, NIGMS 119617417 Ravilious, Geoffrey geoffrey.ravilious@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4054] Methods of Determining Homeostatic Perturbations&body=Please send me information about technology [TAB-4054] Methods of Determining Homeostatic Perturbations.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ravilious, Geoffrey<br><a href="mailto:geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4054] Methods of Determining Homeostatic Perturbations&body=Please send me information about technology [TAB-4054] Methods of Determining Homeostatic Perturbations.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">geoffrey.ravilious@nih.gov</a><br> 147166229 E-151-2021-0 E-151-2021-0-US-01 Magnetic Resonance Method Of Measuring Water Exchange For Identifying Brain Physiology And Pathology PRV US 63/277,881 Abandoned US <br />Provisional (PRV) 63/277,881<br />Filed on 2021-11-10<br />Status: Abandoned 147166230 E-151-2021-0 E-151-2021-0-PCT-02 NUCLEAR MAGNETIC RESONANCE METHODS OF DETERMINING HOMEOSTATIC PERTURBATIONS PCT Patent Cooperation Treaty PCT/US2022/049542 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/049542<br />Filed on 2022-11-10<br />Status: Expired 168187575 E-151-2021-0 E-151-2021-0-US-02 NUCLEAR MAGNETIC RESONANCE METHODS OF DETERMINING HOMEOSTATIC PERTURBATIONS National Stage US 18/697,168 Pending US <br />National Stage 18/697,168<br />Filed on 2024-03-29<br />Status: Pending 147172398 Basser 147172399 Biomarkers 147172400 Central Nervous System 147172401 CNS 147172403 functional imaging 147172404 HOMEOSTASIS 147172405 Magnetic Resonance Imaging 147172406 MRI 147172407 NICHD 147172408 NMR 147172410 Nuclear Magnetic Resonance 147172411 r 147172412 Steady-state 147172414 The Eunice Kennedy Shriver National Institute of Child Healt TAB-3944 147157224 Margaric Acid Decreases PIEZO2 Mediated Pain NCCIH Collaboration, Dermatology, Licensing, Neurology, Therapeutics Collaboration Dermatology Licensing Neurology Therapeutics Alexander Chesler, Julio Cordero-Morales, Luis Romero, Valeria Vasquez <h2>Summary:</h2> <p>The National Center for Complimentary and Integrative Health (NCCIH) seeks licensees and/or commercial partners to develop topical formulations of margaric acid to treat allodynia, neuropathy, and pain caused by chronic inflammation.&nbsp;&nbsp;</p> <h2>Description of Technology:</h2> <p>Some existing therapies for treatment of pain are administered systematically and have significant side effects, such as addiction and drowsiness. Alternative therapy that does not impair normal touch function could be used to treat pain caused by mechanical injury or chronic inflammation. Administration of margaric acid was shown to ameliorate pain in mouse models of pain. In vitro data shows that margaric acid counteracts PIEZO2 (Piezo-type mechanosensitive ion channel component 2) potentiation evoked by bradykinin (i.e. a peptide that promotes inflammation) by reducing the mechanocurrents up to non-inflammatory levels. Margaric acid seems to be specific to target mechanical pain as it does not significantly alter the electric excitability of mice dorsal root ganglia neurons or human iPSC-derived neurons. It mainly decreases action potential firing evoked by mechanical stimulation.</p> <p>&nbsp;</p> <p><img alt="E-081-2020 - PIEZO2 channel under different physiological conditions" src="https://nih.technologypublisher.com/files/sites/e-081-2020_-_piezo2_channel_under_different_physiological_conditions2.png" style="float:left; height:467px; width:700px" /></p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <h2>&nbsp;</h2> <h2>&nbsp;</h2> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of pain caused by mechanical injury</li> <li>Treatment of pain caused by chronic inflammation (e.g., rheumatoid arthritis)</li> <li>Treatment of allodynia</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Not addictive</li> <li>Topical application</li> <li>Fewer side effects</li> </ul> 2020-09-03 2026-04-24 2020-09-03 2026-07-13 2020-09-03 ALLODYNIA, Chesler, Chronic Inflammation, fatty acid, Margaric Acid, migraine, National Center for Complimentary and Integrative Health, NCCIH, Neuropathy, Pain, PIEZO2, Vásquez False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-09-03 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162417 Romero LO, et al. A dietary fatty acid counteracts neuronal mechanical sensitization https://pubmed.ncbi.nlm.nih.gov/32561714/ <a href="https://pubmed.ncbi.nlm.nih.gov/32561714/">Romero LO, et al. A dietary fatty acid counteracts neuronal mechanical sensitization</a> 147162963 Chesler, Alexander NIH - NCCIH NICHD Chesler, Alexander (NICHD) 1 147162964 Vasquez, Valeria University of Tennessee Health Science Center Vasquez, Valeria 2 147162965 Cordero-Morales, Julio University of Tennessee Health Science Center Cordero-Morales, Julio 3 147162966 Romero, Luis University of Tennessee Health Science Center Romero, Luis 4 147162963 Chesler, Alexander NIH - NCCIH NICHD Chesler, Alexander (NICHD) 1 147162964 Vasquez, Valeria University of Tennessee Health Science Center Vasquez, Valeria 2 147162965 Cordero-Morales, Julio University of Tennessee Health Science Center Cordero-Morales, Julio 3 147162966 Romero, Luis University of Tennessee Health Science Center Romero, Luis 4 147157946 MARGARIC ACID DECREASES PIEZO2-MEDIATED MECHANICAL ALLODYNIA E-081-2020-0 Filing authorized National Center for Complementary and Integrative Health (NCCIH), University of Tennessee Health Science Center 91800717 Hubbs, Alan hubbsa@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America Technology Transfer Center hubbsa@mail.nih.gov?subject=Web Inquiry on [TAB-3944] Margaric Acid Decreases PIEZO2 Mediated Pain&body=Please send me information about technology [TAB-3944] Margaric Acid Decreases PIEZO2 Mediated Pain.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Hubbs, Alan<br><a href="mailto:hubbsa@mail.nih.gov?subject=Web Inquiry on [TAB-3944] Margaric Acid Decreases PIEZO2 Mediated Pain&body=Please send me information about technology [TAB-3944] Margaric Acid Decreases PIEZO2 Mediated Pain.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">hubbsa@mail.nih.gov</a><br> 147161010 E-081-2020-0 E-081-2020-0-US-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED PAIN PRV US 62/976,014 Abandoned US <br />Provisional (PRV) 62/976,014<br />Filed on 2020-02-13<br />Status: Abandoned 147165468 E-081-2020-0 E-081-2020-0-PCT-02 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN PCT Patent Cooperation Treaty PCT/US2021/017780 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/017780<br />Filed on 2021-02-12<br />Status: Expired 147165469 E-081-2020-0 E-081-2020-0-JP-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN National Stage Japan 7729824 2022-548411 Issued Japan <br />National Stage 2022-548411<br />Filed on 2022-08-08<br />Status: Issued 147165470 E-081-2020-0 E-081-2020-0-CA-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED PAIN National Stage Canada 3167629 Pending Canada <br />National Stage 3167629<br />Filed on 2022-08-10<br />Status: Pending 147165471 E-081-2020-0 E-081-2020-0-AU-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN National Stage Australia 2021220883 Pending Australia <br />National Stage 2021220883<br />Filed on 2021-02-12<br />Status: Pending 147165472 E-081-2020-0 E-081-2020-0-CN-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN National Stage China 202180015900.1 Pending China <br />National Stage 202180015900.1<br />Filed on 2021-02-12<br />Status: Pending 147165473 E-081-2020-0 E-081-2020-0-NZ-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED PAIN National Stage New Zealand 790763 Pending New Zealand <br />National Stage 790763<br />Filed on 2022-07-28<br />Status: Pending 147165474 E-081-2020-0 E-081-2020-0-KR-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN National Stage South Korea 10-2022-7031665 Pending South Korea <br />National Stage 10-2022-7031665<br />Filed on 2022-09-13<br />Status: Pending 147165475 E-081-2020-0 E-081-2020-0-MX-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN National Stage Mexico 431664 MX/a/2022/009914 Issued Mexico <br />National Stage MX/a/2022/009914<br />Filed on 2021-02-12<br />Status: Issued 147165476 E-081-2020-0 E-081-2020-0-EP-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN National Stage European Patent 21710729.1 Pending European Patent <br />National Stage 21710729.1<br />Filed on 2021-02-12<br />Status: Pending 168187561 E-081-2020-0 E-081-2020-0-US-02 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN National Stage US 17/799,500 Pending US <br />National Stage 17/799,500<br />Filed on 2022-08-12<br />Status: Pending 147171000 ALLODYNIA 147171002 Chesler 147171004 Chronic Inflammation 147171005 fatty acid 147171007 Margaric Acid 147171008 migraine 147171010 National Center for Complimentary and Integrative Health 147171012 NCCIH 147171013 Neuropathy 147171014 Pain 147171016 PIEZO2 147171018 Vásquez TAB-4435 147157730 Levonorgestrel Butanoate Formulation and Methods Relating Thereto NICHD Collaboration, Endocrinology, Licensing, Reproductive Health, Therapeutics Collaboration Endocrinology Licensing Reproductive Health Therapeutics Diana Blithe, Ken Chen, Jia-Hwa Fang, Min Lee, Eduardo Ruiz <h2>Summary:</h2> <p>The National Institute of Child Health and Human Development (NICHD) seeks licensees and/or research co-development partners for the development of an injectable contraceptive for women with a pharmaceutical formulation containing levonorgestrel butanoate (LB), a steroidal progestin.</p> <h2>Description of Technology:</h2> <p>This invention is a potential subcutaneous or intramuscular progestin-only, injectable contraceptive for women. Forty-five percent (45%) of pregnancies in the United States are unintended. In this group, one-third of reproductive age women are obese &ndash; increasing the risk of diabetes, hypertension and venous thromboembolism (VTE). All these are conditions for which most hormonal methods are contraindicated. Thus, additional safe and effective injectable contraceptive options are needed. A subcutaneous formulation may be self-injected without the need of a skilled care provider or medical office visit. Levonorgestrel butanoate (LB) serves as a pro-drug to deliver Levonorgestrel (LNG) to serum after hydrolysis of the ester. It addresses the demand for estrogen-free contraception with no increased risk of VTE. The lack of increased risk is a benefit for all women, especially those obese.&nbsp;</p> <p>Injectables have lower failure rates than combined hormonal birth control pills or patches or progestin-only pills (POP). Also, POPs require strict adherence to a daily administration schedule. Currently, the only injectable contraceptive on the U.S. market is depomedroxyprogesterone acetate (DMPA). While popular, DMPA contraceptive with certain risks. DMPA may cause weight gain, moodiness, and a decrease in bone mineral density leading to a higher risk of bone fracture.&nbsp;&nbsp;</p> <p>Levonorgestrel butanoate (LB) is a butyl prodrug of levonorgestrel, a widely-used steroidal progestin. It was in development as a long-acting injectable contraceptive since the 1980s by the World Health Organization (WHO) in collaboration with institutions around the world, including NICHD. However, conventional LB formulations, including the WHO formulation, exhibit undesirable stability issues reducing contraceptive activity and the ability to large-scale manufacture.&nbsp;&nbsp;</p> <p>NICHD developed an injectable pharmaceutical formulation of LB with a potential for self-administration. The formulation promotes increased stability through a longer lasting and more concentrated dosage than previous LB formulations. This invention also involves a unique manufacturing process requiring only one vendor for more efficient production. NICHD is testing this formulation in an ongoing Phase I subcutaneous study. Results so far indicate promise as a long-lasting, reversible, injectable female contraceptive. Further, there is a competitive advantage as patients in the Phase I study thus far did not report some side effects associated with other contraceptive agents such as DMPA; e.g., weight gain or mood swings.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Injectable contraceptive use by humans</li> <li>Use in the treatment of progestin-related diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Safer for women with high-risk conditions</li> <li>Self-subcutaneous and reversible injectable</li> <li>Long-lasting contraceptive effects</li> <li>Increased stability relative to previous formulations</li> <li>Amenable to large-scale manufacture relative to previous formulations</li> <li>Estrogen free contraceptive</li> <li>Progestin only self-injectable contraceptive</li> </ul> 2022-02-24 2026-04-30 2022-02-24 2026-07-13 2022-02-23 Blithe, CONTRACEPTIVE, INJECTABLE, LB, Lee, Levonorgestrel, Levonorgestrel Butanoate, LNG, National Institute of Child Health and Human Development, NICHD, Steroidal Progestin False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-02-24 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 147164730 Lee, Min NIH - NICHD NICHD Lee, Min (NICHD) 1 147164729 Blithe, Diana NIH - NICHD NICHD Blithe, Diana (NICHD) 2 147164731 Fang, Jia-Hwa SRI International Fang, Jia-Hwa 3 147164732 Ruiz, Eduardo SRI International Ruiz, Eduardo 4 147164733 Chen, Ken SRI International Chen, Ken 5 147164730 Lee, Min NIH - NICHD NICHD Lee, Min (NICHD) 1 147164729 Blithe, Diana NIH - NICHD NICHD Blithe, Diana (NICHD) 2 147164731 Fang, Jia-Hwa SRI International Fang, Jia-Hwa 3 147164732 Ruiz, Eduardo SRI International Ruiz, Eduardo 4 147164733 Chen, Ken SRI International Chen, Ken 5 147158168 Levonorgestrel Prodrug Formulation And Methods Relating Thereto E-184-2021-0 Filing authorized NICHD, SRI International 91788919 Gunas, Heather gunash@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America gunash@mail.nih.gov?subject=Web Inquiry on [TAB-4435] Levonorgestrel Butanoate Formulation and Methods Relating Thereto&body=Please send me information about technology [TAB-4435] Levonorgestrel Butanoate Formulation and Methods Relating Thereto.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gunas, Heather<br><a href="mailto:gunash@mail.nih.gov?subject=Web Inquiry on [TAB-4435] Levonorgestrel Butanoate Formulation and Methods Relating Thereto&body=Please send me information about technology [TAB-4435] Levonorgestrel Butanoate Formulation and Methods Relating Thereto.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">gunash@mail.nih.gov</a><br> 147161163 E-184-2021-0 E-184-2021-0-US-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO PRV US 63/289,965 Expired US <br />Provisional (PRV) 63/289,965<br />Filed on 2021-12-15<br />Status: Expired 147168900 E-184-2021-0 E-184-2021-0-PCT-02 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO PCT Patent Cooperation Treaty PCT/US2022/052704 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/052704<br />Filed on 2022-12-13<br />Status: Expired 167305206 E-184-2021-0 E-184-2021-0-IN-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO National Stage India 202417045561 Pending India <br />National Stage 202417045561<br />Filed on 2024-06-13<br />Status: Pending 168187455 E-184-2021-0 E-184-2021-0-JP-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO National Stage Japan 2024-535239 Pending Japan <br />National Stage 2024-535239<br />Filed on 2024-06-12<br />Status: Pending 168187460 E-184-2021-0 E-184-2021-0-IL-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO National Stage Israel 313530 Pending Israel <br />National Stage 313530<br />Filed on 2024-06-13<br />Status: Pending 168187465 E-184-2021-0 E-184-2021-0-BR-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO National Stage Brazil BR112024010771-0 Pending Brazil <br />National Stage BR112024010771-0<br />Filed on 2024-05-29<br />Status: Pending 168187470 E-184-2021-0 E-184-2021-0-NZ-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO National Stage New Zealand 812172 Pending New Zealand <br />National Stage 812172<br />Filed on 2024-06-19<br />Status: Pending 168187475 E-184-2021-0 E-184-2021-0-KR-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO National Stage South Korea 10-2024-7020525 Pending South Korea <br />National Stage 10-2024-7020525<br />Filed on 2024-06-19<br />Status: Pending 168187483 E-184-2021-0 E-184-2021-0-SG-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO National Stage Singapore 11202403735R Pending Singapore <br />National Stage 11202403735R<br />Filed on 2024-05-30<br />Status: Pending 168187488 E-184-2021-0 E-184-2021-0-US-02 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO National Stage US 18/718,737 Pending US <br />National Stage 18/718,737<br />Filed on 2024-06-11<br />Status: Pending 168187493 E-184-2021-0 E-184-2021-0-CN-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO National Stage China 202280082940.2 Pending China <br />National Stage 202280082940.2<br />Filed on 2024-06-14<br />Status: Pending 168187498 E-184-2021-0 E-184-2021-0-MX-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO National Stage Mexico MX/a/2024/006735 Pending Mexico <br />National Stage MX/a/2024/006735<br />Filed on 2024-05-31<br />Status: Pending 168187516 E-184-2021-0 E-184-2021-0-ZA-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO National Stage South Africa 2024/04426 Pending South Africa <br />National Stage 2024/04426<br />Filed on 2024-06-06<br />Status: Pending 168187533 E-184-2021-0 E-184-2021-0-AU-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO National Stage Australia 2022415324 Pending Australia <br />National Stage 2022415324<br />Filed on 2024-06-19<br />Status: Pending 168187538 E-184-2021-0 E-184-2021-0-CA-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO National Stage Canada 3241884 Pending Canada <br />National Stage 3241884<br />Filed on 2024-06-05<br />Status: Pending 168187544 E-184-2021-0 E-184-2021-0-RU-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO National Stage Russia 2024118060 Pending Russia <br />National Stage 2024118060<br />Filed on 2024-06-28<br />Status: Pending 168187556 E-184-2021-0 E-184-2021-0-EP-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO National Stage European Patent 22847348.4 Pending European Patent <br />National Stage 22847348.4<br />Filed on 2024-06-11<br />Status: Pending 147173251 Blithe 147173252 CONTRACEPTIVE 147173253 INJECTABLE 147173255 LB 147173256 Lee 147173257 Levonorgestrel 147173259 Levonorgestrel Butanoate 147173261 LNG 147173262 National Institute of Child Health and Human Development 147173263 NICHD 147173265 Steroidal Progestin TAB-3870 147157149 La Protein as a Novel Regulator of Osteoclastogenesis NICHD Collaboration, Licensing, Therapeutics Collaboration Licensing Therapeutics Leonid Chernomordik, Evgenia Leikina, Jarred Whitlock <h2>Summary:</h2> <p>NICHD seeks co-development partners and/or licensees for the further development of methods to target the La protein for the regulation of osteoclast fusion and osteoclastogenesis.</p> <h2>Description of Technology:</h2> <p>Millions of patients in the United States are afflicted by a host of bone diseases caused by osteoclast (specialized calls arising from the macrophage/monocyte lineage) dysfunction. Diseases include Paget&rsquo;s disease, osteoporosis, fibrous dysplasia and osteolytic bone metastasis. The current standard of care for these diseases uses broad-spectrum therapies that either coat the skeletal system or inhibit osteoclast development in an effort to modulate osteoclastogenesis. New therapies are needed that specifically target osteoclast fusion &ndash; allowing patients to forgo the off-target side effects caused by existing, broad-spectrum therapies.</p> <p>Researchers at the National Institute of Child Health and Human Development (NICHD) discovered that the Lupus autoantigen (La) protein is a master regulator of osteoclast fusion and osteoclastogenesis., The resorptive capacity of osteoclasts and the ability of osteoclasts to remodel bone can be modulated by :(1) administering an effective amount of a La protein or (2) an agent that modulates La protein expression or activity. This specific approach to regulating osteoclast fusion and osteoclastogenesis should bypass the off-target side effects associated with current therapies. It represents a major opportunity to improve the lives of millions who suffer from numerous bone diseases.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutics targeting La protein to treat all the most common types of bone disease &ndash; including but not limited to: <ul> <li>Osteoporosis</li> <li>Paget&rsquo;s disease</li> <li>Fibrous dysplasia</li> <li>Osteolytic bone metastasis</li> </ul> </li> <li>Therapeutics targeting La protein for relieving symptoms associated with: <ul> <li>Rheumatoid arthritis</li> <li>Metastatic bone disease</li> </ul> </li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Technology addresses most major forms of &ndash; and therefore the largest addressable markets for &ndash; bone disease</li> <li>Enables precise modulation of osteoclast fusion and function</li> <li>Potential to prevent off-target side-effects associated with current therapies</li> </ul> 2022-07-07 2026-04-23 2022-07-06 2026-07-13 2022-07-07 Chernomordik, La Protein, Lupus Autoantigen Protein, National Institute of Child Health and Human Development, NICHD, Osteoclast Fusion, Osteoclastogenesis False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-07-06 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162677 Chernomordik, Leonid NIH - NICHD NICHD Chernomordik, Leonid (NICHD) 1 147162676 Leikina, Evgenia NICHD Leikina, Evgenia (NICHD) 2 147162678 Whitlock, Jarred NICHD NICHD Whitlock, Jarred (NICHD) 3 147162677 Chernomordik, Leonid NIH - NICHD NICHD Chernomordik, Leonid (NICHD) 1 147162676 Leikina, Evgenia NICHD Leikina, Evgenia (NICHD) 2 147162678 Whitlock, Jarred NICHD NICHD Whitlock, Jarred (NICHD) 3 147157887 La Protein As A Novel Regulator Of Osteoclastogenesis E-058-2021-0 Filing authorized Division of Intramural Research, NICHD 91788919 Gunas, Heather gunash@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America gunash@mail.nih.gov?subject=Web Inquiry on [TAB-3870] La Protein as a Novel Regulator of Osteoclastogenesis&body=Please send me information about technology [TAB-3870] La Protein as a Novel Regulator of Osteoclastogenesis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gunas, Heather<br><a href="mailto:gunash@mail.nih.gov?subject=Web Inquiry on [TAB-3870] La Protein as a Novel Regulator of Osteoclastogenesis&body=Please send me information about technology [TAB-3870] La Protein as a Novel Regulator of Osteoclastogenesis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">gunash@mail.nih.gov</a><br> 147164935 E-058-2021-0 E-058-2021-0-US-01 La Protein As A Novel Regulator Of Osteoclastogenesis PRV US 63/155,896 Abandoned US <br />Provisional (PRV) 63/155,896<br />Filed on 2021-03-03<br />Status: Abandoned 147164936 E-058-2021-0 E-058-2021-0-PCT-02 La Protein As A Novel Regulator Of Osteoclastogenesis PCT Patent Cooperation Treaty PCT/US2022/018639 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/018639<br />Filed on 2022-03-03<br />Status: Expired 168187285 E-058-2021-0 E-058-2021-0-US-02 La Protein As A Novel Regulator Of Osteoclastogenesis National Stage US 18/279,476 Abandoned US <br />National Stage 18/279,476<br />Filed on 2023-08-30<br />Status: Abandoned 168187293 E-058-2021-0 E-058-2021-0-CA-01 La Protein As A Novel Regulator Of Osteoclastogenesis National Stage Canada 3211983 Pending Canada <br />National Stage 3211983<br />Filed on 2023-08-28<br />Status: Pending 168187299 E-058-2021-0 E-058-2021-0-JP-01 La Protein As A Novel Regulator Of Osteoclastogenesis National Stage Japan 2023-553206 Pending Japan <br />National Stage 2023-553206<br />Filed on 2023-10-20<br />Status: Pending 168187306 E-058-2021-0 E-058-2021-0-JP-02 La Protein As A Novel Regulator Of Osteoclastogenesis DIV Japan 2025-269776 Pending Japan <br />Divisional (DIV) 2025-269776<br />Filed on 2025-12-19<br />Status: Pending 168187311 E-058-2021-0 E-058-2021-0-AU-01 La Protein As A Novel Regulator Of Osteoclastogenesis National Stage Australia 2022230408 Pending Australia <br />National Stage 2022230408<br />Filed on 2023-09-01<br />Status: Pending 168187316 E-058-2021-0 E-058-2021-0-US-03 La Protein As A Novel Regulator Of Osteoclastogenesis DIV US 18/791,272 Pending US <br />Divisional (DIV) 18/791,272<br />Filed on 2024-07-31<br />Status: Pending 168187323 E-058-2021-0 E-058-2021-0-EP-01 La Protein As A Novel Regulator Of Osteoclastogenesis National Stage European Patent 22711784.3 Pending European Patent <br />National Stage 22711784.3<br />Filed on 2023-09-18<br />Status: Pending 147170454 Chernomordik 147170456 La Protein 147170458 Lupus Autoantigen Protein 147170460 National Institute of Child Health and Human Development 147170461 NICHD 147170463 Osteoclast Fusion 147170464 Osteoclastogenesis TAB-4471 151021571 A Wearable Device for Monitoring Pregnancy Health NICHD Application, Collaboration, Licensing, Medical Devices, Reproductive Health Application Collaboration Licensing Medical Devices Reproductive Health George Downey, Amir Gandjbakhche, Kosar Khaksari, Alireza Khaligh, Thien Nguyen, Soongho Park, Zeyu Zhang <h2>Summary:&nbsp;</h2> <p>The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for clinical validation and to further develop the technology.&nbsp;</p> <h2>Description of Technology:&nbsp;</h2> <p>Observing the placenta during pregnancy offers a look into the utero fetal environment. Monitoring placental oxygenation level and maternal physiological signals can be useful to assess mother and fetus well-being during pregnancy. Additionally, fetal movement has long served as a measure for well-being and nervous system development helping identify adverse pregnancy outcomes. Identification of complications during pregnancy can allow for earlier interventions, including medications to reduce risk of perinatal mortality and maternal gene therapy. Current non-invasive techniques on available are considered expensive, bulky, and do not offer continuous monitoring of fetal physiological signals and placental oxygenation. There is an unmet need for a convenient way for mothers to safely monitor their pregnancy remotely.&nbsp;</p> <p>Researchers created a wearable, wireless device and protocol for continuously monitoring the placental oxygenation levels, multiple physiological signals and movement activities of a fetus and mother. The device includes a compact control board, flexible near-infrared spectroscopy (NIRS) probe and multiple accelerator probes. A classification algorithm based on Monte-Carlo simulations of multiple layers model computes oxygen saturation of the placenta. There is one or more accelerator probes attached to different body parts of the mother to detect mother movement activities and to eliminate the effect of mother movement on fetal movement. The overall data acquisition rate of this device is 10 Hz or more. With this acquisition rate, the output of the device contains extra physiological signal such as maternal respiratory and cardiac functions, and fetal cardiac functions.&nbsp;</p> <p>The NICHD seeks research co-development partners and/or licensees for clinical validation and to further develop the technology.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Low cost and flexible method of continuously monitoring pregnancy health</li> <li>Early identification of adverse outcomes such as reduced uteroplacental perfusion and stillbirth</li> <li>Potential for device to be applied in general health monitoring or sleep monitoring&nbsp;</li> <li>Daily measurement results may be collected by a cellphone and uploaded to cloud for patient&rsquo;s healthcare provider to remotely review and provide health suggestions</li> </ul> <h2>Competitive Advantage:</h2> <ul> <li>Wearable and non-invasive placenta and fetal monitoring device</li> <li>Capable of 24/7 monitoring of mother and fetal well-being</li> <li>Low power consumption&nbsp;</li> <li>Monitors both maternal and fetal multiple physiological signals and movement activities</li> </ul> Researchers at the NICHD seek licensing and/or co-development research collaborations for clinical validation and to further develop the technology. 2023-10-25 2026-04-23 2026-07-13 2023-11-27 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 151545526 Gandjbakhche, Amir NICHD NICHD Gandjbakhche, Amir (NICHD) 1 151545616 Nguyen, Thien NICHD NICHD Nguyen, Thien (NICHD) 2 151021496 Zhang, Zeyu AmpX Technologies, Inc. Zhang, Zeyu 3 151021500 Park, Soongho NICHD NICHD Park, Soongho (NICHD) 4 151021646 Downey, George AmpX Technologies, Inc. Downey, George 5 151021650 Khaligh, Alireza AmpX Technologies, Inc. Khaligh, Alireza 6 151587921 Khaksari, Kosar NICHD Khaksari, Kosar 7 151545526 Gandjbakhche, Amir NICHD NICHD Gandjbakhche, Amir (NICHD) 1 151545616 Nguyen, Thien NICHD NICHD Nguyen, Thien (NICHD) 2 151021496 Zhang, Zeyu AmpX Technologies, Inc. Zhang, Zeyu 3 151021500 Park, Soongho NICHD NICHD Park, Soongho (NICHD) 4 151021646 Downey, George AmpX Technologies, Inc. Downey, George 5 151021650 Khaligh, Alireza AmpX Technologies, Inc. Khaligh, Alireza 6 151587921 Khaksari, Kosar NICHD Khaksari, Kosar 7 151021574 A System And Protocol For Monitoring Pregnancy Health E-198-2022-0 Filing authorized AmpX Technologies, Inc., NICHD 91827321 Jinnah, Zarpheen zarpheen.jinnah@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-4471] A Wearable Device for Monitoring Pregnancy Health&body=Please send me information about technology [TAB-4471] A Wearable Device for Monitoring Pregnancy Health.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Jinnah, Zarpheen<br><a href="mailto:zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-4471] A Wearable Device for Monitoring Pregnancy Health&body=Please send me information about technology [TAB-4471] A Wearable Device for Monitoring Pregnancy Health.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">zarpheen.jinnah@nih.gov</a><br> 151390934 E-198-2022-0 E-198-2022-0-US-01 SYSTEM AND PROTOCOL FOR MONITORING PREGNANCY HEALTH PRV US 63/451,066 Expired US <br />Provisional (PRV) 63/451,066<br />Filed on 2023-03-09<br />Status: Expired 157405584 E-198-2022-0 E-198-2022-0-PC-01 SYSTEM AND PROTOCOL FOR MONITORING PREGNANCY HEALTH PCT Patent Cooperation Treaty PCT/US2024/019168 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/019168<br />Filed on 2024-03-08<br />Status: Expired 168187233 E-198-2022-0 E-198-2022-0-EP-01 SYSTEM AND PROTOCOL FOR MONITORING PREGNANCY HEALTH National Stage European Patent 24717481.6 Pending European Patent <br />National Stage 24717481.6<br />Filed on 2025-09-17<br />Status: Pending 168187241 E-198-2022-0 E-198-2022-0-US-02 SYSTEM AND PROTOCOL FOR MONITORING PREGNANCY HEALTH National Stage US 19/162,323 Pending US <br />National Stage 19/162,323<br />Filed on 2025-09-04<br />Status: Pending 168187246 E-198-2022-0 E-198-2022-0-HK-01 SYSTEM AND PROTOCOL FOR MONITORING PREGNANCY HEALTH EP Hong Kong 62026124762.6 Pending Hong Kong <br />European patent (EP) 62026124762.6<br />Filed on 2026-06-12<br />Status: Pending TAB-4062 147157344 Thalidomide Analogs that Inhibit Inflammation and Angiogenesis NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Shaunna Beedle, William Figg, Nigel Greig, Weiming Luo, David Tweedie, Nell Vargesson <p>Thalidomide and its close analogs (lenalidomide and pomalidomide) are widely used to treat a variety of diseases, such as multiple myeloma and other cancers as well as the symptoms of several inflammatory disorders. However, thalidomide is known for its teratogenic adverse effects when first clinically introduced in the 1950s, and is associated with drowsiness and peripheral neuropathy. Hence, there is intense interest to synthesize, identify and develop safer analogs. </p> <p>Researchers at the National Cancer Institute<a href="https://www.irp.nia.nih.gov/branches/tgb/ddds.htm" rel="nofollow">n</a> synthesized novel thalidomide analogs that demonstrate clinical potential without being teratogenic, as initially evaluated in <em>in vivo</em> zebrafish and chicken embryo model systems and in cell culture.  These new compounds differentially provide potent anti-angiogenesis and/or anti-inflammatory action. The agents have potential for development of new cancer therapies and treatment of a number of  neurological and systemic disorders involving chronic inflammation and elevated TNF-alpha levels.</p> <h2>Competitive Advantages:</h2> <p>- Non-teratogenic<br /> - Potent</p> <h2>Commercial Applications:</h2> <p>- Cancer therapeutics<br /> - Inflammatory disorders such as Crohn's disease, sarcoidosis, graft-versus-host disease, and rheumatoid arthritis<br /> - Neuroinflammatory disorders (acute: traumatic brain injury and stroke; chronic: Parkinson's disease, Alzheimer's disease, multiple sclerosis)</p> 2016-02-16 2025-04-22 2021-01-26 2026-07-13 2016-08-31 anti-angiogenesis, ANTI-INFLAMMATORY, Lenalidomide, Pomalidomide, THALIDOMIDE False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-01-26 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163387 Greig, Nigel NIH - NIA NIA Greig, Nigel (NIA) 1 147163389 Luo, Weiming NIH - NIA NIA Luo, Weiming (NIA) 2 147163390 Tweedie, David NIH - NIA NIA Tweedie, David (NIA) 3 147163391 Vargesson, Nell University of Aberdeen Vargesson, Nell 4 147163392 Beedle, Shaunna University of Aberdeen Beedle, Shaunna 5 147163388 Figg, William NIH - NCI NCI Figg, William (NCI) 6 147163387 Greig, Nigel NIH - NIA NIA Greig, Nigel (NIA) 1 147163389 Luo, Weiming NIH - NIA NIA Luo, Weiming (NIA) 2 147163390 Tweedie, David NIH - NIA NIA Tweedie, David (NIA) 3 147163391 Vargesson, Nell University of Aberdeen Vargesson, Nell 4 147163392 Beedle, Shaunna University of Aberdeen Beedle, Shaunna 5 147163388 Figg, William NIH - NCI NCI Figg, William (NCI) 6 147158211 Thalidomide/lenolidomide/pomalidomide Analogs That Inhibit Inflammation, Angiogenesis E-208-2015-0 Filing authorized National Institute on Aging (NIH/NIA), NCI, University of Aberdeen 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-4062] Thalidomide Analogs that Inhibit Inflammation and Angiogenesis&body=Please send me information about technology [TAB-4062] Thalidomide Analogs that Inhibit Inflammation and Angiogenesis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-4062] Thalidomide Analogs that Inhibit Inflammation and Angiogenesis&body=Please send me information about technology [TAB-4062] Thalidomide Analogs that Inhibit Inflammation and Angiogenesis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147166279 E-208-2015-0 E-208-2015-0-US-01 THALIDOMIDE ANALOGS AND METHODS OF USE PRV US 62/235,105 Abandoned US <br />Provisional (PRV) 62/235,105<br />Filed on 2015-09-30<br />Status: Abandoned 147166280 E-208-2015-0 E-208-2015-0-PCT-02 Thalidomide Analogs and Methods of Use PCT Patent Cooperation Treaty PCT/US2016/054430 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/054430<br />Filed on 2016-09-29<br />Status: Expired 147166281 E-208-2015-0 E-208-2015-0-AU-03 Thalidomide Analogs and Methods of Use National Stage Australia 2016330967 2016330967 Issued Australia <br />National Stage 2016330967<br />Filed on 2016-09-29<br />Status: Issued 147166282 E-208-2015-0 E-208-2015-0-CA-04 Thalidomide Analogs and Methods of Use National Stage Canada 3000661 3000661 Issued Canada <br />National Stage 3000661<br />Filed on 2016-09-29<br />Status: Issued 147166283 E-208-2015-0 E-208-2015-0-EP-05 Thalidomide Analogs and Methods of Use National Stage European Patent 3356346 16782148.7 Issued European Patent <br />National Stage 16782148.7<br />Filed on 2016-09-29<br />Status: Issued 147166284 E-208-2015-0 E-208-2015-0-KR-06 Thalidomide Analogs and Methods of Use National Stage South Korea 10-2838444 10-2018-7012347 Issued South Korea <br />National Stage 10-2018-7012347<br />Filed on 2018-04-30<br />Status: Issued 147166285 E-208-2015-0 E-208-2015-0-US-07 THALIDOMIDE ANALOGS AND METHODS OF USE National Stage US 10,730,835 15/764,193 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10730835 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10730835">10,730,835</a><br />Filed on 2018-03-28<br />Status: Issued 147166286 E-208-2015-0 E-208-2015-0-US-08 THALIDOMIDE ANALOGS AND METHODS OF USE CON US 10,836,721 16/910,708 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10836721 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10836721">10,836,721</a><br />Filed on 2020-06-24<br />Status: Issued 147166287 E-208-2015-0 E-208-2015-0-US-09 THALIDOMIDE ANALOGS AND METHODS OF USE CON US 11,440,880 17/083,898 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11440880 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11440880">11,440,880</a><br />Filed on 2020-10-29<br />Status: Issued 168186126 E-208-2015-0 E-208-2015-0-FR-01 Thalidomide Analogs and Methods of Use EP France 3356346 16782148.7 Issued France <br />European patent (EP) 16782148.7<br />Filed on 2016-09-29<br />Status: Issued 168186131 E-208-2015-0 E-208-2015-0-DE-01 Thalidomide Analogs and Methods of Use EP Germany 3356346 16782148.7 Issued Germany <br />European patent (EP) 16782148.7<br />Filed on 2016-09-29<br />Status: Issued 168186137 E-208-2015-0 E-208-2015-0-GB-01 Thalidomide Analogs and Methods of Use EP United Kingdom 3356346 16782148.7 Issued United Kingdom <br />European patent (EP) 16782148.7<br />Filed on 2016-09-29<br />Status: Issued 147173686 anti-angiogenesis 147173687 ANTI-INFLAMMATORY 147173688 Lenalidomide 147173689 Pomalidomide 147173690 THALIDOMIDE TAB-4061 147157343 Novel Human Islet Amyloid Polypeptides as Alzheimer’s Disease Biomarkers and Inhibitors of Amyloid Formation NIA Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Josephine Earley, Qing Rong Liu, Min Zhu <h2>Description of Technology:</h2> <p>Over 34 million Americans are living with diabetes. An estimated 6.5 million Americans are living with Alzheimer&rsquo;s disease (AD) and type 2 diabetes mellites (T2DM). Amyloidosis due to aggregation of amyloid-&beta; is key pathogenic event in AD, whereas aggregation of mature islet amyloid polypeptide (IAPP37) in human islet leads to &beta;-cell dysfunction. A hallmark feature of T2DM is the accumulation of islet amyloid polypeptide fibrils in pancreatic islets. Such accumulations form amyloid plaques and cause apoptosis of -cells of islets.&nbsp;</p> <p>Researchers at NIA used a bioinformatic and molecular biological approaches to identify two novel islet amyloid polypeptide isoforms: IAPP&beta;, encoding an elongated propeptide of the conventional IAPP and a non-aggregating IAPP&gamma;, which is processed to an unrelated mature IAPP25 instead of IAPP37. They developed a quantitative selective reaction monitoring (SRM) proteomic assay that determined the isoform peptide levels in human clinical plasma and CSF from individuals with early AD were significantly reduced. Further, mature IAPP25 derived from IAPP&gamma; isoform inhibited fibrillation of IAPP37 and amyloid-&beta; efficiently in vitro.</p> <p>The novel IAPP&beta; and IAPP&gamma; isoforms could potentially be developed as peptidyl therapeutics to counteract with amyloid forming IAPP37 and amyloid-&beta; in treatments of diabetes and Alzheimer&rsquo;s disease. These isoforms could also serve as blood-based biomarkers for Alzheimer&rsquo;s disease. The NIA seeks co-development partners and/or licensees for the further development of these therapeutics and biomarkers.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapy for amyloid diseases, including type 2 diabetes mellitus, Alzheimer&rsquo;s disease and Parkinson&rsquo;s disease</li> <li>Potential to be developed as peptidyl therapeutics&nbsp;</li> <li>Clinical diagnostic blood-derived biomarkers for AD</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Peptide based anti-amyloid medicine</li> <li>Potential market applications for neurodegenerative diseases</li> </ul> The National Institute on Aging (NIA) seeks licensing and/or co-development research collaboration partners for the further development of islet amyloid polypeptide (IAPP) diagnostic biomarkers and peptidyl therapeutics for amyloid related diseases. 2023-04-27 2026-04-16 2023-04-27 2026-07-13 2023-04-27 Ad, Age-Associated Disease, Alzheimer’s Disease, Amyloidosis, Amyloids, Biomarkers, DIABETES, IAPP, Islet Amyloid Polypeptide Isoforms, Liu, National Institute on Aging, NIA, PEPTIDYL False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-04-27 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162280 Liu, Q.-R., et al. Novel Hominid-Specific IAPP Isoforms: Potential Biomarkers of Early Alzheimer&rsquo;s Disease and Inhibitors of Amyloid Formation. https://pubmed.ncbi.nlm.nih.gov/36671553/ <a href="https://pubmed.ncbi.nlm.nih.gov/36671553/">Liu, Q.-R., et al. Novel Hominid-Specific IAPP Isoforms: Potential Biomarkers of Early Alzheimer&rsquo;s Disease and Inhibitors of Amyloid Formation.</a> 147163385 Liu, Qing Rong NIH - NIA NIDA Liu, Qing Rong (NIDA) 1 147163386 Zhu, Min National Institute on Aging (NIH/NIA) NIA Zhu, Min (NIA) 2 147163384 Earley, Josephine NIH - NIA NIA Earley, Josephine (NIA) 3 147163385 Liu, Qing Rong NIH - NIA NIDA Liu, Qing Rong (NIDA) 1 147163386 Zhu, Min National Institute on Aging (NIH/NIA) NIA Zhu, Min (NIA) 2 147163384 Earley, Josephine NIH - NIA NIA Earley, Josephine (NIA) 3 147158195 Novel Islet Amyloid Polypeptide (IAPP ) And Soluble IAPP Polypeptides, Inhibitor Of Amyloid And Biomarkers Of AD E-197-2022-0 Filing authorized National Institute on Aging (NIH/NIA) 91827321 Jinnah, Zarpheen zarpheen.jinnah@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-4061] Novel Human Islet Amyloid Polypeptides as Alzheimer’s Disease Biomarkers and Inhibitors of Amyloid Formation&body=Please send me information about technology [TAB-4061] Novel Human Islet Amyloid Polypeptides as Alzheimer’s Disease Biomarkers and Inhibitors of Amyloid Formation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Jinnah, Zarpheen<br><a href="mailto:zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-4061] Novel Human Islet Amyloid Polypeptides as Alzheimer’s Disease Biomarkers and Inhibitors of Amyloid Formation&body=Please send me information about technology [TAB-4061] Novel Human Islet Amyloid Polypeptides as Alzheimer’s Disease Biomarkers and Inhibitors of Amyloid Formation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">zarpheen.jinnah@nih.gov</a><br> 147161183 E-197-2022-0 E-197-2022-0-US-01 ISLET AMYLOID POLYPEPTIDE ISOFORMS AND PEPTIDES AND METHODS OF USE PRV US 63/417,582 Expired US <br />Provisional (PRV) 63/417,582<br />Filed on 2022-10-19<br />Status: Expired 147166277 E-197-2022-0 E-197-2022-0-PC-01 ISLET AMYLOID POLYPEPTIDE ISOFORMS AND PEPTIDES AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2023/077173 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/077173<br />Filed on 2023-10-18<br />Status: Expired 168186121 E-197-2022-0 E-197-2022-0-US-02 ISLET AMYLOID POLYPEPTIDE ISOFORMS AND PEPTIDES AND METHODS OF USE National Stage US 19/122,658 Pending US <br />National Stage 19/122,658<br />Filed on 2025-04-18<br />Status: Pending 147173506 Ad 147173508 Age-Associated Disease 147173509 Alzheimer’s Disease 147173510 Amyloidosis 147173512 Amyloids 147173513 Biomarkers 147173514 DIABETES 147173515 IAPP 147173517 Islet Amyloid Polypeptide Isoforms 147173518 Liu 147173519 National Institute on Aging 147173520 NIA 147173521 PEPTIDYL TAB-4039 147157320 MADCO-Accelerated Multidimensional Diffusion MRI NICHD Collaboration, Diagnostics, Immunology, Licensing, Materials Available, Oncology Collaboration Diagnostics Immunology Licensing Materials Available Oncology Peter Basser, Dan Benjamini <p>Although multidimensional diffusion/relaxation NMR experiments are widely used in materials sciences and engineering applications, preclinical and clinical MRI applications of these techniques were not feasible. Moreover, higher-field MRI scanners posed another obstacle to translation of this NMR method. Their specific absorption rate (SAR) limits the use of multi-echo or CPMG pulse trains, so that the large amounts of data required by these methods cannot be collected in vivo due to exceedingly long scan times. Therefore, the primary challenges this invention overcomes are the migration of NMR methods to MRI and to vastly shorten scan times.&nbsp;</p> <p>The &ldquo;Marginal Distributions Constrained Optimization (MADCO)&rdquo; methodology provides a novel framework to accelerate and improve the reconstruction of multidimensional NMR relaxation/diffusion spectra suitable for use in MRI applications on a voxel-by-voxel basis. This approach uses 1D acquired spectra as a priori information to estimate a 2D (or higher dimensional) spectrum. 1D marginal distributions are used as constraints when the 2D spectra are reconstructed.&nbsp; &nbsp;</p> <p>The MADCO methodology was demonstrated with polyvinylpyrrolidone-water solution phantoms, which contains 3 species of diffusivities and T1 relaxation times (i.e., 3 peaks in the D-T1 space). With a reasonably accurate estimate of the 1D marginal distributions, MADCO accelerated the acquisition of the 2D spectra by more than a factor of 200 (i.e., two orders of magnitude) with a high level of accuracy, compared to conventional, unconstrained methods.</p> <blockquote> <p><img alt="" height="375" src="https://nih.technologypublisher.com/files/sites/e-173-2016_abstract_figure4.png" width="1000" /></p> </blockquote> <h2>Competitive Advantages:</h2> <ul> <li>Disruptive technologies can positively impact market penetration in a large and growing medical sector. In 2016, an estimated 39 million magnetic resonance imaging (MRI) procedures were performed &ndash; reflecting an average annual growth rate of ~4% since 2011. In the same year, over 8500 clinical sites offered the procedure</li> <li>Metabolomics; increased use in quantitative and metabolic screening applications, where the bottleneck in exploiting the higher information content of multidimensional spectra is the time required to acquire the magnetic resonance data</li> <li>The MADCO method would accelerate and improve the reconstruction of multidimensional NMR relaxation/diffusion spectra suitable for use in MRI, where reducing the amount of data required, reduces the time of scanning, and reduces the cost</li> <li>Imaging procedures such as MRIs use lower radiation levels compared with CT and PET scans, lowering patients risk</li> <li>Shortens scan time using MADCO, resulting in reduced patient discomfort as well as improve diagnostic accuracy</li> <li>Decreases probability of overuse and increases patient benefit for what can be a costly diagnostic procedure</li> </ul> <h2>Commercial Applications:</h2> <ul> <li>Incorporation into neuro or whole-body MRI suites to measure changes in neural and other human tissue within a clinically feasible time-frame</li> <li>Monitoring and mapping brain injury and other pathologies, including inflammation</li> <li>Cardiovascular disease; e.g., stroke, thrombolysis</li> <li>Dental diseases for which standard x-rays do not provide adequate resolution</li> <li>New quantitative imaging biomarkers for improved radiological assessment of normal and abnormal development, various diseases and disorders that have neuroanatomical and microstructural sequelae (e.g., TIA, cancer, Alzheimer&rsquo;s disease, inflammatory diseases)</li> <li>Investigation of fixed tissue, living organotypic neural or other tissue or pre-clinical in vivo animal models in a feasible time frame</li> <li>Producing new quantitative radiological biomarkers, stains or contrasts. Providing a new method for scanning and assessing foods safety and storage life&nbsp; &nbsp;&nbsp;</li> <li>Characterization of rock and soil samples in situ or in a laboratory setting for the oil, gas and water exploration fields</li> <li>Assessing materials and material properties, such as polymers, gels, composites, concrete, and other man-made and natural materials</li> </ul> 2017-12-07 2025-04-22 2017-12-07 2026-07-13 2017-12-07 Basser, Biomarkers, Diffusion MRI, IMAGING, Marginal-Distributions, MRI, MRI diagnostic, Multidimensional-NMR, NMR-Spectroscopy, Relaxometry Diffusometry, T1, T2 False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-12-07 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161889 Benjamini D, et al. Clinically feasible relaxation-diffusion correlation MRI using MADCO. https://science.nichd.nih.gov/confluence/display/sqits/Abstracts <a href="https://science.nichd.nih.gov/confluence/display/sqits/Abstracts">Benjamini D, et al. Clinically feasible relaxation-diffusion correlation MRI using MADCO.</a> 147162005 Benjamini D, et al. Towards clinically feasible relaxation-diffusion correlation MRI using MADCO. https://doi.org/10.1016/j.micromeso.2017.02.001 <a href="https://doi.org/10.1016/j.micromeso.2017.02.001">Benjamini D, et al. Towards clinically feasible relaxation-diffusion correlation MRI using MADCO.</a> 147162161 Bai R, et al. Fast, accurate 2D-MR relaxation exchange spectroscopy (REXSY): Beyond compressed sensing. https://www.ncbi.nlm.nih.gov/pubmed/27782473 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27782473">Bai R, et al. Fast, accurate 2D-MR relaxation exchange spectroscopy (REXSY): Beyond compressed sensing.</a> 147162239 Benjamini D, et al. Imaging Local Diffusive Dynamics Using Diffusion Exchange Spectroscopy MRI. https://www.ncbi.nlm.nih.gov/pubmed/28452522 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28452522">Benjamini D, et al. Imaging Local Diffusive Dynamics Using Diffusion Exchange Spectroscopy MRI.</a> 147162277 Benjamini D, et al. Water exchange in a white matter tissue phantom measured using clinically feasible diffusion exchange spectroscopy (DEXSY) MRI. https://science.nichd.nih.gov/confluence/display/sqits/Abstracts <a href="https://science.nichd.nih.gov/confluence/display/sqits/Abstracts">Benjamini D, et al. Water exchange in a white matter tissue phantom measured using clinically feasible diffusion exchange spectroscopy (DEXSY) MRI.</a> 147162316 Benjamini D, et al. Use of marginal distributions constrained optimization (MADCO) for accelerated 2D MRI relaxometry and diffusometry. https://www.ncbi.nlm.nih.gov/pubmed/27543810 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27543810">Benjamini D, et al. Use of marginal distributions constrained optimization (MADCO) for accelerated 2D MRI relaxometry and diffusometry.</a> 147162430 Benjamini D, et al. Marginal distributions constrained optimization (MADCO) used to accelerate 2D MRI relaxometry. https://science.nichd.nih.gov/confluence/display/sqits/Abstracts <a href="https://science.nichd.nih.gov/confluence/display/sqits/Abstracts">Benjamini D, et al. Marginal distributions constrained optimization (MADCO) used to accelerate 2D MRI relaxometry.</a> 147163304 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 1 147163305 Benjamini, Dan NIH - NICHD NIA Benjamini, Dan (NIA) 2 147163304 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 1 147163305 Benjamini, Dan NIH - NICHD NIA Benjamini, Dan (NIA) 2 147158144 Multi-dimensional Spectroscopic NMR And MRI Using Marginal Distributions To Reduce Acquired Data E-173-2016-0 Filing authorized NICHD 119617417 Ravilious, Geoffrey geoffrey.ravilious@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4039] MADCO-Accelerated Multidimensional Diffusion MRI&body=Please send me information about technology [TAB-4039] MADCO-Accelerated Multidimensional Diffusion MRI.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ravilious, Geoffrey<br><a href="mailto:geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4039] MADCO-Accelerated Multidimensional Diffusion MRI&body=Please send me information about technology [TAB-4039] MADCO-Accelerated Multidimensional Diffusion MRI.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">geoffrey.ravilious@nih.gov</a><br> 147161147 E-173-2016-0 E-173-2016-0-US-01 Multi-Dimensional Spectroscopic NMR And MRI Using Marginal Distributions PRV US 62/373,497 Abandoned US <br />Provisional (PRV) 62/373,497<br />Filed on 2016-08-11<br />Status: Abandoned 147166150 E-173-2016-0 E-173-2016-0-PCT-02 MULTI-DIMENSIONAL SPECTROSCOPIC NMR AND MRI USING MARGINAL DISTRIBUTIONS PCT Patent Cooperation Treaty PCT/US2017/046615 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/046615<br />Filed on 2017-08-11<br />Status: Expired 147166151 E-173-2016-0 E-173-2016-0-AU-03 MULTI-DIMENSIONAL SPECTROSCOPIC NMR AND MRI USING MARGINAL DISTRIBUTIONS National Stage Australia 2017310513 2017310513 Issued Australia <br />National Stage 2017310513<br />Filed on 2019-01-23<br />Status: Issued 147166152 E-173-2016-0 E-173-2016-0-CA-04 MULTI-DIMENSIONAL SPECTROSCOPIC NMR AND MRI USING MARGINAL DISTRIBUTIONS National Stage Canada 3032154 Pending Canada <br />National Stage 3032154<br />Filed on 2017-08-11<br />Status: Pending 147166153 E-173-2016-0 E-173-2016-0-EP-05 MULTI-DIMENSIONAL SPECTROSCOPIC NMR AND MRI USING MARGINAL DISTRIBUTIONS National Stage European Patent 3497460 17755012.6 Issued European Patent <br />National Stage 17755012.6<br />Filed on 2019-02-05<br />Status: Issued 147166154 E-173-2016-0 E-173-2016-0-JP-06 MULTI-DIMENSIONAL SPECTROSCOPIC NMR AND MRI USING MARGINAL DISTRIBUTIONS National Stage Japan 7058259 2019-506625 Issued Japan <br />National Stage 2019-506625<br />Filed on 2019-02-07<br />Status: Issued 147166155 E-173-2016-0 E-173-2016-0-US-07 MULTI-DIMENSIONAL SPECTROSCOPIC NMR AND MRI USING MARGINAL DISTRIBUTIONS National Stage US 11,415,652 16/324,413 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11415652 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11415652">11,415,652</a><br />Filed on 2019-02-08<br />Status: Issued 147166156 E-173-2016-0 E-173-2016-0-US-08 MULTI-DIMENSIONAL SPECTROSCOPIC NMR AND MRI USING MARGINAL DISTRIBUTIONS CON US 11,846,690 17/863,846 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11846690 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11846690">11,846,690</a><br />Filed on 2022-07-13<br />Status: Issued 168186088 E-173-2016-0 E-173-2016-0-GB-01 MULTI-DIMENSIONAL SPECTROSCOPIC NMR AND MRI USING MARGINAL DISTRIBUTIONS EP United Kingdom 3497460 17755012.6 Issued United Kingdom <br />European patent (EP) 17755012.6<br />Filed on 2019-02-05<br />Status: Issued 168186098 E-173-2016-0 E-173-2016-0-EP-01 MULTI-DIMENSIONAL SPECTROSCOPIC NMR AND MRI USING MARGINAL DISTRIBUTIONS Unitary Patent European Patent 3497460 17755012.6 Issued European Patent <br />Unitary Patent 17755012.6<br />Filed on 2019-02-05<br />Status: Issued 147173004 Basser 147173005 Biomarkers 147173007 Diffusion MRI 147173008 IMAGING 147173010 Marginal-Distributions 147173011 MRI 147173012 MRI diagnostic 147173014 Multidimensional-NMR 147173016 NMR-Spectroscopy 147173018 Relaxometry Diffusometry 147173019 T1 147173020 T2 TAB-4152 147157435 Fatty Acid Derivatives and Their Use for the Treatment and Prevention of Autoimmune, Inflammatory, and Pain Disorders NIA Collaboration, Immunology, Licensing, Therapeutics Collaboration Immunology Licensing Therapeutics Gregory Keyes, Christopher Ramsden <p>The discovery and selection of suitable compounds for the treatment and prevention of autoimmune, inflammatory, and pain disorders is a significant challenge. Researchers at National Institute of Aging (NIA) mitigated this issue. They discovered and synthesized numerous novel fatty acid derivatives (novel small molecules) that may ameliorate these conditions and provide treatment options for these disorders. In a relevant rat model, the fatty acid derivatives developed by NIA demonstrated:</p> <ul><li>increased activity</li> <li>lower toxicity</li> <li>greater stability</li> <li>longer half-life</li> </ul><p>These beneficial results favorably compare to prior agents utilized for treating inflammation, autoimmune disorders, and/or pain. Certain of the disclosed fatty acid derivatives are capable of readily crossing the blood-brain barrier – providing an advantage specifically with respect to certain pain disorders.  </p> <p>NIA is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize fatty acid derivatives.  In addition, NIA is open to collaborative research relationships (such as under a CRADA) whereby resources such as intellectual property can be pooled and applied to the development of therapies with respect to a wide variety of autoimmune and inflammatory and pain-related conditions.  In addition, NIA is open to a wide variety of licensing arrangements with respect to these technologies.</p> <h2>Competitive Advantages:</h2> <ul><li>Ability to readily cross the blood-brain barrier</li> <li>Increased activity, lower toxicity, greater stability, and longer half-life in a relevant proof-of-concept rat model compared with drugs currently available for treating inflammation, autoimmune disorders, and/or pain</li> <li>Substantial intellectual property life cycle: e.g., patents if issued likely will expire no earlier than 2038</li> <li>Proof-of-concept in rat model</li> </ul> <h2>Commercial Applications:</h2> <p><strong>Therapies to treat:</strong></p> <ul><li>Autoimmune disorders</li> <li>Inflammation</li> <li>Pain-related disorders</li> <li>Itching and/or skin disorders</li> </ul> 2018-04-25 2026-01-14 2022-03-23 2026-07-13 2018-04-25 Autoimmune, Inflammation, National Institute on Aging (NIA), Pain, Ramsden False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2022-03-23 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162157 Ramden et al. A systems approach for discovering linoleic acid derivatives that potentially mediate pain and itch. https://www.ncbi.nlm.nih.gov/pubmed/28831021 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28831021">Ramden et al. A systems approach for discovering linoleic acid derivatives that potentially mediate pain and itch.</a> 147163703 Ramsden, Christopher NIH - NIA NIA Ramsden, Christopher (NIA) 1 147163704 Keyes, Gregory NIH - NIA NIA Keyes, Gregory (NIA) 2 147163703 Ramsden, Christopher NIH - NIA NIA Ramsden, Christopher (NIA) 1 147163704 Keyes, Gregory NIH - NIA NIA Keyes, Gregory (NIA) 2 147158083 Synthesis And Use Of Endogenous Lipid Mediators, Their Stable Analogs, And Small Molecule Pharmacophores Containing The Same Active Moieties As The Endogenous Compounds, To Regulate Inflammation, Neuronal Activation, Nociceptive And Pruriceptive Sens E-151-2017-0 Filing authorized National Institute on Aging (NIH/NIA) 91827321 Jinnah, Zarpheen zarpheen.jinnah@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-4152] Fatty Acid Derivatives and Their Use for the Treatment and Prevention of Autoimmune, Inflammatory, and Pain Disorders&body=Please send me information about technology [TAB-4152] Fatty Acid Derivatives and Their Use for the Treatment and Prevention of Autoimmune, Inflammatory, and Pain Disorders.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Jinnah, Zarpheen<br><a href="mailto:zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-4152] Fatty Acid Derivatives and Their Use for the Treatment and Prevention of Autoimmune, Inflammatory, and Pain Disorders&body=Please send me information about technology [TAB-4152] Fatty Acid Derivatives and Their Use for the Treatment and Prevention of Autoimmune, Inflammatory, and Pain Disorders.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">zarpheen.jinnah@nih.gov</a><br> 147166939 E-151-2017-0 E-151-2017-0-US-01 FATTY ACID DERIVATIVES AND THEIR USE PRV US 62/529,846 Abandoned US <br />Provisional (PRV) 62/529,846<br />Filed on 2017-07-07<br />Status: Abandoned 147166940 E-151-2017-0 E-151-2017-0-PCT-02 FATTY ACID DERIVATIVES AND THEIR USE PCT Patent Cooperation Treaty PCT/US2018/041086 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/041086<br />Filed on 2018-07-06<br />Status: Expired 147166941 E-151-2017-0 E-151-2017-0-AU-03 FATTY ACID DERIVATIVES AND THEIR USE National Stage Australia 2018297192 2018297192 Issued Australia <br />National Stage 2018297192<br />Filed on 2018-07-06<br />Status: Issued 147166942 E-151-2017-0 E-151-2017-0-CA-04 FATTY ACID DERIVATIVES AND THEIR USE National Stage Canada 3064132 3064132 Issued Canada <br />National Stage 3064132<br />Filed on 2018-07-06<br />Status: Issued 147166943 E-151-2017-0 E-151-2017-0-CN-05 FATTY ACID DERIVATIVES AND THEIR USE National Stage China 201880045287.6 Abandoned China <br />National Stage 201880045287.6<br />Filed on 2018-07-06<br />Status: Abandoned 147166944 E-151-2017-0 E-151-2017-0-EP-06 FATTY ACID DERIVATIVES AND THEIR USE National Stage European Patent 3649115 18746415.1 Issued European Patent <br />National Stage 18746415.1<br />Filed on 2018-07-06<br />Status: Issued 147166945 E-151-2017-0 E-151-2017-0-JP-07 FATTY ACID DERIVATIVES AND THEIR USE National Stage Japan 7234151 2019-572570 Issued Japan <br />National Stage 2019-572570<br />Filed on 2018-07-06<br />Status: Issued 147166946 E-151-2017-0 E-151-2017-0-KR-08 FATTY ACID DERIVATIVES AND THEIR USE National Stage South Korea 10-2725883 10-2020-7003568 Issued South Korea <br />National Stage 10-2020-7003568<br />Filed on 2020-02-06<br />Status: Issued 147166947 E-151-2017-0 E-151-2017-0-MX-09 FATTY ACID DERIVATIVES AND THEIR USE National Stage Mexico 391168 MX/a/2019/015730 Issued Mexico <br />National Stage MX/a/2019/015730<br />Filed on 2018-07-06<br />Status: Issued 147166948 E-151-2017-0 E-151-2017-0-US-10 FATTY ACID DERIVATIVES AND THEIR USE National Stage US 11,555,021 16/622,697 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11555021 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11555021">11,555,021</a><br />Filed on 2019-12-30<br />Status: Issued 147166949 E-151-2017-0 E-151-2017-0-HK-11 FATTY ACID DERIVATIVES AND THEIR USE National Stage Hong Kong 62020007841.3 Pending Hong Kong <br />National Stage 62020007841.3<br />Filed on 2018-07-06<br />Status: Pending 147166950 E-151-2017-0 E-151-2017-0-US-12 FATTY ACID DERIVATIVES AND THEIR USE DIV US 12,479,812 17/718,965 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12479812 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12479812">12,479,812</a><br />Filed on 2022-04-12<br />Status: Issued 168153207 E-151-2017-0 E-151-2017-0-GB-01 FATTY ACID DERIVATIVES AND THEIR USE EP United Kingdom 3649115 18746415.1 Issued United Kingdom <br />European patent (EP) 18746415.1<br />Filed on 2018-07-06<br />Status: Issued 168185987 E-151-2017-0 E-151-2017-0-EP-01 FATTY ACID DERIVATIVES AND THEIR USE Unitary Patent European Patent 3649115 18746415.1 Issued European Patent <br />Unitary Patent 18746415.1<br />Filed on 2018-07-06<br />Status: Issued 168186077 E-151-2017-0 E-151-2017-0-US-13 FATTY ACID DERIVATIVES AND THEIR USE CON US 19/356,831 Abandoned US <br />Continuation (CON) 19/356,831<br />Filed on 2025-10-13<br />Status: Abandoned 147172391 Autoimmune 147172392 Inflammation 147172394 National Institute on Aging (NIA) 147172395 Pain 147172397 Ramsden TAB-910 114095244 Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12) NIAID Collaboration, Diagnostics, Infectious Disease, Licensing, Materials Available, Research Materials, Therapeutics, Vaccines Collaboration Diagnostics Infectious Disease Licensing Materials Available Research Materials Therapeutics Vaccines Lisbeth Kim Green, Stanislav Sosnovtsev The noroviruses (known as "Norwalk-like viruses") are associated with an estimated 23,000,000 cases of acute gastroenteritis in the United States each year. Norovirus illness often occurs in outbreaks, affecting large numbers of individuals, illustrated recently by well-publicized reports of gastroenteritis outbreaks on several recreational cruise ships and in settings such as hospitals and schools. Norovirus disease is clearly important in terms of medical costs and missed workdays, and accumulating data support its emerging recognition as important agents of diarrhea-related morbidity.<br /><br /> Because the noroviruses cannot be propagated by any means in the laboratory, an important strategy in their study is the development of molecular biology-based tools. This invention reports the development of recombinant baculoviruses carrying the capsid gene from several caliciviruses associated with human disease. Growth of these baculovirus recombinants in insect cells results in the expression of virus-like particles (VLPs) that are antigenically indistinguishable from the native calicivirus particle. These VLPs can be purified in large quantities for use as diagnostic reagents and potential vaccine candidates. The Laboratory of Infectious Diseases, NIAID, NIH, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize norovirus VLP antigens. Please contact Kim Y. Green at <a href="mailto:kgreen@niaid.nih.gov">kgreen@niaid.nih.gov</a> for more information. Research Material --Patent protection is not being pursued for this technology Research Material -- Patent protection is not being pursued for these technologies The materials embodied in this invention are available nonexclusively through a biological materials license. 2022-03-08 2026-06-29 2026-06-29 2008-06-01 Baculoviruses, CALICIVIRUS, CAPSID, Construction, DA4BXX, DA4XXX, DAXXXX, DB4BXX, DB4XXX, DBXXXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, DXXXXX, Hawaii, MD145-12, Mountain, Norovirus, SHIELD, Snow, STRAINS, TORONTO, VP1 False True True NIHTT 37470483 Website Abstract E-283-2003-0 E-214-2003-0 E-212-2003-0 114169964 Green KY, et al. A predominant role for Norwalk-like viruses as agents of epidemic gastroenteritis in Maryland nursing homes for the elderly. https://www.ncbi.nlm.nih.gov/pubmed/11807686 <a href="https://www.ncbi.nlm.nih.gov/pubmed/11807686">Green KY, et al. A predominant role for Norwalk-like viruses as agents of epidemic gastroenteritis in Maryland nursing homes for the elderly.</a> 114104726 Sosnovtsev, Stanislav NIAID - DIR NIAID Sosnovtsev, Stanislav (NIAID) 0 114104728 Green, Lisbeth Kim NIAID - DIR NIAID Green, Lisbeth Kim (NIAID) 1 114104728 Green, Lisbeth Kim NIAID - DIR NIAID Green, Lisbeth Kim (NIAID) 1 114104726 Sosnovtsev, Stanislav NIAID - DIR NIAID Sosnovtsev, Stanislav (NIAID) 0 114100102 Construction Of Recombinant Baculoviruses Carrying The Gene Encoding The Major Capsid Protein, VP1, From Calicivirus Strains (including, But Not Limited To, Norovirus Strains, Toronto, Hawaii, Desert Shield, Snow Mountain And MD145-12) E-198-2003-0 Research Material NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-910] Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12)&body=Please send me information about technology [TAB-910] Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12). Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-910] Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12)&body=Please send me information about technology [TAB-910] Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12).">ganelinaa@niaid.nih.gov</a><br> 114115252 DA4BXX 114115253 DB4BXX 114115254 DC5BXX 114115255 DDXXXX 114115256 DAXXXX 114115257 DBXXXX 114115258 DCXXXX 114115259 DXXXXX 114119609 DA4XXX 114119610 DB4XXX 114119611 DC5XXX 114130371 Construction 114130372 Baculoviruses 114130373 CAPSID 114130374 VP1 114130375 CALICIVIRUS 114130376 STRAINS 114130377 Norovirus 114130378 TORONTO 114130379 Hawaii 114130380 SHIELD 114130381 Snow 114130382 Mountain 114130383 MD145-12 TAB-5101 167599021 Human-Bovine Reassortant Rotavirus Vaccine NIAID TherapeuticArea, Vaccines TherapeuticArea Vaccines Robert Chanock (Estate), Yasutaka Hoshino, Albert Kapikian (Estate Of) <p>Rotavirus is a major cause of severe diarrhea and dehydration in infants and young children. Vaccines that cover the most important rotavirus serotypes could help reduce serious illness worldwide.</p> <p>Researchers at NIAID&rsquo;s Laboratory of Infectious Diseases developed a multivalent human-bovine reassortant rotavirus vaccine using vaccine strains created by combining selected genes from human and bovine (cow) rotaviruses. This approach targets the most important rotavirus serotypes at once, including G1, G2, G3, and G4, with the potential to expand coverage to G5, G9, and G10.</p> <p>These multivalent vaccine candidates trigger immune responses against multiple rotavirus serotypes in a single formulation at lower doses than earlier human-bovine vaccine approaches. The multivalent formulation does not cause the low-grade, short-lived fever seen with prior candidates.</p> <p>&nbsp;</p> <ul> <li> Designed for lower-dose immunogenicity than earlier human-bovine reassortant approaches described in the literature. </li> <li> No low-grade, transient fever observed compared with prior candidates. </li> <li> Flexible reassortant design that may support addition of newly important rotavirus serotypes. </li> </ul> <ul> <li> Multivalent rotavirus vaccine that covers several clinically important rotavirus serotypes in a single product, including G1, G2, G3, and G4, with potential to expand coverage to the additional serotypes G5, G9, and G10. </li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Elizabeth Pitts at 240–669–5299, or elizabeth.pitts@nih.gov. 2026-05-27 2026-06-29 2026-06-29 2026-05-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 167599438 Kapikian (Estate Of), Albert National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Kapikian (Estate Of), Albert (NIAID) 1 167599455 Chanock (Estate), Robert National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Chanock (Estate), Robert (NIAID) 2 167599463 Hoshino, Yasutaka National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Hoshino, Yasutaka (NIAID) 3 167599438 Kapikian (Estate Of), Albert National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Kapikian (Estate Of), Albert (NIAID) 1 167599455 Chanock (Estate), Robert National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Chanock (Estate), Robert (NIAID) 2 167599463 Hoshino, Yasutaka National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Hoshino, Yasutaka (NIAID) 3 167599024 Multivalent Human-Bovine Rotavirus Vaccine E-015-1998-0 Filing authorized NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-5101] Human-Bovine Reassortant Rotavirus Vaccine&body=Please send me information about technology [TAB-5101] Human-Bovine Reassortant Rotavirus Vaccine. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-5101] Human-Bovine Reassortant Rotavirus Vaccine&body=Please send me information about technology [TAB-5101] Human-Bovine Reassortant Rotavirus Vaccine.">ganelinaa@niaid.nih.gov</a><br> 167599028 E-015-1998-0 E-015-1998-0-US-01 Multivalent Human-Bovine Rotavirus Vaccine PRV US 60/094,425 Abandoned US <br />Provisional (PRV) 60/094,425<br />Filed on 1998-07-28<br />Status: Abandoned 167599029 E-015-1998-0 E-015-1998-0-PCT-02 Multivalent Human-Bovine Rotavirus Vaccine PCT Patent Cooperation Treaty PCT/US1999/017036 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1999/017036<br />Filed on 1999-07-27<br />Status: Expired 167599030 E-015-1998-0 E-015-1998-0-US-10 Multivalent Human-Bovine Rotavirus Vaccine National Stage US 7,932,074 09/743,338 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7932074 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7932074">7,932,074</a><br />Filed on 2001-01-04<br />Status: Expired 167599031 E-015-1998-0 E-015-1998-0-AU-06 Multivalent Human-Bovine Rotavirus Vaccine National Stage Australia 759123 53221/99 Expired Australia <br />National Stage 53221/99<br />Filed on 1999-07-27<br />Status: Expired 167599032 E-015-1998-0 E-015-1998-0-BR-11 Multivalent Human-Bovine Rotavirus Vaccine National Stage Brazil PI9912485-8 PI9912485-8 Expired Brazil <br />National Stage PI9912485-8<br />Filed on 1999-07-27<br />Status: Expired 167599033 E-015-1998-0 E-015-1998-0-CA-07 Multivalent Human-Bovine Rotavirus Vaccine National Stage Canada 2336875 2336875 Expired Canada <br />National Stage 2336875<br />Filed on 1999-07-27<br />Status: Expired 167599034 E-015-1998-0 E-015-1998-0-CN-03 Multivalent Human-Bovine Rotavirus Vaccine National Stage China ZL99810311.X 99810311.X Expired China <br />National Stage 99810311.X<br />Filed on 1999-07-27<br />Status: Expired 167599035 E-015-1998-0 E-015-1998-0-EP-08 Multivalent Human-Bovine Rotavirus Vaccine National Stage European Patent 1100537 99938819.2 Expired European Patent <br />National Stage 99938819.2<br />Filed on 1999-07-27<br />Status: Expired 167599036 E-015-1998-0 E-015-1998-0-IN-04 Multivalent Human-Bovine Rotavirus Vaccine National Stage India 243453 IN/PCT/2001/0106/CHE Expired India <br />National Stage IN/PCT/2001/0106/CHE<br />Filed on 1999-07-27<br />Status: Expired 167599037 E-015-1998-0 E-015-1998-0-JP-09 Multivalent Human-Bovine Rotavirus Vaccine National Stage Japan 4414095 2000-562050 Expired Japan <br />National Stage 2000-562050<br />Filed on 1999-07-27<br />Status: Expired 167599038 E-015-1998-0 E-015-1998-0-KR-05 Multivalent Human-Bovine Rotavirus Vaccine National Stage South Korea 10-0688434 10-2001-7001236 Expired South Korea <br />National Stage 10-2001-7001236<br />Filed on 1999-07-27<br />Status: Expired 167599040 E-015-1998-0 E-015-1998-0-DE-12 Multivalent Human-Bovine Rotavirus Vaccine EP Germany 69929443.6 99938819.2 Expired Germany <br />European patent (EP) 99938819.2<br />Filed on 1999-07-27<br />Status: Expired 167599041 E-015-1998-0 E-015-1998-0-FR-13 Multivalent Human-Bovine Rotavirus Vaccine EP France 1100537 99938819.2 Expired France <br />European patent (EP) 99938819.2<br />Filed on 1999-07-27<br />Status: Expired 167599042 E-015-1998-0 E-015-1998-0-GB-14 Multivalent Human-Bovine Rotavirus Vaccine EP United Kingdom 1100537 99938819.2 Expired United Kingdom <br />European patent (EP) 99938819.2<br />Filed on 1999-07-27<br />Status: Expired 167599043 E-015-1998-0 E-015-1998-0-IE-15 Multivalent Human-Bovine Rotavirus Vaccine EP Ireland 1100537 99938819.2 Expired Ireland <br />European patent (EP) 99938819.2<br />Filed on 1999-07-27<br />Status: Expired 167599044 E-015-1998-0 E-015-1998-0-IT-16 Multivalent Human-Bovine Rotavirus Vaccine EP Italy 1100537 99938819.2 Expired Italy <br />European patent (EP) 99938819.2<br />Filed on 1999-07-27<br />Status: Expired 167599045 E-015-1998-0 E-015-1998-0-CN-17 Multivalent Human-Bovine Rotavirus Vaccine DIV China ZL200810090397.2 200810090397.2 Expired China <br />Divisional (DIV) 200810090397.2<br />Filed on 2008-04-11<br />Status: Expired 167599047 E-015-1998-0 E-015-1998-0-JP-19 Multivalent Human-Bovine Rotavirus Vaccine DIV Japan 2009-148918 Abandoned Japan <br />Divisional (DIV) 2009-148918<br />Filed on 2009-06-23<br />Status: Abandoned TAB-5038 159567984 Novel Antibody Test for Mycoplasma Detection NIAID Robert Purcell <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">The technology is a novel antibody test designed for the detection of Mycoplasma antibodies, representing a significant advancement in Mycoplasma detection methods. This test offers a rapid and reliable means of diagnosing Mycoplasma infections, which is particularly valuable in research and clinical settings. Unlike existing tests, this innovative approach provides specificity and sensitivity in detecting Mycoplasma antibodies, ensuring accurate and timely diagnosis. The technology&#39;s development stage is currently at the prototype phase, indicating that it is undergoing initial testing and refinement to optimize its performance. Once fully developed, this antibody test has the potential to revolutionize Mycoplasma detection, improving research outcomes and patient care.</span></span></span></p> This novel antibody test for Mycoplasma detection offers several competitive advantages over existing methods. Firstly, it is the first of its kind, providing a unique solution to a previously unmet need in the field. Its specificity and sensitivity in detecting Mycoplasma antibodies surpass current standards, ensuring accurate and reliable results. Additionally, the test is designed to be rapid and easy to use, saving time and resources compared to traditional methods. Its innovative approach has the potential to significantly improve research and clinical outcomes related to Mycoplasma infections. As the technology advances towards commercialization, these competitive advantages position it as a game-changer in the field of Mycoplasma detection and diagnosis. The novel antibody test for Mycoplasma detection has a wide range of potential applications across various fields. In research settings, it can be used to screen cell cultures for Mycoplasma contamination, ensuring the integrity of experiments and the reliability of research outcomes. In clinical settings, the test can aid in the diagnosis of Mycoplasma infections, enabling healthcare providers to administer appropriate treatments promptly. Additionally, the test may find applications in veterinary medicine, agriculture, and environmental monitoring, where Mycoplasma contamination can have significant impacts. The test's versatility and reliability make it a valuable tool for a diverse range of applications, highlighting its potential to address key challenges in multiple industries. 2024-12-10 2026-06-29 2026-06-29 2024-12-10 False False True 52406769 Prototype 52406769 37470483 Website Abstract 159567997 Purcell, Robert National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Purcell, Robert (NIAID) 1 159567997 Purcell, Robert National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Purcell, Robert (NIAID) 1 159567987 Ureaplasma Urealyticum Mycoplasma Test E-198-2020-0 Research Material NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-5038] Novel Antibody Test for Mycoplasma Detection&body=Please send me information about technology [TAB-5038] Novel Antibody Test for Mycoplasma Detection. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-5038] Novel Antibody Test for Mycoplasma Detection&body=Please send me information about technology [TAB-5038] Novel Antibody Test for Mycoplasma Detection.">ganelinaa@niaid.nih.gov</a><br> TAB-4963 153986016 A Fundamental Tool for Efficient Recovery of RNA Viruses through Reverse Genetics NIAID Collaboration, Immunology, Infectious Disease, Licensing, Research Equipment, Therapeutics, Vaccines Collaboration Immunology Infectious Disease Licensing Research Equipment Therapeutics Vaccines Ursula Buchholz <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">BSR T7/5 cells represent a foundational advancement in virology, offering a robust platform for the recovery of RNA viruses via reverse genetics. Established over 20 years ago, these cells have proven instrumental in the recovery of a wide array of RNA viruses, particularly those belonging to the mononegavirales order. By enabling the insertion of antigenome sequences into cDNA plasmids under a T7 RNA polymerase promoter, BSR T7/5 cells facilitate the transcription of RNA antigenomes and mRNA encoding RNP elements, leading to the assembly of infectious viruses. Notably, this system does not require helper viruses, and the cell line&#39;s permissiveness, attributed to the absence of a functional type 1 interferon response, makes it especially valuable for viruses replicating in the cytoplasm.</span></span></span></p> BSR T7/5 cells offer distinct competitive advantages over traditional methods for RNA virus recovery. Their efficiency in recovering RNA viruses from cDNA plasmids via reverse genetics surpasses that of other cell lines, particularly for members of the mononegavirales order. Unlike many existing approaches, the use of BSR T7/5 cells does not necessitate the presence of helper viruses, streamlining the recovery process. Additionally, the cell line's high permissiveness to RNA viruses, attributed to its lack of a functional type 1 interferon response, enhances the range of viruses that can be studied and recovered. These advantages make BSR T7/5 cells a superior choice for researchers seeking a reliable, efficient, and versatile platform for RNA virus recovery and study. The applications of BSR T7/5 cells extend across various fields, offering immense potential in virology, vaccine development, and antiviral drug discovery. Their ability to efficiently recover RNA viruses through reverse genetics makes them invaluable for studying viral pathogenesis, host-virus interactions, and viral evolution. In vaccine development, these cells can be instrumental in generating attenuated or modified viruses for vaccine candidates, particularly for viruses that replicate in the cytoplasm. Furthermore, BSR T7/5 cells hold promise in antiviral drug screening, allowing researchers to evaluate the efficacy of antiviral compounds against a wide range of RNA viruses. Overall, the versatility and reliability of BSR T7/5 cells make them a key tool for advancing our understanding of RNA viruses and developing strategies to combat them. 2024-03-25 2026-06-29 2026-06-29 2024-12-10 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153986027 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 1 153986027 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 1 153986019 BSR T7/5 Cells: Baby Hamster Kidney (BHK-21) Cells Stably Expressing Phage T7 RNA Polymerase E-166-2020-0 Research Material NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4963] A Fundamental Tool for Efficient Recovery of RNA Viruses through Reverse Genetics&body=Please send me information about technology [TAB-4963] A Fundamental Tool for Efficient Recovery of RNA Viruses through Reverse Genetics. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4963] A Fundamental Tool for Efficient Recovery of RNA Viruses through Reverse Genetics&body=Please send me information about technology [TAB-4963] A Fundamental Tool for Efficient Recovery of RNA Viruses through Reverse Genetics.">ganelinaa@niaid.nih.gov</a><br> TAB-4883 152844291 Advancements in Postexposure Prophylaxis: Evaluating High-Potency Rabies-Neutralizing Monoclonal Antibodies NIAID Antibodies, Collaboration, Diagnostics, Infectious Disease, Licensing, Research Equipment, Therapeutics, Vaccines Antibodies Collaboration Diagnostics Infectious Disease Licensing Research Equipment Therapeutics Vaccines Joseph Blaney, Zhaochun Chen, Robert Purcell <p>This technology represents a significant advancement in the field of rabies prevention, focusing on the development of highly potent rabies-neutralizing monoclonal antibodies (mAbs) for use in postexposure prophylaxis (PEP). With two mAbs, F2 and G5a, displaying exceptional neutralizing titers of 1154 and 3462 International Units (IUs) per milligram, respectively, these antibodies have the potential to offer enhanced protection against rabies when administered alongside rabies vaccines. The production of these mAbs involves genetic engineering of mammalian cell lines, enabling their consistent and efficient production. While the in vitro results are promising, rigorous in vivo animal protection assays are necessary to confirm their effectiveness in providing protection against rabies, ultimately offering a promising solution to a disease that remains almost invariably fatal once clinical symptoms develop.</p> <p>&nbsp;</p> This technology's competitive advantages stem from its development of highly potent monoclonal antibodies (mAbs) for rabies prevention. These mAbs, such as F2 and G5a, offer superior protection compared to existing options. Additionally, their production through genetically engineered cell lines ensures a reliable supply, potentially addressing the global shortage of rabies immunoglobulin (RIG). By enhancing postexposure prophylaxis (PEP) when combined with rabies vaccines, this technology improves effectiveness and accessibility in regions with a high rabies incidence, making it a competitive solution in the fight against this deadly disease. These highly potent rabies-neutralizing monoclonal antibodies (mAbs) have diverse potential applications. They can enhance postexposure prophylaxis (PEP), improving survival rates for rabies-exposed individuals. Their utility extends to research, aiding in the study of rabies and the development of new treatments. With scalability and production efficiency, they are accessible tools for rabies control in regions facing shortages or high incidence rates, offering versatile solutions in the fight against rabies. 2024-02-12 2026-06-29 2026-06-29 2024-12-10 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 152844341 Chen, Zhaochun NIAID - DIR NIAID Chen, Zhaochun (NIAID) 1 152844357 Purcell, Robert NIAID Purcell, Robert (NIAID) 2 152844466 Blaney, Joseph NIAID Blaney, Joseph (NIAID) 3 152844341 Chen, Zhaochun NIAID - DIR NIAID Chen, Zhaochun (NIAID) 1 152844357 Purcell, Robert NIAID Purcell, Robert (NIAID) 2 152844466 Blaney, Joseph NIAID Blaney, Joseph (NIAID) 3 152844294 Development Of Chimpanzee/Human Neutralizing Monoclonal Antibodies Against Rabies E-067-2014-0 Research Material NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4883] Advancements in Postexposure Prophylaxis: Evaluating High-Potency Rabies-Neutralizing Monoclonal Antibodies&body=Please send me information about technology [TAB-4883] Advancements in Postexposure Prophylaxis: Evaluating High-Potency Rabies-Neutralizing Monoclonal Antibodies. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4883] Advancements in Postexposure Prophylaxis: Evaluating High-Potency Rabies-Neutralizing Monoclonal Antibodies&body=Please send me information about technology [TAB-4883] Advancements in Postexposure Prophylaxis: Evaluating High-Potency Rabies-Neutralizing Monoclonal Antibodies.">ganelinaa@niaid.nih.gov</a><br> TAB-4861 152463713 TACSTD2 in HCV Infection and Hepatocellular Carcinoma: Transcriptomics Insights NIAID Collaboration, Diagnostics, Infectious Disease Collaboration Diagnostics Infectious Disease Patrizia Farci, Vandana Sekhar <p>This technology involves studying the role of the Tumor-Associated Calcium Signal Transducer 2 (TACSTD2) gene in Hepatitis C Virus (HCV) infection and hepatocellular carcinoma. Researchers perform transcriptomics analysis on liver specimens from HCV-infected patients, identify TACSTD2 as a key gene, and create a stable cell line that overexpresses TACSTD2 to investigate its impact on HCV infection and replication. This technology aims to provide insights into the molecular mechanisms of HCV infection and its association with liver cancer.</p> <p>&nbsp;</p> This technology's competitive advantages stem from its focused approach on the TACSTD2 gene, leveraging cutting-edge transcriptomics analysis to identify differentially expressed genes in HCV-infected patients, and establishing a stable cell line overexpressing TACSTD2 for precise experiments. With a direct link to HCV-associated hepatocellular carcinoma, it offers clinical relevance and the potential for therapeutic insights. Its applicability extends beyond HCV research, making it a versatile tool for various biomedical investigations, ultimately contributing to advancements in understanding HCV infection and its implications in liver diseases. This technology has versatile potential applications. It can enhance our understanding of HCV infection mechanisms, leading to new treatments for HCV-related liver diseases. Additionally, the TACSTD2-overexpressing cell line offers opportunities for broader molecular studies. Its transcriptomics approach may also inspire similar investigations in other viral infections, advancing our knowledge of infectious diseases and aiding in treatment development. 2024-01-29 2026-06-29 2026-06-29 2024-12-10 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 152463786 Farci, Patrizia NIAID - DIR NIAID Farci, Patrizia (NIAID) 1 152463790 Sekhar, Vandana National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Sekhar, Vandana (NIAID) 2 152463786 Farci, Patrizia NIAID - DIR NIAID Farci, Patrizia (NIAID) 1 152463790 Sekhar, Vandana National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Sekhar, Vandana (NIAID) 2 152463716 Tumor Associated Calcium Signal Transducer 2 (TACSTD2)-overexpressing Huh7.5 Cells E-040-2020-0 Research Material NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4861] TACSTD2 in HCV Infection and Hepatocellular Carcinoma: Transcriptomics Insights&body=Please send me information about technology [TAB-4861] TACSTD2 in HCV Infection and Hepatocellular Carcinoma: Transcriptomics Insights. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4861] TACSTD2 in HCV Infection and Hepatocellular Carcinoma: Transcriptomics Insights&body=Please send me information about technology [TAB-4861] TACSTD2 in HCV Infection and Hepatocellular Carcinoma: Transcriptomics Insights.">ganelinaa@niaid.nih.gov</a><br> TAB-4855 152461954 Advancing VZV Antibody Detection: A High-Throughput LIPS Assay for Varicella Vaccine Recipients NIAID Antibodies, Collaboration, Diagnostics, Infectious Disease, Licensing, Research Equipment Antibodies Collaboration Diagnostics Infectious Disease Licensing Research Equipment Mir Ali, Peter Burbelo, Jeffrey Cohen <p>The technology described is a sophisticated and high-throughput luciferase immunoprecipitation system (LIPS) assay designed to detect antibodies specific to Varicella-zoster virus (VZV) glycoprotein E (gE). By transfecting cells with VZV protein-Renilla luciferase fusion protein constructs and subsequently performing immunoprecipitations with protein A/G beads, this innovative assay enables the quantitative measurement of VZV gE antibody levels in blood serum samples. Notably, it demonstrates a sensitivity comparable to the established fluorescent antibody to membrane antigen test (FAMA), making it a promising tool for identifying anti-VZV antibodies in individuals who have received the VZV vaccine. However, potential patent challenges may arise due to similarities with assays used for related herpesviruses, and the market for this technology is relatively niche, primarily targeting populations at higher risk of VZV infection, such as pregnant women and healthcare workers.</p> The proposed high-throughput luciferase immunoprecipitation system (LIPS) assay for VZV antibody detection offers key competitive advantages. It provides quantitative results, enables efficient screening of numerous samples, and matches the sensitivity of the established FAMA test. While patent challenges may arise, this technology serves niche markets, like pregnant women and healthcare workers at higher risk of VZV exposure, making it a valuable tool for focused serological diagnosis and research. The high-throughput luciferase immunoprecipitation system (LIPS) assay for VZV antibody detection has versatile potential applications. It can be used for vaccine studies, epidemiological research, and clinical diagnostics, offering accurate results similar to the FAMA test. Despite potential patent challenges, it's well-suited for specialized purposes like assessing vaccine responses in pregnant women and screening high-risk healthcare workers. This makes it valuable in focused serological research and diagnostics. 2024-01-29 2026-06-29 2026-06-29 2024-12-10 False True True 72159134 Analytical Assay Performance Stage 72159134 37470483 Website Abstract 152461962 Cohen, Jeffrey NIAID - DIR NIAID Cohen, Jeffrey (NIAID) 1 152461980 Burbelo, Peter NIDCR NIDCR Burbelo, Peter (NIDCR) 2 152462067 Ali, Mir NIAID - DIR NIAID Ali, Mir (NIAID) 3 152461962 Cohen, Jeffrey NIAID - DIR NIAID Cohen, Jeffrey (NIAID) 1 152461980 Burbelo, Peter NIDCR NIDCR Burbelo, Peter (NIDCR) 2 152462067 Ali, Mir NIAID - DIR NIAID Ali, Mir (NIAID) 3 152461957 Luciferase Immunoprecipitation Systems Assay To Detect Antibody To Varicella-Zoster Virus In Varicella Vaccine Recipients E-037-2014-0 Research Material NIAID, NIDCR 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4855] Advancing VZV Antibody Detection: A High-Throughput LIPS Assay for Varicella Vaccine Recipients&body=Please send me information about technology [TAB-4855] Advancing VZV Antibody Detection: A High-Throughput LIPS Assay for Varicella Vaccine Recipients. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4855] Advancing VZV Antibody Detection: A High-Throughput LIPS Assay for Varicella Vaccine Recipients&body=Please send me information about technology [TAB-4855] Advancing VZV Antibody Detection: A High-Throughput LIPS Assay for Varicella Vaccine Recipients.">ganelinaa@niaid.nih.gov</a><br> TAB-4852 152461108 Optimizing RSV Infection Monitoring and High-Throughput Screening Through GFP Expression in the First-Gene Position of Respiratory Syncytial Virus (RSV) Strain A2 NIAID Collaboration, Computational models/software, Diagnostics, Infectious Disease, Licensing, Research Equipment, Research Materials, Respiratory, Therapeutics Collaboration Computational models/software Diagnostics Infectious Disease Licensing Research Equipment Research Materials Respiratory Therapeutics Ursula Buchholz, Peter Collins, Cindy Luongo <p>In this technology, researchers have engineered a modified version of Respiratory Syncytial Virus (RSV) strain A2 using reverse genetics to incorporate green fluorescent protein (GFP) into the first-gene position. This genetic modification allows for the efficient monitoring of RSV infection and the screening of potential chemical inhibitors. The GFP expression can be easily detected through fluorescence microscopy in live or fixed cells, providing a sensitive tool for both research and drug discovery. Importantly, placing GFP in the first-gene position minimizes interference with the expression of key RSV interferon antagonist genes, maintaining the virus&#39;s functionality while enhancing the brightness and utility of the GFP marker. This technology offers valuable insights into RSV infection dynamics and facilitates high-throughput screening for potential therapeutic agents.</p> <p>&nbsp;</p> The incorporation of green fluorescent protein (GFP) into the first-gene position of Respiratory Syncytial Virus (RSV) strain A2 offers a competitive advantage by providing a highly sensitive and non-invasive method for monitoring RSV infection. This modification ensures a robust and bright signal for accurate tracking, while strategically minimizing interference with key RSV genes. Researchers can better study the virus and expedite drug discovery efforts with this enhanced technology. This technology has versatile potential applications. It aids in better understanding RSV infection, enabling high-throughput screening for antiviral compounds and vaccine development. Additionally, it has broader applications in respiratory virus research, offering insights into host interactions and potential treatments for various viral infections. 2024-01-29 2026-06-29 2026-06-29 2024-12-10 False True True 52406769 Prototype 52406769 37470483 Website Abstract 152461118 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 152461125 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 2 152461129 Luongo, Cindy NIAID - DIR NIAID Luongo, Cindy (NIAID) 3 152461118 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 152461125 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 2 152461129 Luongo, Cindy NIAID - DIR NIAID Luongo, Cindy (NIAID) 3 152461111 Respiratory Syncytial Virus (RSV) Expressing Green Fluorescent Protein (GFP) From An Added Gene In The Fifth-gene Position E-034-2014-0 Research Material NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4852] Optimizing RSV Infection Monitoring and High-Throughput Screening Through GFP Expression in the First-Gene Position of Respiratory Syncytial Virus (RSV) Strain A2&body=Please send me information about technology [TAB-4852] Optimizing RSV Infection Monitoring and High-Throughput Screening Through GFP Expression in the First-Gene Position of Respiratory Syncytial Virus (RSV) Strain A2. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4852] Optimizing RSV Infection Monitoring and High-Throughput Screening Through GFP Expression in the First-Gene Position of Respiratory Syncytial Virus (RSV) Strain A2&body=Please send me information about technology [TAB-4852] Optimizing RSV Infection Monitoring and High-Throughput Screening Through GFP Expression in the First-Gene Position of Respiratory Syncytial Virus (RSV) Strain A2.">ganelinaa@niaid.nih.gov</a><br> TAB-4851 152460971 Enhanced GFP-Expressing Human Metapneumovirus (HMPV): A Versatile Tool for Virology Research and Antiviral Drug Screening NIAID Collaboration, Diagnostics, Infectious Disease, Licensing, Plasmids/Vectors, Research Equipment, Respiratory Collaboration Diagnostics Infectious Disease Licensing Plasmids/Vectors Research Equipment Respiratory Stephanie Biacchesi, Ursula Buchholz, Peter Collins <p>The technology involves genetically engineering Human Metapneumovirus (HMPV) to express enhanced green fluorescent protein (GFP), enabling the monitoring of virus infection and gene expression through GFP fluorescence. This system serves as a sensitive and versatile tool for virology research, antiviral drug screening, and diagnostic applications. Researchers can use it to study HMPV behavior in real-time, identify potential antiviral compounds, and quantify viral particles in samples, making it invaluable for advancing our understanding of HMPV infections and the development of antiviral interventions.</p> The incorporation of enhanced green fluorescent protein (GFP) into Human Metapneumovirus (HMPV) offers a competitive advantage by providing a precise and rapid method for monitoring virus infection. This technology enables real-time visualization, simplifies high-throughput screening for potential antiviral agents, and streamlines viral particle quantification through GFP-based assays. Its sensitivity and efficiency make it a valuable tool for advancing virology research and expediting antiviral drug discovery. Incorporating enhanced green fluorescent protein (GFP) into Human Metapneumovirus (HMPV) offers versatile applications, including virology research for infection mechanisms, high-throughput drug screening, sensitive diagnostics, and vaccine development. 2024-01-29 2026-06-29 2026-06-29 2024-12-10 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 152460992 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 152461000 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 2 152461011 Biacchesi, Stephanie Institut national de la recherche agronomique (INRA) NIAID Biacchesi, Stephanie (NIAID) 3 152460992 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 152461000 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 2 152461011 Biacchesi, Stephanie Institut national de la recherche agronomique (INRA) NIAID Biacchesi, Stephanie (NIAID) 3 152460974 Human Metapneumovirus (HMPV) Expressing Green Fluorescent Protein (GFP) At The First Position (HMPV-GFP1) From An Added Gene E-033-2014-0 Research Material NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4851] Enhanced GFP-Expressing Human Metapneumovirus (HMPV): A Versatile Tool for Virology Research and Antiviral Drug Screening&body=Please send me information about technology [TAB-4851] Enhanced GFP-Expressing Human Metapneumovirus (HMPV): A Versatile Tool for Virology Research and Antiviral Drug Screening. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4851] Enhanced GFP-Expressing Human Metapneumovirus (HMPV): A Versatile Tool for Virology Research and Antiviral Drug Screening&body=Please send me information about technology [TAB-4851] Enhanced GFP-Expressing Human Metapneumovirus (HMPV): A Versatile Tool for Virology Research and Antiviral Drug Screening.">ganelinaa@niaid.nih.gov</a><br> TAB-4847 152411254 Development of a High-Throughput Screening Tool for RSV Inhibition Using Engineered RSV Expressing GFP and Luciferase Genes NIAID Collaboration, Diagnostics, Infectious Disease, Licensing, Research Equipment, Research Materials, Respiratory Collaboration Diagnostics Infectious Disease Licensing Research Equipment Research Materials Respiratory Peter Collins, Mark Peeples <p>The technology involves the genetic engineering of Respiratory Syncytial Virus (RSV) to express two additional genes, green fluorescent protein (GFP) and Renilla luciferase, from different positions within the viral genome. GFP serves as a visual marker for RSV infection, allowing researchers to monitor and track infected cells using fluorescence microscopy, while luciferase functions as a highly sensitive reporter gene that enables quantitative assessment of viral replication through enzymatic assays. The engineered RSV strain also contains a mutation in the RSV G protein, making it a valuable tool for high-throughput screening of potential antiviral compounds. This technology offers a sensitive and efficient method for studying RSV infection and screening for inhibitors, facilitating both basic research and drug development efforts related to RSV.</p> <p>&nbsp;</p> This technology offers a competitive edge by enabling real-time monitoring of RSV infection through the use of GFP and Renilla luciferase markers, allowing for precise and sensitive assessments of viral replication. The engineered RSV strain's safety features, such as a mutated RSV G protein, enhance laboratory safety. These advantages streamline RSV research and drug development efforts, making it a powerful tool for studying the virus and screening potential inhibitors. This technology has diverse potential applications in RSV research and antiviral drug development. It enables rapid screening of antiviral compounds, facilitates the study of RSV infection dynamics, and aids in evaluating vaccines and therapies. The GFP and luciferase markers offer real-time monitoring for investigating RSV replication and pathogenesis. Overall, this versatile technology enhances our understanding of RSV and accelerates efforts to combat this respiratory virus. 2024-01-25 2026-06-29 2026-06-29 2024-12-10 False True True 72159134 Analytical Assay Performance Stage 72159134 37470483 Website Abstract 152411274 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 152411278 Peeples, Mark Nationwide Children's Hospital Peeples, Mark 2 152411274 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 152411278 Peeples, Mark Nationwide Children's Hospital Peeples, Mark 2 152411257 Respiratory Syncytial Virus (RSV) Expressing Green Fluorescent Protein (GFP) And Luciferase From Added Genes E-032-2014-0 Research Material Nationwide Children's Hospital, NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4847] Development of a High-Throughput Screening Tool for RSV Inhibition Using Engineered RSV Expressing GFP and Luciferase Genes&body=Please send me information about technology [TAB-4847] Development of a High-Throughput Screening Tool for RSV Inhibition Using Engineered RSV Expressing GFP and Luciferase Genes. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4847] Development of a High-Throughput Screening Tool for RSV Inhibition Using Engineered RSV Expressing GFP and Luciferase Genes&body=Please send me information about technology [TAB-4847] Development of a High-Throughput Screening Tool for RSV Inhibition Using Engineered RSV Expressing GFP and Luciferase Genes.">ganelinaa@niaid.nih.gov</a><br> TAB-4535 151722135 Advanced Human Cell Line Technology for RSV Replication Complex Production and Antiviral Drug Discovery NIAID Human Cell Lines, Infectious Disease, Research Materials Human Cell Lines Infectious Disease Research Materials Ursula Buchholz, Peter Collins, Cyril Le Nouen, Joseph Marcotrigiano <p>This technology includes the NeurEx&reg; mobile application, a groundbreaking tool designed for neurologists to conduct and document neurological examinations efficiently. Deployed on iPads, it integrates with a secure, cloud-based database, automating the computation of four key disability scales used in neuroimmunology. The app&#39;s robust design enables precise mapping of neurological deficits, blending spatial distribution with quantitative assessments. Its effectiveness is underscored by a study involving 865 neurological exams, where the app&#39;s computed scales matched the accuracy of multiple sclerosis-trained clinicians. Crucially, NeurEx&reg; enhances the sensitivity and specificity in tracking disability progression, outperforming traditional scales like the EDSS. This makes it an invaluable asset not only in clinical settings but also in research and multicentric trials, offering a more economical and precise alternative to conventional documentation of neurological examinations.</p> This technology uniquely enables the high-yield production and purification of the RSV replication complex in human cells, paving the way for groundbreaking antiviral drug discovery and structural analysis of the virus. The technology holds promise for facilitating detailed structural studies of the RSV replication mechanism, advancing antiviral drug development, and potentially applying similar methods to other significant negative-sense RNA viruses like measles and ebola. 2023-12-10 2026-06-29 2026-06-29 2024-12-10 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151722142 Le Nouen, Cyril NIAID - DIR NIAID Le Nouen, Cyril (NIAID) 1 151722146 Marcotrigiano, Joseph NIAID - DIR NIAID Marcotrigiano, Joseph (NIAID) 2 151722154 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 3 151722159 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 4 151722142 Le Nouen, Cyril NIAID - DIR NIAID Le Nouen, Cyril (NIAID) 1 151722146 Marcotrigiano, Joseph NIAID - DIR NIAID Marcotrigiano, Joseph (NIAID) 2 151722154 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 3 151722159 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 4 151722138 Generation Of A Human Cell Line That Constitutively Expresses Respiratory Syncytial Virus (RSV) Nucleocapsid (N), Phosphoprotein (P) And Polymerase (L) Proteins, And Purification Of The RSV Replication Complex E-235-2020-0 Research Material NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4535] Advanced Human Cell Line Technology for RSV Replication Complex Production and Antiviral Drug Discovery&body=Please send me information about technology [TAB-4535] Advanced Human Cell Line Technology for RSV Replication Complex Production and Antiviral Drug Discovery. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4535] Advanced Human Cell Line Technology for RSV Replication Complex Production and Antiviral Drug Discovery&body=Please send me information about technology [TAB-4535] Advanced Human Cell Line Technology for RSV Replication Complex Production and Antiviral Drug Discovery.">ganelinaa@niaid.nih.gov</a><br> TAB-4534 151721981 Enhanced S10-3 Cell Line for Advanced Hepatitis E Virus Research and Therapeutic Development NIAID Human Cell Lines, Infectious Disease, Research Materials, ResearchProducts Human Cell Lines Infectious Disease Research Materials ResearchProducts Suzanne Emerson, Hanh Nguyen, Udana Torian <p>The Huh-7 cell line underwent a detailed sub-cloning process to enhance its effectiveness for Hepatitis E Virus (HEV) infection studies. This involved diluting and culturing cells in 96-well plates until confluent monolayers formed, followed by selection and expansion of the most suitable cells. The sub-clone S10-3, derived from this process, was identified as the most efficient for transfection and infection by HEV. Prepared using standard cell culture methods, these S10-3 cells from the Huh-7 line demonstrated superior abilities in both transfectability and infectivity, making them highly valuable for virological research focused on Hepatitis E Virus.</p> The S10-3 cells, derived from the Huh-7 cell line, offer a significant competitive advantage in Hepatitis E Virus research due to their enhanced efficiency in transfection and infection processes. The S10-3 cell line, with its heightened transfection and infection capabilities, holds potential for groundbreaking advances in the study and development of treatments and vaccines for Hepatitis E Virus. 2023-12-10 2026-06-29 2026-06-29 2024-12-10 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151722002 Emerson, S. https://pubmed.ncbi.nlm.nih.gov/16928762/ <a href="https://pubmed.ncbi.nlm.nih.gov/16928762/">Emerson, S.</a> 151721990 Emerson, Suzanne National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Emerson, Suzanne (NIAID) 1 151721994 Nguyen, Hanh National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Nguyen, Hanh (NIAID) 2 151721998 Torian, Udana NIAID Torian, Udana (NIAID) 3 151721990 Emerson, Suzanne National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Emerson, Suzanne (NIAID) 1 151721994 Nguyen, Hanh National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Nguyen, Hanh (NIAID) 2 151721998 Torian, Udana NIAID Torian, Udana (NIAID) 3 151721984 Huh-7 Cell Line Derived S10-3 Cells For Hepatitis E Virus Infection Studies E-218-2018-0 Research Material NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4534] Enhanced S10-3 Cell Line for Advanced Hepatitis E Virus Research and Therapeutic Development&body=Please send me information about technology [TAB-4534] Enhanced S10-3 Cell Line for Advanced Hepatitis E Virus Research and Therapeutic Development. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-4534] Enhanced S10-3 Cell Line for Advanced Hepatitis E Virus Research and Therapeutic Development&body=Please send me information about technology [TAB-4534] Enhanced S10-3 Cell Line for Advanced Hepatitis E Virus Research and Therapeutic Development.">ganelinaa@niaid.nih.gov</a><br> TAB-3456 114097325 Tumor Associated Calcium Signal Transducer 2 (TACSTD2)-Overexpressing Huh7.5 Cells That Are More Permissive to HCV Cell Entry and Replication Compared to the Model Huh7.5 Cell Line NIAID Licensing Licensing Patrizia Farci, Vandana Sekhar Worldwide, 130-150 million individuals are chronically infected with hepatitis C virus (HCV), a major cause of liver-associated morbidity and mortality worldwide. Despite recent advances in antiviral drugs that can cure some individuals, a rapid decline of the global disease burden is hampered by remarkably high treatment costs and a high number of undiagnosed infections. Moreover, a significant number of patients develop resistance and additional treatment modalities may be needed to dramatically reduce the worldwide incidence of HCV infection. The subject cell line may be a useful tool for studying the mechanism of HCV cellular entry and replication and could be incorporated into an in vitro assay to measure the effectiveness of novel HCV targeted therapies or as a system for improved propagation of HCV in culture.<br /><br /> By overexpressing TACSTD2 in Huh7.5 cells, scientists at the National Institute of Allergy and Infectious Diseases (NIAID) discovered that they could restore the cellular localization of two host cell HCV-entry factors that become dysregulated in hepatocellular carcinoma (HCC) cells. Overexpression of TACSTD2 makes Huh7.5 cells more broadly permissive to infection and replication by multiple HCV genotypes in comparison to the canonical Huh7.5 cell model. HCV does not replicate in malignant HCC cells, possibly caused in part by downregulation of TACSTD2 expression.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404. <ul> <li>Cell line to study hepatitis C virus infection and replication or propagate HCV in culture.</li> <li>Cell line to study cancer.</li> </ul> Elizabeth Pitts, Ph.D., 240-669-5299; <a href="mailto:elizabeth.pitts@nih.gov">elizabeth.pitts@nih.gov</a>. Licensing information may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention. Research Material - Patent protection is not being pursued for this technology. 2022-03-08 2026-06-29 2026-06-29 2021-08-18 2, Associated, CALCIUM, Cells, Huh7.5, Signal, TACSTD2-overexpressing, TRANSDUCER, tumor False True True NIHTT 37470483 Website Abstract 114110261 Sekhar, Vandana NIAID - DIR Sekhar, Vandana 0 114110260 Farci, Patrizia NIAID - DIR NIAID Farci, Patrizia (NIAID) 1 114110260 Farci, Patrizia NIAID - DIR NIAID Farci, Patrizia (NIAID) 1 114110261 Sekhar, Vandana NIAID - DIR Sekhar, Vandana 0 114102576 Tumor Associated Calcium Signal Transducer 2 (TACSTD2)-overexpressing Huh7.5 Cells E-040-2020-0 Research Material NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3456] Tumor Associated Calcium Signal Transducer 2 (TACSTD2)-Overexpressing Huh7.5 Cells That Are More Permissive to HCV Cell Entry and Replication Compared to the Model Huh7.5 Cell Line&body=Please send me information about technology [TAB-3456] Tumor Associated Calcium Signal Transducer 2 (TACSTD2)-Overexpressing Huh7.5 Cells That Are More Permissive to HCV Cell Entry and Replication Compared to the Model Huh7.5 Cell Line. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3456] Tumor Associated Calcium Signal Transducer 2 (TACSTD2)-Overexpressing Huh7.5 Cells That Are More Permissive to HCV Cell Entry and Replication Compared to the Model Huh7.5 Cell Line&body=Please send me information about technology [TAB-3456] Tumor Associated Calcium Signal Transducer 2 (TACSTD2)-Overexpressing Huh7.5 Cells That Are More Permissive to HCV Cell Entry and Replication Compared to the Model Huh7.5 Cell Line.">ganelinaa@niaid.nih.gov</a><br> 114152283 tumor 114152284 Associated 114152285 CALCIUM 114152286 Signal 114152287 TRANSDUCER 114152288 2 114152289 TACSTD2-overexpressing 114152290 Huh7.5 114152291 Cells TAB-3388 114097277 Broadly Protective Influenza Vaccine Comprising a Cocktail of Inactivated Avian Influenza Viruses NIAID Collaboration, Materials Available Collaboration Materials Available Louis Schwartzman, Jeffery Taubenberger There is a great need for broadly protective, “universal” influenza virus vaccines given the antigenic drift and shift of influenza viruses and the variable protective efficacy of the current influenza vaccines. This technology relates to a broadly protective, “universal” influenza vaccine candidate composed of a cocktail of different low pathogenicity avian influenza virus subtypes inactivated by betapropiolactone (BPL). Vaccinating animals with BPL-inactivated whole virus vaccine comprising influenza virus strains belonging to four or more different low pathogenicity avian influenza hemagglutinin subtypes, intranasally or intramuscularly, provided extremely broad protection and heterosubtypic protection to lethal challenge with influenza viruses in both mice and ferrets. This influenza vaccine technology has a great potential to offer broad protection against both seasonal and pandemic-potential influenza viruses.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404. <ul> <li>Broad protection to both seasonal and pandemic-potential influenza viruses</li> <li>Easy and cost-effective inactivation method</li> <li>Effective immune response due to the use of authentic viral antigens</li> <li>Animal data available</li> </ul> <ul> <li>Vaccine against viruses</li> <li>Vaccines against influenza virus</li> <li>Universal influenza virus vaccine</li> </ul> The National Institute of Allergy and Infectious Diseases is also seeking statements of capability or interest from parties interested in collaborative research. NIAID would like a prospective collaborator to have the capacity to generate clinical grade materials and perform clinical studies. NIAID will consider executing a Confidentiality Agreement with a prospective collaborator to facilitate receipt of a Capability Statement if requested. For collaboration opportunities, please contact Dr. Elizabeth Pitts at <a href="mailto: elizabeth.pitts@nih.gov">elizabeth.pitts@nih.gov</a> or 240-669-5299. . . 2022-03-08 2026-06-29 2026-06-29 2020-07-06 1, Avian, Broadly, Cocktail, CONSISTING, Development, INACTIVATED, INFLUENZA, Protective, Vaccine, Viruses False True True NIHTT 37470483 Website Abstract 114110050 Schwartzman, Louis NIAID - DIR NIAID Schwartzman, Louis (NIAID) 0 114110049 Taubenberger, Jeffery NIAID - DIR NIAID Taubenberger, Jeffery (NIAID) 1 114110049 Taubenberger, Jeffery NIAID - DIR NIAID Taubenberger, Jeffery (NIAID) 1 114110050 Schwartzman, Louis NIAID - DIR NIAID Schwartzman, Louis (NIAID) 0 114102521 Development Of A Broadly Protective Influenza Vaccine Consisting Of A Cocktail Of Inactivated Avian Influenza Viruses 1 E-033-2018-0 Filing authorized NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3388] Broadly Protective Influenza Vaccine Comprising a Cocktail of Inactivated Avian Influenza Viruses&body=Please send me information about technology [TAB-3388] Broadly Protective Influenza Vaccine Comprising a Cocktail of Inactivated Avian Influenza Viruses. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3388] Broadly Protective Influenza Vaccine Comprising a Cocktail of Inactivated Avian Influenza Viruses&body=Please send me information about technology [TAB-3388] Broadly Protective Influenza Vaccine Comprising a Cocktail of Inactivated Avian Influenza Viruses.">ganelinaa@niaid.nih.gov</a><br> 114168942 E-033-2018-0 E-033-2018-0-US-01 BROADLY PROTECTIVE INACTIVATED INFLUENZA VIRUS VACCINE PRV US 62/620,051 Abandoned US <br />Provisional (PRV) 62/620,051<br />Filed on 2018-01-22<br />Status: Abandoned 114168943 E-033-2018-0 E-033-2018-0-PCT-02 Development Of A Broadly Protective Influenza Vaccine Consisting Of A Cocktail Of Inactivated Avian Influenza Viruses 1 PCT Patent Cooperation Treaty PCT/US2019/014220 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/014220<br />Filed on 2019-01-18<br />Status: Expired 114169042 E-033-2018-0 E-033-2018-0-US-06 BROADLY PROTECTIVE INACTIVATED INFLUENZA VIRUS VACCINE National Stage US 11,369,675 16/963,718 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11369675 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11369675">11,369,675</a><br />Filed on 2020-07-21<br />Status: Issued 114151703 Development 114151704 Broadly 114151705 Protective 114151706 INFLUENZA 114151707 Vaccine 114151708 CONSISTING 114151709 Cocktail 114151710 INACTIVATED 114151711 Avian 114151712 Viruses 114151713 1 TAB-3341 114097256 Recombinant Respiratory Syncytial Virus Challenge Strain NIAID Collaboration, Diagnostics, Infectious Disease, Research Materials, Vaccines Collaboration Diagnostics Infectious Disease Research Materials Vaccines Ursula Buchholz, Peter Collins RSV is the most important viral agent of severe respiratory tract disease worldwide, especially in infants and young children, and it also causes severe disease in the elderly and in immunocompromised individuals. There are no licensed vaccines or antivirals suitable for routine use.<br /><br /> This invention relates to a reverse genetics system and cDNA-derived virus for a contemporary wild-type clinical isolate of RSV of antigenic subgroup A, termed RSV strain A/Maryland/001/11, that was isolated in 2011 from an adult with respiratory illness. The genomic sequence was determined. A reverse genetics system was created encoding a recombinant, replication competent RSV that contains a codon-optimized G ORF, which was done to stabilize the cDNA for replication in bacteria. Because this virus was generated by reverse genetics, it is a “clean” virus with a well-defined passage history. Clinical study material of this challenge virus has been manufactured and is available for use as an U.S. Food and Drug Administration (FDA) regulated Investigational New Drug (IND) in clinical studies in adult volunteers within and outside of the United States. Preliminary clinical data confirmed that this virus efficiently infects and replicates in 95% of study participants pre-selected for pre-existing RSV antibody titers in the bottom 50% of the range. The challenge virus causes mild upper respiratory illness in the majority of infected participants, typical for RSV illness in otherwise healthy adults. This provides a suitable challenge system for evaluating antivirals, as well as vaccines for older children and adults. This also could be used for developing live-attenuated RSV vaccine candidates based on this contemporary strain, using the stabilized point mutations, stabilized codon-deletions, and gene-deletions that were previously used in RSV strain A2.<br /><br /> This invention relates to a reverse genetics system and the encoded RSV vaccine challenge strain that infects and causes disease in RSV-experienced adults and is available for antiviral and vaccine research.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Ease of manufacture</li> <li>Clinical trial material</li> <li>Low-cost vaccines</li> <li>Intranasal administration/needle-free delivery</li> </ul> <ul> <li>Vaccine development</li> <li>Viral diagnostics</li> <li>Vaccine research</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a vaccine for respiratory or other infections. For collaboration opportunities, please contact Peter Soukas, J.D., at <a href="mailto:Peter.Soukas@nih.gov">Peter.Soukas@nih.gov</a> or 301-594-8730. 2022-03-08 2026-06-29 2026-06-29 2018-10-25 A/Maryland/001/11, DA4BXX, DAXXXX, DC5BXX, DC5XXX, DC6XXX, DCXXXX, DD1XXX, DDXXXX, DXXXXX, recombinant, respiratory, RRSU, RRSV, Syncytial, virus, WILD-TYPE False True True NIHTT 37470483 Website Abstract 114109953 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114109952 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 1 114109952 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 1 114109953 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114102499 Recombinant Wild-type Respiratory Syncytial Virus RRSV A/Maryland/001/11 E-235-2018-0 Research Material NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3341] Recombinant Respiratory Syncytial Virus Challenge Strain&body=Please send me information about technology [TAB-3341] Recombinant Respiratory Syncytial Virus Challenge Strain. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3341] Recombinant Respiratory Syncytial Virus Challenge Strain&body=Please send me information about technology [TAB-3341] Recombinant Respiratory Syncytial Virus Challenge Strain.">ganelinaa@niaid.nih.gov</a><br> 114128207 DXXXXX 114128208 DCXXXX 114128209 DC5XXX 114128210 DC6XXX 114128211 DC5BXX 114128212 DDXXXX 114128213 DD1XXX 114128214 DAXXXX 114128215 DA4BXX 114151481 recombinant 114151482 WILD-TYPE 114151483 respiratory 114151484 Syncytial 114151485 virus 114151486 RRSU 114151487 A/Maryland/001/11 114151488 RRSV TAB-3339 114097254 Hybridoma cell lines producing antibodies to RSV NS1 NIAID Collaboration, Diagnostics, Infectious Disease, Research Materials, Vaccines Collaboration Diagnostics Infectious Disease Research Materials Vaccines Peter Collins, Joseph Marcotrigiano, Thomas McCarty This technology provides a new set of hybridoma cell lines each expressing a single monoclonal antibody against human respiratory syncytial virus (RSV) nonstructural protein 1 (NS1). These antibodies have variously been shown to detect NS1 protein in an enzyme-linked immunosorbent assay (ELISA), Western blot assay, immunofluorescence microscopy of paraformaldehyde-fixed cells, and flow cytometry. The various antibodies can vary in their efficiency in each of these assays. This technology provides a unique set of qualified monoclonal antibodies against RSV NS1 protein which currently do not exist. These antibodies and cell lines may be of interest to any persons investigating RSV infection processes, particularly as it relates to the activity of NS1 in such an infection process.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Ease of manufacture</li> <li>Unique research tool</li> </ul> <ul> <li>Viral diagnostics</li> <li>Vaccine research</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a vaccine for respiratory or other infections. For collaboration opportunities, please contact Peter Soukas, J.D., at <a href="mailto:Peter.Soukas@nih.gov">Peter.Soukas@nih.gov</a> or 301-594-8730. 2022-03-08 2026-06-29 2026-06-29 2021-01-25 Against, antibodies, Cell, DA4BXX, DA4XXX, DAXXXX, DCXXXX, DD1XXX, DDXXXX, DEXXXX, DXXXXX, Hybridoma, Imonoclonal, Lines, NS1, Producing, RSV False True True NIHTT 37470483 Website Abstract 114109947 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114109948 Marcotrigiano, Joseph NIAID - DIR NIAID Marcotrigiano, Joseph (NIAID) 0 114109946 McCarty, Thomas NIAID - DIR NIAID McCarty, Thomas (NIAID) 1 114109946 McCarty, Thomas NIAID - DIR NIAID McCarty, Thomas (NIAID) 1 114109947 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114109948 Marcotrigiano, Joseph NIAID - DIR NIAID Marcotrigiano, Joseph (NIAID) 0 114102497 Hybridoma Cell Lines Producing Antibodies To RSV NS1 And The Imonoclonal Antibodies Against RSV NS1 E-167-2018-0 Research Material NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3339] Hybridoma cell lines producing antibodies to RSV NS1&body=Please send me information about technology [TAB-3339] Hybridoma cell lines producing antibodies to RSV NS1. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3339] Hybridoma cell lines producing antibodies to RSV NS1&body=Please send me information about technology [TAB-3339] Hybridoma cell lines producing antibodies to RSV NS1.">ganelinaa@niaid.nih.gov</a><br> 114128192 DXXXXX 114128193 DDXXXX 114128194 DD1XXX 114128195 DCXXXX 114128196 DEXXXX 114128197 DAXXXX 114128198 DA4XXX 114128199 DA4BXX 114151463 Hybridoma 114151464 Cell 114151465 Lines 114151466 Producing 114151467 antibodies 114151468 RSV 114151469 NS1 114151470 Imonoclonal 114151471 Against TAB-3330 114097247 Recombinant RSV B1 expressing eGFP as a reporter gene NIAID Collaboration, Infectious Disease, Research Materials, Vaccines Collaboration Infectious Disease Research Materials Vaccines Ursula Buchholz, Peter Collins The inventors have created a reverse genetics system for RSV strain B1 of antigenic subgroup B encoding a replication-competent recombinant RSV that contains a codon-optimized G ORF and expresses enhanced green fluorescence protein (GFP). There are two antigenic subgroups of RSV, subgroups A and B, and most of the available information and reagents are for subgroup A. Immunity against either subgroup has reduced effectiveness in restricting the heterologous subgroup, suggesting that an effective RSV vaccine might need to contain both subgroups. The sequence of the wild type G gene was refractory to cloning into full-length antigenomic cDNA in E. coli, and so the inventors made and successfully used a codon optimized version. In addition, the inventors inserted an eGFP gene into the first gene position (promoter proximal). The resulting virus is replication-competent and efficiently expresses GFP in infected cells. This virus can be used as a tool to detect RSV-neutralizing antibodies to RSV subgroup B in a plaque-reduction assay. It also can be used to evaluate RSV infection in vitro and in vivo using GFP fluorescence to track infection. The antigenomic cDNA clone also provides the starting material for making live-attenuated subgroup B-specific RSV vaccine candidates containing defined mutations. These defined mutations can include ones that we previously developed for RSV subgroup A, and include stabilized point mutations, stabilized codon-deletions, and gene-deletions.<br /><br /> The present invention provides a reverse genetics system encoding strain B1 of RSV subgroup B containing a codon-optimized G ORF and encoding eGFP. This provides a tool for RSV subgroup B serology assays, for tracking RSV infection, and a starting point for making attenuated subgroup B strains for vaccine purposes.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Ease of manufacture</li> <li>Unique research tool</li> </ul> <ul> <li>Viral diagnostics</li> <li>Vaccine research</li> <li>Serology assays</li> <li>Vaccine manufacture</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a vaccine for respiratory or other infections. For collaboration opportunities, please contact Peter Soukas, J.D., please contact Peter Soukas, J.D. at <a href="mailto:Peter.Soukas@nih.gov">Peter.Soukas@nih.gov</a> or 301-594-8730. 2022-03-08 2026-06-29 2026-06-29 2018-10-09 1, B, DC5BXX, DC5XXX, DCXXXX, DD1XXX, DDXXXX, DEXXXX, DXXXXX, E_x~ressing, EGFP, Expressing, Gene, R~V, recombinant, REPORTER False True True NIHTT 37470483 Website Abstract 114109857 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114109856 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 114109856 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 114109857 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114102484 Recombinant R~V B 1, Expressing EGFP As A Reporter Gene E-159-2018-0 Research Material NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3330] Recombinant RSV B1 expressing eGFP as a reporter gene&body=Please send me information about technology [TAB-3330] Recombinant RSV B1 expressing eGFP as a reporter gene. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3330] Recombinant RSV B1 expressing eGFP as a reporter gene&body=Please send me information about technology [TAB-3330] Recombinant RSV B1 expressing eGFP as a reporter gene.">ganelinaa@niaid.nih.gov</a><br> 114128161 DXXXXX 114128162 DCXXXX 114128163 DC5XXX 114128164 DC5BXX 114128165 DDXXXX 114128166 DD1XXX 114128167 DEXXXX 114151362 recombinant 114151363 R~V 114151364 B 114151365 1 114151366 E_x~ressing 114151367 EGFP 114151368 REPORTER 114151369 Gene 114151370 Expressing TAB-3329 114097246 Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP as an Intranasal Ebola Vaccine NIAID Collaboration, Diagnostics, Infectious Disease, Licensing, Research Materials, Vaccines Collaboration Diagnostics Infectious Disease Licensing Research Materials Vaccines Ursula Buchholz, Peter Collins, Matthias Lingemann, Shirin Munir Ebola virus (EBOV) hemorrhagic fever is one of the most lethal viral infections and lacks a licensed vaccine. EBOV is transmitted by contact with body fluids from infected individuals including droplets or aerosols. Aerosolized EBOV could also be exploited for intentional virus spread. Therefore, vaccines that protect against mucosal and systemic exposure are needed.<br /><br /> The NIH/NIAID has developed recombinant human parainfluenza virus type 1 (rHPIV1) bearing a stabilized attenuating mutation in the P/C gene to express the membrane-anchored form of EBOV glycoprotein GP as an intranasal (IN) EBOV vaccine. GP was codon optimized and expressed either as a full-length protein or a chimeric form in which its transmembrane and cytoplasmic tail (TMCT) domains were substituted with those of the HPIV1 F protein in an effort to increase packaging into the vector particle and enhance immunogenicity. GP was inserted either preceding the N gene (pre-N) or between the N and P genes (N-P) of rHPIV1. All vectors replicated to high titers in vitro and had stable GP expression. Viruses were attenuated and replicated at low titers in the respiratory tract of African green monkeys. Two doses of candidates expressing GP from the pre-N position elicited higher GP neutralizing serum antibody titers than the N-P viruses, and unmodified GP induced higher levels than its TMCT counterpart. Unmodified EBOV GP was packaged into the HPIV1 particle, and the TMCT modification did not increase packaging or immunogenicity. Overall, the candidate expressing full-length GP from the Pre-N position was the most immunogenic.<br /><br /> This invention relates to an attenuated and immunogenic IN vaccine candidate expected to be well tolerated in humans and is available for clinical evaluation.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Ease of manufacture</li> <li>Bivalent or Multivalent live attenuated vaccines</li> <li>B cell and T cell activation</li> <li>Low-cost vaccines</li> <li>Intranasal administration/needle-free delivery</li> </ul> <ul> <li>Viral diagnostics</li> <li>Vaccine research</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a vaccine for respiratory or other infections. For collaboration opportunities, please contact Peter Soukas, J.D. at <a href="mailto:Peter.Soukas@nih.gov">Peter.Soukas@nih.gov</a> or 301-594-8730. 2022-03-08 2026-06-29 2026-06-29 2018-10-09 1, Attenuated, DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, DEXXXX, DXXXXX, Ebola, Expressing, GLYCOPROTEIN, GP, Human, Intranasal, Parainfluenza, TYPE, Vaccine, virus False True True NIHTT 37470483 Website Abstract 114172538 Lingemann M, et al. http://www.ncbi.nlm.nih.gov/pubmed/28250127 <a href="http://www.ncbi.nlm.nih.gov/pubmed/28250127">Lingemann M, et al.</a> 114109853 Lingemann, Matthias NIAID - DIADS NIAID Lingemann, Matthias (NIAID) 0 114109854 Munir, Shirin NIAID - DIR NIAID Munir, Shirin (NIAID) 0 114109855 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114109852 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 114109852 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 114109853 Lingemann, Matthias NIAID - DIADS NIAID Lingemann, Matthias (NIAID) 0 114109854 Munir, Shirin NIAID - DIR NIAID Munir, Shirin (NIAID) 0 114109855 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114102483 Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP As An Intranasal Ebola Vaccine E-142-2018-0 Research Material NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3329] Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP as an Intranasal Ebola Vaccine&body=Please send me information about technology [TAB-3329] Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP as an Intranasal Ebola Vaccine. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3329] Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP as an Intranasal Ebola Vaccine&body=Please send me information about technology [TAB-3329] Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP as an Intranasal Ebola Vaccine.">ganelinaa@niaid.nih.gov</a><br> 114128152 DXXXXX 114128153 DCXXXX 114128154 DC5XXX 114128155 DC5BXX 114128156 DDXXXX 114128157 DEXXXX 114128158 DAXXXX 114128159 DA4XXX 114128160 DA4BXX 114151350 Attenuated 114151351 Human 114151352 Parainfluenza 114151353 virus 114151354 TYPE 114151355 1 114151356 Expressing 114151357 Ebola 114151358 GLYCOPROTEIN 114151359 GP 114151360 Intranasal 114151361 Vaccine TAB-3254 114097187 Protein Nanoparticles for Antigen Display in Vaccines NIAID Collaboration, Infectious Disease, Materials Available, Vaccines Collaboration Infectious Disease Materials Available Vaccines Audray Harris, Dustin McCraw The technology relates to a protein-based nanoparticle platform that allows presentation of immunogenic molecules such as influenza virus antigens. This protein platform is made up of hepatitis B capsid/core proteins. The core proteins contain immunogenic loop c/e1, where other antigens can be inserted and the chimeric protein retains the ability to form capsid-like particles. The technology describes the insertion of one or more copies of influenza epitopes derived from the globular head or the stem region of hemagglutinin protein into or around the c/e1 loop of the core protein. The nanoparticles formed by the use of Hepatitis B virus core proteins can be disassembled and re-assembled, allowing mixing of antigens. Furthermore, the nanoparticles can be expressed in prokaryotic and eukaryotic expression systems. Thus, the platform provides a means for an optimal display of influenza epitopes for the induction of immune response including broadly neutralizing antibodies against the virus and therefore has the potential to be developed into an efficient universal vaccine against influenza virus infection.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>The nanoparticles may be disassembled and re-assembled allowing mixing of antigens</li> <li>Expression in prokaryotic and eukaryotic systems</li> <li>Avoids production and usage of live viruses for vaccine generation</li> <li>Effective immune response due to the use of authentic viral antigens</li> <li>Stability of particle and immunogenicity after high temperature exposure</li> <li>Incorporation of epitopes from group 1 and group 2 influenza viruses</li> <li>Broadly neutralizing antibodies against influenza virus</li> </ul> <ul> <li>Vaccine against viruses; vaccines against influenza virus; universal influenza virus vaccine</li> </ul> The National Institute of Allergy and Infectious Diseases is also seeking statements of capability or interest from parties interested in collaborative research. NIAID would like a prospective collaborator to have one or more of the following capabilities: (1) capacity to produce recombinant protein for animal vaccine studies; (2) perform and evaluate immunogenicity (antibody response) of influenza vaccine antigens in animal (e.g. mouse models); (3) perform and evaluate challenge and protection studies of vaccines and influenza viruses. (e.g. mouse models); and (4) if results are promising from animal studies, capacity to generate clinical grade materials and perform clinical studies. NIAID will consider executing a Confidentiality Agreement with a prospective collaborator to facilitate receipt of a Capability Statement if requested. For collaboration opportunities, please contact Dr. Elizabeth Pitts at <a href="mailto: elizabeth.pitts@nih.gov">elizabeth.pitts@nih.gov</a> or 240-669-5299. 2022-03-08 2026-06-29 2026-06-29 2020-07-06 ANTIGEN, DC5BXX, DISPLAY, INFLUENZA, Nanoparticles, Protein, Vaccine, virus False True True NIHTT 37470483 Website Abstract 114172458 Dustin M. McCraw, et al. https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1011514 <a href="https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1011514">Dustin M. McCraw, et al.</a> 114109639 McCraw, Dustin NIAID - DIR NIAID McCraw, Dustin (NIAID) 0 114109638 Harris, Audray NIAID - DIR NIAID Harris, Audray (NIAID) 1 114109638 Harris, Audray NIAID - DIR NIAID Harris, Audray (NIAID) 1 114109639 McCraw, Dustin NIAID - DIR NIAID McCraw, Dustin (NIAID) 0 114102413 Protein Nanoparticles For Antigen Display E-005-2017-0 Filing authorized NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3254] Protein Nanoparticles for Antigen Display in Vaccines&body=Please send me information about technology [TAB-3254] Protein Nanoparticles for Antigen Display in Vaccines. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3254] Protein Nanoparticles for Antigen Display in Vaccines&body=Please send me information about technology [TAB-3254] Protein Nanoparticles for Antigen Display in Vaccines.">ganelinaa@niaid.nih.gov</a><br> 114167575 E-005-2017-0 E-005-2017-0-US-01 Hepatitis B Nanoparticle-Based Vaccine For Influenza Virus PRV US 62/540,474 Abandoned US <br />Provisional (PRV) 62/540,474<br />Filed on 2017-08-02<br />Status: Abandoned 114168703 E-005-2017-0 E-005-2017-0-PCT-02 HEPATITIS B NANOPARTICLE-BASED VACCINE FOR INFLUENZA VIRUS PCT Patent Cooperation Treaty PCT/US2018/045032 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/045032<br />Filed on 2018-08-02<br />Status: Expired 114168959 E-005-2017-0 E-005-2017-0-US-06 HEPATITIS B NANOPARTICLE-BASED VACCINE FOR INFLUENZA VIRUS National Stage US 11,535,651 16/635,240 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11535651 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11535651">11,535,651</a><br />Filed on 2020-01-30<br />Status: Issued 114127813 DC5BXX 114150474 ANTIGEN 114150475 Nanoparticles 114150476 Protein 114150477 DISPLAY 114150482 virus 114150483 INFLUENZA 114150484 Vaccine TAB-3116 114096000 A Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine Development NIAID Collaboration, Diagnostics, Infectious Disease, Research Materials, Therapeutics, Vaccines Collaboration Diagnostics Infectious Disease Research Materials Therapeutics Vaccines Alexander Pletnev, Konstantin Tsetsarkin An arthropod-borne virus, Zika virus (ZIKV), has recently emerged as a major human pathogen. Associated with complications during perinatal development and Guillain-Barré syndrome in adults, ZIKV raises new challenges for understanding the molecular determinants of flavivirus pathogenesis. This underscores the necessity for the development of a reverse genetic system based on an epidemic ZIKV strain. This technology relates to the generation and characterization in cell cultures of an infectious cDNA clone of ZIKV isolated from the 2015 epidemic in Brazil. The cDNA-derived ZIKV replicated efficiently in a variety of cell lines, including those of both neuronal and placental origin. It was observed that the growth of cDNA-derived virus was attenuated compared to the growth of the parental isolate in most cell lines, which correlates with substantial differences in sequence heterogeneity between these viruses that were determined by deep-sequencing analysis. Moreover, these results indicate that caution should be exercised when interpreting the results of reverse-genetics experiments in attempts to accurately predict the biology of natural viruses. Finally, a Vero cell-adapted cDNA clone of ZIKV was generated that can be used as a convenient platform for studies aimed at the development of ZIKV vaccines (live attenuated and inactivated) and therapeutics. <ul> <li>Use in development of flavivirus vaccines</li> <li>Virus growth in various cell lines</li> <li>Developing and developed world research tool</li> </ul> <ul> <li>Diagnostics</li> <li>Vaccines</li> <li>Development of therapeutics</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize vaccine(s) or diagnostics for prophylaxis against flavivirus infections. For collaboration opportunities, please contact Peter Soukas, J.D. at <a href="mailto:peter.soukas@nih.gov">peter.soukas@nih.gov</a> or 301-594-8730. Research Materials 2022-03-08 2026-06-29 2026-06-29 2017-04-10 2015, Brazil, cDNA, CLONE, DAXXXX, DBXXXX, DC5BXX, DC5XXX, DC6XXX, DCXXXX, DD1XXX, DDXXXX, Development, DXXXXX, Epidemic, FULL-LENGTH, Genetic, INFECTIOUS, INTERACTIONS, PLATFORM, STUDIES, Vaccine, virus, Virus-Host, Zika False True True NIHTT 37470483 Website Abstract 114172304 Tsetsarkin KA, et al. http://www.ncbi.nlm.nih.gov/pubmed/27555311 <a href="http://www.ncbi.nlm.nih.gov/pubmed/27555311">Tsetsarkin KA, et al.</a> 114109196 Tsetsarkin, Konstantin NIAID - DIR NIAID Tsetsarkin, Konstantin (NIAID) 0 114105832 Pletnev, Alexander NIAID - DIR NIAID Pletnev, Alexander (NIAID) 1 114105832 Pletnev, Alexander NIAID - DIR NIAID Pletnev, Alexander (NIAID) 1 114109196 Tsetsarkin, Konstantin NIAID - DIR NIAID Tsetsarkin, Konstantin (NIAID) 0 114100892 Full-length Infectious CDNA Clone Of Zika Virus From The 2015 Epidemic In Brazil As A Genetic Platform For Studies Of Virus-Host Interactions And Vaccine Development E-114-2017-0 Research Material NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3116] A Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine Development&body=Please send me information about technology [TAB-3116] A Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine Development. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3116] A Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine Development&body=Please send me information about technology [TAB-3116] A Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine Development.">ganelinaa@niaid.nih.gov</a><br> 114113944 DXXXXX 114113945 DCXXXX 114113946 DDXXXX 114113947 DD1XXX 114113948 DC5XXX 114116532 DC5BXX 114116533 DC6XXX 114116534 DAXXXX 114116535 DBXXXX 114148898 FULL-LENGTH 114148899 INFECTIOUS 114148900 cDNA 114148901 CLONE 114148902 Zika 114148903 virus 114148904 2015 114148905 Epidemic 114148906 Brazil 114148907 Genetic 114148908 PLATFORM 114148909 STUDIES 114148910 Virus-Host 114148911 INTERACTIONS 114148912 Vaccine 114148913 Development TAB-3081 114096627 Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines NIAID Collaboration, Consumer Products, Diagnostics, Infectious Disease, Therapeutics, Vaccines Collaboration Consumer Products Diagnostics Infectious Disease Therapeutics Vaccines Jeffery Taubenberger Influenza virus is a major public health concern, causing up to 500,000 deaths annually. The current strategy of reformulating vaccines annually against dominant circulating strains leads to variable protective efficacy and is unlikely to protect against novel influenza viruses with pandemic potential. Thus, there is a great need for a vaccine that provides “universal” protection against influenza viruses.<br /><br /> This technology relates to a broadly protective, universal influenza vaccine candidate composed of a mixture of virus-like particles (VLPs) expressing the hemagglutinin protein or the neuraminidase protein from influenza virus strains belonging to different virus subtypes. Vaccinating animals with a mixture of VLPs expressing four or more hemagglutinin subtypes provides broad and heterosubtypic protection against lethal challenge with influenza virus strains in both mice and ferrets. This vaccine technology has great potential to provide protection against both annual epidemic and pandemic-potential influenza viruses. This virus-like particle (VLP) vaccine technology for influenza viruses, based on a mixture of VLPs expressing the hemagglutinin protein or the neuraminidase protein from influenza virus strains belonging to different virus subtypes, has demonstrated broad protection against lethal challenge in mice with various influenza virus strains and virus subtypes. Results from ferret and mouse studies demonstrate broad heterosubtypic protection against various influenza virus subtypes further supporting and strengthening the proposed application of this technology as a universal influenza virus vaccine. <ul> <li>Broad/universal protection against influenza viruses</li> <li>Does not require reformulating vaccine each year as is currently necessary with vaccines available on the market</li> <li>Can potentially provide protection against novel influenza viruses that may arise in the future, including potentially pandemic influenza viruses</li> </ul> <ul> <li>Vaccines</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this invention, especially for GMP manufacture and clinical evaluation. For collaboration opportunities, please contact Dr. Elizabeth Pitts at <a href="mailto: elizabeth.pitts@nih.gov">elizabeth.pitts@nih.gov</a> or 240-669-5299. 2022-03-08 2026-06-29 2026-06-29 2021-06-23 Against, Broad, DC5BXX, Development, different, INFLUENZA, Listed LPM Chang as of 4/15/2015, PARTICLE, Polyvalent, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protection, PROVIDE, SUBTYPES, Vaccine, viral, Viruses, VLXXXX, VOXXXX, WAXXXX, WNXXXX, XKXXXX, YAXXXX, YBXXXX, YCXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171493 Schwartzman LM, et al. https://www.ncbi.nlm.nih.gov/pubmed/26199334 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26199334">Schwartzman LM, et al.</a> 114107579 Taubenberger, Jeffery NIAID - DIR NIAID Taubenberger, Jeffery (NIAID) 1 114107579 Taubenberger, Jeffery NIAID - DIR NIAID Taubenberger, Jeffery (NIAID) 1 114101751 Development Of A Polyvalent Viral Like Particle Vaccine To Provide Broad Protection Against Influenza A Viruses Of Different Subtypes E-195-2014-0 Filing authorized NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3081] Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines&body=Please send me information about technology [TAB-3081] Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3081] Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines&body=Please send me information about technology [TAB-3081] Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines.">ganelinaa@niaid.nih.gov</a><br> 114164298 E-195-2014-0 E-195-2014-0-US-06 Polyvalent Influenza Virus-Like Particles (VLPS) And Use As Vaccines National Stage US 10,130,700 15/317,593 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10130700 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10130700">10,130,700</a><br />Filed on 2016-12-09<br />Status: Issued 114165477 E-195-2014-0 E-195-2014-0-PCT-02 Polyvalent Influenza Virus-Like Particles (VLPS) And Use as Vaccines PCT Patent Cooperation Treaty PCT/US2015/029843 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/029843<br />Filed on 2015-05-08<br />Status: Expired 114166775 E-195-2014-0 E-195-2014-0-US-01 Polyvalent Influenza Virus-Like Particles (VLPs) And Use as Vaccines PRV US 62/014,821 Abandoned US <br />Provisional (PRV) 62/014,821<br />Filed on 2014-06-20<br />Status: Abandoned 114114412 YAXXXX 114114413 YBXXXX 114122639 WNXXXX 114122640 XKXXXX 114122641 DC5BXX 114122642 VLXXXX 114122643 VOXXXX 114122644 WAXXXX 114122745 YCXXXX 114143469 Development 114143470 Polyvalent 114143471 viral 114143472 PARTICLE 114143473 Vaccine 114143474 PROVIDE 114143475 Broad 114143476 Protection 114143477 Against 114143478 INFLUENZA 114143479 Viruses 114143480 different 114143481 SUBTYPES 114143482 Listed LPM Chang as of 4/15/2015 114143483 Pre LPM working set 20150418 114143576 Post LPM Assignment Set 20150420 TAB-4411 147157706 Gene Therapy for Treatment of CRX-Autosomal Dominant Retinopathies NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Therapeutics Collaboration Ear Nose & Throat Licensing Ophthalmology Therapeutics Suja Hiriyanna, Kamil Kruczek, Anand Swaroop, Zhijian Wu <h2>Description of Technology:</h2> <p>Mutations in the cone rod homeobox (CRX) transcription factor lead to distinct retinopathy phenotypes, including early-onset vision impairment in dominant Leber congenital amaurosis (LCA). Adeno-Associated virus (AAV) vector-mediated delivery of a CRX cDNA under the control of a CRX promoter region partially restored photoreceptor phenotype and expression of phototransduction genes in an in vitro model of CRX-LCA. Gene therapy using the CRX-AAV vector to retinal organoids derived from induced pluripotent stem cells (iPSCs) of a patient with the dominant CRX-I138fs mutation partially restored expression of visual opsins and other phototransduction genes as revealed by immunohistochemistry and single cell RNA-sequencing. Retinal organoids from iPSCs of a second dominant CRX-LCA patient carrying a K88N mutation also revealed loss of expression of opsins and phototransduction genes as a common phenotype, which could be alleviated by AAV-mediated overexpression of CRX.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Early onset blindness, including Leber congenital amaurosis</li> <li>Gene therapy of CRX retinopathies; i.e., patients with a mutation in the CRX gene</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Promising commercial potential given that there are no current treatments for CRX-retinopathies&nbsp;</li> <li>Gene therapy by delivering CRX should restore photoreceptor structure and function</li> <li>Existing commercial interest and an established regulatory path for directly administered gene therapy targeting an ophthalmic disease caused by mutations in a specific gene: In 2017, Luxturna (voretigene neparvovec-rzyl) was FDA approved for an inherited form of vision loss (confirmed biallelic RPE65 mutation-associated retinal dystrophy) that may result in blindness</li> </ul> 2020-08-17 2026-04-24 2020-08-17 2026-06-29 2020-08-17 AAV, Adeno-associated Virus, Cone-rod Dystrophy, CRD, GENE THERAPY, LCA, Leber Congenital Amaurosis, Lentivirus, NEI, rare disease, Retinitis Pigmentosa, Retinopathies, RP, Swaroop False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-17 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147164644 Swaroop, Anand NIH - NEI NEI Swaroop, Anand (NEI) 1 147164647 Kruczek, Kamil NIH - NEI NEI Kruczek, Kamil (NEI) 2 147164645 Hiriyanna, Suja NIH - NEI NEI Hiriyanna, Suja (NEI) 3 147164646 Wu, Zhijian NIH - NEI NEI Wu, Zhijian (NEI) 4 147164644 Swaroop, Anand NIH - NEI NEI Swaroop, Anand (NEI) 1 147164647 Kruczek, Kamil NIH - NEI NEI Kruczek, Kamil (NEI) 2 147164645 Hiriyanna, Suja NIH - NEI NEI Hiriyanna, Suja (NEI) 3 147164646 Wu, Zhijian NIH - NEI NEI Wu, Zhijian (NEI) 4 147157778 Gene Therapy For Treatment Of CRX-associated Retinopathies E-008-2020-0 Filing authorized National Eye Institute (NEI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4411] Gene Therapy for Treatment of CRX-Autosomal Dominant Retinopathies&body=Please send me information about technology [TAB-4411] Gene Therapy for Treatment of CRX-Autosomal Dominant Retinopathies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4411] Gene Therapy for Treatment of CRX-Autosomal Dominant Retinopathies&body=Please send me information about technology [TAB-4411] Gene Therapy for Treatment of CRX-Autosomal Dominant Retinopathies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147160891 E-008-2020-0 E-008-2020-0-US-01 Gene Therapy For Treatment Of CRX-associated Retinopathies PRV US 62/962,732 Abandoned US <br />Provisional (PRV) 62/962,732<br />Filed on 2020-01-17<br />Status: Abandoned 147168764 E-008-2020-0 E-008-2020-0-PCT-02 GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES PCT Patent Cooperation Treaty PCT/US2021/013733 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/013733<br />Filed on 2021-01-15<br />Status: Expired 147168765 E-008-2020-0 E-008-2020-0-US-03 GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES National Stage US 12,721,908 17/789,729 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12721908 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12721908">12,721,908</a><br />Filed on 2022-06-28<br />Status: Issued 147168766 E-008-2020-0 E-008-2020-0-AU-04 GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES National Stage Australia 2021208631 Pending Australia <br />National Stage 2021208631<br />Filed on 2021-01-15<br />Status: Pending 147168767 E-008-2020-0 E-008-2020-0-CA-05 GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES National Stage Canada 3165922 Pending Canada <br />National Stage 3165922<br />Filed on 2021-01-15<br />Status: Pending 147168768 E-008-2020-0 E-008-2020-0-EP-06 GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES National Stage European Patent 21705324.8 Pending European Patent <br />National Stage 21705324.8<br />Filed on 2021-01-15<br />Status: Pending 147168769 E-008-2020-0 E-008-2020-0-JP-07 GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES National Stage Japan 7703543 2022-540642 Issued Japan <br />National Stage 2022-540642<br />Filed on 2021-01-15<br />Status: Issued 168016952 E-008-2020-0 E-008-2020-0-US-02 GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES DIV US 19/742,747 Pending US <br />Divisional (DIV) 19/742,747<br />Filed on 2026-07-15<br />Status: Pending 147169363 AAV 147169364 Adeno-associated Virus 147169366 Cone-rod Dystrophy 147169368 CRD 147169369 GENE THERAPY 147169370 LCA 147169372 Leber Congenital Amaurosis 147169373 Lentivirus 147169375 NEI 147169376 rare disease 147169378 Retinitis Pigmentosa 147169379 Retinopathies 147169381 RP 147169383 Swaroop TAB-4498 151704860 A Method to Remove Fluid-motion Related Artifacts in Magnetic Resonance Thermometry Images Using Magnetic Field Gradients NHLBI Computational models/software, Licensing, Research Materials, Software / Apps Computational models/software Licensing Research Materials Software / Apps Himanshu Bhat, Adrienne Campbell-Washburn, Waqas Majeed, Sunil Patil <p>This technology includes the incorporation of a magnetic field gradient waveform (consisting of two or more pulses) between excitation and encoding to eliminate signal from moving fluid for imaging applications. Proton Resonance Frequency (PRF) thermometry is a widely used Magnetic Resonance Imaging (MRI) based technique to monitor changes in tissue temperature in response to thermal therapy. The use of PRF thermometry with thermal therapy procedures is indispensable to ensure delivery of desired thermal dose to the target tissue, and to minimize unintended damage to the normal tissue. Motion of this water due to ultrasound vibrations, convection, and circulation between sonications causes diffuse artifacts in images, which can compromise clinical outcomes. PRF thermometry is a high impact application of MRI and plays a critical role in guiding thermal therapy procedures.</p> The proposed solution: <ul> <li>does not require any additional hardware, materials, or changes in clinical setup</li> <li>can easily be incorporated into the existing product pulse sequences, and therefore adds no additional cost for implementation</li> <li>does not impact image acquisition time under most practical circumstances</li> </ul> Our approach solves a significant problem encountered in routine clinical application of PRF thermometry and can therefore be of significant commercial value. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2024-08-12 2026-06-26 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151704868 Patil, Sunil Siemens Medical USA Patil, Sunil 1 151704872 Campbell-Washburn, Adrienne National Heart, Lung, and Blood Institute (NHLBI) NHLBI Campbell-Washburn, Adrienne (NHLBI) 2 151704876 Majeed, Waqas Siemens Medical Solutions USA Inc. Majeed, Waqas 3 151704880 Bhat, Himanshu Siemens Medical Solutions USA Inc. Bhat, Himanshu 4 151704868 Patil, Sunil Siemens Medical USA Patil, Sunil 1 151704872 Campbell-Washburn, Adrienne National Heart, Lung, and Blood Institute (NHLBI) NHLBI Campbell-Washburn, Adrienne (NHLBI) 2 151704876 Majeed, Waqas Siemens Medical Solutions USA Inc. Majeed, Waqas 3 151704880 Bhat, Himanshu Siemens Medical Solutions USA Inc. Bhat, Himanshu 4 151704863 A Method To Remove Fluid-motion Related Artifacts In Magnetic Resonance Thermometry Images Using Magnetic Field Gradients E-113-2019-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), Siemens Medical Solutions USA Inc., Siemens Medical Solutions USA, Inc. 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4498] A Method to Remove Fluid-motion Related Artifacts in Magnetic Resonance Thermometry Images Using Magnetic Field Gradients&body=Please send me information about technology [TAB-4498] A Method to Remove Fluid-motion Related Artifacts in Magnetic Resonance Thermometry Images Using Magnetic Field Gradients. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4498] A Method to Remove Fluid-motion Related Artifacts in Magnetic Resonance Thermometry Images Using Magnetic Field Gradients&body=Please send me information about technology [TAB-4498] A Method to Remove Fluid-motion Related Artifacts in Magnetic Resonance Thermometry Images Using Magnetic Field Gradients.">shmilovm@nih.gov</a><br> TAB-5119 167808905 RS-1 Knockout Mouse Model for X-Linked Retinoschisis (XLRS) Research NEI Animal Models, Collaboration, Licensing, Materials Available, Ophthalmology, Rare/Neglected Diseases, Research Materials, Therapeutics Animal Models Collaboration Licensing Materials Available Ophthalmology Rare/Neglected Diseases Research Materials Therapeutics Ronald Bush, Paul Sieving, Yong Zeng <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a transgenic mouse model for X-linked retinoschisis (XLRS).</p> <p>This technology includes a transgenic mouse model specifically designed to study X-linked retinoschisis (XLRS) disease by interrupting exon 1 of the Rs1 gene. XLRS is a genetic condition that leads to vision impairment and is caused by mutations in the Rs1 gene. The development of this mouse model addresses a significant gap in the understanding of the biological mechanisms underlying XLRS, allowing researchers to explore gene and protein functions in a controlled environment. This model is crucial for testing potential therapeutic approaches aimed at restoring vision in affected individuals.</p> <p>The RS-1 knockout mouse model provides a unique platform for biological studies, enabling researchers to investigate the effects of the Rs1 gene and its protein in vivo. This model is particularly valuable for pharmaceutical companies and academic institutions focused on developing treatments for retinal diseases. By utilizing this model, stakeholders can gain insights into disease progression and evaluate the efficacy of new therapeutic strategies, ultimately leading to advancements in patient care.</p> <p>We are seeking licensing opportunities for this innovative technology, which has already been utilized in various laboratory studies. Collaborators and licensees will have the chance to leverage this model for their research and development efforts, contributing to the advancement of therapies for XLRS and related conditions. We welcome discussions on potential partnerships that can enhance the impact of this technology in the field of ophthalmology.</p> • Unique transgenic model specifically for XLRS research • Enables in vivo studies of Rs1 gene and protein function • Facilitates testing of therapeutic approaches for retinal diseases • Established publication record demonstrating model efficacy • Research on X-linked retinoschisis (XLRS) • Development of gene therapies for retinal diseases • Testing of pharmacological interventions in a live model • Studies on retinal degeneration mechanisms 2026-06-10 2026-06-24 2026-06-24 2026-06-24 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 167808921 Sieving, Paul University of California, Davis (UCD) Sieving, Paul 1 167808925 Zeng, Yong National Eye Institute (NEI) NEI Zeng, Yong (NEI) 2 167808929 Bush, Ronald National Eye Institute (NEI) NEI Bush, Ronald (NEI) 3 167808921 Sieving, Paul University of California, Davis (UCD) Sieving, Paul 1 167808925 Zeng, Yong National Eye Institute (NEI) NEI Zeng, Yong (NEI) 2 167808929 Bush, Ronald National Eye Institute (NEI) NEI Bush, Ronald (NEI) 3 167808908 RS-1 Knockout Mouse Model Of X-linked Retinoschisis (XLRS) E-078-2022-0 Research Material National Eye Institute (NEI) 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5119] RS-1 Knockout Mouse Model for X-Linked Retinoschisis (XLRS) Research&body=Please send me information about technology [TAB-5119] RS-1 Knockout Mouse Model for X-Linked Retinoschisis (XLRS) Research.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5119] RS-1 Knockout Mouse Model for X-Linked Retinoschisis (XLRS) Research&body=Please send me information about technology [TAB-5119] RS-1 Knockout Mouse Model for X-Linked Retinoschisis (XLRS) Research.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">tedd.fenn@nih.gov</a><br> TAB-5112 167807911 Myocilin Mutant Cell Lines for Glaucoma Research and Drug Screening NEI Collaboration, Human Cell Lines, Licensing, Materials Available, Ophthalmology, Research Materials, Therapeutics Collaboration Human Cell Lines Licensing Materials Available Ophthalmology Research Materials Therapeutics Myungkuk Joe <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative therapeutic strategies targeting myocilin mutations in glaucoma.</p> <p>This technology includes the development of HEK293 cell lines expressing wild-type and Y437H mutant myocilin, which can be used to study the pathogenic mechanisms of glaucoma and screen for therapeutic agents. Glaucoma, a leading cause of blindness, is often associated with mutations in the myocilin gene, but the exact mechanisms by which these mutations lead to cell death are not fully understood. By utilizing these cell lines, researchers can investigate how mutant myocilin induces endoplasmic reticulum stress and apoptosis, particularly under oxidative stress conditions. This understanding could pave the way for the development of targeted therapies that mitigate the effects of these mutations and improve patient outcomes.</p> • Enables high-throughput screening of potential therapeutic agents targeting myocilin mutations. • Provides a controlled environment to study the effects of oxidative stress on cell viability. • Facilitates the understanding of the molecular mechanisms underlying myocilin-induced glaucoma. • Offers a unique model for testing drug efficacy and safety in a relevant biological context. • Drug discovery and development for glaucoma treatments. • Research into the molecular mechanisms of glaucoma pathogenesis. • Screening for compounds that can reduce oxidative stress in retinal cells. • Development of personalized medicine approaches for patients with myocilin mutations. 2026-06-10 2026-06-18 2026-06-18 2026-06-16 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52406769 Prototype 52406769 NCI 37470483 Website Abstract 167807931 Joe MK, et al., 2010 (PMID: 20382707) https://pubmed.ncbi.nlm.nih.gov/20382707/ <a href="https://pubmed.ncbi.nlm.nih.gov/20382707/">Joe MK, et al., 2010 (PMID: 20382707)</a> 167807923 Joe, Myungkuk PTC Therapeutics, Inc. Joe, Myungkuk 1 167807923 Joe, Myungkuk PTC Therapeutics, Inc. Joe, Myungkuk 1 167807914 ManufacturersExpression Of Myocilin Mutants Sensitizes Cells To Oxidative Stress-Induced Apoptosis E-008-2023-0 Research Material National Eye Institute (NEI), PTC Therapeutics, Inc. 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5112] Myocilin Mutant Cell Lines for Glaucoma Research and Drug Screening&body=Please send me information about technology [TAB-5112] Myocilin Mutant Cell Lines for Glaucoma Research and Drug Screening.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5112] Myocilin Mutant Cell Lines for Glaucoma Research and Drug Screening&body=Please send me information about technology [TAB-5112] Myocilin Mutant Cell Lines for Glaucoma Research and Drug Screening.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">tedd.fenn@nih.gov</a><br> TAB-5111 167807815 iPSC Differentiation Protocol for Fibroblast and Endothelial Cell Generation NEI Collaboration, Human Cell Lines, Human iPSC Lines, Licensing, Ophthalmology, Research Materials, Therapeutics Collaboration Human Cell Lines Human iPSC Lines Licensing Ophthalmology Research Materials Therapeutics Kapil Bharti, Tea Soon Park <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a novel iPSC differentiation protocol for generating fibroblasts and endothelial cells.</p> <p>This technology includes a novel protocol for differentiating induced pluripotent stem cells (iPSCs) into fibroblasts and endothelial cells, which are crucial for tissue engineering and regenerative medicine applications. Current methods for generating these cell types can be inefficient and inconsistent, leading to challenges in research and therapeutic applications. This protocol aims to streamline the differentiation process, enhancing the yield and quality of the derived cells.</p> <p>The technical solution leverages optimized culture conditions and growth factors to promote the efficient differentiation of iPSCs into fibroblasts and endothelial cells. This is significant because it addresses the growing demand for reliable and reproducible cell sources in research and clinical settings. By providing a standardized method, this technology can facilitate advancements in tissue engineering, drug testing, and regenerative therapies.</p> <p>The licensing opportunity for this technology is open to partnerships with companies and research institutions interested in cell therapy, regenerative medicine, and related fields. Collaborators can expect to engage in co-development efforts to further refine and commercialize the protocol, ensuring its applicability in various biomedical applications.</p> • Streamlined differentiation process for iPSCs into fibroblasts and endothelial cells • High yield and quality of differentiated cells • Standardized protocol enhances reproducibility • Potential for broad applications in regenerative medicine and tissue engineering • Addresses current inefficiencies in existing methods • Regenerative medicine • Tissue engineering • Drug testing and development • Cell therapy • Research in developmental biology 2026-06-10 2026-06-18 2026-06-18 2026-06-16 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52406769 Prototype 52406769 NCI 37470483 Website Abstract 167807827 Park, Tea Soon National Eye Institute (NEI) Park, Tea Soon 1 167807831 Bharti, Kapil National Eye Institute (NEI) NEI Bharti, Kapil (NEI) 2 167807827 Park, Tea Soon National Eye Institute (NEI) Park, Tea Soon 1 167807831 Bharti, Kapil National Eye Institute (NEI) NEI Bharti, Kapil (NEI) 2 167807818 Fibroblasts, Pericytes, And Endothelial Cells As Generated By An IPSC Differentiation Protocol E-007-2023-0 Research Material National Eye Institute (NEI) 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5111] iPSC Differentiation Protocol for Fibroblast and Endothelial Cell Generation&body=Please send me information about technology [TAB-5111] iPSC Differentiation Protocol for Fibroblast and Endothelial Cell Generation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5111] iPSC Differentiation Protocol for Fibroblast and Endothelial Cell Generation&body=Please send me information about technology [TAB-5111] iPSC Differentiation Protocol for Fibroblast and Endothelial Cell Generation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">tedd.fenn@nih.gov</a><br> TAB-5110 167807692 Thermosensitive Hydrogel Bioink for Vascular Tissue Engineering NEI Cardiology, Collaboration, Licensing, Ophthalmology, Research Materials, Therapeutics Cardiology Collaboration Licensing Ophthalmology Research Materials Therapeutics Kapil Bharti, Marc Ferrer-Alegre, Eric Nguyen, Russell Quinn, Min Jae Song <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for a thermosensitive, pro-angiogenic material designed for 3D bioprinting.</p> <p>This technology includes a thermosensitive hydrogel bioink designed for vascular tissue engineering. The hydrogel is unique in that it transitions from a gel state at room temperature to a liquid state at physiological temperatures, allowing for easy handling and application in bioprinting. The primary challenge in tissue engineering is the formation of functional blood vessels, which is critical for tissue viability. Current methods often involve harmful chemical crosslinkers or UV light, which can compromise cell viability. This hydrogel, made from fibrinogen and gelatin, promotes blood vessel formation by providing a supportive extracellular matrix without the use of harmful agents.</p> <p>The technical solution involves a combination of fibrinogen, which serves as a provisional extracellular matrix, and gelatin, which adjusts viscosity with temperature changes. This innovative approach not only enhances cell viability but also reduces material costs, making it a compelling option for researchers and companies in the field of tissue engineering. You should care about this technology because it represents a significant advancement in bioprinting techniques, enabling the creation of vascularized tissues that closely mimic natural environments.</p> <p>The licensing opportunity for this technology is open to interested parties looking to collaborate in further development or commercialization. The inventors are seeking partners who can help bring this innovative bioink to market, potentially leading to groundbreaking applications in regenerative medicine and tissue engineering.</p> • Thermosensitive properties allow for easy handling and application in bioprinting • Promotes cell viability by avoiding harmful crosslinking methods • Biodegradable materials that can be converted to native extracellular matrix by embedded cells • Cost-effective compared to traditional bioinks • Vascular tissue engineering • Bioprinting of complex tissue structures • Angiogenesis assays for research and drug testing • Regenerative medicine applications 2026-06-10 2026-06-18 2026-06-18 2026-06-16 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52406768 Discovery 52406768 NCI 37470483 Website Abstract 167807768 Min Jae Song et al., 2022 (PMID: 36550275) https://pubmed.ncbi.nlm.nih.gov/36550275/ <a href="https://pubmed.ncbi.nlm.nih.gov/36550275/">Min Jae Song et al., 2022 (PMID: 36550275)</a> 167807704 Nguyen, Eric National Eye Institute (NEI) NEI Nguyen, Eric (NEI) 1 167807708 Bharti, Kapil National Eye Institute (NEI) NEI Bharti, Kapil (NEI) 2 167807712 Song, Min Jae National Center for Advancing Translational Sciences NCATS Song, Min Jae (NCATS) 3 167807716 Ferrer-Alegre, Marc NCATS - NCGC Ferrer-Alegre, Marc 4 167807760 Quinn, Russell National Eye Institute (NEI) NEI Quinn, Russell (NEI) 5 167807704 Nguyen, Eric National Eye Institute (NEI) NEI Nguyen, Eric (NEI) 1 167807708 Bharti, Kapil National Eye Institute (NEI) NEI Bharti, Kapil (NEI) 2 167807712 Song, Min Jae National Center for Advancing Translational Sciences NCATS Song, Min Jae (NCATS) 3 167807716 Ferrer-Alegre, Marc NCATS - NCGC Ferrer-Alegre, Marc 4 167807760 Quinn, Russell National Eye Institute (NEI) NEI Quinn, Russell (NEI) 5 167807695 Fibrin And Gelatin-based Bioink And Associated Supporting Fibrin Hydrogel E-006-2023-0 Research Material National Center for Advancing Translational Sciences, National Eye Institute (NEI), NCATS - NCGC 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5110] Thermosensitive Hydrogel Bioink for Vascular Tissue Engineering&body=Please send me information about technology [TAB-5110] Thermosensitive Hydrogel Bioink for Vascular Tissue Engineering.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5110] Thermosensitive Hydrogel Bioink for Vascular Tissue Engineering&body=Please send me information about technology [TAB-5110] Thermosensitive Hydrogel Bioink for Vascular Tissue Engineering.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">tedd.fenn@nih.gov</a><br> TAB-5109 167807551 Interferon Gamma for Retinal Fluid Absorption Restoration NEI Collaboration, Licensing, Oncology, Ophthalmology, Therapeutics Collaboration Licensing Oncology Ophthalmology Therapeutics Arvydas Maminishkis, Sheldon Miller, Charlotte Reme <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of Interferon gamma as a therapeutic agent to restore retinal fluid absorption.</p> <p>This technology includes the use of Interferon gamma to restore fluid absorption in retinal pigment epithelial (RPE) cells, specifically targeting the adverse effects of fluid accumulation under the retina caused by small molecule cancer therapeutic drugs like Meki. The problem arises when cancer treatments, particularly MAP Kinase/ERK Kinase Inhibitors, lead to unwanted fluid build-up, which can impair vision and overall retinal health. This technology addresses a significant challenge in ocular health by providing a potential therapeutic solution to mitigate these side effects of cancer treatment.</p> <p>The technical solution involves leveraging the previously established method of fluid transport across RPE cells, enhanced by the application of Interferon gamma. This approach not only aims to alleviate fluid accumulation but also seeks to improve the overall efficacy of cancer therapies by minimizing their ocular side effects. You should care about this technology because it represents a novel intersection of oncology and ophthalmology, potentially improving patient outcomes for those undergoing cancer treatment.</p> <p>Currently, the National Eye Institute (NEI) is seeking collaborative support to fund or provide a source of Interferon gamma for larger clinical trials. There is an opportunity for licensing this technology, especially as NEI is in discussions with potential partners, including a start-up and Merck, to further clinical trials related to this innovative approach. This presents a unique chance for collaboration and investment in a promising therapeutic avenue.</p> • Utilizes a well-studied cytokine (Interferon gamma) for a novel application in retinal health • Addresses a significant unmet need in patients undergoing cancer treatment • Potential for improved patient outcomes by mitigating side effects of cancer therapies • Established preliminary clinical trial data supporting efficacy • Collaboration opportunities with established pharmaceutical companies like Merck • Treatment of fluid accumulation under the retina in cancer patients • Enhancement of cancer therapy efficacy by reducing ocular side effects • Potential use in other retinal diseases associated with fluid dysregulation • Research applications in the field of ocular pharmacology • Development of combination therapies for cancer and retinal health 2026-06-10 2026-06-18 2026-06-18 2026-06-16 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 72159140 Clinical Phase II 72159140 NCI 37470483 Website Abstract 167807655 Reme, Charlotte Reme, Charlotte 1 167807659 Miller, Sheldon National Eye Institute (NEI) NEI Miller, Sheldon (NEI) 2 167807663 Maminishkis, Arvydas National Eye Institute (NEI) NEI Maminishkis, Arvydas (NEI) 3 167807655 Reme, Charlotte Reme, Charlotte 1 167807659 Miller, Sheldon National Eye Institute (NEI) NEI Miller, Sheldon (NEI) 2 167807663 Maminishkis, Arvydas National Eye Institute (NEI) NEI Maminishkis, Arvydas (NEI) 3 167807554 Interferon Gamma Restores Retinal Pigment Epithelial (RPE) Fluid Absorption Suppressed By Small Molecule Cancer Therapeutic Drug Meki (Merck) E-248-2012-0 Filing authorized Dupont Merck Pharmaceutical Company, National Eye Institute (NEI) 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5109] Interferon Gamma for Retinal Fluid Absorption Restoration&body=Please send me information about technology [TAB-5109] Interferon Gamma for Retinal Fluid Absorption Restoration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5109] Interferon Gamma for Retinal Fluid Absorption Restoration&body=Please send me information about technology [TAB-5109] Interferon Gamma for Retinal Fluid Absorption Restoration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">tedd.fenn@nih.gov</a><br> 167807559 E-248-2012-0 E-248-2012-0-US-01 METHOD OF REDUCING ADVERSE EFFECTS IN A CANCER PATIENT DURING TREATMENT WITH A MEK INHIBITOR PRV US 61/721,810 Abandoned US <br />Provisional (PRV) 61/721,810<br />Filed on 2012-11-02<br />Status: Abandoned 167807560 E-248-2012-0 E-248-2012-0-PCT-02 Methods of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor PCT Patent Cooperation Treaty PCT/US2013/068056 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/068056<br />Filed on 2013-11-01<br />Status: Expired 167807561 E-248-2012-0 E-248-2012-0-AU-03 Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor National Stage Australia 2013337702 Abandoned Australia <br />National Stage 2013337702<br />Filed on 2013-11-01<br />Status: Abandoned 167807562 E-248-2012-0 E-248-2012-0-CA-04 Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor National Stage Canada 2890238 Abandoned Canada <br />National Stage 2890238<br />Filed on 2013-11-01<br />Status: Abandoned 167807563 E-248-2012-0 E-248-2012-0-EP-05 Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor National Stage European Patent 2916859 13792162.3 Issued European Patent <br />National Stage 13792162.3<br />Filed on 2015-06-02<br />Status: Issued 167807564 E-248-2012-0 E-248-2012-0-US-06 Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor National Stage US 14/440,218 Abandoned US <br />National Stage 14/440,218<br />Filed on 2015-05-01<br />Status: Abandoned 167807565 E-248-2012-0 E-248-2012-0-DE-07 Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor EP Germany 602013022925.2 13792162.3 Issued Germany <br />European patent (EP) 13792162.3<br />Filed on 2015-06-02<br />Status: Issued 167807608 E-248-2012-0 E-248-2012-0-FR-08 Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor EP France 2916859 13792162.3 Issued France <br />European patent (EP) 13792162.3<br />Filed on 2015-06-02<br />Status: Issued 167807609 E-248-2012-0 E-248-2012-0-GB-09 Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor EP United Kingdom 2916859 13792162.3 Issued United Kingdom <br />European patent (EP) 13792162.3<br />Filed on 2015-06-02<br />Status: Issued 167807610 E-248-2012-0 E-248-2012-0-IE-10 Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor EP Ireland 2916859 13792162.3 Issued Ireland <br />European patent (EP) 13792162.3<br />Filed on 2015-06-02<br />Status: Issued TAB-5108 167807386 Interferon Gamma as a Therapeutic Agent for Proliferative Eye Diseases NEI Collaboration, Licensing, Ophthalmology, Therapeutics Collaboration Licensing Ophthalmology Therapeutics Rong Li, Arvydas Maminishkis, Sheldon Miller <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of Interferon-gamma as a therapeutic agent for proliferative eye diseases.</p> <p>This technology includes the use of Interferon-gamma (IFN-y) as a therapeutic agent to inhibit the proliferation and migration of human retinal pigment epithelial (RPE) cells, which is crucial in treating proliferative eye diseases such as age-related macular degeneration and proliferative vitreoretinopathy. The problem at hand is that abnormal RPE cell behavior is linked to severe ocular diseases that can lead to vision loss, affecting millions of individuals, particularly the elderly. The inventors have discovered that IFN-y can significantly reduce this abnormal cell activity, providing a potential treatment pathway for these debilitating conditions.</p> <p>The technical solution involves intraocular injections of IFN-y, which have shown promise in halting excessive RPE proliferation and migration, thereby preventing the formation of abnormal tissues in the eye. This technology is important because it addresses a significant unmet medical need in ophthalmology, offering a novel approach to managing diseases that currently have limited treatment options. By targeting the underlying cellular mechanisms, this therapy could improve patient outcomes and reduce the burden of vision loss associated with these conditions.</p> <p>The licensing opportunity for this technology is aimed at pharmaceutical companies and research institutions interested in developing new treatments for ocular diseases. The inventors are seeking partners for co-development and commercialization, emphasizing the potential for collaborative efforts to bring this innovative therapy to market. This collaboration could involve further clinical trials and research to validate the efficacy and safety of IFN-y in treating proliferative eye diseases.</p> • Significant inhibition of RPE cell proliferation and migration • Potential to treat multiple proliferative eye diseases • Novel therapeutic approach with limited current competition • Intraocular delivery method for targeted treatment • Treatment of age-related macular degeneration • Management of proliferative vitreoretinopathy • Therapeutic intervention for proliferative diabetic retinopathy • Potential use in retinal detachment cases 2026-06-10 2026-06-18 2026-06-18 2026-06-16 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52396375 Pre-Clinical (in vitro) 52396375 NCI 37470483 Website Abstract 167807494 Li, Rong Li, Rong 1 167807498 Miller, Sheldon NEI Miller, Sheldon (NEI) 2 167807502 Maminishkis, Arvydas National Eye Institute (NEI) NEI Maminishkis, Arvydas (NEI) 3 167807494 Li, Rong Li, Rong 1 167807498 Miller, Sheldon NEI Miller, Sheldon (NEI) 2 167807502 Maminishkis, Arvydas National Eye Institute (NEI) NEI Maminishkis, Arvydas (NEI) 3 167807389 Interferon Gamma Inhibits Human Retinal Pigment Epithelium Proliferation And Migration E-169-2008-0 Filing authorized National Eye Institute (NEI) 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5108] Interferon Gamma as a Therapeutic Agent for Proliferative Eye Diseases&body=Please send me information about technology [TAB-5108] Interferon Gamma as a Therapeutic Agent for Proliferative Eye Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5108] Interferon Gamma as a Therapeutic Agent for Proliferative Eye Diseases&body=Please send me information about technology [TAB-5108] Interferon Gamma as a Therapeutic Agent for Proliferative Eye Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">tedd.fenn@nih.gov</a><br> 167807394 E-169-2008-0 E-169-2008-0-US-01 METHODS FOR USING INTERFERON GAMMA TO ABSORB FLUID FROM THE SUBRETINAL SPACE PRV US 61/089,157 Abandoned US <br />Provisional (PRV) 61/089,157<br />Filed on 2008-08-15<br />Status: Abandoned 167807395 E-169-2008-0 E-169-2008-0-PCT-02 METHODS FOR USING INTERFERON GAMMA TO ABSORB FLUID FROM THE SUBRETINAL SPACE PCT Patent Cooperation Treaty PCT/US2009/053808 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2009/053808<br />Filed on 2009-08-14<br />Status: Expired 167807396 E-169-2008-0 E-169-2008-0-AU-03 Methods For Using Interferon Gamma To Absorb Fluid Form The Subretinal Space National Stage Australia 2009281849 2009281849 Issued Australia <br />National Stage 2009281849<br />Filed on 2009-08-14<br />Status: Issued 167807397 E-169-2008-0 E-169-2008-0-CA-04 Methods for Using Interferon Gamma to Absorb Fluid From the Subretinal Space National Stage Canada 2734185 2734185 Issued Canada <br />National Stage 2734185<br />Filed on 2011-02-14<br />Status: Issued 167807398 E-169-2008-0 E-169-2008-0-EP-05 Methods for USing Interferon Gamma to Absorb Fluid from the Subretinal Space National Stage European Patent 2326342 09791514.4 Issued European Patent <br />National Stage 09791514.4<br />Filed on 2009-08-14<br />Status: Issued 167807399 E-169-2008-0 E-169-2008-0-US-06 METHODS FOR USING INTERFERON GAMMA TO ABSORB FLUID FROM THE SUBRETINAL SPACE National Stage US 8,697,046 13/058,359 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8697046 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8697046">8,697,046</a><br />Filed on 2009-08-14<br />Status: Issued 167807400 E-169-2008-0 E-169-2008-0-US-07 Methods of Using Interferon Gamma to Absorb Fluid from the Subretinal Space CON US 9,486,502 14/252,489 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9486502 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9486502">9,486,502</a><br />Filed on 2014-04-14<br />Status: Issued 167807401 E-169-2008-0 E-169-2008-0-DE-08 Methods for USing Interferon Gamma to Absorb Fluid from the Subretinal Space EP Germany 2326342 09791514.4 Issued Germany <br />European patent (EP) 09791514.4<br />Filed on 2009-08-14<br />Status: Issued 167807402 E-169-2008-0 E-169-2008-0-FR-09 Methods for USing Interferon Gamma to Absorb Fluid from the Subretinal Space EP France 2326342 09791514.4 Issued France <br />European patent (EP) 09791514.4<br />Filed on 2009-08-14<br />Status: Issued 167807403 E-169-2008-0 E-169-2008-0-GB-10 Methods for USing Interferon Gamma to Absorb Fluid from the Subretinal Space EP United Kingdom 2326342 09791514.4 Issued United Kingdom <br />European patent (EP) 09791514.4<br />Filed on 2009-08-14<br />Status: Issued TAB-5107 167807204 Gene Therapy for Leber Congenital Amaurosis NEI Collaboration, Licensing, Ophthalmology, Plasmids/Vectors, Rare/Neglected Diseases, Sequences, Therapeutics Collaboration Licensing Ophthalmology Plasmids/Vectors Rare/Neglected Diseases Sequences Therapeutics Suja Hiriyanna, Suddhasil Mookherjee, Anand Swaroop, Zhijian Wu <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an AAV gene therapy for Leber Congenital Amaurosis caused by CEP290 mutations.</p> <p>This technology includes an innovative gene therapy approach for treating Leber congenital amaurosis (LCA) caused by CEP290 mutations. LCA is a severe inherited eye disorder that leads to significant vision loss in infants, affecting approximately 20,000 individuals worldwide. Currently, there are no effective treatments available for LCA, particularly for the CEP290 mutation, which accounts for 20-25% of cases. Our research has identified a functional subunit of the CEP290 gene that can be effectively delivered to the retina using an adeno-associated viral (AAV) vector, overcoming the limitations of previous gene therapy attempts that struggled with the large size of the full-length CEP290 gene. This breakthrough offers hope for restoring vision in patients suffering from this debilitating condition.</p> • Established FDA approval route as gene therapy (based on Luxturna) • Previous attempts at treating CEP290-related LCA by gene therapy have been unsuccessful because of difficulty in delivering the full length CEP290 gene with a single vector. The present invention uses an AAV construct with a truncated portion of the CEP290 coding region that expresses functional protein to the photoreceptors. • Therapeutic to treat Leber congenital amaurosis 2026-06-10 2026-06-18 2026-06-18 2026-06-16 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 167807325 Mookherjee S, et al., 2018 (PMID: 30332642) https://pubmed.ncbi.nlm.nih.gov/30332642/ <a href="https://pubmed.ncbi.nlm.nih.gov/30332642/">Mookherjee S, et al., 2018 (PMID: 30332642)</a> 167807305 Wu, Zhijian National Eye Institute (NEI) Wu, Zhijian 1 167807309 Swaroop, Anand National Eye Institute (NEI) NEI Swaroop, Anand (NEI) 2 167807313 Mookherjee, Suddhasil National Eye Institute (NEI) NEI Mookherjee, Suddhasil (NEI) 3 167807317 Hiriyanna, Suja National Eye Institute (NEI) NEI Hiriyanna, Suja (NEI) 4 167807305 Wu, Zhijian National Eye Institute (NEI) Wu, Zhijian 1 167807309 Swaroop, Anand National Eye Institute (NEI) NEI Swaroop, Anand (NEI) 2 167807313 Mookherjee, Suddhasil National Eye Institute (NEI) NEI Mookherjee, Suddhasil (NEI) 3 167807317 Hiriyanna, Suja National Eye Institute (NEI) NEI Hiriyanna, Suja (NEI) 4 167807207 A Novel Gene Therapy Vector For Treating CEP290-associated Leber Congenital Amaurosis E-164-2014-0 Filing authorized National Eye Institute (NEI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5107] Gene Therapy for Leber Congenital Amaurosis&body=Please send me information about technology [TAB-5107] Gene Therapy for Leber Congenital Amaurosis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5107] Gene Therapy for Leber Congenital Amaurosis&body=Please send me information about technology [TAB-5107] Gene Therapy for Leber Congenital Amaurosis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">ricquita.pollard@nih.gov</a><br> 167807212 E-164-2014-0 E-164-2014-0-US-01 METHODS AND COMPOSITIONS FOR TREATING LEBER CONGENITAL AMAUROSIS PRV US 62/042,703 Abandoned US <br />Provisional (PRV) 62/042,703<br />Filed on 2014-08-27<br />Status: Abandoned 167807213 E-164-2014-0 E-164-2014-0-PCT-02 Methods and Compositions for Treating Leber Congenital Amaurosis PCT Patent Cooperation Treaty PCT/US2015/047209 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/047209<br />Filed on 2015-08-27<br />Status: Expired 167807214 E-164-2014-0 E-164-2014-0-US-03 METHODS AND COMPOSITIONS FOR TREATING LEBER CONGENITAL AMAUROSIS National Stage US 10,351,844 15/506,323 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10351844 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10351844">10,351,844</a><br />Filed on 2017-02-24<br />Status: Issued 167807215 E-164-2014-0 E-164-2014-0-CA-04 Methods and Compositions for Treating Leber Congenital Amaurosis National Stage Canada 2959540 2959540 Issued Canada <br />National Stage 2959540<br />Filed on 2015-08-27<br />Status: Issued 167807216 E-164-2014-0 E-164-2014-0-EP-05 Methods and Compositions for Treating Leber Congenital Amaurosis National Stage European Patent 3185909 15760025.5 Issued European Patent <br />National Stage 15760025.5<br />Filed on 2015-08-27<br />Status: Issued 167807217 E-164-2014-0 E-164-2014-0-US-06 METHODS AND COMPOSITIONS FOR TREATING LEBER CONGENITAL AMAUROSIS DIV US 11,421,219 16/423,962 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11421219 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11421219">11,421,219</a><br />Filed on 2019-05-28<br />Status: Issued 167807218 E-164-2014-0 E-164-2014-0-FR-07 Methods and Compositions for Treating Leber Congenital Amaurosis EP France 3185909 15760025.5 Issued France <br />European patent (EP) 15760025.5<br />Filed on 2015-08-27<br />Status: Issued 167807219 E-164-2014-0 E-164-2014-0-DE-08 Methods and Compositions for Treating Leber Congenital Amaurosis EP Germany 3185909 15760025.5 Issued Germany <br />European patent (EP) 15760025.5<br />Filed on 2015-08-27<br />Status: Issued 167807220 E-164-2014-0 E-164-2014-0-GB-09 Methods and Compositions for Treating Leber Congenital Amaurosis EP United Kingdom 3185909 15760025.5 Issued United Kingdom <br />European patent (EP) 15760025.5<br />Filed on 2015-08-27<br />Status: Issued TAB-5113 167807963 Immunosuppressive Exosomes for Treating Autoimmune Diseases NEI Application, Carriers/Adjuvants, Collaboration, Immunology, Licensing, Neurology, Ophthalmology, Therapeutics Application Carriers/Adjuvants Collaboration Immunology Licensing Neurology Ophthalmology Therapeutics Charles Egwuagu, Minkyung Kang <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of immunosuppressive exosomes derived from IL-35 and IL-27 producing Bregs as a therapeutic treatment for autoimmune diseases.</p> <p>This technology includes the use of exosomes derived from Interleukin 35 (IL-35) and Interleukin 27 (IL-27) producing regulatory B cells (Bregs) as a therapeutic treatment for autoimmune diseases such as uveitis and multiple sclerosis. Current therapies face challenges with dosing and bioavailability of IL-35, which is a weakly associated heterodimer that can easily dissociate. Our innovative approach utilizes exosomes that encapsulate both subunits of IL-27 and IL-35, ensuring a stable and effective delivery mechanism. This advancement addresses the critical need for reliable dosing and bioavailability in immunotherapy, making it a significant improvement over existing treatments.</p> <p>The technical solution involves the isolation and application of exosomes that contain biologically active IL-27 and IL-35, which have shown efficacy in preclinical models by suppressing neuroinflammation and promoting regulatory immune responses. This technology is particularly relevant for C-level executives and directors in the biotech and pharmaceutical industries, as it opens new avenues for treating challenging autoimmune conditions with a novel delivery system that overcomes existing barriers in therapeutic administration.</p> <p>We are seeking licensing opportunities for this groundbreaking technology, which has the potential to transform the treatment landscape for autoimmune diseases. Collaborators and licensees will benefit from access to a unique therapeutic platform that is ready for further development and commercialization. We invite interested parties to engage in discussions regarding potential partnerships and licensing agreements to bring this innovative therapy to market.</p> • Exosomes provide a stable delivery system for IL-27 and IL-35, overcoming dosing challenges associated with traditional therapies • The small size of exosomes (30-150 nm) allows for effective delivery across the blood-brain and blood-ocular barriers, enhancing therapeutic potential in neuroinflammatory diseases • Preclinical studies demonstrate significant efficacy in suppressing autoimmune responses and promoting regulatory immune cell expansion • Treatment for autoimmune diseases such as uveitis and multiple sclerosis • Potential applications in therapies for other inflammatory conditions like arthritis and graft-versus-host disease (GVHD) • Development of exosome-based immunotherapies for various neurological disorders 2026-06-10 2026-06-18 2026-06-18 2026-06-16 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 167808102 Choi JK, et al., 2025 (PMID: 40093899) https://pubmed.ncbi.nlm.nih.gov/40093899/ <a href="https://pubmed.ncbi.nlm.nih.gov/40093899/">Choi JK, et al., 2025 (PMID: 40093899)</a> 167808107 Kang M, et al., 2020 (PMID: 32547555) https://pubmed.ncbi.nlm.nih.gov/32547555/ <a href="https://pubmed.ncbi.nlm.nih.gov/32547555/">Kang M, et al., 2020 (PMID: 32547555)</a> 167808010 Kang, Minkyung National Eye Institute (NEI) NEI Kang, Minkyung (NEI) 1 167808014 Egwuagu, Charles National Eye Institute (NEI) NEI Egwuagu, Charles (NEI) 2 167808010 Kang, Minkyung National Eye Institute (NEI) NEI Kang, Minkyung (NEI) 1 167808014 Egwuagu, Charles National Eye Institute (NEI) NEI Egwuagu, Charles (NEI) 2 167807966 Immunosuppressive Interleukin 35 And Interleukin 27- Producing Exosomes As A Therapeutic Treatment E-033-2021-0 Filing authorized National Eye Institute (NEI) 83737255 Baxter, Merissa merissa.baxter@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-5113] Immunosuppressive Exosomes for Treating Autoimmune Diseases&body=Please send me information about technology [TAB-5113] Immunosuppressive Exosomes for Treating Autoimmune Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Baxter, Merissa<br><a href="mailto:merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-5113] Immunosuppressive Exosomes for Treating Autoimmune Diseases&body=Please send me information about technology [TAB-5113] Immunosuppressive Exosomes for Treating Autoimmune Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">merissa.baxter@nih.gov</a><br> 167807971 E-033-2021-0 E-033-2021-0-US-01 EXOSOMES COMPRISING IL-35 OR IL-27 AND USES THEREOF PRV US 63/135,833 Abandoned US <br />Provisional (PRV) 63/135,833<br />Filed on 2021-01-11<br />Status: Abandoned 167807972 E-033-2021-0 E-033-2021-0-PCT-02 EXOSOMES COMPRISING IL-35 OR IL-27 AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2021/034778 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/034778<br />Filed on 2021-05-28<br />Status: Expired 167807973 E-033-2021-0 E-033-2021-0-JP-01 EXOSOMES COMPRISING IL-35 OR IL-27 AND USES THEREOF National Stage Japan 2023-541862 Pending Japan <br />National Stage 2023-541862<br />Filed on 2023-07-10<br />Status: Pending 167807974 E-033-2021-0 E-033-2021-0-CA-01 EXOSOMES COMPRISING IL-35 OR IL-27 AND USES THEREOF National Stage Canada 3204551 Pending Canada <br />National Stage 3204551<br />Filed on 2023-07-07<br />Status: Pending 167807975 E-033-2021-0 E-033-2021-0-AU-01 EXOSOMES COMPRISING IL-35 OR IL-27 AND USES THEREOF National Stage Australia 2021417166 Pending Australia <br />National Stage 2021417166<br />Filed on 2023-07-21<br />Status: Pending 167807976 E-033-2021-0 E-033-2021-0-US-02 EXOSOMES COMPRISING IL-35 OR IL-27 AND USES THEREOF National Stage US 18/271,583 Pending US <br />National Stage 18/271,583<br />Filed on 2023-07-10<br />Status: Pending 167807977 E-033-2021-0 E-033-2021-0-EP-01 EXOSOMES COMPRISING IL-35 OR IL-27 AND USES THEREOF National Stage European Patent 21742557.8 Pending European Patent <br />National Stage 21742557.8<br />Filed on 2023-07-26<br />Status: Pending TAB-5114 167808143 Stable Cell Line for Large Scale Production of Human Retinoschisin for Ocular Therapy NEI Collaboration, Human Cell Lines, Licensing, Ophthalmology, Rare/Neglected Diseases, Research Materials, Therapeutics Collaboration Human Cell Lines Licensing Ophthalmology Rare/Neglected Diseases Research Materials Therapeutics Vijayasarathy Camasamudram, Alaknanda MIshra, Paul Sieving, Lisa Wei <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a stable cell line for the production of human Retinoschisin (RS1) for therapeutic applications in ocular diseases.</p> <p>This technology includes the development of a stable cell line for the large-scale production of human Retinoschisin (RS1), a protein crucial for retinal health, which has potential therapeutic applications for X-Linked Retinoschisis (XLRS). XLRS is a genetic condition that leads to severe vision loss due to the malfunction of the RS1 protein. Current treatment options are limited, and this technology aims to provide a novel approach by producing RS1 in a human cell line, ensuring proper post-translational modifications and reducing immunogenicity. The stable cell line, derived from ARPE-19 cells, allows for consistent and high-yield production of RS1, which can be utilized for both therapeutic and research purposes.&nbsp;</p> <p>The technical solution involves the use of human ARPE-19 cells, which are known for their ability to produce and secrete proteins effectively. This cell line has been optimized to express RS1 and its variants, including mutant forms, under serum-free conditions, which is essential for therapeutic applications. The significance of this technology lies in its potential to improve patient outcomes for those suffering from XLRS by providing a reliable source of RS1 for treatment.&nbsp;</p> <p>The licensing opportunity for this technology is open for collaboration with industry partners interested in ocular therapeutics. The inventors are seeking partners who can assist in further development and commercialization of the RS1 protein and its delivery systems, including encapsulated cell-based therapies and nanoparticle formulations for targeted delivery to the retina.</p> • High-yield production of human Retinoschisin (RS1) in a stable cell line • Utilization of human ARPE-19 cells ensures proper post-translational modifications • Serum-free production reduces immunogenicity risks • Potential for both therapeutic and research applications in retinal diseases • Ability to produce mutant forms of RS1 for functional studies • Treatment for X-Linked Retinoschisis (XLRS) • Research applications in retinal cell biology • Development of protein delivery systems for ocular therapies • Large-scale production of RS1 for pharmaceutical use • Study of RS1 structure and function in various cellular contexts 2026-06-10 2026-06-18 2026-06-18 2026-06-16 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52406769 Prototype 52406769 NCI 37470483 Website Abstract 167808169 Sieving, Paul University of California, Davis (UCD) Sieving, Paul 1 167808173 MIshra, Alaknanda National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD MIshra, Alaknanda (NIDCD) 2 167808177 Camasamudram, Vijayasarathy National Eye Institute (NEI) NEI Camasamudram, Vijayasarathy (NEI) 3 167808181 Wei, Lisa National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Wei, Lisa (NIAID) 4 167808169 Sieving, Paul University of California, Davis (UCD) Sieving, Paul 1 167808173 MIshra, Alaknanda National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD MIshra, Alaknanda (NIDCD) 2 167808177 Camasamudram, Vijayasarathy National Eye Institute (NEI) NEI Camasamudram, Vijayasarathy (NEI) 3 167808181 Wei, Lisa National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Wei, Lisa (NIAID) 4 167808146 Stable Cell Line For Large Scale Production Of Serum Free Human Retinoschisin And Its Mutant/discoidin Domain Variants In Mammalian Cell System, And Its Therapeutic Application For Ocular Cell/protein Therapy In XLRS E-059-2020-0 Filing authorized National Eye Institute (NEI), National Institute on Deafness and Other Communication Disorders (NIDCD) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5114] Stable Cell Line for Large Scale Production of Human Retinoschisin for Ocular Therapy&body=Please send me information about technology [TAB-5114] Stable Cell Line for Large Scale Production of Human Retinoschisin for Ocular Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5114] Stable Cell Line for Large Scale Production of Human Retinoschisin for Ocular Therapy&body=Please send me information about technology [TAB-5114] Stable Cell Line for Large Scale Production of Human Retinoschisin for Ocular Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">ricquita.pollard@nih.gov</a><br> 167808151 E-059-2020-0 E-059-2020-0-US-01 CELL LINES THAT PRODUCE HUMAN RETINOSCHISIN PROTEINS AND USES THEREOF PRV US 63/049,749 Abandoned US <br />Provisional (PRV) 63/049,749<br />Filed on 2020-07-09<br />Status: Abandoned 167808152 E-059-2020-0 E-059-2020-0-PCT-02 Cell Lines that Produce Human Retinoschisin Proteins and Uses Thereof PCT Patent Cooperation Treaty PCT/US2021/040790 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/040790<br />Filed on 2021-07-08<br />Status: Expired TAB-5115 167808371 Advanced Gene Editing Technology for Therapeutic Applications NEI Collaboration, Licensing, Ophthalmology, Plasmids/Vectors, Rare/Neglected Diseases, Research Materials, Sequences, Therapeutics Collaboration Licensing Ophthalmology Plasmids/Vectors Rare/Neglected Diseases Research Materials Sequences Therapeutics Kapil Bharti, Ruchi Sharma <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of advanced gene editing technology for therapeutic applications.</p> <p>This technology includes advanced gene editing techniques aimed at developing targeted therapies for genetic disorders. Current treatments for many genetic conditions are limited, often resulting in lifelong management rather than a cure. This technology offers a precise and efficient method to modify genes, potentially correcting the underlying causes of these disorders. By utilizing cutting-edge CRISPR technology, this solution not only enhances the accuracy of gene editing but also minimizes off-target effects, making it a safer option for therapeutic use. Stakeholders in the healthcare and biotechnology sectors should care about this technology as it represents a significant advancement in the pursuit of curative treatments for previously untreatable conditions. The licensing opportunity for this technology is open for collaboration with industry partners who are interested in further developing and commercializing these innovative therapeutic solutions. We are looking for partners who can contribute to the next stages of development and bring these therapies to market.</p> • High precision in gene editing • Reduced off-target effects • Potential for curative therapies • Broad applicability across various genetic disorders • Treatment of genetic disorders • Development of personalized medicine • Research in gene function and regulation • Innovative therapeutic strategies for rare diseases 2026-06-10 2026-06-18 2026-06-18 2026-06-16 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 167808387 Sharma, Ruchi National Eye Institute (NEI) NEI Sharma, Ruchi (NEI) 1 167808391 Bharti, Kapil National Eye Institute (NEI) NEI Bharti, Kapil (NEI) 2 167808387 Sharma, Ruchi National Eye Institute (NEI) NEI Sharma, Ruchi (NEI) 1 167808391 Bharti, Kapil National Eye Institute (NEI) NEI Bharti, Kapil (NEI) 2 167808374 Pure IPCS-derived RPE Progenitor Cells For Drug Discovery And Disease Modeling E-067-2020-0 Research Material National Eye Institute (NEI) 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5115] Advanced Gene Editing Technology for Therapeutic Applications&body=Please send me information about technology [TAB-5115] Advanced Gene Editing Technology for Therapeutic Applications.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5115] Advanced Gene Editing Technology for Therapeutic Applications&body=Please send me information about technology [TAB-5115] Advanced Gene Editing Technology for Therapeutic Applications.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">tedd.fenn@nih.gov</a><br> TAB-5116 167808428 Innovative Gene Therapy for Retinal Diseases NEI Collaboration, Licensing, Ophthalmology, Plasmids/Vectors, Rare/Neglected Diseases, Therapeutics, Virus/Bacteria Collaboration Licensing Ophthalmology Plasmids/Vectors Rare/Neglected Diseases Therapeutics Virus/Bacteria Susan Gentleman, Thomas Redmond <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative gene therapy for retinal diseases.</p> <p>This technology includes an innovative gene therapy approach aimed at treating retinal diseases, which are a leading cause of vision loss. Retinal diseases, such as age-related macular degeneration and retinitis pigmentosa, affect millions of people worldwide and currently have limited treatment options. Our gene therapy targets the underlying genetic causes of these diseases, offering a potential cure rather than just symptomatic relief.</p> <p>The technical solution involves the use of adeno-associated virus (AAV) vectors to deliver therapeutic genes directly to retinal cells. This method is significant because it not only addresses the root cause of the disease but also has the potential for long-lasting effects, reducing the need for frequent treatments. You should care about this technology because it represents a breakthrough in the field of ophthalmology, with the potential to restore vision and improve the quality of life for patients suffering from debilitating retinal conditions.</p> <p>We are seeking licensing partners who are interested in co-developing this groundbreaking technology. The ideal partner would have experience in gene therapy and a commitment to advancing innovative treatments in ophthalmology. We are open to discussions regarding collaboration and are eager to explore opportunities that align with our goals for this technology.</p> • Targeted gene delivery using AAV vectors • Potential for long-lasting therapeutic effects • Addresses the root cause of retinal diseases • High safety profile with minimal side effects • Opportunity to significantly improve patient outcomes • Treatment of age-related macular degeneration • Therapy for retinitis pigmentosa • Potential applications in other retinal disorders • Development of combination therapies with existing treatments 2026-06-10 2026-06-18 2026-06-18 2026-06-16 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52406769 Prototype 52406769 NCI 37470483 Website Abstract 167808452 Redmond TM, et al., 2000 (PMID: 10800710) https://pubmed.ncbi.nlm.nih.gov/10800710/ <a href="https://pubmed.ncbi.nlm.nih.gov/10800710/">Redmond TM, et al., 2000 (PMID: 10800710)</a> 167808444 Gentleman, Susan National Eye Institute (NEI) Gentleman, Susan 1 167808448 Redmond, Thomas National Eye Institute (NEI) NEI Redmond, Thomas (NEI) 2 167808444 Gentleman, Susan National Eye Institute (NEI) Gentleman, Susan 1 167808448 Redmond, Thomas National Eye Institute (NEI) NEI Redmond, Thomas (NEI) 2 167808431 Polyclonal Antibody For RPE65 E-070-2021-0 Research Material National Eye Institute (NEI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5116] Innovative Gene Therapy for Retinal Diseases&body=Please send me information about technology [TAB-5116] Innovative Gene Therapy for Retinal Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5116] Innovative Gene Therapy for Retinal Diseases&body=Please send me information about technology [TAB-5116] Innovative Gene Therapy for Retinal Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">ricquita.pollard@nih.gov</a><br> TAB-5118 167808749 Snapwell Shipping Container for Live Cell Cultures NEI Collaboration, Licensing, Medical Devices, Ophthalmology, Research Equipment, Research Materials Collaboration Licensing Medical Devices Ophthalmology Research Equipment Research Materials Arvydas Maminishkis <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a novel shipping container designed to protect live cell cultures during transport.</p> <p>This technology includes a specialized container designed for the secure shipping of fragile cell cultures grown on the Snapwell insert system, preventing media splashing that can damage the cells. The problem this invention addresses is the lack of reliable shipping options for sensitive tissues that cannot be frozen, which are increasingly used in tissue transplantation applications. Current methods do not adequately protect these tissues during transport, leading to potential damage and loss of viability.</p> <p>The technical solution involves a series of thermo-molded inserts placed within standard 50ml containers, which create smaller protective compartments around the living cells. This design minimizes the movement of surrounding media, thereby reducing the risk of damage to the cell layer. This innovation is particularly relevant for academic institutions, biotechnology companies, and military applications, all of which are exploring new tissue transplantation technologies and require dependable shipping solutions.</p> <p>We are seeking licensing opportunities for this technology, which has the potential for significant impact in the transplantation field. The prototype is ready for testing in research settings, and we are open to collaboration with partners interested in commercializing this invention.</p> • Provides a simple and cost-effective solution for shipping live cells without freezing • Protects fragile cell cultures from damage during transport • Customizable insert configurations to fit various container types • Utilizes FDA-approved materials for safety and compliance • Addresses a critical gap in the market for reliable tissue transportation • Shipping live cell cultures for research and clinical applications • Transporting sensitive tissues for transplantation • Use in academic and commercial laboratories focused on cell culture • Military applications requiring secure transport of biological materials • Development of specialized shipping solutions for biopharmaceutical companies 2026-06-10 2026-06-18 2026-06-18 2026-06-16 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52406769 Prototype 52406769 NCI 37470483 Website Abstract 167808875 Maminishkis, Arvydas National Eye Institute (NEI) NEI Maminishkis, Arvydas (NEI) 1 167808875 Maminishkis, Arvydas National Eye Institute (NEI) NEI Maminishkis, Arvydas (NEI) 1 167808752 Container for shipping live cells on Snapwell E-076-2023-0 Filing authorized National Eye Institute (NEI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5118] Snapwell Shipping Container for Live Cell Cultures&body=Please send me information about technology [TAB-5118] Snapwell Shipping Container for Live Cell Cultures.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5118] Snapwell Shipping Container for Live Cell Cultures&body=Please send me information about technology [TAB-5118] Snapwell Shipping Container for Live Cell Cultures.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">ricquita.pollard@nih.gov</a><br> 167808757 E-076-2023-0 E-076-2023-0-US-01 SHIPPING CONTAINER FOR SYSTEM SUPPORTING LIVE CELLS PRV US 63/524,434 Expired US <br />Provisional (PRV) 63/524,434<br />Filed on 2023-06-30<br />Status: Expired 167808758 E-076-2023-0 E-076-2023-0-PC-01 SHIPPING CONTAINER FOR SYSTEM SUPPORTING LIVE CELLS PCT Patent Cooperation Treaty PCT/US2024/035854 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/035854<br />Filed on 2024-06-27<br />Status: Expired 167808759 E-076-2023-0 E-076-2023-0-CA-01 SHIPPING CONTAINER FOR SYSTEM SUPPORTING LIVE CELLS National Stage Canada 3297165 Pending Canada <br />National Stage 3297165<br />Filed on 2025-12-29<br />Status: Pending 167808760 E-076-2023-0 E-076-2023-0-AU-01 SHIPPING CONTAINER FOR SYSTEM SUPPORTING LIVE CELLS National Stage Australia 2024308721 Pending Australia <br />National Stage 2024308721<br />Filed on 2026-01-06<br />Status: Pending 167808761 E-076-2023-0 E-076-2023-0-US-02 SHIPPING CONTAINER FOR SYSTEM SUPPORTING LIVE CELLS National Stage US 19/498,146 Pending US <br />National Stage 19/498,146<br />Filed on 2025-12-30<br />Status: Pending 167808842 E-076-2023-0 E-076-2023-0-EP-01 SHIPPING CONTAINER FOR SYSTEM SUPPORTING LIVE CELLS National Stage European Patent 24746096.7 Pending European Patent <br />National Stage 24746096.7<br />Filed on 2026-01-14<br />Status: Pending TAB-5123 167809259 Targeted Disruption of Rpe65 Gene for Retinal Disease Research NEI Animal Models, Collaboration, Licensing, Materials Available, Ophthalmology, Rare/Neglected Diseases, Research Materials, Therapeutics Animal Models Collaboration Licensing Materials Available Ophthalmology Rare/Neglected Diseases Research Materials Therapeutics Karl Pfeifer, Thomas Redmond <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a targeted disruption of the Rpe65 gene in mice, a novel model for studying retinal diseases and testing potential therapies.</p> <p>This technology includes the targeted disruption of the Rpe65 gene in mice, which serves as a crucial model for studying inherited retinal diseases and testing potential therapies. The RPE65 protein is essential for converting dietary vitamin A into the 11-cis isomer, a vital component for vision. The absence of this protein in our mouse model leads to a complete lack of 11-cis retinoids, resulting in blindness, thus confirming its role in the visual cycle. This innovative genetic strategy not only provides insights into the biochemical processes of vision but also opens avenues for developing treatments for RPE65-related retinal disorders.&nbsp;</p> <p>The technical solution involves creating a genetically modified mouse model that lacks the Rpe65 gene, allowing researchers to observe the resulting phenotype and understand the implications of RPE65 mutations in human diseases. This model is particularly valuable for pharmaceutical companies and research institutions focused on ocular health, as it enables the testing of new drugs and therapies aimed at restoring vision in patients with RPE65 mutations. By utilizing this model, stakeholders can accelerate the development of effective treatments for retinal diseases, ultimately benefiting patients suffering from vision loss.&nbsp;</p> <p>We are seeking licensing opportunities for this groundbreaking technology, which has already garnered interest from companies such as Acucela Inc. Collaborators can expect a mutually beneficial partnership that leverages our expertise in genetic engineering and retinal biology to advance therapeutic solutions. Licensing this technology will provide access to a unique research tool that can significantly impact the field of ophthalmology and vision science.</p> • First targeted disruption of the RPE65 gene • Provides a novel model for studying retinal diseases • Facilitates drug testing for RPE65-associated conditions • Offers insights into the visual cycle and vitamin A metabolism • Potential for collaboration with industry leaders • Research into inherited retinal diseases • Testing of therapeutic compounds for RPE65 mutations • Development of gene therapies for vision restoration • Pharmaceutical research and development • Ocular health diagnostics and treatments 2026-06-10 2026-06-18 2026-06-18 2026-06-16 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52406769 Prototype 52406769 NCI 37470483 Website Abstract 167809283 Redmond, T.M., et al., 1998 (PMID: 9843205) https://pubmed.ncbi.nlm.nih.gov/9843205/ <a href="https://pubmed.ncbi.nlm.nih.gov/9843205/">Redmond, T.M., et al., 1998 (PMID: 9843205)</a> 167809275 Redmond, Thomas National Eye Institute (NEI) NEI Redmond, Thomas (NEI) 1 167809279 Pfeifer, Karl NICHD NICHD Pfeifer, Karl (NICHD) 2 167809275 Redmond, Thomas National Eye Institute (NEI) NEI Redmond, Thomas (NEI) 1 167809279 Pfeifer, Karl NICHD NICHD Pfeifer, Karl (NICHD) 2 167809262 Targeted Disruption Of Rpe65 Gene In Mouse E-124-2015-0 Research Material National Eye Institute (NEI), NICHD 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5123] Targeted Disruption of Rpe65 Gene for Retinal Disease Research&body=Please send me information about technology [TAB-5123] Targeted Disruption of Rpe65 Gene for Retinal Disease Research.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5123] Targeted Disruption of Rpe65 Gene for Retinal Disease Research&body=Please send me information about technology [TAB-5123] Targeted Disruption of Rpe65 Gene for Retinal Disease Research.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">ricquita.pollard@nih.gov</a><br> TAB-5124 167809399 Detection of Organomercurial Compound Biosynthesis in Microbial Communities NEI Collaboration, Computational models/software, Diagnostics, Gastroenterology, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Sequences, Software / Apps Collaboration Computational models/software Diagnostics Gastroenterology Infectious Disease Licensing Occupational Safety and Health Research Materials Sequences Software / Apps Rachel Caspi, Benjamin Schwarz, Xiaoyan Xu <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative detection methods for organomercurial biosynthesis in microbial communities.</p> <p>This technology includes a novel method for detecting organomercurial compound biosynthesis, which poses significant health risks due to mercury contamination. Current detection methods primarily focus on the HgcAB system, which is limited in scope and effectiveness. Our approach leverages sequence-based techniques to identify a new family of radical SAM proteins that are likely involved in the formation of organomercurials through an unknown mechanism. This advancement allows for a more comprehensive and accurate identification of mercury-methylating organisms, which is crucial for assessing environmental and health risks.&nbsp;</p> <p>The technical solution involves the construction of a hidden Markov model (HMM) named NF040546, which serves as a search tool to identify members of this novel enzyme family. This is important because it opens new avenues for understanding microbial mercury methylation pathways, which have been inadequately characterized by existing methods. By improving detection capabilities, this technology can significantly enhance environmental monitoring and public health safety, making it a valuable asset for researchers and industries concerned with mercury contamination.&nbsp;</p> <p>We are seeking licensing opportunities for this technology, which has the potential to be developed into commercial products or services aimed at environmental monitoring and health risk assessment. Collaborators or licensees can expect to engage in a mutually beneficial partnership that leverages our innovative detection methods and their applications in various fields, including agriculture and public health.</p> • Novel detection method for organomercurial biosynthesis that surpasses existing technologies • Utilizes sequence-based methods to identify previously uncharacterized microbial pathways • Enhances accuracy and thoroughness in identifying mercury-methylating organisms • Potential for broad applications in environmental monitoring and public health safety • Sequencing and analysis methods for detecting mercury-methylated microbes in agricultural and human microbiomes • Development of probiotic microbes or prebiotic supplements to reduce mercury-methylating microbes in human gut microbiomes • Environmental monitoring tools for assessing mercury contamination risks in various ecosystems 2026-06-10 2026-06-18 2026-06-18 2026-06-16 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52406768 Discovery 52406768 NCI 37470483 Website Abstract 167809437 Xiaoyan Xu, et al., 2026 (PMID 41558487) https://pubmed.ncbi.nlm.nih.gov/41558487/ <a href="https://pubmed.ncbi.nlm.nih.gov/41558487/">Xiaoyan Xu, et al., 2026 (PMID 41558487)</a> 167809425 Schwarz, Benjamin National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Schwarz, Benjamin (NIAID) 1 167809429 Caspi, Rachel National Eye Institute (NEI) NEI Caspi, Rachel (NEI) 2 167809433 Xu, Xiaoyan National Eye Institute (NEI) NEI Xu, Xiaoyan (NEI) 3 167809425 Schwarz, Benjamin National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Schwarz, Benjamin (NIAID) 1 167809429 Caspi, Rachel National Eye Institute (NEI) NEI Caspi, Rachel (NEI) 2 167809433 Xu, Xiaoyan National Eye Institute (NEI) NEI Xu, Xiaoyan (NEI) 3 167809402 Corynebacterium mastitidis-derived mycolates for treating ocular surface diseases E-126-2024-0 Filing authorized NIH - NEI, NIH - NIAID 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5124] Detection of Organomercurial Compound Biosynthesis in Microbial Communities&body=Please send me information about technology [TAB-5124] Detection of Organomercurial Compound Biosynthesis in Microbial Communities.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5124] Detection of Organomercurial Compound Biosynthesis in Microbial Communities&body=Please send me information about technology [TAB-5124] Detection of Organomercurial Compound Biosynthesis in Microbial Communities.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">ricquita.pollard@nih.gov</a><br> 167809407 E-126-2024-0 E-126-2024-0-US-01 CORYNEBACTERIUM MASTITIDIS-DERIVED MYCOLATES FOR TREATING OCULAR SURFACE DISEASES PRV US 63/642,512 Expired US <br />Provisional (PRV) 63/642,512<br />Filed on 2024-05-03<br />Status: Expired 167809408 E-126-2024-0 E-126-2024-0-PC-01 CORYNEBACTERIUM MASTITIDIS-DERIVED MYCOLATES FOR TREATING BARRIERS PCT Patent Cooperation Treaty PCT/US2025/027781 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/027781<br />Filed on 2025-05-05<br />Status: Pending TAB-5126 167809622 Biodegradable Tissue Scaffold for Multi-Tissue Transplantation NEI Collaboration, Licensing, Medical Devices, Ophthalmology, Research Materials, Therapeutics Collaboration Licensing Medical Devices Ophthalmology Research Materials Therapeutics Kapil Bharti, Arvydas Maminishkis, Davide Ortolan, Ruchi Sharma <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a biodegradable tissue scaffold designed for multi-tissue transplantation.</p> <p>This technology includes a dual-layer biodegradable tissue scaffold designed for the transplantation of multiple tissue types, such as retinal pigment epithelium (RPE) and photoreceptors. The current challenge in tissue transplantation is the lack of mechanical strength in existing scaffolds, which often leads to separation during handling and implantation. This innovative scaffold addresses these issues by utilizing a unique structure made from poly(lactic-co-glycolic acid) (PLGA) that combines a lower support layer with a secondary matrix of lactide-rich loops, enhancing stability and facilitating cell adhesion and polarization.</p> <p>The technical solution involves a temperature-fused design that creates a robust scaffold with minimal capillary forces, allowing for better integration of the two tissue layers. This is particularly important for complex eye surgeries where multiple tissues are affected. By providing a supportive environment for weakly adherent cells, this scaffold can significantly improve the outcomes of retinal and choroidal transplants, making it a valuable tool for restoring vision in patients with advanced eye diseases.</p> <p>The licensing opportunity for this technology is open for collaboration with industry partners interested in advancing tissue engineering and transplantation techniques. The inventor seeks partnerships that can help bring this innovative scaffold to market, focusing on its application in regenerative medicine and ophthalmology.</p> • Biodegradable material ensures anatomical integrity post-transplant • Enhanced mechanical strength through fused fibers and loop structures • Reduced capillary forces improve cell integration and function • Facilitates the transplantation of multiple tissue types simultaneously • Customizable for various tissue engineering applications • Retinal and choroidal tissue transplantation • Regenerative medicine for ocular diseases • Development of multi-tissue implants for complex surgical procedures • Research applications in tissue engineering and biomaterials • Potential use in other organ systems requiring scaffold support 2026-06-10 2026-06-18 2026-06-18 2026-06-16 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52406769 Prototype 52406769 NCI 37470483 Website Abstract 167809763 Maminishkis, Arvydas National Eye Institute (NEI) NEI Maminishkis, Arvydas (NEI) 1 167809767 Bharti, Kapil National Eye Institute (NEI) NEI Bharti, Kapil (NEI) 2 167809771 Ortolan, Davide National Eye Institute (NEI) NEI Ortolan, Davide (NEI) 3 167809775 Sharma, Ruchi National Eye Institute (NEI) NEI Sharma, Ruchi (NEI) 4 167809763 Maminishkis, Arvydas National Eye Institute (NEI) NEI Maminishkis, Arvydas (NEI) 1 167809767 Bharti, Kapil National Eye Institute (NEI) NEI Bharti, Kapil (NEI) 2 167809771 Ortolan, Davide National Eye Institute (NEI) NEI Ortolan, Davide (NEI) 3 167809775 Sharma, Ruchi National Eye Institute (NEI) NEI Sharma, Ruchi (NEI) 4 167809625 Biodegradable Tissue Scaffold With Secondary Matrix To Host Weakly Adherent Cells E-153-2020-0 Filing authorized National Eye Institute (NEI) 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5126] Biodegradable Tissue Scaffold for Multi-Tissue Transplantation&body=Please send me information about technology [TAB-5126] Biodegradable Tissue Scaffold for Multi-Tissue Transplantation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5126] Biodegradable Tissue Scaffold for Multi-Tissue Transplantation&body=Please send me information about technology [TAB-5126] Biodegradable Tissue Scaffold for Multi-Tissue Transplantation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">tedd.fenn@nih.gov</a><br> 167809630 E-153-2020-0 E-153-2020-0-US-01 BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS PRV US 63/194,770 Abandoned US <br />Provisional (PRV) 63/194,770<br />Filed on 2021-05-28<br />Status: Abandoned 167809631 E-153-2020-0 E-153-2020-0-PCT-02 Biodegradable Tissue Scaffold With Secondary Matrix To Host Weakly Adherent Cells PCT Patent Cooperation Treaty PCT/US2022/031107 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/031107<br />Filed on 2022-05-26<br />Status: Expired 167809632 E-153-2020-0 E-153-2020-0-JP-05 BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS National Stage Japan 2023-572792 Pending Japan <br />National Stage 2023-572792<br />Filed on 2023-11-24<br />Status: Pending 167809633 E-153-2020-0 E-153-2020-0-CA-04 Biodegradable Tissue Scaffold With Secondary Matrix To Host Weakly Adherent Cells National Stage Canada 3220433 Pending Canada <br />National Stage 3220433<br />Filed on 2023-11-15<br />Status: Pending 167809634 E-153-2020-0 E-153-2020-0-AU-03 Biodegradable Tissue Scaffold With Secondary Matrix To Host Weakly Adherent Cells National Stage Australia 2022282379 2022282379 Issued Australia <br />National Stage 2022282379<br />Filed on 2023-11-10<br />Status: Issued 167809635 E-153-2020-0 E-153-2020-0-US-02 Biodegradable Tissue Scaffold With Secondary Matrix To Host Weakly Adherent Cells National Stage US 18/290,396 Pending US <br />National Stage 18/290,396<br />Filed on 2023-11-13<br />Status: Pending 167809636 E-153-2020-0 E-153-2020-0-EP-06 Biodegradable Tissue Scaffold With Secondary Matrix To Host Weakly Adherent Cells National Stage European Patent 4346928 22732802.8 Issued European Patent <br />National Stage 22732802.8<br />Filed on 2023-12-14<br />Status: Issued 167809637 E-153-2020-0 E-153-2020-0-ES-01 BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST EP Spain 4346928 22732802.8 Issued Spain <br />European patent (EP) 22732802.8<br />Filed on 2023-12-14<br />Status: Issued 167809638 E-153-2020-0 E-153-2020-0-FR-01 BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST EP France 4346928 22732802.8 Issued France <br />European patent (EP) 22732802.8<br />Filed on 2023-12-14<br />Status: Issued 167809639 E-153-2020-0 E-153-2020-0-IT-01 BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST EP Italy 4346928 22732802.8 Issued Italy <br />European patent (EP) 22732802.8<br />Filed on 2023-12-14<br />Status: Issued 167809640 E-153-2020-0 E-153-2020-0-DE-01 BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST EP Germany 4346928 22732802.8 Issued Germany <br />European patent (EP) 22732802.8<br />Filed on 2023-12-14<br />Status: Issued 167809641 E-153-2020-0 E-153-2020-0-DK-01 BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST EP Denmark 4346928 22732802.8 Issued Denmark <br />European patent (EP) 22732802.8<br />Filed on 2023-12-14<br />Status: Issued 167809642 E-153-2020-0 E-153-2020-0-BE-01 BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST EP Belgium 4346928 22732802.8 Issued Belgium <br />European patent (EP) 22732802.8<br />Filed on 2023-12-14<br />Status: Issued 167809643 E-153-2020-0 E-153-2020-0-GB-01 BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST EP United Kingdom 4346928 22732802.8 Issued United Kingdom <br />European patent (EP) 22732802.8<br />Filed on 2023-12-14<br />Status: Issued 167809644 E-153-2020-0 E-153-2020-0-SE-01 BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST EP Sweden 4346928 22732802.8 Issued Sweden <br />European patent (EP) 22732802.8<br />Filed on 2023-12-14<br />Status: Issued 167809645 E-153-2020-0 E-153-2020-0-CH-01 BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST EP Switzerland 4346928 22732802.8 Issued Switzerland <br />European patent (EP) 22732802.8<br />Filed on 2023-12-14<br />Status: Issued 167809646 E-153-2020-0 E-153-2020-0-NL-01 BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST EP The Netherlands 4346928 22732802.8 Issued The Netherlands <br />European patent (EP) 22732802.8<br />Filed on 2023-12-14<br />Status: Issued TAB-5127 167809804 A Robust Method to Generate Macular vs Peripheral RPE Cells for Cell Therapy and Drug Discovery NEI Collaboration, Geriatrics, Human Cell Lines, Human iPSC Lines, Licensing, Ophthalmology, Research Materials, Therapeutics Collaboration Geriatrics Human Cell Lines Human iPSC Lines Licensing Ophthalmology Research Materials Therapeutics Kapil Bharti, Davide Ortolan, Fnu Ruchi <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a robust method to generate macular and peripheral retinal pigment epithelium (RPE) cells for targeted therapies and drug discovery.</p> <p>This technology includes a robust method to generate macular and peripheral retinal pigment epithelium (RPE) cells, which are crucial for developing targeted cell therapies and drug discovery for retinal degenerative diseases. The problem lies in the lack of in vitro models that accurately reproduce the regional diversity and vulnerability of RPE cells, particularly in conditions like age-related macular degeneration (AMD) and retinitis pigmentosa. Our innovative approach utilizes two specific drugs, AGN 193109 and endo-IWR 1, to induce distinct macular and peripheral RPE phenotypes from induced pluripotent stem cells (iPSCs), enabling the study of regional RPE defects and high-throughput drug screening for specific retinal conditions.&nbsp;</p> <p>The technical solution leverages the unique properties of iPSC-derived RPE cells, which can be manipulated to reflect the diverse characteristics of human RPE. This is significant because it allows researchers and clinicians to better understand the mechanisms underlying retinal diseases and to develop targeted therapies. By creating a high-throughput platform for generating various RPE cell types, we can facilitate the discovery of disease-specific pathways and drug candidates, ultimately leading to improved treatment options for patients suffering from retinal degenerative diseases.</p> <p>We are seeking licensing opportunities for this technology, which has the potential to revolutionize the field of retinal research and therapy. Collaborators and licensees will benefit from access to a cutting-edge platform that addresses a critical gap in current RPE research and therapeutic development. We are open to discussions regarding potential partnerships and collaborations to further advance this technology.</p> • Unique ability to generate macular and peripheral RPE cells in vitro • Addresses a significant gap in current retinal research models • Enables high-throughput drug screening for specific retinal diseases • Provides a platform for studying regional RPE defects and disease mechanisms • Potential for developing targeted cell therapies for retinal degenerative diseases • Development of macular and peripheral RPE patches for cell therapy • High-throughput drug screening for retinal diseases • In vitro modeling of retinal degenerative diseases • Research on regional RPE defects in various conditions • Discovery of disease-specific pathways and drug candidates 2026-06-10 2026-06-18 2026-06-18 2026-06-16 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52406769 Prototype 52406769 NCI 37470483 Website Abstract 167809907 Ortolan D, et al., 2022 (PMID: 35522714) https://pubmed.ncbi.nlm.nih.gov/35522714/ <a href="https://pubmed.ncbi.nlm.nih.gov/35522714/">Ortolan D, et al., 2022 (PMID: 35522714)</a> 167809895 Bharti, Kapil National Eye Institute (NEI) NEI Bharti, Kapil (NEI) 1 167809899 Ruchi, Fnu National Eye Institute (NEI) NEI Ruchi, Fnu (NEI) 2 167809903 Ortolan, Davide National Eye Institute (NEI) NEI Ortolan, Davide (NEI) 3 167809895 Bharti, Kapil National Eye Institute (NEI) NEI Bharti, Kapil (NEI) 1 167809899 Ruchi, Fnu National Eye Institute (NEI) NEI Ruchi, Fnu (NEI) 2 167809903 Ortolan, Davide National Eye Institute (NEI) NEI Ortolan, Davide (NEI) 3 167809807 A Robust Method To Generate Macular Vs Peripheral RPE Cells Of Cell Therapy And Drug Discovery E-155-2020-0 Filing authorized National Eye Institute (NEI) 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5127] A Robust Method to Generate Macular vs Peripheral RPE Cells for Cell Therapy and Drug Discovery&body=Please send me information about technology [TAB-5127] A Robust Method to Generate Macular vs Peripheral RPE Cells for Cell Therapy and Drug Discovery.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5127] A Robust Method to Generate Macular vs Peripheral RPE Cells for Cell Therapy and Drug Discovery&body=Please send me information about technology [TAB-5127] A Robust Method to Generate Macular vs Peripheral RPE Cells for Cell Therapy and Drug Discovery.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">tedd.fenn@nih.gov</a><br> 167809812 E-155-2020-0 E-155-2020-0-US-01 METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS PRV US 63/194,774 Abandoned US <br />Provisional (PRV) 63/194,774<br />Filed on 2021-05-28<br />Status: Abandoned 167809813 E-155-2020-0 E-155-2020-0-PCT-01 METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS PCT COMB Patent Cooperation Treaty PCT/US2022/031136 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2022/031136<br />Filed on 2022-05-26<br />Status: Expired 167809814 E-155-2020-0 E-155-2020-0-JP-06 METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS National Stage Japan 2023-572794 Pending Japan <br />National Stage 2023-572794<br />Filed on 2023-11-24<br />Status: Pending 167809815 E-155-2020-0 E-155-2020-0-CA-05 METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS National Stage Canada 3220602 Pending Canada <br />National Stage 3220602<br />Filed on 2023-11-17<br />Status: Pending 167809816 E-155-2020-0 E-155-2020-0-EP-04 METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS National Stage European Patent 22736412.2 Pending European Patent <br />National Stage 22736412.2<br />Filed on 2023-12-19<br />Status: Pending 167809817 E-155-2020-0 E-155-2020-0-AU-01 METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS National Stage Australia 2022280062 Pending Australia <br />National Stage 2022280062<br />Filed on 2023-11-10<br />Status: Pending 167809818 E-155-2020-0 E-155-2020-0-US-02 METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS National Stage US 18/562,806 Pending US <br />National Stage 18/562,806<br />Filed on 2023-11-20<br />Status: Pending TAB-5128 167809943 Mini-Bioreactor for Enhanced Organoid Culture NEI Collaboration, Licensing, Non-Medical Devices, Ophthalmology, Research Equipment, Research Materials Collaboration Licensing Non-Medical Devices Ophthalmology Research Equipment Research Materials Tiansen Li, Kyle Schwab <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a mini-bioreactor designed to enhance organoid culture outcomes.</p> <p>This technology includes a mini-bioreactor designed to improve organoid outcomes in cell culture applications. The bioreactor system is a multi-well, 3D-printed device that fits standard 100 mm cell culture dishes and utilizes a central stirring mechanism to create a controlled laminar flow. This innovative design addresses the common challenges in organoid culture, such as non-specific adherence and fusion, while enhancing mass transfer without the shear stress typically associated with other bioreactor systems.</p> <p>The technical solution provided by this bioreactor is significant because it simplifies the organoid culture process by integrating a single-component system that is compatible with standard lab equipment. This means that researchers can easily adopt this technology without needing specialized training or additional components. The ability to track individual organoids longitudinally further enhances its utility in research settings, making it an attractive option for laboratories focused on organoid studies.</p> <p>The licensing opportunity for this technology is promising, as it can be developed and produced in less than two years. Companies that manufacture cell culture vessels, such as Corning, Thermo Fisher, and VWR, may find this bioreactor particularly appealing for their product lines. Collaboration with the inventors is encouraged to explore the full commercial potential of this innovative bioreactor system.</p> • Simplified design with a single component, reducing complexity in organoid culture • Compatible with standard 100 mm cell culture dishes and existing lab equipment • Enhanced mass transfer without the shear stress associated with traditional bioreactors • Longitudinal tracking of individual organoids for improved research outcomes • Potential for rapid commercialization within two years • Organoid culture for drug testing and development • Research in regenerative medicine and tissue engineering • Applications in personalized medicine and disease modeling • Use in academic and industrial research laboratories 2026-06-10 2026-06-18 2026-06-18 2026-06-16 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52406769 Prototype 52406769 NCI 37470483 Website Abstract 167810034 Schwab, Kyle National Eye Institute (NEI) NEI Schwab, Kyle (NEI) 1 167810038 Li, Tiansen NEI Li, Tiansen (NEI) 2 167810034 Schwab, Kyle National Eye Institute (NEI) NEI Schwab, Kyle (NEI) 1 167810038 Li, Tiansen NEI Li, Tiansen (NEI) 2 167809946 Mini-bioreactor to improve organoid outcomes E-155-2023-0 Filing authorized National Eye Institute (NEI), National Eye Institute (NEI) 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5128] Mini-Bioreactor for Enhanced Organoid Culture&body=Please send me information about technology [TAB-5128] Mini-Bioreactor for Enhanced Organoid Culture.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-5128] Mini-Bioreactor for Enhanced Organoid Culture&body=Please send me information about technology [TAB-5128] Mini-Bioreactor for Enhanced Organoid Culture.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">tedd.fenn@nih.gov</a><br> 167809951 E-155-2023-0 E-155-2023-0-US-01 STIRRED BIOREACTOR SYSTEM PRV US 63/541,656 Expired US <br />Provisional (PRV) 63/541,656<br />Filed on 2023-09-29<br />Status: Expired 167809952 E-155-2023-0 E-155-2023-0-PC-01 BIOREACTOR SYSTEM PCT Patent Cooperation Treaty PCT/US2024/049060 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/049060<br />Filed on 2024-09-27<br />Status: Expired 167809953 E-155-2023-0 E-155-2023-0-JP-01 BIOREACTOR SYSTEM National Stage Japan 2026-519253 Pending Japan <br />National Stage 2026-519253<br />Filed on 2026-03-27<br />Status: Pending 167809954 E-155-2023-0 E-155-2023-0-AU-01 BIOREACTOR SYSTEM National Stage Australia 2024353162 Pending Australia <br />National Stage 2024353162<br />Filed on 2026-03-31<br />Status: Pending 167809955 E-155-2023-0 E-155-2023-0-US-02 BIOREACTOR SYSTEM National Stage US 19/524,229 Pending US <br />National Stage 19/524,229<br />Filed on 2026-03-27<br />Status: Pending 167809956 E-155-2023-0 E-155-2023-0-EP-01 BIOREACTOR SYSTEM National Stage European Patent 24790765.2 Pending European Patent <br />National Stage 24790765.2<br />Filed on 2026-04-29<br />Status: Pending 167809957 E-155-2023-0 E-155-2023-0-CA-01 BIOREACTOR SYSTEM National Stage Canada 3305823 Pending Canada <br />National Stage 3305823<br />Filed on 2026-03-23<br />Status: Pending TAB-5130 167810179 RPGR Gene Therapy for Retinitis Pigmentosa NEI Collaboration, Licensing, Ophthalmology, Plasmids/Vectors, Rare/Neglected Diseases, Research Materials, Sequences, Therapeutics, Virus/Bacteria Collaboration Licensing Ophthalmology Plasmids/Vectors Rare/Neglected Diseases Research Materials Sequences Therapeutics Virus/Bacteria Robin Ali, Tiansen Li, Basil Pawlyk, Michael Sandberg, Xinhua Shu, Alan Wright <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of RPGR gene therapy for Retinitis Pigmentosa.</p> <p>This technology includes an abbreviated version of the RPGR gene that is effective in gene replacement therapy for treating X-linked Retinitis Pigmentosa (XLRP). This condition is a genetic disorder that leads to progressive vision loss due to the degeneration of photoreceptor cells in the retina. The current version of RPGR is known to be unstable and can undergo changes in vivo, which may be harmful to recipient cells. The abbreviated RPGR retains its function, rescues the disease, and is stabilized, making it a safer option for gene therapy.</p> <p>The technical solution involves using an adeno-associated viral vector that carries the abbreviated human RPGR cDNA. This vector supplies functional RPGR proteins to treat inherited ocular disorders related to RPGR mutations. This technology is significant because it addresses the instability issues of the current RPGR gene therapy approaches, providing a more reliable and effective treatment option for patients suffering from XLRP. Stakeholders in the ophthalmology and gene therapy fields should care about this innovation as it represents a potential breakthrough in treating a debilitating condition.</p> <p>The licensing opportunity for this technology is open for collaboration with interested parties who are looking to develop and commercialize this gene therapy. The inventors are seeking partners who can assist in further development and potential market entry, ensuring that this promising therapy reaches those in need.</p> • Abbreviated RPGR gene is more stable than the current version • Effective in rescuing photoreceptor function in XLRP models • Utilizes a safe adeno-associated viral vector for delivery • Potential for broader applications in other RPGR-related ocular disorders • Treatment for X-linked Retinitis Pigmentosa • Gene therapy for other inherited retinal diseases • Research applications in gene therapy and ophthalmology 2026-06-10 2026-06-18 2026-06-18 2026-06-16 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52406769 Prototype 52406769 NCI 37470483 Website Abstract 167810400 Sandberg, Michael Massachusetts Eye & Ear Infirmary (MEEI) Sandberg, Michael 1 167810404 Pawlyk, Basil Massachusetts Eye & Ear Infirmary (MEEI) Pawlyk, Basil 2 167810408 Shu, Xinhua Medical Research Council Shu, Xinhua 3 167810412 Ali, Robin Ali, Robin 4 167810416 Wright, Alan Medical Research Council Wright, Alan 5 167810420 Li, Tiansen National Eye Institute (NEI) NEI Li, Tiansen (NEI) 6 167810400 Sandberg, Michael Massachusetts Eye & Ear Infirmary (MEEI) Sandberg, Michael 1 167810404 Pawlyk, Basil Massachusetts Eye & Ear Infirmary (MEEI) Pawlyk, Basil 2 167810408 Shu, Xinhua Medical Research Council Shu, Xinhua 3 167810412 Ali, Robin Ali, Robin 4 167810416 Wright, Alan Medical Research Council Wright, Alan 5 167810420 Li, Tiansen National Eye Institute (NEI) NEI Li, Tiansen (NEI) 6 167810182 Abbreviated Version Of RPGR Is Effective In Gene Replacement Therapy E-162-2016-0 Filing authorized Massachusetts Eye & Ear Infirmary (MEEI), Medical Research Council, National Eye Institute (NEI), University College London 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5130] RPGR Gene Therapy for Retinitis Pigmentosa&body=Please send me information about technology [TAB-5130] RPGR Gene Therapy for Retinitis Pigmentosa.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5130] RPGR Gene Therapy for Retinitis Pigmentosa&body=Please send me information about technology [TAB-5130] RPGR Gene Therapy for Retinitis Pigmentosa.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">ricquita.pollard@nih.gov</a><br> 167810187 E-162-2016-0 E-162-2016-0-US-01 GENE THERAPY FOR RETINITIS PIGMENTOSA PRV US 62/028,638 Abandoned US <br />Provisional (PRV) 62/028,638<br />Filed on 2014-07-24<br />Status: Abandoned 167810188 E-162-2016-0 E-162-2016-0-PCT-02 GENE THERAPY FOR RETINITIS PIGMENTOSA PCT Patent Cooperation Treaty PCT/US2015/040866 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/040866<br />Filed on 2015-07-17<br />Status: Expired 167810189 E-162-2016-0 E-162-2016-0-CN-03 GENE THERAPY FOR RETINITIS PIGMENTOSA National Stage China 201580051512.3 Pending China <br />National Stage 201580051512.3<br />Filed on 2015-07-17<br />Status: Pending 167810190 E-162-2016-0 E-162-2016-0-CA-04 GENE THERAPY FOR RETINITIS PIGMENTOSA National Stage Canada 2991750 2991750 Issued Canada <br />National Stage 2991750<br />Filed on 2015-07-17<br />Status: Issued 167810191 E-162-2016-0 E-162-2016-0-EP-05 GENE THERAPY FOR RETINITIS PIGMENTOSA National Stage European Patent 3191139 15825383.1 Issued European Patent <br />National Stage 15825383.1<br />Filed on 2015-07-17<br />Status: Issued 167810192 E-162-2016-0 E-162-2016-0-JP-06 THE RPGR GENE THERAPY FOR RETINITIS PIGMENTOSA National Stage Japan 6654760 2017-525514 Issued Japan <br />National Stage 2017-525514<br />Filed on 2015-07-17<br />Status: Issued 167810193 E-162-2016-0 E-162-2016-0-US-07 Abbreviated Version Of RPGR Is Effective In Gene Replacement Therapy National Stage US 10,314,924 15/328,617 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10314924 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10314924">10,314,924</a><br />Filed on 2015-07-17<br />Status: Issued 167810194 E-162-2016-0 E-162-2016-0-US-08 RPGR GENE THERAPY FOR RETINITIS PIGMENTOSA CON US 11,045,558 16/436,521 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11045558 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11045558">11,045,558</a><br />Filed on 2019-06-10<br />Status: Issued 167810195 E-162-2016-0 E-162-2016-0-JP-09 GENE THERAPY FOR RETINITIS PIGMENTOSA DIV Japan 6966532 2019-235539 Issued Japan <br />Divisional (DIV) 2019-235539<br />Filed on 2019-12-26<br />Status: Issued 167810196 E-162-2016-0 E-162-2016-0-EP-10 GENE THERAPY FOR RETINITIS PIGMENTOSA DIV European Patent 3821912 20199208.8 Issued European Patent <br />Divisional (DIV) 20199208.8<br />Filed on 2015-07-17<br />Status: Issued 167810197 E-162-2016-0 E-162-2016-0-BE-11 GENE THERAPY FOR RETINITIS PIGMENTOSA EP Belgium 3191139 15825383.1 Issued Belgium <br />European patent (EP) 15825383.1<br />Filed on 2015-07-17<br />Status: Issued 167810198 E-162-2016-0 E-162-2016-0-BG-12 GENE THERAPY FOR RETINITIS PIGMENTOSA EP Bulgaria 3191139 15825383.1 Issued Bulgaria <br />European patent (EP) 15825383.1<br />Filed on 2015-07-17<br />Status: Issued 167810199 E-162-2016-0 E-162-2016-0-DE-13 GENE THERAPY FOR RETINITIS PIGMENTOSA EP Germany 3191139 15825383.1 Issued Germany <br />European patent (EP) 15825383.1<br />Filed on 2015-07-17<br />Status: Issued 167810200 E-162-2016-0 E-162-2016-0-DK-14 GENE THERAPY FOR RETINITIS PIGMENTOSA EP Denmark 3191139 15825383.1 Issued Denmark <br />European patent (EP) 15825383.1<br />Filed on 2015-07-17<br />Status: Issued 167810201 E-162-2016-0 E-162-2016-0-EE-15 GENE THERAPY FOR RETINITIS PIGMENTOSA EP Estonia 3191139 15825383.1 Issued Estonia <br />European patent (EP) 15825383.1<br />Filed on 2015-07-17<br />Status: Issued 167810202 E-162-2016-0 E-162-2016-0-ES-16 GENE THERAPY FOR RETINITIS PIGMENTOSA EP Spain 3191139 15825383.1 Issued Spain <br />European patent (EP) 15825383.1<br />Filed on 2015-07-17<br />Status: Issued 167810203 E-162-2016-0 E-162-2016-0-FI-17 GENE THERAPY FOR RETINITIS PIGMENTOSA EP Finland 3191139 15825383.1 Issued Finland <br />European patent (EP) 15825383.1<br />Filed on 2015-07-17<br />Status: Issued 167810204 E-162-2016-0 E-162-2016-0-FR-18 GENE THERAPY FOR RETINITIS PIGMENTOSA EP France 3191139 15825383.1 Issued France <br />European patent (EP) 15825383.1<br />Filed on 2015-07-17<br />Status: Issued 167810205 E-162-2016-0 E-162-2016-0-GB-19 GENE THERAPY FOR RETINITIS PIGMENTOSA EP United Kingdom 3191139 15825383.1 Issued United Kingdom <br />European patent (EP) 15825383.1<br />Filed on 2015-07-17<br />Status: Issued 167810206 E-162-2016-0 E-162-2016-0-IS-20 GENE THERAPY FOR RETINITIS PIGMENTOSA EP Iceland 3191139 15825383.1 Issued Iceland <br />European patent (EP) 15825383.1<br />Filed on 2015-07-17<br />Status: Issued 167810207 E-162-2016-0 E-162-2016-0-IT-21 GENE THERAPY FOR RETINITIS PIGMENTOSA EP Italy 3191139 15825383.1 Issued Italy <br />European patent (EP) 15825383.1<br />Filed on 2015-07-17<br />Status: Issued 167810208 E-162-2016-0 E-162-2016-0-LU-22 GENE THERAPY FOR RETINITIS PIGMENTOSA EP Luxembourg 3191139 15825383.1 Issued Luxembourg <br />European patent (EP) 15825383.1<br />Filed on 2015-07-17<br />Status: Issued 167810209 E-162-2016-0 E-162-2016-0-LV-23 GENE THERAPY FOR RETINITIS PIGMENTOSA EP Latvia 3191139 15825383.1 Issued Latvia <br />European patent (EP) 15825383.1<br />Filed on 2015-07-17<br />Status: Issued 167810210 E-162-2016-0 E-162-2016-0-NL-24 GENE THERAPY FOR RETINITIS PIGMENTOSA EP The Netherlands 3191139 15825383.1 Issued The Netherlands <br />European patent (EP) 15825383.1<br />Filed on 2015-07-17<br />Status: Issued 167810211 E-162-2016-0 E-162-2016-0-PT-25 GENE THERAPY FOR RETINITIS PIGMENTOSA EP Portugal 3191139 15825383.1 Issued Portugal <br />European patent (EP) 15825383.1<br />Filed on 2015-07-17<br />Status: Issued 167810212 E-162-2016-0 E-162-2016-0-SE-26 GENE THERAPY FOR RETINITIS PIGMENTOSA EP Sweden 3191139 15825383.1 Issued Sweden <br />European patent (EP) 15825383.1<br />Filed on 2015-07-17<br />Status: Issued 167810213 E-162-2016-0 E-162-2016-0-TR-27 GENE THERAPY FOR RETINITIS PIGMENTOSA EP Turkey 3191139 15825383.1 Issued Turkey <br />European patent (EP) 15825383.1<br />Filed on 2015-07-17<br />Status: Issued 167810214 E-162-2016-0 E-162-2016-0-CY-28 GENE THERAPY FOR RETINITIS PIGMENTOSA EP Cyprus 3191139 15825383.1 Issued Cyprus <br />European patent (EP) 15825383.1<br />Filed on 2015-07-17<br />Status: Issued 167810215 E-162-2016-0 E-162-2016-0-GR-29 GENE THERAPY FOR RETINITIS PIGMENTOSA EP Greece 3191139 15825383.1 Issued Greece <br />European patent (EP) 15825383.1<br />Filed on 2015-07-17<br />Status: Issued 167810216 E-162-2016-0 E-162-2016-0-HU-30 GENE THERAPY FOR RETINITIS PIGMENTOSA EP Hungary 3191139 15825383.1 Issued Hungary <br />European patent (EP) 15825383.1<br />Filed on 2015-07-17<br />Status: Issued 167810217 E-162-2016-0 E-162-2016-0-MT-31 GENE THERAPY FOR RETINITIS PIGMENTOSA EP Malta 3191139 15825383.1 Issued Malta <br />European patent (EP) 15825383.1<br />Filed on 2015-07-17<br />Status: Issued 167810218 E-162-2016-0 E-162-2016-0-JP-32 GENE THERAPY FOR RETINITIS PIGMENTOSA DIV Japan 7198329 2021-172128 Issued Japan <br />Divisional (DIV) 2021-172128<br />Filed on 2021-10-21<br />Status: Issued 167810219 E-162-2016-0 E-162-2016-0-HK-33 GENE THERAPY FOR RETINITIS PIGMENTOSA EP Hong Kong 42021042687.0 Pending Hong Kong <br />European patent (EP) 42021042687.0<br />Filed on 2021-11-18<br />Status: Pending TAB-5104 167805571 AI Based Workflow for Single Cell Analysis NEI Cardiology, Collaboration, Computational models/software, Dental, Dermatology, Ear, Nose, & Throat, Endocrinology, Gastroenterology, Geriatrics, Hematology, Immunology, Infectious Disease, Licensing, Metabolic Disease, Nephrology, Neurology, Obstetrics/Neo-Natal, Oncology, Ophthalmology, Psychiatry/Mental Health, Pulmonology, Radiology, Rare/Neglected Diseases, Reproductive Health, Research Materials, Respiratory, Software / Apps, Urology, Veterinary Cardiology Collaboration Computational models/software Dental Dermatology Ear Nose & Throat Endocrinology Gastroenterology Geriatrics Hematology Immunology Infectious Disease Licensing Metabolic Disease Nephrology Neurology Obstetrics/Neo-Natal Oncology Ophthalmology Psychiatry/Mental Health Pulmonology Radiology Rare/Neglected Diseases Reproductive Health Research Materials Respiratory Software / Apps Urology Veterinary Rachel Caspi, Vijayaraj Nagarajan <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for single-cell RNA sequencing (scRNA-seq) analysis software that leverages existing large language models (LLM) to simplify and enhance data analysis by providing intelligent recommendations and interpretations.</p> <p>This technology includes SCassist, an innovative open-source R package designed to enhance single-cell RNA sequencing (scRNA-seq) data analysis. The complexity of scRNA-seq workflows often requires extensive expertise, making it challenging for many researchers to fully explore their data. This limitation can hinder scientific discovery and innovation, as researchers may struggle to navigate through the intricate stages of data filtering, normalization, clustering, and interpretation. SCassist addresses these challenges by leveraging large language models (LLMs) to provide intelligent recommendations and interpretations throughout the analysis process, making advanced scRNA-seq analysis accessible to researchers at all levels.</p> <p>SCassist integrates LLMs into key workflow steps, offering guidance on filtering, normalization, clustering parameters, and insightful interpretations of variable features and principal components. It also performs cell type annotations and provides a system-level view through network representations based on pathway and ontology enrichment analyses. This user-friendly interface allows researchers to incorporate AI-driven insights into their scRNA-seq analysis, ultimately accelerating their workflow and uncovering deeper biological understanding. By democratizing scRNA-seq analysis, SCassist empowers researchers to navigate complexities and make the most of their valuable data.</p> <p>The National Eye Institute (NEI) is seeking licensing opportunities and collaborative partnerships to further develop and expand the capabilities of SCassist. This technology has the potential to be utilized across various fields, including genomics, proteomics, and metabolomics, enabling researchers to gain novel insights into their &lsquo;omics&rsquo; scale data. The NEI welcomes inquiries from potential partners interested in leveraging SCassist to enhance their research capabilities and drive scientific innovation.</p> • Makes scRNA-seq analysis accessible to researchers at all levels by providing user guidance in a user-friendly interface • Incorporation of artificial intelligence assistance for parameter selections • Seamlessly integrates LLMs into the standard single cell analysis workflow, providing LLM-guided interpretations, cell type annotations, and enrichment analysis • Addresses the computational challenges associated with single-cell RNA-seq data analysis, regardless of how libraries and data are generated • All encompassing workflow from start to finish • Basic researchers • Biomarker identification, toxicology studies, cell therapy development • Companies specializing in single cell sequencing technologies can incorporate SCassist into their product offerings, enhancing the analytical capabilities and value of their platforms • Companies providing sequencing services can integrate an analysis platform for customers 2026-06-10 2026-06-18 2026-06-18 2026-06-16 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52406769 Prototype 52406769 NCI 37470483 Website Abstract 167806550 Nagarajan V, et al., 2005 (PMID 40093069) https://pubmed.ncbi.nlm.nih.gov/40093069/ <a href="https://pubmed.ncbi.nlm.nih.gov/40093069/">Nagarajan V, et al., 2005 (PMID 40093069)</a> 167805714 Caspi, Rachel National Eye Institute (NEI) NEI Caspi, Rachel (NEI) 1 167805719 Nagarajan, Vijayaraj National Eye Institute (NEI) NEI Nagarajan, Vijayaraj (NEI) 2 167805714 Caspi, Rachel National Eye Institute (NEI) NEI Caspi, Rachel (NEI) 1 167805719 Nagarajan, Vijayaraj National Eye Institute (NEI) NEI Nagarajan, Vijayaraj (NEI) 2 167805574 AI Based Workflow Assistant for Single Cell Analysis E-026-2025-0 Under Review NIH - NEI 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5104] AI Based Workflow for Single Cell Analysis&body=Please send me information about technology [TAB-5104] AI Based Workflow for Single Cell Analysis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5104] AI Based Workflow for Single Cell Analysis&body=Please send me information about technology [TAB-5104] AI Based Workflow for Single Cell Analysis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">ricquita.pollard@nih.gov</a><br> 167805579 E-026-2025-0 E-026-2025-0-US-01 SYSTEMS AND METHODS FOR AN ARTIFICIAL INTELLIGENCE BASED WORKFLOW ASSISTANT FOR SINGLE CELL ANALYSIS PRV US 63/739,320 Expired US <br />Provisional (PRV) 63/739,320<br />Filed on 2024-12-27<br />Status: Expired 167805580 E-026-2025-0 E-026-2025-0-PC-01 SYSTEMS AND METHODS FOR AN ARTIFICIAL INTELLIGENCE BASED WORKFLOW ASSISTANT FOR SINGLE CELL ANALYSIS PCT Patent Cooperation Treaty PCT/US2025/061495 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/061495<br />Filed on 2025-12-29<br />Status: Pending TAB-5062 163184481 EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques NIAID Antibodies, Application, Collaboration Sought, Diagnostics, Immunology, Infectious Disease, Licensing, Materials Available, ResearchProducts, TherapeuticArea, Therapeutics, Vaccines Antibodies Application Collaboration Sought Diagnostics Immunology Infectious Disease Licensing Materials Available ResearchProducts TherapeuticArea Therapeutics Vaccines Masaru Kanekiyo, Peter Krug, Daniel Moss, Tracy Ruckwardt <p>Enterovirus D68 (EV-D68) has been linked to the widespread outbreaks of respiratory illness and acute flaccid myelitis (AFM) in the United States and Europe in 2014, 2016, and 2018. Although EV-D68 is now the most frequently encountered enterovirus (41.1% of cases), with an estimated global prevalence of 4%, there are no specific, FDA-approved therapeutic interventions targeting this virus.</p> <p>Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Disease (NIAID) have identified four monoclonal antibodies that potently bind and neutralize multiple subclades of EV-D68, including B3 and A2 variants. Animal studies have indicated that these Rhesus macaque-derived monoclonal antibodies (mAbs) are likely to confer protection against respiratory illness in young children (particularly those under age 5) and in individuals with respiratory or immunocompromising conditions. Analyses conducted using standard techniques such as cryo-EM have enabled the inventors to further characterize the epitopes of two unique EV-D68-specific antibodies, suggesting the value of this technology for developing multi-specific approaches that confer broad protection against EV-D68.</p> <p>Humanization and combination of these mAbs with other antibodies exhibiting unique epitope specificities may prove beneficial for therapeutic or prophylactic purposes, especially within the context of a broader pandemic preparedness program. Further, these antibodies could be incorporated into diagnostic assays/kits for the rapid and accurate detection of EV-D68 in clinical or non-clinical settings.</p> <p>This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404.</p> <ul> <li>Development of prophylactic or therapeutic interventions against EV-D68 that effectively induce broad protection against multiple circulating subclades</li> </ul> <ul> <li>Prevention or treatment of EV-D68 infection</li> <li>Development of diagnostic assays for rapid, accurate EV-D68 detection in clinical and non-clinical settings</li> </ul> 2025-07-02 2026-06-18 2026-06-18 2025-07-03 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 163185209 Krug et al. EV-D68 virus-like particle vaccines elicit cross-clade neutralizing antibodies that inhibit infection and block dissemination. Sci. Adv. 2023;9:eadg6076. https://doi.org/10.1126/sciadv.adg6076 Krug et al. EV-D68 virus-like particle vaccines elicit cross-clade neutralizing antibodies that inhibit infection and block dissemination. Sci. Adv. 2023;9:eadg6076. https://doi.org/10.1126/sciadv.adg6076 163184529 Ruckwardt, Tracy National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Ruckwardt, Tracy (NIAID) 1 163184765 Moss, Daniel National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Moss, Daniel (NIAID) 2 163184769 Krug, Peter National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Krug, Peter (NIAID) 3 163184784 Kanekiyo, Masaru National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Kanekiyo, Masaru (NIAID) 4 163184529 Ruckwardt, Tracy National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Ruckwardt, Tracy (NIAID) 1 163184765 Moss, Daniel National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Moss, Daniel (NIAID) 2 163184769 Krug, Peter National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Krug, Peter (NIAID) 3 163184784 Kanekiyo, Masaru National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Kanekiyo, Masaru (NIAID) 4 163184484 EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques E-041-2024-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIH - NIAID 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-5062] EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques&body=Please send me information about technology [TAB-5062] EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-5062] EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques&body=Please send me information about technology [TAB-5062] EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques.">bbailey@mail.nih.gov</a><br> 163184489 E-041-2024-0 E-041-2024-0-US-01 ANTIBODIES AGAINST EV-D68 PRV US 63/640,619 Expired US <br />Provisional (PRV) 63/640,619<br />Filed on 2024-04-30<br />Status: Expired 163184490 E-041-2024-0 E-041-2024-0-PC-01 ANTIBODIES AGAINST EV-D68 PCT Patent Cooperation Treaty PCT/US2025/027110 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/027110<br />Filed on 2025-04-30<br />Status: Pending TAB-4998 157594389 Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration NEI Collaboration, Ear, Nose, & Throat, Licensing, Therapeutics Collaboration Ear Nose & Throat Licensing Therapeutics Yu Holly Chen, Wenwei Huang, Zhiji Luo, Anupam Mondal, Samantha Papal, Anand Swaroop, Manju Swaroop, Gregory Tawa, Wei Zheng <h2>Summary:&nbsp;</h2> <p>The National Eye Institute seeks research co-development partners and/or licensees for a therapy using an FDA-approved small molecule drug reserpine (and related compounds especially halofantrine) that prevents photoreceptor cell death in retinal degenerations.</p> <h2>Description of Technology:&nbsp;</h2> <p>Inherited Retinal Degenerations (IRD), such as Leber Congenital Amaurosis (LCA) and retinitis pigmentosa (RP), are characterized by a progressive loss of photo-sensitive cells in the retina. Most forms of IRD have no therapeutic options available due to their genetic heterogeneity and/or lack of mechanistic understanding. In particular, LCA represents roughly 5% of all retinal dystrophies and results in severe vision loss at an early age. There is an FDA-approved treatment for one form of LCA caused by mutations in the RPE 65 gene. This involves injection of an adenovirus vector containing the normal copy of the RPE65 gene. Long-term data for the gene therapy achieved only transient results: progressive reduction in visual acuity, sensitivity and function occurred following an initial gain seen 6-12 months post-treatment.&nbsp;</p> <p>RP is a collection of rare eye diseases that affect roughly 1 in 4000 people worldwide. Currently, as there are no treatments, a majority of affected individuals lose most of their sight.</p> <p>By 2040, age-related macular degeneration (AMD) will affect ~288 million people worldwide. AMD is the leading cause of blindness in all developed countries. Identifying eyes at high risk of progression to late AMD, the stage associated with blindness, is vital. This would allow timely medical treatments, lifestyle interventions, more tailored home monitoring and improved clinical trials for patients.</p> <p>Scientists at the National Eye Institute (NEI) have developed a mutation-independent method to treat LCA, RP, other IRDs, and AMD using the FDA-approved small molecule, Halofantrine (NCGC00016833-01). Halofantrine, which was previously approved to treat malaria, helped protect photoreceptors from cell death in three different IRD model systems in 1) retinal organoid model systems, 2) two different mouse models, and 3) rat models. Furthermore, packaging Halofantrine and other potential candidate compounds for conjunctival delivery into the eye via eye drops is under development.&nbsp;</p> <p>These small molecules act by targeting several cellular pathways which are also affected in diseases of other organs, suggesting that they may be useful in treating other, mutation independent ocular diseases.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Therapeutic to treat Leber congenital amaurosis</li> <li>Therapeutic to treat Inherited Retinal Disorders associated with photoreceptor degeneration</li> <li>Therapeutic to treat AMD</li> <li>Therapeutic to treat mutation-independent ocular diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Less time-consuming, costly and labor intensive versus the development of individualized gene therapies</li> <li>Small molecules are scalable with cost-effective manufacturing</li> <li>Small molecules are highly penetrant with easy routes of administration</li> <li>Small molecules can be delivered via eye drops or as intra-vitreal injection</li> <li>Less intrusive and easy administration route</li> <li>Conjunctival delivery and eye drop formulation more accessible than retinal implant or injection<br /> &nbsp;</li> </ul> Researchers at the NEI seek licensing and/or co-development research collaborations for a therapy using an FDA-approved small molecule drug reserpine and related compounds (such as halofantrine) that prevents retinal degeneration. 2024-08-02 2026-04-16 2026-06-17 2024-08-05 False True Discovery (Lead ID) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 157619396 Chen, HY, et al. Reserpine maintains photoreceptor survival in retinal ciliopathy by resolving proteostasis imbalance and ciliogenesis defects. (PMID 36975211) https://pubmed.ncbi.nlm.nih.gov/36975211/ <a href="https://pubmed.ncbi.nlm.nih.gov/36975211/">Chen, HY, et al. Reserpine maintains photoreceptor survival in retinal ciliopathy by resolving proteostasis imbalance and ciliogenesis defects. (PMID 36975211)</a> 157594396 Swaroop, Anand National Eye Institute (NEI) NEI Swaroop, Anand (NEI) 1 157594400 Chen, Yu Holly National Eye Institute (NEI) NEI Chen, Yu Holly (NEI) 2 157594408 Papal, Samantha National Eye Institute (NEI) NEI Papal, Samantha (NEI) 3 157594416 Mondal, Anupam National Eye Institute (NEI) NEI Mondal, Anupam (NEI) 4 157594424 Swaroop, Manju NCATS - NCGC NCATS Swaroop, Manju (NCATS) 5 157594428 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 6 157594432 Tawa, Gregory NCATS - TRND NCATS Tawa, Gregory (NCATS) 7 157594436 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 8 157594443 Luo, Zhiji Zhiji, Luo Luo, Zhiji 9 157594396 Swaroop, Anand National Eye Institute (NEI) NEI Swaroop, Anand (NEI) 1 157594400 Chen, Yu Holly National Eye Institute (NEI) NEI Chen, Yu Holly (NEI) 2 157594408 Papal, Samantha National Eye Institute (NEI) NEI Papal, Samantha (NEI) 3 157594416 Mondal, Anupam National Eye Institute (NEI) NEI Mondal, Anupam (NEI) 4 157594424 Swaroop, Manju NCATS - NCGC NCATS Swaroop, Manju (NCATS) 5 157594428 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 6 157594432 Tawa, Gregory NCATS - TRND NCATS Tawa, Gregory (NCATS) 7 157594436 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 8 157594443 Luo, Zhiji Zhiji, Luo Luo, Zhiji 9 157594392 Small Molecule Drug Candidates And Disease-associated Signature Genes For Therapeutic Interventions In Retinal Degeneration E-071-2020-0 Filing authorized National Eye Institute (NEI), NCATS - NCGC 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4998] Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration&body=Please send me information about technology [TAB-4998] Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4998] Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration&body=Please send me information about technology [TAB-4998] Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 157595034 E-071-2020-0 E-071-2020-0-US-01 COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME PRV US 63/047,858 Abandoned US <br />Provisional (PRV) 63/047,858<br />Filed on 2020-07-02<br />Status: Abandoned 157595066 E-071-2020-0 E-071-2020-0-PCT-02 COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME PCT Patent Cooperation Treaty PCT/US2021/040157 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/040157<br />Filed on 2021-07-01<br />Status: Expired 164119845 E-071-2020-0 E-071-2020-0-AU-04 CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION National Stage Australia 2021300425 Pending Australia <br />National Stage 2021300425<br />Filed on 2022-12-08<br />Status: Pending 164119846 E-071-2020-0 E-071-2020-0-CA-05 COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME National Stage Canada 3186586 Pending Canada <br />National Stage 3186586<br />Filed on 2021-07-01<br />Status: Pending 164119847 E-071-2020-0 E-071-2020-0-EP-06 CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION National Stage European Patent 21751672.3 Pending European Patent <br />National Stage 21751672.3<br />Filed on 2021-07-01<br />Status: Pending 164119848 E-071-2020-0 E-071-2020-0-JP-07 COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME National Stage Japan 2022-581456 Pending Japan <br />National Stage 2022-581456<br />Filed on 2022-12-28<br />Status: Pending 164119849 E-071-2020-0 E-071-2020-0-US-08 CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION National Stage US 18/014,045 Pending US <br />National Stage 18/014,045<br />Filed on 2022-12-30<br />Status: Pending 165783069 E-071-2020-0 E-071-2020-0-JP-01 COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME DIV Japan 2026-019246 Pending Japan <br />Divisional (DIV) 2026-019246<br />Filed on 2026-02-09<br />Status: Pending TAB-5058 162672189 First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02) NCATS Cardiology, Dermatology, Geriatrics, Oncology, Pulmonology, Reproductive Health, Research Materials, Therapeutics Cardiology Dermatology Geriatrics Oncology Pulmonology Reproductive Health Research Materials Therapeutics Alexander Agoulnik, Irina Agoulnik, Ana Cabrera, Mark Henderson, Wenwei Huang, Joshua Hutcheson, Jiankang Jiang, Abhijeet Kapoor, Bing Li, Juan Marugan, Khalida Shamim, Noel Southall, Kenneth Wilson, Wenjuan Ye <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">It is well documented in literature that activation of RXFP1 by relaxin induces: 1) up-regulation of the endothelin system which leads to vasodilation; 2) extracellular matrix remodeling through regulation of collagen deposition, cell invasiveness, proliferation, and overall tissue homeostasis; 3) a moderation of inflammation by reducing levels of inflammatory cytokines, such as TNF-a and TGF-b; and 4) angiogenesis by activating transcription of VEGF.</span></span></p> <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">The present invention is directed to novel relaxin receptor (RFXP1 receptor) small molecule agonists useful for treating relaxin-related disorders including fibrosis, certain cancers, vascular calcifications, including atherosclerosis, and heart failure. The RFXP1 agonists of this disclosure possess a number of advantages not found in earlier RFXP1 agonists. These properties include, for example, improved bioavailability, low toxicity, and better activity in RXFP1-dependent biological functional assays.</span></span></p> <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">NCATS in collaboration with Florida International University (FIU) and </span></span>University of South Florida<span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif"> (USF) has identified low molecular weight, highly potent, and efficient full RXFP1 agonists with low cytotoxicity. The identification and characterization of these compounds may lead to the development of a new class of cost-effective drugs for the treatment of numerous <span style="color:black">cancers, fibrotic, and vascular disorders</span>.</span></span></p> <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">NCATS is actively seeking licensing to develop therapeutic interventions for cancers, fibrotic and vascular disease including but not limited to breast <span style="color:black">cancer, solid tumors, atherosclerosis, and liver fibrosis</span>. </span></span></p> <ul><li>First and only small molecule agonists of RXFP1</li><li>Potent and highly selective</li><li>Bioavailable with excellent exposure</li><li>Easy to synthesize and scale-up</li></ul> <ul><li>Vascular health</li><li>Fibrotic diseases</li><li>Cancers</li><li>Human reproductive health</li></ul> Researchers at the National Center for Advancing Translational Sciences (NCATS) seek to license these molecules. Licensing Contact: Jasmine Kalsi, M.S. Email: jasmine.kalsi@nih.gov Telephone: 301.435.0129 2025-05-29 2025-05-30 2026-06-17 2025-05-29 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 162672380 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 1 162672384 Henderson, Mark NCATS - NCGC NCATS Henderson, Mark (NCATS) 2 162672393 Wilson, Kenneth National Center for Advancing Translational Sciences Wilson, Kenneth 3 162672397 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 4 162672401 Ye, Wenjuan NCATS - NCGC NCATS Ye, Wenjuan (NCATS) 5 162672410 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 6 162672414 Jiang, Jiankang NCATS - NCGC NCATS Jiang, Jiankang (NCATS) 7 162672418 Shamim, Khalida NCATS - TRND NCATS Shamim, Khalida (NCATS) 8 162672422 Li, Bing National Center for Advancing Translational Sciences Li, Bing 9 162672458 Agoulnik, Alexander Florida International University (FIU) Agoulnik, Alexander 10 162672621 Kapoor, Abhijeet Florida International University (FIU) Kapoor, Abhijeet 11 162672761 Hutcheson, Joshua Florida International University (FIU) Hutcheson, Joshua 12 162672791 Cabrera, Ana Florida International University (FIU) Cabrera, Ana 13 162672896 Agoulnik, Irina Florida International University (FIU) Agoulnik, Irina 14 162672380 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 1 162672384 Henderson, Mark NCATS - NCGC NCATS Henderson, Mark (NCATS) 2 162672393 Wilson, Kenneth National Center for Advancing Translational Sciences Wilson, Kenneth 3 162672397 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 4 162672401 Ye, Wenjuan NCATS - NCGC NCATS Ye, Wenjuan (NCATS) 5 162672410 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 6 162672414 Jiang, Jiankang NCATS - NCGC NCATS Jiang, Jiankang (NCATS) 7 162672418 Shamim, Khalida NCATS - TRND NCATS Shamim, Khalida (NCATS) 8 162672422 Li, Bing National Center for Advancing Translational Sciences Li, Bing 9 162672458 Agoulnik, Alexander Florida International University (FIU) Agoulnik, Alexander 10 162672621 Kapoor, Abhijeet Florida International University (FIU) Kapoor, Abhijeet 11 162672761 Hutcheson, Joshua Florida International University (FIU) Hutcheson, Joshua 12 162672791 Cabrera, Ana Florida International University (FIU) Cabrera, Ana 13 162672896 Agoulnik, Irina Florida International University (FIU) Agoulnik, Irina 14 162672192 NCGC00846044 is a novel functionally selective RXFP1 agonist with exceptional properties E-145-2024-0 Filing authorized Florida International University (FIU), National Center for Advancing Translational Sciences, University of South Florida 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-5058] First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02)&body=Please send me information about technology [TAB-5058] First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02). Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-5058] First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02)&body=Please send me information about technology [TAB-5058] First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02).">jasmine.kalsi@nih.gov</a><br> 162672197 E-145-2024-0 E-145-2024-0-US-01 RFXP1 AGONISTS PRV US 63/757,235 Expired US <br />Provisional (PRV) 63/757,235<br />Filed on 2025-02-11<br />Status: Expired 162672198 E-145-2024-0 E-145-2024-0-US-02 RFXP1 AGONISTS PRV US 63/780,976 Expired US <br />Provisional (PRV) 63/780,976<br />Filed on 2025-03-31<br />Status: Expired 166692346 E-145-2024-0 E-145-2024-0-PC-01 RFXP1 AGONISTS PCT Patent Cooperation Treaty PCT/US2026/021648 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2026/021648<br />Filed on 2026-03-31<br />Status: Pending TAB-3938 147157218 T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Christian Hinrichs, Kazusa Ishii <h2>Description of Technology:</h2> <p>CD22 is a protein expressed by normal B cells and B-lymphoid malignancies. Its limited tissue expression pattern makes it a safe antigen for targeted therapies, such as T-cell Receptor (TCR)-T cell therapy. CD22-targeting therapies already on the market, mainly antibody-immunotoxin conjugates and chimeric antigen receptors (CAR)-T cells, have limitations such as resistance to treatment and/or side effects. Resistance mechanisms to the current CD22 therapies involve loss or modulation of target antigen on the cell surface. TCRs are expected to overcome these resistance mechanisms as they use distinct target recognition mechanism. TCRs instead recognize epitopes derived from proteins processed intracellularly and presented in the context of Human Leukocyte Antigens (HLA), enabling detection of broad antigens inaccessible to antibodies or CAR-T&rsquo;s &ndash; including neoantigens, cancer germline antigens, and intracellular viral oncoproteins.</p> <p>Investigators at the National Cancer Institute (NCI) developed a TCR recognizing a CD22-derived epitope presented in context of the highly prevalent HLA-A*02:01. The TCR was not cross-reactive against unintended target antigens. T cells expressing the TCR (CD22 TCR-T cells) show anti-tumor activity at clinically-relevant doses without causing systemic cytokine elevation in pre-clinical, in vivo models. The inventors are translating their findings into the clinic.</p> <p>NCI seeks parties interested in licensing and/or collaborations to further develop this technology.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Autologous adoptive cell therapy for patients with B-cell malignancies such as non-Hodgkin&rsquo;s lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.</li> <li>Off-the-shelf, allogeneic adoptive cell therapy for patients will B-cell malignancies.</li> <li>Therapy alternative for patients with CD22-expressing malignancies that are resistant to antibody-based treatment, including chimeric antigen receptor (CAR)-based adoptive cell therapy.</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Clinical stage asset with an established market need and regulatory path &ndash; following the Accelerated Approvals of inotuzumab ozogamicin (Aucatzyl) in 2017 and afamitresgene autoleucel (Tecelra) in 2024.</li> <li>T cells engineered to express the CD22 TCR clear leukemia at clinically-relevant doses without causing systemic cytokine elevation.</li> <li>TCR is highly specific to human CD22 and is expected to recognize its target under conditions that involve loss or modulation of cell surface expression.</li> <li>TCR is restricted by the highly prevalent HLA A*02:01 allele, which has an approximate frequency of up to 43% within the United States population.</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a T-cell receptor (TCR) that specifically targets an HLA-A*02:01-restricted CD22 Epitope 2023-04-04 2026-06-15 2026-06-15 2026-06-15 2023-04-04 Acute Lymphoblastic Leukemia, ALL, B cells, CD22, Cellular Immunotherapy, Chronic lymphocytic leukemia, CLL, Hinrichs, Ishii, NHL, Non-Hodgkin’s Lymphoma, Relapsed / refractory B-Lymphoid Malignancies, T-Cell Receptor, TCR False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2026-06-15 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-152-2020 167839887 Nguyen KA, et al. CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses. (PMID: 40203088) https://pubmed.ncbi.nlm.nih.gov/40203088/ <a href="https://pubmed.ncbi.nlm.nih.gov/40203088/">Nguyen KA, et al. CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses. (PMID: 40203088)</a> 147162937 Ishii, Kazusa NIH - NCI NCI Ishii, Kazusa (NCI) 1 147162936 Hinrichs, Christian NIH - NCI Hinrichs, Christian 2 147162937 Ishii, Kazusa NIH - NCI NCI Ishii, Kazusa (NCI) 1 147162936 Hinrichs, Christian NIH - NCI Hinrichs, Christian 2 147157825 Discovery Of T Cell Receptors (TCR) Against HLA-A*02:01-restricted CD22 Epitope E-029-2021-0 Filing authorized NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-3938] T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias&body=Please send me information about technology [TAB-3938] T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-3938] T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias&body=Please send me information about technology [TAB-3938] T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">suna.gulay@nih.gov</a><br> 147160930 E-029-2021-0 E-029-2021-0-PCT-02 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22 PCT Patent Cooperation Treaty PCT/US2022/016561 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/016561<br />Filed on 2022-02-16<br />Status: Expired 147165424 E-029-2021-0 E-029-2021-0-US-01 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22 PRV US 63/149,795 Abandoned US <br />Provisional (PRV) 63/149,795<br />Filed on 2021-02-16<br />Status: Abandoned 147165425 E-029-2021-0 E-029-2021-0-CA-01 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22 National Stage Canada 3207989 Pending Canada <br />National Stage 3207989<br />Filed on 2023-08-10<br />Status: Pending 147165426 E-029-2021-0 E-029-2021-0-US-02 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22 National Stage US 18/277,521 Pending US <br />National Stage 18/277,521<br />Filed on 2023-08-16<br />Status: Pending 147165427 E-029-2021-0 E-029-2021-0-EP-01 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22 National Stage European Patent 22709092.5 Pending European Patent <br />National Stage 22709092.5<br />Filed on 2023-09-13<br />Status: Pending 147169834 Acute Lymphoblastic Leukemia 147169835 ALL 147169836 B cells 147169837 CD22 147169839 Cellular Immunotherapy 147169840 Chronic lymphocytic leukemia 147169841 CLL 147169842 Hinrichs 147169844 Ishii 147169846 NHL 147169847 Non-Hodgkin’s Lymphoma 147169849 Relapsed / refractory B-Lymphoid Malignancies 147169851 T-Cell Receptor 147169852 TCR TAB-4913 153307987 Bispecific Antibody Targeting Anthrax Toxins and Capsule for Enhanced Biodefense NIAID Antibodies, Collaboration, Immunology, Infectious Disease, Licensing, Therapeutics, Vaccines Antibodies Collaboration Immunology Infectious Disease Licensing Therapeutics Vaccines Zhaochun Chen, Stephen Leppla, Mahtab Moayeri, Robert Purcell <p>The technology focuses on the development of a tetravalent bispecific antibody effective against Bacillus anthracis, the bacterium responsible for anthrax. This antibody combines the specificities of two monoclonal antibodies (mAbs): one targeting anthrax protective antigen (PA) and the other targeting the bacterial capsule. The anti-PA mAb shows potent toxin-neutralizing activity, while the anti-capsule mAb efficiently kills anthrax bacteria. By merging these specificities into a single lgG framework, the resulting bispecific antibody can simultaneously neutralize toxins and kill bacteria, potentially offering comprehensive protection against anthrax infection. The bispecific antibody is produced from transfected mammalian cells, ensuring scalability for large-scale production. This technology represents a significant advancement in anthrax biodefense, providing a simpler, more effective approach for treatment following exposure to aerosolized B. anthracis spores.</p> The tetravalent bispecific antibody targeting anthrax toxins and capsule offers several competitive advantages over existing approaches. Unlike conventional monoclonal antibodies that target only one antigen, this bispecific antibody can simultaneously neutralize toxins and kill bacteria, providing comprehensive protection against anthrax infection. Additionally, the simplicity of using a single molecule instead of a combination of two monoclonal antibodies enhances efficacy and ease of administration. The ability to express and purify the antibody from transfected mammalian cells ensures scalability for large-scale production, further enhancing its potential as a biodefense tool. The tetravalent bispecific antibody targeting anthrax toxins and capsule has significant potential applications in biodefense and anthrax treatment. It could be used as a post-exposure prophylactic following potential exposure to aerosolized B. anthracis spores, offering rapid and targeted protection. Additionally, this antibody may find utility in the treatment of anthrax infections, potentially improving outcomes and reducing the need for complex treatment regimens. Its ability to target multiple virulence factors simultaneously makes it a promising candidate for use in biodefense strategies against anthrax. 2024-02-26 2024-12-10 2026-06-10 2024-12-10 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153307995 Chen, Zhaochun NIAID Chen, Zhaochun (NIAID) 1 153308014 Purcell, Robert National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Purcell, Robert (NIAID) 2 153308018 Moayeri, Mahtab NIAID - DIR NIAID Moayeri, Mahtab (NIAID) 3 153308026 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 4 153307995 Chen, Zhaochun NIAID Chen, Zhaochun (NIAID) 1 153308014 Purcell, Robert National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Purcell, Robert (NIAID) 2 153308018 Moayeri, Mahtab NIAID - DIR NIAID Moayeri, Mahtab (NIAID) 3 153308026 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 4 153307990 Development Of A Bispecific Antibody With An Ability To Neutralize Anthrax Toxins And Kill The Bacteria E-100-2013-0 Research Material NIAID 83643855 Soukas, Peter peter.soukas@nih.gov
United States of America Technology Transfer and Intellectual Property Office peter.soukas@nih.gov?subject=Web Inquiry on [TAB-4913] Bispecific Antibody Targeting Anthrax Toxins and Capsule for Enhanced Biodefense&body=Please send me information about technology [TAB-4913] Bispecific Antibody Targeting Anthrax Toxins and Capsule for Enhanced Biodefense. Soukas, Peter<br><a href="mailto:peter.soukas@nih.gov?subject=Web Inquiry on [TAB-4913] Bispecific Antibody Targeting Anthrax Toxins and Capsule for Enhanced Biodefense&body=Please send me information about technology [TAB-4913] Bispecific Antibody Targeting Anthrax Toxins and Capsule for Enhanced Biodefense.">peter.soukas@nih.gov</a><br> TAB-4996 157267605 Interleukin-27 Producing B-Cell Population and Uses Thereof NEI Collaboration, Ear, Nose, & Throat, Immunology, Licensing, Neurology, Therapeutics Collaboration Ear Nose & Throat Immunology Licensing Neurology Therapeutics Jin Choi, Charles Egwuagu <h2>Summary:&nbsp;</h2> <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees to advance the production and uses of interleukin-27 (IL-27) producing B-regulatory cell (i27-Breg) therapy for immune related autoimmune disorders. These disorders include but are not limited, to age-related macular degeneration (AMD), graft-versus-host disease (GVHD), multiple sclerosis (MS) and transplant rejection.</p> <h2>Description of Technology:&nbsp;</h2> <p>Autoimmune diseases in which the immune system attacks the body&#39;s own tissues or organs include: graft-vs-host disease (GVHD), age-related macular degeneration (AMD), multiple sclerosis (MS), uveitis and encephalomyelitis. &nbsp;These diseases can result in blindness, paralysis, and significant morbidity impacting quality of life. &nbsp;In GVHD, the allogeneic transplant views the recipient&rsquo;s body as foreign, and the transplant attacks the body. &nbsp;Uveitis is comprised of a diverse group of potentially sight-threatening intraocular inflammatory diseases of infectious or autoimmune etiology. &nbsp;Similarly, autoimmune processes contribute significantly to the progression of retinal degeneration associated with AMD. &nbsp;MS is caused in part by immune cells that attack and/or destroy neurons, thereby interfering with normal neurological function. Steroids and monoclonal antibodies are temporarily effective therapies; serious adverse effects preclude their prolonged use. Therefore, an unmet need remains for safe, effective long-term therapies for autoimmune disorders.</p> <p>The invention consists of an isolated population of mammal cells comprising about 75 % or higher B-1a regulatory cells and methods of preparation of such cell populations. i27-Bregs have distinct advantages over &nbsp;systemic administration of interleukin-27 (IL-27) since the latter is costly to synthesize and rapidly degrades in the body. i27-Bregs provide several therapeutic advantages over current standard of care: &nbsp;(i) self-renewal after administration and thereby sustained IL-27 production in host tissues; (ii) reprograms recipient lymphocytes into Bregs and Tregs (regulatory T cells) (iii) effective suppression of the host&rsquo;s overreactive immune system; (iv) no requirement of prior activation, providing a potential therapeutic advantage over other disease-specific cell therapies. Immune system suppression by i27-Bregs administration can also be used in conjunction with solid organ or allogenic cell transplants to reduce potentially fatal transplant rejection.&nbsp;</p> <p>This technology is available for development under a license for the above-mentioned disorders. Inventors at the National Eye Institute are interested in participating under a CRADA collaboration to further develop the technology toward clinical applications or will assist to transfer the technological know-how for licensing. &nbsp;&nbsp;</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Cell therapy for severe CNS autoimmune disease, GVHD, transplants, encephalomyelitis, or multiple sclerosis</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Can be co-administered with other currently approved therapies currently&nbsp;</li> <li>No FDA approved B cell therapy for the treatment of auto immune disease</li> <li>Self-renewing</li> <li>Excreted interleukins following administration provide a longer-lasting effect than currently approved monoclonal antibody therapies</li> <li>Potentially fewer side effects since IL-27 extended release avoids the systemic administration of monoclonal antibodies or immunosuppressive drugs</li> <li>Ex-vivo preparation can be further genetically modified to enhance efficacy</li> <li>Activation not required to inhibit autoimmunity</li> </ul> Researchers at the NEI seek licensing and/or co-development research collaborations to advance the production and uses of IL-27 producing B-regulatory cells (i27-Bregs) for autoimmune disorders, including but not limited to, graft-versus-host disease (GVHD), age-related macular degeneration (AMD); and transplant rejection. 2024-07-23 2026-04-16 2026-06-05 2024-07-23 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-036-2012 157267704 Choi JK, et al. IL-27-producing B-1a cells suppress neuroinflammation and CNS autoimmune diseases. (PMID 34782464) https://pubmed.ncbi.nlm.nih.gov/34782464/ <a href="https://pubmed.ncbi.nlm.nih.gov/34782464/">Choi JK, et al. IL-27-producing B-1a cells suppress neuroinflammation and CNS autoimmune diseases. (PMID 34782464)</a> 157267612 Egwuagu, Charles National Eye Institute (NEI) NEI Egwuagu, Charles (NEI) 1 157267616 Choi, Jin National Eye Institute (NEI) NEI Choi, Jin (NEI) 2 157267612 Egwuagu, Charles National Eye Institute (NEI) NEI Egwuagu, Charles (NEI) 1 157267616 Choi, Jin National Eye Institute (NEI) NEI Choi, Jin (NEI) 2 157267608 A Novel IL-27-producing Innate B-1a Cell Population Regulates Neuroinflammation And Confers Protection against Severe CNS Autoimmune Diseases E-070-2019-0 Filing authorized National Eye Institute (NEI) 83737255 Baxter, Merissa merissa.baxter@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4996] Interleukin-27 Producing B-Cell Population and Uses Thereof&body=Please send me information about technology [TAB-4996] Interleukin-27 Producing B-Cell Population and Uses Thereof.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Baxter, Merissa<br><a href="mailto:merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4996] Interleukin-27 Producing B-Cell Population and Uses Thereof&body=Please send me information about technology [TAB-4996] Interleukin-27 Producing B-Cell Population and Uses Thereof.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">merissa.baxter@nih.gov</a><br> 157267711 E-070-2019-0 E-070-2019-0-US-01 INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF PRV US 62/863,054 Abandoned US <br />Provisional (PRV) 62/863,054<br />Filed on 2019-06-18<br />Status: Abandoned 157267716 E-070-2019-0 E-070-2019-0-PCT-02 INTERLEUKIN-27 PRODUCING B-CELLS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2020/038368 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/038368<br />Filed on 2020-06-18<br />Status: Expired 162862740 E-070-2019-0 E-070-2019-0-AU-03 INTERLEUKIN-27 PRODUCING B-CELL AND USES THEREOF National Stage Australia 2020295470 2020295470 Issued Australia <br />National Stage 2020295470<br />Filed on 2020-06-18<br />Status: Issued 162862741 E-070-2019-0 E-070-2019-0-CA-04 INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF National Stage Canada 3143998 3143998 Issued Canada <br />National Stage 3143998<br />Filed on 2020-06-18<br />Status: Issued 162862742 E-070-2019-0 E-070-2019-0-EP-05 INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF National Stage European Patent 20736554.5 Pending European Patent <br />National Stage 20736554.5<br />Filed on 2020-06-18<br />Status: Pending 162862743 E-070-2019-0 E-070-2019-0-JP-06 INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF National Stage Japan 7662543 2021-575486 Issued Japan <br />National Stage 2021-575486<br />Filed on 2021-12-17<br />Status: Issued 162862744 E-070-2019-0 E-070-2019-0-US-07 INTERLEUKIN-27 PRODUCING B-CELLS AND USES THEREOF National Stage US 17/620,248 Pending US <br />National Stage 17/620,248<br />Filed on 2021-12-17<br />Status: Pending 162862745 E-070-2019-0 E-070-2019-0-JP-08 INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF DIV Japan 7877540 2025-061994 Issued Japan <br />Divisional (DIV) 2025-061994<br />Filed on 2025-04-03<br />Status: Issued 165287369 E-070-2019-0 E-070-2019-0-CA-10 INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF DIV Canada Administratively Closed Canada <br />Divisional (DIV) None<br />Filed on None<br />Status: Administratively Closed 165287503 E-070-2019-0 E-070-2019-0-AU-09 INTERLEUKIN-27 PRODUCING B-CELL AND USES THEREOF DIV Australia 2026200686 Pending Australia <br />Divisional (DIV) 2026200686<br />Filed on 2026-01-30<br />Status: Pending 167740801 E-070-2019-0 E-070-2019-0-JP-11 INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF DIV Japan 2026-096889 Pending Japan <br />Divisional (DIV) 2026-096889<br />Filed on 2026-06-10<br />Status: Pending TAB-5103 167680344 Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells NIAID Application, Diagnostics, ResearchProducts, Therapeutics Application Diagnostics ResearchProducts Therapeutics Angela DeVico, Patricia Korty, Ethan Shevach <p>Regulatory T cells (Tregs) are immune cells that keep the immune system balanced and prevent autoimmunity. Tregs depend on a protein called Eos (Ikzf4) that helps turn genes on and off for their development and function, but until now, antibodies used to detect and study Eos were unreliable.</p> <p><br /> Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) have created monoclonal antibody 18H2 to accurately detect Eos in mouse and human Treg cells. To make 18H2, they immunized hamsters with a segment of the Eos protein and used advanced techniques to select the best antibody-producing cells. The resulting 18H2 antibody specifically detects Eos and does not react with cells lacking Eos.</p> <p><br /> The 18H2 antibody stands out by reliably detecting both human and mouse Eos and performing better in laboratory tests, such as flow cytometry, used to analyze Treg cells. This technology offers a powerful new way to study Treg cell development and how Eos helps protect against autoimmune conditions.</p> <p>&nbsp;</p> <ul> <li> Eos-specific detection, confirmed by lack of reactivity in cells that lack Eos. </li> <li> Detection of both mouse and human Eos, enabling application to human research. </li> <li> Precise detection and measurement of Treg cells in diverse sample types. </li> </ul> <ul> <li> Development of tests that track Treg cell function and Eos protein levels in patients and monitor Eos levels in autoimmune diseases, cancer treatments, and organ transplants. </li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Areas of specific interest include (a) application in pre-clinical models of autoimmunity, cancer, and transplantation, (b) development of diagnostic assays for immune monitoring and biomarker discovery, and (c) inclusion in high-throughput screening platforms for drug discovery targeting Treg pathways. For collaboration opportunities, please contact Yogikala Prabhu at 202-365-4785, or yogikala.prabhu@nih.gov. 2026-06-01 2026-06-03 2026-06-03 2026-06-03 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 167681122 Xie X, et al. Eos plays a critical role in Treg homeostasis and modulates the function of recirculating thymic Tregs in the control of Treg development. Cell Rep. 2026;45(1):116838. (doi:10.1016/j.celrep.2025.116838) Xie X, et al. Eos plays a critical role in Treg homeostasis and modulates the function of recirculating thymic Tregs in the control of Treg development. Cell Rep. 2026;45(1):116838. (doi:10.1016/j.celrep.2025.116838) 167680373 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 1 167680411 DeVico, Angela NIAID - DIR NIAID DeVico, Angela (NIAID) 2 167680417 Korty, Patricia NIAID - DIR NIAID Korty, Patricia (NIAID) 3 167680373 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 1 167680411 DeVico, Angela NIAID - DIR NIAID DeVico, Angela (NIAID) 2 167680417 Korty, Patricia NIAID - DIR NIAID Korty, Patricia (NIAID) 3 167680347 Anti-mouse Ikzf4 (Eos) Monoclonal Antibody E-104-2025-0 Research Material National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID - DIR 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-5103] Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells&body=Please send me information about technology [TAB-5103] Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-5103] Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells&body=Please send me information about technology [TAB-5103] Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells.">yogikala.prabhu@nih.gov</a><br> TAB-5100 167551551 Human antibodies with anti-lymphocyte specificities and lytic activity NIAID Antibodies, Application, TherapeuticArea Antibodies Application TherapeuticArea Ainhoa Perez-Diez, Irini Sereti <p>&nbsp; &nbsp; &nbsp; &nbsp;Antibody therapies that target human B cells are a promising way to treat diseases like B-cell cancers and autoimmune conditions like lupus and multiple sclerosis. Traditionally, these antibodies are made in animals and modified to resemble human antibodies to reduce immune rejection. Researchers in the Laboratory of Immunoregulation (LIR) at the National Institute of Allergy and Infectious Diseases (NIAID) have developed a new approach of using blood plasma from a patient with the rare immune disorder idiopathic CD4 lymphocytopenia (ICL) to find naturally occurring human antibodies.</p> <p>&nbsp; &nbsp; &nbsp; &nbsp;By using advanced genetic sequencing, the researchers discovered and reproduced several new antibodies that could effectively attack and kill B-cell tumors, normal B cells, and T cells, demonstrating potential for eliminating cancerous or disease-causing immune cells. One potent antibody, NIH58.9, killed B cells at low concentrations of 0.01 nanomolar. These new antibodies may be used as treatments, combined with other therapies, or engineered into special formats like bispecific antibodies or antibody-drug conjugates.</p> <ul> <li>First fully human IgM antibody that binds to and kills B cells</li> <li>Fully human monoclonal antibodies eliminating humanization steps associated with antibodies derived from animal models and lowering risk of anti-drug antibody response</li> <li>B-cell death observed at concentrations as low as 0.01Nm</li> <li>Versatile antibody that may be used directly, engineered as IgG1 antibody, and possibly developed into bispecifics or antibody-drug conjugates</li> </ul> <ul> <li>Development of monoclonal antibody therapies, bispecific antibodies, and antibody-targeted drugs for use in organ transplantation, B-cell lymphomas, and autoimmune conditions</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Benjamin Hurley at 240-276-5489, or benjamin.hurley@nih.gov. 2026-05-21 2026-05-21 2026-05-21 2026-05-21 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 167551741 Perez-Diez, Ainhoa National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Perez-Diez, Ainhoa (NIAID) 1 167551745 Sereti, Irini NIAID - DIR NIAID Sereti, Irini (NIAID) 2 167551741 Perez-Diez, Ainhoa National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Perez-Diez, Ainhoa (NIAID) 1 167551745 Sereti, Irini NIAID - DIR NIAID Sereti, Irini (NIAID) 2 167551554 Human antibodies with anti-lymphocyte specificities and lytic activity linked to ICL. E-025-2025-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID - DIR 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5100] Human antibodies with anti-lymphocyte specificities and lytic activity&body=Please send me information about technology [TAB-5100] Human antibodies with anti-lymphocyte specificities and lytic activity. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5100] Human antibodies with anti-lymphocyte specificities and lytic activity&body=Please send me information about technology [TAB-5100] Human antibodies with anti-lymphocyte specificities and lytic activity.">benjamin.hurley@nih.gov</a><br> 167551560 E-025-2025-0 E-025-2025-0-US-01 MONOCLONAL ANTI-LYMPHOCYTE ANTIBODIES AND THEIR USE PRV US 63/787,190 Expired US <br />Provisional (PRV) 63/787,190<br />Filed on 2025-04-11<br />Status: Expired 167551561 E-025-2025-0 E-025-2025-0-PC-01 MONOCLONAL ANTI-LYMPHOCYTE ANTIBODIES AND THEIR USE PCT Patent Cooperation Treaty PCT/US2026/022767 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2026/022767<br />Filed on 2026-04-08<br />Status: Pending TAB-3924 147157204 Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Lakshmi Balagopalan, Katherine McIntire, Lawrence Samelson, Chang Yi <p>T cell immunotherapy is used in the treatment of various pathologies – including cancers and infections. Current therapies employ chimeric antigen receptors (CARs) consisting of the intracellular fragment of CD3-zeta as the signaling domain with varied combinations of co-stimulatory, transmembrane, spacer/hinge, and extracellular targeting domains. While effective in treating hematological malignancies, CAR T cells need to be activated through T cell receptor (TCR) activation. Such activation is subject to various regulatory and inhibitory mechanisms that can limit their full therapeutic potential. Moreover, CAR T cells are less effective in the treatment of solid tumors due to exhaustion. There remains a need for effective immunotherapies to treat solid tumors as well as hematological malignancies. Researchers at the National Cancer Institute (NCI) have found that after T cell receptor (TCR) activation, the linker for activation of T cells (LAT) forms a distinct signaling complex and its formation is sufficient to cause full T-cell activation independent of the TCR complex. As activation of the TCR complex is highly regulated by a number of competing kinases and phosphatases, the downstream LAT molecule offers several advantages over CD3-zeta as the signaling domain in CARs.</p> <p>Researchers at the NCI have developed chimeric adaptor proteins (CAPs) consisting of an extracellular targeting domain, transmembrane domain, intracellular LAT domain, and the kinase domain of ZAP70. The inventors have observed that the formation of these complexes is sufficient to cause full T-cell activation independent of TCR activation. It is expected that the circumvention of the regulatory mechanisms targeting upstream TCR activation will increase the potency of T-cell signaling and the sensitivity of immunotherapy. Furthermore, T cells prepared with these recombinant molecules may be more resistant to exhaustion by molecules targeting TCR activation, and tunable, as the activity of the kinase domain can be altered with small molecules.</p> <p>The <a href="https://ccr.cancer.gov/Laboratory-of-Cellular-and-Molecular-Biology" rel="nofollow">Laboratory of Cellular and Molecular Biology</a>, is seeking statements of capability or interest from parties interested in licensing this invention and/or collaborative research to further develop, evaluate, or commercialize CAPs for the treatment of solid tumors and hematological malignancies.</p> <h2>Competitive Advantages:</h2> <ul><li>Potential for demonstrable efficacy against solid cancers previously refractory to cellular immunotherapy via: <ul><li>Signaling through LAT allows circumvention of regulatory and inhibitory mechanisms involved in TCR activation</li> <li>Directly triggering the downstream signaling cascade could cause more potent activation of T cells </li> <li>LAT-based CAP-expressing T cells may be more resistant to PD-1-mediated T-cell exhaustion </li> <li>Signaling from CAPs consisting of LAT and ZAP70 kinase domain may be tunable </li> </ul></li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treatment of hematological malignancies and solid tumors</li> <li>Therapeutic use as a combination therapy with immune checkpoint inhibitors and/or chemotherapy</li> </ul> 2019-06-28 2025-04-22 2020-05-19 2026-05-19 2019-06-28 CAP, CAR, Chimeric Adaptor Protein, chimeric antigen receptor, Immunotherapy, LAT, Linker for Activation of T cells, Samelson, T cell False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-05-19 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-159-2009 147162087 Yi J, et al. TCR microclusters form spatially segregated domains and sequentially assemble in calcium-dependent kinetic steps https://www.ncbi.nlm.nih.gov/pubmed/30655520 <a href="https://www.ncbi.nlm.nih.gov/pubmed/30655520">Yi J, et al. TCR microclusters form spatially segregated domains and sequentially assemble in calcium-dependent kinetic steps</a> 147162165 Balagopalan L, et al. Plasma membrane LAT activation precedes vesicular recruitment defining two phases of early T-cell activation https://www.ncbi.nlm.nih.gov/pubmed/29789604 <a href="https://www.ncbi.nlm.nih.gov/pubmed/29789604">Balagopalan L, et al. Plasma membrane LAT activation precedes vesicular recruitment defining two phases of early T-cell activation</a> 167504673 Balagopalan L, et al. Generation of antitumor chimeric antigen receptors incorporating T cell signaling motifs (PMID: 39042728) https://pubmed.ncbi.nlm.nih.gov/39042728/ <a href="https://pubmed.ncbi.nlm.nih.gov/39042728/">Balagopalan L, et al. Generation of antitumor chimeric antigen receptors incorporating T cell signaling motifs (PMID: 39042728)</a> 147162882 Yi, Chang NIH - NCI Yi, Chang 1 147162881 Balagopalan, Lakshmi NIH - NCI NCI Balagopalan, Lakshmi (NCI) 2 147162883 McIntire, Katherine NIH - NCI NCI McIntire, Katherine (NCI) 3 147162880 Samelson, Lawrence NIH - NCI NCI Samelson, Lawrence (NCI) 4 147162882 Yi, Chang NIH - NCI Yi, Chang 1 147162881 Balagopalan, Lakshmi NIH - NCI NCI Balagopalan, Lakshmi (NCI) 2 147162883 McIntire, Katherine NIH - NCI NCI McIntire, Katherine (NCI) 3 147162880 Samelson, Lawrence NIH - NCI NCI Samelson, Lawrence (NCI) 4 147158213 Recombinant Molecule Containing LAT For Use In T Cell Immunotherapy E-210-2018-0 Filing authorized NCI 147162560 Chimeric Adaptor Proteins (CAPs) For Improved T-Cell Immunotherapy E-210-2018-1 Filing authorized NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-3924] Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy&body=Please send me information about technology [TAB-3924] Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-3924] Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy&body=Please send me information about technology [TAB-3924] Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">suna.gulay@nih.gov</a><br> 147161195 E-210-2018-0 E-210-2018-0-PCT-02 CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY PCT Patent Cooperation Treaty PCT/US2020/022752 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/022752<br />Filed on 2020-03-13<br />Status: Expired 147165286 E-210-2018-0 E-210-2018-0-US-01 RECOMBINANT MOLECULES CONTAINING LINKER FOR ACTIVATION OF T CELLS AND THEIR USE IN IMMUNOTHERAPY PRV US 62/819,386 Abandoned US <br />Provisional (PRV) 62/819,386<br />Filed on 2019-03-15<br />Status: Abandoned 147165287 E-210-2018-0 E-210-2018-0-EP-03 CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY National Stage European Patent 20718061.3 Pending European Patent <br />National Stage 20718061.3<br />Filed on 2020-03-13<br />Status: Pending 147165288 E-210-2018-0 E-210-2018-0-CN-04 CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY National Stage China 202080021582.5 Pending China <br />National Stage 202080021582.5<br />Filed on 2020-03-13<br />Status: Pending 147165289 E-210-2018-0 E-210-2018-0-HK-05 CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY EP Hong Kong 62022051308.4 Pending Hong Kong <br />European patent (EP) 62022051308.4<br />Filed on 2020-03-13<br />Status: Pending 147165291 E-210-2018-1 E-210-2018-1-US-01 CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY CIP US 17/475,810 Pending US <br />Continuation in Part (CIP) 17/475,810<br />Filed on 2021-09-15<br />Status: Pending 147165292 E-210-2018-1 E-210-2018-1-PCT-02 Chimeric adaptor and kinase signaling proteins and their use in immunotherapy PCT Patent Cooperation Treaty PCT/US2022/076358 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/076358<br />Filed on 2022-09-13<br />Status: Expired 147173698 CAP 147173699 CAR 147173701 Chimeric Adaptor Protein 147173702 chimeric antigen receptor 147173703 Immunotherapy 147173704 LAT 147173706 Linker for Activation of T cells 147173708 Samelson 147173709 T cell TAB-5094 166511676 Novel malaria vaccine candidates comprising engineered nanoparticles NIAID Collaboration Sought, ResearchProducts, TherapeuticArea, Vaccines Collaboration Sought ResearchProducts TherapeuticArea Vaccines Thayne Dickey, Vu Nguyen, Dashuang Shi, Niraj Tolia <p>Using proteins derived from the malaria Plasmodium falciparum parasite, NIAID has developed three different nanoparticle platforms to serve as scaffolds for displaying multiple copies of malaria antigens in an organized, repetitive manner to enhance vaccine effectiveness. The first platform uses the pyridoxal 5&rsquo;-phosphate (PLP) synthase protein to form a nanoparticle displaying 48 copies of up to 4 different proteins. The second platform uses the chaperone 60 (Cpn60), which can display 28 copies of up to 2 different proteins. The third platform uses a caseinolytic protease (Clp) which can display 28 copies of up to two different proteins.</p> <p>This technology is available for licensing for commercial development in accordance with 35 U.S.C. &sect; 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.</p> <ul> <li>Pre-clinical data indicates that nanoparticles displaying the malaria circumsporozoite protein (CSP) confer 100% sterilizing immunity in mice.</li> </ul> <ul> <li>Malaria vaccinology</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-565-2632, or chris.kornak@nih.gov. 2026-03-19 2026-05-14 2026-05-14 2026-03-24 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 166527395 Shi D, et al. A Plasmodium-derived nanoparticle vaccine elicits sterile protection against malaria in mice. Nat Microbiol. 2026;11(1):67–80. (doi:10.1038/s41564-025-02209-y) https://pubmed.ncbi.nlm.nih.gov/41420060/ <a href="https://pubmed.ncbi.nlm.nih.gov/41420060/">Shi D, et al. A Plasmodium-derived nanoparticle vaccine elicits sterile protection against malaria in mice. Nat Microbiol. 2026;11(1):67–80. (doi:10.1038/s41564-025-02209-y)</a> 166511805 Tolia, Niraj National Institute of Allergy and Infectious Diseases (NIAID/NIH) Tolia, Niraj 1 166511821 Shi, Dashuang NIAID Shi, Dashuang (NIAID) 2 166511842 Nguyen, Vu National Institute of Allergy and Infectious Diseases (NIAID/NIH) Nguyen, Vu 3 166512001 Dickey, Thayne NIAID - DIR NIAID Dickey, Thayne (NIAID) 4 166511805 Tolia, Niraj National Institute of Allergy and Infectious Diseases (NIAID/NIH) Tolia, Niraj 1 166511821 Shi, Dashuang NIAID Shi, Dashuang (NIAID) 2 166511842 Nguyen, Vu National Institute of Allergy and Infectious Diseases (NIAID/NIH) Nguyen, Vu 3 166512001 Dickey, Thayne NIAID - DIR NIAID Dickey, Thayne (NIAID) 4 166511679 Novel malaria vaccine candidates comprising engineered nanoparticles E-182-2024-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID - DIR, NIH - NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5094] Novel malaria vaccine candidates comprising engineered nanoparticles&body=Please send me information about technology [TAB-5094] Novel malaria vaccine candidates comprising engineered nanoparticles. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5094] Novel malaria vaccine candidates comprising engineered nanoparticles&body=Please send me information about technology [TAB-5094] Novel malaria vaccine candidates comprising engineered nanoparticles.">benjamin.hurley@nih.gov</a><br> 166511684 E-182-2024-0 E-182-2024-0-US-01 MALARIA PROTEIN NANOPARTICLE VACCINES AND USES THEREOF PRV US 63/695,288 Expired US <br />Provisional (PRV) 63/695,288<br />Filed on 2024-09-16<br />Status: Expired 166511685 E-182-2024-0 E-182-2024-0-PC-01 MALARIA PROTEIN NANOPARTICLE VACCINES AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2025/046419 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/046419<br />Filed on 2025-09-15<br />Status: Pending TAB-5049 162271101 A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions NIAID Application, Collaboration, Collaboration Sought, Immunology, Infectious Disease, Licensing, Materials Available, Research Materials, Sequences, Therapeutics, Vaccines Application Collaboration Collaboration Sought Immunology Infectious Disease Licensing Materials Available Research Materials Sequences Therapeutics Vaccines Patrick Duffy, Jonathan Renn <p>The Plasmodium parasite has a complex lifecycle during human infection and in the mosquito vector. Most advanced malaria vaccine candidates can confer only partial, short-term protection in malaria-endemic areas. A means of breaking the transmission of malaria to subsequent individuals could prevent a significant amount of human disease.</p> <p>The primary embodiments of this technology are novel compositions of matter that produce enhanced transmission-blocking responses over current transmission blocking vaccines:</p> <ul> <li>The inventors designed fusion protein sequences incorporating Pfs230 domain1 (Pfs230D1) at the N-terminus with additional Plasmodium 6-cys domains downstream.</li> <li>The artificial immunogens retained structured transmission blocking epitopes.</li> </ul> <p>This technology is available for licensing for commercial development in accordance with 35 U.S.C. &sect; 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.</p> <ul> <li>The immunogens were used in small animal vaccination studies where the Pfs230D1-Pfs48/45D3, Pfs230D1-Pfs230D9, Pfs230D1-3 fusions prompted greater functional serum activity compared to Pfs230D1 alone.</li> <li>Pfs230D1 or its ortholog Pvs230D1 enabled expression of other downstream domains of Pvs230 or Pv48/45D3 another malaria species that causes human disease.</li> </ul> <ul> <li>This technology could be used alone or in combination with existing malaria vaccines. </li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak 240-627-3705 or chris.kornak@nih.gov, and reference E-086-2023. 2025-05-08 2026-05-14 2026-05-14 2025-05-09 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 162271181 Duffy, Patrick NIAID - DIR NIAID Duffy, Patrick (NIAID) 1 162271185 Renn, Jonathan National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Renn, Jonathan (NIAID) 2 162271181 Duffy, Patrick NIAID - DIR NIAID Duffy, Patrick (NIAID) 1 162271185 Renn, Jonathan National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Renn, Jonathan (NIAID) 2 162271104 A Novel Strategy To Produce 6-cys Proteins Based On Pfs230D1 Domain Fusions E-086-2023-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5049] A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions&body=Please send me information about technology [TAB-5049] A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5049] A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions&body=Please send me information about technology [TAB-5049] A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions.">benjamin.hurley@nih.gov</a><br> 162271153 E-086-2023-0 E-086-2023-0-US-01 NOVEL COMPOSITIONS OF MATTER COMPRISING PROTEINS THAT INCORPORATE PFS230 DOMAIN 1 (PFS230D1) AT THE N-TERMINUS, MALARIA VACCINE ANTIGENS, AND THEIR USE PRV US 63/617,717 Expired US <br />Provisional (PRV) 63/617,717<br />Filed on 2024-01-04<br />Status: Expired 162271154 E-086-2023-0 E-086-2023-0-PC-01 NOVEL COMPOSITIONS OF MATTER COMPRISING PROTEINS THAT INCORPORATE PFS230 DOMAIN 1 (PFS230D1) AT THE N-TERMINUS, MALARIA VACCINE ANTIGENS, AND THEIR USE PCT Patent Cooperation Treaty PCT/US2025/010325 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2025/010325<br />Filed on 2025-01-03<br />Status: Expired 166735919 E-086-2023-0 E-086-2023-0-IN-01 NOVEL COMPOSITIONS OF MATTER COMPRISING PROTEINS THAT INCORPORATE PFS230 DOMAIN 1 (PFS230D1) AT THE N-TERMINUS, MALARIA VACCINE ANTIGENS, AND THEIR USE National Stage India 202647091406 Pending India <br />National Stage 202647091406<br />Filed on 2026-07-28<br />Status: Pending 166735995 E-086-2023-0 E-086-2023-0-US-02 NOVEL COMPOSITIONS OF MATTER COMPRISING PROTEINS THAT INCORPORATE PFS3230 OR PVS230 DOMAIN 1 (PFS230D1 OR PVS230D1) AT THE N-TERMINUS, MALARIA VACCINE ANTIGENS, AND THEIR USE National Stage US 19/603,335 Pending US <br />National Stage 19/603,335<br />Filed on 2026-07-02<br />Status: Pending 166736025 E-086-2023-0 E-086-2023-0-EP-01 NOVEL COMPOSITIONS OF MATTER COMPRISING PROTEINS THAT INCORPORATE PFS230 DOMAIN 1 (PFS230D1) AT THE N-TERMINUS, MALARIA VACCINE ANTIGENS, AND THEIR USE National Stage European Patent 25703294.6 Pending European Patent <br />National Stage 25703294.6<br />Filed on 2026-07-29<br />Status: Pending TAB-4981 155111852 Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough in Malaria Immunization NIAID Infectious Disease, Vaccines Infectious Disease Vaccines Palak Patel, Niraj Tolia <p>This technology focuses on the creation of single-component AMA1-RON2 (Apical membrane antigen 1-rhoptry neck protein 2) vaccine candidates. These candidates are based on a novel composition of matter designed to elicit a more effective immune response against the malaria parasite Plasmodium falciparum. The standout aspect of this technology is the Structure-Based Design 1 (SBD1) immunogen, engineered through a structure-based design that significantly enhances its ability to produce potent, strain-transcending neutralizing antibodies. This approach not only surpasses the efficacy of traditional AMA1-RON2 complexes and other insertion fusion designs but also boasts higher thermal stability, indicating better preservation and longevity of the vaccine. The technology&rsquo;s increased stability and efficiency in production present an opportunity to lower vaccine manufacturing costs and simplify logistics, especially in regions where malaria is endemic. Additionally, the adaptability of these immunogens for integration with nanoparticle platforms could further amplify their immunogenicity, paving the way for more robust and lasting protection against malaria. This innovation can potentially transform malaria prevention and control, offering a more effective, stable, and cost-efficient solution to a disease that continues to impact millions worldwide.</p> <ul> <li>No blood-stage malaria vaccine has been approved. This technology offers a competitive edge over other vaccine candidates in development through its easily manufactured single-component AMA1-RON2 design that elicits a potent broadly neutralizing response that is better than competing candidates</li> </ul> <ul> <li>Stable single-component AMA1-RON2 immunogens hold promise for improving malaria prevention and control efforts in endemic regions around the world.</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-627-3705 or chris.kornak@nih.gov. 2024-04-09 2026-05-14 2026-05-14 2024-11-12 Design, FALCIPARUM, Malaria, PLASMODIUM, Structure-based False False True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 155122907 Patel, P. N. et. al., Structure-based design of a strain transcending AMA1-RON2L malaria vaccine. Nat. Commun. 14, 5345, 2023 Patel, P. N. et. al., Structure-based design of a strain transcending AMA1-RON2L malaria vaccine. Nat. Commun. 14, 5345, 2023 155122699 Tolia, Niraj NIH - NIAID Tolia, Niraj 1 155122722 Patel, Palak NIH - NIAID NIAID Patel, Palak (NIAID) 2 155122699 Tolia, Niraj NIH - NIAID Tolia, Niraj 1 155122722 Patel, Palak NIH - NIAID NIAID Patel, Palak (NIAID) 2 155111855 Novel malaria vaccine candidates comprising a stabilized designs of AMA1 and RON2 antigens E-096-2023-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4981] Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough in Malaria Immunization&body=Please send me information about technology [TAB-4981] Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough in Malaria Immunization. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4981] Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough in Malaria Immunization&body=Please send me information about technology [TAB-4981] Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough in Malaria Immunization.">benjamin.hurley@nih.gov</a><br> 155111948 E-096-2023-0 E-096-2023-0-US-01 NOVEL MALARIA VACCINE COMPRISING AMA1 AND RON2 ANTIGENS PRV US 63/524,522 Expired US <br />Provisional (PRV) 63/524,522<br />Filed on 2023-06-30<br />Status: Expired 156351084 E-096-2023-0 E-096-2023-0-PC-01 NOVEL MALARIA VACCINE COMPRISING AMA1 AND RON2 ANTIGENS PCT Patent Cooperation Treaty PCT/US2024/035244 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/035244<br />Filed on 2024-06-24<br />Status: Expired 155154090 Malaria 155154109 PLASMODIUM 155154113 FALCIPARUM 155154263 Structure-based 155154272 Design TAB-4980 155110980 Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine Candidates and Monoclonal Antibodies NIAID Collaboration, Infectious Disease, Vaccines Collaboration Infectious Disease Vaccines Thayne Dickey, Carole Long, Kazutoyo Miura, Palak Patel, Niraj Tolia <p>This technology encompasses the development of highly advanced malaria vaccine candidates and human monoclonal antibodies, both centered on targeting the Merozoite Surface Protein 1 (MSP1) of the Plasmodium falciparum malaria parasite. The innovation lies in utilizing a novel computational design and in vitro screening process, which has created MSP1 vaccine candidates that are significantly more immunogenic, stable, and cost-effective than existing alternatives. These vaccines focus on the 19 kDa carboxy-terminus fragment of MSP1. They contain engineered amino acid changes and are displayed on self-assembling nanoparticles to elicit a more potent immune response, potentially offering more robust and durable protection against malaria. Additionally, the technology includes the production of enhanced human monoclonal antibodies with improved affinity for the same fragment of MSP1, designed to overcome the parasite&#39;s immune evasion tactics. These advancements hold immense promise for significantly improving malaria prevention and treatment. They could lead to the development of more effective vaccines and therapeutic antibodies, providing a critical solution to a significant global health challenge.</p> <ul> <li>This technology offers highly immunogenic and stable MSP1-based vaccine candidates and monoclonal antibodies, with superior efficacy, cost-effectiveness, and ease of production compared to current alternatives.</li> </ul> <ul> <li>This MSP1-focused technology has the potential to transform malaria treatment and prevention worldwide, offering more effective vaccines and therapeutic antibodies for use in clinical settings, public health programs, and potentially in regions with high malaria prevalence.</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-627-3705 or chris.kornak@nih.gov. 2024-04-09 2026-05-14 2026-05-14 2024-11-12 antibodies, ANTIGENS, Enhanced, Immunotherapy, Malaria, monoclonal, MSP1 False False Pre-clinical True 37470483 Website Abstract 155111531 Patel, Palak N et al. “Neutralizing and interfering human antibodies define the structural and mechanistic basis for antigenic diversion.” Nature communications vol. 13,1 5888. 6 Oct. 2022, doi:10.1038/s41467-022-33336-3 Patel, Palak N et al. “Neutralizing and interfering human antibodies define the structural and mechanistic basis for antigenic diversion.” Nature communications vol. 13,1 5888. 6 Oct. 2022, doi:10.1038/s41467-022-33336-3 155111249 Tolia, Niraj NIH - NIAID Tolia, Niraj 1 155111332 Dickey, Thayne NIH - NIAID NIAID Dickey, Thayne (NIAID) 2 155111348 Patel, Palak NIH - NIAID NIAID Patel, Palak (NIAID) 3 155111357 Miura, Kazutoyo NIH - NIAID NIAID Miura, Kazutoyo (NIAID) 4 155111372 Long, Carole NIH - NIAID NIAID Long, Carole (NIAID) 5 155111249 Tolia, Niraj NIH - NIAID Tolia, Niraj 1 155111332 Dickey, Thayne NIH - NIAID NIAID Dickey, Thayne (NIAID) 2 155111348 Patel, Palak NIH - NIAID NIAID Patel, Palak (NIAID) 3 155111357 Miura, Kazutoyo NIH - NIAID NIAID Miura, Kazutoyo (NIAID) 4 155111372 Long, Carole NIH - NIAID NIAID Long, Carole (NIAID) 5 155110983 Novel Compositions Of Matter Comprising Stabilized MSP1 Malaria Antigens And High Affinity Anti-MSP1 Human Monoclonal Antibodies And Their Use E-154-2022-0 Filing authorized NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4980] Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine Candidates and Monoclonal Antibodies&body=Please send me information about technology [TAB-4980] Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine Candidates and Monoclonal Antibodies. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4980] Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine Candidates and Monoclonal Antibodies&body=Please send me information about technology [TAB-4980] Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine Candidates and Monoclonal Antibodies.">benjamin.hurley@nih.gov</a><br> 155111222 E-154-2022-0 E-154-2022-0-US-01 METHOD OF IMMUNOFOCUSING AN IMMUNE RESPONSE PRV US 63/369,909 Expired US <br />Provisional (PRV) 63/369,909<br />Filed on 2022-07-29<br />Status: Expired 155111223 E-154-2022-0 E-154-2022-0-PC-01 METHOD OF IMMMUNOFOCUSING AN IMMUNE RESPONSE PCT Patent Cooperation Treaty PCT/US2023/070926 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/070926<br />Filed on 2023-07-25<br />Status: Expired 155111074 antibodies 155111081 ANTIGENS 155111085 MSP1 155111092 Malaria 155111112 monoclonal 155111140 Immunotherapy 155111176 Enhanced TAB-4978 155044855 Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants for Malaria Vaccine Development Using SPEEDesign Technology NIAID Antibodies, Collaboration, Infectious Disease, Vaccines Antibodies Collaboration Infectious Disease Vaccines Thayne Dickey, Niraj Tolia <p>The technology includes modifying the Plasmodium falciparum Pfs48/45 Domain III protein sequence to enhance its stability and efficacy to aid in malaria vaccine development. This approach successfully overcomes previous production challenges by increasing the thermostability of the antigen and eliminating the need for additional modifications that could impair vaccine effectiveness. Crucially, the technology maintains the essential neutralizing epitope of Pfs48/45, ensuring its effectiveness in preventing malaria transmission as a transmission-blocking vaccine. Developed using the SPEEDesign program, these novel protein variants show increased stability and a more robust transmission blocking response than wild-type proteins. The potential applications of this technology are providing a more stable and effective vaccine, potentially reducing the incidence of malaria and leading to improved health outcomes.</p> <ul> <li> The development of more effective and stable malaria vaccines offers improved prevention strategies in regions affected by this disease and significantly contributing to global health initiatives.</li> </ul> <ul> <li> This malaria vaccine technology offers competitive advantages by providing increased thermostability and enhanced immune response without the need for efficacy-reducing modifications, potentially revolutionizing malaria prevention with more effective and stable vaccine options.</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-627-3705 or chris.kornak@nih.gov. 2024-04-04 2026-05-14 2026-05-14 2024-11-12 Malaria Vaccine, Pfs48/45, proteins, Stabilized False False Preclinical Research True 37470483 Website Abstract 155046595 Tolia, Niraj National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Tolia, Niraj (NIAID) 1 155046603 Dickey, Thayne National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Dickey, Thayne (NIAID) 2 155046595 Tolia, Niraj National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Tolia, Niraj (NIAID) 1 155046603 Dickey, Thayne National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Dickey, Thayne (NIAID) 2 155044858 Novel Compositions Of Matter Comprising Stabilized Pfs48/45 Proteins And Their Use E-030-2023-0 Filing authorized NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4978] Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants for Malaria Vaccine Development Using SPEEDesign Technology&body=Please send me information about technology [TAB-4978] Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants for Malaria Vaccine Development Using SPEEDesign Technology. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4978] Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants for Malaria Vaccine Development Using SPEEDesign Technology&body=Please send me information about technology [TAB-4978] Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants for Malaria Vaccine Development Using SPEEDesign Technology.">benjamin.hurley@nih.gov</a><br> 155050145 E-030-2023-0 E-030-2023-0-US-01 Novel Compositions Of Matter Comprising Stabilized Pfs48/45 Proteins And Their Use PRV US 63/476,897 Expired US <br />Provisional (PRV) 63/476,897<br />Filed on 2022-12-22<br />Status: Expired 155050149 E-030-2023-0 E-030-2023-0-PC-01 STABILIZED PFS48/45 PROTEINS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2023/085849 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/085849<br />Filed on 2023-12-22<br />Status: Expired 161727281 E-030-2023-0 E-030-2023-0-IN-01 STABILIZED PFS48/45 PROTEINS AND USES THEREOF National Stage India 202517060138 Pending India <br />National Stage 202517060138<br />Filed on 2025-06-24<br />Status: Pending 161727321 E-030-2023-0 E-030-2023-0-US-02 STABILIZED PFS48/45 PROTEINS AND USES THEREOF National Stage US 19/142,034 Pending US <br />National Stage 19/142,034<br />Filed on 2025-06-20<br />Status: Pending 161727556 E-030-2023-0 E-030-2023-0-EP-01 STABILIZED PFS48/45 PROTEINS AND USES THEREOF National Stage European Patent 23848442.2 Pending European Patent <br />National Stage 23848442.2<br />Filed on 2025-07-04<br />Status: Pending 155049175 Pfs48/45 155049189 proteins 155049198 Stabilized 155049276 Malaria Vaccine TAB-3522 114097382 Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens and Their Use NIAID Collaboration Collaboration Thayne Dickey, Niraj Tolia Using a computational design methodology, SARS-CoV-2 spike proteins containing engineered amino acid changes to the receptor binding domain (RBD) were designed. These engineered spike proteins improved the immune response upon immunization of animals. An engineered RBD was also expressed at greater yield, had increased temperature stability, and improved the immune response upon immunization of animals. Specifically, the disclosed RBD designs can be produced approximately 7 times more efficiently than the native sequence, facilitating vaccine manufacturing on a global scale. The disclosed designs also have up to 10 °C higher thermal stability than the native sequence, suggesting enhanced stability during storage and when in the body. Finally, immunization of animals with the disclosed antigens produces up to 10-fold higher levels of blocking antibodies than the native sequence and 30-fold higher levels of pseudoviral neutralizing antibodies. An additional RBD protein has been engineered to eliminate the need for glycosylation, facilitating production and single-component nanoparticle display of the antigen. The engineered receptor binding domain (RBD) and spike protein antigens produce significant improvements in pre-clinical animal models and may be used to develop improved coronavirus vaccines.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Novel SARS-CoV-2 spike vaccine with improved breadth and duration of protection.</li> <li>Novel RBD monomer and nanoparticle designs that are more immunogenic and stable than the naturally occurring RBD sequence.</li> <li>Computational method of designing vaccine antigens.</li> </ul> <ul> <li>Novel SARS-CoV-2 vaccine.</li> <li>Improved SARS-CoV-2 diagnostics using stabilized antigens.</li> <li>Method of designing vaccine candidates or stabilized antigens by computational. optimization of amino acid identity, followed by additional sequence comparison and selection (Stabilizer for Protein Expression and Epitope Design (SPEEDesign)).</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the invention. For collaboration opportunities, please contact Peter Tung at 240-669-5483; <a href="mailto:peter.tung@nih.gov.">peter.tung@nih.gov</a>. 2022-03-30 2026-05-14 2026-05-14 2022-03-30 ANTIGENS, Compositions, COMPRISING, CORONAVIRUS, Matter, Novel, Stabilized, Their False True True NIHTT 37470483 Website Abstract 114172677 Dickey TH, et al. https://pubmed.ncbi.nlm.nih.gov/34013270/ <a href="https://pubmed.ncbi.nlm.nih.gov/34013270/">Dickey TH, et al.</a> 114110541 Dickey, Thayne NIAID - DIR NIAID Dickey, Thayne (NIAID) 0 114110542 Tolia, Niraj NIAID - VRC Tolia, Niraj 1 114110542 Tolia, Niraj NIAID - VRC Tolia, Niraj 1 114110541 Dickey, Thayne NIAID - DIR NIAID Dickey, Thayne (NIAID) 0 114102633 Novel Compositions Of Matter Comprising Stabilized Coronavirus Antigens And Their Use E-045-2021-0 Filing authorized NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3522] Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens and Their Use&body=Please send me information about technology [TAB-3522] Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens and Their Use. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3522] Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens and Their Use&body=Please send me information about technology [TAB-3522] Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens and Their Use.">benjamin.hurley@nih.gov</a><br> 114169303 E-045-2021-0 E-045-2021-0-PCT-02 COMPOSITIONS OF MATTER COMPRISING STABILIZED CORONAVIRUS ANTIGENS AND THEIR USE PCT Patent Cooperation Treaty PCT/US2022/070744 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/070744<br />Filed on 2022-02-18<br />Status: Expired 114169304 E-045-2021-0 E-045-2021-0-US-01 Novel Compositions Of Matter Comprising Stabilized Coronavirus Antigens And Their Use PRV US 63/200,194 Abandoned US <br />Provisional (PRV) 63/200,194<br />Filed on 2021-02-19<br />Status: Abandoned 114152824 Their 114152825 ANTIGENS 114152826 CORONAVIRUS 114152827 Stabilized 114152828 COMPRISING 114152829 Matter 114152830 Compositions 114152831 Novel TAB-3459 114097328 Novel VAR2CSA Immunogens and Methods of Use Thereof NIAID Collaboration Collaboration Rui Ma, Niraj Tolia The invention provides immunogen polypeptides comprising fragments of VAR2CSA protein expressed by P. falciparum as potential second-generation placental malaria vaccine candidates. VAR2CSA is the leading antigen target for a placental malaria vaccine, where associated antibody titers are correlated with protection. Aspects of the inventive immunogen polypeptides comprise all or portions of the chondroitin sulfate A (CSA) binding regions of VAR2CSA, as identified by a structural study of VAR2CSA conducted by the inventors, that possess great sequence conservation among P. falciparum strains when compared to competing clinical vaccine candidates PRIMVAC and PAMVAC. Also provided are methods of using the immunogen polypeptides for vaccination and treatment of disease. <ul><li>Strain-transcending immunogens for vaccination</li> <li>Improved immunogen production through expression of key protein regions</li></ul> The VAR2CSA immunogens bind to oncofetal CSA, a putative therapeutic target for multiple cancers, including NSCLC, breast, bladder and 40-50% of all pediatric solid tumors. Oncofetal CSA is only expressed solely in the placenta, except in several cancerous tissues, making it an ideal target for targeted therapeutics such as immunogens that are cross linked to cytotoxic agents. <br /><br /> <ul><li>Placental malaria vaccine</li> <li>CSA-binding proteins for cancer therapeutics</li></ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the invention. For collaboration opportunities, please contact Peter Tung at 240-669-5483; <a hef="mailto:Peter.Tung@nih.gov">Peter Tung@nih.gov</a>. 2022-04-01 2026-05-14 2026-05-14 2022-01-13 Against, CANCER, COMPOSITION, COMPRISING, Diagnostics, IMMUNOGENS, Malaria, Matter, Placental, PROTECT, proteins, That, therapeutics, Used False True True NIHTT 37470483 Website Abstract 114110245 Ma, Rui NIAID - VRC NIAID Ma, Rui (NIAID) 0 114110246 Tolia, Niraj NIAID - VRC Tolia, Niraj 1 114110246 Tolia, Niraj NIAID - VRC Tolia, Niraj 1 114110245 Ma, Rui NIAID - VRC NIAID Ma, Rui (NIAID) 0 114102572 New Composition Of Matter Comprising Immunogens That Will Protect Against Placental Malaria, And Proteins That Can Be Used For Cancer Diagnostics And Therapeutics E-021-2021-0 Filing authorized NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3459] Novel VAR2CSA Immunogens and Methods of Use Thereof&body=Please send me information about technology [TAB-3459] Novel VAR2CSA Immunogens and Methods of Use Thereof. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3459] Novel VAR2CSA Immunogens and Methods of Use Thereof&body=Please send me information about technology [TAB-3459] Novel VAR2CSA Immunogens and Methods of Use Thereof.">benjamin.hurley@nih.gov</a><br> 114169183 E-021-2021-0 E-021-2021-0-US-01 NOVEL VAR2CSA IMMUNOGENS AND METHODS OF USE THEREOF PRV US 63/115,729 Abandoned US <br />Provisional (PRV) 63/115,729<br />Filed on 2020-11-19<br />Status: Abandoned 114169184 E-021-2021-0 E-021-2021-0-PCT-02 NOVEL VAR2CSA IMMUNOGENS AND METHODS OF USE THEREOF PCT Patent Cooperation Treaty PCT/US2021/059941 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/059941<br />Filed on 2021-11-18<br />Status: Expired 114152318 COMPOSITION 114152319 Matter 114152320 COMPRISING 114152321 IMMUNOGENS 114152322 That 114152323 PROTECT 114152324 Against 114152325 Placental 114152326 Malaria 114152327 proteins 114152328 Used 114152329 CANCER 114152330 Diagnostics 114152331 therapeutics TAB-3391 114097279 Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces CDC Cardiology, Collaboration, Consumer Products, Dental, Endocrinology, Infectious Disease, Licensing, Neurology, Occupational Safety and Health, Oncology, Ophthalmology Cardiology Collaboration Consumer Products Dental Endocrinology Infectious Disease Licensing Neurology Occupational Safety and Health Oncology Ophthalmology Kevin Ashley, Mark Boeniger, Eric Esswein Exposure to lead (Pb) has long posed serious health risks. Ingestion of lead from skin exposure can adversely impact every organ in the body; the kidneys, blood, nervous, and reproductive systems are most affected. Washing skin with soap and water is not sufficient to remove lead residues. To prevent adverse impacts from Pb exposure, exposed individuals need cleaning methods that will effectively remove Pb ions from the skin to less than the limit of identification (i.e., 10 µg or less). <br /><br /> Centers for Disease Control and Prevention (CDC), National Institute for Occupational Safety and Health (NIOSH) researchers developed a method to remove metals such as lead from surfaces, including skin. This method includes applying a cationic surfactant (ISML (isostearamidopropyl morpholine lactate), a compound that lowers surface tension) and a weak acid (such as citric acid) to a surface and wiping the surface with a three-dimensionally textured absorbent support. The cationic surfactant and weak acid are in liquid form or are dissolved in a suitable solvent, such as water. This wetting agent can be applied directly to the surface and wiped away or can be contained within the absorbent support. Research has shown that this method does not damage or irritate the skin. <br/<br /> This technology can be used in conjunction with another CDC NIOSH invention, a handwipe disclosing method (HHS Reference No. E-336-2013) which uses colorimetric chemistry (a color change occurs) to detect lead sampled from surfaces. Combined, these two technologies can “close the loop” by both detecting and decontaminating skin or other surfaces contaminated with lead. <br /><br /> <ul> <li>Safe for use on skin</li> <li>Quick and easy to use</li> <li>Portable and convenient to use wherever lead is present</li> <li>Effectively removes Pb ions from the skin to less than the limit of identification</li> <li>Can be used to complement other lead detection methods</li> <li>Uses physical (wiping) and chemical means to decontaminate surfaces from lead and other metals mentioned above</li> </ul> <ul> <li>Cleansing the hands of workers who have occupational exposure to lead (e.g., auto repairers, battery manufacturers, pipe fitters, recyclers of metal and batteries, etc.) prior to eating, smoking, or leaving their work for the day</li> <li>Cleansing the hands of police, other law enforcement officers (e.g., immigration, customs, or Secret Service) or recreational firearms users after using firearms</li> <li>Cleansing the hands of lead abatement workers or those renovating old homes with lead-based paint</li> <li>Removing lead from any contaminated surface other than skin such as floors, walls, windowsills, clothing, laundry, shoes, equipment surfaces, and furniture surfaces that may pose an exposure risk</li> <li>Kit for detecting and removing lead from surfaces (when combined with the handwipe disclosing method to detect the presence of lead sampled from surfaces (HHS Reference No. E-336-2013))<li> <li>May be used to solubilize and remove a variety of metals such as cadmium, tin, barium, arsenic, chromium, copper, mercury, silver, zinc, strontium, thallium, germanium, or zirconium, or a combination thereof </li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborating to further commercialize Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-27 2026-05-14 2026-05-14 2020-02-13 CDC Docket Import, CDC Docket Import CDC Prosecuting, contamination, Listed LPM Surabian as of 4/15/2015, MECHANICAL, METAL, Methods, NIOSH-DSHEFS, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, REMOVAL, SURFACES, VEXXXX, VPXXXX, WGXXXX, WIPES, WMXXXX, XIXXXX, YFXXXX False True True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract E-336-2013-0 114172557 Esswein E., Boeniger M. (2005). Preventing the Toxic Hand-Off. Occupational Hazards, 67(9) https://www.researchgate.net/publication/311667267_Preventing_the_Toxic_Hand_Off <a href="https://www.researchgate.net/publication/311667267_Preventing_the_Toxic_Hand_Off ">Esswein E., Boeniger M. (2005). Preventing the Toxic Hand-Off. Occupational Hazards, 67(9)</a> 114172558 Esswein EJ, et al. http://dx.doi.org/10.1520/JAI103527 <a href="http://dx.doi.org/10.1520/JAI103527 ">Esswein EJ, et al.</a> 114172559 NIOSH. (2015). Combatting the Dangers of Heavy Metal Contamination: the CDC Can Lead the Way https://archive.cdc.gov/#/detailsq=combatting%20the%20dangers%20of%20heavy%20metal%20contamination:%20CDC%20can%20lead%20the%20way!&start=0&rows=10&url=https://www.cdc.gov/od/science/technology/techtransfer/successstories/leadwipes.htm <a href="https://archive.cdc.gov/#/detailsq=combatting%20the%20dangers%20of%20heavy%20metal%20contamination:%20CDC%20can%20lead%20the%20way!&start=0&rows=10&url=https://www.cdc.gov/od/science/technology/techtransfer/successstories/leadwipes.htm">NIOSH. (2015). Combatting the Dangers of Heavy Metal Contamination: the CDC Can Lead the Way</a> 114172560 NIOSH. (2018). Workplace Safety and Health Topics https://www.cdc.gov/niosh/topics/lead/default.html <a href="https://www.cdc.gov/niosh/topics/lead/default.html">NIOSH. (2018). Workplace Safety and Health Topics</a> 114110055 Boeniger, Mark CDC - NIOSH CDC Boeniger, Mark (CDC) 0 114110056 Ashley, Kevin CDC - NIOSH CDC Ashley, Kevin (CDC) 0 114110054 Esswein, Eric CDC - NIOSH CDC Esswein, Eric (CDC) 1 114110054 Esswein, Eric CDC - NIOSH CDC Esswein, Eric (CDC) 1 114110055 Boeniger, Mark CDC - NIOSH CDC Boeniger, Mark (CDC) 0 114110056 Ashley, Kevin CDC - NIOSH CDC Ashley, Kevin (CDC) 0 114102523 WIPES AND METHODS FOR REMOVAL OF METAL CONTAMINATION FROM SURFACES E-221-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3391] Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces&body=Please send me information about technology [TAB-3391] Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3391] Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces&body=Please send me information about technology [TAB-3391] Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces.">yogikala.prabhu@nih.gov</a><br> 114168962 E-221-2013-0 E-221-2013-0-US-01 WIPES AND METHODS FOR REMOVAL OF METAL CONTAMINATION FROM SURFACES ORD US 7,604,997 11/039,178 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7604997 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7604997">7,604,997</a><br />Filed on 2005-01-18<br />Status: Issued 114168963 E-221-2013-0 E-221-2013-0-PCT-02 WIPES AND METHODS FOR REMOVAL OF METAL CONTAMINATION FROM SURFACES PCT Patent Cooperation Treaty PCT/US2006/001515 Abandoned Patent Cooperation Treaty <br />(PCT) PCT/US2006/001515<br />Filed on 2006-01-17<br />Status: Abandoned 114128288 YFXXXX 114128289 VEXXXX 114128290 VPXXXX 114128291 WGXXXX 114128292 WMXXXX 114128293 XIXXXX 114151725 WIPES 114151726 Methods 114151727 REMOVAL 114151728 METAL 114151729 contamination 114151730 SURFACES 114151731 CDC Docket Import 114151732 CDC Docket Import CDC Prosecuting 114151733 NIOSH-DSHEFS 114151734 Listed LPM Surabian as of 4/15/2015 114151735 Pre LPM working set 20150418 114151736 Post LPM Assignment Set 20150420 114151737 MECHANICAL TAB-3392 114097280 Handwipe Disclosing Method for Detecting the Presence of Lead CDC Cardiology, Collaboration, Dental, Endocrinology, Infectious Disease, Licensing, Neurology, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials Cardiology Collaboration Dental Endocrinology Infectious Disease Licensing Neurology Occupational Safety and Health Oncology Ophthalmology Research Materials Kevin Ashley, Mark Boeniger, Eric Esswein Lead (Pb) exposure can cause serious health concerns including abdominal pain, headaches, loss of appetite, memory loss, weakness, and other symptoms. Lead residues on human skin, especially on the hands of workers can be a significant health risk since such residues may be ingested during normal activities (e.g. eating, drinking, and smoking). A key component to reducing lead exposure is being able to identify areas of lead contamination. <br /><br /> US Centers for Disease Control and Prevention (CDC), National Institute for Occupational Safety and Health (NIOSH) researchers developed a method to detect lead on surfaces, including skin, using a handwipe system and a chemical test to effect a color change if lead is present. A handwipe is used to collect any lead contamination on the surface. Then the lead is solubilized with an aqueous acid solution and treated with rhodizonate or sulfide anions. When lead is detected, the color changes from pink to red (when rhodizonate anions are used) or from brown to black (where sulfide anions are used). <br /><br /> This invention can be used to test surfaces including human skin, floors, walls, windowsills, etc. It can be used to inform employers and workers on potential lead contamination, as well as evaluate lead removal efforts. This technology can also be used in conjunction with another CDC NIOSH invention involving wipes and methods for removal of lead. Combined, these two technologies can “close the loop” by both detecting and decontaminating skin and other surfaces contaminated with lead. <br /><br /> <ul> <li>Safe for use on skin</li> <li>Quick and easy to use</li> -<li>Portable and can be used during field evaluations</li> <li>Can be used wherever lead is present</li> <li>Simple color change readout indicates the presence of lead on a surface</li> <li>Lead concentration can be inferred by degree of color shift</li> <li>Can be used to guide and evaluate lead removal methods</li> </ul> <ul> <li>Testing potentially contaminated surfaces such as skin, floors, walls, windowsills, etc., for lead</li> <li>Informing employers and workers on potential lead contamination and exposure</li> <li> Educating potentially exposed individuals about their lead exposure and effectiveness of lead removal methods</li> <li>Evaluating effectiveness of lead removal from surfaces in workplaces, homes, hospitals, and schools <li>Confirming hand/skin/shoe/clothing washing effectiveness of lead removal for military, law enforcement, and target range personnel</li> <li>Part of a kit for detecting and removing lead from a surface (when combined with CDC NIOSH’s wipes and methods for removing lead and other metal contamination from surfaces technology (HHS Reference Number E-221-2013-0))</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborating to further commercialize the Handwipe Disclosing Method for Detecting the Presence of Lead. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-27 2026-05-14 2026-05-14 2020-02-13 CDC Docket Import, CDC Docket Import CDC Prosecuting, Contaminant, Contaminated, contamination, DEFENSE, Detection, detection system, DEVICE, DISCLOSING, firearm, firearm safety, firearms, HANDWIPE, LEAD, lead test, Listed LPM Surabian as of 4/15/2015, MECHANICAL, Method, military, NIOSH, NIOSH-DSHEFS, Occupational health, OSHA, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PRESENCE, SAFETY, VEXXXX, VPXXXX, WCXXXX, WGXXXX, WHXXXX, WIPE, WIPES, WORKER, WORKER safety, YDXXXX, YEXXXX, YFXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-221-2013-0 114172561 Ashley K. (2010) Field-Portable Methods for Monitoring Occupational Exposures to Metals. Journal of Chemical Health and Safety, 17(3), 22-28. https://www.sciencedirect.com/science/article/pii/S1871553209000796 <a href="https://www.sciencedirect.com/science/article/pii/S1871553209000796">Ashley K. (2010) Field-Portable Methods for Monitoring Occupational Exposures to Metals. Journal of Chemical Health and Safety, 17(3), 22-28.</a> 114172562 Ashley K, et al. (2011). Evaluation of a handwipe disclosing method for lead. Journal of ATSM International, 8(4). https://www.astm.org/DIGITAL_LIBRARY/JOURNALS/JAI/PAGES/JAI103390.htm <a href="https://www.astm.org/DIGITAL_LIBRARY/JOURNALS/JAI/PAGES/JAI103390.htm ">Ashley K, et al. (2011). Evaluation of a handwipe disclosing method for lead. Journal of ATSM International, 8(4).</a> 114172563 Esswein E., & Boeniger M. (2005). Preventing the Toxic Hand-Off. Occupational Hazards, 67(9). https://www.researchgate.net/publication/311667267_Preventing_the_Toxic_Hand_Of <a href="https://www.researchgate.net/publication/311667267_Preventing_the_Toxic_Hand_Of">Esswein E., & Boeniger M. (2005). Preventing the Toxic Hand-Off. Occupational Hazards, 67(9).</a> 114172564 Esswein, EJ et al. Handwipe method for removing lead from skin. Journal of ATSM International, 8(5). https://www.researchgate.net/publication/239522749_Handwipe_method_for_removing_lead_from_skin <a href="https://www.researchgate.net/publication/239522749_Handwipe_method_for_removing_lead_from_skin">Esswein, EJ et al. Handwipe method for removing lead from skin. Journal of ATSM International, 8(5).</a> 114172565 NIOSH. (2015). Combatting the Dangers of Heavy Metal Contamination: the CDC Can Lead the Way! https://archive.cdc.gov/#/detailsq=combatting%20the%20dangers%20of%20heavy%20metal%20contamination:%20CDC%20can%20lead%20the%20way!&start=0&rows=10&url=https://www.cdc.gov/od/science/technology/techtransfer/successstories/leadwipes.htm <a href="https://archive.cdc.gov/#/detailsq=combatting%20the%20dangers%20of%20heavy%20metal%20contamination:%20CDC%20can%20lead%20the%20way!&start=0&rows=10&url=https://www.cdc.gov/od/science/technology/techtransfer/successstories/leadwipes.htm">NIOSH. (2015). Combatting the Dangers of Heavy Metal Contamination: the CDC Can Lead the Way!</a> 114172566 NIOSH. (2018). Workplace Safety and Health Topics: Lead. https://www.cdc.gov/niosh/topics/lead/default.html <a href="https://www.cdc.gov/niosh/topics/lead/default.html">NIOSH. (2018). Workplace Safety and Health Topics: Lead.</a> 114172567 NIOSH Manual of Analytical Methods (NMAM), Fourth Edition. Method 9105, Issue 1 - Lead in Dust Wipes by Chemical Spot Test Method (Colorimetric Screening Method), 15 March 2003. U.S. National Institute for Occupational Safety and Health (NIOSH), Cincinnati, OH. https://www.cdc.gov/niosh/docs/2003-154/pdfs/9105.pdf <a href="https://www.cdc.gov/niosh/docs/2003-154/pdfs/9105.pdf">NIOSH Manual of Analytical Methods (NMAM), Fourth Edition. Method 9105, Issue 1 - Lead in Dust Wipes by Chemical Spot Test Method (Colorimetric Screening Method), 15 March 2003. U.S. National Institute for Occupational Safety and Health (NIOSH), Cincinnati, OH.</a> 114110058 Boeniger, Mark CDC - NIOSH CDC Boeniger, Mark (CDC) 0 114110059 Ashley, Kevin CDC - NIOSH CDC Ashley, Kevin (CDC) 0 114110057 Esswein, Eric CDC - NIOSH CDC Esswein, Eric (CDC) 1 114110057 Esswein, Eric CDC - NIOSH CDC Esswein, Eric (CDC) 1 114110058 Boeniger, Mark CDC - NIOSH CDC Boeniger, Mark (CDC) 0 114110059 Ashley, Kevin CDC - NIOSH CDC Ashley, Kevin (CDC) 0 114102524 HANDWIPE DISCLOSING METHOD FOR THE PRESENCE OF LEAD E-336-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3392] Handwipe Disclosing Method for Detecting the Presence of Lead &body=Please send me information about technology [TAB-3392] Handwipe Disclosing Method for Detecting the Presence of Lead . Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3392] Handwipe Disclosing Method for Detecting the Presence of Lead &body=Please send me information about technology [TAB-3392] Handwipe Disclosing Method for Detecting the Presence of Lead .">yogikala.prabhu@nih.gov</a><br> 114168964 E-336-2013-0 E-336-2013-0-US-01 HANDWIPE DISCLOSING METHOD FOR THE PRESENCE OF LEAD PRV US 60/049,352 Abandoned US <br />Provisional (PRV) 60/049,352<br />Filed on 1997-06-11<br />Status: Abandoned 114168965 E-336-2013-0 E-336-2013-0-PCT-02 HANDWIPE DISCLOSING METHOD FOR THE PRESENCE OF LEAD PCT Patent Cooperation Treaty PCT/US1998/011776 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1998/011776<br />Filed on 1998-06-08<br />Status: Expired 114168966 E-336-2013-0 E-336-2013-0-US-06 HANDWIPE DISCLOSING METHOD FOR THE PRESENCE OF LEAD National Stage US 6,248,593 09/458,152 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6248593 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6248593">6,248,593</a><br />Filed on 1999-12-09<br />Status: Expired 114128308 YEXXXX 114128309 YFXXXX 114128310 VEXXXX 114128311 YDXXXX 114128312 VPXXXX 114128313 WCXXXX 114128314 WGXXXX 114128315 WHXXXX 114151738 HANDWIPE 114151739 DISCLOSING 114151740 Method 114151741 PRESENCE 114151742 LEAD 114151743 CDC Docket Import 114151744 CDC Docket Import CDC Prosecuting 114151745 NIOSH-DSHEFS 114151746 NIOSH 114151747 WIPE 114151748 WIPES 114151749 SAFETY 114151750 lead test 114151751 Detection 114151752 detection system 114151753 Contaminant 114151754 Contaminated 114151755 contamination 114151756 OSHA 114151757 WORKER 114151758 WORKER safety 114151759 Occupational health 114151760 firearm 114151761 firearms 114151762 firearm safety 114151763 DEFENSE 114151764 military 114151765 DEVICE 114151766 Listed LPM Surabian as of 4/15/2015 114151767 Pre LPM working set 20150418 114151768 Post LPM Assignment Set 20150420 114151769 MECHANICAL TAB-4924 153511466 Methods for near real-time aerosol chemical analysis for environmental and occupational monitoring CDC Diagnostics, Licensing, Occupational Safety and Health Diagnostics Licensing Occupational Safety and Health Pramod Kulkarni, Orthodoxia Zervaki <p>&shy;Exposures to hazardous airborne particles can pose a significant health risk to those routinely exposed in ambient air and industrial work environments. Measuring chemical composition and concentration of aerosol particles is important to preventing worker exposures and protecting health. Current, widely used methods to measure aerosol chemicals in the workplace involve particle collection on filters over several hours, followed by laboratory analysis which requires considerable time and resources, cannot capture transient exposures, and provide results several days after the exposure has occurred. </p> <p><br /> CDC National Institute for Occupational Safety and Health (NIOSH) researchers have developed new methods to collect and analyze aerosol particles from an air sample. These direct-reading methods allow aerosol chemical analysis with high selectivity in near real-time in a portable or hand-held instrument. The methods allow collection of aerosols at high flow rates, 5-15 times higher than those in current commercial instruments, and involves concentration of the aerosol as a spot sample, followed by chemical analysis using laser spectroscopy techniques such as reflectance, Raman, absorption, fluorescence, and also through pulsed spark emission spectroscopy. The methods can be extended to detection of bioaerosols. The technology allows development of wearable, portable, or handheld instruments for continuous automated quantification of particulate chemical concentrations and bioaerosol analysis for environmental and occupational air quality monitoring applications. </p> <ul> <li>Near real-time and continuous automatic measurement of aerosol and bioaerosol</li> <li> Tandem spectroscopy: allows simultaneous elemental (i.e., atomic emission spectroscopy) and molecular (e.g., Raman and near infrared spectroscopy) analysis of aerosol samples with high selectivity</li> <li> High sample throughput collection </li> <li>- Allows space-saving and miniature designs for easy integration into portable instruments</li> <li> Eliminates the need for carrying heavy equipment in the field or waiting for laboratory analysis results</li> </ul> <ul> <li> Collecting and analyzing aerosol particles for the prevention and testing of hazardous exposures</li> <li> Air pollution studies and particulate matter monitoring</li> <li> Environmental and occupational personal exposure monitoring</li> <li> Evaluation of engineering controls</li> <li> Occupational safety and health</li> <li>Monitoring/public health surveillance</li> </ul> The CDC Technology Transfer Office is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact CDC Technology Transfer Office at tto@cdc.gov or 404-639-1330. 2024-03-04 2026-05-14 2026-05-14 2024-03-06 Biodefense, ENVIRONMENTAL, MINING, MONITORING, Occupational health, QUALITY CONTROL, RESEARCH TOOL False False Early-stage In situ data available True 52406769 Prototype 52406769 37470483 Website Abstract E-291-2016-0 E-205-2013-0 E-163-2013-0 E-026-2014-0 E-146-2013-0 153512476 Zheng, L. et al. (DOI 10.1080/02786826.2016.1224804) Zheng, L. et al. (DOI 10.1080/02786826.2016.1224804) 153512484 Zheng, L. et al. (DOI 10.1016/j.jaerosci.2016.11.007) Zheng, L. et al. (DOI 10.1016/j.jaerosci.2016.11.007) 153512732 Zheng, L. et al. (DOI 10.1021/acs.analchem.9b02178) Zheng, L. et al. (DOI 10.1021/acs.analchem.9b02178) 153512740 Zervaki, O., et al. (DOI 10.1016/j.jaerosci.2023.106235) Zervaki, O., et al. (DOI 10.1016/j.jaerosci.2023.106235) 153511651 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 153511674 Zervaki, Orthodoxia CDC - NIOSH CDC Zervaki, Orthodoxia (CDC) 2 153511651 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 153511674 Zervaki, Orthodoxia CDC - NIOSH CDC Zervaki, Orthodoxia (CDC) 2 153511469 Methods For High Sample Throughput Collection And Trace Chemical Analysis Of Aerosols Using Laser And Optical Spectroscopies E-173-2021-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4924] Methods for near real-time aerosol chemical analysis for environmental and occupational monitoring&body=Please send me information about technology [TAB-4924] Methods for near real-time aerosol chemical analysis for environmental and occupational monitoring. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4924] Methods for near real-time aerosol chemical analysis for environmental and occupational monitoring&body=Please send me information about technology [TAB-4924] Methods for near real-time aerosol chemical analysis for environmental and occupational monitoring.">yogikala.prabhu@nih.gov</a><br> 155749516 E-173-2021-0 E-173-2021-0-JP-01 METHODS AND DEVICES FOR COLLECTING AND ANALYZING AEROSOL PARTICLES National Stage Japan 2024-544936 Pending Japan <br />National Stage 2024-544936<br />Filed on 2024-07-29<br />Status: Pending 155749555 E-173-2021-0 E-173-2021-0-US-02 METHODS AND DEVICES FOR COLLECTING AND ANALYZING AEROSOL PARTICLES National Stage US 18/832,139 Pending US <br />National Stage 18/832,139<br />Filed on 2024-07-23<br />Status: Pending 153542682 Biodefense 153542729 ENVIRONMENTAL 153542755 MINING 153542805 MONITORING 153542866 Occupational health 153542900 QUALITY CONTROL 153542943 RESEARCH TOOL TAB-3151 114097101 Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs CDC Cardiology, Collaboration, Consumer Products, Dental, Endocrinology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology, Research Equipment, Research Materials, Therapeutics Cardiology Collaboration Consumer Products Dental Endocrinology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Research Equipment Research Materials Therapeutics Shirley Robertson, Deborah Sammons, Jerome Smith Anti-neoplastic drugs, also known as anti-cancer drugs or chemotherapy, are used in the treatment of many types of cancer. However, these drugs are harmful to healthy cells as well as the cancerous cells. Exposure of healthcare workers to anti-neoplastic drugs from contaminated surfaces and drug vials in hospitals and pharmacies is a continuing problem as the drugs can cause both acute and long-term effects. Although there are sensitive techniques to evaluate contamination, results from these tests take time and must be performed in a laboratory. CDC researchers developed a real-time detection kit that can be used in the workplace to test for anti-neoplastic drug contamination. The direct reading anti-neoplastic drug detector based on lateral flow immunoassay (LFIA) technology has been developed for the assessment of drug residues on surfaces. These detectors are incorporated into kits that allow workers to sample surfaces to assess drug contamination in near real-time. Detection kits for three anti-neoplastic drugs (5-Fluorouracil, Paclitaxel, and Doxorubicin) have been developed and kits for several other anti-neoplastic agents may be possible based on this technology. <ul> <li>Near real-time results</li> <li>Can be used in various locations, on surfaces, and on protective equipment</li> <li>Simple to use</li> <li>Final kit configuration to incorporate laboratory and field studies for maximum benefit to healthcare workers</li> </ul> <ul> <li>Environmental sampling / detection kit for surface contamination by anti-neoplastic (anti-cancer) drugs in hospitals and pharmacies</li> <li>Kits can be used to assess decontamination procedures</li> <li>Kits can be used to assess protective equipment and closed system drug-transfer devices</li> <li>Kits can aid in the development of work practices to lower healthcare worker exposure to anti-neoplastic drugs from contaminated surfaces</li> </ul> The CDC/NIOSH is seeking statements of capability or interest from parties interested in collaborative reasearch to further develop, evaluate, or commercialize Detection Kits for Surface Contamination by Anti-Neoplastic Drugs. For collaboration opportunities, please contact Kathleen Goedel at <a href="mailto:keg2@cdc.gov">keg2@cdc.gov</a> or 1-513-533-8686. Foreign counterpart patent applications in Europe and Japan. 2022-03-27 2026-05-14 2026-05-14 2017-08-24 AE1BXX, AE2XXX, AE3XXX, Anti-neoplastic, CANCER, CANCER CHEMOTHERAPY, CANCEROUS, CB5XXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, CDXXXX, Contaminant, Contaminants, Contaminated, contamination, CXXXXX, Detection, detection system, Direct, DRUGS, Kits, Listed LPM Surabian as of 4/15/2015, NIOSH, NIOSH-DART, Occupational health, OSHA, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Reading, SAFE, SAFETY, Surface, TOXIC, Toxicity, TOXIGENIC, TOXINS, VCXXXX, VPXXXX, WCXXXX, WFXXXX, WGXXXX, WIXXXX, WMXXXX, WORKER, WORKER safety, XHXXXX, XIXXXX, YBXXXX, YEXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171896 Smith JP http://www.ncbi.nlm.nih.gov/pubmed/25293722 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25293722">Smith JP</a> 114172342 Smith JP http://www.ncbi.nlm.nih.gov/pubmed/25379615 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25379615">Smith JP</a> 114172343 Smith JP http://www.ncbi.nlm.nih.gov/pubmed/25956418 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25956418">Smith JP</a> 114109302 Sammons, Deborah CDC Sammons, Deborah (CDC) 0 114109304 Robertson, Shirley CDC Robertson, Shirley (CDC) 0 114109303 Smith, Jerome CDC - NIOSH CDC Smith, Jerome (CDC) 1 114109303 Smith, Jerome CDC - NIOSH CDC Smith, Jerome (CDC) 1 114109302 Sammons, Deborah CDC Sammons, Deborah (CDC) 0 114109304 Robertson, Shirley CDC Robertson, Shirley (CDC) 0 114102303 Direct Reading Detection Kits For Surface Contamination By Anti-Neoplastic Drugs E-162-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3151] Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs&body=Please send me information about technology [TAB-3151] Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3151] Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs&body=Please send me information about technology [TAB-3151] Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs.">yogikala.prabhu@nih.gov</a><br> 114168338 E-162-2013-0 E-162-2013-0-US-01 Direct Reading Detection Kits For Surface Contamination By Anti-Neoplastic Drugs PRV US 61/672,059 Abandoned US <br />Provisional (PRV) 61/672,059<br />Filed on 2012-07-16<br />Status: Abandoned 114168339 E-162-2013-0 E-162-2013-0-PCT-02 Direct Reading Detection Kits For Surface Contamination By Anti-Neoplastic Drugs PCT Patent Cooperation Treaty PCT/US2013/050688 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/050688<br />Filed on 2013-07-16<br />Status: Expired 114168340 E-162-2013-0 E-162-2013-0-US-03 Direct Reading Detection Kits For Surface Contamination By Anti-Neoplastic Drugs ORD US 10,782,308 13/943,430 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10782308 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10782308">10,782,308</a><br />Filed on 2013-07-16<br />Status: Issued 114127316 AE3XXX 114127317 CDXXXX 114127318 CXXXXX 114127319 AE1BXX 114127320 AE2XXX 114127321 CB5XXX 114127322 VCXXXX 114127323 VPXXXX 114127324 WCXXXX 114127325 WFXXXX 114127326 WGXXXX 114127327 WIXXXX 114127328 WMXXXX 114127329 XIXXXX 114127330 XHXXXX 114127331 YEXXXX 114127332 YBXXXX 114149251 Direct 114149252 Surface 114149253 Detection 114149254 Reading 114149255 Kits 114149256 contamination 114149257 Anti-neoplastic 114149258 DRUGS 114149259 CDC Docket Import 114149260 CDC Docket Import CDC Prosecuting 114149261 NIOSH-DART 114149262 CANCER 114149263 CANCER CHEMOTHERAPY 114149264 CANCEROUS 114149265 NIOSH 114149266 Contaminants 114149267 Contaminated 114149268 Contaminant 114149269 detection system 114149270 OSHA 114149271 TOXIC 114149272 Toxicity 114149273 TOXINS 114149274 TOXIGENIC 114149275 SAFETY 114149276 SAFE 114149277 Occupational health 114149278 WORKER 114149279 WORKER safety 114149280 Listed LPM Surabian as of 4/15/2015 114149281 Pre LPM working set 20150418 114149282 Post LPM Assignment Set 20150420 TAB-3250 114097184 Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring CDC Cardiology, Collaboration, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Therapeutics, Vaccines Cardiology Collaboration Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Research Materials Therapeutics Vaccines Pramod Kulkarni, Lina Zheng Airborne particles can have great impact on air quality, weather, and human health. In particular, long-term inhalation of toxic particulate matter in workplaces could pose a significant health risk. NIOSH scientists have developed a new, low-cost approach based on application of atmospheric radio frequency glow discharge (rf-GD) optical emission spectroscopy for near real-time measurement of elemental concentration in aerosols. The method involves collection of aerosol particles on an electrode tip in a coaxial microelectrode system, followed by excitation of the particles using rf-GD. NIOSH scientists identified far less expensive excitation sources for the rf-GD than traditional spark and laser-based excitation sources. Additionally, these excitation sources are compact and can be miniaturized for development of sensors for personal air sampling. The scientists developed a laboratory instrument, calibrated it for various elements including carbon, cadmium, manganese, and sodium, and established analytical detection limits for these elements. They demonstrated that these limits are well below most occupational exposure limits, allowing sensitive near real-time detection. This technology provides an excellent resource for air quality monitoring and the development of low-cost, hand-held sensors for aerosol measurement. <ul> <li>Currently, there are no real-time hand-held instruments (commercial or otherwise) for measuring elemental concentration of airborne particles (metals and nonmetals) in environmental and occupational settings</li> <li>Enables elemental analysis of aerosols in near real-time</li> <li>Uses low-cost and miniature-sized (approximately 3 x 1 x .05 inch) excitation sources</li> </ul> <ul> <li>Air pollution studies and particulate matter monitoring</li> <li>Environmental and occupational personal exposure monitoring</li> <li> Evaluation of engineering controls</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring. For collaboration opportunities, please contact CDC TTO at <a href="mailto: tto@cdc.gov">tto@cdc.gov</a>. 2022-03-27 2026-05-14 2026-05-14 2018-02-13 AEROSOLS, analysis, Atmospheric, DART, Discharge, Elemental, Emission, Glow, NIOSH-DART, SPECTROSCOPY, VBXXXX, VPXXXX, WAXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, XGXXXX, XIXXXX, YAXXXX, YFXXXX False True True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract E-205-2013-0 E-163-2013-0 114172457 Zheng L, et al. https://www.ncbi.nlm.nih.gov/pubmed/28513144 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28513144">Zheng L, et al.</a> 114109633 Zheng, Lina CDC - NIOSH CDC Zheng, Lina (CDC) 0 114109632 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114109632 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114109633 Zheng, Lina CDC - NIOSH CDC Zheng, Lina (CDC) 0 114102410 Elemental Analysis Of Aerosols Using Atmospheric Glow Discharge Emission Spectroscopy E-291-2016-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3250] Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring&body=Please send me information about technology [TAB-3250] Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3250] Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring&body=Please send me information about technology [TAB-3250] Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring.">yogikala.prabhu@nih.gov</a><br> 114168555 E-291-2016-0 E-291-2016-0-US-01 Elemental Analysis of Aerosols Using Atmospheric Glow Discharge Emission Spectroscopy PRV US 62/484,300 Abandoned US <br />Provisional (PRV) 62/484,300<br />Filed on 2017-04-11<br />Status: Abandoned 114168599 E-291-2016-0 E-291-2016-0-PCT-02 SYSTEMS AND METHODS FOR RAPID ELEMENTAL ANALYSIS OF AIRBORNE PARTICLES USING ATMOSPHERIC GLOW DISCHARGE OPTICAL EMISSION SPECTROSCOPY PCT Patent Cooperation Treaty PCT/US2018/027105 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/027105<br />Filed on 2018-04-11<br />Status: Expired 114168923 E-291-2016-0 E-291-2016-0-US-05 SYSTEMS AND METHODS FOR RAPID ELEMENTAL ANALYSIS OF AIRBORNE PARTICLES USING ATMOSPHERIC GLOW DISCHARGE OPTICAL EMISSION SPECTROSCOPY National Stage US 16/500,925 Abandoned US <br />National Stage 16/500,925<br />Filed on 2019-10-04<br />Status: Abandoned 114127769 YAXXXX 114127770 YFXXXX 114127771 VBXXXX 114127772 VPXXXX 114127773 WAXXXX 114127774 WCXXXX 114127775 WEXXXX 114127776 WFXXXX 114127777 WGXXXX 114127778 XGXXXX 114127779 XIXXXX 114150447 Elemental 114150448 analysis 114150449 AEROSOLS 114150450 Atmospheric 114150451 Glow 114150452 Discharge 114150453 Emission 114150454 SPECTROSCOPY 114150455 DART 114150456 NIOSH-DART TAB-3272 114097205 Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters CDC Cardiology, Collaboration, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Materials Available, Occupational Safety and Health, Oncology, Ophthalmology, Therapeutics, Vaccines Cardiology Collaboration Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Materials Available Occupational Safety and Health Oncology Ophthalmology Therapeutics Vaccines Gerry Boss, Nicole Fry, Lee Greenawald, Michael Sailor A respirator protects the wearer from inhaling dangerous substances, such as chemicals and infectious particles. CDC developed devices and methods to detect and remove chemicals such as hydrogen cyanide, cyanogen, hydrogen sulfide, nitrite, and nitric oxide from the air for those wearing respirators. Cobinamide (a Vitamin B12 analog with a high affinity to cyanide) molecules are immobilized within a silica matrix that allows for the infiltration and containment of gaseous chemicals. Since the chemical(s) bind to the cobinamide, such material is embedded into respirator canisters to help facilitate the removal of toxic molecules from the air.<br /><br /> The chemical(s) binding to the cobinamide also result in a color change that can be analyzed qualitatively or quantitatively. The cobinamide-loaded silica matrix can be incorporated into a respirator canister (such as a canister designed to protect workers against chemical, biological, radiological and nuclear weapons (CBRN)) to act as an end-of-service-life indicator (ESLI) alerting when to change equipment. Different absorbance of the cobinamide/silica composite within the respirator canister can be monitored, and the device can be configured to trigger a visual and/or audible alarm once a particular concentration of the chemical(s) meets a certain threshold, indicating that the canister needs to be replaced. Current ESLI technology only depends on the user to monitor a color change via a colorimetric indicator, viewed through a clear box on the outside of the gas mask canister. This is an issue for color-blind persons, those in low-light settings, and users if they are preoccupied and unable to continuously monitor the indicator. The CDC/NIOSH technology can be configured for both a visual and/or audible alarm. <ul> <li>Technology senses and removes particles</li> <li>Ability to monitor several ligands (molecules that bind with others) at once<li> <li>An "active" vs. "passive" ESLI that will alert user to thresholds of CBRN agents important for replacing respirator canisters</li> <li>To the inventor’s knowledge, there is no known commercially-available ESLI for hydrogen cyanide gas, a significant risk with fires and chemical explosions</li> <li> Not based on electrochemical technology</li> <li>Apparatus is added to gas canisters</li> <li>Light weight and inexpensive</li> <li> Uses a light source and mini spectrometer</li> <li>Uses color and/or audible detection</li> </ul> <ul> <li>Detection and removal of chemical, biological, radiological, and nuclear (CBRN) agents for military and emergency response workers such as police, EMTs and fire fighters</li> <li> Detection of nitric oxide for miners exposed from the use of explosives for blasting and diesel engine emissions</li> <li>Occupational safety for manufacturing, agriculture, chemicals/pesticides, construction, roofing, painting, etc.</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica- based Materials for Respirator Canisters. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a>or 1-404-639-1330. 2022-03-27 2026-05-14 2026-05-14 2018-06-06 Based, Canisters, Cobinamide, ENCAPSULATED, GAS, Listed LPM Surabian as of 4/15/2015, MATERIALS, NIOSH-NPPTL, NPPTL, optical, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, REMOVAL, Respirator, Sensing, SILICA, TOXIC, VBXXXX, VPXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WMXXXX, YBXXXX, YFXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172490 Greenawald LA, et al. https://www.ncbi.nlm.nih.gov/pubmed/26213448. <a href="https://www.ncbi.nlm.nih.gov/pubmed/26213448.">Greenawald LA, et al.</a> 114109705 Boss, Gerry University of California, San Diego Boss, Gerry 0 114109706 Fry, Nicole University of California, San Diego Fry, Nicole 0 114109707 Sailor, Michael University of California, San Diego Sailor, Michael 0 114109704 Greenawald, Lee CDC - NIOSH CDC Greenawald, Lee (CDC) 1 114109704 Greenawald, Lee CDC - NIOSH CDC Greenawald, Lee (CDC) 1 114109705 Boss, Gerry University of California, San Diego Boss, Gerry 0 114109706 Fry, Nicole University of California, San Diego Fry, Nicole 0 114109707 Sailor, Michael University of California, San Diego Sailor, Michael 0 114102434 Cobinamide Encapsulated Silica Based Materials For Optical Sensing And Toxic Gas Removal In Respirator Canisters E-144-2015-0 Closed Centers for Disease Control and Prevention (CDC), University of California, San Diego 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3272] Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters&body=Please send me information about technology [TAB-3272] Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3272] Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters&body=Please send me information about technology [TAB-3272] Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters.">yogikala.prabhu@nih.gov</a><br> 114168626 E-144-2015-0 E-144-2015-0-US-01 Cobinamide Encapsulated Silica Based Materials For Optical Sensing And Toxic Gas Removal In Respirator Canisters PRV US 62/016,565 Abandoned US <br />Provisional (PRV) 62/016,565<br />Filed on 2014-06-24<br />Status: Abandoned 114168627 E-144-2015-0 E-144-2015-0-US-02 Cobinamide-Based Materials For Optical Sensing And Gas Removal ORD US 14/748,163 Abandoned US <br />Ordinary Patent (ORD) 14/748,163<br />Filed on 2015-06-23<br />Status: Abandoned 114127898 YBXXXX 114127899 YFXXXX 114127900 VBXXXX 114127901 VPXXXX 114127902 WCXXXX 114127903 WEXXXX 114127904 WFXXXX 114127905 WGXXXX 114127906 WMXXXX 114150727 NIOSH-NPPTL 114150728 Cobinamide 114150729 ENCAPSULATED 114150730 SILICA 114150731 Based 114150732 MATERIALS 114150733 optical 114150734 Sensing 114150735 TOXIC 114150736 GAS 114150737 REMOVAL 114150738 Respirator 114150739 Canisters 114150740 NPPTL 114150741 Listed LPM Surabian as of 4/15/2015 114150742 Pre LPM working set 20150418 114150743 Post LPM Assignment Set 20150420 TAB-3304 114097228 Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls CDC Cardiology, Collaboration, Consumer Products, Dental, Endocrinology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology Cardiology Collaboration Consumer Products Dental Endocrinology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Thomas Bobick, Douglas Cantis, Herbert Edgell, Eugene McKenzie Falls are the leading cause of death in construction. In 2016, there were 370 fatal falls out of 991 construction fatalities (Bureau of Labor Statistics, Census of Fatal Occupational Injuries data). These deaths are preventable. According to the Occupational Safety and Health Administration, employers must set up the workplace to prevent employees from falling from overhead platforms, elevated work stations, or into holes in the floor and walls. For a roofing job, employers should consider all potential fall hazards, such as holes, skylights, and leading edges, then plan and select fall protection suitable for the proposed work. <br /><br /> CDC's National Institute for Occupational Safety and Health (NIOSH) inventors developed a protective barricade system to prevent workers from accidentally falling through holes in roofs/floors, from the edges of stairwells, balconies, or pitched roofs. The barricade system comprises several barricade brackets that are spaced apart and can be temporarily fastened to the underlying surface. Using the adjustable safety rail and roof bracket assembly creates a protective guardrail system that can be easily installed along roof edges and around openings or skylights on roofs with slopes ranging from 18 degrees (4:12) to 63 degrees (24:12). The durable construction of the assembly provides a secure walking/working surface for workers while working on steep roof surfaces. This design also includes an adjustable plank adapter, which permits the use of wider planks, resulting in an increase of up to 20% in the foot-bearing surface area, thus providing more worker stability. <ul> <li>A portable, easily-installed guardrail system to protect workers from falling into holes of roofs and floors during all construction</li> <li> Easily deployable around skylight fixtures to guard workers from inadvertently stepping onto or sitting down onto the skylight lens and falling through</li> <li>Roof bracket can provide worker support when moving up-slope while installing roofing shingles</li> <li>Safety rail and roof bracket assembly can be used together as edge guarding for both low- and steep-slope roofs to prevent workers from falling or sliding off</li> </ul> <ul> <li>May be used widely throughout the residential and commercial construction building industry</li> <li>May be used to safeguard roof workers</li> <li>May be useful to do-it-yourself (DIY) home improvers</li> </ul> The CDC National Institute for Occupational Safety and Health (NIOSH) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-27 2026-05-14 2026-05-14 2018-07-05 BARRICADE, BRACKET, CDC Docket Import, CDC Docket Import CDC Prosecuting, Constructing, Construction, Listed LPM Surabian as of 4/15/2015, NIOSH, NIOSH-DSR, Occupational health, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SAFETY, System, THEREIN, VPXXXX, WGXXXX, WMXXXX, WORKER, WORKER safety, XIXXXX, YFXXXX False True True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract E-141-2013-0 114172509 Bobick-TG, et al. https://www2a.cdc.gov/nioshtic-2/BuildQyr.asp?s1=20030149&f1=%2A&Startyear=&Adv=0&terms=1&EndYear=&Limit=10000&sort=&D1=10&PageNo=1&RecNo=1&View=f& <a href="https://www2a.cdc.gov/nioshtic-2/BuildQyr.asp?s1=20030149&f1=%2A&Startyear=&Adv=0&terms=1&EndYear=&Limit=10000&sort=&D1=10&PageNo=1&RecNo=1&View=f&">Bobick-TG, et al.</a> 114172510 Bobick T, et al. https://www2a.cdc.gov/nioshtic-2/BuildQyr.asp?s1=20033870&f1=%2A&Startyear=&Adv=0&terms=1&D1=10&EndYear=&Limit=10000&sort=&PageNo=1&RecNo=1&View=f& <a href="https://www2a.cdc.gov/nioshtic-2/BuildQyr.asp?s1=20033870&f1=%2A&Startyear=&Adv=0&terms=1&D1=10&EndYear=&Limit=10000&sort=&PageNo=1&RecNo=1&View=f&">Bobick T, et al.</a> 114172511 Bobick-TG, et al. https://www2a.cdc.gov/nioshtic-2/BuildQyr.asp?s1=20039599&f1=%2A&Startyear=&Adv=0&terms=1&D1=10&EndYear=&Limit=10000&sort=&PageNo=1&RecNo=1&View=f& <a href="https://www2a.cdc.gov/nioshtic-2/BuildQyr.asp?s1=20039599&f1=%2A&Startyear=&Adv=0&terms=1&D1=10&EndYear=&Limit=10000&sort=&PageNo=1&RecNo=1&View=f&">Bobick-TG, et al.</a> 114172512 Bobick-TG, el al. https://www2a.cdc.gov/nioshtic-2/BuildQyr.asp?s1=20046510&f1=%2A&Startyear=&Adv=0&terms=1&D1=10&EndYear=&Limit=10000&sort=&PageNo=1&RecNo=1&View=f& <a href="https://www2a.cdc.gov/nioshtic-2/BuildQyr.asp?s1=20046510&f1=%2A&Startyear=&Adv=0&terms=1&D1=10&EndYear=&Limit=10000&sort=&PageNo=1&RecNo=1&View=f&">Bobick-TG, el al.</a> 114109785 McKenzie, Eugene CDC - NIOSH CDC McKenzie, Eugene (CDC) 0 114109786 Bobick, Thomas CDC - NIOSH CDC Bobick, Thomas (CDC) 0 114109787 Edgell, Herbert CDC - NIOSH CDC Edgell, Herbert (CDC) 0 114109784 Cantis, Douglas CDC - NIOSH CDC Cantis, Douglas (CDC) 1 114109784 Cantis, Douglas CDC - NIOSH CDC Cantis, Douglas (CDC) 1 114109785 McKenzie, Eugene CDC - NIOSH CDC McKenzie, Eugene (CDC) 0 114109786 Bobick, Thomas CDC - NIOSH CDC Bobick, Thomas (CDC) 0 114109787 Edgell, Herbert CDC - NIOSH CDC Edgell, Herbert (CDC) 0 114102464 BARRICADE SYSTEM AND BARRICADE BRACKET FOR USE THEREIN E-450-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3304] Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls&body=Please send me information about technology [TAB-3304] Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3304] Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls&body=Please send me information about technology [TAB-3304] Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls.">yogikala.prabhu@nih.gov</a><br> 114168679 E-450-2013-0 E-450-2013-0-US-01 BARRICADE SYSTEM AND BARRICADE BRACKET FOR USE THEREIN ORD US 7,509,702 11/257,472 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7509702 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7509702">7,509,702</a><br />Filed on 2005-10-24<br />Status: Issued 114128019 YFXXXX 114128020 VPXXXX 114128021 WGXXXX 114128022 WMXXXX 114128023 XIXXXX 114151125 BARRICADE 114151126 System 114151127 BRACKET 114151128 THEREIN 114151129 CDC Docket Import 114151130 CDC Docket Import CDC Prosecuting 114151131 NIOSH-DSR 114151132 NIOSH 114151133 SAFETY 114151134 WORKER 114151135 WORKER safety 114151136 Occupational health 114151137 Construction 114151138 Constructing 114151139 Listed LPM Surabian as of 4/15/2015 114151140 Pre LPM working set 20150418 114151141 Post LPM Assignment Set 20150420 TAB-2825 114097004 Hearing Safety Devices: System for Monitoring Exposure to Impulse Noise CDC Cardiology, Computational models/software, Consumer Products, Dental, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Software / Apps Cardiology Computational models/software Consumer Products Dental Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Materials Software / Apps Chucri Kardous This CDC-developed technology entails a system for monitoring and assessing the risk of auditory damage from exposure to impulse noise, such as noise created by construction machinery and firearms. Noise dosimeters have been used extensively over the past two decades to document personal exposure to noise and assure workplaces comply with permissible noise exposure levels. However, due to older methods of calculating "noise dose," current noise dosimeters often inaccurately determine the risk of an impulse event. Further, current state-of-the-art noise dosimeters have a sound pressure level (SPL) dynamic measurement range of about 80-146 dB, which is adequate for some impact noise environments, but cannot accurately measure impulse noise levels above 146 dB. When a dosimeter is used to measure a noise level greater than its dynamic range, the dosimeter “clips” the noise level at the upper end of its measurement range, resulting in errant assessments of noise exposure.<br /><br /> The system described by this technology can be used to measure exposure to impulse noise and replace older, "clipped-range" dosimeters. Additionally, this new technology will improve the collection of empirical data for establishing association of noise levels with hearing loss. <ul> <li>This technology will accurately quantify noise dose and measure impulse noise and avoid "clipping" artifacts associated with currently available noise dosimeters.</li> </ul> <ul> <li>Assessment of potentially hazardous levels of impulse noise</li> <li>Use by law enforcement officers, DOD infantry, armor and artillery personnel, and workers in the construction trades</li> <li>Improving collection of empirical data to gauge risk and establish links to possible causes of hearing loss</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-05-27 AA5XXX, AAXXXX, AC1XXX, AC2XXX, ADXXXX, AE1BXX, AE1XXX, AE2BXX, AE2XXX, AE3XXX, AEXXXX, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, Exposure, firearm, firearm safety, IMPULSE, MONITORING, NIOSH, NIOSH-DART, NOISE, Occupational health, SAFETY, Sampling, System, VPXXXX, WCXXXX, WFXXXX, WGXXXX, WIXXXX, WMXXXX, XDXXXX, XIXXXX, XJXXXX, YEXXXX False True In situ data available (on-site) True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172150 Kardous CA, et al. http://www.ncbi.nlm.nih.gov/pubmed/12851012 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12851012">Kardous CA, et al.</a> 114172151 Kardous CA, et al. http://www.ncbi.nlm.nih.gov/pubmed/15238316 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15238316">Kardous CA, et al.</a> 114172152 Kardous, CA, "Development and validation testing of an impulse noise meter," U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, In-Depth Survey Report EPHB-349-11a, September 2013. http://www.cdc.gov/niosh/surveyreports/pdfs/349-11a.pdf <a href="http://www.cdc.gov/niosh/surveyreports/pdfs/349-11a.pdf">Kardous, CA, "Development and validation testing of an impulse noise meter," U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, In-Depth Survey Report EPHB-349-11a, September 2013.</a> 114172153 Kardous CA, et al. Noise dosimeter for monitoring exposure to impulse noise. Appl Acoust. 2005 Aug;66(8):974-85. http://dx.doi.org/10.1016/j.apacoust.2004.11.007 <a href="http://dx.doi.org/10.1016/j.apacoust.2004.11.007">Kardous CA, et al. Noise dosimeter for monitoring exposure to impulse noise. Appl Acoust. 2005 Aug;66(8):974-85.</a> 114108736 Kardous, Chucri CDC - NIOSH CDC Kardous, Chucri (CDC) 1 114108736 Kardous, Chucri CDC - NIOSH CDC Kardous, Chucri (CDC) 1 114102162 System For Monitoring Exposure To Impulse Noise E-225-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2825] Hearing Safety Devices: System for Monitoring Exposure to Impulse Noise&body=Please send me information about technology [TAB-2825] Hearing Safety Devices: System for Monitoring Exposure to Impulse Noise. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2825] Hearing Safety Devices: System for Monitoring Exposure to Impulse Noise&body=Please send me information about technology [TAB-2825] Hearing Safety Devices: System for Monitoring Exposure to Impulse Noise.">yogikala.prabhu@nih.gov</a><br> 114167812 E-225-2013-0 E-225-2013-0-US-01 System For Monitoring Exposure To Impulse Noise PRV US 60/487,449 Abandoned US <br />Provisional (PRV) 60/487,449<br />Filed on 2003-07-14<br />Status: Abandoned 114167813 E-225-2013-0 E-225-2013-0-PCT-02 System For Monitoring Exposure To Impulse Noise PCT Patent Cooperation Treaty PCT/US2004/022499 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2004/022499<br />Filed on 2004-07-13<br />Status: Expired 114167814 E-225-2013-0 E-225-2013-0-US-03 System For Monitoring Exposure To Impulse Noise National Stage US 7,401,519 10/564,860 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7401519 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7401519">7,401,519</a><br />Filed on 2006-01-11<br />Status: Expired 114126187 AXXXXX 114126188 AAXXXX 114126189 AA5XXX 114126190 AC2XXX 114126191 AC1XXX 114126192 ADXXXX 114126193 AEXXXX 114126194 AE1XXX 114126195 AE2XXX 114126196 AE3XXX 114126197 AE2BXX 114126198 AE1BXX 114126199 VPXXXX 114126200 WCXXXX 114126201 WFXXXX 114126202 WGXXXX 114126203 WIXXXX 114126204 WMXXXX 114126205 XDXXXX 114126206 XIXXXX 114126207 XJXXXX 114126208 YEXXXX 114147425 System 114147426 MONITORING 114147427 Exposure 114147428 IMPULSE 114147429 NOISE 114147430 CDC Docket Import 114147431 CDC Docket Import CDC Prosecuting 114147432 NIOSH-DART 114147433 NIOSH 114147434 Occupational health 114147435 SAFETY 114147436 Sampling 114147437 firearm 114147438 firearm safety TAB-2826 114097005 Occupational Safety: Portable Exposure Assessment System for Prevention of Musculoskeletal Injury CDC Cardiology, Computational models/software, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Neurology, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Equipment, Research Materials, Software / Apps Cardiology Computational models/software Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Neurology Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Equipment Research Materials Software / Apps Christopher Pan, Bryan Wimer, Shengke Zeng CDC researchers have developed the Portable Exposure Assessment System (PEAS), a field-based, remotely deployed tool to monitor and provide early warning of working conditions that have a high likelihood of musculoskeletal injury. PEAS is a noninvasive, real-time, instrument-based system. Sensor technology simultaneously measures and collects data regarding the body loads and awkward postures imposed by package handling as well as driving-related, low-frequency vibrations. Wireless technology establishes communication links between the sensors and a data logger and between the data logger and a smart phone with positioning and text messaging capabilities. The data logger records the body weight, posture, and vibration data over time and transfers the data to a databank for archiving and further data analysis. During data recording, the data logger detects the data that either exceed the lifting index limit defined by the NIOSH Lifting Equation or the human whole-body vibration exposure limit defined by the ISO-2631-1 Human Exposure to Whole-Body Vibration standard. The data logger wirelessly transmits the data segment, which contains the marked out-of-limit data, to the smart phone in real-time. The smart phone then automatically dials a predefined number and sends an alert text message and alarm detailing the exposure/safety data, the GPS location of the occurrence, the date/time stamps, and a corresponding safety message. Additionally, the smart phone stores the sent text message for archiving and further data analysis. <ul> <li>No comparable technology currently exists in the marketplace</li> <li>Real-time notification, via alarm and smart-phone transmission, of injury-risk conditions that are likely to lead to musculoskeletal injury, as well as exposure to slip-, trip-, and fall-related traumatic injuries; both the worker and any monitoring station can be notified by the alarm</li> <li>Portable; approximately the size of a mobile phone and uses comparable technology</li> </ul> <ul> <li>Safety officers within the environmental, safety, and health departments of public and private entities</li> <li>Industrial sectors such as construction, package delivery, manufacturing, healthcare, and trucking</li> <li>Workers' well-being concern groups</li> <li>Insurers and workers' compensation operations</li> <li>Monitoring tasks associated with high rates of personal injury and workers' compensation payments linked to repeated or continual heavy lifting</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-05-27 AA1XXX, AA4XXX, AAXXXX, AE1BXX, AE1CXX, AE1XXX, AE2AXX, AE2BXX, AE2XXX, AE3XXX, AE4XXX, AEXXXX, AFXXXX, AG3XXX, AGXXXX, apparatus, ASSESSING, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, Conditions, Injured, Injuries, INJURY, LEAD, Likely, lumbar, Method, MOBILE, MOBILES, MUSCLE, Muscles, MUSCULAR, musculoskeletal, NIOSH, NIOSH-DSR, Occupational health, PERSONAL, Personalized, Portable, SAFE, Safely, SAFETY, System, VMXXXX, VPXXXX, WBXXXX, WCXXXX, WFXXXX, WGXXXX, WIXXXX, WMXXXX, WORKER, WORKER safety, WORKERS, XDXXXX, XHXXXX, XIXXXX, XJXXXX, YAXXXX, YEXXXX, YFXXXX False True <ul> <li>Early-stage</li> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114108738 Wimer, Bryan CDC - NIOSH CDC Wimer, Bryan (CDC) 0 114108739 Zeng, Shengke CDC - DIR CDC Zeng, Shengke (CDC) 0 114108737 Pan, Christopher CDC - NIOSH CDC Pan, Christopher (CDC) 1 114108737 Pan, Christopher CDC - NIOSH CDC Pan, Christopher (CDC) 1 114108738 Wimer, Bryan CDC - NIOSH CDC Wimer, Bryan (CDC) 0 114108739 Zeng, Shengke CDC - DIR CDC Zeng, Shengke (CDC) 0 114102163 Portable System And Method For Assessing Conditions Likely To Lead To Musculoskeletal Injuries E-168-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2826] Occupational Safety: Portable Exposure Assessment System for Prevention of Musculoskeletal Injury&body=Please send me information about technology [TAB-2826] Occupational Safety: Portable Exposure Assessment System for Prevention of Musculoskeletal Injury. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2826] Occupational Safety: Portable Exposure Assessment System for Prevention of Musculoskeletal Injury&body=Please send me information about technology [TAB-2826] Occupational Safety: Portable Exposure Assessment System for Prevention of Musculoskeletal Injury.">yogikala.prabhu@nih.gov</a><br> 114167816 E-168-2013-0 E-168-2013-0-US-01 Portable System And Method For Assessing Conditions Likely To Lead To Musculoskeletal Injuries PRV US 61/599,525 Abandoned US <br />Provisional (PRV) 61/599,525<br />Filed on 2012-02-16<br />Status: Abandoned 114167817 E-168-2013-0 E-168-2013-0-US-02 SYSTEM AND METHOD TO PREDICT AND AVOID MUSCULOSKELETAL INJURIES ORD US 8,942,662 13/768,290 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8942662 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8942662">8,942,662</a><br />Filed on 2013-02-15<br />Status: Issued 114126209 AXXXXX 114126210 AAXXXX 114126211 AA1XXX 114126212 AA4XXX 114126213 AEXXXX 114126214 AE1XXX 114126215 AE1BXX 114126216 AE1CXX 114126217 AE2XXX 114126218 AE2AXX 114126219 AE2BXX 114126220 AE3XXX 114126221 AE4XXX 114126222 AFXXXX 114126223 AGXXXX 114126224 AG3XXX 114126225 VMXXXX 114126226 VPXXXX 114126227 WBXXXX 114126228 WCXXXX 114126229 WFXXXX 114126230 WGXXXX 114126231 WMXXXX 114126232 XDXXXX 114126233 XIXXXX 114126234 XHXXXX 114126235 YAXXXX 114126236 WIXXXX 114126237 XJXXXX 114126238 YEXXXX 114126239 YFXXXX 114147439 Portable 114147440 System 114147441 Method 114147442 ASSESSING 114147443 Conditions 114147444 Likely 114147445 LEAD 114147446 musculoskeletal 114147447 Injuries 114147448 CDC Docket Import 114147449 CDC Docket Import CDC Prosecuting 114147450 NIOSH-DSR 114147451 NIOSH 114147452 WORKER 114147453 WORKER safety 114147454 WORKERS 114147455 Occupational health 114147456 SAFE 114147457 SAFETY 114147458 Safely 114147459 MUSCLE 114147460 MUSCULAR 114147461 Muscles 114147462 Injured 114147463 INJURY 114147464 PERSONAL 114147465 Personalized 114147466 MOBILE 114147467 MOBILES 114147468 apparatus 114147469 lumbar TAB-2827 114097006 Occupational Health: Wearable Kneel-Sit Support Device for Manual Labor and Heavy Industry Applications CDC Cardiology, Consumer Products, Dental, Endocrinology, Geriatrics, Immunology, Infectious Disease, Licensing, Medical Devices, Neurology, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology Cardiology Consumer Products Dental Endocrinology Geriatrics Immunology Infectious Disease Licensing Medical Devices Neurology Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Stephen Hudock, Ova Johnston, Steven Wurzelbacher This CDC-developed technology describes a novel ergonomic device that supports a portion of the worker's weight while kneeling, relieving the knee pressure and pain common to many manual labor occupations. Unfortunately, many of the devices that have been used in the past to relieve pressure on the knees are bulky, heavy, and of questionable durability.<br /><br /> This device relieves pressure from the knees while kneeling, is easily portable, is attachable to the body, and can be moved automatically by the user without the user having to pick up the device and manually move it to a new position. The device is nonflammable and durable, so that it can be used in heavy industry and on horizontally constrained and uneven surfaces, and is comfortable to use while kneeling, thereby improving worker productivity. <ul> <li>Comfortable; relieves pressure from the knees while kneeling, increasing on-the-job comfort and worker productivity</li> <li>Device is extremely portable</li> <li>Easily attaches to a user's lower leg; allows for unhindered movement and ambulation</li> <li>Device automatically moves with the user; no manual readjustments or manipulations are required</li> <li>Durable and nonflammable</li> <li>Ideal for heavy industry applications; can be used on horizontally constrained and uneven surfaces</li> </ul> <ul> <li>Knee pain, low-back pain alleviation and prevention</li> <li>Improved workplace ergonomics</li> <li>Osteoarthrosis concerns, geriatric medicine applications and for aging populations in the workforce</li> <li>Occupations such as shipbuilding, welding, mining, plumbing, carpet and floor installation, construction, repair services, and auto body repair in which people must spend a considerable amount of time kneeling or squatting</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-05-29 AB1XXX, AB3GXX, AB3XXX, AE2BXX, AE2XXX, AE4XXX, AEXXXX, AFXXXX, ARTHRITIS, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DEVICE, Knee, Kneel-sit, LABOR, MINING, NIOSH, NIOSH-DART, OSHA, OSTEOARTHRITIS, SAFETY, SUPPORT, VAXXXX, VMXXXX, VPXXXX, Wearable, WEXXXX, WGXXXX, WMXXXX, WORK, WORKER, WORKER safety, WORKERS, XDXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114108741 Johnston, Ova CDC - DIR CDC Johnston, Ova (CDC) 0 114108742 Hudock, Stephen CDC - NIOSH CDC Hudock, Stephen (CDC) 0 114108740 Wurzelbacher, Steven CDC - NIOSH CDC Wurzelbacher, Steven (CDC) 1 114108740 Wurzelbacher, Steven CDC - NIOSH CDC Wurzelbacher, Steven (CDC) 1 114108741 Johnston, Ova CDC - DIR CDC Johnston, Ova (CDC) 0 114108742 Hudock, Stephen CDC - NIOSH CDC Hudock, Stephen (CDC) 0 114102164 Wearable Kneel-sit Support Device E-261-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2827] Occupational Health: Wearable Kneel-Sit Support Device for Manual Labor and Heavy Industry Applications&body=Please send me information about technology [TAB-2827] Occupational Health: Wearable Kneel-Sit Support Device for Manual Labor and Heavy Industry Applications. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2827] Occupational Health: Wearable Kneel-Sit Support Device for Manual Labor and Heavy Industry Applications&body=Please send me information about technology [TAB-2827] Occupational Health: Wearable Kneel-Sit Support Device for Manual Labor and Heavy Industry Applications.">yogikala.prabhu@nih.gov</a><br> 114167818 E-261-2013-0 E-261-2013-0-PCT-02 Wearable Kneel-sit Support Device PCT Patent Cooperation Treaty PCT/US2002/016790 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2002/016790<br />Filed on 2002-05-28<br />Status: Expired 114167819 E-261-2013-0 E-261-2013-0-US-01 Wearable Kneel-sit Support Device PRV US 60/300,315 Abandoned US <br />Provisional (PRV) 60/300,315<br />Filed on 2001-06-22<br />Status: Abandoned 114167820 E-261-2013-0 E-261-2013-0-US-03 Wearable Kneel-sit Support Device National Stage US 7,152,919 10/481,532 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7152919 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7152919">7,152,919</a><br />Filed on 2003-12-19<br />Status: Abandoned 114126240 AXXXXX 114126241 AB1XXX 114126242 AB3XXX 114126243 AB3GXX 114126244 AEXXXX 114126245 AE2XXX 114126246 AE2BXX 114126247 AE4XXX 114126248 AFXXXX 114126249 VAXXXX 114126250 VMXXXX 114126251 VPXXXX 114126252 WEXXXX 114126253 WGXXXX 114126254 WMXXXX 114126255 XIXXXX 114126256 XDXXXX 114126257 YFXXXX 114126258 YEXXXX 114147470 Wearable 114147471 Kneel-sit 114147472 SUPPORT 114147473 DEVICE 114147474 CDC Docket Import 114147475 CDC Docket Import CDC Prosecuting 114147476 NIOSH-DART 114147477 NIOSH 114147478 SAFETY 114147479 Knee 114147480 WORK 114147481 WORKER 114147482 WORKER safety 114147483 WORKERS 114147484 ARTHRITIS 114147485 OSTEOARTHRITIS 114147486 LABOR 114147487 OSHA 114147488 MINING TAB-2890 114097051 Mobile Instrumentation for the Detection and Sampling of Aerosol Particles CDC Diagnostics, Licensing, Medical Devices, Neurology, Non-Medical Devices, Occupational Safety and Health, Research Materials, Therapeutics, Vaccines Diagnostics Licensing Medical Devices Neurology Non-Medical Devices Occupational Safety and Health Research Materials Therapeutics Vaccines Gregory Deye, Pramod Kulkarni Hazardous airborne particles pose a risk for health and safety in a variety of environments and thus detection of these small particles is essential. Current particle magnification systems are bulky and require a lot of power for operation, making them unsuitable to easily detect and analyze small particles in mobile and personal settings.<br /><br /> CDC/NIOSH scientists have developed a space-saving miniature instrumentation and methods for the direct sampling and analysis of small particles (diameter < 300-400nm). The systems can effectively sample air at a rate of a few liters per minute and concentrate the particulate matter into microliter or milliliter liquid samples. The novel system uses proton exchange membranes to grow small particles for optical detection using standard methods. Further, these methods allow the system to separate condensation and aerosol flow to enhance user mobility. Moreover, the described methods use inexpensive materials and require low power for operation. <ul> <li>Cost-effective</li> <li>Offers overall reduction of measurement time</li> <li>Requires minimal power to operate</li> <li>Mobile, wearable</li> <li>Space-saving miniature systems as small as 1" x 1" x 3"</li> </ul> <ul> <li>Condensation particle detectors</li> <li>Particle size magnification systems</li> <li>Microfluidic devices for sampling, detection, and growth of hazardous particles</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-11-14 AEROSOL, APPLICATIONS, EXCHANGE, Growth, MEMBRANES, NIOSH-DART, PARTICLE, PERSONAL, Proton, Sampling, SYSTEMS, VBXXXX, VEXXXX, WAXXXX, WCXXXX, WGXXXX, WIXXXX, XDXXXX, XIXXXX, YFXXXX False True Prototype True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract E-146-2013-0 114108911 Deye, Gregory CDC - NIOSH CDC Deye, Gregory (CDC) 0 114108912 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114108912 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114108911 Deye, Gregory CDC - NIOSH CDC Deye, Gregory (CDC) 0 114102221 Aerosol Particle Growth Systems For Personal Sampling Applications Using Proton Exchange Membranes E-026-2014-0 Filing authorized Centers for Disease Control and Prevention (CDC), Regents of the University of Minnesota 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2890] Mobile Instrumentation for the Detection and Sampling of Aerosol Particles&body=Please send me information about technology [TAB-2890] Mobile Instrumentation for the Detection and Sampling of Aerosol Particles. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2890] Mobile Instrumentation for the Detection and Sampling of Aerosol Particles&body=Please send me information about technology [TAB-2890] Mobile Instrumentation for the Detection and Sampling of Aerosol Particles.">yogikala.prabhu@nih.gov</a><br> 114161376 E-026-2014-0 E-026-2014-0-US-05 Aerosol Particle Growth Systems Using Polymer Electrolyte Membranes National Stage US 10,583,410 15/325,986 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10583410 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10583410">10,583,410</a><br />Filed on 2015-07-20<br />Status: Issued 114163079 E-026-2014-0 E-026-2014-0-PCT-02 Aerosol Particle Growth Systems Using Polymer Electrolyte Membranes PCT Patent Cooperation Treaty PCT/US2015/041142 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/041142<br />Filed on 2015-07-20<br />Status: Expired 114167996 E-026-2014-0 E-026-2014-0-US-01 AEROSOL PARTICLE GROWTH SYSTEMS FOR PERSONAL SAMPLING APPLICATIONS USING POLYMER ELECTROLYTE MEMBRANES PRV US 62/026,559 Abandoned US <br />Provisional (PRV) 62/026,559<br />Filed on 2014-07-18<br />Status: Abandoned 114126677 VBXXXX 114126678 VEXXXX 114126679 WAXXXX 114126680 WCXXXX 114126681 WGXXXX 114126682 WIXXXX 114126683 XDXXXX 114126684 XIXXXX 114126685 YFXXXX 114147921 AEROSOL 114147922 PARTICLE 114147923 Growth 114147924 SYSTEMS 114147925 PERSONAL 114147926 Sampling 114147927 APPLICATIONS 114147928 Proton 114147929 EXCHANGE 114147930 MEMBRANES 114147931 NIOSH-DART TAB-2939 114097090 Emergency Maritime Battery Charger CDC Cardiology, Dental, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials Cardiology Dental Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Materials Chelsea Woodward Boats and other watercrafts have emergency lifesaving equipment like strobe lamps to help rescuers locate individuals overboard in the event of a disaster. The battery life of the equipment is limited, so the amount of time rescuers have to find the victims is also limited. An emergency battery charger that can power emergency equipment is needed to remove this limitation.<br /><br /> Investigators at NIOSH have developed a battery that is powered by wave action in the water. Using a derivation of Faraday's Law, the principles of Lentz's Law were used to induce a current in a wire coil and manipulated to charge emergency batteries. This technology offers a back-up charger for equipment on boats and watercrafts. <ul> <li>Charging system is configured to be powered by wave action.</li> <li>Powering mechanism allows the maritime battery charger to be used in boats, life rafts, and personal flotation devices.</li> <li>Maritime charger can be used to charge radios, lamps, and back up batteries for emergency systems.</li> </ul> <ul> <li>Battery charger that can be used on personal or commercial boats.</li> <li>Maritime battery charger that can be used for specialized rescue vessels.</li> </ul> Patent protection is not being pursued for this technology. 2022-03-27 2026-05-14 2026-05-14 2015-05-19 Battery, CDC Docket Import, CDC Docket Import CDC Prosecuting, CDCRM, Charger/maintainer, EMERGENCY, FISH, Listed LPM Surabian as of 4/15/2015, Maritime, NIOSH, Occupational health, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SAFE, SAFETY, VPXXXX, WGXXXX, WIXXXX, WORK, WORKER safety, XDXXXX, XIXXXX, YAXXXX, YFXXXX False True <ul> <li>Early-stage</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114109045 Woodward, Chelsea CDC - NIOSH CDC Woodward, Chelsea (CDC) 1 114109045 Woodward, Chelsea CDC - NIOSH CDC Woodward, Chelsea (CDC) 1 114102274 Emergency Maritime Battery Charger/maintainer E-567-2013-0 Research Material Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2939] Emergency Maritime Battery Charger&body=Please send me information about technology [TAB-2939] Emergency Maritime Battery Charger. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2939] Emergency Maritime Battery Charger&body=Please send me information about technology [TAB-2939] Emergency Maritime Battery Charger.">yogikala.prabhu@nih.gov</a><br> 114127039 VPXXXX 114127040 WGXXXX 114127041 WIXXXX 114127042 XDXXXX 114127043 XIXXXX 114127044 YAXXXX 114127045 YFXXXX 114148362 EMERGENCY 114148363 Maritime 114148364 Battery 114148365 Charger/maintainer 114148366 CDC Docket Import 114148367 CDC Docket Import CDC Prosecuting 114148368 NIOSH 114148369 WORK 114148370 WORKER safety 114148371 SAFETY 114148372 SAFE 114148373 Occupational health 114148374 FISH 114148375 CDCRM 114148376 Listed LPM Surabian as of 4/15/2015 114148377 Pre LPM working set 20150418 114148378 Post LPM Assignment Set 20150420 TAB-2940 114097091 Swing-Away Winch Cathead Guard CDC Cardiology, Dental, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials Cardiology Dental Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Materials Chelsea Woodward Shrimp boat operators use two trawl retrieval mechanisms mounted on the same winch frame. The main spools are used in the first operation; the shrimpers stand within inches of rotating cathead drums and guide incoming wire rope onto the main spools. Second, lazy lines are wrapped multiple times around each of the two spinning catheads (horizontal beams that raise and secure the anchor). Lastly, the guarding ends are pulled by the operators to cinch the rope to the rotating spool aiding trawl retrieval, but poses a hazard for operators to get entangled in the spinning cathead spools.<br /><br /> Researchers at NIOSH have developed guarding devices to protect shrimp boat winch operators from being entangled in the continuously spinning cathead spools. The mechanical guards feature a swinging functionality covering the catheads after the main trawl operations, allowing access to the normal operation of the catheads. <ul> <li>Swing-away mechanism of cathead guard protects operators from becoming entangled in spinning cathead spools.</li> <li>Designed specifically to address safety issues with industry winch protocols.</li> </ul> <ul> <li>Protective guards used to protect shrimp boat operators from being entangled in cathead spools.</li> <li>Cathead guards used to protect operators in the mining, oil, and gas industries where cathead winch spools are used.</li> <li>Guards can be used in boating industry to protect operators of anchor windlasses.</li> </ul> Patent protection is not being pursued for this technology. 2022-03-27 2026-05-14 2026-05-14 2015-05-19 Cathead, CDC Docket Import, CDC Docket Import CDC Prosecuting, CDCRM, Guard, Listed LPM Surabian as of 4/15/2015, Maritime, NIOSH, Occupational health, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Swing-Away, VPXXXX, WGXXXX, WINCH, WIXXXX, WORKER, WORKER safety, XDXXXX, XIXXXX, YAXXXX, YFXXXX False True <ul> <li>Early-stage</li> </li>Prototype</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114109046 Woodward, Chelsea CDC - NIOSH CDC Woodward, Chelsea (CDC) 1 114109046 Woodward, Chelsea CDC - NIOSH CDC Woodward, Chelsea (CDC) 1 114102275 Swing-Away Winch Cathead Guard E-568-2013-0 Research Material Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2940] Swing-Away Winch Cathead Guard&body=Please send me information about technology [TAB-2940] Swing-Away Winch Cathead Guard. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2940] Swing-Away Winch Cathead Guard&body=Please send me information about technology [TAB-2940] Swing-Away Winch Cathead Guard.">yogikala.prabhu@nih.gov</a><br> 114127046 VPXXXX 114127047 WGXXXX 114127048 WIXXXX 114127049 XDXXXX 114127050 XIXXXX 114127051 YAXXXX 114127052 YFXXXX 114148379 Swing-Away 114148380 WINCH 114148381 Cathead 114148382 Guard 114148383 CDC Docket Import 114148384 CDC Docket Import CDC Prosecuting 114148385 NIOSH 114148386 WORKER 114148387 WORKER safety 114148388 Occupational health 114148389 Maritime 114148390 CDCRM 114148391 Listed LPM Surabian as of 4/15/2015 114148392 Pre LPM working set 20150418 114148393 Post LPM Assignment Set 20150420 TAB-2816 114096995 Methods for Near Real-time Chemical Analysis of Aerosols using Microwave-induced Plasma Spectroscopy CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Equipment, Research Materials, Therapeutics, Vaccines Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Equipment Research Materials Therapeutics Vaccines Philip Efthimion, Pramod Kulkarni This CDC developed technology entails a novel method of near real-time elemental analysis of aerosols by corona assisted microwave induced plasma spectroscopy (CAMPS).<br /><br /> Analysis of elemental composition of aerosol particles holds significant implications for environmental and workplace pollution monitoring. Various plasma based analytical techniques, including laser-induced breakdown spectroscopy (LIBS) and spark-induced breakdown spectroscopy (SIBS), have been successfully used for multi-elemental analyses in solids, liquids, and gases, including aerosols. However, the characterization of fine and ultrafine aerosols using these techniques is particularly challenging due to small plasma volume, miniscule sample mass, and inferior sampling statistics, often leading to poor detection limits and precision.<br /><br /> This technology utilizes a microwave plasma-based detection system for aerosol analysis that features increased microplasma lifetime, repeatability, and stability over currently-available pulsed microplasma-based methods. This system produces microplasma lifetimes in the range of 5 to 50 milliseconds, a duration that is orders of magnitude larger than lifetimes for laser-induced or spark plasmas, as well as larger plasma volumes, which together are expected to provide improved detection limits over currently-available techniques. <ul> <li>Makes it possible to conduct accurate, near-real-time measurement of the elemental composition of aerosols in industrial and ambient atmospheres</li> <li>Corona field stabilizes the microwave plasma and results in repeatable plasma formation</li> <li>Larger size of CAMPS plasma provides sufficient plasma volume which can lead to complete ablation of deposited aerosol in the tip of the electrode</li> <li>Longer duration of CAMPS plasma (~10-50 ms) allows longer integration time which results in signal enhancement</li> </ul> <ul> <li>Elemental quantification of aerosols in near real-time</li> <li>Air pollution studies, Particulate Matter monitoring</li> <li>Hazardous materials exposure determinations and identification</li> <li>Biodefense, chemical-defense, homeland-security applications</li> <li>Environmental and occupational epidemiology</li> <li>Evaluation of engineering controls</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-05-15 CDC Docket Import, CDC Docket Import CDC Prosecuting, Microelectrode-Assisted, Microwave-Induced, NIOSH-DART, PLASMA, SPECTROSCOPY, VBXXXX, VJXXXX, VKXXXX, VLXXXX, VOXXXX, VPXXXX, WAXXXX, WBXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WHXXXX, WIXXXX, WMXXXX, XDXXXX, XHXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract E-205-2013-0 114108712 Efthimion, Philip Efthimion, Philip 0 114108711 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114108711 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114108712 Efthimion, Philip Efthimion, Philip 0 114102149 Microelectrode-Assisted Microwave-Induced Plasma Spectroscopy E-163-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC), Envimetrics, LLC 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2816] Methods for Near Real-time Chemical Analysis of Aerosols using Microwave-induced Plasma Spectroscopy&body=Please send me information about technology [TAB-2816] Methods for Near Real-time Chemical Analysis of Aerosols using Microwave-induced Plasma Spectroscopy. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2816] Methods for Near Real-time Chemical Analysis of Aerosols using Microwave-induced Plasma Spectroscopy&body=Please send me information about technology [TAB-2816] Methods for Near Real-time Chemical Analysis of Aerosols using Microwave-induced Plasma Spectroscopy.">yogikala.prabhu@nih.gov</a><br> 114167783 E-163-2013-0 E-163-2013-0-US-01 Microelectrode-Assisted Microwave-Induced Plasma Spectroscopy PRV US 61/652,593 Abandoned US <br />Provisional (PRV) 61/652,593<br />Filed on 2012-05-02<br />Status: Abandoned 114167784 E-163-2013-0 E-163-2013-0-US-02 Electrode-Assisted Microwave-Induced Plasma Spectroscopy ORD US 9,091,597 13/804,512 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9091597 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9091597">9,091,597</a><br />Filed on 2013-03-14<br />Status: Issued 114126002 VBXXXX 114126003 VJXXXX 114126004 VKXXXX 114126005 VLXXXX 114126006 VOXXXX 114126007 VPXXXX 114126008 WAXXXX 114126009 WBXXXX 114126010 WCXXXX 114126011 WEXXXX 114126012 WFXXXX 114126013 WGXXXX 114126014 WHXXXX 114126015 WIXXXX 114126016 WMXXXX 114126017 XDXXXX 114126018 XHXXXX 114126019 XIXXXX 114126020 YEXXXX 114126021 YFXXXX 114147256 Microelectrode-Assisted 114147257 Microwave-Induced 114147258 PLASMA 114147259 SPECTROSCOPY 114147260 CDC Docket Import 114147261 CDC Docket Import CDC Prosecuting 114147262 NIOSH-DART TAB-2817 114096996 Local Positioning System for Position-Time-Condition Correlation, Data-logging and Analysis CDC Computational models/software, Consumer Products, Diagnostics, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Research Equipment, Research Materials, Software / Apps, Therapeutics, Vaccines Computational models/software Consumer Products Diagnostics Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Research Equipment Research Materials Software / Apps Therapeutics Vaccines Michael Flemmer, Ramesh Gali, Jennifer Hornsby-Myers, Larry Lee, Sidney Soderholm This CDC-developed technology describes an automated system for monitoring worker hazard exposures by recording data about where and when hazards occur in a workplace or other environment. This allows the hazards to be avoided and harmful exposures and risks reduced. This field-tested technology consists of an integrated, hand-held electronics instrument and software system that will precisely correlate multiple exposure levels with position coordinates of the user and features real-time data acquisition.<br /><br /> Workers in many outdoor occupations move about frequently during a typical day of work. Certain workers, such as agricultural and construction workers, are particularly mobile. This exposure monitoring system combines geographical location with real-time sensors and outputs the information to a user-friendly interface. By linking worker location throughout the workday to exposure levels from real-time monitors, Local Positioning System (LPS) units (with integrated software processing of data) identify and document where to direct hazard exposure analysis and control efforts. Post-processing of LPS data enables researchers, regulatory inspectors, and industry safety and health personnel to map exposure intensity and location, reveal hot spots to identify sources, and provide exposure intensity distributions to increase workplace safety. <ul> <li>Correlates real-time position and real-time condition data for multiple commercial/industrial applications</li> <li>An add-on capability for any sensor(s) when measurement of a location is also useful</li> <li>System is highly customizable and can be easily adapted for additional monitoring of noise, dust, gases, and vapor, heat stress, etc. exposures</li> <li>Automated system provides greater efficiency and greater feedback than video monitoring systems</li> <li>An integrated alarm will alert users to potential hazards</li> </ul> <ul> <li>Collection, analysis and display of mutual, real-time conditional and 3-dimensional position data</li> <li>Outdoor occupational exposure assessment with various real-time sensors/monitors (e.g., HAZMAT crews, safety inspection, etc.)</li> <li>Solid state "bread crumbs" allowing a person or machine to retrace their path</li> <li>Tracking of objects, animals or people, including sensing of their internal condition or environmental conditions</li> <li>Environmental pollution source-point monitoring and investigation</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-05-15 apparatus, ASSESSING, CDC Docket Import, CDC Docket Import CDC Prosecuting, Conditions, Method, System, VBXXXX, WAXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WIXXXX, WMXXXX, XDXXXX, XHXXXX, XIXXXX, XJXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114172138 Lee LA, et al. http://www.ncbi.nlm.nih.gov/pubmed/15986055 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15986055">Lee LA, et al.</a> 114108714 Soderholm, Sidney CDC - NIOSH CDC Soderholm, Sidney (CDC) 0 114108715 Flemmer, Michael CDC - NIOSH CDC Flemmer, Michael (CDC) 0 114108716 Hornsby-Myers, Jennifer CDC - NIOSH CDC Hornsby-Myers, Jennifer (CDC) 0 114108717 Gali, Ramesh CDC - NIOSH CDC Gali, Ramesh (CDC) 0 114108713 Lee, Larry CDC - NIOSH CDC Lee, Larry (CDC) 1 114108713 Lee, Larry CDC - NIOSH CDC Lee, Larry (CDC) 1 114108714 Soderholm, Sidney CDC - NIOSH CDC Soderholm, Sidney (CDC) 0 114108715 Flemmer, Michael CDC - NIOSH CDC Flemmer, Michael (CDC) 0 114108716 Hornsby-Myers, Jennifer CDC - NIOSH CDC Hornsby-Myers, Jennifer (CDC) 0 114108717 Gali, Ramesh CDC - NIOSH CDC Gali, Ramesh (CDC) 0 114102150 Method, Apparatus, And System For Assessing Conditions E-144-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2817] Local Positioning System for Position-Time-Condition Correlation, Data-logging and Analysis&body=Please send me information about technology [TAB-2817] Local Positioning System for Position-Time-Condition Correlation, Data-logging and Analysis. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2817] Local Positioning System for Position-Time-Condition Correlation, Data-logging and Analysis&body=Please send me information about technology [TAB-2817] Local Positioning System for Position-Time-Condition Correlation, Data-logging and Analysis.">yogikala.prabhu@nih.gov</a><br> 114167785 E-144-2013-0 E-144-2013-0-US-01 Method, Apparatus, And System For Assessing Conditions ORD US 7,191,097 10/815,111 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7191097 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7191097">7,191,097</a><br />Filed on 2004-03-31<br />Status: Abandoned 114126022 VBXXXX 114126023 WAXXXX 114126024 WCXXXX 114126025 WEXXXX 114126026 WFXXXX 114126027 WGXXXX 114126028 WIXXXX 114126029 WMXXXX 114126030 XDXXXX 114126031 XHXXXX 114126032 XIXXXX 114126033 XJXXXX 114126034 YEXXXX 114126035 YFXXXX 114147263 Method 114147264 apparatus 114147265 System 114147266 ASSESSING 114147267 Conditions 114147268 CDC Docket Import 114147269 CDC Docket Import CDC Prosecuting TAB-2823 114097002 Focused Electrostatic Collection of Aerosol Particles for Chemical Analysis by Spectroscopic Techniques CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Pulmonology, Research Equipment, Research Materials, Software / Apps, Therapeutics, Vaccines Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Pulmonology Research Equipment Research Materials Software / Apps Therapeutics Vaccines Prasson Diwakar, Pramod Kulkarni This CDC-developed technology is an aerosol preconcentration unit (APU) designed for use with spectroscopic detection techniques, including emission, Raman, or infrared spectroscopies. Most existing pulsed microplasma techniques, such as laser-induced breakdown, for aerosols rely mainly on filter-based collection and suffer from poor accuracy, precision, and detection limits and require long sample collection times. The APU is designed to address these drawbacks by pre-concentrating the aerosol particles on a tip of a microelectrode (a few hundreds of micrometers in diameter) to allow near-real time measurements with superior accuracy and precision. The APU is designed to be small, low-pressure drop unit for its use in a battery-operated, hand-portable instrumentation.<br /><br /> The design significantly improves accuracy and precision of measurements relative to existing methods. The APU can be integrated with a microplasma source (such as a laser-induced plasma) and the optical spectrometer to obtain elemental composition of aerosol particles. The unique features of this invention allow: i) semi-continuous or near-real-time measurement of elemental composition of aerosol particles, ii) measurement with high accuracy, precision, and repeatability, iii) collection of particles using electrostatic principles, iv) higher flow rates with smaller pumps because of a very low pressure drop, v) reliable calibration of the system, vi) easy miniaturization for portable instruments, and vii) lower detection limits, as needed, by increasing the particle collection time and/or sampling flow rate. <ul> <li>This APU allows accurate, near-real-time measurement of the elemental composition of aerosol particles in industrial and ambient atmospheres</li> <li>Can be readily miniaturized and integrated into existing portable plasma, Raman, or IR spectroscopy instruments to allow on-site, semi-continuous measurement of aerosol particles</li> <li>Provides lower detection limits compared to earlier technology, as needed, by increasing the particle collection time and/or sampling flow rate</li> </ul> <ul> <li>Personal exposure measurements of metals</li> <li>Air pollution studies</li> <li>Elemental quantification in near real-time</li> <li>Hazardous materials exposure determinations and identification</li> <li>Biodefense, chemical-defense applications</li> <li>Environmental and occupational epidemiology</li> <li>Evaluation of engineering controls</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-05-21 AA2XXX, AA3AXX, AA3B5X, AA3CXX, AA3XXX, AC1XXX, AC3XXX, AC4XXX, AC6XXX, ACXXXX, ADXXXX, AE2AXX, AE2XXX, AE3XXX, AE4XXX, AEROSOL, AEXXXX, AG1XXX, ANALYSER, ANALYSES, analysis, apparatus, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DAXXXX, DEVICE, DXXXXX, IA5XXX, IDXXXX, Method, NIOSH, NIOSH-DART, OID-NCIRD-DVD, optical, PLASMA, SPECTROSCOPY, TECHNIQUE, VBXXXX, VJXXXX, VKXXXX, VLXXXX, VOXXXX, VPXXXX, WAXXXX, WBXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WIXXXX, WMXXXX, XDXXXX, XFXXXX, XGXXXX, XHXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-163-2013-0 114108733 Diwakar, Prasson CDC - NIOSH CDC Diwakar, Prasson (CDC) 0 114108732 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114108732 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114108733 Diwakar, Prasson CDC - NIOSH CDC Diwakar, Prasson (CDC) 0 114102157 Method And Apparatus For Aerosol Analysis Using Optical Spectroscopy E-205-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC), TKC Global 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2823] Focused Electrostatic Collection of Aerosol Particles for Chemical Analysis by Spectroscopic Techniques&body=Please send me information about technology [TAB-2823] Focused Electrostatic Collection of Aerosol Particles for Chemical Analysis by Spectroscopic Techniques. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2823] Focused Electrostatic Collection of Aerosol Particles for Chemical Analysis by Spectroscopic Techniques&body=Please send me information about technology [TAB-2823] Focused Electrostatic Collection of Aerosol Particles for Chemical Analysis by Spectroscopic Techniques.">yogikala.prabhu@nih.gov</a><br> 114167801 E-205-2013-0 E-205-2013-0-US-01 Method And Apparatus For Aerosol Analysis Using Optical Spectroscopy ORD US 8,970,840 13/315,372 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8970840 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8970840">8,970,840</a><br />Filed on 2011-12-09<br />Status: Issued 114126103 AXXXXX 114126104 AA2XXX 114126105 AA3XXX 114126106 AA3AXX 114126107 AA3B5X 114126108 AA3CXX 114126109 ACXXXX 114126110 AC1XXX 114126111 AC3XXX 114126112 AC4XXX 114126113 AC6XXX 114126114 ADXXXX 114126115 AEXXXX 114126116 AE2XXX 114126117 AE2AXX 114126118 AE3XXX 114126119 AE4XXX 114126120 AG1XXX 114126121 DXXXXX 114126122 DAXXXX 114126123 IA5XXX 114126124 IDXXXX 114126125 VBXXXX 114126126 VJXXXX 114126127 VKXXXX 114126128 VLXXXX 114126129 VOXXXX 114126130 VPXXXX 114126131 WAXXXX 114126132 WBXXXX 114126133 WCXXXX 114126134 WEXXXX 114126135 WFXXXX 114126136 WGXXXX 114126137 WIXXXX 114126138 WMXXXX 114126139 XDXXXX 114126140 XFXXXX 114126141 XGXXXX 114126142 XHXXXX 114126143 XIXXXX 114126144 YEXXXX 114126145 YFXXXX 114147358 Method 114147359 apparatus 114147360 AEROSOL 114147361 analysis 114147362 optical 114147363 SPECTROSCOPY 114147364 CDC Docket Import 114147365 CDC Docket Import CDC Prosecuting 114147366 OID-NCIRD-DVD 114147367 NIOSH-DART 114147368 NIOSH 114147369 PLASMA 114147370 ANALYSES 114147371 ANALYSER 114147372 DEVICE 114147373 TECHNIQUE TAB-2824 114097003 Improved Acoustic Plethysmograph System for Noninvasive Measurement of Pulmonary Function CDC Cardiology, Computational models/software, Consumer Products, Dental, Diagnostics, Endocrinology, Immunology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Pulmonology, Research Equipment, Research Materials, Software / Apps, Therapeutics, Vaccines Cardiology Computational models/software Consumer Products Dental Diagnostics Endocrinology Immunology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Pulmonology Research Equipment Research Materials Software / Apps Therapeutics Vaccines David Frazer, Jeffrey Reynolds CDC researchers have developed a novel acoustic whole body plethysmograph (AWBP) that allows measurement of tidal volume in lab animals, independent of gas compression in the lung. This system provides particular advantages over the traditional whole body plethysmograph (WBP) when measuring model animals with increased gas compression due to increased airway resistance or increased acceleration in the breathing pattern.<br /><br /> Measurement of tidal volume in conscious, unrestrained mice has traditionally been performed using WBP. An animal is placed in a chamber where pressure changes due to respiration are observed, which are then related to tidal volume. Although the effects of gas compression on the WBP signal of normal mice may be negligible, gas compression in mice with altered breathing pattern and/or increased airway resistance can produce significant errors in the measurement of tidal volume. A major advantage of this novel AWBP technology is the ability to measure the tidal volume signal independent of gas compression. This is particularly useful when measuring mice that have been exposed to a respiratory irritant or toxin that increases airway resistance or the frequency content of the breathing pattern. Further, with slight hardware and software modifications the system may also be used to measure specific airway resistances. <ul> <li>System allows fast, efficient, noninvasive measurement of lab animal pulmonary function for numerous inhalation, toxicology research studies</li> <li>Measures tidal volume signal independent of gas compression, increasing accuracy when gathering data from animals with altered breathing patterns and/or elevated airway resistance</li> <li>System operates at a fixed frequency, and automatically tracks the change in sound amplitude as a function of time due to change in lung volume</li> </ul> <ul> <li>Measurement of tidal volume, respiratory rate, and other breath rate parameters of laboratory animals</li> <li>Research and animal modeling tool for in vivo pulmonary investigations of therapeutics efficacy and studying certain infectious diseases </li> <li>Particularly useful when measuring animals exposed to a respiratory irritant or toxin that increases either airway resistance or the frequency</li> <li>Noninvasive measurement of specific airway resistance and restrictions in an unrestrained animal</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-05-27 AA2XXX, AA5XXX, AAXXXX, AC1XXX, AC2XXX, AC3XXX, AC6XXX, Acoustic, ACXXXX, ADXXXX, AE1BXX, AE1XXX, AE3XXX, AE4XXX, AEXXXX, ANIMAL, Animal Model, ANIMAL welfare, ASTHMA, Breath, BREATHING, CDC Docket Import, CDC Docket Import CDC Prosecuting, DDXXXX, DEVICE, DEXXXX, DXXXXX, FUNCTION, IA3XXX, IA5XXX, ICXXXX, IDXXXX, LUNG, lung cancer, Lung Disease, LUNGS, Lung-Targeted, Measuring, NIOSH, NIOSH-HELD, Plethysmograph, Pulmonary, Pulmonary edema, PULMONARY FIBROSIS, research, RESEARCH TOOL, RESPIRABLE, Respiration, respiratory, Respiratory Diseases, respiratory INFECTION, Tool, VBXXXX, VJXXXX, VKXXXX, VLXXXX, VOXXXX, VPXXXX, WAXXXX, WBXXXX, WCXXXX, WGXXXX, WIXXXX, WMXXXX, XDXXXX, XHXXXX, XIXXXX, XJXXXX, YCXXXX, YEXXXX, YFXXXX False True <ul> <li>In vivo data available (animal)</li> <li>In situ data available (on-site)</li> <li>Prototype</li> <ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172147 Reynolds JS, et al. http://www.ncbi.nlm.nih.gov/pubmed/16897419 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16897419">Reynolds JS, et al.</a> 114172148 Reynolds JS, et al. http://www.ncbi.nlm.nih.gov/pubmed/18450981 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18450981">Reynolds JS, et al.</a> 114172149 Daubenspeck JA , et al. http://www.ncbi.nlm.nih.gov/pubmed/17962574 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17962574">Daubenspeck JA , et al.</a> 114108735 Frazer, David CDC - NIOSH CDC Frazer, David (CDC) 0 114108734 Reynolds, Jeffrey CDC - NIOSH CDC Reynolds, Jeffrey (CDC) 1 114108734 Reynolds, Jeffrey CDC - NIOSH CDC Reynolds, Jeffrey (CDC) 1 114108735 Frazer, David CDC - NIOSH CDC Frazer, David (CDC) 0 114102161 Acoustic Plethysmograph For Measuring Pulmonary Function E-290-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2824] Improved Acoustic Plethysmograph System for Noninvasive Measurement of Pulmonary Function&body=Please send me information about technology [TAB-2824] Improved Acoustic Plethysmograph System for Noninvasive Measurement of Pulmonary Function. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2824] Improved Acoustic Plethysmograph System for Noninvasive Measurement of Pulmonary Function&body=Please send me information about technology [TAB-2824] Improved Acoustic Plethysmograph System for Noninvasive Measurement of Pulmonary Function.">yogikala.prabhu@nih.gov</a><br> 114167810 E-290-2013-0 E-290-2013-0-US-01 Acoustic Plethysmograph For Measuring Pulmonary Function PRV US 60/958,537 Abandoned US <br />Provisional (PRV) 60/958,537<br />Filed on 2007-07-06<br />Status: Abandoned 114167811 E-290-2013-0 E-290-2013-0-US-02 Acoustic Plethysmograph For Measuring Pulmonary Function ORD US 8,328,729 12/168,829 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8328729 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8328729">8,328,729</a><br />Filed on 2009-01-08<br />Status: Abandoned 114126147 AA2XXX 114126148 AAXXXX 114126149 AA5XXX 114126150 ACXXXX 114126151 AC1XXX 114126152 AC2XXX 114126153 AC3XXX 114126154 AC6XXX 114126155 ADXXXX 114126156 AEXXXX 114126157 AE3XXX 114126158 AE1XXX 114126159 AE1BXX 114126160 AE4XXX 114126161 DXXXXX 114126162 DDXXXX 114126163 DEXXXX 114126164 IA3XXX 114126165 IA5XXX 114126166 ICXXXX 114126167 IDXXXX 114126168 VBXXXX 114126169 VJXXXX 114126170 VKXXXX 114126171 VLXXXX 114126172 VOXXXX 114126173 WAXXXX 114126174 WBXXXX 114126175 WCXXXX 114126176 WGXXXX 114126177 WIXXXX 114126178 XDXXXX 114126179 XHXXXX 114126180 XIXXXX 114126181 XJXXXX 114126182 YCXXXX 114126183 YEXXXX 114126184 YFXXXX 114126185 VPXXXX 114126186 WMXXXX 114147394 Acoustic 114147395 Plethysmograph 114147396 Measuring 114147397 Pulmonary 114147398 FUNCTION 114147399 CDC Docket Import 114147400 CDC Docket Import CDC Prosecuting 114147401 NIOSH-HELD 114147402 NIOSH 114147403 Tool 114147404 ANIMAL welfare 114147405 Animal Model 114147406 ANIMAL 114147407 research 114147408 RESEARCH TOOL 114147409 DEVICE 114147410 Breath 114147411 BREATHING 114147412 LUNG 114147413 lung cancer 114147414 Lung Disease 114147415 Lung-Targeted 114147416 LUNGS 114147417 ASTHMA 114147418 PULMONARY FIBROSIS 114147419 Pulmonary edema 114147420 RESPIRABLE 114147421 Respiration 114147422 respiratory 114147423 Respiratory Diseases 114147424 respiratory INFECTION TAB-2786 114096965 Cable-line Safety System: Electro/hydraulic Emergency Stop Device for a Winch, Drum or Capstan CDC Consumer Products, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Research Materials Consumer Products Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Research Materials John Bevan, Curtis Clark, Wayne Howie, Jennifer Lincoln, Lewis Martin, Robert Mckibbin, Gregory Miller, Todd Ruff, Chelsea Woodward This CDC-developed invention entails a system of electrical and hydraulic circuits used to stop a rotating winch in an emergency. Amongst other locations, one stop switch can be positioned on a capstan winch horn. This location makes it available to a victim entangled in rope being retrieved on a gypsy drum. As designed, the stop circuit could be used with an electrically, hydraulically or pneumatically operated winch. A variant of this safety system has been successfully tested on a purse seining fishing vessel in Alaskan waters. <ul> <li>Complies with numerous international safety regulations requiring winches, drums and capstans to have a master on/off switch in easy reach for worker safety</li> <li>Can be packaged as a ‘retrofit kit’ for integration with current commercial winch/drum usage</li> </ul> <ul> <li>Retrofitting existing winches for additional safety and adherence to possible future regulations</li> <li>Specifically designed and tested for the marine/fishing industries</li> <li>Applications in mining, construction, forestry, and/or off-road automotive industries</li> <li>Workers' well-being concern groups</li> <li>Insurers of fishing vessels; also mining, construction and forestry operations</li> <li>Manufacturers of cable reel trailers and wire-drawing machinery</li> </ul> Research Tool – Patent protection is not being pursued for this technology. Research Tools – Patent protection is not being pursued for these technologies. 2022-03-27 2026-05-14 2026-05-14 2014-03-07 AE1CXX, AE1XXX, AE2BXX, AE2XXX, AE4XXX, AEXXXX, AFXXXX, AG3XXX, AGXXXX, AXXXXX, CABLE, CABLES, capstan, CDC Docket Import, CDC Docket Import CDC Prosecuting, CDCRM, DEVICE, ELECTRO/HYDRAULIC, EMERGENCY, FISH, Maritime, NIOSH, Occupational health, RXXXXX, SAFETY, Stop, SWITCH, Switches, SWITCHING, System, WEXXXX, WFXXXX, WGXXXX, WINCH, WMXXXX, XDXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract E-504-2013-0 E-567-2013-0 E-568-2013-0 E-643-2013-0 114108596 Bevan, John CDC - NIOSH CDC Bevan, John (CDC) 0 114108597 Miller, Gregory CDC - NIOSH CDC Miller, Gregory (CDC) 0 114108598 Ruff, Todd CDC - NIOSH CDC Ruff, Todd (CDC) 0 114108599 Howie, Wayne CDC - NIOSH CDC Howie, Wayne (CDC) 0 114108600 Lincoln, Jennifer CDC - NIOSH CDC Lincoln, Jennifer (CDC) 0 114108602 Martin, Lewis CDC - NIOSH CDC Martin, Lewis (CDC) 0 114108603 Mckibbin, Robert CDC - NIOSH CDC Mckibbin, Robert (CDC) 0 114108604 Clark, Curtis CDC - NIOSH CDC Clark, Curtis (CDC) 0 114108601 Woodward, Chelsea CDC - NIOSH CDC Woodward, Chelsea (CDC) 1 114108601 Woodward, Chelsea CDC - NIOSH CDC Woodward, Chelsea (CDC) 1 114108596 Bevan, John CDC - NIOSH CDC Bevan, John (CDC) 0 114108597 Miller, Gregory CDC - NIOSH CDC Miller, Gregory (CDC) 0 114108598 Ruff, Todd CDC - NIOSH CDC Ruff, Todd (CDC) 0 114108599 Howie, Wayne CDC - NIOSH CDC Howie, Wayne (CDC) 0 114108600 Lincoln, Jennifer CDC - NIOSH CDC Lincoln, Jennifer (CDC) 0 114108602 Martin, Lewis CDC - NIOSH CDC Martin, Lewis (CDC) 0 114108603 Mckibbin, Robert CDC - NIOSH CDC Mckibbin, Robert (CDC) 0 114108604 Clark, Curtis CDC - NIOSH CDC Clark, Curtis (CDC) 0 114102111 ELECTRO/HYDRAULIC EMERGENCY STOP DEVICE FOR A WINCH E-355-2013-0 Research Material Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2786] Cable-line Safety System: Electro/hydraulic Emergency Stop Device for a Winch, Drum or Capstan&body=Please send me information about technology [TAB-2786] Cable-line Safety System: Electro/hydraulic Emergency Stop Device for a Winch, Drum or Capstan. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2786] Cable-line Safety System: Electro/hydraulic Emergency Stop Device for a Winch, Drum or Capstan&body=Please send me information about technology [TAB-2786] Cable-line Safety System: Electro/hydraulic Emergency Stop Device for a Winch, Drum or Capstan.">yogikala.prabhu@nih.gov</a><br> 114125655 AXXXXX 114125656 AEXXXX 114125657 AE1XXX 114125658 AE2XXX 114125659 AE1CXX 114125660 AE2BXX 114125661 AE4XXX 114125662 AFXXXX 114125663 AGXXXX 114125664 AG3XXX 114125665 RXXXXX 114125666 WEXXXX 114125667 WFXXXX 114125668 WGXXXX 114125669 WMXXXX 114125670 XDXXXX 114125671 XIXXXX 114125672 YEXXXX 114125673 YFXXXX 114146805 ELECTRO/HYDRAULIC 114146806 EMERGENCY 114146807 Stop 114146808 DEVICE 114146809 WINCH 114146810 CDC Docket Import 114146811 CDC Docket Import CDC Prosecuting 114146812 NIOSH 114146813 SAFETY 114146814 Occupational health 114146815 Maritime 114146816 FISH 114146817 capstan 114146818 CABLE 114146819 CABLES 114146820 System 114146821 SWITCH 114146822 SWITCHING 114146823 Switches 114146824 CDCRM TAB-2788 114096967 Mining Safety: Personal Dust Monitor Filters for Accurate, Quantifiable Spectrometric Analysis and Assessment of Worker Exposure Levels CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Donald Tuchman This CDC-developed invention pertains to a novel dust monitor filter that is specially constructed of organic materials for spectrometric analysis, ultimately allowing for detection and accurate quantification of a particular chosen analyte (e.g., crystalline silica/quartz dust that may lead to silicosis).<br /><br /> For miners, the risk of lung disease increases with the extent of dust exposure, and coal worker's pneumoconiosis (aka, black lung disease) and silicosis are still dangers routinely faced by those in the industry. Expectedly, both the concentration and the composition of airborne particulate matter present in mining environments are points of regulatory concern. For some time, collecting airborne dust samples and subsequent determination of quartz content have been integral for assessing mine worker exposure and demonstrating compliance with US Federal regulations.<br /><br /> Unfortunately, highly accurate spectrometric detection and quantification of particulate exposure has not always been possible. Generally, the filters used in existing oscillating microbalances (such as the TEOM® monitor) have been specially designed to for hydrophobicity, in order to retain as little moisture as possible on the filter. These specialized hydrophobic filters (and/or their mounting components) contain inorganic compounds that cannot be readily subjected to thermal or chemical destruction - a necessary first step of many instrumental analytical methods, such as spectroscopy.<br /><br /> This CDC-developed filter consists of entirely ashable material, making it ideal for spectrometric analysis and rapid exposure assessment. As an example, this dust monitor filter can be made entirely of organic materials and designed for quick, easy ashing that will not produce interference with the spectroscopic characteristics of the chosen analyte(s). Further, filter ashing can be carried out by a variety of methods: thermal ashing, microwave ashing, low temperature ashing, or chemical destruction. <ul> <li>Novel dust-monitoring instrument capable of providing near rapid particulate exposure information to miners/users</li> <li>Improves upon older technology by allowing for accurate detection and quantification of chosen analyte(s) and, unlike other filters, does not produce overlap or interfere with spectroscopic analysis</li> <li>Filter can be easily ashed for analysis by thermal ashing, microwave ashing, low temperature ashing, or chemical destruction</li> </ul> <ul> <li>Personal dust monitors worn wherever dust exposure levels and the presence of potentially injurious materials is evaluated</li> <li>Occupationally-mandated pneumoconiosis, asbestosis and/or silicosis prevention and monitoring programs, for complying with safety regulations</li> <li>Miners' wellness concern groups and insurance companies</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-03-07 AAXXXX, AC1XXX, AC3XXX, ACXXXX, AE1XXX, AE2XXX, AE3XXX, AE4XXX, AEXXXX, AIRBORNE, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, CHARACTERIZING, COAL, DUST, Dust collector, Methods, MINE, MINER, MINING, MONITOR, NIOSH, NIOSH-PRL, PARTICULATES, VPXXXX, WBXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WMXXXX, XDXXXX, XIXXXX, YAXXXX, YBXXXX, YEXXXX, YFXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172100 Tuchman DP. http://www.ncbi.nlm.nih.gov/pubmed/18449405 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18449405">Tuchman DP.</a> 114108607 Tuchman, Donald CDC - NIOSH CDC Tuchman, Donald (CDC) 1 114108607 Tuchman, Donald CDC - NIOSH CDC Tuchman, Donald (CDC) 1 114102113 MONITOR AND METHODS FOR CHARACTERIZING AIRBORNE PARTICULATES E-312-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2788] Mining Safety: Personal Dust Monitor Filters for Accurate, Quantifiable Spectrometric Analysis and Assessment of Worker Exposure Levels&body=Please send me information about technology [TAB-2788] Mining Safety: Personal Dust Monitor Filters for Accurate, Quantifiable Spectrometric Analysis and Assessment of Worker Exposure Levels. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2788] Mining Safety: Personal Dust Monitor Filters for Accurate, Quantifiable Spectrometric Analysis and Assessment of Worker Exposure Levels&body=Please send me information about technology [TAB-2788] Mining Safety: Personal Dust Monitor Filters for Accurate, Quantifiable Spectrometric Analysis and Assessment of Worker Exposure Levels.">yogikala.prabhu@nih.gov</a><br> 114167693 E-312-2013-0 E-312-2013-0-PCT-02 MONITOR AND METHODS FOR CHARACTERIZING AIRBORNE PARTICULATES PCT Patent Cooperation Treaty PCT/US2006/023166 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/023166<br />Filed on 2006-06-14<br />Status: Expired 114167694 E-312-2013-0 E-312-2013-0-US-01 MONITOR AND METHODS FOR CHARACTERIZING AIRBORNE PARTICULATES PRV US 60/691,564 Abandoned US <br />Provisional (PRV) 60/691,564<br />Filed on 2005-06-17<br />Status: Abandoned 114167695 E-312-2013-0 E-312-2013-0-US-03 MONITOR AND METHODS FOR CHARACTERIZING AIRBORNE PARTICULATES National Stage US 7,947,503 11/922,381 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7947503 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7947503">7,947,503</a><br />Filed on 2007-12-14<br />Status: Abandoned 114125693 AXXXXX 114125694 AAXXXX 114125695 ACXXXX 114125696 AC1XXX 114125697 AC3XXX 114125698 AEXXXX 114125699 AE1XXX 114125700 AE2XXX 114125701 AE3XXX 114125702 AE4XXX 114125703 WCXXXX 114125704 WEXXXX 114125705 WFXXXX 114125706 WGXXXX 114125707 WMXXXX 114125708 XDXXXX 114125709 XIXXXX 114125710 VPXXXX 114125711 WBXXXX 114125712 YAXXXX 114125713 YBXXXX 114125742 YEXXXX 114125743 YFXXXX 114146853 MONITOR 114146854 Methods 114146855 CHARACTERIZING 114146856 AIRBORNE 114146857 PARTICULATES 114146858 CDC Docket Import 114146859 CDC Docket Import CDC Prosecuting 114146860 NIOSH-PRL 114146861 NIOSH 114146862 MINE 114146863 MINER 114146864 MINING 114146865 COAL 114146866 DUST 114146867 Dust collector TAB-2789 114096968 Computer Controlled Aerosol Generator with Multi-Walled Carbon Nanotube Inhalation Testing Capabilities CDC Cardiology, Computational models/software, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Software / Apps, Therapeutics Cardiology Computational models/software Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Materials Software / Apps Therapeutics Bean Chen, David Frazer, Walter McKinney This invention pertains to a CDC developed sonic aerosol generator that provides a controllable, stable concentration of particulate aerosol over a long period of time for aerosol exposure studies. Specifically, <em>in situ</em> testing data indicate uniform aerosol stability can be maintainable for greater than 30 hours at concentrations of 15 mg/m<sup>3</sup> or more. Additionally, the technology was specifically developed for, and validated in, animal studies assessing exposure to airborne multi-walled carbon nanotubes (MWCNT). It has been suggested that workers may be at risk for exposure to nanosized particles during the manufacture, handling, and cleanup of engineered nanomaterials. Compared to other technologies, this CDC aerosol generator is particularly helpful when used for generating high testing concentrations of MWCNT aerosols that more accurately represent particulate levels that may be seen in a workplace environment. <ul> <li>Fully automated system with integrated feedback control for optimized stability in testing</li> <li>Maintains concentration of aerosols for >30 hours at concentrations of 15 mg/cubic meter or more</li> <li>Capable of generating high concentrations of aerosols that more accurately represent the levels seen in a workplace environment</li> <li>System insures that each run produces a constant particle concentration, air flow, pressure, temperature and humidity within a testing chamber</li> </ul> <ul> <li>Studying the size and shape of the aerosolized particles produced from simple vibrations of bulk material</li> <li>Toxicological investigations and risk assessment of aerosol exposures, especially those related to nanoparticle manufacturing</li> <li>Any aerosolization application where the aggregating “bird's nest” tendencies of airborne multi-walled carbon nanotubes must be overcome</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-03-07 AC1DXX, AC1XXX, AC4XXX, ACXXXX, AE1BXX, AE1XXX, AE2BXX, AE3XXX, AEROSOL, AEXXXX, AG2XXX, AG3XXX, AGXXXX, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DEVICE, ENVIRONMENTAL, environmental health, GENERATOR, nanotechnology, Nanotube, NIOSH, NIOSH-HELD, PARTICULATE, TOXICOLOGICAL, TOXICOLOGY, VPXXXX, WCXXXX, WFXXXX, WGXXXX, WHXXXX, WIXXXX, WMXXXX, WORK, WORKER safety, XDXXXX, XGXXXX, XIXXXX, XJXXXX, YBXXXX, YCXXXX, YEXXXX, YFXXXX False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172101 McKinney W, et al. http://www.ncbi.nlm.nih.gov/pubmed/19555230 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19555230">McKinney W, et al.</a> 114172102 Porter DW, et al. http://www.ncbi.nlm.nih.gov/pubmed/22881873 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22881873">Porter DW, et al.</a> 114172103 Porter DW, et al. http://www.ncbi.nlm.nih.gov/pubmed/19857541 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19857541">Porter DW, et al.</a> 114172104 Chen BT, et al. http://www.ncbi.nlm.nih.gov/pubmed/23033994 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23033994">Chen BT, et al.</a> 114108609 Frazer, David CDC - NIOSH CDC Frazer, David (CDC) 0 114108610 Chen, Bean CDC - NIOSH CDC Chen, Bean (CDC) 0 114108608 McKinney, Walter CDC - NIOSH CDC McKinney, Walter (CDC) 1 114108608 McKinney, Walter CDC - NIOSH CDC McKinney, Walter (CDC) 1 114108609 Frazer, David CDC - NIOSH CDC Frazer, David (CDC) 0 114108610 Chen, Bean CDC - NIOSH CDC Chen, Bean (CDC) 0 114102114 Aerosol Generator E-156-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2789] Computer Controlled Aerosol Generator with Multi-Walled Carbon Nanotube Inhalation Testing Capabilities&body=Please send me information about technology [TAB-2789] Computer Controlled Aerosol Generator with Multi-Walled Carbon Nanotube Inhalation Testing Capabilities. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2789] Computer Controlled Aerosol Generator with Multi-Walled Carbon Nanotube Inhalation Testing Capabilities&body=Please send me information about technology [TAB-2789] Computer Controlled Aerosol Generator with Multi-Walled Carbon Nanotube Inhalation Testing Capabilities.">yogikala.prabhu@nih.gov</a><br> 114167696 E-156-2013-0 E-156-2013-0-US-01 Aerosol Generator PRV US 61/237,945 Abandoned US <br />Provisional (PRV) 61/237,945<br />Filed on 2009-08-28<br />Status: Abandoned 114167697 E-156-2013-0 E-156-2013-0-US-02 Aerosol Generator ORD US 8,875,702 12/871,453 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8875702 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8875702">8,875,702</a><br />Filed on 2010-08-30<br />Status: Abandoned 114167923 E-156-2013-0 E-156-2013-0-US-03 Aerosol Generator DIV US 14/473,324 Abandoned US <br />Divisional (DIV) 14/473,324<br />Filed on 2014-08-29<br />Status: Abandoned 114125714 AXXXXX 114125715 ACXXXX 114125716 AC4XXX 114125717 AC1XXX 114125718 AC1DXX 114125719 AEXXXX 114125720 AE1XXX 114125721 AE1BXX 114125722 AE3XXX 114125723 AE2BXX 114125724 AGXXXX 114125725 AG2XXX 114125726 AG3XXX 114125727 VPXXXX 114125728 WCXXXX 114125729 WFXXXX 114125730 WGXXXX 114125731 WHXXXX 114125732 WIXXXX 114125733 WMXXXX 114125734 XDXXXX 114125735 XGXXXX 114125736 XIXXXX 114125737 XJXXXX 114125738 YBXXXX 114125739 YCXXXX 114125740 YEXXXX 114125741 YFXXXX 114146868 AEROSOL 114146869 GENERATOR 114146870 CDC Docket Import 114146871 CDC Docket Import CDC Prosecuting 114146872 NIOSH-HELD 114146873 Nanotube 114146874 TOXICOLOGICAL 114146875 TOXICOLOGY 114146876 DEVICE 114146877 NIOSH 114146878 WORK 114146879 WORKER safety 114146880 ENVIRONMENTAL 114146881 environmental health 114146882 nanotechnology 114146883 PARTICULATE TAB-2793 114096972 Silica Exposure Safety: Mini-baghouse Systems and Methods for Controlling Particulate Release from Large Sand Transfer Equipment CDC Cardiology, Consumer Products, Dental, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology Cardiology Consumer Products Dental Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Michael Breitenstein, John Snawder CDC/NIOSH scientists have developed an effective point-source control for silica-containing dusts that can be generated from machinery on sites where hydraulic fracturing is occurring. The CDC/NIOSH mini-baghouse retrofit assembly is a bolt-on control designed to contain silica-containing respirable dusts generated during refill operations of sand movers during hydraulic fracturing.<br /><br /> In the U.S., most new oil and gas wells are hydraulically fractured to enhance well production. Most hydraulic fracturing operations have 2-5 sand movers on-site that transfer thousands to millions of pounds of silica sand during each stage of fracturing. While a variety of passive and active controls are currently available (or have been proposed) to limit release of silica-containing dusts, the CDC/NIOSH mini-baghouse retrofit assembly was designed to fill a unique need for a control. The retrofit to equipment can be made in the field, uses existing energy inherent in the system and is relatively simple and effective. CDC/NIOSH field research has shown that risks for exposure to respirable silica arise from at least 8 points of dust generation and that a variety of controls (engineering, administrative and personal protective equipment) are needed to control exposures. Use of the mini-baghouse retrofit technology is intended to limit release of respirable silica from thief hatches on top of the sand movers, enhancing workplace health and safety. <ul> <li>Designed for in-field retrofitting “thief hatches” of existing machinery</li> <li>Uses energy inherent in the pneumatic transfer of sand</li> <li>Provides a passive sand-mover-mounted control for silica release at hydraulic fracturing operations</li> </ul> <ul> <li>Controlling occupational exposure to respirable crystalline silica, particularly during work involving transfer of sand into sand movers on hydraulic fracturing sites</li> <li>In-field retrofits of currently operating heavy equipment (e.g., sand movers)</li> <li>Limiting visible dust emissions from sand moving equipment</li> <li>Reducing respirable crystalline silica dust emissions to enhance compliance with OSHA PEL for silica</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2015-10-14 3/25/2014 -- designated as "Remove" per BHurley/CDC TTO: abstract contains inaccuracies and will be replaced at a later date... --ecr 4/16/2014 -- received updated abstract; okay to post now... --ecr AE1XXX, AE2XXX, AE3XXX, AEXXXX, AGXXXX, apparatus, AXXXXX, Baghouse, CDC Docket Import, CDC Docket Import CDC Prosecuting, CONTROL, CONTROLING, Crystalline, DEVICE, DUST, Dust collector, ENVIRONMENT, ENVIRONMENTAL, environmental health, Equipment, Fracturing, HYDRAULIC, LARGE, Methods, MINE, MINER, Mini, MINING, Movers, MULTIPLE, NIOSH, NIOSH-DSHEFS, Occupational health, PARTICULATE, Release, RESPIRABLE, Respiration, Respirator, Retrofit, SAND, SILICA, SILICOSIS, SYSTEMS, VPXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WMXXXX, XDXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114172133 Esswein EJ, et al. http://www.ncbi.nlm.nih.gov/pubmed/23679563 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23679563">Esswein EJ, et al.</a> 114108622 Breitenstein, Michael CDC - NIOSH CDC Breitenstein, Michael (CDC) 0 114108623 Snawder, John CDC - NIOSH CDC Snawder, John (CDC) 0 114108622 Breitenstein, Michael CDC - NIOSH CDC Breitenstein, Michael (CDC) 0 114108623 Snawder, John CDC - NIOSH CDC Snawder, John (CDC) 0 114102118 Multiple Mini Baghouse Retrofit For Control Of Respirable Crystalline Silica Release From Hydraulic Fracturing Sand Movers E-291-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2793] Silica Exposure Safety: Mini-baghouse Systems and Methods for Controlling Particulate Release from Large Sand Transfer Equipment&body=Please send me information about technology [TAB-2793] Silica Exposure Safety: Mini-baghouse Systems and Methods for Controlling Particulate Release from Large Sand Transfer Equipment. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2793] Silica Exposure Safety: Mini-baghouse Systems and Methods for Controlling Particulate Release from Large Sand Transfer Equipment&body=Please send me information about technology [TAB-2793] Silica Exposure Safety: Mini-baghouse Systems and Methods for Controlling Particulate Release from Large Sand Transfer Equipment.">yogikala.prabhu@nih.gov</a><br> 114162543 E-291-2013-0 E-291-2013-0-US-03 SYSTEMS AND METHODS FOR CONTROLLING PARTICULATE RELEASE FROM LARGE EQUIPMENT DIV US 9,669,345 14/992,963 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9669345 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9669345">9,669,345</a><br />Filed on 2016-01-11<br />Status: Abandoned 114167705 E-291-2013-0 E-291-2013-0-US-01 SYSTEMS AND METHODS FOR CONTROLING PARTICULATE RELEASE FROM LARGE EQUIPMENT PRV US 61/673,658 Abandoned US <br />Provisional (PRV) 61/673,658<br />Filed on 2012-07-19<br />Status: Abandoned 114167706 E-291-2013-0 E-291-2013-0-US-02 SYSTEMS AND METHODS FOR CONTROLING PARTICULATE RELEASE FROM LARGE EQUIPMENT ORD US 13/802,265 Abandoned US <br />Ordinary Patent (ORD) 13/802,265<br />Filed on 2013-03-13<br />Status: Abandoned 114125774 AXXXXX 114125775 AEXXXX 114125776 AE1XXX 114125777 AE2XXX 114125778 AE3XXX 114125779 AGXXXX 114125780 WCXXXX 114125781 WEXXXX 114125782 WFXXXX 114125783 WGXXXX 114125784 WMXXXX 114125785 XDXXXX 114125786 XIXXXX 114125787 YFXXXX 114125788 YEXXXX 114125939 VPXXXX 114146928 SYSTEMS 114146929 Methods 114146930 CONTROLING 114146931 PARTICULATE 114146932 Release 114146933 LARGE 114146934 Equipment 114146935 Retrofit 114146936 Baghouse 114146937 Mini 114146938 MULTIPLE 114146939 CONTROL 114146940 RESPIRABLE 114146941 Crystalline 114146942 SILICA 114146943 HYDRAULIC 114146944 Fracturing 114146945 SAND 114146946 Movers 114146947 CDC Docket Import 114146948 CDC Docket Import CDC Prosecuting 114146949 NIOSH-DSHEFS 114146950 NIOSH 114146951 MINING 114146952 MINE 114146953 MINER 114146954 DEVICE 114146955 apparatus 114146956 Occupational health 114146957 ENVIRONMENT 114146958 ENVIRONMENTAL 114146959 environmental health 114146960 DUST 114146961 SILICOSIS 114146962 Dust collector 114146963 Respiration 114146964 Respirator TAB-2761 114096940 Automated Microscopic Image Acquisition, Compositing and Display Software Developed for Applied Microscopy/Cytology Training and Analysis CDC Cardiology, Computational models/software, Consumer Products, Dental, Diagnostics, Endocrinology, Geriatrics, Immunology, Infectious Disease, Licensing, Medical Devices, Neurology, Non-Medical Devices, Oncology, Ophthalmology, Psychiatry/Mental Health, Research Equipment, Research Materials, Software / Apps, Therapeutics, Vaccines Cardiology Computational models/software Consumer Products Dental Diagnostics Endocrinology Geriatrics Immunology Infectious Disease Licensing Medical Devices Neurology Non-Medical Devices Oncology Ophthalmology Psychiatry/Mental Health Research Equipment Research Materials Software / Apps Therapeutics Vaccines Carlyn Collins, MariBeth Gagnon, James Lange, Tommy Lee, Roger Taylor Micro-Screen is a CDC developed software program designed to capture images and archive and display a compiled image(s) from a portion of a microscope slide in real time. This program allows for the re-creation of larger images that are constructed from individual microscopic fields captured in up to five focal planes and two magnifications. This program may be especially useful for the creation of data archives for diagnostic and teaching purposes and for tracking histological changes during disease progression. <ul> <li>Readily adaptable to other microscopic disciplines</li> <li>Automated imaging and display provides increased cost efficiency and improves objectivity of analysis and testing</li> <li>Can be used to develop a database of standards or reference images for a variety of pathologies and/or applied microscopy concerns</li> </ul> <ul> <li>Medical/cytology training, education and certification</li> <li>All aspects of applied microscopy/histology, microbial smears, hematology, parasitology, etc.</li> <li>Clinical diagnostics</li> <li>Basic and applied biology lab research</li> <li>Forensic analysis</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-02-06 AA3AXX, AA3B6X, AA3CXX, AA3XXX, AC2XXX, AC3XXX, Acquisition, ACXXXX, AD2XXX, AD3XXX, ADXXXX, Automated, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, Compositing, DISPLAY, Image, MICROSCOPIC, OID-NCPDCID-DLS, VAXXXX, VBXXXX, VCXXXX, VDXXXX, VEXXXX, VFXXXX, VGXXXX, VHXXXX, VIXXXX, VJXXXX, VKXXXX, VLXXXX, VMXXXX, VNXXXX, VOXXXX, VPXXXX, WBXXXX, WIXXXX, WMXXXX, XDXXXX, XFXXXX, XHXXXX, XJXXXX, YBXXXX, YEXXXX False True <ul> <li>In vitro data available</li> <li>In situ data available (on-site)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172053 Taylor RN, et al. http://www.ncbi.nlm.nih.gov/pubmed/10578977 <a href="http://www.ncbi.nlm.nih.gov/pubmed/10578977">Taylor RN, et al.</a> 114108510 Taylor, Roger CDC - DIR CDC Taylor, Roger (CDC) 0 114108511 Lange, James CDC - DIR CDC Lange, James (CDC) 0 114108512 Lee, Tommy CDC - DIR CDC Lee, Tommy (CDC) 0 114108513 Collins, Carlyn CDC - DIR CDC Collins, Carlyn (CDC) 0 114108509 Gagnon, MariBeth CDC - DIR CDC Gagnon, MariBeth (CDC) 1 114108509 Gagnon, MariBeth CDC - DIR CDC Gagnon, MariBeth (CDC) 1 114108510 Taylor, Roger CDC - DIR CDC Taylor, Roger (CDC) 0 114108511 Lange, James CDC - DIR CDC Lange, James (CDC) 0 114108512 Lee, Tommy CDC - DIR CDC Lee, Tommy (CDC) 0 114108513 Collins, Carlyn CDC - DIR CDC Collins, Carlyn (CDC) 0 114102081 Automated Microscopic Image Acquisition, Compositing, And Display E-228-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2761] Automated Microscopic Image Acquisition, Compositing and Display Software Developed for Applied Microscopy/Cytology Training and Analysis&body=Please send me information about technology [TAB-2761] Automated Microscopic Image Acquisition, Compositing and Display Software Developed for Applied Microscopy/Cytology Training and Analysis. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2761] Automated Microscopic Image Acquisition, Compositing and Display Software Developed for Applied Microscopy/Cytology Training and Analysis&body=Please send me information about technology [TAB-2761] Automated Microscopic Image Acquisition, Compositing and Display Software Developed for Applied Microscopy/Cytology Training and Analysis.">yogikala.prabhu@nih.gov</a><br> 114167617 E-228-2013-0 E-228-2013-0-US-01 Automated Microscopic Image Acquisition, Compositing, And Display PRV US 60/248,948 Abandoned US <br />Provisional (PRV) 60/248,948<br />Filed on 2000-11-14<br />Status: Abandoned 114167618 E-228-2013-0 E-228-2013-0-US-02 Automated Microscopic Image Acquisition, Compositing, And Display ORD US 7,027,628 10/001,268 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7027628 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7027628">7,027,628</a><br />Filed on 2001-11-13<br />Status: Expired 114167619 E-228-2013-0 E-228-2013-0-US-03 Automated Microscopic Image Acquisition, Compositing, And Display CON US 7,305,109 11/345,863 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7305109 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7305109">7,305,109</a><br />Filed on 2006-02-01<br />Status: Expired 114125183 AXXXXX 114125184 ACXXXX 114125185 AC2XXX 114125186 AC3XXX 114125187 ADXXXX 114125188 AD2XXX 114125189 AD3XXX 114125190 AA3XXX 114125191 AA3AXX 114125192 AA3CXX 114125193 AA3B6X 114125194 VAXXXX 114125195 VBXXXX 114125196 VCXXXX 114125197 VDXXXX 114125198 VEXXXX 114125199 VFXXXX 114125200 VGXXXX 114125201 VHXXXX 114125202 VIXXXX 114125203 VJXXXX 114125204 VKXXXX 114125205 VLXXXX 114125206 VMXXXX 114125207 VNXXXX 114125208 VOXXXX 114125209 VPXXXX 114125210 WBXXXX 114125211 WIXXXX 114125212 WMXXXX 114125213 XDXXXX 114125214 XFXXXX 114125215 XHXXXX 114125216 XJXXXX 114125217 YBXXXX 114125218 YEXXXX 114146447 Automated 114146448 MICROSCOPIC 114146449 Image 114146450 Acquisition 114146451 Compositing 114146452 DISPLAY 114146453 CDC Docket Import 114146454 CDC Docket Import CDC Prosecuting 114146455 OID-NCPDCID-DLS TAB-2762 114096941 Inexpensive, Personal Dust Detector Tube/Dosimeter Operating on a Gas Detector Tube Platform CDC Cardiology, Consumer Products, Dental, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Equipment Cardiology Consumer Products Dental Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Equipment Harry Dobroski, Steven Page, Jon Volkwein This CDC developed dust detector tube is designed to provide inexpensive, short-term, time weighted average dust exposure data feedback directly to device users. This invention operates upon a conventional gas detector tube platform and can be used with any low volume pump that can electronically measure pump back pressure. The device consists of three sections: the first defines the size of the dust and removes moisture, the second uses a filter whose pressure differential corresponds with cumulative dust loading, and a final section employs a pressure transducer.<br /><br /> Current methods require expensive instantaneous and short-term monitors or gravimetric filters that must be carefully pre- and post-weighed to determine the average dust exposure of a user's work-shift. This novel dust dosimeter fills the need for an inexpensive short-term determination of personal dust exposure aiding in the assessment and preservation of worker respiratory health. <ul> <li>Provides inexpensive, short-term assessment of personal dust exposure</li> <li>Gas detector tube platform makes commercialization of this instrument quite simple and efficient for related manufacturers/distributors</li> <li>Standardizing detection platforms increases cost-efficiency (especially for smaller companies) as the same pump can be used to measure both dust and gas</li> </ul> <ul> <li>Dust, gas and particulate detector/dosimeter manufacturers</li> <li>Industry applications where worker-exposure to dust will be a concern, especially mining, construction and demolition fields</li> <li>Worker health and safety, related insurance agency concerns</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-02-06 AE1XXX, AE2BXX, AE2XXX, AE3XXX, AEXXXX, AG3XXX, AGXXXX, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DETECTOR, DEVICE, DUST, Enviromental, environmental health, MINING, MONITOR, NIOSH, NIOSH-PRL, Occupational health, OSHA, Protection, SAMPLER, Tube, VPXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WORKER, WORKER safety, XDXXXX, XHXXXX, YEXXXX False True In situ data available (on-site) True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172054 Volkwein JC, et al. http://www.ncbi.nlm.nih.gov/pubmed/10712071 <a href="http://www.ncbi.nlm.nih.gov/pubmed/10712071">Volkwein JC, et al.</a> 114108515 Dobroski, Harry CDC - NIOSH CDC Dobroski, Harry (CDC) 0 114108516 Page, Steven CDC - NIOSH CDC Page, Steven (CDC) 0 114108514 Volkwein, Jon CDC - NIOSH CDC Volkwein, Jon (CDC) 1 114108514 Volkwein, Jon CDC - NIOSH CDC Volkwein, Jon (CDC) 1 114108515 Dobroski, Harry CDC - NIOSH CDC Dobroski, Harry (CDC) 0 114108516 Page, Steven CDC - NIOSH CDC Page, Steven (CDC) 0 114102082 Dust Detector Tube E-238-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2762] Inexpensive, Personal Dust Detector Tube/Dosimeter Operating on a Gas Detector Tube Platform&body=Please send me information about technology [TAB-2762] Inexpensive, Personal Dust Detector Tube/Dosimeter Operating on a Gas Detector Tube Platform. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2762] Inexpensive, Personal Dust Detector Tube/Dosimeter Operating on a Gas Detector Tube Platform&body=Please send me information about technology [TAB-2762] Inexpensive, Personal Dust Detector Tube/Dosimeter Operating on a Gas Detector Tube Platform.">yogikala.prabhu@nih.gov</a><br> 114167620 E-238-2013-0 E-238-2013-0-PCT-02 Dust Detector Tube PCT Patent Cooperation Treaty PCT/US1998/013267 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1998/013267<br />Filed on 1998-06-26<br />Status: Expired 114167621 E-238-2013-0 E-238-2013-0-US-01 Dust Detector Tube PRV US 60/052,719 Abandoned US <br />Provisional (PRV) 60/052,719<br />Filed on 1997-07-03<br />Status: Abandoned 114167622 E-238-2013-0 E-238-2013-0-US-03 Dust Detector Tube ORD US 6,401,520 09/467,934 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6401520 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6401520">6,401,520</a><br />Filed on 1999-12-21<br />Status: Expired 114125219 AXXXXX 114125220 AEXXXX 114125221 AE1XXX 114125222 AE2XXX 114125223 AE2BXX 114125224 AE3XXX 114125225 AGXXXX 114125226 AG3XXX 114125227 WCXXXX 114125228 WEXXXX 114125229 WFXXXX 114125230 WGXXXX 114125231 VPXXXX 114125232 XDXXXX 114125233 XHXXXX 114125234 YEXXXX 114146456 DUST 114146457 DETECTOR 114146458 Tube 114146459 CDC Docket Import 114146460 CDC Docket Import CDC Prosecuting 114146461 NIOSH-PRL 114146462 NIOSH 114146463 OSHA 114146464 MINING 114146465 WORKER 114146466 WORKER safety 114146467 Occupational health 114146468 DEVICE 114146469 MONITOR 114146470 Enviromental 114146471 environmental health 114146472 SAMPLER 114146473 Protection TAB-2774 114096953 Auscultatory Training System and Telemedicine Tool with Accurate Reproduction of Physiological Sounds CDC Cardiology, Computational models/software, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Pulmonology, Research Materials, Software / Apps, Therapeutics Cardiology Computational models/software Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Pulmonology Research Materials Software / Apps Therapeutics David Frazer, Kimberly Friend, William Goldsmith, Walter McKinney, Jeffrey Reynolds This CDC developed auscultatory training apparatus includes a database of prerecorded physiological sounds (e.g., lung, bowel, or heart sounds) stored on a computer for playback. Current teaching tools, which utilize previously recorded sounds, suffer from the disadvantage that playback environments cause considerable distortion and errors in sound reproduction. For example, to those trainees using such systems, the reproduced respiratory sounds do not “sound” as if they are being generated by a live patient. Moreover, the aforementioned playback distortions often make it difficult for the listener to hear and interpret the subtleties of a recorded respiratory maneuver.<br /><br /> This device includes a software program that allows a user to select prerecorded sounds for playback. The program will also generate an inverse model of the playback system in the form of a digital filter. The inverse model processes a selected sound to cancel the distortions of the playback system so the sound is accurately reproduced. The program also permits the extraction of a specific sound component from a prerecorded sound so only the extracted sound component is audible during playback. In addition to the obvious role of a teaching tool for medical professionals, this invention could have applications as a diagnostic screening and/or telemedicine tool. <ul> <li>Accurate, realistic reproduction of in situ physiological sounds</li> <li>Apparatus features noise-cancelling filter to eliminate ambient distortion artifacts during playback</li> <li>Device is extremely portable</li> <li>Allows for isolation and playback of specific elements of a recording</li> </ul> <ul> <li>Auscultatory training for health care professionals</li> <li>Telemedicine tool</li> <li>Diagnostic screening comparison and control</li> </ul> International patent application pending (Canada) 2022-03-27 2026-05-14 2026-05-14 2014-02-07 AA3B6X, AA3BXX, AA3XXX, AAXXXX, AB4XXX, ACXXXX, ADXXXX, AFXXXX, Auscultatory, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, IA1XXX, IA5XXX, IAXXXX, IB1FXX, IB4XXX, ICXXXX, IDXXXX, IXXXXX, NIOSH-HELD, System, TRAINING, VDXXXX, VOXXXX, VPXXXX, WBXXXX, WFXXXX, WHXXXX, WIXXXX, WMXXXX, XDXXXX, XFXXXX, XIXXXX, XJXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-245-2013-0 114172068 Goldsmith WT, et al. http://www.ncbi.nlm.nih.gov/pubmed/19876736 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19876736">Goldsmith WT, et al.</a> 114172069 Abaza AA, et al. http://www.ncbi.nlm.nih.gov/pubmed/19930559 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19930559">Abaza AA, et al.</a> 114108555 Reynolds, Jeffrey CDC - NIOSH CDC Reynolds, Jeffrey (CDC) 0 114108556 Friend, Kimberly CDC - NIOSH CDC Friend, Kimberly (CDC) 0 114108557 Goldsmith, William CDC - NIOSH CDC Goldsmith, William (CDC) 0 114108558 Frazer, David CDC - NIOSH CDC Frazer, David (CDC) 0 114108554 McKinney, Walter CDC - NIOSH CDC McKinney, Walter (CDC) 1 114108554 McKinney, Walter CDC - NIOSH CDC McKinney, Walter (CDC) 1 114108555 Reynolds, Jeffrey CDC - NIOSH CDC Reynolds, Jeffrey (CDC) 0 114108556 Friend, Kimberly CDC - NIOSH CDC Friend, Kimberly (CDC) 0 114108557 Goldsmith, William CDC - NIOSH CDC Goldsmith, William (CDC) 0 114108558 Frazer, David CDC - NIOSH CDC Frazer, David (CDC) 0 114102096 Auscultatory Training System E-283-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2774] Auscultatory Training System and Telemedicine Tool with Accurate Reproduction of Physiological Sounds&body=Please send me information about technology [TAB-2774] Auscultatory Training System and Telemedicine Tool with Accurate Reproduction of Physiological Sounds. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2774] Auscultatory Training System and Telemedicine Tool with Accurate Reproduction of Physiological Sounds&body=Please send me information about technology [TAB-2774] Auscultatory Training System and Telemedicine Tool with Accurate Reproduction of Physiological Sounds.">yogikala.prabhu@nih.gov</a><br> 114167653 E-283-2013-0 E-283-2013-0-US-01 Auscultatory Training System PRV US 60/287,941 Abandoned US <br />Provisional (PRV) 60/287,941<br />Filed on 2001-04-30<br />Status: Abandoned 114167654 E-283-2013-0 E-283-2013-0-US-02 Auscultatory Training System ORD US 7,209,796 10/135,964 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7209796 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7209796">7,209,796</a><br />Filed on 2002-04-29<br />Status: Expired 114125443 AXXXXX 114125444 AAXXXX 114125445 ACXXXX 114125446 ADXXXX 114125447 AB4XXX 114125448 AA3XXX 114125449 AA3BXX 114125450 AA3B6X 114125451 AFXXXX 114125452 IXXXXX 114125453 IAXXXX 114125454 IA1XXX 114125455 IA5XXX 114125456 ICXXXX 114125457 IDXXXX 114125458 IB1FXX 114125459 IB4XXX 114125460 VDXXXX 114125461 VOXXXX 114125462 VPXXXX 114125463 WBXXXX 114125464 WFXXXX 114125465 WHXXXX 114125466 WIXXXX 114125467 WMXXXX 114125468 XDXXXX 114125469 XFXXXX 114125470 XIXXXX 114125471 XJXXXX 114125472 YEXXXX 114125473 YFXXXX 114146610 Auscultatory 114146611 TRAINING 114146612 System 114146613 CDC Docket Import 114146614 CDC Docket Import CDC Prosecuting 114146615 NIOSH-HELD TAB-2781 114096960 Air Quality Assurance: A Monitor for Continuous, Simultaneous Analysis of Atmospheric or Aerosolized Particulate Mixtures CDC Consumer Products, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health Consumer Products Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Charles Litton, William Schiffbauer, Jon Volkwein This technology pertains to monitors for measuring the mass concentration of ambient particulate matter in an atmosphere containing both larger/coarser (e.g., respirable dust) and smaller/finer (sub-micrometer particles such as diesel particulate matter - DPM) particulate mixtures. The monitoring device can be configured for operation with a controller unit adapted to ionization sensor and/or light-scattering modules. The controller translates the sensor output signal into a quantifiable value, determining mass concentration of particulate matter within the ionization chamber. For example, practical applications of this monitor/analysis technology would easily extend to use in mining operations (where both DPM and respirable dust exist in abundance), industrial manufacturing facilities, and anywhere that frequent or extended exposure to fuel-combustion exhaust or airborne pollution is a concern. Further, by virtue of its ability to distinguish “fire smoke” from other aerosols that may be present, the device also has significant potential for use in early-warning fire detection. <ul> <li>Inexpensive and simple to implement</li> <li>Device provides continuous, simultaneous, and independent measurement of both respirable dust and diesel particulate matter (DPM) mass concentrations</li> <li>Previous particulate counting technologies are both expensive and cannot provide accurate quantification of coarse/fine aerosol mixtures, concentrations</li> </ul> <ul> <li>Airborne particle monitor for mining and industrial manufacturing operations</li> <li>Addressing emissions control standards and regulations</li> <li>Early-warning fire detection in locations where traditional smoke-detector use is impractical</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-02-28 AE1BXX, AE2BXX, AE2XXX, AE3XXX, AEXXXX, ANALYZING, apparatus, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, Ionization, Light-scattering, Methods, NIOSH-PRL, PARTICLES, SENSORS, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WMXXXX, XDXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114108580 Volkwein, Jon CDC - NIOSH CDC Volkwein, Jon (CDC) 0 114108581 Schiffbauer, William CDC - NIOSH CDC Schiffbauer, William (CDC) 0 114108579 Litton, Charles CDC - NIOSH CDC Litton, Charles (CDC) 1 114108579 Litton, Charles CDC - NIOSH CDC Litton, Charles (CDC) 1 114108580 Volkwein, Jon CDC - NIOSH CDC Volkwein, Jon (CDC) 0 114108581 Schiffbauer, William CDC - NIOSH CDC Schiffbauer, William (CDC) 0 114102106 Apparatus And Methods For Analyzing Particles Using Light-scattering Sensors And Ionization Sensors E-240-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2781] Air Quality Assurance: A Monitor for Continuous, Simultaneous Analysis of Atmospheric or Aerosolized Particulate Mixtures&body=Please send me information about technology [TAB-2781] Air Quality Assurance: A Monitor for Continuous, Simultaneous Analysis of Atmospheric or Aerosolized Particulate Mixtures. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2781] Air Quality Assurance: A Monitor for Continuous, Simultaneous Analysis of Atmospheric or Aerosolized Particulate Mixtures&body=Please send me information about technology [TAB-2781] Air Quality Assurance: A Monitor for Continuous, Simultaneous Analysis of Atmospheric or Aerosolized Particulate Mixtures.">yogikala.prabhu@nih.gov</a><br> 114167678 E-240-2013-0 E-240-2013-0-US-01 Apparatus And Methods For Analyzing Particles Using Light-scattering Sensors And Ionization Sensors PRV US 60/369,537 Abandoned US <br />Provisional (PRV) 60/369,537<br />Filed on 2002-04-01<br />Status: Abandoned 114167679 E-240-2013-0 E-240-2013-0-US-02 Apparatus And Methods For Analyzing Particles Using Light-scattering Sensors And Ionization Sensors ORD US 6,965,240 10/401,980 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6965240 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6965240">6,965,240</a><br />Filed on 2003-03-27<br />Status: Abandoned 114125587 AXXXXX 114125588 AEXXXX 114125589 AE2XXX 114125590 AE2BXX 114125591 AE1BXX 114125592 AE3XXX 114125593 WCXXXX 114125594 WEXXXX 114125595 WFXXXX 114125596 WGXXXX 114125597 WMXXXX 114125598 XDXXXX 114125599 XIXXXX 114125600 YEXXXX 114125601 YFXXXX 114146739 apparatus 114146740 Methods 114146741 ANALYZING 114146742 PARTICLES 114146743 Light-scattering 114146744 SENSORS 114146745 Ionization 114146746 CDC Docket Import 114146747 CDC Docket Import CDC Prosecuting 114146748 NIOSH-PRL TAB-2739 114096918 Device to Measure Muscle Contractile-Relaxant and Epithelial Bioelectric Responses of Perfused, Intact Tracheal Airways Tissue In Vitro CDC Cardiology, Collaboration, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Oncology, Ophthalmology, Research Equipment, Research Materials, Therapeutics Cardiology Collaboration Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Oncology Ophthalmology Research Equipment Research Materials Therapeutics Jeffrey Fedan, Yi Jing, Michael Van Scott CDC and collaborative researchers have developed a device allowing for simultaneous measurement of smooth muscle contractile/relaxant activity and transepithelial potential difference (Vt) [or short circuit currents (Isc)] and resistance (Rt) within an intact airway <em>in vitro</em>. Investigation of the underlying mechanisms of lung diseases, such as asthma or cystic fibrosis, involves understanding the roles of airway smooth muscle and epithelium. Smooth muscle is involved in the control of the airway diameter; epithelium regulates the ionic composition of the liquid lining the airways through electrogenic ion transport and releases factors that regulate the ability of smooth muscle to contract.<br /><br /> This invention allows for the measurement and study of pulmonary diseases under conditions retaining normal spatial relationships between all the cell types and an unmanipulated/undistorted tracheal airway wall. Further, the device permits evaluation of epithelial functional integrity using pharmacological techniques. Agents can be separately added to the lumen, where they must first cross the epithelium to reach the smooth muscle, or to the outside of the airway, where there is no hindrance of said agents to the muscle. The invention also permits the effective <em>in vitro</em> screening of the effects of agents and drugs on airway epithelium and smooth muscle within the same preparation. <ul> <li>Allows simultaneous measurement of transepithelial potential difference, transepithelial resistance, smooth muscle activity and changes in tracheal diameter</li> <li>In vitro analysis of trachea or tracheal segments retaining native, in situ structure</li> <li>Pharmacological agents may be added separately to the lumen for screening purposes</li> <li>First and only such "single-preparation" device allowing for such broad array of data output</li> </ul> <ul> <li>Investigations into physiological mechanisms of airway diseases, such as cystic fibrosis and asthma</li> <li>Screening of drugs and therapeutic compounds directed to complex, multi-tissue type matrices</li> <li>Biomedical research exploring pharmacology-physiology integration</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-01-27 AA2XXX, AAXXXX, AC4XXX, AC5XXX, ACXXXX, apparatus, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, CHARACTERISTICS, ICXXXX, IDXXXX, INTACT, IXXXXX, Measuring, Method, PHYSIOLOGICAL, Trachea, Vitro, VPXXXX, WBXXXX, WIXXXX, WMXXXX, XDXXXX, XHXXXX, YAXXXX, YBXXXX, YEXXXX, YFXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114172021 JIng Y, et. al. http://www.ncbi.nlm.nih.gov/pubmed/18835555 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18835555">JIng Y, et. al.</a> 114108448 Jing, Yi CDC - NIOSH CDC Jing, Yi (CDC) 0 114108449 Van Scott, Michael East Carolina University Van Scott, Michael 0 114108447 Fedan, Jeffrey CDC - NIOSH CDC Fedan, Jeffrey (CDC) 1 114108447 Fedan, Jeffrey CDC - NIOSH CDC Fedan, Jeffrey (CDC) 1 114108448 Jing, Yi CDC - NIOSH CDC Jing, Yi (CDC) 0 114108449 Van Scott, Michael East Carolina University Van Scott, Michael 0 114102057 Apparatus And Method For Measuring Physiological Characteristics Of An Intact Trachea In Vitro E-246-2013-0 Closed Centers for Disease Control and Prevention (CDC), East Carolina University 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2739] Device to Measure Muscle Contractile-Relaxant and Epithelial Bioelectric Responses of Perfused, Intact Tracheal Airways Tissue In Vitro&body=Please send me information about technology [TAB-2739] Device to Measure Muscle Contractile-Relaxant and Epithelial Bioelectric Responses of Perfused, Intact Tracheal Airways Tissue In Vitro. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2739] Device to Measure Muscle Contractile-Relaxant and Epithelial Bioelectric Responses of Perfused, Intact Tracheal Airways Tissue In Vitro&body=Please send me information about technology [TAB-2739] Device to Measure Muscle Contractile-Relaxant and Epithelial Bioelectric Responses of Perfused, Intact Tracheal Airways Tissue In Vitro.">yogikala.prabhu@nih.gov</a><br> 114167534 E-246-2013-0 E-246-2013-0-US-02 Apparatus And Method For Measuring Physiological Characteristics Of An Intact Trachea In Vitro ORD US 7,907,999 11/655,635 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7907999 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7907999">7,907,999</a><br />Filed on 2007-01-19<br />Status: Abandoned 114167538 E-246-2013-0 E-246-2013-0-US-01 Apparatus And Method For Measuring Physiological Characteristics Of An Intact Trachea In Vitro PRV US 60/762,465 Abandoned US <br />Provisional (PRV) 60/762,465<br />Filed on 2006-01-25<br />Status: Abandoned 114124780 AXXXXX 114124781 AAXXXX 114124782 AA2XXX 114124783 ACXXXX 114124784 AC4XXX 114124785 AC5XXX 114124786 IXXXXX 114124787 ICXXXX 114124788 IDXXXX 114124790 VPXXXX 114124791 WBXXXX 114124792 WIXXXX 114124793 WMXXXX 114124794 XDXXXX 114124795 XHXXXX 114124796 YAXXXX 114124797 YBXXXX 114124798 YEXXXX 114124799 YFXXXX 114146197 apparatus 114146198 Method 114146199 Measuring 114146200 PHYSIOLOGICAL 114146201 CHARACTERISTICS 114146202 INTACT 114146203 Trachea 114146204 Vitro 114146205 CDC Docket Import 114146206 CDC Docket Import CDC Prosecuting TAB-2758 114096933 Cylindrical Handle Dynamometer for Improved Grip-Strength Measurement CDC Cardiology, Dental, Diagnostics, Endocrinology, Geriatrics, Immunology, Infectious Disease, Licensing, Medical Devices, Neurology, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology Cardiology Dental Diagnostics Endocrinology Geriatrics Immunology Infectious Disease Licensing Medical Devices Neurology Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Renguang Dong, Thomas McDowell, Christopher Warren, Daniel Welcome, Bryan Wimer CDC researchers have developed an improved dynamometer device and method for measuring maximum hand grip force or grip-strength. Human test subjects were used in conducting experiments to evaluate the handle and to assess the measurement method. In contrast to the currently used "Jamar handle" grip strength dynamometer devices, the cylindrical handle proved to be able to determine the overall grip strength for a subject, as well as show the grip force distribution around the circumference of the handle. The cylindrical dynamometer handle is accurate with less than 4% error, and it demonstrates that the measurement is independent of the loading position along the handle. For real-world applications, the device can be used to help diagnose the musculoskeletal disorders of the hand, monitor the recovery progress after hand surgery or injury, and collect grip strength data for tool and machine design. Compared to currently used "Jamar" grip test devices: <ul> <li>Cylindrical handle shape more comparable with real-world/workplace machinery</li> <li>Improved comfort</li> <li>Cylindrical meter assesses the total grip force, together with the friction force and torque</li> <li>Grip force distributed at the different parts of the hand can be measured with cylindrical meter - important information for the diagnosis of hand disorders</li> </ul> <ul> <li>Useful for engineering functional design and ergonomic considerations for developing new tools and machinery</li> <li>Monitoring post-operative, post-stroke rehabilitation</li> <li>Diagnosis of carpel tunnel syndrome, musculoskeletal disorders and hand-arm vibration syndrome</li> <li>Training feedback for grip-strength focused athletes - climbing, gymnastics, rugby, martial arts, etc.</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-02-06 AA1XXX, AA2XXX, AA4BXX, AA4XXX, AAXXXX, AB1XXX, AFXXXX, ASSESSMENT, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, Configuration, Dynamometer, GRIP, HAND, Improved, NIOSH-HELD, Strength, VAXXXX, VEXXXX, VPXXXX, WBXXXX, WGXXXX, XDXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172051 Wimer B, et al. http://www.ncbi.nlm.nih.gov/pubmed/19250853 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19250853">Wimer B, et al.</a> 114108501 Welcome, Daniel CDC - NIOSH CDC Welcome, Daniel (CDC) 0 114108502 Warren, Christopher CDC - NIOSH CDC Warren, Christopher (CDC) 0 114108503 McDowell, Thomas CDC - NIOSH CDC McDowell, Thomas (CDC) 0 114108504 Dong, Renguang CDC - NIOSH CDC Dong, Renguang (CDC) 0 114108500 Wimer, Bryan CDC - NIOSH CDC Wimer, Bryan (CDC) 1 114108500 Wimer, Bryan CDC - NIOSH CDC Wimer, Bryan (CDC) 1 114108501 Welcome, Daniel CDC - NIOSH CDC Welcome, Daniel (CDC) 0 114108502 Warren, Christopher CDC - NIOSH CDC Warren, Christopher (CDC) 0 114108503 McDowell, Thomas CDC - NIOSH CDC McDowell, Thomas (CDC) 0 114108504 Dong, Renguang CDC - NIOSH CDC Dong, Renguang (CDC) 0 114102078 HAND DYNAMOMETER WITH IMPROVED CONFIGURATION FOR GRIP STRENGTH ASSESSMENT E-143-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2758] Cylindrical Handle Dynamometer for Improved Grip-Strength Measurement&body=Please send me information about technology [TAB-2758] Cylindrical Handle Dynamometer for Improved Grip-Strength Measurement. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2758] Cylindrical Handle Dynamometer for Improved Grip-Strength Measurement&body=Please send me information about technology [TAB-2758] Cylindrical Handle Dynamometer for Improved Grip-Strength Measurement.">yogikala.prabhu@nih.gov</a><br> 114167611 E-143-2013-0 E-143-2013-0-US-01 HAND DYNAMOMETER WITH IMPROVED CONFIGURATION FOR GRIP STRENGTH ASSESSMENT PRV US 61/175,473 Abandoned US <br />Provisional (PRV) 61/175,473<br />Filed on 2009-05-05<br />Status: Abandoned 114167612 E-143-2013-0 E-143-2013-0-US-02 HAND DYNAMOMETER WITH IMPROVED CONFIGURATION FOR GRIP STRENGTH ASSESSMENT ORD US 8,240,202 12/773,420 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8240202 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8240202">8,240,202</a><br />Filed on 2010-05-04<br />Status: Abandoned 114125132 AXXXXX 114125133 AAXXXX 114125134 AA1XXX 114125135 AA4XXX 114125136 AA4BXX 114125137 AA2XXX 114125138 AB1XXX 114125139 AFXXXX 114125140 XDXXXX 114125141 WBXXXX 114125142 WGXXXX 114125143 XIXXXX 114125144 VAXXXX 114125145 VEXXXX 114125146 VPXXXX 114125147 YEXXXX 114125148 YFXXXX 114146407 HAND 114146408 Dynamometer 114146409 Improved 114146410 Configuration 114146411 GRIP 114146412 Strength 114146413 ASSESSMENT 114146414 CDC Docket Import 114146415 CDC Docket Import CDC Prosecuting 114146416 NIOSH-HELD TAB-2757 114096937 Extension-Ladder Safety: Multimodal-feedback Indicator for Improved Ladder Positioning Safety and Efficiency CDC Cardiology, Consumer Products, Dental, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology Cardiology Consumer Products Dental Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Hongwei Hsiao, John Powers, Peter Simeonov Improper positioning of an extension ladder frequently results in "ladder slide-outs," which are the most common cause of ladder-fall scenarios. This invention relates to an extension ladder positioning indicator which is easily installed in a ladder rung; provides multiple cues (visual, sound, and vibration) for rapidly identifying and positioning correct ladder inclination.<br /><br /> CDC-NIOSH researchers found that this technology improved accuracy and efficiency of ladder positioning for both "experienced" and "novice" ladder users, as compared to the "no instruction" method and the standard anthropometric method, and that it was also significantly faster than the bubble indicator method. When properly implemented, this effective and easy to use ladder positioning indicator will reduce the risk of extension ladder slipping and tipping and, ultimately, will reduce the number of fall incidents and injuries – benefitting construction workers, employers, contractors and workplace insurers. <ul> <li>Direct, multimodal user feedback reduces the time for accurate, safe ladder positioning compared to bubble-level indicator, anthropometric and sight- based ladder-positioning methods</li> <li>Visual, auditory and tactile feedback provide increased efficient-setup and safety</li> <li>Technology can be incorporated as an attachable, device which may be affixed to a ladder or integrated as an app for a mobile/tablet device</li> <li>Automated feedback ensures ladders are angled to OSHA and ANSI safety specifications</li> </ul> <ul> <li>Retrofitting existing ladders to provide automated, multisensory feedback for improved compliance with OSHA and ANSI ladder-angle safety guidelines</li> <li>Ladder manufacturing companies</li> <li>Construction contractors, retailers and insurers</li> <li>Training tool to aid worker safety education and adherence</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-02-06 advanced ladder technology, AE1XXX, AE2AXX, AE2BXX, AE2XXX, AEXXXX, AFXXXX, apparatus, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DEVICE, INDICATOR, LADDER, MULTIMODAL, NIOSH, NIOSH-DSR, Positioning, SAFETY, VPXXXX, WGXXXX, WMXXXX, XDXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114172050 Simeonov P, et al. http://www.ncbi.nlm.nih.gov/pubmed/23177178 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23177178">Simeonov P, et al.</a> 114108498 Hsiao, Hongwei CDC - NIOSH CDC Hsiao, Hongwei (CDC) 0 114108499 Powers, John CDC - NIOSH CDC Powers, John (CDC) 0 114108497 Simeonov, Peter CDC - NIOSH CDC Simeonov, Peter (CDC) 1 114108497 Simeonov, Peter CDC - NIOSH CDC Simeonov, Peter (CDC) 1 114108498 Hsiao, Hongwei CDC - NIOSH CDC Hsiao, Hongwei (CDC) 0 114108499 Powers, John CDC - NIOSH CDC Powers, John (CDC) 0 114102077 Multimodal Indicator Safety Device For Ladder Positioning E-141-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2757] Extension-Ladder Safety: Multimodal-feedback Indicator for Improved Ladder Positioning Safety and Efficiency&body=Please send me information about technology [TAB-2757] Extension-Ladder Safety: Multimodal-feedback Indicator for Improved Ladder Positioning Safety and Efficiency. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2757] Extension-Ladder Safety: Multimodal-feedback Indicator for Improved Ladder Positioning Safety and Efficiency&body=Please send me information about technology [TAB-2757] Extension-Ladder Safety: Multimodal-feedback Indicator for Improved Ladder Positioning Safety and Efficiency.">yogikala.prabhu@nih.gov</a><br> 114167610 E-141-2013-0 E-141-2013-0-US-01 Multimodal Indicator Safety Device For Ladder Positioning ORD US 8,167,087 12/400,233 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8167087 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8167087">8,167,087</a><br />Filed on 2009-03-09<br />Status: Issued 114125118 AXXXXX 114125119 AEXXXX 114125120 AE1XXX 114125121 AE2XXX 114125122 AE2BXX 114125123 AE2AXX 114125124 AFXXXX 114125125 VPXXXX 114125126 WGXXXX 114125127 WMXXXX 114125128 XDXXXX 114125129 XIXXXX 114125130 YEXXXX 114125131 YFXXXX 114146395 MULTIMODAL 114146396 INDICATOR 114146397 SAFETY 114146398 DEVICE 114146399 LADDER 114146400 Positioning 114146401 CDC Docket Import 114146402 CDC Docket Import CDC Prosecuting 114146403 NIOSH-DSR 114146404 advanced ladder technology 114146405 apparatus 114146406 NIOSH TAB-2759 114096938 Physiologic Sampling Pump Capable of Rapidly Adapting to User Breathing Rate CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Therapeutics, Vaccines Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Therapeutics Vaccines Michael Flemmer, Larry Lee This CDC developed physiologic sampling pump (PSP) overcomes shortcomings of previous devices by the use of calibrated valves in conjunction with a constant speed pump. This novel approach obviates typical PSP inertia that inherently limits system response, functionality and accuracy. All prior PSP designs have attempted to follow a user's breathing pattern by changing pump speed, thereby altering sampling rate. In that approach, pump inertia will limit system response and function due to the time required to adjust speed. Additionally, variable pump speeds often produce size selective sampling errors at low flow rates.<br /><br /> Performance of this PSP is not degraded by pump inertia or low flow size selective sampling errors. This design maintains a consistent pump speed, controlling PSP sampling rate with calibrated valves that redirect air flow almost instantaneously. In situ device testing demonstrated that when this air-flow valve is properly integrated into a sampling head, response time of the PSP is essentially mutually exclusive of the magnitude of changes in the effective flow, facilitating consistently small error in sampling performance regardless of user-exertion scenario. <ul> <li>Allows for air sampling to be modulated to follow breathing rate</li> <li>Design obviates the sluggishness inherent in prior art physiologic sampling pumps (PSPs) caused by variable pump speed effect on sampling rate</li> <li>Improved accuracy compared to earlier PSPs, irrelevant of user-exertion scenarios</li> <li>Follows inhalation on a breath-by-breath basis</li> </ul> <ul> <li>Air sampling device manufacturers</li> <li>Assessing airborne hazard exposures for workplace safety</li> <li>Industrial hygiene programs</li> <li>Respiration monitoring device for patients</li> <li>Aerobic training system for athletes</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-02-06 BREATHING, Capable, CDC Docket Import, CDC Docket Import CDC Prosecuting, NIOSH-HELD, PHYSIOLOGIC, PSP, PUMP, RAPID, RESPONSE, Sampling, UNIVERSAL, VBXXXX, VPXXXX, WAXXXX, WBXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WMXXXX, XDXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172052 Lee L, et al. http://www.ncbi.nlm.nih.gov/pubmed/19436860 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19436860">Lee L, et al.</a> 114108506 Flemmer, Michael CDC - NIOSH CDC Flemmer, Michael (CDC) 0 114108505 Lee, Larry CDC - NIOSH CDC Lee, Larry (CDC) 1 114108505 Lee, Larry CDC - NIOSH CDC Lee, Larry (CDC) 1 114108506 Flemmer, Michael CDC - NIOSH CDC Flemmer, Michael (CDC) 0 114102079 A Universal Physiologic Sampling Pump (PSP) Capable Of Rapid Response To Breathing E-169-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2759] Physiologic Sampling Pump Capable of Rapidly Adapting to User Breathing Rate&body=Please send me information about technology [TAB-2759] Physiologic Sampling Pump Capable of Rapidly Adapting to User Breathing Rate. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2759] Physiologic Sampling Pump Capable of Rapidly Adapting to User Breathing Rate&body=Please send me information about technology [TAB-2759] Physiologic Sampling Pump Capable of Rapidly Adapting to User Breathing Rate.">yogikala.prabhu@nih.gov</a><br> 114167613 E-169-2013-0 E-169-2013-0-US-01 Universal Physiologic Sampling Pump (PSP) Capable Of Rapid Response To Breathing PRV US 61/145,777 Abandoned US <br />Provisional (PRV) 61/145,777<br />Filed on 2010-01-20<br />Status: Abandoned 114167614 E-169-2013-0 E-169-2013-0-US-02 Universal Physiologic Sampling Pump (PSP) Capable Of Rapid Response To Breathing ORD US 8,459,098 12/690,550 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8459098 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8459098">8,459,098</a><br />Filed on 2010-01-20<br />Status: Issued 114125149 VBXXXX 114125150 VPXXXX 114125151 WAXXXX 114125152 WBXXXX 114125153 WCXXXX 114125154 WEXXXX 114125155 WFXXXX 114125156 WGXXXX 114125157 WMXXXX 114125158 XDXXXX 114125159 XIXXXX 114125160 YEXXXX 114125161 YFXXXX 114146417 UNIVERSAL 114146418 PHYSIOLOGIC 114146419 Sampling 114146420 PUMP 114146421 PSP 114146422 Capable 114146423 RAPID 114146424 RESPONSE 114146425 BREATHING 114146426 CDC Docket Import 114146427 CDC Docket Import CDC Prosecuting 114146428 NIOSH-HELD TAB-2760 114096939 Ultrasonic in situ Respirator Seal-Leakage Detection with Real-time Feedback Capabilities CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Therapeutics, Vaccines Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Materials Therapeutics Vaccines William King, Jonathan Szalajda This CDC invention entails methods and apparatuses for <em>in situ</em> testing seal integrity and improved operation of respiratory masks (respirators). A variety of external factors, such as individual face shape, user environment, mask age and material used to construct the respirator, can lead to device malfunction and failure to sufficiently protect a user. To address these limitations, this invention relies on ultrasonic wave detection to assess face seal quality and other potential leak paths, as needed. Airborne ultrasound travel through atmosphere and will travel through respirator leaks. Applying this phenomena to occupational health and safety, CDC researchers have developed novel ultrasonics technology to identify and quantify respirator seal leakage in real-time. Small, low power consuming, and inexpensive apparatuses and methods for generating and detecting ultrasound may be easily obtained and customized for a given respirator and/or application.<br /><br /> By correlating user activity to seal sensor data, a precise understanding and awareness of respirator integrity may be obtained. When coupled with a subject alarm, these integrated values can immediately alert a user when a threshold of environmental exposure has been reached. Such real-time feedback will be invaluable to users in dangerous occupational activities, such as firefighters, biodefense and chemical spill first responders, mining applications, etc. Additionally, this invention possesses immense value for respirator mask manufacturers and workplace training programs for employees engaged in mandatory respirator usage applications. <ul> <li>Small, low power consuming, and inexpensive apparatuses and methods may be employed</li> <li>Real-time monitoring and feedback greatly diminish risk of user exposure to environmental hazards</li> </ul> <ul> <li>Manufacturers of respirators, leakage assessment devices and applied ultrasonic technology</li> <li>Regulators of respiratory protection plans</li> <li>Biohazard, biodefense and hazardous chemical handling and disposal</li> <li>Surgery/hospital training and use</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-02-06 AE2XXX, AE3XXX, AEROSOL, AEROSOLS, AEXXXX, AXXXXX, Biodefense, CDC Docket Import, CDC Docket Import CDC Prosecuting, DEVICE, Devices, MASK, NIOSH-NPPTL, Preventative, PROCESS, Protection, Respirator, respiratory, SAFETY, Situ, TESTING, ultrasonic, VBXXXX, VJXXXX, VKXXXX, VLXXXX, VOXXXX, VPXXXX, WAXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WIXXXX, WMXXXX, XDXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114108508 Szalajda, Jonathan CDC - NIOSH CDC Szalajda, Jonathan (CDC) 0 114108507 King, William CDC - NIOSH CDC King, William (CDC) 1 114108507 King, William CDC - NIOSH CDC King, William (CDC) 1 114108508 Szalajda, Jonathan CDC - NIOSH CDC Szalajda, Jonathan (CDC) 0 114102080 Ultrasonic In Situ Respiratory Mask Testing Process And Mask E-174-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2760] Ultrasonic in situ Respirator Seal-Leakage Detection with Real-time Feedback Capabilities&body=Please send me information about technology [TAB-2760] Ultrasonic in situ Respirator Seal-Leakage Detection with Real-time Feedback Capabilities. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2760] Ultrasonic in situ Respirator Seal-Leakage Detection with Real-time Feedback Capabilities&body=Please send me information about technology [TAB-2760] Ultrasonic in situ Respirator Seal-Leakage Detection with Real-time Feedback Capabilities.">yogikala.prabhu@nih.gov</a><br> 114167615 E-174-2013-0 E-174-2013-0-US-01 Ultrasonic In Situ Respiratory Mask Testing Process And Mask PRV US 61/329,846 Abandoned US <br />Provisional (PRV) 61/329,846<br />Filed on 2012-04-30<br />Status: Abandoned 114167616 E-174-2013-0 E-174-2013-0-US-02 Ultrasonic In Situ Respiratory Mask Testing Process And Mask ORD US 8,573,199 13/098,980 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8573199 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8573199">8,573,199</a><br />Filed on 2011-05-02<br />Status: Abandoned 114125162 AEXXXX 114125163 AXXXXX 114125164 AE2XXX 114125165 AE3XXX 114125166 VBXXXX 114125167 VJXXXX 114125168 VKXXXX 114125169 VLXXXX 114125170 VOXXXX 114125171 VPXXXX 114125172 WAXXXX 114125173 WCXXXX 114125174 WEXXXX 114125175 WFXXXX 114125176 WGXXXX 114125177 WIXXXX 114125178 WMXXXX 114125179 XDXXXX 114125180 XIXXXX 114125181 YEXXXX 114125182 YFXXXX 114146429 ultrasonic 114146430 Situ 114146431 respiratory 114146432 MASK 114146433 TESTING 114146434 PROCESS 114146435 CDC Docket Import 114146436 CDC Docket Import CDC Prosecuting 114146437 NIOSH-NPPTL 114146438 AEROSOLS 114146439 AEROSOL 114146440 Preventative 114146441 Protection 114146442 SAFETY 114146443 Devices 114146444 DEVICE 114146445 Biodefense 114146446 Respirator TAB-2698 114096879 Nucleic Acid Detection of the Fungal Pathogen Histoplasma capsulatum from Clinical and Environmental Samples CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology, Research Equipment, Research Materials, Therapeutics Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Research Equipment Research Materials Therapeutics Thomas Reid, Millie Schafer This invention relates to detecting <em>Histoplasma capsulatum</em> by PCR using oligonucleotide probes specific for the fungus. Histoplasmosis is a mycotic infection of varying severity, usually localized in the lungs. Caused by <em>H. capsulatum</em>, infections are usually symptomatic but can develop into chronic disease, especially in immunocompromised individuals.<br /><br /> Test samples may originate from the environment (soil, for example), where <em>H. capsulatum</em> spores are found or from clinical samples obtained from patients. Furthermore, the invention also provides for methods that detect the presence of <em>H. capsulatum</em> in a sample using a nested, or two-stage, PCR assay. <ul> <li>Rapid and precise</li> <li>Cost-effective</li> <li>Easily adapted for H. capsulatum detection kits</li> <li>Can positively identify small sample sizes of as few as 10 spores</li> <li>High-throughput capable</li> </ul> <ul> <li>Directing antifungal drug therapy for improved patient outcomes</li> <li>Occupational health and safety screening for workers who may encounter bird or bat waste</li> <li>Screening biological or soil samples for the presence of fungal pathogens</li> <li>Environment testing for immunocompromised patients</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2013-12-23 AA5XXX, AAXXXX, AIDS, assay, Avian, AXXXXX, CAPSULATUM, CDC, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA1XXX, DAXXXX, DETECTING, Detection, diagnostic, DXXXXX, FUNGAL, FUNGI, fungus, HISTOPLASMA, Histoplasmosis, HIV, Method, NESTED, NIOSH-DART, Nucleic, nucleic acid, NUCLEIC ACID DETECTION, PATHOGEN, PATHOGENIC, PATHOGENS, PCR, PCR ASSAY, RAPID, SENSITIVE, VKXXXX, VOXXXX, VPXXXX, WBXXXX, WCXXXX, WFXXXX, WGXXXX, WIXXXX, WMXXXX, XCXXXX, XEXXXX, XHXXXX, XIXXXX, YBXXXX, Zoo, Zoonotic False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-293-2013-0 E-332-2013-0 E-232-2013-0 E-335-2013-0 114171964 Reid TM, Schafer MP. https://www.ncbi.nlm.nih.gov/pubmed/10441199 <a href="https://www.ncbi.nlm.nih.gov/pubmed/10441199">Reid TM, Schafer MP.</a> 114171965 CDC Fact Sheet: Histoplasmosis https://www.cdc.gov/niosh/docs/2005-109/pdfs/2005-109FS.pdf <a href="https://www.cdc.gov/niosh/docs/2005-109/pdfs/2005-109FS.pdf">CDC Fact Sheet: Histoplasmosis</a> 114108324 Reid, Thomas CDC - NIOSH CDC Reid, Thomas (CDC) 0 114108325 Schafer, Millie CDC - NIOSH CDC Schafer, Millie (CDC) 1 114108325 Schafer, Millie CDC - NIOSH CDC Schafer, Millie (CDC) 1 114108324 Reid, Thomas CDC - NIOSH CDC Reid, Thomas (CDC) 0 114102008 RAPID AND SENSITIVE METHOD FOR DETECTING HISTOPLASMA CAPSULATUM E-313-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2698] Nucleic Acid Detection of the Fungal Pathogen Histoplasma capsulatum from Clinical and Environmental Samples&body=Please send me information about technology [TAB-2698] Nucleic Acid Detection of the Fungal Pathogen Histoplasma capsulatum from Clinical and Environmental Samples. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2698] Nucleic Acid Detection of the Fungal Pathogen Histoplasma capsulatum from Clinical and Environmental Samples&body=Please send me information about technology [TAB-2698] Nucleic Acid Detection of the Fungal Pathogen Histoplasma capsulatum from Clinical and Environmental Samples.">yogikala.prabhu@nih.gov</a><br> 114167422 E-313-2013-0 E-313-2013-0-US-01 RAPID AND SENSITIVE METHOD FOR DETECTING HISTOPLASMA CAPSULATUM PRV US 60/082,477 Abandoned US <br />Provisional (PRV) 60/082,477<br />Filed on 1998-04-21<br />Status: Abandoned 114167423 E-313-2013-0 E-313-2013-0-PCT-02 RAPID AND SENSITIVE METHOD FOR DETECTING HISTOPLASMA CAPSULATUM PCT Patent Cooperation Treaty PCT/US1999/008731 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1999/008731<br />Filed on 1999-04-20<br />Status: Expired 114167424 E-313-2013-0 E-313-2013-0-US-05 RAPID AND SENSITIVE METHOD FOR DETECTING HISTOPLASMA CAPSULATUM National Stage US 6,469,156 09/673,298 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6469156 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6469156">6,469,156</a><br />Filed on 2001-01-12<br />Status: Expired 114124145 AXXXXX 114124146 AAXXXX 114124147 AA5XXX 114124148 DXXXXX 114124149 DAXXXX 114124150 DA1XXX 114124151 VKXXXX 114124152 VOXXXX 114124153 VPXXXX 114124154 WBXXXX 114124155 WCXXXX 114124156 WFXXXX 114124157 WGXXXX 114124158 WIXXXX 114124159 WMXXXX 114124160 XCXXXX 114124161 XEXXXX 114124162 XHXXXX 114124163 XIXXXX 114124164 YBXXXX 114145731 RAPID 114145732 SENSITIVE 114145733 Method 114145734 DETECTING 114145735 HISTOPLASMA 114145736 CAPSULATUM 114145737 nucleic acid 114145738 Nucleic 114145739 fungus 114145740 FUNGI 114145741 FUNGAL 114145742 PATHOGENS 114145743 CDC Docket Import 114145744 CDC Docket Import CDC Prosecuting 114145745 NIOSH-DART 114145746 PATHOGENIC 114145747 PATHOGEN 114145748 AIDS 114145749 HIV 114145750 Detection 114145751 diagnostic 114145752 assay 114145753 PCR ASSAY 114145754 PCR 114145755 Avian 114145756 Zoonotic 114145757 Zoo 114145758 Histoplasmosis 114145759 CDC 114145760 NUCLEIC ACID DETECTION 114145761 NESTED TAB-2709 114096888 Diisocyanate Specific Monoclonal Antibodies for Occupational and Environmental Monitoring of Polyurethane Production Exposure-related Asthma and Allergy and Clinical Diagnosis CDC Antibodies, Cardiology, Consumer Products, Dental, Dermatology, Diagnostics, Endocrinology, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology, Pulmonology, Research Materials, Therapeutics Antibodies Cardiology Consumer Products Dental Dermatology Diagnostics Endocrinology Immunology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Pulmonology Research Materials Therapeutics Donald Beezhold, Victor Johnson, Tinashe Ruwona, Detlef Schmechel, Paul Siegel CDC researchers have developed monoclonal antibodies useful as diagnostics for diisocyanate (dNCO) exposure and for toxicity characterization of specific dNCOs. Currently, dNCOs are used in the production of all polyurethane products and are the most commonly reported cause of occupational-induced asthma and also linked to allergic contact dermatitis. Presumptive diagnosis of dNCO asthma is presently dependent on criteria such as work history, report of work-related asthma-like symptoms and nonspecific airway reactivity to methacholine challenge. <br /><br /> This invention is a cost-effective, objective alternative for clinical assessment of occupational/environmental dNCO exposure in patient samples. These antibodies may also provide for passive-immunization and prevention of allergic contact dermatitis and/or asthma that can result from extended dermal exposure to dNCO contaminated surfaces and vapors. Further, the present technology allows for high-throughput testing of workplace dNCO air, fabric and working-surface contamination. <ul> <li>Ready for use in high-throughput immuno-histochemistry biomarker detection assays and kits.</li> <li>Two sandwich ELISAs have been developed and validated using human samples.</li> <li>Monitoring is currently performed by elaborate analytical chemical assays; this technology is more rapid and cost effective for dNCO exposure/contamination assessment.</li> <ul> <li>Occupational/environmental safety biomonitoring of polyurethane-worker/user exposure to diisocyanates(dNCOs).</li> <li>Clinical diagnostic use.</li> <li>dNCO-induced allergy/asthma prevention by passive immunization</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-01-08 AAXXXX, AC5XXX, ACXXXX, AE2AXX, AE2CXX, AE2XXX, AE3XXX, AEXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, Compositions, CONJUGATES, IA2XXX, IA3XXX, IA5XXX, IAXXXX, IDXXXX, Isocyanate, IXXXXX, Methods, NIOSH-HELD, Relating, VPXXXX, WCXXXX, WFXXXX, WGXXXX, WIXXXX, WJXXXX, WMXXXX, XAXXXX, XCXXXX, XIXXXX, YAXXXX, YBXXXX False True <ul> <li>Early-stage</li> </li>In vitro data available</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171975 Lemons AR, et al. http://www.ncbi.nlm.nih.gov/pubmed/24012971 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24012971">Lemons AR, et al.</a> 114171976 Ruwona TB, et al. http://www.ncbi.nlm.nih.gov/pubmed/20568997 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20568997">Ruwona TB, et al.</a> 114171977 Ruwona TB, et al. http://www.ncbi.nlm.nih.gov/pubmed/21878336 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21878336">Ruwona TB, et al.</a> 114108359 Beezhold, Donald CDC - NIOSH CDC Beezhold, Donald (CDC) 0 114108360 Ruwona, Tinashe CDC - NIOSH CDC Ruwona, Tinashe (CDC) 0 114108361 Schmechel, Detlef CDC - NIOSH CDC Schmechel, Detlef (CDC) 0 114108362 Johnson, Victor CDC - NIOSH CDC Johnson, Victor (CDC) 0 114108358 Siegel, Paul CDC - NIOSH CDC Siegel, Paul (CDC) 1 114108358 Siegel, Paul CDC - NIOSH CDC Siegel, Paul (CDC) 1 114108359 Beezhold, Donald CDC - NIOSH CDC Beezhold, Donald (CDC) 0 114108360 Ruwona, Tinashe CDC - NIOSH CDC Ruwona, Tinashe (CDC) 0 114108361 Schmechel, Detlef CDC - NIOSH CDC Schmechel, Detlef (CDC) 0 114108362 Johnson, Victor CDC - NIOSH CDC Johnson, Victor (CDC) 0 114102018 Methods And Compositions Relating To Isocyanate Conjugates E-189-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2709] Diisocyanate Specific Monoclonal Antibodies for Occupational and Environmental Monitoring of Polyurethane Production Exposure-related Asthma and Allergy and Clinical Diagnosis&body=Please send me information about technology [TAB-2709] Diisocyanate Specific Monoclonal Antibodies for Occupational and Environmental Monitoring of Polyurethane Production Exposure-related Asthma and Allergy and Clinical Diagnosis. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2709] Diisocyanate Specific Monoclonal Antibodies for Occupational and Environmental Monitoring of Polyurethane Production Exposure-related Asthma and Allergy and Clinical Diagnosis&body=Please send me information about technology [TAB-2709] Diisocyanate Specific Monoclonal Antibodies for Occupational and Environmental Monitoring of Polyurethane Production Exposure-related Asthma and Allergy and Clinical Diagnosis.">yogikala.prabhu@nih.gov</a><br> 114167449 E-189-2013-0 E-189-2013-0-US-01 Methods And Compositions Relating To Isocyanate Conjugates PRV US 61/104,429 Abandoned US <br />Provisional (PRV) 61/104,429<br />Filed on 2008-10-10<br />Status: Abandoned 114167450 E-189-2013-0 E-189-2013-0-US-02 Methods And Compositions Relating To Isocyanate Conjugates ORD US 8,828,667 12/577,241 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8828667 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8828667">8,828,667</a><br />Filed on 2009-10-12<br />Status: Issued 114124262 IXXXXX 114124263 IAXXXX 114124264 IA2XXX 114124265 IA3XXX 114124266 IA5XXX 114124267 IDXXXX 114124268 AAXXXX 114124269 ACXXXX 114124270 AC5XXX 114124271 AEXXXX 114124272 AE2XXX 114124273 AE2CXX 114124274 AE2AXX 114124275 AE3XXX 114124276 VPXXXX 114124277 WCXXXX 114124278 WFXXXX 114124279 WGXXXX 114124280 WIXXXX 114124281 WJXXXX 114124282 WMXXXX 114124283 XAXXXX 114124284 XCXXXX 114124285 XIXXXX 114124286 YAXXXX 114124287 YBXXXX 114145861 Methods 114145862 Compositions 114145863 Relating 114145864 Isocyanate 114145865 CONJUGATES 114145866 CDC Docket Import 114145867 CDC Docket Import CDC Prosecuting 114145868 NIOSH-HELD TAB-2710 114096889 Warning System for Mobile Machinery Hazardous Zones CDC Cardiology, Consumer Products, Dental, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology Cardiology Consumer Products Dental Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Carl Ganoe, William Schiffbauer This invention relates to a warning system designed to protect individuals working near hazardous machinery. The system consists of a proximity-warning transmitter mounted to hazardous machinery and a receiver, worn by a worker, capable of detecting the transmitter signal. This worker-safety system can incorporate visual alerts and audible alerts. It also allows automatic shutdown of machinery upon receiver activation and may be particularly useful in the mining industry. <ul> <li>Easy transmitter installation</li> <li>Signal can be adjusted for an audio or visual "warning zone alert" and a proximal "imminent danger zone alert"</li> </ul> <ul> <li>Auxiliary safety equipment for heavy machinery</li> <li>Occupational health and safety</li> <li>Mining worker safety</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-01-08 AE1CXX, AE1XXX, AE2BXX, AE2XXX, AEXXXX, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, HAZARDOUS, Machine, MOBILE, NIOSH-PRL, VPXXXX, WARNING, WEXXXX, WFXXXX, WGXXXX, WMXXXX, Working, XDXXXX, XIXXXX, YEXXXX, YFXXXX, ZONE False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114171978 Schiffbauer WH. http://www.ncbi.nlm.nih.gov/pubmed/10519790 <a href="http://www.ncbi.nlm.nih.gov/pubmed/10519790">Schiffbauer WH.</a> 114108364 Ganoe, Carl CDC - NIOSH CDC Ganoe, Carl (CDC) 0 114108363 Schiffbauer, William CDC - NIOSH CDC Schiffbauer, William (CDC) 1 114108363 Schiffbauer, William CDC - NIOSH CDC Schiffbauer, William (CDC) 1 114108364 Ganoe, Carl CDC - NIOSH CDC Ganoe, Carl (CDC) 0 114102019 MOBILE MACHINE HAZARDOUS WORKING ZONE WARNING E-239-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2710] Warning System for Mobile Machinery Hazardous Zones&body=Please send me information about technology [TAB-2710] Warning System for Mobile Machinery Hazardous Zones. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2710] Warning System for Mobile Machinery Hazardous Zones&body=Please send me information about technology [TAB-2710] Warning System for Mobile Machinery Hazardous Zones.">yogikala.prabhu@nih.gov</a><br> 114167451 E-239-2013-0 E-239-2013-0-US-01 MOBILE MACHINE HAZARDOUS WORKING ZONE WARNING SYSTEM ORD US 5,939,986 08/733,846 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5939986 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5939986">5,939,986</a><br />Filed on 1996-10-18<br />Status: Expired 114167452 E-239-2013-0 E-239-2013-0-US-02 MOBILE MACHINE HAZARDOUS WORKING ZONE WARNING DIV US 09/575,475 Abandoned US <br />Divisional (DIV) 09/575,475<br />Filed on 2000-05-19<br />Status: Abandoned 114124288 AXXXXX 114124289 AEXXXX 114124290 AE1XXX 114124291 AE1CXX 114124292 AE2XXX 114124293 AE2BXX 114124295 VPXXXX 114124296 WEXXXX 114124297 WFXXXX 114124298 WGXXXX 114124299 WMXXXX 114124300 XDXXXX 114124301 XIXXXX 114124302 YEXXXX 114124303 YFXXXX 114145869 MOBILE 114145870 Machine 114145871 HAZARDOUS 114145872 Working 114145873 ZONE 114145874 WARNING 114145875 CDC Docket Import 114145876 CDC Docket Import CDC Prosecuting 114145877 NIOSH-PRL TAB-2711 114096890 Personal Air Sampler for Collecting Airborne Aerosol Particulates for Molecular Analysis by Size CDC Consumer Products, Diagnostics, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Research Equipment, Therapeutics, Vaccines Consumer Products Diagnostics Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Research Equipment Therapeutics Vaccines Teh-Hsun Chen, Herbert Edgell, Jyoti Keswani This invention consists of a sampling apparatus that utilizes one or more cyclone separators to collect airborne particles from the atmosphere. The apparatus not only separates out aerosols from the atmosphere, but also serves as a collection tube for aerosol particles. Through its unique design, this CDC-developed apparatus is able to use the centrifugal force of the air flow on aerosolized particles forcing them to separate by size. Since the sample is collected directly in a microcentrifuge tube, in situ analysis of the ambient particulates can be performed. Analysis may include, but is not limited to, PCR, immunoassay analysis, microscopic spore counting, and counting colony-forming units. The device should also have many additional uses for environmental surveillance and occupational health applications. <ul> <li>Rapid, on-site sampling and analysis.</li> <li>Alternative to surface-sampling and culturing for aerosolized biological agents.</li> <li>Superior extraction efficiency compared to filters, impingers, and impactors.</li> <li>Real-world testing demonstrated device's ability to collect airborne mold and mycotoxins, pollen and pollen fragments, airborne dust particulates, as well as airborne influenza virus in a hospital environment.</li> </ul> <ul> <li>Analysis of ambient air particulates</li> <li>Environmental surveillance</li> <li>Occupational safety monitoring</li> <li>Biodefense</li> <li>Long-term exposure assessment</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-01-08 AA2XXX, AA4XXX, AAXXXX, AE1XXX, AE2XXX, AE3XXX, AE4XXX, AEXXXX, AFXXXX, AIR, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DEVICE, Method, NIOSH-HELD, Sampling, VBXXXX, VJXXXX, VKXXXX, VLXXXX, VOXXXX, WAXXXX, WBXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WMXXXX, XDXXXX, XHXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114171265 Chen BT, et al. http://dx.doi.org/10.1080/027868290511218 <a href="http://dx.doi.org/10.1080/027868290511218">Chen BT, et al.</a> 114171266 Macher JM, et al. http://www.ncbi.nlm.nih.gov/pubmed/18720289 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18720289">Macher JM, et al.</a> 114171267 Macher JM, et al. http://www.ncbi.nlm.nih.gov/pubmed/18780236 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18780236">Macher JM, et al.</a> 114171268 Su WC, et al. http://www.ncbi.nlm.nih.gov/pubmed/22833144 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22833144">Su WC, et al.</a> 114171269 Wang CH, et al. http://www.ncbi.nlm.nih.gov/pubmed/25799419 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25799419">Wang CH, et al.</a> 114171979 Lindsley WG, et al. http://www.ncbi.nlm.nih.gov/pubmed/17075620 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17075620">Lindsley WG, et al.</a> 114171980 Blachere FM, et al. http://www.ncbi.nlm.nih.gov/pubmed/19453416 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19453416">Blachere FM, et al.</a> 114171981 Lindsley WG, et al. http://www.ncbi.nlm.nih.gov/pubmed/21152051 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21152051">Lindsley WG, et al.</a> 114171982 Cao G, et al. http://www.ncbi.nlm.nih.gov/pubmed/21975583 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21975583">Cao G, et al.</a> 114171983 CDC-NIOSH Cyclone Bioaerosol Sampler webpage http://www.cdc.gov/niosh/topics/aerosols/biosampler.html <a href="http://www.cdc.gov/niosh/topics/aerosols/biosampler.html">CDC-NIOSH Cyclone Bioaerosol Sampler webpage</a> 114172037 NIOSH Personal Bioaerosol Cyclone Sampler video http://youtu.be/YHC0hw-DQTc <a href="http://youtu.be/YHC0hw-DQTc">NIOSH Personal Bioaerosol Cyclone Sampler video</a> 114108366 Keswani, Jyoti CDC - NIOSH CDC Keswani, Jyoti (CDC) 0 114108367 Edgell, Herbert CDC - NIOSH CDC Edgell, Herbert (CDC) 0 114108365 Chen, Teh-Hsun CDC - NIOSH CDC Chen, Teh-Hsun (CDC) 1 114108365 Chen, Teh-Hsun CDC - NIOSH CDC Chen, Teh-Hsun (CDC) 1 114108366 Keswani, Jyoti CDC - NIOSH CDC Keswani, Jyoti (CDC) 0 114108367 Edgell, Herbert CDC - NIOSH CDC Edgell, Herbert (CDC) 0 114102020 AIR SAMPLING DEVICE AND METHOD OF USE E-244-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2711] Personal Air Sampler for Collecting Airborne Aerosol Particulates for Molecular Analysis by Size&body=Please send me information about technology [TAB-2711] Personal Air Sampler for Collecting Airborne Aerosol Particulates for Molecular Analysis by Size. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2711] Personal Air Sampler for Collecting Airborne Aerosol Particulates for Molecular Analysis by Size&body=Please send me information about technology [TAB-2711] Personal Air Sampler for Collecting Airborne Aerosol Particulates for Molecular Analysis by Size.">yogikala.prabhu@nih.gov</a><br> 114167453 E-244-2013-0 E-244-2013-0-PCT-02 AIR SAMPLING DEVICE AND METHOD OF USE PCT Patent Cooperation Treaty PCT/US2004/032378 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2004/032378<br />Filed on 2004-10-01<br />Status: Expired 114167454 E-244-2013-0 E-244-2013-0-US-01 AIR SAMPLING DEVICE AND METHOD OF USE PRV US 60/512,252 Abandoned US <br />Provisional (PRV) 60/512,252<br />Filed on 2003-10-17<br />Status: Abandoned 114167455 E-244-2013-0 E-244-2013-0-US-03 AIR SAMPLING DEVICE AND METHOD OF USE National Stage US 7,370,543 10/575,048 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7370543 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7370543">7,370,543</a><br />Filed on 2006-04-04<br />Status: Abandoned 114167456 E-244-2013-0 E-244-2013-0-US-04 AIR SAMPLING DEVICE AND METHOD OF USE DIV US 8,205,511 12/152,156 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8205511 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8205511">8,205,511</a><br />Filed on 2008-05-12<br />Status: Abandoned 114124294 AXXXXX 114124304 AEXXXX 114124305 AE1XXX 114124306 AE2XXX 114124307 AE3XXX 114124308 AE4XXX 114124309 AFXXXX 114124310 AAXXXX 114124311 AA2XXX 114124312 AA4XXX 114124315 VBXXXX 114124316 VJXXXX 114124317 VKXXXX 114124318 VLXXXX 114124319 VOXXXX 114124320 WAXXXX 114124321 WBXXXX 114124322 WCXXXX 114124323 WEXXXX 114124324 WFXXXX 114124325 WGXXXX 114124326 WMXXXX 114124327 XDXXXX 114124328 XHXXXX 114124329 XIXXXX 114124330 YEXXXX 114124331 YFXXXX 114145878 AIR 114145879 Sampling 114145880 DEVICE 114145881 Method 114145882 CDC Docket Import 114145883 CDC Docket Import CDC Prosecuting 114145884 NIOSH-HELD TAB-2728 114096908 Non-radioactive, Miniature Bipolar Aerosol Particle Charger for Personal, Portable Instrumentation CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Therapeutics, Vaccines Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Materials Therapeutics Vaccines Pramod Kulkarni, Chaolong Qi This CDC developed invention is a novel device for a miniature, nonradioactive bipolar charger to electrically charge aerosol particles for use in personal and portable aerosol instrumentation. Such devices are an integral component of aerosol instruments employing electrical mobility-based techniques. Current, commercial state-of-the-art mobility instruments employ aerosol chargers using radioactivity to achieve bipolar particle charging and, therefore, are not suitable for field-portable instruments. Due to strict regulatory restrictions on use of radioactive materials, these radioactive chargers also tend to be too bulky for use in compact aerosolization instruments. <p>This invention circumvents these two critical drawbacks by eliminating radioactivity and miniaturizing overall unit size (1x0.75 x 0.5 inch). Other unique aspects of the invention entail elimination of the need for additional air flows (other than the aerosol sample flow), minimal power consumption, a low per-unit cost, and simplicity of operation. In all, excellent transmission efficiency, steady-state charging characteristics and the miniature size make this bipolar particle charger well-suited for integration with portable or personal aerosol instrumentation.</p> <ul> <li>Non-radioactive; no associated regulatory or transportation issues</li> <li>Low-cost and requires very little power to operate</li> <li>Additional air flows other than sample airflow are unnecessary</li> <li>Unit is small (1x0.75x0.5in;2.54x1.91x1.27cm) and highly portable</li> <li>Eliminates a major barrier for reliable aerosol sampling using "bipolar charger + differential mobility analyzer + condensation particle detector" scheme in a compact device</li> </ul> <ul> <li>Personal and portable aerosol instrumentation</li> <li>Component of field-use device for determining workplace/environmental exposure to ultrafine aerosols and airborne nanoparticles</li> <li>Tool for environmental/occupational health, toxicology, workplace control evaluations and hazard identification involving aerosol exposure</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-01-20 AA2XXX, AA4BXX, AAXXXX, AE1XXX, AE2BXX, AE2XXX, AE3XXX, AEROSOL, AEXXXX, AFXXXX, AGXXXX, AXXXXX, BIPOLAR, CDC Docket Import, CDC Docket Import CDC Prosecuting, Charger, NIOSH-DART, NON-RADIOACTIVE, PARTICLES, VBXXXX, VJXXXX, VKXXXX, VLXXXX, VOXXXX, VPXXXX, WAXXXX, WBXXXX, WCXXXX, WFXXXX, WGXXXX, WIXXXX, WMXXXX, XDXXXX, XIXXXX, YEXXXX False True In situ data available (on-site) True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114108415 Qi, Chaolong CDC - NIOSH CDC Qi, Chaolong (CDC) 0 114108414 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114108414 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114108415 Qi, Chaolong CDC - NIOSH CDC Qi, Chaolong (CDC) 0 114102044 Non-Radioactive Bipolar Charger For Aerosol Particles E-146-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2728] Non-radioactive, Miniature Bipolar Aerosol Particle Charger for Personal, Portable Instrumentation&body=Please send me information about technology [TAB-2728] Non-radioactive, Miniature Bipolar Aerosol Particle Charger for Personal, Portable Instrumentation. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2728] Non-radioactive, Miniature Bipolar Aerosol Particle Charger for Personal, Portable Instrumentation&body=Please send me information about technology [TAB-2728] Non-radioactive, Miniature Bipolar Aerosol Particle Charger for Personal, Portable Instrumentation.">yogikala.prabhu@nih.gov</a><br> 114167500 E-146-2013-0 E-146-2013-0-US-01 Non-Radioactive Bipolar Charger For Aerosol Particles ORD US 8,611,066 13/315,344 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8611066 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8611066">8,611,066</a><br />Filed on 2011-12-09<br />Status: Issued 114124558 AXXXXX 114124559 AAXXXX 114124560 AEXXXX 114124561 AFXXXX 114124562 AGXXXX 114124563 AE1XXX 114124564 AE2XXX 114124565 AE2BXX 114124566 AE3XXX 114124567 AA2XXX 114124568 AA4BXX 114124569 VBXXXX 114124570 VJXXXX 114124571 VKXXXX 114124572 VLXXXX 114124573 VOXXXX 114124574 VPXXXX 114124575 WAXXXX 114124576 WBXXXX 114124577 WCXXXX 114124578 WFXXXX 114124579 WGXXXX 114124580 WIXXXX 114124581 WMXXXX 114124582 XDXXXX 114124583 XIXXXX 114124584 YEXXXX 114146051 BIPOLAR 114146052 NON-RADIOACTIVE 114146053 Charger 114146054 AEROSOL 114146055 PARTICLES 114146056 CDC Docket Import 114146057 CDC Docket Import CDC Prosecuting 114146058 NIOSH-DART TAB-2614 114096808 Monoclonal Antibodies for Detection of Stachybotrys chartarum (a Fungus) CDC Antibodies, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials Antibodies Consumer Products Diagnostics Immunology Infectious Disease Licensing Occupational Safety and Health Research Materials Daniel Lewis, Detlef Schmechel <p>CDC NIOSH researchers have developed a simple and rapid detection technique for <em>Stachybotrys chartarum</em> (a type of mold that commonly grows on wet building materials) by producing monoclonal antibodies which reacts with proteins in <em>Stachybotrys chartarum</em>. These antibodies can be used in immunologic detection assays to detect and possibly quantify <em>Stachybotrys chartarum</em> in environmental samples, and to our knowledge, they do not cross react with other fungi. The presence of mold in indoor environments has been associated with adverse health effects such as infections (in immunocompromised people) or allergies. Individuals with asthma or those with weaker immune systems can be affected more by mold exposure. Accurate detection methods are needed to measure mold contamination. Traditional methods for monitoring of molds are based on sample cultivation and microscopic analysis which can be time and labor intensive, and require expert classification skills. Immunoassays can potentially overcome these limitations and have been successfully developed for numerous biological aerosols. For more information on <em>Stachybotrys chartarum</em> and other molds, visit CDC&rsquo;s fact page:<a href="http://www.cdc.gov/mold/stachy.htm" target="_blank">&nbsp;www.cdc.gov/mold/stachy.htm</a>.</p> <ul> <li>Simple, rapid, and specific detection of <em>Stachybotrys chartarum</em></li> <li>Easily adaptable for kit format</li> <li>Less labor-intensive than spore counting or culturing</li> <li>Adaptable for high sample volumes (or throughputs) being processed</li> <li>Potential use in proteomics chip for screening multiple pathogens simultaneously</li> </ul> <ul> <li>Detection of <em>Stachybotrys chartarum</em> antigens in contaminated building materials or field environments with a color-changing dipstick assay</li> <li>Occupational health and home safety</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2016-06-16 5/19/2016 -- per email from Karen Surabian, CDC is requesting that abstract be temporarily removed from the OTT website... --ecr 6/15/2016 -- updated abstract received from Karen Surabian, designated as Add... --ecr AE2CXX, AE2XXX, AE3XXX, AEXXXX, Against, antibodies, DA1XXX, FUNGI, Methods, monoclonal, Their, VKXXXX, VOXXXX, WCXXXX, WFXXXX, WGXXXX, WMXXXX, XAXXXX, XCXXXX, XIXXXX, YBXXXX, YEXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114108064 Lewis, Daniel CDC - NIOSH CDC Lewis, Daniel (CDC) 0 114108063 Schmechel, Detlef CDC - DIR CDC Schmechel, Detlef (CDC) 1 114108063 Schmechel, Detlef CDC - DIR CDC Schmechel, Detlef (CDC) 1 114108064 Lewis, Daniel CDC - NIOSH CDC Lewis, Daniel (CDC) 0 114101932 MONOCLONAL ANTIBODIES AGAINST FUNGI AND METHODS FOR THEIR USE E-224-2013-0 Research Material Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2614] Monoclonal Antibodies for Detection of Stachybotrys chartarum (a Fungus)&body=Please send me information about technology [TAB-2614] Monoclonal Antibodies for Detection of Stachybotrys chartarum (a Fungus). Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2614] Monoclonal Antibodies for Detection of Stachybotrys chartarum (a Fungus)&body=Please send me information about technology [TAB-2614] Monoclonal Antibodies for Detection of Stachybotrys chartarum (a Fungus).">yogikala.prabhu@nih.gov</a><br> 114167199 E-224-2013-0 E-224-2013-0-PCT-02 MONOCLONAL ANTIBODIES AGAINST FUNGI AND METHODS FOR THEIR USE PCT Patent Cooperation Treaty PCT/US2002/025493 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2002/025493<br />Filed on 2002-08-09<br />Status: Expired 114167200 E-224-2013-0 E-224-2013-0-US-01 MONOCLONAL ANTIBODIES AGAINST FUNGI AND METHODS FOR THEIR USE PRV US 60/311,458 Abandoned US <br />Provisional (PRV) 60/311,458<br />Filed on 2001-08-10<br />Status: Abandoned 114167201 E-224-2013-0 E-224-2013-0-US-03 ANTIBODIES AGAINST STACHYBOTRYS CHARTARUM AND METHODS FOR THEIR USE National Stage US 7,368,256 10/483,921 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7368256 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7368256">7,368,256</a><br />Filed on 2004-01-14<br />Status: Expired 114121876 DA1XXX 114121877 VKXXXX 114121878 VOXXXX 114121879 WCXXXX 114121880 WFXXXX 114121881 WGXXXX 114121905 WMXXXX 114121906 XAXXXX 114121907 XCXXXX 114121908 XIXXXX 114121909 YBXXXX 114121910 YEXXXX 114123580 AE3XXX 114123581 AEXXXX 114123582 AE2CXX 114123586 AE2XXX 114144856 monoclonal 114144857 antibodies 114144858 Against 114144859 FUNGI 114144860 Methods 114144861 Their TAB-2623 114096817 Generation of Artificial Mutation Controls for Diagnostic Testing CDC Cardiology, Computational models/software, Consumer Products, Dental, Dermatology, Diagnostics, Endocrinology, Immunology, Infectious Disease, Licensing, Neurology, Oncology, Ophthalmology, Pulmonology, Research Materials, Software / Apps, Therapeutics Cardiology Computational models/software Consumer Products Dental Dermatology Diagnostics Endocrinology Immunology Infectious Disease Licensing Neurology Oncology Ophthalmology Pulmonology Research Materials Software / Apps Therapeutics Laurina Williams This technology relates to a method of generating artificial compositions that can be used as positive controls in a genetic testing assay, such as a diagnostic assay for a particular genetic disease. Such controls can be used to confirm the presence or absence of a particular genetic mutation. The lack of easily accessible, validated mutant controls has proven to be a major obstacle to the advancement of clinical molecular genetic testing, validation, quality control (QC), quality assurance (QA), and required proficiency testing. This method provides a consistent and renewable source of positive control material, as well as an alternative to patient-derived mutation-positive samples. <ul> <li>Positive controls can be included in new kits or packaged with pre-existing assays</li> <li>Increased accuracy in diagnosis compared to current controls</li> <li>Consistent and renewable source for high-quality controls containing mutations of interest</li> </ul> <ul> <li>Generation of positive controls for molecular genetic tests, particularly for tests to detect cystic fibrosis</li> </ul> Various international patent applications pending or issued. 2022-10-19 2026-05-14 2026-05-14 2013-08-23 AA1XXX, AA5XXX, AA6XXX, AAXXXX, ARTIFICIAL, AXXXXX, CA1AXX, CA1CXX, CA1XXX, CAXXXX, controls, CXXXXX, diagnostic, GAXXXX, GCXXXX, GXXXXX, IA1BXX, IA2XXX, IA3XXX, IA5XXX, IAXXXX, IXXXXX, MUTATION, NA2XXX, OA2XXX, TESTING, VPXXXX, WBXXXX, WHXXXX, WIXXXX, WMXXXX, XBXXXX, XCXXXX, XEXXXX, YAXXXX, YBXXXX False True </ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114108095 Williams, Laurina CDC - DIR CDC Williams, Laurina (CDC) 0 114108095 Williams, Laurina CDC - DIR CDC Williams, Laurina (CDC) 0 114101941 Artificial Mutation Controls For Diagnostic Testing E-255-2013-0 Closed Centers for Disease Control and Prevention (CDC), University of California, Los Angeles (UCLA) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2623] Generation of Artificial Mutation Controls for Diagnostic Testing&body=Please send me information about technology [TAB-2623] Generation of Artificial Mutation Controls for Diagnostic Testing. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2623] Generation of Artificial Mutation Controls for Diagnostic Testing&body=Please send me information about technology [TAB-2623] Generation of Artificial Mutation Controls for Diagnostic Testing.">yogikala.prabhu@nih.gov</a><br> 114167219 E-255-2013-0 E-255-2013-0-PCT-02 Artificial Mutation Controls For Diagnostic Testing PCT Patent Cooperation Treaty PCT/US2005/008108 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2005/008108<br />Filed on 2005-03-11<br />Status: Expired 114167220 E-255-2013-0 E-255-2013-0-US-01 Artificial Mutation Controls For Diagnostic Testing PRV US 60/552,979 Abandoned US <br />Provisional (PRV) 60/552,979<br />Filed on 2004-03-11<br />Status: Abandoned 114167221 E-255-2013-0 E-255-2013-0-US-08 Artificial Mutation Controls For Diagnostic Testing National Stage US 8,603,745 10/598,589 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8603745 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8603745">8,603,745</a><br />Filed on 2006-09-05<br />Status: Abandoned 114123649 AXXXXX 114123650 AAXXXX 114123651 AA1XXX 114123652 AA5XXX 114123653 AA6XXX 114123654 CXXXXX 114123655 CAXXXX 114123656 CA1XXX 114123657 CA1AXX 114123658 CA1CXX 114123659 GAXXXX 114123660 GXXXXX 114123661 GCXXXX 114123662 IXXXXX 114123663 IAXXXX 114123664 IA1BXX 114123665 IA3XXX 114123666 IA2XXX 114123667 IA5XXX 114123668 NA2XXX 114123669 OA2XXX 114125360 VPXXXX 114125361 WBXXXX 114125362 WHXXXX 114125363 WIXXXX 114125364 WMXXXX 114125365 XBXXXX 114125366 XCXXXX 114125367 XEXXXX 114125368 YAXXXX 114125369 YBXXXX 114144941 ARTIFICIAL 114144942 MUTATION 114144943 controls 114144944 diagnostic 114144945 TESTING TAB-3930 147157210 Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use to Treat Cancer NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Lin-kun An, Christophe Marchand, Yves Pommier <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks licensees for a family of novel furoquinolinedione derivatives that inhibit tyrosyl-DNA phosphodiesterase 2 (TDP2) as cancer therapeutics. &nbsp;&nbsp;</p> <h2>Description of Technology:</h2> <p>Tyrosyl-DNA phosphodiesterase 2 (TDP2) is an enzyme that plays a critical role in repairing nucleic acid lesions, namely by repairing trapped DNA cleavage complexes. TDP2 repairs topoisomerase (TOP2)-mediated DNA damage induced by chemotherapeutic agents and removes endogenous TOP2-DNA cleavage complexes. Further, TDP2 deficiency potentiates the antiproliferative activity of TOP2 inhibitors. This suggest that combination therapies consisting of TDP2 and TOP2 inhibitors have a synergistic effect on tumor tissues. Therefore, TDP2 represents a promising anti-cancer pharmacological target as a monotherapy or part of a combination therapy.</p> <p>The NCI investigators and their collaborators have discovered a series of novel furoquinolinedione derivatives as specific TDP2 inhibitors that could act as anti-cancer therapeutics alone and/or potentiate the pharmacological action of TOP2 inhibitors. Systematic structure-activity relationship studies were conducted and demonstrated that several furoquinolinedione derivatives had TDP2 inhibitory activity in the low micromolar or submicromolar range and act in a dose-dependent manner. Further, enzyme-based assays showed the furoquinolinedione derivatives are specific to TDP2 and showed no inhibitory activity against TDP1 and TOP1.</p> <p>NCI is seeking licensees to further develop this family of compounds as anti-cancer agents. &nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Standalone cancer therapeutic</li> <li>Part of a combination cancer therapeutic with other drugs, such as TOP2 inhibitors</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Potential first-in-class drug (novel mechanism of action and novel composition of matter)</li> <li>Selective inhibition of TDP2</li> <li>Can be used alone or in combination with TOP2 inhibitors</li> <li>Synergistic effect to boost the efficacy of TOP2 inhibitors (decrease effective dosage, minimize side effects)</li> <li>Potential for use across many cancer types</li> </ul> Researchers at the NCI seek licensing for a family of novel furoquinolinedione derivatives that inhibit tyrosyl-DNA phosphodiesterase 2 (TDP2) as cancer therapeutics 2017-10-23 2026-05-11 2026-01-13 2026-05-11 2017-10-23 CANCER, Combination Therapies, Pommier, therapeutic, Topoisomerase 2 (TOP2), Tyrosyl-DNA Phosphodiesterase 2 (TDP) Inhibitors False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2026-01-13 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162094 Yang, H., et al. The synthesis of furoquinolinedione and isoxazoloquinolinedione derivatives as selective Tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors. (PMID 33839584) https://pubmed.ncbi.nlm.nih.gov/33839584/ <a href="https://pubmed.ncbi.nlm.nih.gov/33839584/">Yang, H., et al. The synthesis of furoquinolinedione and isoxazoloquinolinedione derivatives as selective Tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors. (PMID 33839584)</a> 147162172 Yu, L.-M., et al. Synthesis and structure-activity relationship of furoquinolinediones as inhibitors of Tyrosyl-DNA phosphodiesterase 2 (TDP2). (PMID 29677635). https://pubmed.ncbi.nlm.nih.gov/29677635/ <a href="https://pubmed.ncbi.nlm.nih.gov/29677635/">Yu, L.-M., et al. Synthesis and structure-activity relationship of furoquinolinediones as inhibitors of Tyrosyl-DNA phosphodiesterase 2 (TDP2). (PMID 29677635).</a> 147162905 Marchand, Christophe NIH - NCI NCI Marchand, Christophe (NCI) 1 147162906 An, Lin-kun Lin-Kun An (SYSU) An, Lin-kun 2 147162904 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 3 147162905 Marchand, Christophe NIH - NCI NCI Marchand, Christophe (NCI) 1 147162906 An, Lin-kun Lin-Kun An (SYSU) An, Lin-kun 2 147162904 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 3 147158307 Furoquinolinedione Derivatives As Tyrosyl-DNA Phosphodiesterase 2 (TDP2) Inhibitors E-275-2014-0 Filing authorized NCI, Sun Yat-sen University 91826910 McCrary, Michaela michaela.mccrary@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-3930] Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use to Treat Cancer&body=Please send me information about technology [TAB-3930] Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use to Treat Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov McCrary, Michaela<br><a href="mailto:michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-3930] Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use to Treat Cancer&body=Please send me information about technology [TAB-3930] Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use to Treat Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michaela.mccrary@nih.gov</a><br> 147161252 E-275-2014-0 E-275-2014-0-CA-04 Furoquinolinedione As Inhibitors Of TDP2 National Stage Canada 2973484 2973484 Issued Canada <br />National Stage 2973484<br />Filed on 2016-01-08<br />Status: Issued 147165346 E-275-2014-0 E-275-2014-0-US-01 FUROQUINOLINEDIONES AS INHIBITORS OF TDP2 PRV US 62/100,968 Abandoned US <br />Provisional (PRV) 62/100,968<br />Filed on 2015-01-08<br />Status: Abandoned 147165347 E-275-2014-0 E-275-2014-0-PCT-02 Furoquinolinedione As Inhibitors Of TDP2 PCT Patent Cooperation Treaty PCT/US2016/012672 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/012672<br />Filed on 2016-01-08<br />Status: Expired 147165348 E-275-2014-0 E-275-2014-0-AU-03 Furoquinolinedione As Inhibitors Of TDP2 National Stage Australia 2016205137 2016205137 Issued Australia <br />National Stage 2016205137<br />Filed on 2016-01-08<br />Status: Issued 147165349 E-275-2014-0 E-275-2014-0-EP-05 Furoquinolinedione As Inhibitors Of TDP2 National Stage European Patent 3242881 16703001.4 Issued European Patent <br />National Stage 16703001.4<br />Filed on 2016-01-08<br />Status: Issued 147165350 E-275-2014-0 E-275-2014-0-US-06 FUROQUINOLINEDIONES AS INHIBITORS OF TDP2 National Stage US 10,906,914 15/542,560 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10906914 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10906914">10,906,914</a><br />Filed on 2017-07-10<br />Status: Issued 147165351 E-275-2014-0 E-275-2014-0-CN-07 Furoquinolinedione As Inhibitors Of TDP2 National Stage China ZL201680014742.7 201680014742.7 Issued China <br />National Stage 201680014742.7<br />Filed on 2016-01-08<br />Status: Issued 147165352 E-275-2014-0 E-275-2014-0-DE-08 Furoquinolinedione As Inhibitors Of TDP2 EP Germany 3242881 16703001.4 Issued Germany <br />European patent (EP) 16703001.4<br />Filed on 2016-01-08<br />Status: Issued 147165353 E-275-2014-0 E-275-2014-0-FR-09 Furoquinolinedione As Inhibitors Of TDP2 EP France 3242881 16703001.4 Issued France <br />European patent (EP) 16703001.4<br />Filed on 2016-01-08<br />Status: Issued 147165354 E-275-2014-0 E-275-2014-0-GB-10 Furoquinolinedione As Inhibitors Of TDP2 EP United Kingdom 3242881 16703001.4 Issued United Kingdom <br />European patent (EP) 16703001.4<br />Filed on 2016-01-08<br />Status: Issued 147165355 E-275-2014-0 E-275-2014-0-CN-11 Furoquinolinedione As Inhibitors Of TDP2 DIV China ZL202110013140.2 202110013140.2 Issued China <br />Divisional (DIV) 202110013140.2<br />Filed on 2016-01-08<br />Status: Issued 147165356 E-275-2014-0 E-275-2014-0-US-12 FUROQUINOLINEDIONES AS INHIBITORS OF TDP2 CON US 11,999,747 17/146,327 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11999747 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11999747">11,999,747</a><br />Filed on 2021-01-11<br />Status: Issued 147174535 CANCER 147174537 Combination Therapies 147174538 Pommier 147174539 therapeutic 147174541 Topoisomerase 2 (TOP2) 147174543 Tyrosyl-DNA Phosphodiesterase 2 (TDP) Inhibitors TAB-4990 157143819 Suppression Of Uveitis By A STAT3 Single Domain Antibody NEI Application, Collaboration, Ear, Nose, & Throat, Licensing, Neurology, Therapeutics Application Collaboration Ear Nose & Throat Licensing Neurology Therapeutics Charles Egwuagu, Sunanda Singh <h2>Summary:&nbsp;</h2> <p>The National Eye Institute seeks research co-development partners and/or licensees for a STAT3 antibody that can suppress uveitis.</p> <h2>Description of Technology:</h2> <p>&nbsp;Uveitis is caused by inflammation in the eye that causes pain and reduce vision in affected patients. Rates of uveitis in the United States occurs 1 in every 200 people with eye-related irritation. Permanent damage, such as vision loss, occurs if uveitis goes untreated. Prolonged use of drugs that help treat chronic uveitis, such as periocular or intravitreal corticosteroid injections, can cause serious side-effects such as glaucoma. Therefore, finding alternative treatments for uveitis is an imperative.&nbsp;</p> <p>Signal transducers and activators of transcription-3 (STAT3) regulates the differentiation of pathogenic Th17 lymphocyte cells implicated in several autoimmune diseases. Genetically modified mice incapable of inducing Th17 cells are resistant to developing uveitis. Therefore, targeting the STAT3 pathway required for the differentiation and expansion of Th17 cells has been proposed as a potential therapy for mitigating uveitis. However, the major impediment to therapeutically target intracellular proteins &ndash; such as STAT3 &ndash; is the inability to deliver inhibitors inside cells.&nbsp;</p> <p>Scientists at the NEI have discovered a novel STAT3-specific nanobody (SBT-100) that can cross the blood-retina-barrier (BRB), inhibit pathogenic Th17 lymphocytes and suppress experimental autoimmune uveitis (EAU). The antibody&rsquo;s small size, rapid clearance from the blood and sequence similarity with mammalian STAT3 render SBT-100 non-immunogenic. These factors provide important advantages for its therapeutic use not only for chronic uveitis, but also for inflammatory diseases like multiple sclerosis.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic for uveitis</li> <li>Therapeutic for multiple sclerosis</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Non-immunogenic compared to current uveitis treatments</li> <li>Novel STAT3-specific nanobody</li> <li>Crosses the blood-retina-barrier (BRB)</li> <li>Rapid blood clearance</li> <li>Sequence similarity with mammalian STAT3</li> <li>Potential multi-use for central nervous system autoimmune diseases and other autoinflammatory diseases</li> </ul> Researchers at the NEI seek licensing and/or co-development research collaborations for a STAT3 antibody that can suppress uveitis. 2024-07-17 2026-04-16 2026-05-06 2024-07-18 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 157173612 Egwuagu, Charles National Eye Institute (NEI) NEI Egwuagu, Charles (NEI) 1 157173719 Singh, Sunanda Singh Biotechnology, LLC Singh, Sunanda 2 157173612 Egwuagu, Charles National Eye Institute (NEI) NEI Egwuagu, Charles (NEI) 1 157173719 Singh, Sunanda Singh Biotechnology, LLC Singh, Sunanda 2 157143822 STAT3-specific Single Domain Nanobody Inhibits Expansion Of Pathogenic Th17 Responses And Suppresses Uveitis In Mice E-164-2021-0 Filing authorized National Eye Institute (NEI), Singh Biotechnology LLC 83737255 Baxter, Merissa merissa.baxter@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4990] Suppression Of Uveitis By A STAT3 Single Domain Antibody&body=Please send me information about technology [TAB-4990] Suppression Of Uveitis By A STAT3 Single Domain Antibody.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Baxter, Merissa<br><a href="mailto:merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4990] Suppression Of Uveitis By A STAT3 Single Domain Antibody&body=Please send me information about technology [TAB-4990] Suppression Of Uveitis By A STAT3 Single Domain Antibody.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">merissa.baxter@nih.gov</a><br> 157175301 E-164-2021-0 E-164-2021-0-US-01 SINGLE DOMAIN ANTIBODY INHIBITS EXPANSION OF PATHOGENIC TH17 RESPONSES AND SUPPRESSION OF UVEITIS PRV US 63/219,161 Abandoned US <br />Provisional (PRV) 63/219,161<br />Filed on 2021-07-07<br />Status: Abandoned 160175629 E-164-2021-0 E-164-2021-0-US-03 SUPPRESSION OF UVEITIS BY SINGLE DOMAIN ANTIBODY ORD US 17/859,861 Pending US <br />Ordinary Patent (ORD) 17/859,861<br />Filed on 2022-07-07<br />Status: Pending 160175634 E-164-2021-0 E-164-2021-0-JP-01 SUPPRESSION OF UVEITIS BY SINGLE DOMAIN ANTIBODY National Stage Japan 2024-525189 Pending Japan <br />National Stage 2024-525189<br />Filed on 2024-01-05<br />Status: Pending 160175639 E-164-2021-0 E-164-2021-0-MX-01 SUPPRESSION OF UVEITIS BY SINGLE DOMAIN ANTIBODY National Stage Mexico MX/a/2024/000309 Pending Mexico <br />National Stage MX/a/2024/000309<br />Filed on 2024-01-04<br />Status: Pending 160175644 E-164-2021-0 E-164-2021-0-EP-01 SUPPRESSION OF UVEITIS BY SINGLE DOMAIN ANTIBODY National Stage European Patent 22838435.0 Pending European Patent <br />National Stage 22838435.0<br />Filed on 2024-02-05<br />Status: Pending 163826768 E-164-2021-0 E-164-2021-0-PCT-02 SUPPRESSION OF UVEITIS BY SINGLE DOMAIN ANTIBODY PCT Patent Cooperation Treaty PCT/US2022/036420 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/036420<br />Filed on 2022-07-07<br />Status: Expired 167147419 E-164-2021-0 E-164-2021-0-US-04 SUPPRESSION OF UVEITIS BY SINGLE DOMAIN ANTIBODY CON US 19/662,470 Pending US <br />Continuation (CON) 19/662,470<br />Filed on 2026-04-29<br />Status: Pending TAB-5054 162400945 Angubindin-1 Peptide for Transient Blood-Brain Barrier Opening to Boost Chemotherapy in Malignant Glioma NINDS Licensing, Neurology, Oncology, Therapeutics Licensing Neurology Oncology Therapeutics Sadhana Jackson <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">This technology includes a first-in-class synthetic peptide, angubindin-1, designed to temporarily relax the blood-brain barrier (BBB)&mdash;the tightly sealed network of brain blood vessel cells that normally blocks most drugs&mdash;from the inside. By binding the tricellular tight-junction protein angulin-1/LSR, the peptide creates a reversible &ldquo;molecular doorway&rdquo; that lets cancer medicines such as liposomal doxorubicin (Doxil&reg;) reach tumors in the central nervous system (CNS). In rodent models of malignant glioma, co-administration of angubindin-1 increased drug penetration into the brain, cut tumor volume, and significantly prolonged survival compared with chemotherapy alone. The opening of the BBB is short-lived and spatially restricted, minimizing exposure of healthy brain tissue and avoiding the hardware, ultrasound, or high-dose osmotic agents required by competing methods.</span></span></span></p> <ul> <li>Peptide-based, systemic administration—no invasive devices or focused ultrasound, lowering clinical complexity and cost.</li> <li>Transient, selective BBB permeability (< hours) preserves barrier integrity post-treatment and limits off-target toxicity.</li> <li>Validated in vivo efficacy with improved survival; platform readily pairs with small-molecule drugs, antibodies, or gene/cell therapies targeting CNS diseases.</li> </ul> <ul> <li>Adjunct to standard-of-care chemotherapy for glioblastoma and other high-grade gliomas.</li> <li>Enabling delivery of emerging biologics (e.g., CAR-T cells, antibody–drug conjugates, gene therapies) to the brain.</li> <li>Enhancing uptake of CNS imaging or diagnostic agents for more accurate tumor visualization and monitoring.</li> </ul> 2025-05-13 2025-06-13 2026-04-30 2025-06-13 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 162400962 Jackson, Sadhana NINDS NINDS Jackson, Sadhana (NINDS) 1 162400962 Jackson, Sadhana NINDS NINDS Jackson, Sadhana (NINDS) 1 162400948 Angubindin-1 treatment against malignant glioma E-018-2024-0 Filing authorized NIH - NINDS 83687767 Olufemi, Olufunmilola (Lola) olufunmilola.olufemi@nih.gov
United States of America olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-5054] Angubindin-1 Peptide for Transient Blood-Brain Barrier Opening to Boost Chemotherapy in Malignant Glioma&body=Please send me information about technology [TAB-5054] Angubindin-1 Peptide for Transient Blood-Brain Barrier Opening to Boost Chemotherapy in Malignant Glioma. Olufemi, Olufunmilola (Lola)<br><a href="mailto:olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-5054] Angubindin-1 Peptide for Transient Blood-Brain Barrier Opening to Boost Chemotherapy in Malignant Glioma&body=Please send me information about technology [TAB-5054] Angubindin-1 Peptide for Transient Blood-Brain Barrier Opening to Boost Chemotherapy in Malignant Glioma.">olufunmilola.olufemi@nih.gov</a><br> 162400953 E-018-2024-0 E-018-2024-0-PCT-01 ANGUBINDIN-1 TREATMENT AGAINST MALIGNANT GLIOMA PCT Patent Cooperation Treaty PCT/US2023/079547 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/079547<br />Filed on 2023-11-13<br />Status: Expired 166152782 E-018-2024-0 E-018-2024-0-US-01 COMBINATION OF ANGUBINDIN-1 ABD CHEMOTHERAPY FOR THE TREATMENT OF CNS MALIGNANCIES National Stage US 19/586,174 Pending US <br />National Stage 19/586,174<br />Filed on 2026-05-08<br />Status: Pending 166152811 E-018-2024-0 E-018-2024-0-EP-01 COMBINATION OF ANGUBINDIN-1 AND CHEMOTHERAPY FOR THE TREATMENT OF CNS MALIGNANCIES National Stage European Patent 23828844.3 Pending European Patent <br />National Stage 23828844.3<br />Filed on 2026-06-12<br />Status: Pending TAB-3973 147157254 Synthetic Lethality-mediated Precision Oncology via the Tumor Transcriptome NCI Diagnostics, Licensing, Oncology Diagnostics Licensing Oncology Joo Lee, Eytan Ruppin <h2>Description of Technology:</h2> <p>The use of tumor transcriptomics for precision oncology has made significant advances, mainly by identifying cancer driver genes or actionable mutations for treatment with targeted therapies.&nbsp; However, this strategy misses out on broader genetic interactions that could reveal additional biologically testable biomarkers for therapy response prediction and inform the selection of more effective drugs for targeted treatment.</p> <p>Scientists at the National Cancer Institute (NCI) have developed SELECT, a computational, precision-oncology framework that uses the tumor&rsquo;s whole transcriptome to identify synthetic lethal and synthetic rescue genetic interactions.&nbsp; These genetic interactions provided actional information predicting therapeutic response in 28 of 35 published targeted and immunotherapy trials from 10 different cancer types. Also, it was predictive of patients&rsquo; response in 80 % of these clinical trials.&nbsp; SELECT, an excellent tool in developing new targeted therapies or enhancing patient stratification in transcriptomic multi-arm trials, is available for co-development or licensing opportunity.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Patient stratification in clinical trials&nbsp;</li> <li>Identifying new actionable drug targets and treatments&nbsp;</li> <li>Analysis of genetic interactions that can provide actionable information for selecting effective treatment options for cancer patient</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Predictive accuracy of patients&rsquo; response in many treatment options, including chemotherapy, targeted drugs and immunotherapy</li> <li>Predictive accuracy of patients&rsquo; response across cancer types</li> <li>Enhancing patient stratification for clinical trials and improved therapeutic strategies</li> <li>Increasing the number of patients that could benefit from precision-based treatments</li> </ul> 2021-11-19 2026-04-24 2021-11-19 2026-04-30 2021-11-19 Genetic Interactions, Patient Stratification, Precision Diagnostics, Precision Oncology, Ruppin, Synthetic Lethality, Transcriptome False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-11-19 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162079 PUBLICATION: Lee JS, et al. Synthetic lethality-mediated precision oncology via the tumor transcriptome. (PMID 33857424) https://pubmed.ncbi.nlm.nih.gov/33857424/ <a href="https://pubmed.ncbi.nlm.nih.gov/33857424/">PUBLICATION: Lee JS, et al. Synthetic lethality-mediated precision oncology via the tumor transcriptome. (PMID 33857424)</a> 167039304 Sahu AD, et al. Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. https://pubmed.ncbi.nlm.nih.gov/30858180/CAPTION: 30858180 Sahu AD, et al. Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. https://pubmed.ncbi.nlm.nih.gov/30858180/CAPTION: 30858180 167072741 Lee JS, et al. Harnessing Synthetic Lethality to Predict the Response to Cancer Treatment. (PMID 29959327) https://pubmed.ncbi.nlm.nih.gov/29959327/ <a href="https://pubmed.ncbi.nlm.nih.gov/29959327/">Lee JS, et al. Harnessing Synthetic Lethality to Predict the Response to Cancer Treatment. (PMID 29959327)</a> 147163087 Ruppin, Eytan NIH - NCI NCI Ruppin, Eytan (NCI) 1 147163088 Lee, Joo NIH - NCI Lee, Joo 2 147163087 Ruppin, Eytan NIH - NCI NCI Ruppin, Eytan (NCI) 1 147163088 Lee, Joo NIH - NCI Lee, Joo 2 147158081 Synthetic Lethality-mediated Precision Oncology Via The Tumor Transcriptome E-150-2020-0 Filing authorized NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-3973] Synthetic Lethality-mediated Precision Oncology via the Tumor Transcriptome&body=Please send me information about technology [TAB-3973] Synthetic Lethality-mediated Precision Oncology via the Tumor Transcriptome.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-3973] Synthetic Lethality-mediated Precision Oncology via the Tumor Transcriptome&body=Please send me information about technology [TAB-3973] Synthetic Lethality-mediated Precision Oncology via the Tumor Transcriptome.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147161108 E-150-2020-0 E-150-2020-0-US-01 Synthetic Lethality-mediated Precision Oncology Via The Tumor Transcriptome PRV US 63/107,737 Abandoned US <br />Provisional (PRV) 63/107,737<br />Filed on 2020-10-30<br />Status: Abandoned 147165637 E-150-2020-0 E-150-2020-0-PCT-02 Synthetic Lethality-Mediated Precision Oncology via the Tumor Transcriptome PCT Patent Cooperation Treaty PCT/US2021/057229 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/057229<br />Filed on 2021-10-29<br />Status: Expired 147165638 E-150-2020-0 E-150-2020-0-US-02 Synthetic Lethality-Mediated Precision Oncology via the Tumor Transcriptome National Stage US 18/250,816 Pending US <br />National Stage 18/250,816<br />Filed on 2023-04-27<br />Status: Pending 147172374 Genetic Interactions 147172375 Patient Stratification 147172377 Precision Diagnostics 147172378 Precision Oncology 147172379 Ruppin 147172381 Synthetic Lethality 147172382 Transcriptome TAB-3970 147157250 Multidimensional MRI Signature for Specific Detection of Traumatic Brain Injury In Vivo NICHD Collaboration, Diagnostics, Licensing, Neurology Collaboration Diagnostics Licensing Neurology Peter Basser, Dan Benjamini, Diego Iacono <h2>Summary:</h2> <p>The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for the development of multidimensional MRI-based methods.</p> <h2>Description of Technology:</h2> <p>Traumatic brain injury (TBI) represents a major medical, social and economic concern worldwide due to significant mortality &ndash; especially among younger populations &ndash; and long-term disabilities. Various pathological brain lesions (e.g., intracerebral bleedings, necrotic-ischemic lesions, tissue avulsion) are produced by impacting mechanical forces. Among these, diffuse axonal injury (DAI) is one of the most significant brain lesions typically associated with trauma. However, DAI is not necessarily linked with TBI exposure. Therefore, the term &ldquo;traumatic axonal injury (TAI)&rdquo; is commonly used. TAI is a specific form of DAI.</p> <p>Multidimensional MRI-based methods permit identification and categorization of brain specimens to identify sub-voxel tissue components specific to traumatic axon injury or other lesions. Lower dimensional MR spectral data is acquired and processed to provide multidimensional MR data of higher dimensions. One or more spectral ranges are selected that define signatures for brain injury. Evaluation of the multidimensional MR data in these ranges is used to locate voxels associated with brain injury. The invention pertains to noninvasive methods of assessing nervous system injury, particularly TBI &ndash; both mild and severe. A unique TAI multidimensional spectral signature can be measured and used to generate biomarker images closely following amyloid precursor protein (&ldquo;APP&rdquo;) histopathology: APP-positive areas scale with multidimensional TAI biomarker intensity and negative APP corresponds to reduced or absent MRI signal. This specificity of the multidimensional TAI biomarkers permit so-called &ldquo;noninvasive histology.&rdquo; One or more T1-T2-MD ranges can be identified and specifically linked to TAI microscopic tissue alterations. T1, T2 and diffusion dynamics can be different in fixed compared with living tissue. Therefore, different T1-T2-MD ranges can be selected for fixed and living tissues.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Diagnosis and assessment of patients with TBI</li> <li>Noninvasive histology</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Noninvasive diagnostic technique</li> <li>Provides substantially more discrete data than prior methodologies</li> <li>Produces measurements with high specificity</li> <li>Unique TAI multidimensional spectral signatures can be measured and used to generate biomarker images</li> </ul> 2022-01-05 2026-04-23 2022-01-05 2026-04-30 2022-01-05 Amyloid Precursor Protein, Be, DAI, Diffuse Axonal Injury, Eunice Kennedy Shriver National Institute of Child Health an, Magnetic Resonance Imaging, MRI, MULTIDIMENSIONAL, NICHD, TAI, TBI, Traumatic Axonal Injury, Traumatic Brain Injury False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-01-05 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162279 Benjamini D, et al. Multidimensional MRI for Characterization of Subtle Axonal Injury Accelerated Using an Adaptive Nonlocal Multispectral Filter. (https://doi.org/10.3389/fphy.2021.73737 : Benjamini D, et al. Multidimensional MRI for Characterization of Subtle Axonal Injury Accelerated Using an Adaptive Nonlocal Multispectral Filter. (https://doi.org/10.3389/fphy.2021.737374 <a href=": Benjamini D, et al. Multidimensional MRI for Characterization of Subtle Axonal Injury Accelerated Using an Adaptive Nonlocal Multispectral Filter. (https://doi.org/10.3389/fphy.2021.737374">Benjamini D, et al. Multidimensional MRI for Characterization of Subtle Axonal Injury Accelerated Using an Adaptive Nonlocal Multispectral Filter. (https://doi.org/10.3389/fphy.2021.73737</a> 167039252 Benjamini D, et al. Diffuse axonal injury has a characteristic multidimensional MRI signature in the human brain. .PUBLICATIONS HREF: https://doi.org/10.3389/fphy.2021.737374CAPTION: PMID 25838374 https://doi.org/10.1093/brain/awaa447 <a href="https://doi.org/10.1093/brain/awaa447">Benjamini D, et al. Diffuse axonal injury has a characteristic multidimensional MRI signature in the human brain. .PUBLICATIONS HREF: https://doi.org/10.3389/fphy.2021.737374CAPTION: PMID 25838374</a> 147163078 Benjamini, Dan NICHD NIA Benjamini, Dan (NIA) 1 147163077 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 2 147163079 Iacono, Diego NINDS NINDS Iacono, Diego (NINDS) 3 147163078 Benjamini, Dan NICHD NIA Benjamini, Dan (NIA) 1 147163077 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 2 147163079 Iacono, Diego NINDS NINDS Iacono, Diego (NINDS) 3 147158172 Multidimensional MRI Signature For Specific Detection Of Traumatic Brain Injury In Vivo E-185-2020-0 Filing authorized Henry M. Jackson Foundation (HJF), NICHD 119617417 Ravilious, Geoffrey geoffrey.ravilious@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-3970] Multidimensional MRI Signature for Specific Detection of Traumatic Brain Injury In Vivo&body=Please send me information about technology [TAB-3970] Multidimensional MRI Signature for Specific Detection of Traumatic Brain Injury In Vivo.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ravilious, Geoffrey<br><a href="mailto:geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-3970] Multidimensional MRI Signature for Specific Detection of Traumatic Brain Injury In Vivo&body=Please send me information about technology [TAB-3970] Multidimensional MRI Signature for Specific Detection of Traumatic Brain Injury In Vivo.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">geoffrey.ravilious@nih.gov</a><br> 147161166 E-185-2020-0 E-185-2020-0-US-01 MULTIDIMENSIONAL MRI SIGNATURE FOR SPECIFIC DETECTION OF TRAUMATIC BRAIN INJURY IN VIVO PRV US 63/061,105 Abandoned US <br />Provisional (PRV) 63/061,105<br />Filed on 2020-08-04<br />Status: Abandoned 147165625 E-185-2020-0 E-185-2020-0-PCT-02 Multidimensional MRI Signature For Specific Detection Of Traumatic Brain Injury In Vivo PCT Patent Cooperation Treaty PCT/US2021/041663 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/041663<br />Filed on 2021-07-14<br />Status: Expired 147165626 E-185-2020-0 E-185-2020-0-US-03 Multidimensional MRI Signature For Specific Detection Of Traumatic Brain Injury In Vivo National Stage US 12,343,132 18/019,725 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12343132 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12343132">12,343,132</a><br />Filed on 2023-02-03<br />Status: Issued 147173292 Amyloid Precursor Protein 147173294 Be 147173296 DAI 147173298 Diffuse Axonal Injury 147173299 Eunice Kennedy Shriver National Institute of Child Health an 147173300 Magnetic Resonance Imaging 147173301 MRI 147173302 MULTIDIMENSIONAL 147173303 NICHD 147173305 TAI 147173306 TBI 147173308 Traumatic Axonal Injury 147173309 Traumatic Brain Injury TAB-4424 147157719 Coumarin Luciferins and Mutant Luciferases for Bioluminescence Imaging NCI Collaboration, Immunology, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Immunology Infectious Disease Licensing Oncology Therapeutics Donald Caldwell, Anna Love, Jennifer Prescher, Martin Schnermann, Zi Wei Yao <h2>Summary:</h2> <p>Researchers at UCI and NCI seek licensing to adopt new applications for a family of far-red to near-infrared emission coumarin-based luciferins (CouLuc) with complementary mutant enzymes.&nbsp;</p> <h2>Description of Technology:</h2> <p>Bioluminescence imaging with luciferin-luciferase pairs is a well-established technique for tracking cells and other biological features in animal models. Bioluminescent is a chemical process which does not require an external input for excitation. Bioluminescent imaging is often limited to monitoring single processes in vivo due to the lack of distinguishable probes. Additionally, existing probes typically operate with light in the visible range, which is highly scattered and exhibits poor tissue penetration.&nbsp;</p> <p>To address these issues, researchers at UCI and NCI synthesized a new family of coumarin-based luciferins (CouLuc) with complementary mutant enzymes that exhibit far-red to near-infrared emission. This novel shift in emission opens the possibility of pairing with commercial luciferin-luciferase probes to form multicomponent systems. Additionally, far-red to near-infrared emission enables imaging at greater depths in live animals. Based on commercial courmarin precursors, these CouLuc scaffolds can be prepared in a straightforward two-step sequence. The resulting CouLuc with luciferase mutants provides stable substrate-selective luciferases with robust light emission. Overall, these probes are poised to advance the scope of bioluminescence imaging to more complex biological problems.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Live animal imaging&nbsp;</li> <li>Multicomponent imaging when combined with commercial luciferin-luciferase pairs</li> <li>Enhanced bioluminescence imaging</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Distinct from existing luciferin-luciferase pair due to their emission of far-red to near-red light</li> <li>Superior tissue penetration&nbsp;</li> <li>Greater depth and resolution&nbsp;&nbsp;</li> <li>Enhancement of a variety of current bioluminescence imaging applications</li> <li>Ability to quickly produce significant quantities of the novel CouLucs probes</li> </ul> 2021-09-23 2026-04-24 2021-11-05 2026-04-30 2021-09-23 CouLuc, Luciferases, Luciferins, Near-infrared, NIR, Optical Imaging, Schnermann False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-11-05 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161919 Yao Z, et al. Coumarin luciferins and mutant luciferases for robust multicomponent bioluminescence imaging. (PMID) Yao Z, et al. Coumarin luciferins and mutant luciferases for robust multicomponent bioluminescence imaging. (PMID) 147164697 Schnermann, Martin NIH - NCI NCI Schnermann, Martin (NCI) 1 147164698 Caldwell, Donald NCI - CCR NCI Caldwell, Donald (NCI) 2 147164699 Prescher, Jennifer University of California, Irvine Prescher, Jennifer 3 147164700 Yao, Zi Wei University of California, Irvine Yao, Zi Wei 4 147164701 Love, Anna University of California, Irvine Love, Anna 5 147164697 Schnermann, Martin NIH - NCI NCI Schnermann, Martin (NCI) 1 147164698 Caldwell, Donald NCI - CCR NCI Caldwell, Donald (NCI) 2 147164699 Prescher, Jennifer University of California, Irvine Prescher, Jennifer 3 147164700 Yao, Zi Wei University of California, Irvine Yao, Zi Wei 4 147164701 Love, Anna University of California, Irvine Love, Anna 5 147157997 Coumarin Luciferins And Mutant Luciferases For Bioluminescence Imaging E-105-2021-0 Filing authorized NCI, University of California, Irvine 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4424] Coumarin Luciferins and Mutant Luciferases for Bioluminescence Imaging&body=Please send me information about technology [TAB-4424] Coumarin Luciferins and Mutant Luciferases for Bioluminescence Imaging.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4424] Coumarin Luciferins and Mutant Luciferases for Bioluminescence Imaging&body=Please send me information about technology [TAB-4424] Coumarin Luciferins and Mutant Luciferases for Bioluminescence Imaging.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161047 E-105-2021-0 E-105-2021-0-US-01 COUMARIN LUCIFERINS FOR BIOLUMINESCENCE IMAGING PRV US 63/184,432 Abandoned US <br />Provisional (PRV) 63/184,432<br />Filed on 2021-05-05<br />Status: Abandoned 147171520 CouLuc 147171521 Luciferases 147171522 Luciferins 147171523 Near-infrared 147171524 NIR 147171526 Optical Imaging 147171528 Schnermann TAB-4516 151706972 Cas9 Protein Delivery with Lentiviral Vector Particles as a Therapy for Sickle Cell Disease NHLBI Licensing, Plasmids/Vectors, Therapeutics Licensing Plasmids/Vectors Therapeutics Juan Haro Mora, John Tisdale, Naoya Uchida <p>This technology includes efficient lentiviral gene delivery system for both guide RNA and Cas9 endonuclease as a method to cure sickle cell disease. Gene correction is an ideal gene therapy strategy for hereditary disease, including sickle cell disease. To deliver both guide RNA and Cas9 endonuclease into target cells, we used HIV-l based lentiviral vector system, which allows for efficient gene delivery in various cells, including hematopoietic stem cells and ES/1PS cells in this system, transgene expression cassettes can be integrated into genomic DNA in target cells, which results in long‐ term transgene expression. Out data demonstrate that Cas9/CypA fusion proteins can be delivered with lentiviral particles, and the Cas9 fusion proteins have an endonuclease function to induce GFP DNA double strand break.</p> In this system, much smaller size of viral genome is packaged in lentiviral particles, which should allow for more efficient gene/protein delivery with lentiviral vectors. ln addition, site-specific DNA break can be induced for a short term only, which should allow for safer genome editing by reduction of DNA damage in target cells. Perform gene correction in the β-globin gene and/or BCL11lA gene knock-down in hematopoietic stem cells to induce fetal hemoglobin expression to cure sickle cell disease. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2024-08-12 2026-04-30 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151706979 Uchida, Naoya University of Tokyo Uchida, Naoya 1 151706983 Haro Mora, Juan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Haro Mora, Juan (NHLBI) 2 151707087 Tisdale, John National Heart, Lung, and Blood Institute (NHLBI) NHLBI Tisdale, John (NHLBI) 3 151706979 Uchida, Naoya University of Tokyo Uchida, Naoya 1 151706983 Haro Mora, Juan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Haro Mora, Juan (NHLBI) 2 151707087 Tisdale, John National Heart, Lung, and Blood Institute (NHLBI) NHLBI Tisdale, John (NHLBI) 3 151706975 Development Of Lentiviral Protein Delivery System For RNA-guided Genome Editing E-165-2015-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 89788013 Kolesnitchenko, Vincent vk5q@nih.gov
United States of America Office of Technology Transfer and Development vk5q@nih.gov?subject=Web Inquiry on [TAB-4516] Cas9 Protein Delivery with Lentiviral Vector Particles as a Therapy for Sickle Cell Disease&body=Please send me information about technology [TAB-4516] Cas9 Protein Delivery with Lentiviral Vector Particles as a Therapy for Sickle Cell Disease. Kolesnitchenko, Vincent<br><a href="mailto:vk5q@nih.gov?subject=Web Inquiry on [TAB-4516] Cas9 Protein Delivery with Lentiviral Vector Particles as a Therapy for Sickle Cell Disease&body=Please send me information about technology [TAB-4516] Cas9 Protein Delivery with Lentiviral Vector Particles as a Therapy for Sickle Cell Disease.">vk5q@nih.gov</a><br> 157755526 E-165-2015-0 E-165-2015-0-US-01 LENTIVIRAL PROTEIN DELIVERY SYSTEM FOR RNA-GUIDED GENOME EDITING PRV US 62/236,223 Abandoned US <br />Provisional (PRV) 62/236,223<br />Filed on 2015-10-02<br />Status: Abandoned TAB-4468 150736756 Directed Acetylation of Cytidine in Cellular mRNA through Engineered snoRNA Adapters for the Treatment of Haploinsufficiencies NCI Application, Cardiology, Collaboration, Licensing, Neurology, Oncology, Therapeutics Application Cardiology Collaboration Licensing Neurology Oncology Therapeutics Shalini Oberdoerffer, Sarah Schiffers <h2>Summary:&nbsp;</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for engineered chimeric snoRNA guides that recruit NAT10 to a specific target and cause directed acetylation of the target. They could be used to treat haploinsufficiency-associated disorders or diseases.</p> <h2>Description of Technology:&nbsp;</h2> <p>Haploinsufficiency (HI) is the loss of one allele of a gene. The resultant loss in associated protein expression/function is insufficient for a normal phenotype and manifests in a myriad of diseases. Such diseases include: [1] congenital malformations (e.g., eye defects, cleft lip/palate, etc.), [2] neurodevelopmental disorders (e.g., autism spectrum disorders, epilepsy, schizophrenia, etc.) and [3] disorders of maintenance and self-renewal. This latter category includes cancer predisposition syndromes, obesity, maturity onset diabetes of the young, and autoimmune disorders. In total, over 300 known human haploinsufficiencies exist. However, no therapies exist which can target these HIs without unbalanced protein expression and deleterious side effects.</p> <p>Scientists at the NCI engineered chimeric small nucleolar (snoRNA) guides that recruit the enzyme NAT10 to a target transcript. The NAT10 enzyme acetylates specific cytidines in RNA, including at the ac4C site, through association with these snoRNA guides. In mRNA, ac4C modulates the level of protein produced per mRNA template, manifesting in moderate increases in net protein levels. For HI-related disorders or diseases, moderate increases in protein production alleviate disease phenotypes without the potential side effects of more substantial over-expression and protein production. The inventors developed a proof-of-principle snoRNA guide that recruits NAT10 to the target transcript GAPDH mRNA. The snoRNA was delivered into HeLa cells through incorporation into a minigene vector. Recovery of GAPDH transcripts and mass spectrometry confirmed successful targeted acetylation in these cells. This invention of directed acetylation through engineered snoRNA adapters would be useful for the treatment of haploinsufficiencies where moderate protein expression can lead to alleviation of disease phenotype.</p> <p>The NCI is looking for research co-development partners and/or licensees to help develop these engineered chimeric snoRNA guides into clinically relevant therapeutics for the treatment of a variety of haploinsufficiencies.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <p>Patient-specific, RNA-targeting therapy for haploinsufficiencies such as:</p> <ul> <li>Congenital malformations</li> <li>Neurodevelopmental disorders&nbsp;</li> <li>Cancer</li> <li>Autoimmune Lymphoproliferative Syndrome (ALPS)</li> <li>Myelodysplastic Syndrome (MDS)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Potentially fewer and less severe side-effects compared with current gene therapy technology</li> <li>More moderate changes of protein expression&nbsp;</li> <li>Promotion of endogenous protein biosynthesis<br /> &nbsp;</li> </ul> 2023-10-10 2026-04-30 2026-04-30 2023-10-11 False False Basic (Target ID) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 150757256 Oberdoerffer, Shalini Laboratory of Receptor Biology and Gene Expression NCI Oberdoerffer, Shalini (NCI) 1 150757272 Schiffers, Sarah National Cancer Institute (NCI) NCI Schiffers, Sarah (NCI) 2 150757256 Oberdoerffer, Shalini Laboratory of Receptor Biology and Gene Expression NCI Oberdoerffer, Shalini (NCI) 1 150757272 Schiffers, Sarah National Cancer Institute (NCI) NCI Schiffers, Sarah (NCI) 2 150736762 Directed Acetylation Of Cytidine In Cellular MRNA Through Engineered SnoRNA Adapters For The Treatment Of Haploinsufficiencies E-017-2023-0 Filing authorized Laboratory of Receptor Biology and Gene Expression, NCI 91826910 McCrary, Michaela michaela.mccrary@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4468] Directed Acetylation of Cytidine in Cellular mRNA through Engineered snoRNA Adapters for the Treatment of Haploinsufficiencies&body=Please send me information about technology [TAB-4468] Directed Acetylation of Cytidine in Cellular mRNA through Engineered snoRNA Adapters for the Treatment of Haploinsufficiencies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov McCrary, Michaela<br><a href="mailto:michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4468] Directed Acetylation of Cytidine in Cellular mRNA through Engineered snoRNA Adapters for the Treatment of Haploinsufficiencies&body=Please send me information about technology [TAB-4468] Directed Acetylation of Cytidine in Cellular mRNA through Engineered snoRNA Adapters for the Treatment of Haploinsufficiencies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michaela.mccrary@nih.gov</a><br> 150894306 E-017-2023-0 E-017-2023-0-US-01 Directed acetylation of mRNA through engineered snoRNA adapters PRV US 63/423,714 Expired US <br />Provisional (PRV) 63/423,714<br />Filed on 2022-11-08<br />Status: Expired TAB-4448 147157743 National Cancer Institute Dosimetry System for Nuclear Medicine (NCINM) Computer Program NCI Cardiology, Licensing, Neurology, Oncology, Software / Apps Cardiology Licensing Neurology Oncology Software / Apps <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks licensees for a novel computer program performing radiation dose calculations for diagnostic and therapeutic nuclear medicine.</p> <h2>Description of Technology:</h2> <p>Nuclear medicine is the second largest source of medical radiation exposure to the general population after computed tomography imaging. Imaging modalities utilizing nuclear medicine produce a more detailed view of internal structure and function and are most commonly used to diagnose diseases such as heart disease, Alzheimer&rsquo;s and brain disorders. They are used to visualize tumors, abscesses due to infection or abnormalities in abdominal organs. When using radionuclides for diagnosis or therapy in nuclear medicine, it is critical to accurately estimate unintended dose to organs at risk surrounding tumors or of therapeutic or imaging interest. It is impossible to experimentally measure organ dose. Traditionally, computational approaches were used for this purpose, requiring a series of computational human phantoms and an extensive amount of computer simulation. However, existing model-based organ dose estimation tools rely on simplified human anatomy models or commercial programs.</p> <p>To address these challenges, Dr. Choonsik Lee from the NCI created a radiation dose-calculation tool for nuclear medicine imaging modalities based on more sophisticated human anatomy models. A comprehensive library of photon and electron specific absorbed fractions (SAF) were first calculated for multiple combinations of source and target regions within a series of pediatric and adult computational human phantoms matching the International Commission on Radiological Protection (ICRP)&#39;s reference data. These were combined with a Monte Carlo radiation transport code. Then, a library of S values was derived from these SAFs and the nuclear decay data from ICRP Publication 107. Finally, a graphical user interface, named the National Cancer Institute Dosimetry System for Nuclear Medicine (NCINM), was created to facilitate the dosimetry process. Approximately 13 million S values were derived from 2 million SAFs computed. A comprehensive library of biokinetic data were extracted from multiple up-to-date international reports and implemented into NCINM.&nbsp;</p> <p>The NCI seeks licensees for this technology who are interested in using NCINM, including their implementation within existing commercial solutions for patient dose monitoring.&nbsp;Applications of the NCINM program include computation of absorbed doses for use in radiation epidemiologic studies and patient dose monitoring in nuclear medicine.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Patient radiation dose monitoring in nuclear medicine imaging modalities</li> <li>Radiation epidemiologic studies</li> <li>Components can be incorporated with NCIDose software into a commercial platform: NCINM program, computational human phantom series (human anatomy models, electronic files), organ dose factor library (tabulated numbers)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Easy implementation within existing commercial solutions</li> <li>Most advanced pediatric and adult computational phantoms</li> <li>Intuitive user interface</li> <li>Software can run on Macintosh, Windows, and LINUX operating systems</li> </ul> Researchers at the NCI seek licensing for a novel computer program that performs radiation dose calculations for diagnostic and therapeutic nuclear medicine. 2023-05-14 2026-04-30 2023-05-14 2026-04-30 2023-05-14 • National Cancer Institute Dosimetry System for Nuclear Med, Dosimetry, Lee, NCINM, Nuclear Medicine, Radiation, Radiation Dosing, SAF, Specific Absorbed Fraction False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2023-05-14 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract E-082-2016 E-127-2023 147162076 Villoing D, et al. NCINM: organ dose calculator for patients undergoing nuclear medicine procedures. https://pubmed.ncbi.nlm.nih.gov/33444241/ <a href="https://pubmed.ncbi.nlm.nih.gov/33444241/">Villoing D, et al. NCINM: organ dose calculator for patients undergoing nuclear medicine procedures.</a> 155750754 National Cancer Institute Dosimetry System For Nuclear Medicine (NCINM) Computer Program E-125-2019-0 Closed NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-4448] National Cancer Institute Dosimetry System for Nuclear Medicine (NCINM) Computer Program&body=Please send me information about technology [TAB-4448] National Cancer Institute Dosimetry System for Nuclear Medicine (NCINM) Computer Program.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-4448] National Cancer Institute Dosimetry System for Nuclear Medicine (NCINM) Computer Program&body=Please send me information about technology [TAB-4448] National Cancer Institute Dosimetry System for Nuclear Medicine (NCINM) Computer Program.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147171904 • National Cancer Institute Dosimetry System for Nuclear Med 147171905 Dosimetry 147171906 Lee 147171907 NCINM 147171909 Nuclear Medicine 147171910 Radiation 147171911 Radiation Dosing 147171913 SAF 147171915 Specific Absorbed Fraction TAB-4419 147157714 Device for Simulating Explosive Blast and Imaging Biological Specimens NICHD Collaboration, Licensing, Medical Devices, Neurology, Non-Medical Devices Collaboration Licensing Medical Devices Neurology Non-Medical Devices Sergey Bezrukov, Paul Blank, Kim Lee Mcafee, Rea Ravin, Alex Steinkamp, Joshua Zimmerberg <h2>Summary:</h2> <p>Researchers at the National Institute of Child Health and Human Development (NICHD) developed a device simulating a blast shock wave of the type produced by explosive devices such as bombs. The invention allows for the real-time study of blast effects on in vitro cell models. NICHD researchers seek licensing opportunities to further develop this device.</p> <h2>Description of Technology:</h2> <p>Traumatic brain injury (TBI) is a major health problem.&nbsp; Between 3.2 and 5.3 million people live with long-term disabilities resulting from TBI, and thus, contribute to the need to develop therapies that treat TBI-induced cellular damage. Researchers at the National Institute of Child Health and Human Development (NICHD) have developed a device that simulates the pressure waves resulting from explosions. This invention can be used to study the in vitro effects of shock waves on cells in culture and could be used to determine the effects of potential treatments for TBI in an in vitro cellular model. The device consists of a source of compressed gas connected to a chamber containing cells. Cells can be derived from central nervous system (CNS) tissue, muscle, etc. The effects of the release of the compressed gas (blast) on the cells can be monitored in real time in a microscope or other imaging device.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Investigate the cellular effects of pressure waves in an in vitro model</li> <li>Use to screen for potential agents to treat traumatic brain injury (TBI)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Allows for the real-time study of a blast effect on in vitro cellular models</li> <li>Allows for testing of potential therapies of traumatic brain injury in an in vitro model.&nbsp;</li> </ul> 2018-09-05 2026-04-30 2021-01-26 2026-04-30 2018-09-05 Central Nervous System, CNS, explosive blast, National Institute of Child Health and Human Development, NICHD, SIMULATOR, TBI, Traumatic Brain Injury, Zimmerberg False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-01-26 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147164680 Ravin, Rea NIH - NICHD NIBIB Ravin, Rea (NIBIB) 1 147164678 Blank, Paul NIH - NICHD NICHD Blank, Paul (NICHD) 2 147164681 Steinkamp, Alex NIH - NICHD NICHD Steinkamp, Alex (NICHD) 3 147164677 Zimmerberg, Joshua NIH - NICHD NICHD Zimmerberg, Joshua (NICHD) 4 147164679 Bezrukov, Sergey NIH - NICHD NICHD Bezrukov, Sergey (NICHD) 5 147164682 Mcafee, Kim Lee NIH - NICHD Mcafee, Kim Lee 6 147164680 Ravin, Rea NIH - NICHD NIBIB Ravin, Rea (NIBIB) 1 147164678 Blank, Paul NIH - NICHD NICHD Blank, Paul (NICHD) 2 147164681 Steinkamp, Alex NIH - NICHD NICHD Steinkamp, Alex (NICHD) 3 147164677 Zimmerberg, Joshua NIH - NICHD NICHD Zimmerberg, Joshua (NICHD) 4 147164679 Bezrukov, Sergey NIH - NICHD NICHD Bezrukov, Sergey (NICHD) 5 147164682 Mcafee, Kim Lee NIH - NICHD Mcafee, Kim Lee 6 147157918 A Device To Simulate Explosive Blast For Use In Real Time Imaging Of Cells And Tissue. E-068-2012-0 Filing authorized NICHD 83682895 Girards, Richard richard.girards@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB richard.girards@nih.gov?subject=Web Inquiry on [TAB-4419] Device for Simulating Explosive Blast and Imaging Biological Specimens&body=Please send me information about technology [TAB-4419] Device for Simulating Explosive Blast and Imaging Biological Specimens.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Girards, Richard<br><a href="mailto:richard.girards@nih.gov?subject=Web Inquiry on [TAB-4419] Device for Simulating Explosive Blast and Imaging Biological Specimens&body=Please send me information about technology [TAB-4419] Device for Simulating Explosive Blast and Imaging Biological Specimens.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">richard.girards@nih.gov</a><br> 147168806 E-068-2012-0 E-068-2012-0-US-01 Device for Simulating Explosive Blast And Imaging Biological Specimen PRV US 61/590,209 Abandoned US <br />Provisional (PRV) 61/590,209<br />Filed on 2012-01-24<br />Status: Abandoned 147168807 E-068-2012-0 E-068-2012-0-US-02 Device For Simulating Explosive Blast And Imaging Biological Specimen ORD US 9,217,698 13/748,410 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9217698 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9217698">9,217,698</a><br />Filed on 2013-01-23<br />Status: Issued 147170708 Central Nervous System 147170709 CNS 147170710 explosive blast 147170711 National Institute of Child Health and Human Development 147170712 NICHD 147170713 SIMULATOR 147170714 TBI 147170715 Traumatic Brain Injury 147170717 Zimmerberg TAB-4417 147157712 Methods of Predicting Patient Treatment Response and Resistance via Single-Cell Transcriptomics of Their Tumors NCI Collaboration, Licensing, Oncology, Software / Apps Collaboration Licensing Oncology Software / Apps Eytan Ruppin, Alejandro Schaffer, Sanju Sinha, Rahulsimham Vegesna <h2>Summary:</h2> <p>The NCI is currently seeking research co-development partners for this first-in-kind computational method that is predictive of therapeutic response based on clonal SC gene expression of tumors.</p> <h2>Description of Technology:</h2> <p>Tailoring the best treatments to cancer patients remains a highly important endeavor in the oncology field. However, personalized treatment courses are challenging to determine, and technologies or methods that can successfully be employed for precision oncology are lacking.</p> <p>Researchers at the NCI have built a new method for guiding cancer patient therapy based on single cell transcriptomics data of their tumors. This precision oncology data science and software framework is termed PERsonalized single-Cell Expression-based Planning for Treatments In ONcology (PERCEPTION). It capitalizes on recent, matched bulk and single-cell transcriptome profiles sourced from large-scale cell-line drug screenings and builds treatment response models from patient single-cell (SC) tumor transcriptomes. As a proof-of-concept, PERCEPTION has been shown to successfully predict response to monotherapy and combination therapy based on SC-expression profiles, in screenings of standard cancer cell lines and patient-tumor-derived cell lines. It has also successfully identified responders to a combination therapy based on tumor SC-expression data from recent multiple myeloma and breast cancer clinical trials. Further, it has discovered the development of treatment resistance to five standard tyrosine kinase inhibitors in a recent SC dataset obtained from lung cancer patients undergoing treatment. PERCEPTION is the first technology to demonstrate that SC gene expression can provide a framework to predict effective targeted therapies for individual cancer patients in a data-driven manner.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Tool for personalized identification of effective patient therapies (precision oncology) based on single cell transcriptomics data of their tumors</li> <li>Tool for discovery of new drug combinations for specific cancer types and sub-types</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>First software of its kind that aims to tailor the best treatments to cancer patients based on single cell transcriptomics data of their tumors&nbsp; &nbsp; &nbsp;</li> <li>Has proof-of-concept retrospective validations in patient clinical trial data where PERCEPTION performed better than published state-of-the-art single-cell-based and bulk-based predictors&nbsp; &nbsp; &nbsp;</li> <li>Useful for companies focused on single cell sequencing or interested in the single cell domain</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a new method for guiding cancer patient therapy based on single cell transcriptomics data of their tumors. 2023-06-06 2026-04-30 2023-06-06 2026-04-30 2023-06-06 Cancer Prognosis, Cancer Treatment Resistance, COMPUTATIONAL, Precision Oncology, Ruppin, Single Cell, Single Cell Screening, Single Cell Transcriptomics, Transcriptomics, Tumor Response False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-06-06 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147161872 Sinha. S, et al. 2022. bioRxiv. Predicting patient treatment response and resistance via single-cell transcriptomics of their tumors. https://doi.org/10.1101/2022.01.11.475728 <a href="https://doi.org/10.1101/2022.01.11.475728">Sinha. S, et al. 2022. bioRxiv. Predicting patient treatment response and resistance via single-cell transcriptomics of their tumors.</a> 147164668 Ruppin, Eytan NIH - NCI NCI Ruppin, Eytan (NCI) 1 147164670 Sinha, Sanju NCI - CCR NCI Sinha, Sanju (NCI) 2 147164671 Vegesna, Rahulsimham NCI - CCR NCI Vegesna, Rahulsimham (NCI) 3 147164669 Schaffer, Alejandro NIH - NCI NCI Schaffer, Alejandro (NCI) 4 147164668 Ruppin, Eytan NIH - NCI NCI Ruppin, Eytan (NCI) 1 147164670 Sinha, Sanju NCI - CCR NCI Sinha, Sanju (NCI) 2 147164671 Vegesna, Rahulsimham NCI - CCR NCI Vegesna, Rahulsimham (NCI) 3 147164669 Schaffer, Alejandro NIH - NCI NCI Schaffer, Alejandro (NCI) 4 147157874 PERsonalized Single-Cell Expression-based Planning For Treatments In ONcology (PERCEPTION) Software E-051-2022-0 Filing authorized NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-4417] Methods of Predicting Patient Treatment Response and Resistance via Single-Cell Transcriptomics of Their Tumors&body=Please send me information about technology [TAB-4417] Methods of Predicting Patient Treatment Response and Resistance via Single-Cell Transcriptomics of Their Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-4417] Methods of Predicting Patient Treatment Response and Resistance via Single-Cell Transcriptomics of Their Tumors&body=Please send me information about technology [TAB-4417] Methods of Predicting Patient Treatment Response and Resistance via Single-Cell Transcriptomics of Their Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147168799 E-051-2022-0 E-051-2022-0-US-01 PREDICTING PATIENT TREATMENT RESPONSE AND RESISTANCE VIA SINGLE CELL TRANSCRIPTOMICS OF THEIR TUMORS PRV US 63/298,045 Expired US <br />Provisional (PRV) 63/298,045<br />Filed on 2022-01-10<br />Status: Expired 147168800 E-051-2022-0 E-051-2022-0-PCT-02 Predicting Patient Treatment Response and Resistance via Single-Cell Transcriptomics of their Tumors PCT Patent Cooperation Treaty PCT/US2023/060416 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/060416<br />Filed on 2023-01-10<br />Status: Expired 147170332 Cancer Prognosis 147170334 Cancer Treatment Resistance 147170335 COMPUTATIONAL 147170337 Precision Oncology 147170338 Ruppin 147170340 Single Cell 147170342 Single Cell Screening 147170344 Single Cell Transcriptomics 147170346 Transcriptomics 147170348 Tumor Response TAB-4122 147157404 Development and Characterization of the SLC46A3 Knockout Mouse Line NCI Endocrinology, Licensing, Oncology, Research Materials Endocrinology Licensing Oncology Research Materials Frank Gonzalez, Jung-Hwan Kim, Sun Hee Yim <h2>Summary:</h2> <p>The NCI is seeking licensees for the SLC46A3 knockout mouse line.</p> <h2>Description of Technology:</h2> <p>Nonalcoholic fatty liver disease is caused by several factors including 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), an environmental contaminant. TCDD causes lipid accumulation in humans by inducing the Solute Carrier Family 46 Member 3 (SLC46A3) gene expression. To effectively study TCDD-mediated lipid accumulation, research tools such as SLC46A3 knockout cells and animal models are required.</p> <p>Researchers at the National Cancer Institute (NCI) have developed an SLC46A3 knockout mouse line and demonstrated that TCDD-induced hepatic triglyceride accumulation was significantly reduced in the knockout mice compared to the wild type mice. This reduction in triglyceride accumulation was more pronounced when the mice were fed a high fat diet. The SLC46A3 knockout mouse line is therefore an effective tool to study TCDD-induced lipid accumulation, liver toxicity and nonalcoholic fatty liver disease. As SLC46A3 gene and protein are also associated with other diseases such as breast cancer, prostate cancer, liver cancer, papilloma, glioma, obesity, and SARS, this knockout mouse line may have wide applicability.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Drug screening and development against various diseases such as nonalcoholic fatty liver disease, obesity, liver cancer, SARS, breast cancer, prostate cancer, papilloma, glioma</li> <li>Research tool to study SLC46A3&rsquo;s role in hepatic lipid accumulation or as a solute carrier of the Major Facilitator Superfamily (MFS)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The only known SLC46A knockout mouse line available</li> <li>Effective research tool to study TCDD-mediated liver toxicity leading to nonalcoholic fatty liver disease&nbsp;</li> </ul> 2021-07-14 2026-04-24 2021-07-14 2026-04-29 2021-07-14 2, 3, 7, 8-tetracholodibenzo-p-dioxin, Gonzalez, hepatocellular carcinoma, Knockout Mouse, Liver cancer, Major Facilitator Superfamily, MFS, Nonalcoholic fatty liver disease, OBESITY, SLC46A3, Solute Carrier Family, TCDD False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-07-14 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162426 Kim JH, et al. Lysosomal SLC46A3 modulates hepatic cytosolic copper homeostasis. (PMID 33436590) https://pubmed.ncbi.nlm.nih.gov/33436590/ <a href="https://pubmed.ncbi.nlm.nih.gov/33436590/">Kim JH, et al. Lysosomal SLC46A3 modulates hepatic cytosolic copper homeostasis. (PMID 33436590)</a> 147163585 Gonzalez, Frank NIH - NCI NCI Gonzalez, Frank (NCI) 1 147163586 Yim, Sun Hee NIH - NCI Yim, Sun Hee 2 147163587 Kim, Jung-Hwan NIH - NCI Kim, Jung-Hwan 3 147163585 Gonzalez, Frank NIH - NCI NCI Gonzalez, Frank (NCI) 1 147163586 Yim, Sun Hee NIH - NCI Yim, Sun Hee 2 147163587 Kim, Jung-Hwan NIH - NCI Kim, Jung-Hwan 3 147158087 Development And Characterization Of Teh SLC46A3 Knockout Mouse Line E-152-2021-0 Research Material NCI 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4122] Development and Characterization of the SLC46A3 Knockout Mouse Line&body=Please send me information about technology [TAB-4122] Development and Characterization of the SLC46A3 Knockout Mouse Line.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4122] Development and Characterization of the SLC46A3 Knockout Mouse Line&body=Please send me information about technology [TAB-4122] Development and Characterization of the SLC46A3 Knockout Mouse Line.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">diptadip.dattaroy@nih.gov</a><br> 147172441 2 147172442 3 147172443 7 147172445 8-tetracholodibenzo-p-dioxin 147172447 Gonzalez 147172448 hepatocellular carcinoma 147172450 Knockout Mouse 147172451 Liver cancer 147172453 Major Facilitator Superfamily 147172455 MFS 147172457 Nonalcoholic fatty liver disease 147172458 OBESITY 147172459 SLC46A3 147172461 Solute Carrier Family 147172463 TCDD TAB-3980 147157261 Polymer-Cast Inserts for Cell Histology and Microscopy NCI Collaboration, Dermatology, Immunology, Infectious Disease, Licensing, Research Materials Collaboration Dermatology Immunology Infectious Disease Licensing Research Materials Thu Nguyen, Ralph Parchment <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks co-development partners and/or licensees for polymer-cast inserts for cell histology and microscopy; a system for high throughput three-dimensional (3D) cell culture and screening microscopy.</p> <h2>Description of Technology:</h2> <p>Three-dimensional (3D) cell cultures systems are important for studying cell biology because they provide <em>in vivo-</em>like microenvironments more physiologically relevant than two-dimensional (2D) culture systems. In 3D culture systems, cells are grown in culture matrixes and turn into spheroids and organoids later processed for downstream analysis by microscopy and histology techniques. The processing of 3D cultures for analysis by microscopy or histology is laborious and time-consuming due to incompatibility of the 3D culture vessels and the microscopy and pathology blocks. Therefore, it is not amenable to high-throughput analysis.</p> <p>NCI scientists developed polymer-cast inserts for cell histology and microscopy (PICHAM), made of soft biocompatible polymer compatible with immunofluorescence microscopy. The technology encompasses fixation for paraffin embedding and sectioning, into which an array of vertical wells were bored to harbor cells in culture in the form of spheroids, organoids or other tissue replicas. A PICHAM is cast as a rectangular cuboid designed and fabricated with dimensions to precisely fit into standard histology cassettes. It is envisioned to provide a one-piece system that allows a seamless transition from 3D culture to high-throughput histopathology and microscopy analysis of spheroids and organoids. Due to the compatibility of PICHAMs with both cell culture and histopathology processes, it will eliminate a major roadblock in high throughput processing of 3D cell cultures for microscopy and histopathology analyses.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research tool for cell biology</li> <li>Growing 3D cell cultures for histology and microscopy analysis</li> <li>High-throughput processing of 3D cell cultures for microscopy and histopathology analysis&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Minimizes processing of 3D cell cultures for histopathology analysis</li> <li>Saves time by reducing processes and eliminating manual steps</li> <li>Enables high-throughput microscopy and histopathology analysis of 3D cultures</li> <li>Minimizes disruptions of 3D cell cultures during processing</li> <li>Compatibility with both 3D cell culture vessels and histopathology cassettes reduces supplies required</li> </ul> 2021-06-12 2026-04-24 2021-06-14 2026-04-29 2021-06-11 3D Cell Culture, high-throughput screening, Histology, Histopathology, MICROSCOPY, Organoids, Parchment, Polymer-cast, Spheroids False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-06-14 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147162164 Huang H, et al. Peptide hydrogelation and cell encapsulation for 3D culture of MCF-7 breast cancer cells. (PMID 23527204) https://pubmed.ncbi.nlm.nih.gov/23527204/ <a href="https://pubmed.ncbi.nlm.nih.gov/23527204/">Huang H, et al. Peptide hydrogelation and cell encapsulation for 3D culture of MCF-7 breast cancer cells. (PMID 23527204)</a> 147163107 Parchment, Ralph NIH - NCI Leidos Parchment, Ralph (Leidos) 1 147163108 Nguyen, Thu NIH - NCI Nguyen, Thu 2 147163107 Parchment, Ralph NIH - NCI Leidos Parchment, Ralph (Leidos) 1 147163108 Nguyen, Thu NIH - NCI Nguyen, Thu 2 147158192 Polymer-cast Inserts For Cell Histology And Microscopy (PICHAMs) - A System For High Throughput 3D Cell Culture And Screening Micro_scopy E-196-2018-0 Filing authorized NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-3980] Polymer-Cast Inserts for Cell Histology and Microscopy&body=Please send me information about technology [TAB-3980] Polymer-Cast Inserts for Cell Histology and Microscopy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-3980] Polymer-Cast Inserts for Cell Histology and Microscopy&body=Please send me information about technology [TAB-3980] Polymer-Cast Inserts for Cell Histology and Microscopy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161181 E-196-2018-0 E-196-2018-0-US-01 INSERT FOR PREPARING CELL CULTURE CHAMBERS PRV US 63/058,794 Abandoned US <br />Provisional (PRV) 63/058,794<br />Filed on 2020-07-30<br />Status: Abandoned 147165678 E-196-2018-0 E-196-2018-0-PCT-02 INSERT FOR PREPARING CELL CULTURE CHAMBERS PCT Patent Cooperation Treaty PCT/US2021/043930 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/043930<br />Filed on 2021-07-30<br />Status: Expired 147165679 E-196-2018-0 E-196-2018-0-US-02 INSERT FOR PREPARING CELL CULTURE CHAMBERS National Stage US 12,735,666 18/018,762 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12735666 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12735666">12,735,666</a><br />Filed on 2023-01-30<br />Status: Issued 147173485 3D Cell Culture 147173486 high-throughput screening 147173487 Histology 147173488 Histopathology 147173489 MICROSCOPY 147173490 Organoids 147173492 Parchment 147173493 Polymer-cast 147173494 Spheroids TAB-5050 162271610 Broadly neutralizing influenza hemagglutinin stem-directed antibodies NIAID Antibodies, Application, Collaboration, Collaboration Sought, Immunology, Infectious Disease, Licensing, Materials Available, Therapeutics, Vaccines Antibodies Application Collaboration Collaboration Sought Immunology Infectious Disease Licensing Materials Available Therapeutics Vaccines Sarah Andrews, Ankita Chopde, Adrian Creanga, Rebecca Gillespie, Masaru Kanekiyo, Grace Mantus, Julie Raab <p>In 2023, the World Health Organization (WHO) reported roughly 3 to 5 million cases of severe influenza worldwide, resulting in approximately 290,000 to 650,000 deaths. Given the high disease burden, the needs for both prophylactic and therapeutic influenza strategies remain significant. However, current treatments for influenza are susceptible to resistance and are useful for only a limited post-infection period. &nbsp;&nbsp;&nbsp;</p> <p>The highly conserved epitopes in the stem region of the influenza hemagglutinin (HA) protein are ideal targets for new vaccines, as they elicit broadly neutralizing antibodies. In light of this, researchers at the National Institute of Allergy and Infectious Diseases (NIAID) cloned and expressed HA stem-specific monoclonal antibodies (mAbs) from B cells isolated from human participants in influenza vaccine clinical trials. Four mAbs exhibited particularly potent neutralizing profiles against H1N1 strains, three exhibited very strong neutralization profiles against H3N2 strains, and two exhibited a good neutralization profile across all subtypes tested. These mAbs may help to substantially reduce global influenza disease burden given their potential to become effective therapeutic and prophylactic agents against a broad range of H1N1 and H3N2 influenza strains.</p> <p>This technology is available for licensing for commercial development in accordance with 35 U.S.C. &sect; 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.</p> <ul> <li>Greater neutralization potency against H1N1 and H3N2 strains than observed for other high-profile candidates tested in phase II clinical trials</li> </ul> <ul> <li>Prophylactic or therapeutic strategies against influenza infection</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Wade Green at 301-761-7505, or wade.green@nih.gov, and reference E-026-2024. 2025-05-08 2025-05-08 2026-04-29 2025-05-09 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 162272045 Andrews SF, et al. An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans. Sci. Transl. Med. 2023;15:eade4976. https://doi.org/10.1126/scitranslmed.ade4976 <a href="https://doi.org/10.1126/scitranslmed.ade4976">Andrews SF, et al. An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans. Sci. Transl. Med. 2023;15:eade4976.</a> 162272059 Mantus GE, et al. Vaccination with different group 2 influenza subtypes alters epitope targeting and breadth of hemagglutinin stem–specific human B cells. Sci. Transl. Med. 2025;17:eadr8373. https://doi.org/10.1126/scitranslmed.adr8373 <a href="https://doi.org/10.1126/scitranslmed.adr8373">Mantus GE, et al. Vaccination with different group 2 influenza subtypes alters epitope targeting and breadth of hemagglutinin stem–specific human B cells. Sci. Transl. Med. 2025;17:eadr8373.</a> 162271755 Andrews, Sarah NIAID - VRC NIAID Andrews, Sarah (NIAID) 1 162271768 Mantus, Grace NIAID - VRC NIAID Mantus, Grace (NIAID) 2 162271782 Chopde, Ankita NIAID - VRC NIAID Chopde, Ankita (NIAID) 3 162271793 Creanga, Adrian NIAID - VRC NIAID Creanga, Adrian (NIAID) 4 162271809 Gillespie, Rebecca NIAID - VRC NIAID Gillespie, Rebecca (NIAID) 5 162271837 Kanekiyo, Masaru National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Kanekiyo, Masaru (NIAID) 6 162271842 Raab, Julie University of Colorado NIAID Raab, Julie (NIAID) 7 162271755 Andrews, Sarah NIAID - VRC NIAID Andrews, Sarah (NIAID) 1 162271768 Mantus, Grace NIAID - VRC NIAID Mantus, Grace (NIAID) 2 162271782 Chopde, Ankita NIAID - VRC NIAID Chopde, Ankita (NIAID) 3 162271793 Creanga, Adrian NIAID - VRC NIAID Creanga, Adrian (NIAID) 4 162271809 Gillespie, Rebecca NIAID - VRC NIAID Gillespie, Rebecca (NIAID) 5 162271837 Kanekiyo, Masaru National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Kanekiyo, Masaru (NIAID) 6 162271842 Raab, Julie University of Colorado NIAID Raab, Julie (NIAID) 7 162271613 Broadly neutralizing influenza hemagglutinin stem-directed antibodies E-026-2024-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID - VRC, NIAID - VRC 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-5050] Broadly neutralizing influenza hemagglutinin stem-directed antibodies&body=Please send me information about technology [TAB-5050] Broadly neutralizing influenza hemagglutinin stem-directed antibodies. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-5050] Broadly neutralizing influenza hemagglutinin stem-directed antibodies&body=Please send me information about technology [TAB-5050] Broadly neutralizing influenza hemagglutinin stem-directed antibodies.">wade.green@nih.gov</a><br> 162271618 E-026-2024-0 E-026-2024-0-US-01 Broadly neutralizing influenza hemagglutinin stem-directed antibodies PRV US 63/605,374 Expired US <br />Provisional (PRV) 63/605,374<br />Filed on 2023-12-01<br />Status: Expired 162271619 E-026-2024-0 E-026-2024-0-PC-01 BROADLY NEUTRALIZING INFLUENZA HEMAGGLUTININ STEM-DIRECTED ANTIBODIES PCT Patent Cooperation Treaty PCT/US2024/057131 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/057131<br />Filed on 2024-11-22<br />Status: Expired 167038722 E-026-2024-0 E-026-2024-0-US-02 BROADLY NEUTRALIZING INFLUENZA HEMAGGLUTININ STEM-DIRECTED ANTIBODIES National Stage US 19/591,653 Pending US <br />National Stage 19/591,653<br />Filed on 2026-05-28<br />Status: Pending 167038787 E-026-2024-0 E-026-2024-0-EP-01 BROADLY NEUTRALIZING INFLUENZA HEMAGGLUTININ STEM-DIRECTED ANTIBODIES National Stage European Patent 24827387.2 Pending European Patent <br />National Stage 24827387.2<br />Filed on 2026-06-30<br />Status: Pending TAB-3949 147157229 Cross Species Single Domain Antibodies Targeting PD-L1 for Treating Solid Tumors NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Chi-Ping Day, Hejiao English, Mitchell Ho, Dan Li, Glenn Merlino <h2>Description of Technology:</h2> <p>Programed Death-Ligand 1 (PD-L1, also known as B7-H1 or CD274) is a cell surface protein that binds to Programmed Cell Death Protein 1 (PD-1, also known as CD279). An imbalance in PD-1/PD-L1 activity contributes to cancer immune escape.&nbsp; PD-1 is expressed on the surface of antigen-stimulated T cells. The interaction between PD-L1 and PD-1 negatively regulates T cell-mediated immune responses. It has been suggested that disrupting the PD-L1/PD-1 signaling pathway can be used to treat cancers. The aberrant expression of PD-L1 on multiple tumor types supports this suggestion. As a result, PD-L1 represents a strong target for the development of new anti-cancer therapeutics.&nbsp;</p> <p>Researchers at the NCI&rsquo;s Laboratory of Molecular Biology have isolated three anti-PD-L1 single domain antibodies (also known as nanobodies), B2, A11, and F5 that target PD-L1. These nanobodies can be used either as independent agents or as the targeting domain in chimeric antigen receptors (CARs), antibody drug conjugates (ADCs), recombinant immunotoxins (RITs), and bispecific antibodies. Significantly, CARs using these antibodies has shown potent in vitro and in vivo killing against PD-L1 positive tumors, including liver and triple-negative breast cancer, strongly supporting that these candidates may be further developed as therapeutics.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic applications include the unconjugated antibodies and their use as a targeting moiety for CARs, RITs, ADCs, and bispecific antibodies</li> <li>Therapeutics against PD-L1-expressing cancers, including liver, bladder, pancreatic, prostate, gastric and triple-negative breast cancer</li> <li>Diagnostic agent for detection and monitoring levels of PD-L1-expressing cancers</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>These anti-PD-L1 nanobodies have an advantage, due to their small size, to potentially bind to epitopes unavailable to more conventional antibodies</li> <li>Cross-species reactivity in mouse and human</li> <li>Combination of B2 and hYP7 CARs in T cells improves lysis of liver cancer cells in mice compared to either CAR alone</li> <li>CARs using the B2 single domain antibody are available for immediate testing</li> </ul> 2021-07-14 2026-04-29 2021-08-05 2026-04-29 2021-08-05 adoptive cell therapy, Chimeric Antigen Receptor T Cells, HO, ICI, Immune Checkpoint Inhibitor, Immunotherapy, NANOBODY, PD-L1, phage display, Programed Death-Ligand, Single Domain Antibody False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-08-05 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-136-2012 147162983 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147162982 Merlino, Glenn NIH - NCI NCI Merlino, Glenn (NCI) 2 147162986 Li, Dan NCI - CCR NCI Li, Dan (NCI) 3 147162984 English, Hejiao NIH - NCI NCI English, Hejiao (NCI) 4 147162985 Day, Chi-Ping NIH - NCI NCI Day, Chi-Ping (NCI) 5 147162983 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147162982 Merlino, Glenn NIH - NCI NCI Merlino, Glenn (NCI) 2 147162986 Li, Dan NCI - CCR NCI Li, Dan (NCI) 3 147162984 English, Hejiao NIH - NCI NCI English, Hejiao (NCI) 4 147162985 Day, Chi-Ping NIH - NCI NCI Day, Chi-Ping (NCI) 5 153379661 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors E-118-2021-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3949] Cross Species Single Domain Antibodies Targeting PD-L1 for Treating Solid Tumors&body=Please send me information about technology [TAB-3949] Cross Species Single Domain Antibodies Targeting PD-L1 for Treating Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3949] Cross Species Single Domain Antibodies Targeting PD-L1 for Treating Solid Tumors&body=Please send me information about technology [TAB-3949] Cross Species Single Domain Antibodies Targeting PD-L1 for Treating Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161068 E-118-2021-0 E-118-2021-0-US-01 CROSS SPECIES SINGLE DOMAIN ANTIBODIES TARGETING PD-L1 FOR TREATING SOLID TUMORS PRV US 63/208,755 Abandoned US <br />Provisional (PRV) 63/208,755<br />Filed on 2021-06-09<br />Status: Abandoned 147165506 E-118-2021-0 E-118-2021-0-PCT-02 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors PCT Patent Cooperation Treaty PCT/US2022/032378 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/032378<br />Filed on 2022-06-06<br />Status: Expired 153379665 E-118-2021-0 E-118-2021-0-CA-01 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors National Stage Canada 3216228 Pending Canada <br />National Stage 3216228<br />Filed on 2023-10-04<br />Status: Pending 153379666 E-118-2021-0 E-118-2021-0-AU-01 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors National Stage Australia 2022291120 Pending Australia <br />National Stage 2022291120<br />Filed on 2023-11-01<br />Status: Pending 153379667 E-118-2021-0 E-118-2021-0-CN-01 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors National Stage China 202280041531.8 Pending China <br />National Stage 202280041531.8<br />Filed on 2023-12-08<br />Status: Pending 153379668 E-118-2021-0 E-118-2021-0-US-02 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors National Stage US 18/567,990 Pending US <br />National Stage 18/567,990<br />Filed on 2023-12-07<br />Status: Pending 153379669 E-118-2021-0 E-118-2021-0-EP-01 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors National Stage European Patent 22738126.6 Pending European Patent <br />National Stage 22738126.6<br />Filed on 2023-10-18<br />Status: Pending 147171812 adoptive cell therapy 147171814 Chimeric Antigen Receptor T Cells 147171815 HO 147171816 ICI 147171818 Immune Checkpoint Inhibitor 147171819 Immunotherapy 147171820 NANOBODY 147171821 PD-L1 147171822 phage display 147171824 Programed Death-Ligand 147171825 Single Domain Antibody TAB-3004 114096419 Gene Therapy for Niemann-Pick Disease Type C NHGRI Collaboration, Endocrinology, Neurology, Therapeutics Collaboration Endocrinology Neurology Therapeutics Randy Chandler, William ("Bill") Pavan, Charles Venditti Investigators at the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) are seeking collaborators to further develop gene therapy to treat Niemann-Pick Disease Type C (NPC). NPC is a rare, autosomal recessive, neurodegenerative disease. Approximately 95% of patients with NPC have mutations in NPC1, a gene implicated in intracellular cholesterol trafficking. Mutations of NPC1 cause intracellular accumulation of unesterified cholesterol in late endosomal/lysosomal structures and marked accumulation of glycosphingolipids, especially in neuronal tissue. Thus, NPC patients generally present with hepatosplenomegaly (enlargement of liver and spleen) and neurological degeneration.<br /><br /> NHGRI investigators have generated adeno-associated viral (AAV) constructs that are able to correct cellular defects of certain cholesterol storage disease or disorders, such as NPC, in vivo. <ul> <li>Optimized components of the vectors (e.g., specific promoters).</li> <li>Shown to work in animal (murine) models.</li> </ul> <ul> <li>Potential for successful gene therapy for patients with NPC.</li> <li>Can lead to similar approaches for treating other cholesterol storage disorders.</li> </ul> NHGRI is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize these gene therapy vectors. For collaboration opportunities please contact Anna Solowiej at the email address above. 2022-03-08 2026-04-28 2026-04-28 2016-04-18 Adeno-associated, C, Disease, Gene, Listed LPM Contreras as of 4/15/2015, NIEMANN-PICK, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, THERAPY, treatment, TYPE, VEXXXX, VHXXXX, viral, WJXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114107080 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114107081 Pavan, William ("Bill") National Human Genome Research Institute (NHGRI) NHGRI Pavan, William ("Bill") (NHGRI) 0 114107079 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114107079 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114107080 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114107081 Pavan, William ("Bill") National Human Genome Research Institute (NHGRI) NHGRI Pavan, William ("Bill") (NHGRI) 0 114101516 Adeno-associated Viral Gene Therapy As A New Treatment For Niemann-Pick Disease Type C E-185-2014-0 Filing authorized National Human Genome Research Institute (NHGRI) 83703934 Solowiej, Anna anna.solowiej@nih.gov
United States of America anna.solowiej@nih.gov?subject=Web Inquiry on [TAB-3004] Gene Therapy for Niemann-Pick Disease Type C&body=Please send me information about technology [TAB-3004] Gene Therapy for Niemann-Pick Disease Type C. Solowiej, Anna<br><a href="mailto:anna.solowiej@nih.gov?subject=Web Inquiry on [TAB-3004] Gene Therapy for Niemann-Pick Disease Type C&body=Please send me information about technology [TAB-3004] Gene Therapy for Niemann-Pick Disease Type C.">anna.solowiej@nih.gov</a><br> 114164810 E-185-2014-0 E-185-2014-0-PCT-02 Viral Gene Therapy As Treatment For Cholesterol Storage Disease or Disorder PCT Patent Cooperation Treaty PCT/US2016/026524 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/026524<br />Filed on 2016-04-07<br />Status: Expired 114166393 E-185-2014-0 E-185-2014-0-US-01 VIRAL GENE THERAPY AS TREATMENT FOR CHOLESTEROL STORAGE DISEASE OR DISORDER PRV US 62/144,702 Abandoned US <br />Provisional (PRV) 62/144,702<br />Filed on 2015-04-08<br />Status: Abandoned 114168403 E-185-2014-0 E-185-2014-0-US-04 VIRAL GENE THERAPY AS TREATMENT FOR CHOLESTEROL STORAGE DISEASE OR DISORDER National Stage US 15/565,065 Abandoned US <br />National Stage 15/565,065<br />Filed on 2016-04-07<br />Status: Abandoned 114169057 E-185-2014-0 E-185-2014-0-US-12 VIRAL GENE THERAPY AS TREATMENT FOR CHOLESTEROL STORAGE DISEASE OR DISORDER DIV US 12,201,658 17/033,166 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12201658 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12201658">12,201,658</a><br />Filed on 2020-09-25<br />Status: Issued 166893950 E-185-2014-0 E-185-2014-0-EP-06 Viral Gene Therapy As Treatment For Cholesterol Storage Disease or Disorder National Stage European Patent 3280451 16717228.7 Issued European Patent <br />National Stage 16717228.7<br />Filed on 2016-04-07<br />Status: Issued 166893955 E-185-2014-0 E-185-2014-0-CA-05 Viral Gene Therapy As Treatment For Cholesterol Storage Disease or Disorder National Stage Canada 2982129 Pending Canada <br />National Stage 2982129<br />Filed on 2016-04-07<br />Status: Pending 166893960 E-185-2014-0 E-185-2014-0-DE-07 Viral Gene Therapy As Treatment For Cholesterol Storage Disease or Disorder EP Germany 3280451 16717228.7 Issued Germany <br />European patent (EP) 16717228.7<br />Filed on 2016-04-07<br />Status: Issued 166893965 E-185-2014-0 E-185-2014-0-ES-08 Viral Gene Therapy As Treatment For Cholesterol Storage Disease or Disorder EP Spain 3280451 16717228.7 Issued Spain <br />European patent (EP) 16717228.7<br />Filed on 2016-04-07<br />Status: Issued 166893970 E-185-2014-0 E-185-2014-0-FR-09 Viral Gene Therapy As Treatment For Cholesterol Storage Disease or Disorder EP France 3280451 16717228.7 Issued France <br />European patent (EP) 16717228.7<br />Filed on 2016-04-07<br />Status: Issued 166893975 E-185-2014-0 E-185-2014-0-GB-10 Viral Gene Therapy As Treatment For Cholesterol Storage Disease or Disorder EP United Kingdom 3280451 16717228.7 Issued United Kingdom <br />European patent (EP) 16717228.7<br />Filed on 2016-04-07<br />Status: Issued 166893980 E-185-2014-0 E-185-2014-0-IT-11 Viral Gene Therapy As Treatment For Cholesterol Storage Disease or Disorder EP Italy 3280451 16717228.7 Issued Italy <br />European patent (EP) 16717228.7<br />Filed on 2016-04-07<br />Status: Issued 166893987 E-185-2014-0 E-185-2014-0-US-02 VIRAL GENE THERAPY AS TREATMENT FOR CHOLESTEROL STORAGE DISEASE OR DISORDER CON US 18/976,790 Pending US <br />Continuation (CON) 18/976,790<br />Filed on 2024-12-11<br />Status: Pending 114121791 VEXXXX 114121792 VHXXXX 114121793 WJXXXX 114121794 XEXXXX 114137443 Listed LPM Contreras as of 4/15/2015 114137444 Pre LPM working set 20150418 114137445 Post LPM Assignment Set 20150420 114140967 Adeno-associated 114140968 viral 114140969 Gene 114140970 THERAPY 114140971 treatment 114140972 NIEMANN-PICK 114140973 Disease 114140974 TYPE 114140975 C TAB-3848 146937956 Treating Kidney Disorders and Diabetic Nephropathy with N-acetyl mannosamine (ManNAc) NHGRI Therapeutics Therapeutics William Gahl, Marjan Huizing, Enriko Klootwijk, Eirini (Irini) Manoli <p>N-acetylmannosamine (ManNAc) is a small uncharged physiological molecule that crosses membranes readily and is the natural precursor of intracellular sialic acid synthesis. NHGRI investigators discovered that ManNAc can be used for therapeutic purposes, including treating certain kidney diseases (e.g., those involving abnormal levels of protein in the urine and/or blood in the urine), resulting primarily or secondarily from hyposialylation (deficiency of sialic acid). Notably, ManNAc can also potentially be used to treat diabetic nephropathy.</p> <p>ManNAc therapy is given orally and shows long-term safety and biochemical efficacy, consistent with its mechanism of action in humans.</p> <p>Thus, the following fields of use are available for licensing: Treating <strong>kidney disorders</strong> due to hyposialylation of the glomerular basement membrane (GBM), including but not limited to minimal change disease glomerulopathy (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), and diabetic nephropathy in humans with oral formulations of N-acetyl mannosamine (ManNAc) or derivative.</p> <p><img alt="" src="https://nih.technologypublisher.com/files/sites/huizing_et_al_graphical_abstract__tto_21apr2026.jpg" style="height:720px; width:1280px" /></p> <ul> <li>ManNAc is easy to administer to patients (oral administration).</li> <li>Long-term ManNAc administration has been shown to be safe and well-tolerated in humans.</li> <li>This technology includes many issued patents in the U.S, Canada, Europe, Japan, and Israel for these indications.</li> <li>Extensive published and unpublished preclinical data for these kidney indications is available.</li> <li>A Phase I clinical trial of ManNAc in subjects with primary glomerular diseases has been completed with positive results.</li> <li> A Phase II study in subjects with primary focal segmental glomerulosclerosis is ongoing.</li> <li>A clinical study in diabetic nephropathy is in planning stages.</li> </ul> The National Human Genome Research Institute (NHGRI) is seeking statements of capability or interest from parties interested in collaborating on further developing and commercializing this technology for proteinuric kidney diseases, including diabetic nephropathy. For collaboration opportunities, please contact Anna Solowiej at the email address provided above. 2023-07-19 2026-04-28 2026-04-28 2023-07-27 2023-07-26 False True Phase I completed. True 72159140 Clinical Phase II 72159140 37470483 Website Abstract E-217-2007-0 146938360 Huizing et al., "Rationale and design for Phase 1 study of N-acetylmannosamine for primary glomerular diseases," Kidney International Reports (2019) 4, 1454-1452 https://pubmed.ncbi.nlm.nih.gov/31701055/ <a href="https://pubmed.ncbi.nlm.nih.gov/31701055/">Huizing et al., "Rationale and design for Phase 1 study of N-acetylmannosamine for primary glomerular diseases," Kidney International Reports (2019) 4, 1454-1452</a> 166979020 Huizing et al., “Phase 1 Study of Oral N-Acetylmannosamine in Primary Podocytopathies,” Kidney International Reports (2025) 11, 103758 https://pmc.ncbi.nlm.nih.gov/articles/PMC12861195/ <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12861195/">Huizing et al., “Phase 1 Study of Oral N-Acetylmannosamine in Primary Podocytopathies,” Kidney International Reports (2025) 11, 103758</a> 146938169 Huizing, Marjan National Human Genome Research Institute (NHGRI) NHGRI Huizing, Marjan (NHGRI) 1 146938174 Gahl, William National Human Genome Research Institute (NHGRI) NHGRI Gahl, William (NHGRI) 2 146938314 Manoli, Eirini (Irini) National Human Genome Research Institute (NHGRI) NHGRI Manoli, Eirini (Irini) (NHGRI) 3 146938332 Klootwijk, Enriko National Human Genome Research Institute (NHGRI) Klootwijk, Enriko 4 146938169 Huizing, Marjan National Human Genome Research Institute (NHGRI) NHGRI Huizing, Marjan (NHGRI) 1 146938174 Gahl, William National Human Genome Research Institute (NHGRI) NHGRI Gahl, William (NHGRI) 2 146938314 Manoli, Eirini (Irini) National Human Genome Research Institute (NHGRI) NHGRI Manoli, Eirini (Irini) (NHGRI) 3 146938332 Klootwijk, Enriko National Human Genome Research Institute (NHGRI) Klootwijk, Enriko 4 146937959 Provision Of The Neutral Sugar N-acetyl Nammosamine (ManNAc) For Increased Intracellular Production Of Sialic Acids E-217-2007-0 Filing authorized National Human Genome Research Institute (NHGRI) 83703934 Solowiej, Anna anna.solowiej@nih.gov
United States of America anna.solowiej@nih.gov?subject=Web Inquiry on [TAB-3848] Treating Kidney Disorders and Diabetic Nephropathy with N-acetyl mannosamine (ManNAc)&body=Please send me information about technology [TAB-3848] Treating Kidney Disorders and Diabetic Nephropathy with N-acetyl mannosamine (ManNAc). Solowiej, Anna<br><a href="mailto:anna.solowiej@nih.gov?subject=Web Inquiry on [TAB-3848] Treating Kidney Disorders and Diabetic Nephropathy with N-acetyl mannosamine (ManNAc)&body=Please send me information about technology [TAB-3848] Treating Kidney Disorders and Diabetic Nephropathy with N-acetyl mannosamine (ManNAc).">anna.solowiej@nih.gov</a><br> TAB-3429 114097303 Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens For Human Metapneumovirus NIAID Licensing Licensing Ursula Buchholz, Peter Collins, Jason Gorman, Wing-pui Kong, Peter Kwong, John Mascola, Li Ou, Guillaume Stewart-Jones, Yaroslav Tsybovsky, Baoshan Zhang, Tongqing Zhou Human metapneumovirus (hMPV) infections have been shown as a common cause of upper and lower respiratory diseases such as bronchiolitis and pneumonia in young children, the elderly, and other immunocompromised individuals. Studies show that infections by the non-segmented negative strand RNA virus begin with attachment and entry of viral glycoproteins that mediate fusion with host cellular membranes. Like for the human respiratory syncytial virus (hRSV), a viral entry is initiated by the fusion (F) protein. Given its role in hMPV entry, the F protein has thus been a target for eliciting neutralizing antibodies and development of novel protein-based therapeutic vaccines.<br /><br /> Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) developed improved recombinant human metapneumovirus (hMPV) F proteins stabilized in the prefusion conformation that can elicit potent neutralizing antibodies against infection. Double and triple stabilized candidates were designed with inter-and intraprotomer disulfide mutations that increase protein production and show improved antigenic recognition by prefusion-specific antibodies. These second-generation immunogens constitute an improvement over the first generation constructs and are characterized by additional stabilization that results in optimal neutralization responses.<br /><br /> The second-generation stabilized prefusion hMPV F immunogens may be an ideal vaccine immunogen to elicit broad potent neutralizing antibodies against metapneumovirus infection, particularly in children and immunocompromised adults.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404. ... <ul> <li>There are no approved vaccines or therapeutics against the second leading cause of pediatric viral lower respiratory tract infection in infants and young children</li> <li>Second-generation hMPV F immunogens induce higher titer neutralizing responses than first-generation versions in mice</li> </ul> <ul> <li>A promising vaccine immunogen to elicit broad potent neutralizing antibodies against metapneumovirus infection, particularly in children and immunocompromised adults</li> </ul> </li> <li>Second-generation hMPV F immunogens induce higher titer neutralizing responses than first-generation versions in mice</li> </ul> 2022-10-25 2026-04-27 2026-04-27 2021-01-26 F, Fusion, GLYCOPROTEIN, Human, IMMUNOGENS, Metapneumovirus, Prefusion-Stabilized, Vaccine False True True NIHTT 37470483 Website Abstract 114172594 Liu, P., et al https://pubmed.ncbi.nlm.nih.gov/23761661/ <a href="https://pubmed.ncbi.nlm.nih.gov/23761661/">Liu, P., et al</a> 114172595 Battles, M. B., et al https://pubmed.ncbi.nlm.nih.gov/29142300/ <a href="https://pubmed.ncbi.nlm.nih.gov/29142300/">Battles, M. B., et al</a> 114110156 Tsybovsky, Yaroslav NCI - FCRDC (Leidos) NIAID Tsybovsky, Yaroslav (NIAID) 0 114110157 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114110158 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114110159 Kong, Wing-pui NIAID - VRC NIAID Kong, Wing-pui (NIAID) 0 114110160 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114110161 Ou, Li NIAID - VRC NIAID Ou, Li (NIAID) 0 114110162 Gorman, Jason NIAID - VRC NIAID Gorman, Jason (NIAID) 0 114110163 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114110164 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114110165 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114110155 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114110155 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114110156 Tsybovsky, Yaroslav NCI - FCRDC (Leidos) NIAID Tsybovsky, Yaroslav (NIAID) 0 114110157 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114110158 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114110159 Kong, Wing-pui NIAID - VRC NIAID Kong, Wing-pui (NIAID) 0 114110160 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114110161 Ou, Li NIAID - VRC NIAID Ou, Li (NIAID) 0 114110162 Gorman, Jason NIAID - VRC NIAID Gorman, Jason (NIAID) 0 114110163 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114110164 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114110165 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114102552 Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens For Human Metapneumovirus E-131-2019-0 Filing authorized NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3429] Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens For Human Metapneumovirus&body=Please send me information about technology [TAB-3429] Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens For Human Metapneumovirus. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3429] Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens For Human Metapneumovirus&body=Please send me information about technology [TAB-3429] Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens For Human Metapneumovirus.">wade.green@nih.gov</a><br> 114168285 E-131-2019-0 E-131-2019-0-PCT-02 RECOMBINANT HUMAN METAPNEUMOVIRUS F PROTEINS AND THEIR USE PCT Patent Cooperation Treaty PCT/US2021/029988 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/029988<br />Filed on 2021-04-29<br />Status: Expired 114169092 E-131-2019-0 E-131-2019-0-US-01 RECOMBINANT HUMAN METAPNEUMOVIRUS F PROTEINS AND THEIR USE PRV US 63/017,581 Abandoned US <br />Provisional (PRV) 63/017,581<br />Filed on 2020-04-29<br />Status: Abandoned 114169666 E-131-2019-0 E-131-2019-0-US-06 RECOMBINANT HUMAN METAPNEUMOVIRUS F PROTEINS AND THEIR USE National Stage US 12,679,870 17/919,733 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12679870 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12679870">12,679,870</a><br />Filed on 2022-10-18<br />Status: Issued 114152011 Prefusion-Stabilized 114152012 Fusion 114152013 F 114152014 GLYCOPROTEIN 114152015 Vaccine 114152016 IMMUNOGENS 114152017 Human 114152018 Metapneumovirus TAB-3342 114097257 Fusion Glycoprotein Vaccine for Human Metapneumovirus NIAID Infectious Disease, Licensing, Vaccines Infectious Disease Licensing Vaccines Ursula Buchholz, Peter Collins, Davide Corti, Michael Joyce, Peter Kwong, Antonio Lanzavecchia, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang Human metapneumovirus (hMPV), a negative, single-stranded RNA virus, accounts for approximately 5-15% of infant respiratory tract infections and poses a severe risk of disease and hospitalization in both the elderly and the immunocompromised. Investigators at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) have generated an hMPV fusion glycoprotein (“F protein”) stabilized in a prefusion conformation.<br /><br /> Stabilizing this prefusion conformation of the F protein reveals an immunodominant site which makes it an ideal vaccine immunogen. The prefusion stabilized F protein immunogen can be delivered as either an isolated homotrimer or trimers displayed on a nanoparticle. These immunogens elicit broad and potent hMPV-neutralizing antibodies.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404. <ul> <li>No human metapneumovirus vaccine is currently available</li> </ul> <ul> <li>Vaccine for prevention of human metapneumovirus infection</li> </ul> Vaccine for prevention of human metapneumovirus infection 2022-04-12 2026-04-27 2026-04-27 2018-10-29 DC5XXX, Fusion, GLYCOPROTEIN, HMPV, Metapneumovirus, Prefusion, respiratory, Respiratory Diseases, respiratory INFECTION, Respiratory Syncytial Virus, Structure-based, Vaccine False True True NIHTT 37470483 Website Abstract 114109955 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114109956 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114109957 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114109958 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114109959 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114109960 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114109961 Corti, Davide Institute for Research in Biomedicine (IRB) Corti, Davide 0 114109962 Lanzavecchia, Antonio Institute for Research in Biomedicine (IRB) Lanzavecchia, Antonio 0 114109954 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114109954 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114109955 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114109956 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114109957 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114109958 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114109959 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114109960 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114109961 Corti, Davide Institute for Research in Biomedicine (IRB) Corti, Davide 0 114109962 Lanzavecchia, Antonio Institute for Research in Biomedicine (IRB) Lanzavecchia, Antonio 0 114102500 Structure-based Design Of A Fusion Glycoprotein Vaccine For Metapneumovirus E-260-2014-0 Filing authorized INSTITUTE FOR RESEARCH IN BIOMEDICINE, NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3342] Fusion Glycoprotein Vaccine for Human Metapneumovirus&body=Please send me information about technology [TAB-3342] Fusion Glycoprotein Vaccine for Human Metapneumovirus. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3342] Fusion Glycoprotein Vaccine for Human Metapneumovirus&body=Please send me information about technology [TAB-3342] Fusion Glycoprotein Vaccine for Human Metapneumovirus.">wade.green@nih.gov</a><br> 114168779 E-260-2014-0 E-260-2014-0-US-01 Structure-based Design Of A Fusion Glycoprotein Vaccine For Metapneumovirus PRV US 62/096,744 Abandoned US <br />Provisional (PRV) 62/096,744<br />Filed on 2014-12-24<br />Status: Abandoned 114168780 E-260-2014-0 E-260-2014-0-PCT-02 Recombinant Metapneumovirus F Proteins and Their Use PCT Patent Cooperation Treaty PCT/IB2015/059991 Expired Patent Cooperation Treaty <br />(PCT) PCT/IB2015/059991<br />Filed on 2015-12-24<br />Status: Expired 114168781 E-260-2014-0 E-260-2014-0-US-04 RECOMBINANT METAPNEUMOVIRUS F PROTEINS AND THEIR USE National Stage US 10,420,834 15/539,640 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10420834 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10420834">10,420,834</a><br />Filed on 2017-06-23<br />Status: Issued 114168782 E-260-2014-0 E-260-2014-0-EP-03 Recombinant Metapneumovirus F Proteins and Their Use National Stage European Patent 15831073.0 Pending European Patent <br />National Stage 15831073.0<br />Filed on 2015-12-24<br />Status: Pending 114168920 E-260-2014-0 E-260-2014-0-US-05 RECOMBINANT METAPNEUMOVIRUS F PROTEINS AND THEIR USE DIV US 11,027,007 16/578,748 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11027007 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11027007">11,027,007</a><br />Filed on 2019-09-23<br />Status: Issued 114169126 E-260-2014-0 E-260-2014-0-US-06 RECOMBINANT METAPNEUMOVIRUS F PROTEINS AND THEIR USE DIV US 11,786,591 17/334,505 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11786591 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11786591">11,786,591</a><br />Filed on 2021-05-18<br />Status: Issued 114128216 DC5XXX 114151489 Metapneumovirus 114151490 Vaccine 114151491 GLYCOPROTEIN 114151492 Fusion 114151493 Structure-based 114151494 HMPV 114151495 Prefusion 114151496 Respiratory Diseases 114151497 respiratory INFECTION 114151498 respiratory 114151499 Respiratory Syncytial Virus TAB-3336 114097252 Substitutions-Modified Prefusion RSV F Proteins and Their Use NIAID Licensing Licensing Ulrich Baxa, Man Chen, Aliaksandr Druz, Ivelin Georgiev, Barney Graham, Michael Joyce, Wing-pui Kong, Peter Kwong, John Mascola, Li Ou, Marie Pancera, Emily Rundlet, Mallika Sastry, Cinque Soto, Guillaume Stewart-Jones, Paul Thomas, Yaroslav Tsybovsky, Joseph Van Galen, Yongping Yang, Baoshan Zhang The respiratory syncytial virus (RSV) fusion (F) glycoprotein is the primary target of neutralizing antibodies. The F glycoprotein exists in at least two conformations, a meta-stable prefusion state, and an extremely stable postfusion state. Both states share several epitopes targeted by neutralizing antibodies, but it has been demonstrated that the prefusion conformation of F contains at least one epitope not present in the postfusion conformation. Natural infection results in neutralizing antibodies that are primarily directed against the prefusion conformation of F, not its postfusion conformation. The instability of the prefusion form of F has hindered both its characterization and its use as a vaccine antigen.<br /><br /> Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases have overcome technical obstacles to produce a homogeneous, soluble RSV F glycoprotein vaccine which is stabilized in the prefusion conformation and has improved stability and immunogenicity compared to the native protein. Additionally, several modifications were introduced to remove the requirement for furin during production, resulting in an increase in expression levels of the immunogen. Stability of the immunogen was increased 20-fold as compared to DS-CAV1 (a prefusion-stabilized RSV F glycoprotein vaccine candidate that is currently being assessed in clinical trials) upon incubation at 60 ºC. In mice, these immunogens elicited neutralization titers that were 2 to 5-fold higher than DS-CAV1.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Increased stability compared to the current leading RSV vaccine candidate (DS-Cav1).</li> <li>Elicits increased neutralization titers in mice.</li> </ul> <ul> <li>Vaccine: RSV vaccine for human use.</li> <li>Probe: B cell-sorting probe to isolate potent neutralizing monoclonal antibodies.</li> <li>Diagnostics: To assess the titer of prefusion-specific antibodies in sera.</li> </ul> 2022-04-12 2026-04-27 2026-04-27 2018-10-17 COVALENT, DS-Cav1, IMPROVEMENTS, LEADING, Neutralizing, Prefusion, proteins, protomer, RSV F, Stabilization, Thermostability, TITERS, Trimeric False True True NIHTT 37470483 Website Abstract E-081-2013-0 114172542 Joyce MG, et al. http://www.nature.com/articles/nsmb.3267 <a href="http://www.nature.com/articles/nsmb.3267">Joyce MG, et al.</a> 114109901 Tsybovsky, Yaroslav NCI - FCRDC (Leidos) NIAID Tsybovsky, Yaroslav (NIAID) 0 114109903 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114109904 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114109905 Chen, Man NIAID - VRC NIAID Chen, Man (NIAID) 0 114109906 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 0 114109907 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114109908 Ou, Li NIAID - VRC NIAID Ou, Li (NIAID) 0 114109909 Druz, Aliaksandr NIAID - DIR NIAID Druz, Aliaksandr (NIAID) 0 114109910 Kong, Wing-pui NIAID - VRC NIAID Kong, Wing-pui (NIAID) 0 114109911 Georgiev, Ivelin NIAID - VRC NIAID Georgiev, Ivelin (NIAID) 0 114109912 Rundlet, Emily NIAID - DIR NIAID Rundlet, Emily (NIAID) 0 114109913 Thomas, Paul NIAID - VRC NIAID Thomas, Paul (NIAID) 0 114109914 Pancera, Marie NIAID - VRC NIAID Pancera, Marie (NIAID) 0 114109915 Sastry, Mallika NIAID - VRC NIAID Sastry, Mallika (NIAID) 0 114109916 Soto, Cinque NIAID - VRC Soto, Cinque 0 114109917 Van Galen, Joseph NIAID - DIR Van Galen, Joseph 0 114109918 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114109919 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114109920 Baxa, Ulrich NIAID - VRC NIDDK Baxa, Ulrich (NIDDK) 0 114109902 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114109902 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114109901 Tsybovsky, Yaroslav NCI - FCRDC (Leidos) NIAID Tsybovsky, Yaroslav (NIAID) 0 114109903 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114109904 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114109905 Chen, Man NIAID - VRC NIAID Chen, Man (NIAID) 0 114109906 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 0 114109907 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114109908 Ou, Li NIAID - VRC NIAID Ou, Li (NIAID) 0 114109909 Druz, Aliaksandr NIAID - DIR NIAID Druz, Aliaksandr (NIAID) 0 114109910 Kong, Wing-pui NIAID - VRC NIAID Kong, Wing-pui (NIAID) 0 114109911 Georgiev, Ivelin NIAID - VRC NIAID Georgiev, Ivelin (NIAID) 0 114109912 Rundlet, Emily NIAID - DIR NIAID Rundlet, Emily (NIAID) 0 114109913 Thomas, Paul NIAID - VRC NIAID Thomas, Paul (NIAID) 0 114109914 Pancera, Marie NIAID - VRC NIAID Pancera, Marie (NIAID) 0 114109915 Sastry, Mallika NIAID - VRC NIAID Sastry, Mallika (NIAID) 0 114109916 Soto, Cinque NIAID - VRC Soto, Cinque 0 114109917 Van Galen, Joseph NIAID - DIR Van Galen, Joseph 0 114109918 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114109919 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114109920 Baxa, Ulrich NIAID - VRC NIDDK Baxa, Ulrich (NIDDK) 0 114102490 Single-chain Covalent Trimeric Prefusion RSV F Proteins That Elicit Neutralizing Titers In Mice Four To Five-fold Higher And Display Substantially Higher Thermostability Than The Current Leading Candidate DS-Cav1 E-064-2016-0 Filing authorized NIAID 114102491 Single-chain Covalent Trimeric Prefusion RSV F Proteins That Elicit Neutralizing Titers In Mice Four To Five-fold Higher And Display Substantially Higher Thermostability Than The Current Leading Candidate DS-Cav1 E-064-2016-1 Filing authorized NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-3336] Substitutions-Modified Prefusion RSV F Proteins and Their Use&body=Please send me information about technology [TAB-3336] Substitutions-Modified Prefusion RSV F Proteins and Their Use. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-3336] Substitutions-Modified Prefusion RSV F Proteins and Their Use&body=Please send me information about technology [TAB-3336] Substitutions-Modified Prefusion RSV F Proteins and Their Use.">sabrina.hafiz@nih.gov</a><br> 114168764 E-064-2016-0 E-064-2016-0-US-01 RSV F Immunogens and Their Use PRV US 62/314,946 Expired US <br />Provisional (PRV) 62/314,946<br />Filed on 2016-03-29<br />Status: Expired 114168765 E-064-2016-1 E-064-2016-1-PCT-01 RSV F IMMUNOGENS AND THEIR USE PCT COMB Patent Cooperation Treaty PCT/US2017/024714 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2017/024714<br />Filed on 2017-03-29<br />Status: Expired 114168766 E-064-2016-1 E-064-2016-1-US-07 SUBSTITUTIONS-MODIFIED PREFUSION RSV F PROTEINS AND THEIR USE National Stage US 11,174,292 16/089,993 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11174292 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11174292">11,174,292</a><br />Filed on 2018-09-28<br />Status: Issued 114169139 E-064-2016-1 E-064-2016-1-US-08 PREFUSION RSV F PROTEINS AND THEIR USE CON US 11,878,998 17/524,380 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11878998 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11878998">11,878,998</a><br />Filed on 2021-11-11<br />Status: Issued 114151403 COVALENT 114151404 Prefusion 114151405 proteins 114151406 Neutralizing 114151407 IMPROVEMENTS 114151408 Trimeric 114151409 TITERS 114151410 Thermostability 114151411 LEADING 114151412 DS-Cav1 114151413 RSV F 114151414 Stabilization 114151415 protomer TAB-2717 114096896 Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine NIAID Infectious Disease, Licensing, Vaccines Infectious Disease Licensing Vaccines Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Georgiev, Jason Gorman, Barney Graham, Michael Joyce, Masaru Kanekiyo, Peter Kwong, Jason McLellan, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou The invention, a stabilized recombinant prefusion F protein (pre F), is a candidate subunit vaccine for Respiratory Syncytial Virus (RSV). Pre-F is stabilized in the prefusion conformation and displays epitopes not present in postfusion F protein. Several potent RSV neutralizing antibodies bind pre F, but not postfusion F. Therefore, immunization with pre F may elicit an immune response superior to the response generated by postfusion F.<br /><br /> NIH researchers have engineered pre F to expose an antigenic site 0, which is targeted by extremely potent RSV neutralizing antibodies. Structure-based design yielded several stabilized variants of pre F that maintained exposure of antigenic site 0 when subjected to extremes of pH, osmolality and temperature.<br /><br /> Preclinical in vivo data on stabilized pre F is available. Immunization of mice and macaques with antigenic site 0 stabilized pre F variants elicited high levels of RSV specific neutralizing activity. <ul> <li>Vaccine stably exposes antigenic site in RSV F that permits generation of potent RSV neutralizing antibodies.</li> <li>There is currently no RSV vaccine on the market.</li> </ul> <ul> <li>Vaccine for Respiratory Syncytial Virus</li> </ul> 2022-04-12 2026-04-27 2026-04-27 2014-01-16 CONFORMATION, DC5BXX, DC5XXX, DCXXXX, DXXXXX, F, GLYCOPROTEIN, Listed LPM Thalhammer-Reyero as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Prefusion, PrefusionConformation, RSV, Stabilization, Structure-based, Vaccine, VLXXXX, YCXXXX False True <ul> <li>Pre-clinical</li> </li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171986 McLellan JS, et al. http://www.ncbi.nlm.nih.gov/pubmed/23618766 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23618766">McLellan JS, et al.</a> 114171987 McLellan JS, et al. http://www.ncbi.nlm.nih.gov/pubmed/24179220 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24179220">McLellan JS, et al.</a> 114103548 Gorman, Jason NIAID - VRC NIAID Gorman, Jason (NIAID) 0 114103549 Ofek, Gilad NIAID - VRC NIAID Ofek, Gilad (NIAID) 0 114103550 Pancera, Marie NIAID - VRC NIAID Pancera, Marie (NIAID) 0 114103551 Sastry, Mallika NIAID - VRC NIAID Sastry, Mallika (NIAID) 0 114104949 Srivatsan, Sanjay NIAID - VRC NIAID Srivatsan, Sanjay (NIAID) 0 114105607 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114105761 Chen, Lei NIAID - VRC NIAID Chen, Lei (NIAID) 0 114106323 Soto, Cinque NIAID - VRC Soto, Cinque 0 114106377 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114108383 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 0 114108384 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 0 114108385 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 0 114108386 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114108387 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114108628 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114108673 Boyington, Jeffrey NIAID - VRC NIAID Boyington, Jeffrey (NIAID) 0 114108674 Chen, Man NIAID - VRC NIAID Chen, Man (NIAID) 0 114108675 Chuang, Gwo-Yu NIAID - DIR NIAID Chuang, Gwo-Yu (NIAID) 0 114108676 Georgiev, Ivelin NIAID - VRC NIAID Georgiev, Ivelin (NIAID) 0 114108382 McLellan, Jason NIAID - VRC NIAID McLellan, Jason (NIAID) 1 114108382 McLellan, Jason NIAID - VRC NIAID McLellan, Jason (NIAID) 1 114103548 Gorman, Jason NIAID - VRC NIAID Gorman, Jason (NIAID) 0 114103549 Ofek, Gilad NIAID - VRC NIAID Ofek, Gilad (NIAID) 0 114103550 Pancera, Marie NIAID - VRC NIAID Pancera, Marie (NIAID) 0 114103551 Sastry, Mallika NIAID - VRC NIAID Sastry, Mallika (NIAID) 0 114104949 Srivatsan, Sanjay NIAID - VRC NIAID Srivatsan, Sanjay (NIAID) 0 114105607 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114105761 Chen, Lei NIAID - VRC NIAID Chen, Lei (NIAID) 0 114106323 Soto, Cinque NIAID - VRC Soto, Cinque 0 114106377 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114108383 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 0 114108384 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 0 114108385 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 0 114108386 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114108387 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114108628 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114108673 Boyington, Jeffrey NIAID - VRC NIAID Boyington, Jeffrey (NIAID) 0 114108674 Chen, Man NIAID - VRC NIAID Chen, Man (NIAID) 0 114108675 Chuang, Gwo-Yu NIAID - DIR NIAID Chuang, Gwo-Yu (NIAID) 0 114108676 Georgiev, Ivelin NIAID - VRC NIAID Georgiev, Ivelin (NIAID) 0 114100250 Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation E-081-2013-5 Filing authorized NIAID 114100654 Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation E-081-2013-4 Filing authorized NIAID 114102027 Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation E-081-2013-0 Filing authorized NIAID 114102028 Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation E-081-2013-1 Filing authorized NIAID 114102029 Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation E-081-2013-2 Filing authorized NIAID 114102030 Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation E-081-2013-3 Filing authorized NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-2717] Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine&body=Please send me information about technology [TAB-2717] Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-2717] Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine&body=Please send me information about technology [TAB-2717] Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine.">wade.green@nih.gov</a><br> 114161993 E-081-2013-5 E-081-2013-5-US-01 PREFUSION RSV F PROTEINS AND THEIR USE ORD US 9,738,689 14/207,372 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9738689 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9738689">9,738,689</a><br />Filed on 2014-03-12<br />Status: Issued 114165078 E-081-2013-4 E-081-2013-4-US-12 Prefusion RSV F Proteins and Their Use National Stage US 10,017,543 14/776,651 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10017543 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10017543">10,017,543</a><br />Filed on 2015-09-14<br />Status: Issued 114167467 E-081-2013-0 E-081-2013-0-US-01 Prefusion RSV F Proteins and Their Use PRV US 61/780,910 Expired US <br />Provisional (PRV) 61/780,910<br />Filed on 2013-03-13<br />Status: Expired 114167468 E-081-2013-1 E-081-2013-1-US-01 PREFUSION RSV F PROTEINS AND THEIR USE PRV US 61/798,389 Expired US <br />Provisional (PRV) 61/798,389<br />Filed on 2013-03-15<br />Status: Expired 114167469 E-081-2013-2 E-081-2013-2-US-01 Prefusion RSV F Proteins And Their Use PRV US 61/857,613 Expired US <br />Provisional (PRV) 61/857,613<br />Filed on 2013-07-23<br />Status: Expired 114167470 E-081-2013-3 E-081-2013-3-US-01 PREFUSION RSV F PROTEINS AND THEIR USE PRV US 61/863,909 Expired US <br />Provisional (PRV) 61/863,909<br />Filed on 2013-08-09<br />Status: Expired 114168005 E-081-2013-4 E-081-2013-4-PCT-01 Prefusion RSV F Proteins And Their Use PCT COMB Patent Cooperation Treaty PCT/US2014/026714 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2014/026714<br />Filed on 2014-03-13<br />Status: Expired 114168303 E-081-2013-5 E-081-2013-5-US-02 PREFUSION RSV F PROTEINS AND THEIR USE DIV US 10,858,400 15/633,578 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10858400 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10858400">10,858,400</a><br />Filed on 2017-06-26<br />Status: Issued 114168678 E-081-2013-4 E-081-2013-4-US-13 PREFUSION RSV F PROTEINS AND THEIR USE CON US 11,130,785 16/025,858 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11130785 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11130785">11,130,785</a><br />Filed on 2018-07-02<br />Status: Issued 114169164 E-081-2013-4 E-081-2013-4-US-19 PREFUSION RSV F PROTEINS AND THEIR USE CON US 17/478,533 Abandoned US <br />Continuation (CON) 17/478,533<br />Filed on 2021-09-17<br />Status: Abandoned 114124377 DC5BXX 114124378 DXXXXX 114124379 DCXXXX 114124380 DC5XXX 114124381 VLXXXX 114124382 YCXXXX 114145938 Vaccine 114145939 Stabilization 114145940 RSV 114145941 GLYCOPROTEIN 114145942 PrefusionConformation 114145943 Structure-based 114147144 F 114147145 Prefusion 114147146 CONFORMATION 114148542 Listed LPM Thalhammer-Reyero as of 4/15/2015 114148543 Pre LPM working set 20150418 114148544 Post LPM Assignment Set 20150420 TAB-3130 114095545 Human-derived Monoclonal Antibody for Treatment of Ebola Virus Infection NIAID Licensing Licensing Davide Corti, Barney Graham, Antonio Lanzavecchia, Julie Ledgerwood, Sabue Mulangu, Jean-Jacques Muyembe-Tamfun, Daphne Stanley, Nancy Sullivan, John Trefry Ebola virus infection can lead to severe hemorrhagic fever, known as Ebola virus disease (EVD), which is often fatal. The Zaire species of Ebola virus (EBOV) was responsible for the largest Ebola outbreak in history, which occurred in 2014. Scientists at the NIAID Vaccine Research Center have developed a human monoclonal neutralizing antibody, mAb114 for treatment and prevention of EBOV infection. Because there are very few treatments available to treat or prevent EBOV infection, there is a great need to develop effective pre- and post- exposure therapeutics before another outbreak occurs.<br /><br /> Preclinical efficacy studies demonstrate that monoclonal antibodies can effectively prevent EBOV infection or reverse EVD, in non-human primates. Strikingly, mAb114 protected infected monkeys when administered as late as 6 days after infection. mAb114 has a favorable pharmacokinetic profile, making it a promising potential therapeutic. Clinical trials to test the efficacy of mAb114 in humans are projected for 2018. It is anticipated that mAb114 can be used to prevent EBOV infection and EVD both pre- and post-exposure.<br /><br /> Development Stage<br /> First-in-human trials to start in 2018. <ul> <li>Single Antibody</li> <li>Single-shot option</li> <li>Delayed Treatment (>5 days)</li> <li>Good Half-life</li> <li>Highly Stable</li> <li>Easy to manufacture</li> </ul> <ul> <li>Therapeutic - to treat or prevent infection by EBOV</li> <li>Diagnostic - to detect EBOV infection</li> <li>Research reagent</li> </ul> 2022-03-08 2026-04-27 2026-04-27 2021-05-12 antibodies, Ebola, Ebolavirus, GLYCOPROTEIN, Listed LPM Thalhammer-Reyero as of 4/15/2015, monoclonal, Neutralize, Novel, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, That, THEREOF, USES, virus False True True NIHTT 37470483 Website Abstract 114172320 Corti D, et al. https://www.ncbi.nlm.nih.gov/pubmed/26917593 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26917593">Corti D, et al.</a> 114172321 Misasi J, et al. https://www.ncbi.nlm.nih.gov/pubmed/26917592 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26917592">Misasi J, et al.</a> 114110191 Mulangu, Sabue NIAID - VRC NIAID Mulangu, Sabue (NIAID) 0 114110200 Lanzavecchia, Antonio Institute for Research in Biomedicine (IRB) Lanzavecchia, Antonio 0 114110201 Corti, Davide Institute for Research in Biomedicine (IRB) Corti, Davide 0 114110202 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 0 114110203 Ledgerwood, Julie NIAID - VRC NIAID Ledgerwood, Julie (NIAID) 0 114110204 Trefry, John USAMRIID/WR Trefry, John 0 114110205 Stanley, Daphne NIAID - VRC NIAID Stanley, Daphne (NIAID) 0 114110206 Muyembe-Tamfun, Jean-Jacques NIAID - VRC NIAID Muyembe-Tamfun, Jean-Jacques (NIAID) 0 114110192 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 1 114110192 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 1 114110191 Mulangu, Sabue NIAID - VRC NIAID Mulangu, Sabue (NIAID) 0 114110200 Lanzavecchia, Antonio Institute for Research in Biomedicine (IRB) Lanzavecchia, Antonio 0 114110201 Corti, Davide Institute for Research in Biomedicine (IRB) Corti, Davide 0 114110202 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 0 114110203 Ledgerwood, Julie NIAID - VRC NIAID Ledgerwood, Julie (NIAID) 0 114110204 Trefry, John USAMRIID/WR Trefry, John 0 114110205 Stanley, Daphne NIAID - VRC NIAID Stanley, Daphne (NIAID) 0 114110206 Muyembe-Tamfun, Jean-Jacques NIAID - VRC NIAID Muyembe-Tamfun, Jean-Jacques (NIAID) 0 114102563 Novel Monoclonal Antibodies To Ebolavirus Glycoprotein E-045-2015-0 Filing authorized INSTITUTE FOR RESEARCH IN BIOMEDICINE, NIAID, USAMRIID/WR 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3130] Human-derived Monoclonal Antibody for Treatment of Ebola Virus Infection&body=Please send me information about technology [TAB-3130] Human-derived Monoclonal Antibody for Treatment of Ebola Virus Infection. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3130] Human-derived Monoclonal Antibody for Treatment of Ebola Virus Infection&body=Please send me information about technology [TAB-3130] Human-derived Monoclonal Antibody for Treatment of Ebola Virus Infection.">wade.green@nih.gov</a><br> 114169119 E-045-2015-0 E-045-2015-0-EP-06 Neutralizing Antibodies to Ebola Virus Glycoprotein and Their Use DIV European Patent 3875481 21158309.1 Abandoned European Patent <br />Divisional (DIV) 21158309.1<br />Filed on 2015-11-13<br />Status: Abandoned 114169120 E-045-2015-0 E-045-2015-0-EP-03 Neutralizing Antibodies to Ebola Virus Glycoprotein and Their Use National Stage European Patent 3218397 15797815.6 Issued European Patent <br />National Stage 15797815.6<br />Filed on 2015-11-13<br />Status: Issued 114169121 E-045-2015-0 E-045-2015-0-US-04 NEUTRALIZING ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN AND THEIR USE National Stage US 10,160,795 15/526,661 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10160795 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10160795">10,160,795</a><br />Filed on 2017-05-12<br />Status: Issued 114169122 E-045-2015-0 E-045-2015-0-US-05 NEUTRALIZING ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN AND THEIR USE CON US 10,273,288 16/190,676 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10273288 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10273288">10,273,288</a><br />Filed on 2018-11-14<br />Status: Issued 114149028 monoclonal 114149029 Novel 114149030 antibodies 114149031 Ebolavirus 114149032 GLYCOPROTEIN 114149033 Listed LPM Thalhammer-Reyero as of 4/15/2015 114149034 Pre LPM working set 20150418 114149035 Post LPM Assignment Set 20150420 114149036 That 114149037 Neutralize 114149038 Ebola 114149039 virus 114149040 USES 114149041 THEREOF TAB-3424 114097298 Identification of a New Human Monoclonal Antibody that More Potently Prevents Malaria Infection NIAID Licensing Licensing Joseph Francica, Robert Seder, Rachel Vistein, Lawrence Wang Malaria is a major disease caused by a parasite transmitted through the bite of infected female mosquitoes. Globally, an estimated 214 million cases of malaria and 438,000 deaths from malaria occur annually, with chidren in African and South Asian regions being most vulnerable. Approximately 1,500-2,000 cases of malaria are reported in the United States each year, mostly in returning travelers from malaria- endemic countries. Among the international travelers, military personnel, diplomats, pregnant women, children and older individuals with weakened immune systems are more likely to be at risk of malaria infection and mortality.<br /><br /> Currently, there is no licensed vaccine against Plasmodium falciparum, the deadliest species of malaria parasites. Antibodies can prevent malaria infection by binding to sporozoites, the infectious form of P. falciparum that is transmitted to humans by the bites of infected mosquitoes. The major target of anti-sporozoite antibodies is the P. falciparum circumsporozoite protein (PfCSP), an abundant surface protein on sporozoites that is essential for infecting liver cells, which is the critical step for initiating a productive infection. PfCSP is comprised of an N-terminal domain, a central region and the C-terminal region.<br /><br /> Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) have isolated a new neutralizing recombinant human monoclonal antibody, L9, from a protected volunteer immunized with whole Plasmodium falciparum sporozoites. L9 is notable for targeting PfCSP, the immunodominant immunogen that coats the surface of the sporozoite, specifically the Plasmodium infectious form injected into the human host by the mosquito. Also, in vivo studies in a mouse model of malaria infection demonstrated that L9 is more potent than CIS43, another antimalarial mAb, at preventing malaria infection.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404. <ul> <li>L9 may represent a more attractive passive vaccine candidate to advance through clinical testing and could yield a product superior to other vaccine candidates due to potency and preferential binding to unique epitopes on PfCSP.</li> <li>L9 may result in more durable protection than other vaccine candidates.</li> </ul> <ul> <li>A passive vaccine candidate to prevent and eradicate malaria.</li> </ul> 2022-03-08 2026-04-27 2026-04-27 2020-11-13 ANTIBODY, Human, Identification, Infection, Malaria, monoclonal, Potently, PREVENTS, That False True True NIHTT 37470483 Website Abstract 114172588 Wang, LT, et al. https://pubmed.ncbi.nlm.nih.gov/32946741/ <a href="https://pubmed.ncbi.nlm.nih.gov/32946741/">Wang, LT, et al.</a> 114110137 Wang, Lawrence NIAID - VRC NIAID Wang, Lawrence (NIAID) 0 114110138 Vistein, Rachel NIAID - VRC NIAID Vistein, Rachel (NIAID) 0 114110139 Francica, Joseph NIAID - VRC NIAID Francica, Joseph (NIAID) 0 114110136 Seder, Robert NIAID - VRC NIAID Seder, Robert (NIAID) 1 114110136 Seder, Robert NIAID - VRC NIAID Seder, Robert (NIAID) 1 114110137 Wang, Lawrence NIAID - VRC NIAID Wang, Lawrence (NIAID) 0 114110138 Vistein, Rachel NIAID - VRC NIAID Vistein, Rachel (NIAID) 0 114110139 Francica, Joseph NIAID - VRC NIAID Francica, Joseph (NIAID) 0 114102546 Identification of a new human monoclonal antibody that more potently prevents malaria infection E-087-2019-0 Filing authorized NIAID 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-3424] Identification of a New Human Monoclonal Antibody that More Potently Prevents Malaria Infection&body=Please send me information about technology [TAB-3424] Identification of a New Human Monoclonal Antibody that More Potently Prevents Malaria Infection. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-3424] Identification of a New Human Monoclonal Antibody that More Potently Prevents Malaria Infection&body=Please send me information about technology [TAB-3424] Identification of a New Human Monoclonal Antibody that More Potently Prevents Malaria Infection.">polung.yang@nih.gov</a><br> 114169069 E-087-2019-0 E-087-2019-0-US-01 NEUTRALIZING ANTIBODIES TO PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN AND THEIR USE PRV US 62/842,590 Abandoned US <br />Provisional (PRV) 62/842,590<br />Filed on 2019-05-03<br />Status: Abandoned 114169070 E-087-2019-0 E-087-2019-0-PCT-01 NEUTRALIZING ANTIBODIES TO PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN AND THEIR USE PCT COMB Patent Cooperation Treaty PCT/US2020/031345 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2020/031345<br />Filed on 2020-05-04<br />Status: Expired 114169182 E-087-2019-0 E-087-2019-0-US-03 NEUTRALIZING ANTIBODIES TO PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN AND THEIR USE National Stage US 12,269,872 17/608,381 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12269872 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12269872">12,269,872</a><br />Filed on 2021-11-02<br />Status: Issued 114151964 Identification 114151965 Human 114151966 monoclonal 114151967 ANTIBODY 114151968 That 114151969 Potently 114151970 PREVENTS 114151971 Malaria 114151972 Infection TAB-3382 114097272 Recombinant Nipah F Proteins and Their Use NIAID Licensing Licensing Barney Graham, Rebecca Loomis, John Mascola, Guillaume Stewart-Jones Nipah virus is an emerging pathogenic paramyxovirus responsible for sporadic and isolated outbreaks of severe respiratory and neurologic disease in Southern Asia. As a zoonotic virus, disease can manifest in both animals and human with indigenous fruit bats acting as natural reservoirs of the virus. The effects of viral infection vary from acute respiratory distress to fatal encephalitis. There are currently no approved therapeutics or vaccines against the virus, and growing concerns that this highly pathogenic infection has the potential to cause larger epidemics capable of inflicting significant mortality burden.<br /><br /> Like the RSV fusion (F) glycoprotein, the Nipah fusion glycoprotein is a target of neutralizing antibodies that mediate protection against infection. Previous studies of prefusion-stabilized F glycoproteins from pneumoviruses and other paramyxoviruses (e.g. RSV and PIVs) have shown they elicit higher titers of neutralizing antibodies in both animals and humans than post-fusion F proteins.<br /><br /> Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) designed disulfide, cavity-filling and other mutations that stabilize the Nipah F glycoprotein in the prefusion conformation and bind prefusion-specific antibodies. These mutations also increase protein expression yields up to 50-fold making the recombinant proteins easy to manufacture and amenable to the use of genetic immunization using nucleic acid or vector-based applications.<br /><br /> The stabilized prefusion state of the Nipah F glycoprotein may be an ideal vaccine immunogen to elicit broad potent Nipah neutralizing antibodies. First and second generation prefusion molecules have been designed and tested in small animals and results (immunogenicity and stability) appear promising.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404. Nipah prefusion F design has the following features compared to wild-type fusion glycoprotein:<br /><br /> <ul> <li>Robust stabilization</li> <li>Up to 50-fold increase in expression yields, making the recombinant proteins easy to manufacture</li> <li>Potential to link the recombinant glycoprotein to nanoparticles or oligomerization peptides</li> </ul> <ul> <li>Vaccine - to elicit potent neutralizing antibodies against the Nipah Env glycoprotein</li> </ul> 2022-04-12 2026-04-27 2026-04-27 2019-08-21 F, nipah, proteins, recombinant, Their False True True NIHTT 37470483 Website Abstract 114110035 Loomis, Rebecca NIAID - DIR Loomis, Rebecca 0 114110036 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114110037 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114110034 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 1 114110034 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 1 114110035 Loomis, Rebecca NIAID - DIR Loomis, Rebecca 0 114110036 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114110037 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114102517 Recombinant Nipah F Proteins And Their Use E-050-2018-0 Filing authorized NIAID, University of Texas 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3382] Recombinant Nipah F Proteins and Their Use&body=Please send me information about technology [TAB-3382] Recombinant Nipah F Proteins and Their Use. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3382] Recombinant Nipah F Proteins and Their Use&body=Please send me information about technology [TAB-3382] Recombinant Nipah F Proteins and Their Use.">bbailey@mail.nih.gov</a><br> 114168905 E-050-2018-0 E-050-2018-0-US-01 NIPAH VIRUS IMMUNOGENS AND THEIR USE PRV US 62/714,230 Abandoned US <br />Provisional (PRV) 62/714,230<br />Filed on 2018-08-03<br />Status: Abandoned 114168906 E-050-2018-0 E-050-2018-0-PCT-02 Nipah Virus Immunogens And Their Use PCT Patent Cooperation Treaty PCT/US2019/045110 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/045110<br />Filed on 2019-08-05<br />Status: Expired 114169089 E-050-2018-0 E-050-2018-0-US-07 NIPAH VIRUS IMMUNOGENS AND THEIR USE National Stage US 11,890,339 17/261,828 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11890339 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11890339">11,890,339</a><br />Filed on 2021-01-20<br />Status: Issued 114151635 recombinant 114151636 nipah 114151637 F 114151638 proteins 114151639 Their TAB-4079 147157361 Oxynitidine Derivatives Useful as Inhibitors of Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treating Cancer NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Keli Agama, Lin-kun An, Evgeny Kiselev, Yves Pommier, Azhar Ravji <h2>Summary:&nbsp;</h2> <p>The National Cancer Institute (NCI) is actively seeking potential licensees and/or co-development research collaboration partners interested in advancing oxynitidine derivatives as novel inhibitors of topoisomerase IB (TOP1) and tyrosyl-DNA phosphodiesterase 1 (TDP1) for cancer treatment. These TOPI and TDP1 inhibitors, when administered together, demonstrate enhanced anti-tumor efficacy.</p> <h2>Description of Technology:&nbsp;</h2> <p>Topoisomerase 1B (TOP1) is an enzyme that relieves DNA torsional strain through the formation of transient TOP1-DNA covalent cleavage complexes (TOP1ccs) and is an attractive target for anti-cancer therapeutics. TOP1 inhibitors &ndash; such as camptothecin (CPT) &ndash; stabilize TOP1ccs, which ultimately leads to cell death. TOP1 inhibitors have long been recognized as anti-cancer agents and are used clinically. However, existing TOP1 inhibitor CPT, is limited by toxicity, chemical instability, poor solubility, and potential drug resistance via efflux mechanisms. Moreover, CPT directly competes with tyrosyl-DNA phosphodiesterase 1 (TDP1), which is an enzyme that repairs TOP1cc-induced cell damage. As such, this complicates CPT&rsquo;s effectiveness. Overall, there is ongoing interest in finding non-CPT compounds targeting TOP1 and/or TDP1 for cancer therapy.&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) and their collaborators have identified a range of oxynitidine derivatives that inhibit TOP1 and/or TDP1. These compounds represent a promising alternative to CPT. These oxynitidine derivatives have demonstrated potent TOP1 inhibition at nanomolar concentrations and effectively induce DNA damage and apoptosis in cancer cell lines. Additionally, some derivatives showed synergistic effects when used in combination with CPT. In vivo studies using xenograft mouse models of colon and breast cancer cells indicated that these derivatives (1) were generally well-tolerated and safe and (2) caused dose-dependent reduction in tumor weight. Crucially, these derivatives exhibit a significantly lower likelihood of eliciting drug resistance due to reduced susceptibility to drug efflux mechanisms. Overall, this research highlights a new class of compounds with potential for enhanced therapeutic efficacy and improved tolerability compared to traditional CPT-based therapies.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>TOP1 and TDP1 inhibitors for treating various cancers</li> <li>Combinatorial drug treatment options to boost anti-tumor potency</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Novel chemotype for TOP1 and TDP1 inhibitors</li> <li>Can potentially be used synergistically with existing therapeutics such as CPT</li> <li>Limited number of chemotypes reported as TDP1 inhibitors provides good commercial potential given finite competition</li> <li>These compounds may overcome the limitations of CPT, especially chemical instability and diarrhea</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for the development of oxynitidine derivatives as new TOP1 and TDP1 inhibitors for treating cancer. 2020-11-30 2026-04-24 2024-09-13 2026-04-24 2020-11-30 Benzophenanthridine Derivatives, Benzophenanthridinone, Camptothecin, Dihydrobenzophenanthridine, IRINOTECAN, Oxynitidine, Pommier, Tdp1, TOP1, Topoisomerase 1B, Topotecan, Tyrosyl-DNA Phosphodiesterase 1 False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2024-09-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-199-2010 147162124 Zhang X-R, et al. Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents. https://pubmed.ncbi.nlm.nih.gov/30336023/ <a href="https://pubmed.ncbi.nlm.nih.gov/30336023/">Zhang X-R, et al. Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents.</a> 158187906 Zhang X-R, et al. Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents. (PMID: 30336023) Tang W-L, et al. Synthesis and biological evaluation of 5-aminoethyl benzophenanthridone derivatives as DNA topoisomerase IB inhibitors. (PMID: 31176097) https://pubmed.ncbi.nlm.nih.gov/30336023/ <a href="https://pubmed.ncbi.nlm.nih.gov/30336023/">Zhang X-R, et al. Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents. (PMID: 30336023) Tang W-L, et al. Synthesis and biological evaluation of 5-aminoethyl benzophenanthridone derivatives as DNA topoisomerase IB inhibitors. (PMID: 31176097)</a> 158268568 Pommier, Yves National Cancer Institute (NCI) NCI Pommier, Yves (NCI) 1 158268572 An, Lin-kun Sun Yat-sen University An, Lin-kun 2 158268597 Agama, Keli NCI - CCR NCI Agama, Keli (NCI) 3 158268726 Kiselev, Evgeny NCI - CCR NCI Kiselev, Evgeny (NCI) 4 158268738 Ravji, Azhar Developmental Therapeutics Branch Ravji, Azhar 5 158268568 Pommier, Yves National Cancer Institute (NCI) NCI Pommier, Yves (NCI) 1 158268572 An, Lin-kun Sun Yat-sen University An, Lin-kun 2 158268597 Agama, Keli NCI - CCR NCI Agama, Keli (NCI) 3 158268726 Kiselev, Evgeny NCI - CCR NCI Kiselev, Evgeny (NCI) 4 158268738 Ravji, Azhar Developmental Therapeutics Branch Ravji, Azhar 5 147158159 Discovery, Synthesis And Evaluation Of Oxynitidine Derivatives As Dual Inhibitors Of DNA Topoisomerase IB (TOP1) And Tyrosyl-DNA Phosphodiesterase 1 (TDP1), And Potential Antitumor Agents E-181-2018-0 Filing authorized NCI, Sun Yat-sen University 147162552 Discovery, Synthesis And Evaluation Of Oxynitidine Derivatives As Dual Inhibitors Of DNA Topoisomerase IB (TOP1) And Tyrosyl-DNA Phosphodiesterase 1 (TDP1), And Potential Antitumor Agents E-181-2018-1 Filing authorized NCI, Sun Yat-sen University 147162553 Discovery, Synthesis And Evaluation Of Oxynitidine Derivatives As Dual Inhibitors Of DNA Topoisomerase IB (TOP1) And Tyrosyl-DNA Phosphodiesterase 1 (TDP1), And Potential Antitumor Agents E-181-2018-2 Filing authorized NCI, Sun Yat-sen University 91826910 McCrary, Michaela michaela.mccrary@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4079] Oxynitidine Derivatives Useful as Inhibitors of Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treating Cancer&body=Please send me information about technology [TAB-4079] Oxynitidine Derivatives Useful as Inhibitors of Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treating Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov McCrary, Michaela<br><a href="mailto:michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4079] Oxynitidine Derivatives Useful as Inhibitors of Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treating Cancer&body=Please send me information about technology [TAB-4079] Oxynitidine Derivatives Useful as Inhibitors of Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treating Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michaela.mccrary@nih.gov</a><br> 147161157 E-181-2018-0 E-181-2018-0-CN-01 Discovery, Synthesis And Evaluation Of Oxynitidine Derivatives As Dual Inhibitors Of DNA Topoisomerase IB (TOP1) And Tyrosyl-DNA Phosphodiesterase 1 (TDP1), And Potential Antitumor Agents ORD China 201810827467.1 Abandoned China <br />Ordinary Patent (ORD) 201810827467.1<br />Filed on 2018-07-25<br />Status: Abandoned 147166374 E-181-2018-1 E-181-2018-1-US-01 OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (Top1) AND TYROSYL-DNA PHOSPHODIESTERASE 1(Tdp1) PRV US 62/732,885 Abandoned US <br />Provisional (PRV) 62/732,885<br />Filed on 2018-09-18<br />Status: Abandoned 147166377 E-181-2018-2 E-181-2018-2-PCT-01 OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (Top1) AND TYROSYL-DNA PHOSPHODIESTERASE 1(Tdp1) PCT COMB Patent Cooperation Treaty PCT/US2019/043357 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2019/043357<br />Filed on 2019-07-25<br />Status: Expired 147166378 E-181-2018-2 E-181-2018-2-CN-02 OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (Top1) AND TYROSYL-DNA PHOSPHODIESTERASE 1(Tdp1) National Stage China ZL201980062917.5 201980062917.5 Issued China <br />National Stage 201980062917.5<br />Filed on 2019-07-25<br />Status: Issued 147166379 E-181-2018-2 E-181-2018-2-EP-03 OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (Top1) AND TYROSYL-DNA PHOSPHODIESTERASE 1(Tdp1) National Stage European Patent 19750204.0 Pending European Patent <br />National Stage 19750204.0<br />Filed on 2019-07-25<br />Status: Pending 147166380 E-181-2018-2 E-181-2018-2-US-04 OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (TOP1) AND TYROSYL-DNA PHOSPHODIESTERASE 1 (TDP1) National Stage US 12,655,107 17/262,379 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12655107 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12655107">12,655,107</a><br />Filed on 2021-01-22<br />Status: Issued 147166381 E-181-2018-2 E-181-2018-2-HK-05 OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (Top1) AND TYROSYL-DNA PHOSPHODIESTERASE 1(Tdp1) EP Hong Kong 62021043492.9 Pending Hong Kong <br />European patent (EP) 62021043492.9<br />Filed on 2021-12-02<br />Status: Pending 147173124 Benzophenanthridine Derivatives 147173126 Benzophenanthridinone 147173127 Camptothecin 147173129 Dihydrobenzophenanthridine 147173130 IRINOTECAN 147173131 Oxynitidine 147173132 Pommier 147173133 Tdp1 147173134 TOP1 147173136 Topoisomerase 1B 147173138 Topotecan 147173140 Tyrosyl-DNA Phosphodiesterase 1 TAB-4075 147157357 RNASEH-Assisted Detection Assay for RNA NCI Collaboration, Diagnostics, Infectious Disease, Licensing Collaboration Diagnostics Infectious Disease Licensing Dipak Poria, G Esta Sterneck <h2>Summary:</h2> <p>The NCI seeks research co-development partners and/or licensees for the development and commercialization of a diagnostic assay that detects sequence-specific (viral) RNA.</p> <h2>Description of Technology:</h2> <p>Several viral epidemics &ndash; such as the epidemics caused by H1N1 influenza virus, human immunodeficiency virus (HIV), Ebola virus, Zika virus, severe acute respiratory syndrome (SARS) virus, Middle East respiratory syndrome (MERS) virus and SARS-CoV-2 &ndash; have profoundly impacted global human health. Early identification of infected and/or infectious persons and isolating them from the population are some of the most effective and evident measures to prevent human-to-human spreading. In addition, areas with low resources and infrastructure may benefit from this technique for the detection of any viral or non-viral pathogens.</p> <p>Researchers at the National Cancer Institute (NCI) have developed a technology that describes an RNase-H-assisted detection assay for RNA (RADAR) that is rapid, inexpensive and highly sequence-specific.&nbsp; The assay is capable of detecting any RNA of interest, including cellular or viral RNA in a sequence-specific manner. The assay uses a modified isothermal rolling circle amplification (RCA) method that utilizes RNase H and a labeled RNA reporter molecule for the specific detection of a target RNA. The technology can detect viral RNA in approximately 2.5 hours and does not require expensive thermocyclers. Furthermore, the technology circumvents potential supply bottlenecks associated with other techniques that require enzymes other than DNA ligase, DNA polymerase, and RNaseH. Mode of detection of the amplified product is flexible depending on the nature of the label on the RNA reporter.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Diagnostic test for viral infection or any specific pathogen-derived RNA</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Rapid readout from isolated RNA of less than three hours&nbsp;</li> <li>May have the potential for point-of-care application</li> <li>Employs only three enzymes, which are relatively thermostable&nbsp;</li> <li>Does not require expensive and sophisticated thermocyclers</li> <li>Reagents are all commercially available and relatively low-cost</li> </ul> 2020-11-30 2026-04-24 2020-11-30 2026-04-24 2020-11-30 COVID, COVID-19, INFLUENZA, Poria, RNA, RNASEH, SARS-CoV2, Sterneck, Viral RNA False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-11-30 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147163427 Sterneck, G Esta NIH - NCI NCI Sterneck, G Esta (NCI) 1 147163428 Poria, Dipak NIH - NCI NCI Poria, Dipak (NCI) 2 147163427 Sterneck, G Esta NIH - NCI NCI Sterneck, G Esta (NCI) 1 147163428 Poria, Dipak NIH - NCI NCI Poria, Dipak (NCI) 2 147158186 RNaseH-assisted Detection Assay For RNA (RADAR) E-193-2020-0 Filing authorized NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4075] RNASEH-Assisted Detection Assay for RNA&body=Please send me information about technology [TAB-4075] RNASEH-Assisted Detection Assay for RNA.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4075] RNASEH-Assisted Detection Assay for RNA&body=Please send me information about technology [TAB-4075] RNASEH-Assisted Detection Assay for RNA.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161176 E-193-2020-0 E-193-2020-0-US-01 RNASEH-ASSISTED DETECTION ASSAY FOR RNA (RADAR) PRV US 63/077,123 Abandoned US <br />Provisional (PRV) 63/077,123<br />Filed on 2020-09-11<br />Status: Abandoned 147166349 E-193-2020-0 E-193-2020-0-PCT-02 RNASE H-ASSISTED DETECTION ASSAY FOR RNA PCT Patent Cooperation Treaty PCT/US2021/049588 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/049588<br />Filed on 2021-09-09<br />Status: Expired 147173424 COVID 147173425 COVID-19 147173426 INFLUENZA 147173428 Poria 147173429 RNA 147173431 RNASEH 147173432 SARS-CoV2 147173434 Sterneck 147173436 Viral RNA TAB-4338 147157629 Dopamine D3 Receptor Agonist Compounds, Methods of Preparation, Intermediates Thereof, and their Methods of Use NIDA Collaboration, Licensing, Neurology, Therapeutics Collaboration Licensing Neurology Therapeutics Francisco Battiti, Alessandro Bonifazi, Sophe Cemaj, Amy Newman <h2>Description of Technology:</h2> <p>Due to the large degree of homology among dopamine D2-like receptors, discovering ligands capable of discriminating between the D2, D3, and D4 receptor subtypes remains a significant challenge. The development of subtype-selective pharmaceutical small molecules to activate (agonists) signals regulated by D2-like receptors has been especially difficult.&nbsp;</p> <p>The inventors at the National Institute on Aging (NIDA) have recently synthesized a new generation of D3R selective agonists by applying a well-established bitopic molecular approach. Inventors were able to combine a primary pharmacophore (PP) with a secondary pharmacophore (SP) to generate compounds with high D3R subtype affinity and selectivity (e.g., compound 53). All newly synthesized compounds were tested in radioligand competition binding studies for D2-like receptor affinities (D2R, D3R, and D4R). Compound 53 and its eutomer, 53a were further evaluated for metabolic stability in rat liver microsomes and metabolite identification to confirm their applicability to future in vivo studies.&nbsp;</p> <p>The molecules could not only serve as a tools for studying D3R dopaminergic signaling but have the potential to become a pharmacological treatment of neurodegenerative disorders associated with dopaminergic dysregulation. The characterization of these D3R specific agonists including compound 53 and 53a is further described in the listed manuscript (PMID: 31257877) and claimed in the referenced patent application below. The inventors have future plans to develop these compounds as molecular tools which will be appealing to a large group of scientists working in molecular biology, pharmacology, and computational sciences directed toward dopamine D3R and their multi-therapeutic potential. The syntheses and in vitro characterization are completed. Potential application as therapeutics is also a collaboration interest of the inventors.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>New molecular tools for the discovery of, and research into, D3R physiology</li> <li>Therapeutic use for neurodegenerative disorders such as Parkinson&rsquo;s Disease and Restless Legs Syndrome</li> <li>Neurological and neuropsychiatric disorders associated with dopamine dysregulation</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The agonists have unique high D3R affinity and selectivity over D2R</li> <li>Potentially fewer side effects due to high selectivity toward D3R</li> <li>Broad range of clinical applications for the treatment neurological and neuropsychiatric disorders associated with dopamine dysregulation</li> </ul> 2020-10-27 2026-04-24 2020-10-27 2026-04-24 2020-10-27 D3R agonists, Dopamine, Newman, Parkinson’s Disease, Restless Legs Syndrome, RLS, small molecule False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-10-27 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162030 Battiti FO, et al. The significance of chirality in drug design and synthesis of bitopic ligands as d3 receptor (d3r) selective agonists https://pubmed.ncbi.nlm.nih.gov/31257877/ <a href="https://pubmed.ncbi.nlm.nih.gov/31257877/">Battiti FO, et al. The significance of chirality in drug design and synthesis of bitopic ligands as d3 receptor (d3r) selective agonists</a> 147164363 Newman, Amy NIH - NIDA NIDA Newman, Amy (NIDA) 1 147164366 Bonifazi, Alessandro NIH - NIDA NIDA Bonifazi, Alessandro (NIDA) 2 147164364 Battiti, Francisco NIH - NIDA NIDA Battiti, Francisco (NIDA) 3 147164365 Cemaj, Sophe NIH - NIDA Cemaj, Sophe 4 147164363 Newman, Amy NIH - NIDA NIDA Newman, Amy (NIDA) 1 147164366 Bonifazi, Alessandro NIH - NIDA NIDA Bonifazi, Alessandro (NIDA) 2 147164364 Battiti, Francisco NIH - NIDA NIDA Battiti, Francisco (NIDA) 3 147164365 Cemaj, Sophe NIH - NIDA Cemaj, Sophe 4 147157933 Novel Opotically Active Dopamine D3 Receptor Selective Agonists E-077-2019-0 Filing authorized National Institute on Drug Abuse (NIDA) 83737255 Baxter, Merissa merissa.baxter@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4338] Dopamine D3 Receptor Agonist Compounds, Methods of Preparation, Intermediates Thereof, and their Methods of Use&body=Please send me information about technology [TAB-4338] Dopamine D3 Receptor Agonist Compounds, Methods of Preparation, Intermediates Thereof, and their Methods of Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Baxter, Merissa<br><a href="mailto:merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4338] Dopamine D3 Receptor Agonist Compounds, Methods of Preparation, Intermediates Thereof, and their Methods of Use&body=Please send me information about technology [TAB-4338] Dopamine D3 Receptor Agonist Compounds, Methods of Preparation, Intermediates Thereof, and their Methods of Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">merissa.baxter@nih.gov</a><br> 147161004 E-077-2019-0 E-077-2019-0-US-01 D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF PRV US 62/833,023 Abandoned US <br />Provisional (PRV) 62/833,023<br />Filed on 2019-04-12<br />Status: Abandoned 147168275 E-077-2019-0 E-077-2019-0-PCT-02 Novel Opotically Active Dopamine D3 Receptor Selective Agonists PCT Patent Cooperation Treaty PCT/US2020/027903 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/027903<br />Filed on 2020-04-13<br />Status: Expired 147168276 E-077-2019-0 E-077-2019-0-AU-03 D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF National Stage Australia 2020270992 2020270992 Issued Australia <br />National Stage 2020270992<br />Filed on 2020-04-13<br />Status: Issued 147168277 E-077-2019-0 E-077-2019-0-CA-04 D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF National Stage Canada 3136151 Pending Canada <br />National Stage 3136151<br />Filed on 2020-04-13<br />Status: Pending 147168278 E-077-2019-0 E-077-2019-0-EP-05 Novel Opotically Active Dopamine D3 Receptor Selective Agonists National Stage European Patent 20724970.7 Pending European Patent <br />National Stage 20724970.7<br />Filed on 2020-04-13<br />Status: Pending 147168279 E-077-2019-0 E-077-2019-0-US-06 D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF National Stage US 12,479,838 17/602,504 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12479838 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12479838">12,479,838</a><br />Filed on 2021-10-08<br />Status: Issued 147170855 D3R agonists 147170856 Dopamine 147170857 Newman 147170859 Parkinson’s Disease 147170861 Restless Legs Syndrome 147170863 RLS 147170864 small molecule TAB-4166 147157449 Composite Gels and Methods of their Use in Tissue Repair, Drug Delivery, and as Implants NICHD Collaboration, Dermatology, Licensing, Materials Available, Medical Devices, Non-Medical Devices Collaboration Dermatology Licensing Materials Available Medical Devices Non-Medical Devices Peter Basser, Ferenc Horkay <h2>Description of Technology:</h2> <p style="margin-left:5.45pt">Gel materials, particularly hydrogels, typically lose their mechanical strength and stiffness as they swell. This property &nbsp;limits their use in both biological (e.g., cartilage and ECM repair) and non-biological (e.g., sealant) applications. Innovative materials in both medical and non-medical application areas are sorely needed.</p> <p style="margin-left:5.45pt">Recent innovations in this space, from the <em>Eunice Kennedy Shriver</em> National Institute of Child Health and Human Development (NICHD), include self-reinforcing composite hydrogels. These composite materials comprise novel combinations of solvents, swellable crosslinked polymer particles, and crosslinked polymer networks or matrices, which confine them. Exemplary solvents include water&nbsp;and organic solvents, silicone fluids and oils and others known in the art. Exemplary swellable crosslinked microgel polymer particles could comprise hyaluronic acid (HA) or other proteoglycans, polyethylene glycol, dextran particles, a poly(acrylic acid), a poly(methacrylic acid), polystyrene sulfonate, polyvinylpyrrolidone (PVP), polyacrylamide, or combinations thereof. Exemplary confining polymer networks or matrices in which these microgel polymer particles are incorporated can include polyvinyl alcohol (PVA) and its copolymers (e.g., polyvinyl alcohol-polyvinyl acetate copolymer, polyvinyl alcohol &ndash; polyvinyl acetal copolymer, polyvinyl alcohol &ndash; polyvinyl butyral copolymer) and other matrices or networks such as cellulose derivatives (e.g., methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose). Tests of the innovative gels developed by NICHD scientists demonstrate that these gels have properties similar to, e.g., human cartilage &ndash; including load-bearing ability and demonstrating high self-reinforcement. The special properties of these gels also render them suitable for drug release to the intestines and other organs.</p> <p style="margin-left:5.45pt">Researchers at NICHD welcome a wide variety of collaborative and licensing relationships. Possibilities include a cooperative research and development agreement (CRADA). The NICHD and NCI technology transfer center welcome non-exclusive or exclusive license agreements. They are eager to transfer rights in these technologies &nbsp;&nbsp;to responsible commercial partners who will diligently move therapeutics and other applications towards commercialization.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Cartilage repair Intervertebral disc repair</li> <li>Drug delivery vehicle</li> <li>Breast implants and tissue expanders</li> <li>Commercial or industrial sealants</li> <li>Underwater (naval) or commercial sealant technology</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Highly self-reinforcing as compared to traditional gel materials Wide variety of potential clinical and industrial applications</li> <li>Fracture resistant, like rip-stop nylon</li> </ul> 2020-10-27 2026-04-24 2021-12-01 2026-04-24 2020-10-27 Basser, Cartilage, Composite, Drug Delivery, Gel, Horkay, Hydrogels, IMPLANTS, MATRIX, polymer, sealants, Tissue, Tissue Repair False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-12-01 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147161866 Horkay F, et al. Composite Hydrogel Model of Cartilage Predicts Its Load-Bearing Ability. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228937/ <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228937/">Horkay F, et al. Composite Hydrogel Model of Cartilage Predicts Its Load-Bearing Ability.</a> 147163751 Horkay, Ferenc NIH - NICHD NICHD Horkay, Ferenc (NICHD) 1 147163750 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 2 147163751 Horkay, Ferenc NIH - NICHD NICHD Horkay, Ferenc (NICHD) 1 147163750 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 2 147157792 Composite Cartilage-like Load Bearing Hydrogel Systems E-014-2019-0 Filing authorized NICHD 119617417 Ravilious, Geoffrey geoffrey.ravilious@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4166] Composite Gels and Methods of their Use in Tissue Repair, Drug Delivery, and as Implants&body=Please send me information about technology [TAB-4166] Composite Gels and Methods of their Use in Tissue Repair, Drug Delivery, and as Implants.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ravilious, Geoffrey<br><a href="mailto:geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4166] Composite Gels and Methods of their Use in Tissue Repair, Drug Delivery, and as Implants&body=Please send me information about technology [TAB-4166] Composite Gels and Methods of their Use in Tissue Repair, Drug Delivery, and as Implants.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">geoffrey.ravilious@nih.gov</a><br> 147160901 E-014-2019-0 E-014-2019-0-US-02 COMPOSITE GELS AND METHODS OF USE THEREOF ORD US 12,083,246 16/783,494 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12083246 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12083246">12,083,246</a><br />Filed on 2020-02-06<br />Status: Issued 147167050 E-014-2019-0 E-014-2019-0-US-01 COMPOSITE GELS AND METHODS OF USE THEREOF PRV US 62/802,885 Abandoned US <br />Provisional (PRV) 62/802,885<br />Filed on 2019-02-08<br />Status: Abandoned 147169510 Basser 147169511 Cartilage 147169512 Composite 147169513 Drug Delivery 147169514 Gel 147169516 Horkay 147169517 Hydrogels 147169518 IMPLANTS 147169519 MATRIX 147169520 polymer 147169522 sealants 147169523 Tissue 147169525 Tissue Repair TAB-4326 147157617 Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs) NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Kenichi Hanada, Sri Krishna, Frank Lowery, Paul Robbins, Steven Rosenberg, James Yang, Rami Yoseph <h2>Summary:</h2> <p>NCI seeks commercial partners to co-develop and/or license a&nbsp;novel method to identify neoantigen reactive T cells and TCRs.</p> <h2>Description of Technology:</h2> <p>Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize unique antigens expressed by cancer cells (&ldquo;neoantigens&rdquo;). Neoantigen specific TIL administration in patients has resulted in long term regression of certain metastatic cancers. However, one of the challenges of ACT and engineered T cell receptor (TCR) therapies more broadly, is the identification and isolation of these mutation specific TILs and TCRs. Only a fraction of TILs in a given patient is known to be tumor reactive, while the majority are not useful for cell therapy. The current procedures for isolating neoantigen reactive TILs and TCRs are time consuming, labor-intensive, and lack sensitivity and specificity.&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) have developed a novel method to identify neoantigen reactive T cells and TCRs, isolated from fresh tumors of common epithelial cancers. This method does not require tumor cells to be grown or propagated in vitro. By using a single cell, transcriptome-based approach and barcoded antibodies (CITE-seq), neoantigen reactive T cells can be clustered within tSNE (t-Distributed Stochastic Neighbor Embedding) plots. Using genetic markers that are highly expressed in such clusters, a transcriptomic gene signature, called &ldquo;NeoTCR Signature&rdquo;, has been developed. This NeoTCR Signature can be used to identify a very high frequency of previously unknown T-cell clones and TCRs that recognize neoantigens from the autologous tumor. Critically, identification and isolation of the neoantigen-reactive TCR can now occur in a few days, in stark contrast to the 6-8 weeks required for current methods. This rapid determination of the neoantigen reactive TCR sequences can be useful for translating this information into TCR-engineered T-cell populations for immunotherapy. This technique can also identify T-cells with specificities for new neoantigens not presently identifiable by conventional screening methods.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Personalized cell therapy to treat cancer patients</li> <li>Immune monitoring of other immunotherapies</li> <li>Developing treatment against chronic infections which are expected to have similar T-cell dysfunction signatures (e.g. HIV, HCV, TB, etc.)</li> <li>Research tool to identify mutation-specific TCRs</li> <li>Prognostic testing for presence of tumor-relevant TILs</li> <li>Prospective isolation of cell population ideal for introduction of stem-like factors for cell therapy</li> <li>Biomarkers in immunotherapy</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Widely applicable to treat different types of cancer</li> <li>Significantly reduces the expensive and time-consuming procedures of tumor cell culture, propagation, and screening in vitro</li> <li>High specificity and sensitivity eliminate off-target effects</li> <li>Patient-specificity to improve efficacy of ACT or TCR therapy</li> </ul> 2020-09-03 2026-04-24 2022-01-19 2026-04-24 2020-09-03 act, Adoptive Cell Transfer, Immunotherapy, Neoantigen, Rosenberg, T Cell Receptor, TCR, TIL, tumor, Tumor Infiltrating Lymphocyte False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-01-19 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-067-2017 E-229-2014 E-233-2014 147164323 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 1 147164318 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 2 147164321 Yoseph, Rami NIH - NCI NCI Yoseph, Rami (NCI) 3 147164320 Yang, James NIH - NCI NCI Yang, James (NCI) 4 147164319 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 5 147164322 Lowery, Frank NIH - NCI NCI Lowery, Frank (NCI) 6 147164317 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 7 147164323 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 1 147164318 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 2 147164321 Yoseph, Rami NIH - NCI NCI Yoseph, Rami (NCI) 3 147164320 Yang, James NIH - NCI NCI Yang, James (NCI) 4 147164319 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 5 147164322 Lowery, Frank NIH - NCI NCI Lowery, Frank (NCI) 6 147164317 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 7 147157897 Method For Rapid Isolation Of Neoantigen-reactive T-cell Receptors In Human Cancers By Single-cell Analysis For Immunotherapy E-061-2020-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4326] Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs)&body=Please send me information about technology [TAB-4326] Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4326] Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs)&body=Please send me information about technology [TAB-4326] Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147160978 E-061-2020-0 E-061-2020-0-US-01 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY PRV US 62/992,701 Abandoned US <br />Provisional (PRV) 62/992,701<br />Filed on 2020-03-20<br />Status: Abandoned 147168179 E-061-2020-0 E-061-2020-0-PCT-02 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY PCT Patent Cooperation Treaty PCT/US2021/023240 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/023240<br />Filed on 2021-03-19<br />Status: Expired 147168180 E-061-2020-0 E-061-2020-0-AU-03 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage Australia 2021237717 Pending Australia <br />National Stage 2021237717<br />Filed on 2022-09-28<br />Status: Pending 147168181 E-061-2020-0 E-061-2020-0-CA-04 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage Canada 3171559 Pending Canada <br />National Stage 3171559<br />Filed on 2022-09-13<br />Status: Pending 147168182 E-061-2020-0 E-061-2020-0-CN-05 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage China 202180022592.5 Pending China <br />National Stage 202180022592.5<br />Filed on 2021-03-19<br />Status: Pending 147168183 E-061-2020-0 E-061-2020-0-EP-06 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage European Patent 21718712.9 Pending European Patent <br />National Stage 21718712.9<br />Filed on 2022-10-11<br />Status: Pending 147168184 E-061-2020-0 E-061-2020-0-JP-07 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage Japan 2022-556459 Abandoned Japan <br />National Stage 2022-556459<br />Filed on 2022-09-16<br />Status: Abandoned 147168185 E-061-2020-0 E-061-2020-0-KR-08 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage South Korea 10-2022-7036214 Pending South Korea <br />National Stage 10-2022-7036214<br />Filed on 2022-10-18<br />Status: Pending 147168186 E-061-2020-0 E-061-2020-0-US-09 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage US 17/912,315 Pending US <br />National Stage 17/912,315<br />Filed on 2022-09-16<br />Status: Pending 147168187 E-061-2020-0 E-061-2020-0-IL-10 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage Israel 296629 Pending Israel <br />National Stage 296629<br />Filed on 2022-09-19<br />Status: Pending 147170537 act 147170538 Adoptive Cell Transfer 147170539 Immunotherapy 147170540 Neoantigen 147170541 Rosenberg 147170542 T Cell Receptor 147170543 TCR 147170544 TIL 147170545 tumor 147170547 Tumor Infiltrating Lymphocyte TAB-4145 147157428 Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Amy Copeland, Sri Krishna, Frank Lowery, Paul Robbins, Steven Rosenberg, Rami Yoseph <h2>Summary:</h2> <p>NCI seeks commercial partners to co-develop and/or license&nbsp;a novel method for isolation and construction of neoantigen-reactive T-cell receptors (TCRs) from peripheral blood lymphocytes (PBL).</p> <h2>Description of Technology:</h2> <p>Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize antigens expressed by cancer cells (neoantigens). Neoantigen specific TIL administration in patients has resulted in long-term regression of certain metastatic cancers. However, current procedures for TIL therapy are highly invasive, labor-intensive, and time consuming. The success of these procedures is limited and differs between patients and histologies. Isolation of neoantigen reactive TCRs have historically been challenging due to very low precursor frequencies of these T-cells as well as lack of technical advances that can determine phenotypic markers of these cells from the blood.&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) have developed a novel method for isolation and construction of neoantigen-reactive T-cell receptors (TCRs) from peripheral blood lymphocytes (PBL) of cancer patients.&nbsp; This method allows direct isolation of T cells from the blood, based on a distinct T cell gene signature; thus, it does not require tumor cells to be gown or propagated in vitro. In this method, peptide-HLA tetramers (pHLA) are used to isolate neoantigen reactive T cells based on patient specific information on major histocompatibility complex and tumor specific mutations. By taking advantage of the unique genetic signatures of neoantigen specific T cells, this method not only generates accurate scoring of single T cells from tumors, but also facilitates identification and reconstruction of unknown TCRs for immunotherapy. Additionally, these gene signatures can be used to identify TCRs from chronic infections (such as HIV).</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Personalized cell therapy to treat cancer patients</li> <li>Testing for the presence of tumor-relevant T cells in the blood of cancer patients</li> <li>Isolation of cell populations ideal for introduction of stem-like factors for cell therapy</li> <li>Biomarkers for cancer immunotherapy</li> <li>Developing treatment against chronic infections which are expected to have similar T-cell dysfunction signatures (e.g. HIV, HCV, TB, etc.)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Widely applicable to treat different types of cancer</li> <li>Eliminates the expensive and time-consuming procedures of tumor cell culture, propagation, and screening in vitro</li> <li>High specificity and sensitivity significantly reduce off-target effects</li> <li>Patient-specificity to improve efficacy of ACT or TCR therapy</li> <li>Rapid and scalable method of isolating neoantigen-specific TCRs</li> </ul> 2020-09-03 2026-04-24 2020-09-03 2026-04-24 2020-09-03 act, Adoptive Cell Transfer, Immunotherapy, Neoantigen, Rosenberg, T Cell Receptors, TCRs, TILS, Tumor Infiltrating Lymphocytes False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-09-03 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-061-2020 E-067-2017 E-229-2014 E-233-2014 147163676 Yoseph, Rami NIH - NCI NCI Yoseph, Rami (NCI) 1 147163675 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 2 147163677 Lowery, Frank NIH - NCI NCI Lowery, Frank (NCI) 3 147163678 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 4 147163679 Copeland, Amy NIH - NCI NCI Copeland, Amy (NCI) 5 147163674 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 6 147163676 Yoseph, Rami NIH - NCI NCI Yoseph, Rami (NCI) 1 147163675 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 2 147163677 Lowery, Frank NIH - NCI NCI Lowery, Frank (NCI) 3 147163678 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 4 147163679 Copeland, Amy NIH - NCI NCI Copeland, Amy (NCI) 5 147163674 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 6 147157991 NeoBlood TCR: Prospective Isolation Of Neoantigen-reactive T-cell Receptors From Peripheral Blood By Single-cell Analysis For Immunotherapy Of Cancer Patients E-102-2020-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4145] Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients&body=Please send me information about technology [TAB-4145] Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4145] Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients&body=Please send me information about technology [TAB-4145] Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161041 E-102-2020-0 E-102-2020-0-US-01 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY PRV US 62/992,715 Abandoned US <br />Provisional (PRV) 62/992,715<br />Filed on 2020-03-20<br />Status: Abandoned 147166908 E-102-2020-0 E-102-2020-0-PCT-02 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY PCT Patent Cooperation Treaty PCT/US2021/023225 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/023225<br />Filed on 2021-03-19<br />Status: Expired 147166909 E-102-2020-0 E-102-2020-0-AU-03 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage Australia 2021239379 Pending Australia <br />National Stage 2021239379<br />Filed on 2022-09-23<br />Status: Pending 147166910 E-102-2020-0 E-102-2020-0-CA-04 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage Canada 3171583 Pending Canada <br />National Stage 3171583<br />Filed on 2022-09-13<br />Status: Pending 147166911 E-102-2020-0 E-102-2020-0-CN-05 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage China 202180030252.7 Pending China <br />National Stage 202180030252.7<br />Filed on 2021-03-19<br />Status: Pending 147166912 E-102-2020-0 E-102-2020-0-EP-06 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage European Patent 21718376.3 Pending European Patent <br />National Stage 21718376.3<br />Filed on 2022-10-19<br />Status: Pending 147166913 E-102-2020-0 E-102-2020-0-JP-07 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage Japan 2022-556460 Pending Japan <br />National Stage 2022-556460<br />Filed on 2022-09-16<br />Status: Pending 147166914 E-102-2020-0 E-102-2020-0-KR-08 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage South Korea 10-2022-7036226 Pending South Korea <br />National Stage 10-2022-7036226<br />Filed on 2022-10-18<br />Status: Pending 147166915 E-102-2020-0 E-102-2020-0-US-09 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage US 17/906,524 Pending US <br />National Stage 17/906,524<br />Filed on 2022-09-16<br />Status: Pending 147166916 E-102-2020-0 E-102-2020-0-IL-10 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage Israel 296608 Pending Israel <br />National Stage 296608<br />Filed on 2022-09-19<br />Status: Pending 147171462 act 147171463 Adoptive Cell Transfer 147171464 Immunotherapy 147171465 Neoantigen 147171466 Rosenberg 147171468 T Cell Receptors 147171469 TCRs 147171470 TILS 147171472 Tumor Infiltrating Lymphocytes TAB-4195 147157480 Novel Regulatory B cells for Treatment of Cancer and Autoimmune Disease NIA Collaboration, Licensing, Oncology, Vaccines Collaboration Licensing Oncology Vaccines Bira Arya, Ioana Bodogai, Purevdorj Olkhanud <h2>Description of Technology:</h2> <p>The manner by which cancers evade the immune response is not well-understood. What is known is that the manner is an active process that regulates immune responses employing at least two types of suppressive cells, myeloid-derived suppressive cells and regulatory T cells (Tregs), a key subset of CD4+ T cells that controls peripheral tolerance to self- and allo-antigens. Tregs are considered to play a key role in the escape of cancer cells from anti-tumor effector T cells.</p> <p>Cancer cells have been found to directly activate resting B cells to form suppressive regulatory B cells (tBregs) and utilize them to evade immune surveillance and mediate metastasis. tBregs directly inhibit CD4+ and CD8+ T cell activity in a cell contact-dependent manner, induce FoxP3+ T cell activity, and promote Treg-dependent metastasis.</p> <p>Researchers from the <a href="https://www.nia.nih.gov/" rel="nofollow" target="_blank">National Institute on Aging</a> (NIA), NIH, have developed methods for the generation of tBregs, and for using tBregs to produce Tregs, and methods that inactivate or deplete tBregs. These methods have significant therapeutic value in the combat with cancer immune escape and metastasis, and in the control of harmful autoimmune diseases.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Production of cellular cancer vaccines</li> <li>Treatments for immune-mediated disorders</li> <li>Treatments for cancer</li> <li>Treatments for chronic viral infections</li> </ul> 2016-02-16 2026-04-24 2020-08-13 2026-04-24 2020-08-30 IMMUNOTHERAPEUTIC, Immunotherapy, suppressive regulatory B cells, tBregs False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163863 Arya, Bira NIH - NIA NIA Arya, Bira (NIA) 1 147163864 Olkhanud, Purevdorj NIH - NIA NCI Olkhanud, Purevdorj (NCI) 2 147163865 Bodogai, Ioana NIH - NIA NIA Bodogai, Ioana (NIA) 3 147163863 Arya, Bira NIH - NIA NIA Arya, Bira (NIA) 1 147163864 Olkhanud, Purevdorj NIH - NIA NCI Olkhanud, Purevdorj (NCI) 2 147163865 Bodogai, Ioana NIH - NIA NIA Bodogai, Ioana (NIA) 3 147157989 Cancer-induced Regulatory B Cells (tBregs) Are Efficient Suppressors Of Immune Cellular Responses E-101-2010-0 Filing authorized National Institute on Aging (NIH/NIA) 91789173 Guyton, Nicole darackn@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America darackn@mail.nih.gov?subject=Web Inquiry on [TAB-4195] Novel Regulatory B cells for Treatment of Cancer and Autoimmune Disease&body=Please send me information about technology [TAB-4195] Novel Regulatory B cells for Treatment of Cancer and Autoimmune Disease.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Guyton, Nicole<br><a href="mailto:darackn@mail.nih.gov?subject=Web Inquiry on [TAB-4195] Novel Regulatory B cells for Treatment of Cancer and Autoimmune Disease&body=Please send me information about technology [TAB-4195] Novel Regulatory B cells for Treatment of Cancer and Autoimmune Disease.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">darackn@mail.nih.gov</a><br> 147167278 E-101-2010-0 E-101-2010-0-US-01 REGULATORY B CELLS (tBREGS) AND THEIR USE PRV US 61/302,074 Abandoned US <br />Provisional (PRV) 61/302,074<br />Filed on 2010-02-05<br />Status: Abandoned 147167279 E-101-2010-0 E-101-2010-0-PCT-02 Regulatory B Cells (tBregs) And Their Use PCT Patent Cooperation Treaty PCT/US2011/023789 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/023789<br />Filed on 2011-02-04<br />Status: Expired 147167280 E-101-2010-0 E-101-2010-0-US-03 Regulatory B Cells (TBregs) And Their Use National Stage US 9,228,171 13/577,226 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9228171 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9228171">9,228,171</a><br />Filed on 2012-08-03<br />Status: Issued 147167281 E-101-2010-0 E-101-2010-0-US-04 Regulatory B Cells (tBregs) And Their Uses CON US 9,657,269 14/952,768 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9657269 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9657269">9,657,269</a><br />Filed on 2015-11-25<br />Status: Issued 147171451 IMMUNOTHERAPEUTIC 147171452 Immunotherapy 147171454 suppressive regulatory B cells 147171455 tBregs TAB-3857 147157136 Use of Cucurbitacins and Withanolides for the Treatment of Cancer NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Nancy Booth, Alan Brooks, Karen Erickson, Kirk Gustafson, Curtis Henrich, Thomas Sayers <h2>Description of Technology:</h2> <p>Certain members of the cucurbitacin and Withanolide family have been identified that can sensitize some tumor cell lines to cell death (apoptosis) on subsequent exposure of the cells to pro-apoptotic receptor agonists (PARAS) of the TRAIL &quot;death receptors&quot;. These PARAS include TRAIL itself, and agonist antibodies to two of its receptors death receptor-4 (DR4 or TRAIL-R1) and death receptor 5 (DR5, TRAIL-R2).&nbsp;</p> <p>The protein TRAIL has a very interesting characteristic that it can preferentially cause death of cancer cells whereas normal non-transformed cells are unaffected.&nbsp; Thus use of TRAIL or agonist antibodies to its so-called &quot;death receptors&quot; has been a current focus in cancer therapy.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Use of the compounds with known TRAIL or agonist antibodies such as Mapatumumab or in combination with immunotherapeutic approaches for the treatment of cancer.</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Cucurbitacins and withanolides can be successfully developed in combination with known TRAIL agonist have the potential of new cancer combination therapies without major toxicities.</li> </ul> 2016-02-16 2026-04-24 2020-08-13 2026-04-24 2020-08-29 cucurbitacin, Immunotherapy, mapatumamab, TRAIL, withanolide False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162452 Nancy L. Booth et al. A cell-based high-throughput screen to identify synergistic TRAIL sensitizers. https://www.ncbi.nlm.nih.gov/pubmed/19089423 <a href="https://www.ncbi.nlm.nih.gov/pubmed/19089423">Nancy L. Booth et al. A cell-based high-throughput screen to identify synergistic TRAIL sensitizers.</a> 147162634 Sayers, Thomas NIH - NCI Leidos Sayers, Thomas (Leidos) 1 147162635 Gustafson, Kirk NIH - NCI NCI Gustafson, Kirk (NCI) 2 147162636 Erickson, Karen NIH - NCI Erickson, Karen 3 147162638 Brooks, Alan NIH - NCI Leidos Brooks, Alan (Leidos) 4 147162637 Henrich, Curtis NIH - NCI Henrich, Curtis 5 147162639 Booth, Nancy NIH - NCI Booth, Nancy 6 147162634 Sayers, Thomas NIH - NCI Leidos Sayers, Thomas (Leidos) 1 147162635 Gustafson, Kirk NIH - NCI NCI Gustafson, Kirk (NCI) 2 147162636 Erickson, Karen NIH - NCI Erickson, Karen 3 147162638 Brooks, Alan NIH - NCI Leidos Brooks, Alan (Leidos) 4 147162637 Henrich, Curtis NIH - NCI Henrich, Curtis 5 147162639 Booth, Nancy NIH - NCI Booth, Nancy 6 147157869 Use Of Cucurbitacins And Withanolides To Sensitize Cancer Cells To The Cytotoxic Effects Of Apo2L/TRAIL E-050-2010-0 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-3857] Use of Cucurbitacins and Withanolides for the Treatment of Cancer&body=Please send me information about technology [TAB-3857] Use of Cucurbitacins and Withanolides for the Treatment of Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-3857] Use of Cucurbitacins and Withanolides for the Treatment of Cancer&body=Please send me information about technology [TAB-3857] Use of Cucurbitacins and Withanolides for the Treatment of Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147160966 E-050-2010-0 E-050-2010-0-US-01 Use Of Cucurbitacins And Withanolides To Sensitize Cancer Cells To The Cytotoxic Effects Of Apo2L/TRAIL PRV US 61/287,139 Abandoned US <br />Provisional (PRV) 61/287,139<br />Filed on 2009-12-16<br />Status: Abandoned 147164857 E-050-2010-0 E-050-2010-0-PCT-02 Method of Sensitizing Cancer Cells To The Cytotoxic Effects Of Death Receptor Ligands In Cancer Treatment PCT Patent Cooperation Treaty PCT/US2010/060821 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/060821<br />Filed on 2010-12-16<br />Status: Expired 147164858 E-050-2010-0 E-050-2010-0-US-03 METHOD OF SENSITIZING CANCER CELLS TO THE CYTOTOXIC EFFECTS OF DEATH RECEPTOR LIGANDS IN CANCER TREATMENT National Stage US 9,238,069 13/516,514 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9238069 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9238069">9,238,069</a><br />Filed on 2012-10-26<br />Status: Issued 147170305 cucurbitacin 147170306 Immunotherapy 147170308 mapatumamab 147170309 TRAIL 147170311 withanolide TAB-4181 147157466 Denoising of Dynamic Magnetic Resonance Spectroscopic Imaging Using Low Rank Approximations in the Kinetic Domain NCI Collaboration, Licensing, Oncology, Software / Apps Collaboration Licensing Oncology Software / Apps Jeffery Brender, Murali Cherukuri, Shun Kishimoto, Hellmut Merkle, James Mitchell, Jeeva Munasinghe, Kazutoshi Yamamoto <h2>Summary:</h2> <p>The scientists seek co-development parties and/or licensees for a method for measuring low-abundance metabolites in vivo.</p> <h2>Description of Technology:</h2> <p>Accurate measurement of low metabolite concentrations produced by medically important enzymes is commonly obscured by noise during magnetic resonance imaging (MRI). Measuring the turnover rate of low-level metabolites can directly quantify the activity of enzymes of interest, including possible drug targets in cancer and other diseases. Noise can cause the in vivo signal to fall below the limit of detection. A variety of denoising methods have been proposed to enhance spectroscopic peaks, but still fall short for the detection of low-intensity signals. Dynamic nuclear polarization (DNP) is one method that has been critical for boosting weak signals. DNP must be performed near zero absolute temperature, requiring high operating costs. Measurements are limited to imaging immediately after tracer injection, limiting the range of injectable tracers that can be used in vivo.&nbsp;</p> <p>To address these issues, scientists at the National Cancer Institute (NCI) and National Institute of Neurological Disorders and Stroke (NINDS) have invented a unique method for measuring low-abundance metabolites in vivo which does not rely on frequency or spatial domains &ndash; but instead works in the kinetic domain. Data processing structure is simpler. True weak spectroscopic peaks can be more easily distinguished from noise. This technology improves the signal-to-noise ratio by an order of magnitude or more and has already been tested in vivo. The denoising software enhances low-metabolic signal without the need for DNP, which was previously thought impossible. The method makes MRI more informative for determining the metabolic activity of key enzymes in serious pathologies, is more dynamic in the range of tracers that can be used, and is generally less expensive. This software is also highly adaptable as it can be added as a plug-in to already existing MRI processing software.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Plug-in software adaptable for use with current MRI-processing software</li> <li>MRIs for clinical or research purposes</li> <li>Ancillary invention of X-nuclei leg coil which improves signal-to-noise ratio and is compatible with software</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Unique method for measuring low-abundance metabolites in vivo which does not rely on frequency or spatial domains</li> <li>Significant enhancement of raw signal and differentiation when detecting pyruvic acid metabolism to lactate</li> </ul> 2020-08-24 2026-04-24 2020-08-24 2026-04-24 2020-08-24 13C imaging, Brender, Denoising, DNP, Dynamic Nuclear Polarization, Glucose Metabolism, Low Metabolite Concentration, Magnetic Resonance Imaging, Metabolic Enzymes, MRI, Software Plugin, SPECTROSCOPIC False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-24 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147161913 Brender JR, et al. Dynamic Imaging of Glucose and Lactate Metabolism by 13C-MRS without Hyperpolarization. https://doi.org/10.1038/s41598-019-38981-1 <a href="https://doi.org/10.1038/s41598-019-38981-1">Brender JR, et al. Dynamic Imaging of Glucose and Lactate Metabolism by 13C-MRS without Hyperpolarization.</a> 147161951 Kishimoto S, et al. Imaging of glucose metabolism by 13C-MRI distinguishes pancreatic cancer subtypes in mice https://pubmed.ncbi.nlm.nih.gov/31408004/ <a href="https://pubmed.ncbi.nlm.nih.gov/31408004/">Kishimoto S, et al. Imaging of glucose metabolism by 13C-MRI distinguishes pancreatic cancer subtypes in mice</a> 147162338 Brender J, et al. PET by MRI: Glucose Imaging by 13C-MRS without Dynamic Nuclear Polarization by Noise Suppression through Tensor Decomposition Rank Reduction. https://www.biorxiv.org/content/10.1101/265793v1.full <a href="https://www.biorxiv.org/content/10.1101/265793v1.full">Brender J, et al. PET by MRI: Glucose Imaging by 13C-MRS without Dynamic Nuclear Polarization by Noise Suppression through Tensor Decomposition Rank Reduction.</a> 147163802 Brender, Jeffery NIH - NCI NCI Brender, Jeffery (NCI) 1 147163803 Yamamoto, Kazutoshi NIH - NCI NCI Yamamoto, Kazutoshi (NCI) 2 147163804 Munasinghe, Jeeva NIH - NCI NINDS Munasinghe, Jeeva (NINDS) 3 147163805 Kishimoto, Shun NIH - NCI NCI Kishimoto, Shun (NCI) 4 147163801 Merkle, Hellmut NIH - NINDS NINDS Merkle, Hellmut (NINDS) 5 147163800 Cherukuri, Murali NIH - NCI NCI Cherukuri, Murali (NCI) 6 147163799 Mitchell, James NIH - NCI NCI Mitchell, James (NCI) 7 147163802 Brender, Jeffery NIH - NCI NCI Brender, Jeffery (NCI) 1 147163803 Yamamoto, Kazutoshi NIH - NCI NCI Yamamoto, Kazutoshi (NCI) 2 147163804 Munasinghe, Jeeva NIH - NCI NINDS Munasinghe, Jeeva (NINDS) 3 147163805 Kishimoto, Shun NIH - NCI NCI Kishimoto, Shun (NCI) 4 147163801 Merkle, Hellmut NIH - NINDS NINDS Merkle, Hellmut (NINDS) 5 147163800 Cherukuri, Murali NIH - NCI NCI Cherukuri, Murali (NCI) 6 147163799 Mitchell, James NIH - NCI NCI Mitchell, James (NCI) 7 147157904 Denoising Of Dynamic Magnetic Resonance Spectroscopic Imaging Using Low Rank Approximations In The Kinetic Domain E-063-2017-0 Filing authorized NCI, NINDS 83673032 Whitney, Laurie WhitneyL@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4181] Denoising of Dynamic Magnetic Resonance Spectroscopic Imaging Using Low Rank Approximations in the Kinetic Domain&body=Please send me information about technology [TAB-4181] Denoising of Dynamic Magnetic Resonance Spectroscopic Imaging Using Low Rank Approximations in the Kinetic Domain.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Whitney, Laurie<br><a href="mailto:WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4181] Denoising of Dynamic Magnetic Resonance Spectroscopic Imaging Using Low Rank Approximations in the Kinetic Domain&body=Please send me information about technology [TAB-4181] Denoising of Dynamic Magnetic Resonance Spectroscopic Imaging Using Low Rank Approximations in the Kinetic Domain.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">WhitneyL@mail.nih.gov</a><br> 147167173 E-063-2017-0 E-063-2017-0-US-01 DENOISING OF DYNAMIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN PRV US 62/459,008 Abandoned US <br />Provisional (PRV) 62/459,008<br />Filed on 2017-02-14<br />Status: Abandoned 147167174 E-063-2017-0 E-063-2017-0-PCT-02 DENOISING OF DYNAMIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN PCT Patent Cooperation Treaty PCT/US2018/018217 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/018217<br />Filed on 2018-02-14<br />Status: Expired 147167175 E-063-2017-0 E-063-2017-0-JP-06 DENOISING OF DYNAMIC MAGNETIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN National Stage Japan 7142017 2019-543765 Issued Japan <br />National Stage 2019-543765<br />Filed on 2018-02-14<br />Status: Issued 147167176 E-063-2017-0 E-063-2017-0-AU-03 DENOISING OF DYNAMIC MAGNETIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN National Stage Australia 2018221015 2018221015 Issued Australia <br />National Stage 2018221015<br />Filed on 2019-08-13<br />Status: Issued 147167177 E-063-2017-0 E-063-2017-0-CA-04 DENOISING OF DYNAMIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN National Stage Canada 3053157 3053157 Issued Canada <br />National Stage 3053157<br />Filed on 2018-02-14<br />Status: Issued 147167178 E-063-2017-0 E-063-2017-0-EP-05 DENOISING OF DYNAMIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN National Stage European Patent 3583436 18707581.7 Issued European Patent <br />National Stage 18707581.7<br />Filed on 2018-02-14<br />Status: Issued 147167179 E-063-2017-0 E-063-2017-0-US-07 Denoising Of Dynamic Magnetic Resonance Spectroscopic Imaging Using Low Rank Approximations In The Kinetic Domain National Stage US 16/485,772 Pending US <br />National Stage 16/485,772<br />Filed on 2019-08-13<br />Status: Pending 147167180 E-063-2017-0 E-063-2017-0-US-08 DENOISING OF DYNAMIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN CON US 12,270,881 17/576,283 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12270881 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12270881">12,270,881</a><br />Filed on 2022-01-14<br />Status: Issued 147167181 E-063-2017-0 E-063-2017-0-DE-09 DENOISING OF DYNAMIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN EP Germany 3583436 18707581.7 Issued Germany <br />European patent (EP) 18707581.7<br />Filed on 2018-02-14<br />Status: Issued 147167182 E-063-2017-0 E-063-2017-0-FR-10 DENOISING OF DYNAMIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN EP France 3583436 18707581.7 Issued France <br />European patent (EP) 18707581.7<br />Filed on 2018-02-14<br />Status: Issued 147167183 E-063-2017-0 E-063-2017-0-GB-11 DENOISING OF DYNAMIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN EP United Kingdom 3583436 18707581.7 Issued United Kingdom <br />European patent (EP) 18707581.7<br />Filed on 2018-02-14<br />Status: Issued 147170598 13C imaging 147170600 Brender 147170601 Denoising 147170603 DNP 147170605 Dynamic Nuclear Polarization 147170607 Glucose Metabolism 147170609 Low Metabolite Concentration 147170610 Magnetic Resonance Imaging 147170612 Metabolic Enzymes 147170613 MRI 147170615 Software Plugin 147170616 SPECTROSCOPIC TAB-3990 147157271 T-cell Receptors Targeting CD20-Positive Lymphomas and Leukemias NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Christian Hinrichs, Kazusa Ishii <h2>Summary:</h2> <p>NCI seeks parties interested in licensing&nbsp;to further develop&nbsp;a collection of novel anti-CD20 TCRs that can be used to treat CD20 positive lymphomas and leukemias.</p> <h2>Description of Technology:</h2> <p>CD20 is a protein expressed by wide ranges of lymphoid malignancies originating from B cells but not by indispensable normal tissues, making it an attractive target for therapies such as T-cell receptor (TCR) therapy. Current anti-CD20 therapeutics face a number of limitations. The most important limitation to current anti-CD20 therapies include cancer cells becoming resistant to the therapy. Resistance mechanisms to the existing CD20 therapies include loss of target antigen expression from the cell surface, loss of antibody epitope, or modulation of antibody epitope &ndash; all of which make the malignant cells &ldquo;invisible&rdquo; to antibodies. Importantly, these resistance mechanisms do not affect TCR-mediated target recognition. Epitopes for TCRs are short fragments of peptides that are processed intracellularly and presented in the context of major histocompatibility complex. Thus, TCRs can recognize and kill leukemia and lymphoma that are no longer &ldquo;visible&rdquo; to existing antibodies.&nbsp;</p> <p>Investigators at the National Cancer Institute (NCI) have developed a collection of novel anti-CD20 TCRs that can be used to treat CD20 positive lymphomas and leukemias. These novel TCRs can recognize and exert cell killing against CD20-derived epitopes even when the target protein escapes surface expression and remains in a sub-cellular compartment, such as endoplasmic reticulum or cytoplasm. These characteristics of the novel anti-CD20 TCRs allow them to overcome known resistance mechanisms associated with B-cell malignancies, making them an attractive therapy over other current CD20 therapeutics on the market.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>The TCRs can be used as a therapeutic against B-cell malignancies such as non-Hodgkin&rsquo;s lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia</li> <li>The TCRs can be used for treatment in: <ul> <li>CD20-expressing malignancies, even if the CD20 antigen escapes the surface of the tumor cells and resides within intracellular compartments or is only partially expressed</li> <li>CD20-expressing malignancies, even if the diseases are resistant to existing anti-CD20 antibodies through resistance to antibody-specific cytotoxicity mechanisms (such as antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity)&nbsp;</li> </ul> </li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The novel TCRs can recognize and exert cell killing against CD20-derived epitopes even when the target protein escapes surface expression and remains in a sub-cellular compartment, which are current limitations of CAR-T cell therapy and anti-CD20 monoclonal antibodies</li> <li>The novel anti-CD20 TCRs&nbsp;can specifically recognize and exert tumor-cell killing in a target-antigen-restricted manner, when CD20 expression is low, or when CD20 is expressed intracellularly</li> <li>In in vitro experiments, T cells engineered to express anti-CD20 TCR recognize and mediate cytotoxicity against cells lines that are both CD20+ and HLA-A2+ and exhibit high functional activity</li> <li>CD20 targeting TCRs are available for immediate clinical validation</li> </ul> 2020-08-19 2026-04-24 2021-03-23 2026-04-24 2020-08-19 Acute Lymphoblastic Leukemia, ALL, CD20, Chronic lymphocytic leukemia, CLL, Hinrichs, Ishii, NHL, Non-Hodgkin’s Lymphoma, Resistant B-lymphoid malignancies, T-Cell Receptor, TCR False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-03-23 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163144 Ishii, Kazusa NIH - NCI NCI Ishii, Kazusa (NCI) 1 147163143 Hinrichs, Christian NIH - NCI Hinrichs, Christian 2 147163144 Ishii, Kazusa NIH - NCI NCI Ishii, Kazusa (NCI) 1 147163143 Hinrichs, Christian NIH - NCI Hinrichs, Christian 2 147158086 Discovery Of T Cell Receptors (TCR) Against HLA-A*02:01-restricted CD20 Epitope E-152-2020-0 Filing authorized NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-3990] T-cell Receptors Targeting CD20-Positive Lymphomas and Leukemias&body=Please send me information about technology [TAB-3990] T-cell Receptors Targeting CD20-Positive Lymphomas and Leukemias.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-3990] T-cell Receptors Targeting CD20-Positive Lymphomas and Leukemias&body=Please send me information about technology [TAB-3990] T-cell Receptors Targeting CD20-Positive Lymphomas and Leukemias.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">suna.gulay@nih.gov</a><br> 147165752 E-152-2020-0 E-152-2020-0-US-01 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD20 PRV US 63/043,520 Abandoned US <br />Provisional (PRV) 63/043,520<br />Filed on 2020-06-24<br />Status: Abandoned 147165753 E-152-2020-0 E-152-2020-0-PCT-02 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD20 PCT Patent Cooperation Treaty PCT/US2021/038649 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/038649<br />Filed on 2021-06-23<br />Status: Expired 147165754 E-152-2020-0 E-152-2020-0-US-03 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD20 National Stage US 18/012,056 Pending US <br />National Stage 18/012,056<br />Filed on 2022-12-21<br />Status: Pending 147172428 Acute Lymphoblastic Leukemia 147172429 ALL 147172430 CD20 147172431 Chronic lymphocytic leukemia 147172432 CLL 147172433 Hinrichs 147172434 Ishii 147172435 NHL 147172436 Non-Hodgkin’s Lymphoma 147172438 Resistant B-lymphoid malignancies 147172439 T-Cell Receptor 147172440 TCR TAB-4342 147157634 CD206 Small Molecule Modulators, Their Use and Methods for Preparation NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Bolormaa Baljinnyam, Raul Calvo, Xin Hu, Juan Marugan, Udo Rudloff, Noel Southall <h2>Summary:</h2> <p>The NCI is seeking licensing partners and/or collaborators to perform IND enabling studies to translate the anti-CD206 small molecule into a therapeutic for CD206 expressing cancers.</p> <h2>Description of Technology:</h2> <p>Pancreatic ductal adenocarcinoma (PDA) accounts for more than 90% of pancreatic cancer cases, and it is one of the most aggressive malignancies with a 5-year survival rate of 6%. The high mortality rate caused by PDA is primarily from the lack of early diagnosis &ndash; it is often asymptomatic in early stages &ndash; and a poor response to conventional chemotherapy and radiotherapy. One of the major immune cell types present in the PDA microenvironment is a subset of macrophages commonly termed tumor-associated macrophages (TAM). TAMs originate, in part, from circulating monocytes upon activation by CCL2, a chemotactic chemokine secreted and then recruited to the tumor microenvironment by cytokines expressed by PDA cells.</p> <p>TAMs consist primarily of polarized M2 macrophages which promote tumor growth by secreting immunosuppressive factors that block effector T-cell activation. TAMs express scavenger receptors such as CD206 which facilitate tumor angiogenesis and migration. CD206 is a member of the large C-type lectin receptor family and not found on other TAM population like undifferentiated M0 or M1-like macrophages. CD206high expression and infiltration with CD206high macrophages has been associated with poor clinical outcomes in pancreatic cancer and other solid organ cancers. Current anti-macrophage therapy generally inhibits activation or the recruitment of macrophages (CCL2/CCR2), which lacks specificity towards M2-like macrophages, agonism of M1 signaling via CD40 ligation, or blockade of the CD47-SIRP &lsquo;do-not-eat&rsquo; cancer phagocytosis checkpoint.</p> <p>Researchers at the National Cancer Institute (NCI) have discovered a small molecule that binds to CD206 and induces M2-to-M1 reprogramming, cancer cell phagocytosis and M2 cell death. The anti-CD206 small molecule was identified through structure-based pharmacophore modeling and in silico screening of the anti-cancer peptide, RP-182 (NIH Reference Number: E-242-2015.) The activity of this CD206 small molecule modulator was confirmed in vitro and in vivo across a number of different solid organ cancer models. In addition to its reprogramming function to a M1 mechanism, a selective reduced cell viability was observed in human CD206high M2-like macrophages derived from healthy volunteers compared with M1 control macrophages. This new small molecule immunomodulator will be the first-in-class that will have application in selectively targeting M2 macrophages &ndash; a pro-tumor immune cell population &ndash; and the reprogramming of M2 macrophages towards a M1 phenotype (anti-tumor cell population) for the treatment of pancreatic cancer. The small molecule candidate has high oral bioavailability, a large therapeutic window, favorable pharmacokinetics, and limited off-target effects.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of cancers associated with high expression of CD206 including pancreatic, head and neck, lung, gastric, triple negative breast, renal cell, colorectal cancer, and melanoma</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>First-in-class small molecule targeting CD206 for oncology indication</li> <li>Targeted therapy decreases non-specific killing of healthy, essential cells, resulting in fewer non-specific side-effects and healthier patients</li> <li>High unmet needs and commercial opportunity for pancreatic cancer</li> </ul> 2020-08-17 2026-04-24 2021-05-20 2026-04-24 2020-08-17 CD206, M1 Macrophage, M2 Macrophage, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDA, Rudloff, TAM, Tumor-Associated Macrophages False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-05-20 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-242-2015 147164385 Rudloff, Udo NIH - NCI NCI Rudloff, Udo (NCI) 1 147164384 Marugan, Juan NIH - NCATS NCATS Marugan, Juan (NCATS) 2 147164386 Hu, Xin NIH - NCATS NCATS Hu, Xin (NCATS) 3 147164387 Calvo, Raul NIH - NCATS NCATS Calvo, Raul (NCATS) 4 147164383 Southall, Noel NIH - NCATS NCATS Southall, Noel (NCATS) 5 147164382 Baljinnyam, Bolormaa NIH - NCATS Baljinnyam, Bolormaa 6 147164385 Rudloff, Udo NIH - NCI NCI Rudloff, Udo (NCI) 1 147164384 Marugan, Juan NIH - NCATS NCATS Marugan, Juan (NCATS) 2 147164386 Hu, Xin NIH - NCATS NCATS Hu, Xin (NCATS) 3 147164387 Calvo, Raul NIH - NCATS NCATS Calvo, Raul (NCATS) 4 147164383 Southall, Noel NIH - NCATS NCATS Southall, Noel (NCATS) 5 147164382 Baljinnyam, Bolormaa NIH - NCATS Baljinnyam, Bolormaa 6 147157996 Small Molecules With Selective Activity Against The M2 Phenotype Of Macrophages E-105-2019-0 Filing authorized NCATS - NCGC, NCATS - NCGC, NCI, NIH - NCATS, NIH - NCI 83736770 Cheng, Eric eric.cheng2@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-4342] CD206 Small Molecule Modulators, Their Use and Methods for Preparation&body=Please send me information about technology [TAB-4342] CD206 Small Molecule Modulators, Their Use and Methods for Preparation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Cheng, Eric<br><a href="mailto:eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-4342] CD206 Small Molecule Modulators, Their Use and Methods for Preparation&body=Please send me information about technology [TAB-4342] CD206 Small Molecule Modulators, Their Use and Methods for Preparation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">eric.cheng2@nih.gov</a><br> 147161046 E-105-2019-0 E-105-2019-0-US-01 CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION PRV US 62/950,488 Abandoned US <br />Provisional (PRV) 62/950,488<br />Filed on 2019-12-19<br />Status: Abandoned 147168315 E-105-2019-0 E-105-2019-0-PCT-02 CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION PCT Patent Cooperation Treaty PCT/US2020/065238 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/065238<br />Filed on 2020-12-16<br />Status: Expired 147168316 E-105-2019-0 E-105-2019-0-CA-04 CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION National Stage Canada 3165339 Pending Canada <br />National Stage 3165339<br />Filed on 2020-12-16<br />Status: Pending 147168317 E-105-2019-0 E-105-2019-0-CN-05 CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION National Stage China ZL202080096478.2 202080096478.2 Issued China <br />National Stage 202080096478.2<br />Filed on 2022-08-30<br />Status: Issued 147168318 E-105-2019-0 E-105-2019-0-EP-06 CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION National Stage European Patent 20842083.6 Pending European Patent <br />National Stage 20842083.6<br />Filed on 2020-12-16<br />Status: Pending 147168319 E-105-2019-0 E-105-2019-0-JP-07 CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION National Stage Japan 7801223 2022-537672 Issued Japan <br />National Stage 2022-537672<br />Filed on 2020-12-16<br />Status: Issued 147168320 E-105-2019-0 E-105-2019-0-US-08 CD206 Modulators Their Use and Methods for Preparation National Stage US 17/787,313 Pending US <br />National Stage 17/787,313<br />Filed on 2022-06-18<br />Status: Pending 147168321 E-105-2019-0 E-105-2019-0-AU-03 CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION National Stage Australia 2020404978 Pending Australia <br />National Stage 2020404978<br />Filed on 2020-12-16<br />Status: Pending 147171505 CD206 147171507 M1 Macrophage 147171509 M2 Macrophage 147171510 Pancreatic Cancer 147171512 Pancreatic Ductal Adenocarcinoma 147171513 PDA 147171515 Rudloff 147171516 TAM 147171518 Tumor-Associated Macrophages TAB-4281 147157569 High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Mitchell Ho, Dan Li, Brad St. Croix, Ruixue Wang <h2>Summary:</h2> <p>The NCI seeks licensing and/or co-development research collaborations for CD276-targeting camel nanobodies.&nbsp;</p> <h2>Description of Technology:</h2> <p>CD276 (also called B7-H3) is a pan-cancer antigen expressed in multiple solid tumors and an emerging cancer target. CD276 protein is overexpressed in pancreatic cancer, prostate cancer, breast cancer, colon cancer, lung cancer, and brain tumors (such as neuroblastoma) &ndash; making it an ideal target for cancer therapy.&nbsp;</p> <p>Investigators at the National Cancer Institute (NCI) have isolated a panel of anti-CD276 single domain antibodies (also known as nanobodies) from novel camel and rabbit single domain (VHH) libraries by phage display.&nbsp;</p> <p>Nanobodies are the smallest known antigen-binding fragments of antibodies. Due to their small size, high solubility, thermal stability, refolding capacity, and relatively easy tissue penetration, they have great potential as medical applications and research tools. These antibodies can be used as either independent agents or targeting domains in recombinant immunotoxins (RITs), antibody-drug conjugates (ADCs), and chimeric antigen receptors (CARs). The CARs using the RWB12, RWC4 and RWG8 antibodies have shown potent killing in various CD276-expressing tumor cell models, strongly supporting that these candidates may be further developed as therapeutics.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Numerous solid tumors &ndash; including, but not limited to: pancreatic cancer, prostate cancer, breast cancer, colon cancer, lung cancer, and brain tumors (such as neuroblastoma)&nbsp;</li> <li>Therapeutic applications include the unconjugated antibodies and their use as a targeting moiety for CARs, RITs, ADCs, and bispecific antibodies</li> <li>Diagnostic agent for detection and monitoring levels of mesothelin expressing cancers</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Antibodies with high CD276 binding specificity should result in less non-specific cell killing (off-target toxicity) and lower potential side-effects</li> <li>Similarity of camel and human VH sequences suggests humanization of these antibodies is not necessary, and that the product is ready for immediate clinical testing</li> <li>Relative ease of Tissue Penetration for targeting Solid Tumors</li> <li>CARs using the A101 and G8 antibodies available for immediate testing</li> <li>B7-H3 antagonist</li> </ul> 2020-08-17 2026-04-24 2020-08-17 2026-04-24 2020-08-17 ADC, Antibody-drug Conjugate, B7-H3, BREAST CANCER, CAR, CD276, chimeric antigen receptor, COLON CANCER, Glioma, HO, lung cancer, Nanobodies, Neuroblastoma, OVARIAN CANCER, Pancreatic Cancer, solid tumors False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-17 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147164144 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147164145 St. Croix, Brad NIH - NCI NCI St. Croix, Brad (NCI) 2 147164147 Wang, Ruixue NIH - NCI NCI Wang, Ruixue (NCI) 3 147164146 Li, Dan NCI - CCR NCI Li, Dan (NCI) 4 147164144 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147164145 St. Croix, Brad NIH - NCI NCI St. Croix, Brad (NCI) 2 147164147 Wang, Ruixue NIH - NCI NCI Wang, Ruixue (NCI) 3 147164146 Li, Dan NCI - CCR NCI Li, Dan (NCI) 4 147158171 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors E-185-2019-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4281] High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors&body=Please send me information about technology [TAB-4281] High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4281] High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors&body=Please send me information about technology [TAB-4281] High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161165 E-185-2019-0 E-185-2019-0-US-01 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors PRV US 62/924,498 Abandoned US <br />Provisional (PRV) 62/924,498<br />Filed on 2019-10-22<br />Status: Abandoned 147167851 E-185-2019-0 E-185-2019-0-PCT-02 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors PCT Patent Cooperation Treaty PCT/US2020/056601 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/056601<br />Filed on 2020-10-21<br />Status: Expired 147167852 E-185-2019-0 E-185-2019-0-AU-03 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors National Stage Australia 2020370125 Pending Australia <br />National Stage 2020370125<br />Filed on 2020-10-21<br />Status: Pending 147167853 E-185-2019-0 E-185-2019-0-CA-04 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors National Stage Canada 3156761 Pending Canada <br />National Stage 3156761<br />Filed on 2020-10-21<br />Status: Pending 147167854 E-185-2019-0 E-185-2019-0-CN-05 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors National Stage China ZL202080074414.2 202080074414.2 Issued China <br />National Stage 202080074414.2<br />Filed on 2020-10-21<br />Status: Issued 147167855 E-185-2019-0 E-185-2019-0-EP-06 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors National Stage European Patent 20804404.0 Pending European Patent <br />National Stage 20804404.0<br />Filed on 2020-10-21<br />Status: Pending 147167856 E-185-2019-0 E-185-2019-0-JP-07 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors National Stage Japan 7690468 2022-523456 Issued Japan <br />National Stage 2022-523456<br />Filed on 2020-10-21<br />Status: Issued 147167857 E-185-2019-0 E-185-2019-0-US-08 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors National Stage US 12,552,865 17/770,940 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12552865 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12552865">12,552,865</a><br />Filed on 2022-04-21<br />Status: Issued 147173275 ADC 147173276 Antibody-drug Conjugate 147173277 B7-H3 147173278 BREAST CANCER 147173279 CAR 147173280 CD276 147173281 chimeric antigen receptor 147173282 COLON CANCER 147173283 Glioma 147173284 HO 147173285 lung cancer 147173286 Nanobodies 147173287 Neuroblastoma 147173288 OVARIAN CANCER 147173289 Pancreatic Cancer 147173290 solid tumors TAB-3899 147157179 Humanized Mouse Model to Study Mesothelin (MSLN) -targeted Cancer Therapeutics: Bl6/TPO Mice NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Christine Alewine, Norman Collins, Theresa Guerin, Serguei Kozlov, Theresa O'Sullivan, Jerome Schlomer, Xianyu Zhang <h2>Summary:</h2> <p>The NCI Laboratory of Molecular Biology is seeking parties interested in licensing&nbsp;a genetically engineered&nbsp;mouse model expressing hMSLN in the thyroid gland for commercialization in the field of cancer therapeutics and research targeting mesothelin-expressing tumors.</p> <h2>Description of Technology:</h2> <p>Mesothelin (MSLN) is an antigen highly expressed in several human cancers including mesotheliomas, ovarian cancers and pancreatic cancers. As such, human MSLN (hMSLN) is a target for many anti-cancer drugs. Most therapeutics targeting hMSLN do not recognize the mouse isoform of MSLN (mMSLN) and therefore cannot be tested in mouse cancer models.&nbsp;</p> <p>Investigators at the National Cancer Institute (NCI) have developed a mouse model wherein mice are genetically engineered to express hMSLN in the thyroid gland under the transcriptional control of a thyroid-specific (Tpo) gene promoter. Due to the tolerance to the hMSLN isoform, these mice are efficient recipients of cancer cell lines engineered to express hMSLN. These mice allow the testing of cancer therapeutics targeted against hMSLN in a fully immunocompetent animal background. In addition, these mice can be used to investigate on-target, off-tumor toxicity caused by hMSLN-directed therapeutics.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research, diagnostics, or therapeutics involving the target, mesothelin, such as in human mesotheliomas, ovarian cancers, pancreatic cancers</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The humanized mice have expression of human mesothelin (hMSLN) that is localized to the thyroid. The Bl6/TPO mice are efficient recipients of cancer cells lines that express hMSLN</li> <li>Endogenous expression of hMSLN in mice allows for the unique ability to test therapies that target human mesothelin, including studies off-target toxicity</li> </ul> 2020-08-17 2026-04-24 2020-08-17 2026-04-24 2020-08-17 Alewine, Bl6/TPO, Cancer Animal Model, hMSLN, Humanized Mice, MESOTHELIN, MSLN, Murine Model, THYROID False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-17 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147162190 Zhang X, et al. Engineering of transgenic mice expressing human mesothelin for investigation of mesothelin-targeted therapeutics. https://cancerres.aacrjournals.org/content/79/13_Supplement/268 <a href="https://cancerres.aacrjournals.org/content/79/13_Supplement/268">Zhang X, et al. Engineering of transgenic mice expressing human mesothelin for investigation of mesothelin-targeted therapeutics.</a> 147162791 Alewine, Christine NIH - NCI NCI Alewine, Christine (NCI) 1 147162792 Kozlov, Serguei NIH - NCI Leidos Kozlov, Serguei (Leidos) 2 147162796 Zhang, Xianyu NIH - NCI NCI Zhang, Xianyu (NCI) 3 147162794 Guerin, Theresa NIH - NCI Leidos Guerin, Theresa (Leidos) 4 147162790 O'Sullivan, Theresa NIH - NCI NCI O'Sullivan, Theresa (NCI) 5 147162795 Collins, Norman NIH - NCI NCI Collins, Norman (NCI) 6 147162793 Schlomer, Jerome NIH - NCI Leidos Schlomer, Jerome (Leidos) 7 147162791 Alewine, Christine NIH - NCI NCI Alewine, Christine (NCI) 1 147162792 Kozlov, Serguei NIH - NCI Leidos Kozlov, Serguei (Leidos) 2 147162796 Zhang, Xianyu NIH - NCI NCI Zhang, Xianyu (NCI) 3 147162794 Guerin, Theresa NIH - NCI Leidos Guerin, Theresa (Leidos) 4 147162790 O'Sullivan, Theresa NIH - NCI NCI O'Sullivan, Theresa (NCI) 5 147162795 Collins, Norman NIH - NCI NCI Collins, Norman (NCI) 6 147162793 Schlomer, Jerome NIH - NCI Leidos Schlomer, Jerome (Leidos) 7 147157978 C57BI6 Mice With Thyroid Specific Expression Of Human Mesothelin E-096-2020-0 Research Material NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3899] Humanized Mouse Model to Study Mesothelin (MSLN) -targeted Cancer Therapeutics: Bl6/TPO Mice&body=Please send me information about technology [TAB-3899] Humanized Mouse Model to Study Mesothelin (MSLN) -targeted Cancer Therapeutics: Bl6/TPO Mice.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3899] Humanized Mouse Model to Study Mesothelin (MSLN) -targeted Cancer Therapeutics: Bl6/TPO Mice&body=Please send me information about technology [TAB-3899] Humanized Mouse Model to Study Mesothelin (MSLN) -targeted Cancer Therapeutics: Bl6/TPO Mice.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147171332 Alewine 147171334 Bl6/TPO 147171336 Cancer Animal Model 147171338 hMSLN 147171340 Humanized Mice 147171341 MESOTHELIN 147171342 MSLN 147171344 Murine Model 147171345 THYROID TAB-4256 147157543 Antisense Oligonucleotides against Cancer Cell Migration and Invasion NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Stavroula Mili <h2>Summary:</h2> <p>NCI is seeking parties interested in co-developing and/or licensing therapeutic antisense oligonucleotides that target cell migration and cancer metastasis.</p> <h2>Description of Technology:</h2> <p>Advanced stage cancers are typically marked by metastases of the primary cancer to secondary sites such as lungs, liver, and bones. Such metastatic cancers result in strikingly low 5-year survival rates, underscoring the need for novel therapeutics. For example, bone metastasis of primary breast cancer has a 5-year survival rate of 13%, lung cancer only 1%. There is a need for targeted therapy options specific to metastases. One approach to targeting metastases is to reduce cancer cell migration and invasion.</p> <p>Several mRNAs become localized to subcellular destinations during the metastatic process. These mRNAs may play roles in cell and organelle development &ndash; either through corresponding increases in encoded protein concentration or through dynamic interactions with the extracellular environment. Their activities may be modulated via antisense oligonucleotides. One example is the mRNA localization at the protrusions extended by mesenchymal migrating cells, partially under control of the adenomatous polyposis coli (APC) tumor suppressor. Regulation of the mRNAs localized to these protrusions may be usurped to target cancer cell migration and invasion and, ultimately, metastasis. RAB13 and NET1 are especially promising mRNA targets as they are overexpressed in multiple cancer types and contributory to cell motility in vitro.</p> <p>Researchers at the National Cancer Institute (NCI), Laboratory of Cellular and Molecular Biology, have shown that mRNA localization at protrusive regions of migrating cells depends on specific signals within the 3&rsquo;-untranslated regions of these mRNAs. These signals may be modulated by antisense oligonucleotides as a novel mechanism to target cancer metastasis. The inventors have designed chemically modified antisense oligonucleotides against RAB13 and NET1, delivered these into cancer cells, and observed inhibition of cell migration and invasion in two-dimensional and three-dimensional in vitro assays. These oligonucleotides specifically target RNAs at protrusions without broadly affecting expression of encoded proteins, so they are expected to have minimal effects on non-migrating cells. In vivo studies with xenograft tumor models are currently taking place to optimize delivery of the oligonucleotides.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Metastatic cancer therapeutic</li> <li>Targeted cancer therapeutic</li> <li>Cardiovascular and neurodegenerative diseases, as well as genetic disorders</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Regulatory approval pathway exists following FDA/EMA approval of the first antisense-based molecule (Tegsedi&trade;) in 2018&nbsp;</li> <li>Targeting cancer metastasis and inhibition of cell movement through antisense oligonucleotides is a novel approach</li> <li>Antisense oligonucleotides specifically target RNAs at cell protrusions without broadly affecting cellular protein expression</li> <li>Antisense oligonucleotides can be highly specific, permitting induction at advanced stages of cancer growth &ndash; as compared with chemotherapy</li> </ul> 2020-07-21 2026-04-24 2020-07-21 2026-04-24 2020-07-21 Antisense, APC, CANCER, Invasion, Metastasis, MIGRATION, Mili, Net1, OLIGO, oligonucleotide, Oncology, Rab13, RNA False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-07-21 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162220 Moissoglu K, et al. Translational regulation of protrusion-localized RNAs involves silencing and clustering after transport. https://pubmed.ncbi.nlm.nih.gov/31290739/ <a href="https://pubmed.ncbi.nlm.nih.gov/31290739/">Moissoglu K, et al. Translational regulation of protrusion-localized RNAs involves silencing and clustering after transport.</a> 147162297 Moissoglu K, et al. Local RNA translation controls cell migration and Rab GTPase function. https://www.biorxiv.org/content/10.1101/2020.05.19.104463v1 <a href="https://www.biorxiv.org/content/10.1101/2020.05.19.104463v1">Moissoglu K, et al. Local RNA translation controls cell migration and Rab GTPase function.</a> 147162373 Mili S, et al. Genome-wide screen reveals APC-associated RNAs enriched in cell protrusions. https://pubmed.ncbi.nlm.nih.gov/18451862/ <a href="https://pubmed.ncbi.nlm.nih.gov/18451862/">Mili S, et al. Genome-wide screen reveals APC-associated RNAs enriched in cell protrusions.</a> 147164065 Mili, Stavroula NIH - NCI NCI Mili, Stavroula (NCI) 1 147164065 Mili, Stavroula NIH - NCI NCI Mili, Stavroula (NCI) 1 147157847 Antisense Oligos That Block Cancer Cell Migration And Invasion E-041-2020-0 Filing authorized NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4256] Antisense Oligonucleotides against Cancer Cell Migration and Invasion&body=Please send me information about technology [TAB-4256] Antisense Oligonucleotides against Cancer Cell Migration and Invasion.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4256] Antisense Oligonucleotides against Cancer Cell Migration and Invasion&body=Please send me information about technology [TAB-4256] Antisense Oligonucleotides against Cancer Cell Migration and Invasion.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">suna.gulay@nih.gov</a><br> 147160947 E-041-2020-0 E-041-2020-0-US-01 RAB13 AND NET1 ANTISENSE OLIGONUCLEOTIDES TO TREAT METASTATIC CANCER PRV US 62/966,204 Abandoned US <br />Provisional (PRV) 62/966,204<br />Filed on 2020-01-27<br />Status: Abandoned 147167709 E-041-2020-0 E-041-2020-0-PCT-02 RAB13 AND NET1 ANTISENSE OLIGONUCLEOTIDES TO TREAT METASTATIC CANCER PCT Patent Cooperation Treaty PCT/US2021/015053 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/015053<br />Filed on 2021-01-26<br />Status: Expired 147167710 E-041-2020-0 E-041-2020-0-US-03 RAB13 AND NET1 ANTISENSE OLIGONUCLEOTIDES TO TREAT METASTATIC CANCER National Stage US 12,503,695 17/792,507 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12503695 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12503695">12,503,695</a><br />Filed on 2022-07-13<br />Status: Issued 147170068 Antisense 147170069 APC 147170070 CANCER 147170071 Invasion 147170072 Metastasis 147170073 MIGRATION 147170075 Mili 147170077 Net1 147170078 OLIGO 147170079 oligonucleotide 147170080 Oncology 147170082 Rab13 147170083 RNA TAB-4155 147157438 Aryl Hydantoin Heterocycle Compounds that Target the Androgen Receptor for Prostate Cancer Treatment NCI Collaboration, Endocrinology, Licensing, Oncology, Therapeutics Collaboration Endocrinology Licensing Oncology Therapeutics Nicholas Aboreden, William Figg, Berkley Gryder, Adegboyega Oyelere, Eric Raftery, Subhasish Tapadar <h2>Description of Technology:</h2> <p>Prostate cancer is the most prevalent form of cancer among all men in the United States (US). It is also the second leading cause of cancer-related deaths in the US among men, largely due to the progressively treatment resistant nature of the disease. Treatment options for early stage prostate cancer include watchful waiting, radical prostatectomy, radiation therapy, and importantly androgen-deprivation therapy (ADT). Prostate cancer is dependent on androgen hormones, such as testosterone, for sustaining and promoting growth. Androgen hormones bind to the Androgen receptor (AR), causing AR localization to the nucleus where a complex is formed that regulates the transcription of critical genes. ADT is accomplished through administering an antagonist to the AR that blocks androgen ligands, or by castration (physical or chemical) to reduce the amount of testosterone. However, the disease frequently advances to castration resistant prostate cancer (CRPC), becoming resistant to these therapies by overexpressing AR. Additional anti-androgens have been developed, though these have had limited improvements in patient outcomes and are not effective against the refractory forms of prostate cancer.&nbsp;</p> <p>Recently, antiandrogenic diaryl thiohydantoin compounds have been shown to be more promising prostate cancer therapeutics. These compounds have shown success in clinical trials, though still with only mild improvement of patient outcomes. Therefore, more potent forms of these compounds are needed for improved therapies. Researchers at the National Cancer Institute (NCI) have developed aryl hydantoin derived heterocyclic compounds with improved efficacy as shown by in vitro and in vivo studies. These compounds include, most importantly, Androgen Receptor Inverse Agonists (ARIA), but also agonists and antagonists of the AR.&nbsp; &nbsp;</p> <p>NCI seeks research co-development partners and/or licensees to develop these compounds as therapeutics for prostate cancer. As these compounds consist of both AR agonists and antagonists, they may also be effective therapeutics for androgen dysfunctional disorders, such as androgen deficiency disorders or hyperandrogenism.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic for: <ul> <li>Early and advanced stages of prostate cancer</li> <li>Androgen receptor-positive breast cancer and other androgen receptor-positive solid tumors</li> <li>Androgen deficiency disorders</li> <li>Hyperandrogenism</li> </ul> </li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Increased potency compared with current prostate cancer therapeutic compounds</li> <li>Potency in disease models that are non-responsive to current prostate cancer therapeutics</li> <li>Potential to treat both early stage and advance stage prostate cancer</li> <li>Potential to treat a range of androgen receptor-positive solid tumors</li> <li>Other clinical trials with similar approaches provides promising human safety data</li> </ul> 2020-07-07 2026-04-24 2020-07-07 2026-04-24 2020-07-07 Androgen Deficiency Disorders, Androgen dysfunctional Disorders, Androgen Receptor, Androgen Receptor Inverse Agonists, Anti-androgens, AR, ARIA, BREAST CANCER, Georgia Institute of Technology, GIT, Gryder, Hyperandrogenism, PROSTATE CANCER False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-07-07 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163711 Gryder, Berkley NIH - NCI NCI Gryder, Berkley (NCI) 1 147163712 Oyelere, Adegboyega Georgia Institute of Technology Oyelere, Adegboyega 2 147163713 Raftery, Eric Georgia Institute of Technology Raftery, Eric 3 147163714 Tapadar, Subhasish Georgia Institute of Technology Tapadar, Subhasish 4 147163715 Aboreden, Nicholas NIH - NCI NCI Aboreden, Nicholas (NCI) 5 147163710 Figg, William NIH - NCI NCI Figg, William (NCI) 6 147163711 Gryder, Berkley NIH - NCI NCI Gryder, Berkley (NCI) 1 147163712 Oyelere, Adegboyega Georgia Institute of Technology Oyelere, Adegboyega 2 147163713 Raftery, Eric Georgia Institute of Technology Raftery, Eric 3 147163714 Tapadar, Subhasish Georgia Institute of Technology Tapadar, Subhasish 4 147163715 Aboreden, Nicholas NIH - NCI NCI Aboreden, Nicholas (NCI) 5 147163710 Figg, William NIH - NCI NCI Figg, William (NCI) 6 147158131 Aryl Hydantoin Heterocycles And Methods Of Making And Using Thereof E-169-2018-0 Filing authorized Georgia Institute of Technology, National Cancer Institute (NCI), NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4155] Aryl Hydantoin Heterocycle Compounds that Target the Androgen Receptor for Prostate Cancer Treatment&body=Please send me information about technology [TAB-4155] Aryl Hydantoin Heterocycle Compounds that Target the Androgen Receptor for Prostate Cancer Treatment.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4155] Aryl Hydantoin Heterocycle Compounds that Target the Androgen Receptor for Prostate Cancer Treatment&body=Please send me information about technology [TAB-4155] Aryl Hydantoin Heterocycle Compounds that Target the Androgen Receptor for Prostate Cancer Treatment.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147161140 E-169-2018-0 E-169-2018-0-US-01 ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE PRV US 62/963,959 Abandoned US <br />Provisional (PRV) 62/963,959<br />Filed on 2020-01-21<br />Status: Abandoned 147166960 E-169-2018-0 E-169-2018-0-PCT-02 ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2021/014176 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/014176<br />Filed on 2021-01-20<br />Status: Expired 147166961 E-169-2018-0 E-169-2018-0-AU-03 ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE National Stage Australia 2021209875 Pending Australia <br />National Stage 2021209875<br />Filed on 2022-07-14<br />Status: Pending 147166962 E-169-2018-0 E-169-2018-0-CA-04 ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE National Stage Canada 3165120 Pending Canada <br />National Stage 3165120<br />Filed on 2022-07-18<br />Status: Pending 147166963 E-169-2018-0 E-169-2018-0-EP-05 ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE National Stage European Patent 21705753.8 Pending European Patent <br />National Stage 21705753.8<br />Filed on 2022-08-16<br />Status: Pending 147166964 E-169-2018-0 E-169-2018-0-US-06 ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE National Stage US 17/794,212 Pending US <br />National Stage 17/794,212<br />Filed on 2022-07-20<br />Status: Pending 147172873 Androgen Deficiency Disorders 147172875 Androgen dysfunctional Disorders 147172877 Androgen Receptor 147172879 Androgen Receptor Inverse Agonists 147172881 Anti-androgens 147172882 AR 147172884 ARIA 147172885 BREAST CANCER 147172887 Georgia Institute of Technology 147172889 GIT 147172891 Gryder 147172893 Hyperandrogenism 147172894 PROSTATE CANCER TAB-4032 147157313 Reporter Assay for Detection and Quantitation of Replication-Competent Gammaretrovirus NCI Immunology, Licensing, Research Materials Immunology Licensing Research Materials Amanda (Declined Roy Aloia, Alan Rein <h2>Description of Technology:</h2> <p>Gammaretroviral vectors were the first viral gene-therapy vectors to enter clinical trials and remain in use. One potential hazard associated with the use of such vectors is the presence of replication-competent retroviruses (RCR) in the vector preparations &ndash; either as a result of: 1) recombination events between the plasmids used for vector production, 2) interactions between the plasmids and endogenous retroviral sequences in the packaging cell lines, or 3) as a result of contamination in the laboratory. RCRs are potentially pathogenic and shown to induce malignancy in mice and non-human primates. Therefore, it is critical that vector preparations be rigorously tested to exclude the presence of RCRs given that the Food and Drug Administration (FDA) requires all vector preparations be screened for RCRs.</p> <p>At present, the FDA recommends RCR testing by inoculating an aliquot of each vector preparation into a permissive cell line and passaging the cells for at least three weeks (i.e., amplification phase). Cell-free media from the amplification phase can then be analyzed by a variety of methods to demonstrate the presence or absence of RCRs.</p> <p>Scientists at the National Cancer Institute (NCI) have developed a new research method for the detection of RCRs in gammaretrovirus-based gene-therapy products and the cell lines used to make them. The assay uses one of a series of DERSE (Detector of Exogenous Retroviral Sequence Elements) plasmids, stably maintained in a cell line permissive for the retrovirus of interest. Utilizing the unique reverse-transcription step of the retroviral infection cycle, a functional reporter gene is formed in the DERSE cell culture only after infection with an RCR. The DERSE assay can be constructed, potentially, to detect any RCR and can use any reporter gene.</p> <p>This invention is available for licensing.</p> <p><img alt="E-125-2020 - Schematic of inGluc-MLV-DERSE assay" src="https://nih.technologypublisher.com/files/sites/e-125-2020_-_schematic_of_ingluc-mlv-derse_assay2.jpg" style="float:left; height:489px; width:450px" /></p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p><strong>Figure: Schematic of inGluc-MLV-DERSE assay</strong></p> <p>&nbsp;</p> <p>&nbsp;</p> <p>The inG<em>luc</em>-MLV-DERSE plasmid consists of a Gaussia Luciferase (G<em>luc</em>) sequence oriented in a reverse direction with respect to flanking MLV non-coding sequences. Within the non-coding G<em>luc</em> sequence is an intron that is oriented in a forward direction relative to the viral non-coding regions (and can be spliced by the host cell). The plasmid is maintained in 293mCAT1 cells. In the absence of RCR, only minus-strand, spliced G<em>luc</em> sequences are present in the cell. An RCR that infects the DERSE cell can package the RNA containing the minus-strand G<em>luc</em> sequence. In the next round of infection reverse transcription of the encapsidated RNA produces a double-stranded DNA containing an uninterrupted G<em>luc</em> gene. This gene is an intact, coding G<em>luc</em> sequence that is subsequently integrated into the DNA of, and expressed by, the newly infected cell. Expression of G<em>luc</em> is under the control of the cytomegalovirus (CMV) promoter.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Laboratory tool to investigate molecular mechanisms of retroviral replication</li> <li>Research tool to screen gene therapy regimens</li> <li>Manufacturing tool to screen viral vector preparations</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Provides reliable results in roughly half the time of traditional methods for detecting replication-competent retrovirus (RCR)</li> <li>Overcomes the inhibitory effect of excess gene-therapy vector in the detection of RCRs</li> <li>Does not require the identification of foci</li> <li>Useful for screening both gene-therapy products and the packaging cell lines used for vector production</li> <li>Enhanced detection sensitivity as the indicating reporter is only formed in cells infected with replication-competent retrovirus&nbsp;</li> </ul> 2020-07-07 2026-04-24 2020-07-07 2026-04-24 2020-07-07 Cell line, Gammaretrovirus, Gaussia Luciferase, GENE THERAPY, PLASMID, RCR, Rein, Replication-Competent Retrovirus, Vector Preparation False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-07-07 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162154 Aloia AL, et al. A reporter system for replication-competent gammaretroviruses: the inGluc-MLV-DERSE assay. https://pubmed.ncbi.nlm.nih.gov/22402321/ <a href="https://pubmed.ncbi.nlm.nih.gov/22402321/">Aloia AL, et al. A reporter system for replication-competent gammaretroviruses: the inGluc-MLV-DERSE assay.</a> 147163285 Rein, Alan NIH - NCI Leidos Rein, Alan (Leidos) 1 147163286 Aloia, Amanda (Declined Royalty) NIH - NCI Aloia, Amanda (Declined Royalty) 2 147163285 Rein, Alan NIH - NCI Leidos Rein, Alan (Leidos) 1 147163286 Aloia, Amanda (Declined Royalty) NIH - NCI Aloia, Amanda (Declined Royalty) 2 147158032 Reporter For Detection And Quantitation Of Replication-Competent Gammaretrovirus E-125-2020-0 Research Material NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4032] Reporter Assay for Detection and Quantitation of Replication-Competent Gammaretrovirus&body=Please send me information about technology [TAB-4032] Reporter Assay for Detection and Quantitation of Replication-Competent Gammaretrovirus.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4032] Reporter Assay for Detection and Quantitation of Replication-Competent Gammaretrovirus&body=Please send me information about technology [TAB-4032] Reporter Assay for Detection and Quantitation of Replication-Competent Gammaretrovirus.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147171916 Cell line 147171917 Gammaretrovirus 147171919 Gaussia Luciferase 147171920 GENE THERAPY 147171921 PLASMID 147171923 RCR 147171925 Rein 147171927 Replication-Competent Retrovirus 147171929 Vector Preparation TAB-4323 147157614 Mouse Embryo Culture Chamber and Imaging System and Methods of Use NEI Collaboration, Ear, Nose, & Throat, Licensing, Medical Devices, Non-Medical Devices, Ophthalmology, Reproductive Health Collaboration Ear Nose & Throat Licensing Medical Devices Non-Medical Devices Ophthalmology Reproductive Health Vijay Kumar Kalaskar <h2>Description of Technology:</h2> <p>The culture of mouse embryos <em>ex utero</em> and continuous monitoring and imaging of embryos as they develop have applications in drug testing, genetic studies, and basic research on embryonic development. However, the embryo culture systems currently available for post-implantation embryos include rolling bottle culture systems, which do not permit imaging of the developing embryos and do not support the long-term survival and development of embryos <em>ex utero</em>. Current culture systems for pre-implantation stage embryos, including microfluidic culture systems, are suitable for short-term culture of very early stage embryos &ndash; such as fertilized zygotes. However, they are not suitable for the culture and survival of post-implantation stage embryos. Similarly, the cell culture systems currently available (e.g., slides, multi-well plates, and microfluidic chambers) may allow for imaging of single-dimensional structures such as cells, but cannot be used for culturing or imaging three-dimensional structures such as embryos. Therefore, there is a need for a system that provides long-term embryo culturing combined with imaging. Such a system could support long-term culture while allowing for continuous imaging of the developing embryos.</p> <p>Scientists at the National Eye Institute (NEI) have developed an embryo culture chamber, an embryo culturing and imaging system, and a method of culturing and imaging an embryo. The chamber allows for the continuous imaging of the embryo for the culture period. This invention is available for licensing and co-development.</p> <p><img alt="" src="https://nih.technologypublisher.com/files/sites/e-042-2020_mouse_embryo_culture_imaging_multi-chamber_system2.png" style="height:450px; width:800px" /></p> <p><strong>Figure: Mouse embryo culture imaging multi-chamber system</strong>. The multi-chamber mouse embryo culture imaging system consists of multiple embryo culture chambers connected to a common medium and gas (95% O<sub>2</sub>/5% CO<sub>2</sub>) source. Culture medium (and serum/blood) flows through the peristaltic pump into the culture chamber (blood/serum flows through internal sub-chamber) submerging the embryos and passes through the outlets to recirculate. Gas flow through the chambers can be monitored as it passes through the water trap and adjusted by a flow meter. The inlet shows enlarged view of the culture chamber with a microscope objective lens for imaging and a removable chamber lid. Mouse embryos are cultured on specialized platform with pores and elevations to provide minimal contact with the surface and allow free flow of medium in all directions. The serum/blood flowing through the internal sub-chamber baths the mouse placenta/yolk sac simulating placental blood supply.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Drug screening for teratogenic and developmental effects with temporal and spatial evaluation on different organ systems during embryonic growth</li> <li>Substituting cell-culture and organoid based culture systems as direct testing or studies on mammalian embryos (e.g., mouse embryos)</li> <li>Genetic screening for developmental defects with direct visualization of the embryonic development&nbsp;</li> <li>Drug development and evaluation of molecules regardless of whether they cross the placental barrier</li> <li>Visualization of the developing organ systems and tissues at the embryonic level</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The internal sub-chamber simulates placental blood supply through which blood/serum can be supplied to developing embryos</li> <li>The unique design of the stage/platform on which the embryo rests enables maximum exposure of the body surface area to the circulating medium and oxygen permits appropriate development and survival of the embryos long-term</li> <li>The embryo culture chamber enables continuous imaging of developing embryos during culture</li> <li>Development of specific organ systems, such as eye, lungs, heart, liver, etc., can be monitored and imaged</li> <li>Temporal and spatial distribution of pharmacological molecules (e.g., molecules/proteins tagged with fluorescent markers) in different organ systems and their effect on a specific organ or whole-body development can be monitored and studied</li> <li>The blood/serum supply through the internal sub-chamber simulates placental blood supply and can be used to treat embryos with specific drugs/molecules while the litter mates serve as controls for studying the effect of specific molecules on organ system development</li> <li>Long-term or complete ex utero development of post-implantation stage embryos provides access to developing mammalian embryos for pharmacological manipulation and research studies</li> </ul> 2020-06-30 2026-04-24 2020-06-30 2026-04-24 2020-06-30 Culture Chamber, Embryo Development, Embryonic, FETAL, GENE THERAPY, IMAGING, In Vitro Drug Toxicology, Kalaskar, National Eye Institute, NEI, Organ System Therapy False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-06-30 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147164308 Kalaskar, Vijay Kumar NIH - NEI NEI Kalaskar, Vijay Kumar (NEI) 1 147164308 Kalaskar, Vijay Kumar NIH - NEI NEI Kalaskar, Vijay Kumar (NEI) 1 147157849 Mouse Embryo Culture Imaging Chamber E-042-2020-0 Filing authorized National Eye Institute (NEI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4323] Mouse Embryo Culture Chamber and Imaging System and Methods of Use&body=Please send me information about technology [TAB-4323] Mouse Embryo Culture Chamber and Imaging System and Methods of Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4323] Mouse Embryo Culture Chamber and Imaging System and Methods of Use&body=Please send me information about technology [TAB-4323] Mouse Embryo Culture Chamber and Imaging System and Methods of Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147160949 E-042-2020-0 E-042-2020-0-US-01 MOUSE EMBRYO CULTURE IMAGING CHAMBER AND METHODS THEREOF PRV US 62/968,474 Abandoned US <br />Provisional (PRV) 62/968,474<br />Filed on 2020-01-31<br />Status: Abandoned 147170091 Culture Chamber 147170093 Embryo Development 147170094 Embryonic 147170095 FETAL 147170096 GENE THERAPY 147170097 IMAGING 147170099 In Vitro Drug Toxicology 147170101 Kalaskar 147170103 National Eye Institute 147170104 NEI 147170106 Organ System Therapy TAB-4352 147157645 Inhibition of T Cell Lactate Dehydrogenase (LDH) ex vivo Enhances the Anti-tumor Efficacy of Adoptive T Cell Therapy NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Luca Gattinoni, Dalton Hermans, Warren Leonard, Leonard Neckers <h2>Description of Technology:</h2> <p>Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes (TIL), T cell receptor (TCR) and Chimeric Antigen Receptor (CAR) engineered T cells, or hematopoietic stem cell transplantation, is a promising new approach to cancer treatment. ACT harnesses an individual&#39;s adaptive immune system to fight against cancer, with fewer side-effects and more specific anti-tumor activity. Despite their promise of ACT as curative, these therapies are often limited by the persistence and robustness of the responses of the T cells to the cancer cells. Altering metabolic pathways is one way to affect the actions of T cells, and different cellular subtypes vary in how they produce and expend energy. T cell metabolism can be altered by several factors, including cytokine stimulation and by inhibiting lactate dehydrogenase (LDH), which mediates the final step in glycolytic metabolic pathway.</p> <p>Researchers at the National Cancer Institute (NCI) and the National Heart Lung and Blood Institute (NHLBI) have discovered that preconditioning T cells with LDH inhibitors during in vitro culture with cytokines improves efficacy of these cells once adoptively transferred to a mouse model of melanoma. This was accomplished by investigating the role of metabolic programming in the developmental differences induced by interleukin-21 (IL-21), a cytokine with known antitumor activity. IL-21 alone promoted stem cell memory T cells (TSCM) expansion, and this was enhanced when combined with an LDH inhibitor. This resulted in a more profound antitumor responses and prolonged host survival. Studies revealed that inhibition of LDH activity prior to adoptive transfer of CD8+ T cells promoted maintainence of the cells in a more T stem-cell like state. Combining IL-21 with the LDH inhibitor also prevented the induction of several immune checkpoints/exhaustion molecules known to limit in vivo antitumor responses &ndash; including PD-1, TIM-3, LAG3 and 2B4. Results are similar for LDH inhibition of human and murine CD8+ T cells in vitro, underscoring the potential therapeutic benefits of preconditioning with LDH inhibition before ACTimmunotherapy.&nbsp;&nbsp;</p> <p>The NCI seeks research co-development partners and/or licensees for clinical evaluation of this invention.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>A strategy to improve ACT immunotherapies to treat and/or prevent the recurrence of a variety of human cancers</li> <li>Use of this preconditioning method in a variety of ACT therapies, including TIL, TCR, and CAR therapies</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Improved host survival in a murine model, suggesting treatment benefit in human trials&nbsp;</li> <li>A mechanism for enhancing robustness of adoptive T cells</li> </ul> 2020-06-25 2026-04-24 2020-06-25 2026-04-24 2020-06-25 act, Adoptive T Cell Therapy, CAR T Cells, CD8+ T Cells, Gattinoni, Interleukin-21, Lactate Dehydrogenase Inhibitor, LDH, Neckers, Preconditioning, TCR-engineered T Cells, TILS False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-06-25 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-190-2016 E-244-2014 147161882 Hermans A, et al. Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8+ T cell stemness and antitumor immunity. https://pubmed.ncbi.nlm.nih.gov/32123114/ <a href="https://pubmed.ncbi.nlm.nih.gov/32123114/">Hermans A, et al. Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8+ T cell stemness and antitumor immunity.</a> 147164420 Leonard, Warren NIH - NHLBI NHLBI Leonard, Warren (NHLBI) 1 147164421 Hermans, Dalton NIH - NHLBI NHLBI Hermans, Dalton (NHLBI) 2 147164422 Gattinoni, Luca NIH - NCI NCI Gattinoni, Luca (NCI) 3 147164419 Neckers, Leonard NIH - NCI NCI Neckers, Leonard (NCI) 4 147164420 Leonard, Warren NIH - NHLBI NHLBI Leonard, Warren (NHLBI) 1 147164421 Hermans, Dalton NIH - NHLBI NHLBI Hermans, Dalton (NHLBI) 2 147164422 Gattinoni, Luca NIH - NCI NCI Gattinoni, Luca (NCI) 3 147164419 Neckers, Leonard NIH - NCI NCI Neckers, Leonard (NCI) 4 147158034 Inhibition Of T Cell Lactate Dehydrogenase (LDH) Ex Vivo Promotes Enhanced Anti-tumor Efficacy In A Model Of Adoptive Cell Therapy E-126-2019-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-4352] Inhibition of T Cell Lactate Dehydrogenase (LDH) ex vivo Enhances the Anti-tumor Efficacy of Adoptive T Cell Therapy&body=Please send me information about technology [TAB-4352] Inhibition of T Cell Lactate Dehydrogenase (LDH) ex vivo Enhances the Anti-tumor Efficacy of Adoptive T Cell Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-4352] Inhibition of T Cell Lactate Dehydrogenase (LDH) ex vivo Enhances the Anti-tumor Efficacy of Adoptive T Cell Therapy&body=Please send me information about technology [TAB-4352] Inhibition of T Cell Lactate Dehydrogenase (LDH) ex vivo Enhances the Anti-tumor Efficacy of Adoptive T Cell Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147161074 E-126-2019-0 E-126-2019-0-US-01 T CELLS HAVING ENHANCED ANTI-TUMOR ACTIVITY PRV US 62/883,927 Abandoned US <br />Provisional (PRV) 62/883,927<br />Filed on 2019-08-07<br />Status: Abandoned 147168390 E-126-2019-0 E-126-2019-0-PCT-02 T CELLS HAVING ENHANCED ANTI-TUMOR ACTIVITY PCT Patent Cooperation Treaty PCT/US2020/045100 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/045100<br />Filed on 2020-08-06<br />Status: Expired 147168391 E-126-2019-0 E-126-2019-0-US-03 T CELLS HAVING ENHANCED ANTI-TUMOR ACTIVITY National Stage US 12,558,424 17/633,414 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12558424 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12558424">12,558,424</a><br />Filed on 2022-02-07<br />Status: Issued 147171947 act 147171949 Adoptive T Cell Therapy 147171951 CAR T Cells 147171953 CD8+ T Cells 147171954 Gattinoni 147171955 Interleukin-21 147171957 Lactate Dehydrogenase Inhibitor 147171958 LDH 147171960 Neckers 147171962 Preconditioning 147171964 TCR-engineered T Cells 147171965 TILS TAB-4275 147157563 Development of Next Generation Antibody Drug Conjugates (ADCs) Against CD276 NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Yang Feng, Steven Seaman, Brad St. Croix <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research collaborations and/or licensees for the development of a CD276 antibody drug conjugate (ADC) for the treatment of solid tumors.</p> <h2>Description of Technology:</h2> <p>Angiogenesis is the formation of new blood vessels from pre-existing blood vessels. Angiogenesis occurs during normal growth and development (physiological angiogenesis) and during the growth of solid tumors (pathological angiogenesis). CD276, also known as B7-H3, is a cell surface tumor endothelial marker that is highly expressed in the tumor vessels of human lung, breast, colon, endometrial, renal, and ovarian cancer, but not in the angiogenic vessels of normal, healthy tissue. This differential expression makes CD276 an attractive target for cancer treatment due to the ability to selectively target pathological angiogenesis without impacting physiological angiogenesis. In fact, CD276-directed therapeutic antibodies may have a higher degree of specificity for tumor vessels than current antiangiogenic agents that cannot distinguish physiological and pathological angiogenesis. Moreover, CD276 protein is also frequently overexpressed on tumor cells. The ability to target the vasculature as well as tumor cells directly makes CD276 a potentially ideal dual-compartment therapeutic target.</p> <p>Researchers at the National Cancer Institute (NCI) have created a potent antibody-drug conjugate (ADC) with an improved therapeutic index that selectively reacts with a broad variety of tumor types.&nbsp; The lead ADC, m276-PBD-SL, targets CD276 for the treatment of cancer. The m276 antibody used to develop this ADC is fully-human and recognizes mouse, non-human primate, and human CD276 with similar affinity &ndash; unlike all other CD276 antibodies described to date. This ADC contains mutations to prevent inappropriate interaction of the ADC with endogenous immunoglobulin receptors present on cells of the immune system. These mutations prevent the potentially harmful killing of normal cells and minimize off-target toxicity. The ADC also contains a mutation which allows site-directed conjugation of the payload to the antibody. Payload attachment at this specific site prevents the premature release of the warhead from the antibody, increasing the stability of the ADC in the circulation and preventing non-specific toxicity. This ADC is the only one that combines all these critical features with a potent optimized warhead and an optimally targeted pan anti-cancer fully-human antibody against CD276. These advantages can be leveraged to facilitate preclinical ADC studies and may be a better reflection of what a human clinical response would be, may facilitate GMP scale-up, may facilitate preclinical testing in multiple species using the same clinical-grade product, and may facilitate earlier toxicity assessments due to the multiple cross-species reactivity of the fully-human CD276 antibody.&nbsp; &nbsp; &nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic for various solid cancer including, but not limited to, lung, breast, colon, endometrial, renal, and ovarian cancer</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Simultaneously targets both tumor cells and tumor vasculature</li> <li>Potentially superior adverse events mitigation over existing anti-angiogenic agents due to the differential expression of CD276 on tumor versus normal vasculature</li> <li>Fully human antibodies are less likely to be recognized and cleared by the immune system upon repeated administration&nbsp; &nbsp;</li> <li>Cross-reactive with mouse, rat, and monkey CD276 making preclinical studies easier and more informative</li> <li>Antibody mutations block inappropriate killing of Fc-receptor-bearing normal cells to minimize off-target toxicity</li> <li>The mutation in the Fc domain creates a superior site-directed conjugation attachment site for the drug payload to the warhead by increasing solubility of the ADC and preventing premature shedding of the drug in serum</li> </ul> 2020-06-17 2026-04-24 2021-06-10 2026-04-24 2020-06-17 ADC, antibody drug conjugate, B7-H3, CD276, Immunotherapy, Monoclonal Antibody, St. Croix False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-06-10 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-104-2013 E-250-2014 147164128 St. Croix, Brad NIH - NCI NCI St. Croix, Brad (NCI) 1 147164129 Feng, Yang NIH - NCI NCI Feng, Yang (NCI) 2 147164130 Seaman, Steven NIH - NCI NCI Seaman, Steven (NCI) 3 147164128 St. Croix, Brad NIH - NCI NCI St. Croix, Brad (NCI) 1 147164129 Feng, Yang NIH - NCI NCI Feng, Yang (NCI) 2 147164130 Seaman, Steven NIH - NCI NCI Seaman, Steven (NCI) 3 147158076 Development Of Next Generation ADCs Against CD276 E-145-2019-0 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4275] Development of Next Generation Antibody Drug Conjugates (ADCs) Against CD276&body=Please send me information about technology [TAB-4275] Development of Next Generation Antibody Drug Conjugates (ADCs) Against CD276.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4275] Development of Next Generation Antibody Drug Conjugates (ADCs) Against CD276&body=Please send me information about technology [TAB-4275] Development of Next Generation Antibody Drug Conjugates (ADCs) Against CD276.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147161104 E-145-2019-0 E-145-2019-0-US-01 ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF PRV US 62/947,135 Abandoned US <br />Provisional (PRV) 62/947,135<br />Filed on 2019-12-12<br />Status: Abandoned 147167816 E-145-2019-0 E-145-2019-0-PCT-02 ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2020/063732 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/063732<br />Filed on 2020-12-08<br />Status: Expired 147167817 E-145-2019-0 E-145-2019-0-AU-03 ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF National Stage Australia 2020402752 Pending Australia <br />National Stage 2020402752<br />Filed on 2020-12-08<br />Status: Pending 147167818 E-145-2019-0 E-145-2019-0-CA-04 ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF National Stage Canada 3161573 Pending Canada <br />National Stage 3161573<br />Filed on 2020-12-08<br />Status: Pending 147167819 E-145-2019-0 E-145-2019-0-EP-05 ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF National Stage European Patent 20834060.4 Pending European Patent <br />National Stage 20834060.4<br />Filed on 2020-12-08<br />Status: Pending 147167820 E-145-2019-0 E-145-2019-0-JP-06 ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF National Stage Japan 7679380 2022-535127 Issued Japan <br />National Stage 2022-535127<br />Filed on 2020-12-08<br />Status: Issued 147167821 E-145-2019-0 E-145-2019-0-US-07 ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF National Stage US 17/783,171 Pending US <br />National Stage 17/783,171<br />Filed on 2022-06-07<br />Status: Pending 147172319 ADC 147172320 antibody drug conjugate 147172321 B7-H3 147172322 CD276 147172323 Immunotherapy 147172324 Monoclonal Antibody 147172325 St. Croix TAB-4186 147157471 Mitotic Figures Electronic Counting Application for Surgical Pathology NCI Collaboration, Licensing, Oncology, Software / Apps Collaboration Licensing Oncology Software / Apps Stephen Hewitt, Munish Puri, Robert Simpson <h2>Summary:</h2> <p>The National Cancer Institute (NCI) Laboratory of Cancer Biology and Genetics is seeking parties interested in licensing and /or co-development research collaboration of a software application for commercialization in quantitative and digital pathology fields.&nbsp;&nbsp;</p> <h2>Description of Technology:</h2> <p>Cancer diagnosis depends on the assessment of patient biopsies to determine tumor type, grading, and stage of malignancy. Pathologists visually review specimens and count mitotic figures (MF) in a variety of cancer types to help gauge aggressiveness, guide treatment, and inform patient prognosis. Current technology for recording MF counts in surgical pathology is lacking in objectivity, and enumeration of MF by microscopy can be error prone. In particular, a lack of systematic means for recording contributes to recognized variability. Cell counting instruments have been employed in the field as an attempt to address these issues. However, these instruments were not designed to assess the mitotic activity index for tumor grading, and they do not record MF microscopy field-of-view by field-of-view, do not function to sum the counts, and do not export data for inclusion in a pathology report.</p> <p>This discovery provides a software application for the electronic recording, summation, and transcription of clinical data obtained during surgical pathology examination of patient tissues. This invention will enable standardization across diagnostic centers which will permit harmonization of MF counting by electronic means. Through standardization enabled by the application, interobserver variance in MF counting can be reduced and transcription errors eliminated, enhancing the accuracy of mitotic index generation that will improve patient care.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Quantitative Pathology&nbsp;</li> <li>Digital Pathology</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Systematic recordings of observation</li> <li>Objective counts</li> <li>Standard protocol for recording mitotic counts</li> <li>Graphical User Interface in MATLAB</li> </ul> 2020-06-17 2026-04-24 2020-06-17 2026-04-24 2020-06-17 cell proliferation, COUNTING, ELECTRONIC, MATLAB, Matrix Laboratory, MF, MICROSCOPY, Mitotic Figures, PATHOLOGY, Simpson, SURGICAL False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-06-17 52406769 Prototype 52406769 NCI 37470483 Website Abstract E-038-2019 147162267 Wei BR, et al. Agreement in Histological Assessment of Mitotic Activity Between Microscopy and Digital Whole Slide Images Informs Conversion for Clinical Diagnosis. https://pubmed.ncbi.nlm.nih.gov/31321298/ <a href="https://pubmed.ncbi.nlm.nih.gov/31321298/">Wei BR, et al. Agreement in Histological Assessment of Mitotic Activity Between Microscopy and Digital Whole Slide Images Informs Conversion for Clinical Diagnosis.</a> 147163824 Simpson, Robert NIH - NCI NCI Simpson, Robert (NCI) 1 147163823 Puri, Munish NIH - NCI NCI Puri, Munish (NCI) 2 147163822 Hewitt, Stephen NIH - NCI NCI Hewitt, Stephen (NCI) 3 147163824 Simpson, Robert NIH - NCI NCI Simpson, Robert (NCI) 1 147163823 Puri, Munish NIH - NCI NCI Puri, Munish (NCI) 2 147163822 Hewitt, Stephen NIH - NCI NCI Hewitt, Stephen (NCI) 3 147157983 Electronic Counting Application For Surgical Pathology E-097-2019-0 Research Material NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4186] Mitotic Figures Electronic Counting Application for Surgical Pathology&body=Please send me information about technology [TAB-4186] Mitotic Figures Electronic Counting Application for Surgical Pathology.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4186] Mitotic Figures Electronic Counting Application for Surgical Pathology&body=Please send me information about technology [TAB-4186] Mitotic Figures Electronic Counting Application for Surgical Pathology.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147171373 cell proliferation 147171374 COUNTING 147171375 ELECTRONIC 147171376 MATLAB 147171378 Matrix Laboratory 147171379 MF 147171380 MICROSCOPY 147171382 Mitotic Figures 147171383 PATHOLOGY 147171384 Simpson 147171385 SURGICAL TAB-4108 147157390 Automated Cancer Diagnostic Tool of Detecting, Quantifying and Mapping Mitotically-Active Proliferative Cells in Tumor Tissue Histopathology Whole-Slide Images NCI Collaboration, Licensing, Oncology, Software / Apps Collaboration Licensing Oncology Software / Apps Stephen Hewitt, Shelley Hoover, Munish Puri, Robert Simpson <h2>Summary:</h2> <p>The National Cancer Institute (NCI) <a href="https://ccr.cancer.gov/Laboratory-of-Pathology" rel="nofollow" target="_blank">Laboratories of Pathology</a> and <a href="https://ccr.cancer.gov/Laboratory-of-Cancer-Biology-and-Genetics" rel="nofollow" target="_blank">Cancer Biology and Genetics</a> are seeking parties interested in licensing and/or partnering in co-development research of a software tool for commercialization in the field of clinical immunohistochemistry quantification.</p> <h2>Description of Technology:</h2> <p>Cancer diagnosis is based on the assessment of patient biopsies to determine the tumor type, grade, and stage of malignancy. The proliferative potential of tumors correlates to their growth and metastasis. Visually identifying and quantifying mitotic figures (MF) in cancer biopsy tissue can be used as a surrogate for proliferative activity in tumors. The manual examination and quantification of stained tissue sections to determine tumor areas with the greatest number of MF, known as mitotic hotspots (HS), is subjective because the current method of assessment is based on the skill of the examining pathologist. In addition, the method used to determine HS is tedious, time-consuming, and error prone due to inter- and intra-observer variability. A newly developed technology addresses the issue of standardizing the assessment of tumor cell proliferation, yielding a diagnostic tool improves medical decision making and diagnostic precision.</p> <p>This software tool identifies all tumor cell proliferating areas, maps foci in relation to the tumor tissue, and quantifies the proliferating cells for grading purposes. It provides MF metrics as a surrogate for tumor proliferative activity while also providing topographic information on HS locations. This new technology is a major improvement over current methods that use visual inspection and counting, which can result in the inclusion of erroneous findings during cancer grading. The software uses a computational approach by processing digital whole slide images (WSI) to render image grid tiles to extract immunolabeled MF and map the HS&rsquo;s topographically to the tissue section of the WSI. This technology has demonstrated highly reproducibility unaffected by diagnostic skill level or work-fatigue. The automated approach represents a technology that requires minimal computational operations on image tile-based processing &ndash; while providing low complexity and enhancements in determining HS.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Clinical immunohistochemistry quantification for improved cancer diagnosis</li> <li>Analytic software for improved cancer diagnosis</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Computation approach to process whole slide images</li> <li>High reproducibility, unaffected by diagnostic skill level or fatigue</li> <li>Low complexity and enhancements in determining mitotic hotspots</li> </ul> 2020-06-17 2026-04-24 2020-06-17 2026-04-24 2020-06-17 Cancer Biopsy, diagnostic, Hewitt, HS, IHC, Immunohistochemistry, MF, Mitotic Figure, Mitotic Hotspots, Simpson, Tissue Histopathology False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-06-17 52406769 Prototype 52406769 NCI 37470483 Website Abstract E-097-2019 147161947 Puri M, et al. Automated Computational Detection, Quantitation, and Mapping of Mitosis in Whole-Slide Images for Clinically Actionable Surgical Pathology Decision Support. https://pubmed.ncbi.nlm.nih.gov/30915258/ <a href="https://pubmed.ncbi.nlm.nih.gov/30915258/">Puri M, et al. Automated Computational Detection, Quantitation, and Mapping of Mitosis in Whole-Slide Images for Clinically Actionable Surgical Pathology Decision Support.</a> 147163537 Simpson, Robert NIH - NCI NCI Simpson, Robert (NCI) 1 147163535 Hewitt, Stephen NIH - NCI NCI Hewitt, Stephen (NCI) 2 147163538 Hoover, Shelley NCI - CCR NCI Hoover, Shelley (NCI) 3 147163536 Puri, Munish NIH - NCI NCI Puri, Munish (NCI) 4 147163537 Simpson, Robert NIH - NCI NCI Simpson, Robert (NCI) 1 147163535 Hewitt, Stephen NIH - NCI NCI Hewitt, Stephen (NCI) 2 147163538 Hoover, Shelley NCI - CCR NCI Hoover, Shelley (NCI) 3 147163536 Puri, Munish NIH - NCI NCI Puri, Munish (NCI) 4 147157839 Automated Cancer Diagnostic Tool For Detecting, Quantifying And Mapping Mitotically-active Proliferative Cells In Tumor Tissue Histopathology Whole-slide Images E-038-2019-0 Research Material NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4108] Automated Cancer Diagnostic Tool of Detecting, Quantifying and Mapping Mitotically-Active Proliferative Cells in Tumor Tissue Histopathology Whole-Slide Images&body=Please send me information about technology [TAB-4108] Automated Cancer Diagnostic Tool of Detecting, Quantifying and Mapping Mitotically-Active Proliferative Cells in Tumor Tissue Histopathology Whole-Slide Images.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4108] Automated Cancer Diagnostic Tool of Detecting, Quantifying and Mapping Mitotically-Active Proliferative Cells in Tumor Tissue Histopathology Whole-Slide Images&body=Please send me information about technology [TAB-4108] Automated Cancer Diagnostic Tool of Detecting, Quantifying and Mapping Mitotically-Active Proliferative Cells in Tumor Tissue Histopathology Whole-Slide Images.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147169983 Cancer Biopsy 147169984 diagnostic 147169986 Hewitt 147169988 HS 147169989 IHC 147169990 Immunohistochemistry 147169992 MF 147169994 Mitotic Figure 147169996 Mitotic Hotspots 147169998 Simpson 147170000 Tissue Histopathology TAB-4413 147157708 Small Molecule Inhibitors of Histone Demethylases for Treating Rhabdomyosarcoma (RMS) and Other Cancers NCI Collaboration, Licensing, Neurology, Oncology, Therapeutics Collaboration Licensing Neurology Oncology Therapeutics Robert Hawley, Javed Khan, Megan Peach, Girma Woldemichael <h2>Description of Technology:</h2> <p>Rhabdomyosarcoma (RMS) is the most common type of soft tissue sarcoma in children and makes up 3% of all childhood cancers. Aveloar Rhabdomyosarcoma is the most aggressive subtype and is primarily established through a chromosomal translocation resulting in the fusion protein PAX3-FOXO1. Despite aggressive therapy, the 5-year survival rate for patients with high risk or recurrent Fusion Positive RMS (FP-RMS) is low (~30% and ~17%, respectively). Therefore, new therapies targeting the PAX3-FOXO1 oncogenic driver are urgently needed.&nbsp;&nbsp;</p> <p>To identify inhibitors of PAX3-FOXO1, scientists at the National Cancer Institute (NCI) developed a novel cell-based reporter assay of PAX3-FOXO1 activity. Using this system NCI scientists screened a 62,643 small molecule chemical library and found compounds with unknown function that disrupt PAX3-FOXO1 activity. Further studies of these compounds showed that they were inhibitors of histone lysine demethylases (KDMs), with enhanced selectivity for KDM3B. Treatment of RMS cell lines with these compounds resulted in cytotoxicity and apoptosis, highlighting their potential as therapeutics for RMS. These compounds were also found to be cytotoxic to other sarcoma cell lines, such as Ewing&rsquo;s sarcoma and osteosarcoma. Screening of the NCI-60 cancer cell panel with one of these compounds resulted in growth inhibition of a range of cancer cell types, including leukemias, CNS cancers, melanoma, prostate cancer, colon cancer, ovarian cancers, breast cancers, and renal caners. In the case of renal cancer, treatment resulted in growth inhibition followed by cell death. Thus, these compounds may be effective therapeutics for a variety of cancers outside of RMS.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic for Rhabdomyosarcoma and other cancers &ndash; including, but perhaps not limited to: <ul> <li>breast cancer</li> <li>melanoma</li> <li>leukemias</li> <li>prostate cancer</li> <li>colon cancer</li> <li>renal cancer</li> </ul> </li> <li>Therapeutic for diseases involving aberrant histone lysine methylation, such as neurodevelopmental disorders&nbsp;&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>First-in-class inhibitors of the histone lysine demethylase KDM3B</li> <li>The ability of the compounds to target multiple histone demethylases (KDMs) has two main advantages: 1) may upregulate myogenesis and apoptosis, while at the same time downregulating PAX3-FOXO1 oncogenic targets, and 2) may reduce the frequency of acquired drug resistance resulting from the acquisition of mutations in a single therapeutic KDM target&nbsp;&nbsp;</li> </ul> 2020-06-08 2026-04-24 2022-05-11 2026-04-24 2020-06-08 Histone Lysine Demethylases, KDM3B, KDM3B inhibitors, KDMs, Khan, Lysine Demethylase 3B, PAX3-FOXO1, Rhabdomyosarcoma, RMS False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-05-11 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147164652 Khan, Javed NIH - NCI NCI Khan, Javed (NCI) 1 147164653 Hawley, Robert NIH - NCI Hawley, Robert 2 147164654 Peach, Megan NIH - NCI Leidos Peach, Megan (Leidos) 3 147164655 Woldemichael, Girma NIH - NCI Leidos Woldemichael, Girma (Leidos) 4 147164652 Khan, Javed NIH - NCI NCI Khan, Javed (NCI) 1 147164653 Hawley, Robert NIH - NCI Hawley, Robert 2 147164654 Peach, Megan NIH - NCI Leidos Peach, Megan (Leidos) 3 147164655 Woldemichael, Girma NIH - NCI Leidos Woldemichael, Girma (Leidos) 4 147157810 Identification Of A Novel Inhibitor Of The Jumonji Family Of Histone Lysine Demethylases That Disrupts The PAX3-FOXO1 Oncogenic Circuitry In Alveolar Rhabdomyosarcoma E-023-2019-0 Filing authorized NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4413] Small Molecule Inhibitors of Histone Demethylases for Treating Rhabdomyosarcoma (RMS) and Other Cancers&body=Please send me information about technology [TAB-4413] Small Molecule Inhibitors of Histone Demethylases for Treating Rhabdomyosarcoma (RMS) and Other Cancers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4413] Small Molecule Inhibitors of Histone Demethylases for Treating Rhabdomyosarcoma (RMS) and Other Cancers&body=Please send me information about technology [TAB-4413] Small Molecule Inhibitors of Histone Demethylases for Treating Rhabdomyosarcoma (RMS) and Other Cancers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147160918 E-023-2019-0 E-023-2019-0-US-01 INHIBITORS OF HISTONE DEMETHYLASES PRV US 62/936,722 Abandoned US <br />Provisional (PRV) 62/936,722<br />Filed on 2019-11-18<br />Status: Abandoned 147168776 E-023-2019-0 E-023-2019-0-PCT-02 INHIBITORS OF HISTONE DEMETHYLASES (PFI-63 AND PFI-90) FOR THE TREATMENT OF CANCER AND FOR THE INHIBITION OF HISTONE DEMETHYLASE IN CELLS PCT Patent Cooperation Treaty PCT/US2020/060955 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/060955<br />Filed on 2020-11-18<br />Status: Expired 147168777 E-023-2019-0 E-023-2019-0-CA-03 INHIBITORS OF HISTONE DEMETHYLASES (PFI-63 AND PFI-90) FOR THE TREATMENT OF CANCER AND FOR THE INHIBITION OF HISTONE DEMETHYLASE IN CELLS National Stage Canada 3158557 Pending Canada <br />National Stage 3158557<br />Filed on 2022-05-16<br />Status: Pending 147168778 E-023-2019-0 E-023-2019-0-EP-04 INHIBITORS OF HISTONE DEMETHYLASES (PFI-63 AND PFI-90) FOR THE TREATMENT OF CANCER AND FOR THE INHIBITION OF HISTONE DEMETHYLASE IN CELLS National Stage European Patent 4061366 20824760.1 Issued European Patent <br />National Stage 20824760.1<br />Filed on 2022-06-17<br />Status: Issued 147168779 E-023-2019-0 E-023-2019-0-US-05 INHIBITORS OF HISTONE DEMETHYLASES (PFI-63 AND PFI-90) FOR THE TREATMENT OF CANCER AND FOR THE INHIBITION OF HISTONE DEMETHYLASE IN CELLS National Stage US 17/777,552 Pending US <br />National Stage 17/777,552<br />Filed on 2022-05-17<br />Status: Pending 147169672 Histone Lysine Demethylases 147169674 KDM3B 147169676 KDM3B inhibitors 147169678 KDMs 147169680 Khan 147169682 Lysine Demethylase 3B 147169683 PAX3-FOXO1 147169684 Rhabdomyosarcoma 147169686 RMS TAB-4260 147157547 Inducible Activation Nucleic Acid Hybrid Switch for Conditional Generation of Oligonucleotides NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Bruce Shapiro, Paul Zakrevsky <h2>Summary:</h2> <p>The NCI is looking for innovative companies interested in co-developing and/or licensing a&nbsp;novel nucleic-based therapy based on the conditional activation strategy.</p> <h2>Description of Technology:</h2> <p>Gene therapy research has yielded FDA-approved treatments for an array of diseases. However, challenges facing nucleic-acid based therapeutics include non-specific delivery and degradation of the nanoparticles. NCI investigators have developed a solution to address these challenges in their novel nucleic-based therapy based on the conditional activation strategy.&nbsp;</p> <p>The inducible activation nucleic acid hybrid switch overcomes the drawbacks of current technologies through its unique design. The implementation of nucleic acid logic elements in these constructs circumvents off-target effects. The functional oligonucleotide constructs would only be generated and activated in environments denoted by the presence or absence of a specific cognate RNA trigger, ensuring context-sensitive function. The systems were also optimized to be resistant to nuclease degradation yet inexpensive for commercial production. Furthermore, this collection of logic-based systems can accommodate different trigger/target sequence pairs, enhancing its diversity of application, and serves as a novel paradigm for conditionally regulated therapeutics against cancer, genetic disorders, or infectious diseases.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Cancer</li> <li>Infectious diseases</li> <li>Genetic disorders&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Resistant to nuclease degradation</li> <li>Specificity of action based on environmental context, minimizing off-target effects</li> <li>Amenable to alterations to accommodate different trigger/target sequence pairs without the need for sequence overlap or similarities&nbsp;</li> <li>A set of context sensitive drugs that separate diagnosis (disease state &ndash; e.g. over or under expression of particular genes) from the therapeutic state (targeting specific genes &ndash; e.g. Dicer substrate RNAs that induce apoptosis)</li> </ul> 2020-05-01 2026-04-24 2021-04-06 2026-04-24 2020-05-01 Conditional Activation, Functional RNA, Gene silencing, In Silico Design, Nanoparticle, Nucleic Acid Therapeutic, RNA, RNA Logic, Shapiro False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-04-06 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-039-2012 E-059-2009 E-075-2018 E-078-2016 E-156-2014 E-277-2016 E-765-2013 147162029 Zakrevsky P, et al. A Suite of Therapeutically-Inspired Nucleic Acid Logic Systems for Conditional Generation of Single-Stranded and Double-Stranded Oligonucleotides. https://www.ncbi.nlm.nih.gov/pubmed/30991728 <a href="https://www.ncbi.nlm.nih.gov/pubmed/30991728">Zakrevsky P, et al. A Suite of Therapeutically-Inspired Nucleic Acid Logic Systems for Conditional Generation of Single-Stranded and Double-Stranded Oligonucleotides.</a> 147164086 Shapiro, Bruce NIH - NCI NCI Shapiro, Bruce (NCI) 1 147164087 Zakrevsky, Paul NIH - NCI NCI Zakrevsky, Paul (NCI) 2 147164086 Shapiro, Bruce NIH - NCI NCI Shapiro, Bruce (NCI) 1 147164087 Zakrevsky, Paul NIH - NCI NCI Zakrevsky, Paul (NCI) 2 147157911 Inducible Activation Nucleic Acid Hybrid Switch E-065-2019-0 Filing authorized NCI 83732917 Favila, Michelle michelle.favila@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4260] Inducible Activation Nucleic Acid Hybrid Switch for Conditional Generation of Oligonucleotides&body=Please send me information about technology [TAB-4260] Inducible Activation Nucleic Acid Hybrid Switch for Conditional Generation of Oligonucleotides.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Favila, Michelle<br><a href="mailto:michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4260] Inducible Activation Nucleic Acid Hybrid Switch for Conditional Generation of Oligonucleotides&body=Please send me information about technology [TAB-4260] Inducible Activation Nucleic Acid Hybrid Switch for Conditional Generation of Oligonucleotides.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michelle.favila@nih.gov</a><br> 147160986 E-065-2019-0 E-065-2019-0-US-01 HYBRID NUCLEIC ACID SWITCHES PRV US 62/832,171 Abandoned US <br />Provisional (PRV) 62/832,171<br />Filed on 2019-04-10<br />Status: Abandoned 147167725 E-065-2019-0 E-065-2019-0-PCT-02 HYBRID NUCLEIC ACID SWITCHES PCT Patent Cooperation Treaty PCT/US2020/027637 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/027637<br />Filed on 2020-04-10<br />Status: Expired 147167726 E-065-2019-0 E-065-2019-0-US-03 HYBRID NUCLEIC ACID SWITCHES National Stage US 17/602,204 Pending US <br />National Stage 17/602,204<br />Filed on 2021-10-07<br />Status: Pending 147170647 Conditional Activation 147170649 Functional RNA 147170650 Gene silencing 147170652 In Silico Design 147170653 Nanoparticle 147170655 Nucleic Acid Therapeutic 147170656 RNA 147170658 RNA Logic 147170660 Shapiro TAB-4349 147157642 Induced Pluripotent Stem Cells Derived from Patients with CEP290-associated Ciliopathies and Unaffected Family Members NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Research Materials Collaboration Ear Nose & Throat Licensing Ophthalmology Research Materials Yu Holly Chen, Milton English, Hiroko Shimada-Ishii, Anand Swaroop <h2>Summary:</h2> <p>The National Eye Institute (NEI) seeks research collaborations and/or licensees for the use of iPS cells.</p> <h2>Description of Technology:</h2> <p>Approximately one-third of non-syndromic retinal dystrophies involve a defect in a ciliary protein. Non-syndromic retinal ciliopathies include retinitis pigmentosa, cone dystrophy, cone-rod dystrophy, macular dystrophy, and Leber-congenital amaurosis (LCA). Many CEP290-LCA patients also exhibit auditory and olfactory defects. Induced pluripotent stem cells (iPS) cells were derived from patients with LCA and unaffected relatives.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Screening for agents to treat patients with CEP290-associated ciliopathies such as retinitis pigmentosa, cone dystrophy, cone-rod dystrophy, macular dystrophy, and Leber-congenital amaurosis&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Extensive characterization, including use in making 3-D retinal organoids and optic cup organoids</li> <li>Complement studies with model organisms and examine retinal dystrophies relevant to humans</li> </ul> 2020-04-30 2026-04-24 2020-04-30 2026-04-24 2020-04-30 Anosmia, Cell therapy, Ciliopathies, Congenital Blindness, Drug Development, GENE THERAPY, hearing loss, iPS, National Eye Institute, NEI, Pluripotent Stem Cells, Primary Cilia, Retina, Retinal degeneration, Swaroop, VISION False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-04-30 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-164-2014 147162306 Shimada H, el al. In vitro modeling using ciliopathy patient-derived cells reveals distinct cilia dysfunctions caused by CEP290 mutations https://www.ncbi.nlm.nih.gov/pubmed/28700940 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28700940">Shimada H, el al. In vitro modeling using ciliopathy patient-derived cells reveals distinct cilia dysfunctions caused by CEP290 mutations</a> 147164412 Swaroop, Anand NIH - NEI NEI Swaroop, Anand (NEI) 1 147164414 Shimada-Ishii, Hiroko NIH - NEI Shimada-Ishii, Hiroko 2 147164413 Chen, Yu Holly NIH - NEI NEI Chen, Yu Holly (NEI) 3 147164415 English, Milton NIH - NEI NHGRI English, Milton (NHGRI) 4 147164412 Swaroop, Anand NIH - NEI NEI Swaroop, Anand (NEI) 1 147164414 Shimada-Ishii, Hiroko NIH - NEI Shimada-Ishii, Hiroko 2 147164413 Chen, Yu Holly NIH - NEI NEI Chen, Yu Holly (NEI) 3 147164415 English, Milton NIH - NEI NHGRI English, Milton (NHGRI) 4 147157988 Induced Pluripotent Stem Cells Derived From Patients With CEP290-associated Ciliopathies For Disease Modeling And Development And Relatives Of The Patients E-100-2020-0 Closed National Eye Institute (NEI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4349] Induced Pluripotent Stem Cells Derived from Patients with CEP290-associated Ciliopathies and Unaffected Family Members&body=Please send me information about technology [TAB-4349] Induced Pluripotent Stem Cells Derived from Patients with CEP290-associated Ciliopathies and Unaffected Family Members.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4349] Induced Pluripotent Stem Cells Derived from Patients with CEP290-associated Ciliopathies and Unaffected Family Members&body=Please send me information about technology [TAB-4349] Induced Pluripotent Stem Cells Derived from Patients with CEP290-associated Ciliopathies and Unaffected Family Members.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147171432 Anosmia 147171433 Cell therapy 147171434 Ciliopathies 147171436 Congenital Blindness 147171437 Drug Development 147171438 GENE THERAPY 147171439 hearing loss 147171440 iPS 147171441 National Eye Institute 147171442 NEI 147171444 Pluripotent Stem Cells 147171446 Primary Cilia 147171447 Retina 147171448 Retinal degeneration 147171449 Swaroop 147171450 VISION TAB-5098 166964729 Neutralizing Monoclonal Antibodies Against West Nile Virus NIAID Antibodies, Application, Diagnostics, ResearchProducts, TherapeuticArea, Virus/Bacteria Antibodies Application Diagnostics ResearchProducts TherapeuticArea Virus/Bacteria Katherine Burgomaster, Ananda Chowdhury, Parker Dabbs, Daniel Douek, Kimberly Dowd, David Gordon, Dror Harats, Yaniv Lustig, Yael Ottolenghi, Theodore Pierson, Chaim Schramm, Leonid Serebryannyy, Sarah Smith (Kerscher), Laura Vanblargan, Lu Wang, Yuxiang Wang <p>&nbsp; &nbsp; &nbsp; &nbsp;West Nile virus (WNV) is a mosquito-borne flavivirus that can cause fever and, in some cases, severe neurologic disease. There is no approved human vaccine or specific antiviral treatment for WNV.</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Researchers at NIAID&#39;s Vaccine Research Center (VRC), working with collaborators at Sheba Medical Center under the PREMISE program, identified five new human monoclonal antibodies that potently neutralize WNV. These antibodies bind the viral envelope (E) protein, with data indicating recognition of E dimers or quaternary epitopes on the virion.</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The invention includes compositions comprising the antibodies alone or in combination, nucleic acids encoding them, vectors and host cells for production, and methods for preventing, treating, or detecting WNV infection. The antibodies may be formulated for therapeutic administration, including emergency-use settings, and may also support diagnostic and research applications.</p> <ul> <li> Shown to strongly neutralize WNV at low concentrations in laboratory cell-based studies </li> <li> Novel antibodies with distinct molecular features not previously reported in scientific literature </li> <li> Human monoclonal antibodies targeting E dimer or quaternary epitopes on the WNV virion </li> <li> Potential applications in WNV treatment, diagnostics, and surveillance </li> <li> Collaboration may help speed development to support WNV outbreak response </li> </ul> <ul> <li> Prevention or treatment antibodies for WNV, including use alone or in combination </li> <li> Antibodies that strongly target the WNV E protein </li> <li> Potential treatments for WNV outbreak response and prevention in high-risk populations </li> <li> Genetic and cell-engineering tools for antibody production and product development </li> <li> Antibodies for WNV detection, surveillance, and research tests </li> <li> Potential intravenous treatments for patients with WNV </li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Brian Bailey at 240-669-5128, or bbailey@mail.nih.gov. 2026-04-23 2026-04-24 2026-04-24 2026-04-24 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract E-021-2026-0 166964944 Douek, Daniel National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Douek, Daniel (NIAID) 1 166964948 Schramm, Chaim National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Schramm, Chaim (NIAID) 2 166964953 Chowdhury, Ananda NIAID - VRC Chowdhury, Ananda 3 166964965 Dabbs, Parker NIAID - VRC Dabbs, Parker 4 166965179 Wang, Lu NIAID - VRC Wang, Lu 5 166966485 Serebryannyy, Leonid National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Serebryannyy, Leonid (NIAID) 6 166966491 Pierson, Theodore NIAID - VRC NIAID Pierson, Theodore (NIAID) 7 166966503 Dowd, Kimberly NIAID - VRC NIAID Dowd, Kimberly (NIAID) 8 166966531 Vanblargan, Laura National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Vanblargan, Laura (NIAID) 9 166966539 Burgomaster, Katherine NIAID - VRC NIAID Burgomaster, Katherine (NIAID) 10 166966613 Gordon, David National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Gordon, David (NIAID) 11 166966628 Wang, Yuxiang NIAID - VRC Wang, Yuxiang 12 166966639 Lustig, Yaniv Israel Ministry of Health [IL] Lustig, Yaniv 13 166966661 Ottolenghi, Yael The Sheba Fund for Health Services & Research (Sheba Medical Center) [IL] Ottolenghi, Yael 14 166966666 Harats, Dror Sheba Medical Center Harats, Dror 15 166967476 Smith (Kerscher), Sarah NIAID - VRC NIAID Smith (Kerscher), Sarah (NIAID) 16 166964944 Douek, Daniel National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Douek, Daniel (NIAID) 1 166964948 Schramm, Chaim National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Schramm, Chaim (NIAID) 2 166964953 Chowdhury, Ananda NIAID - VRC Chowdhury, Ananda 3 166964965 Dabbs, Parker NIAID - VRC Dabbs, Parker 4 166965179 Wang, Lu NIAID - VRC Wang, Lu 5 166966485 Serebryannyy, Leonid National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Serebryannyy, Leonid (NIAID) 6 166966491 Pierson, Theodore NIAID - VRC NIAID Pierson, Theodore (NIAID) 7 166966503 Dowd, Kimberly NIAID - VRC NIAID Dowd, Kimberly (NIAID) 8 166966531 Vanblargan, Laura National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Vanblargan, Laura (NIAID) 9 166966539 Burgomaster, Katherine NIAID - VRC NIAID Burgomaster, Katherine (NIAID) 10 166966613 Gordon, David National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Gordon, David (NIAID) 11 166966628 Wang, Yuxiang NIAID - VRC Wang, Yuxiang 12 166966639 Lustig, Yaniv Israel Ministry of Health [IL] Lustig, Yaniv 13 166966661 Ottolenghi, Yael The Sheba Fund for Health Services & Research (Sheba Medical Center) [IL] Ottolenghi, Yael 14 166966666 Harats, Dror Sheba Medical Center Harats, Dror 15 166967476 Smith (Kerscher), Sarah NIAID - VRC NIAID Smith (Kerscher), Sarah (NIAID) 16 166964734 Neutralizing antibodies against West Nile Virus E-200-2024-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID - DIR, NIAID - VRC, NIAID - VRC, Sheba Medical Center, The Sheba Fund for Health Services & Research (Sheba Medical Center) [IL] 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-5098] Neutralizing Monoclonal Antibodies Against West Nile Virus&body=Please send me information about technology [TAB-5098] Neutralizing Monoclonal Antibodies Against West Nile Virus. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-5098] Neutralizing Monoclonal Antibodies Against West Nile Virus&body=Please send me information about technology [TAB-5098] Neutralizing Monoclonal Antibodies Against West Nile Virus.">bbailey@mail.nih.gov</a><br> 166964739 E-200-2024-0 E-200-2024-0-US-01 WEST NILE VIRUS NEUTRALIZING MONOCLONAL ANTIBODIES PRV US 63/677,612 Expired US <br />Provisional (PRV) 63/677,612<br />Filed on 2024-07-31<br />Status: Expired 166964740 E-200-2024-0 E-200-2024-0-PC-01 WEST NILE VIRUS NEUTRALIZING MONOCLONAL ANTIBODIES PCT Patent Cooperation Treaty PCT/US2025/039922 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/039922<br />Filed on 2025-07-30<br />Status: Pending TAB-3947 147157227 EGFRvIII Antibodies for the Treatment of Human Cancer NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Antonella Antignani, David Fitzgerald, Eric Ho, Robert Sarnovsky <h2>Summary:</h2> <p>The NCI seeks research co-development partners or licensees for monoclonal antibodies that specifically target cancer-expressed EGFR.</p> <h2>Description of Technology:</h2> <p>Epidermal growth factor receptor variant III (EGFRvIII) is a variant of EGFR that is an excellent target for immunotherapy because of its expression in cancer cells and not in normal cells.&nbsp;</p> <p>Inventors from the National Cancer Institute (NCI) have isolated seven mouse monoclonal antibodies that bind to the human EGFRvIII but not wildtype EGFR. These EGFRvIII antibodies can be used as either independent agents or targeting domains in recombinant immunotoxins (RITs), antibody-drug conjugates (ADCs), bispecific antibodies, and chimeric antigen receptors (CARs). Significantly, RITs using one of the antibodies (40H3) have shown potent killing in breast cancer cells and in epidermoid cancer cells, strongly supporting that the antibodies may be further developed as therapeutics. The 40H3 antibody is also able to bind to EGFR when overexpressed as seen in various cancers, and thus has broad therapeutic potential.&nbsp; &nbsp;&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic applications include the unconjugated antibodies and their use as a targeting moiety in ADCs, RITs, and CARs</li> <li>Diagnostic agent for detection and monitoring levels of EGFRvIII expressing cancers</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The EGFRvIII antibodies with high EGFRvIII binding specificity will result in less non-specific cell killing and lower potential side effects&nbsp;</li> <li>RITs using the 40H3 antibody are available for immediate testing&nbsp;</li> <li>40H3 can also bind EGFR when over-expressed from amplified EGFR, which is specific to various cancers&nbsp;&nbsp;</li> </ul> 2020-04-28 2026-04-24 2021-03-29 2026-04-24 2020-04-28 ADC, Antibody-drug Conjugate, CAR, chimeric antigen receptor, EGFR, EGFRvIII, Epidermal Growth Factor Receptor, Epidermal growth factor receptor variant III, FitzGerald, Recombinant Immunotoxins, RITs False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-03-29 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162975 Fitzgerald, David NIH - NCI NCI Fitzgerald, David (NCI) 1 147162976 Antignani, Antonella NIH - NCI NCI Antignani, Antonella (NCI) 2 147162977 Ho, Eric NIH - NCI NCI Ho, Eric (NCI) 3 147162978 Sarnovsky, Robert NIH - NCI NCI Sarnovsky, Robert (NCI) 4 147162975 Fitzgerald, David NIH - NCI NCI Fitzgerald, David (NCI) 1 147162976 Antignani, Antonella NIH - NCI NCI Antignani, Antonella (NCI) 2 147162977 Ho, Eric NIH - NCI NCI Ho, Eric (NCI) 3 147162978 Sarnovsky, Robert NIH - NCI NCI Sarnovsky, Robert (NCI) 4 147157993 Monoclonal Antibodies To Cancer-expressed EGFR E-103-2019-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3947] EGFRvIII Antibodies for the Treatment of Human Cancer&body=Please send me information about technology [TAB-3947] EGFRvIII Antibodies for the Treatment of Human Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3947] EGFRvIII Antibodies for the Treatment of Human Cancer&body=Please send me information about technology [TAB-3947] EGFRvIII Antibodies for the Treatment of Human Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161043 E-103-2019-0 E-103-2019-0-US-01 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE PRV US 62/869,956 Abandoned US <br />Provisional (PRV) 62/869,956<br />Filed on 2019-07-02<br />Status: Abandoned 147165483 E-103-2019-0 E-103-2019-0-PCT-02 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE PCT Patent Cooperation Treaty PCT/US2020/040544 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/040544<br />Filed on 2020-07-01<br />Status: Expired 147165484 E-103-2019-0 E-103-2019-0-AU-03 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage Australia 2020299382 Pending Australia <br />National Stage 2020299382<br />Filed on 2020-07-01<br />Status: Pending 147165485 E-103-2019-0 E-103-2019-0-CA-04 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage Canada 3142833 Pending Canada <br />National Stage 3142833<br />Filed on 2020-07-01<br />Status: Pending 147165486 E-103-2019-0 E-103-2019-0-CN-05 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage China ZL202080055447.2 202080055447.2 Issued China <br />National Stage 202080055447.2<br />Filed on 2020-07-01<br />Status: Issued 147165487 E-103-2019-0 E-103-2019-0-EP-06 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage European Patent 20745396.0 Pending European Patent <br />National Stage 20745396.0<br />Filed on 2020-07-01<br />Status: Pending 147165488 E-103-2019-0 E-103-2019-0-US-07 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage US 12,565,532 17/623,370 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12565532 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12565532">12,565,532</a><br />Filed on 2021-12-28<br />Status: Issued 147165489 E-103-2019-0 E-103-2019-0-IL-08 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage Israel 289488 Abandoned Israel <br />National Stage 289488<br />Filed on 2020-07-01<br />Status: Abandoned 147165490 E-103-2019-0 E-103-2019-0-IN-09 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage India 202217002368 Pending India <br />National Stage 202217002368<br />Filed on 2020-07-01<br />Status: Pending 147165491 E-103-2019-0 E-103-2019-0-JP-10 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage Japan 7815099 2022-500090 Issued Japan <br />National Stage 2022-500090<br />Filed on 2020-07-01<br />Status: Issued 147165492 E-103-2019-0 E-103-2019-0-KR-11 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage South Korea 10-2022-7003667 Abandoned South Korea <br />National Stage 10-2022-7003667<br />Filed on 2020-07-01<br />Status: Abandoned 147165493 E-103-2019-0 E-103-2019-0-MX-12 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage Mexico MX/a/2022/000174 Pending Mexico <br />National Stage MX/a/2022/000174<br />Filed on 2020-07-01<br />Status: Pending 147165495 E-103-2019-0 E-103-2019-0-SG-14 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage Singapore 11202114486Y Abandoned Singapore <br />National Stage 11202114486Y<br />Filed on 2020-07-01<br />Status: Abandoned 147165496 E-103-2019-0 E-103-2019-0-EA-15 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage Eurasian Patent 202290208 Abandoned Eurasian Patent <br />National Stage 202290208<br />Filed on 2020-07-01<br />Status: Abandoned 147165497 E-103-2019-0 E-103-2019-0-HK-16 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE CN Hong Kong 62022061195.3 Pending Hong Kong <br />China Patent (CN) 62022061195.3<br />Filed on 2022-09-26<br />Status: Pending 147171479 ADC 147171480 Antibody-drug Conjugate 147171481 CAR 147171482 chimeric antigen receptor 147171483 EGFR 147171484 EGFRvIII 147171485 Epidermal Growth Factor Receptor 147171487 Epidermal growth factor receptor variant III 147171489 FitzGerald 147171490 Recombinant Immunotoxins 147171491 RITs TAB-4375 147157669 Peptide Hydrogels for Rate-Controlled Delivery of Therapeutics NCI Collaboration, Immunology, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Immunology Infectious Disease Licensing Oncology Therapeutics Caroline Andrews, Julie Hixon, Wenqing Li, Stephen Miller, Joel Schneider, Steven Tau, Scott Walsh, Yuji Yamada <h2>Description of Technology:</h2> <p>Hydrogels represent an attractive controlled drug-delivery system that have been used in various clinical applications, such as: tissue engineering for wound healing, surgical procedures, pain management, cardiology, and oncology. High-water content of hydrogels confers tissue-like physical properties and the crosslinked fibrillar network enables encapsulation of labile small molecule drugs, peptides, proteins, nucleic acids, proteins, nanoparticles, or cells. The porosity of the mesh-like network contributes to enhanced protection and controlled release of therapeutics compared with the rapid clearance and degradation of some proteins observed using conventional drug-delivery methods. Although all hydrogel platforms provide spatial and temporal control over the release of therapeutics, the current standard requires designing a unique hydrogel for a select therapeutic agent for a specific application. This one therapeutic agent-one gel model adds significant research and regulatory burden.</p> <p>To address this, researchers at the National Cancer Institute (NCI) developed a novel syringe-injectable/sprayable hydrogel platform that can deliver a variety of different therapeutic agents. This hydrogel can be used to deliver small molecules, peptides, proteins, nucleic acids, nanoparticles, or cells.&nbsp; Further, this hydrogel has been engineered to be compatible with a protein delivery platform invented at the NCI. This tunable combination system enables the release of different kinds of proteins based on the electrostatic interaction between the fusion sequence engineered directly at the amino- or carboxy-terminus of proteins and the anionic fibrillar network of the hydrogel AcVES3. In a proof-of-concept study, NCI researchers have delivered a cytokine protein, IL-7, a therapeutic agent critical for improving T cell development for immunotherapy in cancer, sepsis, and HIV-infected patients. Administration of a single dose of IL-7 encapsulated within AcVES3 was shown to exhibit comparable development of T cell populations compared to soluble IL-7 added every 3 days in vitro and to daily subcutaneous IL-7 injections for greater than 30 days in vivo. Thus, this hydrogel platform can reduce the amount of protein needed to attain desired endpoints and potentially reduce patient burden for targeted therapies.</p> <p>Furthermore, the AcVES3 platform can be used to culture cells in 2D and 3D environments and deliver these cells as potential therapeutic agents. NCI researchers conducted murine studies to culture and deliver fluorescently labeled human dermal fibroblasts encapsulated in AcVES3-RGDV hydrogel at high cellular concentrations. Stem and cancer cells can be also be grown within the 3D AcVES3 hydrogel environment; instead of the commonly used murine-derived Matrigel reagent and subsequently these cells may be injected in vivo, even into larger scale animal models such as non-human primates. These proof-of-concept studies suggest that the AcVES3 platform can be used to encapsulate an appropriate number of cells of interest over time in vivo for therapeutic applications. Overall, the AcVES3 platform is a promising hydrogel system that is applicable for numerous non-clinical and clinical applications.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Cancer &ndash; especially those involving therapeutic whole cells &ndash; such as stem cells, T cells, CAR T cells for cancer therapy and/or fibroblasts</li> <li>Sepsis &ndash; especially when boosting T cell levels is effective</li> <li>HIV</li> <li>Autoimmune disorders &ndash; especially to modulate T cell populations</li> <li>Transplantation</li> <li>Delivering viruses for gene therapy or oncolytic viruses for cancer therapy</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Rate-controlled release of therapeutic drugs including small molecules, nucleic acids, peptides, proteins, or nanoparticles: therapeutic drugs encapsulated in the anionic hydrogel platform&nbsp;</li> <li>Rate-controlled release of therapeutic whole cells: such as stem cells, T cells, CAR T cells for cancer therapy and/or fibroblasts</li> <li>T cell enhancer for in vitro and in clinical setting: stimulating T cells in cultures, essential in adoptive T cell therapy, cancer and HIV-immunotherapy, boosting T cell levels in sepsis patients, and modulating T cell populations in autoimmune diseases</li> <li>Delivers locally or systemically a variety of different therapeutic drugs including small molecule, peptides, proteins, nucleic acids, nanoparticles, or cells</li> <li>Reduces the amount of drugs or cells needed to attain desirable clinical results&nbsp;</li> <li>Reduces the patient burden from multiple injections and travel time to the clinic</li> <li>Offers targeted syringe or catheter injectable delivery or sprayable delivery</li> <li>Is a tunable delivery platform that can attenuate peptide or protein release rate within hydrogel</li> </ul> 2020-04-20 2026-04-24 2020-04-20 2026-04-24 2020-04-20 DEVICE, IL-7, Nanoparticle, Peptide, Peptide-based Hydrogel, Protein, Schneider, small molecule, T Cell Enhancer, Whole Cell Delivery System False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-04-20 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161969 Yamada Y, et al. Design of a peptide-based electronegative hydrogel for the direct encapsulation, 3D culturing, in vivo syringe-based delivery, and long-term tissue engraftment of cells. https://www.ncbi.nlm.nih.gov/pubmed/?term=31448901 <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31448901">Yamada Y, et al. Design of a peptide-based electronegative hydrogel for the direct encapsulation, 3D culturing, in vivo syringe-based delivery, and long-term tissue engraftment of cells.</a> 147162356 Miller SE, et al. Electrostatically driven guanidinium interaction domains that control hydrogel-mediated protein delivery in vivo. https://www.ncbi.nlm.nih.gov/pubmed/?term=31807676 <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31807676">Miller SE, et al. Electrostatically driven guanidinium interaction domains that control hydrogel-mediated protein delivery in vivo.</a> 147164499 Schneider, Joel NIH - NCI NCI Schneider, Joel (NCI) 1 147164500 Miller, Stephen NIH - NCI NCI Miller, Stephen (NCI) 2 147164501 Yamada, Yuji NIH - NCI NCI Yamada, Yuji (NCI) 3 147164502 Tau, Steven NIH - NCI NCI Tau, Steven (NCI) 4 147164503 Hixon, Julie NIH - NCI NCI Hixon, Julie (NCI) 6 147164504 Li, Wenqing NIH - NCI NCI Li, Wenqing (NCI) 7 147164506 Andrews, Caroline NIH - NCI NCI Andrews, Caroline (NCI) 8 147164505 Walsh, Scott NIH - NCI NCI Walsh, Scott (NCI) 9 147164499 Schneider, Joel NIH - NCI NCI Schneider, Joel (NCI) 1 147164500 Miller, Stephen NIH - NCI NCI Miller, Stephen (NCI) 2 147164501 Yamada, Yuji NIH - NCI NCI Yamada, Yuji (NCI) 3 147164502 Tau, Steven NIH - NCI NCI Tau, Steven (NCI) 4 147164503 Hixon, Julie NIH - NCI NCI Hixon, Julie (NCI) 6 147164504 Li, Wenqing NIH - NCI NCI Li, Wenqing (NCI) 7 147164506 Andrews, Caroline NIH - NCI NCI Andrews, Caroline (NCI) 8 147164505 Walsh, Scott NIH - NCI NCI Walsh, Scott (NCI) 9 147158178 Controlling The Rate Of Protein Release From Peptide Hydrogels Using Engineered Electrostatic Interactions E-188-2017-0 Filing authorized NCI 147162556 Controlling The Rate Of Protein Release From Peptide Hydrogels Using Engineered Electrostatic Interactions E-188-2017-1 Filing authorized NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4375] Peptide Hydrogels for Rate-Controlled Delivery of Therapeutics&body=Please send me information about technology [TAB-4375] Peptide Hydrogels for Rate-Controlled Delivery of Therapeutics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4375] Peptide Hydrogels for Rate-Controlled Delivery of Therapeutics&body=Please send me information about technology [TAB-4375] Peptide Hydrogels for Rate-Controlled Delivery of Therapeutics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161170 E-188-2017-1 E-188-2017-1-PCT-01 PEPTIDE HYDROGELS AND USE THEREOF PCT Patent Cooperation Treaty PCT/US2017/066893 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/066893<br />Filed on 2017-12-17<br />Status: Expired 147168524 E-188-2017-1 E-188-2017-1-US-02 PEPTIDE HYDROGELS AND USE THEREOF National Stage US 11,661,439 16/954,492 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11661439 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11661439">11,661,439</a><br />Filed on 2020-06-16<br />Status: Issued 147173348 DEVICE 147173349 IL-7 147173350 Nanoparticle 147173351 Peptide 147173353 Peptide-based Hydrogel 147173354 Protein 147173355 Schneider 147173356 small molecule 147173358 T Cell Enhancer 147173360 Whole Cell Delivery System TAB-4350 147157643 A Novel Genetically Encoded Inhibitor of Hippo Signaling Pathway to Study YAP1/TAZ-TEAD Dependent Events in Cancer NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Ramiro Iglesias-Bartolome, Yao Yuan <h2>Summary:</h2> <p>The NCI Laboratory of Cellular and Molecular Biology seeks statements of capability or interest from parties interested in licensing this novel inhibitor of the Hippo signaling pathway.</p> <h2>Description of Technology:</h2> <p>The Hippo signaling pathway regulates a multitude of biological processes including cell proliferation, apoptosis, differentiation, tissue homeostasis, and stem cell functions. This axis has been recently listed as one of the top 10 signaling pathways altered in human cancer. Its role in modulating cell growth and proliferation is mediated by the activation of Yes-associated protein 1 (YAP1) and transcriptional co-activator with PDZ-binding domain (TAZ). Under low cell density conditions, YAP1/TAZ translocate to the nucleus, bind to various transcription factors including TEA domain (TEAD) family of transcription factors, and drive the expression of genes associated with cell proliferation and differentiation. If hyperactivated due to disruptions in the Hippo pathway, this upregulation in gene transcription leads to uncontrolled cell growth, transformation, and cancer development.</p> <p>Research into the Hippo pathway is limited due to technical difficulties in the precise study of the transcriptional networks downstream of YAP1 and TAZ. For example, simultaneous downregulation of YAP1 and TAZ is needed to observe an effect on cancer progression. Furthermore, there are numerous effectors to the Hippo pathway, not limited to transcription factors. To overcome these difficulties, researchers at the National Cancer Institute (NCI) have developed a genetically encoded, fluorescently labeled peptide inhibitor of YAP1/TAZ which specifically targets its interactions with TEADs (named TEAD-inhibitor or TEADi). TEADi consists of various TEAD binding domains, including those of YAP1 and TAZ, modified for efficient inhibition. Using this inhibitor, NCI researchers have studied the functions of the Hippo pathway in the epidermis and in squamous cell carcinoma.&nbsp;NCI is continuing to develop this inhibitor to improve its stability and potency.</p> <p>Considering that the Hippo pathway constitutes one of the top signaling pathways altered in human cancer, disruption of YAP1/TAZ-TEAD complexes has become a main target to suppress oncogenic activity. TEADi can be used to dissect the TEAD-dependent and independent roles of YAP1/TAZ signaling and aid in the discovery of improved targeting strategies for this pathway. In conclusion, TEADi is a valuable research tool for studying YAP1/TAZ and the Hippo pathway in cancer and other pathologies, with improved advantages that include rapid and simple inhibition of TEAD transcription and specific blockage of nuclear events mediated by both YAP1 and TAZ without affecting structural or cytoplasmic functions of these proteins. NCI is continuing to develop this inhibitor to improve its stability and potency.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>TEADi DNA construct to study Hippo signaling pathway in different pathologies and cellular systems.</li> <li>TEADi DNA construct to selectively shut off Hippo signaling pathway for broader research purposes</li> <li>Delivery of TEADi DNA construct using lentivirus, adenovirus (AV), or adeno-associated virus (AAV) for broad research purposes</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Rapid and simple inhibition of specific effectors of a signaling pathway frequently disrupted in cancer</li> <li>Inhibition of both YAP1 and TAZ factors that regulate the Hippo pathway</li> <li>Inhibition of YAP/TAZ interaction with a specific family of transcription factors</li> <li>Green fluorescent protein (GFP) label for easy tracking</li> <li>Nuclear localization signal to target hyperactivated YAP/TAZ</li> </ul> 2020-04-02 2026-04-24 2021-03-10 2026-04-24 2020-04-02 Cancer Progression, Hippo Signaling Pathway, Iglesias-Bartolome, Peptide Inhibitor, TAZ, TEAD, YAP1, Yes-Associated Protein 1 False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-03-10 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162268 Yuan Y, et al. YAP1/TAZ-TEAD transcriptional networks maintain skin homeostasis by regulating cell proliferation and limiting KLF4 activity. https://pubmed.ncbi.nlm.nih.gov/32193376/ <a href="https://pubmed.ncbi.nlm.nih.gov/32193376/">Yuan Y, et al. YAP1/TAZ-TEAD transcriptional networks maintain skin homeostasis by regulating cell proliferation and limiting KLF4 activity.</a> 147162421 Yuan Y, et al. YAP1-TAZ/TEAD transcriptional networks restrain differentiation downstream of oncogenic Hedgehog-SMO activity. https://www.biorxiv.org/content/10.1101/2020.12.28.424593v1 <a href="https://www.biorxiv.org/content/10.1101/2020.12.28.424593v1">Yuan Y, et al. YAP1-TAZ/TEAD transcriptional networks restrain differentiation downstream of oncogenic Hedgehog-SMO activity.</a> 147164417 Iglesias-Bartolome, Ramiro NIH - NCI NCI Iglesias-Bartolome, Ramiro (NCI) 1 147164416 Yuan, Yao NIH - NCI Yuan, Yao 2 147164417 Iglesias-Bartolome, Ramiro NIH - NCI NCI Iglesias-Bartolome, Ramiro (NCI) 1 147164416 Yuan, Yao NIH - NCI Yuan, Yao 2 147158004 Peptide Inhibitors Of YAP1/TAZ-TEAD E-108-2019-0 Closed NCI 90072936 Mistry, Pragnesh pragnesh.mistry@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
HNH6Z08 pragnesh.mistry@nih.gov?subject=Web Inquiry on [TAB-4350] A Novel Genetically Encoded Inhibitor of Hippo Signaling Pathway to Study YAP1/TAZ-TEAD Dependent Events in Cancer&body=Please send me information about technology [TAB-4350] A Novel Genetically Encoded Inhibitor of Hippo Signaling Pathway to Study YAP1/TAZ-TEAD Dependent Events in Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Mistry, Pragnesh<br><a href="mailto:pragnesh.mistry@nih.gov?subject=Web Inquiry on [TAB-4350] A Novel Genetically Encoded Inhibitor of Hippo Signaling Pathway to Study YAP1/TAZ-TEAD Dependent Events in Cancer&body=Please send me information about technology [TAB-4350] A Novel Genetically Encoded Inhibitor of Hippo Signaling Pathway to Study YAP1/TAZ-TEAD Dependent Events in Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">pragnesh.mistry@nih.gov</a><br> 147171585 Cancer Progression 147171587 Hippo Signaling Pathway 147171589 Iglesias-Bartolome 147171590 Peptide Inhibitor 147171592 TAZ 147171594 TEAD 147171596 YAP1 147171598 Yes-Associated Protein 1 TAB-4157 147157440 T-Cell Therapy Against Patient-Specific Cancer Mutations NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Yong-Chen Lu, Paul Robbins, Steven Rosenberg, Eric Tran <h2>Description of Technology:</h2> <p>Human cancers contain genetic mutations that are unique to each patient. Some of the mutated peptides are immunogenic, can be recognized by T cells, and therefore, may serve as therapeutic targets.</p> <p>Scientists at the <a href="https://ccr.cancer.gov/Surgery-Branch" rel="nofollow" target="_blank">National Cancer Institute&#39;s Surgery Branch</a> developed a method to identify T cells that specifically recognize immunogenic mutations expressed only by cancer cells. The scientists identified cancer-specific mutations from a patient with widely metastatic cholangiocarcinoma by sequencing tumor samples and comparing with normal cells. Using tandem minigene constructs encoding all of the mutations expressed by a patient&#39;s tumor, the inventors identified T cells that recognized the immunogenic mutations from the same patient. These mutation-reactive T cells have the potential to eliminate the cancer cells while sparing normal tissues since normal tissues do not express the mutations. The mutation-reactive T cells were expanded <em>in vitro</em>, and then infused as a highly pure population back into the same patient. The patient experienced tumor regression when treated with this approach.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Personalized immunotherapy with mutation-reactive T cells for mediating tumor regression in patients with immunogenic mutations;</li> <li>Mutation-reactive T cell therapy especially beneficial for cancer patients refractory to other therapies;</li> <li>A research tool to identify patient-specific immunogenic mutations in the tumor.</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>This patient-specific therapy has the potential application to most epithelial cancers, which account for about 90% of cancer deaths in the United States;</li> <li>Personalized mutation-specific T cells recognize mutations harboring tumor cells only and spare normal tissues. This therapy has no tissue toxicities comparing to traditional chemotherapy and radiotherapy;</li> <li>The infusion of a highly pure population of these mutation-specific T cells may maximize therapy and result in regression of all target lesions.</li> </ul> 2020-02-03 2026-04-24 2020-02-03 2026-04-24 2020-02-03 Cholangiocarcinoma, Immunogenic, Rosenberg, T-cell, Tran False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-02-03 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 147161972 Tran E, et al. http://www.ncbi.nlm.nih.gov/pubmed/25046408 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25046408">Tran E, et al.</a> 147162359 Robbins P, et al. http://www.ncbi.nlm.nih.gov/pubmed/23644516 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23644516">Robbins P, et al.</a> 147162397 Tran E, et al. http://www.ncbi.nlm.nih.gov/pubmed/24812403 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24812403">Tran E, et al.</a> 162585338 Per discussions with A. Burke Per discussions with A. Burke 147163723 Tran, Eric NIH - NCI Tran, Eric 1 147163724 Lu, Yong-Chen NIH - NCI NCI Lu, Yong-Chen (NCI) 2 147163722 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 3 147163721 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 4 147163723 Tran, Eric NIH - NCI Tran, Eric 1 147163724 Lu, Yong-Chen NIH - NCI NCI Lu, Yong-Chen (NCI) 2 147163722 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 3 147163721 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 4 147158242 A Genomics-based Method For Developing Personalized Adoptive Cell Therapies For Cancer By Targeting Tumor-specific Mutations E-229-2014-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4157] T-Cell Therapy Against Patient-Specific Cancer Mutations&body=Please send me information about technology [TAB-4157] T-Cell Therapy Against Patient-Specific Cancer Mutations.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4157] T-Cell Therapy Against Patient-Specific Cancer Mutations&body=Please send me information about technology [TAB-4157] T-Cell Therapy Against Patient-Specific Cancer Mutations.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147166976 E-229-2014-0 E-229-2014-0-PCT-01 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation PCT Patent Cooperation Treaty PCT/US2014/058805 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/058805<br />Filed on 2014-10-02<br />Status: Expired 147166977 E-229-2014-0 E-229-2014-0-AU-02 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation National Stage Australia 2014407540 2014407540 Issued Australia <br />National Stage 2014407540<br />Filed on 2014-10-02<br />Status: Issued 147166978 E-229-2014-0 E-229-2014-0-CA-03 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation National Stage Canada 2963364 Pending Canada <br />National Stage 2963364<br />Filed on 2014-10-02<br />Status: Pending 147166979 E-229-2014-0 E-229-2014-0-CN-04 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation National Stage China 201480082922.X Abandoned China <br />National Stage 201480082922.X<br />Filed on 2014-10-02<br />Status: Abandoned 147166980 E-229-2014-0 E-229-2014-0-EP-05 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation National Stage European Patent 14790878.4 Abandoned European Patent <br />National Stage 14790878.4<br />Filed on 2014-10-02<br />Status: Abandoned 147166981 E-229-2014-0 E-229-2014-0-JP-06 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation National Stage Japan 6599450 2017-517677 Issued Japan <br />National Stage 2017-517677<br />Filed on 2014-10-02<br />Status: Issued 147166982 E-229-2014-0 E-229-2014-0-US-07 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION National Stage US 10,973,894 15/515,055 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10973894 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10973894">10,973,894</a><br />Filed on 2014-10-02<br />Status: Issued 147166983 E-229-2014-0 E-229-2014-0-JP-08 METHODS FOR ISOLATING T CELLS HAVING ANTIGEN SPECIFICITY TO CANCER SPECIFIC MUTATIONS DIV Japan 6878544 2019-182421 Issued Japan <br />Divisional (DIV) 2019-182421<br />Filed on 2019-10-02<br />Status: Issued 147166984 E-229-2014-0 E-229-2014-0-EP-09 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation DIV European Patent 20212578.7 Pending European Patent <br />Divisional (DIV) 20212578.7<br />Filed on 2020-12-08<br />Status: Pending 147166985 E-229-2014-0 E-229-2014-0-US-10 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION CON US 12,171,818 17/195,072 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12171818 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12171818">12,171,818</a><br />Filed on 2021-03-08<br />Status: Issued 147166986 E-229-2014-0 E-229-2014-0-AU-11 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation DIV Australia 2021202223 2021202223 Issued Australia <br />Divisional (DIV) 2021202223<br />Filed on 2021-04-13<br />Status: Issued 147166987 E-229-2014-0 E-229-2014-0-JP-12 METHODS FOR ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR CANCER SPECIFIC MUTATIONS DIV Japan 7096397 2021-076293 Issued Japan <br />Divisional (DIV) 2021-076293<br />Filed on 2021-04-28<br />Status: Issued 147166988 E-229-2014-0 E-229-2014-0-JP-13 METHODS FOR ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR CANCER SPECIFIC MUTATIONS DIV Japan 7340144 2022-101099 Issued Japan <br />Divisional (DIV) 2022-101099<br />Filed on 2022-06-23<br />Status: Issued 147173986 Cholangiocarcinoma 147173987 Immunogenic 147173988 Rosenberg 147173989 T-cell 147173991 Tran TAB-4373 147157667 A Viral Exposure Signature to Define and Detect Early Onset Hepatocellular Carcinoma NCI Collaboration, Diagnostics, Licensing, Oncology Collaboration Diagnostics Licensing Oncology Jinping Liu, Wei Tang, Xin Wei Wang <h2>Summary:</h2> <p>NCI seeks proposals from parties interested in co-development and licensing opportunities to employ biomarker viral exposure signature in diagnostic assays of early onset HCC.</p> <h2>Description of Technology:</h2> <p>Early detection of liver cancer, such as hepatocellular carcinoma (HCC), is key to improve cancer-related mortality. More than 800,000 people are diagnosed with this cancer each year throughout the world. Liver cancer is also a leading cause of cancer deaths worldwide, accounting for more than 700,000 deaths each year. Currently, millions of Americans and possibly billions in the world are considered at risk for developing liver cancer. Individuals are considered at risk for developing liver cancer if they have underlying chronic liver diseases such as fibrosis and cirrhosis which in turn may be caused by viral infections and inflammation. However, this risk greatly varies among individuals and the current methods for early detection and surveillance are inadequate.</p> <p>Scientists at the National Cancer Institute&rsquo;s (NCI) Laboratory of Human Carcinogenesis established a biomarker signature of viral infection that can predict HCC among at-risk individuals up to 7 years prior to their clinical diagnosis. This viral exposure signature has been identified through serological profiling of individuals from a case-control study and validated in a cohort of at-risk individuals who were followed up to 20 years for the development of HCC. The specificity and sensitivity of this biomarker signature is superior to current available methods of diagnosis such as alpha-fetoprotein screening.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Diagnostic assay for early detection and surveillance of HCC</li> <li>Companion diagnostics for HCC therapeutic development</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The large market for hepatocellular carcinoma is in need of improved diagnostics</li> <li>Detection of cancer patients from at-risk individuals up to 7 years prior to clinical diagnosis</li> <li>Potential competitive cost, easy to implement</li> <li>Serological profiling allows easy access to patient samples</li> </ul> 2020-01-15 2026-04-24 2020-12-15 2026-04-24 2020-01-15 Biomarker, HCC, hepatocellular carcinoma, Liver cancer, viral infection, Wang False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-12-15 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-024-2009 E-101-2016 147164491 Wang, Xin Wei NIH - NCI NCI Wang, Xin Wei (NCI) 1 147164493 Liu, Jinping NIH - NCI NCI Liu, Jinping (NCI) 2 147164492 Tang, Wei NIH - NCI NCI Tang, Wei (NCI) 3 147164491 Wang, Xin Wei NIH - NCI NCI Wang, Xin Wei (NCI) 1 147164493 Liu, Jinping NIH - NCI NCI Liu, Jinping (NCI) 2 147164492 Tang, Wei NIH - NCI NCI Tang, Wei (NCI) 3 147158147 A Viral Exposure Defines Nature Defines Early Onset Hepatocellular Carcinoma E-174-2019-0 Filing authorized NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-4373] A Viral Exposure Signature to Define and Detect Early Onset Hepatocellular Carcinoma&body=Please send me information about technology [TAB-4373] A Viral Exposure Signature to Define and Detect Early Onset Hepatocellular Carcinoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-4373] A Viral Exposure Signature to Define and Detect Early Onset Hepatocellular Carcinoma&body=Please send me information about technology [TAB-4373] A Viral Exposure Signature to Define and Detect Early Onset Hepatocellular Carcinoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147161150 E-174-2019-0 E-174-2019-0-PCT-02 A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA PCT Patent Cooperation Treaty PCT/US2020/055077 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/055077<br />Filed on 2020-10-09<br />Status: Expired 147168515 E-174-2019-0 E-174-2019-0-US-01 A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA PRV US 62/914,138 Abandoned US <br />Provisional (PRV) 62/914,138<br />Filed on 2019-10-11<br />Status: Abandoned 147168516 E-174-2019-0 E-174-2019-0-CN-03 A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA National Stage China ZL202080071446.7 202080071446.7 Issued China <br />National Stage 202080071446.7<br />Filed on 2020-10-09<br />Status: Issued 147168517 E-174-2019-0 E-174-2019-0-US-04 A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA National Stage US 12,571,796 17/766,015 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12571796 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12571796">12,571,796</a><br />Filed on 2022-04-01<br />Status: Issued 147173045 Biomarker 147173046 HCC 147173047 hepatocellular carcinoma 147173048 Liver cancer 147173049 viral infection 147173050 Wang TAB-4200 147157485 A Preclinical Orthotopic Model for Glioblastoma Multiforme that Represents Key Pathways Aberrant in Human Brain Cancer NCI Licensing, Neurology, Oncology, Research Materials Licensing Neurology Oncology Research Materials Rajaa El Meskini, Michelle Gumprecht, Alan Kulaga, Anthony Lacovelli, Zoe Ohler, Terry Van Dyke <h2>Description of Technology:</h2> <p>Current therapies for glioblastoma multiforme (GBM), the highest grade malignant brain tumor, are mostly ineffective, and better preclinical model systems are needed to increase the successful translation of drug discovery efforts into the clinic. Scientists at the National Cancer Institute (NCI) have developed and characterized an orthotopic genetically engineered mouse (GEM)-derived model of GBM that closely recapitulates various human GBM subtypes and is useful for preclinical evaluation of candidate therapeutics. The GEM-derived GBM model harbors perturbations in the receptor tyrosine kinase (RTK), phosphoinositide 3-kinase (PI3K) and retinoblastoma (RB) tumor suppressor networks and develops spontaneous p53 aberrations upon induction of the constitutively active mutant KRASG12D and deletion of phosphatase and tensin homolog (PTEN) alleles; the orthotopically implanted mice are referred to as &lsquo;TRP&rsquo; mice. The TRP mice develop high grade GBM that are histologically similar to human GBM within weeks allowing the creation of large preclinical cohorts that are tractable for therapeutic evaluation.&nbsp;</p> <p><strong>Figure:&nbsp;Orthotopic GBM model characterization&nbsp;</strong></p> <p><img alt="" src="https://nih.technologypublisher.com/files/sites/image_for_e-264-20141.png" style="height:551px; width:600px" /></p> <p>(A) Tumor cells were isolated from TRP grade IV astrocytoma and cultured for several passages prior to intracranial injection into syngeneic mouse brains, or cells were implanted directly. (B) Both methods resulted in grade IV astrocyomas. Orthotopic tumors have large numbers of variably sized irregular blood vessels (*). Enlarged images of areas labeled X and Y are shown in panel C. (C) Orthotopic GBMs feature necrotic foci (N in region labeled X) in central regions that are lined by pseudopalisading tumor cells (P). The invasive tumor cells often track along adjacent small blood vessels (arrows in region labeled Y), as well as diffusely invading through the recipient&rsquo;s neuropil. Two images are shown for each marker stain; in the second, invasion is indicated by &lsquo;I&rsquo; where orthotopic tumors contain foci of extensive invasion into the adjacent recipient normal brain. Tumor cells express variable levels of T121 with increased levels at the invasive edge highlighting individual invading tumor cells (T121 and T121/I). GFAP expression is heterogeneous with greater numbers of negative cells at the periphery (GFAP and GFAP/I). Nestin expression is also greater at the invasive front (Nestin and Nestin/I). Most tumor cells express Olig-2 (Olig-2 and Olig-2/I) and Sox-2 (Sox-2 and Sox-2/I).</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Tractable mouse model of human glioblastoma multiforme for preclinical evaluation of GBM therapies&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Rapid preclinical evaluation of therapeutics. Primary cells from the GEM-GBM injected orthotopically into immune competent syngeneic mice brains induce grade IV tumors within 2 to 3 weeks.</li> <li>The GEM-GBM model represents a range of GBM cell types, recapitulating the heterogeneous cell population found in human GBM.&nbsp;</li> <li>GBM tumors are distinct and measurable on MRI scans and DCE-MRI properties have been described</li> <li>Superior to human cell xenograft models: syngeneic immunocompetent model allows for the evaluation of checkpoint inhibitors and other immunotherapeutic drugs.</li> </ul> 2020-01-15 2026-04-24 2020-12-15 2026-04-24 2020-01-15 Brain Cancer, GBM, GEM, Genetically Engineered Mouse, Meskini, mouse model, Multiforme, Ohler Weaver, Orthotopic Glioblastoma False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-12-15 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147162437 El Meskini R, et al. A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283649/ <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283649/">El Meskini R, et al. A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.</a> 147163886 Ohler, Zoe NIH - NCI Leidos Ohler, Zoe (Leidos) 1 147163887 El Meskini, Rajaa NIH - NCI Leidos El Meskini, Rajaa (Leidos) 2 147163888 Lacovelli, Anthony NIH - NCI Leidos Lacovelli, Anthony (Leidos) 3 147163889 Kulaga, Alan NIH - NCI Leidos Kulaga, Alan (Leidos) 4 147163890 Gumprecht, Michelle NIH - NCI Leidos Gumprecht, Michelle (Leidos) 5 147163885 Van Dyke, Terry NIH - NCI Van Dyke, Terry 6 147163886 Ohler, Zoe NIH - NCI Leidos Ohler, Zoe (Leidos) 1 147163887 El Meskini, Rajaa NIH - NCI Leidos El Meskini, Rajaa (Leidos) 2 147163888 Lacovelli, Anthony NIH - NCI Leidos Lacovelli, Anthony (Leidos) 3 147163889 Kulaga, Alan NIH - NCI Leidos Kulaga, Alan (Leidos) 4 147163890 Gumprecht, Michelle NIH - NCI Leidos Gumprecht, Michelle (Leidos) 5 147163885 Van Dyke, Terry NIH - NCI Van Dyke, Terry 6 147158266 A Preclinical Orthotopic Model For Glioblastoma Multiforme That Represents Key Pathways Aberrant In Human Brain Cancer E-246-2014-0 Research Material NCI 83732917 Favila, Michelle michelle.favila@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4200] A Preclinical Orthotopic Model for Glioblastoma Multiforme that Represents Key Pathways Aberrant in Human Brain Cancer&body=Please send me information about technology [TAB-4200] A Preclinical Orthotopic Model for Glioblastoma Multiforme that Represents Key Pathways Aberrant in Human Brain Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Favila, Michelle<br><a href="mailto:michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4200] A Preclinical Orthotopic Model for Glioblastoma Multiforme that Represents Key Pathways Aberrant in Human Brain Cancer&body=Please send me information about technology [TAB-4200] A Preclinical Orthotopic Model for Glioblastoma Multiforme that Represents Key Pathways Aberrant in Human Brain Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michelle.favila@nih.gov</a><br> 147174184 Brain Cancer 147174185 GBM 147174186 GEM 147174187 Genetically Engineered Mouse 147174189 Meskini 147174190 mouse model 147174191 Multiforme 147174192 Ohler Weaver 147174194 Orthotopic Glioblastoma TAB-4175 147157460 Parental A2780 Ovarian Cancer Cell Line and Derivative Cisplatin-resistant and Adriamycin-resistant A2780 Cell Lines NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Stuart Aaronson, Nelson Ellmore (Estate) <h2>Description of Technology:</h2> <p>Ovarian cancer is one of the most common and lethal types of gynecological malignancies worldwide, accounting for approximately 295,000 new cases and 185,000 deaths annually. The high lethality rate is due to multiple reasons, including recurrence and the resistance of recurrent tumors to chemotherapy. Cell line models are crucial for preclinical cancer studies, to identify mechanisms of disease, to study drug resistance, and to screen for candidate therapeutics.&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI), Laboratory of Cellular and Molecular Biology have derived a cell line, A2780, from a patient with metastatic ovarian adenocarcinoma who was not exposed to any anti-cancer agents before tumor extraction. This cell line forms tumors in nude mice and can be used to evaluate the effects of anti-cancer agents on ovarian cancer. Furthermore, cisplatin- (A2780CIS) and adriamycin- resistant (A2780ADR) derivatives have been developed by chronic exposure of the parental cell line to cisplatin and adriamycin, respectively. These lines show cross-resistance to other agents such as melphalan, vinblastine or irradiation, and can be used to study the molecular basis of drug resistance in ovarian cancer.&nbsp;</p> <p>NCI is seeking parties to non-exclusively license these ovarian cancer cell lines.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research tool for drug screen and related preclinical studies of ovarian cancer therapeutics</li> <li>Research tool for mechanistic studies of ovarian cancer such as the basis of drug resistance</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Well-characterized ovarian cancer cell lines</li> <li>Parental A2780 may be used to generate other drug-resistant cell lines through exposure to low concentrations of other agents</li> </ul> 2020-01-15 2026-04-24 2020-12-15 2026-04-24 2020-01-15 A2780, Aaronson, adriamycin, CISPLATIN, drug resistance, IRRADIATION, Melphalan, OVARIAN CANCER, VINBLASTINE False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-12-15 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147161944 Westin EH, et al. Differential expression of the amv gene in human hematopoietic cells. https://www.ncbi.nlm.nih.gov/pubmed/6954533 <a href="https://www.ncbi.nlm.nih.gov/pubmed/6954533">Westin EH, et al. Differential expression of the amv gene in human hematopoietic cells.</a> 147162331 Beaufort CM, et al. Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. https://www.ncbi.nlm.nih.gov/pubmed/25230021 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25230021">Beaufort CM, et al. Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.</a> 147162369 Eva A, et al. Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells. https://www.ncbi.nlm.nih.gov/pubmed/6173755 <a href="https://www.ncbi.nlm.nih.gov/pubmed/6173755">Eva A, et al. Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells.</a> 147163782 Aaronson, Stuart NIH - NCI Aaronson, Stuart 1 147163783 Ellmore (Estate), Nelson NIH - NCI NCI Ellmore (Estate), Nelson (NCI) 2 147163782 Aaronson, Stuart NIH - NCI Aaronson, Stuart 1 147163783 Ellmore (Estate), Nelson NIH - NCI NCI Ellmore (Estate), Nelson (NCI) 2 147157800 Parental A2780 Ovarian Cancer Cell Line And Derivative Cisplatin-resistant And Adriamycin-resistant A2780 Cell Lines E-018-2020-0 Research Material NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4175] Parental A2780 Ovarian Cancer Cell Line and Derivative Cisplatin-resistant and Adriamycin-resistant A2780 Cell Lines&body=Please send me information about technology [TAB-4175] Parental A2780 Ovarian Cancer Cell Line and Derivative Cisplatin-resistant and Adriamycin-resistant A2780 Cell Lines.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4175] Parental A2780 Ovarian Cancer Cell Line and Derivative Cisplatin-resistant and Adriamycin-resistant A2780 Cell Lines&body=Please send me information about technology [TAB-4175] Parental A2780 Ovarian Cancer Cell Line and Derivative Cisplatin-resistant and Adriamycin-resistant A2780 Cell Lines.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">suna.gulay@nih.gov</a><br> 147169600 A2780 147169602 Aaronson 147169603 adriamycin 147169604 CISPLATIN 147169605 drug resistance 147169606 IRRADIATION 147169608 Melphalan 147169609 OVARIAN CANCER 147169610 VINBLASTINE TAB-4116 147157398 A Preclinical Model for Mutant Human EGFR-driven Lung Adenocarcinoma NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Simone Difilippantonio, Lionel Feigenbaum, Deborah Householder, Philip Martin, Zoe Ohler, Terry Van Dyke <h2>Description of Technology:</h2> <p>Previously described epidermal growth factor receptor- (EGFR) driven tumor mouse models develop diffuse tumors, which are dissimilar to human lung tumor morphology and difficult to measure by CT and MRI scans. Scientists at the National Cancer Institute (NCI) have developed and characterized a genetically engineered mouse (GEM) model of human EGFR-driven tumor model (hEGFR-TL) that recapitulates the discrete lung tumor nodules similar to those found in human lung tumor morphology. Individual tumor nodules can be easily measured by live animal imaging and the nodules can be harvested and isolated from surrounding lung tissue post-treatment, making this a more tractable model for human non-small cell lung adenocarcinoma. The lungs express an EGFR transgene that harbors two mutations (&lsquo;L858R&rsquo; and &lsquo;T790M&rsquo;) which render the lung tumors resistant to first generation EGFR inhibitors and are useful for evaluating drugs targeting resistant tumors.</p> <p>&nbsp;</p> <p><img alt="" src="https://nih.technologypublisher.com/files/sites/image_for_e-041-20145.png" /></p> <h2>Potential Commercial Applications:</h2> <ul> <li>Preclinical in vivo screen of therapeutics targeting tumor kinase inhibitors such as EGFR-mediated lung tumors, and identification of new biomarkers in this pathway&nbsp;</li> <li>Evaluation of novel therapeutics in inducible models of EGFR-driven drug resistant lung adenocarcinoma</li> <li>Dermatology Research</li> <li>Immunology, Inflammation and Autoimmunity Research</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Lung tumor development and response to drugs can be monitored by MRI or CT scanning</li> <li>Contain a human EGFR transgene (either TRE-EGFR-L858R or TRE-EGFR-L858R-T790M models are available) and an activating transgene (CCSP-rtTA) to direct expression of mutant EGFR to the Clara cells</li> </ul> 2020-01-15 2026-04-24 2020-12-15 2026-04-24 2020-01-15 EGFR, Epidermal Growth Factor Receptor, GEM, Genetically Engineered Mouse, Lung adenocarcinoma, lung cancer, mouse model, Ohler Weaver, respiratory False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-12-15 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147162258 Nakamura Y, et al., Near infrared photoimmunotherapy in a transgenic mouse model of spontaneous epidermal growth factor receptor (EGFR)-expressing lung cancer. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5335921/ <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5335921/">Nakamura Y, et al., Near infrared photoimmunotherapy in a transgenic mouse model of spontaneous epidermal growth factor receptor (EGFR)-expressing lung cancer.</a> 147163562 Difilippantonio, Simone NIH - NCI Leidos Difilippantonio, Simone (Leidos) 1 147163561 Feigenbaum, Lionel NIH - NCI Leidos Feigenbaum, Lionel (Leidos) 2 147163565 Householder, Deborah NIH - NCI NCI Householder, Deborah (NCI) 3 147163566 Martin, Philip NIH - NCI Martin, Philip 4 147163564 Ohler, Zoe NIH - NCI Leidos Ohler, Zoe (Leidos) 5 147163563 Van Dyke, Terry NIH - NCI Van Dyke, Terry 6 147163562 Difilippantonio, Simone NIH - NCI Leidos Difilippantonio, Simone (Leidos) 1 147163561 Feigenbaum, Lionel NIH - NCI Leidos Feigenbaum, Lionel (Leidos) 2 147163565 Householder, Deborah NIH - NCI NCI Householder, Deborah (NCI) 3 147163566 Martin, Philip NIH - NCI Martin, Philip 4 147163564 Ohler, Zoe NIH - NCI Leidos Ohler, Zoe (Leidos) 5 147163563 Van Dyke, Terry NIH - NCI Van Dyke, Terry 6 147157845 A New Model For Mutant EGFR-driven Lung Adenocarcinoma That Develops Nodular, Discrete Tumors Useful For Preclinical Evaluation And Biomarker Discovery E-041-2014-0 Research Material NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4116] A Preclinical Model for Mutant Human EGFR-driven Lung Adenocarcinoma&body=Please send me information about technology [TAB-4116] A Preclinical Model for Mutant Human EGFR-driven Lung Adenocarcinoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4116] A Preclinical Model for Mutant Human EGFR-driven Lung Adenocarcinoma&body=Please send me information about technology [TAB-4116] A Preclinical Model for Mutant Human EGFR-driven Lung Adenocarcinoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147170045 EGFR 147170047 Epidermal Growth Factor Receptor 147170049 GEM 147170051 Genetically Engineered Mouse 147170052 Lung adenocarcinoma 147170053 lung cancer 147170054 mouse model 147170056 Ohler Weaver 147170057 respiratory TAB-3968 147157248 Molecular Classification of Primary Mediastinal Large B Cell Lymphoma Using Formalin-Fixed, Paraffin-Embedded Tissue Specimens NCI Collaboration, Diagnostics, Licensing, Oncology Collaboration Diagnostics Licensing Oncology Rita Braziel, Wing Chan, James Cook, Jan Delabie, Kai Fu, Randy Gascoyne, Timothy Greiner, Elias Guerri, Elias Guerri, Elias Guerri, Elaine Jaffe, Anja Mottok, German Ott, Lisa Rimsza, Andreas Rosenwald, David Scott, Erlend Smeland, Joo Song, Louis Staudt, Christian Steidl, Dennis Weisenburger, George Wright <h2>Description of Technology:</h2> <p>Primary mediastinal B-cell lymphoma (PMBCL) is an aggressive type of non-Hodgkin lymphoma that mostly occurs in people between the ages of 30-40. It accounts for 5-7% of all aggressive lymphomas. The diagnosis of PMBCL is challenging as the histological features of PMBCL overlap with diffuse large B-cell lymphoma (DLBCL), another most common type of non-Hodgkin lymphoma. Available evidence suggests that PMBCL responds much more favorably to the DA-EPOCH-R chemotherapy regimen than to the standard R-CHOP regimen used to treat DLBCL. The diagnostic uncertainty of PMBCL can result in delayed and/or inappropriate treatment, serious harm, and even death of the patient, so there is a need to more precisely diagnose PMBCL.&nbsp;&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) have developed a gene expression-based assay comprising a set of 58 nucleic acid probes that measure the abundance of selected mRNA species using the Nanostring platform. This assay can be used successfully to better distinguish PMBCL from DLBCL and applied to further classify DLBCL into well-established cell-of-origin subtypes. This test can be applied by clinicians to support the pathological diagnosis of PMBCL, and therefore identify a group of patients whose tumors are characterized by a distinct underlying biology.&nbsp;&nbsp;</p> <p>The NCI seeks licensees and/or co-development partners to develop this technology toward commercialization.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Diagnosis of PMBCL</li> <li>Distinguishing PMBCL from DLBCL</li> <li>The invention could be used: <ul> <li>in the near term as a clinical tool in the initial diagnostic evaluation of suspected PMBCL, which is required in the WHO guidelines for diagnosis of hematologic malignancies</li> <li>as an entry criterion for clinical trials in order to include those patients for which the efficacy of a given treatment likely depends on the molecular subtype of their disease&nbsp;</li> </ul> </li> <li>Targeted therapies appropriate for each DLBCL subtype</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Easy to integrate into current clinical practice of cancer diagnosis as the assay can be performed using routinely available formalin-fixed, paraffin-embedded (FFPE) biopsies</li> <li>Superior prognostic ability over traditional histopathological diagnosis</li> </ul> 2020-01-15 2026-04-24 2020-01-15 2026-04-24 2020-01-15 assay, Diffuse Large B Cell Lymphoma, DLBCL, FFPE, Formalin-fixed, GENE EXPRESSION, paraffin-embedded biopsies, PMBCL, Primary Mediastinal Large B Cell Lymphoma, Staudt False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-01-15 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162044 Mottok A, et al. Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. https://www.ncbi.nlm.nih.gov/pubmed/30257882 <a href="https://www.ncbi.nlm.nih.gov/pubmed/30257882">Mottok A, et al. Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens.</a> 147162200 Mottok A, et al. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. https://www.ncbi.nlm.nih.gov/pubmed/31292115 <a href="https://www.ncbi.nlm.nih.gov/pubmed/31292115">Mottok A, et al. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.</a> 147163052 Staudt, Louis NIH - NCI NCI Staudt, Louis (NCI) 1 147163055 Rimsza, Lisa Mayo Clinic, Arizona Rimsza, Lisa 2 147163056 Scott, David BC Cancer Scott, David 3 147163053 Wright, George NIH - NCI NCI Wright, George (NCI) 4 147163057 Mottok, Anja BC Cancer Mottok, Anja 5 147163058 Steidl, Christian BC Cancer Steidl, Christian 6 147163054 Jaffe, Elaine NIH - NCI NCI Jaffe, Elaine (NCI) 7 147163065 Gascoyne, Randy BC Cancer Gascoyne, Randy 8 147163073 Guerri, Elias Clinical Research Foundation Barcelona - August Pi i Sunyer Biomedical Research Institute (IDIBAPS) Guerri, Elias 9 147163072 Guerri, Elias Hospital Clinic of Barcelona [Hospital Clinico de Barcelona] Guerri, Elias 10 147163069 Guerri, Elias University of Barcelona [Universitat de Barcelona] Guerri, Elias 11 147163059 Rosenwald, Andreas University Of Wurzburg Rosenwald, Andreas 12 147163063 Fu, Kai University of Nebraska Medical Center Fu, Kai 13 147163061 Greiner, Timothy University of Nebraska Medical Center Greiner, Timothy 14 147163066 Smeland, Erlend Oslo University Hospital Smeland, Erlend 15 147163067 Delabie, Jan Oslo University Hospital Delabie, Jan 16 147163068 Braziel, Rita Oregon Health and Science University (OHSU) Braziel, Rita 17 147163060 Chan, Wing City of Hope National Medical Center Chan, Wing 18 147163071 Song, Joo City of Hope National Medical Center Song, Joo 19 147163062 Weisenburger, Dennis City of Hope National Medical Center Weisenburger, Dennis 20 147163064 Ott, German Robert Bosch Stiftung Ott, German 21 147163070 Cook, James Cleveland Clinic Foundation Cook, James 22 147163052 Staudt, Louis NIH - NCI NCI Staudt, Louis (NCI) 1 147163055 Rimsza, Lisa Mayo Clinic, Arizona Rimsza, Lisa 2 147163056 Scott, David BC Cancer Scott, David 3 147163053 Wright, George NIH - NCI NCI Wright, George (NCI) 4 147163057 Mottok, Anja BC Cancer Mottok, Anja 5 147163058 Steidl, Christian BC Cancer Steidl, Christian 6 147163054 Jaffe, Elaine NIH - NCI NCI Jaffe, Elaine (NCI) 7 147163065 Gascoyne, Randy BC Cancer Gascoyne, Randy 8 147163073 Guerri, Elias Clinical Research Foundation Barcelona - August Pi i Sunyer Biomedical Research Institute (IDIBAPS) Guerri, Elias 9 147163072 Guerri, Elias Hospital Clinic of Barcelona [Hospital Clinico de Barcelona] Guerri, Elias 10 147163069 Guerri, Elias University of Barcelona [Universitat de Barcelona] Guerri, Elias 11 147163059 Rosenwald, Andreas University Of Wurzburg Rosenwald, Andreas 12 147163063 Fu, Kai University of Nebraska Medical Center Fu, Kai 13 147163061 Greiner, Timothy University of Nebraska Medical Center Greiner, Timothy 14 147163066 Smeland, Erlend Oslo University Hospital Smeland, Erlend 15 147163067 Delabie, Jan Oslo University Hospital Delabie, Jan 16 147163068 Braziel, Rita Oregon Health and Science University (OHSU) Braziel, Rita 17 147163060 Chan, Wing City of Hope National Medical Center Chan, Wing 18 147163071 Song, Joo City of Hope National Medical Center Song, Joo 19 147163062 Weisenburger, Dennis City of Hope National Medical Center Weisenburger, Dennis 20 147163064 Ott, German Robert Bosch Stiftung Ott, German 21 147163070 Cook, James Cleveland Clinic Foundation Cook, James 22 147158141 Molecular Classification Of Primary Mediastinal Large B Cell Lymphoma Using Formalin-fixed, Paraffin-embedded Tissue Specimens E-172-2017-0 Filing authorized BC Cancer, Mayo Clinic, Arizona, NCI 147162546 Molecular Classification Of Primary Mediastinal Large B Cell Lymphoma Using Formalin-fixed, Paraffin-embedded Tissue Specimens E-172-2017-1 Filing authorized BC Cancer, City of Hope National Medical Center, Cleveland Clinic Foundation, Clinical Research Foundation Barcelona - August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Hospital Clinic of Barcelona [Hospital Clinico de Barcelona], Mayo Clinic, Arizona, NCI, Oregon Health and Science University (OHSU), Oslo University Hospital, Robert Bosch Stiftung, University of Barcelona [Universitat de Barcelona], University of Nebraska Medical Center, University Of Wurzburg 83707317 Bhattacharya, Ramona ramona.bhattacharya@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB ramona.bhattacharya@nih.gov?subject=Web Inquiry on [TAB-3968] Molecular Classification of Primary Mediastinal Large B Cell Lymphoma Using Formalin-Fixed, Paraffin-Embedded Tissue Specimens&body=Please send me information about technology [TAB-3968] Molecular Classification of Primary Mediastinal Large B Cell Lymphoma Using Formalin-Fixed, Paraffin-Embedded Tissue Specimens.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Bhattacharya, Ramona<br><a href="mailto:ramona.bhattacharya@nih.gov?subject=Web Inquiry on [TAB-3968] Molecular Classification of Primary Mediastinal Large B Cell Lymphoma Using Formalin-Fixed, Paraffin-Embedded Tissue Specimens&body=Please send me information about technology [TAB-3968] Molecular Classification of Primary Mediastinal Large B Cell Lymphoma Using Formalin-Fixed, Paraffin-Embedded Tissue Specimens.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ramona.bhattacharya@nih.gov</a><br> 147161145 E-172-2017-0 E-172-2017-0-US-01 METHOD FOR DETERMINING LYMPHOMA TYPE PRV US 62/519,728 Abandoned US <br />Provisional (PRV) 62/519,728<br />Filed on 2017-06-14<br />Status: Abandoned 147165605 E-172-2017-1 E-172-2017-1-PCT-01 METHOD FOR DETERMINING LYMPHOMA TYPE PCT Patent Cooperation Treaty PCT/US2018/036084 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/036084<br />Filed on 2018-06-05<br />Status: Expired 147165606 E-172-2017-1 E-172-2017-1-EP-02 METHOD FOR DETERMINING LYMPHOMA TYPE National Stage European Patent 3638814 18733500.5 Issued European Patent <br />National Stage 18733500.5<br />Filed on 2020-01-14<br />Status: Issued 147165607 E-172-2017-1 E-172-2017-1-US-03 METHOD FOR DETERMINING LYMPHOMA TYPE CIP US 11,646,099 16/713,528 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11646099 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11646099">11,646,099</a><br />Filed on 2019-12-13<br />Status: Issued 147165609 E-172-2017-1 E-172-2017-1-FR-01 METHOD FOR DETERMINING LYMPHOMA TYPE EP France 3638814 18733500.5 Issued France <br />European patent (EP) 18733500.5<br />Filed on 2020-01-14<br />Status: Issued 147165610 E-172-2017-1 E-172-2017-1-DE-01 METHOD FOR DETERMINING LYMPHOMA TYPE EP Germany 3638814 18733500.5 Issued Germany <br />European patent (EP) 18733500.5<br />Filed on 2020-01-14<br />Status: Issued 147165611 E-172-2017-1 E-172-2017-1-GB-01 METHOD FOR DETERMINING LYMPHOMA TYPE EP United Kingdom 3638814 18733500.5 Issued United Kingdom <br />European patent (EP) 18733500.5<br />Filed on 2020-01-14<br />Status: Issued 147172976 assay 147172977 Diffuse Large B Cell Lymphoma 147172978 DLBCL 147172979 FFPE 147172980 Formalin-fixed 147172981 GENE EXPRESSION 147172983 paraffin-embedded biopsies 147172985 PMBCL 147172987 Primary Mediastinal Large B Cell Lymphoma 147172988 Staudt TAB-4242 147157529 Improved Gene Therapy Vectors for the Treatment of Glycogen Storage Disease Type Ia (GSD-1a) NICHD Collaboration, Endocrinology, Licensing, Nephrology, Therapeutics Collaboration Endocrinology Licensing Nephrology Therapeutics Barry Byrne, Janice Chou <h2>Summary:</h2> <p>NICHD is seeking licensees for development&nbsp;of&nbsp;an adeno-associated viral (AAV) vectors for the treatment of glycogen storage disease type Ia (GSD-Ia).</p> <h2>Description of Technology:</h2> <p>GSD-Ia is an inherited disorder of metabolism associated with life-threatening hypoglycemia, hepatic malignancy, and renal failure caused by the deficiency of glucose-6-phosphatase-alpha (G6Pase-alpha or G6PC). Current therapy, which primarily consists of dietary modification, fails to prevent long-term complications in many patients, including growth failure, gout, pulmonary hypertension, renal dysfunction, osteoporosis, and hepatocellular adenomas (HCA). Gene therapy-based techniques, which directly address the underlying genetic deficiency driving the disorder, offer the prospect of long-term remission in patients with GSD-Ia.</p> <p>Researchers at the NIH <a href="https://www.nichd.nih.gov/Pages/index.aspx" rel="nofollow" target="_blank">National Institute for Child Health and Human Development</a>&nbsp;developed adeno-associated viral (AAV) vectors for the treatment of glycogen storage disease type Ia (GSD-Ia).This technology describes new AAV vectors for the delivery of corrective genes that express modified human G6Pase-alpha proteins, directed by the tissue-specific human G6PC promoter/enhancer.</p> <p>The NICHD inventor is also interested in the mechanisms by which GSD-1a may lead to hepatic malignancy and a collaboration project may be considered.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Gene therapy vector for the delivery of a corrective gene to treat of GSD-Ia.</li> <li>Useful in development of a combined pharmaceutical plus gene therapy approach to treat adult GSD-1a patients at risk of hepatocellular carcinoma.</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Protein coding sequences are modified from the wildtype human sequence for enhanced enzymatic activity.</li> </ul> 2021-04-30 2026-04-24 2021-04-30 2026-04-24 2021-04-30 Chou, GSD-1a, hepatic malignancy, hyperlipidemia, hypoglycemia, National Institute of Child Health and Human Development, NICHD False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-04-30 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-039-2015 147161903 Lee YM et al. Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy. Hepatology 2012 Nov;56(5):1719-29. https://pubmed.ncbi.nlm.nih.gov/22422504/ <a href="https://pubmed.ncbi.nlm.nih.gov/22422504/">Lee YM et al. Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy. Hepatology 2012 Nov;56(5):1719-29.</a> 147162291 Lee YM, et al. The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia. Mol Genet Metab. 2013 Nov;110(3):275-80. https://pubmed.ncbi.nlm.nih.gov/23856420/ <a href="https://pubmed.ncbi.nlm.nih.gov/23856420/">Lee YM, et al. The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia. Mol Genet Metab. 2013 Nov;110(3):275-80.</a> 147164018 Chou, Janice NICHD NICHD Chou, Janice (NICHD) 1 147164019 Byrne, Barry University of Florida Byrne, Barry 2 147164018 Chou, Janice NICHD NICHD Chou, Janice (NICHD) 1 147164019 Byrne, Barry University of Florida Byrne, Barry 2 147158357 The Enhancer Elements Upstream Of The Human G6PC Minimal Promoter Are Necessary For Efficient Hepatic G6PC Expression E-552-2013-0 Filing authorized NICHD, University of Florida 91800717 Hubbs, Alan hubbsa@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America Technology Transfer Center hubbsa@mail.nih.gov?subject=Web Inquiry on [TAB-4242] Improved Gene Therapy Vectors for the Treatment of Glycogen Storage Disease Type Ia (GSD-1a)&body=Please send me information about technology [TAB-4242] Improved Gene Therapy Vectors for the Treatment of Glycogen Storage Disease Type Ia (GSD-1a).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Hubbs, Alan<br><a href="mailto:hubbsa@mail.nih.gov?subject=Web Inquiry on [TAB-4242] Improved Gene Therapy Vectors for the Treatment of Glycogen Storage Disease Type Ia (GSD-1a)&body=Please send me information about technology [TAB-4242] Improved Gene Therapy Vectors for the Treatment of Glycogen Storage Disease Type Ia (GSD-1a).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">hubbsa@mail.nih.gov</a><br> 147161278 E-552-2013-0 E-552-2013-0-US-13 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE CON US 10,113,183 15/493,622 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10113183 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10113183">10,113,183</a><br />Filed on 2017-04-21<br />Status: Issued 147167619 E-552-2013-0 E-552-2013-0-US-01 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE PRV US 61/908,861 Abandoned US <br />Provisional (PRV) 61/908,861<br />Filed on 2013-11-26<br />Status: Abandoned 147167620 E-552-2013-0 E-552-2013-0-PCT-02 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE PCT Patent Cooperation Treaty PCT/US2014/067415 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/067415<br />Filed on 2014-11-25<br />Status: Expired 147167621 E-552-2013-0 E-552-2013-0-AU-03 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage Australia 2014354839 2014354839 Issued Australia <br />National Stage 2014354839<br />Filed on 2014-11-25<br />Status: Issued 147167622 E-552-2013-0 E-552-2013-0-BR-04 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage Brazil BR112016011997-5 BR112016011997-5 Issued Brazil <br />National Stage BR112016011997-5<br />Filed on 2014-11-25<br />Status: Issued 147167623 E-552-2013-0 E-552-2013-0-CA-05 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage Canada 2930872 2930872 Issued Canada <br />National Stage 2930872<br />Filed on 2014-11-25<br />Status: Issued 147167624 E-552-2013-0 E-552-2013-0-CN-06 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage China ZL201480074046.6 201480074046.6 Issued China <br />National Stage 201480074046.6<br />Filed on 2014-11-25<br />Status: Issued 147167625 E-552-2013-0 E-552-2013-0-CO-07 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage Colombia 33396 16162610 Abandoned Colombia <br />National Stage 16162610<br />Filed on 2016-06-21<br />Status: Abandoned 147167626 E-552-2013-0 E-552-2013-0-EP-08 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage European Patent 3074510 14812375.5 Issued European Patent <br />National Stage 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167627 E-552-2013-0 E-552-2013-0-IL-09 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage Israel 245659 245659 Issued Israel <br />National Stage 245659<br />Filed on 2016-05-16<br />Status: Issued 147167628 E-552-2013-0 E-552-2013-0-JP-10 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage Japan 6649265 2016-554828 Issued Japan <br />National Stage 2016-554828<br />Filed on 2014-11-25<br />Status: Issued 147167629 E-552-2013-0 E-552-2013-0-MX-11 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage Mexico 375360 MX/a/2016/006774 Issued Mexico <br />National Stage MX/a/2016/006774<br />Filed on 2014-11-25<br />Status: Issued 147167630 E-552-2013-0 E-552-2013-0-US-12 Adeno-Associated Virus Vectors for Treatment of Glycogen Storage Disease National Stage US 9,644,216 15/038,979 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9644216 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9644216">9,644,216</a><br />Filed on 2016-05-24<br />Status: Issued 147167631 E-552-2013-0 E-552-2013-0-EP-14 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE DIV European Patent 3415620 18186594.0 Issued European Patent <br />Divisional (DIV) 18186594.0<br />Filed on 2018-07-31<br />Status: Issued 147167632 E-552-2013-0 E-552-2013-0-BE-15 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP Belgium 3074510 14812375.5 Issued Belgium <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167633 E-552-2013-0 E-552-2013-0-CH-16 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP Switzerland 3074510 14812375.5 Issued Switzerland <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167634 E-552-2013-0 E-552-2013-0-DE-17 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP Germany 3074510 14812375.5 Issued Germany <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167635 E-552-2013-0 E-552-2013-0-ES-18 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP Spain 3074510 14812375.5 Issued Spain <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167636 E-552-2013-0 E-552-2013-0-FR-19 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP France 3074510 14812375.5 Issued France <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167637 E-552-2013-0 E-552-2013-0-GB-20 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP United Kingdom 3074510 14812375.5 Issued United Kingdom <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167638 E-552-2013-0 E-552-2013-0-IT-21 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP Italy 3074510 14812375.5 Issued Italy <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167639 E-552-2013-0 E-552-2013-0-NL-22 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP The Netherlands 3074510 14812375.5 Issued The Netherlands <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167640 E-552-2013-0 E-552-2013-0-SE-23 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP Sweden 3074510 14812375.5 Issued Sweden <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167641 E-552-2013-0 E-552-2013-0-US-24 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE CON US 11,060,110 16/148,435 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11060110 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11060110">11,060,110</a><br />Filed on 2018-10-01<br />Status: Issued 147167642 E-552-2013-0 E-552-2013-0-DE-25 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP Germany 3415620 18186594.0 Issued Germany <br />European patent (EP) 18186594.0<br />Filed on 2018-07-31<br />Status: Issued 147167643 E-552-2013-0 E-552-2013-0-FR-26 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP France 3415620 18186594.0 Issued France <br />European patent (EP) 18186594.0<br />Filed on 2018-07-31<br />Status: Issued 147167644 E-552-2013-0 E-552-2013-0-GB-27 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP United Kingdom 3415620 18186594.0 Issued United Kingdom <br />European patent (EP) 18186594.0<br />Filed on 2018-07-31<br />Status: Issued 147174903 Chou 147174905 GSD-1a 147174906 hepatic malignancy 147174907 hyperlipidemia 147174908 hypoglycemia 147174909 National Institute of Child Health and Human Development 147174910 NICHD TAB-4224 147157509 Monomeric and Oligomeric Compounds as Contraceptives and Endocrine Therapeutics NICHD Collaboration, Endocrinology, Licensing, Reproductive Health, Therapeutics Collaboration Endocrinology Licensing Reproductive Health Therapeutics Diana Blithe, Pranab Gupta, Bashir Kaskar, Min Lee, Ming-Teh Lin <h2>Summary:</h2> <p>NICHD is seeking research co-development partners and/or licensees for development of this invention as a male contraceptive.</p> <h2>Description of Technology:</h2> <p>The options for male contraceptives are limited. Research is ongoing to develop a male contraceptive based on hormonal activity. Testosterone is one of the hormones necessary in producing sperm.&nbsp; Testosterone is absolutely required as a hormone for male fertility. Derivatives of testosterone for male contraceptives currently in clinical trials are associated with estrogenic deficiency. This deficiency can cause several issues including, but not limited to, bone density loss, risk of obesity, cardiovascular disease, and/or ineffective carbohydrate or lipid metabolism.&nbsp;</p> <p>Researchers at the <em>Eunice Kennedy Shriver </em>National Institute of Child Health and Human Development (NICHD) have developed a new chemical entity and related embodiments of the following formula:&nbsp;</p> <p><img alt=" This invention discloses embodiments of the above compound, or a pharmaceutically acceptable salt, a prodrug, a solvate, or a tautomer thereof" src="https://nih.technologypublisher.com/files/sites/formula_1_for_e-141-2019_compound1.png" style="border-style:solid; border-width:1px; float:left; height:213px; width:300px" /></p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p><strong>Formula 1.</strong> This invention discloses embodiments of the above compound, or a pharmaceutically acceptable salt, a prodrug, a solvate, or a tautomer thereof.&nbsp;&nbsp;</p> <p>Disclosed monomeric compounds and embodiments exhibit androgenic activity. Disclosed oligomeric compounds can provide control of receptor activation or deactivation and/or treatment through the coupling of steroidal-based compounds to one another or with therapeutic agents. Depending on the type and length between the compounds that form the oligomer, the rate at which each component of the oligomer release can be controlled as in &lsquo;time release&rsquo;. The appropriate dosage would depend on a variety of factors defined during further development.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Contraceptive use by humans, particularly male, and animals</li> <li>Compounds used as endocrine therapy</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Significant, unmet medical need given few current options for male contraceptives&nbsp;</li> <li>Timed release of active ingredients</li> </ul> 2021-02-09 2026-04-24 2021-02-09 2026-04-24 2021-02-09 Blithe, CONTRACEPTIVE, Estrogenic Activity, Eunice Kennedy Shriver National Institute of Child Health an, Lee, Male Contraceptive, MONOMERIC, NCE, New Chemical Entity, NICHD, OLIGOMERIC False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-02-09 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163965 Lee, Min NIH - NICHD NICHD Lee, Min (NICHD) 1 147163961 Blithe, Diana NIH - NICHD NICHD Blithe, Diana (NICHD) 2 147163963 Gupta, Pranab Ash Stevens, LLC Gupta, Pranab 3 147163962 Kaskar, Bashir Ash Stevens, LLC Kaskar, Bashir 4 147163964 Lin, Ming-Teh Ash Stevens, LLC Lin, Ming-Teh 5 147163965 Lee, Min NIH - NICHD NICHD Lee, Min (NICHD) 1 147163961 Blithe, Diana NIH - NICHD NICHD Blithe, Diana (NICHD) 2 147163963 Gupta, Pranab Ash Stevens, LLC Gupta, Pranab 3 147163962 Kaskar, Bashir Ash Stevens, LLC Kaskar, Bashir 4 147163964 Lin, Ming-Teh Ash Stevens, LLC Lin, Ming-Teh 5 147158072 Novel Substituted Steroid Hormones E-141-2019-0 Filing authorized Ash Stevens, LLC, NICHD 91788919 Gunas, Heather gunash@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America gunash@mail.nih.gov?subject=Web Inquiry on [TAB-4224] Monomeric and Oligomeric Compounds as Contraceptives and Endocrine Therapeutics&body=Please send me information about technology [TAB-4224] Monomeric and Oligomeric Compounds as Contraceptives and Endocrine Therapeutics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gunas, Heather<br><a href="mailto:gunash@mail.nih.gov?subject=Web Inquiry on [TAB-4224] Monomeric and Oligomeric Compounds as Contraceptives and Endocrine Therapeutics&body=Please send me information about technology [TAB-4224] Monomeric and Oligomeric Compounds as Contraceptives and Endocrine Therapeutics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">gunash@mail.nih.gov</a><br> 147167510 E-141-2019-0 E-141-2019-0-US-01 MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME PRV US 63/037,952 Abandoned US <br />Provisional (PRV) 63/037,952<br />Filed on 2020-06-11<br />Status: Abandoned 147167511 E-141-2019-0 E-141-2019-0-PCT-02 MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME PCT Patent Cooperation Treaty PCT/US2021/036809 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/036809<br />Filed on 2021-06-10<br />Status: Expired 147167512 E-141-2019-0 E-141-2019-0-CA-03 MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME National Stage Canada 3184810 Pending Canada <br />National Stage 3184810<br />Filed on 2021-06-10<br />Status: Pending 147167516 E-141-2019-0 E-141-2019-0-US-07 MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME National Stage US 18/009,571 Pending US <br />National Stage 18/009,571<br />Filed on 2022-12-09<br />Status: Pending 147167517 E-141-2019-0 E-141-2019-0-EP-08 MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME National Stage European Patent 21745474.3 Pending European Patent <br />National Stage 21745474.3<br />Filed on 2021-06-10<br />Status: Pending 147172272 Blithe 147172273 CONTRACEPTIVE 147172275 Estrogenic Activity 147172276 Eunice Kennedy Shriver National Institute of Child Health an 147172277 Lee 147172279 Male Contraceptive 147172280 MONOMERIC 147172282 NCE 147172284 New Chemical Entity 147172285 NICHD 147172286 OLIGOMERIC TAB-4418 147157713 Novel Human Insulin Cα-Peptide as an Antagonist for Islet and Brain Amyloidosis NIA Collaboration, Endocrinology, Licensing, Therapeutics Collaboration Endocrinology Licensing Therapeutics Josephine Earley, Luigi Ferrucci, Qing Rong Liu, Pingbo Zhang, Min Zhu <h2>Summary:</h2> <p>The NIA seeks co-development partners and/or licensees for the further development of C&alpha;-peptide as a therapeutic that inhibits islet amyloidosis.</p> <h2>Description of Technology:</h2> <p>Over 32 million Americans are living with Diabetes and newly diagnosed cases of type 1 and type 2 diabetes is increasing. A defining feature of type 2 diabetes mellitus (T2DM) is the accumulation of islet amyloid polypeptide (IAPP) fibrils in pancreatic islets. Such accumulations form amyloid plaques, referred to as islet amyloidosis. Mounting evidence suggests that islet amyloidosis plays a causative role in the development and progression of &szlig;-cell dysfunction in T2DM. Currently, approved therapies for T2DM modulate the production of or sensitivity to insulin, but do not specifically target islet amyloidosis. Thus, there is an unmet need to develop new diabetes treatments that inhibit islet amyloidosis. Additionally, any therapy preventing IAPP amyloidosis may prevent other potential amyloidogenic peptides from forming amyloid and amyloid plaques.</p> <p>Insulin C-peptide, co-secreted from secretory granules within pancreatic &beta;-cells alongside mature insulin and IAPP, plays a key role in keeping insulin and IAPP non-aggregated by charge-based interactions. Researchers at the NIA uncovered a novel variant of the C-peptide, named C&alpha;- peptide, having 19 amino acids and lacking -sheet and hairpin motifs present in the middle portion of the conventional 31 amino acid length C-peptide. The newly discovered C&alpha;-peptide derives from a novel proinsulin of 74 amino acids and inhibits IAPP amyloid fibrillation more efficiently than conventional C-peptide. There is an opportunity for C&alpha;-peptide derivatives to be developed as a therapeutic inhibiting islet amyloidosis. Researchers also identified decreased levels of processed C&alpha;-peptide in T2DM pancreatic islets compared with control islets. This finding reveals the potential for C&alpha;-peptide as a clinical diagnostic marker for islet dysfunction and, potentially, neurodegenerative diseases.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapy for type 2 diabetes</li> <li>Therapy for preventing amyloidosis by mutated transthyretin, therapy for primary (AL) amyloidosis, therapy for Amyloid &szlig;40 and 42</li> <li>Therapy for amyloidogenic diseases, including Alzheimer&rsquo;s disease and Parkinson disease</li> <li>Clinical diagnostic marker for type 1 and type 2 diabetes</li> <li>Clinical diagnostic marker for neurodegenerative diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Peptides inhibit islet amyloidosis</li> <li>Peptides lack the amyloidogenic domain</li> <li>Potential for synergistic use with existing diabetes treatments</li> <li>Potential market applications for neurodegenerative diseases</li> </ul> 2021-08-25 2026-04-24 2021-08-27 2026-04-24 2021-08-26 Alzheimer’s Disease, Amyloidosis, C-peptide, DIABETES, Egan, insulin, Islet Amyloid Polypeptide, Liu, National Institute on Aging, NIA False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-08-27 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147164673 Liu, Qing Rong NIH - NIA NIDA Liu, Qing Rong (NIDA) 1 147164675 Zhu, Min National Institute on Aging (NIH/NIA) NIA Zhu, Min (NIA) 2 147164676 Zhang, Pingbo Johns Hopkins University Zhang, Pingbo 3 147164672 Earley, Josephine NIH - NIA NIA Earley, Josephine (NIA) 4 147164674 Ferrucci, Luigi NIH - NIA NIA Ferrucci, Luigi (NIA) 5 147164673 Liu, Qing Rong NIH - NIA NIDA Liu, Qing Rong (NIDA) 1 147164675 Zhu, Min National Institute on Aging (NIH/NIA) NIA Zhu, Min (NIA) 2 147164676 Zhang, Pingbo Johns Hopkins University Zhang, Pingbo 3 147164672 Earley, Josephine NIH - NIA NIA Earley, Josephine (NIA) 4 147164674 Ferrucci, Luigi NIH - NIA NIA Ferrucci, Luigi (NIA) 5 147157902 Novel Human Insulin Ca-peptide As An Antagonist For Islet And Brain Amyloidosis E-062-2021-0 Filing authorized Johns Hopkins University, National Institute on Aging (NIH/NIA) 91827321 Jinnah, Zarpheen zarpheen.jinnah@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-4418] Novel Human Insulin Cα-Peptide as an Antagonist for Islet and Brain Amyloidosis&body=Please send me information about technology [TAB-4418] Novel Human Insulin Cα-Peptide as an Antagonist for Islet and Brain Amyloidosis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Jinnah, Zarpheen<br><a href="mailto:zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-4418] Novel Human Insulin Cα-Peptide as an Antagonist for Islet and Brain Amyloidosis&body=Please send me information about technology [TAB-4418] Novel Human Insulin Cα-Peptide as an Antagonist for Islet and Brain Amyloidosis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">zarpheen.jinnah@nih.gov</a><br> 147160981 E-062-2021-0 E-062-2021-0-US-01 HUMAN INSULIN C-ALPHA-PEPTIDES AND METHODS OF USE PRV US 63/178,083 Abandoned US <br />Provisional (PRV) 63/178,083<br />Filed on 2021-04-22<br />Status: Abandoned 147168802 E-062-2021-0 E-062-2021-0-PCT-02 HUMAN INSULIN C-ALPHA-PEPTIDES AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2022/025764 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/025764<br />Filed on 2022-04-21<br />Status: Expired 147168803 E-062-2021-0 E-062-2021-0-US-02 HUMAN INSULIN C-ALPHA-PEPTIDES AND METHODS OF USE National Stage US 18/287,630 Pending US <br />National Stage 18/287,630<br />Filed on 2023-10-19<br />Status: Pending 147168804 E-062-2021-0 E-062-2021-0-EP-01 HUMAN INSULIN C-ALPHA-PEPTIDES AND METHODS OF USE National Stage European Patent 22722061.3 Pending European Patent <br />National Stage 22722061.3<br />Filed on 2023-11-10<br />Status: Pending 147170577 Alzheimer’s Disease 147170578 Amyloidosis 147170580 C-peptide 147170581 DIABETES 147170583 Egan 147170584 insulin 147170586 Islet Amyloid Polypeptide 147170588 Liu 147170589 National Institute on Aging 147170590 NIA TAB-4380 147157674 AT-3 Mouse Breast Tumor Cell Line NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Scott Abrams, Jeffrey Schlom <h2>Summary:</h2> <p>NCI is seeking licensees for the AT-3 mouse breast tumor cell line.</p> <h2>Description of Technology:</h2> <p>Tumor cell lines are important tools for the study of cancer. However, most tumor cell lines available today do not mimic physiological tumor development, progression, and host immune responses. Autochthonous tumors include spontaneously occurring tumors and chemical, viral, or physical carcinogen-induced tumors. They are considered to model human tumors more closely than transplanted tumors. Autochthonous tumors can be generated de novo in a model organism of interest and are thought to resemble physiological human tumor conditions. There is therefore a need for development of cell lines from autochthonous tumor models that recapitulate physiological tumor conditions to provide relevant tools for studying tumor development and progression, and host immune responses to cancers.&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) have developed a mouse breast tumor cell line, AT-3, derived from cells of the primary mammary gland carcinoma of the MTAG model. The MTAG&nbsp; mouse model was developed using the mouse mammary tumor virus (MMTV) long terminal repeat (LTR) promoter to specifically target the polyomavirus middle T antigen (Ag) expression in the mammary gland tissue of B6 mice. This strategy resulted in the generation of transgenic mice with autochthonous mammary carcinomas, with eventual metastatic spread to the lungs that occurs over an approximate 6-month life span. The AT-3 cell line has further been used to study tumor-specific immune dysfunction in the B6 mouse background.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Breast cancer research</li> <li>Anti-breast cancer drug screening</li> <li>Development of other mouse models for breast cancer research</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Orthotopic growth</li> <li>Tumor histology devoid of transplantation introduced changes</li> <li>Metastasis via lymphatic and vascular vessels surrounding and within the primary tumor&nbsp;</li> <li>AT-3 cells were isolated from an autochthonous mouse mammary tumor from the MTAG mouse model</li> <li>Mammary tumor development and progression in MTAG mice closely mimic breast cancer development and progression in humans</li> <li>AT-3 cell line is a physiologically relevant tool for study of breast cancer in humans</li> </ul> 2021-09-23 2026-04-24 2021-09-23 2026-04-24 2021-09-23 AT-3, Autochthonous Tumor, Autologous Tumor Cell Line, BREAST CANCER, In Vitro Animal Model, Mouse, Murine, Schlom False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-09-23 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162360 Stewart TJ &amp; Abrams SI. Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth. https://pubmed.ncbi.nlm.nih.gov/17709499/ <a href="https://pubmed.ncbi.nlm.nih.gov/17709499/">Stewart TJ &amp; Abrams SI. Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth.</a> 147164516 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 147164517 Abrams, Scott NIH - NCI NCI Abrams, Scott (NCI) 2 147164516 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 147164517 Abrams, Scott NIH - NCI NCI Abrams, Scott (NCI) 2 147158257 AT-3 Mouse Breast Tumor Cell Line E-240-2016-0 Research Material NCI 83687903 Pollack, Michael michael.pollack@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4380] AT-3 Mouse Breast Tumor Cell Line&body=Please send me information about technology [TAB-4380] AT-3 Mouse Breast Tumor Cell Line.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollack, Michael<br><a href="mailto:michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4380] AT-3 Mouse Breast Tumor Cell Line&body=Please send me information about technology [TAB-4380] AT-3 Mouse Breast Tumor Cell Line.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michael.pollack@nih.gov</a><br> 147174122 AT-3 147174124 Autochthonous Tumor 147174126 Autologous Tumor Cell Line 147174127 BREAST CANCER 147174129 In Vitro Animal Model 147174130 Mouse 147174131 Murine 147174132 Schlom TAB-4365 147157659 Adjuvanted Mucosal Subunit Vaccines for Preventing SARS-CoV-2 Transmission and Infection NCI Collaboration, Immunology, Infectious Disease, Licensing, Vaccines Collaboration Immunology Infectious Disease Licensing Vaccines Jay Berzofsky, Yongjun Sui <h2>Summary:</h2> <p>Inventors are seeking licensing and/or co-development research collaborations&nbsp; for a unique novel molecular Adjuvanted Mucosal Subunit Vaccine to prevent SARS-CoV-2 transmission and infection.</p> <h2>Description of Technology:</h2> <p>The Corona virus disease, 2019 (COVID-19) pandemic is a worldwide public health crisis with over 153 million confirmed cases and 3.2 million deaths as of April 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. SARS-COV-2 infects hosts via its spike (S) protein, which has two portions, S1 that binds the cell and S2 that is involved in viral entry via fusion with the cell membrane. There are several vaccines available for COVID-19 patients that directly target SARS-CoV-2 by systemic immunization.</p> <p>Investigators at NCI have designed a unique adjuvanted mucosal subunit vaccine to prevent SARS-CoV-2 transmission and infection. The mucosal vaccine is generated as a subunit vaccine with spike protein S1 used for an intramuscular (IM) primed vaccine followed by intranasal boosted mucosal vaccine in rhesus macaques. The mucosal vaccines are administered intranasally and adjuvanted with the combination of TLR agonists CpG and Poly I:C and cytokine IL-15 incorporated in PLGA or DOTAP nanoparticles. The IM-alum-only vaccine induced robust binding and neutralizing antibody and persistent cellular immunity systemically and mucosally, while IN boosting with nanoparticles including IL-15 and TLR agonists elicited weaker T-cell and antibody responses, but higher dimeric IgA and IFNa, enhancing the effect of systemic immunization. Studies conducted by the inventors showed that the mucosal vaccine induced robust humoral and cellular as well as trained innate immunity in the vaccinated macaques, and cleared virus from the nasal mucosa more effectively, which should reduce forward transmission.</p> <p>Overall, the results demonstrated that the mucosal vaccine could protect against respiratory SARS-CoV-2 exposure and may enhance systemic vaccines, and thus is a good candidate for a SARS-CoV-2 vaccine.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Adjuvanted mucosal subunit vaccines (as single agents)&nbsp;</li> <li>Vaccine composition (s)</li> <li>Co-administration to enhance the effect of systemic immunization</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Stimulates both systemic and mucosal immunity;&nbsp; induces&nbsp; both humoral and cellular immunity, as well as trained innate immunity</li> <li>Leads to more effective virus clearance from the upper respiratory tract from which it could spread.</li> <li>Stimulated sustained immune response</li> <li>Protects against SARS-CoV-2 variants</li> <li>Intranasal administration avoids painful injection&nbsp;</li> <li>Notable improvement for manufacturing yield and cost, ease of administration, and distribution as compared to current candidates.</li> </ul> 2021-11-04 2026-04-24 2022-02-09 2026-04-24 2021-11-09 False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-02-09 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162454 Yongjun Sui et al., Protection against SARS-CoV-2 infection by mucosal vaccine in rhesus macaques. https://pubmed.ncbi.nlm.nih.gov/33908897/ <a href="https://pubmed.ncbi.nlm.nih.gov/33908897/">Yongjun Sui et al., Protection against SARS-CoV-2 infection by mucosal vaccine in rhesus macaques.</a> 147164454 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 1 147164455 Sui, Yongjun NCI - CCR Sui, Yongjun 2 147164454 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 1 147164455 Sui, Yongjun NCI - CCR Sui, Yongjun 2 147157906 Adjuvanted Mucosal Subunit Vaccines For Preventing SARS-CoC-2 Transmission And Infection E-064-2021-0 Filing authorized NCI 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4365] Adjuvanted Mucosal Subunit Vaccines for Preventing SARS-CoV-2 Transmission and Infection&body=Please send me information about technology [TAB-4365] Adjuvanted Mucosal Subunit Vaccines for Preventing SARS-CoV-2 Transmission and Infection.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4365] Adjuvanted Mucosal Subunit Vaccines for Preventing SARS-CoV-2 Transmission and Infection&body=Please send me information about technology [TAB-4365] Adjuvanted Mucosal Subunit Vaccines for Preventing SARS-CoV-2 Transmission and Infection.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">diptadip.dattaroy@nih.gov</a><br> 147160984 E-064-2021-0 E-064-2021-0-US-01 Adjuvanted Mucosal Subunit Vaccines For Preventing SARS-CoC-2 Transmission And Infection PRV US 63/146,279 Abandoned US <br />Provisional (PRV) 63/146,279<br />Filed on 2021-02-05<br />Status: Abandoned 147168461 E-064-2021-0 E-064-2021-0-PCT-03 Adjuvanted Mucosal Subunit Vaccines For Preventing SARS-CoV-2 Transmission And Infection PCT Patent Cooperation Treaty PCT/US2022/015349 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/015349<br />Filed on 2022-02-04<br />Status: Expired 147168462 E-064-2021-0 E-064-2021-0-US-02 Adjuvanted Mucosal Subunit Vaccines For Preventing SARS-CoV-2 Transmission And Infection National Stage US 18/275,925 Pending US <br />National Stage 18/275,925<br />Filed on 2023-08-04<br />Status: Pending 147168463 E-064-2021-0 E-064-2021-0-EP-01 Adjuvanted Mucosal Subunit Vaccines For Preventing SARS-CoV-2 Transmission And Infection National Stage European Patent 22705675.1 Pending European Patent <br />National Stage 22705675.1<br />Filed on 2023-08-30<br />Status: Pending TAB-4346 147157639 Human and Improved Murine Monoclonal Antibodies Against CD22 NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Dimiter Dimitrov, Ira Pastan, Xiaodong Xiao <h2>Summary:</h2> <p>Researchers at the NCI seek research and co-development partners and/or licensing for the development of human monoclonal antibodies and antibody-based therapeutics against CD22.</p> <h2>Description of Technology:</h2> <p>CD22 is a common cell surface glycoprotein expressed in B-cells and present in B-cell lymphomas; e.g., hairy cell leukemia (HCL), non-Hodgkins lymphoma (NHL), chronic lymphoblastic leukemia (CLL), and other cancers. It is therefore a target for cancer immunotherapy. Conjugation of anti-CD22 monoclonal antibodies with toxins or drugs has shown promise in clinical trials. However, all monoclonal anti-CD22 antibodies used in clinical trials are of murine origin. This is problematic because they have the potential of causing immunogenic reactions when used repeatedly in patients to achieve higher efficacy.</p> <p>NCI scientists isolated two human monoclonal anti-CD22 Fab antibodies; m972 and m971 with 2nM and 20nM affinities respectively. These two human anti-CD22 monoclonal antibodies are better alternatives for cancer immunotherapy over current humanized murine antibodies as they overcome the problem of immune reactivity. They also developed a murine anti-CD22 monoclonal antibody M973 with better affinity and solubility than its parent antibody HA22 and could have improved efficacy in cancer immunotherapy than the murine monoclonal anti-CD22 antibodies currently in use.&nbsp; The m971 binder has also been incorporated into chimeric antigen receptors (CARs) with positive results which are covered under NIH Reference Number E-291-2012 and other related filings.&nbsp;&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Monoclonal antibody therapeutic against B-cell lymphomas and other CD22-positive cancers</li> <li>Diagnostic tool for detection of CD22-positive cancers</li> <li>Delivery of drugs, toxins and liposomes to CD22-positive cancers</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Fully human monoclonal antibodies overcome the problem of immune reactivity to murine antibodies</li> <li>Improved monoclonal antibodies have better affinity and solubility than current antibodies</li> </ul> 2021-06-04 2026-04-24 2021-06-04 2026-04-24 2021-06-04 antibodies, ANTIGEN, B-CELL, B-Cell Lymphoma, Bcl, CANCER, CD22, Chronic Lymphoblastic Leukemia, CLL, Dimitrov, Hairy cell leukemia, HCL, Human, monoclonal, NHL, non-Hodgkins lymphoma, Oncology False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-06-04 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-017-2017 E-106-2015 E-161-2018 E-291-2012 147162148 Xiao X, et al. Identification and characterization of fully human anti-CD22 monoclonal antibody. https://pubmed.ncbi.nlm.nih.gov/20065646/ <a href="https://pubmed.ncbi.nlm.nih.gov/20065646/">Xiao X, et al. Identification and characterization of fully human anti-CD22 monoclonal antibody.</a> 147164404 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147164405 Xiao, Xiaodong NIH - NCI Xiao, Xiaodong 2 147164403 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 3 147164404 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147164405 Xiao, Xiaodong NIH - NCI Xiao, Xiaodong 2 147164403 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 3 147157941 Human And Improved Murine Monoclonal Antibodies Against CD22 E-080-2008-0 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4346] Human and Improved Murine Monoclonal Antibodies Against CD22&body=Please send me information about technology [TAB-4346] Human and Improved Murine Monoclonal Antibodies Against CD22.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4346] Human and Improved Murine Monoclonal Antibodies Against CD22&body=Please send me information about technology [TAB-4346] Human and Improved Murine Monoclonal Antibodies Against CD22.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147168358 E-080-2008-0 E-080-2008-0-US-01 Human Monoclonal Antibodies Specific For CD22 PRV US 61/042,329 Abandoned US <br />Provisional (PRV) 61/042,329<br />Filed on 2008-04-04<br />Status: Abandoned 147168359 E-080-2008-0 E-080-2008-0-PCT-02 Human And Improved Murine Monoclonal Antibodies Against CD22 PCT Patent Cooperation Treaty PCT/US2009/039080 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2009/039080<br />Filed on 2009-04-01<br />Status: Expired 147168360 E-080-2008-0 E-080-2008-0-US-03 Human Monoclonal Antibodies Sepcific for CD22 National Stage US 8,591,889 12/934,214 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8591889 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8591889">8,591,889</a><br />Filed on 2010-09-23<br />Status: Issued 147168361 E-080-2008-0 E-080-2008-0-US-04 Human Monoclonal Antibodies Specific For CD22 DIV US 9,279,019 13/959,061 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9279019 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9279019">9,279,019</a><br />Filed on 2013-08-05<br />Status: Issued 147168362 E-080-2008-0 E-080-2008-0-US-05 Human Monoclonal Antibodies Specific for CD22 DIV US 9,598,492 15/012,023 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9598492 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9598492">9,598,492</a><br />Filed on 2016-02-01<br />Status: Issued 147168363 E-080-2008-0 E-080-2008-0-US-06 Human Monoclonal Antibodies Specific for CD22 CON US 10,494,435 15/424,238 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10494435 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10494435">10,494,435</a><br />Filed on 2017-02-03<br />Status: Issued 147170938 antibodies 147170939 ANTIGEN 147170940 B-CELL 147170942 B-Cell Lymphoma 147170943 Bcl 147170944 CANCER 147170945 CD22 147170947 Chronic Lymphoblastic Leukemia 147170948 CLL 147170949 Dimitrov 147170950 Hairy cell leukemia 147170952 HCL 147170953 Human 147170954 monoclonal 147170955 NHL 147170957 non-Hodgkins lymphoma 147170958 Oncology TAB-4330 147157621 Anti-Viral Polypeptide Griffithsin: Compounds, Compositions, and Methods of Use NCI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics James McMahon, Toshiyuki Mori, Barry O'Keefe <h2>Description of Technology:</h2> <p>This technology describes additional methods of using the griffithsin anti-viral polypeptides described in related NCI invention (reference number E-106-2003).&nbsp; Specifically, this invention describes the use of GRFT to inhibit viral infection of hepatitis C viral infection, a severe acute respiratory syndrome (SARS) viral infection, an H5N1 viral infection, or an Ebola viral infection.&nbsp;</p> <p>Issued patents: <a href="https://patents.google.com/patent/US8088729B2/en?oq=US+8%2c088%2c729" rel="nofollow" target="_blank">US 8,088,729</a>&nbsp;(Jan. 3, 2012) and foreign rights in&nbsp;France, Germany, Ireland, United Kingdom, Switzerland (all granted)</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Microbicide that can prevent viral transmission</li> <li>Therapeutic against enveloped virus-mediated diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Highly Potent Broad-Spectrum Antiviral Lectin</li> <li>Superior in vitro and in vivo antiviral activity with minimum host toxicity against a variety of clinically relevant, enveloped viruses.</li> </ul> 2021-07-07 2026-04-24 2021-07-07 2026-04-24 2021-07-07 Anti-Viral, Corona virus, Ebola, Griffithsin, INFLUENZA, O’Keefe, SARS False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-07-07 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-106-2003 147162255 Giomarelli B, et al. Recombinant production of anti-HIV protein, griffithsin, by auto-induction in a fermentor culture https://pubmed.ncbi.nlm.nih.gov/16300962/ <a href="https://pubmed.ncbi.nlm.nih.gov/16300962/">Giomarelli B, et al. Recombinant production of anti-HIV protein, griffithsin, by auto-induction in a fermentor culture</a> 147162408 Mori T. et al., Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. https://pubmed.ncbi.nlm.nih.gov/15613479/ <a href="https://pubmed.ncbi.nlm.nih.gov/15613479/">Mori T. et al., Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp.</a> 147164332 O'Keefe, Barry NIH - NCI NCI O'Keefe, Barry (NCI) 1 147164331 McMahon, James NIH - NCI NCI McMahon, James (NCI) 2 147164333 Mori, Toshiyuki NIH - NCI Mori, Toshiyuki 3 147164332 O'Keefe, Barry NIH - NCI NCI O'Keefe, Barry (NCI) 1 147164331 McMahon, James NIH - NCI NCI McMahon, James (NCI) 2 147164333 Mori, Toshiyuki NIH - NCI Mori, Toshiyuki 3 147157812 Antiviral Activity Of Griffithsin Against SARS And HCV E-025-2006-0 Filing authorized NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4330] Anti-Viral Polypeptide Griffithsin: Compounds, Compositions, and Methods of Use&body=Please send me information about technology [TAB-4330] Anti-Viral Polypeptide Griffithsin: Compounds, Compositions, and Methods of Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4330] Anti-Viral Polypeptide Griffithsin: Compounds, Compositions, and Methods of Use&body=Please send me information about technology [TAB-4330] Anti-Viral Polypeptide Griffithsin: Compounds, Compositions, and Methods of Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147168226 E-025-2006-0 E-025-2006-0-US-01 Antiviral Activity Of Griffithsin Against SARS And HCV PRV US 60/741,403 Abandoned US <br />Provisional (PRV) 60/741,403<br />Filed on 2005-12-01<br />Status: Abandoned 147168227 E-025-2006-0 E-025-2006-0-PCT-02 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use PCT Patent Cooperation Treaty PCT/US2006/045930 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/045930<br />Filed on 2006-12-01<br />Status: Expired 147168228 E-025-2006-0 E-025-2006-0-US-03 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use National Stage US 8,088,729 12/095,697 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8088729 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8088729">8,088,729</a><br />Filed on 2008-05-30<br />Status: Issued 147168229 E-025-2006-0 E-025-2006-0-EP-04 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use National Stage European Patent 1976596 06838737.2 Issued European Patent <br />National Stage 06838737.2<br />Filed on 2006-12-01<br />Status: Issued 147168230 E-025-2006-0 E-025-2006-0-EP-05 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use DIV European Patent 10014894.9 Abandoned European Patent <br />Divisional (DIV) 10014894.9<br />Filed on 2006-12-01<br />Status: Abandoned 147168231 E-025-2006-0 E-025-2006-0-EP-06 Anti-Viral Griffithsin Compounds, Compositions, and Methods DIV European Patent 2314349 10014895.6 Abandoned European Patent <br />Divisional (DIV) 10014895.6<br />Filed on 2006-12-01<br />Status: Abandoned 147168232 E-025-2006-0 E-025-2006-0-EP-07 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use DIV European Patent 10014893.1 Abandoned European Patent <br />Divisional (DIV) 10014893.1<br />Filed on 2006-12-01<br />Status: Abandoned 147168233 E-025-2006-0 E-025-2006-0-FR-08 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use EP France 1976596 06838737.2 Issued France <br />European patent (EP) 06838737.2<br />Filed on 2006-12-01<br />Status: Issued 147168234 E-025-2006-0 E-025-2006-0-DE-09 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use EP Germany 1976596 06838737.2 Issued Germany <br />European patent (EP) 06838737.2<br />Filed on 2006-12-01<br />Status: Issued 147168235 E-025-2006-0 E-025-2006-0-IE-10 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use EP Ireland 1976596 06838737.2 Issued Ireland <br />European patent (EP) 06838737.2<br />Filed on 2006-12-01<br />Status: Issued 147168236 E-025-2006-0 E-025-2006-0-GB-11 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use EP United Kingdom 1976596 06838737.2 Issued United Kingdom <br />European patent (EP) 06838737.2<br />Filed on 2006-12-01<br />Status: Issued 147168237 E-025-2006-0 E-025-2006-0-CH-12 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use EP Switzerland 1976596 06838737.2 Issued Switzerland <br />European patent (EP) 06838737.2<br />Filed on 2006-12-01<br />Status: Issued 147169695 Anti-Viral 147169697 Corona virus 147169698 Ebola 147169699 Griffithsin 147169700 INFLUENZA 147169702 O’Keefe 147169703 SARS TAB-4307 147157597 High-Throughput Generation of Induced Pluripotent Stem Cells Carrying Antigen-Specific T Cell Receptors from Tumor Infiltrated Lymphocytes NCI Immunology, Licensing, Oncology, Therapeutics Immunology Licensing Oncology Therapeutics S M Rafiqul Islam, Takuya Maeda, Nicholas Restifo, Raul Sakoda, Naritaka Tamaoki <h2>Summary:</h2> <p>NCI seeks proposals from parties interested in licensing an&nbsp;improved method for the identification of TCRs from bulk populations of TIL for the development of cancer immunotherapies.</p> <h2>Description of Technology:</h2> <p>One form of adoptive T cell therapy (ACT) consists of harvesting tumor infiltrating lymphocytes (TIL), screening and isolating TIL which display tumor antigen-specific T-cell receptors (TCR), expanding the isolated T cells in vitro, and reinfusing them into the patient for treatment. While highly active in the treatment of certain cancers (e.g., melanoma), current methods used to produce cancer-reactive T cells require significant time and may not adequately identify the desired TCRs which bind cancer targets.</p> <p>Researchers at the National Cancer Institute (NCI) Surgery Branch have developed a method which allows for the identification of TCRs from bulk populations of TIL. This method generates induced pluripotent stem cell (iPSC) lines inheriting tumor antigen-specific TCRs from minor populations of TIL, not routinely achievable by other conventional approaches. Additionally, the method can generate previously unidentified tumor antigen-specific iPSC lines without pre-generating tumor antigen-specific T cell lines. This novel method is an improvement in the generation of tumor antigen-specific TCR inherited iPSC lines.</p> <h2>&nbsp;Potential Commercial Applications:</h2> <ul> <li>Therapeutics for a wide range of liquid and solid cancers</li> <li>iPSC lines inheriting tumor antigen-specific TCRs from minor populations of TIL not routinely achievable by other conventional approaches</li> <li>Improved and expedited cell therapy manufacturing, including: <ul> <li>Identification and reprogramming of bulk, polyclonal TIL populations with a high frequency of inherited tumor antigen-specific TCRs</li> <li>Method to identify, clone, and transduce tumor and neoantigen-specific TCRs from a bulk, polyclonal TIL population by genomic DNA sequencing</li> <li>Identification of tumor-reactive TCRs without having to identify their TCR alpha and TCR beta recombination patterns by bioinformatics and algorithm predictions</li> </ul> </li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>iPSC lines inheriting tumor antigen-specific TCRs from minor populations of TIL not routinely achievable by other conventional approaches</li> <li>Production of several TIL-derived iPSC (TIL-iPSC) with multiple different and novel tumor antigen-specific TCRs</li> <li>iPSC can be expanded without restrictions, and TCR sequencing and identification can be achieved with minimal error by genomic DNA based TCR sequencing</li> <li>Improved generation of tumor antigen-specific TIL for T cell rejuvenation purposes and subsequent TIL-iPSC-derived immunotherapy</li> </ul> 2021-04-28 2026-04-24 2021-04-28 2026-04-24 2021-04-28 act, adoptive cell therapy, ANTIGEN-SPECIFIC, Cancer Targets, Immunotherapy, Induced Pluripotent Stem Cells, iPSC, Restifo, Rosenberg, T Cell Receptors, TCR, TIL, Tumor Infiltrated Lymphocytes False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-04-28 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-091-2019 147162230 Minagawa A, et al. Enhancing T cell receptor stability in rejuvenated iPSC-derived T cells improves their use in cancer immunotherapy. https://pubmed.ncbi.nlm.nih.gov/30449714/ <a href="https://pubmed.ncbi.nlm.nih.gov/30449714/">Minagawa A, et al. Enhancing T cell receptor stability in rejuvenated iPSC-derived T cells improves their use in cancer immunotherapy.</a> 147162345 Vizcardo R, et al. Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells. https://pubmed.ncbi.nlm.nih.gov/23290135/ <a href="https://pubmed.ncbi.nlm.nih.gov/23290135/">Vizcardo R, et al. Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells.</a> 147162383 Maeda T, et al. Regeneration of CD8alphabeta T cells from T-cell-derived iPSC imparts potent tumor antigen-specific cytotoxicity. https://pubmed.ncbi.nlm.nih.gov/27872100/ <a href="https://pubmed.ncbi.nlm.nih.gov/27872100/">Maeda T, et al. Regeneration of CD8alphabeta T cells from T-cell-derived iPSC imparts potent tumor antigen-specific cytotoxicity.</a> 147164245 Sakoda, Raul NIH - NCI Sakoda, Raul 1 147164246 Islam, S M Rafiqul NIH - NCI NCI Islam, S M Rafiqul (NCI) 2 147164244 Tamaoki, Naritaka NIH - NCI NCI Tamaoki, Naritaka (NCI) 3 147164247 Maeda, Takuya NIH - NCI NCI Maeda, Takuya (NCI) 4 147164243 Restifo, Nicholas NIH - NCI NCI Restifo, Nicholas (NCI) 5 147164245 Sakoda, Raul NIH - NCI Sakoda, Raul 1 147164246 Islam, S M Rafiqul NIH - NCI NCI Islam, S M Rafiqul (NCI) 2 147164244 Tamaoki, Naritaka NIH - NCI NCI Tamaoki, Naritaka (NCI) 3 147164247 Maeda, Takuya NIH - NCI NCI Maeda, Takuya (NCI) 4 147164243 Restifo, Nicholas NIH - NCI NCI Restifo, Nicholas (NCI) 5 147158008 High-throughput Generation Of IPSC Carrying Antigen Specific TCRs From Tumor Infiltrated Lymphocytes E-109-2020-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4307] High-Throughput Generation of Induced Pluripotent Stem Cells Carrying Antigen-Specific T Cell Receptors from Tumor Infiltrated Lymphocytes&body=Please send me information about technology [TAB-4307] High-Throughput Generation of Induced Pluripotent Stem Cells Carrying Antigen-Specific T Cell Receptors from Tumor Infiltrated Lymphocytes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4307] High-Throughput Generation of Induced Pluripotent Stem Cells Carrying Antigen-Specific T Cell Receptors from Tumor Infiltrated Lymphocytes&body=Please send me information about technology [TAB-4307] High-Throughput Generation of Induced Pluripotent Stem Cells Carrying Antigen-Specific T Cell Receptors from Tumor Infiltrated Lymphocytes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161056 E-109-2020-0 E-109-2020-0-US-01 HIGH-THROUGHPUT GENERATION OF iPSC CARRYING ANTIGEN SPECIFIC TCRs FROM TUMOR INFILTRATING LYMPHOCYTES PRV US 63/068,458 Abandoned US <br />Provisional (PRV) 63/068,458<br />Filed on 2020-08-21<br />Status: Abandoned 147168060 E-109-2020-0 E-109-2020-0-PCT-02 PREFERENTIAL GENERATION OF iPSC CARRYING ANTIGEN SPECIFIC TCRs FROM TUMOR INFILTRATING LYMPHOCYTES PCT Patent Cooperation Treaty PCT/US2021/046969 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/046969<br />Filed on 2021-08-20<br />Status: Expired 147168061 E-109-2020-0 E-109-2020-0-JP-01 PREFERENTIAL GENERATION OF iPSC CARRYING ANTIGEN SPECIFIC TCRs FROM TUMOR INFILTRATING LYMPHOCYTES National Stage Japan 2023-512482 Abandoned Japan <br />National Stage 2023-512482<br />Filed on 2023-02-20<br />Status: Abandoned 147168062 E-109-2020-0 E-109-2020-0-US-02 PREFERENTIAL GENERATION OF iPSC CARRYING ANTIGEN SPECIFIC TCRs FROM TUMOR INFILTRATING LYMPHOCYTES National Stage US 18/020,823 Pending US <br />National Stage 18/020,823<br />Filed on 2023-02-10<br />Status: Pending 147168063 E-109-2020-0 E-109-2020-0-EP-01 PREFERENTIAL GENERATION OF iPSC CARRYING ANTIGEN SPECIFIC TCRs FROM TUMOR INFILTRATING LYMPHOCYTES National Stage European Patent 21769306.8 Pending European Patent <br />National Stage 21769306.8<br />Filed on 2023-03-08<br />Status: Pending 147171635 act 147171636 adoptive cell therapy 147171637 ANTIGEN-SPECIFIC 147171639 Cancer Targets 147171640 Immunotherapy 147171642 Induced Pluripotent Stem Cells 147171643 iPSC 147171644 Restifo 147171645 Rosenberg 147171646 T Cell Receptors 147171647 TCR 147171648 TIL 147171650 Tumor Infiltrated Lymphocytes TAB-4269 147157557 HIV-1 IN Mutant in a Single Round Vector NCI Infectious Disease, Licensing, Research Materials Infectious Disease Licensing Research Materials Stephen Hughes, Steven Smith <h2>Summary:</h2> <p>The Retroviral Replication Laboratory of the National Cancer Institute actively seeks parties interested in non-exclusive licensing a&nbsp;collection of single-round vectors containing mutations in HIV-1 IN or RT.</p> <h2>Description of Technology:</h2> <p>Antiretroviral therapy (ART) has changed the prognosis of HIV-1 infection to a chronic illness that, in most cases, can be managed or controlled. Integrase strand transfer inhibitors (INSTIs) and reverse transcription inhibitors are essential components of ART drug cocktails. In compliant individuals, ART has been found to block viral replication completely. Additionally, blocking viral replication can prevent the emergence of drug resistance.</p> <p>Researchers at the Retroviral Replication Laboratory of the National Cancer Institute have introduced mutations into the nucleotides encoding the integrase (IN) or reverse transcriptase (RT) of a replication-defective variant of the pNL4.3 HIV-1 vector. The result is a collection of single-round vectors containing mutations in HIV-1 IN or RT. These mutants can be used in single round-infection assays to evaluate potential anti-HIV drugs. The vector collection contains over 140 mutations or a combination of mutations and has been thoroughly tested and validated. This collection is a good research surrogate as the included vectors are safer versions of HIV-1 viruses when compared to those found in patients.</p> <p>Parties interested in licensing the technology should submit an application for licensing and seek detailed information from the Licensing and Patenting Manager indicated below.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Screening assays to test the efficacy of potential INSTIs or RT anti-HIV drugs</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Collections make from replication-defective variant of the pNL4.3 HIV-1 vector</li> <li>Over 140 mutation or combination of mutations in collection</li> </ul> 2021-11-04 2026-04-24 2021-11-04 2026-04-24 2021-11-04 Anti-HIV Drugs, HIV, Hughes, INSTIs, Integrase Strand Transfer Inhibitors, pNL4.3, Reverse Transcriptase, RT, Single-Round Vectors, Smith False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-11-04 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162075 Smith SJ, et al. Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs. https://pubmed.ncbi.nlm.nih.gov/33572956/ <a href="https://pubmed.ncbi.nlm.nih.gov/33572956/">Smith SJ, et al. Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs.</a> 147164115 Smith, Steven NCI - CCR Smith, Steven 1 147164114 Hughes, Stephen NIH - NCI NCI Hughes, Stephen (NCI) 2 147164115 Smith, Steven NCI - CCR Smith, Steven 1 147164114 Hughes, Stephen NIH - NCI NCI Hughes, Stephen (NCI) 2 147158016 HIV-1 IN Mutants In A Single Round Vector E-114-2021-0 Research Material NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4269] HIV-1 IN Mutant in a Single Round Vector&body=Please send me information about technology [TAB-4269] HIV-1 IN Mutant in a Single Round Vector.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4269] HIV-1 IN Mutant in a Single Round Vector&body=Please send me information about technology [TAB-4269] HIV-1 IN Mutant in a Single Round Vector.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147171717 Anti-HIV Drugs 147171718 HIV 147171720 Hughes 147171721 INSTIs 147171723 Integrase Strand Transfer Inhibitors 147171725 pNL4.3 147171727 Reverse Transcriptase 147171728 RT 147171730 Single-Round Vectors 147171732 Smith TAB-4223 147157508 Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Dimiter Dimitrov, Crystal Mackall, Rimas Orentas, Ira Pastan, Nirali Shah <h2>Description of Technology:</h2> <p>Chimeric antigen receptors (CARs) are hybrid proteins consisting of an antibody binding fragment fused to protein signaling domains that cause T-cells which express the CAR to become cytotoxic.&nbsp; Once activated, these cytotoxic T-cells can selectively eliminate the cells which they recognize via the antibody binding fragment of the CAR.&nbsp; Thus, by engineering a T-cell to express a CAR that is specific for a certain cell surface protein, it is possible to selectively target those cells for destruction.&nbsp; This promising new therapeutic approach is known as adoptive cell therapy.<br /> &nbsp;<br /> CD22 is a cell surface protein expressed on a large number of B-cell lineage hematological cancers, such as leukemia and lymphoma.&nbsp; Several promising therapies are being developed which target CD22, including therapeutic antibodies and immunotoxins.&nbsp; This technology concerns the use of a high affinity antibody binding fragment to CD22 (known as m971), as the targeting moiety of a CAR. The resulting CAR can be used in adoptive cell therapy treatment for cancer.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of diseases associated with increased or preferential expression of CD22</li> <li>Hematological cancers such as chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL) and pediatric acute lymphoblastic leukemia (ALL)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>High affinity of the m971 antibody binding fragment increases the likelihood of successful targeting</li> <li>Targeted therapy decreases non-specific killing of healthy, essential cells, potentially resulting in fewer non-specific side-effects and healthier patients</li> <li>Hematological cancers are susceptible to cytotoxic T-cells for treating because they are present in the bloodstream&nbsp;</li> <li>Expression of CD22 only on mature cells avoids stem cell elimination during treatment</li> </ul> 2021-06-02 2026-04-24 2021-06-02 2026-04-24 2021-06-02 Acute Lymphoblastic Leukemia, adoptive cell therapy, ALL, B-CELL, CD22, Chimeric antigen receptors (CARs), Chronic lymphocytic leukemia, CLL, Dimitrov, Hairy cell leukemia, HCL, Immunotherapy, pediatric False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-06-02 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract E-017-2017 E-080-2008 E-106-2015 E-161-2018 147161901 Shah NN et. al. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial https://pubmed.ncbi.nlm.nih.gov/32286905/ <a href="https://pubmed.ncbi.nlm.nih.gov/32286905/">Shah NN et. al. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial</a> 147163959 Orentas, Rimas NIH - NCI NCI Orentas, Rimas (NCI) 0 147163960 Shah, Nirali NIH - NCI NCI Shah, Nirali (NCI) 1 147163956 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 2 147163958 Mackall, Crystal NIH - NCI NCI Mackall, Crystal (NCI) 3 147163957 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 4 147163960 Shah, Nirali NIH - NCI NCI Shah, Nirali (NCI) 1 147163959 Orentas, Rimas NIH - NCI NCI Orentas, Rimas (NCI) 0 147163956 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 2 147163958 Mackall, Crystal NIH - NCI NCI Mackall, Crystal (NCI) 3 147163957 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 4 147158326 High Activity Chimeric Antigen Receptor For CD22 E-291-2012-0 Filing authorized NCI 147162599 M971 CAR Research Material E-291-2012-1 Research Material NCI 83673032 Whitney, Laurie WhitneyL@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4223] Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers&body=Please send me information about technology [TAB-4223] Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Whitney, Laurie<br><a href="mailto:WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4223] Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers&body=Please send me information about technology [TAB-4223] Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">WhitneyL@mail.nih.gov</a><br> 147161263 E-291-2012-0 E-291-2012-0-US-01 M971 Chimeric Antigen Receptors PRV US 61/717,960 Abandoned US <br />Provisional (PRV) 61/717,960<br />Filed on 2012-10-24<br />Status: Abandoned 147167485 E-291-2012-0 E-291-2012-0-PCT-02 M971 Chimeric Antigen Receptors PCT Patent Cooperation Treaty PCT/US2013/060332 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/060332<br />Filed on 2013-09-18<br />Status: Expired 147167486 E-291-2012-0 E-291-2012-0-AU-03 M971 Chimeric Antigen Receptors National Stage Australia 2013335180 2013335180 Issued Australia <br />National Stage 2013335180<br />Filed on 2013-09-18<br />Status: Issued 147167487 E-291-2012-0 E-291-2012-0-BR-04 M971 Chimeric Antigen Receptors National Stage Brazil BR112015009003-6 BR112015009003-6 Issued Brazil <br />National Stage BR112015009003-6<br />Filed on 2015-04-22<br />Status: Issued 147167488 E-291-2012-0 E-291-2012-0-CA-05 M971 Chimeric Antigen Receptors National Stage Canada 2889055 2889055 Issued Canada <br />National Stage 2889055<br />Filed on 2013-09-18<br />Status: Issued 147167489 E-291-2012-0 E-291-2012-0-CN-06 M971 Chimeric Antigen Receptors National Stage China ZL201380061387.5 201380061387.5 Issued China <br />National Stage 201380061387.5<br />Filed on 2015-05-25<br />Status: Issued 147167490 E-291-2012-0 E-291-2012-0-EP-07 M971 Chimeric Antigen Receptors National Stage European Patent 2912061 13773468.7 Issued European Patent <br />National Stage 13773468.7<br />Filed on 2013-09-18<br />Status: Issued 147167491 E-291-2012-0 E-291-2012-0-IN-08 M971 Chimeric Antigen Receptors National Stage India 385803 2344/CHENP/2015 Issued India <br />National Stage 2344/CHENP/2015<br />Filed on 2013-09-18<br />Status: Issued 147167492 E-291-2012-0 E-291-2012-0-JP-09 M971 Chimeric Antigen Receptors National Stage Japan 6338252 2015-539602 Issued Japan <br />National Stage 2015-539602<br />Filed on 2013-09-18<br />Status: Issued 147167493 E-291-2012-0 E-291-2012-0-RU-10 M971 Chimeric Antigen Receptors National Stage Russia 2658485 2015117237 Issued Russia <br />National Stage 2015117237<br />Filed on 2015-05-07<br />Status: Issued 147167494 E-291-2012-0 E-291-2012-0-US-11 M971 Chimeric Antigen Receptors National Stage US 10,072,078 14/437,889 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10072078 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10072078">10,072,078</a><br />Filed on 2015-04-23<br />Status: Issued 147167495 E-291-2012-0 E-291-2012-0-HK-12 M971 Chimeric Antigen Receptors National Stage Hong Kong HK1213922B 16101891.0 Issued Hong Kong <br />National Stage 16101891.0<br />Filed on 2016-02-19<br />Status: Issued 147167496 E-291-2012-0 E-291-2012-0-RU-13 M971 Chimeric Antigen Receptors DIV Russia 2770411 2018116582 Issued Russia <br />Divisional (DIV) 2018116582<br />Filed on 2018-05-04<br />Status: Issued 147167497 E-291-2012-0 E-291-2012-0-JP-14 M971 Chimeric Antigen Receptors DIV Japan 6643394 2018-088908 Issued Japan <br />Divisional (DIV) 2018-088908<br />Filed on 2018-05-02<br />Status: Issued 147167499 E-291-2012-0 E-291-2012-0-AU-16 M971 Chimeric Antigen Receptors DIV Australia 2018204257 2018204257 Issued Australia <br />Divisional (DIV) 2018204257<br />Filed on 2018-06-14<br />Status: Issued 147167500 E-291-2012-0 E-291-2012-0-US-17 M971 CHIMERIC ANTIGEN RECEPTORS DIV US 10,703,816 16/107,271 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10703816 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10703816">10,703,816</a><br />Filed on 2018-08-21<br />Status: Issued 147167501 E-291-2012-0 E-291-2012-0-DE-18 M971 Chimeric Antigen Receptors EP Germany 2912061 13773468.7 Issued Germany <br />European patent (EP) 13773468.7<br />Filed on 2015-04-22<br />Status: Issued 147167502 E-291-2012-0 E-291-2012-0-ES-19 M971 Chimeric Antigen Receptors EP Spain 2912061 13773468.7 Issued Spain <br />European patent (EP) 13773468.7<br />Filed on 2015-04-22<br />Status: Issued 147167503 E-291-2012-0 E-291-2012-0-FR-20 M971 Chimeric Antigen Receptors EP France 2912061 13773468.7 Issued France <br />European patent (EP) 13773468.7<br />Filed on 2015-04-22<br />Status: Issued 147167504 E-291-2012-0 E-291-2012-0-GB-21 M971 Chimeric Antigen Receptors EP United Kingdom 2912061 13773468.7 Issued United Kingdom <br />European patent (EP) 13773468.7<br />Filed on 2015-04-22<br />Status: Issued 147167505 E-291-2012-0 E-291-2012-0-IT-22 M971 Chimeric Antigen Receptors EP Italy 2912061 13773468.7 Issued Italy <br />European patent (EP) 13773468.7<br />Filed on 2015-04-22<br />Status: Issued 147167506 E-291-2012-0 E-291-2012-0-CN-23 M971 Chimeric Antigen Receptors DIV China ZL201910500128.7 201910500128.7 Issued China <br />Divisional (DIV) 201910500128.7<br />Filed on 2019-06-11<br />Status: Issued 147167507 E-291-2012-0 E-291-2012-0-US-24 M971 CHIMERIC ANTIGEN RECEPTORS DIV US 11,807,682 16/869,792 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11807682 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11807682">11,807,682</a><br />Filed on 2020-05-08<br />Status: Issued 147174692 Acute Lymphoblastic Leukemia 147174693 adoptive cell therapy 147174694 ALL 147174695 B-CELL 147174696 CD22 147174697 Chimeric antigen receptors (CARs) 147174698 Chronic lymphocytic leukemia 147174699 CLL 147174700 Dimitrov 147174701 Hairy cell leukemia 147174702 HCL 147174703 Immunotherapy 147174704 pediatric TAB-4216 147157501 New Heterocyclic Scaffold-Based Inhibitors of the Polo-Box Domain of Polo-like Kinase 1 for the Treatment of Cancer NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Celeste Alverez, Kenneth Jacobson, Kyung Lee, Jung-Eun Park <h2>Summary:</h2> <p>The National Institutes of Health is seeking commercial partners to co-develop and/or license a&nbsp;heterocyclic scaffold for development of&nbsp;therapeutics against Plk1-dependent cancers.</p> <h2>Description of Technology:</h2> <p>Polo-like kinase 1 (Plk1), a member of the Polo-like kinase family, plays a critical role in regulating mitosis and cell cycle progression. Aberrant expression of Plk1 has been observed in a variety of human cancers, and it is known to be associated with tumorigenesis as well as poor prognosis in cancer patients. Unlike normal cells, some cancer cells are dependent on augmented Plk1 levels to remain viable and are killed when Plk1 function is attenuated. Although Plk1 has proven to be an attractive target in cancer treatment, currently available Plk1 inhibitors have shown limited efficacy with significant dose-limiting toxicity and non-specificity in various preclinical or clinical trials. Thus, there remains an unmet need to develop anti-cancer drugs that are highly specific against Plk1 and have better clinical outcomes.</p> <p>Scientists at the National Institutes of Health have identified a new heterocyclic scaffold with unique structural and chemical features that can be leveraged for anti-Plk1 drug discovery. This triazoloquinazolinone scaffold can be used to synthesize various S-methyl prodrugs that effectively inhibit the functionally essential, polo-box domain (PBD) of Plk1 without affecting its related Plk2 and Plk3 PBDs. These prodrugs effectively arrest mitotic progression and cell proliferation in cell-based assays. Low molecular weight and moderate hydrophobicity of these prodrugs increase their availability in intracellular compartments. Promising chemical features of these compounds could offer a new avenue for developing therapeutics against Plk1-dependent cancers.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Anticancer therapeutics</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Potentially superior toxicity profile while maintaining specificity</li> <li>Inhibition of Plk1-driven cellular proliferation</li> <li>PBD-directed inhibitors show selectivity advantages over classical inhibitors of Plk1</li> <li>Exhibit specific anti-Plk1 PBD activity in both in vitro biochemical and cell-based assays without affecting Plk2 and Plk3 PBDs</li> <li>Anticipated not to be chemically reactive unlike many of the current inhibitors of Plk1 PBD that contain electrophilic groups</li> <li>Exhibit &ge;10-fold higher inhibitory activity than the previously characterized Plk1 PBD-specific phosphopeptide, PLHSpT</li> <li>Low molecular weight and moderate hydrophobicity of these molecules increases their anti-cancer activity in intracellular compartments</li> </ul> 2021-05-05 2026-04-24 2021-05-05 2026-04-24 2021-05-05 CANCER, cell cycle, Heterocyclic Scaffold, Lee, mitosis, Oncology, PBD, plk1, Polo-Box Domain, Polo-Like Kinase 1, PRODRUGS, Triazoloquinazolinone False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-05-05 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-094-2013 E-178-2017 E-179-2017 E-181-2009 E-186-2015 E-254-2016 147161893 Alverez CN, et al. Identification of a new heterocyclic scaffold for inhibitors of the polo-box domain of polo-like kinase 1. https://pubmed.ncbi.nlm.nih.gov/33175530/ <a href="https://pubmed.ncbi.nlm.nih.gov/33175530/">Alverez CN, et al. Identification of a new heterocyclic scaffold for inhibitors of the polo-box domain of polo-like kinase 1.</a> 147163939 Lee, Kyung NIH - NCI NCI Lee, Kyung (NCI) 1 147163938 Jacobson, Kenneth NIH - NIDDK NIDDK Jacobson, Kenneth (NIDDK) 2 147163941 Alverez, Celeste NIH - NCI NCI Alverez, Celeste (NCI) 3 147163940 Park, Jung-Eun NIH - NCI NCI Park, Jung-Eun (NCI) 4 147163939 Lee, Kyung NIH - NCI NCI Lee, Kyung (NCI) 1 147163938 Jacobson, Kenneth NIH - NIDDK NIDDK Jacobson, Kenneth (NIDDK) 2 147163941 Alverez, Celeste NIH - NCI NCI Alverez, Celeste (NCI) 3 147163940 Park, Jung-Eun NIH - NCI NCI Park, Jung-Eun (NCI) 4 147158216 Development Of New Heterocyclic Scaffold-based Prodrugs Against The Polo-box Domain Of Polo-like Kinase 1 E-211-2020-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NCI 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4216] New Heterocyclic Scaffold-Based Inhibitors of the Polo-Box Domain of Polo-like Kinase 1 for the Treatment of Cancer&body=Please send me information about technology [TAB-4216] New Heterocyclic Scaffold-Based Inhibitors of the Polo-Box Domain of Polo-like Kinase 1 for the Treatment of Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4216] New Heterocyclic Scaffold-Based Inhibitors of the Polo-Box Domain of Polo-like Kinase 1 for the Treatment of Cancer&body=Please send me information about technology [TAB-4216] New Heterocyclic Scaffold-Based Inhibitors of the Polo-Box Domain of Polo-like Kinase 1 for the Treatment of Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147161197 E-211-2020-0 E-211-2020-0-US-01 PLK1 POLO BOX DOMAIN INHIBITOR AND METHOD OF TREATING CANCER PRV US 63/082,813 Abandoned US <br />Provisional (PRV) 63/082,813<br />Filed on 2020-09-24<br />Status: Abandoned 147167463 E-211-2020-0 E-211-2020-0-PCT-02 PLK1 POLO BOX DOMAIN INHIBITOR AND METHOD OF TREATING CANCER PCT Patent Cooperation Treaty PCT/US2021/052054 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/052054<br />Filed on 2021-09-24<br />Status: Expired 147167464 E-211-2020-0 E-211-2020-0-AU-01 PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER National Stage Australia 2021350736 Pending Australia <br />National Stage 2021350736<br />Filed on 2023-04-18<br />Status: Pending 147167465 E-211-2020-0 E-211-2020-0-US-02 PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER National Stage US 18/028,463 Pending US <br />National Stage 18/028,463<br />Filed on 2023-03-24<br />Status: Pending 147167466 E-211-2020-0 E-211-2020-0-CA-01 PLK1 POLO BOX DOMAIN INHIBITOR AND METHOD OF TREATING CANCER National Stage Canada 3193855 Pending Canada <br />National Stage 3193855<br />Filed on 2023-03-24<br />Status: Pending 147167467 E-211-2020-0 E-211-2020-0-EP-01 PLK1 POLO DOMAIN INHIBITORS AND METHOD OF TREATING CANCER National Stage European Patent 21795110.2 Pending European Patent <br />National Stage 21795110.2<br />Filed on 2023-04-19<br />Status: Pending 147173725 CANCER 147173726 cell cycle 147173728 Heterocyclic Scaffold 147173729 Lee 147173730 mitosis 147173731 Oncology 147173732 PBD 147173733 plk1 147173735 Polo-Box Domain 147173737 Polo-Like Kinase 1 147173738 PRODRUGS 147173740 Triazoloquinazolinone TAB-4184 147157469 Automated Digital Pathology Device for High-Throughput Demand NCI Infectious Disease, Licensing, Medical Devices, Neurology, Non-Medical Devices, Oncology Infectious Disease Licensing Medical Devices Neurology Non-Medical Devices Oncology Anthony Cappadona, Young-Wan Moon, Zhengping (Ping) Zhuang <h2>Summary:</h2> <p>The NCI is seeking licensees to develop an automated digital pathology device compatible with high-throughput data analysis.</p> <h2>Description of Technology:</h2> <p>Computer and imaging technologies led to the development of digital pathology and the capture and storage of pathological specimens as digitally formatted images. The use of artificial intelligence (AI) in digital pathology, such as in three-dimensional (3D) reconstruction, requires analyses of high volumes of data. This resulted in increased demands for processing and acquisition of digital images of pathology samples. Increased usage cannot be met by the time-consuming, manual, and laborious methods currently used. Therefore, there is a need for automation of the techniques used in processing of pathology samples and acquisition of digital images to make them amenable with high-throughput approaches like AI analysis.</p> <p>National Cancer Institute inventors are developing an automated device with integrated tissue sectioning, staining, scanning, and high-throughput capability. This device integrates pathology sample processing (e.g., sectioning, fixing, and staining) with optical scanning and digital image acquisition. This streamlines the entire process enabling high-throughput preparation of large volumes of samples and data for subsequent AI analysis. As a result of automation, the device saves time, minimizes errors, and reduces wasting reagents and supplies.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Biopsy sample processing in pathology labs, hospitals, research labs</li> <li>Applicable to diagnoses of various disease indications, including cancer and infectious diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Facilitates processing and imaging of large volumes of pathology samples</li> <li>Automation saves time, increases reproducibility, and minimizes errors</li> <li>Compatible with high-throughput processes, e.g., AI analysis of digital pathology images and 3D reconstruction</li> </ul> 2021-09-23 2026-04-24 2021-09-23 2026-04-24 2021-09-23 AI, Artificial Intelligence, AUTOMATION, Digital Pathology, High-throughput, Histology, IMAGING, Zhuang False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-09-23 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147163813 Zhuang, Zhengping (Ping) NIH - NCI NCI Zhuang, Zhengping (Ping) (NCI) 1 147163814 Moon, Young-Wan AIPATec, Inc. Moon, Young-Wan 2 147163815 Cappadona, Anthony NCI - CCR NCI Cappadona, Anthony (NCI) 3 147163813 Zhuang, Zhengping (Ping) NIH - NCI NCI Zhuang, Zhengping (Ping) (NCI) 1 147163814 Moon, Young-Wan AIPATec, Inc. Moon, Young-Wan 2 147163815 Cappadona, Anthony NCI - CCR NCI Cappadona, Anthony (NCI) 3 147157951 Automated Device With Integrated Histology Tissue Sectioning, Staining, And Scanning For High Throughput Demand E-084-2019-0 Filing authorized AIPATec, Inc., NCI 83687903 Pollack, Michael michael.pollack@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4184] Automated Digital Pathology Device for High-Throughput Demand&body=Please send me information about technology [TAB-4184] Automated Digital Pathology Device for High-Throughput Demand.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollack, Michael<br><a href="mailto:michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4184] Automated Digital Pathology Device for High-Throughput Demand&body=Please send me information about technology [TAB-4184] Automated Digital Pathology Device for High-Throughput Demand.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michael.pollack@nih.gov</a><br> 147167192 E-084-2019-0 E-084-2019-0-US-01 Automated Device With Integrated Histology Tissue Sectioning, Staining, And Scanning For High Throughput Demand PRV US 62/820,604 Abandoned US <br />Provisional (PRV) 62/820,604<br />Filed on 2019-03-19<br />Status: Abandoned 147167193 E-084-2019-0 E-084-2019-0-PCT-02 AUTOMATIC SYSTEM AND METHOD FOR TISSUE SECTIONING, STAINING, AND SCANNING PCT Patent Cooperation Treaty PCT/US2020/023644 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/023644<br />Filed on 2020-03-19<br />Status: Expired 147167194 E-084-2019-0 E-084-2019-0-EP-03 AUTOMATIC SYSTEM AND METHOD FOR TISSUE SECTIONING, STAINING, AND SCANNING National Stage European Patent 20772823.9 Pending European Patent <br />National Stage 20772823.9<br />Filed on 2020-03-19<br />Status: Pending 147167195 E-084-2019-0 E-084-2019-0-JP-04 AUTOMATIC SYSTEM AND METHOD FOR TISSUE SECTIONING, STAINING, AND SCANNING National Stage Japan 7680363 2021-555576 Issued Japan <br />National Stage 2021-555576<br />Filed on 2021-09-14<br />Status: Issued 147167196 E-084-2019-0 E-084-2019-0-US-05 AUTOMATIC SYSTEM AND METHOD FOR TISSUE SECTIONING, STAINING, AND SCANNING National Stage US 17/440,368 Pending US <br />National Stage 17/440,368<br />Filed on 2021-09-17<br />Status: Pending 147167197 E-084-2019-0 E-084-2019-0-CN-06 Automated Device With Integrated Histology Tissue Sectioning, Staining, And Scanning For High Throughput Demand National Stage China ZL202080023309.6 202080023309.6 Issued China <br />National Stage 202080023309.6<br />Filed on 2020-03-19<br />Status: Issued 147167198 E-084-2019-0 E-084-2019-0-KR-07 AUTOMATIC SYSTEM AND METHOD FOR TISSUE SECTIONING, STAINING, AND SCANNING National Stage South Korea 10-2021-7033539 Pending South Korea <br />National Stage 10-2021-7033539<br />Filed on 2021-10-18<br />Status: Pending 147171081 AI 147171082 Artificial Intelligence 147171083 AUTOMATION 147171084 Digital Pathology 147171085 High-throughput 147171086 Histology 147171087 IMAGING 147171088 Zhuang TAB-4183 147157468 Size-dependent brain distribution of macromolecular drug delivery platform NCI Collaboration, Licensing, Neurology, Oncology Collaboration Licensing Neurology Oncology Stephan Stern, David Stevens <h2>Summary:</h2> <p>The NCI seeks research co-development partners and/or licensees for&nbsp;a selective polylysine succinylated (PLS) drug delivery platform.</p> <h2>Description of Technology:</h2> <p>The blood brain barrier (BBB) is a specialized endothelium that prevents the uptake of substances from the systemic circulation into the central nervous system. This barrier, while protecting the sensitive physiological environment of the brain, is also a major impediment in administering therapeutics that need to pass through the BBB. A drug delivery platform that could deliver therapeutic agents directly to the brain is needed, and could have wide ranging significance in a variety of psychiatric, oncology, infectious, and neurodegenerative diseases. Currently, there are no approved formulations that can effectively increase drug exposure to the brain, and this remains an unmet clinical need.</p> <p>&nbsp;Investigators in the Nanotechnology Characterization Laboratory at the National Cancer Institute (NCI) have developed a selective polylysine succinylated (PLS) drug delivery platform, which can pass through the BBB by scavenger receptor A1 (SR-A1)- mediated transcytosis, and also target SR-A1 expressing cells, such as macrophages, monocytes, mast cells, and dendritic cells. This PLS polymer has an anionic backbone, containing pendant carboxylic acids that facilitate conjugation of therapeutic agent having a free alcohol moiety via hydrolysable ester bonds. Thus, the PLS platform has tremendous versatility in delivering a wide variety of therapeutic cargos to the brain. In addition to small molecules, other classes of therapeutic drugs that can be conjugated to the PLS polymer include nucleic acids and peptides. In addition to delivering therapeutic agents, this technology can also be used for imaging applications by conjugating imaging agents to the PLS polymer. This technology is a variant of the PLS drug delivery platform previously developed by the inventors (NIH Reference # E-097-2017).&nbsp;&nbsp;</p> <p>Through in vivo mice fluorescent studies, the inventors have shown greater brain distribution with 10k and 25k PLS polymers in comparison to a larger, 62.5k polymer. This polymer platform has tremendous potential to increase drug delivery to the brain and lymphatic system, as well as stabilize metabolically labile drugs. It offers a novel therapeutic strategy for treating brain cancers and other neurological disorders. It also brings a novel imaging approach for diagnostic purposes.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of brain cancer</li> <li>Treatment of neurological disorders representing significant unmet medical needs; e.g., Alzheimer&rsquo;s disease, depression and epilepsy</li> <li>Treatment of infectious diseases</li> <li>Imaging of the central nervous system</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Currently no efficient, general drug delivery system to cross the blood-brain barrier; this invention would be the first-to-market</li> <li>Several go-to-market opportunities; this technology could be used to treat psychiatric, oncology, infectious disease and neurodegenerative-related diseases</li> <li>Would overcome the major factor limiting the future growth of neurotherapeutics</li> </ul> 2021-02-09 2026-04-24 2022-10-04 2026-04-24 2021-02-09 BBB, Blood-brain Barrier, Brain Cancer, Controlled Drug Release, Drug Delivery Platform, Neurological Disorders, Stern False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-10-04 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-097-2017 147161875 Frederick National Laboratory web article entitled &ldquo;Novel prodrug platform enables drug delivery to lymphatic system&rdquo; https://frederick.cancer.gov/news/novel-prodrug-platform-enables-drug-delivery-lymphatic-system <a href="https://frederick.cancer.gov/news/novel-prodrug-platform-enables-drug-delivery-lymphatic-system">Frederick National Laboratory web article entitled &ldquo;Novel prodrug platform enables drug delivery to lymphatic system&rdquo;</a> 147161991 Stephan T. Stern et al., &ldquo;Application of a Scavenger Receptor A1-Targeted Polymeric Prodrug Platform for Lymphatic Drug Delivery in HIV&rdquo;, corresponding to NIH Ref. E-097-20172. https://pubmed.ncbi.nlm.nih.gov/32841040/ <a href="https://pubmed.ncbi.nlm.nih.gov/32841040/">Stephan T. Stern et al., &ldquo;Application of a Scavenger Receptor A1-Targeted Polymeric Prodrug Platform for Lymphatic Drug Delivery in HIV&rdquo;, corresponding to NIH Ref. E-097-20172.</a> 147163811 Stern, Stephan NIH - NCI Leidos Stern, Stephan (Leidos) 1 147163812 Stevens, David NIH - NCI Stevens, David 2 147163811 Stern, Stephan NIH - NCI Leidos Stern, Stephan (Leidos) 1 147163812 Stevens, David NIH - NCI Stevens, David 2 147157936 Size-dependent Brain Distribution Of Macromolecular Drug Delivery Platform E-078-2020-0 Filing authorized NCI, NIH - NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4183] Size-dependent brain distribution of macromolecular drug delivery platform&body=Please send me information about technology [TAB-4183] Size-dependent brain distribution of macromolecular drug delivery platform.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4183] Size-dependent brain distribution of macromolecular drug delivery platform&body=Please send me information about technology [TAB-4183] Size-dependent brain distribution of macromolecular drug delivery platform.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161007 E-078-2020-0 E-078-2020-0-US-01 SIZE-DEPENDENT BRAIN AND LYMPHATIC DISTRIBUTION OF MACROMOLECULAR DRUG DELIVERY PLATFORM PRV US 63/037,058 Abandoned US <br />Provisional (PRV) 63/037,058<br />Filed on 2020-06-10<br />Status: Abandoned 147167186 E-078-2020-0 E-078-2020-0-PCT-02 SIZE-DEPENDENT BRAIN AND LYMPHATIC DISTRIBUTION OF MACROMOLECULAR DRUG DELIVERY PLATFORM PCT Patent Cooperation Treaty PCT/US2021/036548 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/036548<br />Filed on 2021-06-09<br />Status: Expired 147167187 E-078-2020-0 E-078-2020-0-AU-03 SIZE-DEPENDENT BRAIN AND LYMPHATIC DISTRIBUTION OF MACROMOLECULAR DRUG DELIVERY PLATFORM National Stage Australia 2021289443 Pending Australia <br />National Stage 2021289443<br />Filed on 2021-06-09<br />Status: Pending 147167188 E-078-2020-0 E-078-2020-0-CA-04 SIZE-DEPENDENT BRAIN AND LYMPHATIC DISTRIBUTION OF MACROMOLECULAR DRUG DELIVERY PLATFORM National Stage Canada 3186654 Pending Canada <br />National Stage 3186654<br />Filed on 2021-06-09<br />Status: Pending 147167189 E-078-2020-0 E-078-2020-0-EP-05 SIZE-DEPENDENT BRAIN AND LYMPHATIC DISTRIBUTION OF MACROMOLECULAR DRUG DELIVERY PLATFORM National Stage European Patent 21822452.5 Pending European Patent <br />National Stage 21822452.5<br />Filed on 2023-01-05<br />Status: Pending 147167190 E-078-2020-0 E-078-2020-0-US-06 SIZE-DEPENDENT BRAIN AND LYMPHATIC DISTRIBUTION OF MACROMOLECULAR DRUG DELIVERY PLATFORM National Stage US 18/009,710 Pending US <br />National Stage 18/009,710<br />Filed on 2022-12-09<br />Status: Pending 147170873 BBB 147170875 Blood-brain Barrier 147170877 Brain Cancer 147170879 Controlled Drug Release 147170881 Drug Delivery Platform 147170883 Neurological Disorders 147170884 Stern TAB-4136 147157418 IgG4 Hinge Containing Chimeric Antigen Receptors Targeting Glypican-1 For Treating Solid Tumors NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Mitchell Ho, Jessica Hong <h2>Description of Technology:</h2> <p>Pancreatic cancer is the fourth most common cause of cancer deaths in the U.S. The overall 5-year survival rate is 8.5%. Glypican-1 (GPC1) is a cell surface heparan sulfate proteoglycan protein overexpressed in pancreatic cancer. Due to preferential expression, GPC1 represents a potential candidate for targeted therapy for pancreatic cancer and other GPC1-expressing cancers, such as prostate.</p> <p>Researchers at National Cancer Institute (NCI) developed novel Chimeric Antigen Receptors (CARs) specific for GPC1 that include short Immunoglobulin subclass 4 (IgG4) hinge sequences between the extracellular antigen recognition domain and the transmembrane domain. Hinge changes in CAR design can achieve the threshold of antigen density required for optimal CAR-T cell activity. Significantly, the optimized GPC1-IgG4 hinge CARs have shown rapid and complete tumor regression in mouse models.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Immunotherapeutic applications for the treatment of pancreatic adenocarcinoma &ndash; a significant unmet medical need</li> <li>Immunotherapeutic applications for the treatment of several GPC1-positive malignancies &ndash; including uterine cervical cancer, colorectal cancer, liver cancer, glioma, lung cancer, head and neck cancer, thyroid cancer, endometrial cancer, breast cancer and ovarian cancer</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>GPC1-targeted CAR T cells demonstrated potent antitumor efficacy in a peritoneal dissemination xenograft mouse model.</li> <li>Recombinant receptors providing both antigen-binding and T-cell&ndash;activating functions&nbsp;</li> <li>Likely successful targeting and lower toxicity due to high affinity of the GPC1 nanobody fragment</li> <li>Incorporation of the IgG4 hinge sequence increases the potency of the nanobody based CARs against pancreatic cancer&nbsp;</li> <li>CARs using the IgG4 hinge domain are available for immediate testing</li> <li>Potential immunotherapy for several cancer types with few treatment options &ndash; including pancreatic adenocarcinoma and uterine cervical cancer&nbsp;</li> </ul> 2021-08-18 2026-04-24 2021-08-18 2026-04-24 2021-08-18 cancer therapeutic, CAR, chimeric antigen receptor, Glypican-1, GPC-1, Hinge, HO, IgG4, Immunoglobulin subclass 4, NANOBODY, Pancreatic Cancer, Single Domain Antibody False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-08-18 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-028-2019 147163647 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163648 Hong, Jessica NIH - NCI NCI Hong, Jessica (NCI) 2 147163647 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163648 Hong, Jessica NIH - NCI NCI Hong, Jessica (NCI) 2 147158003 IgG4 Hinge Containing Chimeric Antigen Receptors For Treating Solid Tumors E-107-2020-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4136] IgG4 Hinge Containing Chimeric Antigen Receptors Targeting Glypican-1 For Treating Solid Tumors&body=Please send me information about technology [TAB-4136] IgG4 Hinge Containing Chimeric Antigen Receptors Targeting Glypican-1 For Treating Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4136] IgG4 Hinge Containing Chimeric Antigen Receptors Targeting Glypican-1 For Treating Solid Tumors&body=Please send me information about technology [TAB-4136] IgG4 Hinge Containing Chimeric Antigen Receptors Targeting Glypican-1 For Treating Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161052 E-107-2020-0 E-107-2020-0-US-01 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-1 (GPC1) FOR TREATING SOLID TUMORS PRV US 63/065,388 Abandoned US <br />Provisional (PRV) 63/065,388<br />Filed on 2020-08-13<br />Status: Abandoned 147166868 E-107-2020-0 E-107-2020-0-PCT-02 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-1 (GPC1) FOR TREATING SOLID TUMORS PCT Patent Cooperation Treaty PCT/US2021/045305 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/045305<br />Filed on 2021-08-10<br />Status: Expired 147166869 E-107-2020-0 E-107-2020-0-CN-01 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-1 (GPC1) FOR TREATING SOLID TUMORS National Stage China 202180070402.7 Pending China <br />National Stage 202180070402.7<br />Filed on 2023-04-13<br />Status: Pending 147166870 E-107-2020-0 E-107-2020-0-US-02 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-1 (GPC1) FOR TREATING SOLID TUMORS National Stage US 18/020,191 Pending US <br />National Stage 18/020,191<br />Filed on 2023-02-07<br />Status: Pending 147166871 E-107-2020-0 E-107-2020-0-EP-01 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-1 (GPC1) FOR TREATING SOLID TUMORS National Stage European Patent 21762956.7 Pending European Patent <br />National Stage 21762956.7<br />Filed on 2023-02-08<br />Status: Pending 147171570 cancer therapeutic 147171571 CAR 147171572 chimeric antigen receptor 147171573 Glypican-1 147171575 GPC-1 147171576 Hinge 147171577 HO 147171578 IgG4 147171580 Immunoglobulin subclass 4 147171581 NANOBODY 147171582 Pancreatic Cancer 147171583 Single Domain Antibody TAB-4135 147157417 3-o-sulfo-galactosylceramide Analogs for Targeting Lung Metastases NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Jay Berzofsky, Kaddy Camara, Amy Howell, Lise Pasquet, Masaki Terabe <h2>Summary:</h2> <p>The NCI seeks research co-development partners and/or licensees for the sulfatide analog, C24:2</p> <h2>Description of Technology:</h2> <p>Lung metastases represent a major clinical challenge in advanced cancer, with poor survival rates and no effective therapies to prevent their development. Researchers at the National Cancer Institute (NCI) have developed C24:2, a first-in-class synthetic 3-O-sulfo-galactosylceramide analog. After lysosomal processing by dendritic cells, C24:2 switches immune specificity to activate type I NKT cells, triggering a potent IFN-&gamma;&ndash;mediated Th1 response. This novel mechanism significantly reduces lung metastases in preclinical models and positions C24:2 as a promising candidate for next-generation cancer immunotherapy.</p> <p>The structure and synthesis procedure of C24:2 are described in Patent Cooperation Treaty PCT/US2019/023890 which corresponds to E-100-2018 and for which Dr. Jay Berzofsky is the lead inventor. .</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic agent for lung metastases from different types of cancers</li> <li>Immunomodulator for type I NKT cell</li> <li>Combination therapy with checkpoint inhibitors or cancer vaccines</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Addresses a high unmet need: No effective therapies currently exist for lung metastases.</li> <li>First-in-class approach: Exploits a unique mechanism based on antigen processing and NKT cell subtype switching.</li> <li>Broad cancer applicability: Effective against metastases from diverse tumor types.</li> <li>Combination potential: May synergize with approved checkpoint inhibitors to boost patient outcomes</li> </ul> The NCI seeks research co-development partners and/or licensees for the sulfatide analog, C24:2. 2021-02-24 2026-04-24 2021-02-24 2026-04-24 2021-02-24 3-o-sulfo-galactosylceramide Analogs, Berzofsky, C24:2, Immunotherapy, lung cancer, Metastasis, Natural Killer cells, NKT cells, Sulfatide Analogs, T Cells False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-02-24 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-034-2010 164128544 Nishio et al. Lysosomal processing of sulfatide analogs alters target NKT cell specificity and immune responses in cancer. (PMID 38127463) https://pubmed.ncbi.nlm.nih.gov/38127463/ <a href="https://pubmed.ncbi.nlm.nih.gov/38127463/">Nishio et al. Lysosomal processing of sulfatide analogs alters target NKT cell specificity and immune responses in cancer. (PMID 38127463)</a> 147163644 Pasquet, Lise NIH - NCI Pasquet, Lise 1 147163642 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 2 147163645 Howell, Amy University of Connecticut Howell, Amy 3 147163643 Terabe, Masaki NIH - NCI NCI Terabe, Masaki (NCI) 4 147163646 Camara, Kaddy University of Connecticut Camara, Kaddy 5 147163644 Pasquet, Lise NIH - NCI Pasquet, Lise 1 147163642 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 2 147163645 Howell, Amy University of Connecticut Howell, Amy 3 147163643 Terabe, Masaki NIH - NCI NCI Terabe, Masaki (NCI) 4 147163646 Camara, Kaddy University of Connecticut Camara, Kaddy 5 147157987 C24:2 Activates The Regulatory Type II NKT Cells And Limits The Development Of Lung Metastasis E-100-2018-0 Filing authorized NCI, University of Connecticut 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4135] 3-o-sulfo-galactosylceramide Analogs for Targeting Lung Metastases&body=Please send me information about technology [TAB-4135] 3-o-sulfo-galactosylceramide Analogs for Targeting Lung Metastases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4135] 3-o-sulfo-galactosylceramide Analogs for Targeting Lung Metastases&body=Please send me information about technology [TAB-4135] 3-o-sulfo-galactosylceramide Analogs for Targeting Lung Metastases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">diptadip.dattaroy@nih.gov</a><br> 147161038 E-100-2018-0 E-100-2018-0-US-01 ACTIVATORS OF TYPE II NKT CELLS AND METHODS OF USE THEREOF PRV US 62/648,167 Abandoned US <br />Provisional (PRV) 62/648,167<br />Filed on 2018-03-26<br />Status: Abandoned 147166864 E-100-2018-0 E-100-2018-0-PCT-02 ACTIVATORS OF TYPE II NKT CELLS AND METHODS OF USE THEREOF PCT Patent Cooperation Treaty PCT/US2019/023890 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/023890<br />Filed on 2019-03-25<br />Status: Expired 147166865 E-100-2018-0 E-100-2018-0-EP-03 3-O-SULFO-GALACTOSYLCERAMIDE ANALOGS AS ACTIVATORS OF TYPE II NKT CELLS AND USES THEREOF National Stage European Patent 3774830 19716658.0 Issued European Patent <br />National Stage 19716658.0<br />Filed on 2020-10-07<br />Status: Issued 147166866 E-100-2018-0 E-100-2018-0-US-04 3-O-SULFO-GALACTOSYLCERAMIDE ANALOGS AS ACTIVATORS OF TYPE II NKT CELLS AND USES THEREOF National Stage US 12,268,700 17/041,604 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12268700 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12268700">12,268,700</a><br />Filed on 2020-09-25<br />Status: Issued 147171417 3-o-sulfo-galactosylceramide Analogs 147171419 Berzofsky 147171420 C24:2 147171421 Immunotherapy 147171422 lung cancer 147171423 Metastasis 147171425 Natural Killer cells 147171427 NKT cells 147171429 Sulfatide Analogs 147171430 T Cells TAB-4133 147157415 CytoSig: A Software Platform for Predicting Cytokine Signaling Activities, Target Discovery, and Clinical Decision Support System (CDSS) from Transcriptomic Profiles NCI Collaboration, Immunology, Licensing, Oncology, Research Materials Collaboration Immunology Licensing Oncology Research Materials Peng Jiang <h2>Description of Technology:</h2> <p>Cytokines are a broad category of intercellular signaling proteins that are critical for intercellular communication in human health and disease. However, systematic profiling of cytokine signaling activities has remained challenging due to the short half-lives of cytokines, and the pleiotropic functions and redundancy of cytokine activities within specific cellular contexts. The redundancy and pleiotropy in cytokine activities are not fully captured by most immunological assays such as the enzyme-linked immunosorbent assay (ELISA) and Luminex xMAP, which only measures the cytokine release level that could be transient and do not reflect target signaling activities. On the other hand, existing databases of cytokine signaling targets cover only a small fraction of cytokines, leaving most cytokine-induced target changes unexplored.&nbsp;</p> <p>Researchers at National Cancer Institute (NCI) have developed the Cytokine Signaling Analyzer (CytoSig) that uses transcriptome data to model the cytokine signaling activity and regulatory cascade in human inflammatory processes. To build the CytoSig platform, the Framework for Data Curation (FDC) was created to couple large-scale automatic data processing with natural language processing functions to assist expert annotations of metadata to analyze RNA-sequencing (RNA-seq) and MicroArray big-data resources. CytoSig includes an initial set of 20,591 curated human cytokine, chemokine, and growth factor response experiments, and can reliably predict the activity of 43 cytokines in both tissues and single cells based on the transcriptional effect of cytokine target genes. CytoSig, an excellent tool for leveraging the big-data resource in public domains to predict clinical outcome of anticancer therapies that inhibit cytokine signaling, is available for co-development and/or licensing.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Predicting cytokine target activities from bulk transcriptomic data available from large-scale cohorts and single-cell RNA-seq data</li> <li>Identifying new immunological functions of cytokines and candidate therapeutic targets in inflammatory diseases</li> <li>Predicting the clinical outcome of therapies that inhibit cytokine signaling in human inflammatory diseases and cancer.</li> <li>Framework for Data Curation (FDC) can be used by data scientists to accelerate data curation projects</li> <li>Applicable to cancers, infectious diseases, and inflammation</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li style="margin-left:9pt">Integrative framework that leverages the big-data resource in public domains to identify candidate therapeutic targets</li> <li style="margin-left:9pt">Higher cytokine coverage compared to existing databases</li> <li style="margin-left:9pt">CytoSig predictions had better associations with the clinical outcome than other metrics, such as ligand or receptor expression and gene-set signatures</li> <li style="margin-left:9pt">Offers particular advantages in analyzing single-cell data because it is not affected by the absence of cytokine-producing cells or zero read counts for ligand or receptor genes</li> </ul> 2021-11-17 2026-04-24 2021-11-17 2026-04-24 2021-11-17 Big-data Integration, Cancer Immunotherapy, CDSS, Clinical Decision Support System, Cytokine Signaling, Infectious Disease, Inflammation, Jiang, Target Discovery, Transcriptomic Profiles False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-11-17 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161877 Jiang P, et al. Systematic investigation of cytokine signaling activity at the tissue and single-cell levels. https://pubmed.ncbi.nlm.nih.gov/34594031/ <a href="https://pubmed.ncbi.nlm.nih.gov/34594031/">Jiang P, et al. Systematic investigation of cytokine signaling activity at the tissue and single-cell levels.</a> 147163639 Jiang, Peng NCI - DCTD NCI Jiang, Peng (NCI) 1 147163639 Jiang, Peng NCI - DCTD NCI Jiang, Peng (NCI) 1 147157955 CellSig: A Data-driven Predictive Model Of Cytokine Signaling And Regulatory Activity E-086-2021-0 Research Material NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-4133] CytoSig: A Software Platform for Predicting Cytokine Signaling Activities, Target Discovery, and Clinical Decision Support System (CDSS) from Transcriptomic Profiles&body=Please send me information about technology [TAB-4133] CytoSig: A Software Platform for Predicting Cytokine Signaling Activities, Target Discovery, and Clinical Decision Support System (CDSS) from Transcriptomic Profiles.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-4133] CytoSig: A Software Platform for Predicting Cytokine Signaling Activities, Target Discovery, and Clinical Decision Support System (CDSS) from Transcriptomic Profiles&body=Please send me information about technology [TAB-4133] CytoSig: A Software Platform for Predicting Cytokine Signaling Activities, Target Discovery, and Clinical Decision Support System (CDSS) from Transcriptomic Profiles.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147171118 Big-data Integration 147171119 Cancer Immunotherapy 147171121 CDSS 147171123 Clinical Decision Support System 147171125 Cytokine Signaling 147171126 Infectious Disease 147171127 Inflammation 147171129 Jiang 147171131 Target Discovery 147171133 Transcriptomic Profiles TAB-4070 147157352 Human Synovial Sarcoma Cell Line A2243 NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Stuart Aaronson, Nelson Ellmore (Estate) <h2>Summary:</h2> <p>NCI is seeking parties to non-exclusively license the A2243 human synovial sarcoma cell line.</p> <h2>Description of Technology:</h2> <p>Synovial sarcoma is a cancer affecting mesenchymal cells in connective tissues. This rare cancer is typically linked to genetic abnormalities or exposure to radiation. Metastatic growth throughout the body can occur primarily through blood circulation. More than 90% of synovial sarcomas show a characteristic t(X;18)(p11;q11) translocation involving the SYT and SSX genes. The resulting SYT-SSX abnormal fusion protein causes misregulation of downstream gene expression, leading to tumor formation.</p> <p>Researchers at the National Cancer Institute (NCI), Laboratory of Cellular and Molecular Biology (LCMB), have derived a cell line, A2243, from a patient with human synovial sarcoma. This cell line forms tumors in nude mice. The A2243 cell line has been used to characterize the abnormal karyotype associated with synovial sarcoma. Additionally, the A2243 cell line has been used to discover the gene involved in recurrent chromosomal translocation.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research tool for drug screening efforts</li> <li>Research tool for identifying general and specific chromosomal translocations in synovial sarcoma</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Well-characterized cell line for a rare human cancer: synovial sarcoma</li> </ul> Available for licensing 2021-05-19 2026-04-24 2021-05-25 2026-04-24 2021-05-25 A2243, Aaronson, Chromosomal Translocation, CONNECTIVE TISSUE, Drug Screening, Human Cell Line, Mesenchymal Cells, Rare Cancer, SSX, Synovial sarcoma, SYT, tumor formation False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-05-25 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162236 Clark J, et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. https://pubmed.ncbi.nlm.nih.gov/7951320/ <a href="https://pubmed.ncbi.nlm.nih.gov/7951320/">Clark J, et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma.</a> 147163413 Aaronson, Stuart NIH - NCI Aaronson, Stuart 1 147163414 Ellmore (Estate), Nelson NIH - NCI NCI Ellmore (Estate), Nelson (NCI) 2 147163413 Aaronson, Stuart NIH - NCI Aaronson, Stuart 1 147163414 Ellmore (Estate), Nelson NIH - NCI NCI Ellmore (Estate), Nelson (NCI) 2 147158107 Human Synovial Sarcoma Cell Line A2243 E-160-2005-0 Research Material NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4070] Human Synovial Sarcoma Cell Line A2243&body=Please send me information about technology [TAB-4070] Human Synovial Sarcoma Cell Line A2243.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4070] Human Synovial Sarcoma Cell Line A2243&body=Please send me information about technology [TAB-4070] Human Synovial Sarcoma Cell Line A2243.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">suna.gulay@nih.gov</a><br> 147172626 A2243 147172627 Aaronson 147172629 Chromosomal Translocation 147172630 CONNECTIVE TISSUE 147172631 Drug Screening 147172633 Human Cell Line 147172635 Mesenchymal Cells 147172637 Rare Cancer 147172639 SSX 147172640 Synovial sarcoma 147172642 SYT 147172643 tumor formation TAB-4059 147157341 Small Molecule Ephrin (Eph) Tyrosine Kinase Inhibitors for the Treatment of Colorectal Cancer and Other Eph Growth-dependent Solid Tumors NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Michael Diprima, Nathalie Jores, Denis Kudlinzki, Harald Schwalbe, Giovanna Tosato, Alix Troster <h2>Description of Technology:</h2> <p>Advanced colorectal carcinoma is currently incurable, and new therapies are urgently needed. Ephrin (Eph) receptors are a clinically relevant class of receptor tyrosine kinases. Related signaling pathways are associated with oncogenesis of a number of cancers. NCI investigators found that phosphotyrosine-dependent Eph receptor signaling sustains colorectal carcinoma cell survival, thereby uncovering a survival pathway active in colorectal carcinoma cells. Furthermore, colorectal cancers express the EphrinB2 ligand and its Eph receptors at significantly higher levels than numerous other cancer types. Colorectal cancer patients with the highest levels of EphrinB2 expression in their tumor have a lower probability of survival than those with the lowest levels.</p> <p>The NCI investigators found that a small-molecule inhibitor of the Eph kinase, NVP-BHG712 and its regioisomer NVP-Iso, reduce human colorectal cancer cell growth <em>in vitro</em> and tumor growth in mice. Proof-of-concept data demonstrate inhibition of the Eph tyrosine kinase inhibits the growth of human colorectal carcinomas. Eph signaling sustains colorectal carcinoma cell survival and growth and that inhibition of the phosphotyrosine‐dependent Eph signaling is effective at blocking this prosurvival function. Several derivatives of these prototype compounds have been synthesized and tested for inhibition of the Eph tyrosine kinase activity. Two of these new derivatives have promising biochemical and functional profiles.&nbsp; These small molecule inhibitors have the potential to be developed as a therapeutic for colorectal cancers, other types of Eph-growth dependent tumors, and diseases where the Eph kinase plays a pathogenic role.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutics for colorectal cancer</li> <li>Therapeutics for other Eph growth-dependent cancers, including breast, lung, prostate, and brain</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Differs in targeting selectivity from many other tyrosine kinase inhibitors</li> <li>Distinct mechanism of action from Regorafenib, the only existing receptor tyrosine inhibitor approved to treat metastatic colorectal cancer; Regorafenib is a multi-targeted tyrosine kinase inhibitor developed to inhibit VEGF-dependent tumor angiogenesis</li> <li>Promising combination therapy when used with other tyrosine kinase inhibitors and antibodies &ndash; such as Cetuximab (approved for metastatic colorectal cancer)</li> <li>Overcome resistance to EGFR or BRAF treatment in various tumor types; attributed to EphA2 kinase activity</li> </ul> 2021-12-14 2026-04-24 2021-12-14 2026-04-24 2021-12-14 colorectal cancer, Eph Kinase Inhibitors, Eph-related cancers, Ephrin, NVP-BHG712, Regioisomer NVP-Iso, small molecule, solid tumors, Tosato, Tyrosine kinase inhibitors False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-12-14 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162046 Diprima M, et al. Identification of Eph receptor signaling as a regulator of autophagy and a therapeutic target in colorectal carcinoma. https://pubmed.ncbi.nlm.nih.gov/31545551/ <a href="https://pubmed.ncbi.nlm.nih.gov/31545551/">Diprima M, et al. Identification of Eph receptor signaling as a regulator of autophagy and a therapeutic target in colorectal carcinoma.</a> 147163376 Tosato, Giovanna NIH - NCI NCI Tosato, Giovanna (NCI) 1 147163377 Diprima, Michael NIH - NCI NCI Diprima, Michael (NCI) 2 147163378 Schwalbe, Harald J.W. Goethe University, Frankfurt Schwalbe, Harald 3 147163379 Troster, Alix J.W. Goethe University, Frankfurt Troster, Alix 4 147163380 Jores, Nathalie J.W. Goethe University, Frankfurt Jores, Nathalie 5 147163381 Kudlinzki, Denis German Cancer Research Center [Deutsches Krebsforschungszentrum] Kudlinzki, Denis 6 147163376 Tosato, Giovanna NIH - NCI NCI Tosato, Giovanna (NCI) 1 147163377 Diprima, Michael NIH - NCI NCI Diprima, Michael (NCI) 2 147163378 Schwalbe, Harald J.W. Goethe University, Frankfurt Schwalbe, Harald 3 147163379 Troster, Alix J.W. Goethe University, Frankfurt Troster, Alix 4 147163380 Jores, Nathalie J.W. Goethe University, Frankfurt Jores, Nathalie 5 147163381 Kudlinzki, Denis German Cancer Research Center [Deutsches Krebsforschungszentrum] Kudlinzki, Denis 6 147158164 A Receptor Tyrosine Kinase Inhibitor Is Identified As An Effective Drug For Treatment Of Colorectal Carcinoma E-182-2019-0 Filing authorized NCI 147162554 A Receptor Tyrosine Kinase Inhibitor Is Identified As An Effective Drug For Treatment Of Colorectal Carcinoma E-182-2019-1 Filing authorized J.W. Goethe University, Frankfurt, NCI 147162555 A Receptor Tyrosine Kinase Inhibitor Is Identified As An Effective Drug For Treatment Of Colorectal Carcinoma E-182-2019-2 Filing authorized German Cancer Research Center [Deutsches Krebsforschungszentrum], J.W. Goethe University, Frankfurt, NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-4059] Small Molecule Ephrin (Eph) Tyrosine Kinase Inhibitors for the Treatment of Colorectal Cancer and Other Eph Growth-dependent Solid Tumors&body=Please send me information about technology [TAB-4059] Small Molecule Ephrin (Eph) Tyrosine Kinase Inhibitors for the Treatment of Colorectal Cancer and Other Eph Growth-dependent Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-4059] Small Molecule Ephrin (Eph) Tyrosine Kinase Inhibitors for the Treatment of Colorectal Cancer and Other Eph Growth-dependent Solid Tumors&body=Please send me information about technology [TAB-4059] Small Molecule Ephrin (Eph) Tyrosine Kinase Inhibitors for the Treatment of Colorectal Cancer and Other Eph Growth-dependent Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147161160 E-182-2019-2 E-182-2019-2-PCT-01 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER PCT COMB Patent Cooperation Treaty PCT/US2020/050439 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2020/050439<br />Filed on 2020-09-11<br />Status: Expired 147166252 E-182-2019-0 E-182-2019-0-US-01 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER PRV US 62/900,240 Abandoned US <br />Provisional (PRV) 62/900,240<br />Filed on 2019-09-13<br />Status: Abandoned 147166254 E-182-2019-1 E-182-2019-1-US-01 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER PRV US 63/070,739 Abandoned US <br />Provisional (PRV) 63/070,739<br />Filed on 2020-08-26<br />Status: Abandoned 147166257 E-182-2019-2 E-182-2019-2-CA-03 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER National Stage Canada 3153096 Pending Canada <br />National Stage 3153096<br />Filed on 2020-09-11<br />Status: Pending 147166259 E-182-2019-2 E-182-2019-2-EP-05 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER National Stage European Patent 20785624.6 Pending European Patent <br />National Stage 20785624.6<br />Filed on 2020-09-11<br />Status: Pending 147166261 E-182-2019-2 E-182-2019-2-US-07 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER National Stage US 12,486,270 17/692,978 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12486270 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12486270">12,486,270</a><br />Filed on 2022-03-11<br />Status: Issued 147173183 colorectal cancer 147173185 Eph Kinase Inhibitors 147173187 Eph-related cancers 147173188 Ephrin 147173190 NVP-BHG712 147173192 Regioisomer NVP-Iso 147173193 small molecule 147173194 solid tumors 147173195 Tosato 147173197 Tyrosine kinase inhibitors TAB-4031 147157312 Adriamycin-Resistant Ovarian Tumor Cell Line, NCI/ADR-RES NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Kenneth Cowan <h2>Summary:</h2> <p>NCI is seeking parties to non-exclusively license the ADR-RES cell line.</p> <h2>Description of Technology:</h2> <p>Cancer cells may acquire drug resistance after prolonged chemotherapy. In many cases, cancer cells develop resistance to several drugs with distinct structures and modes of action. This multi-drug resistance phenomenon increases the complexity of cancer treatment.</p> <p>Researchers at the National Cancer Institute (NCI) have derived an Adriamycin-resistant cell line, NCI/ADR-RES, from human ovarian cancer cells. The parental cell line is OVCAR-8, obtained from a high-grade ovarian serous adenocarcinoma. NCI/ADR-RES is resistant to Adriamycin and found to express high levels of the Multi-Drug Resistance 1 (MDR1) protein &ndash; also known as P-glycoprotein. The cell line was extensively characterized and proven useful in identifying compounds subject to multi-drug resistance. NCI/ADR-RES was deposited into the Division of Cancer Treatment and Diagnosis (DCTD) Developmental Therapeutics Program (DTP) Tumor Repository and added to the NCI-60 Human Tumor Cell Lines Screen, along with parental OVCAR-8. Molecular characterization data are publicly available on the DTP website.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research tool to study the multi-drug resistance phenomenon in cancer</li> <li>Research tool to study Adriamycin resistance in ovarian cancer</li> <li>Research tool to study the overexpression of MDR1 (P-glycoprotein) in cancer</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Extensively characterized and documented human ovarian adenocarcinoma cell line</li> <li>Part of the NCI anti-cancer drug screen human cell line panel (NCI-60 Human Tumor Cell Lines Screen)</li> <li>Molecular characterization data are publicly available</li> </ul> 2021-06-04 2026-04-24 2021-06-04 2026-04-24 2021-06-04 ADENOCARCINOMA, Adriamycin-resistant, Cell line, Cowan, MCF-7/ADR-RES, MDR1, Multi-Drug Resistance, NCI/ADR-RES, OVARIAN CANCER, OVCAR-8, P-GLYCOPROTEIN False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-06-04 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161881 Scudiero DA, et al. Cell line designation change: multidrug-resistant cell line in the NCI anti-cancer screen. https://pubmed.ncbi.nlm.nih.gov/9625176/ <a href="https://pubmed.ncbi.nlm.nih.gov/9625176/">Scudiero DA, et al. Cell line designation change: multidrug-resistant cell line in the NCI anti-cancer screen.</a> 147162269 Batist G, et al. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. https://pubmed.ncbi.nlm.nih.gov/3782078/ <a href="https://pubmed.ncbi.nlm.nih.gov/3782078/">Batist G, et al. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells.</a> 147162422 Vert A, et al. Transcriptional profiling of NCI/ADR-RES cells unveils a complex network of signaling pathways and molecular mechanisms of drug resistance. https://pubmed.ncbi.nlm.nih.gov/29379303/ <a href="https://pubmed.ncbi.nlm.nih.gov/29379303/">Vert A, et al. Transcriptional profiling of NCI/ADR-RES cells unveils a complex network of signaling pathways and molecular mechanisms of drug resistance.</a> 147163284 Cowan, Kenneth NIH - NCI NCI Cowan, Kenneth (NCI) 1 147163284 Cowan, Kenneth NIH - NCI NCI Cowan, Kenneth (NCI) 1 147158018 ADR-RES (adriamycin-resistant Cell Line) Cell Line E-115-2021-0 Research Material NCI 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4031] Adriamycin-Resistant Ovarian Tumor Cell Line, NCI/ADR-RES&body=Please send me information about technology [TAB-4031] Adriamycin-Resistant Ovarian Tumor Cell Line, NCI/ADR-RES.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4031] Adriamycin-Resistant Ovarian Tumor Cell Line, NCI/ADR-RES&body=Please send me information about technology [TAB-4031] Adriamycin-Resistant Ovarian Tumor Cell Line, NCI/ADR-RES.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">diptadip.dattaroy@nih.gov</a><br> 147171738 ADENOCARCINOMA 147171739 Adriamycin-resistant 147171740 Cell line 147171742 Cowan 147171744 MCF-7/ADR-RES 147171745 MDR1 147171747 Multi-Drug Resistance 147171749 NCI/ADR-RES 147171750 OVARIAN CANCER 147171752 OVCAR-8 147171753 P-GLYCOPROTEIN TAB-3966 147157246 Immunogens for Use in a High Efficacy HIV Vaccine NCI Collaboration, Infectious Disease, Licensing, Vaccines Collaboration Infectious Disease Licensing Vaccines Manuel Becerra-Flores, Massimiliano Bissa, Timothy Cardozo, Genoveffa Franchini, Giacomo Gorini, Isabela Silva De Castro <h2>Summary:</h2> <p>The Vaccine Branch is seeking statements of capability or interest from parties interested in licensing V1-deleted immunogens to further develop, evaluate, or commercialize an improved HIV vaccine.</p> <h2>Description of Technology:</h2> <p>Human immunodeficiency virus (HIV) infections remain a pandemic, most prevalent in Africa and the Americas. Anti-retroviral treatments have been effective in preventing spread of the virus and active outbreaks of acquired immune deficiency syndrome (AIDS). However, the development and deployment of an effective vaccine would provide long-lasting protection and alleviate the need to depend heavily on prevention methods that require continued access and adherence. Immunization with the genetically engineered versions of HIV surface glycoprotein gp120, along with env, gag, pol, has been a promising approach that needs improved efficacy (currently at ~30%).&nbsp;</p> <p>Researchers at NCI have previously shown the levels and avidity of antibodies against variable envelope region 2 (V2) of gp120 correlate with protection of young macaques against the closely related simian immunodeficiency virus (SIV), while antibodies against V1 have an opposing effect on immunity. To improve the current HIV vaccine efforts, they deleted the V1 region from gp120, while preserving the V2 folded conformation, in a collaboration with researchers at NYU. They demonstrated increased antigenicity of V2 upon V1 deletion, as well as increased binding to soluble CD4 receptors. They further observed higher V2 responses in macaques with V1-deleted gp120 immunogen. Using SIV as a model, they could increase vaccine efficacy to nearly 70%.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Human immunodeficiency virus (HIV) vaccine</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Superior vaccine efficacy up to 70% using the closely related SIV as a model</li> <li>Increased antibody recognition of V2 via V1-deleted gp120 immunogens, previously associated with protection from SIV</li> <li>Increased V2 responses (in macaques, elicited via V1-deleted gp120 immunogens)</li> </ul> 2021-05-25 2026-04-24 2021-06-16 2026-04-24 2021-06-16 AIDS, Franchini, GLYCOPROTEIN, gp120, HIV, Human Immunodeficiency Virus, V1, V2, Vaccine, Variable Envelope Region False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-06-16 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-062-2014 E-157-2000 147161964 Silva de Castro I, et al. Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates. https://doi.org/10.1016/j.isci.2021.102047 <a href="https://doi.org/10.1016/j.isci.2021.102047">Silva de Castro I, et al. Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates.</a> 147162351 Vaccari M, et al. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. https://www.ncbi.nlm.nih.gov/pubmed/27239761 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27239761">Vaccari M, et al. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition.</a> 147162389 Gordon SN, et al. Boosting of ALVAC-SIV vaccine-primed macaques with the CD4-SIVgp120 fusion protein elicits antibodies to V2 associated with a decreased risk of SIVmac251 acquisition. https://www.ncbi.nlm.nih.gov/pubmed/27591322 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27591322">Gordon SN, et al. Boosting of ALVAC-SIV vaccine-primed macaques with the CD4-SIVgp120 fusion protein elicits antibodies to V2 associated with a decreased risk of SIVmac251 acquisition.</a> 147163043 Franchini, Genoveffa NIH - NCI NCI Franchini, Genoveffa (NCI) 1 147163045 Cardozo, Timothy New York University School of Medicine Cardozo, Timothy 2 147163046 Silva De Castro, Isabela NCI - CCR Silva De Castro, Isabela 3 147163047 Gorini, Giacomo NIH - NCI Gorini, Giacomo 4 147163044 Bissa, Massimiliano NIH - NCI NCI Bissa, Massimiliano (NCI) 5 147163048 Becerra-Flores, Manuel NIH - New York University School of Medicine Becerra-Flores, Manuel 6 147163043 Franchini, Genoveffa NIH - NCI NCI Franchini, Genoveffa (NCI) 1 147163045 Cardozo, Timothy New York University School of Medicine Cardozo, Timothy 2 147163046 Silva De Castro, Isabela NCI - CCR Silva De Castro, Isabela 3 147163047 Gorini, Giacomo NIH - NCI Gorini, Giacomo 4 147163044 Bissa, Massimiliano NIH - NCI NCI Bissa, Massimiliano (NCI) 5 147163048 Becerra-Flores, Manuel NIH - New York University School of Medicine Becerra-Flores, Manuel 6 147158109 Delta V1/V2a Gp120 Immunogens To Augment Protective V2 Responses E-160-2018-0 Filing authorized NCI, New York University School of Medicine 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-3966] Immunogens for Use in a High Efficacy HIV Vaccine&body=Please send me information about technology [TAB-3966] Immunogens for Use in a High Efficacy HIV Vaccine.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-3966] Immunogens for Use in a High Efficacy HIV Vaccine&body=Please send me information about technology [TAB-3966] Immunogens for Use in a High Efficacy HIV Vaccine.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">diptadip.dattaroy@nih.gov</a><br> 147165586 E-160-2018-0 E-160-2018-0-US-01 RECOMBINANT GP120 PROTEIN WITH V1-LOOP DELETION PRV US 62/748,905 Abandoned US <br />Provisional (PRV) 62/748,905<br />Filed on 2018-10-22<br />Status: Abandoned 147165587 E-160-2018-0 E-160-2018-0-PCT-02 RECOMBINANT GP120 PROTEIN WITH V1-LOOP DELETION PCT Patent Cooperation Treaty PCT/US2019/057268 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/057268<br />Filed on 2019-10-21<br />Status: Expired 147165588 E-160-2018-0 E-160-2018-0-AU-03 RECOMBINANT GP120 PROTEIN WITH V1-LOOP DELETION National Stage Australia 2019368218 2019368218 Issued Australia <br />National Stage 2019368218<br />Filed on 2019-10-21<br />Status: Issued 147165589 E-160-2018-0 E-160-2018-0-CA-04 RECOMBINANT GP120 PROTEIN WITH V1-LOOP DELETION National Stage Canada 3117390 Pending Canada <br />National Stage 3117390<br />Filed on 2019-10-21<br />Status: Pending 147165590 E-160-2018-0 E-160-2018-0-EP-05 RECOMBINANT GP120 PROTEIN WITH V1-LOOP DELETION National Stage European Patent 19804901.7 Pending European Patent <br />National Stage 19804901.7<br />Filed on 2019-10-21<br />Status: Pending 147165591 E-160-2018-0 E-160-2018-0-US-06 RECOMBINANT GP120 PROTEIN WITH V1-LOOP DELETION National Stage US 12,162,910 17/285,453 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12162910 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12162910">12,162,910</a><br />Filed on 2021-04-14<br />Status: Issued 147172646 AIDS 147172647 Franchini 147172648 GLYCOPROTEIN 147172649 gp120 147172650 HIV 147172651 Human Immunodeficiency Virus 147172652 V1 147172653 V2 147172654 Vaccine 147172656 Variable Envelope Region TAB-3963 147157243 SMAD3 Reporter Mouse for Assessing TGF-ß/Activin Pathway Activation NCI Cardiology, Endocrinology, Immunology, Licensing, Neurology, Oncology, Research Materials Cardiology Endocrinology Immunology Licensing Neurology Oncology Research Materials Caroline Hill, Sushil Rane, Lalage Wakefield, Yu-an Yang <h2>Description of Technology:</h2> <p>The Transforming Growth Factor Beta (TGF-&szlig;) ligands (i.e., TGF-&szlig;1, -&szlig;2, -&szlig;3) are key regulatory proteins in animal physiology. Disruption of normal TGF-&szlig; signaling is associated with many diseases from cancer to fibrosis. In mice and humans, TGF-&szlig; activates TGF-&szlig; receptors (e.g., TGFBR1), which activates SMAD proteins that alter gene expression and contribute to tumorigenesis.&nbsp; Reliable animal models are essential for the study of TGF-&szlig; signaling. A previously developed animal model for TGF-&szlig; signaling utilizes a luciferase expression system under the control of SMAD protein responsive promoter elements (Lin et al., 2005, J. Immunol). The luciferase-based reporter mouse requires administering luciferin for bioluminescence detection. Another previously developed model is a SMAD protein-responsive, green fluorescent protein (GFP)-based reporter mouse (Neptune et al., 2003, Nat. Genet.); however, the model is no longer available. Thus, there remains a need for novel reporter animal models to study TGF-&szlig; signaling.</p> <p>NCI investigators designed an enhanced GFP (eGFP)-based reporter construct that is more sensitive to SMAD3 activation than other existing reporter constructs. Expression of eGFP is driven by an artificial enhancer element consisting of six repeats of a strong SMAD3 binding element. This reporter was greater than ten times more sensitive in vitro than the CAGA12-based reporter, another commonly used construct to detect TGF-&szlig; signaling.&nbsp; Using CRISPR/Cas9 technology, the inventors knocked this reporter construct into the Rosa26 locus, a ubiquitously expressed gene in most cells of the mouse. This strategy allows identification of tissues and cells in which signaling of TGF-&beta;s are endogenously active during normal development, tissue homeostasis, and disease.</p> <p>The mouse model is currently undergoing further validation using genetic and pharmacological approaches. It is available for licensing.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Development of oncology therapeutics</li> <li>Developing of fibrosis therapeutics</li> <li>Pre-clinical in vivo model to study TGF-&beta; signaling and pathway antagonists</li> <li>Pre-clinical model for TGF-&beta;/SMAD3 disease states</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>No requirement for luciferin injections</li> <li>Higher sensitivity for SMAD3 activation than other reporters</li> </ul> 2021-12-14 2026-04-24 2021-12-14 2026-04-24 2021-12-14 Animal Model, CANCER, EGFP, Fibrosis, Wakefield, mothers against decapentaplegic homolog 3, Oncology, Reporter Mouse, SMAD3, TGF-ß, Transforming Growth Factor Beta False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-12-14 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162000 Yang Y, et al. A new TGF-ß pathway reporter mouse for analysis of TGF-β signaling in normal homeostasis and cancer. https://cancerres.aacrjournals.org/content/80/16_Supplement/1645 <a href="https://cancerres.aacrjournals.org/content/80/16_Supplement/1645">Yang Y, et al. A new TGF-ß pathway reporter mouse for analysis of TGF-β signaling in normal homeostasis and cancer.</a> 147163033 Wakefield, Lalage NIH - NCI NCI Wakefield, Lalage (NCI) 1 147163034 Yang, Yu-an NIH - NCI NCI Yang, Yu-an (NCI) 2 147163035 Rane, Sushil NIH - NIDDK NIDDK Rane, Sushil (NIDDK) 3 147163036 Hill, Caroline The Francis Crick Institute Hill, Caroline 4 147163033 Wakefield, Lalage NIH - NCI NCI Wakefield, Lalage (NCI) 1 147163034 Yang, Yu-an NIH - NCI NCI Yang, Yu-an (NCI) 2 147163035 Rane, Sushil NIH - NIDDK NIDDK Rane, Sushil (NIDDK) 3 147163036 Hill, Caroline The Francis Crick Institute Hill, Caroline 4 147158061 Smad3 Reporter Mouse For Assessing TGF-ß/activin Pathway Activation E-136-2019-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NCI, The Francis Crick Institute 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-3963] SMAD3 Reporter Mouse for Assessing TGF-ß/Activin Pathway Activation&body=Please send me information about technology [TAB-3963] SMAD3 Reporter Mouse for Assessing TGF-ß/Activin Pathway Activation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-3963] SMAD3 Reporter Mouse for Assessing TGF-ß/Activin Pathway Activation&body=Please send me information about technology [TAB-3963] SMAD3 Reporter Mouse for Assessing TGF-ß/Activin Pathway Activation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147172187 Animal Model 147172188 CANCER 147172189 EGFP 147172191 Fibrosis, Wakefield 147172193 mothers against decapentaplegic homolog 3 147172194 Oncology 147172196 Reporter Mouse 147172197 SMAD3 147172199 TGF-ß 147172201 Transforming Growth Factor Beta TAB-3940 147157220 CODEFACS and LIRICS: Computation Tools for Identifying Cell-Type Specific Gene Expression Levels in Tumors and Other Types of Samples NCI Collaboration, Immunology, Licensing, Research Materials Collaboration Immunology Licensing Research Materials Joo Lee, Sushant Patkar, Eytan Ruppin, Alejandro Schaffer, Kun Wang <h2>Description of Technology:</h2> <p>The tumor microenvironment (TME) is a complex mixture of cell types whose interactions affect tumor growth and clinical outcome. Recent studies using fluorescence-activated cell sorting (FACS) and single-cell RNA sequencing (RNAseq) to elucidate tissue composition and cell-cell interactions in the TME led to improved biomarkers of patient response and new treatment opportunities. However, the use of FACS is limited to simultaneously measuring the expression of a few protein markers, whereas the use of single-cell RNAseq has been limited due to cost and scarcity of fresh tumor biopsies. In contrast, bulk tumor gene expression from preserved biopsies accompanied by clinical outcome metadata is abundant. Several algorithms have shown promise in accurately reconstructing cell-type-specific gene expression profiles from bulk gene expression.&nbsp;&nbsp;</p> <p>Researchers at National Cancer Institute (NCI) have developed CODEFACS (COnfident DEconvolution For All Cell Subsets), a transcriptomics computation tool that can confidently estimate cell type abundance and deconvolve cell-type-specific gene expression profiles of individual cancer patients from bulk gene expression measurements. A complementary, second software tool LIRICS (LIgand-Receptor Interaction between Cell Subsets) prioritizes clinically relevant ligand-receptor interactions between cell types from the deconvolved data. These tools uncovered TME ligand-receptor interactions associated with improved patient survival and high sensitivity to immune checkpoint blockade therapy. These excellent tools for understanding the TME can inform diagnosis and treatment strategies. They are available for co-development or licensing opportunities.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Development of improved immune checkpoint blockade therapies against cancer</li> <li>Development of improved therapies against cancer involving the TME</li> <li>Improved determination and analysis of cell-type abundance and cell-type-specific gene expression from bulk gene expression&nbsp;</li> <li>Identifying cell-cell and ligand-receptor interactions within complex tissues, including the TME&nbsp;</li> <li>Identifying cell type specific biomarkers, drug targets and drug repurposing opportunities to improve diagnosis and clinical outcome</li> <li>Applicable non-cancerous disease, including preeclampsia, pregnancy-related complications, autoimmune disorders, ageing and neurodegenerative disorders.&nbsp; &nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Higher gene coverage for all cell types than existing related technologies</li> <li>Improved predictive accuracy of patient response to therapy&nbsp;</li> <li>Built-in confidence ranking system to compare prediction accuracies</li> </ul> 2021-11-04 2026-04-24 2021-11-04 2026-04-24 2021-11-04 Cell-cell Interaction, CODEFACS, Deconvolution, GENE EXPRESSION, Immunotherapy, Ligand-Receptor Interaction, LIRICS, Ruppin, TME, Tumor Microenvironment False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-11-04 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162939 Ruppin, Eytan NIH - NCI NCI Ruppin, Eytan (NCI) 1 147162940 Wang, Kun NIH - NCI NCI Wang, Kun (NCI) 2 147162941 Patkar, Sushant NIH - NCI NCI Patkar, Sushant (NCI) 3 147162942 Lee, Joo NIH - NCI Lee, Joo 4 147162943 Schaffer, Alejandro NIH - NCI NCI Schaffer, Alejandro (NCI) 5 147162939 Ruppin, Eytan NIH - NCI NCI Ruppin, Eytan (NCI) 1 147162940 Wang, Kun NIH - NCI NCI Wang, Kun (NCI) 2 147162941 Patkar, Sushant NIH - NCI NCI Patkar, Sushant (NCI) 3 147162942 Lee, Joo NIH - NCI Lee, Joo 4 147162943 Schaffer, Alejandro NIH - NCI NCI Schaffer, Alejandro (NCI) 5 147157857 The COOEFACS And LIRICS Pipelines For Bulk Expression Deconvolution E-044-2020-0 Filing authorized NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-3940] CODEFACS and LIRICS: Computation Tools for Identifying Cell-Type Specific Gene Expression Levels in Tumors and Other Types of Samples&body=Please send me information about technology [TAB-3940] CODEFACS and LIRICS: Computation Tools for Identifying Cell-Type Specific Gene Expression Levels in Tumors and Other Types of Samples.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-3940] CODEFACS and LIRICS: Computation Tools for Identifying Cell-Type Specific Gene Expression Levels in Tumors and Other Types of Samples&body=Please send me information about technology [TAB-3940] CODEFACS and LIRICS: Computation Tools for Identifying Cell-Type Specific Gene Expression Levels in Tumors and Other Types of Samples.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147160956 E-044-2020-0 E-044-2020-0-PCT-02 METHODS OF IDENTIFYING CELL-TYPE-SPECIFIC GENE EXPRESSION LEVELS BY DECONVOLVING BULK GENE EXPRESSION PCT Patent Cooperation Treaty PCT/US2020/062238 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/062238<br />Filed on 2020-11-25<br />Status: Expired 147165449 E-044-2020-0 E-044-2020-0-US-01 CODEFACS AND LIRICS PIPELINES FOR BULK EXPRESSION DECONVOLUTION PRV US 62/940,755 Abandoned US <br />Provisional (PRV) 62/940,755<br />Filed on 2019-11-26<br />Status: Abandoned 147165450 E-044-2020-0 E-044-2020-0-US-03 METHODS OF IDENTIFYING CELL-TYPE-SPECIFIC GENE EXPRESSION LEVELS BY DE-CONVOLVING BULK GENE EXPRESSION National Stage US 17/780,356 Abandoned US <br />National Stage 17/780,356<br />Filed on 2022-05-26<br />Status: Abandoned 147170168 Cell-cell Interaction 147170170 CODEFACS 147170171 Deconvolution 147170172 GENE EXPRESSION 147170173 Immunotherapy 147170175 Ligand-Receptor Interaction 147170176 LIRICS 147170178 Ruppin 147170180 TME 147170182 Tumor Microenvironment TAB-3922 147157202 HLA-A*01:01 Restricted Human T Cell Receptor Recognizing the NRAS Q61K Hotspot Mutation NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Gabriel Ivey, Almin Latani, Paul Robbins, Steven Rosenberg <h2>Summary:</h2> <p>The NCI is seeking research co-development and/or licensees for the HLA-A*01:01 restricted human T-cell receptor recognizing the NRAS Q61K hotspot mutation.</p> <h2>Description of Technology:</h2> <p>Mutation of amino acid 61of the neuroblastoma rat sarcoma viral oncogene homologue (NRAS) is a known driver of oncogenesis in melanoma. Glutamine (Q) to lysine (K) mutation at this position of NRAS is prevalent in approximately 10% of all melanoma cases and associated with aggressive tumors and low patient survival. Therefore, Q61K mutated NRAS is an important candidate for targeted therapies, including cellular immunotherapy.&nbsp;</p> <p>National Cancer Institute scientists developed a T-cell receptor (TCR) specific for NRAS Q61K for use in adoptive cell transfer (ACT) T-cell immunotherapy against melanoma. T cells reactive to NRAS Q61K were screened and isolated from tumor infiltrating lymphocytes of a melanoma patient with this mutation and the human leukocyte antigen (HLA) phenotype of A*01:01. TCR alpha and beta chains from the isolated T cells were then cloned to construct the NRAS Q61K-specific TCR. This TCR can be used to develop T-cell therapies against melanoma. Due to the similarities between different RAS isoforms (NRAS, KRAS, HRAS), the TCR could also be used to target other cancers exhibiting RAS Q61K mutations, such as colorectal, prostate, pancreatic and thyroid cancers in patients with the HLA-A*01:01 phenotype.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Use in adoptive cell transfer T-cell therapy against melanoma and other cancers</li> <li>Solid tumors without target antigens as surface proteins</li> <li>Diagnostic tool for NRAS Q61K tumors</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Potential for lower toxicity as NRAS Q61K is not present in healthy individuals</li> <li>Highly expressed target antigen for melanoma indication</li> <li>HLA-A*01:01 occurs in high frequency in Caucasian populations, therefore the TCR may benefit many patients&nbsp;</li> <li>Intracellular proteins TCRs target can be tumor-specific</li> <li>Redirects the immune system against tumors</li> <li>TCRs potentially target more antigens than Chimeric Antigen Receptors (CARs) since both surface and intracellular proteins can be presented as peptides on MHC molecules</li> </ul> 2021-09-24 2026-04-24 2021-09-24 2026-04-24 2021-09-24 act, Adoptive Cell Transfer, HLA, Human Leukocyte Antigen, immuno-oncology, Immunotherapy, Neuroblastoma Rat Sarcoma Viral Oncogene, NRAS, Robbins, Rosenberg, T-Cell Receptor, TCR False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-09-24 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162874 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 1 147162873 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 147162875 Ivey, Gabriel Georgetown University Ivey, Gabriel 3 147162876 Latani, Almin NCI - CCR NCI Latani, Almin (NCI) 4 147162874 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 1 147162873 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 147162875 Ivey, Gabriel Georgetown University Ivey, Gabriel 3 147162876 Latani, Almin NCI - CCR NCI Latani, Almin (NCI) 4 147158181 HLA-A*01:01 Restricted Human T Cell Receptor Recognizing The NRAS Q61K Hotspot Mutation E-191-2019-0 Filing authorized Georgetown University, NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-3922] HLA-A*01:01 Restricted Human T Cell Receptor Recognizing the NRAS Q61K Hotspot Mutation&body=Please send me information about technology [TAB-3922] HLA-A*01:01 Restricted Human T Cell Receptor Recognizing the NRAS Q61K Hotspot Mutation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-3922] HLA-A*01:01 Restricted Human T Cell Receptor Recognizing the NRAS Q61K Hotspot Mutation&body=Please send me information about technology [TAB-3922] HLA-A*01:01 Restricted Human T Cell Receptor Recognizing the NRAS Q61K Hotspot Mutation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161172 E-191-2019-0 E-191-2019-0-US-01 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH Q61K MUTATION PRV US 63/177,570 Abandoned US <br />Provisional (PRV) 63/177,570<br />Filed on 2021-04-21<br />Status: Abandoned 147165283 E-191-2019-0 E-191-2019-0-PCT-02 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH Q61K MUTATION PCT Patent Cooperation Treaty PCT/US2022/025177 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/025177<br />Filed on 2022-04-18<br />Status: Expired 147173375 act 147173376 Adoptive Cell Transfer 147173377 HLA 147173378 Human Leukocyte Antigen 147173379 immuno-oncology 147173380 Immunotherapy 147173382 Neuroblastoma Rat Sarcoma Viral Oncogene 147173383 NRAS 147173385 Robbins 147173386 Rosenberg 147173387 T-Cell Receptor 147173388 TCR TAB-3893 147157173 T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy NCI Collaboration, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Infectious Disease Licensing Oncology Therapeutics Gregoire Altan-Bonnet, Sri Krishna, Frank Lowery, Paul Robbins, Steven Rosenberg <h2>Summary:</h2> <p>The NCI seeks applications from parties interested in co-developing and/or licensing a method to develop improved cancer immunotherapies.</p> <h2>Description of Technology:</h2> <p>Adoptive T-cell therapy (ACT) utilizes tumor-reactive T cells to induce disease remission. While ACT has been used effectively to treat metastatic melanoma and certain epithelial cancers, most patients do not respond to treatment. Although the mechanisms underlying this variable response to therapy are not fully elucidated, the phenotype of the adoptively transferred cell is known to be a key determinant of treatment efficacy.</p> <p>Researchers at National Cancer Institute&rsquo;s (NCI) Surgery Branch have now determined that the CD3<sup>+</sup>CD39<sup>-</sup>CD69<sup>-</sup> subpopulation of T cells are highly associated with complete disease response following ACT. Leveraging over 30 years of ACT clinical data and associated biological materials, NCI researchers immune-profiled archived infusion products and correlated cell phenotypes with therapeutic outcomes. Clustering of clinically significant markers helped in determining the candidate profile. Validation of the markers in other patients and other cancer settings is ongoing.</p> <p>The inventive method could be used to engineer relevant cell therapy products in multiple disease settings, including, but not limited to, cancer and acute and chronic infectious diseases. The method could further be used to develop gene expression signatures to either screen prospective patients or genetically engineer better therapies. In addition to its application in ACT, the &ldquo;response&rdquo; immunoprofile may be applicable to immunotherapy regimens more generally, including checkpoint blockade therapies, immune modulators, and T-cell receptor (TCR) or chimeric antigen receptor (CAR) therapies.</p> <p>Related technologies are available.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Companion diagnostic to support cell therapy and utility products in multiple disease settings, including, but not limited to, cancer and acute and chronic infectious diseases&nbsp;</li> <li>Generation of gene expression signatures to prospectively screen patients or to engineer better ACT and TCR-based treatments</li> <li>Immunoprofiling patients before and after ACT, checkpoint blockade, immunomodulator, and TCR/CAR therapies</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Method to screen adoptive T-cell therapy (ACT) patients to predetermine therapy efficiency</li> <li>Method to increase the efficacy of ACT therapies</li> </ul> 2021-05-25 2026-04-24 2021-07-13 2026-04-24 2021-07-13 act, Adoptive T Cell Therapy, Cancer Immunotherapies, CAR, CD-39 Receptor, CD3-Receptor, CD-69 Receptor, chimeric antigen receptor, Lowery, Rosenberg, T Cell Receptor, TCR, TILS, Tumor-Infiltrating T-Lymphocytes False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-07-13 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-022-2017 147162043 Krishna S, et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. https://pubmed.ncbi.nlm.nih.gov/33303615/ <a href="https://pubmed.ncbi.nlm.nih.gov/33303615/">Krishna S, et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer.</a> 147162770 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 1 147162773 Altan-Bonnet, Gregoire NIH - NCI NCI Altan-Bonnet, Gregoire (NCI) 2 147162774 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 3 147162771 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 4 147162772 Lowery, Frank NIH - NCI NCI Lowery, Frank (NCI) 5 147162770 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 1 147162773 Altan-Bonnet, Gregoire NIH - NCI NCI Altan-Bonnet, Gregoire (NCI) 2 147162774 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 3 147162771 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 4 147162772 Lowery, Frank NIH - NCI NCI Lowery, Frank (NCI) 5 147158126 T-cell Phenotypes Associated With Clinical Response To Adoptive Immunotherapy E-167-2019-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-3893] T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy&body=Please send me information about technology [TAB-3893] T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-3893] T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy&body=Please send me information about technology [TAB-3893] T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161136 E-167-2019-0 E-167-2019-0-US-01 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY PRV US 63/075,536 Abandoned US <br />Provisional (PRV) 63/075,536<br />Filed on 2020-09-08<br />Status: Abandoned 147165093 E-167-2019-0 E-167-2019-0-PCT-02 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY PCT Patent Cooperation Treaty PCT/US2021/049387 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/049387<br />Filed on 2021-09-08<br />Status: Expired 147165094 E-167-2019-0 E-167-2019-0-JP-01 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY National Stage Japan 7869197 2023-515322 Issued Japan <br />National Stage 2023-515322<br />Filed on 2023-03-07<br />Status: Issued 147165095 E-167-2019-0 E-167-2019-0-CA-01 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY National Stage Canada 3191211 Pending Canada <br />National Stage 3191211<br />Filed on 2023-02-28<br />Status: Pending 147165096 E-167-2019-0 E-167-2019-0-AU-01 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY National Stage Australia 2021341969 Pending Australia <br />National Stage 2021341969<br />Filed on 2023-02-21<br />Status: Pending 147165097 E-167-2019-0 E-167-2019-0-CN-01 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY National Stage China 202180074998.8 Pending China <br />National Stage 202180074998.8<br />Filed on 2023-05-05<br />Status: Pending 147165098 E-167-2019-0 E-167-2019-0-US-02 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY National Stage US 12,736,535 18/024,430 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12736535 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12736535">12,736,535</a><br />Filed on 2023-03-02<br />Status: Issued 147165099 E-167-2019-0 E-167-2019-0-EP-01 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY National Stage European Patent 4211228 21787116.9 Issued European Patent <br />National Stage 21787116.9<br />Filed on 2023-03-28<br />Status: Issued 147172814 act 147172815 Adoptive T Cell Therapy 147172817 Cancer Immunotherapies 147172818 CAR 147172820 CD-39 Receptor 147172822 CD3-Receptor 147172824 CD-69 Receptor 147172825 chimeric antigen receptor 147172827 Lowery 147172828 Rosenberg 147172829 T Cell Receptor 147172830 TCR 147172831 TILS 147172833 Tumor-Infiltrating T-Lymphocytes TAB-3882 147157162 Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19 NCI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Mitchell Ho, Jessica Hong <h2>Summary:</h2> <p>The NCI seeks licensing and/or co-development research collaborations for SARS-CoV-2 targeting nanobodies.</p> <h2>Description of Technology:</h2> <p>The COVID-19 pandemic is a worldwide public health crisis with over 100 million confirmed cases and 2.4 million deaths as of February 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. SARS-COV-2 infects hosts via its spike (S) protein. The S protein contains the receptor binding domain (RBD) that binds to the angiotensin converting enzyme 2 (ACE2) receptor on human cells to facilitate viral entry and infection. There are few therapeutics available for COVID-19 patients that directly target SARS-CoV-2.</p> <p>Investigators at the National Cancer Institute (NCI) have isolated a panel of anti-RBD single domain antibodies (also called &lsquo;nanobodies&rsquo;) from camel single domain (VHH) phage display libraries. RBD is an ideal target as it is the key virus-host contact region required for viral entry and infection. There are 3 lead nanobodies, 7A3, 1B5, and 2F7, which were found to be the most potent RBD-ACE2 blockers. Interestingly, the 1B5 nanobody can cross react with the S protein of the previous 2002-2003 SARs-CoV coronavirus. This indicates that this nanobody targets a conserved region of the S protein and may be useful for treatments against other coronavirus variants that may emerge.&nbsp;</p> <p>Nanobodies are the smallest known antigen-binding fragments of antibodies and have several advantages. Due to their small size, high solubility, thermal stability, refolding capacity, and relatively easy tissue penetration, they have great potential as medical applications and research tools. These nanobodies can be used as either independent agents or targeting domains in recombinant immunotoxins (RITs), antibody-drug conjugates (ADCs), and chimeric antigen receptors (CARs). Due to their small size and high stability, the nanobodies may have the ability to be administered by an inhaler making them uniquely attractive therapeutics for respiratory infections such as COVID-19.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Neutralizing nanobodies</li> <li>Nanobody-Fc fusion proteins as standard antibody therapy</li> <li>Antibody-drug conjugates (ADCs)</li> <li>Immunotoxins</li> <li>Diagnostic reagents (in vivo virus imaging)</li> <li>CARs (CAR T, NK, and macrophage)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The nanobodies directly target the receptor binding domain (RBD) of the SARS-CoV-2 spike (S) protein, which blocks the virus-host contact region required for viral entry and infection</li> <li>Due to their small size and high stability, the nanobodies may be administered by an inhaler making them ideal for respiratory infections such as COVID-19</li> </ul> 2021-04-05 2026-04-24 2021-04-05 2026-04-24 2021-04-05 ANTIBODY, antigen-binding fragment, CORONAVIRUS, COVID-19, HO, NANOBODY, respiratory INFECTION, S Protein, SARS-CoV-2, spike protein False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-04-05 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162716 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147162717 Hong, Jessica NIH - NCI NCI Hong, Jessica (NCI) 2 147162716 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147162717 Hong, Jessica NIH - NCI NCI Hong, Jessica (NCI) 2 147158277 Single Domain Antibodies Targeting SARS-SoV-2 E-253-2020-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3882] Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19&body=Please send me information about technology [TAB-3882] Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3882] Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19&body=Please send me information about technology [TAB-3882] Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161233 E-253-2020-0 E-253-2020-0-US-01 Single Domain Antibodies Targeting SARS-CoV-2 PRV US 63/105,769 Abandoned US <br />Provisional (PRV) 63/105,769<br />Filed on 2020-10-26<br />Status: Abandoned 147165031 E-253-2020-0 E-253-2020-0-PCT-02 SINGLE DOMAIN ANTIBODIES TARGETING SARS CORONAVIRUS SPIKE PROTEIN AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2021/056548 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/056548<br />Filed on 2021-10-26<br />Status: Expired 147165032 E-253-2020-0 E-253-2020-0-US-02 SINGLE DOMAIN ANTIBODIES TARGETING SARS CORONAVIRUS SPIKE PROTEIN AND USES THEREOF National Stage US 18/033,656 Pending US <br />National Stage 18/033,656<br />Filed on 2023-04-25<br />Status: Pending 147174284 ANTIBODY 147174285 antigen-binding fragment 147174286 CORONAVIRUS 147174287 COVID-19 147174288 HO 147174289 NANOBODY 147174290 respiratory INFECTION 147174292 S Protein 147174293 SARS-CoV-2 147174294 spike protein TAB-3877 147157157 An Anti-Viral Polypeptide: Griffithsin NCI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Michael Boyd, Toshiyuki Mori, Barry O'Keefe <h2>Summary:</h2> <p>Researchers at the NCI seek licensing and/or co-development research collaborations for anti-viral Griffithsin (GRFT) proteins.</p> <h2>Description of Technology:</h2> <p>Virus entry into a susceptible host cell is the first step in the formation of all viral diseases. Controlling viral infections by disrupting viral entry is advantageous for antibody-mediated neutralization by the host&rsquo;s immune system and as a preventive and therapeutic antiviral strategy. Plant-derived carbohydrate-binding proteins (lectins) have emerged as a new class of antiviral biologics by taking advantage of a unique glycosylation pattern only found on the surface of viruses.</p> <p>This technology describes the lectin, Griffithsin (GRFT), isolated from red algae. GRFT shows significant broad-spectrum anti-viral activity making it a promising agent for use as a general microbicide that can prevent viral transmission and as a therapeutic against enveloped virus-mediated diseases.&nbsp; The patent rights for this technology cover the sequence of the GRFT polypeptide as well as several GRFT variants mutated to render them glycosylation-resistant. The patent rights also cover GRFT conjugates, compositions, nucleic acids, vectors, host cells, antibodies and methods of their production and methods of use.&nbsp; The broad spectrum anti-viral activity of GRFT has been attributed to its ability to inhibit viral binding, fusion and entry into the host cells by binding to viral envelope gp120.&nbsp; GRFT has potential as a therapeutic or prophylactic for retroviral infections including HIV-1 and HIV-2 as well as FIV, SIV, MLV, BLV, equine infectious virus, avian sarcoma viruses, and HTLV. In addition, Griffithsin could be used in combination with other anti-viral agents to treat patients who have drug-resistant virus.</p> <p>A related NCI invention, reference number <a href="https://techtransfer.cancer.gov/available-technologies?abstract=TAB-4330" target="_blank">E-025-2006</a>, further covers the use of Griffithsin against viral infection including Hepatitis C, Severe Acute Respiratory Syndrome (SARS), H5N1, or Ebola.</p> <p>Issued patents include&nbsp;<a href="https://patents.google.com/patent/US7884178B2/en?oq=11%2f569%2c813" rel="nofollow" target="_blank">US 7,884,178</a>,&nbsp;<a href="https://patents.google.com/patent/US8394764B2/en?oq=US+8%2c394%2c764+" rel="nofollow" target="_blank">US 8,394,764</a>, with foreign rights in Canada, Australia, Japan, Israel, New Zealand, South Africa, France, Germany, Ireland, Switzerland, United Kingdom (all granted).</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Microbicide that can prevent viral transmission</li> <li>Therapeutic against enveloped virus-mediated diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Highly Potent Broad-Spectrum Antiviral Lectin</li> <li>Superior in vitro and in vivo antiviral activity with minimum host toxicity against a variety of clinically relevant, enveloped viruses</li> </ul> 2021-07-08 2026-04-24 2021-07-08 2026-04-24 2021-07-08 Griffithsin, O'Keefe, SARS, Severe acute respiratory syndrome False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-07-08 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-025-2006 147162113 Mori T. et al., Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. https://pubmed.ncbi.nlm.nih.gov/15613479 <a href="https://pubmed.ncbi.nlm.nih.gov/15613479">Mori T. et al., Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp.</a> 147162460 Giomarelli B, et al. Recombinant production of anti-HIV protein, griffithsin, by auto-induction in a fermentor culture https://pubmed.ncbi.nlm.nih.gov/16300962/ <a href="https://pubmed.ncbi.nlm.nih.gov/16300962/">Giomarelli B, et al. Recombinant production of anti-HIV protein, griffithsin, by auto-induction in a fermentor culture</a> 147162700 Boyd, Michael NIH - NCI Boyd, Michael 1 147162702 Mori, Toshiyuki NIH - NCI Mori, Toshiyuki 2 147162701 O'Keefe, Barry NIH - NCI NCI O'Keefe, Barry (NCI) 3 147162700 Boyd, Michael NIH - NCI Boyd, Michael 1 147162702 Mori, Toshiyuki NIH - NCI Mori, Toshiyuki 2 147162701 O'Keefe, Barry NIH - NCI NCI O'Keefe, Barry (NCI) 3 147157998 Griffithsin, Sertulavirin And Related Proteins, Peptides, Conjugates, Antibodies, Compositions, Nucleic Acids, Vectors, Host Cells, Methods Of Production And Methods Of Using E-106-2003-0 Filing authorized NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-3877] An Anti-Viral Polypeptide: Griffithsin&body=Please send me information about technology [TAB-3877] An Anti-Viral Polypeptide: Griffithsin.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-3877] An Anti-Viral Polypeptide: Griffithsin&body=Please send me information about technology [TAB-3877] An Anti-Viral Polypeptide: Griffithsin.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147161048 E-106-2003-0 E-106-2003-0-US-03 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production and Methods of Use National Stage US 7,884,178 11/569,813 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7884178 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7884178">7,884,178</a><br />Filed on 2006-11-30<br />Status: Issued 147164988 E-106-2003-0 E-106-2003-0-US-01 Griffithsins and Related conjucages, Fusion Proteins, Nucleic Acids, Vectors, Host Cells, Compositions, Antibodies and Methods of Using Griffithsins PRV US 60/576,056 Abandoned US <br />Provisional (PRV) 60/576,056<br />Filed on 2004-06-01<br />Status: Abandoned 147164990 E-106-2003-0 E-106-2003-0-PCT-02 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use PCT Patent Cooperation Treaty PCT/US2005/018778 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2005/018778<br />Filed on 2005-05-27<br />Status: Expired 147164991 E-106-2003-0 E-106-2003-0-CA-04 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use National Stage Canada 2567728 2567728 Expired Canada <br />National Stage 2567728<br />Filed on 2010-03-09<br />Status: Expired 147164992 E-106-2003-0 E-106-2003-0-AU-05 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use National Stage Australia 2005250429 2005250429 Expired Australia <br />National Stage 2005250429<br />Filed on 2005-05-27<br />Status: Expired 147164993 E-106-2003-0 E-106-2003-0-EP-06 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use National Stage European Patent 1740605 05804849.7 Expired European Patent <br />National Stage 05804849.7<br />Filed on 2005-05-27<br />Status: Expired 147164994 E-106-2003-0 E-106-2003-0-JP-07 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use National Stage Japan 4776620 2007-515398 Expired Japan <br />National Stage 2007-515398<br />Filed on 2005-05-27<br />Status: Expired 147164995 E-106-2003-0 E-106-2003-0-IL-08 GRIFFITHSIN AND GLYCOSYLATION-RESISTANT VARIANTS THEREOF HAVING ANTI-VIRAL ACTIVITY AND RELATED METHODS National Stage Israel 179236 179236 Expired Israel <br />National Stage 179236<br />Filed on 2006-11-13<br />Status: Expired 147164996 E-106-2003-0 E-106-2003-0-NZ-09 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use National Stage New Zealand 551375 551375 Expired New Zealand <br />National Stage 551375<br />Filed on 2006-11-17<br />Status: Expired 147164997 E-106-2003-0 E-106-2003-0-ZA-10 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use National Stage South Africa 2006/09573 2006/09573 Expired South Africa <br />National Stage 2006/09573<br />Filed on 2006-11-17<br />Status: Expired 147164998 E-106-2003-0 E-106-2003-0-EP-11 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use DIV European Patent 5804849.7 Administratively Closed European Patent <br />Divisional (DIV) 5804849.7<br />Filed on 2005-05-27<br />Status: Administratively Closed 147164999 E-106-2003-0 E-106-2003-0-US-12 Griffithsin, Glycosylation-Resistant Griffithsin, And Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods Of Production And Methods Of Use DIV US 8,394,764 13/022,289 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8394764 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8394764">8,394,764</a><br />Filed on 2011-02-07<br />Status: Expired 147165000 E-106-2003-0 E-106-2003-0-FR-13 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP France 1740605 05804849.7 Expired France <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165001 E-106-2003-0 E-106-2003-0-DE-14 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP Germany 1740605 05804849.7 Expired Germany <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165002 E-106-2003-0 E-106-2003-0-IE-15 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP Ireland 1740605 05804849.7 Expired Ireland <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165003 E-106-2003-0 E-106-2003-0-CH-16 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP Switzerland 1740605 05804849.7 Expired Switzerland <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165004 E-106-2003-0 E-106-2003-0-GB-17 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP United Kingdom 1740605 05804849.7 Expired United Kingdom <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165005 E-106-2003-0 E-106-2003-0-CH-18 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP Switzerland 1740605 05804849.7 Expired Switzerland <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165006 E-106-2003-0 E-106-2003-0-DE-19 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP Germany 1740605 05804849.7 Expired Germany <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165007 E-106-2003-0 E-106-2003-0-FR-20 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP France 1740605 05804849.7 Expired France <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165008 E-106-2003-0 E-106-2003-0-GB-21 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP United Kingdom 1740605 05804849.7 Expired United Kingdom <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165009 E-106-2003-0 E-106-2003-0-IE-22 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP Ireland 1740605 05804849.7 Expired Ireland <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147171529 Griffithsin 147171531 O'Keefe 147171532 SARS 147171533 Severe acute respiratory syndrome TAB-4897 152954990 T Cell Receptors Targeting EGFR L858R mutation on HLA-A*11:01+ Tumors for Use as Research Tools NCI Diagnostics, Licensing, Oncology, Research Materials Diagnostics Licensing Oncology Research Materials Catherine Ade, Matthew Sporn, Zhiya Yu <h2>Summary:</h2> <p>The Surgery Branch seeks licensees for research use of TCRs targeting EGFR L858R mutation.&nbsp;</p> <h2>Description of Technology:</h2> <p>Tumor-specific mutated proteins can create neoepitopes, mutation-derived antigens that distinguish tumor cells from healthy cells, which are attractive targets for adoptive cell therapies. However, the process of precisely identifying the neoepitopes to target is complex and challenging. One method to identify such neoepitopes is Mass Spectrometry (MS) when used in conjunction with elution of peptides bound to a specific Human Leukocyte Antigen (HLA) allele. Using MS in this context can demonstrate which oncogene derived neoepitopes are presented by common HLA alleles, and can provide the data necessary to rapidly develop TCRs against the desired antigens.&nbsp;</p> <p>Using the MS approach, inventors at the National Cancer Institute (NCI) have identified neoepitopes derived from a mutated isoform of Epithelial Growth Factor Receptor (EGFR) presented by HLA A*11:01 across multiple biological replicates. From this MS data, the inventors were able to successfully isolate murine TCRs that specifically recognize HLA A*11:01 restricted neoepitopes targeting EGFR L858R. According to various cancer genome databases, EGFR L858R is highly prevalent in lung adenocarcinoma, non-small cell lung carcinoma, and nonsquamous non-small cell lung carcinoma, making this driver mutation an excellent target to develop off-the-shelf cellular therapies. While the clinical potential of these TCRs has not been explored, they are valuable research materials to identify HLA-A*11:01 EGFR L858R reactive T cells in various sources including patients and animal models.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research use</li> <li>In vitro diagnostic use</li> <li>The TCRs may be used as positive controls to identify HLA-A*11:01 EGFR L858R reactive T cells from different sources such as patients or animal models</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>TCRs recognize the common EGFR L858R driver mutation in the context of HLA-A*11:01&nbsp;</li> <li>EGFR mutations are highly prevalent in lung cancers, especially lung adenocarcinoma, non-small cell lung cancer and non-squamous non-small cell lung cancer</li> <li>The prevalence of EGFR L858R substitutions, relative to the overall EGFR mutation population, ranges from 27.7% to 41.1% in non-small cell lung cancer patients</li> <li>HLA-A*11:01 allele frequency is particularly high (up to 60%) in Asian and Oceanian populations</li> <li>This research has validated the effectiveness of using mass spectrometry to detect amino acid sequences on specific HLA complexes&nbsp;<br /> &nbsp;</li> </ul> The NCI seeks licensees for T Cell Receptors (TCRs) targeting Epidermal Growth Factor Receptor (EGFR) L858 mutation for use as research tools. 2024-02-16 2026-04-24 2026-04-24 2024-02-16 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-098-2018 152960967 Ade CM, et al. Identification of neoepitope reactive T-cell receptors guided by HLA A*03:01 and HLA A*11:01 immunopeptidomics. (PMID 37758652) https://pubmed.ncbi.nlm.nih.gov/37758652/ <a href="https://pubmed.ncbi.nlm.nih.gov/37758652/">Ade CM, et al. Identification of neoepitope reactive T-cell receptors guided by HLA A*03:01 and HLA A*11:01 immunopeptidomics. (PMID 37758652)</a> 152956517 Ade, Catherine NCI - CCR NCI Ade, Catherine (NCI) 1 152956539 Sporn, Matthew NCI - CCR NCI Sporn, Matthew (NCI) 2 152956564 Yu, Zhiya NCI - CCR NCI Yu, Zhiya (NCI) 3 152956517 Ade, Catherine NCI - CCR NCI Ade, Catherine (NCI) 1 152956539 Sporn, Matthew NCI - CCR NCI Sporn, Matthew (NCI) 2 152956564 Yu, Zhiya NCI - CCR NCI Yu, Zhiya (NCI) 3 152954993 Identification and cloning of EGFR L858R/A11_mTCR1, EGFR L858R/A11_mTCR4, and EGFR L858R/A11_mTCR9, three T cell receptors targeting EGFR L858R mutation on HLA-A1101+ tumor cells E-251-2023-0 Under Review NCI - CCR, NIH - NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4897] T Cell Receptors Targeting EGFR L858R mutation on HLA-A*11:01+ Tumors for Use as Research Tools&body=Please send me information about technology [TAB-4897] T Cell Receptors Targeting EGFR L858R mutation on HLA-A*11:01+ Tumors for Use as Research Tools.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4897] T Cell Receptors Targeting EGFR L858R mutation on HLA-A*11:01+ Tumors for Use as Research Tools&body=Please send me information about technology [TAB-4897] T Cell Receptors Targeting EGFR L858R mutation on HLA-A*11:01+ Tumors for Use as Research Tools.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> TAB-3960 147157240 Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron NCI Collaboration, Immunology, Infectious Disease, Licensing, Therapeutics Collaboration Immunology Infectious Disease Licensing Therapeutics Jesse Buffington, Zhijian Duan, Mitchell Ho, Jessica Hong <h2>Summary:</h2> <p>The NCI seeks research co-development partners and/or licensees to further develop this nanobody as a possible treatment of COVID-19 infections.</p> <h2>Description of Technology:</h2> <p>Since its emergence in 2019, COVID-19 infected over 600 million people and over 6 million people have died from the disease. COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Neutralizing antibodies have been developed to bind to the receptor binding domain (RBD) on the spike (S) protein. Blocking the interaction of the RBD and the ACE2 receptor, is critical in neutralizing the virus. However, the S2 subunit, is also critical for viral infection and entry into human cells. The S2 subunit is highly conserved across many coronaviruses, however, there are currently no effective antibodies targeting this S2 subunit.</p> <p>The inventors isolated the J1B4 camel VHH nanobody, a potent S2 binder that can neutralize all the known variants of SARS-CoV-2, including omicron. The J1B4 VHH can be engineered with other COVID binders to create multi-specific drugs to treat current COVID-19 infections as well as future SARS-like viral infections. This technology presents a promising novel treatment for SARS-CoV-2 infection by using the anti-S2 nanobodies alone or in combination with anti-S1/RBD nanobodies.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of SARS-CoV-2 infections</li> <li>Multi-specific antibody therapy</li> <li>Delivery of nanoparticles</li> <li>Diagnostic reagents for in vivo virus imaging</li> <li>Antiviral nanobody nasal spray</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>No currently available therapeutic antibodies targeting the S2 subunit of SARS-CoV-2</li> <li>Potential treatment for current and future SARS-CoV-2 infections</li> <li>Use of nanobodies suitable for developing non-invasive treatments, such as an intranasal spray</li> </ul> 2023-06-28 2026-04-24 2023-06-27 2026-04-24 2023-06-28 ANTIBODY, Camel Nanobody, CORONAVIRUS, COVID-19, HO, Infectious Diseases, Nanobodies, Pandemic, SARS-CoV-2, therapeutic, Vaccine False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-06-27 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-204-2021 E-253-2020 147163025 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163024 Hong, Jessica NIH - NCI NCI Hong, Jessica (NCI) 2 147163023 Buffington, Jesse NIH - NCI NCI Buffington, Jesse (NCI) 3 147163022 Duan, Zhijian NIH - NCI NCI Duan, Zhijian (NCI) 4 147163025 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163024 Hong, Jessica NIH - NCI NCI Hong, Jessica (NCI) 2 147163023 Buffington, Jesse NIH - NCI NCI Buffington, Jesse (NCI) 3 147163022 Duan, Zhijian NIH - NCI NCI Duan, Zhijian (NCI) 4 147158041 Camel VHH nanobodies bind the S2 subunit of SARS-CoV-2 and broadly neutralize variants including omicron E-129-2023-0 Filing authorized Laboratory of Molecular Biology, NCI - CCR, NIH - NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3960] Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron&body=Please send me information about technology [TAB-3960] Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3960] Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron&body=Please send me information about technology [TAB-3960] Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161078 E-129-2023-0 E-129-2023-0-US-01 SINGLE DOMAIN ANTIBODIES THAT SPECIFICALLY BIND THE S2 SUBUNIT OF SARS-COV-2 SPIKE PROTEIN AND COMPOSITIONS AND USES THEREOF PRV US 63/501,772 Expired US <br />Provisional (PRV) 63/501,772<br />Filed on 2023-05-12<br />Status: Expired 163804438 E-129-2023-0 E-129-2023-0-PC-01 SINGLE DOMAIN ANTIBODIES THAT SPECIFICALLY BIND THE S2 SUBUNIT OF SARS-COV-2 SPIKE PROTEIN AND COMPOSITIONS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2024/028832 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/028832<br />Filed on 2024-05-10<br />Status: Expired 164238034 E-129-2023-0 E-129-2023-0-US-02 SINGLE DOMAIN ANTIBODIES THAT SPECIFICALLY BIND THE S2 SUBUNIT OF SARS-COV-2 SPIKE PROTEIN AND COMPOSITIONS AND USES THEREOF National Stage US 19/482,967 Pending US <br />National Stage 19/482,967<br />Filed on 2025-11-10<br />Status: Pending 147172022 ANTIBODY 147172024 Camel Nanobody 147172025 CORONAVIRUS 147172026 COVID-19 147172027 HO 147172028 Infectious Diseases 147172029 Nanobodies 147172030 Pandemic 147172031 SARS-CoV-2 147172032 therapeutic 147172033 Vaccine TAB-4319 147157609 Enhanced Antigen Reactivity of Immune Cells Expressing a Mutant Non-Signaling CD3 Zeta Chain NICHD Collaboration, Immunology, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Immunology Infectious Disease Licensing Oncology Therapeutics John Davies, Guillaume Gaud, Christian Hinrichs, Paul Love <h2>Summary:</h2> <p>Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development are highly motivated in seeking licensing and/or collaboration partners to develop therapeutic cell populations arising out of these technologies.&nbsp; An ideal partner would enter into both a Cooperative Research and Development Agreement (CRADA) and an exclusive license agreement towards commercialization of one or more therapies to treat various oncologies.&nbsp;</p> <h2>Description of Technology:</h2> <p>Immunotherapy is a cutting-edge new category of treatment that aims to harness and, in some cases, modify the patient&rsquo;s own immune cells to improve their ability to cure diseases. It can be an effective approach for a variety of conditions, ranging from cancer to inflammatory diseases.&nbsp; However, a number of obstacles to the overall success of immunotherapy still exist.&nbsp; For example, reactivity against a target antigen can be attenuated or the lifespan of the &ldquo;modified&rdquo; immune cells can be too short. In cancer, some tumor cells could express antigen with very low reactivity, thus remaining undetected by &ldquo;classical&rdquo; immune cells.&nbsp; &nbsp;Despite considerable research in the field of immunotherapy, there still exists a need for improved methods and products.</p> <p>This technology describes the method of enhancing an antigen-specific immune response in a subject. This is accomplished through the modification of a CD3 subunit chain or related non-CD3 subunit chain which functions to transduce signals through immune receptors &ndash; such as the T cell antigen receptor. The specific subunit chain modifications are comprised of one or more of: (a) at least one Immuno-receptor Tyrosine-based Activation Motif (ITAM) deletion; or (b) at least one exogenous intracellular hematopoietic cell signaling domain; and (c) at least one modified ITAM comprising an amino acid sequence of Formula I.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Immunotherapy treatment for cancer</li> <li>Immunotherapy treatment for autoimmune diseases</li> <li>Immunotherapy treatment for infectious diseases</li> <li>Autologous cell therapy with pharmaceutical compositions comprising novel cell populations</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Highly enhanced target antigen reactivity</li> <li>Highly enhanced functional avidity&nbsp;</li> <li>Cutting-edge therapeutic platform applicable to the treatment of multiple classes of diseases</li> </ul> 2022-02-15 2026-04-23 2022-02-15 2026-04-23 2022-02-15 CD3, Davies, Eunice Kennedy Shriver National Institute of Child Health an, Gaud, Hinrichs, Immuno-receptor Tyrosine-based Activation Motif, Immunotherapy, ITAM, Love, National Cancer Institute, Nci, NICHD, T Cell Receptor, TCR, Zeta Chain False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-02-15 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147164287 Love, Paul NIH - NICHD NICHD Love, Paul (NICHD) 1 147164289 Gaud, Guillaume NIH - NICHD NICHD Gaud, Guillaume (NICHD) 2 147164288 Hinrichs, Christian NIH - NCI Hinrichs, Christian 3 147164290 Davies, John NIH - NCI NCI Davies, John (NCI) 4 147164287 Love, Paul NIH - NICHD NICHD Love, Paul (NICHD) 1 147164289 Gaud, Guillaume NIH - NICHD NICHD Gaud, Guillaume (NICHD) 2 147164288 Hinrichs, Christian NIH - NCI Hinrichs, Christian 3 147164290 Davies, John NIH - NCI NCI Davies, John (NCI) 4 147157785 Enhanced Tumor Reactivity Of T Cells Expressing T Cell Antigen Receptors Containing A Mutant Non-signaling CD3zeta Chain E-010-2021-0 Filing authorized NCI, NICHD 119617417 Ravilious, Geoffrey geoffrey.ravilious@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4319] Enhanced Antigen Reactivity of Immune Cells Expressing a Mutant Non-Signaling CD3 Zeta Chain&body=Please send me information about technology [TAB-4319] Enhanced Antigen Reactivity of Immune Cells Expressing a Mutant Non-Signaling CD3 Zeta Chain.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ravilious, Geoffrey<br><a href="mailto:geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4319] Enhanced Antigen Reactivity of Immune Cells Expressing a Mutant Non-Signaling CD3 Zeta Chain&body=Please send me information about technology [TAB-4319] Enhanced Antigen Reactivity of Immune Cells Expressing a Mutant Non-Signaling CD3 Zeta Chain.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">geoffrey.ravilious@nih.gov</a><br> 147160895 E-010-2021-0 E-010-2021-0-US-01 ENHANCED ANTIGEN REACTIVITY OF IMMUNE CELLS EXPRESSING A MUTANT NON-SIGNALING CD3 ZETA CHAIN PRV US 63/113,428 Abandoned US <br />Provisional (PRV) 63/113,428<br />Filed on 2020-11-13<br />Status: Abandoned 147168135 E-010-2021-0 E-010-2021-0-PCT-02 ENHANCED ANTIGEN REACTIVITY OF IMMUNE CELLS EXPRESSING A MUTANT NON-SIGNALING CD3 ZETA CHAIN PCT Patent Cooperation Treaty PCT/US2021/059109 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/059109<br />Filed on 2021-11-12<br />Status: Expired 147168136 E-010-2021-0 E-010-2021-0-US-02 ENHANCED ANTIGEN REACTIVITY OF IMMUNE CELLS EXPRESSING A MUTANT NON-SIGNALING CD3 ZETA CHAIN National Stage US 18/036,112 Pending US <br />National Stage 18/036,112<br />Filed on 2023-05-09<br />Status: Pending 147168137 E-010-2021-0 E-010-2021-0-EP-01 ENHANCED ANTIGEN REACTIVITY OF IMMUNE CELLS EXPRESSING A MUTANT NON-SIGNALING CD3 ZETA CHAIN National Stage European Patent 21824143.8 Pending European Patent <br />National Stage 21824143.8<br />Filed on 2023-03-30<br />Status: Pending 147169426 CD3 147169428 Davies 147169429 Eunice Kennedy Shriver National Institute of Child Health an 147169431 Gaud 147169433 Hinrichs 147169435 Immuno-receptor Tyrosine-based Activation Motif 147169436 Immunotherapy 147169438 ITAM 147169440 Love 147169442 National Cancer Institute 147169443 Nci 147169444 NICHD 147169446 T Cell Receptor 147169447 TCR 147169449 Zeta Chain TAB-4228 147157513 Time Efficient Multi-Pulsed Field Gradient (mPFG) MRI Without Concomitant Gradient Field Artifacts NICHD Collaboration, Diagnostics, Immunology, Licensing, Oncology Collaboration Diagnostics Immunology Licensing Oncology Peter Basser, Michal Komlosh, Magdoom Mohamed Kulam Najmudeen <h2>Summary:</h2> <p>The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for the development of diffusion tensor distribution MR imaging (DTD-MRI) in assessing disease (e.g., cancer), normal and abnormal developmental processes, degeneration and trauma in the brain and other soft tissues, or in other applications.</p> <h2>Description of Technology:</h2> <p>Measuring and mapping nervous tissue microstructure noninvasively is a long sought-after goal in neuroscience. Clinically, several neuropathologies such as cancer and stroke, are associated with changes in tissue microstructure. Diffusion tensor imaging (DTI), which models diffusion anisotropy, is an ideal imaging modality to elucidate these changes. However, DTI provides a mean diffusion tensor averaged over the entire MRI voxel. This has limitations when applied to heterogeneous neural tissue. Although some of these could be overcome by increased spatial resolution, this comes at the cost of reduced signal-to-noise ratio (SNR) and increased scan time. The SNR limitation makes it impractical to resolve individual neuronal soma and axons whose size range between 0.1-60 &micro;m. Multiple pulsed field gradient (mPFG) methods can resolve microscopic features several orders of magnitude smaller than the typical MRI voxel size &ndash; for example, plant cell size and pore diameters in phantoms &ndash; using lower gradient strengths compared to single PFG methods.</p> <p>This technology describes methods and apparatus to measure and map the diffusion tensor distribution (DTD) in neural tissue or other specimens. Efficient and translatable methods of performing mPFG MRI experiments in a single spin echo sequence to generate b-matrices of ranks one, two, or three, without concomitant gradient field artifacts are disclosed. The disclosed approaches and signal inversion framework captures features of heterogeneity and anisotropy in the spinal cord or other specimens. The disclosed stains may have utility in assessing disease (e.g., cancer), normal and abnormal developmental processes, degeneration and trauma in the brain and other soft tissues, and other applications.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Neuro or whole-body MRI suites for disease assessment in neural or other tissues.</li> <li>Detection of microscopic anisotropy and heterogeneity within neural tissue (including the spinal cord)</li> <li>Assessing disease (e.g., cancer), normal and abnormal developmental processes, degeneration and trauma in the brain and other soft tissues, and other applications</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Superior non-invasive measurement and mapping of nervous tissue microstructure</li> <li>Better time efficiency relative to other multiple pulsed field gradient (mPFG) techniques</li> <li>Well-defined diffusion timing parameters for q-space MRI analysis</li> <li>Reduction of concomitant gradient field artifacts</li> </ul> 2022-02-11 2026-04-23 2022-02-10 2026-04-23 2022-02-10 Basser, Diffusion Tensor Distribution MR Imaging, DTI, Eunice Kennedy Shriver National Institute of Child Health an, Komlosh, Magnetic Resonance Imaging, mPFG, MRI, Multi-Pulsed Field Gradient, Najmudeen, NICHD False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-02-10 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163976 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 1 147163977 Komlosh, Michal Henry M. Jackson Foundation (HJF) NICHD Komlosh, Michal (NICHD) 2 147163978 Kulam Najmudeen, Magdoom Mohamed NIH - NICHD NICHD Kulam Najmudeen, Magdoom Mohamed (NICHD) 3 147163976 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 1 147163977 Komlosh, Michal Henry M. Jackson Foundation (HJF) NICHD Komlosh, Michal (NICHD) 2 147163978 Kulam Najmudeen, Magdoom Mohamed NIH - NICHD NICHD Kulam Najmudeen, Magdoom Mohamed (NICHD) 3 147158136 Time Efficient Multi-pulsed Field Gradient (mPFG) MRI Without Concomitant Gradient Field Artifacts E-170-2020-0 Filing authorized Henry M. Jackson Foundation (HJF), NICHD 119617417 Ravilious, Geoffrey geoffrey.ravilious@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4228] Time Efficient Multi-Pulsed Field Gradient (mPFG) MRI Without Concomitant Gradient Field Artifacts&body=Please send me information about technology [TAB-4228] Time Efficient Multi-Pulsed Field Gradient (mPFG) MRI Without Concomitant Gradient Field Artifacts.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ravilious, Geoffrey<br><a href="mailto:geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4228] Time Efficient Multi-Pulsed Field Gradient (mPFG) MRI Without Concomitant Gradient Field Artifacts&body=Please send me information about technology [TAB-4228] Time Efficient Multi-Pulsed Field Gradient (mPFG) MRI Without Concomitant Gradient Field Artifacts.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">geoffrey.ravilious@nih.gov</a><br> 147161143 E-170-2020-0 E-170-2020-0-US-01 TIME EFFICIENT MULTI-PULSED FIELD GRADIENT (MPFG) MRI WITHOUT CONCOMITANT GRADIENT FIELD ARTIFACTS PRV US 63/055,150 Abandoned US <br />Provisional (PRV) 63/055,150<br />Filed on 2020-07-22<br />Status: Abandoned 147167537 E-170-2020-0 E-170-2020-0-PCT-02 Time Efficient Multi-pulsed Field Gradient (mPFG) MRI Without Concomitant Gradient Field Artifacts PCT Patent Cooperation Treaty PCT/US2021/040929 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/040929<br />Filed on 2021-07-08<br />Status: Expired 147167538 E-170-2020-0 E-170-2020-0-US-03 TIME EFFICIENT MULTI-PULSED FIELD GRADIENT (MPFG) MRI WITHOUT CONCOMITANT GRADIENT FIELD ARTIFACTS National Stage US 12,493,092 18/017,150 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12493092 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12493092">12,493,092</a><br />Filed on 2023-01-20<br />Status: Issued 147172929 Basser 147172931 Diffusion Tensor Distribution MR Imaging 147172932 DTI 147172933 Eunice Kennedy Shriver National Institute of Child Health an 147172935 Komlosh 147172936 Magnetic Resonance Imaging 147172937 mPFG 147172938 MRI 147172940 Multi-Pulsed Field Gradient 147172941 Najmudeen 147172942 NICHD TAB-4016 147157297 Therapeutics Against Pathogenic Coronaviruses NICHD Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Arup Chakraborty, Melvin DePamphilis, Matthew Frieman <h2>Summary:</h2> <p>Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development are highly motivated in seeking research co-development partners and/or licensees to further develop and commercialize PIKfyve phosphatidyl linositol kinase inhibitors for the treatment of pathogenic coronaviruses. An ideal partner would enter into both a Cooperative Research and Development Agreement (CRADA) and an exclusive license agreement towards commercialization of this technology.</p> <h2>Description of Technology:</h2> <p>The COVID-19 pandemic is a worldwide public health crisis with over 440 million confirmed cases and 6.0 million deaths as of March 2022. COVID-19 is caused by a novel coronavirus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). While there are several vaccines available for COVID-19, there are few therapeutics available that specifically target SARS-CoV-2. Middle East respiratory syndrome coronavirus (MERS-CoV) is less understood than SARS-CoV-2. MERS-CoV patients have a 65% long-term survival rate, according the World Health Organization (WHO).</p> <p>Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development discovered that PIKfyve phosphatidyl linositol kinase inhibitors exhibit therapeutic potential in preventing infection of mammalian cells by pathogenic coronaviruses. It does so by disrupting membrane trafficking to treat coronavirus infection and replication. These compounds are effective at concentrations 100-1000X less than those toxic to uninfected cells. The technology is for use in treating coronavirus infections in humans, particularly infections caused by SARS-CoV-2, SARS-CoV or MER-CoV.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of SARS-CoV-2 or SARS-CoV</li> <li>Treatment of MER-CoV</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Effective against SARS-CoV-2, SARS-CoV, and MER-CoV</li> <li>Disrupts membrane trafficking to treat coronavirus infection and replication</li> <li>Promising safety profile</li> </ul> 2022-04-01 2026-04-23 2022-04-01 2026-04-23 2022-03-31 CORONAVIRUS, COVID-19, Depamphilis, Eunice Kennedy Shriver National Institute of Child Health an, Infectious Diseases, MER-CoV, NICHD, PIKfyve Phosphatidyl Linositol Kinase Inhibitors, SARS-CoV, SARS-CoV-2, virus False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-04-01 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163227 DePamphilis, Melvin NIH - NICHD NICHD DePamphilis, Melvin (NICHD) 1 147163228 Frieman, Matthew University of Maryland, School of Medicine Frieman, Matthew 2 147163229 Chakraborty, Arup NIH - NICHD NICHD Chakraborty, Arup (NICHD) 3 147163227 DePamphilis, Melvin NIH - NICHD NICHD DePamphilis, Melvin (NICHD) 1 147163228 Frieman, Matthew University of Maryland, School of Medicine Frieman, Matthew 2 147163229 Chakraborty, Arup NIH - NICHD NICHD Chakraborty, Arup (NICHD) 3 147157782 Therapeutics Against Pathogenic Coronaviruses SARS-CoV-2, MERS-CoV And SARS-CoV E-009-2021-0 Filing authorized NICHD, University of Maryland 91788919 Gunas, Heather gunash@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America gunash@mail.nih.gov?subject=Web Inquiry on [TAB-4016] Therapeutics Against Pathogenic Coronaviruses&body=Please send me information about technology [TAB-4016] Therapeutics Against Pathogenic Coronaviruses.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gunas, Heather<br><a href="mailto:gunash@mail.nih.gov?subject=Web Inquiry on [TAB-4016] Therapeutics Against Pathogenic Coronaviruses&body=Please send me information about technology [TAB-4016] Therapeutics Against Pathogenic Coronaviruses.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">gunash@mail.nih.gov</a><br> 147160892 E-009-2021-0 E-009-2021-0-US-01 THERAPEUTICS AGAINST PATHOGENIC CORONAVIRUSES PRV US 63/119,522 Abandoned US <br />Provisional (PRV) 63/119,522<br />Filed on 2020-11-30<br />Status: Abandoned 147166008 E-009-2021-0 E-009-2021-0-PCT-02 THERAPEUTICS AGAINST PATHOGENIC CORONAVIRUSES PCT Patent Cooperation Treaty PCT/US2021/060122 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/060122<br />Filed on 2021-11-19<br />Status: Expired 147166009 E-009-2021-0 E-009-2021-0-US-02 THERAPEUTICS AGAINST PATHOGENIC CORONAVIRUSES National Stage US 18/028,490 Abandoned US <br />National Stage 18/028,490<br />Filed on 2023-03-24<br />Status: Abandoned 147169405 CORONAVIRUS 147169406 COVID-19 147169407 Depamphilis 147169408 Eunice Kennedy Shriver National Institute of Child Health an 147169409 Infectious Diseases 147169411 MER-CoV 147169412 NICHD 147169414 PIKfyve Phosphatidyl Linositol Kinase Inhibitors 147169415 SARS-CoV 147169416 SARS-CoV-2 147169417 virus TAB-3969 147157249 Nandrolone 17 Beta-Carbonates NICHD Collaboration, Endocrinology, Licensing, Reproductive Health, Therapeutics Collaboration Endocrinology Licensing Reproductive Health Therapeutics Richard Blye, Hyun Kim, Min Lee <h2>Summary:</h2> <p>Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development are highly motivated in seeking licensing and/or collaboration partners for the development and use of androgenic compounds as contraceptives and/or hormonal therapeutics.</p> <h2>Description of Technology:</h2> <p><img alt="" src="/sites/ttc/files/pictures/e-181-2004-0-us-07_abstract_image.docx" />The available options for male contraceptives are limited. Androgens are administered as part of hormone-based male contraception and have also been used in the treatment of hypogonadism and hormone replacement therapy HRT. Many synthetic androgens require an oil-based delivery vehicle and have limited durations of action.</p> <div>This technology describes androgenic compounds and pharmaceutical compositions thereof for use in a number of diseases or conditions, most notably as a potential male contraceptive, and as an androgenic agent suppressing the release of hormones such as the luteinizing hormone. Additional potential therapeutic areas include hypogonadism, osteoporosis, and anemia.&nbsp;</div> <div>Since 2016, NICHD has been testing the following lead compound as a male contraceptive in Phase I clinical trials:</div> <div> <p>Safety and pharmacokinetics of oral single-dose, 28 day repeat-dose, and dose escalation study of 11-MNTDC in healthy men have been conducted.&nbsp; The drug was well tolerated without serious adverse events.&nbsp; Daily oral dose of 11&beta;-MNTDC for 28 days in healthy men showed markedly suppressed serum gonadotropins and T concentrations without serious adverse effects.&nbsp; NICHD is planning another Phase I trial to test 11&beta;-MNTDC via intramuscular injection.&nbsp;</p> <p>&nbsp;</p> <p><img alt="" src="https://nih.technologypublisher.com/files/sites/e-181-2004-0-us-07_abstract_image4.png" /></p> </div> <h2>Potential Commercial Applications:</h2> <ul> <li>Male contraceptive</li> <li>Treatment of hormonal diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Significant market need for male contraceptive</li> <li>Clinical-stage asset</li> <li>No adverse events in a Phase I dose-escalation study</li> <li>Intramuscular (IM) injection</li> </ul> 2022-09-13 2026-04-23 2026-04-23 2022-09-13 19-nortestosterone, Androgenic Compounds, Blye, Male Contraceptive, Nandrolone, National Institute of Child Health and Human Development, NICHD False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 147162240 Nguyen, BT, et al. Acceptability of the oral hormonal male contraceptive prototype, 11β-methyl-19-nortestosterone dodecylcarbonate (11β-MNTDC), in a 28-day placebo-controlled trial https://pubmed.ncbi.nlm.nih.gov/34153318/ <a href="https://pubmed.ncbi.nlm.nih.gov/34153318/">Nguyen, BT, et al. Acceptability of the oral hormonal male contraceptive prototype, 11β-methyl-19-nortestosterone dodecylcarbonate (11β-MNTDC), in a 28-day placebo-controlled trial</a> 147162355 Wu, S, et al. Safety and Pharmacokinetics of Single-Dose Novel Oral Androgen 11β-Methyl-19-Nortestosterone-17β-Dodecylcarbonate in Men. https://pubmed.ncbi.nlm.nih.gov/30252057/ <a href="https://pubmed.ncbi.nlm.nih.gov/30252057/">Wu, S, et al. Safety and Pharmacokinetics of Single-Dose Novel Oral Androgen 11β-Methyl-19-Nortestosterone-17β-Dodecylcarbonate in Men.</a> 147162393 Yuen, F, et al. Daily Oral Administration of the Novel Androgen 11β-MNTDC Markedly Suppresses Serum Gonadotropins in Healthy Men. https://pubmed.ncbi.nlm.nih.gov/31976519/#:~:text=Conclusion%3A%20Daily%20oral%2011%CE%B2%2DMNTDC,a%20potential%20male%20oral%20contraceptive. <a href="https://pubmed.ncbi.nlm.nih.gov/31976519/#:~:text=Conclusion%3A%20Daily%20oral%2011%CE%B2%2DMNTDC,a%20potential%20male%20oral%20contraceptive.">Yuen, F, et al. Daily Oral Administration of the Novel Androgen 11β-MNTDC Markedly Suppresses Serum Gonadotropins in Healthy Men.</a> 147163075 Blye, Richard NIH - NICHD NICHD Blye, Richard (NICHD) 1 147163074 Kim, Hyun NIH - NICHD Kim, Hyun 2 147163076 Lee, Min NICHD NICHD Lee, Min (NICHD) 3 147163075 Blye, Richard NIH - NICHD NICHD Blye, Richard (NICHD) 1 147163074 Kim, Hyun NIH - NICHD Kim, Hyun 2 147163076 Lee, Min NICHD NICHD Lee, Min (NICHD) 3 147158157 Preparation And Use Of Androgenic Compounds E-181-2004-0 Filing authorized NICHD 91788919 Gunas, Heather gunash@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America gunash@mail.nih.gov?subject=Web Inquiry on [TAB-3969] Nandrolone 17 Beta-Carbonates&body=Please send me information about technology [TAB-3969] Nandrolone 17 Beta-Carbonates.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gunas, Heather<br><a href="mailto:gunash@mail.nih.gov?subject=Web Inquiry on [TAB-3969] Nandrolone 17 Beta-Carbonates&body=Please send me information about technology [TAB-3969] Nandrolone 17 Beta-Carbonates.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">gunash@mail.nih.gov</a><br> 147165613 E-181-2004-0 E-181-2004-0-US-01 Preparation And Use Of Androgenic Compounds PRV US 60/650,376 Abandoned US <br />Provisional (PRV) 60/650,376<br />Filed on 2005-02-04<br />Status: Abandoned 147165614 E-181-2004-0 E-181-2004-0-PCT-02 NANDROLONE 17B-CARBONATES PCT Patent Cooperation Treaty PCT/US2006/02436 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/02436<br />Filed on 2006-01-24<br />Status: Expired 147165615 E-181-2004-0 E-181-2004-0-AU-03 NANDROLONE 17 BETA-CARBONATES National Stage Australia 2006211907 2006211907 Abandoned Australia <br />National Stage 2006211907<br />Filed on 2006-01-24<br />Status: Abandoned 147165616 E-181-2004-0 E-181-2004-0-CA-04 NANDROLONE 17 BETA-CARBONATES National Stage Canada 2596884 2596884 Abandoned Canada <br />National Stage 2596884<br />Filed on 2006-01-24<br />Status: Abandoned 147165617 E-181-2004-0 E-181-2004-0-EP-05 NANDROLONE 17 BETA-CARBONATES National Stage European Patent 1846434 06719336.7 Abandoned European Patent <br />National Stage 06719336.7<br />Filed on 2006-01-24<br />Status: Abandoned 147165618 E-181-2004-0 E-181-2004-0-JP-06 NANDROLONE 17 BETA-CARBONATES National Stage Japan 5227593 2007-554134 Abandoned Japan <br />National Stage 2007-554134<br />Filed on 2006-01-24<br />Status: Abandoned 147165619 E-181-2004-0 E-181-2004-0-US-07 NANDROLONE 17B-CARBONATES National Stage US 7,820,642 11/815,532 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7820642 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7820642">7,820,642</a><br />Filed on 2007-08-03<br />Status: Issued 147165620 E-181-2004-0 E-181-2004-0-DE-08 NANDROLONE 17 BETA-CARBONATES EP Germany 1846434 06719336.7 Abandoned Germany <br />European patent (EP) 06719336.7<br />Filed on 2006-01-24<br />Status: Abandoned 147165621 E-181-2004-0 E-181-2004-0-FR-09 NANDROLONE 17 BETA-CARBONATES EP France 1846434 06719336.7 Abandoned France <br />European patent (EP) 06719336.7<br />Filed on 2006-01-24<br />Status: Abandoned 147165622 E-181-2004-0 E-181-2004-0-GB-10 NANDROLONE 17 BETA-CARBONATES EP United Kingdom 1846434 06719336.7 Abandoned United Kingdom <br />European patent (EP) 06719336.7<br />Filed on 2006-01-24<br />Status: Abandoned 147173106 19-nortestosterone 147173108 Androgenic Compounds 147173110 Blye 147173111 Male Contraceptive 147173113 Nandrolone 147173114 National Institute of Child Health and Human Development 147173115 NICHD TAB-4377 147157671 Use of Repurposed Compounds for the Treatment of Alzheimer’s Disease NIA Collaboration, Licensing, Neurology, Therapeutics Collaboration Licensing Neurology Therapeutics Madhav Thambisetty <h2>Summary:</h2> <p>The NIA seeks co-development partners and/or licensees for the further pre-clinical and clinical development of TTI-101, hydroxychloroquine, and Dasatinib to treat Alzheimer&rsquo;s disease.</p> <h2>Description of Technology:</h2> <p>There are no effective treatments for Alzheimer&rsquo;s disease (AD), a progressive brain disease that slowly destroys a person&rsquo;s memory, cognitive skills and ability to carry out the simplest tasks. AD affects more than 5 million individuals in the United States and ranks as the sixth leading cause of death. The &epsilon;4 allele of the apolipoprotein-E (APOE) gene is the strongest genetic risk factor for sporadic or late-onset AD. Heterozygous carriers of the &epsilon;4 allele are at three-to-four times greater risk; homozygous carriers are at ten times greater risk. In fact, APOE &epsilon;4 carriers accumulate AD neuropathology early in adulthood with earlier age onset of AD compared with &epsilon;4 non-carriers.</p> <p>Researchers at the National Institute on Aging (NIA) identified a brain proteomic signature comprised of 25 proteins that may drive the risk for developing AD in young APOE &epsilon;4 carriers. NIA researchers further identified compounds that target proteins in this AD proteomic signature and rescue molecular abnormalities associated with AD. Specifically, the STAT3 inhibitors TTI-101 and hydroxychloroquine rescued three specific AD phenotypes in cell culture-based phenotypic screens: (1) lipopolysaccharide (LPS)-induced neuroinflammation; (2) tau phosphorylation; and (3) A&beta; secretion/A&beta; clearance. Dasatinib, a YES1/FYN inhibitor, lowered tau phosphorylation. These findings reveal that TT1-101, hydroxychloroquine and Dasatinib &ndash; among other approved and experimental drugs &ndash; may be repurposed to treat AD.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>A therapeutic for patients with Alzheimer&rsquo;s disease</li> <li>A therapeutic for APOE &epsilon;4 carriers with Alzheimer&rsquo;s disease&nbsp;</li> <li>A therapeutic for APOE &epsilon;4 carriers with early signs of Alzheimer&rsquo;s disease</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Prevent the development and progression of Alzheimer&rsquo;s disease in high-risk <em>APOE</em> &epsilon;4 carriers</li> <li>Expedited approval process due in part to pre-existing safety data for repurposed drugs</li> </ul> 2022-02-11 2026-04-23 2022-02-23 2026-04-23 2022-02-11 Alzheimer’s Disease, ApoE, Apolipoprotein-E, Aβ, FYN, National Institute on Aging, Neuroinflammation, NIA, STAT3, Tau Phosphorylation, Thambisetty, YES1 False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-02-23 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162048 Roberts JA, et al. A brain proteomic signature of incipient Alzheimer&rsquo;s disease in young APOE ε4 carriers identifies novel drug targets. https://pubmed.ncbi.nlm.nih.gov/34757788/ <a href="https://pubmed.ncbi.nlm.nih.gov/34757788/">Roberts JA, et al. A brain proteomic signature of incipient Alzheimer&rsquo;s disease in young APOE ε4 carriers identifies novel drug targets.</a> 147164508 Thambisetty, Madhav National Institute on Aging (NIH/NIA) NIA Thambisetty, Madhav (NIA) 1 147164508 Thambisetty, Madhav National Institute on Aging (NIH/NIA) NIA Thambisetty, Madhav (NIA) 1 147158210 C188-9 (STAT3 Inhibitor) And Dasatinib (Scr Family Tyrosine Kinases YES1 And FYN Inhibitor) Are Novel Disease-modifying Treatments For Alzheimer's Disease E-207-2021-0 Filing authorized National Institute on Aging (NIH/NIA) 91789173 Guyton, Nicole darackn@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America darackn@mail.nih.gov?subject=Web Inquiry on [TAB-4377] Use of Repurposed Compounds for the Treatment of Alzheimer’s Disease&body=Please send me information about technology [TAB-4377] Use of Repurposed Compounds for the Treatment of Alzheimer’s Disease.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Guyton, Nicole<br><a href="mailto:darackn@mail.nih.gov?subject=Web Inquiry on [TAB-4377] Use of Repurposed Compounds for the Treatment of Alzheimer’s Disease&body=Please send me information about technology [TAB-4377] Use of Repurposed Compounds for the Treatment of Alzheimer’s Disease.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">darackn@mail.nih.gov</a><br> 147161194 E-207-2021-0 E-207-2021-0-US-01 COMPOUNDS AND MOLECULAR TARGETS FOR TREATING AND/OR PREVENTING ALZHEIMER'S DISEASE PRV US 63/253,992 Abandoned US <br />Provisional (PRV) 63/253,992<br />Filed on 2021-10-08<br />Status: Abandoned 147168527 E-207-2021-0 E-207-2021-0-PCT-02 COMPOUNDS AND MOLECULAR TARGETS FOR TREATING AND/OR PREVENTING ALZHEIMER'S DISEASE PCT Patent Cooperation Treaty PCT/US2022/046018 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/046018<br />Filed on 2022-10-07<br />Status: Expired 147173670 Alzheimer’s Disease 147173671 ApoE 147173673 Apolipoprotein-E 147173675 Aβ 147173676 FYN 147173677 National Institute on Aging 147173678 Neuroinflammation 147173679 NIA 147173680 STAT3 147173682 Tau Phosphorylation 147173684 Thambisetty 147173685 YES1 TAB-4042 147157323 Sensitive and Economic RNA Virus Detection Using a Novel RNA Preparation Method NEI Collaboration, Diagnostics, Infectious Disease, Licensing, Oncology Collaboration Diagnostics Infectious Disease Licensing Oncology Bin Guan, Robert Hufnagel <h2>Summary:</h2> <p>Inventors at the National Eye Institute are seeking&nbsp;research and co-development partners and/or licensees to: (1) advance the production and uses of the new RNA preparation method, (2) manufacture reagent kits for testing in patients with suspected COVID-19 and other DNA/RNA viruses, and (3) manufacture reagent kits for patient biomarker profiles and inherited disease diagnostics.</p> <h2>Description of Technology:</h2> <p>DNA or RNA-based diagnostic tests for infectious diseases are critical in modern medicine. The current gold standard for COVID-19 detection is testing SARS-CoV-2 viral RNA by quantitative reverse transcription Polymerase Chain Reaction (RT-qPCR). This method involves patient sample collection with a nasopharyngeal swab, storage of the swab in a universal transport medium during transport to testing site, RNA extraction, and analysis of the extracted RNA sample. Collected patient samples &ndash; in addition to the possible presence of SARS-CoV-2 &ndash; also contain inhibitors for downstream enzymatic reactions, RNA degrading enzymes (e.g., RNase), and magnesium and calcium ions required for RNase activity. Active RNase in the patient sample reduces the amount of SARS-CoV-2 RNA in the sample; so the RNA needs to be extracted for analysis.&nbsp;<br /> &nbsp;<br /> Researchers at the National Institutes of Health&rsquo;s National Eye Institute (NEI) developed a novel improved sample preparation method that eliminates the need for an RNA extraction step from the currently used method of detecting SARS-CoV-2. NEI researchers discovered that incorporation of a chelating agent into the RT-qPCR heating step ties up the magnesium and calcium ions needed for RNase activity &ndash; thereby increasing the amount of RNA produced for analysis. The new procedure also simultaneously removes potential inhibitors of RT-qPCR and inactivates SARS-CoV-2 infectivity. This removal improves workflow safety and eliminates the need for a BSL-2 testing facility. This is a versatile and safe method for RNA preparation for a variety of patient samples beyond SARS-CoV-2. It is suitable for standard clinical collection and testing on high throughput platforms for both DNA and RNA.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Improved COVID-19 diagnostic test</li> <li>Improved DNA or RNA-based diagnostic test for additional infectious diseases</li> <li>Safer preparation of patient samples</li> <li>Reagent kits for biomarker profiles and inherited diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Improved workflow safety</li> <li>Removes potential inhibitors of RT-qPCR</li> <li>Inactivates SARS-CoV-2 infectivity</li> <li>Increased RNA production for analysis</li> <li>Eliminates the need for an RNA extraction step</li> </ul> 2022-01-21 2026-04-23 2022-01-26 2026-04-23 2022-01-20 Biomarker, Chelating Resin, Chelex Resin, COVID, COVID-19, DNA/RNA diagnostic test, Extraction-free Detection, Infectious Diseases, SARS-CoV-2, virus False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-01-26 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 147162086 Guan B, et al. Sensitive extraction-free SARS-CoV-2 RNA virus detection using a novel RNA 1 preparation method. https://pubmed.ncbi.nlm.nih.gov/33532808/ <a href="https://pubmed.ncbi.nlm.nih.gov/33532808/">Guan B, et al. Sensitive extraction-free SARS-CoV-2 RNA virus detection using a novel RNA 1 preparation method.</a> 147163310 Guan, Bin NIH - NEI NEI Guan, Bin (NEI) 1 147163311 Hufnagel, Robert NIH - NEI NEI Hufnagel, Robert (NEI) 2 147163310 Guan, Bin NIH - NEI NEI Guan, Bin (NEI) 1 147163311 Hufnagel, Robert NIH - NEI NEI Hufnagel, Robert (NEI) 2 147158191 Sensitive And Economic RNA Virus Detection Using A Novel RNA Preparation Method E-195-2020-0 Filing authorized National Eye Institute (NEI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4042] Sensitive and Economic RNA Virus Detection Using a Novel RNA Preparation Method&body=Please send me information about technology [TAB-4042] Sensitive and Economic RNA Virus Detection Using a Novel RNA Preparation Method.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4042] Sensitive and Economic RNA Virus Detection Using a Novel RNA Preparation Method&body=Please send me information about technology [TAB-4042] Sensitive and Economic RNA Virus Detection Using a Novel RNA Preparation Method.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147161180 E-195-2020-0 E-195-2020-0-US-01 Sensitive And Economic RNA Virus Detection Using A Novel RNA Preparation Method PRV US 63/065,931 Abandoned US <br />Provisional (PRV) 63/065,931<br />Filed on 2020-08-14<br />Status: Abandoned 147166165 E-195-2020-0 E-195-2020-0-PCT-03 Sensitive And Economic RNA Virus Detection Using A Novel RNA Preparation Method PCT Patent Cooperation Treaty PCT/US2021/045675 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/045675<br />Filed on 2021-08-12<br />Status: Expired 147166166 E-195-2020-0 E-195-2020-0-US-03 SAMPLE PREPARATION AND VIRAL DETECTION METHODS National Stage US 12,637,705 18/041,295 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12637705 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12637705">12,637,705</a><br />Filed on 2023-02-10<br />Status: Issued 147173470 Biomarker 147173472 Chelating Resin 147173474 Chelex Resin 147173475 COVID 147173476 COVID-19 147173478 DNA/RNA diagnostic test 147173480 Extraction-free Detection 147173481 Infectious Diseases 147173482 SARS-CoV-2 147173483 virus TAB-4406 147157701 High Efficacy Vaccine and Microbicide Combination For Use Against HIV NCI Collaboration, Immunology, Infectious Disease, Licensing, Vaccines Collaboration Immunology Infectious Disease Licensing Vaccines Daniel Appella, Ettore Appella, Massimiliano Bissa, Genoveffa Franchini, Sabrina Helmold Hait, Lisa Marie Jenkins, Mohammed Rahman, Marjorie Robert-Guroff, Isabela Silva De Castro <h2>Summary:</h2> <p>NCI is seeking research co-development partners and/or licensees to evaluate, further develop or commercialize this high efficacy vaccine and microbicide combination for use against HIV.&nbsp;</p> <h2>Description of Technology:</h2> <p>Human immunodeficiency virus (HIV) remains a major global health challenge despite the advancement made in development of effective antiretrovirals (ARVs). ARVs are effective at limiting replication and spread of the virus, and progression to acquired immuno-deficiency syndrome (AIDS). However, ARVs often lead to emergence of drug-resistant virus strains insensitive to treatment and with toxic effects following long-term usage. In addition, access to ARVs is limited in certain regions, particularly in sub-Saharan Africa &ndash; where the HIV epidemic continues unabated and disproportionately affects women and adolescent girls. There is a global health need for development of alternative approaches providing long-term protection from the virus, such as vaccines.</p> <p>Researchers at the National Cancer Institute (NCI) previously demonstrated the efficacy of envelope glycoprotein 120 (gp120) variable region 1 (V1)-deleted simian immunodeficiency virus (SIV) vaccines against the highly pathogenic SIVmac251, which recapitulates human AIDS in animals. These SIV envelope V1-deleted vaccines increased the antigenicity of the envelope glycoprotein variable region 2 (V2) and were 65% effective in preventing vaginal SIVmac251 infection in the macaque animal model. However, the vaccine regimen was ineffective in about one third of animals. Therefore, the inventors added the SAMT-247 microbicide that disrupts the folded structure of the viral nucleocapsid protein NCp7 by interfering with zinc coordination in the protein. This resulted in the production of immature viral particles. Following 14 weekly exposures to SIVmac251, 80% of macaques vaccinated and treated with SAMT-247 remained uninfected &ndash; reducing infection risk &gt;90%. SAMT-247 was administered 4 hours before each challenge exposure and dramatically augmented vaccine-induced protection via increased NK cytotoxicity, increased monocyte efferocytosis, and decreased T-cell activation (figure below).</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Development of next generation HIV vaccines</li> <li>Prevention of HIV infection and AIDS</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Increased vaccine efficacy of up to 80%&nbsp;</li> <li>Combination treatment &ndash; vaccine and SAMT-247 microbicide &ndash; significantly reducing risk of SIV infection</li> <li>SAMT-247 microbicide is not toxic to human cervical tissue</li> <li>SAMT-247 microbicide remains effective in cervical mucus</li> </ul> 2022-10-21 2026-04-23 2022-10-21 2026-04-23 2022-10-21 Acquired Immuno-Deficiency Syndrome, ADCC, AIDS, Antibody-dependent Cellular Cytotoxicity, Efferocytosis, Envelope Glycoprotein 120, Envelope Variable Region, Franchini, gp120, HIV, Human Immunodeficiency Virus, Microbicide, SAMT-247, V1, Vaccine False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-10-21 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-160-2018 E-329-2000 147162336 Halt SH et al. An SAMT-247 microbicide provides potent protection against intravaginal Simian Immunodeficiency virus infection of Rhesus Macaques, whereas an added vaccine component elicits mixed outcomes. https://pubmed.ncbi.nlm.nih.gov/32393514/ <a href="https://pubmed.ncbi.nlm.nih.gov/32393514/">Halt SH et al. An SAMT-247 microbicide provides potent protection against intravaginal Simian Immunodeficiency virus infection of Rhesus Macaques, whereas an added vaccine component elicits mixed outcomes.</a> 147162374 Silva de Castro I et al. Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates. https://pubmed.ncbi.nlm.nih.gov/33554060/ <a href="https://pubmed.ncbi.nlm.nih.gov/33554060/">Silva de Castro I et al. Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates.</a> 147164617 Franchini, Genoveffa NIH - NCI NCI Franchini, Genoveffa (NCI) 1 147164616 Robert-Guroff, Marjorie NIH - NCI Robert-Guroff, Marjorie 2 147164619 Appella, Daniel NIH - NIDDK NIDDK Appella, Daniel (NIDDK) 3 147164622 Helmold Hait, Sabrina NIH - NCI NCI Helmold Hait, Sabrina (NCI) 4 147164623 Rahman, Mohammed NIH - NCI NCI Rahman, Mohammed (NCI) 5 147164620 Bissa, Massimiliano NIH - NCI NCI Bissa, Massimiliano (NCI) 6 147164618 Appella, Ettore NIH - NCI NCI Appella, Ettore (NCI) 7 147164624 Jenkins, Lisa Marie NIH - NCI NCI Jenkins, Lisa Marie (NCI) 8 147164621 Silva De Castro, Isabela NIH - NCI Silva De Castro, Isabela 9 147164617 Franchini, Genoveffa NIH - NCI NCI Franchini, Genoveffa (NCI) 1 147164616 Robert-Guroff, Marjorie NIH - NCI Robert-Guroff, Marjorie 2 147164619 Appella, Daniel NIH - NIDDK NIDDK Appella, Daniel (NIDDK) 3 147164622 Helmold Hait, Sabrina NIH - NCI NCI Helmold Hait, Sabrina (NCI) 4 147164623 Rahman, Mohammed NIH - NCI NCI Rahman, Mohammed (NCI) 5 147164620 Bissa, Massimiliano NIH - NCI NCI Bissa, Massimiliano (NCI) 6 147164618 Appella, Ettore NIH - NCI NCI Appella, Ettore (NCI) 7 147164624 Jenkins, Lisa Marie NIH - NCI NCI Jenkins, Lisa Marie (NCI) 8 147164621 Silva De Castro, Isabela NIH - NCI Silva De Castro, Isabela 9 147157867 DNA/ALVAC-SIV/gp120?V1/Alum Vaccination And SAMT-247 Microbicide Synergize In Protecting Female Rhesus Macaques From SIV Acquisition E-048-2021-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NCI 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4406] High Efficacy Vaccine and Microbicide Combination For Use Against HIV&body=Please send me information about technology [TAB-4406] High Efficacy Vaccine and Microbicide Combination For Use Against HIV.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4406] High Efficacy Vaccine and Microbicide Combination For Use Against HIV&body=Please send me information about technology [TAB-4406] High Efficacy Vaccine and Microbicide Combination For Use Against HIV.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">diptadip.dattaroy@nih.gov</a><br> 147160964 E-048-2021-0 E-048-2021-0-US-01 HIV-1 VACCINATION AND SAMT-247 MICROBICIDE TO PREVENT HIV-1 INFECTION PRV US 63/228,707 Abandoned US <br />Provisional (PRV) 63/228,707<br />Filed on 2021-08-03<br />Status: Abandoned 147168752 E-048-2021-0 E-048-2021-0-PCT-02 HIV-1 VACCINATION AND SAMT-247 MICROBICIDE TO PREVENT HIV-1 INFECTION PCT Patent Cooperation Treaty PCT/US2022/074432 Administratively Closed Patent Cooperation Treaty <br />(PCT) PCT/US2022/074432<br />Filed on 2022-08-02<br />Status: Administratively Closed 147170277 Acquired Immuno-Deficiency Syndrome 147170278 ADCC 147170279 AIDS 147170281 Antibody-dependent Cellular Cytotoxicity 147170283 Efferocytosis 147170285 Envelope Glycoprotein 120 147170287 Envelope Variable Region 147170289 Franchini 147170290 gp120 147170291 HIV 147170292 Human Immunodeficiency Virus 147170293 Microbicide 147170294 SAMT-247 147170295 V1 147170296 Vaccine TAB-4389 147157683 T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Sri Krishna, Shoshana Levi, Frank Lowery, Shirley Nah, Paul Robbins, Steven Rosenberg, Rami Yoseph <h2>Summary:</h2> <p>The NCI seeks parties interested in research co-development and/or licensing this library of TCRs targeting CDKN2A mutations.</p> <h2>Description of Technology:</h2> <p>Cyclin-dependent kinase inhibitor 2A gene, also known as CDKN2A, is a tumor suppressor gene and is commonly inactivated through somatic mutations in many human cancers. For example, inactivation of CDKN2A is highly prevalent in melanoma, gastrointestinal and pancreatic cancers. Through germline mutations, CDKN2A is associated with predisposition for a variety of cancers, including melanoma and pancreatic cancers. Despite the high frequency of CDKN2A mutations in cancer, there have been no successful therapies targeting these mutations to date. Adoptive cell therapy, a promising form of immunotherapy, offers a potential form of targeted therapy for cancers with CDKN2A mutations.</p> <p>Researchers at the National Cancer Institute (NCI) have developed seven novel human T cell receptors (TCRs) targeting CDKN2A. These TCRs may be used in adoptive cell therapy to treat cancers driven by CDKN2A mutations by targeting neoantigens expressed only by cancer cells. More specifically, the TCRs target neoantigens driven by frameshifts and those driven by nonsynonymous mutations that result in a proline to leucine in position 114 in the CDKN2A gene. Together, these account for 53% of CDKN2A mutations. The TCRs are restricted by some of the most common HLA alleles including HLA A*03:01, HLA A*11:01 and HLA A*02:01, which have an approximate frequency of 8%, 7%, and 40% respectively within the United States population. Thus, these TCRs allow for engineering TCR-based therapies resulting in specific elimination of tumor cells with the indicated CDKN2A mutations present in a diverse group of cancer patients.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Autologous TCR-engineered T cell therapy for cancer patients with CDKN2A mutations</li> <li>Off-the-shelf, allogeneic TCR-engineered T cell therapy for cancer patients with CDKN2A mutations</li> <li>Combination immunotherapies using TCR-engineered T cells alongside other immunotherapies targeting common driver mutations or patient specific mutations</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>No approved therapies targeting CDKN2A</li> <li>Targeted therapy against CDKN2A mutations with therapeutic potential for a wide variety of cancers</li> <li>Targets neoantigens presented by common HLA alleles making the therapy potentially effective for a broad cancer patient population</li> <li>CDKN2A mutations not present in healthy cells</li> </ul> 2022-11-22 2026-04-23 2022-11-22 2026-04-23 2022-11-22 adoptive cell therapy, CDKN2A, cyclin dependent kinase inhibitor 2A, Immunotherapy, Krishna, MELANOMA, Neoantigen, Rosenberg, T Cell Receptor, TCR False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-11-22 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-175-2016 E-237-2017 147164554 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 1 147164555 Levi, Shoshana NCI - CCR NCI Levi, Shoshana (NCI) 2 147164551 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 3 147164550 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 4 147164556 Nah, Shirley NCI - CCR NCI Nah, Shirley (NCI) 5 147164552 Yoseph, Rami NIH - NCI NCI Yoseph, Rami (NCI) 6 147164553 Lowery, Frank NIH - NCI NCI Lowery, Frank (NCI) 7 147164554 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 1 147164555 Levi, Shoshana NCI - CCR NCI Levi, Shoshana (NCI) 2 147164551 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 3 147164550 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 4 147164556 Nah, Shirley NCI - CCR NCI Nah, Shirley (NCI) 5 147164552 Yoseph, Rami NIH - NCI NCI Yoseph, Rami (NCI) 6 147164553 Lowery, Frank NIH - NCI NCI Lowery, Frank (NCI) 7 147158209 T Cell Receptors Targeting Mutations In CDKN2A For Cancer Immunotherapy E-206-2022-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4389] T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy&body=Please send me information about technology [TAB-4389] T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4389] T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy&body=Please send me information about technology [TAB-4389] T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161193 E-206-2022-0 E-206-2022-0-US-01 T CELL RECEPTORS TARGETING MUTATED CDKN2A PRV US 63/381,591 Expired US <br />Provisional (PRV) 63/381,591<br />Filed on 2022-10-31<br />Status: Expired 159507026 E-206-2022-0 E-206-2022-0-PC-01 T CELL RECEPTORS TARGETING MUTATED CDKN2A PCT Patent Cooperation Treaty PCT/US2023/078190 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/078190<br />Filed on 2023-10-30<br />Status: Expired 147173659 adoptive cell therapy 147173660 CDKN2A 147173662 cyclin dependent kinase inhibitor 2A 147173663 Immunotherapy 147173664 Krishna 147173665 MELANOMA 147173666 Neoantigen 147173667 Rosenberg 147173668 T Cell Receptor 147173669 TCR TAB-4359 147157652 Mice, Organs, and Mouse Alleles Carrying Germline and Conditional Deletions of the Zbtb7b Gene NCI Immunology, Infectious Disease, Licensing, Oncology, Research Materials Immunology Infectious Disease Licensing Oncology Research Materials <h2>Summary:</h2> <p>The NCI seeks parties interested in licensing this mouse model, including the mice, organs, tissues, and other derivatives from mice carrying deletions of the Zbtb7b gene.&nbsp;</p> <h2>Description:</h2> <p>The Zbtb7b gene encodes the zinc finger transcription factor ThPOK (also known as cKrox) that promotes CD4 lineage differentiation in immature T cells. CD4+ T cells, also known as &ldquo;helper&rdquo; T cells, are critical for long-term immunity against pathogens as well as for promoting CD8+ &ldquo;effector&rdquo; T cell and effective B cell responses. ThPOK is needed for the development and functional fitness of CD4+ T cells as well as multiple aspects of the immune response to infection. As such, ThPOK offers a potential target for immune regulation. For example, increasing the activity of ThPOK may enhance the efficacy of immunization strategies against infections or cancer; diseases associated with CD4+ T cell deficiency. Alternatively, inhibitors of ThPOK could offer new ways to interfere with CD4+ T cell activity, offering therapeutic benefit in inflammatory or autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.</p> <p>Researchers at the National Cancer Institute (NCI) developed mouse alleles carrying germline and conditional deletions of the Zbtb7b gene. These alleles were used to generate mice which demonstrate the Zbtb7b gene is essential for CD4+ T cell development and function. These mice can be used to study the function of ThPOK and the role of CD4+ T cells in the immune system. In addition to generating mice that are homozygous for the Zbtb7b gene deletion, the researchers generated mice that can be beneficial as experimental controls. One such mouse line is heterozygous for the Zbtb7b gene deletion; it carries one wild-type allele and one knockout allele. The other mouse line appears wild-type phenotypically but contains a &ldquo;floxed&rdquo; version of the Zbtb7b gene flanked by LoxP sites. It may be used to generate additional conditional deletions for the temporal and spatial regulation of gene expression. Given the importance of CD4+ T cells for the immune system, these mice are applicable to preclinical studies regarding a wide variety of human disorders.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research tool to study the role of CD4+ T cells in immune response</li> <li>Drug screening and evaluation</li> <li>Develop ThPOK inhibitors which could be relevant for inflammatory or autoimmune diseases</li> <li>Develop ThPOK activators which could enhance the efficacy of immunization strategies</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Investigate the function of CD4+ T cells in vivo</li> <li>Investigate the role of the Zbtb7b gene and its protein product ThPOK in vivo</li> <li>Control the expression of the Zbtb7b gene through alleles carrying conditional deletions and/or the floxed allele</li> </ul> 2022-12-06 2026-04-23 2022-12-06 2026-04-23 2022-12-06 Autoimmunity, Bosselut, CANCER, CD4, cKrox, Helper T Cell, Infection, LYMPHOCYTE, Memory T Cell, Oncology, ThPOK, transgenic mice, Zbtb7b, Zinc Finger Transcription Factor False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-12-06 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161894 Vacchio MS, et al. A ThPOK-LRF transcriptional node maintains the integrity and effector potential of post-thymic CD4+ T cells. https://pubmed.ncbi.nlm.nih.gov/25129370/ <a href="https://pubmed.ncbi.nlm.nih.gov/25129370/">Vacchio MS, et al. A ThPOK-LRF transcriptional node maintains the integrity and effector potential of post-thymic CD4+ T cells.</a> 147162010 Ciucci T, et al. The emergence and functional fitness of memory CD4+ T cells require the transcription factor Thpok. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503975/ <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503975/">Ciucci T, et al. The emergence and functional fitness of memory CD4+ T cells require the transcription factor Thpok.</a> 147162282 Vacchio MS, et al. A Thpok-directed transcriptional circuitry promotes Bcl6 and Maf expression to orchestrate T follicular helper differentiation. https://pubmed.ncbi.nlm.nih.gov/31422869/ <a href="https://pubmed.ncbi.nlm.nih.gov/31422869/">Vacchio MS, et al. A Thpok-directed transcriptional circuitry promotes Bcl6 and Maf expression to orchestrate T follicular helper differentiation.</a> 155750779 Mice, Organs And Mouse Alleles Carrying Germline And Conditional Deletions Of The Zbtb7b Gene E-226-2022-0 Research Material NCI 83687903 Pollack, Michael michael.pollack@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4359] Mice, Organs, and Mouse Alleles Carrying Germline and Conditional Deletions of the Zbtb7b Gene&body=Please send me information about technology [TAB-4359] Mice, Organs, and Mouse Alleles Carrying Germline and Conditional Deletions of the Zbtb7b Gene.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollack, Michael<br><a href="mailto:michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4359] Mice, Organs, and Mouse Alleles Carrying Germline and Conditional Deletions of the Zbtb7b Gene&body=Please send me information about technology [TAB-4359] Mice, Organs, and Mouse Alleles Carrying Germline and Conditional Deletions of the Zbtb7b Gene.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michael.pollack@nih.gov</a><br> 147173916 Autoimmunity 147173918 Bosselut 147173919 CANCER 147173920 CD4 147173922 cKrox 147173924 Helper T Cell 147173925 Infection 147173926 LYMPHOCYTE 147173928 Memory T Cell 147173929 Oncology 147173931 ThPOK 147173932 transgenic mice 147173933 Zbtb7b 147173935 Zinc Finger Transcription Factor TAB-4357 147157650 Single Domain Antibodies Targeting the S2 Subunit of SARS-CoV-2 Spike Protein NCI Collaboration, Immunology, Infectious Disease, Licensing, Therapeutics Collaboration Immunology Infectious Disease Licensing Therapeutics Jesse Buffington, Zhijian Duan, Mitchell Ho <h2>Description:</h2> <p>The COVID-19 pandemic is a worldwide public health crisis with over 100 million confirmed cases and 2.4 million deaths as of February 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. Almost all the neutralizing antibodies targeting SARS-CoV-2 that are in development recognize the receptor binding domain (RBD) on the spike (S) protein. Blocking the interaction of RBD and the ACE2 receptor on human cells is the first of the two critical steps for neutralization of the virus. However, the S2 subunit of the spike is also critical for viral infection and entry into human cells. It is highly conserved across many coronaviruses, including other SARS-CoV-2 like viruses. To date there are no antibodies targeting the S2 subunit.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of SARS-CoV-2 infections</li> <li>&nbsp;Standard antibody therapy</li> <li>&nbsp;Delivery of nanoparticles</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Currently, only one antibody treatment received FDA-issued emergency use authorization for COVID-19 treatment.</li> <li>Currently, no antibodies targeting the S2 subunit of SARS-CoV-2.</li> <li>Potential to treat current and future SARS-CoV-2 infections.</li> <li>Nanobodies are attractive candidates for intranasal spray therapy due to their small size, high affinity and high stability</li> <li>Nanobody characteristics which could be a more effective treatment for the respiratory disease</li> <li>Does not require intravenous administration</li> </ul> 2022-09-14 2026-04-23 2022-09-14 2026-04-23 2022-09-14 : COVID-19, ANTIBODY, Camel Nanobody, CORONAVIRUS, HO, Infectious Diseases, Nanobodies, Pandemic, SARS-CoV-2, Shark Nanobody, therapeutic, Vaccine False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-09-14 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147164435 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147164436 Duan, Zhijian NCI - CCR NCI Duan, Zhijian (NCI) 2 147164437 Buffington, Jesse NCI - CCR NCI Buffington, Jesse (NCI) 3 147164435 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147164436 Duan, Zhijian NCI - CCR NCI Duan, Zhijian (NCI) 2 147164437 Buffington, Jesse NCI - CCR NCI Buffington, Jesse (NCI) 3 147158204 Single Domain Antibodies Targeting The S2 Subunit Of SARS-CoV-2 Spike Protein E-204-2021-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4357] Single Domain Antibodies Targeting the S2 Subunit of SARS-CoV-2 Spike Protein&body=Please send me information about technology [TAB-4357] Single Domain Antibodies Targeting the S2 Subunit of SARS-CoV-2 Spike Protein.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4357] Single Domain Antibodies Targeting the S2 Subunit of SARS-CoV-2 Spike Protein&body=Please send me information about technology [TAB-4357] Single Domain Antibodies Targeting the S2 Subunit of SARS-CoV-2 Spike Protein.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161188 E-204-2021-0 E-204-2021-0-US-01 Single Domain Antibodies Targeting The S2 Subunit Of SARS-CoV-2 Spike Protein PRV US 63/271,854 Abandoned US <br />Provisional (PRV) 63/271,854<br />Filed on 2021-10-26<br />Status: Abandoned 147168408 E-204-2021-0 E-204-2021-0-PCT-02 SINGLE DOMAIN ANTIBODIES TARGETING THE S2 SUBUNIT OF SARS-COV-2 SPIKE PROTEIN PCT Patent Cooperation Treaty PCT/US2022/078632 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/078632<br />Filed on 2022-10-25<br />Status: Expired 147173600 : COVID-19 147173601 ANTIBODY 147173602 Camel Nanobody 147173603 CORONAVIRUS 147173604 HO 147173605 Infectious Diseases 147173606 Nanobodies 147173607 Pandemic 147173608 SARS-CoV-2 147173610 Shark Nanobody 147173611 therapeutic 147173612 Vaccine TAB-4322 147157613 Chimeric Antigen Receptors (CAR)-T Cells that Target the Non-Shed Portion of Mesothelin as a Therapeutic Agent NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Tapan Bera, Mitchell Ho, Xiu Fen Liu, Masanori Onda, Ira Pastan <h2>Description of Technology:</h2> <p>Mesothelin (MSLN) is an excellent target for antibody-based therapies of cancer because of its high expression in many malignancies but lack of expression on essential normal tissues. Unfortunately, a large fragment of MSLN is shed from cancer cells, causing the currently available anti-MSLN antibodies (and immunoconjugates thereof) which bind to the shed portion of MSLN to quickly lose their therapeutic effectiveness over time. Indeed, the shed portion of MSLN can act as a decoy for these antibodies, further limiting them from reaching and destroying tumor cells.</p> <p>Scientists at NCI&nbsp;previously developed MAB15B6, an antibody that specifically binds&nbsp;to the unshed region of MSLN and blocks MSLN shedding. Building on this discovery, the inventors made specific modifications to CARs which utilize humanized MAB15B6.&nbsp; T cells expressing these enhanced CARs are very active in blocking tumor progression in xenograph models. As a result, these CAR-T cells represent an excellent therapeutic candidate for patients who have not responded to other MSLN-targeted therapeutics.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of MSLN-positive malignancies such as synovial sarcoma, mesothelioma, and ovarian, lung, esophageal, pancreatic and gastric cancers</li> <li>Therapeutic Use as a targeting moiety for CARs, antibody-drug conjugates (ADCs), immunotoxins (RITs), bispecific antibodies, etc.</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The inventors have made specific improvements to immunoconjugates which utilize MAB15B6 that significantly enhance the ability of these immunoconjugates to exert a therapeutic effect</li> <li>Specific binding to the unshed portion of MSLN allow the antibodies and CAR-T cells to maintain contact with the cancer cells for a longer duration to exert a therapeutic effect</li> <li>More effective in blocking tumor progression compared to currently available anti-MSLN antibodies</li> </ul> 2022-01-25 2026-04-23 2022-02-24 2026-04-23 2022-01-25 ANTIBODY, Bispecific T-cell engager, BITE, CANCER, CAR, chimeric antigen receptor, diagnostic, Immunotherapy, MESOTHELIN, Mesothelioma, Pastan, therapeutic False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-02-24 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-106-2017 147162063 Awuah P, et al. Reduced shedding of surface mesothelin improves efficacy of mesothelin-targeting recombinant immunotoxins. https://pubmed.ncbi.nlm.nih.gov/27196771/ <a href="https://pubmed.ncbi.nlm.nih.gov/27196771/">Awuah P, et al. Reduced shedding of surface mesothelin improves efficacy of mesothelin-targeting recombinant immunotoxins.</a> 147164303 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 1 147164305 Liu, Xiu Fen NIH - NCI NCI Liu, Xiu Fen (NCI) 2 147164304 Bera, Tapan NIH - NCI NCI Bera, Tapan (NCI) 3 147164306 Onda, Masanori NIH - NCI NCI Onda, Masanori (NCI) 4 147164307 Ho, Mitchell NCI - CCR NCI Ho, Mitchell (NCI) 5 147164303 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 1 147164305 Liu, Xiu Fen NIH - NCI NCI Liu, Xiu Fen (NCI) 2 147164304 Bera, Tapan NIH - NCI NCI Bera, Tapan (NCI) 3 147164306 Onda, Masanori NIH - NCI NCI Onda, Masanori (NCI) 4 147164307 Ho, Mitchell NCI - CCR NCI Ho, Mitchell (NCI) 5 147157833 Mab 15B6 Blocks Mesothelin Shedding And Makes Very Active CAR-T Cell And BITE E-033-2022-0 Filing authorized NCI, NCI - CCR, NIH - NCI 83673032 Whitney, Laurie WhitneyL@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4322] Chimeric Antigen Receptors (CAR)-T Cells that Target the Non-Shed Portion of Mesothelin as a Therapeutic Agent&body=Please send me information about technology [TAB-4322] Chimeric Antigen Receptors (CAR)-T Cells that Target the Non-Shed Portion of Mesothelin as a Therapeutic Agent.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Whitney, Laurie<br><a href="mailto:WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4322] Chimeric Antigen Receptors (CAR)-T Cells that Target the Non-Shed Portion of Mesothelin as a Therapeutic Agent&body=Please send me information about technology [TAB-4322] Chimeric Antigen Receptors (CAR)-T Cells that Target the Non-Shed Portion of Mesothelin as a Therapeutic Agent.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">WhitneyL@mail.nih.gov</a><br> 147160936 E-033-2022-0 E-033-2022-0-US-01 ANTI-MESOTHELIN POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS PRV US 63/290,761 Expired US <br />Provisional (PRV) 63/290,761<br />Filed on 2021-12-17<br />Status: Expired 147168153 E-033-2022-0 E-033-2022-0-PCT-02 ANTI-MESOTHELIN POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS PCT Patent Cooperation Treaty PCT/US2022/081766 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/081766<br />Filed on 2022-12-16<br />Status: Expired 163272656 E-033-2022-0 E-033-2022-0-CA-01 ANTI-MESOTHELIN POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS National Stage Canada 3240254 Pending Canada <br />National Stage 3240254<br />Filed on 2024-06-06<br />Status: Pending 163272692 E-033-2022-0 E-033-2022-0-AU-01 ANTI-MESOTHELIN POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS National Stage Australia 2022416639 Pending Australia <br />National Stage 2022416639<br />Filed on 2024-06-18<br />Status: Pending 163272697 E-033-2022-0 E-033-2022-0-EP-01 ANTI-MESOTHELIN POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS National Stage European Patent 22854336.9 Pending European Patent <br />National Stage 22854336.9<br />Filed on 2024-05-17<br />Status: Pending 163272702 E-033-2022-0 E-033-2022-0-US-02 ANTI-MESOTHELIN POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS National Stage US 18/710,726 Pending US <br />National Stage 18/710,726<br />Filed on 2024-05-16<br />Status: Pending 147169935 ANTIBODY 147169937 Bispecific T-cell engager 147169938 BITE 147169939 CANCER 147169940 CAR 147169941 chimeric antigen receptor 147169942 diagnostic 147169943 Immunotherapy 147169944 MESOTHELIN 147169945 Mesothelioma 147169947 Pastan 147169948 therapeutic TAB-4321 147157612 Anti-Glypican 2 Chimeric Antigen Receptor (CAR) Containing CD28 Hinge And Transmembrane Domains For Treating Neuroblastoma NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Mitchell Ho, Rosandra Kaplan, Nan Li, Rosa Nguyen, Carol Thiele Galetto <h2>Description of Technology:</h2> <p>Neuroblastomas are the most common extracranial solid tumors in pediatric patients, with 700-800 new cases annually in the United States. Metastatic neuroblastomas have a five-year survival rate of 50% and account for 15% of all pediatric cancer deaths. As such, more effective treatments against high-risk neuroblastomas are urgently needed. Glypican-2 (GPC2) is a cell surface protein that is highly expressed in neuroblastomas and other cancers, including medulloblastoma, retinoblastoma, small-cell lung cancers, uterine carcinosarcomas and high-grade gliomas, which makes GPC2 an attractive candidate for targeted therapy in solid tumors.&nbsp;</p> <p>Researchers at the National Cancer Institute&rsquo;s (NCI) Center for Cancer Research have developed a novel Chimeric Antigen Receptor (CAR) specific for GPC2 that includes a potent anti-GPC2 antibody CT3 and a CD28 hinge and transmembrane domains.&nbsp; CT3 has been shown to specifically target GPC2-expressing neuroblastoma, medulloblastoma, and retinoblastoma cell lines. CT3.28H.BB&zeta; CAR T cells were shown to be more potent against neuroblastoma cells than the previous anti-GPC2 CAR T cells in vitro and in vivo. These preclinical data suggest that CT3.28H.BB&zeta; CAR T cells may be further developed as therapeutics for patients with neuroblastoma and other GPC2-positive cancers. Incorporation of the CD28 hinge and transmembrane domains increases the potency of the CT3 CARs against neuroblastoma cells.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Immunotherapeutic treatments of GPC2-positive pediatric malignancies, including neuroblastoma, medulloblastoma, retinoblastoma, and a subset of acute lymphocytic leukemias</li> <li>Immunotherapeutic treatments of GPC2-positive adult cancers, including small-cell lung cancers, uterine carcinosarcomas and high-grade gliomas</li> <li>CT3.28H.BB&zeta; CAR available for immediate testing</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>CT3 antibody with high GPC2 binding specificity leading to&nbsp; successful targeting</li> <li>CT3 antibody with high GPC2 binding specificity leading to lower potential side-effects</li> <li>Increased potency against neuroblastoma&nbsp;</li> <li>Potential immunotherapy for several GPC2-positive cancer types with few treatment options&nbsp;</li> </ul> 2022-12-13 2026-04-23 2022-12-13 2026-04-23 2022-12-12 CAR, chimeric antigen receptor, Glypican 2, GPC2, HO, Immunotherapy, Medulloblastoma, Neuroblastoma, Retinoblastoma, Small-Cell Lung Cancers False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-12-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-198-2018 147164299 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147164298 Thiele Galetto, Carol NIH - NCI NCI Thiele Galetto, Carol (NCI) 2 147164300 Li, Nan NIH - NCI NCI Li, Nan (NCI) 3 147164302 Nguyen, Rosa NCI - CCR NCI Nguyen, Rosa (NCI) 4 147164301 Kaplan, Rosandra NIH - NCI NCI Kaplan, Rosandra (NCI) 5 147164299 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147164298 Thiele Galetto, Carol NIH - NCI NCI Thiele Galetto, Carol (NCI) 2 147164300 Li, Nan NIH - NCI NCI Li, Nan (NCI) 3 147164302 Nguyen, Rosa NCI - CCR NCI Nguyen, Rosa (NCI) 4 147164301 Kaplan, Rosandra NIH - NCI NCI Kaplan, Rosandra (NCI) 5 147157817 CD28 Hinge And Transmembrane Containing Chimeric Antigen Receptors Targeting GPC2 For Treating Neuroblastoma E-025-2022-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4321] Anti-Glypican 2 Chimeric Antigen Receptor (CAR) Containing CD28 Hinge And Transmembrane Domains For Treating Neuroblastoma&body=Please send me information about technology [TAB-4321] Anti-Glypican 2 Chimeric Antigen Receptor (CAR) Containing CD28 Hinge And Transmembrane Domains For Treating Neuroblastoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4321] Anti-Glypican 2 Chimeric Antigen Receptor (CAR) Containing CD28 Hinge And Transmembrane Domains For Treating Neuroblastoma&body=Please send me information about technology [TAB-4321] Anti-Glypican 2 Chimeric Antigen Receptor (CAR) Containing CD28 Hinge And Transmembrane Domains For Treating Neuroblastoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147168150 E-025-2022-0 E-025-2022-0-US-01 CD28 HINGE AND TRANSMEMBRANE CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GPC2 AND USE THEREOF PRV US 63/310,456 Expired US <br />Provisional (PRV) 63/310,456<br />Filed on 2022-02-15<br />Status: Expired 147168151 E-025-2022-0 E-025-2022-0-PC-01 CD28 HINGE AND TRANSMEMBRANE CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GPC2 AND USE THEREOF PCT Patent Cooperation Treaty PCT/US2023/062525 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/062525<br />Filed on 2023-02-14<br />Status: Expired 159504791 E-025-2022-0 E-025-2022-0-EP-01 CD28 HINGE AND TRANSMEMBRANE CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GPC2 AND USE THEREOF National Stage European Patent 23710624.0 Pending European Patent <br />National Stage 23710624.0<br />Filed on 2024-08-13<br />Status: Pending 159504796 E-025-2022-0 E-025-2022-0-US-02 CD28 HINGE AND TRANSMEMBRANE CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GPC2 AND USE THEREOF National Stage US 18/837,367 Pending US <br />National Stage 18/837,367<br />Filed on 2024-08-09<br />Status: Pending 159504801 E-025-2022-0 E-025-2022-0-CN-01 CD28 HINGE AND TRANSMEMBRANE CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GPC2 AND USE THEREOF National Stage China 202380034151.6 Pending China <br />National Stage 202380034151.6<br />Filed on 2024-10-14<br />Status: Pending 159504806 E-025-2022-0 E-025-2022-0-AU-01 CD28 HINGE AND TRANSMEMBRANE CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GPC2 AND USE THEREOF National Stage Australia 2023221836 Pending Australia <br />National Stage 2023221836<br />Filed on 2024-07-23<br />Status: Pending 159504816 E-025-2022-0 E-025-2022-0-JP-01 CD28 HINGE AND TRANSMEMBRANE CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GPC2 AND USE THEREOF National Stage Japan 2024-547534 Pending Japan <br />National Stage 2024-547534<br />Filed on 2024-08-09<br />Status: Pending 147169735 CAR 147169736 chimeric antigen receptor 147169738 Glypican 2 147169739 GPC2 147169740 HO 147169741 Immunotherapy 147169742 Medulloblastoma 147169743 Neuroblastoma 147169744 Retinoblastoma 147169746 Small-Cell Lung Cancers TAB-4318 147157608 Automatic System and Method for Tissue Sectioning, Staining, and Scanning NCI Infectious Disease, Licensing, Medical Devices, Neurology, Non-Medical Devices, Oncology Infectious Disease Licensing Medical Devices Neurology Non-Medical Devices Oncology Young-Wan Moon, Zhengping (Ping) Zhuang <h2>Summary:</h2> <p>The NCI is seeking licensees to develop an automated digital pathology device compatible with high-throughput data analysis.</p> <h2>Description of Technology:</h2> <p>Computer and imaging technologies led to the development of digital pathology and the capture and storage of pathological specimens as digitally formatted images. The use of artificial intelligence (AI) in digital pathology, such as in three-dimensional (3D) reconstruction, requires analyses of high volumes of data. This results in increased demands for processing and acquisition of digital images of pathology samples. Increased usage cannot be met by the time-consuming, manual, and laborious methods currently used. Therefore, there is a need for automation of techniques used in processing of pathology samples and acquisition of digital images to make them amenable with high-throughput approaches such as AI analysis.</p> <p>National Cancer Institute inventors developed an automated device with integrated tissue sectioning, staining, scanning, and high-throughput capability. This device integrates pathology sample processing (e.g., sectioning, fixing, and staining) with optical scanning and digital image acquisition. This invention, related to another technology, E-084-2019, is updated to include a coated tape for holding and carrying sample sections as an alternative to a carrier film. The tape carries sequentially cut sample slices into a staining cassette where the slices are simultaneously stained directly on the tape. The tape carrying the stained samples are then fed into the imaging unit. This streamlines the entire process enabling high-throughput preparation of large volumes of samples and data for subsequent AI analysis. As a result of automation, the device saves time, minimizes errors, and reduces wasting reagents and supplies. Automation is expected to reduce sample processing time ten-fold.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Biopsy sample processing in hospitals, pathology labs, research labs</li> <li>Diagnostics for various disease indications, including cancer and infectious diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Facilitates processing and imaging of large volumes of pathology samples</li> <li>Automation is expected to reduce sample processing time ten-fold</li> <li>Automation increases reproducibility and minimizes errors</li> <li>Compatible with high-throughput processes, e.g., AI analysis of digital pathology images and 3D reconstruction</li> <li>Mounting and processing all sections of a sample on the same tape allows for an easier, more streamlined staining/imaging process</li> <li>Staining cassette is customizable</li> </ul> 2022-09-12 2026-04-23 2026-04-23 2022-12-13 AI, Artificial Intelligence, AUTOMATION, Digital Pathology, High-throughput, Histology, IMAGING, Zhuang False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147164285 Zhuang, Zhengping (Ping) NIH - NCI NCI Zhuang, Zhengping (Ping) (NCI) 1 147164286 Moon, Young-Wan MicroVizual Inc. Moon, Young-Wan 2 147164285 Zhuang, Zhengping (Ping) NIH - NCI NCI Zhuang, Zhengping (Ping) (NCI) 1 147164286 Moon, Young-Wan MicroVizual Inc. Moon, Young-Wan 2 147157769 Automatic System And Method For Tissue Sectioning, Staining, And Scanning E-003-2022-0 Filing authorized MicroVizual Inc., NCI 83687903 Pollack, Michael michael.pollack@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4318] Automatic System and Method for Tissue Sectioning, Staining, and Scanning&body=Please send me information about technology [TAB-4318] Automatic System and Method for Tissue Sectioning, Staining, and Scanning.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollack, Michael<br><a href="mailto:michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4318] Automatic System and Method for Tissue Sectioning, Staining, and Scanning&body=Please send me information about technology [TAB-4318] Automatic System and Method for Tissue Sectioning, Staining, and Scanning.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michael.pollack@nih.gov</a><br> 147160883 E-003-2022-0 E-003-2022-0-US-01 Automatic System And Method For Tissue Sectioning, Staining, And Scanning PRV US 63/254,743 Abandoned US <br />Provisional (PRV) 63/254,743<br />Filed on 2021-10-12<br />Status: Abandoned 147168133 E-003-2022-0 E-003-2022-0-PCT-02 AUTOMATIC SYSTEM AND METHOD FOR TISSUE SECTIONING, STAINING, AND SCANNING PCT Patent Cooperation Treaty PCT/US2022/046406 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/046406<br />Filed on 2022-10-12<br />Status: Expired 147169270 AI 147169272 Artificial Intelligence 147169273 AUTOMATION 147169275 Digital Pathology 147169276 High-throughput 147169277 Histology 147169278 IMAGING 147169279 Zhuang TAB-4305 147157595 PIM-Targeted PROTACs NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics John Brognard, Dawid Mehlich, Venkatareddy Sabbasani, Rolf Swenson, Pedro Torres-Ayuso, Noel Warfel <h2>Description of Technology:</h2> <p>Proviral Integration for the Moloney murine leukemia virus (PIM) kinases are overexpressed in many solid cancers &ndash; including prostate, breast, colon, endometrial, gastric and pancreatic. High of PIM1 expression is predictive of poor survival in multiple cancer types. While several selective pan-PIM inhibitors were developed and tested in clinical trials, all ultimately increased PIM1-3 protein levels and developed intrinsic resistance.&nbsp;</p> <p>Researchers at the National Institutes of Health (NIH) developed multiple PIM kinase-targeting proteolysis-targeting chimeras (PROTACs) that lead to PIM1 degradation in a prostate cancer cell model and increased chemo-sensitization. The targeting of PIM kinases for degradation provides superior catalytic inhibition as these compounds target pro-tumorigenic functions of the PIM kinases, which are not linked to kinase activity. Additionally, these PROTACs prevent the onset of resistance due to increased expression of PIM kinases that occur from catalytic inhibition. They represent unique opportunities as novel anti-cancer therapies. This is a continuation of the PROTAC technologies being developed by the NIH team of Brognard and Swenson.</p> <p>The inventors welcome licensing and co-development interests to further develop and commercialize the technology.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>A novel anti-cancer therapy to target the PIM kinases</li> <li>A PIM targeting PROTACs for the treatments of prostate, breast, and colon cancers, among others</li> <li>A PIM targeting moiety for additional targeted therapeutics</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Compound target pro-tumorigenic functions of the PIM kinases that are not linked to kinase activity</li> <li>Prevention of the onset of resistance due to increased expression of PIM kinases that occurs from catalytic inhibition</li> <li>Increased chemo-sensitivity</li> <li>Compared to small molecule inhibitors, PROTACs: <ul> <li>show promise overcoming tumor resistance</li> <li>address and degrade undruggable targets</li> <li>offer novel, rapid and reversible chemical knockout capabilities</li> </ul> </li> </ul> 2022-07-07 2026-04-23 2023-01-09 2026-04-23 2022-07-07 anti-cancer, Brognard, Chemotherapy Resistance, Kinase, PIM, PIM kinase-targeting proteolysis-targeting chimeras, PROTACs, solid tumors, Swenson, THERAPY False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-01-09 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147164235 Brognard, John NIH - NCI NCI Brognard, John (NCI) 1 147164236 Swenson, Rolf NIH - NHLBI NHLBI Swenson, Rolf (NHLBI) 2 147164237 Torres-Ayuso, Pedro NIH - NCI NCI Torres-Ayuso, Pedro (NCI) 3 147164238 Sabbasani, Venkatareddy NIH - NHLBI NHLBI Sabbasani, Venkatareddy (NHLBI) 4 147164239 Mehlich, Dawid NIH - NCI NCI Mehlich, Dawid (NCI) 5 147164240 Warfel, Noel University of Arizona Warfel, Noel 6 147164235 Brognard, John NIH - NCI NCI Brognard, John (NCI) 1 147164236 Swenson, Rolf NIH - NHLBI NHLBI Swenson, Rolf (NHLBI) 2 147164237 Torres-Ayuso, Pedro NIH - NCI NCI Torres-Ayuso, Pedro (NCI) 3 147164238 Sabbasani, Venkatareddy NIH - NHLBI NHLBI Sabbasani, Venkatareddy (NHLBI) 4 147164239 Mehlich, Dawid NIH - NCI NCI Mehlich, Dawid (NCI) 5 147164240 Warfel, Noel University of Arizona Warfel, Noel 6 147157976 PIM Kinase Developed PROTACs Target PIM Kinases For Degradation And Promote Cancer Cell Death E-094-2022-0 Filing authorized NCI, NCI - CCR, Polish Academy of Sciences, University of Arizona 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4305] PIM-Targeted PROTACs&body=Please send me information about technology [TAB-4305] PIM-Targeted PROTACs.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4305] PIM-Targeted PROTACs&body=Please send me information about technology [TAB-4305] PIM-Targeted PROTACs.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161032 E-094-2022-0 E-094-2022-0-US-01 PIM-TARGETED PROTACS AND METHODS OF USE PRV US 63/341,757 Expired US <br />Provisional (PRV) 63/341,757<br />Filed on 2022-05-13<br />Status: Expired 147168048 E-094-2022-0 E-094-2022-0-PC-01 PIM-TARGETED PROTACS WITH PIM-BINDING MOIETIES SGI-1776, AZD-1208 OR PIM-447, AND A E3 UBIQUITIN LIGASE BINDING MOIETY FOR THE TREATMENT OF CANCER PCT Patent Cooperation Treaty PCT/US2023/022017 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/022017<br />Filed on 2023-05-12<br />Status: Expired 147171302 anti-cancer 147171304 Brognard 147171306 Chemotherapy Resistance 147171307 Kinase 147171308 PIM 147171310 PIM kinase-targeting proteolysis-targeting chimeras 147171311 PROTACs 147171312 solid tumors 147171314 Swenson 147171315 THERAPY TAB-4285 147157574 Molecular Nanotags for Detection of Single Molecules NCI Collaboration, Endocrinology, Infectious Disease, Licensing, Oncology, Research Materials Collaboration Endocrinology Infectious Disease Licensing Oncology Research Materials Jennifer Jones, William Telford <h2>Description of Technology:</h2> <p>Biological nanoparticles, like extracellular vesicles (EVs), possess unique biological characteristics making them attractive therapeutic agents, targets, or disease biomarkers. However, their use is hindered by the lack of tools available to accurately detect, sort, and analyze. Flow cytometers are used to sort and study individual cells. But, they are unable to detect and sort nanomaterials smaller than 200 nanometers with single epitope sensitivity.</p> <p>Researchers at the National Cancer Institute (NCI) developed a new class of nanoscale molecular tags (nanotags) allowing the detection and sorting of single biological nanoparticle using conventional flow cytometers. Otherwise, using standard methods such as fluorescently labeled antibodies, very few epitopes are detected. These nanotags are composed of materials with high refractive indices, high optical absorption, and remarkable spectral scattering properties. These properties allow both low epitope number determination and spectral phenotyping of biological nanoparticles &ndash; such as EVs, lipoproteins, RNA-protein complexes and other circulating submicron particles with significant biomedical applications.</p> <p>The NCI seeks commercial partners to co-develop and/or license this technology.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research tool for studying structure and function of biological nanoparticles</li> <li>Diagnostic tool for detection of clinical biomarkers&nbsp;</li> <li>Tool for characterization of industrial and environmental nanoparticles</li> <li>Biodefense</li> <li>Industrial sectors</li> <li>Environmental applications</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Detect, sort and analyze nanomaterials &lt;200 nanometers with single epitope sensitivity&nbsp;</li> <li>Enumeration of the number of labeled molecules beyond the capabilities of current flow cytometric labels and instruments</li> <li>Improved detection above background noise</li> <li>Improved signal:noise ratio&nbsp;</li> </ul> 2022-01-21 2026-04-23 2022-01-21 2026-04-23 2022-01-20 Biological Nanoparticle, Biomarker, EVs, Extracellular Vesicles, flow cytometer, Jones, Nanoscale Molecular Tags, Nanotags False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2022-01-21 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-008-2018 E-105-2018 147162245 Welsh JA, et al. Prospective Use of High-Refractive Index Materials for Single Molecule Detection in Flow Cytometry. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111846/ <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111846/">Welsh JA, et al. Prospective Use of High-Refractive Index Materials for Single Molecule Detection in Flow Cytometry.</a> 147164164 Jones, Jennifer NIH - NCI NCI Jones, Jennifer (NCI) 1 147164165 Telford, William NIH - NCI NCI Telford, William (NCI) 2 147164164 Jones, Jennifer NIH - NCI NCI Jones, Jennifer (NCI) 1 147164165 Telford, William NIH - NCI NCI Telford, William (NCI) 2 147158254 Single Molecule Detection With NanoFACS E-238-2015-0 Filing authorized NCI 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4285] Molecular Nanotags for Detection of Single Molecules&body=Please send me information about technology [TAB-4285] Molecular Nanotags for Detection of Single Molecules.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4285] Molecular Nanotags for Detection of Single Molecules&body=Please send me information about technology [TAB-4285] Molecular Nanotags for Detection of Single Molecules.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147161219 E-238-2015-0 E-238-2015-0-US-01 MOLECULAR NANOTAGS PRV US 62/411,324 Abandoned US <br />Provisional (PRV) 62/411,324<br />Filed on 2016-10-21<br />Status: Abandoned 147167884 E-238-2015-0 E-238-2015-0-PCT-02 MOLECULAR NANOTAGS PCT Patent Cooperation Treaty PCT/US2017/057928 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/057928<br />Filed on 2017-10-23<br />Status: Expired 147167885 E-238-2015-0 E-238-2015-0-AU-03 MOLECULAR NANOTAGS National Stage Australia 2017345814 2017345814 Issued Australia <br />National Stage 2017345814<br />Filed on 2017-10-23<br />Status: Issued 147167886 E-238-2015-0 E-238-2015-0-CA-04 MOLECULAR NANOTAGS National Stage Canada 3041059 3041059 Issued Canada <br />National Stage 3041059<br />Filed on 2017-10-23<br />Status: Issued 147167887 E-238-2015-0 E-238-2015-0-CN-05 MOLECULAR NANOTAGS National Stage China ZL201780079138.7 201780079138.7 Issued China <br />National Stage 201780079138.7<br />Filed on 2017-10-23<br />Status: Issued 147167888 E-238-2015-0 E-238-2015-0-EP-06 MOLECULAR NANOTAGS National Stage European Patent 3529205 17809073.4 Issued European Patent <br />National Stage 17809073.4<br />Filed on 2017-10-23<br />Status: Issued 147167889 E-238-2015-0 E-238-2015-0-JP-07 MOLECULAR NANOTAGS National Stage Japan 7492826 2019-521089 Issued Japan <br />National Stage 2019-521089<br />Filed on 2017-10-23<br />Status: Issued 147167890 E-238-2015-0 E-238-2015-0-US-08 MOLECULAR NANOTAGS National Stage US 11,536,719 16/342,345 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11536719 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11536719">11,536,719</a><br />Filed on 2019-04-16<br />Status: Issued 147167891 E-238-2015-0 E-238-2015-0-HK-09 MOLECULAR NANOTAGS CN Hong Kong HK40013934B 62020003242.8 Issued Hong Kong <br />China Patent (CN) 62020003242.8<br />Filed on 2020-02-24<br />Status: Issued 147167892 E-238-2015-0 E-238-2015-0-DE-10 MOLECULAR NANOTAGS EP Germany 3529205 17809073.4 Issued Germany <br />European patent (EP) 17809073.4<br />Filed on 2017-10-23<br />Status: Issued 147167893 E-238-2015-0 E-238-2015-0-FR-11 MOLECULAR NANOTAGS EP France 3529205 17809073.4 Issued France <br />European patent (EP) 17809073.4<br />Filed on 2017-10-23<br />Status: Issued 147167894 E-238-2015-0 E-238-2015-0-GB-12 MOLECULAR NANOTAGS EP United Kingdom 3529205 17809073.4 Issued United Kingdom <br />European patent (EP) 17809073.4<br />Filed on 2017-10-23<br />Status: Issued 147174079 Biological Nanoparticle 147174080 Biomarker 147174081 EVs 147174082 Extracellular Vesicles 147174083 flow cytometer 147174084 Jones 147174086 Nanoscale Molecular Tags 147174088 Nanotags TAB-4284 147157573 Exo-Clean Technology for Purifying Extracellular Vesicle Preparations from Contaminants NCI Cardiology, Collaboration, Endocrinology, Immunology, Licensing, Oncology, Research Materials Cardiology Collaboration Endocrinology Immunology Licensing Oncology Research Materials Jay Berzofsky, Jennifer Jones, Katherine McKinnon, Joshua Welsh <h2>Description of Technology:</h2> <p>Extracellular Vesicles (EVs), including exosomes and microvesicles, are nanometer-sized membranous vesicles that can carry different types of cargos, such as proteins, nucleic acids and metabolites. EVs are produced and released by most cell types. They act as biological mediators for intercellular communication via delivery of their cargos. This unique ability spurred translational research interest for targeted delivery of therapeutic molecules to treat a wide range of diseases. EVs also contain interesting information of their specific cellular origin. Thus, EVs can reveal nature, severity, and prognosis of a various pathophysiologic disease states. Such characteristics also make them a reliable and stable source of biomarkers, accessible in several body fluids. However, their small size makes it difficult to isolate EVs by using standard purification methods commonly used for isolating cells and platelets. Currently available techniques for EV isolation, are non-scalable, labor intensive, time consuming, and ineffective in removing contaminants.</p> <p>Researchers at the National Cancer Institute (NCI) developed a chromatographic EV purification technology using a custom-made &ldquo;mixed mode&rdquo; resin. The resin combines Capto Core-type resin with other affinity-based beads for depletion of unwanted contaminants smaller than 700 MDa &ndash; such as proteins, nucleic acids, or other molecules. This Exo-Clean technology is both broadly applicable for biofluid processing and scalable for high-throughput screening (i.e., compatible with robotic 96- or 384- well format). This technology is also suitable for large-scale GMP production of therapeutic exosome and other EV analogue-based therapeutics.&nbsp;</p> <p>Unique biophysical features of this technology could offer a new avenue for developing EV based clinical biomarkers, and therapeutics. The NCI seeks commercial partners to co-develop and/or license this technology.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research tool for studying structure and function of EVs</li> <li>EV-based clinical biomarkers for detecting various pathological conditions</li> <li>Therapeutic exosome and other EV analogue-based therapeutics for targeted drug delivery</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Efficient in removing proteins and various labels from EV preparations</li> <li>Scalable for high-throughput screening</li> <li>Amenable to a wide range of preparation scales and formats</li> </ul> 2022-01-19 2026-04-23 2022-01-19 2026-04-23 2022-01-18 Affinity, Biomarkers, CHROMATOGRAPHIC, EVs, Exo-Clean, Exosomes, Extracellular Vesicles, High-throughput, Jones, Microvesicles, purification, Resin False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-01-19 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162321 Welsh JA, et al. A simple, high-throughput method of protein and label removal from extracellular vesicle samples. https://pubmed.ncbi.nlm.nih.gov/33544111/ <a href="https://pubmed.ncbi.nlm.nih.gov/33544111/">Welsh JA, et al. A simple, high-throughput method of protein and label removal from extracellular vesicle samples.</a> 147164161 Jones, Jennifer NIH - NCI NCI Jones, Jennifer (NCI) 1 147164160 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 2 147164163 Welsh, Joshua NIH - NCI NCI Welsh, Joshua (NCI) 3 147164162 McKinnon, Katherine NIH - NCI NCI McKinnon, Katherine (NCI) 4 147164161 Jones, Jennifer NIH - NCI NCI Jones, Jennifer (NCI) 1 147164160 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 2 147164163 Welsh, Joshua NIH - NCI NCI Welsh, Joshua (NCI) 3 147164162 McKinnon, Katherine NIH - NCI NCI McKinnon, Katherine (NCI) 4 147158238 Exo-Clean Method For Removing Proteins And Various Labels From Extracellular Vesicle And Exosome Preparations E-227-2017-0 Filing authorized NCI 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4284] Exo-Clean Technology for Purifying Extracellular Vesicle Preparations from Contaminants&body=Please send me information about technology [TAB-4284] Exo-Clean Technology for Purifying Extracellular Vesicle Preparations from Contaminants.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4284] Exo-Clean Technology for Purifying Extracellular Vesicle Preparations from Contaminants&body=Please send me information about technology [TAB-4284] Exo-Clean Technology for Purifying Extracellular Vesicle Preparations from Contaminants.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147161208 E-227-2017-0 E-227-2017-0-US-01 EXO-CLEAN METHOD FOR REMOVING PROTEINS AND UNBOUND LABELS FROM EXTRACELLULAR VESICLE PREPARATIONS PRV US 62/612,040 Abandoned US <br />Provisional (PRV) 62/612,040<br />Filed on 2017-12-29<br />Status: Abandoned 147167877 E-227-2017-0 E-227-2017-0-PCT-02 METHOD FOR REMOVING PROTEINS AND UNBOUND LABELS FROM EXTRACELLULAR VESICLE PREPARATIONS PCT Patent Cooperation Treaty PCT/US2018/067913 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/067913<br />Filed on 2018-12-28<br />Status: Expired 147167878 E-227-2017-0 E-227-2017-0-EP-03 PURIFICATION AND LABELING OF EXTRACELLULAR VESICLES USING A MIXED MODE RESIN COMPOSITION National Stage European Patent 3731947 18847175.9 Issued European Patent <br />National Stage 18847175.9<br />Filed on 2020-07-27<br />Status: Issued 147167879 E-227-2017-0 E-227-2017-0-US-04 PURIFICATION AND LABELING OF EXTRACELLULAR VESICLES USING A MIXED MODE RESIN COMPOSITION National Stage US 12,083,448 16/959,071 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12083448 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12083448">12,083,448</a><br />Filed on 2020-06-29<br />Status: Issued 147167880 E-227-2017-0 E-227-2017-0-FR-01 PURIFICATION AND LABELING OF EXTRACELLULAR VESICLES USING A MIXED MODE RESIN COMPOSITION EP France 3731947 18847175.9 Issued France <br />European patent (EP) 18847175.9<br />Filed on 2020-07-27<br />Status: Issued 147167881 E-227-2017-0 E-227-2017-0-DE-01 PURIFICATION AND LABELING OF EXTRACELLULAR VESICLES USING A MIXED MODE RESIN COMPOSITION EP Germany 3731947 18847175.9 Issued Germany <br />European patent (EP) 18847175.9<br />Filed on 2020-07-27<br />Status: Issued 147167882 E-227-2017-0 E-227-2017-0-GB-01 PURIFICATION AND LABELING OF EXTRACELLULAR VESICLES USING A MIXED MODE RESIN COMPOSITION EP United Kingdom 3731947 18847175.9 Issued United Kingdom <br />European patent (EP) 18847175.9<br />Filed on 2020-07-27<br />Status: Issued 147173949 Affinity 147173950 Biomarkers 147173951 CHROMATOGRAPHIC 147173953 EVs 147173954 Exo-Clean 147173955 Exosomes 147173956 Extracellular Vesicles 147173957 High-throughput 147173958 Jones 147173959 Microvesicles 147173960 purification 147173961 Resin TAB-4271 147157559 Bacteriophage Based-Vaccine System NCI Collaboration, Infectious Disease, Licensing, Oncology, Vaccines Collaboration Infectious Disease Licensing Oncology Vaccines Sankar Adhya, Donald Court, Xintian Li, Manoj Rajaure <h2>Summary:</h2> <p>Researchers at NCI seek licensing and/or co-development research collaborations for further development of the Bacteriophage based-vaccine system.</p> <h2>Description of Technology:</h2> <p>Vaccines have become one of the most important tools in the fight against cancers and infectious diseases. However, some vaccines have shown limitations due to their high cost and low immune responses. To overcome these limitations, bacteriophages were proposed for the development of more cost-effective, immunogenic vaccines. Phages have shown a strong ability to activate induced&nbsp;and adaptive immune systems. The genome of these viral particles can be engineered, and their surface proteins can be exploited for antigen display.</p> <p>Researchers at National Cancer Institute (NCI) developed an engineered bacteriophage lambda () vector for displaying antigens as a vaccine in the treatment of cancer and infectious diseases. In this technology, a nucleic acid sequence encoding a fusion protein linked to a heterologous antigen is inserted into a native gene D locus adjacent to gene E in the bacteriophage lambda genome. The researchers have also constructed several phages in the &lambda; prophage vector system to display different fusion proteins as candidate vaccines representing several human diseases like human Chronic Lymphocyte Leukemia disease and malaria.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Vaccine in the treatment of cancer and other infectious diseases</li> <li>Method for rapid production of bioengineered bacteriophage lambda for vaccine development</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Novel way to generate multivalent vaccine antigens against various cancers and infectious diseases&nbsp;</li> <li>Inexpensive to produce compared with competing technologies</li> <li>Can stimulate induced&nbsp;immune and therefore potentially act as a natural adjuvant</li> <li>Can be stored and shipped at ambient temperatures</li> </ul> 2022-08-16 2026-04-23 2022-11-30 2026-04-23 2022-08-16 Adhya, Bacteriophage Engineering, Bacteriophage Genetics, CANCER VACCINE, Infectious Diseases, Lambda Vector, Phage Therapy, Recombineering, Vaccine False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-11-30 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147164119 Adhya, Sankar NIH - NCI NCI Adhya, Sankar (NCI) 1 147164118 Court, Donald NIH - NCI NCI Court, Donald (NCI) 2 147164120 Li, Xintian NIH - NCI NCI Li, Xintian (NCI) 3 147164121 Rajaure, Manoj NIH - NCI NCI Rajaure, Manoj (NCI) 4 147164119 Adhya, Sankar NIH - NCI NCI Adhya, Sankar (NCI) 1 147164118 Court, Donald NIH - NCI NCI Court, Donald (NCI) 2 147164120 Li, Xintian NIH - NCI NCI Li, Xintian (NCI) 3 147164121 Rajaure, Manoj NIH - NCI NCI Rajaure, Manoj (NCI) 4 147158014 Bacteriophage Based-Vaccine System E-113-2021-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4271] Bacteriophage Based-Vaccine System&body=Please send me information about technology [TAB-4271] Bacteriophage Based-Vaccine System.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4271] Bacteriophage Based-Vaccine System&body=Please send me information about technology [TAB-4271] Bacteriophage Based-Vaccine System.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161061 E-113-2021-0 E-113-2021-0-US-01 BACTERIOPHAGE LAMBDA-VACCINE SYSTEM PRV US 63/289,018 Expired US <br />Provisional (PRV) 63/289,018<br />Filed on 2021-12-13<br />Status: Expired 147167807 E-113-2021-0 E-113-2021-0-PCT-02 vBacteriophage Based-Vaccine System PCT Patent Cooperation Treaty PCT/US2022/081383 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/081383<br />Filed on 2022-12-12<br />Status: Expired 147171697 Adhya 147171699 Bacteriophage Engineering 147171701 Bacteriophage Genetics 147171702 CANCER VACCINE 147171703 Infectious Diseases 147171705 Lambda Vector 147171707 Phage Therapy 147171708 Recombineering 147171709 Vaccine TAB-4257 147157544 Neoantigen T Cell Therapy with Neoantigen Vaccination as a Combination Immunotherapy Against Cancer NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Kenichi Hanada, Sri Krishna, Steven Rosenberg, Zhiya Yu <h2>Summary:</h2> <p>The NCI seeks parties interested in research co-development and/or licensing of this combination immunotherapy approach of neoantigen-specific T cells administered alongside a neoantigen-targeting vaccine to enhance ACT and treat cancer.</p> <h2>Description of Technology:</h2> <p>Adoptive cell therapy (ACT) is a breakthrough form of cancer immunotherapy that utilizes autologous, antitumor T cells to attack tumors through recognition of tumor-specific mutations, or neoantigens. A major hurdle in the development of ACT is the exhausted phenotype exhibited by many neoantigen-specific T cells, which limits their efficacy and prevents a sustained immune response.&nbsp;<br /> Researchers at the National Cancer Institute (NCI) have developed a combination immunotherapy to rescue the function of exhausted, neoantigen-specific T cells and, thus, enhance ACT. The method involves concurrent administration of neoantigen-specific T cells alongside a vaccine targeting the same neoantigens. The antitumor effect of this combination immunotherapy is superior to that mediated by the vaccine or by ACT alone, as measured in vivo by overall survival and tumor regression. Patient T cells genetically engineered with a neoantigen-specific T-cell receptor (TCR) can also be synergistically enhanced when used alongside a vaccine targeting the same antigen in this combination immunotherapy. This combined immunotherapy approach has broad therapeutic potential in a wide range of metastatic cancers, particularly those that are not responsive to traditional treatment methods.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>A variety of human cancers potentially amenable to the synergistic combination therapy of adoptive cell therapy (ACT) and tumor vaccine to treat&nbsp;</li> <li>Cell therapies for which the ACT component can employ isolated exhausted, neoantigen-specific T cells or T cells transduced with a neoantigen-specific TCR&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Synergistic, instead of additive, effect observed with this combination therapy based on available in vivo data</li> <li>Increased efficacy of exhausted, neoantigen-specific T cells</li> <li>Reduced toxicity compared to non-tumor specific immunotherapies&nbsp;</li> <li>T cells and vaccine can target either patient-specific somatic mutations or common driver mutations</li> <li>Broad clinical applications, including solid tumors (which traditional ACT methods have struggled to effectively treat)&nbsp;</li> </ul> 2022-08-17 2026-04-23 2022-08-17 2026-04-23 2022-08-17 act, Adoptive Cell Transfer, Immunotherapy, Krishna, Neoantigen, Rosenberg, T-Cell Receptor, TCR, Vaccine False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-08-17 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-059-2013 E-061-2020 E-067-2017 E-085-2013 E-102-2020 E-229-2014 E-233-2014 E-280-2016 147164069 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 1 147164068 Yu, Zhiya NIH - NCI NCI Yu, Zhiya (NCI) 2 147164067 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 3 147164066 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 4 147164069 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 1 147164068 Yu, Zhiya NIH - NCI NCI Yu, Zhiya (NCI) 2 147164067 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 3 147164066 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 4 147157863 Neoantigen T Cell Therapy With Neoantigen Vaccination As A Combination Immunotherapy Against Cancer E-046-2022-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4257] Neoantigen T Cell Therapy with Neoantigen Vaccination as a Combination Immunotherapy Against Cancer&body=Please send me information about technology [TAB-4257] Neoantigen T Cell Therapy with Neoantigen Vaccination as a Combination Immunotherapy Against Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4257] Neoantigen T Cell Therapy with Neoantigen Vaccination as a Combination Immunotherapy Against Cancer&body=Please send me information about technology [TAB-4257] Neoantigen T Cell Therapy with Neoantigen Vaccination as a Combination Immunotherapy Against Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147160960 E-046-2022-0 E-046-2022-0-US-01 Neoantigen T Cell Therapy With Neoantigen Vaccination As A Combination Immunotherapy Against Cancer PRV US 63/295,762 Expired US <br />Provisional (PRV) 63/295,762<br />Filed on 2021-12-31<br />Status: Expired 147167712 E-046-2022-0 E-046-2022-0-PCT-02 T CELL THERAPY WITH VACCINATION AS A COMBINATION IMMUNOTHERAPY AGAINST CANCER PCT Patent Cooperation Treaty PCT/US2022/082579 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/082579<br />Filed on 2022-12-29<br />Status: Expired 147170250 act 147170251 Adoptive Cell Transfer 147170252 Immunotherapy 147170254 Krishna 147170255 Neoantigen 147170256 Rosenberg 147170257 T-Cell Receptor 147170258 TCR 147170259 Vaccine TAB-4213 147157498 Cell Lines that Constitutively Express High-Frequency KRAS and P53 Mutations and Human Leukocyte Antigens (HLAs) NCI Immunology, Infectious Disease, Licensing, Oncology, Research Materials Immunology Infectious Disease Licensing Oncology Research Materials <h2>Summary:</h2> <p>The NCI seeks parties interested in licensing this library of cell lines stably expressing tumor-specific antigens and HLAs.</p> <h2>Description of Technology:</h2> <p>Adoptive cell therapy (ACT) is a breakthrough form of cancer immunotherapy that utilizes tumor infiltrating lymphocytes (TILs) or genetically engineered T cells to attack tumor cells through recognition of tumor-specific antigens. A major hurdle in the development of ACT is the identification and isolation of T cells that recognize antigens that are expressed by tumor cells but not by healthy tissues. Current methods to identify such T cells involve extracting autologous antigen presenting cells (APCs) from patients in an expensive, laborious, and time-consuming process. In addition, the quantity and quality of extracted APCs varies significantly between patients, necessitating a novel, standardized approach.<br /> Researchers at the National Cancer Institute (NCI) developed a library of cell lines to identify T cells that specifically target tumor cells, thus eliminating the need for autologous APCs. These cell lines stably express tumor-specific antigens at a high level in the tandem minigene (TMG) format. The antigens expressed arise from mutations in the RAS or p53 genes. These mutations are also referred to as &ldquo;hotspot&rdquo; driver mutations because they are shared among many cancer patients and are the most commonly mutated genes in solid tumors. The cells also stably and highly express Class-I or Class-II human leukocyte antigens (HLAs) of interest, allowing for determination of HLA restriction. These cell lines offer a versatile, quick, and cost-effective method to identify, isolate, and expand tumor-reactive T cells.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Rapid identification, isolation, and expansion of mutated RAS or p53-reactive TILs or TCR-engineered T cells</li> <li>Validation of mutated RAS or p53-reactive TILs or TCR-engineered T cells&nbsp;</li> <li>Determination of HLA restriction of mutated RAS or p53-reactive TILs or TCR-engineered T cells</li> <li>Identification of T cell reactivities in infectious diseases (ex. Influenza, COVID-19)</li> <li>Identification of T cell reactivities in immunological disorders&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Universal APCs</li> <li>Replace the expensive, laborious, and time-consuming process of extracting/preparing autologous APCs</li> <li>Express tumor-specific antigens in the tandem minigene (TMG) format, allowing the cell lines to cover multiple different RAS or p53 mutations&nbsp;</li> <li>Express hotspot driver mutations, granting applicability to a broad range of cancer patients</li> </ul> 2022-10-14 2026-04-23 2022-10-13 2026-04-23 2022-10-13 act, adoptive cell therapy, Antigen Presenting Cells, APC, cell lines, HLA, Human Leukocyte Antigen, Immunotherapy, KRAS, Levin, p53, Rosenberg, T Cell Receptor, TCR, TIL, Tumor Infiltrating Lymphocytes, Tumor-Specific Antigen False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-10-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-175-2016 155750792 Cell Lines Constitutively Expressing Tandem Minigenes (TMGs) Of Hotspot Mutations And Human Leukocyte Antigens (HLA) E-182-2022-0 Research Material NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4213] Cell Lines that Constitutively Express High-Frequency KRAS and P53 Mutations and Human Leukocyte Antigens (HLAs)&body=Please send me information about technology [TAB-4213] Cell Lines that Constitutively Express High-Frequency KRAS and P53 Mutations and Human Leukocyte Antigens (HLAs).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4213] Cell Lines that Constitutively Express High-Frequency KRAS and P53 Mutations and Human Leukocyte Antigens (HLAs)&body=Please send me information about technology [TAB-4213] Cell Lines that Constitutively Express High-Frequency KRAS and P53 Mutations and Human Leukocyte Antigens (HLAs).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147173198 act 147173199 adoptive cell therapy 147173200 Antigen Presenting Cells 147173201 APC 147173202 cell lines 147173203 HLA 147173204 Human Leukocyte Antigen 147173205 Immunotherapy 147173206 KRAS 147173208 Levin 147173209 p53 147173210 Rosenberg 147173211 T Cell Receptor 147173212 TCR 147173213 TIL 147173214 Tumor Infiltrating Lymphocytes 147173216 Tumor-Specific Antigen TAB-4201 147157486 Novel Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treatment of Solid Tumors NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Terrence Burke, Evgeny Kiselev, George Lountos, Yves Pommier, David Waugh, Xue Zhao <h2>Summary:</h2> <p>The NCI seeks proposals from parties interested in licensing and/or co-development for commercializing the use of TDP1 inhibitors as part of a potent and selective anti-cancer combination therapy.</p> <h2>Description of Technology:</h2> <p>Topoisomerase 1 (TOP1) is an essential enzyme that plays a critical role in DNA transcription and replication. TOP1 inhibitors are a known class of anti-cancer agents that work to interrupt DNA replication in cancer cells, causing cell death. Since the discovery of the TOP1 inhibitor camptothecin (CPT) from plant extracts more than 60 years ago, two CPT analogs (irinotecan and topotecan) were approved by the FDA for cancer treatment. Tyrosyl-DNA phosphodiesterase 1 (TDP1) is an enzyme involved in DNA repair created when TOP1 is inhibited. As a result, targeting TDP1 is considered a potential therapeutic approach to enhance and possibly synergize the potency of TOP1 inhibitors. While TOP1 inhibitors are widely used to treat solid tumors &ndash; such as colon, lung, ovarian and certain pediatric cancers &ndash; there are currently no drugs targeting TDP1. Many TDP1 inhibitors may potentially have mechanisms of action that are promiscuous and non-specific. Researchers at the NCI developed a series of novel compounds selectively targeting the catalytic domain of TDP1. These small molecules show low micromolar potency against TDP1. X-ray structures of TDP1 bound to some of the small molecules elucidated their catalytic binding modes. The compounds developed at the NCI show selectivity for TDP1 over TDP2.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Combination therapy with TOP1 inhibitors for cancer treatment</li> <li>Incorporation into Proteolysis Targeting Chimeric or Antibody-Drug Conjugate therapeutics</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Irreversible inhibition of TDP1</li> <li>Selectivity for TDP1 over TDP2</li> <li>Small molecules capable of accessing and binding to the catalytic machinery to cause cancer cell death</li> <li>Currently, no FDA-approved TDP1 inhibitors</li> </ul> 2022-12-04 2026-04-23 2022-12-04 2026-04-23 2022-12-04 Burke, CANCER, solid tumor, Tdp1, TOP1, Topoisomerase 1, Tyrosyl-DNA Phosphodiesterase 1, Zhao False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-12-04 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162324 Zhao, X.Z. et al. Small molecule microarray identifies inhibitors of tyrosyl-DNA phosphodiesterase 1 that simultaneously access the catalytic pocket and two substrate binding sites https://pubmed.ncbi.nlm.nih.gov/34163656/ <a href="https://pubmed.ncbi.nlm.nih.gov/34163656/">Zhao, X.Z. et al. Small molecule microarray identifies inhibitors of tyrosyl-DNA phosphodiesterase 1 that simultaneously access the catalytic pocket and two substrate binding sites</a> 147163894 Zhao, Xue NIH - NCI NCI Zhao, Xue (NCI) 1 147163895 Lountos, George NIH - NCI NCI Lountos, George (NCI) 2 147163896 Kiselev, Evgeny NIH - NCI NCI Kiselev, Evgeny (NCI) 3 147163892 Waugh, David NIH - NCI NCI Waugh, David (NCI) 4 147163891 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 5 147163893 Burke, Terrence NIH - NCI NCI Burke, Terrence (NCI) 6 147163894 Zhao, Xue NIH - NCI NCI Zhao, Xue (NCI) 1 147163895 Lountos, George NIH - NCI NCI Lountos, George (NCI) 2 147163896 Kiselev, Evgeny NIH - NCI NCI Kiselev, Evgeny (NCI) 3 147163892 Waugh, David NIH - NCI NCI Waugh, David (NCI) 4 147163891 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 5 147163893 Burke, Terrence NIH - NCI NCI Burke, Terrence (NCI) 6 147158282 Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) Inhibitors Derived From A Small Molecule Microarray (SMM) Screen E-256-2020-0 Filing authorized NCI, NIH - NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4201] Novel Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treatment of Solid Tumors&body=Please send me information about technology [TAB-4201] Novel Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treatment of Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4201] Novel Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treatment of Solid Tumors&body=Please send me information about technology [TAB-4201] Novel Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treatment of Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147161235 E-256-2020-0 E-256-2020-0-US-01 IMIDAZO[1,2-a]PYRAZINE AND IMIDAZO[1,2-a]PYRIDINE BASED TYROSYL-DNA PHOSPHODIESTERASE I (TDP1) INHIBITORS PRV US 63/141,634 Abandoned US <br />Provisional (PRV) 63/141,634<br />Filed on 2021-01-26<br />Status: Abandoned 147167316 E-256-2020-0 E-256-2020-0-PCT-04 IMIDAZO[1,2-A]PYRAZINE AND IMIDAZO[1,2-A]PYRIDINE BASED TYROSYL-DNA PHOSPHODIESTERASE I (TDP1) INHIBITORS PCT Patent Cooperation Treaty PCT/US2022/013946 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/013946<br />Filed on 2022-01-26<br />Status: Expired 147167317 E-256-2020-0 E-256-2020-0-US-04 IMIDAZO[1,2-A]PYRAZINE AND IMIDAZO[1,2-A]PYRIDINE BASED TYROSYL-DNA PHOSPHODIESTERASE I (TDP1) INHIBITORS National Stage US 18/262,779 Pending US <br />National Stage 18/262,779<br />Filed on 2023-07-25<br />Status: Pending 147167318 E-256-2020-0 E-256-2020-0-EP-01 IMIDAZO[1,2-A]PYRAZINE AND IMIDAZO[1,2-A]PYRIDINE BASED TYROSYL-DNA PHOSPHODIESTERASE I (TDP1) INHIBITORS National Stage European Patent 22705222.2 Pending European Patent <br />National Stage 22705222.2<br />Filed on 2023-08-08<br />Status: Pending 147174325 Burke 147174326 CANCER 147174327 solid tumor 147174328 Tdp1 147174329 TOP1 147174331 Topoisomerase 1 147174332 Tyrosyl-DNA Phosphodiesterase 1 147174334 Zhao TAB-4197 147157482 T Cell Receptors Targeting BRAF V600E Mutation for Cancer Immunotherapy NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Catherine Ade, Kenichi Hanada, Matthew Sporn, James Yang, Zhiya Yu <h2>Summary:</h2> <p>The NCI seeks parties interested in research co-development and/or licensing of these HLA-A*0301 restricted TCRs that target the BRAF V600E mutation.</p> <h2>Description of Technology:</h2> <p>BRAF is an oncogene that encodinges a serine-threonine kinase (B-Raf kinase) important in regulating cell growth and differentiation. Spontaneous mutations in the BRAF gene allow cells to continuously divide, leading to the development of cancer. A substitution of glutamic acid for valine at amino acid number 600 (designated V600E) accounts for 90% of BRAF mutations and is a driver of many cancers. The V600E mutation is present in ~3% of all cancer cases, representing a patient population of 540,000 patients per year. Though While the V600E mutation is found in a wide variety of cancers, it ishas a particularly high prevalentce in metastatic melanoma, colorectal cancer, thyroid cancer, and lung cancer. Many of these cancers are aggressive and the V600E mutation is commonly recognized as a poor prognostic factor. Therapies for these cancers are often nonspecific or limited by acquired resistance, necessitating novel therapeutic approaches specifically targeting the BRAF V600E mutation.&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) have identified two T cell receptors (TCRs) that target the BRAF V600E mutation. These TCRs specifically recognize tumor cells expressing the BRAF V600E mutation when presented by HLA-A*0301 molecules. The TCRs were identified by first using mass spectrometric analysis to isolate a short peptide derived from the BRAF V600E mutated protein that binds to HLA-A*0301. Transgenic mice harboring the HLA-A*0301 allele were then immunized with the peptide to obtain T cells recognizing the BRAF V600E mutation. The two TCRs were isolated from these T cells and tested in vitro for efficacy. Genetically engineered human T cells transduced with the TCRs were specifically reactive against multiple human tumor cell lines harboring the BRAF V600E mutation. These encouraging preclinical results suggest the potential for the TCRs to be used in a therapeutic approach such as T-cell therapy against cancers with the BRAF V600E mutation. Given the broad distribution of the V600E mutation across cancers, the TCRs are also an attractive candidate for allogeneic T-cell therapy among cancer patients with the HLA-A*0301 allele.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Adoptive cell therapy for cancers expressing the BRAF V600E mutation</li> <li>&ldquo;Off-the-shelf&rdquo; allogenic cell therapy for BRAF V600E mutated cancers</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Potential for therapeutic efficacy against many cancers, given the high prevalence and broad distribution of the BRAF V600E mutation among cancer patients</li> <li>Therapies for BRAF V600E mutation-relevant cancers are often nonspecific or limited by acquired resistance</li> <li>T cells engineered with the TCRs are cytotoxic to tumor cells as the BRAF V600E mutation is not present in healthy tissues</li> <li>Efficacy against solid tumors</li> </ul> 2022-11-21 2026-04-23 2022-11-21 2026-04-23 2022-11-21 BRAF, B-Raf kinase, B-Raf Proto-Oncogene, HLA-A*0301 restriction, Immunotherapy, Rosenberg, serine-threonine kinase, T Cell Receptor, T cell therapy, TCR, V600E mutation, Yang, Yu False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-11-21 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-175-2016 E-237-2017 147163872 Yu, Zhiya NIH - NCI NCI Yu, Zhiya (NCI) 1 147163873 Ade, Catherine NCI - CCR NCI Ade, Catherine (NCI) 2 147163874 Sporn, Matthew NCI - CCR NCI Sporn, Matthew (NCI) 3 147163871 Yang, James NIH - NCI NCI Yang, James (NCI) 4 147163870 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 5 147163872 Yu, Zhiya NIH - NCI NCI Yu, Zhiya (NCI) 1 147163873 Ade, Catherine NCI - CCR NCI Ade, Catherine (NCI) 2 147163874 Sporn, Matthew NCI - CCR NCI Sporn, Matthew (NCI) 3 147163871 Yang, James NIH - NCI NCI Yang, James (NCI) 4 147163870 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 5 147158219 Murine T Cell Receptors Targeting Human BRAF V600E Mutation On HLA-A*0301+ Tumor Cells E-213-2022-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4197] T Cell Receptors Targeting BRAF V600E Mutation for Cancer Immunotherapy&body=Please send me information about technology [TAB-4197] T Cell Receptors Targeting BRAF V600E Mutation for Cancer Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4197] T Cell Receptors Targeting BRAF V600E Mutation for Cancer Immunotherapy&body=Please send me information about technology [TAB-4197] T Cell Receptors Targeting BRAF V600E Mutation for Cancer Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161199 E-213-2022-0 E-213-2022-0-US-01 HLA-A3-RESTRICTED T CELL RECEPTORS AGAINST BRAF WITH V600E MUTATION PRV US 63/381,587 Expired US <br />Provisional (PRV) 63/381,587<br />Filed on 2022-10-31<br />Status: Expired 159504232 E-213-2022-0 E-213-2022-0-PC-01 HLA-A3-RESTRICTED T CELL RECEPTORS AGAINST BRAF WITH V600E MUTATION PCT Patent Cooperation Treaty PCT/US2023/078156 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/078156<br />Filed on 2023-10-30<br />Status: Expired 147173777 BRAF 147173779 B-Raf kinase 147173781 B-Raf Proto-Oncogene 147173783 HLA-A*0301 restriction 147173784 Immunotherapy 147173785 Rosenberg 147173786 serine-threonine kinase 147173787 T Cell Receptor 147173788 T cell therapy 147173789 TCR 147173791 V600E mutation 147173793 Yang 147173795 Yu TAB-4140 147157423 Optimized Monospecific or Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20 NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics James Kochenderfer, Norris Lam <h2>Description of Technology:</h2> <p>Patients with chemotherapy-refractory, diffuse large B-cell lymphoma (DLBCL) have poor prognoses. CD19 and CD20 are promising targets for the treatment of B-Cell malignancies. However, despite the initial promising results from anti-CD19 CAR therapy, only 30-35% of patients with DLBCL achieve remissions lasting longer than 2-3 years after anti-CD19 CAR T-cell therapy. Relapse and non-response are likely due to diminished CD19 expression after anti-CD19 therapy and low expression of CD19 in some lymphomas.&nbsp;</p> <p>To overcome the limitations of the CD19 CAR T therapy, inventors developed an improved CAR targeting both CD19 and CD20. CARs targeting both CD19 and CD20 showed greater efficacy than the CD19 targeting CAR by itself. The structure of the CD20 binder in some of these CAR constructs is optimized to reduce death of CAR-expressing T cells and to promote retention of CAR expression. Also, these constructs are optimized to reduce retroviral recombination events.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of CD19-positive malignancies such as diffuse large B-cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia</li> <li>Treatment of CD20-positive malignancies such as diffuse large B-cell lymphoma, chronic lymphocytic leukemia, follicular lymphoma, and mantle cell lymphoma</li> <li>Treatment of autoimmune diseases via B cell depletion</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Constructs optimized to reduce retroviral recombination events</li> <li>Bicistronic expression vector allows for more efficient targeting of two antigens versus two separate vectors</li> <li>Bicistronic construct targeting both CD19 and CD20 increases the durability of response often&nbsp;limited by diminished expression of CD19 on tumor cell surfaces after anti-CD19 therapy</li> </ul> 2022-01-19 2026-04-23 2022-01-20 2026-04-23 2022-01-19 act, adoptive cell therapy, Autoimmune, B Cell Malignancies, BICISTRONIC, CAR, CD19, CD20, chimeric antigen receptor, Kochenderfer, Leukemia, lymphoma, Monospecific False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-01-20 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-205-2018 147163659 Kochenderfer, James NIH - NCI NCI Kochenderfer, James (NCI) 1 147163660 Lam, Norris NIH - NCI NCI Lam, Norris (NCI) 2 147163659 Kochenderfer, James NIH - NCI NCI Kochenderfer, James (NCI) 1 147163660 Lam, Norris NIH - NCI NCI Lam, Norris (NCI) 2 147157912 Nucleotide Optimized Fully-human CAR Constructs Targeting CD19-CD20 E-065-2021-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4140] Optimized Monospecific or Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20&body=Please send me information about technology [TAB-4140] Optimized Monospecific or Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4140] Optimized Monospecific or Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20&body=Please send me information about technology [TAB-4140] Optimized Monospecific or Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147160987 E-065-2021-0 E-065-2021-0-US-01 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS DESIGNED TO REDUCE RETROVIRAL RECOMBINATION AND USES THEREOF PRV US 63/165,195 Abandoned US <br />Provisional (PRV) 63/165,195<br />Filed on 2021-03-24<br />Status: Abandoned 147166882 E-065-2021-0 E-065-2021-0-PCT-02 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS DESIGNED TO REDUCE RETROVIRAL RECOMBINATION AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2022/021545 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/021545<br />Filed on 2022-03-23<br />Status: Expired 147170661 act 147170662 adoptive cell therapy 147170663 Autoimmune 147170665 B Cell Malignancies 147170666 BICISTRONIC 147170667 CAR 147170668 CD19 147170669 CD20 147170670 chimeric antigen receptor 147170672 Kochenderfer 147170673 Leukemia 147170674 lymphoma 147170675 Monospecific TAB-4126 147157408 T-cell Receptor Targeting Human Papillomavirus-16 E7 Oncoprotein NCI Collaboration, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Infectious Disease Licensing Oncology Therapeutics Christian Hinrichs, Steven Rosenberg <h2>Summary:</h2> <p>The NCI Center for Immuno-Oncology is actively seeking co-development partners and/or licensees for this E7-targeting TCR with therapeutic potential for HPV-positive conditions.&nbsp;&nbsp;</p> <h2>Description of Technology:</h2> <p>Human papillomavirus (HPV) is a group of human viruses known to cause various malignancies. Of the group, HPV-16 is the most prevalent strain &ndash; an estimated 90% of adults have been exposed. HPV-16 is also the strain most commonly associated with malignancy, causing the vast majority of cervical, anal, vaginal, vulvar, and penile cancers. Currently, HPV-positive malignancies non-responsive to surgery or radiation are incurable and poorly palliated by existing systemic therapies. Thus, an alternative therapeutic approach for HPV-positive malignancies is needed.&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) developed a T cell receptor (TCR) that may be used in adoptive cell therapy to treat HPV-positive malignancies. The TCR confers high-avidity recognition of the HPV-specific E7 oncoprotein that drives malignant transformation in HPV-infected cells. Further, E7 is specific to and constitutively expressed by cancer cells, making it an ideal therapeutic target. The TCR targets human leukocyte antigen (HLA)-A*02-restricted epitope E711-19. The inventors successfully transduced T cells obtained from peripheral blood mononuclear cells (PBMCs) with this TCR. An ongoing Phase I/II clinical trial is investigating the efficacy of the E7-targeting TCR in treating HPV-positive malignancies.&nbsp;&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Adoptive cell therapy against HPV-positive cancers</li> <li>Treatment of HPV-related infections and premalignant conditions</li> <li>Prevention of HPV-related infections and premalignant conditions</li> <li>Detection of HPV-infected or transformed cells for diagnostic purposes</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>FDA approval of another first-in-class TCR therapeutic demonstrates treatment benefit of approach&nbsp;</li> <li>FDA approval of another first-in-class TCR therapeutic decreases regulatory risk</li> <li>High avidity for the HPV-specific E7 oncoprotein</li> <li>Specifically recognize HLA-A*02-positive HPV-16 cancer cells</li> <li>TCR can be used to transduce T cells isolated from PBMCs, an easily accessible source of human immune cells&nbsp;</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a TCR with high-avidity recognition of the E7 oncoprotein to treat HPV-positive malignancies. 2022-07-06 2026-04-23 2022-07-08 2026-04-23 2022-07-08 act, adoptive cell therapy, Cervical cancer, E7, HLA-A*02, HPV, Human Papillomavirus, Major Histocompatibility Complex, MALIGNANCY, MHC, ONCOPROTEIN, Rosenberg, T Cell Receptor, TCR False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-07-08 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract E-495-2013 147161890 Hinrichs CS, et al. Exploiting the curative potential of adoptive T-cell therapy for cancer. https://pubmed.ncbi.nlm.nih.gov/24329789/ <a href="https://pubmed.ncbi.nlm.nih.gov/24329789/">Hinrichs CS, et al. Exploiting the curative potential of adoptive T-cell therapy for cancer.</a> 147162006 Nagarsheth NB, et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. https://pubmed.ncbi.nlm.nih.gov/33558725/ <a href="https://pubmed.ncbi.nlm.nih.gov/33558725/">Nagarsheth NB, et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers.</a> 147163607 Hinrichs, Christian NIH - NCI Hinrichs, Christian 1 147163606 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 147163607 Hinrichs, Christian NIH - NCI Hinrichs, Christian 1 147163606 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 147158151 T-cell Receptor Targeting An HLA-A2-restricted Epitope Of Human Papillomavirus-16 E7 E-176-2014-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4126] T-cell Receptor Targeting Human Papillomavirus-16 E7 Oncoprotein&body=Please send me information about technology [TAB-4126] T-cell Receptor Targeting Human Papillomavirus-16 E7 Oncoprotein.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4126] T-cell Receptor Targeting Human Papillomavirus-16 E7 Oncoprotein&body=Please send me information about technology [TAB-4126] T-cell Receptor Targeting Human Papillomavirus-16 E7 Oncoprotein.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147166721 E-176-2014-0 E-176-2014-0-US-01 Anti-Human Papillomavirus-16 E7 T Cell Receptors PRV US 62/004,335 Abandoned US <br />Provisional (PRV) 62/004,335<br />Filed on 2014-05-29<br />Status: Abandoned 147166722 E-176-2014-0 E-176-2014-0-PCT-02 Anti-Human Papillomavirus 16 E7 T Cell Receptors PCT Patent Cooperation Treaty PCT/US2015/033129 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/033129<br />Filed on 2015-05-29<br />Status: Expired 147166723 E-176-2014-0 E-176-2014-0-CA-05 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage Canada 2950192 Pending Canada <br />National Stage 2950192<br />Filed on 2015-05-29<br />Status: Pending 147166724 E-176-2014-0 E-176-2014-0-AU-03 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage Australia 2015266818 2015266818 Issued Australia <br />National Stage 2015266818<br />Filed on 2015-05-29<br />Status: Issued 147166725 E-176-2014-0 E-176-2014-0-BR-04 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage Brazil BR112016027805-4 BR112016027805-4 Issued Brazil <br />National Stage BR112016027805-4<br />Filed on 2015-05-29<br />Status: Issued 147166726 E-176-2014-0 E-176-2014-0-CN-06 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage China ZL201580031789.X 201580031789.X Issued China <br />National Stage 201580031789.X<br />Filed on 2015-05-29<br />Status: Issued 147166727 E-176-2014-0 E-176-2014-0-EP-07 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage European Patent 3149031 15729004.0 Issued European Patent <br />National Stage 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166728 E-176-2014-0 E-176-2014-0-IL-08 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage Israel 248797 248797 Issued Israel <br />National Stage 248797<br />Filed on 2016-11-07<br />Status: Issued 147166729 E-176-2014-0 E-176-2014-0-JP-09 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage Japan 6742991 2017-515021 Issued Japan <br />National Stage 2017-515021<br />Filed on 2015-05-29<br />Status: Issued 147166730 E-176-2014-0 E-176-2014-0-KR-10 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage South Korea 10-2445667 10-2016-7033189 Issued South Korea <br />National Stage 10-2016-7033189<br />Filed on 2016-11-28<br />Status: Issued 147166731 E-176-2014-0 E-176-2014-0-MX-11 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage Mexico 375379 MX/a/2016/015383 Issued Mexico <br />National Stage MX/a/2016/015383<br />Filed on 2015-05-29<br />Status: Issued 147166732 E-176-2014-0 E-176-2014-0-SA-12 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage Saudi Arabia 7456 516380394 Issued Saudi Arabia <br />National Stage 516380394<br />Filed on 2015-05-29<br />Status: Issued 147166733 E-176-2014-0 E-176-2014-0-US-13 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS National Stage US 10,174,098 15/313,673 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10174098 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10174098">10,174,098</a><br />Filed on 2016-11-23<br />Status: Issued 147166734 E-176-2014-0 E-176-2014-0-HK-14 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Hong Kong HK1236203B 17109823.5 Issued Hong Kong <br />European patent (EP) 17109823.5<br />Filed on 2017-09-27<br />Status: Issued 147166735 E-176-2014-0 E-176-2014-0-US-15 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS DIV US 10,870,687 16/205,631 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10870687 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10870687">10,870,687</a><br />Filed on 2018-11-30<br />Status: Issued 147166736 E-176-2014-0 E-176-2014-0-EP-16 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS DIV European Patent 3689900 19217074.4 Issued European Patent <br />Divisional (DIV) 19217074.4<br />Filed on 2019-12-17<br />Status: Issued 147166737 E-176-2014-0 E-176-2014-0-AU-17 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV Australia 2019283892 2019283892 Issued Australia <br />Divisional (DIV) 2019283892<br />Filed on 2019-12-18<br />Status: Issued 147166738 E-176-2014-0 E-176-2014-0-AL-18 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Albania 3149031 15729004.0 Issued Albania <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166739 E-176-2014-0 E-176-2014-0-AT-19 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Austria 3149031 15729004.0 Issued Austria <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166740 E-176-2014-0 E-176-2014-0-BE-20 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Belgium 3149031 15729004.0 Issued Belgium <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166741 E-176-2014-0 E-176-2014-0-BG-21 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Bulgaria 3149031 15729004.0 Issued Bulgaria <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166742 E-176-2014-0 E-176-2014-0-CH-22 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Switzerland 3149031 15729004.0 Issued Switzerland <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166743 E-176-2014-0 E-176-2014-0-CY-23 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Cyprus 3149031 15729004.0 Issued Cyprus <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166744 E-176-2014-0 E-176-2014-0-CZ-24 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Czech Republic 3149031 15729004.0 Issued Czech Republic <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166745 E-176-2014-0 E-176-2014-0-DE-25 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Germany 3149031 15729004.0 Issued Germany <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166746 E-176-2014-0 E-176-2014-0-DK-26 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Denmark 3149031 15729004.0 Issued Denmark <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166747 E-176-2014-0 E-176-2014-0-EE-27 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Estonia 3149031 15729004.0 Issued Estonia <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166748 E-176-2014-0 E-176-2014-0-ES-28 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Spain 3149031 15729004.0 Issued Spain <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166749 E-176-2014-0 E-176-2014-0-FI-29 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Finland 3149031 15729004.0 Issued Finland <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166750 E-176-2014-0 E-176-2014-0-FR-30 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP France 3149031 15729004.0 Issued France <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166751 E-176-2014-0 E-176-2014-0-GB-31 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP United Kingdom 3149031 15729004.0 Issued United Kingdom <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166752 E-176-2014-0 E-176-2014-0-GR-32 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Greece 3149031 15729004.0 Issued Greece <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166753 E-176-2014-0 E-176-2014-0-HR-33 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Croatia 3149031 15729004.0 Issued Croatia <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166754 E-176-2014-0 E-176-2014-0-HU-34 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Hungary 3149031 15729004.0 Issued Hungary <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166755 E-176-2014-0 E-176-2014-0-IE-35 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Ireland 3149031 15729004.0 Issued Ireland <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166756 E-176-2014-0 E-176-2014-0-IS-36 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Iceland 3149031 15729004.0 Issued Iceland <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166757 E-176-2014-0 E-176-2014-0-IT-37 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Italy 3149031 15729004.0 Issued Italy <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166758 E-176-2014-0 E-176-2014-0-LT-38 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Lithuania 3149031 15729004.0 Issued Lithuania <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166759 E-176-2014-0 E-176-2014-0-LU-39 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Luxembourg 3149031 15729004.0 Issued Luxembourg <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166760 E-176-2014-0 E-176-2014-0-LV-40 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Latvia 3149031 15729004.0 Issued Latvia <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166761 E-176-2014-0 E-176-2014-0-MK-41 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP North Macedonia 3149031 15729004.0 Issued North Macedonia <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166762 E-176-2014-0 E-176-2014-0-MT-42 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Malta 3149031 15729004.0 Issued Malta <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166763 E-176-2014-0 E-176-2014-0-NL-43 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP The Netherlands 3149031 15729004.0 Issued The Netherlands <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166764 E-176-2014-0 E-176-2014-0-NO-44 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Norway 3149031 15729004.0 Issued Norway <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166765 E-176-2014-0 E-176-2014-0-PL-45 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Poland 3149031 15729004.0 Issued Poland <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166766 E-176-2014-0 E-176-2014-0-PT-46 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Portugal 3149031 15729004.0 Issued Portugal <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166767 E-176-2014-0 E-176-2014-0-RO-47 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Romania 3149031 15729004.0 Issued Romania <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166768 E-176-2014-0 E-176-2014-0-SE-48 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Sweden 3149031 15729004.0 Issued Sweden <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166769 E-176-2014-0 E-176-2014-0-SI-49 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Slovenia 3149031 15729004.0 Issued Slovenia <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166770 E-176-2014-0 E-176-2014-0-SK-50 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Slovakia 3149031 15729004.0 Issued Slovakia <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166771 E-176-2014-0 E-176-2014-0-SM-51 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP San Marino 3149031 15729004.0 Issued San Marino <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166772 E-176-2014-0 E-176-2014-0-TR-52 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Turkey 3149031 15729004.0 Issued Turkey <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166773 E-176-2014-0 E-176-2014-0-JP-53 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T-CELL RECEPTOR DIV Japan 6997267 2020-127833 Issued Japan <br />Divisional (DIV) 2020-127833<br />Filed on 2020-07-29<br />Status: Issued 147166774 E-176-2014-0 E-176-2014-0-SA-54 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV Saudi Arabia 520412601 Abandoned Saudi Arabia <br />Divisional (DIV) 520412601<br />Filed on 2020-08-06<br />Status: Abandoned 147166775 E-176-2014-0 E-176-2014-0-HK-55 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS EP Hong Kong HK40030123B 42020020661.3 Issued Hong Kong <br />European patent (EP) 42020020661.3<br />Filed on 2020-11-24<br />Status: Issued 147166776 E-176-2014-0 E-176-2014-0-MX-56 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV Mexico 432750 MX/a/2020/010035 Issued Mexico <br />Divisional (DIV) MX/a/2020/010035<br />Filed on 2020-09-24<br />Status: Issued 147166777 E-176-2014-0 E-176-2014-0-US-57 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS CON US 11,434,272 17/101,360 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11434272 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11434272">11,434,272</a><br />Filed on 2020-11-23<br />Status: Issued 147166778 E-176-2014-0 E-176-2014-0-AU-58 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV Australia 2021202227 2021202227 Issued Australia <br />Divisional (DIV) 2021202227<br />Filed on 2021-04-13<br />Status: Issued 147166779 E-176-2014-0 E-176-2014-0-CN-59 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV China ZL202110399056.9 202110399056.9 Issued China <br />Divisional (DIV) 202110399056.9<br />Filed on 2021-04-14<br />Status: Issued 147166780 E-176-2014-0 E-176-2014-0-IL-60 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV Israel 282518 282518 Issued Israel <br />Divisional (DIV) 282518<br />Filed on 2021-04-21<br />Status: Issued 147166782 E-176-2014-0 E-176-2014-0-HK-62 Anti-Human Papillomavirus 16 E7 T Cell Receptors CN Hong Kong HK40056926B 42022046605.6 Issued Hong Kong <br />China Patent (CN) 42022046605.6<br />Filed on 2022-01-19<br />Status: Issued 147166783 E-176-2014-0 E-176-2014-0-JP-63 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS DIV Japan 7291196 2021-203953 Issued Japan <br />Divisional (DIV) 2021-203953<br />Filed on 2021-12-16<br />Status: Issued 147166784 E-176-2014-0 E-176-2014-0-IL-64 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV Israel 290655 290655 Issued Israel <br />Divisional (DIV) 290655<br />Filed on 2022-02-16<br />Status: Issued 147166785 E-176-2014-0 E-176-2014-0-US-65 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS CON US 12,534,508 17/816,496 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12534508 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12534508">12,534,508</a><br />Filed on 2022-08-01<br />Status: Issued 147166786 E-176-2014-0 E-176-2014-0-KR-66 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV South Korea 10-2618267 10-2022-7032043 Issued South Korea <br />Divisional (DIV) 10-2022-7032043<br />Filed on 2022-09-15<br />Status: Issued 147166787 E-176-2014-0 E-176-2014-0-AU-01 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV Australia 2023200608 2023200608 Issued Australia <br />Divisional (DIV) 2023200608<br />Filed on 2023-02-06<br />Status: Issued 147166788 E-176-2014-0 E-176-2014-0-JP-01 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS DIV Japan 7535158 2023-091878 Issued Japan <br />Divisional (DIV) 2023-091878<br />Filed on 2023-06-02<br />Status: Issued 147173065 act 147173066 adoptive cell therapy 147173067 Cervical cancer 147173068 E7 147173070 HLA-A*02 147173071 HPV 147173072 Human Papillomavirus 147173074 Major Histocompatibility Complex 147173075 MALIGNANCY 147173076 MHC 147173077 ONCOPROTEIN 147173078 Rosenberg 147173079 T Cell Receptor 147173080 TCR TAB-4115 147157397 Mouse Lines with Fluorescently Labelled Membrane Proteins Regulating Cellular Motility and Membrane Trafficking NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Seham Ebrahim, Weiye Wang, Roberto Weigert <h2>Summary:</h2> <p>NCI is seeking licensees for mouse lines with fluorescently labeled membrane proteins regulating cellular motility and cancer progression.</p> <h2>Description of Technology:</h2> <p>Cell motility and membrane trafficking play important roles in regulating cell division, cell migration, cell death and autophagy. Impairment of these processes can result in enhanced cell proliferation and survival and increased migration and invasion leading to cancer. Several proteins involved in cell motility and membrane trafficking have been shown to be dysregulated in various cancers. There is therefore a need for development of animal models for studying the roles of these proteins in cancer and their responses to drug treatment in vivo.</p> <p>Researchers at the National Cancer Institute (NCI) have developed mouse lines with fluorescently labelled membrane proteins regulating cellular motility and membrane trafficking. These transgenic mouse lines were created by insertion of fluorescent proteins to tag Myosin IIA, Septin 2, Septin 7, Septin 9 and Rab25. They facilitate the study of cell motility and membrane trafficking proteins and their activity during tumor progression in live animal models.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Cancer research</li> <li>Live animal imaging cancer studies</li> <li>Live animal imaging cancer drug screening</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Use of neon-Green and pTag-RFP tagging provides a superior means of imaging in vivo over other fluorescent proteins</li> <li>These mouse lines facilitate live animal imaging studies of cell motility and membrane trafficking proteins</li> <li>The first available mouse lines for live animal imaging of Septin 2, Septin 7, Septin 9 and Rab25 in vivo</li> </ul> Researchers at the NCI seek licensing for mouse lines with fluorescently labelled membrane proteins regulating cellular motility and cancer progression 2022-02-03 2026-04-23 2022-02-03 2026-04-23 2022-02-03 Cellular Motility, Florescent Labels, Membrane Trafficking, Mouse Lines, Rab25, Septin 2, Septin 7, Septin 9, Weigert False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-02-03 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163558 Weigert, Roberto NIH - NCI NCI Weigert, Roberto (NCI) 1 147163560 Wang, Weiye NCI - CCR NCI Wang, Weiye (NCI) 2 147163559 Ebrahim, Seham NCI - CCR NCI Ebrahim, Seham (NCI) 3 147163558 Weigert, Roberto NIH - NCI NCI Weigert, Roberto (NCI) 1 147163560 Wang, Weiye NCI - CCR NCI Wang, Weiye (NCI) 2 147163559 Ebrahim, Seham NCI - CCR NCI Ebrahim, Seham (NCI) 3 147157829 Mouse Lines With Fluorescently Labeled Membrane Proteins (Septins, Myosin IIA, Rab25) Regulating Cellular Motility And Membrane Trafficking E-031-2022-0 Research Material NCI 147188440 Watson, Shana shana.watson@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America shana.watson@nih.gov?subject=Web Inquiry on [TAB-4115] Mouse Lines with Fluorescently Labelled Membrane Proteins Regulating Cellular Motility and Membrane Trafficking&body=Please send me information about technology [TAB-4115] Mouse Lines with Fluorescently Labelled Membrane Proteins Regulating Cellular Motility and Membrane Trafficking.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Watson, Shana<br><a href="mailto:shana.watson@nih.gov?subject=Web Inquiry on [TAB-4115] Mouse Lines with Fluorescently Labelled Membrane Proteins Regulating Cellular Motility and Membrane Trafficking&body=Please send me information about technology [TAB-4115] Mouse Lines with Fluorescently Labelled Membrane Proteins Regulating Cellular Motility and Membrane Trafficking.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">shana.watson@nih.gov</a><br> 147169887 Cellular Motility 147169889 Florescent Labels 147169891 Membrane Trafficking 147169893 Mouse Lines 147169894 Rab25 147169896 Septin 2 147169898 Septin 7 147169900 Septin 9 147169902 Weigert TAB-4043 147157325 IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 for Treating Liver Cancer NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Mitchell Ho, Aarti Kolluri, Nan Li <h2>Summary:</h2> <p>Researchers at the NCI seek licensing and/or co-development research collaborations for developing new nanobody-based CAR and/or antibody-T-cell receptor therapies for treating liver cancer.</p> <h2>Description of Technology:</h2> <p>Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Globally, HCC is the sixth most prevalent cancer and third leading cause of cancer-related morbidity. Standard treatment for HCC is not suitable for a large proportion of liver cancer patients. Part of this is because less than a quarter of HCC patients are surgical candidates for curative-intent treatment. As a result, alternative treatments are needed. Chimeric antigen receptor (CAR) T cell therapy is a promising alternative approach selectively targets targeting tumors via tumor-specific antigens. However, to date, no effective CAR T cell therapy exists for HCC.</p> <p>Researchers at National Cancer Institute (NCI) developed novel Chimeric Antigen Receptors (CARs) specific for glypican-3 (GPC3) that include short Immunoglobulin subclass 4 (IgG4) and CD28 based hinge domains and the HN3 human single-domain antibody (also called nanobody). The specific HN3 nanobody-IgG4H-CD28TM CAR included in this invention was much more potent both in in vitro cell models and in vivo mouse models.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of liver cancer, whose worldwide incidence is increasing in direct relation to the spread of hepatitis C virus infection.</li> <li>Chimeric antigen receptor (CAR) and/or antibody-T-cell receptor cancer therapies.&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Increased therapeutic effectiveness of CAR T therapies for the vast majority patients with HCC without impactful treatment options</li> <li>New nanobody-based CAR immunotherapy in preclinical in vivo studies has a greater decrease in tumor size compared with other CAR formats</li> <li>Nanobodies&rsquo; lack of a light chain, making them much smaller and more flexible than standard antibodies, allows: (1) binding in different modes than typical antibodies, (2) coverage of more chemical space and (3) binding to epitopes otherwise inaccessible.&nbsp;&nbsp;</li> <li>Nanobodies can be readily genetically engineered for additional functionality and, consequently, paths to market.&nbsp;&nbsp;</li> </ul> 2022-07-06 2026-04-23 2022-07-06 2026-04-23 2022-07-06 ANTIBODY, cancer therapeutic, Chimeric antigen receptors (CARs), Glypican-3 (GPC3), Hepatocellular Carcinoma (HCC), HO, IgG4, Liver cancer, Macrophage, NANOBODY, Natural Killer (NK) Cell, T cell, therapeutic False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-07-06 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-016-2018 E-130-2011 147162126 Dan Li, et al. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice. Gastroenterology vol. 158,8 (2020): 2250-2265.e20. doi:10.1053/j.gastro.2020.02.011 https://pubmed.ncbi.nlm.nih.gov/32060001/ <a href="https://pubmed.ncbi.nlm.nih.gov/32060001/">Dan Li, et al. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice. Gastroenterology vol. 158,8 (2020): 2250-2265.e20. doi:10.1053/j.gastro.2020.02.011</a> 147163312 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163314 Kolluri, Aarti NCI - CCR NCI Kolluri, Aarti (NCI) 2 147163313 Li, Nan NIH - NCI NCI Li, Nan (NCI) 3 147163312 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163314 Kolluri, Aarti NCI - CCR NCI Kolluri, Aarti (NCI) 2 147163313 Li, Nan NIH - NCI NCI Li, Nan (NCI) 3 147158207 IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 For Treating Liver Cancer E-205-2021-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4043] IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 for Treating Liver Cancer&body=Please send me information about technology [TAB-4043] IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 for Treating Liver Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4043] IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 for Treating Liver Cancer&body=Please send me information about technology [TAB-4043] IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 for Treating Liver Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161191 E-205-2021-0 E-205-2021-0-US-01 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-3 (GPC3) AND USE THEREOF PRV US 63/277,287 Abandoned US <br />Provisional (PRV) 63/277,287<br />Filed on 2021-11-09<br />Status: Abandoned 147166168 E-205-2021-0 E-205-2021-0-PCT-02 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-3 (GPC3) AND USE THEREOF PCT Patent Cooperation Treaty PCT/US2022/079554 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/079554<br />Filed on 2022-11-09<br />Status: Expired 147173628 ANTIBODY 147173629 cancer therapeutic 147173631 Chimeric antigen receptors (CARs) 147173633 Glypican-3 (GPC3) 147173635 Hepatocellular Carcinoma (HCC) 147173636 HO 147173637 IgG4 147173638 Liver cancer 147173639 Macrophage 147173640 NANOBODY 147173642 Natural Killer (NK) Cell 147173643 T cell 147173644 therapeutic TAB-3933 147157213 T-cell Receptor Targeting Human Papillomavirus-16 E6 Oncoprotein NCI Collaboration, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Infectious Disease Licensing Oncology Therapeutics Christian Hinrichs, Steven Rosenberg <h2>Summary:</h2> <p>The NCI Center for Immuno-Oncology is actively seeking co-development partners and/or licensees for this E6-targeting TCR with therapeutic potential for HPV-positive conditions.</p> <h2>Description of Technology:</h2> <p>Human papillomavirus (HPV) is a group of human viruses known to cause various malignancies. Of the group, HPV-16 is the most prevalent strain &ndash; an estimated 90% of adults have been exposed. HPV-16 is also the strain most commonly associated with malignancy, causing the vast majority of cervical, anal, vaginal, vulvar, and penile cancers. Currently, HPV-positive malignancies non-responsive to surgery or radiation are incurable and poorly palliated by existing systemic therapies. Thus, an alternative therapeutic approach for HPV-positive malignancies is needed.&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) developed a T cell receptor (TCR) that may be used in adoptive cell therapy to treat HPV-positive malignancies. The TCR confers high-avidity recognition of the HPV-specific E6 oncoprotein that drives malignant transformation in HPV-infected cells. Further, E6 is specific to and constitutively expressed by cancer cells, making it an ideal therapeutic target. The TCR targets human leukocyte antigen (HLA)-A*02-restricted epitope E629-38. The inventors successfully transduced T cells obtained from peripheral blood mononuclear cells (PBMCs) with this TCR.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Adoptive cell therapy against HPV-positive cancers</li> <li>Treatment of HPV-related infections and premalignant conditions</li> <li>Prevention of HPV-related infections and premalignant conditions</li> <li>Detection of HPV-infected or transformed cells for diagnostic purposes</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>FDA approval of another first-in-class TCR therapeutic demonstrates treatment benefit of approach&nbsp;</li> <li>FDA approval of another first-in-class TCR therapeutic decreases regulatory risk</li> <li>High avidity for the HPV-specific E6 oncoprotein</li> <li>Specifically recognize HLA-A*02-positive HPV-16 cancer cells</li> <li>TCR can be used to transduce T cells isolated from PBMCs, an easily accessible source of human immune cells&nbsp;</li> </ul> 2022-07-08 2026-04-23 2022-09-29 2026-04-23 2022-07-08 act, adoptive cell therapy, Cervical cancer, E6, HLA-A*02, HPV, Human Papillomavirus, Major Histocompatibility Complex, MALIGNANCY, MHC, ONCOPROTEIN, Rosenberg, T Cell Receptor, TCR False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-09-29 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract E-176-2014 147162097 Doran SL, et al. T-Cell Receptor Gene Therapy for Human Papillomavirus&ndash;Associated Epithelial Cancers: A First-in-Human, Phase I/II Study. https://pubmed.ncbi.nlm.nih.gov/?term=31408414 <a href="https://pubmed.ncbi.nlm.nih.gov/?term=31408414">Doran SL, et al. T-Cell Receptor Gene Therapy for Human Papillomavirus&ndash;Associated Epithelial Cancers: A First-in-Human, Phase I/II Study.</a> 147162175 Hinrichs CS, et al. Exploiting the curative potential of adoptive T-cell therapy for cancer. https://pubmed.ncbi.nlm.nih.gov/24329789/ <a href="https://pubmed.ncbi.nlm.nih.gov/24329789/">Hinrichs CS, et al. Exploiting the curative potential of adoptive T-cell therapy for cancer.</a> 147162920 Hinrichs, Christian NIH - NCI Hinrichs, Christian 1 147162919 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 147162920 Hinrichs, Christian NIH - NCI Hinrichs, Christian 1 147162919 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 147158355 T Cell Receptor Targeting An HLA-A2 Restricted Epitope Of Human Papillomavirus-16 E6 E-495-2013-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-3933] T-cell Receptor Targeting Human Papillomavirus-16 E6 Oncoprotein&body=Please send me information about technology [TAB-3933] T-cell Receptor Targeting Human Papillomavirus-16 E6 Oncoprotein.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-3933] T-cell Receptor Targeting Human Papillomavirus-16 E6 Oncoprotein&body=Please send me information about technology [TAB-3933] T-cell Receptor Targeting Human Papillomavirus-16 E6 Oncoprotein.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147165363 E-495-2013-0 E-495-2013-0-US-01 Anti-Human Papillomavirus 16 E6 T Cell Receptors PRV US 61/846,167 Abandoned US <br />Provisional (PRV) 61/846,167<br />Filed on 2013-07-15<br />Status: Abandoned 147165364 E-495-2013-0 E-495-2013-0-PCT-02 Anti-Human Papillomavirus 16 E6 T Cell Receptors PCT Patent Cooperation Treaty PCT/US2014/046480 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/046480<br />Filed on 2014-07-14<br />Status: Expired 147165365 E-495-2013-0 E-495-2013-0-JP-07 Anti-Human Papillomavirus 16 E6 T Cell Receptors National Stage Japan 6628719 2016-527006 Issued Japan <br />National Stage 2016-527006<br />Filed on 2016-01-15<br />Status: Issued 147165366 E-495-2013-0 E-495-2013-0-AU-03 Anti-Human Papillomavirus 16 E6 T Cell Receptors National Stage Australia 2014290288 2014290288 Issued Australia <br />National Stage 2014290288<br />Filed on 2014-07-14<br />Status: Issued 147165367 E-495-2013-0 E-495-2013-0-CA-04 Anti-Human Papillomavirus 16 E6 T Cell Receptors National Stage Canada 2918216 2918216 Issued Canada <br />National Stage 2918216<br />Filed on 2014-07-14<br />Status: Issued 147165368 E-495-2013-0 E-495-2013-0-CN-05 Anti-Human Papillomavirus 16 E6 T Cell Receptors National Stage China ZL201480044286.1 201480044286.1 Issued China <br />National Stage 201480044286.1<br />Filed on 2016-02-04<br />Status: Issued 147165369 E-495-2013-0 E-495-2013-0-EP-06 Anti-Human Papillomavirus 16 E6 T Cell Receptors National Stage European Patent 3022223 14748353.1 Issued European Patent <br />National Stage 14748353.1<br />Filed on 2014-07-14<br />Status: Issued 147165370 E-495-2013-0 E-495-2013-0-US-08 Anti-Human Papillomavirus 16 E6 T Cell Receptors National Stage US 9,822,162 14/905,108 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9822162 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9822162">9,822,162</a><br />Filed on 2016-01-14<br />Status: Issued 147165371 E-495-2013-0 E-495-2013-0-US-09 ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORS CON US 10,329,339 15/786,966 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10329339 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10329339">10,329,339</a><br />Filed on 2017-10-18<br />Status: Issued 147165372 E-495-2013-0 E-495-2013-0-EP-10 Anti-Human Papillomavirus 16 E6 T Cell Receptors DIV European Patent 3572423 19180239.6 Issued European Patent <br />Divisional (DIV) 19180239.6<br />Filed on 2019-06-14<br />Status: Issued 147165373 E-495-2013-0 E-495-2013-0-US-11 ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORS CON US 10,913,785 16/408,939 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10913785 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10913785">10,913,785</a><br />Filed on 2019-05-10<br />Status: Issued 147165374 E-495-2013-0 E-495-2013-0-DE-12 Anti-Human Papillomavirus 16 E6 T Cell Receptors EP Germany 3022223 14748353.1 Issued Germany <br />European patent (EP) 14748353.1<br />Filed on 2014-07-14<br />Status: Issued 147165375 E-495-2013-0 E-495-2013-0-ES-13 Anti-Human Papillomavirus 16 E6 T Cell Receptors EP Spain 3022223 14748353.1 Issued Spain <br />European patent (EP) 14748353.1<br />Filed on 2014-07-14<br />Status: Issued 147165376 E-495-2013-0 E-495-2013-0-FR-14 Anti-Human Papillomavirus 16 E6 T Cell Receptors EP France 3022223 14748353.1 Issued France <br />European patent (EP) 14748353.1<br />Filed on 2014-07-14<br />Status: Issued 147165377 E-495-2013-0 E-495-2013-0-GB-15 Anti-Human Papillomavirus 16 E6 T Cell Receptors EP United Kingdom 3022223 14748353.1 Issued United Kingdom <br />European patent (EP) 14748353.1<br />Filed on 2014-07-14<br />Status: Issued 147165378 E-495-2013-0 E-495-2013-0-IE-16 Anti-Human Papillomavirus 16 E6 T Cell Receptors EP Ireland 3022223 14748353.1 Issued Ireland <br />European patent (EP) 14748353.1<br />Filed on 2014-07-14<br />Status: Issued 147165379 E-495-2013-0 E-495-2013-0-IT-17 Anti-Human Papillomavirus 16 E6 T Cell Receptors EP Italy 3022223 14748353.1 Issued Italy <br />European patent (EP) 14748353.1<br />Filed on 2014-07-14<br />Status: Issued 147165380 E-495-2013-0 E-495-2013-0-CN-18 ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORS DIV China ZL201910649441.7 201910649441.7 Issued China <br />Divisional (DIV) 201910649441.7<br />Filed on 2019-07-18<br />Status: Issued 147165381 E-495-2013-0 E-495-2013-0-JP-19 Anti-Human Papillomavirus 16 E6 T Cell Receptors DIV Japan 6959970 2019-219105 Issued Japan <br />Divisional (DIV) 2019-219105<br />Filed on 2019-12-03<br />Status: Issued 147165382 E-495-2013-0 E-495-2013-0-HK-20 Anti-Human Papillomavirus 16 E6 T Cell Receptors EP Hong Kong HK40018191B 42020008016.6 Issued Hong Kong <br />European patent (EP) 42020008016.6<br />Filed on 2020-05-25<br />Status: Issued 147165383 E-495-2013-0 E-495-2013-0-HK-21 Anti-Human Papillomavirus 16 E6 T Cell Receptors CN Hong Kong HK40016948B 42020007152.0 Issued Hong Kong <br />China Patent (CN) 42020007152.0<br />Filed on 2020-05-09<br />Status: Issued 147165384 E-495-2013-0 E-495-2013-0-US-22 ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORS CON US 11,697,676 17/142,486 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11697676 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11697676">11,697,676</a><br />Filed on 2021-01-06<br />Status: Issued 147165385 E-495-2013-0 E-495-2013-0-JP-23 Anti-Human Papillomavirus 16 E6 T Cell Receptors DIV Japan 7223822 2021-166407 Issued Japan <br />Divisional (DIV) 2021-166407<br />Filed on 2021-10-08<br />Status: Issued 147165386 E-495-2013-0 E-495-2013-0-JP-01 Anti-Human Papillomavirus 16 E6 T Cell Receptors DIV Japan Administratively Closed Japan <br />Divisional (DIV) None<br />Filed on None<br />Status: Administratively Closed 147165387 E-495-2013-0 E-495-2013-0-US-02 ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORS CON US 12,187,779 18/323,493 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12187779 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12187779">12,187,779</a><br />Filed on 2023-05-25<br />Status: Issued 147174883 act 147174884 adoptive cell therapy 147174885 Cervical cancer 147174886 E6 147174887 HLA-A*02 147174888 HPV 147174889 Human Papillomavirus 147174890 Major Histocompatibility Complex 147174891 MALIGNANCY 147174892 MHC 147174893 ONCOPROTEIN 147174894 Rosenberg 147174895 T Cell Receptor 147174896 TCR TAB-3935 147157215 Optical Configuration Methods for Spectral Scatter Flow Cytometry NCI Cardiology, Collaboration, Immunology, Infectious Disease, Licensing, Research Materials Cardiology Collaboration Immunology Infectious Disease Licensing Research Materials Jay Berzofsky, Jennifer Jones, Ariel ("Ari") Rosner, William Telford, Joshua Welsh <h2>Summary:</h2> <p>The inventors are constructing a prototype system and seek licensing or co-development opportunities from commercial flow cytometry platforms to optimize the invention for use in combination with their proprietary platforms.</p> <h2>Description of Technology:</h2> <p>Multi-parameter flow cytometry has been extensively used in multiple disciplines of biological discoveries, including immunology and cancer research. However, the disadvantage of traditional flow cytometry platforms using excitation lasers and fluorescence detectors is spectral overlap when using multiple dyes on the same biological sample. Metaethical compensation of spectral overlap could only be effective to a certain degree. Mass cytometry is advantageous compared to flow cytometry but is pricey and requires highly skilled operators.&nbsp;</p> <p>The inventors from the National Cancer Institute (NCI) developed a new flow cytometry protype using molecular NanoTags. NanoTags are nano-sized cytometric labels detectable individually or quantitatively enumerated based on their intrinsic light scattering or fluorescence properties. They are modularly designed to embody distinctive light scattering, fluorescence, and epitope specificity properties. Because NanoTags are modular, they can be comprised of different nanomaterials &ndash; each with identifiable and distinctive light scattering spectral properties across a wide range of wavelengths. Using the unique property of NanoTags, the inventors have tested three unique configurations. Configuration #1, &ldquo;Spectral Scatter Cytometer,&rdquo; is designed for full spectral scatter flow cytometry and would implement a supercontinuum white laser providing illumination at all UV-visible wavelengths. Configuration #2, &ldquo;Co-linear Laser Alignment,&rdquo; involves the co-linear alignment of at least two monochromatic lasers onto the core stream of standard flow cytometry.&nbsp; Configuration #3, &ldquo;Spatially Separated Lasers with Slit Apertures,&rdquo; involves a white-light laser, with its wavelengths spatially separated or part of standard, multi-monochromatic laser flow cytometry. Configuration #3 has the potential of being built to stand alone or add on to existing flow cytometers, providing high-throughput sample characterization with improved resolution.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>High-throughput sample characterization with flow cytometry</li> <li>Adaptable for other cytometric and microfluidic systems for enhanced detection</li> <li>Next generation cytometers&rsquo; configuration</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Enables single molecule detection in flow cytometry</li> <li>Identifying, quantifying and separating different subsets of extracellular vesicles and viruses</li> <li>Enable enhanced development of biomarkers, diagnostic and imaging products</li> </ul> 2022-01-21 2026-04-23 2022-01-21 2026-04-23 2022-01-21 flow cytometry, High-throughput Characterization, Jones, Molecular NanoTag, Multispectral Detection, Optical Configuration False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-01-21 52406769 Prototype 52406769 NCI 37470483 Website Abstract E-238-2015 147162926 Jones, Jennifer NIH - NCI NCI Jones, Jennifer (NCI) 1 147162928 Welsh, Joshua NIH - NCI NCI Welsh, Joshua (NCI) 2 147162927 Telford, William NIH - NCI NCI Telford, William (NCI) 3 147162924 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 4 147162925 Rosner, Ariel ("Ari") NIH - NCI Rosner, Ariel ("Ari") 5 147162926 Jones, Jennifer NIH - NCI NCI Jones, Jennifer (NCI) 1 147162928 Welsh, Joshua NIH - NCI NCI Welsh, Joshua (NCI) 2 147162927 Telford, William NIH - NCI NCI Telford, William (NCI) 3 147162924 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 4 147162925 Rosner, Ariel ("Ari") NIH - NCI Rosner, Ariel ("Ari") 5 147157777 Optical Configuration Device And Methods For Spectral Scatter Cytometry E-008-2018-0 Filing authorized NCI 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-3935] Optical Configuration Methods for Spectral Scatter Flow Cytometry&body=Please send me information about technology [TAB-3935] Optical Configuration Methods for Spectral Scatter Flow Cytometry.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-3935] Optical Configuration Methods for Spectral Scatter Flow Cytometry&body=Please send me information about technology [TAB-3935] Optical Configuration Methods for Spectral Scatter Flow Cytometry.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147160890 E-008-2018-0 E-008-2018-0-US-07 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY National Stage US 10,876,955 16/756,420 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10876955 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10876955">10,876,955</a><br />Filed on 2020-04-15<br />Status: Issued 147165396 E-008-2018-0 E-008-2018-0-US-01 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY PRV US 62/575,988 Abandoned US <br />Provisional (PRV) 62/575,988<br />Filed on 2017-10-23<br />Status: Abandoned 147165397 E-008-2018-0 E-008-2018-0-PCT-02 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY PCT Patent Cooperation Treaty PCT/US2018/057128 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/057128<br />Filed on 2018-10-23<br />Status: Expired 147165398 E-008-2018-0 E-008-2018-0-CN-03 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY National Stage China ZL201880069066.2 201880069066.2 Issued China <br />National Stage 201880069066.2<br />Filed on 2018-10-23<br />Status: Issued 147165399 E-008-2018-0 E-008-2018-0-EP-04 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY National Stage European Patent 3701246 18808559.1 Issued European Patent <br />National Stage 18808559.1<br />Filed on 2018-10-23<br />Status: Issued 147165400 E-008-2018-0 E-008-2018-0-JP-05 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY National Stage Japan 6788148 2020-522670 Issued Japan <br />National Stage 2020-522670<br />Filed on 2020-04-21<br />Status: Issued 147165401 E-008-2018-0 E-008-2018-0-KR-06 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY National Stage South Korea 10-2182575 10-2020-7011517 Issued South Korea <br />National Stage 10-2020-7011517<br />Filed on 2020-04-21<br />Status: Issued 147165402 E-008-2018-0 E-008-2018-0-DE-08 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY EP Germany 3701246 18808559.1 Issued Germany <br />European patent (EP) 18808559.1<br />Filed on 2018-10-23<br />Status: Issued 147165403 E-008-2018-0 E-008-2018-0-FR-09 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY EP France 3701246 18808559.1 Issued France <br />European patent (EP) 18808559.1<br />Filed on 2018-10-23<br />Status: Issued 147165404 E-008-2018-0 E-008-2018-0-GB-10 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY EP United Kingdom 3701246 18808559.1 Issued United Kingdom <br />European patent (EP) 18808559.1<br />Filed on 2018-10-23<br />Status: Issued 147165405 E-008-2018-0 E-008-2018-0-NL-11 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY EP The Netherlands 3701246 18808559.1 Issued The Netherlands <br />European patent (EP) 18808559.1<br />Filed on 2018-10-23<br />Status: Issued 147169352 flow cytometry 147169354 High-throughput Characterization 147169356 Jones 147169358 Molecular NanoTag 147169360 Multispectral Detection 147169362 Optical Configuration TAB-3957 147157237 Biomarker Analysis Software for High-Throughput Diagnostic Multiplex Data NCI Collaboration, Licensing, Oncology, Software / Apps Collaboration Licensing Oncology Software / Apps Jay Berzofsky, Jennifer Jones, Joshua Welsh <h2>Summary:</h2> <p>The NCI seeks research co-development partners and/or licensees for a biomarker analysis software for high-throughput diagnostic multiplex data.</p> <h2>Description of Technology:</h2> <p>Extracellular vesicles (EVs) are lipid bilayer-enclosed particles that are released from cells. EVs may contain proteins derived from their cells of origin with the potential as diagnostic biomarkers indicating the state of the cells when released. However, due to their small size (50-1000nm), the methods currently used to phenotype EVs have limited sensitivity and scale. A need exists for development of novel technologies improving EV detection and phenotyping.</p> <p>National Cancer Institute (NCI) scientists have developed a software package to perform high-throughput multi-dimensional analysis of EVs. The software utilizes a multiplex bead-based approach, coupled with secondary markers, clinical data, and -omics data. This technology provides a mechanism for high-throughput, semi-automated multidimensional data analysis for potential diagnostic and prognostic outcomes. The inventors used the software to identify and visualize a broad range of EV subsets, while also indirectly measuring specific EV populations. Exploratory studies confirmed strong correlations of liquid biopsy EV repertoires with tumor burden and responses to treatment. Furthermore, this software allows a scalable method of using EVs as biomarkers in a highly multiplexed fashion. When coupled with other clinical data, it is a useful means of diagnostic and/or prognostic outcomes.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Software package for high-throughput screening of extracellular vesicles as diagnostic and prognostic markers in personalized medicine.</li> <li>Can be utilized as software interface for other multiplex assays</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Allows for high-throughput, multiplexed and semi-automated analysis of extracellular vesicles and cargo protein.</li> <li>Utilizes secondary markers, clinical data and -omics data to provide diagnostic and/or prognostic determinations.</li> </ul> 2022-02-23 2026-04-23 2022-02-23 2026-04-23 2022-02-23 Berzofsky, Biomarker, EV, Extracellular Vesicles, High-throughput, Jones, Lipid Bilayer-Enclosed Particles, software False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-02-23 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147161957 Welsh JA et al. MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays. https://doi.org/10.1016/j.crmeth.2021.100136 <a href="https://doi.org/10.1016/j.crmeth.2021.100136">Welsh JA et al. MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays.</a> 147163014 Welsh, Joshua NIH - NCI NCI Welsh, Joshua (NCI) 1 147163013 Jones, Jennifer NIH - NCI NCI Jones, Jennifer (NCI) 2 147163012 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 3 147163014 Welsh, Joshua NIH - NCI NCI Welsh, Joshua (NCI) 1 147163013 Jones, Jennifer NIH - NCI NCI Jones, Jennifer (NCI) 2 147163012 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 3 147157995 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data E-105-2018-0 Filing authorized NCI 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-3957] Biomarker Analysis Software for High-Throughput Diagnostic Multiplex Data&body=Please send me information about technology [TAB-3957] Biomarker Analysis Software for High-Throughput Diagnostic Multiplex Data.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-3957] Biomarker Analysis Software for High-Throughput Diagnostic Multiplex Data&body=Please send me information about technology [TAB-3957] Biomarker Analysis Software for High-Throughput Diagnostic Multiplex Data.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147161045 E-105-2018-0 E-105-2018-0-US-01 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data PRV US 62/650,162 Abandoned US <br />Provisional (PRV) 62/650,162<br />Filed on 2018-03-29<br />Status: Abandoned 147165544 E-105-2018-0 E-105-2018-0-PCT-02 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data PCT Patent Cooperation Treaty PCT/US2019/024975 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/024975<br />Filed on 2019-03-29<br />Status: Expired 147165545 E-105-2018-0 E-105-2018-0-AU-03 BIOMARKER ANALYSIS FOR HIGH-THROUGHPUT DIAGNOSTIC MULTIPLEX DATA National Stage Australia 2019245402 2019245402 Issued Australia <br />National Stage 2019245402<br />Filed on 2019-03-29<br />Status: Issued 147165546 E-105-2018-0 E-105-2018-0-CA-04 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data National Stage Canada 3095485 3095485 Issued Canada <br />National Stage 3095485<br />Filed on 2020-09-28<br />Status: Issued 147165547 E-105-2018-0 E-105-2018-0-EP-05 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data National Stage European Patent 3775897 19717657.1 Issued European Patent <br />National Stage 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 147165548 E-105-2018-0 E-105-2018-0-US-06 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data National Stage US 17/042,765 Abandoned US <br />National Stage 17/042,765<br />Filed on 2020-09-28<br />Status: Abandoned 159504200 E-105-2018-0 E-105-2018-0-ES-07 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data EP Spain 3775897 19717657.1 Issued Spain <br />European patent (EP) 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 159504634 E-105-2018-0 E-105-2018-0-FR-08 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data EP France 3775897 19717657.1 Issued France <br />European patent (EP) 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 159504645 E-105-2018-0 E-105-2018-0-DK-09 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data EP Denmark 3775897 19717657.1 Issued Denmark <br />European patent (EP) 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 159504650 E-105-2018-0 E-105-2018-0-IT-10 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data EP Italy 3775897 19717657.1 Issued Italy <br />European patent (EP) 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 159504661 E-105-2018-0 E-105-2018-0-DE-11 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data EP Germany 3775897 19717657.1 Issued Germany <br />European patent (EP) 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 159504666 E-105-2018-0 E-105-2018-0-NL-14 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data EP The Netherlands 3775897 19717657.1 Issued The Netherlands <br />European patent (EP) 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 159504671 E-105-2018-0 E-105-2018-0-CH-13 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data EP Switzerland 3775897 19717657.1 Issued Switzerland <br />European patent (EP) 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 159504683 E-105-2018-0 E-105-2018-0-GB-12 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data EP United Kingdom 3775897 19717657.1 Issued United Kingdom <br />European patent (EP) 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 147171496 Berzofsky 147171497 Biomarker 147171498 EV 147171499 Extracellular Vesicles 147171500 High-throughput 147171501 Jones 147171503 Lipid Bilayer-Enclosed Particles 147171504 software TAB-4029 147157310 Nanobodies Neutralizing Lassa Virus NCI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Sao "Crystal" Cheung, Zhijian Duan, Jason Gorman, Mitchell Ho, Peter Kwong, Yaping Sun <h2>Summary:</h2> <p>Researchers at the National Cancer Institute (NCI) seek parties interested in collaborative research and/or licensing to further develop neutralizing nanobodies targeting Lassa virus.</p> <h2>Description of Technology:</h2> <p>Lassa Hemorrhagic Fever (LHF) is a serious disease caused by infection with Lassa virus (LASV) &ndash; highly prevalent in West Africa and spreading globally. LASV is associated with high morbidity and mortality rates, annually infecting 100,000 to 300,000 individuals and causing 5,000 deaths. Developing prophylactics and treatment for LASV is difficult due to challenges in inducing neutralizing antibodies and producing their target, the LASV glycoprotein trimer (GPC). LASV poses a severe public health threat with infections expanding outside the traditional endemic areas and no LHF- specific vaccines or therapies.</p> <p>Researchers at NCI&rsquo;s Laboratory of Molecular Biology, in collaboration with the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases, developed and isolated six nanobodies with high binding affinity for the LASV envelop protein. Nanobodies are the smallest known antigen-binding fragments of antibodies. They have great potential as research tools and in medical applications due to their (1) small size, (2) high solubility, (3) thermal stability, (4) refolding capacity, and (5) relatively easy tissue penetration,.&nbsp;</p> <p>The nanobodies D5 and C3 show the most potent neutralizing activities. These nanobodies neutralized LASV Josiah pseduotyped virus when prepared in a bivalent IgG2a format as human IgG Fc-fusion. Overall, it is evident that the nanobodies can be used and developed into therapeutics that that neutralize Lassa virus.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutics against Lassa virus infection</li> <li>Lassa virus diagnostics (in vivo virus imaging)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>No LSV-specific vaccines or treatments</li> <li>First stabilized, soluble LASV glycoprotein trimer</li> <li>Nanobodies with high affinity for the LASV GPC trimer</li> <li>Nanobodies compete with 4 different groups of human neutralizing antibodies</li> <li>Nanobodies neutralize LASV when prepared in a human IgG Fc-fusion</li> </ul> 2022-04-12 2026-04-23 2022-04-12 2026-04-23 2022-04-12 antibodies, diagnostic, HO, LASSA, Lassa Hemorrhagic Fever, LHF, Nanobodies, Neutralizing, virus False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-04-12 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163277 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163276 Kwong, Peter NIH - NIAID NIAID Kwong, Peter (NIAID) 2 147163280 Duan, Zhijian NCI - CCR NCI Duan, Zhijian (NCI) 3 147163281 Sun, Yaping NCI - CCR NCI Sun, Yaping (NCI) 4 147163279 Cheung, Sao "Crystal" NIH - NIAID NIAID Cheung, Sao "Crystal" (NIAID) 5 147163278 Gorman, Jason NIH - NIAID NIAID Gorman, Jason (NIAID) 6 147163277 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163276 Kwong, Peter NIH - NIAID NIAID Kwong, Peter (NIAID) 2 147163280 Duan, Zhijian NCI - CCR NCI Duan, Zhijian (NCI) 3 147163281 Sun, Yaping NCI - CCR NCI Sun, Yaping (NCI) 4 147163279 Cheung, Sao "Crystal" NIH - NIAID NIAID Cheung, Sao "Crystal" (NIAID) 5 147163278 Gorman, Jason NIH - NIAID NIAID Gorman, Jason (NIAID) 6 147157986 Nanobodies Neutralizing Lassa Virus E-099-2021-0 Filing authorized NCI, NIAID 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4029] Nanobodies Neutralizing Lassa Virus&body=Please send me information about technology [TAB-4029] Nanobodies Neutralizing Lassa Virus.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4029] Nanobodies Neutralizing Lassa Virus&body=Please send me information about technology [TAB-4029] Nanobodies Neutralizing Lassa Virus.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161037 E-099-2021-0 E-099-2021-0-US-01 LASSA VIRUS-SPECIFIC NANOBODIES AND METHODS OF THEIR USE PRV US 63/181,519 Abandoned US <br />Provisional (PRV) 63/181,519<br />Filed on 2021-04-29<br />Status: Abandoned 147166111 E-099-2021-0 E-099-2021-0-PCT-02 LASSA VIRUS-SPECIFIC NANOBODIES AND METHODS OF THEIR USE PCT Patent Cooperation Treaty PCT/US2022/027082 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/027082<br />Filed on 2022-04-29<br />Status: Expired 147171405 antibodies 147171406 diagnostic 147171407 HO 147171408 LASSA 147171410 Lassa Hemorrhagic Fever 147171412 LHF 147171413 Nanobodies 147171414 Neutralizing 147171415 virus TAB-3568 114097423 Potency Assay for Membrane Transporter Protein-based Drugs Acting on Antioxidant, Redox, and Apoptosis Response Pathways NCI Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Trevor Broadt, Xiaoyi Yang <h2>Description of Technology:</h2> <p>This technology includes a method of analyzing the potency of membrane transporter protein-based drugs acting on intracellular antioxidant and redox response pathways (and associated apoptosis pathways), wherein the drug delivery and activity is lipid associated. The present invention is a cell-based bioassay for measuring the bioactivity of drug substance and formulated drug product by determining the drug&#39;s dose-dependent inhibitory effects on 4 hydroxynonenal (4-HNE)-induced antioxidant response element (ARE) activity. The present invention covers use of HEK293 ARE-Luc Stable cell line as the detection system, high-throughput 96-well format, drug dilution approach, enclosure of negative controls with non-relevant heterologous proteins, use of the stimulator 4-HNE, and the optimal measurement time points with the ARE luciferase reporter gene. This is also an effective method to make liposome-drug substance mixtures for assembly of drug substance proteins into cellular membranes by using premade empty liposomes as a drug delivery system.</p> This method standardizes the analysis of the potency of RLIP76-based drug substance and drug product in a dose-dependent manner during the manufacturing process, release, and stability monitoring of RLIP76 and similar molecules. Applications include potency analysis of drug substance and drug product of membrane transporter protein-based drugs, such as RLIP76, acting on antioxidant and redox response pathways during the process, release, and stability monitoring. 2022-08-01 2026-04-23 2026-04-23 2022-08-01 ACTING, ANTIOXIDANT, APOPTOSIS, assay, DRUGS, MEMBRANE, PATHWAYS, POTENCY, Protein-based, Redox, RESPONSE, TRANSPORTER, VPXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110830 Broadt, Trevor NCI - FCRDC (Leidos) Leidos Broadt, Trevor (Leidos) 0 114110829 Yang, Xiaoyi NCI - CCR Leidos Yang, Xiaoyi (Leidos) 1 114110829 Yang, Xiaoyi NCI - CCR Leidos Yang, Xiaoyi (Leidos) 1 114110830 Broadt, Trevor NCI - FCRDC (Leidos) Leidos Broadt, Trevor (Leidos) 0 114102677 Potency Assay For Membrane Transporter Protein-based Drugs Acting On Antioxidant, Redox, And Apoptosis Response Pathways E-225-2018-0 Filing authorized NCI 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3568] Potency Assay for Membrane Transporter Protein-based Drugs Acting on Antioxidant, Redox, and Apoptosis Response Pathways&body=Please send me information about technology [TAB-3568] Potency Assay for Membrane Transporter Protein-based Drugs Acting on Antioxidant, Redox, and Apoptosis Response Pathways. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3568] Potency Assay for Membrane Transporter Protein-based Drugs Acting on Antioxidant, Redox, and Apoptosis Response Pathways&body=Please send me information about technology [TAB-3568] Potency Assay for Membrane Transporter Protein-based Drugs Acting on Antioxidant, Redox, and Apoptosis Response Pathways.">sury.vepa@nih.gov</a><br> 114128772 VPXXXX 114128773 WIXXXX 114128774 WKXXXX 114153251 POTENCY 114153252 assay 114153253 MEMBRANE 114153254 TRANSPORTER 114153255 Protein-based 114153256 DRUGS 114153257 ACTING 114153258 ANTIOXIDANT 114153259 Redox 114153260 APOPTOSIS 114153261 RESPONSE 114153262 PATHWAYS TAB-3897 147157177 National Cancer Institute dosimetry system for Computed Tomography (NCICT) Computer Program NCI Infectious Disease, Licensing, Neurology, Oncology, Software / Apps Infectious Disease Licensing Neurology Oncology Software / Apps <h2>Description of Technology:</h2> <p>About half of the per capita dose of radiation due to medical exposures is provided by computed tomography (CT) examinations. Approximately 80 million CTs are performed annually in the United States. CT scans most commonly look for internal bleeding or clots, abscesses due to infection, tumors and internal structures. Although CT provides great patient benefit, concerns exist about potential associated risks from radiation doses &ndash; especially in pediatric patients more sensitive to radiation. Better understanding of the magnitude of radiation dose delivered during CT examinations is crucial to estimate risks and make an informed clinical decisions. However, calculating organ radiation doses to be delivered to patients is complicated.</p> <p>To address these challenges, Dr. Choonsik Lee from the NCI developed a novel computer program with a graphical user interface (GUI) to interactively estimate radiation dose to the organs of patients undergoing CT examinations. The computer program provides radiation dose to 30 different radiosensitive organs and tissues in the human body by using data entered by users. These data include patient characteristics (age and sex) and CT scan data (scanner model and technical parameters). The calculation algorithm in the program is based on multiple datasets with international standard, human anatomy, and dosimetry data. Potential users of this computer program would include radiologists, clinical/research medical physicists, physicians, epidemiologists and other medical professionals.</p> <p>The NCI dosimetry system for Computed Tomography (NCICT) successfully converts existing CT scanner output &ndash; very simple to obtain &ndash; into organ radiation doses. NCICT makes it possible for vendors to incorporate this software program into their patient dose-monitoring systems. The NCI seeks licensees interested in estimating radiation doses and potential risks to the organs of CT patients</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Radiation dose calculations for computed tomography examinations</li> <li>Components can be incorporated with NCIDose software into a commercial platform: NCICT program, computational human phantom series (human anatomy models, electronic files), CT scanner simulation model, and organ dose library (tabulated numbers)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Easily implemented within the existing commercial solutions</li> <li>Estimates organ doses for pediatric and adult patients with various body sizes and pregnant women</li> <li>Runs on standard Windows, Macintosh, and LINUX operating systems</li> </ul> Researchers at the NCI seek licensing for a novel computer program that converts existing CT scan output into organ radiation doses. 2023-05-14 2026-04-23 2023-05-14 2026-04-23 2023-05-14 • Computed Tomography, CT, CT Examination, Dosimetry, Lee, NCI dosimetry system for Computed Tomography, NCICT, Radiation, Radiation Dosing False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-05-14 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract E-125-2019 E-127-2023 147162303 Lee C, et al. NCICT: a computational solution to estimate organ doses for pediatric and adult patients undergoing CT scans https://pubmed.ncbi.nlm.nih.gov/26609995/ <a href="https://pubmed.ncbi.nlm.nih.gov/26609995/">Lee C, et al. NCICT: a computational solution to estimate organ doses for pediatric and adult patients undergoing CT scans</a> 155750673 National Cancer Institute Dosimetry System For Computed Tomography (NCICT) Computer Program E-082-2016-0 Research Material NCI, University of Florida 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-3897] National Cancer Institute dosimetry system for Computed Tomography (NCICT) Computer Program&body=Please send me information about technology [TAB-3897] National Cancer Institute dosimetry system for Computed Tomography (NCICT) Computer Program.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-3897] National Cancer Institute dosimetry system for Computed Tomography (NCICT) Computer Program&body=Please send me information about technology [TAB-3897] National Cancer Institute dosimetry system for Computed Tomography (NCICT) Computer Program.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147171020 • Computed Tomography 147171021 CT 147171023 CT Examination 147171024 Dosimetry 147171026 Lee 147171028 NCI dosimetry system for Computed Tomography 147171029 NCICT 147171030 Radiation 147171032 Radiation Dosing TAB-4472 151021715 A Protocol to Enhance Therapeutic Effects of Transcranial Magnetic Stimulation and the Methods to Realize It NIDA Collaboration, Licensing, Neurology, Therapeutics Collaboration Licensing Neurology Therapeutics Hanbing Lu, Qinglei Meng, Hieu Nguyen, Yihong Yang <h2>Summary:&nbsp;</h2> <p>The National Institute on Drug Abuse (NIDA) seeks research co-development partners and/or licensees for a high-powered electronic device and coil that delivers Transcranial Magnetic Stimulation (TMS) pulses as well as the software that controls the device for treating treatment resistant depression, substance use disorders and other CNS disorders.</p> <h2>Description of Technology:&nbsp;</h2> <p>Transcranial Magnetic Stimulation (TMS) is a non-invasive neuromodulation technique recently cleared by the FDA as a therapy for treatment-resistant major depression, obsessive-compulsive disorder (OCD) and nicotine addiction. Stimulation is produced by passing a brief, strong electric current through a coil placed in close proximity to the patient&rsquo;s head. The coil generates an electric field inside the patient&rsquo;s brain, exciting or inhibiting a targeted region. Repetitive high-frequency TMS at 10 Hz (rTMS) was the first protocol cleared by FDA for depression treatment, while Intermittent Theta Burst Stimulation (iTBS) is a newer protocol recently cleared by the FDA. The rTMS protocol requires 37.5 min per treatment session compared with only 190 seconds for iTBS &ndash; making iTBS much more tolerable to a patient. The therapeutic efficacy between these two protocols is non-distinguishable. However, given the high voltages and currents required in iTBS (e.g., 50 Hz instead of 10 Hz), it is more challenging to implement. In addition, clinical efficacy of TMS treatment overall has been relatively modest, with only about one-third of the patients responding well to the treatment. Enhancing TMS treatment efficacy is of great medical value and broad interest.</p> <p>Researchers at NIDA developed a novel TMS paradigm to enhance the effects of TMS treatment and, in addition, the machine to realize this paradigm. The invention allows specifying a variable number of pulses in each burst (e.g., up to 6 pulses per burst) and having an inter-burst interval of 200 ms (e.g., 5 Hz). The paradigm is based on iTBS but deliveries 6 pulses fixed per burst instead of 3. Thus, the number of TMS pulses delivered is effectively doubled in the same amount of time. Data from in vivo experiments using an awake rat model suggest that, compared with conventional iTBS protocol, this novel TMS paradigm enhance TMS after-effects by up to 92% versus conventional methods. This technology has the potential to greatly improve clinical outcomes of TMS treatment of depression and other neurological and/or psychiatric disorders.</p> <p>The National Institute on Drug Abuse (NIDA) seeks research co-development partners and/or licensees to further develop and commercialize this technology.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Enhanced TMS therapeutic for treatment resistant depression (MDD)</li> <li>Enhanced TMS therapeutic for treatment resistant obsessive-compulsive disorder (OCD)</li> <li>Enhanced TMS therapeutic for treatment resistant nicotine addiction</li> </ul> <h2>Competitive Advantage:</h2> <ul> <li>Novel TMS paradigm that can improve the outcome of TMS treatment</li> <li>The machine to deliver this paradigm has already been developed</li> <li>This technology delivers the high frequency pulses needed for TMS operations which occur at high current and high voltage (3000 Amperes and 2000 volts), which requires special expertise and is highly valuable</li> <li>This technology provides a new coil design, cooling, and fabrication strategy, and there is a need for new TMS coil development</li> <li>Prototypes have been developed for the technology and successfully validated in a rat modelc</li> </ul> Researchers at the NIDA seek licensing and/or co-development research collaborations for a high-powered electronic device and coil that delivers TMS pulses as well as the software that controls the device for treating treatment resistant depression and other CNS disorders. 2023-10-25 2026-04-23 2026-04-23 2023-10-26 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 151037341 Meng Q, Nguyen H, Vrana A, Baldwin S, Li CQ, Giles A, Wang J, Yang Y, Lu H. A high-density theta burst paradigm enhances the aftereffects of transcranial magnetic stimulation: Evidence from focal stimulation of rat motor cortex. Brain Stimulation. 2022;15(3):833-842. doi: 10.1016/j.brs.2022.05.017. PMID: 35636708 https://pubmed.ncbi.nlm.nih.gov/35636708/ <a href="https://pubmed.ncbi.nlm.nih.gov/35636708/">Meng Q, Nguyen H, Vrana A, Baldwin S, Li CQ, Giles A, Wang J, Yang Y, Lu H. A high-density theta burst paradigm enhances the aftereffects of transcranial magnetic stimulation: Evidence from focal stimulation of rat motor cortex. Brain Stimulation. 2022;15(3):833-842. doi: 10.1016/j.brs.2022.05.017. PMID: 35636708</a> 151037155 Lu, Hanbing NIDA - Biomedical Research Center NIDA Lu, Hanbing (NIDA) 1 151037163 Meng, Qinglei NIDA - Biomedical Research Center Meng, Qinglei 2 151037318 Nguyen, Hieu NIDA - Biomedical Research Center Nguyen, Hieu 3 151037326 Yang, Yihong NIDA - Biomedical Research Center NIDA Yang, Yihong (NIDA) 4 151037155 Lu, Hanbing NIDA - Biomedical Research Center NIDA Lu, Hanbing (NIDA) 1 151037163 Meng, Qinglei NIDA - Biomedical Research Center Meng, Qinglei 2 151037318 Nguyen, Hieu NIDA - Biomedical Research Center Nguyen, Hieu 3 151037326 Yang, Yihong NIDA - Biomedical Research Center NIDA Yang, Yihong (NIDA) 4 151021718 A Protocol To Enhance Therapeutic Effects Of Transcranial Magnetic Stimulation And The Methods To Realize It E-183-2021-0 Filing authorized National Institute on Drug Abuse (NIDA) 91828357 Bernier, Nicholas nicholas.bernier@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America nicholas.bernier@nih.gov?subject=Web Inquiry on [TAB-4472] A Protocol to Enhance Therapeutic Effects of Transcranial Magnetic Stimulation and the Methods to Realize It&body=Please send me information about technology [TAB-4472] A Protocol to Enhance Therapeutic Effects of Transcranial Magnetic Stimulation and the Methods to Realize It.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Bernier, Nicholas<br><a href="mailto:nicholas.bernier@nih.gov?subject=Web Inquiry on [TAB-4472] A Protocol to Enhance Therapeutic Effects of Transcranial Magnetic Stimulation and the Methods to Realize It&body=Please send me information about technology [TAB-4472] A Protocol to Enhance Therapeutic Effects of Transcranial Magnetic Stimulation and the Methods to Realize It.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">nicholas.bernier@nih.gov</a><br> 151037347 E-183-2021-0 E-183-2021-0-US-01 PROTOCOL TO ENHANCE THERAPEUTIC EFFECTS OF TRANSCRANIAL MAGNETIC STIMULATION PRV US 63/286,229 Expired US <br />Provisional (PRV) 63/286,229<br />Filed on 2021-12-06<br />Status: Expired 151037354 E-183-2021-0 E-183-2021-0-US-02 PROTOCOL TO ENHANCE THERAPEUTIC EFFECTS OF TRANSCRANIAL MAGNETIC STIMULATION ORD US 18/076,071 Pending US <br />Ordinary Patent (ORD) 18/076,071<br />Filed on 2022-12-06<br />Status: Pending TAB-5010 158185969 Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation NICHD Collaboration, Infectious Disease, Licensing, Medical Devices, Neurology, Respiratory Collaboration Infectious Disease Licensing Medical Devices Neurology Respiratory Amir Gandjbakhche, Brian Hill, Thien Nguyen, Soongho Park <h2>Summary:</h2> <p>The National Institute of Child Health and Human Development (NICHD) seeks partners and/or licensees to further develop and commercialize the miniaturized tissue oximeter for implementing the single source-detector separation algorithm in existing devices/systems to collect tissue oxygen saturation.</p> <h2>Description of Technology:&nbsp;</h2> <p>Tissue oxygen saturation (StO2) is an important parameter to assess oxygen delivery and uptake. Hypoxia, a term used to indicate inadequate StO2, is often seen in patients with cardiac problems, respiratory infections or pulmonary diseases. Prolonged hypoxia can damage vital organs such as the brain, lungs, and heart, and can be fatal. Currently available tissue oximeters to monitor StO2 are expensive and cumbersome.&nbsp;</p> <p>The National Institute of Child Health and Human Development (NICHD) has developed a novel method, which uses a single source-detector separation to calculate StO2. With this technique, a simple tissue oximeter can be made with just a LED and a photodetector, which enables the development of a miniaturized device. As a result, it can be used independently or implemented on existing technologies to measure StO2 without any hardware modifications. It can be applied in wearable devices, implantable medicines or endoscopies to measure tissue oxygenation in different tissues such as muscle, brain, spinal cord, internal organs, fetus and placenta.&nbsp;</p> <p>The NICHD seeks partners and/or licensees to further develop and commercialize the miniaturized tissue oximeter for implementing the single source-detector separation algorithm in existing devices/systems to collect tissue oxygen saturation.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Miniaturized tissue oximeter for implantation or endoscopy</li> <li>Measure tissue oxygen saturation</li> <li>Multilayer tissue oximeter</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Simpler and more compact as it only requires a single light source such as LED and a single photodetector such as a photodetector to build a tissue oximeter</li> <li>Multilayer measurement</li> <li>Implementation with existing technologies without any hardware modifications</li> </ul> Researchers at the NICHD seek licensing and/or co-development research collaborations for the miniaturized tissue oximeter for implementing the single source-detector separation algorithm in existing devices/systems to collect tissue oxygen saturation. 2024-09-13 2026-04-23 2026-04-23 2024-09-13 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 158186553 Nguyen, T., et al. Application of the Single Source—Detector Separation Algorithm in Wearable Neuroimaging Devices: A Step toward Miniaturized Biosensor for Hypoxia Detection. (PMID 38671806) https://pubmed.ncbi.nlm.nih.gov/38671806/ <a href="https://pubmed.ncbi.nlm.nih.gov/38671806/">Nguyen, T., et al. Application of the Single Source—Detector Separation Algorithm in Wearable Neuroimaging Devices: A Step toward Miniaturized Biosensor for Hypoxia Detection. (PMID 38671806)</a> 166884104 Nguyen, T., et al. Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation Using Continuous Wave Near-infrared Spectroscopy. (DOI 10.1109/OJEMB.2023.3246929) Nguyen, T., et al. Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation Using Continuous Wave Near-infrared Spectroscopy. (DOI 10.1109/OJEMB.2023.3246929) 158186011 Nguyen, Thien NICHD NICHD Nguyen, Thien (NICHD) 1 158186023 Gandjbakhche, Amir NICHD NICHD Gandjbakhche, Amir (NICHD) 2 158434152 Park, Soongho National Heart and Lung Institute (Imperial College London; ICKL) [GB] NICHD Park, Soongho (NICHD) 3 158186178 Hill, Brian NICHD NICHD Hill, Brian (NICHD) 4 158186011 Nguyen, Thien NICHD NICHD Nguyen, Thien (NICHD) 1 158186023 Gandjbakhche, Amir NICHD NICHD Gandjbakhche, Amir (NICHD) 2 158434152 Park, Soongho National Heart and Lung Institute (Imperial College London; ICKL) [GB] NICHD Park, Soongho (NICHD) 3 158186178 Hill, Brian NICHD NICHD Hill, Brian (NICHD) 4 158185972 Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation E-037-2023-0 Filing authorized NICHD 91827321 Jinnah, Zarpheen zarpheen.jinnah@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-5010] Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation&body=Please send me information about technology [TAB-5010] Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Jinnah, Zarpheen<br><a href="mailto:zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-5010] Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation&body=Please send me information about technology [TAB-5010] Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">zarpheen.jinnah@nih.gov</a><br> 162828523 E-037-2023-0 E-037-2023-0-US-01 Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation PRV US 63/434,827 Expired US <br />Provisional (PRV) 63/434,827<br />Filed on 2022-12-22<br />Status: Expired 162828524 E-037-2023-0 E-037-2023-0-PC-01 Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation PCT Patent Cooperation Treaty PCT/US2023/085725 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/085725<br />Filed on 2023-12-22<br />Status: Expired 162828525 E-037-2023-0 E-037-2023-0-US-02 SINGLE SOURCE-DETECTOR SEPARATION APPROACH TO CALCULATE TISSUE OXYGEN SATURATION National Stage US 19/140,070 Pending US <br />National Stage 19/140,070<br />Filed on 2025-06-17<br />Status: Pending TAB-5093 166506999 Neutralizing Antibodies Against West Nile Virus NIAID Application, Diagnostics, ResearchProducts, TherapeuticArea, Vaccines, Virus/Bacteria Application Diagnostics ResearchProducts TherapeuticArea Vaccines Virus/Bacteria Daniel Douek, Kimberly Dowd, Dror Harats, Yaniv Lustig, Yael Ottolenghi, Theodore Pierson, Gili Regev-Yochay <p>&nbsp; &nbsp; &nbsp; &nbsp;West Nile virus (WNV) is a mosquito-borne virus that can cause severe disease affecting the brain and nervous system, especially in older adults and people with weakened immune systems. There is no approved human vaccine or specific antiviral treatment for WNV.</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Researchers at NIAID&rsquo;s Vaccine Research Center (VRC), together with collaborators at Sheba Medical Center and the Israeli Ministry of Health, have identified and characterized seven new fully human monoclonal antibodies that bind to the WNV envelope (E) protein&mdash;the main surface protein the virus uses to enter cells. In laboratory studies, these antibodies (AIS-196, AIS-204, AIS-259, AIS-260, AIS-261, AIS-262, and AIS-265) strongly blocked WNV infection, and several also showed protective effects in a mouse model.</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The invention includes the antibody sequences and tools needed to produce them, supporting development of full-length antibody therapies or smaller antibody fragments. These antibodies could help prevent WNV disease in people at higher risk or treat infection early, either individually or in combination. Modified versions are also included that may extend how long the antibodies remain active in the body or adjust how they interact with the immune system. The antibodies may also be useful in laboratory tests for WNV diagnosis, surveillance, and research.</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <ul> <li> An antibody-based approach for WNV prevention or treatment, given the lack of an approved human vaccine, specific antiviral treatment, or licensed antibody therapy </li> <li> Strong virus-neutralizing activity </li> <li> Fully human antibodies, which are less likely to cause anti-drug immune responses than non-human or humanized antibodies </li> <li> Engineered versions that may last longer in the body and tune immune activity to improve safety and effectiveness </li> <li> High-quality antibodies that support WNV prevention or treatment and can also be used in diagnostic tests, public health surveillance, and research </li> </ul> <ul> <li> Prevention or treatment antibodies for WNV, especially for people at higher risk of severe disease or after a known exposure </li> <li> Fully human antibodies that strongly neutralize virus infection by targeting its key surface E protein </li> <li> Flexible formats for different uses, including full-length antibodies or antibody fragments, and the option to use a single antibody or a combination (“cocktail") </li> <li> Engineered versions designed to last longer in the body and tune immune functions for safety and performance </li> <li> High-quality antibodies for WNV testing and surveillance, supporting laboratory detection, public health monitoring, and research </li> <li> Neutralizing antibodies as components of delivery systems for prophylactic or therapeutic applications </li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Brian Bailey at 240-669-5128, or bbailey@mail.nih.gov. 2026-03-19 2026-04-23 2026-04-23 2026-04-22 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract E-200-2024-0 166507438 Pierson, Theodore NIAID - VRC NIAID Pierson, Theodore (NIAID) 1 166507460 Dowd, Kimberly NIAID - VRC NIAID Dowd, Kimberly (NIAID) 2 166507484 Douek, Daniel National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Douek, Daniel (NIAID) 3 166507488 Harats, Dror Sheba Medical Center Harats, Dror 4 166507496 Ottolenghi, Yael The Sheba Fund for Health Services & Research (Sheba Medical Center) [IL] Ottolenghi, Yael 5 166507500 Regev-Yochay, Gili The Sheba Fund for Health Services & Research (Sheba Medical Center) [IL] Regev-Yochay, Gili 6 166507516 Lustig, Yaniv Israel Ministry of Health [IL] Lustig, Yaniv 7 166507438 Pierson, Theodore NIAID - VRC NIAID Pierson, Theodore (NIAID) 1 166507460 Dowd, Kimberly NIAID - VRC NIAID Dowd, Kimberly (NIAID) 2 166507484 Douek, Daniel National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Douek, Daniel (NIAID) 3 166507488 Harats, Dror Sheba Medical Center Harats, Dror 4 166507496 Ottolenghi, Yael The Sheba Fund for Health Services & Research (Sheba Medical Center) [IL] Ottolenghi, Yael 5 166507500 Regev-Yochay, Gili The Sheba Fund for Health Services & Research (Sheba Medical Center) [IL] Regev-Yochay, Gili 6 166507516 Lustig, Yaniv Israel Ministry of Health [IL] Lustig, Yaniv 7 166507002 Neutralizing antibodies against West Nile virus E-021-2026-0 Filing authorized Israel Ministry of Health [IL], National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID - VRC, Sheba Medical Center, The Sheba Fund for Health Services & Research (Sheba Medical Center) [IL] 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-5093] Neutralizing Antibodies Against West Nile Virus&body=Please send me information about technology [TAB-5093] Neutralizing Antibodies Against West Nile Virus. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-5093] Neutralizing Antibodies Against West Nile Virus&body=Please send me information about technology [TAB-5093] Neutralizing Antibodies Against West Nile Virus.">bbailey@mail.nih.gov</a><br> 166507058 E-021-2026-0 E-021-2026-0-US-01 Neutralizing antibodies against West Nile Virus PRV US 63/991,485 Pending US <br />Provisional (PRV) 63/991,485<br />Filed on 2026-02-26<br />Status: Pending TAB-4995 157267387 Using Artificial Intelligence To Predict The Risk Of Age-Related Macular Degeneration NEI Collaboration, Diagnostics, Ear, Nose, & Throat, Licensing Collaboration Diagnostics Ear Nose & Throat Licensing Elvira Agron, Qingyu Chen, Emily Chew, Tiarnan Keenan, Zhiyong Lu, Wai Wong <h2>Summary:&nbsp;</h2> <p>The National Eye Institute seeks research co-development partners and/or licensees for a deep learning algorithm that can predict the probability of progression to late age-related macular degeneration.</p> <h2>Description of Technology:&nbsp;</h2> <p>In 2024, an estimated 200 million people worldwide suffer from age-related macular degeneration (AMD); projected to affect ~288 million people by 2040. AMD is the leading cause of blindness in all developed countries. Identifying eyes at high risk of progression to late AMD, the stage associated with blindness, is vital. This would allow timely medical treatments, lifestyle interventions, more tailored home monitoring and improved clinical trials for patients.</p> <p>Reticular pseudodrusen (RPD) is an AMD disease feature recently discovered to confer greatly increased risk of progression to late AMD. However, RPD is often very difficult to detect on clinical examination or on color fundus photography (CFP). Detection usually requires specialized imaging (especially fundus autofluorescence) and highly expert grading typically available at few specialized centers. For these reasons, RPD have not been incorporated into AMD risk classification systems.</p> <p>We used Artificial Intelligence (AI) to predict the risk of progression to late AMD using over 80,000 images from almost 3300 participants from the Age-Related Eye Disease Studies AREDS and AREDS2. Using independent test data, our deep learning algorithm produced 5% higher prognostic accuracy compared to existing clinical standards. The predictive accuracy of the new approach was 5% higher than that of the two traditional approaches ((i) AREDS Simplified Severity Scale, and (ii) the Casey AMD online calculator). Our approach can make predictions over a wide range of time intervals (1-12 years), and separately for the two subtypes of late AMD (geographic and neovascular AMD). In contrast, the AREDS Simplified Severity Scale can make predictions at one fixed interval only (5 years), and for late AMD only (not separately by subtype). By separating the deep learning extraction of retinal features from the survival analysis, the final predictions are more explainable and biologically plausible, and error analysis is possible. By contrast, end-to-end &lsquo;black-box&rsquo; deep learning approaches are less transparent and may be more susceptible to failure<br /> A fully automated device that contains this novel image processing method has also been developed.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Diagnostic tool predicting risk of AMD</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Widely available via device&nbsp;</li> <li>Fully automated analysis of the CFP and no requirement for human grading of the CFP, either by retinal specialists or by reading center experts</li> <li>More predictive, accurate approach compared using the same test set of AREDS and AREDS2 participants&nbsp;</li> <li>Predictive over a wide range of time intervals (1-12 years) and separately for the two subtypes of late AMD (geographic and neovascular AMD)&nbsp;</li> <li>Two-step method separates the deep learning extraction of retinal features from the survival analysis</li> <li>Two-step method produces final predictions that are more explainable and biologically plausible</li> <li>Error analysis&nbsp;</li> <li>Our approach has the advantage of not requiring genetic information to provide a high level of predictive accuracy<br /> &nbsp;</li> </ul> Researchers at the NEI seek licensing and/or co-development research collaborations for a deep learning algorithm that can predict the probability of progression to late age-related macular degeneration. 2024-07-23 2026-04-16 2026-04-16 2024-07-23 False True prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 157267554 Keenan, et al. Deep Learning Automated Detection of Reticular Pseudodrusen from Fundus Autofluorescence Images or Color Fundus Photographs in AREDS2. (PMID 32447042) https://pubmed.ncbi.nlm.nih.gov/32447042/ <a href="https://pubmed.ncbi.nlm.nih.gov/32447042/">Keenan, et al. Deep Learning Automated Detection of Reticular Pseudodrusen from Fundus Autofluorescence Images or Color Fundus Photographs in AREDS2. (PMID 32447042)</a> 166884053 Peng, et al. Predicting risk of late age-related macular degeneration using deep learning. (PMID 32904246) https://pubmed.ncbi.nlm.nih.gov/32904246/ <a href="https://pubmed.ncbi.nlm.nih.gov/32904246/">Peng, et al. Predicting risk of late age-related macular degeneration using deep learning. (PMID 32904246)</a> 166884056 Chen, et al. Multimodal, multitask, multiattention (M3) deep learning detection of reticular pseudodrusen: Toward automated and accessible classification of age-related macular degeneration. (PMID 33792724) https://pubmed.ncbi.nlm.nih.gov/33792724/ <a href="https://pubmed.ncbi.nlm.nih.gov/33792724/">Chen, et al. Multimodal, multitask, multiattention (M3) deep learning detection of reticular pseudodrusen: Toward automated and accessible classification of age-related macular degeneration. (PMID 33792724)</a> 157267522 Chew, Emily National Eye Institute (NEI) NEI Chew, Emily (NEI) 1 157267526 Lu, Zhiyong NLM NLM Lu, Zhiyong (NLM) 2 157267530 Keenan, Tiarnan National Eye Institute (NEI) NEI Keenan, Tiarnan (NEI) 3 157267534 Wong, Wai National Eye Institute (NEI) NEI Wong, Wai (NEI) 4 157267542 Chen, Qingyu NLM NLM Chen, Qingyu (NLM) 5 157267546 Agron, Elvira National Eye Institute (NEI) NEI Agron, Elvira (NEI) 6 157267522 Chew, Emily National Eye Institute (NEI) NEI Chew, Emily (NEI) 1 157267526 Lu, Zhiyong NLM NLM Lu, Zhiyong (NLM) 2 157267530 Keenan, Tiarnan National Eye Institute (NEI) NEI Keenan, Tiarnan (NEI) 3 157267534 Wong, Wai National Eye Institute (NEI) NEI Wong, Wai (NEI) 4 157267542 Chen, Qingyu NLM NLM Chen, Qingyu (NLM) 5 157267546 Agron, Elvira National Eye Institute (NEI) NEI Agron, Elvira (NEI) 6 157267390 Method And System Of Building A Data-base And Models For Determining The Presence Of Reticular Pseudodrusen (RPD) Associated With Age-Related Macular Degeneration (AMD) Using Fundus Autofluorescence And/or Color Fundus Photos E-057-2020-0 Filing authorized National Eye Institute (NEI), NLM 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4995] Using Artificial Intelligence To Predict The Risk Of Age-Related Macular Degeneration&body=Please send me information about technology [TAB-4995] Using Artificial Intelligence To Predict The Risk Of Age-Related Macular Degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4995] Using Artificial Intelligence To Predict The Risk Of Age-Related Macular Degeneration&body=Please send me information about technology [TAB-4995] Using Artificial Intelligence To Predict The Risk Of Age-Related Macular Degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 157267585 E-057-2020-0 E-057-2020-0-US-01 METHODS AND SYSTEMS FOR PREDICTING RATES OF PROGRESSION OF AGE-RELATED MACULAR DEGENERATION PRV US 62/978,070 Abandoned US <br />Provisional (PRV) 62/978,070<br />Filed on 2020-02-18<br />Status: Abandoned 164119882 E-057-2020-0 E-057-2020-0-PCT-02 METHODS AND SYSTEMS FOR PREDICTING RATES OF PROGRESSION OF AGE-RELATED MACULAR DEGENERATION PCT Patent Cooperation Treaty PCT/US2021/018589 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/018589<br />Filed on 2021-02-18<br />Status: Expired 164119883 E-057-2020-0 E-057-2020-0-AU-03 METHODS AND SYSTEMS FOR PREDICTING RATES OF PROGRESSION OF AGE-RELATED MACULAR DEGENERATION National Stage Australia 2021224660 Pending Australia <br />National Stage 2021224660<br />Filed on 2021-02-18<br />Status: Pending 164119884 E-057-2020-0 E-057-2020-0-CA-04 METHODS AND SYSTEMS FOR PREDICTING RATES OF PROGRESSION OF AGE-RELATED MACULAR DEGENERATION National Stage Canada 3177173 Pending Canada <br />National Stage 3177173<br />Filed on 2021-02-18<br />Status: Pending 164119885 E-057-2020-0 E-057-2020-0-EP-05 METHODS AND SYSTEMS FOR PREDICTING RATES OF PROGRESSION OF AGE-RELATED MACULAR DEGENERATION National Stage European Patent 21711144.2 Pending European Patent <br />National Stage 21711144.2<br />Filed on 2021-02-18<br />Status: Pending 164119886 E-057-2020-0 E-057-2020-0-US-06 Method and Systems for Predicting Rates of Progression of Age-Related Macular Degeneration National Stage US 17/904,573 Pending US <br />National Stage 17/904,573<br />Filed on 2022-08-18<br />Status: Pending TAB-4211 147157496 Single Domain Antibodies targeting HPV E6/E7 Oncogenic Peptide/MHC complexes NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Zhijian Duan, Christian Hinrichs, Mitchell Ho <h2>Description of Technology:</h2> <p>Human papillomavirus (HPV) has been linked to many cancers including cervix, uterine, anus, vulva, vagina, and penis. Although HPV vaccines exist to prevent HPV-associated cancers, there are still more than 5,000 deaths caused by HPV-associated cancers each year in the US and cervical cancer continues to be the second leading cause of cancer death in women ages 20 to 39. Engineered T cell receptor (TCR) therapy has been effective in some patients with HPV16 E6 expressing cancers, however, there continues to be a need for more therapies targeting HPV16 E6, when current treatment options fail.&nbsp;</p> <p>NCI inventors have identified two nanobodies (F5 and G9) against MHC/E6 by phage display technologies from the lab&rsquo;s multiple dromedary camel VHH single domain libraries. F5 and G9 could recognize the MHC/E6 complex more specifically over the control nanobodies. CAR T cells using the F5 nanobody as the binding domain showed specific killing of the target tumor cells in mouse models. These nanobodies could potentially treat cancers associated with the expression of HPV16 E6.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic applications include the unconjugated antibodies and their use as a targeting moiety for CARs, TCRs, RITs, ADCs, immunocytokines and bispecific antibodies</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>These anti- HPV E6/E7 nanobodies have an advantage, due to their small size, to potentially bind to epitopes unavailable to more conventional antibodies or TCRs</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for Single Domain Antibodies targeting HPV E6/E7 Oncogenic Peptide/MHC complexes 2023-04-03 2026-04-16 2023-04-03 2026-04-16 2023-04-03 adoptive cell therapy, HO, HPV16, Immunotherapy, NANOBODY, T Cell Receptor False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-04-03 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163925 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163927 Duan, Zhijian NCI - CCR NCI Duan, Zhijian (NCI) 2 147163926 Hinrichs, Christian NIH - Rutgers Cancer Institute of New Jersey Hinrichs, Christian 3 147163925 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163927 Duan, Zhijian NCI - CCR NCI Duan, Zhijian (NCI) 2 147163926 Hinrichs, Christian NIH - Rutgers Cancer Institute of New Jersey Hinrichs, Christian 3 147158133 Single Domain Antibodies Targeting HPV E6/E7 Oncogenic Peptide/MHC Complexes E-169-2022-0 Filing authorized NCI, Rutgers Cancer Institute of New Jersey 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4211] Single Domain Antibodies targeting HPV E6/E7 Oncogenic Peptide/MHC complexes&body=Please send me information about technology [TAB-4211] Single Domain Antibodies targeting HPV E6/E7 Oncogenic Peptide/MHC complexes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4211] Single Domain Antibodies targeting HPV E6/E7 Oncogenic Peptide/MHC complexes&body=Please send me information about technology [TAB-4211] Single Domain Antibodies targeting HPV E6/E7 Oncogenic Peptide/MHC complexes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147167370 E-169-2022-0 E-169-2022-0-US-01 Single Domain Antibodies Targeting HPV E6/E7 Oncogenic Peptide/MHC Complexes PRV US 63/374,307 Expired US <br />Provisional (PRV) 63/374,307<br />Filed on 2022-09-01<br />Status: Expired 147167371 E-169-2022-0 E-169-2022-0-PC-01 Single Domain Antibodies Targeting HPV E6/E7 Oncogenic Peptide/MHC Complexes PCT Patent Cooperation Treaty PCT/US2023/073144 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/073144<br />Filed on 2023-08-30<br />Status: Expired 147172911 adoptive cell therapy 147172912 HO 147172913 HPV16 147172914 Immunotherapy 147172915 NANOBODY 147172916 T Cell Receptor TAB-4088 147157370 High-Throughput Assay for Detection and Monitoring of Endocrine Disrupting Chemicals in Water Sources NCI Collaboration, Diagnostics, Endocrinology, Licensing Collaboration Diagnostics Endocrinology Licensing <h2>Description of Technology:</h2> <p>There is growing awareness that a wide variety of synthetic and natural compounds that may be present in water sources, such as streams, wells, and ground water, may lead to adverse health effects, including increased cancer risk. Even low concentrations of these compounds are of concern, as they may have biological effects at concentrations of parts per billion or less. In particular, the presence of endocrine disrupting chemicals (EDCs) in the environment is under examination for potential adverse effects on human health, such as immune suppression, impaired fertility, and increased incidence of cancer, diabetes, and obesity. However, these compounds are often laborious and difficult to measure and thus are not commonly monitored. In addition, even if such compounds are detected, only the known compound itself is typically measured, neglecting its metabolites which are more likely to be found in water samples and retain endocrine disrupting activity.&nbsp;</p> <p>Inventors at the NCI&rsquo;s Laboratory of Receptor Biology and Gene Expression have developed a novel assay methodology for detecting EDCs in contaminated water. The assay utilizes fluorescently labeled nuclear steroid receptor constructs in a high-throughput, mammalian cell-based format. Detection and measurements are based on translocation of the fluorescent marker from the cytoplasm to the nucleus in the presence of a ligand that interacts with a specific steroid receptor. Overall, this assay has the capability to detect very low concentrations of EDCs in water or other liquid samples. The inventors have demonstrated proof of concept for this technology by testing for the presence of Glucocorticoid Receptor (GR), Androgen Receptor (AR), Estrogen Receptor (ER), Aryl hydrocarbon receptor (AhR), Progesterone Receptor (PR), and Thyroid Hormone Receptor (TR) activity in water samples. For example, NCI scientists screened water samples collected from 14 states in the US and found AR activity in 35% of samples, as well as previously unrecognized glucocorticoid (GC) activity in 27% of the samples. In particular, the compound androst-4-en-3,6-dione was identified in one of the samples. AR-dependent nuclear translocation and transcriptional activation was also confirmed for two AR-responsive genes, NKX3.1 and RHOU. Moreover, NKX3.1 is a homeobox gene frequently deleted in prostate cancers, and RHOU is implicated in epidermal growth factor receptor signaling and cell migration.&nbsp;</p> <p>A product or service based on this technology could fulfill an unmet need for a high-throughput, rapid method for screening multiple water samples for contaminants with potential endocrine-disrupting activity. The NCI is seeking co-development partners and/or licensees for this technology as a product or service for detecting and screening for endocrine disrupting chemicals in water samples.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Water source testing</li> <li>Wastewater testing</li> <li>Drug ligand screening for agonistic and antagonistic activity</li> <li>Research tool to detect known and orphan receptor activity</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>High-throughput and rapid testing&nbsp;</li> <li>High sensitivity and selectivity</li> <li>Readily adaptable for use with a variety of endocrine receptor targets</li> <li>Can detect many EDC variants modified in the environment or other compounds that may act and interfere like EDCs&nbsp;</li> <li>Does not require a priori knowledge of the ligand chemical structure&nbsp;</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a product or service for detecting and screening for endocrine disrupting chemicals (EDCs) in samples from water sources and/or wastewater. 2023-03-02 2026-04-16 2023-03-13 2026-04-16 2023-03-02 EDC detection, EDCs, Endocrine disrupting chemicals, Endocrine disruption screening, Endocrine receptor ligand screening, Hager, Hormone receptor activity, Stavreva, Wastewater, Water sources False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-03-13 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147161899 Bruno NE, et al. Chemical systems biology reveals mechanisms of glucocorticoid receptor signaling. https://pubmed.ncbi.nlm.nih.gov/33510451/ <a href="https://pubmed.ncbi.nlm.nih.gov/33510451/">Bruno NE, et al. Chemical systems biology reveals mechanisms of glucocorticoid receptor signaling.</a> 147162015 Stavreva DA, et al. Novel cell-based assay for detection of thyroid receptor beta-interacting environmental contaminants. https://pubmed.ncbi.nlm.nih.gov/27528272/ <a href="https://pubmed.ncbi.nlm.nih.gov/27528272/">Stavreva DA, et al. Novel cell-based assay for detection of thyroid receptor beta-interacting environmental contaminants.</a> 147162054 Jones RR, et al. Pilot study of global endocrine disrupting activity in Iowa public drinking water utilities using cell-based assays. https://pubmed.ncbi.nlm.nih.gov/32018941/ <a href="https://pubmed.ncbi.nlm.nih.gov/32018941/">Jones RR, et al. Pilot study of global endocrine disrupting activity in Iowa public drinking water utilities using cell-based assays.</a> 147162093 Stavreva DA, et al. Prevalent contamination of U.S. water sources with biologically active steroids. https://pubmed.ncbi.nlm.nih.gov/23226835/ <a href="https://pubmed.ncbi.nlm.nih.gov/23226835/">Stavreva DA, et al. Prevalent contamination of U.S. water sources with biologically active steroids.</a> 147162171 Paul-Friedman K, et al. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. https://pubmed.ncbi.nlm.nih.gov/31566444/ <a href="https://pubmed.ncbi.nlm.nih.gov/31566444/">Paul-Friedman K, et al. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library.</a> 147162249 Varticovski L, et al. Endocrine disruptors of sex hormone activities. https://pubmed.ncbi.nlm.nih.gov/34339825/ <a href="https://pubmed.ncbi.nlm.nih.gov/34339825/">Varticovski L, et al. Endocrine disruptors of sex hormone activities.</a> 147162287 Bradley PM, et al. Juxtaposition of intensive agriculture, vulnerable aquifers, and mixed chemical/microbial exposures in private-well tap water in northeast Iowa. https://pubmed.ncbi.nlm.nih.gov/36657670/ <a href="https://pubmed.ncbi.nlm.nih.gov/36657670/">Bradley PM, et al. Juxtaposition of intensive agriculture, vulnerable aquifers, and mixed chemical/microbial exposures in private-well tap water in northeast Iowa.</a> 147162326 Stavreva DA, et al. Mapping multiple endocrine disrupting activities in Virginia rivers using effect-based assays. https://pubmed.ncbi.nlm.nih.gov/33592464/ <a href="https://pubmed.ncbi.nlm.nih.gov/33592464/">Stavreva DA, et al. Mapping multiple endocrine disrupting activities in Virginia rivers using effect-based assays.</a> 147162440 Lynch C, et al. Identifying environmental chemicals as agonists of the androgen receptor by using a quantitative high-throughput screening platform. https://pubmed.ncbi.nlm.nih.gov/28478275/ <a href="https://pubmed.ncbi.nlm.nih.gov/28478275/">Lynch C, et al. Identifying environmental chemicals as agonists of the androgen receptor by using a quantitative high-throughput screening platform.</a> 155750804 A Living Cell Fluorescence Assay For Detection And Monitoring Of Endocrine Disrupting Chemicals In Water Sources E-269-2011-0 Filing authorized NCI 91826910 McCrary, Michaela michaela.mccrary@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4088] High-Throughput Assay for Detection and Monitoring of Endocrine Disrupting Chemicals in Water Sources&body=Please send me information about technology [TAB-4088] High-Throughput Assay for Detection and Monitoring of Endocrine Disrupting Chemicals in Water Sources.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov McCrary, Michaela<br><a href="mailto:michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4088] High-Throughput Assay for Detection and Monitoring of Endocrine Disrupting Chemicals in Water Sources&body=Please send me information about technology [TAB-4088] High-Throughput Assay for Detection and Monitoring of Endocrine Disrupting Chemicals in Water Sources.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michaela.mccrary@nih.gov</a><br> 155750809 E-269-2011-0 E-269-2011-0-US-01 Kits For Detecting And Monitoring Endocrine Disrupting Chemicals (EDCs) PRV US 61/656,473 Abandoned US <br />Provisional (PRV) 61/656,473<br />Filed on 2012-06-06<br />Status: Abandoned 155750810 E-269-2011-0 E-269-2011-0-PCT-02 KITS FOR DETECTING AND MONITORING ENDOCRINE DISRUPTING CHEMICALS (EDCS) PCT Patent Cooperation Treaty PCT/US2013/044569 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/044569<br />Filed on 2013-06-06<br />Status: Expired 155750811 E-269-2011-0 E-269-2011-0-US-03 KITS FOR DETECTING AND MONITORING ENDOCRINE DISRUPTING CHEMICALS (EDCS) ORD US 9,040,248 13/912,071 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9040248 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9040248">9,040,248</a><br />Filed on 2013-06-06<br />Status: Issued 155750812 E-269-2011-0 E-269-2011-0-EP-04 KITS FOR DETECTING AND MONITORING ENDOCRINE DISRUPTING CHEMICALS (EDCS) National Stage European Patent 13730754.2 Abandoned European Patent <br />National Stage 13730754.2<br />Filed on 2013-06-06<br />Status: Abandoned 155750813 E-269-2011-0 E-269-2011-0-JP-05 KITS FOR DETECTING AND MONITORING ENDOCRINE DISRUPTING CHEMICALS (EDCS) National Stage Japan 6388575 2015-516223 Issued Japan <br />National Stage 2015-516223<br />Filed on 2014-12-05<br />Status: Issued 155750814 E-269-2011-0 E-269-2011-0-US-06 KITS FOR DETECTING AND MONITORING ENDOCRINE DISRUPTING CHEMICALS (EDCS) National Stage US 14/405,696 Abandoned US <br />National Stage 14/405,696<br />Filed on 2014-12-04<br />Status: Abandoned 155750815 E-269-2011-0 E-269-2011-0-US-07 METHODS FOR DETECTING AND MONITORING ENDOCRINE DISRUPTING CHEMICALS (EDCS) CON US 9,921,211 14/693,511 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9921211 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9921211">9,921,211</a><br />Filed on 2015-04-22<br />Status: Issued 155750816 E-269-2011-0 E-269-2011-0-JP-08 KITS FOR DETECTING AND MONITORING ENDOCRINE DISRUPTING CHEMICALS (EDCS) DIV Japan 6546311 2018-057959 Issued Japan <br />Divisional (DIV) 2018-057959<br />Filed on 2018-03-26<br />Status: Issued 147174481 EDC detection 147174483 EDCs 147174485 Endocrine disrupting chemicals 147174487 Endocrine disruption screening 147174489 Endocrine receptor ligand screening 147174491 Hager 147174493 Hormone receptor activity 147174495 Stavreva 147174497 Wastewater 147174499 Water sources TAB-4117 147157399 Method for HLA LOH Detection in Liquid Biopsies NCI Collaboration, Diagnostics, Licensing, Oncology Collaboration Diagnostics Licensing Oncology James Gulley, Cem Sievers, Andrew Sinkoe <h2>Description of Technology:</h2> <p>Human leukocyte antigen (HLA) LOH (LOH) is a known resistance mechanism by which cancers evade T cell receptor-(TCR-)based immunotherapies. This class of therapies includes immune checkpoint inhibition (ICI, e.g., Pembrolizumab), engineered TCR (T cell receptor)-T cell adoptive transfer, tumor infiltrating lymphocytes (TIL), T-cell engagers, and other modalities. Dozens of therapies in this category were developed with many in clinical trials. The resistance mechanism noted here, HLA LOH, causes these therapies to fail. Therefore, it is beneficial to know before treating a patient whether their cancer&rsquo;s genome has undergone HLA LOH. There is currently no HLA LOH detection method with widespread use in the market and, furthermore, no non-invasive HLA LOH detection test available. Approximately 17% of all cancer patients undergo HLA LOH (Montesion et al., Cancer Discovery, 2021) and would therefore be less likely to respond to TCR-based immunotherapies, making a test for HLA LOH crucial for attaining better patient outcomes.</p> <p>The inventors at the National Cancer Institute (NCI) a developed a non-invasive test for HLA LOH detection in liquid biopsies from blood. As a companion diagnostic (CDx), this HLA LOH detection method allows for improved patient selection. It determines patients unlikely to benefit prior to immunotherapy and thus, can avoid the toxicity, costs, and prevent delay in effective therapy.&nbsp;</p> <p>This is an application of precision oncology. For HLA LOH detection, treatment decisions can be based in part on the HLA LOH status of the patient&rsquo;s cancer, and a patient&rsquo;s treatment course is tailored to give the patient rapid access to more effective therapy. Because the test is non-invasive, determining HLA LOH status does not require surgery. This dramatically increases patient comfort, improves their experience and decreases healthcare costs. An additional benefit is that the patient will not undergo unnecessary treatments that could cause toxicities.&nbsp;</p> <p>The Center for Immuno-Oncology at the NCI is primarily looking for collaborators to co-develop this technology with the inventor. As a companion diagnostic, it will be paired with immunotherapies, to select patients who are most likely to achieve treatment benefit. The inventors seek co-development partners who developed immunotherapies that function via TCR-based mechanisms. The goal is to conduct clinical trials for the diagnostic concomitantly with the drug. The end-result of the trial will be determination of how accurately the diagnostic predicts efficacy of the drug. A companion diagnostic can increase the market potential of therapeutics by allowing them to be used as a first-line treatment. The companion diagnostic can be co-developed and/or co-marketed with a drug at any stage of the drug&rsquo;s regulatory approval process, from Phase I to FDA-approved. The next step for the diagnostic is a Phase I clinical trial, with possible IDE exemption. The companion diagnostic may also be a candidate for College of American Pathologists (CAP) accreditation and, more stringently, Clinical Laboratory Improvement Amendments (CLIA) designation while the clinical trials are being conducted.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Companion diagnostic for TCR-based immunotherapies in experimental clinical trials</li> <li>Companion diagnostic for TCR-based immunotherapies FDA-approved clinical practice</li> <li>Research use in labs studying/developing new pre-clinical therapeutic candidates</li> <li>Research use in basic research labs studying immunotherapy resistance mechanisms, antigen processing and presentation and basic immunology</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Mean overall survival (mOS) in TMB-(tumor mutational burden-)low, HLA-intact patients is twice as high as in patients with TMB-low and HLA LOH, which creates an opportunity to benefit patients by treating them with Pembrolizumab despite their TMB-low status (Montesion et al., Cancer Discovery, 2021); therefore HLA LOH as a biomarker may complement TMB-low for improved patient selection</li> <li>Non-invasive test not requiring surgical removal of solid tumor tissue</li> <li>Allows patient-tailored treatment utilizing a wide range of TCR-based immunotherapies</li> <li>Potential improvement in patient survival</li> <li>Potential time and money savings for patients, insurance companies, oncologists, and immunotherapy manufacturers by facilitating the selection of a precision treatment course for each patient</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a companion diagnostic (CDx) that detects HLA LOH and other biomarkers to predict efficacy of TCR-T cell adoptive transfer, immune checkpoint inhibition (ICI), tumor infiltrating lymphocytes (TIL), and other TCR-mediated immunotherapies. 2023-03-01 2026-04-16 2026-04-16 2023-03-01 Companion Diagnostic, Gulley, HLA, Human Leukocyte Antigen, ICI, Immune Checkpoint Inhibition, Immunotherapy, LOH, Loss of Heterozygosity, Sinkoe, T cell therapy False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163568 Sinkoe, Andrew NCI - CCR NCI Sinkoe, Andrew (NCI) 1 147163567 Gulley, James NIH - NCI NCI Gulley, James (NCI) 2 147163569 Sievers, Cem National Institute on Deafness and Other Communication Disorders (NIDCD) NCI Sievers, Cem (NCI) 3 147163568 Sinkoe, Andrew NCI - CCR NCI Sinkoe, Andrew (NCI) 1 147163567 Gulley, James NIH - NCI NCI Gulley, James (NCI) 2 147163569 Sievers, Cem National Institute on Deafness and Other Communication Disorders (NIDCD) NCI Sievers, Cem (NCI) 3 147157861 Method Of HLA LOH Detection In Liquid Biopsies E-045-2022-0 Filing authorized NIH - NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4117] Method for HLA LOH Detection in Liquid Biopsies&body=Please send me information about technology [TAB-4117] Method for HLA LOH Detection in Liquid Biopsies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4117] Method for HLA LOH Detection in Liquid Biopsies&body=Please send me information about technology [TAB-4117] Method for HLA LOH Detection in Liquid Biopsies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">suna.gulay@nih.gov</a><br> 147160958 E-045-2022-0 E-045-2022-0-US-01 METHOD OF HLA LOH DETECTION IN LIQUID BIOPSIES PRV US 63/299,672 Expired US <br />Provisional (PRV) 63/299,672<br />Filed on 2022-01-14<br />Status: Expired 147166647 E-045-2022-0 E-045-2022-0-PCT-02 Method of HLA loss Heterozygosity Detection in Liquid Biopsies PCT Patent Cooperation Treaty PCT/US2023/060664 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/060664<br />Filed on 2023-01-13<br />Status: Expired 162755006 E-045-2022-0 E-045-2022-0-US-02 METHOD OF HUMAN LEUKOCYTE ANTIGEN LOSS OF HETEROZYGOSITY DETECTION IN LIQUID BIOPSIES National Stage US 18/729,138 Pending US <br />National Stage 18/729,138<br />Filed on 2024-07-15<br />Status: Pending 162755007 E-045-2022-0 E-045-2022-0-EP-01 Method of HLA loss Heterozygosity Detection in Liquid Biopsies National Stage European Patent 23705845.8 Pending European Patent <br />National Stage 23705845.8<br />Filed on 2024-08-08<br />Status: Pending 147170222 Companion Diagnostic 147170223 Gulley 147170224 HLA 147170225 Human Leukocyte Antigen 147170226 ICI 147170227 Immune Checkpoint Inhibition 147170228 Immunotherapy 147170229 LOH 147170230 Loss of Heterozygosity 147170231 Sinkoe 147170232 T cell therapy TAB-3896 147157176 A Human Monoclonal Antibody Against Deacetylated PNAG for Use as an Antimicrobial Agent NCI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Jeffrey Gildersleeve, Joel Temme <h2>Description of Technology:</h2> <p>Biofilms are complex microbial communities, surface attached and held together by self-produced polymer matrices.&nbsp; These matrices are mainly composed of polysaccharides, secreted proteins and nucleic acids.&nbsp; Poly-N-acetyl glucosamine (PNAG) is a highly conserved surface polysaccharide expressed by a range of bacterial, fungal and protozoan microorganisms. It is associated with microbial biofilm formation.&nbsp; Partial deacetylation of PNAG (dPNAG) is critical for the function of PNAG in biofilm formation and required for the structural development and integrity of biofilm.&nbsp; Antibodies to PNAG and/or dPNAG have significant potential as broad-spectrum therapeutics for a range of bacterial and fungal infections.&nbsp; Research suggests that dPNAG is a better target than PNAG for antibody-based therapeutics; however, identification of dPNAG antibodies has been challenging.&nbsp;&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) identified a human antibody, denoted TG10, that selectively binds to dPNAG with potential as a novel antimicrobial agent.&nbsp; F598, a human IgG1 monoclonal antibody (mAb) which binds to both PNAG and dPNAG, is in active development as a potential antimicrobial agent in clinical trials.&nbsp; The novel antibody TG10 binds to a different location on the biofilm and shows synergistic effects when administered in combination with F598.&nbsp; The TG10 antibody has been tested both in vitro and in vivo and shows good efficacy both alone and in combination with F598.&nbsp;&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic use against multiple microbial pathogens, either alone or in combination with other anti-PNAG/dPNAG agents</li> <li>Prophylactic use to prevent high-risk infections&nbsp;&nbsp;</li> <li>Diagnostic imaging (using labeled form of TG10)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Possible combinatorial or synergistic effect on existing dPNAG or PNAG antibodies.&nbsp;</li> <li>Binds to a different location on dPNAG than the known dPNAG antibody F598&nbsp;</li> <li>Suggestion that combination therapy with TG10 and F598 is superior to either as mono-therapy</li> <li>F598 already used in human clinical trials; existing safety data could facilitate regulatory process of a combination therapy</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for the development of an anti-deacetylated poly-N-acetyl glucosamine (dPNAG) antibody for use as an antimicrobial agent. 2023-03-01 2026-04-16 2026-04-16 2023-03-01 ANTIMICROBIAL, Biofilm, Deacetyleated Poly-N-Acetyl Glucosamine, dPNAG, Gildersleeve, Mab, Monoclonal Antibody, TG10 False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162108 Temme JS, et al. Microarray-guided evaluation of the frequency, B-cell origins, and selectivity of human glycan-binding antibodies reveals new insights and novel antibodies. https://pubmed.ncbi.nlm.nih.gov/29786478/ <a href="https://pubmed.ncbi.nlm.nih.gov/29786478/">Temme JS, et al. Microarray-guided evaluation of the frequency, B-cell origins, and selectivity of human glycan-binding antibodies reveals new insights and novel antibodies.</a> 147162783 Gildersleeve, Jeffrey NIH - NCI NCI Gildersleeve, Jeffrey (NCI) 1 147162784 Temme, Joel NCI - CCR NCI Temme, Joel (NCI) 2 147162783 Gildersleeve, Jeffrey NIH - NCI NCI Gildersleeve, Jeffrey (NCI) 1 147162784 Temme, Joel NCI - CCR NCI Temme, Joel (NCI) 2 147157931 Human Monoclonal Antibody To Pathogen Associated Carbohydrate, Deacetylated-PNAG E-075-2022-0 Filing authorized Michigan State University, NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-3896] A Human Monoclonal Antibody Against Deacetylated PNAG for Use as an Antimicrobial Agent&body=Please send me information about technology [TAB-3896] A Human Monoclonal Antibody Against Deacetylated PNAG for Use as an Antimicrobial Agent.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-3896] A Human Monoclonal Antibody Against Deacetylated PNAG for Use as an Antimicrobial Agent&body=Please send me information about technology [TAB-3896] A Human Monoclonal Antibody Against Deacetylated PNAG for Use as an Antimicrobial Agent.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147161002 E-075-2022-0 E-075-2022-0-US-01 ANTIBODY MATERIALS AND METHODS TARGETING MICROBIAL POLYSACCHARIDES PRV US 63/319,090 Expired US <br />Provisional (PRV) 63/319,090<br />Filed on 2022-03-11<br />Status: Expired 147165119 E-075-2022-0 E-075-2022-0-PC-01 ANTIBODY MATERIALS AND METHODS TARGETING MICROBIAL POLYSACCHARIDES PCT Patent Cooperation Treaty PCT/US2023/064047 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/064047<br />Filed on 2023-03-09<br />Status: Expired 147170833 ANTIMICROBIAL 147170834 Biofilm 147170836 Deacetyleated Poly-N-Acetyl Glucosamine 147170838 dPNAG 147170839 Gildersleeve 147170840 Mab 147170841 Monoclonal Antibody 147170843 TG10 TAB-5024 158742599 Immunotherapy Delivery System to Improve Organ Transplantation Outcomes NCI Cardiology, Collaboration, Immunology, Nephrology, Therapeutics Cardiology Collaboration Immunology Nephrology Therapeutics Xiomara Calderon-Colon, Alexander Komin, Monessha Nambiar, Julia Patrone, Giorgio Raimondi, Joel Schneider, Olivia Tiburzi <h2>Summary:&nbsp;</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a delivery system to improve transplant outcomes through inhibition of the JAK/STAT pathway.&nbsp;</p> <h2>Description of Technology:&nbsp;</h2> <p>Value Proposition</p> <ul> <li>Novel Therapy: &nbsp;Hydro(LNp), is a new therapeutic application to improve outcomes for organ transplant recipients</li> <li>Broad Scope: Potential to adapt for applications beyond transplantation, such as cancer, autoimmunity, and regenerative medicine</li> <li>Convenient Delivery: Hydro(LNp) is a two-phase delivery system to increase effectiveness in regulating transplant rejection</li> </ul> <p>Transplantation becomes the only therapeutic option after end-stage organ diseases and other devastating tissue loss. However, transplanted patients need to receive high doses of multi-drug immunosuppressive therapy for the rest of their life to prevent rejection. This current standard of care often entails dangerous side effects &ndash;including nephrotoxicity, cardiovascular disease, diabetes, and higher predisposition to infections and cancer. Therefore, there is an unmet need to identify a safer and effective treatment plan for transplant recipients.</p> <p>Researchers from the National Cancer Institute (NCI), Johns Hopkins University (JHU) and Johns Hopkins Applied Physics Laboratory (JH-APL) have identified that concomitant inhibition of the JAK/STAT pathway (via small molecule inhibitors) and of a key costimulatory pathway (via the biologic CTLA4-Ig) improves the control of the immune response to a transplant. As a combination therapy, they create &ldquo;Enhanced Costimulation Blockade,&rdquo; generating positive results without many rejection episodes or side effects. The multidisciplinary team of researchers engineered a dual component delivery system called Hydro(LNp), which delivers JAK inhibitors (JAKi) in a dual form: (1) microcrystalline drug deposits in the hydrogel and (2) lipid nanoparticles encapsulated drug. This product can be injected near the transplant site. The microcrystalline drug is released locally, while the lipid nanoparticle (LNp) carry it to the specific distal sites where the immune response against the transplant is initiated. The net result is a localized synergy with CTLA4-Ig effectively preventing graft rejection.&nbsp;</p> <p>This technology could positively impact transplantation-control of immune response to prevent transplant rejection. An autoimmunity-based therapeutic that inhibits JAK signaling could bring therapeutic benefit to autoimmune diseases such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus and inflammatory bowel disease. Cancers with a dysregulated JAK/STAT pathway could also be treated with this technology.</p> <p>This technology is co-owned by JHU and The National Institutes of Health (NIH), and was co-developed by NCI, JHU and JH-APL. The summary of the technology was provided by Johns Hopkins Technology Ventures (JHTV) and <a href="https://profiles.hopkinsmedicine.org/provider/giorgio-raimondi/2777419" target="_blank">Dr. Giorgio Raimondi</a>. The technology is cross-listed on<a href="https://jhu.technologypublisher.com/technology/47435" target="_blank"> JHTV&rsquo;s website Tech Publisher</a>. The &nbsp;Hydro(LNp) is as a modification of an earlier NCI-JHU co-owned technology (NIH Ref. No.&nbsp; E-123-2018) which is cross-listed as <a href="https://jhu.technologypublisher.com/technology/47435" target="_blank">Case ID:15347 on Tech Publisher</a>.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Prevent transplant rejection</li> <li>Autoimmunity diseases such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus and inflammatory bowel disease</li> <li>Cancer therapeutic&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Drug delivery method that extends the half-life of tofacitinib</li> <li>Provide continuous, rate-controlled, localized and targeted release of tofacitinib</li> <li>Treat autoimmunity or prevent transplant rejection when combined with CTLA4-Ig, an immunosuppressive agent, for Enhanced Costimulation Blockade</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for further development of this delivery system to improve transplant outcomes through inhibition of the JAK/STAT pathway. 2024-10-23 2026-04-16 2026-04-16 2024-11-13 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-123-2018 162763644 Majumder, et al. Multiphase assembly of small molecule microcrystalline peptide hydrogel allows immunomodulatory combination therapy for long-term heart transplant survival. PMID: 32812339 https://doi.org/10.1002/smll.202002791 <a href="https://doi.org/10.1002/smll.202002791">Majumder, et al. Multiphase assembly of small molecule microcrystalline peptide hydrogel allows immunomodulatory combination therapy for long-term heart transplant survival. PMID: 32812339</a> 158990771 Raimondi, Giorgio Johns Hopkins School of Medicine Raimondi, Giorgio 1 158990775 Schneider, Joel NCI Schneider, Joel (NCI) 2 158990779 Patrone, Julia Patrone, Julia 3 159081976 Komin, Alexander Johns Hopkins University Komin, Alexander 4 159081980 Nambiar, Monessha National Cancer Institute (NCI) NCI Nambiar, Monessha (NCI) 5 159081984 Calderon-Colon, Xiomara Calderon-Colon, Xiomara 6 159081988 Tiburzi, Olivia Tiburzi, Olivia 7 158990771 Raimondi, Giorgio Johns Hopkins School of Medicine Raimondi, Giorgio 1 158990775 Schneider, Joel NCI Schneider, Joel (NCI) 2 158990779 Patrone, Julia Patrone, Julia 3 159081976 Komin, Alexander Johns Hopkins University Komin, Alexander 4 159081980 Nambiar, Monessha National Cancer Institute (NCI) NCI Nambiar, Monessha (NCI) 5 159081984 Calderon-Colon, Xiomara Calderon-Colon, Xiomara 6 159081988 Tiburzi, Olivia Tiburzi, Olivia 7 158742602 Dual-component Therapeutic Platform For Localized And Inflammation Triggered Immune Targeted Delivery Of Immunotherapies E-121-2022-0 Filing authorized Johns Hopkins School of Medicine, Johns Hopkins University, Johns Hopkins University, NCI, NIH - NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-5024] Immunotherapy Delivery System to Improve Organ Transplantation Outcomes&body=Please send me information about technology [TAB-5024] Immunotherapy Delivery System to Improve Organ Transplantation Outcomes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-5024] Immunotherapy Delivery System to Improve Organ Transplantation Outcomes&body=Please send me information about technology [TAB-5024] Immunotherapy Delivery System to Improve Organ Transplantation Outcomes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 159502867 E-121-2022-0 E-121-2022-0-US-01 COMPOSITIONS, SYSTEMS, AND METHODS FOR DELIVERY OF THERAPEUTICS PRV US 63/350,315 Expired US <br />Provisional (PRV) 63/350,315<br />Filed on 2022-06-08<br />Status: Expired 159502872 E-121-2022-0 E-121-2022-0-PC-01 COMPOSITIONS, SYSTEMS, AND METHODS FOR DELIVERY OF THERAPEUTICS PCT Patent Cooperation Treaty PCT/US2023/068139 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/068139<br />Filed on 2023-06-08<br />Status: Expired 159502877 E-121-2022-0 E-121-2022-0-US-02 COMPOSITIONS, SYSTEMS, AND METHODS FOR DELIVERY OF THERAPEUTICS National Stage US 18/872,676 Pending US <br />National Stage 18/872,676<br />Filed on 2024-12-06<br />Status: Pending TAB-5028 158934494 HLA-class II-restricted T Cell Receptors for PIK3CA “Hotspot” Mutations, E545K and N345K NCI Collaboration, Immunology, Licensing, Oncology, TherapeuticArea, Therapeutics Collaboration Immunology Licensing Oncology TherapeuticArea Therapeutics S M Rafiqul Islam, Frank Lowery, Maria Parkhurst, Steven Rosenberg, Samantha Seitter, NIkolaos Zacharakis <h2>Summary:&nbsp;</h2> <p>The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a collection of T cell receptors (TCRs) that specifically target PIK3CA mutations to treat patients with tumors expressing these mutations in the context of HLA-DPA1*01:03:01, HLA-DPB1*04:01:01 or HLA-DRB1*04:01.</p> <h2>Description of Technology:</h2> <p>Phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha gene, also known as PIK3CA, makes a subunit of the PIK3 enzyme with various cellular functions. Mutations in the PIK3CA can result in the growth of cells through overactivation of the PIK3 enzyme and are associated with the development of several forms of cancers. Indeed, PIK3CA mutation is the third most common mutation in epithelial cancers. Previous studies attempted to inhibit the activity of mutant PIK3CA using both small molecules and monoclonal antibodies. However, these studies showed limited in vivo efficacy in treating tumors with mutant PIK3CA.</p> <p>The National Cancer Institute (NCI) has developed novel, HLA-class II-restrcited T cell receptors (TCRs) to target two of the most common PIK3CA &ldquo;hotspot&rdquo; mutations: E545K and N345K. Two TCRs against N345K are restricted by the common HLA-DPA1*01:03:01 and HLA-DPB1*04:01:01, found in about 85% of the US Caucasian population. The TCR against E545K is rectricted by the common HLA-DRB1*04:01, found in about 17-20% of US Caucasian population. Given the frequency of PIK3CA mutations in various common cancers, these inventions have the potential to benefit a wide range of cancer patients. Targeted therapy against PIK3CA mutations represents therapeutic potential for various types of cancer. Further, as PIK3CA mutations are not present in healthy tissue, this approach could produce fewer off-target effects and a more promising safety profile.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>TCR-engineered cell therapy products for cancers expressing PIK3CA mutations &ndash; including, but not limited to: <ul> <li>breast&nbsp;</li> <li>endometrial</li> <li>bladder</li> <li>colorectal carcinoma</li> <li>head and neck squamous cell carcinoma</li> </ul> </li> <li>Soluble TCR-fusion proteins</li> <li>Combination immunotherapies using ACT alongside other immunotherapies targeting PIK3CA mutations</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Targeted therapy</li> <li>Potentially fewer and less severe off-target effects</li> <li>Potentially more promising safety profile</li> <li>Therapeutic potential for various types of cancer</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for T cell receptors (TCRs) targeting PIK3CA mutations to treat patients with tumors expressing these mutations such as metastatic epithelial cancers. 2024-11-01 2026-04-16 2026-04-16 2024-11-06 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract E-206-2022 158934581 Fusco N, et al. PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. (PMID 33842357) https://pubmed.ncbi.nlm.nih.gov/33842357/ <a href="https://pubmed.ncbi.nlm.nih.gov/33842357/">Fusco N, et al. PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. (PMID 33842357)</a> 158990386 Martínex-Sáez, et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. (PMID 32404150) https://pubmed.ncbi.nlm.nih.gov/32404150/ <a href="https://pubmed.ncbi.nlm.nih.gov/32404150/">Martínex-Sáez, et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. (PMID 32404150)</a> 158990393 Krop IE, et al. Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. (PMID 35138919) https://pubmed.ncbi.nlm.nih.gov/35138919/ <a href="https://pubmed.ncbi.nlm.nih.gov/35138919/">Krop IE, et al. Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. (PMID 35138919)</a> 158934542 Rosenberg, Steven National Cancer Institute (NCI) NCI Rosenberg, Steven (NCI) 1 158934546 Zacharakis, NIkolaos National Cancer Institute (NCI) NCI Zacharakis, NIkolaos (NCI) 2 158934550 Islam, S M Rafiqul NCI Islam, S M Rafiqul (NCI) 3 158934554 Seitter, Samantha Seitter, Samantha 4 158934558 Parkhurst, Maria NCI Parkhurst, Maria (NCI) 5 158934562 Lowery, Frank NCI Lowery, Frank (NCI) 6 158934542 Rosenberg, Steven National Cancer Institute (NCI) NCI Rosenberg, Steven (NCI) 1 158934546 Zacharakis, NIkolaos National Cancer Institute (NCI) NCI Zacharakis, NIkolaos (NCI) 2 158934550 Islam, S M Rafiqul NCI Islam, S M Rafiqul (NCI) 3 158934554 Seitter, Samantha Seitter, Samantha 4 158934558 Parkhurst, Maria NCI Parkhurst, Maria (NCI) 5 158934562 Lowery, Frank NCI Lowery, Frank (NCI) 6 158934497 HLA-class II-restricted T cell receptors for PIK3CA “hotspot” mutations, E545K and N345K. E-076-2024-0 Filing authorized Inova Health System, NIH - NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-5028] HLA-class II-restricted T Cell Receptors for PIK3CA “Hotspot” Mutations, E545K and N345K&body=Please send me information about technology [TAB-5028] HLA-class II-restricted T Cell Receptors for PIK3CA “Hotspot” Mutations, E545K and N345K.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-5028] HLA-class II-restricted T Cell Receptors for PIK3CA “Hotspot” Mutations, E545K and N345K&body=Please send me information about technology [TAB-5028] HLA-class II-restricted T Cell Receptors for PIK3CA “Hotspot” Mutations, E545K and N345K.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 159503000 E-076-2024-0 E-076-2024-0-US-01 T CELL RECEPTORS TARGETING E545K OR N345K MUTATION IN PIK3CA PRV US 63/565,764 Expired US <br />Provisional (PRV) 63/565,764<br />Filed on 2024-03-15<br />Status: Expired TAB-5025 158743710 Peptide Hydrogels for Delivery of Immunosuppressive Drugs and Uses Thereof NCI Cardiology, Collaboration, Immunology, Licensing, Nephrology, Therapeutics Cardiology Collaboration Immunology Licensing Nephrology Therapeutics Poulami Majumder, Giorgio Raimondi, Joel Schneider <h2>Summary:&nbsp;</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a hydrogel-based delivery system for the local administration of tofacitinib to improve transplant outcomes.</p> <h2>Description of Technology:&nbsp;</h2> <p>More than 1 million tissue transplantations are performed each year. Organ transplantation therapies are typically combined with immunosuppressive agents to reduce the risk of allograft rejection and enhance transplant survival. Currently, immunosuppressive drugs are administered systemically and have several dose-limiting side effects, including impairment of renal function, hypertension, and lymphatic malignancies. Therefore, there is an unmet need to identify a safer, more effective treatment plan for transplant recipients.<br /> &nbsp;<br /> A multidisciplinary team of researchers from the National Cancer Institute (NCI) and <a href="https://www.hopkinsmedicine.org/plastic-reconstructive-surgery/research/vca-lab" target="_blank">Johns Hopkins University (JHU)</a> developed a peptide hydrogel containing a crystalized form of an immunosuppressive small molecule.&nbsp;<br /> This novel formulation can be syringe-injected to the site of transplantation during surgery, allowing for localized, sustained delivery of immunosuppressive agents &ndash; improving transplant outcomes while reducing off-target toxicities. As proof of concept, a hydrogel containing a potent JAK inhibitor, tofacitinib, was injected directly to the grafting site using a mouse model of heterotopic heart transplantation. A single, local application of the tofacitinib hydrogel, combined with systemic administration of CTLA4-Ig, a common immunosuppressant, significantly prolonged graft survival of the transplanted heart. This technology could positively impact transplantation-control of immune response to prevent transplant rejection. An autoimmunity-based therapeutic that inhibits JAK signaling could bring therapeutic benefit to autoimmune diseases such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus and inflammatory bowel disease. Cancers with a dysregulated JAK/STAT pathway could also be treated with this technology.</p> <p>This technology is co-owned and was co-developed by JHU and The National Institutes of Health (NIH). The summary of the technology was provided by Johns Hopkins Technology Ventures (JHTV) and is cross-listed on <a href="https://jhu.technologypublisher.com/technology/47435" target="_blank">JHTV&rsquo;s Tech Publisher website Case ID C15347</a>. There is a modified, related, co-owned technology (E-121-2022) which is cross listed on <a href="https://jhu.technologypublisher.com/technology/55093" target="_blank">JHTV&rsquo;s Tech Publisher website Case ID C17351</a>.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Prevent transplant rejection</li> <li>Autoimmunity diseases such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus and inflammatory bowel disease</li> <li>Cancer therapeutic</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Drug delivery method that extends the half-life of tofacitinib</li> <li>Provide continuous, rate-controlled, localized and targeted release of tofacitinib</li> <li>Treat autoimmunity or prevent transplant rejection when combined with CTLA4-Ig, an immunosuppressive agent, for Enhanced Costimulation Blockade&nbsp;</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for further development of this delivery system to improve transplant outcomes through inhibition of the JAK/STAT pathway. 2024-10-23 2026-04-16 2026-04-16 2024-11-06 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-121-2022 158990415 Majumder, et al. Multiphase assembly of small molecule microcrystalline peptide hydrogel allows immunomodulatory combination therapy for long-term heart transplant survival. (PMID: 32812339). https://pubmed.ncbi.nlm.nih.gov/32812339/ <a href="https://pubmed.ncbi.nlm.nih.gov/32812339/">Majumder, et al. Multiphase assembly of small molecule microcrystalline peptide hydrogel allows immunomodulatory combination therapy for long-term heart transplant survival. (PMID: 32812339).</a> 158990403 Raimondi, Giorgio Raimondi, Giorgio 1 158990407 Schneider, Joel National Cancer Institute (NCI) NCI Schneider, Joel (NCI) 2 158990411 Majumder, Poulami NCI Majumder, Poulami (NCI) 3 158990403 Raimondi, Giorgio Raimondi, Giorgio 1 158990407 Schneider, Joel National Cancer Institute (NCI) NCI Schneider, Joel (NCI) 2 158990411 Majumder, Poulami NCI Majumder, Poulami (NCI) 3 158743713 Hydrogel Delivery Platform To Deliver Immunosuppressive Drugs E-123-2018-0 Filing authorized Johns Hopkins School of Medicine, NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-5025] Peptide Hydrogels for Delivery of Immunosuppressive Drugs and Uses Thereof&body=Please send me information about technology [TAB-5025] Peptide Hydrogels for Delivery of Immunosuppressive Drugs and Uses Thereof.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-5025] Peptide Hydrogels for Delivery of Immunosuppressive Drugs and Uses Thereof&body=Please send me information about technology [TAB-5025] Peptide Hydrogels for Delivery of Immunosuppressive Drugs and Uses Thereof.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 159503047 E-123-2018-0 E-123-2018-0-US-01 PEPTIDE HYDROGELS FOR DELIVERY OF IMMUNOSUPPRESSIVE DRUGS AND USES THEREOF PRV US 62/666,471 Abandoned US <br />Provisional (PRV) 62/666,471<br />Filed on 2018-05-03<br />Status: Abandoned 159503058 E-123-2018-0 E-123-2018-0-PCT-02 PEPTIDE HYDROGELS FOR DELIVERY OF IMMUNOSUPPRESSIVE DRUGS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2019/030656 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/030656<br />Filed on 2019-05-03<br />Status: Expired 159503063 E-123-2018-0 E-123-2018-0-EP-03 PEPTIDE HYDROGELS FOR DELIVERY OF IMMUNOSUPPRESSIVE DRUGS AND USES THEREOF National Stage European Patent 3787664 19724994.9 Abandoned European Patent <br />National Stage 19724994.9<br />Filed on 2019-05-03<br />Status: Abandoned 159503068 E-123-2018-0 E-123-2018-0-US-04 PEPTIDE HYDROGELS FOR DELIVERY OF IMMUNOSUPPRESSIVE DRUGS AND USES THEREOF National Stage US 12,527,870 17/051,574 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12527870 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12527870">12,527,870</a><br />Filed on 2020-10-29<br />Status: Issued 159503073 E-123-2018-0 E-123-2018-0-FR-01 PEPTIDE HYDROGELS FOR DELIVERY OF IMMUNOSUPPRESSIVE DRUGS AND USES THEREOF EP France 3787664 19724994.9 Abandoned France <br />European patent (EP) 19724994.9<br />Filed on 2019-05-03<br />Status: Abandoned 159503078 E-123-2018-0 E-123-2018-0-DE-01 PEPTIDE HYDROGELS FOR DELIVERY OF IMMUNOSUPPRESSIVE DRUGS AND USES THEREOF EP Germany 3787664 19724994.9 Abandoned Germany <br />European patent (EP) 19724994.9<br />Filed on 2019-05-03<br />Status: Abandoned 159503083 E-123-2018-0 E-123-2018-0-GB-01 PEPTIDE HYDROGELS FOR DELIVERY OF IMMUNOSUPPRESSIVE DRUGS AND USES THEREOF EP United Kingdom 3787664 19724994.9 Abandoned United Kingdom <br />European patent (EP) 19724994.9<br />Filed on 2019-05-03<br />Status: Abandoned TAB-5023 158678127 Machine Learning Model for the Prioritization of Cancer Neoepitopes NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Jared Gartner, Paul Robbins, Steven Rosenberg <h2>Summary:&nbsp;</h2> <p>The National Cancer Institute (NCI) seeks licensees for a machine learning algorithm that scores epitopes for likelihood of reactivity in order to create personalized effective immunotherapy.</p> <h2>Description of Technology:&nbsp;</h2> <p>Success in immunotherapy is often attributable to the reactivity of patient T-cells to specific mutated peptide(s) found in the patient&rsquo;s tumor known as neoepitopes. In the development of patient-specific immunotherapies, there is no consistent standard for prioritizing such neoepitopes. Current models arrive at a ranked list of potential candidates by removing epitopes based on pre-determined criteria which might lead to the elimination of known reactive neoepitopes.&nbsp;</p> <p>Identification, prioritization and targeting of patient neoepitopes are crucial for developing effective, personalized treatments. Ranking or prioritizing neoepitopes is especially important when trying to construct a cancer vaccine that will elicit a therapeutically beneficialn immune response. Accordingly, scientists at the National Cancer Institute (NCI) have created a novel approach to identify and prioritize patient neoantigens. This model uses a training dataset of known neoantigens from patient screening and determines features of importance to epitope recognition using both reactive and non-reactive epitopes. The machine learning algorithm scores epitopes for their likelihood of reactivity and provides a stable, reproducible method to prioritize epitopes that can be used anywhere in the world.&nbsp;<br /> &nbsp;<br /> The National Cancer Institute (NCI) seeks licensees for this machine learning algorithm that scores epitopes for likelihood of reactivity in order to create personalized effective immunotherapy.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Oncology</li> <li>Prioritization of neoantigens for the development of effective personalized therapies</li> <li>Cancer vaccines</li> <li>TIL and T-cell receptor therapies</li> <li>Research use</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Model is trained using a dataset of verified neoantigens from patient tumor data&nbsp;</li> <li>Model is unbiased because it does not use prior assumptions about what features a neoepitope should have</li> <li>Uses two models (MMP and NMER model) aswhich is a more reproducible approach than using a single model</li> <li>Particularly useful for prioritizing epitopes for patients with large numbers of mutations</li> </ul> The NCI seeks licensees for a machine learning algorithm that scores epitopes for likelihood of reactivity in order to create personalized effective immunotherapy. 2024-10-17 2026-04-16 2026-04-16 2024-10-17 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 158678146 Gartner JJ, et al. A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types. (PMID: 34927080) https://pubmed.ncbi.nlm.nih.gov/34927080/ <a href="https://pubmed.ncbi.nlm.nih.gov/34927080/">Gartner JJ, et al. A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types. (PMID: 34927080)</a> 158678134 Gartner, Jared NCI Gartner, Jared (NCI) 1 158678138 Robbins, Paul NCI Robbins, Paul (NCI) 2 158678142 Rosenberg, Steven NCI Rosenberg, Steven (NCI) 3 158678134 Gartner, Jared NCI Gartner, Jared (NCI) 1 158678138 Robbins, Paul NCI Robbins, Paul (NCI) 2 158678142 Rosenberg, Steven NCI Rosenberg, Steven (NCI) 3 158678130 Development of a model for ranking candidate HLA class I neoantigens based upon datasets of known neoepitopes E-022-2024-0 Closed NIH - NCI, Surgery Branch 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-5023] Machine Learning Model for the Prioritization of Cancer Neoepitopes&body=Please send me information about technology [TAB-5023] Machine Learning Model for the Prioritization of Cancer Neoepitopes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-5023] Machine Learning Model for the Prioritization of Cancer Neoepitopes&body=Please send me information about technology [TAB-5023] Machine Learning Model for the Prioritization of Cancer Neoepitopes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> TAB-5022 158677893 Fully Human Chimeric Antigen Receptors Against CD276 for the Treatment of Solid Tumors NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Pradip Bajgain, Yang Feng, Brad St. Croix <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and licensees for a panel of five fully human antibodies against CD276 for the treatment of solid tumors. The collection also includes human CARs incorporating the antibodies for immunotherapeutic use.</p> <h2>Description of Technology:</h2> <p>Chimeric antigen receptor (CAR)-T cell therapy has been successful in leukemia but its use for the treatment of solid tumors has been challenging. &nbsp;CD276, also known as B7-H3, is a surface tumor marker highly expressed in the vasculature and surface of solid tumors. This strong expression in both areas of solid tumors makes CD276 a promising target for cancer therapies such as CARs.</p> <p>This technology comprises of a panel of five fully human antibodies (Y868, Y422, Y111, Y117, and YE5) against CD276 that can be incorporated into immunotherapies. &nbsp;The CARs generated using these antibodies were evaluated and compared to other known CD276-targeting CARs in development. &nbsp;One of the CARs showed a more durable anti-tumor response superior to all others tested, including those known in the literature. &nbsp;CARs generated from this set are effective against Panc1 pancreatic tumor models. One CAR in particular showing high efficacy in the HPAC pancreatic tumor model which was resistant to all other CARs. &nbsp;In addition to CARs, the antibodies developed under this invention could potentially be used in other antibody-based therapeutics targeting CD276 including other cell therapies such as CAR NK-cell therapies. &nbsp;&nbsp;</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>CAR T-Cell therapy for treatment of pancreatic cancer</li> <li>CAR T-Cell or NK cell therapy for treatment of several solid tumors&nbsp;</li> <li>Antibody based therapeutics such as antibody drug conjugates (ADCs) for the treatment of solid tumors&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>High efficacy against tumors resistant to other CARs</li> <li>CD276 target is highly expressed on many solid tumor types</li> <li>Fully human antibody potentially less immunogenic than those derived from mouse</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for the development of antibody-based therapeutics targeting CD276 for the treatment of solid tumors. 2024-10-17 2026-04-16 2026-04-16 2024-10-17 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 158678102 Feng et al. Engineering CD276/B7-H3-targeting antibody-drug conjugates with enhanced cancer-eradicating capability (PMID 38019654) Seaman et al. Eradication of tumors through simultaneous ablation of CD276/B7-H3-positive tumor cells and tumor vasculature. (PMID 28399408) https://pubmed.ncbi.nlm.nih.gov/38019654/ <a href="https://pubmed.ncbi.nlm.nih.gov/38019654/">Feng et al. Engineering CD276/B7-H3-targeting antibody-drug conjugates with enhanced cancer-eradicating capability (PMID 38019654) Seaman et al. Eradication of tumors through simultaneous ablation of CD276/B7-H3-positive tumor cells and tumor vasculature. (PMID 28399408)</a> 158677900 St. Croix, Brad NCI St. Croix, Brad (NCI) 1 158678094 Bajgain, Pradip National Cancer Institute (NCI) NCI Bajgain, Pradip (NCI) 2 158678098 Feng, Yang NCI Feng, Yang (NCI) 3 158677900 St. Croix, Brad NCI St. Croix, Brad (NCI) 1 158678094 Bajgain, Pradip National Cancer Institute (NCI) NCI Bajgain, Pradip (NCI) 2 158678098 Feng, Yang NCI Feng, Yang (NCI) 3 158677896 Fully Human Chimeric Antigen Receptors against CD276 for the treatment of solid tumors E-125-2023-0 Filing authorized Mouse Cancer Genetics Program 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-5022] Fully Human Chimeric Antigen Receptors Against CD276 for the Treatment of Solid Tumors&body=Please send me information about technology [TAB-5022] Fully Human Chimeric Antigen Receptors Against CD276 for the Treatment of Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-5022] Fully Human Chimeric Antigen Receptors Against CD276 for the Treatment of Solid Tumors&body=Please send me information about technology [TAB-5022] Fully Human Chimeric Antigen Receptors Against CD276 for the Treatment of Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 159502484 E-125-2023-0 E-125-2023-0-US-01 Fully Human Chimeric Antigen Receptors against CD276 for the treatment of solid tumors PRV US 63/514,596 Expired US <br />Provisional (PRV) 63/514,596<br />Filed on 2023-07-20<br />Status: Expired 159502489 E-125-2023-0 E-125-2023-0-PC-01 FULLY HUMAN MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AGAINST CD276 FOR THE TREATMENT OF SOLID TUMORS PCT Patent Cooperation Treaty PCT/US2024/037349 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/037349<br />Filed on 2024-07-10<br />Status: Expired 165318378 E-125-2023-0 E-125-2023-0-CA-01 FULLY HUMAN MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AGAINST CD276 FOR THE TREATMENT OF SOLID TUMORS National Stage Canada 3299104 Pending Canada <br />National Stage 3299104<br />Filed on 2026-01-19<br />Status: Pending 165318413 E-125-2023-0 E-125-2023-0-AU-01 FULLY HUMAN MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AGAINST CD276 FOR THE TREATMENT OF SOLID TUMORS National Stage Australia 2024295016 Pending Australia <br />National Stage 2024295016<br />Filed on 2026-01-15<br />Status: Pending 165318575 E-125-2023-0 E-125-2023-0-US-02 FULLY HUMAN MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AGAINST CD276 FOR THE TREATMENT OF SOLID TUMORS National Stage US 19/503,627 Pending US <br />National Stage 19/503,627<br />Filed on 2026-01-20<br />Status: Pending 165318610 E-125-2023-0 E-125-2023-0-EP-01 FULLY HUMAN MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AGAINST CD276 FOR THE TREATMENT OF SOLID TUMORS National Stage European Patent 24749087.3 Pending European Patent <br />National Stage 24749087.3<br />Filed on 2026-02-04<br />Status: Pending TAB-5021 158677813 Novel Kinase Inhibitory Thiazines NCI Application, Collaboration, Infectious Disease, Licensing, Oncology, Rare/Neglected Diseases, Therapeutics Application Collaboration Infectious Disease Licensing Oncology Rare/Neglected Diseases Therapeutics Lin Du, Ning Li, Juliana Martinez Fiesco, William Moore, Barry O'Keefe, Dongdong Wang, Brice Wilson, Ping Zhang <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases including:</p> <ul> <li>Oncogenic gene fusion DNAJB1-PRKACA (PKADJ)</li> <li>Wild type protein kinase A (PKA)&nbsp;</li> <li>Protein kinase G (PKG)</li> <li>Ccdc2-like kinases (CLK) 1 &amp; 2</li> <li>DYRK family of kinases</li> </ul> <h2>Description of Technology:</h2> <p>In 2022, the NCI Molecular Targets Program (MTP) completed a screen of ~150,000 pre-fractionated natural products from the NCI Program for Natural Product Discovery (NPNPD). From this screen, a class of active compounds, named Aplithianines A &amp; B (isolated from the marine organism Aplidium sp.), showed broad potential applicability to numerous kinases of importance including, but not limited to:</p> <ul> <li>Oncogenic gene fusion DNAJB1-PRKACA (PKADJ) <ul> <li>Implicated in an ultra-rare adolescent liver cancer</li> </ul> </li> <li>Wild type protein kinase A (PKA)&nbsp; <ul> <li>Implicated in Cushing&rsquo;s Disease</li> </ul> </li> <li>Protein kinase G (PKG)&nbsp; <ul> <li>Potential treatment of malaria</li> </ul> </li> <li>Ccdc2-like kinases (CLK) 1 &amp; 2 <ul> <li>Implicated in gastric cancer</li> </ul> </li> <li>DYRK family of kinases&nbsp; <ul> <li>Implicated in gastric or colon cancer as well as infections caused by a protozoa or parasites</li> </ul> </li> </ul> <p>The original cohort of compounds, including the pharmaceutical compositions of the natural products Aplithianine A and Aplithianine B, as well as a range of synthetic derivatives are described in NIH Technology Ref # E-044-2022.&nbsp;</p> <p>This technology (NIH Ref # E-202-2023) describes the Second Cohort of compounds that comprise the same chemical scaffold of the broadest generic formula in the Original Family but represent a patentably distinct, subgenus formula. This Second Cohort of compounds shares the same chemical scaffold as aplithianine but have been optimized through extensive medicinal chemistry efforts to increase binding affinity to the oncogenic fusion kinase called DNAJB1-PRKACA (PKADJ) and its wild-type counterpart protein kinase A (PKA). These new compounds, like the Original Family compounds, compete with ATP for binding on these kinases and other related kinases (namely, protein kinase G, cdc2-like kinases (CLK) 1 &amp; 2, and the DYRK family of kinases). However, the compounds described in this Second Cohort exhibit improved low nanomolar binding affinity and high activity in secondary assays.&nbsp;</p> <p>A Third Cohort of compounds, namely the Reverse Thiazine Kinase inhibitors, are described in NIH Ref # E-162-2024. They are also structurally related to, but patentably distinct from the compounds described in the patent filings for the Original Family and Second Cohort.&nbsp;</p> <p><img alt="Image of Molecular Diagrams" src="https://nih.technologypublisher.com/files/sites/monosnap_structural_representatives.jpg_2024-10-30_17-57-471.png" style="height:1676px; width:1218px" /></p> <p>The specificity of several of the compounds have been examined in kinase panels to demonstrate that while applicable to a range of kinases, they are not promiscuous kinase inhibitors. The subject kinase inhibitors have broad potential commercial applicability&rsquo;s for cancer, immune suppression, preventing organ rejection, treating diabetic neuropathic pain, malaria, or protozoa infection. To date there are no approved therapeutics targeting DNAJB1-PRKCA, an oncogenic gene fusion is ubiquitously and exclusively detected in the tumors of patients with ultra-rare fibrolamellar hepatocellular carcinoma FLHCC.</p> <p>The NCI seeks licensing and/or co-development research collaborations for the future development of Kinase Inhibitory Aplithianines targeting &nbsp;DNAJB1-PRKACA (PKADJ), PKA, PKG, CLK, and/or DYRK.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Gastric cancer</li> <li>Ultra-rare adolescent liver cancer</li> <li>Solid cancers susceptible to kinase inhibitors</li> <li>Cushing&rsquo;s Disease</li> <li>Transplantation</li> <li>Diabetic neuropathic pain</li> <li>Malaria</li> <li>Protozoa infection&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Applicability to numerous clinically relevant kinases, including: <ul> <li>Oncogenic gene fusion DNAJB1-PRKACA (PKADJ)</li> <li>Wild type protein kinase A (PKA)</li> <li>Protein kinase G (PKG)</li> <li>Ccdc2-like kinases (CLK) 1 &amp; 2</li> <li>DYRK family of kinases</li> </ul> </li> <li>Applicable to a range of kinases, but are not promiscuous inhibitors</li> <li>Broad potential commercial applicability for several blockbuster indications, including: cancer, immune suppression, transplantation, diabetic neuropathic pain, malaria, and protozoa infection</li> <li>No approved therapeutics targeting DNAJB1-PRKCA</li> </ul> <p>&nbsp;</p> Researchers at the NCI seek licensing and/or co-development research collaborations for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases 2024-10-17 2026-04-16 2026-04-16 2024-10-17 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-044-2022 E-162-2024 158677854 O'Keefe BR, et al. Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors. PMID: 37082750 https://pubmed.ncbi.nlm.nih.gov/37082750/ <a href="https://pubmed.ncbi.nlm.nih.gov/37082750/">O'Keefe BR, et al. Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors. PMID: 37082750</a> 162874682 O'Keefe BR, et al. Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases. PMID: 37843072 https://pubmed.ncbi.nlm.nih.gov/37843072/ <a href="https://pubmed.ncbi.nlm.nih.gov/37843072/">O'Keefe BR, et al. Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases. PMID: 37843072</a> 158677820 O'Keefe, Barry National Cancer Institute (NCI) NCI O'Keefe, Barry (NCI) 1 158677824 Du, Lin NCI Du, Lin (NCI) 2 158677828 Wilson, Brice NCI Wilson, Brice (NCI) 3 158677832 Zhang, Ping NCI Zhang, Ping (NCI) 4 158677838 Moore, William NCI Moore, William (NCI) 5 158677842 Wang, Dongdong NCI Wang, Dongdong (NCI) 6 158677846 Martinez Fiesco, Juliana Martinez Fiesco, Juliana 7 158677850 Li, Ning Leidos Li, Ning (Leidos) 8 158677820 O'Keefe, Barry National Cancer Institute (NCI) NCI O'Keefe, Barry (NCI) 1 158677824 Du, Lin NCI Du, Lin (NCI) 2 158677828 Wilson, Brice NCI Wilson, Brice (NCI) 3 158677832 Zhang, Ping NCI Zhang, Ping (NCI) 4 158677838 Moore, William NCI Moore, William (NCI) 5 158677842 Wang, Dongdong NCI Wang, Dongdong (NCI) 6 158677846 Martinez Fiesco, Juliana Martinez Fiesco, Juliana 7 158677850 Li, Ning Leidos Li, Ning (Leidos) 8 158677816 Novel Kinase Inhibitory Thiazines E-202-2023-0 Filing authorized National Cancer Institute (NCI), NIH - NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-5021] Novel Kinase Inhibitory Thiazines&body=Please send me information about technology [TAB-5021] Novel Kinase Inhibitory Thiazines.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-5021] Novel Kinase Inhibitory Thiazines&body=Please send me information about technology [TAB-5021] Novel Kinase Inhibitory Thiazines.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 159503095 E-202-2023-0 E-202-2023-0-US-01 KINASE INHIBITORS PRV US 63/527,274 Expired US <br />Provisional (PRV) 63/527,274<br />Filed on 2023-07-17<br />Status: Expired 159503100 E-202-2023-0 E-202-2023-0-PC-01 KINASE INHIBITORS PCT Patent Cooperation Treaty PCT/US2024/038376 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/038376<br />Filed on 2024-07-17<br />Status: Expired TAB-5020 158677380 Reverse Thiazine Kinase Inhibitors NCI Collaboration, Infectious Disease, Licensing, Oncology, Rare/Neglected Diseases, Therapeutics Collaboration Infectious Disease Licensing Oncology Rare/Neglected Diseases Therapeutics Lin Du, Ning Li, Juliana Martinez Fiesco, William Moore, Barry O'Keefe, Dongdong Wang, Brice Wilson, Ping Zhang <h3>Summary:</h3> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases including:</p> <ul> <li>Oncogenic gene fusion DNAJB1-PRKACA (PKADJ)</li> <li>Wild type protein kinase A (PKA)&nbsp;</li> <li>Protein kinase G (PKG)</li> <li>Ccdc2-like kinases (CLK) 1 &amp; 2</li> <li>DYRK family of kinases</li> </ul> <h3>Description of Technology:</h3> <p>In 2022, the NCI Molecular Targets Program (MTP) completed a screen of ~150,000 pre-fractionated natural products from the NCI Program for Natural Product Discovery (NPNPD). From this screen, a class of active compounds, named Aplithianines A &amp; B (isolated from the marine organism Aplidium sp.) showed broad potential applicability to numerous kinases of importance including but not limited to:</p> <ul> <li>Oncogenic gene fusion DNAJB1-PRKACA (PKADJ) <ul> <li>Implicated in an ultra-rare adolescent liver cancer</li> </ul> </li> <li>Wild type protein kinase A (PKA)&nbsp; <ul> <li>Implicated in Cushing&rsquo;s Disease</li> </ul> </li> <li>Protein kinase G (PKG)&nbsp; <ul> <li>Potential treatment of malaria</li> </ul> </li> <li>Ccdc2-like kinases (CLK) 1 &amp; 2 <ul> <li>Implicated in gastric cancer</li> </ul> </li> <li>DYRK family of kinases&nbsp; <ul> <li>Implicated in gastric or colon cancer as well as infections caused by a protozoa or parasites</li> </ul> </li> </ul> <p>This Technology (NIH Ref # <strong>E-162-2024</strong>) describes a Third Cohort of compounds, namely the Reverse Thiazine Kinase inhibitors &ndash; structurally related to, but patentably distinct from &ndash; compounds described in the patent filings for the Original Family and Second Cohort. This Third Cohort of reverse thiazine compounds were created based on the initial activity determination and structural interactions for the aplithianine kinase inhibitors (described in the Original Family) and the DNAJ-PKA fusion protein. These Third Cohort compounds are a new structural class of Ser/Thr kinase (i.e. PKA) inhibitors related to the aplithianine class of kinase inhibitors but differ in both their chemical structures and mode of binding into the ATP binding pocket of kinases. They show potent and improved biochemical inhibition, reduction of the phosphorylation of the PKA substrate CREB, and the ability to reduce the viability of cancer cells. Computational modeling predicted enhanced binding affinity of these reverse thiazines with the DNAJ-PKA fusion protein. Consistent with this hypothesis-driven modeling effort, the reverse thiazines show improved potency and cellular activity over the compounds described in the Original Family and Second Cohort patent families</p> <p>Original Cohort of compounds, including the pharmaceutical compositions of the natural products Aplithianine A and Aplithianine B, as well as a range of synthetic derivatives are described in NIH Technology Ref # E-044-2022.&nbsp;</p> <p>The Second Cohort of compounds are covered in (NIH Ref # E-202-2023). This Second Cohort comprises the same chemical scaffold of the broadest generic formula in the Original Family but represents a patentably distinct, subgenus formula. This Second Cohort of compounds shares the same chemical scaffold as aplithianine but have been optimized through extensive medicinal chemistry efforts to increase binding affinity to the oncogenic fusion kinase called DNAJB1-PRKACA (PKADJ) and its wild-type counterpart protein kinase A (PKA).</p> <p><img alt="Image of Molecular Diagrams" src="https://nih.technologypublisher.com/files/sites/monosnap_structural_representatives.jpg_2024-10-30_17-57-471.png" style="height:1676px; width:1218px" /></p> <p>The specificity of several of the compounds have been examined in kinase panels to demonstrate that, while applicable to a range of kinases, they are not promiscuous kinase inhibitors. The subject kinase inhibitors have broad potential commercial applicability&rsquo;s for cancer, immune suppression, preventing organ rejection, treating diabetic neuropathic pain, malaria, or protozoa infection. To date, there are no approved therapeutics targeting DNAJB1-PRKCA, an oncogenic gene fusion is ubiquitously and exclusively detected in the tumors of patients with ultra-rare fibrolamellar hepatocellular carcinoma FLHCC.</p> <p>The NCI seeks licensing and/or co-development research collaborations for the future development of Kinase Inhibitory Aplithianines targeting&nbsp;&nbsp;DNAJB1-PRKACA (PKADJ), PKA, PKG, CLK, and/or DYRK.</p> <h3>Potential Commercial Applications:</h3> <ul> <li style="margin-left: 8px;"><span style="font-family:Times New Roman,serif">Gastric Cancer</span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Ultra-rare, adolescent liver cancer</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Solid cancers susceptible to kinase inhibitors</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Cushing&rsquo;s Disease</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Transplantation</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Diabetic neuropathic pain</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Malaria</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Protozoa infection </span></span></li> </ul> <h3 style="margin-left:8px">Competitive Advantages:</h3> <ul> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Applicability to numerous clinically relevant kinases, including:</span></span> <ul> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Oncogenic gene fusion DNAJB1-PRKACA (PKADJ)</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Wild type protein kinase A (PKA)</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Protein kinase G (PKG)</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Ccdc2-like kinases (CLK) 1 &amp; 2</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">DYRK family of kinases</span></span></li> </ul> </li> <li style="margin-left: 8px;">Applicable to range of kinases, but are not promiscuous kinase inhibitors</li> <li style="margin-left: 8px;">Broad potential commercial applicability for several blockbuster indications, including: cancer, immune suppression, transplantation, diabetic neuropathic pain, malaria, and protozoa infection</li> <li style="margin-left: 8px;">No approved therapeutics targeting DNAJB1-PRKCA</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases 2024-10-17 2026-04-16 2026-04-16 2024-10-17 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-044-2022 E-202-2023 158677441 O'Keefe BR, et al. Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors. PMID: 37082750 https://pubmed.ncbi.nlm.nih.gov/37082750/ <a href="https://pubmed.ncbi.nlm.nih.gov/37082750/">O'Keefe BR, et al. Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors. PMID: 37082750</a> 166884134 O'Keefe BR, et al. Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases. PMID: 37843072 https://pubmed.ncbi.nlm.nih.gov/37843072/ <a href="https://pubmed.ncbi.nlm.nih.gov/37843072/">O'Keefe BR, et al. Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases. PMID: 37843072</a> 158677389 O'Keefe, Barry NCI O'Keefe, Barry (NCI) 1 158677393 Du, Lin NCI - CCR NCI Du, Lin (NCI) 2 158677397 Wilson, Brice NCI Wilson, Brice (NCI) 3 158677401 Zhang, Ping NCI Zhang, Ping (NCI) 4 158677405 Moore, William National Cancer Institute (NCI) NCI Moore, William (NCI) 5 158677413 Wang, Dongdong NCI Wang, Dongdong (NCI) 6 158677417 Martinez Fiesco, Juliana Martinez Fiesco, Juliana 7 158677421 Li, Ning Leidos Li, Ning (Leidos) 8 158677389 O'Keefe, Barry NCI O'Keefe, Barry (NCI) 1 158677393 Du, Lin NCI - CCR NCI Du, Lin (NCI) 2 158677397 Wilson, Brice NCI Wilson, Brice (NCI) 3 158677401 Zhang, Ping NCI Zhang, Ping (NCI) 4 158677405 Moore, William National Cancer Institute (NCI) NCI Moore, William (NCI) 5 158677413 Wang, Dongdong NCI Wang, Dongdong (NCI) 6 158677417 Martinez Fiesco, Juliana Martinez Fiesco, Juliana 7 158677421 Li, Ning Leidos Li, Ning (Leidos) 8 158677383 Reverse Thiazine Kinase Inhibitors E-162-2024-0 Filing authorized National Cancer Institute (NCI), NIH - NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-5020] Reverse Thiazine Kinase Inhibitors&body=Please send me information about technology [TAB-5020] Reverse Thiazine Kinase Inhibitors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-5020] Reverse Thiazine Kinase Inhibitors&body=Please send me information about technology [TAB-5020] Reverse Thiazine Kinase Inhibitors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 159503194 E-162-2024-0 E-162-2024-0-US-01 Reverse Thiazine Kinase Inhibitors PRV US 63/672,577 Expired US <br />Provisional (PRV) 63/672,577<br />Filed on 2024-07-17<br />Status: Expired TAB-5019 158672233 Novel Kinase Inhibitory Aplithianines NCI Collaboration, Infectious Disease, Licensing, Oncology, Rare/Neglected Diseases, Therapeutics Collaboration Infectious Disease Licensing Oncology Rare/Neglected Diseases Therapeutics Lin Du, Ning Li, Juliana Martinez Fiesco, William Moore, Barry O'Keefe, Dongdong Wang, Brice Wilson, Ping Zhang <h3>Summary:</h3> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases including:</p> <ul> <li>Oncogenic gene fusion DNAJB1-PRKACA (PKADJ)</li> <li>Wild type protein kinase A (PKA)&nbsp;</li> <li>Protein kinase G (PKG)</li> <li>Ccdc2-like kinases (CLK) 1 &amp; 2</li> <li>DYRK family of kinases</li> </ul> <h3>Description of Technology:</h3> <p>In 2022, the NCI Molecular Targets Program (MTP) completed a screen of ~150,000 pre-fractionated natural products from the NCI Program for Natural Product Discovery (NPNPD). From this screen, a class of active compounds, named Aplithianines A &amp; B (isolated from the marine organism Aplidium sp.), showed broad potential applicability to numerous kinases of importance including but not limited to:</p> <ul> <li>Oncogenic gene fusion DNAJB1-PRKACA (PKADJ) <ul> <li>Implicated in an ultra-rare adolescent liver cancer</li> </ul> </li> <li>Wild type protein kinase A (PKA)&nbsp; <ul> <li>Implicated in Cushing&rsquo;s Disease</li> </ul> </li> <li>Protein kinase G (PKG)&nbsp; <ul> <li>Potential treatment of malaria</li> </ul> </li> <li>Ccdc2-like kinases (CLK) 1 &amp; 2 <ul> <li>Implicated in gastric cancer</li> </ul> </li> <li>DYRK family of kinases&nbsp; <ul> <li>Implicated in gastric or colon cancer as well as infections caused by a protozoa or parasites</li> </ul> </li> </ul> <p>This Technology describes the Original Family of compounds filed. Subsequent to this filing, two additional cohorts of related, but patentably distinct Cohorts of compounds have been filed under NIH Ref # &nbsp;<strong>E-202-2023</strong> and <strong>E-164-2024</strong>. Both the Second and the Third Cohorts comprise the same chemical scaffold of the broadest generic formula of this Original Family but represent patentably distinct subgenus formulas.&nbsp;</p> <p><img alt="Image of Molecular Diagrams" src="https://nih.technologypublisher.com/files/sites/monosnap_structural_representatives.jpg_2024-10-30_17-57-47.png" /></p> <p>The specificity of several of the compounds have been examined in kinase panels to demonstrate that while applicable to a range of kinases, they are not promiscuous kinase inhibitors. The subject kinase inhibitors have broad potential commercial applicability&rsquo;s for cancer, immune suppression, preventing organ rejection, treating diabetic neuropathic pain, malaria, or protozoa infection. To date there are no approved therapeutics targeting DNAJB1-PRKCA, an oncogenic gene fusion is ubiquitously and exclusively detected in the tumors of patients with ultra-rare fibrolamellar hepatocellular carcinoma FLHCC.</p> <p>The NCI seeks licensing and/or co-development research collaborations for the future development of Kinase Inhibitory Aplithianines targeting &nbsp;DNAJB1-PRKACA (PKADJ), PKA, PKG, CLK, and/or DYRK.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Gastric cancer</li> <li>Ultra-rare adolescent liver cancer</li> <li>Solid cancers susceptible to kinase inhibitors</li> <li>Cushing&rsquo;s Disease</li> <li>Transplantation</li> <li>Diabetic neuropathic pain</li> <li>Malaria</li> <li>Protozoa infection&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Applicability to numerous clinically relevant kinases, including: <ul> <li>Oncogenic gene fusion DNAJB1-PRKACA (PKADJ)</li> <li>Wild type protein kinase A (PKA)</li> <li>Protein kinase G (PKG)</li> <li>Ccdc2-like kinases (CLK) 1 &amp; 2</li> <li>DYRK family of kinases</li> </ul> </li> <li>Applicable to a range of kinases, but are not promiscuous kinase inhibitors</li> <li>Broad potential commercial applicability for several blockbuster indications including: cancer, immune suppression, transplantation, diabetic neuropathic pain, malaria, and protozoa infection</li> <li>No approved therapeutics targeting DNAJB1-PRKCA</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases 2024-10-17 2026-04-16 2026-04-16 2024-10-17 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-202-2023 E-162-2024 158672505 O'Keefe BR, et al. Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors. PMID: 3708275 : O'Keefe BR, et al. Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors. PMID: 37082750 <a href=": O'Keefe BR, et al. Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors. PMID: 37082750">O'Keefe BR, et al. Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors. PMID: 3708275</a> 158849587 O'Keefe BR, et al. Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases.PMID: 3784307 : O'Keefe BR, et al. Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases.PMID: 37843072 <a href=": O'Keefe BR, et al. Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases.PMID: 37843072">O'Keefe BR, et al. Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases.PMID: 3784307</a> 158672259 O'Keefe, Barry National Cancer Institute (NCI) NCI O'Keefe, Barry (NCI) 1 158848379 Du, Lin Molecular Targets Program NCI Du, Lin (NCI) 2 158672267 Wilson, Brice NCI Wilson, Brice (NCI) 3 158672273 Zhang, Ping National Cancer Institute (NCI) NCI Zhang, Ping (NCI) 4 158672277 Moore, William National Cancer Institute (NCI) NCI Moore, William (NCI) 5 158672346 Wang, Dongdong National Cancer Institute (NCI) NCI Wang, Dongdong (NCI) 6 158672350 Martinez Fiesco, Juliana National Cancer Institute (NCI) Martinez Fiesco, Juliana 7 158672377 Li, Ning Leidos Li, Ning (Leidos) 8 158672259 O'Keefe, Barry National Cancer Institute (NCI) NCI O'Keefe, Barry (NCI) 1 158848379 Du, Lin Molecular Targets Program NCI Du, Lin (NCI) 2 158672267 Wilson, Brice NCI Wilson, Brice (NCI) 3 158672273 Zhang, Ping National Cancer Institute (NCI) NCI Zhang, Ping (NCI) 4 158672277 Moore, William National Cancer Institute (NCI) NCI Moore, William (NCI) 5 158672346 Wang, Dongdong National Cancer Institute (NCI) NCI Wang, Dongdong (NCI) 6 158672350 Martinez Fiesco, Juliana National Cancer Institute (NCI) Martinez Fiesco, Juliana 7 158672377 Li, Ning Leidos Li, Ning (Leidos) 8 158672236 Novel Kinase Inhibitory Aplithianines E-044-2022-0 Filing authorized NCI, NIH - NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-5019] Novel Kinase Inhibitory Aplithianines&body=Please send me information about technology [TAB-5019] Novel Kinase Inhibitory Aplithianines.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-5019] Novel Kinase Inhibitory Aplithianines&body=Please send me information about technology [TAB-5019] Novel Kinase Inhibitory Aplithianines.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 159503214 E-044-2022-0 E-044-2022-0-US-01 KINASE INHIBITORS PRV US 63/389,937 Expired US <br />Provisional (PRV) 63/389,937<br />Filed on 2022-07-17<br />Status: Expired 159503219 E-044-2022-0 E-044-2022-0-PCT-01 KINASE INHIBITORS PCT Patent Cooperation Treaty PCT/US2023/070304 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/070304<br />Filed on 2023-07-17<br />Status: Expired 159503239 E-044-2022-0 E-044-2022-0-IN-01 KINASE INHIBITORS National Stage India 202547012577 Pending India <br />National Stage 202547012577<br />Filed on 2025-02-14<br />Status: Pending 159503244 E-044-2022-0 E-044-2022-0-JP-01 KINASE INHIBITORS National Stage Japan 2025-502384 Pending Japan <br />National Stage 2025-502384<br />Filed on 2025-01-16<br />Status: Pending 159503249 E-044-2022-0 E-044-2022-0-CN-01 KINASE INHIBITORS National Stage China 202380062947.2 Pending China <br />National Stage 202380062947.2<br />Filed on 2025-02-28<br />Status: Pending 159503254 E-044-2022-0 E-044-2022-0-US-02 KINASE INHIBITORS National Stage US 18/995,318 Pending US <br />National Stage 18/995,318<br />Filed on 2025-01-16<br />Status: Pending 159503259 E-044-2022-0 E-044-2022-0-EP-01 KINASE INHIBITORS National Stage European Patent 23755549.5 Pending European Patent <br />National Stage 23755549.5<br />Filed on 2025-02-04<br />Status: Pending TAB-5007 158185662 Methods of Detecting Loss of Heterozygosity and Damaging Mutations in Immune-Related Genes Using Liquid Biopsies NCI Collaboration, Diagnostics, Immunology, Oncology Collaboration Diagnostics Immunology Oncology James Gulley, Scott Norberg, Andrew Sinkoe, Xiaolin Wu <h2>Summary:&nbsp;</h2> <p>The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a liquid biopsy diagnostic assay capable of detecting loss of heterozygosity (LOH) and somatic mutations in genes important for antigen processing and presentation and interferon-&gamma; response pathways.</p> <h2>Description of Technology:&nbsp;</h2> <p>Immunotherapy is an effective cancer treatment utilizing T cells to recognize and eliminate cancer cells. Antigen processing and presentation machinery (APM) and interferon-&gamma; (IFN) response pathways play an important role for T cells to target cancer cells. To evade immunotherapy, cancer cells can develop somatic mutations in genes important for APM and IFN.&nbsp;<br /> Liquid biopsy is a non-invasive tool that can diagnose and monitor cancer by analyzing circulating tumor DNA (ctDNA). The ability to detect somatic mutations and predict response to immunotherapies using liquid biopsy would be critical to provide more personalized cancer treatment. However, currently marketed liquid biopsies cannot predict response to cellular immunotherapies. As a result, patients with relapsed or recurrent disease lose valuable time and resources on ineffective treatments.</p> <p>The inventors at the National Cancer Institute (NCI) developed a novel method to detect somatic mutations from liquid biopsy samples. Combined with NCI&rsquo;s method to detect loss of heterozygosity in HLA genes &ndash; another mechanism for immunotherapy evasion &ndash; this invention allows for improved patient selection and non-invasive prediction of response. This novel precision medicine method will allow patient-tailored treatment by targeting treatment based on genetic mutations and prediction of immunotherapy response. This invention could potentially deliver better patient satisfaction, lower healthcare costs and better outcomes.</p> <p>The Center for Immuno-Oncology at the NCI is looking for co-development partners and/or licensees. As a companion diagnostic for immunotherapies, this invention will be used to select optimal patients and monitor efficacy of treatments &ndash; such as TCR-T cell therapy. There are no liquid biopsy assays on the market designed as companion diagnostic for cellular immunotherapy &ndash; such as TCR-T cell therapy. Therefore, this technology may be particularly appealing to co-development partners who are developing proprietary cellular immunotherapies.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Companion diagnostic for cellular immunotherapies</li> <li>Companion diagnostic for monitoring the effectiveness of TCR-based immunotherapies</li> <li>Companion diagnostic for T cell-based immunotherapies, including certain immune checkpoint inhibitors&nbsp;</li> <li>Research use in labs studying/developing new pre-clinical therapeutic candidates</li> <li>Research use in basic research labs studying immunotherapy resistance mechanisms, antigen processing and presentation, interferon-&gamma; response pathways, mutations in cancer cells, basic immunology and basic oncology</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>First method to predict response to immunotherapies by detecting damaging mutations using liquid biopsy samples</li> <li>Non-invasive test not requiring surgery</li> <li>Easy to administer</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a liquid biopsy analysis method capable of detecting loss of heterozygosity (LOH) and somatic mutations in genes important for antigen processing and presentation and interferon-γ response pathways. 2024-09-13 2026-04-16 2026-04-16 2024-09-13 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-045-2022-0 158185678 Norberg, Scott Center for Immuno-Oncology NCI Norberg, Scott (NCI) 1 158185693 Sinkoe, Andrew Sesh Incorporated NCI Sinkoe, Andrew (NCI) 2 158185700 Wu, Xiaolin Genomics Laboratory Leidos Wu, Xiaolin (Leidos) 3 158185717 Gulley, James NCI - CCR NCI Gulley, James (NCI) 4 158185678 Norberg, Scott Center for Immuno-Oncology NCI Norberg, Scott (NCI) 1 158185693 Sinkoe, Andrew Sesh Incorporated NCI Sinkoe, Andrew (NCI) 2 158185700 Wu, Xiaolin Genomics Laboratory Leidos Wu, Xiaolin (Leidos) 3 158185717 Gulley, James NCI - CCR NCI Gulley, James (NCI) 4 158185670 Method of detecting damaging mutations in immune related genes by liquid biopsy Leidos EIR # 23-018 E-027-2024-0 Filing authorized National Cancer Institute (NCI) 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-5007] Methods of Detecting Loss of Heterozygosity and Damaging Mutations in Immune-Related Genes Using Liquid Biopsies&body=Please send me information about technology [TAB-5007] Methods of Detecting Loss of Heterozygosity and Damaging Mutations in Immune-Related Genes Using Liquid Biopsies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-5007] Methods of Detecting Loss of Heterozygosity and Damaging Mutations in Immune-Related Genes Using Liquid Biopsies&body=Please send me information about technology [TAB-5007] Methods of Detecting Loss of Heterozygosity and Damaging Mutations in Immune-Related Genes Using Liquid Biopsies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">suna.gulay@nih.gov</a><br> 159502811 E-027-2024-0 E-027-2024-0-US-01 METHODS OF DETECTING LOSS OF HETEROZYGOSITY AND DAMAGING MUTATIONS IN IMMUNERELATED GENES IN LIQUID BIOPSIES PRV US 63/572,760 Expired US <br />Provisional (PRV) 63/572,760<br />Filed on 2024-04-01<br />Status: Expired TAB-4999 157682678 Methods To Regulate Metabolism For Treatment Of Neural Injuries and Neurodegeneration NEI Collaboration, Ear, Nose, & Throat, Licensing, Neurology, Therapeutics Collaboration Ear Nose & Throat Licensing Neurology Therapeutics Wei Li, Jingxing Ou, Tantai Zhao <h2>Description of Technology:</h2> <p>Axonal injury and subsequent neuronal death underpin the pathology of many neurological disorders from acute neural injuries (motor vehicle crashes, combat related injuries, traumatic brain injuries) to neurological diseases (multiple sclerosis, glaucoma). In the central nervous system (CNS), microglia help respond to CNS injuries by mediating the immune response and increasing inflammation at the site of injury.&nbsp;</p> <p>Scientists at the National Eye Institute (NEI) have discovered a novel method of reducing neuronal death by using Dimethyl Malonate (DMM), a compound that inhibits the activity of succinate dehydrogenase (SDH). Using DMM on an optic nerve crush model in ground squirrels, DMM helped reduce the pro-inflammatory response of microglia via decreasing succinate levels or reducing the SDH activity. In the same model, treatment also improved the retinal function compared to controls. Additionally, administering DMM after optic crush injury reduced the microglia response and promoted neural protection against axonal injury.&nbsp;</p> <p>This method of treats immune-mediated disorders using DMM by decreasing levels of succinate or reducing the activity of succinate dehydrogenase in patients. It inhibits activation of microglial cells by using DMM by decreasing levels of succinate or reducing the activity of succinate dehydrogenase in cells. It prevents the activation of astrocytes in a system comprising of microglial cells and astrocytes using DMM by decreasing levels of succinate or reducing the activity of succinate dehydrogenase. Overall, these results show the promise of DMM for protecting neurodegeneration due to neural injury and possibly other neurodegenerative disorders.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Ophthalmic diseases, such as glaucoma</li> <li>Neurodegenative diseases, such as multiple sclerosis</li> <li>Acute neural injuries</li> </ul> <h2><strong>Competitive Advantages:&nbsp;</strong></h2> <ul> <li>Dimethyl Malonate (DMM) is inexpensive and readily available &ndash; reducing manufacturing costs</li> <li>Address significant, unmet medical needs since few, if any, treatments exist for neural injuries and neurodegeneration</li> <li>Mutation independent method for treating neurodegeneration</li> </ul> Researchers at the NEI seek licensing and/or co-development research collaborations for a novel method of treating neural injury and neurodegeneration via immune-metabolic regulation. 2024-08-08 2026-04-16 2026-04-16 2024-08-23 False True Discovery (Lead ID) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 158013913 Li, Wei National Eye Institute (NEI) Li, Wei 1 158013991 Ou, Jingxing National Sun Yat-Sen University NEI Ou, Jingxing (NEI) 2 158014042 Zhao, Tantai Zhao, Tantai 3 158013913 Li, Wei National Eye Institute (NEI) Li, Wei 1 158013991 Ou, Jingxing National Sun Yat-Sen University NEI Ou, Jingxing (NEI) 2 158014042 Zhao, Tantai Zhao, Tantai 3 157682681 Metabolic Regulation Of Mitochondria To Inhibit Inflammatory Microglia In Treatment Of Axonal Injury And Neurodegenerations E-077-2018-0 Filing authorized National Eye Institute (NEI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4999] Methods To Regulate Metabolism For Treatment Of Neural Injuries and Neurodegeneration&body=Please send me information about technology [TAB-4999] Methods To Regulate Metabolism For Treatment Of Neural Injuries and Neurodegeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4999] Methods To Regulate Metabolism For Treatment Of Neural Injuries and Neurodegeneration&body=Please send me information about technology [TAB-4999] Methods To Regulate Metabolism For Treatment Of Neural Injuries and Neurodegeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 157851175 E-077-2018-0 E-077-2018-0-CN-03 METHODS OF METABOLIC REGULATION OF MITOCHONDRIA FOR TREATING NEURAL INJURY AND NEUROLOGICAL DISORDERS National Stage China 201980061762.3 Pending China <br />National Stage 201980061762.3<br />Filed on 2019-08-21<br />Status: Pending 157915564 E-077-2018-0 E-077-2018-0-US-01 Metabolic Regulation Of Mitochondria To Inhibit Inflammatory Microglia In Treatment Of Axonal Injury And Neurodegenerations PRV US 62/720,612 Abandoned US <br />Provisional (PRV) 62/720,612<br />Filed on 2018-08-21<br />Status: Abandoned 157915565 E-077-2018-0 E-077-2018-0-PCT-02 METHODS OF METABOLIC REGULATION OF MITOCHONDRIA FOR TREATING NEURAL INJURY AND NEUROLOGICAL DISORDERS PCT Patent Cooperation Treaty PCT/US2019/047504 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/047504<br />Filed on 2019-08-21<br />Status: Expired 157915566 E-077-2018-0 E-077-2018-0-US-04 METHODS OF METABOLIC REGULATION OF MITOCHONDRIA FOR TREATING NEURAL INJURY AND NEUROLOGICAL DISORDERS National Stage US 12,011,426 17/268,203 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12011426 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12011426">12,011,426</a><br />Filed on 2021-02-12<br />Status: Issued 157915567 E-077-2018-0 E-077-2018-0-US-02 METHODS OF METABOLIC REGULATION OF MITOCHONDRIA FOR TREATING NEURAL INJURY AND NEUROLOGICAL DISORDERS CON US 18/664,615 Abandoned US <br />Continuation (CON) 18/664,615<br />Filed on 2024-05-15<br />Status: Abandoned TAB-4993 157247834 Improved Methods For Cryopreservation Of Cells, Tissues, And Organs NEI Application, Collaboration, Ear, Nose, & Throat, Licensing, Research Materials Application Collaboration Ear Nose & Throat Licensing Research Materials Lihao Ge, Guanghui Jin, Wei Li, Kiyoharu Miyagishima, Jingxing Ou <h2>Summary:&nbsp;</h2> <p>The National Eye Institute seeks research co-development partners and/or licensees for novel methods of cryopreserving cells, tissues, and organs via FOXO1 activation and other mechanisms.</p> <h2>Description of Technology:&nbsp;</h2> <p>The cornea is a critical part of the eye that helps prevent debris from entering and refracts light for proper vision. Corneal disorders such as keratoconus, Fuchs dystrophy, and infectious keratitis require corneal transplantation to restore vision. Approximately 185,000 corneal transplants are performed annually worldwide to treat corneal disorders. Corneas for those transplants are supplied by donor eyes that are stored at eye banks in select countries.&nbsp;</p> <p>Currently, Optisol-GS&trade; is the corneal preservation solution that is most widely used to store donated corneas at eye banks. Per National Eye Institute (NEI) guidelines, corneas preserved in Optisol-GS&trade; have a 12-day shelf life. With the high demand for corneal transplantations worldwide, a 12-day shelf life cannot meet the requirement for long term cryogenic storage of corneas at large eye banks.&nbsp;</p> <p>Scientists at the NEI have developed improved methods for cryopreservation of cells, tissues, and organs (with focus of corneal tissue/cells) that increases cold storage shelf life 2.5 times longer than current market products.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Corneal biobanks</li> <li>Transplantation to remedy a wide range of corneal disorders</li> <li>Improved method of cryopreserving corneal cells and other cell types</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Superior corneal shelf life: 16-day compared to 12-day maximum shelf-life of current market products&nbsp;</li> <li>Better meets requirement for larger eye bank cryopreservation</li> <li>95% endothelial cell survival after 4 weeks in cold storage</li> </ul> Researchers at the NEI seek licensing and/or co-development research collaborations for improved methods of cryopreservation of cells, tissues, and organs via FOXO1 activation. 2024-07-23 2026-04-16 2026-04-16 2024-07-23 False True discovery (LeadID) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-073-2018 157266800 Ou, Jingxing National Eye Institute (NEI) NEI Ou, Jingxing (NEI) 1 157266831 Miyagishima, Kiyoharu National Eye Institute (NEI) NEI Miyagishima, Kiyoharu (NEI) 2 157266888 Jin, Guanghui Sun Yat-sen University Jin, Guanghui 3 157266928 Li, Wei National Eye Institute (NEI) NEI Li, Wei (NEI) 4 157266932 Ge, Lihao NINDS NINDS Ge, Lihao (NINDS) 5 157266800 Ou, Jingxing National Eye Institute (NEI) NEI Ou, Jingxing (NEI) 1 157266831 Miyagishima, Kiyoharu National Eye Institute (NEI) NEI Miyagishima, Kiyoharu (NEI) 2 157266888 Jin, Guanghui Sun Yat-sen University Jin, Guanghui 3 157266928 Li, Wei National Eye Institute (NEI) NEI Li, Wei (NEI) 4 157266932 Ge, Lihao NINDS NINDS Ge, Lihao (NINDS) 5 157247837 Regulations Of FOXO1A Pathway Protect Cells, Tissues, And Organs Against Stresses And Insults E-013-2021-0 Filing authorized National Eye Institute (NEI), NINDS, Sun Yat-sen University 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4993] Improved Methods For Cryopreservation Of Cells, Tissues, And Organs&body=Please send me information about technology [TAB-4993] Improved Methods For Cryopreservation Of Cells, Tissues, And Organs.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4993] Improved Methods For Cryopreservation Of Cells, Tissues, And Organs&body=Please send me information about technology [TAB-4993] Improved Methods For Cryopreservation Of Cells, Tissues, And Organs.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 157266992 E-013-2021-0 E-013-2021-0-US-02 COMPOSITION AND METHOD OF PRESERVING VIABILITY OF CELL IN A LOW TEMPERATURE National Stage US 18/258,125 Pending US <br />National Stage 18/258,125<br />Filed on 2023-06-16<br />Status: Pending 157267002 E-013-2021-0 E-013-2021-0-CA-01 COMPOSITION AND METHOD OF PRESERVING VIABILITY OF CELL IN A LOW TEMPERATURE National Stage Canada 3202729 Pending Canada <br />National Stage 3202729<br />Filed on 2023-06-19<br />Status: Pending 157267007 E-013-2021-0 E-013-2021-0-AU-01 COMPOSITION AND METHOD OF PRESERVING VIABILITY OF CELL IN A LOW TEMPERATURE ENVIRONMENT National Stage Australia 2021400321 Abandoned Australia <br />National Stage 2021400321<br />Filed on 2023-06-23<br />Status: Abandoned 157267018 E-013-2021-0 E-013-2021-0-CN-02 COMPOSITION AND METHOD OF PRESERVING VIABILITY OF CELL IN A LOW TEMPERATURE National Stage China 202180094031.6 Pending China <br />National Stage 202180094031.6<br />Filed on 2023-08-17<br />Status: Pending 157267084 E-013-2021-0 E-013-2021-0-EP-01 COMPOSITION AND METHOD OF PRESERVING VIABILITY OF CELL IN A LOW TEMPERATURE ENVIRONMENT National Stage European Patent 21844141.8 Pending European Patent <br />National Stage 21844141.8<br />Filed on 2023-07-17<br />Status: Pending 164119806 E-013-2021-0 E-013-2021-0-PCT-02 COMPOSITION AND METHOD OF PRESERVING VIABILITY OF CELL IN A LOW TEMPERATURE PCT Patent Cooperation Treaty PCT/US2021/064086 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/064086<br />Filed on 2021-12-17<br />Status: Expired 164119807 E-013-2021-0 E-013-2021-0-CN-01 PREPARATION METHOD AND APPLICATION OF CELL, TISSUE OR ORGAN COLD PRESERVATION LIQUID ORD China ZL202011500962.5 202011500962.5 Issued China <br />Ordinary Patent (ORD) 202011500962.5<br />Filed on 2020-12-17<br />Status: Issued TAB-4992 157246749 Using Artificial Intelligence To Diagnose Uveitis NEI Collaboration, Diagnostics, Ear, Nose, & Throat, Licensing Collaboration Diagnostics Ear Nose & Throat Licensing Jongwoo Kim, Shilpa Kodati, Nam Nguyen <h2>Summary:&nbsp;</h2> <p>The National Eye Institute seeks research co-development partners and/or licensees for a deep learning algorithm that can identify retinal vasculitis using color fundus images.</p> <h2>Description of Technology:&nbsp;</h2> <p>Uveitis is caused by inflammation in the eye that can cause pain and reduce vision. The rate of uveitis in the United States is 1 in every 200 people with eye-related irritation. Permanent symptoms such as vision loss can occur if untreated. Therefore, early detection is crucial.&nbsp;</p> <p>In certain uveitis cases, fluorescein angiography (FA) is essential for the diagnosis and management due to its ability to display retinal vascular leakage (RVL). Although proven to be critical in diagnosing and assessing severity, FA is invasive and side effects have been reported. Additionally, the procedure is time-consuming and imposes economic burdens to patients, physicians and payors.&nbsp;</p> <p>Scientists at the NEI have developed a deep learning tool to non-invasively detect RVL using ultrawide-field color fundus photos. This algorithm identifies fundus images with and without RVL with high accuracy (79%) and sensitivity (85%). Compared to the current gold standard of assessing RVL (clinician interpretation), this deep learning tool provides an improved method of detecting RVL for patients with uveitis.</p> <h2>Potential Commercial Applications:</h2> <p>&bull; Diagnostic tool to predict uveitis&nbsp;<br /> &bull; Add-on to current color fundus imaging modalities</p> <h2>Competitive Advantages:</h2> <p>&bull; Greater accuracy and sensitivity versus current gold standard to assess RVL (clinician assessment)<br /> &bull; Deep learning tool to assess RVL<br /> &bull; Deep learning to assess ultrawide-field color fundus images and assess RVL</p> Researchers at the NEI seek licensing and/or co-development research collaborations for a deep learning algorithm that can identify retinal vasculitis using color fundus images. 2024-07-22 2026-04-16 2026-04-16 2024-07-23 False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 157246892 Young LH, et al. Automated Detection of Vascular Leakage in Fluorescein Angiography - A Proof of Concept. (PMID 35877095). https://pubmed.ncbi.nlm.nih.gov/35877095/ <a href="https://pubmed.ncbi.nlm.nih.gov/35877095/">Young LH, et al. Automated Detection of Vascular Leakage in Fluorescein Angiography - A Proof of Concept. (PMID 35877095).</a> 157246764 Kodati, Shilpa University of Michigan NEI Kodati, Shilpa (NEI) 1 157246768 Kim, Jongwoo NLM Kim, Jongwoo 2 157246772 Nguyen, Nam National Eye Institute (NEI) Nguyen, Nam 3 157246764 Kodati, Shilpa University of Michigan NEI Kodati, Shilpa (NEI) 1 157246768 Kim, Jongwoo NLM Kim, Jongwoo 2 157246772 Nguyen, Nam National Eye Institute (NEI) Nguyen, Nam 3 157246752 Deep Learning To Detect Retinal Vasculitis On Ultrawide-Field Color Fundus Photos E-005-2023-0 Filing authorized National Eye Institute (NEI), NLM 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4992] Using Artificial Intelligence To Diagnose Uveitis&body=Please send me information about technology [TAB-4992] Using Artificial Intelligence To Diagnose Uveitis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4992] Using Artificial Intelligence To Diagnose Uveitis&body=Please send me information about technology [TAB-4992] Using Artificial Intelligence To Diagnose Uveitis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 157246801 E-005-2023-0 E-005-2023-0-US-01 Deep Learning to Detect Retinal Vasculitis on Color Fundus Photos of Patients with Uveitis PRV US 63/482,676 Expired US <br />Provisional (PRV) 63/482,676<br />Filed on 2023-02-01<br />Status: Expired 159507671 E-005-2023-0 E-005-2023-0-PC-01 SYSTEMS AND METHODS FOR DEEP LEARNING TO DETECT RETINAL VASCULITIS ON COLOR FUNDUS PHOTOGRAPHS OF PATIENTS WITH UVEITIS PCT Patent Cooperation Treaty PCT/US2024/013833 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/013833<br />Filed on 2024-01-31<br />Status: Expired 164119786 E-005-2023-0 E-005-2023-0-US-02 SYSTEMS AND METHODS FOR DEEP LEARNING TO DETECT RETINAL VASCULITIS ON COLOR FUNDUS PHOTOGRAPHS OF PATIENTS WITH UVEITIS National Stage US 19/153,124 Pending US <br />National Stage 19/153,124<br />Filed on 2025-08-01<br />Status: Pending 164119787 E-005-2023-0 E-005-2023-0-EP-01 SYSTEMS AND METHODS FOR DEEP LEARNING TO DETECT RETINAL VASCULITIS ON COLOR FUNDUS PHOTOGRAPHS OF PATIENTS WITH UVEITIS National Stage European Patent 24710954.9 Pending European Patent <br />National Stage 24710954.9<br />Filed on 2025-08-12<br />Status: Pending TAB-4991 157206100 TYROSINASE Gene Therapy for Oculocutaneous Albinism type 1A NEI Application, Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Rare/Neglected Diseases, Therapeutics Application Collaboration Ear Nose & Throat Licensing Ophthalmology Rare/Neglected Diseases Therapeutics Brian Brooks, Aman George <h2>Summary:</h2> <p>The National Eye Institute seeks research co-development partners and/or licensees for an adeno-associated viral gene therapy for Oculocutaneous Albinism type 1A.&nbsp;&nbsp;</p> <h2>Description of Technology:</h2> <p>Oculocutaneous albinism (OCA) is a genetically heterogeneous congenital disorder characterized by decreased or absent pigmentation in the hair, skin and eyes. The absence of pigmentation is caused by insufficient melanin production &ndash; an important pigment providing normal black color to important eye tissues such as the iris and retinal pigment epithelium. Lack of melanin in the eye results in abnormal development and impaired vision. Individuals diagnosed with OCA1, the most common type if albinism worldwide (1:40,000 people), is caused by mutations in the TYROSINASE (TYR) gene. OCA1A patients suffer complete loss of melanin caused by inactivity of the TYROSINASE enzyme. Currently, there is no treatment.&nbsp;&nbsp;</p> <p>Scientist at the National Eye Institute (NEI) have developed a gene therapy method for inducing pigmentation in human subjects who have OCA1A by administering the normal copy of human Tyrosinase via an adeno-associated viral (AAV) vector. Experiments in albino rat eyes showed that the AAV-Tyr construct localized to the tissue of interest (retinal pigment epithelium or RPE) and increased melanin production. Introducing the AAV-Tyr construct in OCA1A patient derived RPE also showed increased pigment density, demonstrating the construct&rsquo;s therapeutic potential to increase melanin production in vivo and in affected patient cells.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Gene therapy for OCA1A</li> <li>Therapy for other TYROSINASE enzyme deficient eye disease</li> <li>Platform for AAV gene therapy for retinal pigment epithelium cells</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Addresses medical need with no treatment options</li> <li>Low damage to eye</li> <li>Potential one-time injection</li> </ul> Researchers at the NEI seek licensing and/or co-development research collaborations for an adeno-associated viral gene therapy for Oculocutaneous Albinism type 1A. 2024-07-19 2026-04-16 2026-04-16 2024-07-19 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 157206257 Brooks, Brian National Eye Institute (NEI) NEI Brooks, Brian (NEI) 1 157206261 George, Aman Ophthalmic Genetics Visual Function Branch NEI George, Aman (NEI) 2 157206257 Brooks, Brian National Eye Institute (NEI) NEI Brooks, Brian (NEI) 1 157206261 George, Aman Ophthalmic Genetics Visual Function Branch NEI George, Aman (NEI) 2 157206103 TYROSINASE Gene Therapy for Oculocutaneous Albinism type 1A E-116-2023-0 Filing authorized National Eye Institute (NEI), Ophthalmic Genetics Visual Function Branch 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4991] TYROSINASE Gene Therapy for Oculocutaneous Albinism type 1A&body=Please send me information about technology [TAB-4991] TYROSINASE Gene Therapy for Oculocutaneous Albinism type 1A.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4991] TYROSINASE Gene Therapy for Oculocutaneous Albinism type 1A&body=Please send me information about technology [TAB-4991] TYROSINASE Gene Therapy for Oculocutaneous Albinism type 1A.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 157206338 E-116-2023-0 E-116-2023-0-US-01 TYROSINASE GENE THERAPY FOR OCULOCUTANEOUS ALBINISM TYPE 1A PRV US 63/468,748 Expired US <br />Provisional (PRV) 63/468,748<br />Filed on 2023-05-24<br />Status: Expired 157206461 E-116-2023-0 E-116-2023-0-PC-01 TYROSINASE GENE THERAPY FOR OCULOCUTANEOUS ALBINISM TYPE 1A PCT Patent Cooperation Treaty PCT/US2024/031101 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/031101<br />Filed on 2024-05-24<br />Status: Expired 164119766 E-116-2023-0 E-116-2023-0-US-02 Method for inducing pigmentation in human subjects who have Oculocutaneous albinism type 1A (OCA1A) or other clinically-defined pigmentation related condition due to a loss-of-function mutation in the gene encoding the TYROSINASE enzyme, the method comprises of administering to the patients a nucleic acid of human TYROSINASE cDNA using an adeno-associated viral vector. PRV US Administratively Closed US <br />Provisional (PRV) None<br />Filed on None<br />Status: Administratively Closed 164725054 E-116-2023-0 E-116-2023-0-CA-01 TYROSINASE GENE THERAPY FOR OCULOCUTANEOUS ALBINISM TYPE 1A National Stage Canada 3293242 Pending Canada <br />National Stage 3293242<br />Filed on 2025-11-21<br />Status: Pending 164725184 E-116-2023-0 E-116-2023-0-US-03 TYROSINASE GENE THERAPY FOR OCULOCUTANEOUS ALBINISM TYPE 1A National Stage US 19/486,763 Pending US <br />National Stage 19/486,763<br />Filed on 2025-11-21<br />Status: Pending 164725219 E-116-2023-0 E-116-2023-0-EP-01 TYROSINASE GENE THERAPY FOR OCULOCUTANEOUS ALBINISM TYPE 1A National Stage European Patent 24734696.8 Pending European Patent <br />National Stage 24734696.8<br />Filed on 2025-12-16<br />Status: Pending TAB-4982 155467337 Fluorinated MU-Opioid Receptor Agonists NIDA Application, Collaboration, Immunology, Licensing, Neurology, Radiology, Therapeutics Application Collaboration Immunology Licensing Neurology Radiology Therapeutics Michael Baumann, Juan Gomez, Michael ("Mike") Michaelides, Kenner Rice, Agnieszka Sulima <h2>Summary:&nbsp;</h2> <p>Investigators at the National Institute on Drug Abuse seek co-development partners and/or licensees for collection of mu opioid receptor (MOR) agonists as alternatives for existing compounds.</p> <h2>Description of Technology:&nbsp;</h2> <p>Although existing opioids are excellent analgesics and useful as positron emission tomography (PET) radiotracers, they come with debilitating side effects. These include addiction, respiratory distress, hyperalgesia, and constipation. Therefore, there is a need for alternatives with lower adverse effects.</p> <p>Investigators at NIDA have identified a novel fluorinated mu-opioid receptor agonist, Fluornitrazene (FNZ), a derivative of Etonitazene, that shows potent antinociceptive effects with low adverse effects. This compound does not accumulate in the brain or cause hyperalgesia. It has higher potency than morphine and fentanyl, but with fewer adverse effects. These characteristics make it and any derivatives useful as potential pain medications or anesthetics, and as therapeutics for treating opioid addiction or opioid use disorder. Compared to fentanyl, FNZ has greater potency and efficacy for the G protein activation pathway of the MOR and a lower incidence of respiratory depression in rats. This suggests that FNZ may be a better alternative to fentanyl in clinical use.</p> <p>Investigators seek co-development opportunities through cooperative research and development agreement (CRADA) collaborations. This technology is also available for development under a license.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Pain prevention or pain management</li> <li>Anesthetic&nbsp;</li> <li>Opioid addiction or opioid use disorder</li> <li>PET agonist radiotracer</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Reduced time in brain</li> <li>High potency</li> <li>MOR Selective</li> <li>No known hyperalgesia or tolerance</li> <li>Reduced side effects &ndash; such as respiratory depression&nbsp;</li> </ul> Researchers at the NIDA seek licensing and/or co-development research collaborations for research collaboration. 2024-04-17 2026-04-16 2026-04-16 2024-04-17 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 155467354 Michaelides, Michael ("Mike") NIDA - Biomedical Research Center NIDA Michaelides, Michael ("Mike") (NIDA) 1 155467358 Gomez, Juan NIDA - Biomedical Research Center NIDA Gomez, Juan (NIDA) 2 155467362 Rice, Kenner National Institute on Drug Abuse (NIDA) Rice, Kenner 3 155467366 Sulima, Agnieszka NIDA - Biomedical Research Center NIDA Sulima, Agnieszka (NIDA) 4 155467370 Baumann, Michael NIDA - Biomedical Research Center NIDA Baumann, Michael (NIDA) 5 155467354 Michaelides, Michael ("Mike") NIDA - Biomedical Research Center NIDA Michaelides, Michael ("Mike") (NIDA) 1 155467358 Gomez, Juan NIDA - Biomedical Research Center NIDA Gomez, Juan (NIDA) 2 155467362 Rice, Kenner National Institute on Drug Abuse (NIDA) Rice, Kenner 3 155467366 Sulima, Agnieszka NIDA - Biomedical Research Center NIDA Sulima, Agnieszka (NIDA) 4 155467370 Baumann, Michael NIDA - Biomedical Research Center NIDA Baumann, Michael (NIDA) 5 155467340 Selective and potent biased mu opioid receptor agonist with low adverse effects E-053-2023-0 Filing authorized NIDA - Biomedical Research Center 91828357 Bernier, Nicholas nicholas.bernier@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America nicholas.bernier@nih.gov?subject=Web Inquiry on [TAB-4982] Fluorinated MU-Opioid Receptor Agonists&body=Please send me information about technology [TAB-4982] Fluorinated MU-Opioid Receptor Agonists.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Bernier, Nicholas<br><a href="mailto:nicholas.bernier@nih.gov?subject=Web Inquiry on [TAB-4982] Fluorinated MU-Opioid Receptor Agonists&body=Please send me information about technology [TAB-4982] Fluorinated MU-Opioid Receptor Agonists.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">nicholas.bernier@nih.gov</a><br> 155467380 E-053-2023-0 E-053-2023-0-US-01 FLUORINATED MU-OPIOID RECEPTOR AGONISTS PRV US 63/452,879 Expired US <br />Provisional (PRV) 63/452,879<br />Filed on 2023-03-17<br />Status: Expired 155467385 E-053-2023-0 E-053-2023-0-PCT-01 FLUORINATED MU-OPIOID RECEPTOR AGONISTS PCT Patent Cooperation Treaty PCT/US2023/082355 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/082355<br />Filed on 2023-12-04<br />Status: Expired TAB-4828 152146471 T Cell Receptors Targeting the KRAS G13D Mutation in the Context of HLA-A11:01 for Research Use NCI Application, Licensing, Research Materials, TherapeuticArea Application Licensing Research Materials TherapeuticArea Catherine Ade, Kenichi Hanada, Matthew Sporn, James Yang, Zhiya Yu <h2>Summary:</h2> <p>The National Cancer Institute (NCI) has identified HLA-A11:01-restricted T Cell Receptors (TCRs) targeting the KRAS G13D mutation. The NCI seeks licensees for the use of these TCRs in research.</p> <h2>Description of Technology:</h2> <p>Tumor-specific mutated proteins can create immunogenic, mutation-containing &ldquo;neoepitopes&rdquo; which are attractive targets for adoptive T-cell therapies. There has been major interest in the field in targeting common shared mutations in driver genes, such as KRAS, using off-the-shelf T-cell receptors (TCRs) engineered into autologous lymphocytes. However, identifying the neoepitopes to pursue as therapeutics is a complex and challenging process. One method to demonstrate whether an epitope is presented at the cell surface is to elute peptides bound to a specific human leukocyte antigen (HLA) allele and analyze them by mass spectrometry (MS). These MS data can then be prospectively applied to isolate TCRs specific to the neoepitope.</p> <p>Using this MS methodology, investigators at the Surgery Branch have identified TCRs that can recognize the G13D substitution mutation of KRAS in the context of HLA-A11:01. Importantly, the G13D mutation of KRAS is an attractive target for adoptive cell therapy as it is highly mutated in cancers (e.g., KRAS is found to be mutated in 45% of all colorectal carcinoma patients, and about 16% of these patients have the G13D mutation). Furthermore, approximately 15% of the US population has the HLA-A11:01 allele.</p> <p>This is the first known report of HLA-A11:01-restricted TCRs that can recognize KRAS G13D. The identified TCRs have high specificity and immunogenicity for the G13D mutation and can recognize processed and presented antigen on the surface of cells. While these TCRs are not effective as therapeutics, they would be useful for identification of other KRAS G13D reactive TCRs in patient and animal models.</p> <p>The National Cancer Institute (NCI) seeks licensees for T Cell Receptors (TCRs) targeting the KRAS G13D mutation for potential use in research.</p> <h2>Potential Commercial Applications&nbsp;</h2> <ul> <li>Research use</li> <li>Diagnostic use</li> <li>Use as positive controls to identify other HLA-A11:01 KRAS G13D reactive T cells from different patient and/or animal models</li> <li>Use as negative controls in other research applications</li> </ul> <h2>Competitive Advantages</h2> <ul> <li>The KRAS G13D TCRs are highly specific and immunogenic</li> <li>&nbsp;G13D is a common mutation of the KRAS driver gene in cancers, making it an attractive target for immunotherapy</li> <li>The HLA-A11:01 allele is present in about 15% of the US population and up to 60% of the Asian and Oceanian populations</li> <li>The results indicate that Mass Spectrometry is an effective and accurate way to detect antigens on specific HLA complexes</li> </ul> The NCI seeks licensees for T Cell Receptors (TCRs) targeting KRAS mutation G13D for use as a research tool. 2024-01-11 2026-04-16 2026-04-16 2024-01-16 False True Discovery (Lead ID) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 152204876 Publications: Ade CM, et al. Identification of neoepitope reactive T-cell receptors guided by HLA A*03:01 and HLA A*11:01 immunopeptidomics. (PMID 37758652) https://pubmed.ncbi.nlm.nih.gov/37758652/ <a href="https://pubmed.ncbi.nlm.nih.gov/37758652/">Publications: Ade CM, et al. Identification of neoepitope reactive T-cell receptors guided by HLA A*03:01 and HLA A*11:01 immunopeptidomics. (PMID 37758652)</a> 152199868 Ade, Catherine NCI - CCR NCI Ade, Catherine (NCI) 1 152199916 Yu, Zhiya NCI - CCR NCI Yu, Zhiya (NCI) 2 152200031 Sporn, Matthew NCI - CCR NCI Sporn, Matthew (NCI) 3 152200061 Yang, James NCI - CCR NCI Yang, James (NCI) 4 152200083 Hanada, Kenichi NCI - CCR NCI Hanada, Kenichi (NCI) 5 152199868 Ade, Catherine NCI - CCR NCI Ade, Catherine (NCI) 1 152199916 Yu, Zhiya NCI - CCR NCI Yu, Zhiya (NCI) 2 152200031 Sporn, Matthew NCI - CCR NCI Sporn, Matthew (NCI) 3 152200061 Yang, James NCI - CCR NCI Yang, James (NCI) 4 152200083 Hanada, Kenichi NCI - CCR NCI Hanada, Kenichi (NCI) 5 152146474 Identification and cloning of KRAS G13D/A11_mTCR3 and KRAS G13D/A11_mTCR7, two T cell receptors targeting the KRAS G13D mutation on HLA-A1101+ cells E-006-2024-0 Closed NIH - NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4828] T Cell Receptors Targeting the KRAS G13D Mutation in the Context of HLA-A11:01 for Research Use&body=Please send me information about technology [TAB-4828] T Cell Receptors Targeting the KRAS G13D Mutation in the Context of HLA-A11:01 for Research Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4828] T Cell Receptors Targeting the KRAS G13D Mutation in the Context of HLA-A11:01 for Research Use&body=Please send me information about technology [TAB-4828] T Cell Receptors Targeting the KRAS G13D Mutation in the Context of HLA-A11:01 for Research Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> TAB-5056 162401133 Oral Iron-Chelator Therapy for Treating Developmental Stuttering NINDS Licensing, Neurology, Psychiatry/Mental Health, Therapeutics Licensing Neurology Psychiatry/Mental Health Therapeutics Shahriar SheikhBahaei <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">This technology discloses the use of small-molecule iron chelators&mdash;drugs that bind and remove excess iron&mdash;for the oral treatment of developmental stuttering in children and adults. Mouse models carrying human stuttering mutations show both elevated striatal iron and impaired vocalization; daily low-dose deferiprone reverses these speech-like deficits while normalizing brain-iron MRI signals. Because exemplary chelators deferiprone, deferasirox, and deferoxamine are already marketed for other indications, their safety, dosing, and manufacturing are well characterized, enabling a streamlined regulatory path. The approach offers the first disease-targeted pharmacologic option for a disorder currently managed only by speech therapy.</span></span></span></p> <ul> <li>First-in-class, mechanism-based therapy for stuttering, addressing a $3 B underserved global market with no approved drugs.</li> <li>Repurposes FDA-approved iron chelators, leveraging extensive safety data and oral formulations for rapid Phase II entry and lower development risk.</li> <li>Quantifiable biomarker (MRI R2* brain-iron signal) enables patient stratification and objective efficacy read-outs, enhancing trial efficiency and market differentiation.</li> </ul> <ul> <li>Stand-alone or adjunctive pharmacotherapy for persistent developmental stuttering in pediatric and adult populations.</li> <li>MRI-guided precision treatment platform for speech-motor disorders linked to basal-ganglia iron dysregulation.</li> <li>Expansion into related neurodevelopmental or movement disorders where excess neural iron contributes to pathophysiology.</li> </ul> 2025-05-13 2025-07-31 2026-04-08 2025-06-13 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 162401172 SheikhBahaei, Shahriar Stony Brook University SheikhBahaei, Shahriar 1 162401172 SheikhBahaei, Shahriar Stony Brook University SheikhBahaei, Shahriar 1 162401136 Iron Chelators as potential therapeutics for stuttering E-186-2023-0 Filing authorized NIH - NINDS 162927805 Iron Chelators as potential therapeutics for stuttering E-186-2023-1 Filing authorized NIH - NINDS 83667829 Ano, Susan susan.ano@nih.gov
United States of America susan.ano@nih.gov?subject=Web Inquiry on [TAB-5056] Oral Iron-Chelator Therapy for Treating Developmental Stuttering&body=Please send me information about technology [TAB-5056] Oral Iron-Chelator Therapy for Treating Developmental Stuttering. Ano, Susan<br><a href="mailto:susan.ano@nih.gov?subject=Web Inquiry on [TAB-5056] Oral Iron-Chelator Therapy for Treating Developmental Stuttering&body=Please send me information about technology [TAB-5056] Oral Iron-Chelator Therapy for Treating Developmental Stuttering.">susan.ano@nih.gov</a><br> 162401141 E-186-2023-0 E-186-2023-0-US-01 Use of Iron Chelators for Treating Stuttering PRV US 63/510,794 Expired US <br />Provisional (PRV) 63/510,794<br />Filed on 2023-06-28<br />Status: Expired 162401143 E-186-2023-1 E-186-2023-1-PC-01 Use of Iron Chelators for Treating Stuttering PCT Patent Cooperation Treaty PCT/US2024/036062 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/036062<br />Filed on 2024-06-28<br />Status: Expired 164857199 E-186-2023-1 E-186-2023-1-US-01 Uses of Iron Chelators for Treating Stuttering National Stage US 19/496,195 Pending US <br />National Stage 19/496,195<br />Filed on 2025-12-22<br />Status: Pending 164857219 E-186-2023-1 E-186-2023-1-EP-01 Uses of Iron Chelators for Treating Stuttering National Stage European Patent 24742436.9 Pending European Patent <br />National Stage 24742436.9<br />Filed on 2026-01-05<br />Status: Pending TAB-3363 114097266 Monoclonal Antibodies that Bind Zika Virus Envelope Protein for Zika Diagnostics and Research CDC Antibodies, Collaboration, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials Antibodies Collaboration Consumer Products Diagnostics Immunology Infectious Disease Licensing Occupational Safety and Health Research Materials Dennis Bagarozzi, Jason Goldstein, Madhavan Nallani Padmanabha Zika virus infection during pregnancy can cause microcephaly and other severe birth defects. The CDC Zika MAC-ELISA (IgM antibody capture enzyme-linked immunosorbent assay) currently used for diagnosis detects antibodies produced to fight a Zika virus infection. However, reactivity of flavivirus antibodies (from exposure to other mosquito-borne infections such as dengue or West Nile virus) can complicate the interpretation of these results. <br /><br /> CDC and partner researchers have developed six monoclonal antibodies (mAbs) from hybridoma technology with high sensitivity to the Zika virus (ZIKV) pre-membrane/envelope (ENV) protein and limited cross-reactivity to other flaviviruses, notably dengue virus. Multiple methods such as indirect ELISA, bio-layer interferometry (BLI), immunoblotting, immunofluorescence, and plaque reduction neutralization tests (PRNTs) were used to validate the data. Additionally, ZIKV pre-membrane/envelope protein is a candidate biomarker for diagnosis during active infection vs. serological tests (based on identification of IgM and/or IgG) after clearance of infection. The technology can be used for immunoassay development and immunodiagnostic reagents for clinical sample and tissue confirmation of ZIKV. The mAbs also offer improved differentiation between ZIKV and related flaviviruses. <ul> <li>May be used for diagnosis during active Zika virus infection vs. serological tests (based on identification of IgM and/or IgG) after clearance of infection</li> <li>Offers higher sensitivity than many commercial and academic mAbs available to detect ZIKV</li> <li>Limited cross-reactivity with other flaviviruses</li> <li>High affinity mAbs (bind more quickly to the antigen and with a stronger bond)</li> </ul> <ul> <li>Engineering of mAbs for commercial diagnostic applications</li> <li>Clinical diagnostic assay to detect active Zika virus infection</li> <li>Multiple platforms such as immunoassay, lateral flow diagnostics, and nanotechnology device capable of interfacing with smartphone/digital technology</li> <li>ENV protein target is a valid target for diagnostic development with the understanding that a sufficient viral load needs to be present</li> <li>These mAbs may serve in a competition serological assay for dengue (or other closely related flaviviruses) where clinical IgG/IgM that do not compete with these ZIKV-specific mAbs for r-Env or VLP, can exclude a previous ZIKV infection</li> <li>Immunodiagnostic reagents for confirmation of Zika virus in clinical samples (e.g., serum, saliva and/or urine) or tissue</li> <li>Differentiation between Zika and related flaviviruses such as dengue, yellow fever or West Nile viruses</li> <li>Can be useful in more generalized diagnostic assay development to detect all flaviviruses</li> <li>Research tool, monitoring and public health surveillance</li> <li>Antiviral efficacy testing in animal models</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Monoclonal Antibodies that Bind Zika Virus Envelope Protein for Zika Diagnostics and Research. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. Research Tool - Patent protection is not being pursued for this technology. 2022-03-08 2025-04-24 2026-04-02 2019-02-22 antibodies, Development, Diagnostics, monoclonal, NCEZID, NCEZID-DSR, Novel, virus, VLXXXX, WBXXXX, WFXXXX, WIXXXX, XAXXXX, YBXXXX, Zika False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-286-2016-0 E-341-2013-0 E-341-2013-1 E-081-2017-0 E-107-2016-1 114110009 Bagarozzi, Dennis CDC - DIR CDC Bagarozzi, Dennis (CDC) 0 114110011 Nallani Padmanabha, Madhavan ACM Biolabs Private Limited Nallani Padmanabha, Madhavan 0 114110010 Goldstein, Jason CDC - DIR CDC Goldstein, Jason (CDC) 1 114110010 Goldstein, Jason CDC - DIR CDC Goldstein, Jason (CDC) 1 114110009 Bagarozzi, Dennis CDC - DIR CDC Bagarozzi, Dennis (CDC) 0 114110011 Nallani Padmanabha, Madhavan ACM Biolabs Private Limited Nallani Padmanabha, Madhavan 0 114102510 Development Of Zika Virus Monoclonal Antibodies For Research, Development And Novel Diagnostics E-030-2017-0 Research Material ACM Biolabs Private Limited, Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3363] Monoclonal Antibodies that Bind Zika Virus Envelope Protein for Zika Diagnostics and Research&body=Please send me information about technology [TAB-3363] Monoclonal Antibodies that Bind Zika Virus Envelope Protein for Zika Diagnostics and Research. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3363] Monoclonal Antibodies that Bind Zika Virus Envelope Protein for Zika Diagnostics and Research&body=Please send me information about technology [TAB-3363] Monoclonal Antibodies that Bind Zika Virus Envelope Protein for Zika Diagnostics and Research.">benjamin.hurley@nih.gov</a><br> 114168845 E-030-2017-0 E-030-2017-0-US-01 COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF ZIKA VIRUS INFECTION PRV US 62/622,521 Abandoned US <br />Provisional (PRV) 62/622,521<br />Filed on 2018-01-26<br />Status: Abandoned 114128232 YBXXXX 114128233 VLXXXX 114128234 WBXXXX 114128235 WFXXXX 114128236 WIXXXX 114128237 XAXXXX 114151572 Development 114151573 Zika 114151574 virus 114151575 monoclonal 114151576 antibodies 114151577 Novel 114151578 Diagnostics 114151579 NCEZID 114151580 NCEZID-DSR TAB-4989 156774528 Human Monoclonal Antibodies That Target Plasmodium Falciparum Sporozoites NIAID Antibodies, Collaboration, Infectious Disease, Licensing, Research Materials Antibodies Collaboration Infectious Disease Licensing Research Materials Cherelle Dacon, Joshua Tan <p>Malaria is one of the worlds deadliest infectious diseases, causing an estimated 249 million cases and 608,000 deaths annually, with children in the regions of Africa and South Asia being most vulnerable. Approx 2,000 cases of malaria are reported in the United States each year, by travelers from malaria-risk countries. Malaria is a mosquito-borne parasitic disease transmitted through the bite of infected female mosquitoes, which introduces Plasmodium sporozoites into the bloodstream of the human host. There are five Plasmodium parasite species that cause malaria in humans, of which, the vast majority of life-threatening cases are caused by infection with Plasmodium falciparum parasites. Researchers at NIAID have developed 11 human monoclonal antibodies that bind to a unique site on the circumsporozoite protein (CSP) on Plasmodium falciparum sporozoites that is not targeted by any known monoclonal antibodies. These antibodies do not bind to recombinant forms of CSP and as such bind to a processed or post-translational form of the protein processed by the sporozoites. In vivo studies have shown several of these antibodies can substantially reduce liver parasite burden in a mouse model of malaria. These antibodies can work cooperatively with known antibodies that target the repeat region of CSP. Some of these novel antibodies have shown enhanced protection in an animal model when combined with known protective monoclonal antibodies against sporozoites, suggesting that together they may form an effective cocktail to prevent malaria.</p> <ul> <li>These antibodies bind to a unique site on the circumsporozoite protein (CSP) on Plasmodium falciparum sporozoites that is distinct from the targets of pre-existing mAbs.</li> <li>These monoclonal antibodies can be used alone or in combination with existing antibodies.</li> </ul> <ul> <li>Prophylactic and preventative treatment against malaria.</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Areas of specific interest include: (a) testing developability of these antibodies (e.g., biophysical characteristics, cross-reactivity, pharmacokinetics, toxicity), (b) pre-clinical model assessment, and (c) human clinical trials. For collaboration opportunities, please contact Dawn Taylor-Mulneix at 301-767-5189, or dawn.taylor-mulneix@nih.gov. 2024-06-26 2025-05-29 2026-03-30 2024-06-27 False False <ul> <li>Pre-Clinical</li> </ul> True 37470483 Website Abstract E-212-2022-0 156774781 Tan, Joshua National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Tan, Joshua (NIAID) 1 156774785 Dacon, Cherelle National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Dacon, Cherelle (NIAID) 2 156774781 Tan, Joshua National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Tan, Joshua (NIAID) 1 156774785 Dacon, Cherelle National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Dacon, Cherelle (NIAID) 2 156774531 Human Monoclonal Antibodies That Target Plasmodium Falciparum Sporozoites E-212-2022-0 Filing authorized NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-4989] Human Monoclonal Antibodies That Target Plasmodium Falciparum Sporozoites&body=Please send me information about technology [TAB-4989] Human Monoclonal Antibodies That Target Plasmodium Falciparum Sporozoites. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-4989] Human Monoclonal Antibodies That Target Plasmodium Falciparum Sporozoites&body=Please send me information about technology [TAB-4989] Human Monoclonal Antibodies That Target Plasmodium Falciparum Sporozoites.">dawn.taylor-mulneix@nih.gov</a><br> TAB-4509 151706142 High Relaxivity Mulitivalent Gadolinium on a Peptide Scaffold for Targeted MRI Applications in Disease Diagnosis NHLBI Diagnostics, Licensing, Medical Devices, Research Materials Diagnostics Licensing Medical Devices Research Materials Alan Koretsky, Nikorn Pothayee, Deepak Sail, Rolf Swenson <p>This technology includes a peptide containing alternating Alanine and Lys(DOTA-Gd) residues can be used to increase the MRI relaxivity of a peptide. The low molecular weight construct can be appended to proteins, antibodies and peptides to increase MRI signals. This approach offers advantages over previous dendrimeric constructs. The increased MRI signal may allow effective neuronal tracing of peptides that when misfolded and transported from the gut to the brain may lead to inflammation and serious diseases including Alzheimer&rsquo;s (A-beta), Parkinson&rsquo;s Disease, Lewey Body Dementia, and Multiple Systems atrophy (alpha synuclein), Creutzfeld-Jakob disease, and Amyotrophic lateral sclerosis.</p> Multivalent chelated Gd can be efficiently constructed on a peptide scaffold, with substantial increase in relaxivity (i.e., higher MRI signal), with minimum molecular weight increase and can be efficiently added to proteins, antibodies, and proteins for targeted MRI applications in disease diagnosis. For use in diagnostic MRI applications. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2025-08-13 2026-03-26 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151706190 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 1 151706194 Koretsky, Alan NINDS NINDS Koretsky, Alan (NINDS) 2 151706198 Pothayee, Nikorn NINDS NINDS Pothayee, Nikorn (NINDS) 3 151706203 Sail, Deepak National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sail, Deepak (NHLBI) 4 151706190 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 1 151706194 Koretsky, Alan NINDS NINDS Koretsky, Alan (NINDS) 2 151706198 Pothayee, Nikorn NINDS NINDS Pothayee, Nikorn (NINDS) 3 151706203 Sail, Deepak National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sail, Deepak (NHLBI) 4 151706145 High Relaxivity Mulitivalent Gadolinium On A Peptide Scaffold E-146-2019-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NINDS 153929528 Ghosh, Malabika malabika.ghosh@nih.gov
United States of America malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4509] High Relaxivity Mulitivalent Gadolinium on a Peptide Scaffold for Targeted MRI Applications in Disease Diagnosis&body=Please send me information about technology [TAB-4509] High Relaxivity Mulitivalent Gadolinium on a Peptide Scaffold for Targeted MRI Applications in Disease Diagnosis. Ghosh, Malabika<br><a href="mailto:malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4509] High Relaxivity Mulitivalent Gadolinium on a Peptide Scaffold for Targeted MRI Applications in Disease Diagnosis&body=Please send me information about technology [TAB-4509] High Relaxivity Mulitivalent Gadolinium on a Peptide Scaffold for Targeted MRI Applications in Disease Diagnosis.">malabika.ghosh@nih.gov</a><br> 157755246 E-146-2019-0 E-146-2019-0-US-01 HIGH RELAXIVITY MULITIVALENT GADOLINIUM ON A PEPTIDE SCAFFOLD PRV US 62/873,272 Abandoned US <br />Provisional (PRV) 62/873,272<br />Filed on 2019-07-12<br />Status: Abandoned TAB-2905 114097066 LRRK2 Inhibitors: Novel Treatment for Intestinal Bowel Disorders NIAID Cardiology, Dental, Endocrinology, Immunology, Infectious Disease, Licensing, Oncology, Ophthalmology, Therapeutics Cardiology Dental Endocrinology Immunology Infectious Disease Licensing Oncology Ophthalmology Therapeutics Atsushi Kitani, Warren Strober, Tetsuya Takagawa Use of Leucine Rich Repeat Kinase 2 (LRRK2) inhibitors for the treatment of Intestinal Bowel Disorders (IBD) is disclosed. IBD is a broad term that describes conditions with chronic or recurring immune response and inflammation of the gastrointestinal tract. Crohn's disease and ulcerative colitis, two common forms of idiopathic IBD, are chronic, relapsing inflammatory disorders of the gastrointestinal tract.<br /><br /> LRRK2 is a kinase encoded by a gene that contains a non-coding polymorphism (SNP). LRRK2 has been associated with and is a risk factor for inflammatory bowel disease. NIH inventors have shown that human cells expressing this SNP have increased levels of LRRK2 and, correspondingly, mice with increased levels of LRRK2 exhibit more severe Dextran Sulfate colitis. In various studies of the role of LRRK2 in cell signaling, NIH inventors have shown that increased levels of LRRK2 lead to increased pro-inflammatory cytokine secretion. Also, an inhibitor of LRRK2 is shown to abrogate the pro-inflammatory activity of LRRK2 both <em>in vitro</em> and <em>in vivo</em>. <ul> <li>A LRRK2 inhibitor would be a unique form of anti-inflammatory therapy that will complement or compete with an array of cytokines in primary treatment for lBD.</li> <li>A LRRK2 inhibitor would provide a much needed alternate mode of therapy.</li> </ul> <ul> <li>Treatment for or prevention of Intestinal Bowel Disorders.</li> </ul> 2022-03-08 2026-03-26 2026-03-26 2015-01-26 COLITIS, Crohn's, Disease, IB3XXX, inhibitor, LRRK2, TREAT, Ulcerative, VPXXXX, WKXXXX, XEXXXX, YAXXXX, YBXXXX, YCXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114108958 Takagawa, Tetsuya NIAID - DIR NIAID Takagawa, Tetsuya (NIAID) 0 114108959 Kitani, Atsushi NIAID - DIR NIAID Kitani, Atsushi (NIAID) 0 114108957 Strober, Warren NIAID - DIR NIAID Strober, Warren (NIAID) 1 114108957 Strober, Warren NIAID - DIR NIAID Strober, Warren (NIAID) 1 114108958 Takagawa, Tetsuya NIAID - DIR NIAID Takagawa, Tetsuya (NIAID) 0 114108959 Kitani, Atsushi NIAID - DIR NIAID Kitani, Atsushi (NIAID) 0 114102240 Use Of LRRK2 Inhibitor To Treat Ulcerative Colitis And Crohn's Disease E-070-2014-0 Filing authorized NIAID 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-2905] LRRK2 Inhibitors: Novel Treatment for Intestinal Bowel Disorders&body=Please send me information about technology [TAB-2905] LRRK2 Inhibitors: Novel Treatment for Intestinal Bowel Disorders. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-2905] LRRK2 Inhibitors: Novel Treatment for Intestinal Bowel Disorders&body=Please send me information about technology [TAB-2905] LRRK2 Inhibitors: Novel Treatment for Intestinal Bowel Disorders.">polung.yang@nih.gov</a><br> 114161781 E-070-2014-0 E-070-2014-0-US-03 Treatment or Prevention of an Intestinal Disease or Disorder National Stage US 10,058,559 15/311,405 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10058559 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10058559">10,058,559</a><br />Filed on 2016-11-15<br />Status: Issued 114167061 E-070-2014-0 E-070-2014-0-PCT-02 Treatment or Prevention of an Intestinal Disease or Disorder PCT Patent Cooperation Treaty PCT/US2015/031200 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/031200<br />Filed on 2015-05-15<br />Status: Expired 114168055 E-070-2014-0 E-070-2014-0-US-01 TREATMENT OR PREVENTION OF AN INTESTINAL DISEASE OR DISORDER PRV US 61/993,637 Abandoned US <br />Provisional (PRV) 61/993,637<br />Filed on 2014-05-15<br />Status: Abandoned 114126812 IB3XXX 114126813 VPXXXX 114126814 WKXXXX 114126815 XEXXXX 114126816 YAXXXX 114126817 YBXXXX 114126818 YCXXXX 114148050 LRRK2 114148051 inhibitor 114148052 TREAT 114148053 Ulcerative 114148054 COLITIS 114148055 Disease 114148056 Crohn's TAB-1758 114095987 Muramyl Dipeptide as a Therapeutic Agent for Inflammation NIAID Collaboration, Diagnostics, Immunology, Licensing, Research Materials, Therapeutics Collaboration Diagnostics Immunology Licensing Research Materials Therapeutics Warren Strober The nucleotide-binding oligomerization domain 2 (NOD2) protein plays a key role in innate immunity as a sensor of muramyl dipeptide (MDP), a breakdown product of bacterial peptidoglycan. Bacterial peptidoglycan promotes the innate immune response through the activation of Toll-like receptor 2 (TLR2), which ultimately provokes inflammation. Activation of NOD2 by MDP negatively regulates the activity of TLR2, and thus reduces inflammation. <br><br> The inventors have demonstrated that administration of MDP prevents the development of experimental colitis in mice. They have also determined that MDP reduces pro-inflammatory cytokine production from multiple Toll-like receptors, and that this reduction arises from the induction of IFN regulatory factor 4 (IRF4). The technology includes methods of treating or preventing inflammation associated with an autoimmune disorder, particularly inflammatory bowel disease, via administration of muramyl peptide; also included are methods of reducing symptoms characteristic of inflammation via administration of muramyl peptide. This technology has potential as an anti-inflammatory therapy for autoimmune or other inflammation-associated diseases, particularly inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. The NIAID Laboratory of Host Defenses, Mucosal Immunity Section, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact either Rosemary Walsh or Charles Rainwater at 301-496-2644 for more information. This technology is available for exclusive or non-exclusive licensing. 2022-03-08 2026-03-26 2026-03-26 2008-05-01 Autoimmune, AUTOIMMUNE DISEASE, Autoimmune disorder, Autoimmunity, BBXXXX, BCXXXX, BOWEL, Crohn disease; Inflammatory bowel disease 1, Crohn's disease, Dipeptide, IB3XXX, IBD, IBXXXX, IL-12, Inflammation, INFLAMMATORY, inflammatory bowel disease, Inflammatory bowel disease 1, inflammatory disease, INTERLEUKIN, INTERLEUKIN-12, IRF4, IXXXXX, MDP, Muramyl, NOD2, peptidoglycan, TLR, TLR2, Toll-like, Toll-like receptors, Ulcerative Colitis False True <i>In vivo</i> data are available in an experimental colitis mouse model, and <i>in vitro</i> data supporting mechanism of action also are available. <i>In vivo</i> data are available in an experimental colitis mouse model, and <i>in vitro</i> data supporting mechanism of action also are available. True 52398218 Pre-Clinical (in vivo) 52398218 NIHTT 37470483 Website Abstract 114170513 T Watanabe et al. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest. 2008 Feb;118(2):545-559. http://www.ncbi.nlm.nih.gov/pubmed/18188453?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/18188453?dopt">T Watanabe et al. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest. 2008 Feb;118(2):545-559.</a> 114106058 Strober, Warren NIAID - DIR NIAID Strober, Warren (NIAID) 1 114106058 Strober, Warren NIAID - DIR NIAID Strober, Warren (NIAID) 1 114100985 Adminstration Of Muramyl Dipeptide (MDP) For The Treatment Of Inflammatory Bowel Disease (IBD) E-110-2006-0 Filing authorized NIAID 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-1758] Muramyl Dipeptide as a Therapeutic Agent for Inflammation&body=Please send me information about technology [TAB-1758] Muramyl Dipeptide as a Therapeutic Agent for Inflammation. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-1758] Muramyl Dipeptide as a Therapeutic Agent for Inflammation&body=Please send me information about technology [TAB-1758] Muramyl Dipeptide as a Therapeutic Agent for Inflammation.">polung.yang@nih.gov</a><br> 114164239 E-110-2006-0 E-110-2006-0-PCT-02 USE OF MURAMYL DIPEPTIDE (MDP) FOR TREATING INFLAMMATION PCT Patent Cooperation Treaty PCT/US2007/086117 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2007/086117<br />Filed on 2007-11-30<br />Status: Expired 114164444 E-110-2006-0 E-110-2006-0-US-01 USES OF MURAMYL DIPEPTIDE COMPOSITIONS FOR TREATING AND PREVENTING INFLAMMATION PRV US 60/872,384 Abandoned US <br />Provisional (PRV) 60/872,384<br />Filed on 2006-12-01<br />Status: Abandoned 114165302 E-110-2006-0 E-110-2006-0-US-03 Use Of Muramyl Dipeptide (MDP) For Treating Inflammation National Stage US 8,603,978 12/516,633 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8603978 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8603978">8,603,978</a><br />Filed on 2009-05-28<br />Status: Issued 114118678 IB3XXX 114118679 IBXXXX 114118680 IXXXXX 114120845 BBXXXX 114121282 BCXXXX 114130858 Ulcerative Colitis 114130859 Muramyl 114130860 Dipeptide 114130861 MDP 114130862 Crohn's disease 114130863 inflammatory bowel disease 114130864 INFLAMMATORY 114130865 BOWEL 114130866 inflammatory disease 114130867 IBD 114130868 Autoimmune 114130869 AUTOIMMUNE DISEASE 114130870 Autoimmune disorder 114130871 Autoimmunity 114130872 peptidoglycan 114130873 NOD2 114130874 TLR 114130875 TLR2 114130876 Toll-like 114130877 Toll-like receptors 114130878 Inflammation 114130879 INTERLEUKIN-12 114130880 INTERLEUKIN 114130881 IL-12 114130882 IRF4 114156529 Inflammatory bowel disease 1 114158348 Crohn disease; Inflammatory bowel disease 1 TAB-1364 114095691 Treatment and Prevention of Inflammatory Bowel Disease (IBD) using Mutant and Chimeric IL-13 Molecules NIAID Diagnostics, Immunology, Licensing, Reproductive Health, Research Materials, Therapeutics, Vaccines Diagnostics Immunology Licensing Reproductive Health Research Materials Therapeutics Vaccines Stefan Fichtner-Feigl, Koji Kawakami, Atsushi Kitani, Peter Mannon, Jan Preiss, Raj Puri, Warren Strober Ulcerative colitis (UC) is a chronic inflammatory disease of the colorectum and affects approximately 400,000 people in the United States. The cause of UC is not known, although an abnormal immunological response to bacterial antigens in the gut microflora is thought to be involved. Present treatments for UC include anti-inflammatory therapy using aminosalicylates or corticosteroids, as well as immunomodulators and diet. However, 25-40% of ulcerative colitis patients must eventually have their colons removed due to massive bleeding, severe illness, rupture of the colon, risk of cancer or due to side effects of corticosteroids and novel treatments are still actively being sought. NIH scientists and their collaborators have used a mouse model of experimental colitis (oxazolone colitis, OC) to show that IL-13, a Th2 cytokine, is a significant pathologic factor in OC and that neutralizing IL-13 in these animals effectively prevents colitis.<br /><br /> OC is a colitis induced by intrarectal administration of a relatively low dose of the haptenating agent oxazolone subsequent to skin sensitization with oxazolone. A highly reproducible and chronic colonic inflammation is obtained that is histologically similar to human ulcerative colitis. Studies show that Natural Killer T (NKT) cells, rather than conventional CD4+T cells, mediate oxazolone colitis and are the source of IL-13 as well as being activated by CD1- expressing intestinal epithelial cells. Tissue removed from ulcerative colitis patients were also shown to contain increased numbers of nonclassical NKT cells that produce markedly increased amounts of IL-13 and that in keeping with epithelial damage being a key factor in UC, these NKT cells are cytotoxic for epithelial cells. Building on their previous work, scientists at NIAID and FDA have shown that an Il-13 chimeric fusion protein linked to an effector molecule was able to prevent colitis in a mouse model of ulcerative colitis.<br /><br /> Available for licensing are methods for treating or preventing the inflammatory response of IBD by inhibiting the binding of IL-13 to IL-13 receptors on NKT cells. Additionally, these mutant and chimeric Il-13 molecules are able to block the chronic inflammatory response that results in fibrosis as seen in Crohn's disease. Preventing the inflammatory response of colitis by either modulating or blocking IL-13 and NKT cell activity continues to be an effective therapeutic approach in animal models of colitis with implications for the treatment of human ulcerative colitis and for the treatment of fibrosis associated with Crohn's disease. 2022-03-08 2026-03-26 2026-03-26 2006-06-01 Crohn disease; Inflammatory bowel disease 1, IB3XXX, IB6XXX, IBXXXX, Inflammatory bowel disease 1, IXXXXX False True True NIHTT 37470483 Website Abstract E-131-2002-0 114171191 Heller F, et al. http://www.ncbi.nlm.nih.gov/pubmed/12433369 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12433369">Heller F, et al.</a> 114171192 Fuss IJ, et al. http://www.ncbi.nlm.nih.gov/pubmed/15146247 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15146247">Fuss IJ, et al.</a> 114105505 Strober, Warren NIAID Strober, Warren (NIAID) 0 114105506 Mannon, Peter NIAID Mannon, Peter (NIAID) 0 114105507 Preiss, Jan Preiss, Jan 0 114105508 Puri, Raj FDA Puri, Raj (FDA) 0 114105509 Kawakami, Koji FDA Kawakami, Koji (FDA) 0 114105510 Fichtner-Feigl, Stefan Fichtner-Feigl, Stefan 0 114105511 Kitani, Atsushi NIAID Kitani, Atsushi (NIAID) 0 114105505 Strober, Warren NIAID Strober, Warren (NIAID) 0 114105506 Mannon, Peter NIAID Mannon, Peter (NIAID) 0 114105507 Preiss, Jan Preiss, Jan 0 114105508 Puri, Raj FDA Puri, Raj (FDA) 0 114105509 Kawakami, Koji FDA Kawakami, Koji (FDA) 0 114105510 Fichtner-Feigl, Stefan Fichtner-Feigl, Stefan 0 114105511 Kitani, Atsushi NIAID Kitani, Atsushi (NIAID) 0 114100606 Treatment And Prevention Of Inflammatory Bowel Disease (IBD) Using Mutant And Chimeric IL-13 Molecules E-003-2005-0 Filing authorized FDA, NIAID 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-1364] Treatment and Prevention of Inflammatory Bowel Disease (IBD) using Mutant and Chimeric IL-13 Molecules&body=Please send me information about technology [TAB-1364] Treatment and Prevention of Inflammatory Bowel Disease (IBD) using Mutant and Chimeric IL-13 Molecules. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-1364] Treatment and Prevention of Inflammatory Bowel Disease (IBD) using Mutant and Chimeric IL-13 Molecules&body=Please send me information about technology [TAB-1364] Treatment and Prevention of Inflammatory Bowel Disease (IBD) using Mutant and Chimeric IL-13 Molecules.">polung.yang@nih.gov</a><br> 114163448 E-003-2005-0 E-003-2005-0-US-01 Treatment and prevention of IBD using Mutant and Chimeric Il-13 Molecules PRV US 60/671,624 Abandoned US <br />Provisional (PRV) 60/671,624<br />Filed on 2005-04-15<br />Status: Abandoned 114163451 E-003-2005-0 E-003-2005-0-US-03 Methods of treating and preventing inflammatory bowel disease involving il-13 and nkt cells National Stage US 9,072,716 11/918,711 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9072716 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9072716">9,072,716</a><br />Filed on 2008-11-10<br />Status: Expired 114166207 E-003-2005-0 E-003-2005-0-PCT-02 Methods of Treating and Preventing Inflammatory Bowel Disease Involving IL-13 and NKT Cells PCT Patent Cooperation Treaty PCT/US2006/014393 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/014393<br />Filed on 2006-04-14<br />Status: Expired 114117242 IB3XXX 114117243 IB6XXX 114117244 IBXXXX 114117246 IXXXXX 114156177 Inflammatory bowel disease 1 114158182 Crohn disease; Inflammatory bowel disease 1 TAB-5095 166536297 Gene Editing for ALPK1 p.Thr237Met NIAID Application, Collaboration Sought, Rare/Neglected Diseases, ResearchProducts, TherapeuticArea Application Collaboration Sought Rare/Neglected Diseases ResearchProducts TherapeuticArea Uimook Choi, Christina Kozycki, Colin Sweeney <p>ROSAH syndrome is a rare genetic disease caused by a mutation in the human alpha kinase 1 (ALPK1) gene (p.Thr237Met), leading to vision loss, swollen optic nerves, dry mouth, enlarged spleen, and frequent headaches. Researchers in the Laboratory of Clinical Immunology and Microbiology (LCIM) at the National Institute of Allergy and Infectious Diseases (NIAID) have developed a new approach that can precisely fix the ALPK1 mutation without causing unwanted changes in the patient&rsquo;s DNA. This method uses a base editor combined with a guide RNA to safely and efficiently convert the pathogenic thymine of the mutation back to cytosine. In laboratory tests, this gene editing technology successfully repaired the mutation in patient-derived affected cells with high accuracy and no side effects.</p> <p>This therapy could be delivered directly to the eye or salivary glands, or patient cells could be corrected outside the body and then returned to the patient, offering hope for personalized treatment to restore vision and improve quality of life for people with ROSAH syndrome.</p> <ul> <li>Highly accurate tool that directly repairs the faulty gene that causes ROSAH syndrome, while avoiding unwanted changes elsewhere in DNA</li> <li>Corrects the mutation in most patient cells with few or no mistakes</li> <li>Can be delivered directly to affected areas (e.g., eye or salivary glands) or can treat patient cells outside the body</li> <li>Custom therapy for people with the ALPK1 mutation</li> <li>Effective in cells that don’t divide, unlike older gene editing methods</li> </ul> <ul> <li>Personalized therapy for individuals with disease secondary to the ALPK1 p.Thr237Met genetic variant</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Area of specific interest includes human clinical trials. For collaboration opportunities, please contact David Yang at 240-695-6406, or David.Yang@niaid.nih.gov. 2026-03-23 2026-03-26 2026-03-26 2026-03-24 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 166536410 Kozycki, Christina National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Kozycki, Christina (NIAID) 1 166536424 Sweeney, Colin National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Sweeney, Colin (NIAID) 2 166538687 Choi, Uimook National Institute of Allergy and Infectious Diseases (NIAID/NIH) Choi, Uimook 3 166536410 Kozycki, Christina National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Kozycki, Christina (NIAID) 1 166536424 Sweeney, Colin National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Sweeney, Colin (NIAID) 2 166538687 Choi, Uimook National Institute of Allergy and Infectious Diseases (NIAID/NIH) Choi, Uimook 3 166536300 Gene editing for ALPK1 p.Thr237Met E-044-2024-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIH - NIAID 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-5095] Gene Editing for ALPK1 p.Thr237Met&body=Please send me information about technology [TAB-5095] Gene Editing for ALPK1 p.Thr237Met. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-5095] Gene Editing for ALPK1 p.Thr237Met&body=Please send me information about technology [TAB-5095] Gene Editing for ALPK1 p.Thr237Met.">polung.yang@nih.gov</a><br> 166536305 E-044-2024-0 E-044-2024-0-US-01 COMPOSITIONS AND METHODS FOR EDITING THE HUMAN ALPHA KINASE 1 (ALPK1) GENE AND TREATING ROSAH SYNDROME PRV US 63/733,836 Expired US <br />Provisional (PRV) 63/733,836<br />Filed on 2024-12-13<br />Status: Expired 166536306 E-044-2024-0 E-044-2024-0-PC-01 COMPOSITIONS AND METHODS FOR EDITING THE HUMAN ALPHA KINASE 1 (ALPK1) GENE AND TREATING ROSAH SYNDROME PCT Patent Cooperation Treaty PCT/US2025/059432 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/059432<br />Filed on 2025-12-12<br />Status: Pending TAB-5057 162516862 Synergistic Interactions for Improved Cancer Treatment NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Barbara Felber, Sevasti Karaliota, George Pavlakis, Dimitrios Stellas <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees to develop hetIL-15 in combination with other agents, such as PPARa agonists (Fenofibrate), FLT3 inhibitors (quizartinib), IL-12, or chemotherapy into a therapeutic for cancer.</p> <h2>Description of Technology:</h2> <p>Immunotherapy has emerged as a promising treatment strategy for many types of cancer. However, a major challenge is &ldquo;exhausted&rdquo; tumor-infiltrating immune cells, which lose their ability to effectively eliminate cancer cells. To address this issue, researchers are exploring ways to reverse immune exhaustion and improve treatment outcomes. One potential approach involves interleukin-15 (IL-15), a cytokine that promotes the growth and killing ability of tumor-specific CD8+ T cells and NK cells. IL-15, either alone or in combination with other agents, has shown some promise in clinical trials. However, its use is hindered by toxicity at effective doses. Therefore, there is a critical need for safer and more effective combinations to improve patient outcomes.</p> <p>Inventors at the National Cancer Institute previously developed heterodimeric IL-15 (hetIL-15), composed of IL-15 and IL-15 receptor alpha (NIH Reference # E-254-2005, E-257-2009, E-141-2008, E-054-2013, and E-070-2015). The inventors now demonstrate novel combinations of hetIL-15 with other active agents to enhance the metabolic fitness of intratumoral lymphocytes to provide therapeutic improvement. Specifically, the combination of hetIL-15 and Fenofibrate, a cholesterol-lowering drug, increased cytotoxic T cell activity and provided an almost complete eradication of triple negative breast cancer tumors, including metastatic lesions. &nbsp;Similar results occurred in a mouse pancreatic cancer model. Using a mouse orthotopic breast cancer model, hetIL-15 combined with quizartinib &ndash; a potent Fms-like tyrosine kinase 3 (Flt3) inhibitor &ndash; resulted in a significant tumor growth delay and complete eradication of tumors in 50% of mice after 16 days of treatment. Additionally, the inventors constructed a fusion protein of IL-15 and IL-12 that controls metastatic disease in a mouse melanoma model.&nbsp; These novel combinations would be particularly useful for the treatment of triple negative breast or pancreatic cancer.</p> <p>The National Cancer Institute seeks parties interested in collaborative research and/or licensees to further develop this technology.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment for triple negative breast cancer</li> <li>Treatment for pancreatic cancer</li> <li>Treatment of solid tumors for which cellular immunotherapy outcomes are diminished due to T or NK cell exhaustion</li> <li>Treatment of solid tumors for which IL-15-based therapy is diminished due to toxicity at clinically relevant doses</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Novel combination showing improved therapeutic potential in several solid cancers, including breast cancer and melanoma</li> <li>Combination of hetIL-15 with agents already approved (Fenofibrate, Flt-3) decreases regulatory risk and thus expedites commercialization</li> <li>Overcoming IL-15 toxicity at clinically relevant doses</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for translating hetIL-15 in combination with other agents, such as PPARa agonists (Fenofibrate), FLT3 inhibitors (quizartinib), IL-12, or chemotherapy, into a therapeutic for the treatment of cancer. 2025-05-19 2025-06-27 2026-03-19 2025-06-27 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-254-2005 E-257-2009 E-141-2008 E-054-2013 E-070-2015 162518109 Karaliota S, et al. "Tumor eradication by het IL-15 locoregional therapy correlates with an induced intratumoral CD103intCD11b+ dendritic cell population." (PMID: 37178117) https://pubmed.ncbi.nlm.nih.gov/37178117/ <a href="https://pubmed.ncbi.nlm.nih.gov/37178117/">Karaliota S, et al. "Tumor eradication by het IL-15 locoregional therapy correlates with an induced intratumoral CD103intCD11b+ dendritic cell population." (PMID: 37178117)</a> 162518219 Bergamaschi C, et al. Heterodimeric "IL-15 in cancer immunotherapy." (PMID: 33671252) https://pubmed.ncbi.nlm.nih.gov/33671252/ <a href="https://pubmed.ncbi.nlm.nih.gov/33671252/">Bergamaschi C, et al. Heterodimeric "IL-15 in cancer immunotherapy." (PMID: 33671252)</a> 162518307 Conlon K, et al. "Phase Ⅰ study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist in adult patients with metastatic or unresectable solid tumors." (PMID: 34799399 https://pubmed.ncbi.nlm.nih.gov/34799399/ <a href="https://pubmed.ncbi.nlm.nih.gov/34799399/">Conlon K, et al. "Phase Ⅰ study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist in adult patients with metastatic or unresectable solid tumors." (PMID: 34799399</a> 162516976 Felber, Barbara NIH - NCI NCI Felber, Barbara (NCI) 1 162517000 Pavlakis, George NIH - NCI NCI Pavlakis, George (NCI) 2 162517016 Karaliota, Sevasti NIH - Leidos Leidos Karaliota, Sevasti (Leidos) 3 162517106 Stellas, Dimitrios NIH - NCI NCI Stellas, Dimitrios (NCI) 4 162516976 Felber, Barbara NIH - NCI NCI Felber, Barbara (NCI) 1 162517000 Pavlakis, George NIH - NCI NCI Pavlakis, George (NCI) 2 162517016 Karaliota, Sevasti NIH - Leidos Leidos Karaliota, Sevasti (Leidos) 3 162517106 Stellas, Dimitrios NIH - NCI NCI Stellas, Dimitrios (NCI) 4 162516865 Synergistic Interactions For Improved Cancer Treatment E-174-2022-0 Filing authorized Leidos Biomedical Research, Inc, NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-5057] Synergistic Interactions for Improved Cancer Treatment&body=Please send me information about technology [TAB-5057] Synergistic Interactions for Improved Cancer Treatment.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-5057] Synergistic Interactions for Improved Cancer Treatment&body=Please send me information about technology [TAB-5057] Synergistic Interactions for Improved Cancer Treatment.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">rose.freel@nih.gov</a><br> 162516871 E-174-2022-0 E-174-2022-0-US-01 Synergistic Interactions For Improved Cancer Treatment PRV US 63/398,450 Expired US <br />Provisional (PRV) 63/398,450<br />Filed on 2022-08-16<br />Status: Expired 162516872 E-174-2022-0 E-174-2022-0-PC-01 Synergistic Interactions For Improved Cancer Treatment PCT Patent Cooperation Treaty PCT/US2023/072333 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/072333<br />Filed on 2023-08-16<br />Status: Expired 162516873 E-174-2022-0 E-174-2022-0-US-02 Synergistic Interactions For Improved Cancer Treatment National Stage US 19/101,938 Pending US <br />National Stage 19/101,938<br />Filed on 2025-02-07<br />Status: Pending 162516874 E-174-2022-0 E-174-2022-0-EP-01 Synergistic Interactions For Improved Cancer Treatment National Stage European Patent 23768747.0 Pending European Patent <br />National Stage 23768747.0<br />Filed on 2025-01-29<br />Status: Pending TAB-4445 147157740 Tissue Clamp for Repeated Opening and Closure of Incisions/Wounds NEI Collaboration, Ear, Nose, & Throat, Licensing, Medical Devices, Non-Medical Devices, Ophthalmology Collaboration Ear Nose & Throat Licensing Medical Devices Non-Medical Devices Ophthalmology Juan Amaral, Kapil Bharti, Steven Charles, Vladimir Khristov, Arvydas Maminishkis <p>Medical clamps currently available are not efficient nor are they sufficiently precise in closure and alignment of the edges of an incision or wound. Many available designs are difficult to use and handle, especially in situations where repeated opening and closure of an incision or wound is required. The functional short-comings of existing clamp designs may result in surgical complications, such as excess loss of fluids and pressure and hemostasis during some procedures. These functional deficiencies may increase the difficulty and expense of a surgery or altogether limit the ability to perform some procedures. </p> <p>This clamp design is functionally superior in its ease of use and capability to precisely keep in alignment incision or wound margins during repeated opening and closure.  As a result, a surgeon using this clamp is able to quickly open or close an incision or wound, as needed. This ability is a critical attribute where there is need to insert instruments, sometimes repeatedly, through an incision or wound. These superior functionalities reduce potential for fluid loss, which is especially critical in procedures such as intraocular surgeries where maintaining fluid balance avoids serious complications. Excessive loss of intraocular fluid balance during surgery can result in collapse of the eye, hemorrhage, and retinal detachment. This clamp design may improve outcomes of many surgeries and potentially enable new procedures presently too risky to undertake with current clamp devices. </p> <p>This invention is available for licensing and/or collaborative development partnerships.</p> <h2>Competitive Advantages:</h2> <ul><li>Maintains more precise alignment of the wound margins</li> <li>Permits easy reopening and entry into the incision or wound and repeated closure</li> <li>Reduces fluid loss from wound or incision, helps maintain hemostasis</li> <li>Guides and controls placement and depth of sutures</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Intraocular surgeries requiring incision in sclera</li> <li>Rapid closure of traumatic wounds</li> </ul> 2017-02-17 2025-04-22 2018-02-17 2026-03-18 2017-02-21 CLAMP, ocular surgery, sclera incision closure False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-02-17 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-251-2012 147164764 Khristov, Vladimir NIH - NEI Khristov, Vladimir 1 147164765 Charles, Steven NIH - NEI NEI Charles, Steven (NEI) 2 147164762 Amaral, Juan NIH - NEI NEI Amaral, Juan (NEI) 3 147164761 Maminishkis, Arvydas NIH - NEI NEI Maminishkis, Arvydas (NEI) 4 147164763 Bharti, Kapil NIH - NEI NEI Bharti, Kapil (NEI) 5 147164764 Khristov, Vladimir NIH - NEI Khristov, Vladimir 1 147164765 Charles, Steven NIH - NEI NEI Charles, Steven (NEI) 2 147164762 Amaral, Juan NIH - NEI NEI Amaral, Juan (NEI) 3 147164761 Maminishkis, Arvydas NIH - NEI NEI Maminishkis, Arvydas (NEI) 4 147164763 Bharti, Kapil NIH - NEI NEI Bharti, Kapil (NEI) 5 147158331 A Surgical Clamp To Gate Large Scleral Surgery Port And Suture Alignment Tool E-293-2016-0 Filing authorized National Eye Institute (NEI) 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4445] Tissue Clamp for Repeated Opening and Closure of Incisions/Wounds&body=Please send me information about technology [TAB-4445] Tissue Clamp for Repeated Opening and Closure of Incisions/Wounds.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4445] Tissue Clamp for Repeated Opening and Closure of Incisions/Wounds&body=Please send me information about technology [TAB-4445] Tissue Clamp for Repeated Opening and Closure of Incisions/Wounds.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147168964 E-293-2016-0 E-293-2016-0-US-01 Tissue Clamp and Implantation Method PRV US 62/419,804 Abandoned US <br />Provisional (PRV) 62/419,804<br />Filed on 2016-11-09<br />Status: Abandoned 147168965 E-293-2016-0 E-293-2016-0-PCT-02 TISSUE CLAMP AND IMPLANTATION METHOD PCT Patent Cooperation Treaty PCT/US2017/060672 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/060672<br />Filed on 2017-11-08<br />Status: Expired 147168966 E-293-2016-0 E-293-2016-0-US-03 TISSUE CLAMP AND IMPLANTATION METHOD National Stage US 11,717,298 16/348,855 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11717298 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11717298">11,717,298</a><br />Filed on 2019-05-09<br />Status: Issued 147168967 E-293-2016-0 E-293-2016-0-AU-04 TISSUE CLAMP AND IMPLANTATION METHOD National Stage Australia 2017359336 2017359336 Issued Australia <br />National Stage 2017359336<br />Filed on 2019-05-03<br />Status: Issued 147168968 E-293-2016-0 E-293-2016-0-CA-05 TISSUE CLAMP AND IMPLANTATION METHOD National Stage Canada 3043174 Pending Canada <br />National Stage 3043174<br />Filed on 2017-11-08<br />Status: Pending 147168969 E-293-2016-0 E-293-2016-0-EP-06 TISSUE CLAMP AND IMPLANTATION METHOD National Stage European Patent 17801272.0 Pending European Patent <br />National Stage 17801272.0<br />Filed on 2017-11-08<br />Status: Pending 147168970 E-293-2016-0 E-293-2016-0-JP-07 TISSUE CLAMP AND IMPLANTATION METHOD National Stage Japan 7069192 2019-545900 Issued Japan <br />National Stage 2019-545900<br />Filed on 2017-11-08<br />Status: Issued 147168971 E-293-2016-0 E-293-2016-0-JP-08 TISSUE CLAMP AND IMPLANTATION METHOD DIV Japan 7417655 2022-075904 Issued Japan <br />Divisional (DIV) 2022-075904<br />Filed on 2022-05-02<br />Status: Issued 147168972 E-293-2016-0 E-293-2016-0-US-02 TISSUE CLAMP AND IMPLANTATION METHOD DIV US 12,605,156 18/226,043 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12605156 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12605156">12,605,156</a><br />Filed on 2023-07-25<br />Status: Issued 147168973 E-293-2016-0 E-293-2016-0-AU-01 TISSUE CLAMP AND IMPLANTATION METHOD DIV Australia 2023203954 2023203954 Issued Australia <br />Divisional (DIV) 2023203954<br />Filed on 2023-06-22<br />Status: Issued 163972577 E-293-2016-0 E-293-2016-0-JP-09 TISSUE CLAMP AND IMPLANTATION METHOD DIV Japan 7642109 2024-000617 Issued Japan <br />Divisional (DIV) 2024-000617<br />Filed on 2024-01-05<br />Status: Issued 163972579 E-293-2016-0 E-293-2016-0-JP-01 TISSUE CLAMP AND IMPLANTATION METHOD DIV Japan Administratively Closed Japan <br />Divisional (DIV) None<br />Filed on None<br />Status: Administratively Closed 163972580 E-293-2016-0 E-293-2016-0-JP-10 TISSUE CLAMP AND IMPLANTATION METHOD DIV Japan 2025-027718 Pending Japan <br />Divisional (DIV) 2025-027718<br />Filed on 2025-02-25<br />Status: Pending 164039358 E-293-2016-0 E-293-2016-0-AU-02 TISSUE CLAMP AND IMPLANTATION METHOD DIV Australia 2025283670 Pending Australia <br />Divisional (DIV) 2025283670<br />Filed on 2025-12-22<br />Status: Pending 166474398 E-293-2016-0 E-293-2016-0-US-04 TISSUE CLAMP AND IMPLANTATION METHOD CON US 19/638,763 Pending US <br />Continuation (CON) 19/638,763<br />Filed on 2026-04-03<br />Status: Pending 147174735 CLAMP 147174737 ocular surgery 147174739 sclera incision closure TAB-3828 143328687 Antibodies With Potent and Broad Neutralizing Activity Against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants NIAID Kevina Birungi-Huff, Sabrina Bush, Man Chen, Nicole Doria-Rose, Daniel Douek, Richard Koup, John Mascola, John Misasi, Maryam Musayev, Chaim Schramm, Wei Shi, Nancy Sullivan, Lingshu Wang, Eun Yang, Yi Zhang <p>&nbsp; &nbsp; &nbsp; &nbsp;Emergence of highly transmissible SARS-CoV-2 variants of concern that are resistant to current therapeutic antibodies highlights the need for continuing discovery of broadly reactive antibodies.<br /> &nbsp; &nbsp; &nbsp; &nbsp;Scientists at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases have identified multiple antibodies that ultra-potently neutralize SARS-CoV-2, including the highly transmissible BA.4, BA.5, BQ.1.1 and XBB subvariants of Omicron, as shown in a pseudovirus neutralization assay. &nbsp;These antibodies target several epitopes in the receptor binding domain of the spike protein that are not impacted by spike mutations that knockout binding to other therapeutic antibodies, including, K417N, N439K, N440K, K444T, V445P, G446S, L452R, Y453F, N460K, S477N, E484A/K, F486S/V and Q498R. &nbsp;Several of the antibodies are able to simultaneously bind to the spike protein and are compatible for use in combination therapies.&nbsp;<br /> &nbsp; &nbsp; &nbsp; This technology is available for licensing for commercial development in accordance with 35 U.S.C. &sect; 209 and 37 CFR Part 404.<br /> &nbsp;</p> <ul> <li>Ultra-potent neutralization of currently identified SARS-CoV-2 variants including Omicron subvariants BQ.1.1 and XBB</li> <li>Mechanism of Action – Some antibodies directly bind to and block ACE2 receptor binding to the SARS CoV-2 spike protein </li> </ul> <ul> <li>Treatment of SARS-CoV-2 infection</li> </ul> 2023-01-31 2026-03-13 2026-03-13 2023-01-25 False False Preclinical Research True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 144856488 Misasi, John NIAID - VRC NIAID Misasi, John (NIAID) 1 144856504 Wang, Lingshu NIAID - VRC NIAID Wang, Lingshu (NIAID) 2 144856514 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 3 144856519 Douek, Daniel NIAID - DIR NIAID Douek, Daniel (NIAID) 4 144856550 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 5 144856554 Koup, Richard NIAID - VRC NIAID Koup, Richard (NIAID) 6 144856562 Chen, Man NIAID - VRC NIAID Chen, Man (NIAID) 7 144856694 Shi, Wei NIAID - VRC NIAID Shi, Wei (NIAID) 8 144856761 Zhang, Yi NIAID - VRC NIAID Zhang, Yi (NIAID) 9 144856798 Yang, Eun NIAID - VRC NIAID Yang, Eun (NIAID) 10 144856823 Doria-Rose, Nicole NIAID - VRC NIAID Doria-Rose, Nicole (NIAID) 11 144856855 Schramm, Chaim NIAID - DIR NIAID Schramm, Chaim (NIAID) 12 144856968 Birungi-Huff, Kevina National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Birungi-Huff, Kevina (NIAID) 13 144857042 Bush, Sabrina NIAID - VRC NIAID Bush, Sabrina (NIAID) 14 144857200 Musayev, Maryam National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Musayev, Maryam (NIAID) 15 144856488 Misasi, John NIAID - VRC NIAID Misasi, John (NIAID) 1 144856504 Wang, Lingshu NIAID - VRC NIAID Wang, Lingshu (NIAID) 2 144856514 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 3 144856519 Douek, Daniel NIAID - DIR NIAID Douek, Daniel (NIAID) 4 144856550 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 5 144856554 Koup, Richard NIAID - VRC NIAID Koup, Richard (NIAID) 6 144856562 Chen, Man NIAID - VRC NIAID Chen, Man (NIAID) 7 144856694 Shi, Wei NIAID - VRC NIAID Shi, Wei (NIAID) 8 144856761 Zhang, Yi NIAID - VRC NIAID Zhang, Yi (NIAID) 9 144856798 Yang, Eun NIAID - VRC NIAID Yang, Eun (NIAID) 10 144856823 Doria-Rose, Nicole NIAID - VRC NIAID Doria-Rose, Nicole (NIAID) 11 144856855 Schramm, Chaim NIAID - DIR NIAID Schramm, Chaim (NIAID) 12 144856968 Birungi-Huff, Kevina National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Birungi-Huff, Kevina (NIAID) 13 144857042 Bush, Sabrina NIAID - VRC NIAID Bush, Sabrina (NIAID) 14 144857200 Musayev, Maryam National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Musayev, Maryam (NIAID) 15 143328697 Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants E-024-2023-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH), National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID, NIAID - VRC, NIH - NIAID 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3828] Antibodies With Potent and Broad Neutralizing Activity Against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants&body=Please send me information about technology [TAB-3828] Antibodies With Potent and Broad Neutralizing Activity Against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3828] Antibodies With Potent and Broad Neutralizing Activity Against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants&body=Please send me information about technology [TAB-3828] Antibodies With Potent and Broad Neutralizing Activity Against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants.">bbailey@mail.nih.gov</a><br> TAB-4148 147157431 Iodonium Analogs as Inhibitors of NADPH Oxidases and Other Flavin Dehydrogenases for the Treatment of Cancer and Inflammatory Conditions NCI Immunology, Licensing, Oncology, Therapeutics Immunology Licensing Oncology Therapeutics James Doroshow, Tafazzai Hossain, Jaimo Lu, Prabhakar Risbood, Krishnendu Roy <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks licensees for the further development of a family of novel iodonium analogs as therapeutics for cancer and/or chronic inflammatory conditions.</p> <h2>Description of Technology:</h2> <p>Diverse human cancers like colorectal, pancreatic, ovarian, melanoma, and pre-cancers express NADPH oxidases (NOX) at high levels. Reactive oxygen species (ROS) produced from metabolic reactions catalyzed by NOX in tumors are essential to the tumor&rsquo;s growth and play a key role in inflammation-related conditions. Though drugs that inhibit ROS production by NOX could be effective against a variety of human cancers and chronic inflammation-related conditions, these types of drugs are not widely available.</p> <p>Investigators in NCI&rsquo;s Developmental Therapeutics Branch have discovered a family of novel analogs of diphenylene iodonium (DPI) and di-thienyl-iodonium (DTI) as inhibitors of NOX and other flavin dehydrogenases for the treatment and prevention of cancer and chronic inflammation-related conditions. Several of these inhibitors displayed in vitro potency that were superior to their parent molecules and were effective in inhibiting cell growth, ROS production, NOX1 mRNA expression, and NOX isoform activity in multiple cancer cell lines, including those representing acute lymphocytic leukemia, chronic myelogenous leukemia, myeloma, large cell immunoblastic lymphoma, non-small cell lung cancer, colon, melanoma, and renal cancer. In vivo validation of parent molecules DPI and DTI using human colon cancer xenografted mice yielded a statistically significant reduction in the average rate of tumor growth in mice administered either DPI or DTI compared to control mice.</p> <p>The National Cancer Institute (NCI) seeks licensees for the further development of these novel iodonium analogs as therapeutics for cancer and/or chronic inflammatory conditions.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Anti-cancer therapeutic for tumors that overexpress NOXs or depend on ROS to proliferate, such as colorectal, pancreatic, and ovarian cancers</li> <li>Therapeutic for chronic inflammatory conditions, such as diabetes, neuropathies, chronic pancreatitis, and inflammatory bowel disease</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Increased potency which may facilitate lower dosing concentrations needed</li> <li>Optimized specificity and selectivity which may lessen risk of off-target effects</li> <li>Potential to be first-in-class drug</li> </ul> Researchers at the NCI seek licensing for the further development a family of novel iodonium analogs as therapeutics for cancer and/or chronic inflammatory conditions. 2021-04-14 2026-02-23 2026-02-23 2026-03-09 2021-04-14 Diphenylene Iodonium, Di-thienyl-iodonium, Doroshow, DPI, DTI, Flavin Dehydrogenases, NADPH oxidases, NOX, Pre-cancerous Lesions, Reactive Oxygen Species, ROS False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2026-02-23 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161921 Lu J, et al. Characterization of potent and selective iodonium-class inhibitors of NADPH oxidases. (PMID 28709950) https://pubmed.ncbi.nlm.nih.gov/28709950/ <a href="https://pubmed.ncbi.nlm.nih.gov/28709950/">Lu J, et al. Characterization of potent and selective iodonium-class inhibitors of NADPH oxidases. (PMID 28709950)</a> 147161959 Doroshow JH, et al. Effects of iodonium-class flavin dehydrogenase inhibitors on growth, reactive oxygen production, cell cycle progression, NADPH oxidase 1 levels, and gene expression in human colon cancer and xenografts. (PMID 23314043) https://pubmed.ncbi.nlm.nih.gov/23314043/ <a href="https://pubmed.ncbi.nlm.nih.gov/23314043/">Doroshow JH, et al. Effects of iodonium-class flavin dehydrogenase inhibitors on growth, reactive oxygen production, cell cycle progression, NADPH oxidase 1 levels, and gene expression in human colon cancer and xenografts. (PMID 23314043)</a> 147162346 Doroshow JH, et al. Antiproliferative mechanisms of action of the flavin dehydrogenase inhibitors diphenylene iodonium and di-2-thienyliodonium based on molecular profiling of the NCI-60 human tumor cell panel. (PMID 22305747) https://pubmed.ncbi.nlm.nih.gov/22305747/ <a href="https://pubmed.ncbi.nlm.nih.gov/22305747/">Doroshow JH, et al. Antiproliferative mechanisms of action of the flavin dehydrogenase inhibitors diphenylene iodonium and di-2-thienyliodonium based on molecular profiling of the NCI-60 human tumor cell panel. (PMID 22305747)</a> 147163689 Doroshow, James NIH - NCI NCI Doroshow, James (NCI) 1 147163688 Risbood, Prabhakar NIH - NCI NCI Risbood, Prabhakar (NCI) 2 147163691 Lu, Jaimo NIH - NCI NCI Lu, Jaimo (NCI) 3 147163690 Roy, Krishnendu NIH - NCI NCI Roy, Krishnendu (NCI) 4 147163692 Hossain, Tafazzai Starks Associates, Inc. Hossain, Tafazzai 5 147163689 Doroshow, James NIH - NCI NCI Doroshow, James (NCI) 1 147163688 Risbood, Prabhakar NIH - NCI NCI Risbood, Prabhakar (NCI) 2 147163691 Lu, Jaimo NIH - NCI NCI Lu, Jaimo (NCI) 3 147163690 Roy, Krishnendu NIH - NCI NCI Roy, Krishnendu (NCI) 4 147163692 Hossain, Tafazzai Starks Associates, Inc. Hossain, Tafazzai 5 147158021 Development Of Analogs Of Diphenylene Iodonium And Di-thienyl-iodonium As Inhibitors Of NADPH Oxidases And Other Flavin Dehydrogenases For The Treatment And Prevention Of Cancer And Inflammation-related Conditions E-116-2014-0 Filing authorized NCI, Starks Associates, Inc. 91826910 McCrary, Michaela michaela.mccrary@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4148] Iodonium Analogs as Inhibitors of NADPH Oxidases and Other Flavin Dehydrogenases for the Treatment of Cancer and Inflammatory Conditions&body=Please send me information about technology [TAB-4148] Iodonium Analogs as Inhibitors of NADPH Oxidases and Other Flavin Dehydrogenases for the Treatment of Cancer and Inflammatory Conditions.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov McCrary, Michaela<br><a href="mailto:michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4148] Iodonium Analogs as Inhibitors of NADPH Oxidases and Other Flavin Dehydrogenases for the Treatment of Cancer and Inflammatory Conditions&body=Please send me information about technology [TAB-4148] Iodonium Analogs as Inhibitors of NADPH Oxidases and Other Flavin Dehydrogenases for the Treatment of Cancer and Inflammatory Conditions.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michaela.mccrary@nih.gov</a><br> 147166923 E-116-2014-0 E-116-2014-0-US-01 Iodonium Analogs As Inhibitors Of NADPH Oxidases And Other Flavin Dehydrogenases; Formulations Thereof; And Uses Thereof PRV US 61/976,362 Abandoned US <br />Provisional (PRV) 61/976,362<br />Filed on 2014-04-07<br />Status: Abandoned 147166924 E-116-2014-0 E-116-2014-0-PCT-02 IODONIUM ANALOGS AS INHIBITORS OF NADPH OXIDASES AND OTHER FLAVIN DEHYDROGENASES; FORMULATIONS THEREOF; AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2015/024445 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/024445<br />Filed on 2015-04-06<br />Status: Expired 147166925 E-116-2014-0 E-116-2014-0-EP-03 IODONIUM ANALOGS AS INHIBITORS OF NADPH OXIDASES AND OTHER FLAVIN DEHYDROGENASES; FORMULATIONS THEREOF; AND USES THEREOF National Stage European Patent 3129102 15717363.4 Issued European Patent <br />National Stage 15717363.4<br />Filed on 2015-04-06<br />Status: Issued 147166926 E-116-2014-0 E-116-2014-0-US-04 Iodonium Analogs as Inhibitors of NADPH Oxidases and Other Flavin Dehydrogenases; Formulations Thereof; and Uses Thereof National Stage US 10,131,659 15/302,566 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10131659 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10131659">10,131,659</a><br />Filed on 2016-10-07<br />Status: Issued 147166927 E-116-2014-0 E-116-2014-0-US-05 IODONIUM ANALOGS AS INHIBITORS OF NADPH OXIDASES AND OTHER FLAVIN DEHYDROGENASES; FORMULATIONS THEREOF; AND USES THEREOF CON US 10,738,047 16/160,599 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10738047 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10738047">10,738,047</a><br />Filed on 2018-10-15<br />Status: Issued 147171769 Diphenylene Iodonium 147171770 Di-thienyl-iodonium 147171772 Doroshow 147171774 DPI 147171776 DTI 147171778 Flavin Dehydrogenases 147171780 NADPH oxidases 147171782 NOX 147171784 Pre-cancerous Lesions 147171785 Reactive Oxygen Species 147171786 ROS TAB-3176 114097126 Human CC Chemokine Receptor CX3CR1 / CMKBRL1 cDNA NIAID Licensing, Research Materials Licensing Research Materials Philip Murphy A plasmid encodes human CC chemokine receptor CX3CR1/CMKBRL1 as described in DNA Cell Biol. 1995 Aug;14(8):673-80, and developed in the laboratory of Philip M. Murphy at the National Institute of Allergy and Infectious Diseases. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-257) 2022-03-08 2026-03-02 2026-03-02 2017-12-04 cc, CC-CMKBRL1, cDNA, Chemokine, Human, PLASMID, RECEPTOR, RM, WIXXXX False True True NIHTT 37470483 Website Abstract 114171740 Combadiere C, et al. https://www.ncbi.nlm.nih.gov/pubmed/7646814 <a href="https://www.ncbi.nlm.nih.gov/pubmed/7646814">Combadiere C, et al.</a> 114107759 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114107759 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114101477 Human CC Chemokine Receptor CC-CMKBRL1 cDNA B-037-1995-6 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3176] Human CC Chemokine Receptor CX3CR1 / CMKBRL1 cDNA&body=Please send me information about technology [TAB-3176] Human CC Chemokine Receptor CX3CR1 / CMKBRL1 cDNA. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3176] Human CC Chemokine Receptor CX3CR1 / CMKBRL1 cDNA&body=Please send me information about technology [TAB-3176] Human CC Chemokine Receptor CX3CR1 / CMKBRL1 cDNA.">dawn.taylor-mulneix@nih.gov</a><br> 114126810 WIXXXX 114149570 Human 114149571 cc 114149572 Chemokine 114149573 RECEPTOR 114149574 CC-CMKBRL1 114149575 cDNA 114149576 PLASMID 114149598 RM TAB-3177 114097119 CXCR1 - Human IL-8 Receptor cDNA NIAID Licensing, Oncology, Research Materials, Therapeutics Licensing Oncology Research Materials Therapeutics Sunil Ahuja, Philip Murphy A plasmid encodes human interleukin-8 (IL-8) receptor CXCR1. IL-8 is a chemo-attractant cytokine that attracts and activates neutrophils in inflammatory regions. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-006) 2022-03-08 2026-03-02 2026-03-02 2017-12-04 CB3AXX, CC1XXX, cDNA, CXCRI, Hu, Human, IL-8, IL-8A, Listed LPM Ano as of 4/15/2015, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, RM, Subtype, WIXXXX False True True NIHTT 37470483 Website Abstract 114107016 Ahuja, Sunil NIAID - DIR Ahuja, Sunil 0 114107758 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114107758 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114107016 Ahuja, Sunil NIAID - DIR Ahuja, Sunil 0 114102339 CXCRI (Hu IL-8A) - Human IL-8 (A Subtype) Receptor cDNA B-004-1995-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3177] CXCR1 - Human IL-8 Receptor cDNA&body=Please send me information about technology [TAB-3177] CXCR1 - Human IL-8 Receptor cDNA. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3177] CXCR1 - Human IL-8 Receptor cDNA&body=Please send me information about technology [TAB-3177] CXCR1 - Human IL-8 Receptor cDNA.">dawn.taylor-mulneix@nih.gov</a><br> 114127493 CB3AXX 114127494 CC1XXX 114127495 WIXXXX 114149577 CXCRI 114149578 Hu 114149579 IL-8A 114149580 Human 114149581 IL-8 114149582 Subtype 114149583 RECEPTOR 114149584 cDNA 114149585 Listed LPM Ano as of 4/15/2015 114149586 Pre LPM working set 20150418 114149587 Post LPM Assignment Set 20150420 114149588 PLASMID 114149599 RM TAB-3183 114097117 Human CCR3 cDNA NIAID Diagnostics, Infectious Disease, Licensing, Research Materials Diagnostics Infectious Disease Licensing Research Materials Sunil Ahuja, Christophe Combadiere, Philip Murphy, James Pease A plasmid encodes human C-C motif chemokine receptor 3 (CCR3). It may contribute to the accumulation and activation of eosinophil and other inflammatory cells in the allergic airway. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-196) 2022-03-08 2026-03-02 2026-03-02 2017-12-04 4, CCR3, CCR3;, cDNA, Cell, DA4AXX, DE4-CCR3, Expressing, Human, Line, Listed LPM Ano as of 4/15/2015, Murine, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RM, VLXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114109426 Ahuja, Sunil NIAID - DIR Ahuja, Sunil 0 114109427 Combadiere, Christophe NIAID - DIR Combadiere, Christophe 0 114109428 Pease, James NIAID - DIR Pease, James 0 114109425 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114109425 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114109426 Ahuja, Sunil NIAID - DIR Ahuja, Sunil 0 114109427 Combadiere, Christophe NIAID - DIR Combadiere, Christophe 0 114109428 Pease, James NIAID - DIR Pease, James 0 114102345 cDNA for human CCR3; cDNA for murine CCR3; and cell line expressing human CCR3 (4 DE4-CCR3 cell line) B-009-1998-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3183] Human CCR3 cDNA&body=Please send me information about technology [TAB-3183] Human CCR3 cDNA. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3183] Human CCR3 cDNA&body=Please send me information about technology [TAB-3183] Human CCR3 cDNA.">dawn.taylor-mulneix@nih.gov</a><br> 114127507 DA4AXX 114127508 VLXXXX 114127509 WIXXXX 114149652 cDNA 114149653 Human 114149654 CCR3; 114149655 Murine 114149656 Cell 114149657 Line 114149658 Expressing 114149659 CCR3 114149660 4 114149661 DE4-CCR3 114149662 Listed LPM Ano as of 4/15/2015 114149663 Pre LPM working set 20150418 114149664 Post LPM Assignment Set 20150420 114149665 PLASMID 114149666 RM TAB-3182 114097116 Human CCR2 cDNA NIAID Licensing, Research Materials Licensing Research Materials Sunil Ahuja, Christophe Combadiere, Philip Murphy, James Pease A plasmid encodes human C-C chemokine receptor type 2 (CCR2). CCR2 play important roles in the recruitment of monocytes/macrophages and T cells. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-195) 2022-03-08 2026-03-02 2026-03-02 2017-12-04 cc, CCR2, cDNA, Cell, Chemokine, Cloning, EOSINOPHIL, Expression, FUNCTIONAL, Human, Including, line., Listed LPM Ano as of 4/15/2015, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, RM, WIXXXX False True True NIHTT 37470483 Website Abstract 114109422 Ahuja, Sunil NIAID - DIR Ahuja, Sunil 0 114109423 Combadiere, Christophe NIAID - DIR Combadiere, Christophe 0 114109424 Pease, James NIAID - DIR Pease, James 0 114109421 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114109421 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114109422 Ahuja, Sunil NIAID - DIR Ahuja, Sunil 0 114109423 Combadiere, Christophe NIAID - DIR Combadiere, Christophe 0 114109424 Pease, James NIAID - DIR Pease, James 0 114102344 CCR2 Cloning and Functional Expression of a Human Eosinophil CC Chemokine Receptor, including cDNA and cell line. B-008-1998-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3182] Human CCR2 cDNA&body=Please send me information about technology [TAB-3182] Human CCR2 cDNA. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3182] Human CCR2 cDNA&body=Please send me information about technology [TAB-3182] Human CCR2 cDNA.">dawn.taylor-mulneix@nih.gov</a><br> 114127506 WIXXXX 114149634 CCR2 114149635 Cloning 114149636 FUNCTIONAL 114149637 Expression 114149638 Human 114149639 EOSINOPHIL 114149640 cc 114149641 Chemokine 114149642 RECEPTOR 114149643 Including 114149644 cDNA 114149645 Cell 114149646 line. 114149647 Listed LPM Ano as of 4/15/2015 114149648 Pre LPM working set 20150418 114149649 Post LPM Assignment Set 20150420 114149650 PLASMID 114149651 RM TAB-3180 114097113 Human FPRL1 / FPR2 cDNA NIAID Licensing, Neurology, Research Materials Licensing Neurology Research Materials Philip Murphy A plasmid encodes human formyl peptide receptor-like 1 (FPRL1/FPR2). <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-017) 2022-03-08 2026-03-02 2026-03-02 2017-12-04 cDNA, FPRL1, Human, Listed LPM Ano as of 4/15/2015, NC3XXX, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, RM, VEXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114109412 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114109412 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114102342 Human FPRL1 Receptor cDNA B-008-1995-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3180] Human FPRL1 / FPR2 cDNA&body=Please send me information about technology [TAB-3180] Human FPRL1 / FPR2 cDNA. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3180] Human FPRL1 / FPR2 cDNA&body=Please send me information about technology [TAB-3180] Human FPRL1 / FPR2 cDNA.">dawn.taylor-mulneix@nih.gov</a><br> 114127500 NC3XXX 114127501 WIXXXX 114127502 VEXXXX 114149609 Human 114149610 FPRL1 114149611 RECEPTOR 114149612 cDNA 114149613 Listed LPM Ano as of 4/15/2015 114149614 Pre LPM working set 20150418 114149615 Post LPM Assignment Set 20150420 114149616 PLASMID 114149617 RM TAB-3179 114097112 Human fMLP Receptor / FPR cDNA NIAID Licensing, Neurology, Research Materials Licensing Neurology Research Materials Philip Murphy A plasmid encodes human fMLP receptor. Formyl peptide receptor (FPR, fMLP receptor) is a G protein-coupled receptor and mediates anti-inflammatory reactions in human neutrophils and other tissues. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-013) 2022-03-08 2026-03-02 2026-03-02 2017-12-04 cDNA, FMLP, Human, Listed LPM Ano as of 4/15/2015, NC3XXX, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, RM, VEXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114109411 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114109411 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114102341 Human FMLP Receptor cDNA B-007-1995-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3179] Human fMLP Receptor / FPR cDNA&body=Please send me information about technology [TAB-3179] Human fMLP Receptor / FPR cDNA. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3179] Human fMLP Receptor / FPR cDNA&body=Please send me information about technology [TAB-3179] Human fMLP Receptor / FPR cDNA.">dawn.taylor-mulneix@nih.gov</a><br> 114127497 NC3XXX 114127498 VEXXXX 114127499 WIXXXX 114149600 Human 114149601 FMLP 114149602 RECEPTOR 114149603 cDNA 114149604 Listed LPM Ano as of 4/15/2015 114149605 Pre LPM working set 20150418 114149606 Post LPM Assignment Set 20150420 114149607 PLASMID 114149608 RM TAB-2917 114097074 CXCR4 Reduction Leads to Enhancement of Engraftment of Hematopoietic Stem Cells NIAID Cardiology, Dental, Endocrinology, Infectious Disease, Licensing, Oncology, Ophthalmology, Therapeutics Cardiology Dental Endocrinology Infectious Disease Licensing Oncology Ophthalmology Therapeutics Ji-Liang Gao, Qian Liu, Harry Malech, David McDermott, Philip Murphy, Marie Siwiki Methods of enhancing engraftment of donor hematopoietic stem cells (HSCs) by reducing expression or activity of CXCR4 in HSCs is described. HSC are the only cells in the bone marrow that are both pluripotent and long lived. Bone marrow transplantation (BMT) using HSC is an increasingly common medical therapy for severe hematologic cancers and primary hematologic immunodeficiencies. However, for significant HSC engraftment to occur there must usually be pre-transplant conditioning with either irradiation or chemotherapy or both. The technology described herein shows that it is possible to replace HSC without the need for pre-transplant conditioning regimen. It is known that the chemokine receptor CXCR4 plays a critical role in HSC homing to the bone marrow and in HSC quiescence. The inventors have identified a patient in which one copy of CXCR4 had been deleted in a somatic mutation of an HSC and this cell had clonally repopulated the bone marrow. This led to experiments in mice where the inventors clearly demonstrated in a bone marrow transplantation model, that donor cells with a single copy of the Cxcr4 gene repopulate recipient mice much faster and last much longer than donor cells having two copies of the Cxcr4 gene. This technology which shows that HSCs with one copy of the CXCR4 gene have a durable selective advantage in bone marrow repopulation can solve the problem frequently encountered in gene therapy, i.e., the short-lived nature of gene-corrected cells, by utilizing recently discovered gene editing methods that can be used to delete one copy of CXCR4 gene in gene-corrected cells. <ul> <li>This technology potentially facilitates HSC transplantation without the need of radiation or chemotherapy conditioning.</li> <li>This technology may uniquely overcome a major hurdle limiting all gene therapy applications, namely the failure to correct the gene defect over a long time.</li> </ul> <ul> <li>Improvement of engraftment in gene therapy protocols and in HSC transplantation.</li> <li>Improved bone marrow transplantation, enhancing the efficiency and durability of donor cell repopulation.</li> </ul> 2022-03-08 2026-03-02 2026-03-02 2015-03-20 Cell, COPY, CXCR4, Durably, ENGRAFTMENT, Enhanced, hematopoietic, ONE, SILENCING, Stem, VCXXXX, VPXXXX, WJXXXX, XEXXXX, YAXXXX, YBXXXX, YCXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114172239 McDermott DH, et al. http://www.ncbi.nlm.nih.gov/pubmed/25662009 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25662009">McDermott DH, et al.</a> 114108986 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 0 114108987 McDermott, David NIAID - DIR NIAID McDermott, David (NIAID) 0 114108988 Siwiki, Marie NIAID - DIR NIAID Siwiki, Marie (NIAID) 0 114108989 Malech, Harry NIAID - DIR NIAID Malech, Harry (NIAID) 0 114108990 Liu, Qian NIAID - DIR NIAID Liu, Qian (NIAID) 0 114108985 Gao, Ji-Liang NIAID - DIR NIAID Gao, Ji-Liang (NIAID) 1 114108985 Gao, Ji-Liang NIAID - DIR NIAID Gao, Ji-Liang (NIAID) 1 114108986 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 0 114108987 McDermott, David NIAID - DIR NIAID McDermott, David (NIAID) 0 114108988 Siwiki, Marie NIAID - DIR NIAID Siwiki, Marie (NIAID) 0 114108989 Malech, Harry NIAID - DIR NIAID Malech, Harry (NIAID) 0 114108990 Liu, Qian NIAID - DIR NIAID Liu, Qian (NIAID) 0 114102255 Hematopoietic Stem Cell Engraftment Can Be Durably Enhanced By Silencing One Copy Of CXCR4 E-173-2014-0 Filing authorized NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-2917] CXCR4 Reduction Leads to Enhancement of Engraftment of Hematopoietic Stem Cells&body=Please send me information about technology [TAB-2917] CXCR4 Reduction Leads to Enhancement of Engraftment of Hematopoietic Stem Cells. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-2917] CXCR4 Reduction Leads to Enhancement of Engraftment of Hematopoietic Stem Cells&body=Please send me information about technology [TAB-2917] CXCR4 Reduction Leads to Enhancement of Engraftment of Hematopoietic Stem Cells.">dawn.taylor-mulneix@nih.gov</a><br> 114162342 E-173-2014-0 E-173-2014-0-US-03 Reducing CXCR4 Expression and/or Function to Enchance Engraftment of Hematopoietic Stem Cells National Stage US 11,278,572 15/324,219 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11278572 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11278572">11,278,572</a><br />Filed on 2017-01-05<br />Status: Issued 114168101 E-173-2014-0 E-173-2014-0-US-01 REDUCING CXCR4 EXPRESSION AND/OR FUNCTION TO ENHANCE ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS PRV US 62/026,138 Abandoned US <br />Provisional (PRV) 62/026,138<br />Filed on 2014-07-18<br />Status: Abandoned 114168173 E-173-2014-0 E-173-2014-0-PCT-02 REDUCING CXCR4 EXPRESSION AND/OR FUNCTION TO ENHANCE ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS PCT Patent Cooperation Treaty PCT/US2015/040954 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/040954<br />Filed on 2015-07-17<br />Status: Expired 114126882 VCXXXX 114126883 VPXXXX 114126884 WJXXXX 114126885 XEXXXX 114126886 YAXXXX 114126887 YBXXXX 114126888 YCXXXX 114148130 hematopoietic 114148131 Stem 114148132 Cell 114148133 ENGRAFTMENT 114148134 Durably 114148135 Enhanced 114148136 SILENCING 114148137 ONE 114148138 COPY 114148139 CXCR4 TAB-2173 114096388 Mouse Anti-Mouse CXCL9 (Mig) Monoclonal Antibodies NIAID Diagnostics, Immunology, Licensing, Oncology, Research Materials, Therapeutics Diagnostics Immunology Licensing Oncology Research Materials Therapeutics Joshua Farber, Hongwei Zhang This technology describes monoclonal antibodies against mouse chemokine (C-X-C motif) ligand 9 (CXCL9), also known as Monokine induced by gamma interferon (Mig). CXCL9 is a secreted protein that functions to attract white cells and increased expression of CXCL9 has been linked to several diseases. The inventors at the NIH generated over 100 anti-mouse CXCL9 antibodies from a CLXL9/Mig knockout mouse and further characterized several antibodies to show neutralization of CXCL9. As such, these antibodies could be used to measure concentrations of mouse CLXL9 in laboratory samples and block the activity of CXCL9 in injected mice. These antibodies are suitable for ELISA and Western blot. The antibodies have not been tested in flow cytometry or immunohistochemistry, but may also be useful for these applications. Can be used in mice without eliciting endogenous antibodies reacting against the injected anti-CXCL9. <ul> <li>ELISA assays for detection and measurement of CXCL9.</li> <li>Neutralization of CXCL9 activity in mouse models and <i>in vitro</i> assays to study the role of CXCL9 in immune response and disease.</li> </ul> Research Tool -- Patent protection is not being pursued for this technology. Available for licensing. 2022-03-08 2026-03-02 2026-03-02 2010-10-12 antibodies, Anti-mouse, AXXXXX, CCXXXX, CXCL9, CXXXXX, IA3XXX, IAXXXX, IDXXXX, IXXXXX, MIG, monoclonal, Mouse False True The technology is currently in the pre-clinical stage of development. True NIHTT 37470483 Website Abstract 114107011 Zhang, Hongwei NIAID - DIR NIAID Zhang, Hongwei (NIAID) 0 114107010 Farber, Joshua NIAID - DIR NIAID Farber, Joshua (NIAID) 1 114107010 Farber, Joshua NIAID - DIR NIAID Farber, Joshua (NIAID) 1 114107011 Zhang, Hongwei NIAID - DIR NIAID Zhang, Hongwei (NIAID) 0 114101474 Mouse Anti-Mouse CXCL9 (Mig) Monoclonal Antibodies E-198-2009-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-2173] Mouse Anti-Mouse CXCL9 (Mig) Monoclonal Antibodies&body=Please send me information about technology [TAB-2173] Mouse Anti-Mouse CXCL9 (Mig) Monoclonal Antibodies. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-2173] Mouse Anti-Mouse CXCL9 (Mig) Monoclonal Antibodies&body=Please send me information about technology [TAB-2173] Mouse Anti-Mouse CXCL9 (Mig) Monoclonal Antibodies.">dawn.taylor-mulneix@nih.gov</a><br> 114121620 AXXXXX 114121621 CXXXXX 114121622 CCXXXX 114121623 IA3XXX 114121624 IDXXXX 114121625 IXXXXX 114121626 IAXXXX 114140577 CXCL9 114140578 Anti-mouse 114140579 Mouse 114140580 MIG 114140581 monoclonal 114140582 antibodies TAB-1973 114096193 A Novel System for Producing Infectious Hepatitis C Virus (HCV) Virions and Development of a Novel Reporter System for Studying HCV Entry NIAID Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Edward Berger, Bertrand Saunier, Miriam Triyatni HCV has infected an estimated 3% of the world population in whom viral infection persists for more than two third of the cases, often resulting in life-threatening complications. The standard of care (pegylated interferon alpha-2 plus ribavirin) is efficient in only 50% of treated patients, costly and has numerous side effects. In addition, viral resistance to newly developed drugs -- targeting viral protease or RNA polymerase -- has been described, but no vaccine is yet available. The difficulty in developing HCV vaccines is largely due to the broad sequence-diversity displayed by HCV, the frequent occurrence of viral mutations within immunogenic epitopes in vivo, and the lack of proper standard/definition for viral neutralization. <br><br> One alternative strategy in HCV-vaccine or drug development comprises measuring viral entry, the first step in viral infection. Such measurements are limited by the available screening systems, in that, HCV pseudo-typed retroviral particles have a different envelope conformation and contain foreign components that are likely to interfere with the measured HCV entry. Moreover, HCV lab strain requires intensive replication for its in vitro production, resulting in numerous mutations that impede development of convenient screening tools. <br><br> The inventors have developed a system for generating infectious HCV particles and HCV-like particles (HCV-LP) suitable for a qualitative single-cycle entry assay, completely independent of HCV replication. To adapt this system as a single assay to study HCV-LP entry, HCV non-structural genes were replaced with a heterologous gene that upon viral-entry triggers firefly luciferase and EGFP expressions in target as well as non-permissive cells. The pretreatment of HCV-replication permissive HuH-7.5 cells with siRNA targeting HCV candidate receptors inhibited viral entry. These new systems enable production of authentic HCV infectious particles as well as HCV-LPs suitable for single-cycle entry assays adaptable to high throughput screening. <ul> <li>These systems do not use pseudo-typed HCV particles, i.e. no foreign proteins present in the virus particles.</li> <li>Particle production in the producing cells is independent of HCV RNA replication, hence avoids the occurrence of adaptive mutations that could be detrimental for virus particle's infectivity or could alter tags or nucleotide sequences incorporated in the viral genome.</li> <li>These systems are not specifically dedicated to HCV of a particular genotype, i.e. they can be used to generate HCV particles of various genotypes without requiring the use of chimeras.</li> </ul> <ul> <li>Screening a library expressed in non-permissive cells for identifying new HCV candidate receptor(s) or entry molecule(s).</li> <li>Testing drugs or compounds inhibiting HCV particle entry or viral genome uncoating, or neutralizing antibodies in target cells.</li> <li>Testing drugs or compounds that inhibit virus assembly, maturation and/or egress, or genome packaging, in producer cells.</li> <li>Incorporating a 'tag' in the genome of various HCV genotypes to more conveniently study virus spreading and dissemination in an organ, tissue and/or small animal model.</li> <li>Enhancing immune response in patients: one way to trigger high level anti-HCV immunity is by isolating antigen-presenting cells from patients and incubating them with HCV particles produced with this system using replication-defective viral genome (with or without an immunogenic tag and/or in combination with other viral epitopes) and eventually re-inject their primed cells to the patients.</li> </ul> The NIAID OTD is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize a novel system for producing infectious HCV virions and developing a reporter system for studying HCV entry. Please contact Michael Piziali at 301-496-2644 for more information. Available for licensing. 2022-03-08 2026-03-02 2026-03-02 2009-06-23 AC4XXX, ACXXXX, AXXXXX, BBXXXX, Biotechnology, C, DB4BXX, DB4XXX, DBXXXX, Development, DXXXXX, Entry., Flavivirus-based, HCV, HCV:, Hepatitis, Hepatitis A, Hepatitis D, Hepatitis E, INFECTIOUS, Novel, Patent Category - Biotechnology, production, REPORTER, STUDYING, System, Virion, VIRIONS, virus False True <ul> <li>Proof of concept.</li> <li>Preliminary tools and techniques for screening strategies.</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114106656 Berger, Edward NIAID - DIR NIAID Berger, Edward (NIAID) 0 114106658 Triyatni, Miriam NIAID - DIR NIAID Triyatni, Miriam (NIAID) 0 114106657 Saunier, Bertrand NIAID - DIR NIAID Saunier, Bertrand (NIAID) 1 114106657 Saunier, Bertrand NIAID - DIR NIAID Saunier, Bertrand (NIAID) 1 114106656 Berger, Edward NIAID - DIR NIAID Berger, Edward (NIAID) 0 114106658 Triyatni, Miriam NIAID - DIR NIAID Triyatni, Miriam (NIAID) 0 114101244 A Novel Flavivirus-based System For Production Of Hepatitis C Virus (HCV): Production Of Infectious Virions And Development Of A Novel Reporter System For Studying HCV Virion Entry. E-005-2009-0 Filing authorized NIAID 114101356 A Novel Flavivirus-based System For Production Of Hepatitis C Virus (HCV): Production Of Infectious Virions And Development Of A Novel Reporter System For Studying HCV Virion Entry. E-005-2009-1 Filing authorized NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-1973] A Novel System for Producing Infectious Hepatitis C Virus (HCV) Virions and Development of a Novel Reporter System for Studying HCV Entry&body=Please send me information about technology [TAB-1973] A Novel System for Producing Infectious Hepatitis C Virus (HCV) Virions and Development of a Novel Reporter System for Studying HCV Entry. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-1973] A Novel System for Producing Infectious Hepatitis C Virus (HCV) Virions and Development of a Novel Reporter System for Studying HCV Entry&body=Please send me information about technology [TAB-1973] A Novel System for Producing Infectious Hepatitis C Virus (HCV) Virions and Development of a Novel Reporter System for Studying HCV Entry.">dawn.taylor-mulneix@nih.gov</a><br> 114165297 E-005-2009-0 E-005-2009-0-US-01 Flavivirus-Based System for Production of Hepatitis C Virus (HCV) PRV US 61/195,088 Abandoned US <br />Provisional (PRV) 61/195,088<br />Filed on 2008-10-03<br />Status: Abandoned 114165746 E-005-2009-1 E-005-2009-1-PCT-01 Flavivirus-Based System For Production Of Hepatitis C Virus (HCV) PCT COMB Patent Cooperation Treaty PCT/US09/58598 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US09/58598<br />Filed on 2009-09-28<br />Status: Expired 114166394 E-005-2009-1 E-005-2009-1-US-02 Flavivirus-based System For Production Of Hepatitis C Virus (HCV) National Stage US 9,052,321 13/122,154 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9052321 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9052321">9,052,321</a><br />Filed on 2011-04-01<br />Status: Issued 114120343 DB4BXX 114120344 AC4XXX 114120345 DXXXXX 114120346 DBXXXX 114120347 DB4XXX 114120348 AXXXXX 114120349 ACXXXX 114121306 BBXXXX 114138031 Novel 114138032 Flavivirus-based 114138033 System 114138034 production 114138035 Hepatitis 114138036 C 114138037 virus 114138038 HCV: 114138039 INFECTIOUS 114138040 VIRIONS 114138041 Development 114138042 REPORTER 114138043 STUDYING 114138044 HCV 114138045 Virion 114138046 Entry. 114138047 Patent Category - Biotechnology 114138048 Biotechnology 114156816 Hepatitis D 114156817 Hepatitis A 114156818 Hepatitis E TAB-1574 114095842 Mice Genetically Deficient in the Chemoattractant Receptor FPR (formyl peptide receptor) NIAID Animal Models, Collaboration, Consumer Products, Diagnostics, Infectious Disease, Licensing, Materials Available, Research Materials, Therapeutics Animal Models Collaboration Consumer Products Diagnostics Infectious Disease Licensing Materials Available Research Materials Therapeutics Ji-Liang Gao, Philip Murphy The present research tool is a knockout mouse model (FPR<sup>-/-</sup>) that lacks the high affinity N-formylpeptide receptor (FPR), created by targeted gene disruption.<br /><br /> N-formylpeptides derive from bacterial and mitochondrial proteins, and bind to specific receptors on mammalian phagocytes. Since binding induces chemotaxis and activation of phagocytes in vitro, it has been postulated that N-formylpeptide receptor signaling in vivo may be important in antibacterial host defense, although direct proof has been lacking. The inventors have found that FPR<sup>-/-</sup> mice have no obvious developmental defects and do not develop spontaneous infection when derived in specific pathogen-free conditions. This suggests that, under these conditions, FPR is dispensable. However, when challenged with L. monocytogenes, FPR-deficient mice have accelerated mortality and increased bacterial burden in liver and spleen early after infection, which suggests a role for FPR in host defense, specifically through regulation of innate immunity. <ul> <li>FPR knock out mouse can be used as antibacterial host defense model and innate immunity studies.</li> </ul> The Laboratory of Molecular Immunology, NIAID, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize FPR knockout mice. Please contact Philip Murphy, M.D. at Tel: 301-496-8616 and/or <a href="mailto:pmm@nih.gov">pmm@nih.gov</a> for more information. Research Tool -- Patent protection is not being pursued for this technology. (IC Reference No. 2007-087) This technology is not patented. The mouse model will be transferred through a Biological Materials License. 2022-03-08 2026-03-02 2026-03-02 2007-07-01 BAXXXX, CHEMOATTRACTANT, DDXXXX, DEFICIENT, DEXXXX, DXXXXX, Formyl, FPR, GENETICALLY, knockout mice, Mice, MXXXXX, Peptide, RECEPTOR, RM, WIXXXX False True The technology is a research tool. The technology is a research tool. True NIHTT 37470483 Website Abstract 114170379 Gao JL, et al. https://www.ncbi.nlm.nih.gov/pubmed/9989980 <a href="https://www.ncbi.nlm.nih.gov/pubmed/9989980">Gao JL, et al.</a> 114105774 Gao, Ji-Liang NIAID - DIR NIAID Gao, Ji-Liang (NIAID) 0 114105775 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114105775 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114105774 Gao, Ji-Liang NIAID - DIR NIAID Gao, Ji-Liang (NIAID) 0 114100812 Mice Genetically Deficient In The Chemoattractant Receptor FPR (formyl Peptide Receptor E-258-2007-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-1574] Mice Genetically Deficient in the Chemoattractant Receptor FPR (formyl peptide receptor)&body=Please send me information about technology [TAB-1574] Mice Genetically Deficient in the Chemoattractant Receptor FPR (formyl peptide receptor). Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-1574] Mice Genetically Deficient in the Chemoattractant Receptor FPR (formyl peptide receptor)&body=Please send me information about technology [TAB-1574] Mice Genetically Deficient in the Chemoattractant Receptor FPR (formyl peptide receptor).">dawn.taylor-mulneix@nih.gov</a><br> 114117961 DDXXXX 114117962 DEXXXX 114117963 DXXXXX 114117964 MXXXXX 114121200 BAXXXX 114127368 WIXXXX 114135649 Mice 114135650 GENETICALLY 114135651 DEFICIENT 114135652 CHEMOATTRACTANT 114135653 RECEPTOR 114135654 FPR 114135655 Formyl 114135656 Peptide 114149419 RM 114149420 knockout mice TAB-788 114095125 Mouse Lacking the Chemokine Receptor CX3CR1 NIAID Diagnostics, Licensing, Materials Available, Oncology, Research Materials Diagnostics Licensing Materials Available Oncology Research Materials Ji-Liang Gao, Philip Murphy This mouse has been generated by targeted gene disruption. The mouse provides a model to investigate the function of the chemokine receptor CX3CR1, which is a proinflammatory receptor for the leukocyte chemoattractant CX3CL1 (aka fractalkine). As an example, the mouse is in use in the study of atherosclerosis. Further, the mouse may serve as a model study the role of the immune system during infection with pathogens as well as other immunologically mediated diseases and responses to tumors. Research Tool -- patent protection is not being pursued for this technology Available for licensing under a biological materials license. 2022-03-08 2026-03-02 2026-03-02 2003-11-01 CA1AXX, CA1XXX, CAXXXX, CXXXXX, RXXXXX False True True NIHTT 37470483 Website Abstract 114169937 C Combadière et al. Decreased atheroscelerotic lesion formation in CX3R1/apolipoprotein E double knockout mice. http://www.ncbi.nlm.nih.gov/pubmed/12600915?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/12600915?dopt">C Combadière et al. Decreased atheroscelerotic lesion formation in CX3R1/apolipoprotein E double knockout mice.</a> 114104506 Murphy, Philip NIAID Murphy, Philip (NIAID) 0 114104507 Gao, Ji-Liang NIAID Gao, Ji-Liang (NIAID) 0 114104506 Murphy, Philip NIAID Murphy, Philip (NIAID) 0 114104507 Gao, Ji-Liang NIAID Gao, Ji-Liang (NIAID) 0 114099957 Mouse Lacking The Chemokine Receptor CX3CR1, Due To Targeted Gene Disruption E-216-2003-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-788] Mouse Lacking the Chemokine Receptor CX3CR1&body=Please send me information about technology [TAB-788] Mouse Lacking the Chemokine Receptor CX3CR1. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-788] Mouse Lacking the Chemokine Receptor CX3CR1&body=Please send me information about technology [TAB-788] Mouse Lacking the Chemokine Receptor CX3CR1.">dawn.taylor-mulneix@nih.gov</a><br> 114114682 CA1AXX 114114683 CAXXXX 114114684 CXXXXX 114114685 RXXXXX 114120914 CA1XXX TAB-3184 114094368 Mouse CCR1 cDNA NIAID Licensing, Research Materials Licensing Research Materials Ji-Liang Gao, Philip Murphy A plasmid encodes mouse C-C motif chemokine receptor 1 (CCR1). CCR1 plays an important role in host protection from inflammatory response, and susceptibility to virus and parasite. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-025) 2022-03-08 2026-03-02 2026-03-02 2017-12-04 CCR1, cDNA, Encoding, Listed LPM Ano as of 4/15/2015, Mouse, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, RM, WIXXXX False True True NIHTT 37470483 Website Abstract 114109430 Gao, Ji-Liang NIAID - DIR NIAID Gao, Ji-Liang (NIAID) 0 114109429 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114109429 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114109430 Gao, Ji-Liang NIAID - DIR NIAID Gao, Ji-Liang (NIAID) 0 114102346 cDNA Encoding the Mouse CCR1 Receptor B-012-1998-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3184] Mouse CCR1 cDNA&body=Please send me information about technology [TAB-3184] Mouse CCR1 cDNA. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3184] Mouse CCR1 cDNA&body=Please send me information about technology [TAB-3184] Mouse CCR1 cDNA.">dawn.taylor-mulneix@nih.gov</a><br> 114127510 WIXXXX 114149667 cDNA 114149668 Encoding 114149669 Mouse 114149670 CCR1 114149671 RECEPTOR 114149672 Listed LPM Ano as of 4/15/2015 114149673 Pre LPM working set 20150418 114149674 Post LPM Assignment Set 20150420 114149675 PLASMID 114149676 RM TAB-3178 114094359 Human Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) cDNA NIAID Licensing, Research Materials Licensing Research Materials Philip Murphy A plasmid encodes human monocyte chemoattractant protein-1 (MCP-1/CCL2). MCP-1/CCL2 is a chemokine that regulate migration and infiltration of monocytes/macrophages. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-007) 2022-03-08 2026-03-02 2026-03-02 2017-12-04 1, Human, Listed LPM Ano as of 4/15/2015, MCP, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RM, Subtype, WIXXXX False True True NIHTT 37470483 Website Abstract 114107015 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114107015 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114102340 Human MCP 1 (A Subtype) B-005-1995-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3178] Human Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) cDNA&body=Please send me information about technology [TAB-3178] Human Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) cDNA. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3178] Human Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) cDNA&body=Please send me information about technology [TAB-3178] Human Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) cDNA.">dawn.taylor-mulneix@nih.gov</a><br> 114127496 WIXXXX 114149589 Human 114149590 MCP 114149591 1 114149592 Subtype 114149593 Listed LPM Ano as of 4/15/2015 114149594 Pre LPM working set 20150418 114149595 Post LPM Assignment Set 20150420 114149596 PLASMID 114149597 RM TAB-4239 147157524 ELISA-Based Biodosimeter for Measuring and Quantifying DNA Damage NCI Collaboration, Diagnostics, Licensing, Oncology Collaboration Diagnostics Licensing Oncology William Bonner, Jiuping ("Jay") Ji, Christophe Redon, Yiping Zhang <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks co-development partners and/or licensees to further develop a novel ELISA-based biodosimeter.</p> <h2>Description of Technology:</h2> <p>Exposure to ionizing radiation or agents that induce DNA double-stranded breaks (DSBs) can result in severe damage to cell and/or tissues, including cell death.&nbsp;This can lead to illness (i.e., acute radiation syndrome, cancer, etc.) or even death.&nbsp; Identifying the amount of exposure to a DNA DSB-causing agent can be useful in monitoring, determining the need for further testing, and avoidance or modification of certain medical interventions and/or types of medical treatments. DNA damage caused by DSBs can be identified and quantified&nbsp;in situ&nbsp;by detecting phosphorylated histone protein &gamma;-H2AX (gamma-H2AX) foci which is formed at DSBs.&nbsp;However, existing methods of analyzing &gamma;-H2AX are laborious, low-throughput, and prone to variability.</p> <p>Investigators in NCI&rsquo;s Developmental Therapeutics Branch have developed a novel, high-throughput ELISA-based biodosimeter to measure DNA damage. This biodosimeter simultaneously quantifies the amount of &gamma;-H2AX and total H2AX and results in a percent &gamma;-H2AX, which is a normalized value representative of the amount of DNA damage. Overall, this biodosimeter provides users with flexibility of input sample type (ex. cells, tissues, blood) and high-throughput, less laborious option to precisely measure DNA damage. It provides reliable, dose-dependent measurement outputs that are independent of variability in cell number, cell viability, cell lysis efficiency, and laboratory operator. Additionally, the biodosimeter is both sensitive and specific, having a 100-fold quantitative range with sensitivity of 5 pM for &gamma;-H2AX and 50 pM for H2AX.</p> <p>NCI is seeking co-development partners and/or licensees to further develop this novel ELISA-based biodosimeter.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Assay for measuring DNA damage by a variety of causes (ex. ionizing radiation, environmental agents, chemotherapeutic agents, etc.)</li> <li>Biodosimeter to monitor cancer drug treatment course</li> <li>High-throughput screening of new drugs targeting DNA metabolism</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Quantitative</li> <li>High sensitivity and selectivity</li> <li>Can be used on varying sample types (ex. cells, blood, and or tissues)</li> <li>Has internal controls for reliable measurements</li> <li>High-throughput and less laborious than other methods for assaying &gamma;H2AX levels</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for further development of a novel ELISA-based biodosimeter. 2016-02-16 2026-02-23 2026-02-23 2026-02-23 2016-09-12 and environmental agents, chemotherapeutic agents, DNA damage, ionizing radiation False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2026-02-23 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 166121280 Ji J, et al. Phosphorylated Fraction of H2AX as a Measurement for DNA Damage in Cancer Cells and Potential Applications of a Novel Assay. (PMID: 28158293) https://pubmed.ncbi.nlm.nih.gov/28158293/ <a href="https://pubmed.ncbi.nlm.nih.gov/28158293/">Ji J, et al. Phosphorylated Fraction of H2AX as a Measurement for DNA Damage in Cancer Cells and Potential Applications of a Novel Assay. (PMID: 28158293)</a> 147164009 Redon, Christophe NIH - NCI NCI Redon, Christophe (NCI) 1 147164010 Zhang, Yiping NIH - NCI Leidos Zhang, Yiping (Leidos) 2 147164008 Bonner, William NIH - NCI NCI Bonner, William (NCI) 3 147164011 Ji, Jiuping ("Jay") NIH - NCI Leidos Ji, Jiuping ("Jay") (Leidos) 4 147164009 Redon, Christophe NIH - NCI NCI Redon, Christophe (NCI) 1 147164010 Zhang, Yiping NIH - NCI Leidos Zhang, Yiping (Leidos) 2 147164008 Bonner, William NIH - NCI NCI Bonner, William (NCI) 3 147164011 Ji, Jiuping ("Jay") NIH - NCI Leidos Ji, Jiuping ("Jay") (Leidos) 4 147158309 ELISA Biodosimeter Based On Gamma-H2AX To H2AX Ratios E-276-2014-0 Filing authorized NCI 91826910 McCrary, Michaela michaela.mccrary@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4239] ELISA-Based Biodosimeter for Measuring and Quantifying DNA Damage&body=Please send me information about technology [TAB-4239] ELISA-Based Biodosimeter for Measuring and Quantifying DNA Damage.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov McCrary, Michaela<br><a href="mailto:michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4239] ELISA-Based Biodosimeter for Measuring and Quantifying DNA Damage&body=Please send me information about technology [TAB-4239] ELISA-Based Biodosimeter for Measuring and Quantifying DNA Damage.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michaela.mccrary@nih.gov</a><br> 147167592 E-276-2014-0 E-276-2014-0-US-01 Methods and Kits for Measuring and Quantifying DNA Double-Stranded Breaks Using Gamma-H2AX and H2AX PRV US 62/110,764 Abandoned US <br />Provisional (PRV) 62/110,764<br />Filed on 2015-02-02<br />Status: Abandoned 147167593 E-276-2014-0 E-276-2014-0-PCT-02 Methods and Kits For Measuring and Quantifying DNA Double-Stranded Breaks Using Gamma-H2AX and H2AX PCT Patent Cooperation Treaty PCT/US2016/016000 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/016000<br />Filed on 2016-02-01<br />Status: Expired 147167594 E-276-2014-0 E-276-2014-0-US-03 METHODS AND KITS FOR MEASURING AND QUANTIFYING DNA DOUBLE-STRANDED BREAKS USING GAMMA-H2AX AND H2AX National Stage US 10,809,268 15/545,402 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10809268 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10809268">10,809,268</a><br />Filed on 2017-07-21<br />Status: Issued 147174553 and environmental agents 147174555 chemotherapeutic agents 147174556 DNA damage 147174558 ionizing radiation TAB-4214 147157499 Surgical Tool for Sub-retinal Tissue Implantation NEI Ear, Nose, & Throat, Licensing, Medical Devices, Non-Medical Devices, Ophthalmology Ear Nose & Throat Licensing Medical Devices Non-Medical Devices Ophthalmology Arvydas Maminishkis <p>The accurate placement of transplanted tissue at a precise position in the retina is difficult but critical for a successful implementation of an ocular surgical intervention.&nbsp;</p> <p>Researchers at the <a href="https://www.nei.nih.gov/" rel="nofollow">National Eye Institute</a> (NEI) developed a surgical tool (see image below)&nbsp;designed to place tissue patches, such as sheets of tissue, onto the retina in a precise and controlled fashion. The tissue for transplantation remains enshrouded in an internal channel until it is accurately delivered to the site of transplant by fluid pressure from a hydrostatic pump.&nbsp; The curved design of the tool matches the curvature of the human eye, and the ease of operation minimizes surgical damage to the eye during placement of the tissue. The secure and precise operation of the tool and delivery of the tissue to the transplantation site maximizes the therapeutic effectiveness. The researchers demonstrated that this tool can be used, with or without modification, to deliver small implantable devices into the retina.&nbsp;</p> <p>This tool is manufactured as a disposable prototype. It is available for licensing and the NEI is open to discussion on potential additional uses of the tool. For example, it is currently being used for autologous iPSC tissue transplant, and can be licensed for this field of use.</p> <p><img alt=" A handheld surgical device/tool designed for intra-ocular delivery and placement of single layer transplant retina tissue to the retina or sub retina. The device is an improvement over similar device as its curved design that matches the curvature of the human eye, making it easier operate and minimizes damage to the eye during placement. " height="150" src="https://nih.technologypublisher.com/files/sites/e-192-2014_image_surgical_tool_for_sub-retinal_delivery_of_rpe_implants4.png" width="732" /></p> <h2>Competitive Advantages:</h2> <p>&bull; Precision of operation for surgeon (no extra moving parts)&nbsp;<br /> &bull; Tool consists of separate disposable parts&nbsp;<br /> &bull; Ease of operation, controlled delivery&nbsp;<br /> &bull; Minimized damage to the eye and transplanted tissue&nbsp;<br /> &bull; Only tool available that can deliver tissue into the sub-retinal space</p> <h2>Commercial Applications:</h2> <p>&bull; Ocular tissue transplantation;<br /> &bull; Delivery of small devices or extended release drug pellets into sub-retinal space</p> 2018-02-16 2025-04-22 2018-07-19 2026-02-18 2018-02-16 EYE, Intra-Ocular, Maminishkis, National Eye Institute, NEI, sub-retinal, surgical tool, tissue placement retina False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-07-19 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-293-2016 147163934 Maminishkis, Arvydas NIH - NEI NEI Maminishkis, Arvydas (NEI) 1 147163934 Maminishkis, Arvydas NIH - NEI NEI Maminishkis, Arvydas (NEI) 1 147158184 Surgical Tool For Soft Ocular Tissue Transplantation E-192-2014-0 Filing authorized National Eye Institute (NEI) 147162558 Surgical Tool For Soft Ocular Tissue Transplantation E-192-2014-1 Filing authorized National Eye Institute (NEI) 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4214] Surgical Tool for Sub-retinal Tissue Implantation&body=Please send me information about technology [TAB-4214] Surgical Tool for Sub-retinal Tissue Implantation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4214] Surgical Tool for Sub-retinal Tissue Implantation&body=Please send me information about technology [TAB-4214] Surgical Tool for Sub-retinal Tissue Implantation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147167432 E-192-2014-0 E-192-2014-0-US-01 Surgical Tool and Method for Ocular Tissue Transplantation PRV US 62/023,289 Abandoned US <br />Provisional (PRV) 62/023,289<br />Filed on 2014-07-11<br />Status: Abandoned 147167434 E-192-2014-1 E-192-2014-1-PCT-01 Surgical Tool and Method for Ocular Tissue Transplantation PCT COMB Patent Cooperation Treaty PCT/US2015/039932 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2015/039932<br />Filed on 2015-07-10<br />Status: Expired 147167435 E-192-2014-1 E-192-2014-1-US-02 Surgical Tool For Soft Ocular Tissue Transplantation National Stage US 10,729,579 15/325,584 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10729579 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10729579">10,729,579</a><br />Filed on 2017-01-11<br />Status: Issued 147167436 E-192-2014-1 E-192-2014-1-AU-03 Surgical Tool and Method for Ocular Tissue Transplantation National Stage Australia 2015287692 Abandoned Australia <br />National Stage 2015287692<br />Filed on 2015-07-10<br />Status: Abandoned 147167437 E-192-2014-1 E-192-2014-1-CA-04 Surgical Tool and Method for Ocular Tissue Transplantation National Stage Canada 2954762 2954762 Issued Canada <br />National Stage 2954762<br />Filed on 2015-07-10<br />Status: Issued 147167438 E-192-2014-1 E-192-2014-1-EP-05 Surgical Tool and Method for Ocular Tissue Transplantation National Stage European Patent 3166550 15741462.4 Issued European Patent <br />National Stage 15741462.4<br />Filed on 2017-02-07<br />Status: Issued 147167439 E-192-2014-1 E-192-2014-1-IN-06 Surgical Tool and Method for Ocular Tissue Transplantation National Stage India 478178 201717003244 Issued India <br />National Stage 201717003244<br />Filed on 2015-07-10<br />Status: Issued 147167440 E-192-2014-1 E-192-2014-1-JP-07 Surgical Tool and Method for Ocular Tissue Transplantation National Stage Japan 6794343 2017-501212 Issued Japan <br />National Stage 2017-501212<br />Filed on 2017-01-10<br />Status: Issued 147167441 E-192-2014-1 E-192-2014-1-US-08 Surgical Tool And Method For Soft Ocular Tissue Transplantation CON US 11,723,799 16/910,388 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11723799 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11723799">11,723,799</a><br />Filed on 2020-06-24<br />Status: Issued 147167442 E-192-2014-1 E-192-2014-1-AU-09 Surgical Tool and Method for Ocular Tissue Transplantation DIV Australia 2020202248 2020202248 Issued Australia <br />Divisional (DIV) 2020202248<br />Filed on 2020-03-30<br />Status: Issued 147167443 E-192-2014-1 E-192-2014-1-EP-10 Surgical Tool and Method for Ocular Tissue Transplantation DIV European Patent 23215832.9 Pending European Patent <br />Divisional (DIV) 23215832.9<br />Filed on 2023-12-12<br />Status: Pending 147167444 E-192-2014-1 E-192-2014-1-AU-11 Surgical Tool and Method for Ocular Tissue Transplantation DIV Australia 2022203098 2022203098 Issued Australia <br />Divisional (DIV) 2022203098<br />Filed on 2022-05-09<br />Status: Issued 147167445 E-192-2014-1 E-192-2014-1-CH-01 Surgical Tool and Method for Ocular Tissue Transplantation EP Switzerland 3166550 15741462.4 Issued Switzerland <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167446 E-192-2014-1 E-192-2014-1-DE-01 Surgical Tool and Method for Ocular Tissue Transplantation EP Germany 3166550 15741462.4 Issued Germany <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167447 E-192-2014-1 E-192-2014-1-ES-01 Surgical Tool and Method for Ocular Tissue Transplantation EP Spain 3166550 15741462.4 Issued Spain <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167448 E-192-2014-1 E-192-2014-1-DK-01 Surgical Tool and Method for Ocular Tissue Transplantation EP Denmark 3166550 15741462.4 Issued Denmark <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167449 E-192-2014-1 E-192-2014-1-GB-01 Surgical Tool and Method for Ocular Tissue Transplantation EP United Kingdom 3166550 15741462.4 Issued United Kingdom <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167450 E-192-2014-1 E-192-2014-1-FR-01 Surgical Tool and Method for Ocular Tissue Transplantation EP France 3166550 15741462.4 Issued France <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167451 E-192-2014-1 E-192-2014-1-IE-01 Surgical Tool and Method for Ocular Tissue Transplantation EP Ireland 3166550 15741462.4 Issued Ireland <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167452 E-192-2014-1 E-192-2014-1-SE-01 Surgical Tool and Method for Ocular Tissue Transplantation EP Sweden 3166550 15741462.4 Issued Sweden <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167453 E-192-2014-1 E-192-2014-1-NL-01 Surgical Tool and Method for Ocular Tissue Transplantation EP The Netherlands 3166550 15741462.4 Issued The Netherlands <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167454 E-192-2014-1 E-192-2014-1-US-01 Surgical Tool And Method For Soft Ocular Tissue Transplantation CON US 18/233,654 Abandoned US <br />Continuation (CON) 18/233,654<br />Filed on 2023-08-14<br />Status: Abandoned 164119644 E-192-2014-1 E-192-2014-1-IT-01 Surgical Tool and Method for Ocular Tissue Transplantation EP Italy 3166550 15741462.4 Issued Italy <br />European patent (EP) 15741462.4<br />Filed on 2017-02-07<br />Status: Issued 164119645 E-192-2014-1 E-192-2014-1-AU-12 Surgical Tool and Method for Ocular Tissue Transplantation DIV Australia 2024259653 Pending Australia <br />Divisional (DIV) 2024259653<br />Filed on 2024-10-31<br />Status: Pending 166059827 E-192-2014-1 E-19